0001561032-23-000003.txt : 20230317 0001561032-23-000003.hdr.sgml : 20230317 20230317081451 ACCESSION NUMBER: 0001561032-23-000003 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 112 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230317 DATE AS OF CHANGE: 20230317 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Healthcare Trust, Inc. CENTRAL INDEX KEY: 0001561032 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 383888962 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39153 FILM NUMBER: 23740737 BUSINESS ADDRESS: STREET 1: 650 FIFTH AVENUE STREET 2: 30TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 212-415-6500 MAIL ADDRESS: STREET 1: 650 FIFTH AVENUE STREET 2: 30TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: American Realty Capital Healthcare Trust II, Inc. DATE OF NAME CHANGE: 20121025 10-K 1 hct-20221231.htm 10-K HTI 12.31.2022 hct-20221231
00015610322022FYFALSEhttp://fasb.org/us-gaap/2022#Revenueshttp://fasb.org/us-gaap/2022#RevenuesP6M0.0833P3Yhttp://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent00015610322022-01-012022-12-310001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2022-01-012022-12-310001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2022-01-012022-12-3100015610322022-06-30iso4217:USD00015610322023-03-14xbrli:shares00015610322022-12-3100015610322021-12-31xbrli:pure0001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2022-12-31iso4217:USDxbrli:shares0001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2021-12-310001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2021-12-310001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2022-12-3100015610322021-01-012021-12-3100015610322020-01-012020-12-310001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-12-310001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-12-310001561032us-gaap:CommonStockMember2019-12-310001561032us-gaap:AdditionalPaidInCapitalMember2019-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001561032us-gaap:RetainedEarningsMember2019-12-310001561032us-gaap:ParentMember2019-12-310001561032us-gaap:NoncontrollingInterestMember2019-12-3100015610322019-12-310001561032us-gaap:AdditionalPaidInCapitalMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2020-01-012020-12-310001561032us-gaap:ParentMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2020-01-012020-12-310001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2020-01-012020-12-310001561032us-gaap:CommonStockMember2020-01-012020-12-310001561032us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001561032us-gaap:ParentMember2020-01-012020-12-310001561032us-gaap:RetainedEarningsMember2020-01-012020-12-310001561032us-gaap:NoncontrollingInterestMember2020-01-012020-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-12-310001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-12-310001561032us-gaap:CommonStockMember2020-12-310001561032us-gaap:AdditionalPaidInCapitalMember2020-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001561032us-gaap:RetainedEarningsMember2020-12-310001561032us-gaap:ParentMember2020-12-310001561032us-gaap:NoncontrollingInterestMember2020-12-3100015610322020-12-310001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2021-01-012021-12-310001561032us-gaap:AdditionalPaidInCapitalMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2021-01-012021-12-310001561032us-gaap:ParentMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2021-01-012021-12-310001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2021-01-012021-12-310001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2021-01-012021-12-310001561032us-gaap:AdditionalPaidInCapitalMemberhct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2021-01-012021-12-310001561032us-gaap:ParentMemberhct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2021-01-012021-12-310001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2021-01-012021-12-310001561032us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001561032us-gaap:ParentMember2021-01-012021-12-310001561032us-gaap:CommonStockMember2021-01-012021-12-310001561032us-gaap:RetainedEarningsMember2021-01-012021-12-310001561032us-gaap:RetainedEarningsMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2021-01-012021-12-310001561032us-gaap:RetainedEarningsMemberhct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2021-01-012021-12-310001561032us-gaap:NoncontrollingInterestMember2021-01-012021-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2021-12-310001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2021-12-310001561032us-gaap:CommonStockMember2021-12-310001561032us-gaap:AdditionalPaidInCapitalMember2021-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001561032us-gaap:RetainedEarningsMember2021-12-310001561032us-gaap:ParentMember2021-12-310001561032us-gaap:NoncontrollingInterestMember2021-12-310001561032us-gaap:ParentMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2022-01-012022-12-310001561032us-gaap:AdditionalPaidInCapitalMemberhct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2022-01-012022-12-310001561032us-gaap:ParentMemberhct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2022-01-012022-12-310001561032us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001561032us-gaap:ParentMember2022-01-012022-12-310001561032us-gaap:CommonStockMember2022-01-012022-12-310001561032us-gaap:RetainedEarningsMember2022-01-012022-12-310001561032us-gaap:RetainedEarningsMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2022-01-012022-12-310001561032us-gaap:RetainedEarningsMemberhct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2022-01-012022-12-310001561032us-gaap:NoncontrollingInterestMember2022-01-012022-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2022-12-310001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2022-12-310001561032us-gaap:CommonStockMember2022-12-310001561032us-gaap:AdditionalPaidInCapitalMember2022-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001561032us-gaap:RetainedEarningsMember2022-12-310001561032us-gaap:ParentMember2022-12-310001561032us-gaap:NoncontrollingInterestMember2022-12-310001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2020-01-012020-12-31hct:propertyhct:stateutr:sqfthct:segmenthct:contractorhct:land_parcel00015610322020-10-012022-12-310001561032us-gaap:LineOfCreditMember2019-01-012019-12-310001561032srt:RestatementAdjustmentMemberus-gaap:LineOfCreditMember2019-01-012019-12-310001561032hct:SeniorsHousingCommunitiesMember2022-01-012022-12-310001561032hct:SeniorsHousingCommunitiesMember2021-01-012021-12-310001561032hct:SeniorsHousingCommunitiesMember2020-01-012020-12-310001561032srt:MinimumMember2022-01-012022-12-310001561032srt:MaximumMember2022-01-012022-12-310001561032us-gaap:BuildingMember2022-01-012022-12-310001561032us-gaap:LandImprovementsMember2022-01-012022-12-310001561032srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2022-01-012022-12-310001561032srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2022-01-012022-12-31hct:lease0001561032us-gaap:DomesticCountryMember2022-12-310001561032us-gaap:DomesticCountryMember2018-01-010001561032hct:MultitenantMOBMember2022-01-012022-12-310001561032hct:SingleTenantMOBMember2022-01-012022-12-310001561032hct:MedicalOfficeBuildingsMember2022-01-012022-12-310001561032us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-12-310001561032us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-01-012021-12-310001561032us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2020-01-012020-12-310001561032us-gaap:LeasesAcquiredInPlaceMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-12-310001561032us-gaap:LeasesAcquiredInPlaceMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-01-012021-12-310001561032us-gaap:LeasesAcquiredInPlaceMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2020-01-012020-12-310001561032us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:AboveMarketLeasesMember2022-01-012022-12-310001561032us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:AboveMarketLeasesMember2021-01-012021-12-310001561032us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:AboveMarketLeasesMember2020-01-012020-12-310001561032us-gaap:LeasesAcquiredInPlaceMember2022-01-012022-12-310001561032us-gaap:AboveMarketLeasesMember2022-01-012022-12-310001561032hct:BelowMarketLeasesMember2022-01-012022-12-310001561032us-gaap:LeasesAcquiredInPlaceMember2021-01-012021-12-310001561032us-gaap:AboveMarketLeasesMember2021-01-012021-12-310001561032hct:BelowMarketLeasesMember2021-01-012021-12-310001561032us-gaap:LeasesAcquiredInPlaceMember2020-01-012020-12-310001561032us-gaap:AboveMarketLeasesMember2020-01-012020-12-310001561032hct:BelowMarketLeasesMember2020-01-012020-12-310001561032us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberstpr:FL2022-01-012022-12-310001561032us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberstpr:FL2021-01-012021-12-310001561032us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberstpr:FL2020-01-012020-12-310001561032us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberstpr:PA2020-01-012020-12-310001561032us-gaap:LeasesAcquiredInPlaceMember2022-12-310001561032us-gaap:LeasesAcquiredInPlaceMember2021-12-310001561032hct:IntangibleMarketLeaseAssetsMember2022-12-310001561032hct:IntangibleMarketLeaseAssetsMember2021-12-310001561032us-gaap:OtherIntangibleAssetsMember2022-12-310001561032us-gaap:OtherIntangibleAssetsMember2021-12-310001561032hct:DepreciationandAmortizationExpenseMemberhct:InplaceLeasesandOtherIntangibleAssetsMember2022-01-012022-12-310001561032hct:DepreciationandAmortizationExpenseMemberhct:InplaceLeasesandOtherIntangibleAssetsMember2021-01-012021-12-310001561032hct:DepreciationandAmortizationExpenseMemberhct:InplaceLeasesandOtherIntangibleAssetsMember2020-01-012020-12-310001561032hct:RentalIncomeMemberhct:AboveandBelowMarketLeasesMember2022-01-012022-12-310001561032hct:RentalIncomeMemberhct:AboveandBelowMarketLeasesMember2021-01-012021-12-310001561032hct:RentalIncomeMemberhct:AboveandBelowMarketLeasesMember2020-01-012020-12-310001561032hct:AboveMarketGroundLeaseMemberhct:PropertyOperatingandMaintenanceExpenseMember2022-01-012022-12-310001561032hct:AboveMarketGroundLeaseMemberhct:PropertyOperatingandMaintenanceExpenseMember2021-01-012021-12-310001561032hct:AboveMarketGroundLeaseMemberhct:PropertyOperatingandMaintenanceExpenseMember2020-01-012020-12-310001561032us-gaap:LeasesAcquiredInPlaceMemberhct:AmortizationExpenseMember2022-12-310001561032us-gaap:OtherIntangibleAssetsMemberhct:AmortizationExpenseMember2022-12-310001561032hct:AmortizationExpenseMember2022-12-310001561032hct:RentalIncomeMemberus-gaap:AboveMarketLeasesMember2022-12-310001561032hct:BelowMarketLeaseMemberhct:RentalIncomeMember2022-12-310001561032hct:RentalIncomeMember2022-12-310001561032hct:LaSallePropertiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-03-022022-03-020001561032hct:LaSallePropertiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-03-020001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:LienSettlementOnFormerlyDisposedPropertiesMember2022-01-012022-12-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-12-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-12-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:HamptonRiverPortolioMember2021-12-212021-12-210001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:HamptonRiverPortolioMember2021-12-210001561032hct:NuVistaJupiterMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2021-05-140001561032hct:NuVistaJupiterMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2021-05-142021-05-140001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:WellingtonGreenMember2021-05-140001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:WellingtonGreenMember2021-05-142021-05-140001561032stpr:MIus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2021-01-152021-01-150001561032stpr:MIus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2021-01-150001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2021-12-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2021-01-012021-12-310001561032hct:SkilledNursingFacilitiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:LutzFloridaMember2020-12-150001561032hct:SkilledNursingFacilitiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:LutzFloridaMember2020-12-152020-12-150001561032stpr:MIus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2020-11-022020-11-020001561032stpr:MIus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2020-11-020001561032hct:MedicalOfficeBuildingsMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-03-190001561032hct:MedicalOfficeBuildingsMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-03-192020-03-190001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-12-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-12-310001561032hct:LaSallePropertiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2021-01-012021-12-310001561032hct:NuVistaJupiterMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-12-310001561032hct:NuVistaJupiterMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2019-01-012019-12-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:WellingtonGreenMember2021-01-012021-12-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:WellingtonGreenMember2020-01-012020-12-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:WellingtonGreenMember2019-01-012019-12-310001561032stpr:MIus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2020-01-012020-12-310001561032stpr:MIus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2019-01-012019-12-310001561032stpr:MIus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2020-11-300001561032hct:SkilledNursingFacilitiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:LutzFloridaMember2019-01-012019-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMemberhct:MOBPropertyIllinoisSkilledNursingFacilitiesMember2022-01-012022-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMemberhct:MOBPropertyIllinoisSkilledNursingFacilitiesMember2021-01-012021-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMemberhct:MOBPropertyIllinoisSkilledNursingFacilitiesMember2020-01-012020-12-310001561032hct:MOBPropertySassafrasMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2022-01-012022-12-310001561032hct:MOBPropertySassafrasMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2021-01-012021-12-310001561032hct:MOBPropertySassafrasMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2020-01-012020-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MOBPropertySunCityArizonaMemberhct:MedicalOfficeBuildingsMember2022-01-012022-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MOBPropertySunCityArizonaMemberhct:MedicalOfficeBuildingsMember2021-01-012021-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MOBPropertySunCityArizonaMemberhct:MedicalOfficeBuildingsMember2020-01-012020-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2022-01-012022-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2021-01-012021-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2020-01-012020-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:VariousSeniorsHousingCommunitiesMember2022-01-012022-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:VariousSeniorsHousingCommunitiesMember2021-01-012021-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:VariousSeniorsHousingCommunitiesMember2020-01-012020-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:LaSallePropertiesMember2022-01-012022-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:LaSallePropertiesMember2021-01-012021-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:LaSallePropertiesMember2020-01-012020-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:WellingtonGreenMember2022-01-012022-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:WellingtonGreenMember2021-01-012021-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:WellingtonGreenMember2020-01-012020-12-310001561032hct:MichiganPropertiesMemberhct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-12-310001561032hct:MichiganPropertiesMemberhct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2021-01-012021-12-310001561032hct:MichiganPropertiesMemberhct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-12-310001561032hct:NuVistaJupiterMemberhct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-12-310001561032hct:NuVistaJupiterMemberhct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2021-01-012021-12-310001561032hct:NuVistaJupiterMemberhct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2021-01-012021-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2021-01-012021-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MOBPropertyIllinoisSkilledNursingFacilitiesMember2022-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:VariousSeniorsHousingCommunitiesMemberhct:SeniorsHousingCommunitiesMember2022-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:VariousSeniorsHousingCommunitiesMemberhct:SeniorsHousingCommunitiesMember2022-01-012022-12-310001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:LaSallePropertiesMemberhct:SeniorsHousingCommunitiesMember2022-01-012022-12-310001561032hct:WellingtonMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:WellingtonGreenMember2020-01-012020-12-310001561032hct:PalmValleyMedicalPlazaAZMemberus-gaap:MortgagesMember2022-12-310001561032hct:PalmValleyMedicalPlazaAZMemberus-gaap:MortgagesMember2021-12-310001561032hct:MedicalCenterVPeoriaAZMemberus-gaap:MortgagesMember2022-12-310001561032hct:MedicalCenterVPeoriaAZMemberus-gaap:MortgagesMember2021-12-310001561032hct:FoxRidgeSeniorLivingatBryantBryantMemberus-gaap:MortgagesMember2022-12-310001561032hct:FoxRidgeSeniorLivingatBryantBryantMemberus-gaap:MortgagesMember2021-12-310001561032us-gaap:MortgagesMemberhct:FoxRidgeSeniorLivingatChenalLittleRockMember2022-12-310001561032us-gaap:MortgagesMemberhct:FoxRidgeSeniorLivingatChenalLittleRockMember2021-12-310001561032hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMemberus-gaap:MortgagesMember2022-12-310001561032hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMemberus-gaap:MortgagesMember2021-12-310001561032hct:MOBLoanMemberus-gaap:MortgagesMember2022-12-310001561032hct:MOBLoanMemberus-gaap:MortgagesMember2021-12-310001561032hct:MultiPropertyCMBSLoanMemberus-gaap:MortgagesMember2022-12-310001561032hct:MultiPropertyCMBSLoanMemberus-gaap:MortgagesMember2021-12-310001561032hct:ShilohIllinoisMemberus-gaap:MortgagesMember2022-12-310001561032hct:ShilohIllinoisMemberus-gaap:MortgagesMember2021-12-310001561032hct:BMOMOBLoanMemberus-gaap:MortgagesMember2022-12-310001561032hct:BMOMOBLoanMemberus-gaap:MortgagesMember2021-12-310001561032us-gaap:MortgagesMember2022-12-310001561032us-gaap:MortgagesMember2021-12-310001561032hct:MOBLoanMemberhct:LIBORBasedInterestRateSwapMember2022-12-310001561032hct:MOBLoanMemberhct:LIBORBasedInterestRateSwapMember2021-12-310001561032hct:BMOMOBLoanMemberus-gaap:MortgagesMember2021-11-150001561032hct:BMOMOBLoanMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:MortgagesMember2021-11-152021-11-150001561032hct:BMOMOBLoanMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:MortgagesMember2021-11-150001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-310001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-12-310001561032hct:TermLoanMemberus-gaap:LineOfCreditMember2022-12-310001561032hct:TermLoanMemberus-gaap:LineOfCreditMember2021-12-310001561032us-gaap:LineOfCreditMember2022-12-310001561032us-gaap:LineOfCreditMember2021-12-310001561032hct:MasterCreditFacilityMemberhct:CapitalOneFacilityMemberus-gaap:LineOfCreditMember2022-12-310001561032hct:MasterCreditFacilityMemberhct:CapitalOneFacilityMemberus-gaap:LineOfCreditMember2021-12-310001561032hct:MasterCreditFacilityMemberus-gaap:LineOfCreditMemberhct:KeyBankFacilityMember2022-12-310001561032hct:MasterCreditFacilityMemberus-gaap:LineOfCreditMemberhct:KeyBankFacilityMember2021-12-310001561032hct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-310001561032hct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2021-12-31hct:encumberedProperty0001561032us-gaap:NondesignatedMemberus-gaap:InterestRateCapMember2022-12-31hct:instrument0001561032hct:MasterCreditFacilityMemberus-gaap:InterestRateCapMember2022-12-310001561032hct:MasterCreditFacilityMemberhct:CapitalOneFacilityMemberus-gaap:InterestRateCapMember2022-12-310001561032hct:MasterCreditFacilityMemberus-gaap:InterestRateCapMemberhct:KeyBankFacilityMember2022-12-310001561032us-gaap:RevolvingCreditFacilityMemberhct:TermLoanMember2022-01-012022-12-310001561032hct:TermLoanMemberhct:SOFRBasedInterestRateSwapMember2022-09-300001561032hct:TermLoanMemberhct:SOFRBasedInterestRateSwapMember2022-12-310001561032us-gaap:LineOfCreditMemberhct:LIBORBasedInterestRateSwapMember2022-12-310001561032us-gaap:LineOfCreditMemberhct:LIBORBasedInterestRateSwapMember2021-12-310001561032hct:MasterCreditFacilityMember2022-12-310001561032hct:NewCreditFacilitiesMember2022-12-310001561032hct:UnencumberedPropertiesMember2022-12-310001561032hct:TermLoanMember2022-01-012022-12-310001561032hct:TermLoanMember2022-12-310001561032srt:MinimumMemberus-gaap:SecuredDebtMember2022-12-310001561032us-gaap:SecuredDebtMembersrt:MaximumMember2022-12-310001561032us-gaap:SecuredDebtMember2022-12-310001561032hct:DayPriortoCommencementQuarterMemberMemberhct:NewCreditFacilitiesMember2022-12-310001561032hct:CommencementQuarterMember2022-01-012022-12-310001561032srt:MinimumMemberhct:CovenantPeriodAfterJune302021Member2022-01-012022-12-310001561032hct:CommencementQuarterMemberhct:NewCreditFacilitiesMember2022-12-310001561032hct:CommencementQuarterMembersrt:MinimumMemberhct:NewCreditFacilitiesMember2022-01-012022-12-310001561032hct:CovenantPeriodFromJuly12021throughCommencementQuarterMember2022-01-012022-12-310001561032hct:CovenantPeriodAfterCommencementQuarterMember2022-01-012022-12-310001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberhct:CovenantPeriodQuarterEndingJune302022ThroughJune302023Member2022-01-012022-12-310001561032us-gaap:RevolvingCreditFacilityMemberhct:CovenantPeriodQuarterEndingSeptember302023ThroughDecember312023Memberus-gaap:LineOfCreditMember2022-01-012022-12-310001561032us-gaap:RevolvingCreditFacilityMemberhct:CovenantPeriodQuarterEndingMarch312024AndThereafterMemberus-gaap:LineOfCreditMember2022-01-012022-12-310001561032us-gaap:RevolvingCreditFacilityMemberhct:CovenantPeriodFromAndAfterCommencementQuarterMemberus-gaap:LineOfCreditMember2022-01-012022-12-310001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-01-012022-12-310001561032us-gaap:LineOfCreditMember2022-12-310001561032us-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2022-01-012022-12-310001561032us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2022-01-012022-12-310001561032us-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberhct:CovenantPeriodAugust112022UntilCommencementQuarterMemberus-gaap:LineOfCreditMemberhct:SecuredOvernightFinancingRateSOFRMember2022-01-012022-12-310001561032us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberhct:CovenantPeriodAugust112022UntilCommencementQuarterMemberus-gaap:LineOfCreditMemberhct:SecuredOvernightFinancingRateSOFRMember2022-01-012022-12-310001561032us-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberhct:CovenantPeriodAugust112022UntilCommencementQuarterMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2022-01-012022-12-310001561032us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberhct:CovenantPeriodAugust112022UntilCommencementQuarterMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2022-01-012022-12-310001561032hct:CommencementQuarterMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:LineOfCreditMemberhct:SecuredOvernightFinancingRateSOFRMember2022-01-012022-12-310001561032hct:CommencementQuarterMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMemberhct:SecuredOvernightFinancingRateSOFRMember2022-01-012022-12-310001561032hct:CommencementQuarterMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2022-01-012022-12-310001561032hct:CommencementQuarterMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2022-01-012022-12-310001561032srt:MinimumMemberhct:TermLoanMemberhct:CovenantPeriodAugust112022UntilCommencementQuarterMemberhct:SecuredOvernightFinancingRateSOFRMember2022-01-012022-12-310001561032hct:TermLoanMembersrt:MaximumMemberhct:CovenantPeriodAugust112022UntilCommencementQuarterMemberhct:SecuredOvernightFinancingRateSOFRMember2022-01-012022-12-310001561032srt:MinimumMemberhct:TermLoanMemberhct:CovenantPeriodAugust112022UntilCommencementQuarterMemberus-gaap:BaseRateMember2022-01-012022-12-310001561032hct:TermLoanMembersrt:MaximumMemberhct:CovenantPeriodAugust112022UntilCommencementQuarterMemberus-gaap:BaseRateMember2022-01-012022-12-310001561032hct:CommencementQuarterMembersrt:MinimumMemberhct:TermLoanMemberhct:SecuredOvernightFinancingRateSOFRMember2022-01-012022-12-310001561032hct:CommencementQuarterMemberhct:TermLoanMembersrt:MaximumMemberhct:SecuredOvernightFinancingRateSOFRMember2022-01-012022-12-310001561032hct:CommencementQuarterMembersrt:MinimumMemberhct:TermLoanMemberus-gaap:BaseRateMember2022-01-012022-12-310001561032hct:CommencementQuarterMemberhct:TermLoanMembersrt:MaximumMemberus-gaap:BaseRateMember2022-01-012022-12-310001561032hct:CommencementQuarterMemberhct:SecuredOvernightFinancingRateSOFRMember2022-12-310001561032us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2023-03-170001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2023-01-012023-03-17hct:derivative00015610322020-11-012020-11-300001561032hct:MasterCreditFacilityMember2020-11-012020-11-300001561032us-gaap:DesignatedAsHedgingInstrumentMemberhct:LIBORBasedBorrowingsMember2022-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberhct:LIBORBasedVariableRateMember2022-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberhct:LIBORBasedInterestRateSwapMember2022-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueInputsLevel2Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueInputsLevel1Memberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueInputsLevel2Memberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueMeasurementsRecurringMemberus-gaap:NondesignatedMember2022-12-310001561032us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueInputsLevel1Memberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001561032us-gaap:FairValueInputsLevel2Memberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001561032us-gaap:FairValueMeasurementsRecurringMemberus-gaap:NondesignatedMember2021-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001561032us-gaap:FairValueInputsLevel2Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001561032us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001561032us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001561032us-gaap:FairValueMeasurementsRecurringMember2021-12-310001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMemberstpr:TX2022-12-310001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMemberstpr:TXhct:MedicalOfficeBuildingsMember2022-12-310001561032hct:SeniorsHousingCommunitiesMemberhct:DisposalGroupHeldforuseNotDiscontinuedOperationsMemberstpr:TX2022-12-310001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMemberstpr:TX2021-12-310001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMemberstpr:TXhct:MedicalOfficeBuildingsMember2021-12-310001561032hct:SeniorsHousingCommunitiesMemberhct:DisposalGroupHeldforuseNotDiscontinuedOperationsMemberstpr:TX2021-12-310001561032hct:SeniorsHousingCommunitiesMemberstpr:TXus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-03-310001561032us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MortgagesMember2022-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:MortgagesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001561032us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MortgagesMember2021-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:MortgagesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001561032us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMember2022-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001561032us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMember2021-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001561032us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhct:FannieCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-310001561032us-gaap:FairValueInputsLevel3Memberhct:FannieCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001561032us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhct:FannieCreditFacilityMemberus-gaap:LineOfCreditMember2021-12-310001561032us-gaap:FairValueInputsLevel3Memberhct:FannieCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:DerivativeFinancialInstrumentsAssetsMember2022-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:DerivativeFinancialInstrumentsAssetsMember2021-12-310001561032us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-12-310001561032us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-12-310001561032us-gaap:DerivativeFinancialInstrumentsAssetsMemberus-gaap:NondesignatedMemberus-gaap:InterestRateCapMember2022-12-310001561032us-gaap:DerivativeFinancialInstrumentsAssetsMemberus-gaap:NondesignatedMemberus-gaap:InterestRateCapMember2021-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-12-310001561032srt:MinimumMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMembersrt:MaximumMemberus-gaap:InterestRateSwapMember2022-12-310001561032hct:MOBLoanMemberus-gaap:MortgagesMember2017-06-300001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2019-10-012019-12-310001561032hct:MOBLoanMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2019-12-310001561032us-gaap:InterestRateContractMemberhct:MOBLoanMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2019-10-012019-12-310001561032us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2022-01-012022-12-310001561032us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2021-01-012021-12-310001561032us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2020-01-012020-12-310001561032us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310001561032hct:MOBLoanMemberhct:SOFRBasedInterestRateSwapMemberus-gaap:MortgagesMember2022-12-310001561032us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2022-12-310001561032hct:SOFRBasedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001561032hct:SOFRBasedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberhct:LIBORBasedInterestRateSwapMember2021-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-01-012022-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-01-012021-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2020-01-012020-12-310001561032us-gaap:NondesignatedMemberus-gaap:InterestRateCapMember2021-12-310001561032hct:TenderOfferMember2020-01-090001561032hct:TenderOfferMember2020-01-092020-01-0900015610322020-01-092020-01-0900015610322020-02-262020-02-2600015610322012-10-152021-12-3100015610322012-10-152022-12-310001561032srt:MaximumMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2022-12-310001561032hct:PublicStockOfferingMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2022-12-310001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2020-09-300001561032hct:PublicStockOfferingMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2021-05-310001561032hct:PublicStockOfferingMemberhct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2021-10-040001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2021-10-042021-10-040001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2021-10-040001561032hct:DelistingMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2022-01-012022-12-310001561032hct:PublicOfferingMember2021-05-112021-05-110001561032us-gaap:OverAllotmentOptionMember2021-05-112021-05-110001561032us-gaap:NoncontrollingInterestMember2021-09-300001561032hct:PreferredStockEquityLineMember2020-09-150001561032hct:PreferredStockEquityLineMember2021-01-012021-12-310001561032hct:PreferredStockEquityLineMember2021-12-310001561032hct:PreferredStockEquityLineMember2021-07-012021-09-300001561032hct:PublicStockOfferingMemberhct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2022-12-310001561032hct:DelistingMemberhct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2022-01-012022-12-31hct:directorhct:dividend0001561032hct:PublicStockOfferingMember2021-10-062021-10-060001561032us-gaap:OverAllotmentOptionMember2021-10-062021-10-060001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2021-10-062021-10-060001561032hct:PublicStockOfferingMember2021-10-0600015610322013-04-012013-04-3000015610322017-04-012017-04-0100015610322018-03-012018-03-0100015610322020-10-012020-10-0100015610322021-01-042021-01-0400015610322021-04-022021-04-0200015610322021-07-012021-07-0100015610322021-10-012021-10-0100015610322022-01-032022-01-0300015610322022-04-012022-04-0100015610322022-07-012022-07-0100015610322022-10-032022-10-030001561032us-gaap:SubsequentEventMember2023-01-032023-01-030001561032hct:SpecialLimitedPartnerMemberhct:AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember2022-12-310001561032hct:SpecialLimitedPartnerMemberhct:AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember2021-12-310001561032hct:TaxDepreciationDeductionMemberhct:AdvisorMember2022-12-3100015610322017-02-172017-02-170001561032hct:SecondAmendedandRestatedAdvisoryAgreementMember2017-02-172017-02-170001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember2017-02-172017-02-170001561032hct:AdvanceOnLoanOrOtherInvestmentMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:AdvisorMember2022-12-310001561032hct:SpecialLimitedPartnerMemberhct:PreTaxNonCompoundedReturnOnCapitalContributionMemberhct:AnnualTargetedInvestorReturnMemberhct:HealthcareTrustSpecialLimitedPartnershipLLCMember2022-12-310001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:AdvisorMemberhct:ContractPurchasePriceMember2022-12-310001561032hct:AdvisorMember2022-01-012022-12-310001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:MonthlyBaseManagementFeeMember2017-02-172017-02-170001561032hct:QuarterlyVariableManagementFeeBenchmarkOneMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember2022-01-012022-12-310001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:QuarterlyVariableManagementFeeBenchmarkTwoMember2022-01-012022-12-310001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:AdvisorMemberhct:GrossRevenueStandAloneSingleTenantNetLeasedPropertiesMember2022-12-310001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:AdvisorMemberhct:GrossRevenueExcludingStandAloneSingleTenantNetLeasedPropertiesMember2022-12-310001561032hct:GrossRevenueManagedPropertiesMembersrt:MaximumMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:AdvisorMember2022-12-310001561032hct:AmendedandRestatedPropertyManagementandLeasingAgreementMember2017-02-172017-02-170001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ReimbursementsofAdministrativeServicesMember2022-01-012022-12-310001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ReimbursementsofAdministrativeServicesMember2021-01-012021-12-310001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ReimbursementsofAdministrativeServicesMember2020-01-012020-12-310001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ReimbursementsofAdministrativeServicesMember2022-07-012022-09-300001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ConsumerPriceIndexMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMember2019-07-252019-07-250001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:CappedReimbursementAmountMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMember2019-07-252019-07-250001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:RealEstateCostMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMember2019-07-252019-07-250001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:AdvisorMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMember2019-07-252019-07-250001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:AdvisorAndCompanyMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMember2019-07-252019-07-250001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ReimbursementsOfEmployeeBonusesOfTheAdvisorMember2019-01-012019-12-310001561032hct:A2019BonusAwardsMember2019-12-310001561032hct:A2019BonusAwardsMember2020-09-300001561032hct:A2019BonusAwardsMember2022-12-310001561032hct:A2019BonusAwardsMember2022-01-012022-12-310001561032hct:A2020BonusAwardsMember2021-04-012021-06-300001561032hct:A2020BonusAwardsMemberhct:AdvisorMember2021-04-012021-06-300001561032hct:SeverancePaymentsMember2020-12-310001561032hct:AcquisitionCostsReimbursementsMember2022-01-012022-12-310001561032hct:AcquisitionCostsReimbursementsMember2021-01-012021-12-310001561032hct:AcquisitionCostsReimbursementsMember2020-01-012020-12-310001561032hct:AcquisitionCostsReimbursementsMember2022-12-310001561032hct:AcquisitionCostsReimbursementsMember2021-12-310001561032hct:AssetManagementFeesMember2022-01-012022-12-310001561032hct:AssetManagementFeesMember2021-01-012021-12-310001561032hct:AssetManagementFeesMember2020-01-012020-12-310001561032hct:AssetManagementFeesMember2022-12-310001561032hct:AssetManagementFeesMember2021-12-310001561032hct:PropertyManagementAndLeasingFeesMember2022-01-012022-12-310001561032hct:PropertyManagementAndLeasingFeesMember2021-01-012021-12-310001561032hct:PropertyManagementAndLeasingFeesMember2020-01-012020-12-310001561032hct:PropertyManagementAndLeasingFeesMember2022-12-310001561032hct:PropertyManagementAndLeasingFeesMember2021-12-310001561032hct:TransferAgentandOtherProfessionalFeesMember2022-01-012022-12-310001561032hct:TransferAgentandOtherProfessionalFeesMember2021-01-012021-12-310001561032hct:TransferAgentandOtherProfessionalFeesMember2020-01-012020-12-310001561032hct:TransferAgentandOtherProfessionalFeesMember2022-12-310001561032hct:TransferAgentandOtherProfessionalFeesMember2021-12-310001561032hct:ProfessionalFeesCreditDueFromAdvisorMember2022-01-012022-12-310001561032hct:ProfessionalFeesCreditDueFromAdvisorMember2021-01-012021-12-310001561032hct:ProfessionalFeesCreditDueFromAdvisorMember2020-01-012020-12-310001561032hct:ProfessionalFeesCreditDueFromAdvisorMember2022-12-310001561032hct:ProfessionalFeesCreditDueFromAdvisorMember2021-12-310001561032hct:DistributionsOnClassBUnitsMember2022-01-012022-12-310001561032hct:DistributionsOnClassBUnitsMember2021-01-012021-12-310001561032hct:DistributionsOnClassBUnitsMember2020-01-012020-12-310001561032hct:DistributionsOnClassBUnitsMember2022-12-310001561032hct:DistributionsOnClassBUnitsMember2021-12-310001561032hct:CappedReimbursementAmountMember2022-01-012022-12-310001561032hct:CappedReimbursementAmountMember2021-01-012021-12-310001561032hct:CappedReimbursementAmountMember2020-01-012020-12-310001561032hct:A2020BonusAwardsMemberhct:AdvisorMember2021-12-310001561032hct:PrepaidExpensesAndOtherAssetsMemberhct:PropertyManagementAndLeasingFeesMember2022-01-012022-12-310001561032hct:PrepaidExpensesAndOtherAssetsMemberhct:PropertyManagementAndLeasingFeesMember2021-01-012021-12-310001561032hct:SpecialLimitedPartnerMemberhct:ExcessOfAdjustedMarketValueOfRealEstateAssetsPlusDistributionsOverAggregateContributedInvestorCapitalMemberhct:HealthcareTrustSpecialLimitedPartnershipLLCMember2022-12-310001561032hct:SpecialLimitedPartnerMemberhct:NetSaleProceedsAfterReturnOfCapitalContributionsAndAnnualTargetedInvestorReturnMemberhct:HealthcareTrustSpecialLimitedPartnershipLLCMember2022-12-310001561032hct:SecondAmendedandRestatedAdvisoryAgreementMembersrt:AffiliatedEntityMemberhct:AdvisorMember2022-01-012022-12-310001561032hct:TransitionFeeMember2022-01-012022-12-310001561032hct:SubjectFeesTransitionFeeNotinExcessoftheProductMember2022-01-012022-12-310001561032hct:SubjectFeesMember2022-01-012022-12-310001561032hct:ChangeinControlFeeMember2022-01-012022-12-310001561032hct:VariableManagementIncentiveFeeMember2022-01-012022-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2022-01-012022-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2022-12-310001561032srt:MinimumMemberhct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2022-01-012022-12-310001561032srt:MaximumMemberhct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2022-01-012022-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2019-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2020-01-012020-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2020-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2021-01-012021-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2021-12-310001561032srt:DirectorMember2020-01-012020-12-310001561032srt:DirectorMember2022-01-012022-12-310001561032srt:DirectorMember2021-01-012021-12-310001561032us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310001561032hct:SeriesAPreferredUnitMember2022-12-310001561032hct:SeriesAPreferredUnitMember2021-12-310001561032hct:CommonOperatingPartnershipUnitMember2022-12-310001561032hct:CommonOperatingPartnershipUnitMember2021-12-310001561032hct:SeriesAPreferredUnitMember2022-01-012022-12-310001561032hct:SeriesAPreferredUnitMember2021-01-012021-12-310001561032us-gaap:NoncontrollingInterestMember2014-11-300001561032hct:CommonOPUnitMember2022-01-012022-12-310001561032hct:CommonOPUnitMember2021-01-012021-12-310001561032hct:CommonOPUnitMember2020-01-012020-12-310001561032hct:OpUnitsMember2022-01-012022-12-310001561032hct:UnityPointClinicPortfolioMember2020-11-042020-11-040001561032hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMemberus-gaap:NoncontrollingInterestMember2022-12-310001561032hct:HealthcareTrustOperatingPartnershipL.P.Memberhct:PlazaDelRioMedicalOfficeCampusPortfolioAZMemberus-gaap:NoncontrollingInterestMember2022-12-310001561032hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMemberus-gaap:NoncontrollingInterestMember2021-12-310001561032hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMemberus-gaap:NoncontrollingInterestMember2022-01-012022-12-310001561032hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMemberus-gaap:NoncontrollingInterestMember2021-01-012021-12-310001561032hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMemberus-gaap:NoncontrollingInterestMember2020-01-012020-12-310001561032us-gaap:RestrictedStockMember2022-01-012022-12-310001561032us-gaap:RestrictedStockMember2021-01-012021-12-310001561032us-gaap:RestrictedStockMember2020-01-012020-12-310001561032hct:OpUnitsMember2021-01-012021-12-310001561032hct:OpUnitsMember2020-01-012020-12-310001561032hct:ClassBUnitsMember2022-01-012022-12-310001561032hct:ClassBUnitsMember2021-01-012021-12-310001561032hct:ClassBUnitsMember2020-01-012020-12-310001561032us-gaap:RestrictedStockMember2022-12-310001561032us-gaap:RestrictedStockMember2021-12-310001561032us-gaap:RestrictedStockMember2020-12-310001561032hct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMemberhct:AdvisorMember2022-12-310001561032hct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMemberhct:AdvisorMember2021-12-310001561032hct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMemberhct:AdvisorMember2020-12-3100015610322021-10-012021-12-310001561032hct:MedicalOfficeBuildingsMember2022-01-012022-12-310001561032hct:SeniorsHousingCommunitiesMember2022-01-012022-12-310001561032hct:MedicalOfficeBuildingsMember2021-01-012021-12-310001561032hct:SeniorsHousingCommunitiesMember2021-01-012021-12-310001561032hct:MedicalOfficeBuildingsMember2020-01-012020-12-310001561032hct:SeniorsHousingCommunitiesMember2020-01-012020-12-310001561032hct:MedicalOfficeBuildingsMember2022-12-310001561032hct:MedicalOfficeBuildingsMember2021-12-310001561032hct:SeniorsHousingCommunitiesMember2022-12-310001561032hct:SeniorsHousingCommunitiesMember2021-12-310001561032us-gaap:OperatingSegmentsMemberhct:MedicalOfficeBuildingsMember2022-01-012022-12-310001561032us-gaap:OperatingSegmentsMemberhct:MedicalOfficeBuildingsMember2021-01-012021-12-310001561032us-gaap:OperatingSegmentsMemberhct:MedicalOfficeBuildingsMember2020-01-012020-12-310001561032us-gaap:OperatingSegmentsMemberhct:SeniorsHousingCommunitiesMember2022-01-012022-12-310001561032us-gaap:OperatingSegmentsMemberhct:SeniorsHousingCommunitiesMember2021-01-012021-12-310001561032us-gaap:OperatingSegmentsMemberhct:SeniorsHousingCommunitiesMember2020-01-012020-12-310001561032us-gaap:OperatingSegmentsMember2022-01-012022-12-310001561032us-gaap:OperatingSegmentsMember2021-01-012021-12-310001561032us-gaap:OperatingSegmentsMember2020-01-012020-12-310001561032us-gaap:LandMember2021-12-310001561032hct:LIBORBasedInterestRateSwapMemberus-gaap:SubsequentEventMember2023-01-012023-03-170001561032hct:LIBORBasedInterestRateSwapMemberus-gaap:SubsequentEventMember2023-03-170001561032hct:FourSingleTenantMOBPropertiesMemberus-gaap:SubsequentEventMember2023-01-012023-03-170001561032hct:FreseniusMedicalCareWinfieldALMember2022-12-310001561032hct:AdenaHealthCenterJacksonOHMember2022-12-310001561032hct:OuachitaCommunityHospitalWestMonroeLAMember2022-12-310001561032hct:CareMeridianLittletonCO.Member2022-12-310001561032hct:OakLawnMedicalCenterOakLawnIL.Member2022-12-310001561032hct:SurgeryCenterofTempleTempleTX.Member2022-12-310001561032hct:GreenvilleHealthSystemGreenvilleSCMember2022-12-310001561032hct:StockbridgeFamilyMedicalStockbridgeMember2022-12-310001561032hct:ArrowheadMedicalPlazaIIGlendaleMember2022-12-310001561032hct:VillageCenterParkwayStockbridgeMember2022-12-310001561032hct:CreeksideMOBDouglasvilleMember2022-12-310001561032hct:BowieGatewayMedicalCenterBowieMember2022-12-310001561032hct:CampusatCrooksAuburnBuildingDRochesterHillsMember2022-12-310001561032hct:BerwynMedicalCenterBerwynMember2022-12-310001561032hct:CountrysideMedicalArtsSafetyHarborMember2022-12-310001561032hct:St.AndrewsMedicalParkVeniceMember2022-12-310001561032hct:CampusatCrooksAuburnBuildingCRochesterHillsJuneMember2022-12-310001561032hct:LagunaProfessionalCenterElkGroveMember2022-12-310001561032hct:UCDavisMOBElkGroveMember2022-12-310001561032hct:EstateatHydeParkTampaJulyMember2022-12-310001561032hct:AutumnRidgeOfClarkstonClarkstonAugustMember2022-12-310001561032hct:SunnybrookofBurlingtonBurlingtonMember2022-12-310001561032hct:SunnybrookofCarrollCarrollAugust26Member2022-12-310001561032hct:PrairieHillsatCedarRapidsCedarRapidsAugustMember2022-12-310001561032hct:PrairieHillsatClintonClintonAugustMember2022-12-310001561032hct:PrairieHillsatDesMoinesDesMoinesAugustMember2022-12-310001561032hct:SunnybrookofFairfieldFairfieldAugust26Member2022-12-310001561032hct:SunnybrookofFt.MadisonFt.MadisonAugust26Member2022-12-310001561032hct:PrairieHillsatIndependenceIndependenceMember2022-12-310001561032hct:SunnybrookofMT.PleasantMt.PleasantAugust26Member2022-12-310001561032hct:SunnybrookofMuscatineMuscatineAugust26Member2022-12-310001561032hct:PrairieHillsatOttumwaOttumwaAugustMember2022-12-310001561032hct:PrairieHillsatTiptonTiptonAugustMember2022-12-310001561032hct:LibertyCourtDixonMember2022-12-310001561032hct:LakesideVistaHollandMember2022-12-310001561032hct:TheAtriumRockfordMember2022-12-310001561032hct:ArrowheadMedicalPlazaIGlendaleMember2022-12-310001561032hct:SunnybrookofBurlingtonLandBurlingtonAugustMember2022-12-310001561032hct:CommunityHealthMOBHarrisburgMember2022-12-310001561032hct:BradyMOBHarrisburgMember2022-12-310001561032hct:LandisMemorialHarrisburgSeptemberMember2022-12-310001561032hct:FOCIIMechanicsburgMember2022-12-310001561032hct:FOCClinicalMechanicsburgMember2022-12-310001561032hct:FOCIMechanicsburgMember2022-12-310001561032hct:CopperSpringsSeniorLivingMeridianSeptemberMember2022-12-310001561032hct:AddingtonPlaceofBrunswickBrunswickSeptemberMember2022-12-310001561032hct:AddingtonPlaceofDublinDublinSeptemberMember2022-12-310001561032hct:AllegroatElizabethtownElizabethtownSeptemberMember2022-12-310001561032hct:AddingtonPlaceofJohnsCreekJohnsCreekSeptemberMember2022-12-310001561032hct:AllegroatJupiterJupiterSeptemberMember2022-12-310001561032hct:AddingtonPlaceofLeesSummitLeesSummitSeptemberMember2022-12-310001561032hct:AddingtonPlaceatMillsRosewellMember2022-12-310001561032hct:AddingtonPlaceofCollegeHarbourStPetersburgSeptemberMember2022-12-310001561032hct:AllegroatStuartStuartSeptemberMember2022-12-310001561032hct:AllegroatTarponTarponSpringsSeptemberMember2022-12-310001561032hct:AddingtonPlaceofTitusvilleTitusvilleMember2022-12-310001561032hct:AllegroatStPetersburgLandStPetersburgSeptemberMember2022-12-310001561032hct:GatewayMedicalOfficeBuildingClarksvilleOctoberMember2022-12-310001561032hct:DyerBuildingDyerOctoberMember2022-12-310001561032hct:A757BuildingMunsterOctoberMember2022-12-310001561032hct:A761BuildingMunsterOctoberMember2022-12-310001561032hct:A759BuildingMunsterOctoberMember2022-12-310001561032hct:ScherervilleBuildingScherervilleMember2022-12-310001561032hct:MeadowbrookSeniorLivingAgouraHillsNovemberMember2022-12-310001561032hct:MountVernonMedicalOfficeBuildingMountVernonNovemberMember2022-12-310001561032hct:WellingtonatHersheysMillWestChesterMember2022-12-310001561032hct:EyeSpecialtyGroupMedicalBuildingMemphisDecemberMember2022-12-310001561032hct:AddingtonPlaceofAlpharettaAlpharettaMember2022-12-310001561032hct:AddingtonPlaceofPrairieVillagePrairieVillageMember2022-12-310001561032hct:BloomMOBHarrisburgDecemberMember2022-12-310001561032hct:MedicalSciencesPavilionHarrisburgDecemberMember2022-12-310001561032hct:WoodGlenNursingandRehabCenterWestChicagoDecemberMember2022-12-310001561032hct:PinnacleCenterSouthavenDecemberMember2022-12-310001561032hct:ParadiseValleyMedicalPlazaPhoenixDecemberMember2022-12-310001561032hct:VictoryMedicalCenteratCraigRanchMcKinneyMember2022-12-310001561032hct:RivershoresHealthcareRehabCentreMarseillesDecemberMember2022-12-310001561032hct:MortonTerraceHealthcareRehabCentreMortonDecemberMember2022-12-310001561032hct:MortonVillaHealthcareRehabCentreMortonMember2022-12-310001561032hct:TheHeightsHealthcarerehabCentrePeoriaHeightsDecemberMember2022-12-310001561032hct:ColonialHealthcareRehabCentrePrincetonDecemberMember2022-12-310001561032hct:CapitolHealthcareRehabCentreSpringfieldDecemberMember2022-12-310001561032hct:AcuitySpecialtyHospitalMesaMember2022-12-310001561032hct:AcuitySpecialtyHospitalSunCityMember2022-12-310001561032hct:AddingtonPlaceofShoalCreekKansasCityMember2022-12-310001561032hct:AuroraHealthCenterGreenBayMember2022-12-310001561032hct:AuroraHealthcareCenterGreenvilleWIMember2022-12-310001561032hct:AuraSheboyanClinicKielMarchMember2022-12-310001561032hct:AuroraHealthcareCenterPlymouthWIMember2022-12-310001561032hct:AuroraHealthcareCenterWaterfordWIMember2022-12-310001561032hct:AuroraHealthcareCenterWautomaWIMember2022-12-310001561032hct:ArborViewAssistedLivingandMemoryCareBurlingtonMarchMember2022-12-310001561032hct:AdvancedOrthopaedicMedicalCenterRichmondAprilMember2022-12-310001561032hct:PalmValleyMedicalPlazaGoodyearAprilMember2022-12-310001561032hct:PhysiciansPlazaofRoaneCountyHarrimanMember2022-12-310001561032hct:AdventistHealthLaceyMedicalPlazaHanfordMember2022-12-310001561032hct:MedicalCenterIPeoriaMayMember2022-12-310001561032hct:MedicalCenterIIPeoriaMayMember2022-12-310001561032hct:CommercialCenterPeoriaMayMember2022-12-310001561032hct:MedicalCenterIIIPeoriaMember2022-12-310001561032hct:MorrowMedicalCenterMorrowJuneMember2022-12-310001561032hct:BelmarMedicalBuildingLakewoodJuneMember2022-12-310001561032hct:AddingtonPlaceNorthvilleMember2022-12-310001561032hct:ConroeMedicalArtsandSurgeryCenterConroeMember2022-12-310001561032hct:MedicalCenterVPeoriaAZMember2022-12-310001561032hct:LegacyMedicalVillagePlanoMember2022-12-310001561032hct:ScrippsCedarMedicalCenterVistaAugustMember2022-12-310001561032hct:RamseyWoodsCudahyMember2022-12-310001561032hct:EastCoastSquareWestCedarPointOctoberMember2022-12-310001561032hct:EastCoastSquareNorthMoreheadCityOctoberMember2022-12-310001561032hct:EastsideCancerinstituteGreenvilleOctoberMember2022-12-310001561032hct:SassafrasMedicalBuildingErieMember2022-12-310001561032hct:SkyLakesKlamathMedicalClinicKlamathFallsMember2022-12-310001561032hct:CourtyardFountainsGreshamORMember2022-12-310001561032hct:PresenceHealingArtsPavilionNewLenoxDecemberMember2022-12-310001561032hct:MainlandMedicalArtsPavilionTexasCityMember2022-12-310001561032hct:RenaissanceonPeachtreeAtlantaMember2022-12-310001561032hct:FoxRidgeSeniorLivingatBryantBryantDecemberMember2022-12-310001561032hct:FoxRidgeSeniorLivingatChenalLittleRockDecemberMember2022-12-310001561032hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember2022-12-310001561032hct:HighDesertMedicalGroupMedicalOfficeBuildingLancasterMember2022-12-310001561032hct:NorthsideHospitalMedicalOfficeBuildingCantonMember2022-12-310001561032hct:WestMichiganSurgeryCenterBigRapidsMember2022-12-310001561032hct:CamelliaWalkAssistedLivingAndMemoryCareEvansMember2022-12-310001561032hct:CedarhurstofCollinsvilleMember2022-12-310001561032hct:ArcadianCoveAssistedLivingMember2022-12-310001561032hct:BeaumontMedicalCenterWarrenMember2022-12-310001561032hct:DaVitaHudsonMember2022-12-310001561032hct:DaVitaBayBreezeMember2022-12-310001561032hct:GreenfieldMedicalPlazaGilbertMember2022-12-310001561032hct:RAIClearwaterMember2022-12-310001561032hct:IllinoisCancerCareGalesburgMember2022-12-310001561032hct:UnityPointClinicMuscatineMember2022-12-310001561032hct:LeeMemorialHealthSystemOutpatientCenterFortMeyersMember2022-12-310001561032hct:DecaturMedicalOfficeBuildingMember2022-12-310001561032hct:MadisonMedicalPlazaJolietMember2022-12-310001561032hct:WoodlakeOfficeCenterMember2022-12-310001561032hct:RockwallMedicalPlazaMember2022-12-310001561032hct:MetroHealthBuckeyeHealthCenterClevelandMember2022-12-310001561032hct:UnityPointClinicMolineMember2022-12-310001561032hct:VAOutpatientClinicGalesburgMember2022-12-310001561032hct:PhilipProfessionalCenterLawrencevilleGAMember2022-12-310001561032hct:TexasChildrensHospitalHoustonMember2022-12-310001561032hct:FloridaMedicalHeartcareMember2022-12-310001561032hct:FloridaMedicalSomersetMember2022-12-310001561032hct:FloridaMedicalTampaPalmsMember2022-12-310001561032hct:FloridaMedicalWesleyChapelMember2022-12-310001561032hct:AuroraHealthCenterMilwaukeeAprilMember2022-12-310001561032hct:VascularSurgeryAssociatesMember2022-12-310001561032hct:GlendaleMOBFarmingtonHillsMIMember2022-12-310001561032hct:CrittentonWashingtonMOBMember2022-12-310001561032hct:CrittentonSterlingHeightsMOBMember2022-12-310001561032hct:AdvocateAuroraMOBElkhornWIMember2022-12-310001561032hct:PulmonaryCriticalCareMedicineAccocLemoyneMember2022-12-310001561032hct:DignityEmerusBlueDiamondRoadLasVegasMember2022-12-310001561032hct:DignityEmerusCraigRoadNorthLasVegasMember2022-12-310001561032hct:GreenfieldMOBGreenfieldMember2022-12-310001561032hct:MilwaukeeMOBSouthMilwaukeeMember2022-12-310001561032hct:StFrancisWIMOBStFrancisMember2022-12-310001561032hct:LancasterMedicalArtsMOBLancasterMember2022-12-310001561032hct:WomensHealthcareGroupMOBYorkMember2022-12-310001561032hct:PioneerSpineSportsNorthamptonMember2022-12-310001561032hct:PioneerSpineSportsSpringfieldMember2022-12-310001561032hct:PioneerSpineSportsWestSpringfieldMember2022-12-310001561032hct:FelicitaVidaEscondidoMember2022-12-310001561032hct:CedarhurstOfEdwardsvilleEdwardsvilleMember2022-12-310001561032hct:UMPCSirThomasCourtHarrisburgMember2022-12-310001561032hct:UMPCFisherRoadMechanicsburgMember2022-12-310001561032hct:SwedishAmericanMOBRoscoeMember2022-12-310001561032hct:CedarhurstOfSpartaSpartaMember2022-12-310001561032hct:UMPCChambersHillHarrisburgMember2022-12-310001561032hct:CedarhurstOfShilohShilohMember2022-12-310001561032hct:BayshoreNaplesMemoryCareNaplesMember2022-12-310001561032hct:CirclevilleMOBCirclevilleMember2022-12-310001561032hct:KingwoodExecutiveCenterKingwoodTXMember2022-12-310001561032hct:OrthoOneHilliardHilliardOHMember2022-12-310001561032hct:SouthDouglasMOBMidwestCityOKMember2022-12-310001561032hct:FortWayneOpthomologyEngleFortWayneINMember2022-12-310001561032hct:FortWayneOpthomologyDupontFortWayneINMember2022-12-310001561032hct:StPetersAlbany2PalisadesAlbanyNYMember2022-12-310001561032hct:HefnerPointeMedicalCenterOklahomaCityOKMember2022-12-310001561032hct:StPetersTroy2NewHampshireTroyNYMember2022-12-310001561032hct:StPetersAlbanyNY4PalisadesMember2022-12-310001561032hct:StPetersAlbanyNY5PalisadesMember2022-12-310001561032hct:StLukesHeartVascularCenterEastStroudsburgMember2022-12-310001561032hct:MetropolitanEyeLakeshoreSurgeryStClairMIMember2022-12-310001561032hct:NaiduClinicOdessaTXMember2022-12-310001561032hct:BelpreVCancerCenterBelpreOHMember2022-12-310001561032hct:CenterForAdvancedDermatologyLakewoodCOMember2022-12-310001561032hct:FloridaMedicalClinicTampaFLMember2022-12-310001561032hct:PensacolaNephrologyMOBPensacolaFLMember2022-12-310001561032hct:MillenniumEyeCareFreeholdNJMember2022-12-310001561032hct:AtlantaGastroenterologyAssociatesLawrencevilleGAMember2022-12-310001561032hct:BoneAndJointSpecialistsMerrillvilleINMember2022-12-310001561032hct:EasternCarolinaENTGreenvilleNCMember2022-12-310001561032us-gaap:FurnitureAndFixturesMember2022-01-012022-12-310001561032srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberhct:ReclassificationFromHeldForSaleToRealEstateInvestmentsMember2020-01-012020-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
 For the fiscal year ended December 31, 2022
 or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
For the transition period from _________ to __________
Commission file number: 001-39153
hct-20221231_g1.jpg
Healthcare Trust, Inc.
(Exact name of registrant as specified in its charter) 
Maryland38-3888962
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
650 Fifth Ave.30th Floor, New YorkNY                 10019
__________________________________________________________________________________ ___________________________________________________________________________
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (212) 415-6500
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share
HTIAThe Nasdaq Global Market
7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per shareHTIBThe Nasdaq Global Market
Securities registered pursuant to Section 12 (g) of the Act:
Common stock, $0.01 par value per share
(Title of class)
Common Share Purchase Rights
(Title of class)
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No  
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer Accelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes No
There is no established public market for the registrant’s shares of common stock.
As of March 14, 2023, the registrant had 106,566,638 shares of common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement to be delivered to stockholders in connection with the registrant’s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K. The registrant intends to file its proxy statement within 120 days after its fiscal year end.


HEALTHCARE TRUST, INC.

FORM 10-K
Year Ended December 31, 2022


Page

2

Forward-Looking Statements
Certain statements included in this Annual Report on Form 10-K are forward-looking statements. Those statements include statements regarding the intent, belief or current expectations of Healthcare Trust, Inc. (“we,” “our” or “us”) and members of our management team, as well as the assumptions on which such statements are based, and generally are identified by the use of words such as “may,” “will,” “seeks,” “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “should” or similar expressions. Actual results may differ materially from those contemplated by such forward-looking statements. Further, forward-looking statements speak only as of the date they are made, and we undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required to do so by law.
These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause our actual results to differ materially from those presented in our forward-looking statements are set forth in “Risk Factors” (Part I, Item 1A of this Annual Report on Form 10-K), “Quantitative and Qualitative Disclosures about Market Risk” (Part II, Item 7A of this Annual Report on Form 10-K), and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (Part II, Item 7 of this Annual Report on Form 10-K).
3

PART I
Item 1. Business
We are an externally managed real estate investment trust for U.S. federal income tax purposes (“REIT”) that focuses on acquiring and managing a diversified portfolio of healthcare-related real estate, focused on medical office and other healthcare-related buildings (“MOBs”), and senior housing operating properties (“SHOPs”). As described in further detail herein, we operate in two reportable business segments for management and internal financial reporting purposes: MOBs and SHOPs.
As of December 31, 2022, we owned 202 properties located in 34 states and comprised of 9.1 million rentable square feet. The following table summarizes our portfolio of properties as of December 31, 2022:
Asset TypeNumber of PropertiesRentable Square Feet
Gross
Asset Value (1)
(In thousands)
Medical Office and Other Healthcare-Related Buildings150 5,090,957 $1,423,804 
Seniors Housing — Operating Properties (2)
52 (3)4,030,413 1,140,608 
Total Portfolio202 9,121,370 $2,564,412 
________
(1)Gross asset value represents total real estate investments, at cost ($2.6 billion total at December 31, 2022), net of gross market lease intangible liabilities ($23.5 million total at December 31, 2022). Impairment charges are already reflected within gross asset value.
(2)As of December 31, 2022, we had 4,374 rentable units in our SHOP segment.
(3)Includes two land parcels.

In constructing our portfolio, we are committed to diversifying our assets by geographic region. The following table details the geographic distribution, by region, of our portfolio as of December 31, 2022:
Geographic RegionNumber of Properties
Annualized Rental Income (1)
Rentable
Square Feet
Rentable Units in SHOP Segment
(In thousands)
Northeast25 $35,412 1,624,153 289 
South70 125,111 3,211,198 1,849 
Midwest76 106,233 2,799,910 1,642 
West31 46,862 1,486,109 594 
Total Portfolio202 $313,618 9,121,370 4,374 
________
(1)    Annualized rental income on a straight-line basis for the leases in place in the property portfolio as of December 31, 2022, which includes tenant concessions such as free rent, as applicable, as well as annualized gross revenue from our SHOPs (as defined below) for the fourth quarter of 2022.
Investment Strategy
Our investment strategy is guided by three core principles: (1) maintaining a balanced, well-diversified portfolio of high-quality assets; (2) pursuing accretive and opportunistic investment opportunities; and (3) maintaining a strong and flexible capital structure.
We have invested, and expect to continue investing, primarily in MOBs and seniors housing properties, primarily structured as SHOPs. In addition, we may invest in facilities leased to hospitals, including rehabilitation hospitals, long-term acute care centers, surgery centers, inpatient rehabilitation facilities, special medical and diagnostic service providers, laboratories, research firms, pharmaceutical and medical supply manufacturers and health insurance firms. Our SHOP investments are held through a structure permitted under the REIT Investment Diversification and Empowerment Act of 2007 ("RIDEA"). We generally acquire a fee interest in any property we acquire (a “fee interest” is the absolute, legal possession and ownership of land, property, or rights), although we may also acquire a leasehold interest (a “leasehold interest” is a right to enjoy the exclusive possession and use of an asset or property for a stated definite period as created by a written lease). We have and may continue to acquire properties through a joint venture or the acquisition of substantially all of the interests of an entity which in turn owns the real property. We also may make preferred equity investments in an entity.
4

Healthcare is the single largest industry in the United States based on contribution to Gross Domestic Product (“GDP”). According to the National Health Expenditures Projections, 2021 - 2030 report prepared by the Centers for Medicare and Medicaid Services (“CMS”): (i) national health expenditures are projected to grow on average 5.1% per year for 2021 through 2030 and at an average annual growth rate of 5.3% per year from 2025 through 2030 and (ii) the healthcare industry projected share of GDP is projected to decrease slightly from 19.7% of U.S. GDP in 2020 to 19.6% by 2030. The increase in expenditures is projected to lead to significant growth in healthcare employment. According to the U.S. Department of Labor’s Bureau of Labor Statistics (the “Bureau of Labor Statistics”), the healthcare industry was one of the largest industries in the United States, providing approximately 21 million seasonally adjusted jobs as of December 31, 2021. According to the Bureau of Labor Statistics, employment of healthcare occupations (healthcare practitioners and technical occupations and healthcare support) is projected to grow 13% from 2021 to 2031, adding approximately 2 million new jobs. This growth is expected due to an aging population and the projected increase in the number of individuals who will have access to health insurance. We believe that the continued growth in employment in the healthcare industry will lead to growth in demand for MOBs and other facilities that serve the healthcare industry. Since the beginning of the COVID-19 pandemic, the senior housing industry has been experiencing ongoing staffing shortages; however, the Bureau of Labor Statistics reported employment increases for nursing and assisted living facilities in 2022.
In addition to the growth in national health expenditures and corresponding increases in employment in the healthcare sector, the nature of healthcare delivery continues to evolve due to the COVID-19 pandemic, impact of government programs, regulatory changes and consumer preferences. We believe these changes have increased the need for capital among healthcare providers and increased incentives for these providers to develop more efficient real estate solutions in order to enhance the delivery of quality healthcare.
We believe that the aging population, improved chronic disease management, technological advances and healthcare reform will positively affect the demand for MOBs, seniors housing properties and other healthcare-related facilities and generate attractive investment opportunities. The first wave of Baby Boomers, the largest segment of the U.S. population, began turning 65 in 2011. According to the U.S. Census Bureau, the U.S. population over 65 will grow to 94.7 million in 2060, up from 49.2 million in 2016. This group will grow more rapidly than the overall population. Thus, its share of the population will increase to 23% in 2060, from 15% in 2016. Patients with diseases that were once life threatening are now being treated with specialized medical care and an arsenal of new pharmaceuticals. Advances in research, diagnostics, surgical procedures, pharmaceuticals and a focus on healthier lifestyles have led to people living longer. Finally, we believe that healthcare reform in the U.S. will continue to drive an increase in demand for medical services, and in particular, in the post-acute and long-term services which our tenants and operators provide. We may invest in healthcare assets through development and joint venture partnerships.
As of December 31, 2022, 2021 and 2020, none of our tenants (together with their affiliates) had annualized rental income on a straight-line basis representing 10% or greater of total annualized rental income on a straight-line basis for the portfolio.
The following table lists the states where we had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of December 31, 2022, 2021 and 2020:
December 31,
State202220212020
Florida (1)
19.2%17.7%20.6%
Pennsylvania**10.4%
________
*    State’s annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income on a straight-line basis for all portfolio properties as of the period specified.
(1)In May 2021, the Company’s skilled nursing facility in Wellington, Florida, and the Company’s development property in Jupiter, Florida were sold. In December 2020, the Company’s skilled nursing facility in Lutz, Florida was sold.
Medical Office and Other Healthcare-Related Buildings
As of December 31, 2022, we owned 150 MOBs and other health care related buildings under lease totaling 5.1 million square feet. These properties are leased to tenants that provide healthcare services that typically consist of:
physicians’ offices and examination rooms,
pharmacies,
hospital ancillary service space and outpatient services such as diagnostic imaging centers, rehabilitation clinics and ambulatory surgery centers,
hospitals,
post-acute care facilities,
skilled nursing facilities (“SNFs”) and;
5

other facilities.
Certain of our properties can be located on or near hospital campuses and require significant plumbing, electrical and mechanical systems to accommodate diagnostic imaging equipment such as x-rays or other imaging equipment, and may also have significant plumbing to accommodate physician exam rooms. In addition, MOBs are often built to accommodate higher structural loads for certain equipment and may contain specialized construction such as cancer radiation therapy vaults for cancer treatment.
Hospitals can include general acute care hospitals, inpatient rehabilitation hospitals, long-term acute care hospitals and surgical and specialty hospitals. These facilities provide inpatient diagnosis and treatment, both medical and surgical, and provide a broad array of inpatient and outpatient services including surgery, rehabilitation therapy as well as diagnostic and treatment services. Post-acute facilities offer restorative, rehabilitative and custodial care for people not requiring the more extensive and complex treatment available at acute care hospitals. We include these types of assets in our MOB and other health care related segment when the property is leased to a tenant that operates the property.
There are a variety of types of MOBs: on campus, off campus, affiliated and non-affiliated. On campus MOBs are physically located on a hospital’s campus, often on land leased from the hospital. A hospital typically creates strong tenant demand which leads to high tenant retention. Off campus properties are located independent of a hospital’s location. Affiliated MOBs may be located on campus or off campus, but are affiliated with a hospital or health system. In some respects, affiliated MOBs are similar to on campus MOBs because the hospital relationship drives tenant demand and retention. Finally, non-affiliated MOBs are not affiliated with any hospital or health system, but may contain physician offices and other healthcare services. We favor affiliated MOBs versus non-affiliated MOBs because of the relationship and synergy with the sponsoring hospital or health system and buildings not affiliated with the hospital or health system but anchored or entirely occupied by a long-tenured physician practice.
The following table reflects the on campus, off campus, affiliated and non-affiliated MOB composition of our portfolio as of December 31, 2022:
MOB ClassificationNumber of PropertiesRentable Square Feet
On Campus19 1,111,254 
Off Campus131 3,979,703 
Total
150 5,090,957 
Affiliated72 2,920,284 
Non-affiliated78 2,170,673 
Total
150 5,090,957 
Seniors Housing Properties
As of December 31, 2022, we owned 52 seniors housing properties under the RIDEA structure in our SHOP segment. Under RIDEA, a REIT may lease qualified healthcare properties on an arm’s length basis to a taxable REIT subsidiary (“TRS”) if the property is operated on behalf of such subsidiary by an independent qualifying management company, which we also refer to as an operator who qualifies as an eligible independent contractor. Our seniors housing properties as of December 31, 2022 primarily consist of assisted living facilities (2,352 units), memory care facilities (1,109 units) and independent living facilities (882 units). These facilities cater to different segments of the elderly population based upon their personal needs and need for assistance with the activities of daily living. Services provided by our operators or tenants in these facilities are primarily paid for by the residents directly and are less reliant on government reimbursement programs such as Medicaid and Medicare.
Assisted living facilities are licensed care facilities that provide personal care services, support and housing for those who need help with activities of daily living, such as bathing, eating and dressing, yet require limited medical care. The programs and services may include transportation, social activities, exercise and fitness programs, beauty or barber shop access, hobby and craft activities, community excursions, meals in a dining room setting and other activities sought by residents. Assisted living facilities are often in apartment-like buildings with private residences ranging from single rooms to large apartments.
Certain assisted living facilities may offer a separate facility that provides a higher level of care for residents requiring memory care as a result of Alzheimer’s disease or other forms of dementia. Levels of personal assistance are based in part on local regulations.
Independent living facilities are designed to meet the needs of seniors who choose to live in an environment surrounded by their peers with services such as housekeeping, meals and activities. These residents generally do not need assistance with
6

activities of daily living, however, in some of our facilities, residents have the option to contract for these services. However, independent living facilities on their own are not treated as qualified health care properties eligible to be leased to a TRS.
Ancillary revenues and revenues from sub-acute care services are derived from providing services beyond room and board and include occupational, physical, speech, respiratory and intravenous therapy, wound care, oncology treatment, brain injury care and orthopedic therapy, as well as sales of pharmaceutical products and other services. Certain facilities provide some of the foregoing services on an outpatient basis. During the years ended December 31, 2021 and 2020, we took efforts to divest from SNFs through our property dispositions, and we have also converted many SNF units to memory care units in our existing properties, which have significantly reduced our SNF operations. As of December 31, 2022 our seniors housing properties included 31 SNF units.
Impact of COVID-19 Pandemic
During the first quarter of 2020, the global COVID-19 pandemic that has spread around the world and to every state in the U.S. commenced. The COVID-19 pandemic has had, and could continue to have, an adverse impact on economic conditions, including a global economic slowdown and recession that may continue for some time. The rapid development and fluidity of the situation precludes any prediction as to the ultimate adverse impact of COVID-19 on economic and market conditions. The COVID-19 pandemic had, and another pandemic in the future could have, impacts across many sectors and areas of the global economy and financial markets, leading to significant adverse impacts on economic activity including volatility in financial markets. Our MOB tenants and SHOP properties operate businesses that require in-person interactions with their patients and residents, and concern regarding the transmission of COVID-19 impacted the willingness of persons to, among other things, live in or use facilities at our properties, and impacted the revenues generated by our tenants.
Our ability to lease space and negotiate and maintain favorable rents and the results of operations at our SHOPs could also continue to be negatively impacted by a prolonged recession in the U.S. economy. Moreover, the demand for leasing space at our MOB properties could decline, which could negatively impact occupancy percentage, revenue and net income. Additionally, downturns or stagnation of the U.S. housing market as a result of an economic downturn could adversely affect the ability, or perceived ability, of seniors to afford the resident fees and services at our SHOPs. Further, recent and continuing increases in inflation brought about by labor shortages, supply chain disruptions and increases in interest rates have adversely impacted, and may continue to impact, our results of operations. Moreover, these increases in the rate of inflation, the ongoing war in Ukraine and related sanctions, supply chain disruptions and increases in interest rates may also impact the ability of our tenants and residents to pay rent and hence our results of operations and liquidity. For more information about the risks and uncertainties associated with inflation, the ongoing war in Ukraine and related sanctions and labor shortages, please see the sections “Inflation” and “Part II—Item 1A. Risk Factors” below.
Beginning in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect us in a number of ways that vary by operating segment:

7

COVID-19 Impact — MOB Segment
The financial stability and overall health of our tenants is critical to our business. We took a proactive approach to achieve mutually agreeable solutions with our tenants and in some cases, during the year ended December 31, 2020, we executed lease amendments providing for deferral of rent. Since the year ended December 31, 2020, we have not entered into any rent deferral agreements with any of our tenants in this segment, and all amounts previously deferred under prior rent deferral agreements have been collected.
COVID-19 Impact — SHOP Segment
In our SHOP segment, occupancy trended downward from March 2020 until June 2021 and has since stabilized and begun to recover. We also experienced lower inquiry volumes and reduced in-person tours since the onset of the COVID-19 pandemic. In addition, starting in March 2020, operating costs began to rise materially, including for services, labor, personal protective equipment and other supplies, as our operators took appropriate actions to protect residents and caregivers. We generally bear these cost increases at our SHOPs, which were partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), and to a lesser extent, cost recoveries for personal protective equipment from residents. These cost increases became more prominent throughout the year ended December 31, 2022 from a combination of factors: (i) we were impacted by rising inflation which generally increased the costs of services and supplies, (ii) we relied more on the use of temporary contract labor and agencies due to a shortage of qualified personnel and (iii) the amounts we paid to third party providers for wages, including overtime wages, and bonuses increased. Future developments in the course of the pandemic, increases to inflation, labor shortages and supply chain disruptions may cause further adverse impacts to our occupancy and cost levels, and these trends may continue to impact us and have material adverse effects on our revenues and net income in future quarters. While the continued development of COVID-19 vaccines may limit those effects, the effectiveness of vaccines and the willingness to receive vaccines are highly uncertain and cannot be predicted with confidence.
The financial impact of the COVID-19 pandemic on us has been partially offset by funds received under the CARES Act. We received $4.5 million, $5.1 million and $3.6 million in these funds during the years ended December 31, 2022, 2021 and 2020, respectively. For accounting purposes, we consider these funds as grant contributions from the government. The full amounts received were recognized as a reduction of property operating expenses in our consolidated statement of operations for the years ended December 31, 2022, 2021 and 2020, respectively, to offset incurred COVID-19 expenses. We do not anticipate that any further funds under the CARES Act will be received, and there can be no assurance that the CARES Act program will be extended or any further amounts received under currently effective or potential future government programs.
Organizational Structure
Substantially all of our business is conducted through Healthcare Trust Operating Partnership, L.P. (the “OP”), a Delaware limited partnership, and its wholly owned subsidiaries. Our Advisor manages our day-to-day business with the assistance of our property manager, Healthcare Trust Properties, LLC (the “Property Manager”). Our Advisor and Property Manager are under common control with AR Global Investments, LLC (“AR Global”) and these related parties receive compensation and fees for providing services to us. We also reimburse these entities for certain expenses they incur in providing these services to us. Healthcare Trust Special Limited Partnership, LLC (the “Special Limited Partner”), which is also under common control with AR Global, has an interest in us through ownership of interests in our OP.
We own our SHOPs through the RIDEA structure, pursuant to which, a REIT may lease “qualified healthcare properties” on an arm’s length basis to a TRS if the property is operated on behalf of such subsidiary by a person who qualifies as an “eligible independent contractor.” We view this as a structure primarily to be used on properties that present attractive valuation entry points with long term growth prospects or drive growth by: (i) transitioning the asset to a new third-party operator that can bring scale, operating efficiencies, or ancillary services; or (ii) investing capital to reposition the asset.
Financing Strategies and Policies
We utilize a combination of debt and equity to fund our investment activity. Our debt and equity levels are determined by management in consultation with the Board. For short-term purposes, we may borrow from our revolving credit facility (our “Revolving Credit Facility”) and our Fannie Mae Master Credit Facilities, which include a secured credit facility with KeyBank National Association (the “KeyBank Facility”) and a secured credit facility with Capital One Multifamily Finance, LLC, an affiliate of Capital One, National Association (the “Capital One Facility”). The KeyBank Facility and Capital One Facility are referred to herein together as the “Fannie Mae Master Credit Facilities”. Our senior secured credit facility with KeyBank National Association (our “Credit Facility”) consists of two components, our Revolving Credit Facility and our term loan (our “Term Loan”). Our Credit Facility is secured by a pledged pool of the equity interests and related rights in wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base thereunder. We may seek and even replace current borrowings with longer-term capital such as senior secured or unsecured notes or other forms of long-term financing. We may invest in properties subject to existing mortgage indebtedness, which we assume as part of the acquisition. In addition, we may obtain financing secured by previously unencumbered properties in which we have invested or may refinance properties acquired on a leveraged basis. In our agreements with our lenders, we are subject to
8

restrictions with respect to secured and unsecured indebtedness, including restrictions on permitted investments, distributions and maintenance of a maximum leverage ratio, a minimum fixed charge coverage ratio, among other things. As of December 31, 2022 we were in compliance with these covenants. As of December 31, 2022, our total debt leverage ratio (net debt divided by gross asset value) was approximately 41.5%. Net debt totaled $1.1 billion, which represents gross debt ($1.1 billion) less cash and cash equivalents ($53.7 million). Gross asset value totaled $2.6 billion, which represents total real estate investments, at cost ($2.6 billion), net of gross market lease intangible liabilities ($23.5 million). Cumulative impairment charges are already reflected within gross asset value.
Tax Status
We elected to be taxed as a REIT under Sections 856 through 860 of Internal Revenue Code of 1986, as amended (the “Code”), commencing with our taxable year ended December 31, 2013. Commencing with that taxable year, we have been organized and operated in a manner so that we qualify as a REIT under the Code. We intend to continue to operate in such a manner, but can provide no assurance be given that we will operate in a manner so as to remain qualified as a REIT. To continue to qualify as a REIT, we must, among other things, distribute at least 90% of our REIT taxable income, which does not equal net income as calculated in accordance with accounting principles generally accepted in the United States (“GAAP”), determined without regard to the deduction for dividends paid and excluding net capital gains, and must comply with a number of other organizational and operational requirements. If we continue to qualify as a REIT, we generally will not be subject to U.S. federal corporate income tax on the portion of our REIT taxable income that we distribute to our stockholders. Even if we continue to qualify for taxation as a REIT, we may be subject to certain state and local taxes on our income and properties as well as U.S. federal income and excise taxes on our undistributed income.
Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties. Generally, to qualify as a REIT, we cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS. Accordingly, we have formed a TRS that is wholly owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf. As of December 31, 2022, we owned 52 seniors housing properties, including two land parcels, which we lease to our TRS. The TRS is a wholly-owned subsidiary of the OP.
Competition
The market for MOB and SHOP real estate is highly competitive. We compete in all of our markets based on a number of factors that include location, rental rates, security, suitability of the property’s design to prospective tenants’ needs and the manner in which the property is operated and marketed. In addition, we compete with other entities engaged in real estate investment activities to locate suitable properties to acquire, tenants to occupy our properties and purchasers to buy our properties. These competitors include other REITs, private investment funds, specialty finance companies, institutional investors, pension funds and their advisors and other entities. There are also other REITs with asset acquisition objectives similar to ours, and others may be organized in the future. Some of these competitors, including larger REITs, have substantially greater marketing and financial resources than we have and generally may be able to accept more risk than we can prudently manage, including risks with respect to the creditworthiness of tenants. In addition, these same entities seek financing through similar channels.

9

Overview
The healthcare industry is one of the most regulated industries in the United States and is currently experiencing rapid regulatory change and uncertainty. The regulatory uncertainty and the potential impact on our tenants and operators could have an adverse material effect on their ability to satisfy their contractual obligations.    
Our tenants and operators must comply with a wide range of complex federal, state, and local laws and regulations, and the healthcare industry, in general, is the subject to increased enforcement and penalties in all areas. Fraud and abuse continues to be an enforcement priority at both the federal and state levels including, but not limited to, the Federal Anti-Kickback Statute, the Federal Physician Self-Referral Statute (commonly known as the “Stark Law”), the False Claims Act (“FCA”), the Civil Monetary Penalties Law (“CMPL”), and a range of other federal and state regulations relating to waste, cost control, and healthcare management. The business and operations of our tenants and operators and therefore our business could be materially impacted by, among other things, a significant expansion of applicable federal, state or local laws and regulations, legislative changes or new judicial challenges to the Patient Protection and Affordable Care Act (the “Affordable Care Act” or “ACA”), future attempts to reform healthcare, new interpretations of existing laws and regulations, and changes or increased emphasis on certain enforcement priorities. Our SHOP segment derives minimal revenues from Medicare and Medicaid so the impact of federal enforcement relating to waste, cost control, and healthcare management is limited; however, facilities may be subject to increased enforcement and scrutiny under state laws. In our SHOP segment, only one property receives payments from Medicare and Medicaid, and a small percentage of our assisted living revenue is derived from Medicaid. For our MOB segment, our tenants and operators could be effected, which could impact our tenants’ ability to pay rent.
Our tenants and operators are subject to extensive federal, state, and local laws, regulations and industry standards which govern business operations, physical plant and structure, patient and employee health and safety, access to facilities, patient rights - including privacy, price transparency, fewer restrictions on access to care - and security of health information. Our tenants’ and operators’ failure to comply with any of these laws could result in loss of licensure, denial of reimbursement, imposition of fines or other penalties, suspension or exclusion from the government sponsored Medicare and Medicaid programs, loss of accreditation or certification, reputational damage and closure of a facility. In addition, both government and private third-party payors will likely continue their efforts to reduce reimbursement. The Medicare and Medicaid programs have adopted a variety of initiatives which have been incorporated and expanded by private insurance carriers, including health maintenance organizations and other health plans, to extract greater discounts and impose more stringent cost controls upon healthcare provider operations. Examples include, but are not limited to, changes in reimbursement rates and methodologies such as bundled payments, capitation payments, and discounted fee structures. Our tenants and operators may also face significant limits on the scope of services reimbursed and on reimbursement rates and fees. All of these changes could impact our tenants’ ability to pay rent or other obligations to us.
Licensure, Certification and Certificate of Need
Our tenants operate hospitals, assisted living facilities, a skilled nursing facility and other healthcare entities and providers that receive reimbursement for services from third-party payors, including the government sponsored Medicare and Medicaid programs and private insurance carriers. To participate in the Medicare and Medicaid programs, tenants and operators of healthcare facilities and other healthcare providers must comply with the regulations previously referenced, as well as with licensing, certification and, in some states, certificate of need (“CON”) requirements.
In granting and renewing these licenses and certifications, the state regulatory agencies consider numerous factors relating to a facility’s operations, including, but not limited to, the plant and physical structure, admission and discharge standards, staffing, training, patient and consumer rights, medication guidelines and other rules. In the SHOP segment if a tenant and/or operator fails to maintain or renew any required license, certification or other regulatory approval, or to correct serious deficiencies identified in compliance surveys, the tenant and/or operator could be prohibited from continuing operations at a facility.
A loss of licensure or certification, as well as a change in participation status, could also adversely affect a tenant or operator’s ability to receive payments from the Medicare and Medicaid programs, which, in turn, could adversely affect the tenant or operator’s ability to satisfy its contractual obligations, including making rental payments under, and otherwise complying with the terms of, its leases with us. In addition, if we have to replace an operator, we may experience difficulties in finding a replacement because our ability to replace the operator may be affected by federal and state laws governing changes in control and ownership.
10

Licensing and certification requirements also subject our tenants, and potentially operators, to compliance surveys and audits which are critical to the ongoing operations of the facilities. Our healthcare facilities must meet licensing and Medicare or Medicaid certification requirement, to the extend applicable relating to the type of facility and its equipment, personnel and standard of medical care, as well as comply with other federal, state and local laws and regulations. Healthcare facilities undergo periodic on-site licensure surveys, which generally are limited if the facility is accredited by The Joint Commission or other recognized accreditation organizations. A loss of licensure or certification could adversely affect a facility’s ability to receive payments from the Medicare and Medicaid programs, which, in turn, could adversely affect its ability to satisfy its contractual obligations, including making rental payments under, and otherwise complying with, the terms of the tenant’s leases or the operator’s contractual obligation with us.
In some states, healthcare facilities are subject to various state CON laws requiring governmental approval prior to the development or expansion of healthcare facilities and services. The approval process in these states generally requires a facility to demonstrate the need for additional or expanded healthcare facilities or services. CONs, where applicable, can also be conditions to regulatory approval of changes in ownership or control of licensed facilities, addition of beds, investment in major capital equipment, introduction of new services, termination of services previously approved through the CON process and other control or operational changes.
CON laws and regulations may restrict a tenant and operator’s ability to expand properties and grow the tenant and operator’s business in certain circumstances, which could have an adverse effect on the tenant’s or operator’s revenues and, in turn, negatively impact their ability to make rental payments under, and otherwise comply with the terms of their leases with us.
Fraud and Abuse Enforcement
Various federal and state laws and regulations are aimed at actions that may constitute fraud and abuse by healthcare entities and providers who participate in, submit or cause to be submitted claims for payment to, or make or receive referrals in connection with government-funded healthcare programs, including Medicare and Medicaid. The federal laws include, for example, the following:
The Federal Anti-Kickback Statute (42 USC Section 1320a-7b(b) of the Social Security Act) which prohibits the knowing and willful solicitation, offer, payment or acceptance of any remuneration, directly or indirectly, overtly or covertly, in cash or in kind in return for: (i) referring an individual to a person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part under a federal health care program; or (ii) purchasing, leasing, ordering, or arranging for or recommending purchasing, leasing, or ordering any good, facility, service, or item for which payment may be made in whole or in party under a federal health care program;
The Stark Law (42 USC Section 1395nn), which prohibits referrals by physicians of Medicare patients to providers of a broad range of designated healthcare services in which the physicians (or their immediate family members) have ownership interests or certain other financial arrangements, unless an exception applies, and prohibits the designated health services entity from submitting claims to Medicare for those services resulting from a prohibited referral;
The FCA (31 USC Sections 3729-3733) creates liability for any person who submits a false claim to the government or causes another to submit a false claim to the government or knowingly makes a false record or statement to get a false claim paid by the government. In what is known as reverse false claims, the FCA imposes liability where a person acts improperly to avoid having to pay money to the government. The FCA also creates liability for people who conspire to violate the FCA; and
The CMPL (42 USC 1320a-7a for healthcare) authorizes the U.S. Department of Health and Human Services (the “HHS”) to impose civil penalties administratively for fraudulent acts. The scope of the Office of the Inspector General’s authority to enforce the CMPL was increased in 2016.
Courts have interpreted the fraud and abuse laws broadly. Sanctions for violating these federal laws include substantial criminal and civil penalties such as punitive sanctions, damage assessments, monetary penalties, imprisonment, denial of Medicare and Medicaid payments, and exclusion from Medicare and Medicaid programs. These laws also impose an affirmative duty on tenants to ensure that they do not employ or contract with persons excluded from Medicare, Medicaid and other government programs. Many states have adopted laws similar to, or more expansive than, the federal fraud and abuse laws. States have also adopted and are enforcing laws that increase the regulatory burden and potential liability of healthcare entities including, but not limited to, patient protections, such as minimum staffing levels, criminal background checks, sanctions for employing excluded providers, restrictions on the use and disclosure of health information, and these state laws have their own penalties which may be in addition to federal penalties.
11

In the ordinary course of their business, the tenants, and potentially operators at our properties are regularly subject to inquiries, audits and investigations conducted by federal and state agencies that oversee applicable laws and regulations. Increased funding for investigation and enforcement efforts, accompanied by an increased pressure to eliminate government waste, has led to a significant increase in the number of investigations and enforcement actions over the past several years, a trend which is not anticipated to decrease considerably. Significant enforcement activity has been the result of actions brought by regulators, who file complaints in the name of the U.S. (and, if applicable, particular states) under the FCA or equivalent state statutes. Also, the qui tam and whistleblower provisions of the FCA allow private individuals to bring actions on behalf of the government alleging that the government was defrauded. Individuals have tremendous potential financial gain in bringing whistleblower claims as the statute provides that the individual will receive a portion of the money recouped. Additionally, violations of the FCA can result in treble damages.
Violations of federal or state law or FCA actions against a tenant or operator of our properties could have a material adverse effect on the tenant’s and operator’s liquidity, financial condition or results of operations. Such a negative impact on a tenant’s or operator’s financial health could adversely affect its ability to satisfy its contractual obligations, including making rental payments under, and otherwise complying with the terms of, its leases and other agreements with us. Federal and state fraud and abuse laws may also restrict the terms of agreements with tenants and operators.
Privacy and Security of Health Information
Various federal and state laws protect the privacy and security of health information. For example, the Health Insurance Portability and Accountability Act of 1996, its implementing regulations and related federal laws and regulations (commonly referred to as “HIPAA”) to protect the privacy and security of individually identifiable health information by limiting its use and disclosure. Many states have implemented similar laws to limit the use and disclosure of patient specific health information. The federal government has increased its HIPAA enforcement efforts over the past few years, which has increased the number of audits and enforcement actions, some of which have resulted in significant penalties to healthcare providers. Violations of federal and state privacy and security laws could have a material adverse effect on a tenant and operator’s financial condition or operations, which could adversely affect its ability to satisfy its contractual obligations, including making rental payments under, and otherwise complying with the terms of, its leases and other agreements with us.
Reimbursement
We and our tenants derive a large portion of our revenues from insurance payments with the remainder coming from Medicare and Medicaid reimbursement and private pay. The reimbursement methodologies for healthcare facilities are constantly changing and federal and state authorities may implement new or modified reimbursement methodologies that may negatively impact healthcare operations. For example, the ACA enacted certain reductions in Medicare reimbursement rates for various healthcare providers, as well as certain other changes to Medicare payment methodologies.
The ACA has faced ongoing legal challenges, including litigation seeking to invalidate some or all of the law or the manner in which it has been interpreted. While there are no current challenges to the ACA, that could change based on the make-up of Congress and the presidential administration. The uncertain status of the ACA and of the state Medicaid programs, among other things, affect our ability to plan for the future.
Federal and state budget pressures also continue to escalate and, in an effort to address actual or potential budget shortfalls, Congress and many state legislatures may continue to enact reductions to Medicare and Medicaid expenditures through cuts in rates paid to providers or restrictions in eligibility and benefits.
In addition to legislative and executive actions relating to the scope of the ACA, increased enforcement will likely continue to impact the financial framework for healthcare tenants and facilities. For example, CMS is focused on reducing what it considers to be payment errors by identifying, reporting, and implementing actions to reduce payment error vulnerabilities. In November 2020, CMS announced its successes in reducing the 2020 Medicare improper payment rate and specifically called out the successes of its actions to address improper payments in home health and SNF claims. In 2021, CMS again successfully reduced the 2021 Medicare improper payment rate. The risk of improper payments in our SHOP segment is limited as only one property receives Medicare and Medicaid payments and a small percentage of our revenues come from assisted living facilities participating in Medicaid.
In addition, CMS’s continuing transition of Medicare from a traditional fee for service reimbursement model to a capitated value-based and bundled payment approach, which shifts the financial responsibility of certain patients to providers, will continue to create unprecedented challenges for providers.
Another notable Medicare health care reform initiative, the Medicare Access and CHIP Reauthorization Act of 2015 (“MACRA”), permanently repealed the Sustainable Growth Rate formula, and provided for an annual rate increase of 0.5% for physicians through 2019, but imposed a six-year freeze on fee updates from 2020 through 2025. MACRA established a new payment framework, called the Quality Payment Program, which modified certain Medicare payments to “eligible clinicians,” including physicians, dentists, and other practitioners. MACRA represents a fundamental change in physician reimbursement. The implications of MACRA continue to be uncertain and will depend on future regulatory activity and physician activity in the marketplace. MACRA reporting requirements and quality metrics may encourage physicians to move from smaller practices to
12

larger physician groups or hospital employment, leading to further consolidation of the industry. These and other shifts in payment and risk sharing within an outcome-based model are leading to, among other trends, increasing use of management tools to oversee individual providers and coordinate their services. The focus on utilization puts downward pressure on the number and expense of services provided as payors are moving away from a fee for service model. The continued trend toward capitated, value-based, and bundled payment approaches has the potential to diminish the market for certain healthcare providers, particularly specialist physicians and providers of particular diagnostic technologies. This could adversely impact the medical properties that house these physicians and medical technology providers.
Certain of our facilities are also subject to periodic pre- and post-payment reviews and other audits by governmental authorities, which could result in recoupments, denials, or delay of payments. Additionally, the introduction and explosion of new stakeholders competing with traditional providers in the health market, as well as telemedicine, telehealth and mobile health, are disrupting the heath industry and could lead to new trends in payment. All of the factors discussed-recoupment of past payments or denial or delay of future payments-could adversely affect a tenant’s or operator’s ability to satisfy its contractual obligations, including making rental payments under, and otherwise complying with the terms of its leases and other agreements with us. Assisted and independent living services generally are not reimbursable under government reimbursement programs, such as Medicare and Medicaid. Most of the resident fee revenues generated by our SHOPs, therefore, are derived from private pay sources consisting of the income or assets of residents or their family members. The rates for these residents are set by the facilities based on local market conditions and operating costs.
We regularly assess the financial implications of reimbursement rule changes on our tenants and operators, but we cannot make any assurances that current rules or future updates will not materially adversely affect our tenants and operators, which, in turn, could have a material adverse effect on their ability to pay rent and other obligations to us. See Item 1A. “Risk Factors — Risks Related to the Healthcare Industry — Reductions or changes in reimbursement from third-party payors, including Medicare and Medicaid, or delays in receiving these reimbursements could adversely affect the profitability of our tenants and operators and hinder their ability to make rent payments to us” and “A reduction in Medicare payment rates for skilled nursing facilities may have an adverse effect on the Medicare reimbursements received by one of our tenants.”
Other Regulations
Our investments are subject to various federal, state and local laws, ordinances and regulations, including, among other things, the Americans with Disabilities Act of 1990, zoning regulations, land use controls, environmental controls relating to air and water quality, noise pollution and indirect environmental impacts such as increased motor vehicle activity. We did not make any material capital expenditures in connection with these regulations during the year ended December 31, 2022 and we do not expect that we will be required to make any such material capital expenditures during 2023. We believe that we have all permits and approvals necessary under current law to operate our investments.
Environmental Regulations
As an owner of real property, we are subject to various federal, state and local laws and regulations regarding environmental, health and safety matters. These laws and regulations address, among other things, asbestos, polychlorinated biphenyls, fuel, oil management, wastewater discharges, air emissions, radioactive materials, medical wastes, and hazardous wastes, and in certain cases, the costs of complying with these laws and regulations and the penalties for non-compliance can be substantial. Even with respect to properties that we do not operate or manage, we may be held primarily or jointly and severally liable for costs relating to the investigation and clean-up of any property from which there is or has been an actual or threatened release of a regulated material and any other affected properties, regardless of whether we knew of or caused the release. Such costs typically are not limited by law or regulation and could exceed the property’s value. In addition, we may be liable for certain other costs, such as governmental fines and injuries to persons, property or natural resources, as a result of any such actual or threatened release.
Under the terms of our lease and management agreements, we generally have a right to indemnification by the tenants, operators and managers of our properties for any contamination caused by them. However, we cannot make any assurances that our tenants, operators and managers will have the financial capability or willingness to satisfy their respective indemnification obligations to us, and any such inability or unwillingness to do so may require us to satisfy the underlying environmental claims.
We did not make any material capital expenditures in connection with environmental, health, and safety laws, ordinances and regulations during the year ended December 31, 2022 and do not expect that we will be required to make any such material capital expenditures during 2023.
13

Human Capital Resources
We are an externally managed company and thus have no employees. We have retained the Advisor pursuant to a long-term advisory contract to manage our affairs on a day-to-day basis. We have also entered into agreements with our Property Manager to manage and lease our properties. The employees of the Advisor, Property Manager, and their respective affiliates perform a full range of services for us, including acquisitions, property management, accounting, legal, asset management, investor relations and all general administrative services. We depend on the Advisor and the Property Manager for services that are essential to us. If the Advisor and the Property Manager were unable to provide these services to us, we would be required to provide these services ourselves or obtain them from other sources.
Estimate of Net Asset Value
On April 1, 2022, we published an estimate of per share asset value (“Estimated Per-Share NAV”) equal to $15.00 as of December 31, 2021. Our previous Estimated Per-Share NAV was equal to $14.50 as of December 31, 2020. The Estimated Per-Share NAV has not been adjusted since publication and will not be adjusted until the Board determines a new Estimated Per-Share NAV which is expected in early April 2023. Dividends paid in the form of additional shares of common stock will, all things equal, cause the value of each share of common stock to decline because the number of shares outstanding increase when dividends paid in stock are issued. We intend to publish Estimated Per-Share NAV periodically at the discretion of our board of directors (the “Board”), provided that such estimates will be made at least once annually.
Available Information
We electronically file annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and all amendments to those filings with the Securities and Exchange Commission (“SEC”). One may read and copy any materials we file with the SEC at the SEC’s Internet address located at https://www.sec.gov. The website contains reports, proxy statements and information statements, and other information, which one may obtain free of charge. In addition, copies of our filings with the SEC may be obtained from our website www.healthcaretrustinc.com. Access to these filings is free of charge. We are not incorporating our website or any information from these websites into this Annual Report on Form 10-K.
Item 1A. Risk Factors
Set forth below are the risk factors that we believe are material to our investors and a summary thereof. The occurrence of any of the risks discussed in this Annual Report on Form 10-K could have a material adverse effect on our business, financial condition, results of operations and ability to pay dividends and they may also impact other distributions and the value of an investment in our common and preferred stock.
Summary Risk Factors
Our operating results are affected by economic and regulatory changes that have an adverse impact on the real estate market in general.
Our property portfolio has a high concentration of properties located in Florida. Our properties may be adversely affected by economic cycles and risks inherent to those states.
Our Credit Facility restricts us from paying cash distributions on or repurchasing our common stock until we satisfy certain conditions and there can be no assurance we will be able to resume paying distributions on our common stock, and at what rate, or continue paying dividends on our 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (the “Series A Preferred Stock”) and our 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, par value $0.01 par value per share (the “Series B Preferred Stock”).
Our Credit Facility restricts our ability to use cash that would otherwise be available to us, and there can be no assurance our available liquidity will be sufficient to meet our capital needs.
We are subject to risks associated with a pandemic, epidemic or outbreak of a contagious disease, such as the ongoing global COVID-19 pandemic, including negative impacts on our tenants and operators and their respective businesses.
Inflation and continuing increases in the inflation rate will have an adverse effect on our investments and results of operations.
No public market currently exists, or may ever exist, for shares of our common stock and our shares are, and may continue to be, illiquid.
In owning properties we may experience, among other things, unforeseen costs associated with complying with laws and regulations and other costs, potential difficulties selling properties and potential damages or losses resulting from climate change.
We focus on acquiring and owning a diversified portfolio of healthcare-related assets located in the United States and are subject to risks inherent in concentrating investments in the healthcare industry.
14

The healthcare industry is heavily regulated, and we, our tenants, and operators may be impacted by new or existing laws or regulations, or changes to these laws or regulations, such as the CARES Act and the auditing and reporting requirements instituted by the CARES Act.
Loss of licensure or failure to obtain licensure could result in the inability of tenants to make lease payments to us.
We depend on tenants for our rental revenue and, accordingly, our rental revenue depends upon the success and economic viability of our tenants. Lease terminations, tenant default and bankruptcy have adversely affected and could in the future adversely affect our income and cash flow.
We assume additional operating risks and are subject to additional regulation and liability because we depend on eligible independent contractors to manage some of our facilities.
We have substantial indebtedness and may be unable to repay, refinance, restructure or extend our indebtedness as it becomes due. Increases in interest rates could increase the amount of our debt payments. We will likely incur additional indebtedness in the future.
We depend on our Advisor and our Property Manager to provide us with executive officers, key personnel and all services required for us to conduct our operations and our operating performance may be impacted by an adverse changes in the financial health or reputation of our Advisor and our Property Manager.
All of our executive officers face conflicts of interest, such as conflicts created by the terms of our agreements with the Advisor and compensation payable thereunder, conflicts allocating investment opportunities to us, and conflicts in allocating their time and attention to our matters. Conflicts that arise may not be resolved in our favor and could result in actions that are adverse to us.
We have long-term agreements with our Advisor and its affiliates that may be terminated only in limited circumstances and may require us to pay a termination fee in some cases.
Estimated Per-Share NAV may not accurately reflect the value of our assets and may not represent what a stockholder may receive on a sale of the shares, what they may receive upon a liquidation of our assets and distribution of the net proceeds or what a third party may pay to acquire us.
The stockholder rights plan adopted by our board of directors, our classified board and other aspects of our corporate structure and Maryland law may discourage a third party from acquiring us in a manner that might result in a premium price to our stockholders.
Restrictions on share ownership contained in our charter may inhibit market activity in shares of our stock and restrict our business combination opportunities.
We may fail to continue to qualify as a REIT.

Risks Related to Our Properties and Operations

Our property portfolio has a high concentration of properties located in one state. Our properties may be adversely affected by economic cycles and risks inherent to those states.

A total of 10% or more of our consolidated annualized rental income on a straight-line basis for the fiscal year ended December 31, 2022 was generated from the state below:
State
Percentage of Straight-Line Rental Income
Florida
19.2%

Any adverse situation that disproportionately affects operations or investments in the states listed above may have a magnified adverse effect on our portfolio. Real estate markets are subject to economic downturns, as they have been in the past, and we cannot predict how economic conditions will impact this market in both the short and long-term. Declines in the economy or a decline in the real estate market in these states could hurt our financial performance and the value of our properties. Factors that may negatively affect economic conditions include:
business layoffs or downsizing;
industry slowdowns;
relocations of businesses;
climate change;
changing demographics;
15

increased telecommuting and use of alternative workplaces;
infrastructure quality;
any oversupply of, or reduced demand for, real estate;
concessions or reduced rental rates under new leases for properties where tenants defaulted;
increased insurance premiums;
state budgets and payment to providers under Medicaid or other state healthcare programs; and
changes in reimbursement for healthcare services from commercial insurers.
We may be unable to enter into contracts for and complete property acquisitions on advantageous terms or our property acquisitions may not perform as we expect.
One of our goals is to increase assets through acquiring additional properties, and pursuing this investment objective exposes us to numerous risks, including:
competition from other real estate investors with significant capital resources;
we may acquire properties that are not accretive;
we may not successfully integrate, manage and lease the properties we acquire in a fashion that meets our expectations or market conditions may result in future vacancies and lower-than expected rental rates;
we expect to finance future acquisitions primarily with additional borrowings under our Revolving Credit Facility, and there can be no assurance as to how much borrowing capacity will be available for this purpose
we may be unable to assume existing debt financing or obtain property-level debt financing or raise equity required to fund acquisitions from other sources on favorable terms, or at all;
we may need to spend more than budgeted amounts to make necessary improvements or renovations to acquired properties;
agreements for the acquisition of properties are typically subject to customary conditions to closing that may or may not be completed, and we may spend significant time and money on potential acquisitions that we do not consummate;
the process of acquiring or pursuing the acquisition of a new property may divert the attention of our management team from our existing business operations; and
we may acquire properties without recourse, or with only limited recourse, for liabilities, whether known or unknown.
We rely upon our Advisor and the real estate professionals employed by affiliates of our Advisor to identify suitable investments. There can be no assurance that our Advisor will be successful in doing so on financially attractive terms or that our objectives will be achieved. If our Advisor is unable to timely locate suitable investments, we may be unable to meet our investment objectives.
We have not paid our distributions on our common stock in cash since 2020, and there can be no assurance we will pay distributions on our common stock in cash in the future.
All dividends or other distributions on our common stock are paid in the discretion of our board of directors. We have not paid cash distributions since 2020. We have recently been issuing dividends in the form of common stock valued at the Estimated Per-Share NAV in effect on the applicable date. There is no assurance we will continue to do so or when or if we will pay dividends or distributions in cash. We last published an Estimated Per-Share NAV on April 1, 2022. The estimate was as of December 31, 2021 and has not been adjusted since publication and will not be adjusted until the Board determines a new Estimated Per-Share NAV which is expected in early April 2023. Dividends issued in the form of additional shares of common stock will, all things equal, cause the value of each share of common stock to decline because the number of shares outstanding will increase when stock dividends are issued; however, because each common stockholder will receive the same number of new shares, the total value of a common stockholder’s investment, all things equal, will not change assuming no sales or other transfers. As described herein, we will not be able to pay cash distributions on our common stock until we satisfy certain conditions set forth in our Revolving Credit Facility. Our ability to make future cash distributions on our common stock will depend on our future cash flows and indebtedness and may further depend on our ability to obtain additional liquidity, which may not be available on favorable terms, or at all. Further, if we do not pay dividends on our Series A Preferred Stock or Series B Preferred Stock, any accrued and unpaid dividends payable with respect to the Series A Preferred Stock or Series B Preferred Stock become part of the liquidation preference thereof, as applicable, and, whenever dividends on the Series A Preferred Stock or Series B Preferred Stock are in arrears, whether or not authorized or declared, for six or more quarterly periods, holders of Series A Preferred Stock or Series B Preferred Stock will have the right to elect two additional directors to serve on our board.
We are subject to risks associated with a pandemic, epidemic or outbreak of a contagious disease, such as the COVID-19 pandemic.
The COVID-19 pandemic has had, and another pandemic in the future could have, repercussions across many sectors and areas of the global economy and financial markets, leading to significant adverse impacts on economic activity including volatility in financial markets.
The impact of the COVID-19 pandemic evolved rapidly. In many states and cities where our properties are located, measures including “shelter-in-place” or “stay-at-home” orders were issued by local, state and federal authorities for much of 2020 and early part of 2021 and social distancing measures that resulted in closure and limitations on the operations of many
16

businesses and organizations. Although most of these measures have been lifted, they may be reinstated in the future in response to COVID-19 or other pandemics, endemics or health emergencies. Our tenants and SHOP properties operate businesses that require in-person interactions with their patients and residents. COVID-19 has impacted, and will likely continue to impact, the willingness of persons to, among other things, live in or use facilities at our properties, and impact the revenues generated by our tenants which may further impact the ability of our tenants to pay their rent obligations to us when due.
Our ability to lease space and negotiate and maintain favorable rents and the results of operations at our SHOPs could also continue to be negatively impacted by a prolonged recession in the U.S. Additionally, downturns or stagnation the U.S. housing market as a result of an economic downturn could adversely affect the ability, or perceived ability, of seniors to afford the resident fees and services at our seniors housing properties. Moreover, the demand for leasing space at our MOB properties could decline further negatively impacting occupancy percentage, revenue and net income.
MOB Segment
Within our MOB portfolio, the transmission of COVID-19 has impacted, and could continue to impact, the willingness of persons to seek medical care for non-urgent issues. Further, the COVID-19 pandemic adversely impacted, and may continue to impact, the business of our MOB tenants by causing a decline in the number of patients seeking treatment, by disrupting or delaying production and delivery of medical supplies such as necessary pharmaceuticals (including due to a diversion of resources and priorities toward the treatment of COVID-19) or by causing staffing shortages, which disrupted property operations. The complete or partial closures of, or other operational issues at, one or more of our properties resulting from the impacts of COVID-19, and may continue to increase the risk of rent deferrals or non-payment of contractual obligations by our tenants or operators.
As a result of these and other factors, tenants or operators that experience deteriorating financial conditions as a result of the outbreak of COVID-19 have been, or may, in the future be, unwilling or unable to pay us in full or on a timely basis due to bankruptcy, lack of liquidity, lack of funding, operational failures, or for other reasons. We reported cash collections of nearly 100% for the MOB facilities segment for the year ended December 31, 2022 as of February 28, 2023. However, the impact of the COVID-19 pandemic on our tenants and operators and thus our ability to collect rents in future periods cannot be determined as present and the amount of cash rent collected during the past two years may not be indicative of any future period.
SHOP Segment
Starting in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect us in a number of ways. In our SHOP portfolio, occupancy has decreased compared to that in March 2020. During the pandemic, governmental policies and implementation of infection control best practices materially limited or closed communities to new resident move-ins which affected our ability to fill vacancies. We have also experienced lower inquiry volumes and reduced in-person tours during the pandemic. In addition, starting in mid-March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as our tenants and operators took appropriate actions to protect residents and caregivers. At the SHOP facilities, we generally bear these cost increases. See below for additional information on the CARES Act. These trends accelerated beginning in the second quarter of 2020, continued into early 2021, until stabilizing in the third quarter. Future developments in the course of the pandemic may have adverse impacts on our occupancy and cost levels, and these trends may continue to impact us in the future and have a material adverse effect on our revenues and results of operations.
COVID-19 and its variants have been particularly harmful to seniors and persons with other pre-existing health conditions. There have been incidences of infection among the residents and staff at our SHOPs. Further incidences, or the perception that outbreaks may occur, could materially and adversely affect our revenues and net income, as well as cause significant reputational harm to us and our tenants, managers and operators. Due to the contagious nature of COVID-19, residents at our SHOPSs may decide to leave the community and the workforce at these facilities may similarly shrink. The tenants and operators may be required, or may otherwise determine that it would be prudent, to impose a quarantine of an indeterminate duration. We have and may also be required to incur additional costs to identify, contain and remedy the direct or indirect impacts of the COVID-19 pandemic, including costs related to implementing quarantines and vaccinations. Moreover, if seniors housing properties across the U.S. experience high levels of residents infected with COVID-19, including its variants, and related deaths, potential residents may delay or forego moving into seniors housing properties. As a result, our operating results from our SHOPs, and the value of these properties, may be materially adversely affected.
The long-term impact on our tenants and operators in our SHOP segment cannot be determined at present. We may continue to experience defaults and additional requests for rent deferrals or abatements or other allowances particularly if our tenants continue to experience financial distress and increased operating costs or if healthcare facilities and SHOPs continue to experience downward pressures on occupancy and increased costs. Furthermore, if we declare any tenants in default for non-payment of rent or other potential breaches of their leases with us, we might not be able to recover and may experience delays and additional costs in enforcing our rights as landlord to recover amounts due to us. Our ability to recover amounts under the terms of our leases may also be restricted or delayed as a result of any federal, state or local restrictions on tenant evictions for
17

failure to make contractual rent payments, which may result in higher reserves for bad debt. If any of our tenants, any guarantor of a tenant’s lease obligations or an operator, files for bankruptcy, we could be further adversely affected due to loss of revenue and a decline in income produced by the property or properties.
Other Impacts
In addition to the impacts on us, our tenants and operators described above, the COVID-19 pandemic has also impacted us in other ways and enhanced certain risks that could have a significant adverse effect on our business, financial condition and results of operations and our ability to pay distributions (including dividends on our Series A Preferred Stock and Series B Preferred Stock) and other distributions to our stockholders including:
difficulty accessing debt and equity capital on favorable terms, or at all, if global financial markets become disrupted or unstable or credit conditions deteriorate;
disruption and instability in financial markets or deteriorations in credit and financing conditions could have an impact on the overall amount of capital being invested in real estate and could result in price or value decreases for real estate assets, which could negatively impact the value of our assets and may result in future acquisitions generating lower overall economic returns;
the volatility in stock markets caused by, among other things, the COVID-19 pandemic or the ongoing war in Ukraine could negatively impact the trading price of our Series A Preferred Stock, our Series B Preferred Stock and the value of our common stock and dilute our stockholders’ interest in us if we sell additional equity securities at prices less than the prices our stockholders paid for their shares;
limiting the number of properties we may seek to acquire due to capital availability;
that planned dispositions may not occur within the expected timeframe or at all because of buyer terminations or withdrawals related to the pandemic, capital constraints or other factors relating to the pandemic, including closing conditions that are dependent on the occurrence of events linked to the pandemic;
until we satisfy certain conditions, our Credit Facility restricts us from paying cash distributions on, or repurchasing, shares of our common stock, and we must use all of the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to prepay amounts outstanding under the revolving portion of the Credit Facility;
our ability to maintain sufficient availability under our Credit Facility to fund the purchase of properties and meet other capital requirements which may be adversely affected to the extent the decreases in cash rent collected from our tenants and income from our operators cause a decrease in availability of future borrowings under our Credit Facility;
if we are unable to comply with financial covenants and other obligations under our Credit Facility and other debt agreements we could default under those agreements which could potentially result in an acceleration of our indebtedness and foreclosure on our properties and could otherwise negatively impact our liquidity;
we have recognized, and may need to recognize further, impairment charges on our assets;
one or more counterparties to our derivative financial instruments could default on their obligations to us increasing the risk that we may not realize the benefits of utilizing these instruments;
we may be required to record reserves on previously accrued amounts in cases where it is subsequently concluded that collection is not probable;
tenants and operators may be subject to lawsuits related to COVID-19 outbreaks that may occur at our properties and insurance coverage may not be sufficient to cover any potential losses further straining their financial condition;
difficulty in repositioning properties where we or our tenants or operators have terminated or do not renew the leases or management agreements with another tenant or operator may be exacerbated by the COVID-19 pandemic, as new tenants or operators may not be willing to take on the increased exposure, especially while active cases are occurring;
difficulties completing capital improvements at our properties on a timely basis, on budget or at all, could affect the value of our properties;
our ability to ensure business continuity in the event our Advisor’s continuity of operations plan is not effective or is improperly implemented or deployed during a disruption;
increased operating risks resulting from changes to our Advisor’s operations and remote work arrangements, including the potential effects on our financial reporting systems and internal controls and procedures, cybersecurity risks and increased vulnerability to security breaches, information technology disruptions and other similar events;
increased operating risks resulting from changes to operations of our operators, including their personnel, which may adversely impact the service provided by our operators with respect to our SHOPs; and
18

complying with REIT requirements during a period of reduced cash flow could cause us to liquidate otherwise attractive investments or borrow funds on unfavorable conditions.
The extent to which the COVID-19 pandemic, or a future pandemic, impacts our operations and those of our tenants and operators will depend on future developments, including the scope, severity and duration of the pandemic, one or more resurgences of the virus, or its variants, which could result in further government restrictions, the efficacy of available vaccines and boosters or other remedies developed, the efficacy of on-going efforts to distribute and administer available vaccines and boosters, the actions taken to contain the pandemic or mitigate its impact, including vaccine mandates and the direct and indirect economic effects of the pandemic and containment measures, among others, which are highly uncertain and cannot be predicted with confidence but could be material. The situation is rapidly changing and additional impacts to the business may arise that we are not aware of currently. The rapid development and fluidity of this situation precludes any prediction as to the full adverse impact of the COVID-19 pandemic, but a prolonged or resurgent outbreak as well as related mitigation efforts could continue to have a material adverse effect. Moreover, many risk factors set forth in this Annual Report on Form 10-K should be interpreted as heightened risks as a result of the COVID-19 pandemic.
There is uncertainty surrounding the administration and effect of the CARES Act and the auditing and reporting requirements instituted by the CARES Act.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law, which provided funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. We received $4.5 million, $5.1 million and $3.6 million in these funds during the years ended December 31, 2022, 2021, and 2020, respectively. We do not anticipate that any further funds under the CARES Act will be received and, there can be no assurance that any further amounts will be received under potential future government programs related to COVID-19. We consider the funds to be a grant contribution from the government and the full amount was recognized as a reduction of property operating expenses in our consolidated statements of operations for the years ended December 31, 2022, 2021 and 2020.
As a condition of the funds received under the CARES Act, we had to attest to certain terms and conditions, and must comply with detailed reporting and auditing requirements. While we do not anticipate any finding of non-compliance, such a finding could result in consequences including repayment of funds received.
If a tenant or lease guarantor declares bankruptcy or becomes insolvent, we may be unable to collect balances due under relevant leases.
We have previously had tenants file for bankruptcy and seek the protections afforded under Title 11 of the United States Code. There is no assurance we will not experience this in the future. A bankruptcy filing by one of our tenants or any guarantor of a tenant’s lease obligations would result in a stay of all efforts by us to collect pre-bankruptcy debts from these entities or their assets, unless we receive an enabling order from the bankruptcy court. Post-bankruptcy debts would be required to be paid currently. If a lease is assumed by the tenant, all pre-bankruptcy balances owing under it must be paid in full. If a lease is rejected by a tenant in bankruptcy, we would only have a general unsecured claim for damages. If a lease is rejected, it is unlikely we would receive any payments from the tenant because our claim is capped at the rent reserved under the lease, without acceleration, for the greater of one year or 15% of the remaining term of the lease, but not greater than three years, plus rent already due but unpaid as of the date of the bankruptcy filing (post-bankruptcy rent would be payable in full). This claim could be paid only if funds were available, and then only in the same percentage as that realized on other unsecured claims.
A tenant or lease guarantor bankruptcy could delay efforts to collect past due balances under the relevant leases, and could ultimately preclude full collection of these sums. A tenant or lease guarantor bankruptcy could cause a decrease or cessation of rental payments that would mean a reduction in our cash flow and the amount available for dividends and other distributions to our stockholders. In the event of a bankruptcy, there is no assurance that the debtor in possession or the bankruptcy trustee will assume the lease.
A sale-leaseback transaction may be recharacterized in a tenant’s bankruptcy proceeding.
We may enter into sale-leaseback transactions, where we purchase a property and then lease the same property back to the seller, who becomes our tenant as part of the transaction. In the event of the bankruptcy of a tenant, a transaction structured as a sale-leaseback may be recharacterized as either a financing or a joint venture, and either type of recharacterization could adversely affect our business. If the sale-leaseback were recharacterized as a financing, we might not be considered the owner of the property, and as a result would have the status of a creditor. In that event, we would no longer have the right to sell or encumber our ownership interest in the property. Instead, we would have a claim against the tenant for the amounts owed under the lease. The tenant/debtor might have the ability to propose a plan restructuring the term, interest rate and amortization schedule of its outstanding balance. If this plan were confirmed by the bankruptcy court, we would be bound by the new terms. If the sale-leaseback were recharacterized as a joint venture, our lessee and we could be treated as co-venturers with regard to
19

the property. As a result, we could be held liable, under some circumstances, for debts incurred by the lessee relating to the property. Either of these outcomes could adversely affect our cash flow.
Our results of operations have been, and may continue to be, adversely impacted by our inability to collect rent from tenants.
On occasion, tenants at certain properties in our MOB segment and residents at certain properties in our SHOP segment have been in default under their leases to us. These defaults negatively impact our results of operations. We incurred $3.2 million, $1.1 million and $2.7 million of bad debt expense, including straight-line rent write-offs, related to tenants in default under their leases to us during the years ended December 31, 2022, 2021 and 2020, respectively.
Further, even if we replace tenants in default to us in a manner that will allow us to transition the properties leased to those tenants to our SHOP segment, there can be no assurance this strategy will be successful and we may be more exposed to changes in property operating expenses. There also can be no assurance that we will be able to replace these tenants on a timely basis, or at all, and our results of operations may therefore continue to be adversely impacted by bad debt expenses related to our inability to collect rent from defaulting tenants. Transitions will also increase our exposure to risks associated with operating in this structure.
Our tenants or operators that experience deteriorating financial conditions have been, or may, in the future be, unwilling or unable to pay us in full or on a timely basis due to bankruptcy, lack of liquidity, lack of funding, operational failures, or for other reasons. There is no assurance we will continue to collect at the current rates. Our ability to collect rents in future periods may be impacted by issues or events that cannot be determined as present and the amount of cash rent collected during 2022 may not be indicative of any future period.
Our operating results are affected by economic and regulatory changes that have an adverse impact on the real estate market.
Our operating results and the value of our properties are subject to risks, including:
changes in national and market-specific economic conditions;
changes in supply of or demand for competing properties in our market area;
changes in interest rates and availability of financing on favorable terms;
changes in tax, real estate, environmental and zoning laws;
periods of high interest rates and tight money supply; and
the possibility that one or more of our tenants will not pay their rental obligations.
Properties may have vacancies for a significant period of time.
A property may have vacancies either due to tenant defaults or the expiration of leases. If vacancies continue for a long period of time, our revenues and net income will be adversely impacted. In addition, the value of a property depends principally on the cash flow generated by the properties. Prolonged vacancies reduce our cash flow.
We obtain only limited warranties when we purchase a property and therefore have only limited recourse if our due diligence did not identify any issues that lower the value of our property.
We have acquired and may continue to acquire properties in “as is” condition on a “where is” basis and “with all faults,” without any warranties of merchantability or fitness for a particular use or purpose. In addition, purchase agreements we entered into may contain only limited warranties, representations and indemnifications that will only survive for a limited period after the closing. The purchase of properties with limited warranties increases the risk that we may lose some or all our invested capital in the property as well as the loss of rental income from that property if a situation or loss occurs after the fact for which we have limited or no remedy.
Our properties and tenants may be unable to compete successfully.
The properties we have acquired and will acquire may face competition from nearby hospitals, senior housing properties and other medical office buildings and medical facilities that provide comparable services. Some of those competing facilities are owned by governmental agencies and supported by tax revenues, and others are owned by nonprofit corporations and may be supported to a large extent by endowments and charitable contributions. These types of support are not available to our properties. Similarly, our tenants face competition from other medical practices in nearby hospitals and other medical facilities. Additionally, the introduction and explosion of new stakeholders competing with traditional providers in the healthcare market, including companies such as telemedicine, telehealth and mhealth, are disrupting the healthcare industry. Our tenants’ failure to compete successfully with these other practices and providers could adversely affect their ability to make rental payments, which could adversely affect our rental revenues.
Further, from time to time and for reasons beyond our control, referral sources, including physicians and managed care organizations, may change their lists of hospitals or physicians to which they refer patients. This could adversely affect the ability of our tenants to make rental payments.
We may be unable to secure funds for future tenant improvements or capital needs.
20

If a tenant does not renew its lease or otherwise vacates its space, we will likely be required to expend substantial funds to improve and refurbish the vacated space. In addition, we are typically responsible for any major structural repairs, such as repairs to the foundation, exterior walls and rooftops, even if our leases with tenants may require tenants to pay routine property maintenance costs. If we need additional capital in the future to improve or maintain our properties or for any other reason, we may have to obtain financing from sources beyond our cash flow from operations, such as borrowings, property sales or future equity offerings to fund these capital requirements. These sources of funding may not be available on attractive terms or at all. Failure to procure additional funding for additional funding improvements would impact the value of the applicable property or our ability to lease the applicable property on favorable terms, if at all.
We have acquired or financed, and may continue to acquire or finance, properties with lock-out provisions which may prohibit us from selling a property, or may require us to maintain specified debt levels for a period of years on some properties.
Lock-out provisions, such as the provisions contained in certain mortgage loans we have entered into, could materially restrict our ability to sell or otherwise dispose of properties or refinance properties, including by requiring a yield maintenance premium to be paid in connection with the required prepayment of principal upon a sale or disposition. Lock-out provisions may also prohibit us from reducing the outstanding indebtedness with respect to any properties, refinancing such indebtedness on a non-recourse basis at maturity, or increasing the amount of indebtedness with respect to such properties. Lock-out provisions could also impair our ability to take other actions during the lock-out period that may otherwise be in the best interests of our stockholders. In particular, lock-out provisions could preclude us from participating in major transactions that could result in a disposition of our assets or a change in control. Payment of yield maintenance premiums in connection with dispositions or refinancings could adversely affect our cash flow.
Rising expenses could reduce cash flow.
The properties that we own or may acquire are subject to operating risks, any or all of which may negatively affect us. If any property is not fully occupied or if rents are being paid in an amount that is insufficient to cover operating expenses, we could be required to expend funds with respect to that property for operating expenses. Properties may be subject to increases in tax rates, utility costs, operating expenses, insurance costs, repairs and maintenance and administrative expenses. We may not be able to negotiate leases on a triple-net basis or on a basis requiring the tenants to pay all or some of such expenses, in which event we may have to pay those costs. If we are unable to lease properties on a triple-net basis or on a basis requiring the tenants to pay all or some of such expenses, or if tenants fail to pay required tax, utility and other impositions, we could be required to pay those costs.
Inflation and continuing increases in the inflation rate may have an adverse effect on our investments and results of operations.
Recent increases and continuing increases in the rate of inflation, both real and anticipated, may impact our investments and results of operations. Inflation could erode the value of long-term leases that do not contain indexed escalation provisions, or contain fixed annual rent escalation provisions that are at rates lower than the rate of inflation, and increase expenses including those that cannot be passed through under our leases. Increased inflation could also increase our general and administrative expenses and, as a result of an increase in market interest rate in response to higher than anticipated inflation rate, increase our mortgage and debt interest costs, and these costs could increase at a rate higher than our rent increases. An increase in our expenses, or expenses paid or incurred by our Advisor or its affiliates that are reimbursed by us pursuant to the advisory agreement, or a failure of revenues to increase at least with inflation could adversely impact our results of operations.
For the year ended December 31, 2022, the increase to the 12-month Consumer Price Index for all items, as published by the Bureau of Labor Statistics, was 6.5%. To help mitigate the adverse impact of inflation, approximately 90% of our leases with tenants in our MOB segment contain rent escalation provisions in their base rent which average 2.3% per year. These provisions generally increase rental rates during the terms of the leases either at fixed rates or indexed escalations (based on the Consumer Price Index or other measures). Leases with fixed or no escalation provisions may not keep pace with current rates of inflation, whereas leases with indexed escalations may provide more protection against inflation. Approximately 86% are fixed-rate, 4.1% are based on the Consumer Price Index and 10% do not contain any escalation provisions.
In addition to base rent, our net leases require the single-tenant MOB leases to pay all the properties operating expenses and our multi-tenant MOB leases to pay their allocable share of operating expenses, which may include common area maintenance costs, real estate taxes and insurance. Increased operating costs paid by our tenants under these net leases could have an adverse impact on our tenants if increases in their operating expenses exceed increases in their revenue, which may adversely affect our tenants’ ability to pay rent owed to us or property expenses to be paid, or reimbursed to us, by our tenants. Renewals of leases or future leases for our net lease properties may not be negotiated on a triple-net basis or on a basis requiring the tenants to pay all or some of such expenses, in which event we may have to pay those costs. If we are unable to lease properties on a triple-net basis or on a basis requiring the tenants to pay all or some of such expenses, or if tenants fail to pay required tax, utility and other impositions, we could be required to pay those costs.
21

Leases with residents at our SHOPs typically do not have rent escalations, however, we are able to renew leases at market rates as they mature due to their short-term nature. As inflation rates increase or persist at high levels, the cost of providing medical care at our SHOPs, particularly labor costs, will increase. If we are unable to admit new residents or renew resident leases at market rates, while bearing these increased costs from providing services to our residents, our results of operations may be affected.
Damage from catastrophic weather and other natural events and climate change could result in losses to us.
Certain of our properties are located in areas that may experience catastrophic weather and other natural events from time to time, including hurricanes or other severe weather, flooding, fires, snow or ice storms, windstorms or, earthquakes. These adverse weather and natural events could cause substantial damages or losses to our properties which could exceed our insurance coverage. In the event of a loss in excess of insured limits, we could lose our capital invested in the affected property, as well as anticipated future revenue from that property. We could also continue to be obligated to repay any mortgage indebtedness or other obligations related to the property.
To the extent that significant changes in the climate occur, we may experience extreme weather and changes in precipitation and temperature and rising sea levels, all of which may result in physical damage to or a decrease in demand for properties located in these areas or affected by these conditions. The impact of climate change may be material in nature, including destruction of our properties, or occur for lengthy periods of time.
Growing public concern about climate change has resulted in the increased focus of local, state, regional, national and international regulatory bodies on greenhouse gas (“GHG”) emissions and climate change issues. Legislation to regulate GHG emissions has periodically been introduced in the U.S. Congress, and there has been a wide-ranging policy debate, both in the U.S. and internationally, regarding the impact of these gases and possible means for their regulation. Federal, state or foreign legislation or regulation on climate change could result in increased capital expenditures to improve the energy efficiency of our existing properties or to protect them from the consequence of climate change and could also result in increased compliance costs or additional operating restrictions that could adversely impact the businesses of our tenants and their ability to pay rent.
We may suffer uninsured losses relating to real property or have to pay expensive premiums for insurance coverage.
Our general liability, property and umbrella liability insurance coverage on all our properties may not be adequate to insure against liability claims and provide for the costs of defense. Similarly, we may not have adequate coverage against the risk of direct physical damage or to reimburse us on a replacement cost basis for costs incurred to repair or rebuild each property. Moreover, there are types of losses, generally catastrophic in nature, such as losses due to wars, acts of terrorism, earthquakes, floods, hurricanes, pollution or environmental matters that are uninsurable or not economically insurable, or may be insured subject to limitations, such as large deductibles or co-payments. Insurance risks associated with such catastrophic events could sharply increase the premiums we pay for coverage against property and casualty claims.
This risk is particularly relevant with respect to potential acts of terrorism. The Terrorism Risk Insurance Act of 2002 (the “TRIA”), under which the U.S. federal government bears a significant portion of insured losses caused by terrorism, will expire on December 31, 2027, and there can be no assurance that Congress will act to renew or replace the TRIA following its expiration. In the event that the TRIA is not renewed or replaced, terrorism insurance may become difficult or impossible to obtain at reasonable costs or at all, which may result in adverse impacts and additional costs to us.
Changes in the cost or availability of insurance due to the non-renewal of the TRIA or for other reasons could expose us to uninsured casualty losses. If any of our properties incurs a casualty loss that is not fully insured, the value of our assets will be reduced by any uninsured loss. In addition, other than any working capital reserve or other reserves we may establish, we have no source of funding to repair or reconstruct any uninsured property. Also, to the extent we must pay unexpectedly large amounts for insurance, we could suffer reduced earnings that would result in less cash flow.
Additionally, mortgage lenders insist in some cases that commercial property owners purchase coverage against terrorism as a condition for providing mortgage loans. Accordingly, to the extent terrorism risk insurance policies are not available at reasonable costs, if at all, our ability to finance or refinance indebtedness secured by our properties could be impaired. In such instances, we may be required to provide other financial support, either through financial assurances or self-insurance, to cover potential losses. We may not have adequate, or any, coverage for the losses.
Actual or threatened terrorist attacks and other acts of violence, civilian unrest or war may affect the markets in which we operate our business and our profitability.
We own properties in densely populated areas that are susceptible to terrorist attack or damage. Because our properties are generally open to the public, they are exposed to a number of incidents that may take place within or around their premises and that are beyond our control or ability to prevent. Any actual or threatened act of terror, mass shooting or other violence could have a negative effect on our business, including us losing our tenants or being forced to close one or more of our properties for some time. If any of these incidents were to occur, the relevant property could face material damage to its image and the revenue generated therefrom. In addition, we may be exposed to civil liability and be required to indemnify the victims, and our insurance premiums could rise, any of which could adversely affect us.
22

In addition, actual or threatened terrorist activity or violent criminal acts, including terrorist acts against public institutions or buildings or modes of public transportation (including airlines, trains or buses) could have a negative effect on our business, the value of our properties and our results of operations. More generally, any terrorist attack, other act of violence or war, including armed conflicts, could result in increased volatility in, or damage to, the worldwide financial markets and economy, including demand for properties and availability of financing. Increased economic volatility could adversely affect our tenants’ abilities to conduct their operations profitably or our ability to borrow money or issue capital stock at acceptable prices.
Real estate-related taxes may increase and these increases may not be passed on to tenants.
From time to time our property taxes increase as property values or assessment rates change or for other reasons. An increase in the assessed valuation of a property for real estate tax purposes will result in an increase in the related real estate taxes on that property. There is no assurance that renewal leases or future leases will be negotiated on a basis that passes such taxes on to the tenant.
Covenants, conditions and restrictions may impact our ability to operate a property.
Some of our properties are contiguous to other parcels of real property, comprising part of the same commercial center. In connection with such properties, there are significant covenants, conditions and restrictions restricting the operation of such properties and any improvements on such properties, and related to granting easements on such properties. Moreover, the operation and management of the contiguous properties may impact such properties. Compliance with covenants, conditions and restrictions may adversely affect our operating costs and reduce the amount of cash flow that we generate.
Our operating results may be negatively affected by potential development and construction delays and resultant increased costs and risks.
We have acquired and developed, and may in the future acquire and develop, properties upon which we will construct improvements. In connection with our development activities, we are subject to uncertainties associated with re-zoning for development, environmental concerns of governmental entities or community groups and our builder or partner’s ability to build in conformity with plans, specifications, budgeted costs, and timetables. Performance also may be affected or delayed by conditions beyond our control. For example, we experienced substantial delays and incurred significant additional costs associated with development of a property located in Jupiter, Florida, a property we subsequently sold at a price below the amount we had invested. We would be exposed to the risks in connection with any other properties we develop. We may incur additional risks when we make periodic progress payments or other advances to builders before they complete construction. If a builder or development partner fails to perform, we may resort to legal action to rescind the purchase or the construction contract or to compel performance, but there can be no assurance any legal action would be successful. These and other factors can result in increased costs of a project or loss of our investment. In addition, we will be subject to normal lease-up risks relating to newly constructed projects. We also must rely on rental income and expense projections and estimates of the fair market value of property upon completion of construction when agreeing upon a price at the time we acquire the property. If our projections are inaccurate, we may pay too much for a property, and our return on our investment could suffer.
We compete with third parties in acquiring properties and other investments and attracting credit worthy tenants.
We compete with many other entities engaged in real estate investment activities, including individuals, corporations, private investment funds, bank and insurance company investment accounts, other REITs, real estate limited partnerships, and other entities engaged in real estate investment activities, many of which have greater resources than we do. These entities may enjoy significant competitive advantages that result from, among other things, a lower cost of capital and enhanced operating efficiencies. In addition, the number of entities and the amount of funds competing for suitable investments may increase. Increased demand for assets will likely increase acquisition prices.
We also compete with other comparable properties for tenants, which impacts our ability to rent space and the amount of rent charged. We could be adversely affected if additional competitive properties are built in locations near our properties, causing increased competition for creditworthy tenants. This could result in decreased cash flow from our properties and may require us to make capital improvements to properties that we would not have otherwise made, further impacting property cash flows.
Discovery of previously undetected environmentally hazardous conditions may adversely affect our operating results.
We are subject to various federal, state and local laws and regulations that (a) regulate certain activities and operations that may have environmental or health and safety effects, such as the management, generation, release or disposal of regulated materials, substances or wastes, (b) impose liability for the costs of cleaning up, and damages to natural resources from, past spills, waste disposals on and off-site, or other releases of hazardous materials or regulated substances, and (c) regulate workplace safety. Compliance with these laws and regulations could increase our operational costs. Violation of these laws may subject us to significant fines, penalties or disposal costs, which could negatively impact our results of operations, financial position and cash flows. Under various federal, state and local environmental laws (including those of foreign jurisdictions), a current or previous owner or operator of currently or formerly owned, leased or operated real property may be liable for the cost of removing or remediating hazardous or toxic substances on, under or in such property. The costs of removing or remediating could be substantial. These laws often impose liability whether or not the owner or operator knew of, or was responsible for, the
23

presence of such hazardous or toxic substances. Certain environmental laws and common law principles could be used to impose liability for release of, and exposure to, hazardous substances, including asbestos-containing materials into the air, and third parties may seek recovery from owners or operators of real properties for personal injury or property damage associated with exposure to released hazardous substances. In addition, when excessive moisture accumulates in buildings or on building materials, mold growth may occur, particularly if the moisture problem remains undiscovered or is not addressed over a period of time. Some molds may produce airborne toxins or irritants. Concern about indoor exposure to mold has been increasing, as exposure to mold may cause a variety of adverse health effects and symptoms, including allergic or other reactions. As a result, the presence of significant mold at any of our properties could require us to undertake a costly remediation program to contain or remove the mold from the affected property or development project. Accordingly, we may incur significant costs to defend against claims of liability, to comply with environmental regulatory requirements, to remediate any contaminated property, or to pay personal injury claims.
Moreover, environmental laws also may impose liens on property or other restrictions on the manner in which property may be used or businesses may be operated, and these restrictions may require substantial expenditures or prevent us or our Property Manager and its assignees from operating such properties. Compliance with new or more stringent laws or regulations or stricter interpretation of existing laws may require us to incur material expenditures. Future laws, ordinances or regulations or the discovery of currently unknown conditions or non-compliances may impose material liability under environmental laws.
If we sell properties by providing financing to purchasers, defaults by the purchasers would adversely affect our cash flows.
In some instances, we may sell our properties by providing financing to purchasers. If we do so, we will bear the risk that the purchaser may default on its debt, requiring us to seek remedies, a process which may be time-consuming and costly. Further, the borrower may have defenses that could limit or eliminate our remedies. In addition, even in the absence of a purchaser default, the proceeds from the sale will be delayed until the promissory notes or other property we may accept upon the sale are actually paid, sold, refinanced or otherwise disposed of. In some cases, we may receive initial down payments in cash and other property in the year of sale in an amount less than the selling price and subsequent payments will be spread over a number of years.
We assume additional operational risks and are subject to additional regulation and liability because we depend on eligible independent contractors to manage some of our facilities.
We invest in SHOPs using the RIDEA structure which permits REITs such as us to lease certain types of healthcare facilities that we own or partially own to a TRS, provided that our TRS hires an independent qualifying management company to operate the facility. Under this structure, the independent qualifying management company, which we also refer to as an operator, receives a management fee from our TRS for operating the facility as an independent contractor. As the owner of the facility, we assume most of the operational risk because we lease our facility to our own partially- or wholly-owned subsidiary rather than a third-party operator. We are therefore responsible for any operating deficits incurred by the facility. As of December 31, 2022, we had four eligible independent contractors operating 52 SHOPs (including two land parcels). We may in the future, transition other MOB facilities, which may or may not be experiencing declining performance, to third-party managed facilities using the RIDEA structure, in connection with which they would also transition from our MOB segment to our SHOP segment. There can be no assurance these transitions will improve performance of the properties, and they will also increase our exposure to risks associated with operating in this structure.
The income we generate from SHOPs is subject to a number of operational risks including fluctuations in occupancy levels and resident fee levels, increases in the cost of food, materials, energy, labor (as a result of unionization or otherwise) or other services, rent control regulations, national and regional economic conditions, the imposition of new or increased taxes, capital expenditure requirements, professional and general liability claims, and the availability and cost of professional and general liability insurance. As noted herein, we have experienced declines in occupancy at our SHOPs since the onset of the pandemic. There is no assurance we will be able to mitigate these declines. Further, we rely on the personnel, expertise, technical resources and information systems, proprietary information, good faith and judgment of our operators to set appropriate resident fees, provide accurate property-level financial results for our properties in a timely manner and to otherwise operate our SHOPs in compliance with the terms of our management agreements and all applicable laws and regulations. We also depend on our operators to attract and retain skilled management personnel who are responsible for the day-to-day operations of our SHOPs. A shortage of nurses or other trained personnel or general inflationary pressures have forced the operator to enhance pay and benefit packages to compete effectively for personnel, but it may not be able to offset these added costs by increasing the rates charged to residents. The impact on staffing has resulted in increased turnover amongst staff and greater reliance on staffing agencies, which could have the effect of increased insurance premiums. Any additional increase in labor costs and other property operating expenses, any failure to attract and retain qualified personnel, or significant changes in the operator’s senior management or equity ownership could adversely affect the income we receive from our SHOPs.
The tenants of our SHOPs are generally required to be holders of the applicable healthcare licenses for the healthcare services they administer. Any delay in obtaining the license, or failure to obtain one at all, could result in a delay or an inability to collect a significant portion of our revenue from the impacted property. Furthermore, this licensing requirement subjects us (through our ownership interest in our TRS) to various regulatory laws, including those described herein. Most states regulate
24

and inspect healthcare facility operations, patient care, construction and the safety of the physical environment. If one or more of our healthcare real estate facilities fails to comply with applicable laws, our TRS, if it holds the healthcare license and is the entity enrolled in government health care programs, would be subject to penalties including loss or suspension of license, certification or accreditation, exclusion from government healthcare programs such as Medicare or Medicaid, administrative sanctions, civil monetary penalties, and in certain instances, criminal penalties. Additionally, when we receive individually identifiable health information relating to residents of our TRS-operated healthcare facilities, we may be subject to federal and state data privacy and confidentiality laws and rules, and could be subject to liability in the event of an audit, complaint, or data breach. Furthermore, to the extent our TRS holds the healthcare license, it could have exposure to professional liability claims arising out of an alleged breach of the applicable standard of care rules.
Joint venture investments could be adversely affected by our lack of sole decision-making authority, our reliance on the financial condition of co-venturers and disputes between us and our co-venturers.
We have made investments in certain assets through joint ventures and may continue to enter into joint ventures, partnerships and other co-ownership arrangements (including preferred equity investments) in the future. In such event, we may not be in a position to exercise sole decision-making authority regarding the joint venture. Investments in joint ventures may, under certain circumstances, involve risks not present were a third-party not involved, including the possibility that partners or co-venturers might become bankrupt or fail to fund their required capital contributions. Co-venturers may have economic or other business interests or goals which are inconsistent with our business interests or goals, and may be in a position to take actions contrary to our policies or objectives. These investments may also have the potential risk of impasses on decisions, such as a sale, because neither we nor the co-venturer would have full control over the joint venture. Disputes between us and co-venturers may result in litigation or arbitration that would increase our expenses and prevent our officers or directors from focusing their time and effort on our business. Consequently, actions by or disputes with co-venturers might result in subjecting properties owned by the joint venture to additional risk. In addition, we may in certain circumstances be liable for the actions of our co-venturers.
We may incur costs associated with complying with the Americans with Disabilities Act.
Our properties must also comply with the Americans with Disabilities Act of 1990 (the “Disabilities Act”). Under the Disabilities Act, all places of public accommodation are required to comply with federal requirements related to access and use by disabled persons. The Disabilities Act has separate compliance requirements for “public accommodations” and “commercial facilities” that generally require that buildings and services, including restaurants and retail stores, be made accessible and available to people with disabilities. The Disabilities Act’s requirements could require removal of access barriers and could result in the imposition of injunctive relief, monetary penalties, or, in some cases, an award of damages. A determination that a property does not comply with the Disabilities Act could result in liability for both governmental fines and damages. If we are required to make unanticipated major modifications to any of our properties to comply with the Disabilities Act which are determined not to be the responsibility of our tenants, we could incur unanticipated expenses that could have an adverse impact upon our cash flow.
Net leases may not result in fair market lease rates over time.
Some of our rental income is generated by properties leased to tenants under net leases, which generally provide the tenant greater discretion in using the leased property than ordinary property leases, such as the right to freely sublease the property, to make alterations in the leased premises and to terminate the lease prior to its expiration under specified circumstances. Furthermore, net leases typically have longer lease terms and, thus, there is an increased risk that contractual rental increases in future years will fail to result in fair market rental rates during those years. Moreover, inflation could erode the value of long-term leases that do not contain indexed escalation provisions.
We may be unable to renew leases or re-lease space as leases expire.
We may be unable to renew expiring leases on terms and conditions that are as, or more, favorable as the terms and conditions of the expiring leases. In addition, vacancies may occur at one or more of our properties due to a default by a tenant on its lease or expiration of a lease. Healthcare facilities in general and MOBs in particular tend to be specifically suited for the particular needs of their tenants and major renovations and expenditures may be required in order for us to re-lease vacant space. Vacancies may reduce the value of a property as a result of reduced cash flow generated by the property.
Our properties have been and may continue to be subject to impairment charges.
We periodically evaluate our real estate investments for impairment indicators. The judgment regarding the existence of impairment indicators is based on factors such as market conditions, tenant performance and legal structure. For example, the early termination of, or default under, a lease by a major tenant may lead to an impairment charge. If we determine that an impairment has occurred, we are required to make a downward adjustment to the net carrying value of the property. Impairment charges also indicate a potential permanent adverse change in the fundamental operating characteristics of the impaired property. There is no assurance that these adverse changes will be reversed in the future and the decline in the impaired property’s value could be permanent. We have incurred impairment charges, which have an immediate direct impact on our net income for GAAP purposes, including $27.6 million, during the year ended December 31, 2022. There can be no assurance that
25

we will not take additional charges in the future. Any future impairment could have a material adverse effect on our results in the period in which the charge is taken.
Our real estate investments are relatively illiquid, and therefore we may not be able to dispose of properties when we desire to do so or on favorable terms.
Investments in real properties are relatively illiquid. We may not be able to quickly alter our portfolio or generate capital by selling properties. The real estate market is affected by many factors, such as general economic conditions, the availability of financing, interest rates and other factors, including supply and demand, that are beyond our control. If we need or desire to sell a property or properties, we cannot predict whether we will be able to do so at a price or on the terms and conditions acceptable to us. We cannot predict the length of time needed to find a willing purchaser and to close the sale of a property. Further, we may be required to invest monies to correct defects or to make improvements before a property can be sold. We can make no assurance that we will have funds available to correct these defects or to make these improvements. Moreover, in acquiring a property or incurring debt securing a property, we may agree to restrictions that prohibit the sale of that property for a period of time or impose other restrictions, such as a limitation on the amount of debt that can be placed or repaid on that property. These types of provisions restrict our ability to sell a property.
In addition, applicable provisions of the Code impose restrictions on the ability of a REIT to dispose of properties that are not applicable to other types of real estate companies. Thus, we may be unable to realize our investment objectives by selling or otherwise disposing of a property, or refinancing debt secured by the property, at attractive prices within any given period of time or may otherwise be unable to complete any exit strategy.
Geopolitical instability due to the ongoing military conflict between Russia and Ukraine may adversely impact the U.S. and global economies.
On February 24, 2022, Russian troops invaded Ukraine starting a military conflict, the length and breadth of which is highly unpredictable. Coupled with existing supply disruptions and changes in Federal Reserve policies on interest rates, this war has exacerbated, and may continue to exacerbate, inflation and significant volatility in commodity prices, credit and capital markets, as well as supply chain disruptions.
Additionally, the U.S., the European Union, and other countries, as well as other public and private actors and companies have imposed sanctions and other penalties on Russia including removing Russian-based financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system and restricting imports of Russian oil, liquefied natural gas and coal. These sanctions have caused supply disruptions in the oil and gas markets and could continue to cause significant increases in energy prices, which could have a material effect on inflation and may trigger a recession in the U.S., among other areas. These factors may result in the weakening of the financial condition of or the bankruptcy or insolvency of a significant tenant or a number of smaller tenants, which would adversely impact their ability to pay rents as they come due. As a result, our financial condition and results of operations may be negatively affected since our revenue is largely dependent on the success and economic viability of our tenants.
These and other sanctions that may be imposed as well as the ongoing conflict could further adversely affect the global economy and financial markets and cause further instability, negatively impacting liquidity in the capital markets and potentially making it more difficult for us to access additional debt or equity financing on attractive terms in the future.
In addition, the U.S. government has warned of the potential for Russian cyberattacks. The risk of Russian cyberattacks may also create market volatility and economic uncertainty particularly if these attacks occur and spread to a broad array of countries and networks.

Risks Related to the Healthcare Industry

Our real estate investments are concentrated in healthcare-related facilities, and we may be negatively impacted by adverse trends in the healthcare industry.
We own and seek to acquire a diversified portfolio of healthcare-related assets including MOBs, SHOPs and other healthcare-related facilities. We are subject to risks inherent in concentrating investments in real estate and, in particular, healthcare-related assets. A downturn in the commercial real estate industry generally could significantly adversely affect the value of our properties. A downturn in the healthcare industry could particularly negatively affect our lessees’ ability to make lease payments to us and our ability to pay dividends and other distributions to our stockholders. These adverse effects could be more pronounced than if we diversified our investments outside of real estate or if our portfolio did not include a concentration in healthcare-related assets.
Furthermore, the healthcare industry currently is experiencing rapid regulatory changes and uncertainty; changes in the demand for and methods of delivering healthcare services; changes in third-party reimbursement policies; significant unused capacity in certain areas, which has created substantial competition for patients among healthcare providers in those areas; expansion of insurance providers into patient care; continuing pressure by private and governmental payors to reduce payments
26

to providers of services; and increased scrutiny of billing, referral and other practices by federal and state authorities. These factors may adversely affect the economic performance of some or all of our tenants and, in turn, our revenues and cash flows.
Certain of our properties in our MOB Segment may not have efficient alternative uses, so the loss of a tenant may cause us to not be able to find a replacement or cause us to spend considerable capital to adapt the property to an alternative use.
Some of our properties and the properties we will seek to acquire are healthcare-related assets that may only be suitable for similar healthcare-related tenants. If we or our tenants terminate the leases for these properties or our tenants lose their regulatory authority to operate such properties, we may not be able to locate suitable replacement tenants to lease the properties for their specialized uses. Alternatively, we may be required to spend substantial amounts to adapt the properties to other uses.
The healthcare industry is heavily regulated, and new laws or regulations, changes to existing laws or regulations, loss of licensure or failure to obtain licensure could result in the inability of our tenants to make rent payments to us.
The healthcare industry is heavily regulated by federal, state and local governmental bodies. Our tenants and operators generally are subject to laws and regulations covering, among other things, licensure, certification for participation in government programs, relationships with physicians and other referral sources, and the privacy and security of patient health information. Changes in these laws and regulations could negatively affect the ability of our tenants to make lease payments to us. In some states, healthcare facilities are subject to various state CON laws requiring governmental approval prior to the development or expansion of healthcare facilities and services. The approval process in these states generally requires a facility to demonstrate the need for additional or expanded healthcare facilities or services. CONs, where applicable, can also be conditions to regulatory approval of changes in ownership or control of licensed facilities, addition of beds, investment in major capital equipment, introduction of new services, termination of services previously approved through the CON process and other control or operational changes. Many of our medical facilities and their tenants may require a license or CON to operate. Failure to obtain a license or CON, or loss of a required license or CON, would prevent a facility from operating in the manner intended by the tenant and may restrict a tenant’s or operator’s ability to expand properties and grow the tenant’s or operator’s business in certain circumstances, which could have an adverse effect on the operator’s or tenant’s revenues, and in turn, negatively impact their ability to make rental payments under, and otherwise comply with the terms of their leases with us. State CON laws are not uniform throughout the United States and are subject to change. We cannot predict the impact of state CON laws on our improvement of medical facilities or the operations of our tenants and operators. In addition, state CON laws often materially impact the ability of competitors to enter into the marketplace of our facilities. The repeal of CON laws could allow competitors to freely operate in previously closed markets. This could negatively affect the ability of our tenants’ to make rental payments to us. In limited circumstances, loss of state licensure or certification or closure of a facility could ultimately result in loss of authority to operate the facility and require new CON authorization to re-institute operations.
Furthermore, uncertainty surrounding the implementation of the Affordable Care Act may adversely affect our tenants. As the primary vehicle for comprehensive healthcare reform in the United States, the Affordable Care Act was designed to reduce the number of individuals in the United States without health insurance and change the ways in which healthcare is organized, delivered and reimbursed. The Affordable Care Act has faced ongoing legal challenges, including litigation seeking to invalidate some or all of the law or the manner in which it has been interpreted. The legal challenges and legislative initiatives to roll back the Affordable Care Act continues and the outcomes are uncertain. In June of 2021, the Supreme Court of the United States for a third time declined to invalidate the Affordable Care Act. There is no assurance that future litigation or legislative initiatives will not attempt to do so. There are no current challenges to the Affordable Care Act but that could change based on the makeup of Congress and presidential administration. The regulatory uncertainty and the potential impact on our tenants could have an adverse material effect on their ability to satisfy their contractual obligations. Further, we are unable to predict the scope of future federal, state and local regulations and legislation, including Medicare and Medicaid statutes and regulations or judicial decisions, or the intensity of enforcement efforts with respect to such regulations and legislation, and any changes in the regulatory or judicial framework may have a material adverse effect on our tenants.
Health insurance coverage under the Affordable Care Act is likely going to continue to expand 2023. However, the repeal of the individual mandate penalty included in the Tax Cuts and Jobs Act of 2017, recent actions to increase the availability of insurance policies that do not include Affordable Care Act minimum benefit standards, and support for Medicaid work requirements will likely impact the market. Accordingly, current and future payments under federal and state healthcare programs may not be sufficient to sustain a facility’s operations, which could adversely affect its ability to satisfy its contractual obligations, including making rental payments under, and otherwise complying with the terms of, the facility’s leases and other agreements with us. These risks could be mitigated by our limited participation in governmental-sponsored payor programs.
The Affordable Care Act includes program integrity provisions that both create new authorities and expand existing authorities for federal and state governments to address fraud, waste and abuse in federal health programs. In addition, the Affordable Care Act expands reporting requirements and responsibilities related to facility ownership and management, patient safety and care quality. In the ordinary course of their businesses, our tenants and operators may be regularly subjected to inquiries, investigations and audits by federal and state agencies that oversee these laws and regulations. If they do not comply with the additional reporting requirements and responsibilities, the ability of our tenants’ to participate in federal health
27

programs may be adversely affected. Moreover, there may be other comprehensive healthcare reform legislation, which, depending on how they are implemented, could materially and adversely affect our operators.
The Affordable Care Act also requires the reporting and return of overpayments. Healthcare providers that fail to report and return an overpayment could face potential liability under the FCA and the CMPL and exclusion from federal healthcare programs. Accordingly, if our tenants fail to comply with the Affordable Care Act’s requirements, they may be subject to significant monetary penalties and excluded from participation in Medicare and Medicaid, which could materially and adversely affect their ability to pay rent and satisfy other financial obligations to us.
Reductions or changes in reimbursement from third-party payors, including Medicare and Medicaid, or delays in receiving these reimbursements, could adversely affect the profitability of our tenants and operators and hinder their ability to make rent payments to us.
Our tenants and operators may receive payments from the federal Medicare program, state Medicaid programs, private insurance carriers and health maintenance organizations, among others. Efforts by such payors to reduce healthcare costs have intensified in recent years and will likely continue, which may result in reductions or slower growth in reimbursement for certain services provided by some of our tenants and operators. The Medicare and Medicaid programs have adopted a variety of initiatives which have been incorporated and expanded by private insurance carriers, including health maintenance organizations and other health plans, to extract greater discounts and impose more stringent cost controls upon healthcare provider operations. Examples include, but are not limited to, changes in reimbursement rates and methodologies, such as bundled payments, capitation payments and discounted fee structures. As a result, our tenants and operators may face significant limits on the reimbursed and on reimbursement rates and fees. All of these changes could impact the ability of our tenants’ to pay rent or our operator’s ability to meet their obligations to us. In addition, tenants and operators in certain states have experienced delays; some of which are, have been, and may be late in receiving reimbursements, which have adversely affected their ability to make rent payments to us. Further, failure of any of our tenants or operators to comply with various laws and regulations could jeopardize their ability to continue participating in Medicare, Medicaid and other government-sponsored payment programs.
The healthcare industry continues to face various challenges, including increased government and private payor pressure on healthcare providers to control or reduce costs. Coverage expansions under the Affordable Care Act through the Medicaid expansion and health insurance exchanges may be scaled back or eliminated in the future due to ongoing legal challenges and the future status of the Affordable Care Act is unknown. We cannot ensure that of our tenants or operators who currently depend on governmental or private payer reimbursement will be adequately reimbursed for the services they provide.
Any slowdown in the United States economy can negatively affect state budgets, thereby putting pressure on states to decrease spending on state programs including Medicaid. The need to control Medicaid expenditures may be exacerbated by the potential for increased enrollment in state Medicaid programs due to unemployment and declines in family incomes. Historically, some states have attempted to reduce Medicaid spending by limiting benefits and tightening Medicaid eligibility requirements. Potential reductions to Medicaid program spending in response to state budgetary pressures could negatively impact the ability of our tenants and operators to successfully operate their businesses.
Our tenants and operators may continue to experience a shift in payor mix away from fee-for-service payors, resulting in an increase in the percentage of revenues attributable to managed care payors, and general industry trends that include pressures to control healthcare costs. In addition, some of our tenants and operators may be subject to value-based purchasing programs, which base reimbursement on the quality and efficiency of care provided by facilities and require the public reporting of quality data and preventable adverse events to receive full reimbursement. Pressures to control healthcare costs and a shift away from traditional health insurance reimbursement to managed care plans have resulted in an increase in the number of patients whose healthcare coverage is provided under managed care plans, such as health maintenance organizations and preferred provider organizations. Medicare Access and CHIP Reauthorization Act (“MACRA”) has also established a new payment framework, which modified certain Medicare payments to eligible clinicians, representing a fundamental change to physician reimbursement. These changes could have a material adverse effect on the financial condition of some or all of our tenants in our properties. The financial impact on our tenants could restrict their ability to make rent payments to us.
Required regulatory approvals can delay or prohibit transfers of our healthcare facilities.
Transfers of healthcare facilities to successor tenants and/or operators are typically subject to regulatory approvals or ratifications, including, but not limited to, change of ownership approvals, zoning approvals, and Medicare and Medicaid provider arrangements that are either not required, or enjoy reduced requirements, in connection with transfers of other types of commercial operations and other types of real estate. The replacement of any tenant and/or operator could be delayed by the regulatory approval process of any federal, state or local government agency necessary for the transfer of the facility or the replacement of the tenant or, if applicable, operator, licensed to operate the facility. If we are unable to find a suitable replacement tenant or operator upon favorable terms, or at all, we may take possession of a facility, which could expose us to successor liability, require us to indemnify subsequent entities to whom we transfer the operating rights and licenses, or require us to spend substantial time and funds to preserve the value of the property and adapt the facility to other use. Furthermore,
28

transitioning to a new tenant and/or operator could cause disruptions at the operations of the properties and, if there is a delay in the new tenant or operator obtaining its ability to receive reimbursement from third-party payors.
A reduction in Medicare payment rates for skilled nursing facilities may have an adverse effect on the Medicare reimbursements received by one of our tenants.
Several government initiatives have resulted in reductions in funding of the Medicare and Medicaid programs and additional changes in reimbursement regulations by the Centers for Medicare & Medicaid Services (“CMS”), contributing to pressure to contain healthcare costs and additional operational requirements, which may impact the ability of our tenant to make rent payments to us. The Medicare and Medicaid programs have adopted a variety of initiatives which have been incorporated and expanded by private insurance carriers, including health maintenance organizations and other health plans, to extract greater discounts and impose more stringent cost controls upon healthcare provider operations. As a result, our tenant may face reductions in reimbursement rates and fees. A delay in receiving reimbursements could adversely affect its ability to make rent payments to us. Similar delays, or reductions in reimbursements, may continue to impose financial and operational challenges for our tenants and tenant, which may affect its ability to make contractual payments to us. These risks could be mitigated by our limited participation in government-sponsored payor programs.
There have been numerous initiatives on the federal and state levels for comprehensive reforms affecting the payment for, and availability of, healthcare services. We may own and acquire skilled nursing facility assets that rely on revenue from Medicaid or Medicare. Our one SNF has, and may continue to experience, limited increases or reductions in Medicare payments and aspects of certain of these government initiatives, such as further reductions in funding of the Medicare and Medicaid programs, additional changes in reimbursement regulations by CMS, enhanced pressure to contain healthcare costs by Medicare, Medicaid and other payors, and additional operational requirements may adversely affect their ability to make rental payments. For example, CMS is focused on reducing what it considers to be payment errors by identifying, reporting, and implementing actions to reduce payment error vulnerabilities.
In addition, CMS is currently in the midst of transitioning Medicare from traditional fee for service reimbursement models to a capitated system, which means medical providers are given a set fee per patient regardless of treatment required, and value-based and bundled payment approaches, where the government pays a set amount for each beneficiary for a defined period of time, based on that person’s underlying medical needs, rather than based on the actual services provided. Providers and facilities are increasing responsible to care for and be financially responsible for certain populations of patients under the population health models and this shift in patient management paradigm is creating and will continue to create unprecedented challenges for providers and impact their ability to pay rent to us.
Certain of our facilities may be subject to pre- and post-payment reviews and audits by governmental authorities, which could result in recoupments, denials or delay of payments and could adversely affect the profitability of our tenants and operators.
Certain of our facilities may be subject to periodic pre- and post-payment reviews and audits by governmental authorities. If the review or audit shows a facility is not in compliance with federal and state requirements, previous payments to the facility may be recouped and future payments may be denied or delayed. Recoupments, denials or delay of payments could adversely affect the profitability of our tenants and hinder their ability to make rent payments to us and the ability of our operators to satisfy their ongoing contractual obligations.
Events that adversely affect the ability of seniors and their families to afford daily resident fees at our SHOPs could cause our occupancy rates and resident fee revenues to decline.
Assisted and independent living services generally are not reimbursable under as Medicare and our facilities have limited participation in Medicaid. Most of the resident fee revenues generated by our SHOPs, therefore, are derived from private pay sources consisting of the income or assets of residents or their family members. The rates for these residents are set by the facilities based on local market conditions and operating costs. In light of the significant expense associated with building new properties and staffing and other costs of providing services, typically only seniors with income or assets that meet or exceed the comparable region median can afford the daily resident and care fees at our SHOPs. A weak economy, depressed housing market or changes in demographics could adversely affect their continued ability to do so. If the operators of our SHOPs are unable to attract and retain seniors that have sufficient income, assets or other resources to pay the fees associated with assisted and independent living services, the occupancy rates, resident fee revenues and results of operations of our SHOPs could decline.
Residents in our SHOPs may terminate leases.
State regulations generally require assisted living communities to have a written lease agreement with each resident that permits the resident to terminate his or her lease for any reason on reasonable notice, unlike typical apartment lease agreements that have initial terms of one year or longer. Due to these lease termination rights and the advanced age of the residents, the resident turnover rate in our SHOPs may be difficult to predict. A large number of resident lease agreements may terminate at or around the same time, and the affected units may remain unoccupied.
29

Some tenants and operators of our healthcare-related assets must comply with fraud and abuse laws, the violation of which by either may jeopardize the tenant’s ability to make rent payments to us.
There are various federal and state laws prohibiting fraudulent and abusive business practices by healthcare providers who participate in, receive payments from or are in a position to make referrals in connection with government-sponsored healthcare programs, including the Medicare and Medicaid programs.
Our lease arrangements with certain tenants and our management agreements with certain operators may also be subject to these fraud and abuse laws. These laws include the Federal Anti-Kickback Statute, which prohibits, among other things, the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, the referral of any item or service reimbursed by Medicare or Medicaid; the Federal Physician Self-Referral Prohibition (commonly referred to as the “Stark Law”), which, subject to specific exceptions, restricts physicians from making referrals for specifically designated health services for which payment may be made under Medicare or Medicaid programs to an entity with which the physician, or an immediate family member, has a financial relationship; the FCA, which prohibits any person from knowingly presenting false or fraudulent claims for payment to the federal government, including claims paid by the Medicare and Medicaid programs; and the CMPL, which authorizes the U.S. Department of Health and Human Services to impose monetary penalties for certain fraudulent acts. Additionally, some states may have laws similar to the Federal Anti-Kickback Statute and the Stark Law expanding their respective prohibitions to private insurance.
Each of these laws includes substantial criminal or civil penalties for violations that range from punitive sanctions, damage assessments, penalties, imprisonment, denial of Medicare and Medicaid payments or exclusion from the Medicare and Medicaid programs. Certain laws, such as the FCA, allow for individuals to bring whistleblower actions on behalf of the government for violations thereof. Individuals have tremendous potential financial gain in bringing whistleblower claims as the FCA statute provides that the individual will receive between 15% and 30% of the money recouped. Additionally, violations of the FCA can result in treble damages. Significant enforcement activity has been the result of actions brought by these individuals. Additionally, certain states in which the facilities are located also have similar fraud and abuse laws. Federal and state adoption and enforcement of such laws increase the regulatory burden and costs, and potential liability, of healthcare providers. Investigation by a federal or state governmental body for violation of fraud and abuse laws, and these state laws have their own penalties which may be in additional to federal penalties.
Investigation by a federal or state governmental body for violation of fraud and abuse laws or imposition of any of these penalties upon one of our tenants could jeopardize that tenant’s and operator’s business, reputation, and ability to operate or to make rent payments. Increased funding for investigation and enforcement efforts, accompanied by an increased pressure to eliminate government waste, has led to a significant increase in the number of investigations and enforcement actions over the past several years, a trend which is not anticipated to decrease considerably.
Tenants and operators of our healthcare-related assets may be subject to significant legal actions that could subject them to increased operating costs and substantial uninsured liabilities, which may affect their ability to pay their rent payments to us.
As is typical in the healthcare industry, certain types of tenants and operators of our healthcare-related assets may often become subject to claims that their services have resulted in patient injury or other adverse effects. The insurance coverage maintained by these tenants and operators may not cover all claims made against them or continue to be available at a reasonable cost, if at all. In some states, insurance coverage for the risk of punitive damages arising from professional liability and general liability claims or litigation may not, in certain cases, be available to these tenants due to state law prohibitions or limitations of availability. As a result, these types of tenants and operators operating in these states may be liable for punitive damage awards that are either not covered or are in excess of their insurance policy limits. Recently, there has been an increase in governmental investigations of certain healthcare providers, particularly in the area of Medicare and Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Insurance may not be available to cover such losses. Any adverse determination in a legal proceeding or governmental investigation, whether currently asserted or arising in the future, could have a material adverse effect on a tenant’s or operator’s financial condition. If a tenant or operator is unable to obtain or maintain insurance coverage, if judgments are obtained in excess of the insurance coverage, if a tenant or operator is required to pay uninsured punitive damages, or if a tenant or operator is subject to an uninsurable government enforcement action, the tenant could be exposed to substantial additional liabilities, which may affect the tenant’s or operator’s business, operations and the tenant’s ability to pay rent to us.
30

We may experience adverse effects as a result of potential financial and operational challenges faced by the tenants and operators of any seniors housing facilities and skilled nursing facilities we own or acquire.
Tenants and operators of any seniors housing facilities and skilled nursing facilities may face operational challenges from potentially reduced revenue streams and increased demands on their existing financial resources. The resources of our skilled nursing units are primarily derived from government-funded reimbursement programs, such as Medicare and Medicaid. Accordingly, our one SNF and limited assisted living facilities that participate in Medicaid could be subject to the potential negative effects of decreased reimbursement rates or other changes in reimbursement policy or programs offered through such reimbursement programs. Revenue may also be adversely affected as a result of falling occupancy rates or slow lease-ups for assisted and independent living facilities due to various factors, including the ongoing COVID-19 pandemic and its related effects. In addition, our facility operators may incur additional demands on their existing financial resources as a result of increases in seniors housing facility operator liability, insurance premiums and other operational expenses, which is worsened by the nationwide staffing shortage. The economic deterioration of a tenant or operator could cause such operator to file for bankruptcy protection. The bankruptcy or insolvency of a tenant or operator may adversely affect the income produced by the property or properties it operates.
The performance and economic condition of our tenant and operators may be negatively affected if they fail to comply with various complex federal and state laws that govern a wide array of referrals, relationships and licensure requirements in the senior healthcare industry. The violation of any of these laws or regulations by a seniors housing facility tenant or operator may result in the imposition of fines or other penalties that could jeopardize that tenant’s or operator’s ability to make payments to us or to continue operating its facility. In addition, legislative proposals are commonly being introduced or proposed in federal and state legislatures that could affect major changes in the seniors housing sector, either nationally or at the state level. Any such legislation could materially impact our tenant or operators in an adverse fashion.
We may change our targeted investments without stockholder consent.
We have acquired and expect to continue to acquire a diversified portfolio of healthcare-related assets including MOBs, SHOPs and other healthcare-related facilities. However, the board may change our investment policies in its sole discretion. We may change our targeted investments and investment guidelines at any time without the consent of our stockholders, which could result in our making investments that are different from, and possibly riskier than, initially anticipated by increasing our exposure to, among other things, interest rate risk, default risk and real estate market fluctuations.
If we internalize our management functions, we would be required to pay a transition fee and would not have the right to retain our management or personnel.
We may engage in an internalization transaction and become self-managed in the future. If we internalize our management functions, under the terms of our advisory agreement we would be required to pay a transition fee to our Advisor upon termination of the advisory agreement in connection with an internalization that could be up to 4.5 times the compensation paid to our Advisor in the previous year, plus expenses. We also would not have any right to retain our executive officers or other personnel of our Advisor who currently manage our day-to-day operations. An inability to manage an internalization transaction effectively could thus result in our incurring excess costs and suffering deficiencies in our disclosure controls and procedures or our internal control over financial reporting. These deficiencies could cause us to incur additional costs, and our management’s attention could be diverted from most effectively managing our investments, which could result in litigation and resulting associated costs in connection with the internalization transaction.
We may terminate our advisory agreement in only limited circumstances, which may require payment of a termination fee.
We have limited rights to terminate our Advisor. The initial term of our advisory agreement expires on February 16, 2027, but is automatically renewed upon expiration for consecutive ten-year terms unless notice of termination is provided by either party 365 days in advance of the expiration of the term. Further, we may terminate the agreement only under limited circumstances. In the event of a termination in connection with a change in control of us, we would be required to pay a termination fee that could be up to four times the compensation paid to our Advisor in the previous year, plus expenses. The limited termination rights will make it difficult for us to renegotiate the terms of the advisory agreement or replace our Advisor even if the terms of the advisory agreement are no longer consistent with the terms generally available to externally-managed REITs for similar services.
Our business and operations could suffer if our Advisor or any other party that provides us with services essential to our operations experiences system failures or cyber incidents or a deficiency in cybersecurity.
The internal information technology networks and related systems of our Advisor and other parties that provide us with services essential to our operations (including our tenants, operators, and other third-party operators of our healthcare facilities) are vulnerable to damage from any number of sources, including computer viruses, unauthorized access, energy blackouts, natural disasters, terrorism, war and telecommunication failures. Any system failure or accident that causes interruptions in our operations could result in a material disruption to our business. We may also incur additional costs to remedy damages caused by these disruptions.
31

As reliance on technology has increased, so have the risks posed to those systems. Our Advisor and other parties that provide us with services essential to our operations must continuously monitor and develop their networks and information technology to prevent, detect, address and mitigate the risk of unauthorized access, misuse, computer viruses, and social engineering, such as phishing. Our Advisor is continuously working, including with the aid of third-party service providers, to install new, and to upgrade existing, network and information technology systems, to create processes for risk assessment, testing, prioritization, remediation, risk acceptance, and reporting, and to provide awareness training around phishing, malware and other cyber risks to ensure that our Advisor and other parties that provide us with services essential to our operations are protected against cyber risks and security breaches and that we are also therefore so protected. However, these upgrades, processes, new technology and training may not be sufficient to protect us from all risks. Even the most well protected information, networks, systems and facilities remain potentially vulnerable because the techniques and technologies used in attempted attacks and intrusions evolve and generally are not recognized until launched against a target. In some cases, attempted attacks and intrusions are designed not to be detected and, in fact, may not be detected.
The remediation costs and lost revenues experienced by a subject of an intentional cyberattack or other event which results in unauthorized third-party access to systems to disrupt operations, corrupt data or steal confidential information may be significant and significant resources may be required to repair system damage, protect against the threat of future security breaches or to alleviate problems, including reputational harm, loss of revenues and litigation, caused by any breaches. Additionally, any failure to adequately protect against unauthorized or unlawful processing of personal data, or to take appropriate action in cases of infringement may result in significant penalties under privacy law.
Furthermore, a security breach or other significant disruption involving the information technology networks and related systems of our Advisor or any other party that provides us with services essential to our operations could:
result in misstated financial reports, violations of loan covenants, missed reporting deadlines or missed permitting deadlines;
affect our ability to properly monitor our compliance with the rules and regulations regarding our qualification as a REIT;
result in the unauthorized access to, and destruction, loss, theft, misappropriation or release of, proprietary, confidential, sensitive or otherwise valuable information (including information about our tenant operators and other third-party operators of our healthcare facilities, as well as the patients or residents at those facilities), which others could use to compete against us or for disruptive, destructive or otherwise harmful purposes and outcomes;
result in our inability to maintain the building systems relied upon by our tenants for the efficient use of their leased space;
require significant management attention and resources to remedy any damages that result;
subject us to claims for breach of contract, damages, credits, penalties or termination of leases or other agreements; or
adversely impact our reputation among our tenants, operators and investors generally.
Although our Advisor and other parties that provide us with services essential to our operations intend to continue to implement industry-standard security measures, there can be no assurance that those measures will be sufficient, and any material adverse effect experienced by our Advisor and other parties that provide us with services essential to our operations could, in turn, have an adverse impact on us.
We depend on our Advisor and Property Manager to provide us with executive officers, key personnel and all services required for us to conduct our operations and our operating performance may be impacted by any adverse changes in the financial health or reputation of our Advisor.
We have no employees. Personnel and services that we require are provided to us under contracts with our Advisor and its affiliates including our Property Manager. We depend on our Advisor and our Property Manager to manage our operations and acquire and manage certain of our real estate assets. Our Advisor makes all decisions with respect to the management of our company, subject to the supervision of, and any guidelines established by, the board.
Our success depends to a significant degree upon the contributions of our executive officers and other key personnel of our Advisor and its affiliates, including Edward M. Weil, Jr., our chief executive officer, and Scott Lappetito, our chief financial officer, treasurer and secretary. Neither our Advisor nor any of its affiliates has an employment agreement with these key personnel and we cannot guarantee that all, or any particular one, of these individuals will remain employed by our Advisor or one of its affiliates and otherwise available to continue to perform services for us. Further, we do not maintain key person life insurance on any person. We believe that our success depends, in large part, upon the ability of our Advisor to hire, retain or contract for services of highly skilled managerial, operational and marketing personnel. Competition for skilled personnel is intense, and there can be no assurance that our Advisor will be successful in attracting and retaining skilled personnel. If our Advisor loses or is unable to obtain the services of skilled personnel due to, among other things, an overall labor shortage, lack of skilled labor, increased turnover or labor inflation, our Advisor’s ability to manage our business and implement our investment strategies could be delayed or hindered.
32

Any adverse changes in the financial condition or financial health of, or our relationship with, our Advisor or Property Manager, including any change resulting from an adverse outcome in any litigation could hinder their ability to successfully manage our operations and our investments. Additionally, changes in ownership or management practices, the occurrence of adverse events affecting our Advisor or its affiliates or other companies advised by our Advisor or its affiliates could create adverse publicity and adversely affect us and our relationship with lenders, tenants, operators or counterparties.
We may in the future acquire or originate real estate debt or invest in real estate-related securities issued by real estate market participants, which would expose us to additional risks.
We may in the future acquire or originate first mortgage debt loans, mezzanine loans, preferred equity or securitized loans, CMBS, preferred equity and other higher-yielding structured debt and equity investments. Doing so would expose us not only to the risks and uncertainties we are currently exposed to through our direct investments in real estate but also to additional risks and uncertainties attendant to investing in and holding these types of investments, such as:
risk of defaults by borrowers in paying debt service on outstanding indebtedness and to other impairments of our loans and investments;
increased competition from entities engaged in mortgage lending and, or investing in our target assets;
deterioration in the performance of properties securing our investments may cause deterioration in the performance of our investments and, potentially, principal losses to us;
fluctuations in interest rates and credit spreads could reduce our ability to generate income on our loans and other investments;
difficulty in redeploying the proceeds from repayments of our existing loans and investments;
the illiquidity of certain of these investments;
lack of control over certain of our loans and investments;
the potential need to foreclose on certain of the loans we originate or acquire, which could result in losses;
additional risks, including the risks of the securitization process, posed by investments in CMBS and other similar structured finance investments, as well as those we structure, sponsor or arrange; use of leverage may create a mismatch with the duration and interest rate of the investments that we finance;
risks related to the operating performance or trading price volatility of any publicly-traded and private companies primarily engaged in real estate businesses we invest in; and
the need to structure, select and more closely monitor our investments such that we continue to maintain our qualification as a REIT and our exemption from registration under the Investment Company Act of 1940, as amended.

Risks Related to our Indebtedness

Our level of indebtedness may increase our business risks.
As of December 31, 2022, we had total outstanding indebtedness of $1.1 billion. We may incur additional indebtedness in the future for various purposes. The amount of our indebtedness could have material adverse consequences for us, including:
hindering our ability to adjust to changing market, industry or economic conditions;
limiting our ability to access the capital markets to raise additional equity or debt on favorable terms or at all, whether to refinance maturing debt, to fund acquisitions, to fund dividends and other distributions or for other corporate purposes;
limiting the amount of free cash flow available for future operations, acquisitions, dividends and other distributions, stock repurchases or other uses; and
making us more vulnerable to economic or industry downturns, including interest rate increases.
In most instances, we acquire real properties by using either existing financing or borrowing new funds. We may incur debt and pledge the underlying property as security for that debt to obtain funds to acquire additional properties or for other corporate purposes. We may also borrow if we need funds to satisfy the REIT tax qualification requirement that we generally distribute annually to our stockholders at least 90% of our REIT taxable income (which does not equal net income as calculated in accordance with GAAP), determined without regard to the deduction for dividends paid and excluding any net capital gain. We also may borrow if we otherwise deem it necessary or advisable to assure that we maintain our qualification as a REIT.
If there is a shortfall between the cash flow from a property and the cash flow needed to service mortgage debt on that property, especially if we acquire the property when it is being developed or under construction, we may use additional borrowings to fund the shortfall. Using debt increases the risk of loss because defaults on indebtedness secured by a property may result in lenders initiating foreclosure actions. In that case, we could lose the property securing the loan that is in default. For U.S. federal income tax purposes, a foreclosure of any of our properties would be treated as a sale of the property for a
33

purchase price equal to the outstanding balance of the debt secured by the mortgage. If the outstanding balance of the debt secured by the mortgage exceeds our tax basis in the property, we would recognize taxable income on foreclosure, but would not receive any cash proceeds. In this event, we may be unable to pay the amount of distributions required in order to maintain our REIT status. We may also fully or partially guarantee mortgage debt incurred by the subsidiary entities that own our properties. In those cases, we will be responsible to the lender for repaying the debt if it is not paid by the entity. In the case of mortgages containing cross-collateralization or cross-default provisions, a default on a single mortgage could affect multiple properties.
Our Credit Facility contains various covenants that may restrict our ability to take certain actions and may restrict our ability to use our cash and make investments.
Our Credit Facility contains various covenants that may restrict our ability to take certain actions. For example, we may not pay distributions to holders of common stock in cash or make any other cash distributions (including repurchases of shares of our common stock) on our common stock until we meet certain requirements. We may, however, pay dividends on the Series A Preferred Stock and Series B Preferred Stock, or any other preferred stock we may issue and any cash distributions necessary to maintain our status as a REIT. The restrictions on paying cash distributions will no longer apply starting in the quarter in which we make an election and, as of the day prior to the commencement of the applicable quarter, we have a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million, giving effect to the aggregate amount of distributions projected to be paid by us during the applicable quarter, our ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5%, and our Fixed Charge Coverage Ratio is not less than 1.50 to 1.00 for the most recently ended four fiscal quarters. There can be no assurance as to if, or when, we will be able to satisfy these conditions. Moreover, we will only be permitted to pay cash distributions if the aggregate distributions (as defined in the Credit Facility and including dividends on Series A Preferred Stock, Series B Preferred Stock or any other class of preferred stock that may be issued) for any period of four fiscal quarters do not exceed 95% of Modified FFO (as defined in the Credit Facility) for the same period based only on fiscal quarters after we make the election and begin paying distributions.
The lenders have reduced the covenant requiring a minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges based on the four most recently ended fiscal quarters, from 1.50:1.00 to (a) 1.20:1.00 for the period that commenced with the quarter ended June 30, 2022 through the quarter ending June 30, 2023, (b) 1.35:1.00 for the period commencing with the quarter ending September 30, 2023 through the quarter ending December 31, 2023 and (c) 1.45:1.00 for the period commencing with the quarter ending March 31, 2024 and continuing thereafter; provided, however, that from and after the Commencement Quarter, we must satisfy a minimum Fixed Charge Coverage Ratio of 1.50:1.00. Prospectively, based upon our current expectations, we believe our operating results through June 30, 2023 will allow us to comply with these covenants. However, we believe our operating results may not be sufficient to comply with the increased Fixed Charge Coverage Ratio, which increases from 1.20:1.00 to 1.35:1.00 commencing with the quarter ending September 30, 2023 and thereafter. Absent a waiver or modification from the lender group, failure to comply with the Fixed Charge Coverage Ratio would constitute an Event of Default and the balance of the Credit Facility would be due and payable. We have obtained such waivers and modifications from the lender group in the past, but there can be no assurance that such a waiver or modification will be granted in future periods.
Covenants in our Credit Facility also require us to maintain a combination of cash, cash equivalents and availability for future borrowings under our Revolving Credit Facility totaling at least $50.0 million. As of December 31, 2022, we had $53.7 million of cash and cash equivalents, and $203.4 million was available for future borrowings under our Revolving Credit Facility. Our Credit Facility also restricts how we may use our sources of liquidity. Certain restrictions and conditions contained in the Credit Facility will no longer apply starting in the quarter in which we make an election as, as of the day prior to the commencement of the applicable quarter we have a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million, giving effect to the aggregate amount of distributions projected to be paid by us during the applicable quarter, our ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5% and, as revised by the Fourth Amendment, our Fixed Charge Coverage Ratio is not less than 1.50 to 1.00 for the most recently ended four fiscal quarters (the “Commencement Quarter”). The fiscal quarter ended June 30, 2021 was the first quarter that could have been the Commencement Quarter. We did not satisfy the conditions during the quarter ended December 31, 2022 in order to elect the quarter ending March 31, 2023 as the Commencement Quarter. There can be no assurance as to if, or when, we will, or will be able to, elect the Commencement Quarter, including to the extent we may be unable to satisfy these conditions in future periods. Until the first day of the Commencement Quarter, we must use all of the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to repay amounts outstanding under the Revolving Credit Facility, to the extent there are any such amounts outstanding. We may borrow additional amounts if all relevant conditions are met, including sufficient availability for future borrowings. There can be no assurance these conditions will be met.
The availability for future borrowings under the Credit Facility is calculated using the adjusted net operating income of the real estate assets comprising the borrowing base, and availability has been, and may continue to be, adversely affected by the
34

decreases in net operating income at the properties comprising the borrowing base from the use of contract labor for care providers and, to a lesser extent, the amount we pay in overtime wages and bonuses. In connection with the Fourth Amendment, the borrowing base advance rate was reduced from 55% to 52.5% (until we elect the Commencement Quarter, after which the borrowing base advance rate would revert back to 55%), which may also impact our availability. Our ability to increase the amount of cash we generate from property operations depends on a variety of factors as well as our ability to complete acquisitions of new properties on favorable terms and our ability to improve operations at our existing properties. There can be no assurance that we will complete acquisitions on a timely basis or on favorable terms and conditions, if at all, particularly if we do not have a source of capital available that will allow us to do so. Our ability to improve operations at our existing properties is also subject to a variety of risks and uncertainties, many of which are beyond our control, and there can be no assurance we will be successful in achieving this objective. Because shares of common stock are only offered and sold pursuant to our distribution reinvestment plan (“DRIP”) in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as we pay distributions in stock instead of cash, so this source of capital will not be available unless and until we are able to resume paying cash distributions on our common stock. There is also no assurance that participation in the DRIP will be maintained at current or higher levels if the DRIP becomes a source of capital in the future.
Other financing arrangements have restrictive covenants.
The agreements governing our borrowings contain provisions that affect or restrict our policies regarding dividends and other distributions and our operations, require us to satisfy financial coverage ratios, and may restrict our ability to, among other things, incur additional indebtedness, make certain investments, replace our Advisor, discontinue insurance coverage, merge with another company, and create, incur or assume liens. These or other limitations may adversely affect our flexibility and our ability to achieve our investment and operating objectives.
Changes in the debt markets could have a material adverse impact on our earnings and financial condition.
The commercial real estate debt markets are subject to volatility, resulting in, from time to time, the tightening of underwriting standards by lenders and credit rating agencies and reductions in the availability of financing. For example, recent credit and capital market conditions have been characterized by volatility and a tightening of credit standards. This may impact our ability to access capital on favorable terms, in a timely manner, or at all, which could make obtaining funding for our capital needs more challenging or expensive. We also face a heightened level of interest rate risk as the U.S. Federal Reserve Board tapers its quantitative easing program and raises interest rates. All of these actions will likely lead to increases in borrowing costs.
If our overall cost of borrowings continue to increase, either due to increases in the index rates or due to increases in lender spreads, we will need to factor such increases into pricing and projected returns for any future acquisitions. This may result in future acquisitions generating lower overall economic returns. Volatility in the debt markets, may negatively impact our ability to borrow monies to finance the purchase of, or other activities related to, our real estate assets may be negatively impacted. If we are unable to borrow monies on terms and conditions that we find acceptable, our ability to purchase properties and meet other capital requirements may be limited, and the return on the properties we do purchase may be lower. In addition, we may find it difficult, costly or impossible to refinance maturing indebtedness.
Furthermore, the state of the debt markets could have an impact on the overall amount of capital being invested in real estate, which may result in price or value decreases of real estate assets and could negatively impact the value of our assets.
Increases in interest rates may make it difficult for us to finance or refinance indebtedness secured by our properties.
We have borrowed, and may continue to borrow monies, secured and unsecured by our properties. Increases in interest rates may adversely impact our ability to refinance our indebtedness, including the indebtedness secured by our properties, as the loans come due or we otherwise desire to do so on favorable terms, or at all. If interest rates are higher when the indebtedness is refinanced, we may not be able to refinance indebtedness secured by the properties and we may be required to obtain equity to repay the loan or to increase the collateral for the loan.
Increasing interest rates could increase the amount of our debt payments and we may be adversely affected by uncertainty surrounding the LIBOR.
We have incurred, and may continue to incur, variable-rate debt. Increases in interest rates on our variable-rate debt would increase our interest cost.
We have mortgages, credit facilities and derivative agreements that have terms that are based on the London Interbank Offered Rate (“LIBOR”). As of December 31, 2022, we have nine designated interest rate swaps with a notional amount of $578.5 million, which effectively fixes a portion of our variable-rate debt. In July 2017, the Financial Conduct Authority (the authority that regulates LIBOR) announced it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee which identified the Secured Overnight Financing Rate (“SOFR”) as its preferred alternative to LIBOR in derivatives and other financial contracts. They ceased publishing the one-week and two-month USD LIBOR settings effective December 31, 2021. The remaining USD LIBOR settings, including the USD LIBOR rates currently relevant to us,
35

will continue to be published through June 30, 2023. We are monitoring and evaluating the risks related to changes in LIBOR availability, which include potential changes in interest paid on debt and amounts received and paid on interest rate swaps. In addition, the value of debt or derivative instruments tied to LIBOR will also be impacted as LIBOR is limited and discontinued and contracts must be transitioned to a new alternative rate. In some instances, transitioning to an alternative rate may require negotiation with lenders and other counterparties and could present challenges. Certain of our agreements that have terms that are based on LIBOR have alternative rates already contained in the agreements while others do not. We anticipate that we will either utilize the alternative rates contained in the agreements or negotiate a replacement reference rate for LIBOR with the lenders and derivative counterparties. The consequences of these developments cannot be entirely predicted and could include an increase in the cost of our variable rate debt. The consequences of these developments cannot be entirely predicted and could include an increase in the cost of our variable rate indebtedness.
Any hedging strategies we utilize may not be successful in mitigating our risks.
We have and may continue to enter into hedging transactions to manage risk of interest rate changes, price changes or currency fluctuations with respect to borrowings made or to be made to acquire or own real estate assets. To the extent that we use derivative financial instruments, we will be exposed to credit, basis and legal enforceability risks. Derivative financial instruments may include interest rate swap contracts, interest rate cap or floor contracts, futures or forward contracts, options or repurchase agreements. In this context, credit risk is the failure of the counterparty to perform under the terms of the derivative contract. If the fair value of a derivative contract is positive, the counterparty owes us, which creates credit risk for us. Basis risk occurs when the index upon which the contract is based is more or less variable than the index upon which the hedged asset or liability is based, thereby making the hedge less effective. Finally, legal enforceability risks encompass general contractual risks, including the risk that the counterparty will breach the terms of, or fail to perform its obligations under, the derivative contract.

Risks Related to Conflicts of Interest

Our Advisor faces conflicts of interest relating to the purchase and leasing of properties and these conflicts may not be resolved in our favor, which could adversely affect our investment opportunities.
We rely on our Advisor and its executive officers and other key real estate professionals at our Advisor and our Property Manager to identify suitable investment opportunities for us. Several of these individuals are also executive officers or key real estate professionals at AR Global and other entities advised by affiliates of AR Global. Many investment opportunities that are suitable for us may also be suitable for other entities advised by affiliates of AR Global. We do not have any agreements with any of these entities that govern the allocation of investment opportunities. Thus, the executive officers and real estate professionals at our Advisor could direct attractive investment opportunities to other entities advised by affiliates of AR Global.
We and other entities advised by affiliates of AR Global also rely on these executive officers and other key real estate professionals to supervise the property management and leasing of properties. These individuals, as well as AR Global, as an entity are not prohibited from engaging, directly or indirectly, in any business or from possessing interests in other businesses and ventures, including businesses and ventures involved in the acquisition, development, ownership, leasing or sale of real estate investments.
In addition, we may acquire properties in geographic areas where other entities advised by affiliates of AR Global own properties, and if we may acquire properties from, or sell properties to, other entities advised by affiliates of AR Global. If one of the other entities advised by affiliates of AR Global attracts a tenant that we are competing for, we could suffer a loss of revenue due to delays in locating another suitable tenant.
Our Advisor faces conflicts of interest relating to joint ventures, which could result in a disproportionate benefit to the other venture partners at our expense.
We may enter into joint ventures with other entities advised by affiliates of AR Global for the acquisition, development or improvement of properties. Our Advisor may have conflicts of interest in determining which entities advised by affiliates of AR Global should enter into any particular joint venture agreement. The co-venturer may have economic or business interests or goals that are or may become inconsistent with our business interests or goals. In addition, our Advisor may face a conflict in structuring the terms of the relationship between our interests and the interest of the affiliated co-venturer and in managing the joint venture. Due to the role of our Advisor and its affiliates, agreements and transactions between the co-venturers with respect to any joint venture will not have the benefit of arm’s-length negotiation of the type normally conducted between unrelated co-venturers, which may result in the co‑venturer receiving benefits greater than the benefits that we receive. In addition, we may assume liabilities related to the joint venture that exceeds the percentage of our investment in the joint venture.
Our Advisor, AR Global and their officers and employees and certain of our executive officers and other key personnel face competing demands relating to their time, and this may cause our operating results to suffer.
36

Our Advisor, AR Global and their officers and employees and certain of our executive officers and other key personnel and their respective affiliates are key personnel, general partners, sponsors, managers, owners and advisors of other real estate investment programs, including entities advised by affiliates of AR Global, some of which have investment objectives and legal and financial obligations similar to ours and may have other business interests as well. Because these entities and individuals have competing demands on their time and resources, they may have conflicts of interest in allocating their time between our business and these other activities.
All of our executive officers, some of our directors and the key real estate and other professionals assembled by our Advisor and our Property Manager face conflicts of interest related to their positions or interests in entities related to AR Global, which could hinder our ability to implement our business strategy.
All of our executive officers, and the key real estate and other professionals assembled by our Advisor and Property Manager are also executive officers, directors, managers, key professionals or holders of a direct or indirect interests in our Advisor, our Property Manager or other AR Global-affiliated entities. Through AR Global’s affiliates, some of these persons work on behalf of entities advised by affiliates of AR Global. In addition, all of our executive officers and some of our directors serve in similar capacities for other entities advised by affiliates of our Advisor. As a result, they have duties to each of these entities, which duties could conflict with the duties they owe to us and could result in action or inaction detrimental to our business. Conflicts with our business and interests are most likely to arise from (a) allocation of investments and management time and services between us and the other entities; (b) compensation to our Advisor or Property Manager; (c) our purchase of properties from, or sale of properties to, entities advised by affiliates of our Advisor; and (d) investments with entities advised by affiliates of our Advisor. Conflicts of interest may hinder our ability to implement our business strategy, and, if we do not successfully implement our business strategy.
Our Advisor faces conflicts of interest relating to the structure of the compensation it may receive.
Under our advisory agreement, the Advisor is entitled to substantial minimum compensation regardless of performance as well as incentive compensation. The variable base management fee payable to the Advisor under the advisory agreement increases proportionately with the cumulative net proceeds of any equity (including convertible equity and certain convertible debt but excluding proceeds from the DRIP) raised by us. In addition, the limited partnership agreement of our OP requires it to pay a subordinated incentive listing distribution to the “Special Limited Partner,” an affiliate of our Advisor, in connection with a listing or other liquidity event, such as the sale of all or substantially all of our assets, or if we terminate the advisory agreement, even for “cause.” The Special Limited Partner is also entitled to participate in the distribution of net sales proceeds. These arrangements may result in the Advisor taking actions or recommending investments that are riskier or more speculative absent these compensation arrangements. In addition, these fees and other compensation payable to the Advisor reduce the cash available for investment or other corporate purposes.

Risks Related to our Corporate Structure

Our common stock is not traded on a national securities exchange, and our SRP, which provides for repurchases only in the event of death or disability of a stockholder, is suspended. Stockholders may have to hold their shares for an indefinite period of time.
Our common stock is not listed on a national securities exchange and there is otherwise no active trading market for the shares and our SRP is suspended. Even if not suspended, our SRP includes numerous restrictions that limit a stockholder’s ability to sell shares of common stock to us, including limiting repurchases only to stockholders that have died or become disabled, limiting the total value of repurchases pursuant to our SRP to the amount of proceeds received from issuances of common stock pursuant to the DRIP and limiting repurchases in any fiscal semester to 2.5% of the average number of shares outstanding during the previous fiscal year. These limits are subject to the authority of the board to identify another source of funds for repurchases under the SRP. The board may also reject any request for repurchase of shares at its discretion or amend, suspend or terminate our SRP upon notice in its discretion. Shares that are repurchased will be repurchased at a price equal to the applicable Estimated Per-Share NAV and may be at a substantial discount to the price the stockholder paid for the shares. We are also restricted from making any share repurchases until the Commencement Quarter and, after that, to the extent they would be aggregated with dividends and other distributions to our stockholders under the covenant in our Credit Facility, all of which may further limit the amount that may be repurchased.
The Estimated Per-Share NAV of our common stock is based upon subjective judgments, assumptions and opinions about future events, and may not reflect the amount that our stockholders might receive for their shares.
We intend to publish an updated Estimated Per-Share NAV as of December 31, 2022 in early April 2023. Our Advisor has engaged an independent valuer to perform appraisals of our real estate assets in accordance with valuation guidelines established by the board. As with any methodology used to estimate value, the valuation methodologies that will be used by any independent valuer to value our properties involve subjective judgments concerning factors such as comparable sales, rental and operating expense data, capitalization or discount rate, and projections of future rent and expenses.
37

Under our valuation guidelines, our independent valuer estimates the market value of our principal real estate and real estate-related assets, and our Advisor makes a recommendation as to the net value of our real estate and real estate-related assets and liabilities taking into consideration such estimate provided by the independent valuer. Our Advisor reviews the valuation provided by the independent valuer for consistency with our valuation guidelines and the reasonableness of the independent valuer’s conclusions. The independent directors of the board oversee and review the appraisals and valuations and make a final determination of the Estimated Per-Share NAV. The independent directors of the board rely on our Advisor’s input, including its view of the estimate and the appraisals performed by the independent valuer, but the independent directors of the board may, in their discretion, consider other factors. Although the valuations of our real estate assets by the independent valuer are reviewed by our Advisor and approved by the independent directors of the board, neither our Advisor nor the independent directors of the board will independently verify the appraised value of our properties and valuations do not necessarily represent the price at which we would be able to sell any asset. As a result, the appraised value of a particular property may be greater or less than its potential realizable value, which would cause our Estimated per-share NAV to be greater or less than the potential realizable value of our assets.
The price at which shares of our common stock may be sold under the DRIP and the price at which shares of our common stock may be repurchased by us pursuant to the SRP are based on Estimated Per-Share NAV and may not reflect the price that our stockholders would receive for their shares in a market transaction, the proceeds that would be received upon our liquidation or the price that a third-party would pay to acquire us.
Because Estimated Per-Share NAV is only determined annually, it may differ significantly from our actual per‑share net asset value at any given time.
Our board estimates the per-share net asset value of our common stock only on an annual basis. In connection with any valuation, the board estimate of the value of our real estate and real estate-related assets will be partly based on appraisals of our properties. Because the process of making this estimate is conducted annually, this process may not account for material events that occur after the estimate has been completed for that year. Material events could include the appraised value of our properties substantially changing actual property operating results differing from what we originally budgeted or dividends and other distributions to stockholders exceeding cash flow generated by us. Any such material event could cause a change in the Estimated Per-Share NAV that would not be reflected until the next valuation. Also, cash dividends and other distributions in excess of our cash flows provided by operations could decrease our Estimated Per-Share NAV. The Estimated Per-Share NAV reflected Stock Dividends actually issued as of December 31, 2021, but has not been adjusted to reflect or consider any of the other stock dividends that were issued and will not be adjusted for stock dividends paid or that may be issued in the future until the Board determines a new Estimated Per-Share NAV which is expected in early April 2023. Dividends paid in the form of additional shares of common stock will, all things equal, cause the value of each share of common stock to decline because the number of shares outstanding increases when dividends paid in stock are issued reducing the Estimated Per-Share NAV. The Estimated Per-Share NAV may not reflect the value of shares of our common stock at any given time, and our estimated per-share NAV may differ significantly from our actual per-share net asset value at any given time.
The trading price of our Series A Preferred Stock and Series B Preferred Stock may fluctuate significantly.
The trading price of our Series A Preferred Stock and Series B Preferred Stock may be volatile and subject to significant price and volume fluctuations in response to market and other factors, and is impacted by a number of factors, many of which are outside our control. Among the factors that could affect the trading price are:
our financial condition, including the level of our indebtedness, and performance;
our ability to grow through property acquisitions, the terms and pace of any acquisitions we may make and the availability and terms of financing for those acquisitions;
the financial condition of our tenants, including tenant bankruptcies or defaults;
actual or anticipated quarterly fluctuations in our operating results and financial condition;
the amount and frequency of our payment of dividends and other distributions;
additional sales of equity securities, including Series A Preferred Stock, Series B Preferred Stock, common stock or any other equity interests, or the perception that additional sales may occur;
the reputation of REITs and real estate investments generally and the attractiveness of REIT equity securities in comparison to other equity securities, and fixed income debt securities;
our reputation and the reputation of AR Global and its affiliates or other entities advised by AR Global and its affiliates;
uncertainty and volatility in the equity and credit markets;
increases in interest rates;
inflation and continuing increases in the real or perceived inflation rate;
changes in revenue or earnings estimates, if any, or publication of research reports and recommendations by financial analysts or actions taken by rating agencies with respect to our securities or those of other REITs;
failure to meet analyst revenue or earnings estimates;
strategic actions by us or our competitors, such as acquisitions or restructurings;
38

the extent of investment in our Series A Preferred Stock and Series B Preferred Stock by institutional investors;
the extent of short-selling of our Series A Preferred Stock and Series B Preferred Stock;
general financial and economic market conditions and, in particular, developments related to market conditions for REITs and other real estate related companies;
failure to maintain our REIT status;
changes in tax laws;
domestic and international economic factors unrelated to our performance; and
all other risk factors addressed elsewhere in this Annual Report on Form 10-K for the year ended December 31, 2022.
Moreover, although shares of Series A Preferred Stock and Series B Preferred Stock are listed on The Nasdaq Global Market, there can be no assurance that the trading volume for shares will provide sufficient liquidity for holders to sell their shares at the time of their choosing or that the trading price for shares will equal or exceed the price paid for the shares. Because the shares of Series A Preferred Stock and Series B Preferred Stock carry a fixed dividend rate, the trading price in the secondary market will be influenced by changes in interest rates and will tend to move inversely to changes in interest rates. In particular, an increase in market interest rates may result in higher yields on other financial instruments and may lead purchasers of shares of Series A Preferred Stock and Series B Preferred Stock to demand a higher yield on their purchase price, which could adversely affect the market price of those shares. An increase in interest rates available to investors could also reduce the value of our common stock.
The limit on the number of shares a person may own may discourage a third-party from acquiring us in a manner that might result in a premium price to our stockholders.
Our charter, with certain exceptions, authorizes our directors to take such actions as are necessary and desirable to preserve our qualification as a REIT. Unless exempted (prospectively or retroactively) by the board, no person may own more than 9.8% in value of the aggregate of our outstanding shares of our capital stock or more than 9.8% (in value or in number of shares, whichever is more restrictive) of any class or series of shares of our capital stock. This restriction may have the effect of delaying, deferring or preventing a change in control of us, including an extraordinary transaction (such as a merger, tender offer or sale of all or substantially all our assets) that might provide a premium price for holders of our common stock.
The terms of our Series A Preferred Stock, Series B Preferred Stock, and the terms of other preferred stock we may issue, may discourage a third- party from acquiring us in a manner that might result in a premium price to stockholders.
The change of control conversion and redemption features of the Series A Preferred Stock and Series B Preferred Stock may make it more difficult for a party to acquire us or discourage a party from seeking to acquire us. Upon the occurrence of a change of control, holders of Series A Preferred Stock and Series B Preferred Stock will, under certain circumstances, have the right to convert some of or all their shares of Series A Preferred Stock and Series B Preferred Stock into shares of our common stock (or equivalent value of alternative consideration) and under these circumstances we will also have a change of control redemption right to redeem shares of Series A Preferred Stock and Series B Preferred Stock. Upon exercise of this conversion right, the holders will be limited to a maximum number of shares of our common stock pursuant to a predetermined ratio. These features of the Series A Preferred Stock and Series B Preferred Stock may have the effect of discouraging a third-party from seeking to acquire us or of delaying, deferring or preventing a change of control under circumstances that otherwise could provide the holders of our common stock with the opportunity to realize a premium over the then-current market price or that stockholders may otherwise believe is in their best interests. We may also issue other classes or series of preferred stock that could also have the same effect.
We may issue additional equity securities in the future.
Our stockholders do not have preemptive rights to any shares issued by us in the future. Our charter authorizes us to issue up to 350,000,000 shares of stock, consisting of 300,000,000 shares of common stock, par value $0.01 per share, and 50,000,000 shares of preferred stock, par value $0.01 per share. As of December 31, 2022, we had the following stock issued and outstanding: (i) 105,080,531 shares of common stock; (ii) 3,977,144 shares of Series A Preferred Stock; and (iii) 3,630,000 shares of Series B Preferred Stock. Subject to the approval rights of holders of our Series A Preferred Stock and Series B Preferred Stock regarding authorization or issuance of equity securities ranking senior to the Series A Preferred Stock or Series B Preferred Stock, the board, without approval of our common stockholders, may amend our charter from time to time to increase or decrease the aggregate number of authorized shares of stock, or the number of authorized shares of any class or series of stock or may classify or reclassify any unissued shares into other classes or series of stock without obtaining stockholder approval and establish the preferences, conversion or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications or terms or conditions of redemption of the stock.
All of our authorized but unissued shares of stock may be issued in the discretion of the board. The issuance of additional shares of our common stock could dilute the interests of the holders of our common stock, and any issuance of shares of preferred stock senior to our common stock, such as our Series A Preferred Stock and Series B Preferred Stock, or any incurrence of additional indebtedness, could affect our ability to pay distributions on our common stock. The issuance of additional shares of preferred stock ranking equal or senior to our Series A Preferred Stock and Series B Preferred Stock, including preferred stock convertible into shares of our common stock, could dilute the interests of the holders of common
39

stock, Series A Preferred Stock, Series B Preferred Stock and any issuance of shares of preferred stock senior to our Series A Preferred Stock, Series B Preferred Stock or incurrence of additional indebtedness could affect our ability to pay dividends on, redeem or pay the liquidation preference on our Series A Preferred Stock and Series B Preferred Stock. These issuances could also adversely affect our Estimated Per-Share NAV or the trading price of our Series A Preferred Stock and Series B Preferred Stock.
We may issue shares in public or private offerings in the future, including shares of our common stock issued as awards to our officers, directors and other eligible persons, pursuant to the advisory agreement in payment of fees thereunder and pursuant to the DRIP. We may also issue partnership units in the OP designated as “Common OP Units” to sellers of properties we acquire which, subject to satisfying certain requirements, would give the holder of Common OP Units the option to redeem Common OP Units for shares of our common stock or cash at our option. We also may issue securities that are convertible into shares of our common stock.
Because our decision to issue equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings. The issuance of additional equity securities could adversely affect stockholders.
We have a classified board, which may discourage a third-party from acquiring us in a manner that might result in a premium price to our stockholders.
The board is divided into three classes of directors. At each annual meeting, directors of one class are elected to serve until the annual meeting of stockholders held in the third year following the year of their election and until their successors are duly elected and qualify. The classification of our directors may have the effect of delaying, deferring or preventing a change in control of us, including an extraordinary transaction (such as a merger, tender offer or sale of all or substantially all our assets) that might result in a premium price for our stockholders.
Maryland law prohibits certain business combinations, which may make it more difficult for us to be acquired and may discourage a third-party from acquiring us in a manner that might result in a premium price to our stockholders.
Under Maryland law, “business combinations” between a Maryland corporation and an interested stockholder or an affiliate of an interested stockholder are prohibited for five years after the most recent date on which the interested stockholder becomes an interested stockholder. These business combinations include, but are not limited to, a merger, consolidation, share exchange or, in circumstances specified in the statute, an asset transfer or issuance or reclassification of equity securities. An interested stockholder is defined as:
any person who beneficially owns, directly or indirectly, 10% or more of the voting power of the corporation’s outstanding voting stock; or
an affiliate or associate of the corporation who, at any time within the two-year period prior to the date in question, was the beneficial owner of, directly or indirectly, 10% or more of the voting power of the then outstanding stock of the corporation.
A person is not an interested stockholder under the statute if the board of directors approved in advance the transaction by which he or she otherwise would have become an interested stockholder. However, in approving a transaction, the board of directors may provide that its approval is subject to compliance, at or after the time of approval, with any terms and conditions determined by the board of directors.
After the five-year prohibition, any business combination between the Maryland corporation and an interested stockholder generally must be recommended by the board of directors of the corporation and approved by the affirmative vote of at least:
80% of the votes entitled to be cast by holders of outstanding shares of voting stock of the corporation; and
two-thirds of the votes entitled to be cast by holders of voting stock of the corporation other than shares held by the interested stockholder with whom or with whose affiliate the business combination is to be effected or held by an affiliate or associate of the interested stockholder.
These super-majority vote requirements do not apply if the corporation’s common stockholders receive a minimum price, as defined under Maryland law, for their shares in the form of cash or other consideration in the same form as previously paid by the interested stockholder for its shares. The business combination statute permits various exemptions from its provisions, including business combinations that are exempted by the board of directors prior to the time that the interested stockholder becomes an interested stockholder. Pursuant to the statute, the board has exempted any business combination involving our Advisor or any affiliate of our Advisor. Consequently, the five-year prohibition and the super-majority vote requirements will not apply to business combinations between us and our Advisor or any affiliate of our Advisor. As a result, our Advisor and any affiliate of our Advisor may be able to enter into business combinations with us that may not be in the best interests of our stockholders, without compliance with the super-majority vote requirements and the other provisions of the statute. The business combination statute may discourage others from trying to acquire control of us and increase the difficulty of consummating any offer.
40

Our bylaws designate the Circuit Court for Baltimore City, Maryland as the sole and exclusive forum for certain actions and proceedings that may be initiated by our stockholders.
Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Circuit Court for Baltimore City, Maryland, or, if that court does not have jurisdiction, the United States District Court for the District of Maryland, Northern Division, is the sole and exclusive forum for (a) any derivative action or proceeding brought on our behalf, other than actions arising under federal securities laws; (b) any Internal Corporate Claim, as such term is defined in the Maryland General Corporation Law (the “MGCL”), or any successor provision thereof, including, without limitation, (i) any action asserting a claim of breach of any duty owed by any of our directors, officers or other employees to us or to our stockholders or (ii) any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the MGCL, our charter or our bylaws; or (c) any other action asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine. Our bylaws also provide that unless we consent in writing, none of the foregoing actions, claims or proceedings may be brought in any court sitting outside the State of Maryland and the federal district courts are, to the fullest extent permitted by law, the sole and exclusive forum for the resolution of any complaint asserting a cause of action under the Securities Act. These choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that the stockholder believes is favorable. Alternatively, if a court were to find these provisions of our bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving these matters in other jurisdictions.
Certain provisions in our bylaws and agreements may deter, delay or prevent a change in our control.
Provisions contained in our bylaws may deter, delay or prevent a change in control of our board of directors, including, for example, provisions requiring qualifications for an individual to serve as a director and a requirement that certain of our directors be “Managing Directors” and other directors be “Independent Directors”, as defined in our governing documents. As changes occur in the marketplace for corporate governance policies, the provisions may change, be removed or new ones may be added.
Maryland law limits the ability of a third-party to buy a large stake in us and exercise voting power in electing directors, which may discourage a third-party from acquiring us in a manner that might result in a premium price to our stockholders.
The Maryland Control Share Acquisition Act provides that holders of “control shares” of a Maryland corporation acquired in a “control share acquisition” have no voting rights except to the extent approved by the stockholders by the affirmative vote of two-thirds of all the votes entitled to be cast on the matter, excluding all shares of stock owned by the acquirer, by officers or by employees who are directors of the corporation. “Control shares” are voting shares of stock which, if aggregated with all other shares of stock owned by the acquirer or in respect of which the acquirer can exercise or direct the exercise of voting power (except solely by virtue of a revocable proxy), would entitle the acquirer to exercise voting power in electing directors within specified ranges of voting power. Control shares do not include shares the acquiring person is then entitled to vote as a result of having previously obtained stockholder approval or shares acquired directly from the corporation. A “control share acquisition” means the acquisition of issued and outstanding control shares. The Maryland Control Share Acquisition Act does not apply (a) to shares acquired in a merger, consolidation or share exchange if the corporation is a party to the transaction, or (b) to acquisitions approved or exempted by the charter or bylaws of the corporation.
Our bylaws contain a provision exempting from the Maryland Control Share Acquisition Act any and all acquisitions of our stock by any person. There can be no assurance that this provision will not be amended or eliminated at any time in the future.
If our stockholders do not agree with the decisions of the board, our stockholders only have limited control over changes in our policies and operations and may not be able to change our policies and operations.
The board determines our major policies, including our policies regarding investments, financing, growth, debt capitalization, REIT qualification and dividends and other distributions. The board may amend or revise these and other policies without a vote of the stockholders except to the extent that the policies are set forth in our charter. Under MGCL and our charter, our common stockholders have a right to vote only on the following:
the election or removal of directors;
amendment of our charter, except that the board may amend our charter without stockholder approval to (a) increase or decrease the aggregate number of our shares of stock or the number of shares of stock of any class or series that we have the authority to issue, (b) effect certain reverse stock splits, and (c) change our name or the name or other designation or the par value of any class or series of our stock and the aggregate par value of our stock;
our liquidation or dissolution;
certain reorganizations of our company; and
certain mergers, consolidations or sales or other dispositions of all or substantially all our assets
All other matters are subject to the discretion of the board. Holders of our Series A Preferred Stock and Series B Preferred Stock have extremely limited voting rights.
41

The stockholder rights plan adopted by our board of directors may discourage a third-party from acquiring us in a manner that might result in a premium price to our stockholders.
Our board of directors previously adopted a stockholder rights plan that will expire in May 2023 or sooner under certain circumstances. In connection with the rights plan, in December 2020, we paid a dividend of one common share purchase right for each share of our common stock outstanding as authorized by our board in its discretion. If a person or entity, together with its affiliates and associates, acquires beneficial ownership of 2.0% or more of our then outstanding common stock, subject to certain exceptions, each right would entitle its holder (other than the acquirer, its affiliates and associates) to purchase additional shares of our common stock at a substantial discount to the then current per share estimated net asset value. In addition, under certain circumstances, we may exchange the rights (other than rights beneficially owned by the acquirer, its affiliates and associates), in whole or in part, for shares of common stock on a one-for-one basis. The stockholder rights plan could make it more difficult for a third-party to acquire the Company or a large block of our common stock without the approval of our board or directors, which may discourage a third-party from acquiring us in a manner that might result in a premium price to our stockholders.
We depend on our OP and its subsidiaries for cash flow and are structurally subordinated in right of payment to the obligations of our OP and its subsidiaries.
We conduct, and intend to continue conducting, all of our business operations through our OP, and, accordingly, we rely on distributions from our OP and its subsidiaries to provide cash to pay our obligations. There is no assurance that our OP or its subsidiaries will be able to, or be permitted to, pay distributions to us that will enable us to pay dividends and other distributions to our stockholders and meet our other obligations. Each of our OP’s subsidiaries is a distinct legal entity and, under certain circumstances, legal and contractual restrictions may limit our ability to obtain cash from these entities. In addition, any claims we may have will be structurally subordinated to all existing and future liabilities and obligations of our OP and its subsidiaries. Therefore, in the event of our bankruptcy, liquidation or reorganization, our assets and those of our OP and its subsidiaries will be available to satisfy the claims of our creditors or to pay dividends and other distributions to our stockholders only after all the liabilities and obligations of our OP and its subsidiaries have been paid in full.
We indemnify our officers, directors, our Advisor and its affiliates against claims or liability they may become subject to due to their service to us, and our rights and the rights of our stockholders to recover claims against our officers, directors, our Advisor and its affiliates are limited.
Maryland law provides that a director has no liability in that capacity if he or she performs his or her duties in good faith, in a manner he or she reasonably believes to be in the corporation’s best interests and with the care that an ordinarily prudent person in a like position would use under similar circumstances. In addition, subject to certain limitations set forth therein or under Maryland law, our charter provides that no director or officer will be liable to us or our stockholders for monetary damages and permits us to indemnify our directors and officers from liability and advance certain expenses to them in connection with claims or liability they may become subject to due to their service to us, and we are not restricted from indemnifying our Advisor or its affiliates on a similar basis. We have entered into indemnification agreements consistent with Maryland law and our charter with our directors and officers, certain former directors and officers, our Advisor and AR Global. We and our stockholders may have more limited rights against our directors, officers, employees and agents, and our Advisor and its affiliates, than might otherwise exist under common law, which could reduce the recovery of our stockholders and our recovery against them. In addition, we may be obligated to fund the defense costs incurred by our directors, officers, employees and agents or our Advisor and its affiliates in some cases. Subject to conditions and exceptions, we also indemnify our Advisor and its affiliates from losses arising in the performance of their duties under the advisory agreement and have agreed to advance certain expenses to them in connection with claims or liability they may become subject to due to their service to us.

U.S. Federal Income Tax Risks

Our failure to remain qualified as a REIT would subject us to U.S. federal income tax and potentially state and local tax.
We elected to be taxed as a REIT, commencing with our taxable year ended December 31, 2013, and intend to operate in a manner that will allow us to continue to qualify as a REIT for U.S. federal income tax purposes. However, we may terminate our REIT qualification inadvertently, or if the Board determines that doing so is in our best interests. Our qualification as a REIT depends upon our satisfaction of certain asset, income, organizational, distribution, stockholder ownership and other requirements on a continuing basis. We have structured, and intend to continue structuring, our activities in a manner designed to satisfy all the requirements to qualify as a REIT. However, the REIT qualification requirements are extremely complex and interpretation of the U.S. federal income tax laws governing qualification as a REIT is limited. Furthermore, any opinion of our counsel, including tax counsel, as to our eligibility to remain qualified as a REIT is not binding on the Internal Revenue Service (the “IRS”) and is not a guarantee that we will continue to qualify as a REIT. Accordingly, we cannot be certain that we will be successful in operating so that we can remain qualified as a REIT. Our ability to satisfy the asset tests depends on our analysis of the characterization and fair market values of our assets, some of which are not susceptible to a precise determination, and
42

for which we will not obtain independent appraisals. Our compliance with the REIT income or quarterly asset requirements also depends on our ability to successfully manage the composition of our income and assets on an ongoing basis. Accordingly, if certain of our operations were to be recharacterized by the IRS, such recharacterization would jeopardize our ability to satisfy all requirements for qualification as a REIT. Furthermore, future legislative, judicial or administrative changes to the U.S. federal income tax laws could be applied retroactively, which could result in our disqualification as a REIT.
If we fail to continue to qualify as a REIT for any taxable year, and we do not qualify for certain statutory relief provisions, we will be subject to U.S. federal income tax on our taxable income at the corporate rate. In addition, we would generally be disqualified from treatment as a REIT for the four taxable years following the year in which we lose our REIT qualification. Losing our REIT qualification would reduce our net earnings available for investment or distribution to stockholders because of the additional tax liability. In addition, amounts paid to stockholders that are treated as dividends for U.S. federal income tax purposes would no longer qualify for the dividends paid deduction, and we would no longer be required to make distributions. If we lose our REIT qualification, we might be required to borrow funds or liquidate some investments in order to pay the applicable taxes.
Even as a REIT, in certain circumstances, we may incur tax liabilities that would reduce our cash available for distribution to our stockholders.
Even as a REIT, we may be subject to U.S. federal, state and local income taxes. For example, net income from the sale of properties that are “dealer” properties sold by a REIT and that do not meet a safe harbor available under the Code (a “prohibited transaction” under the Code) will be subject to a 100% tax. We may not make sufficient distributions to avoid excise taxes applicable to REITs. Similarly, if we were to fail an income test (and did not lose our REIT status because such failure was due to reasonable cause and not willful neglect), we would be subject to tax on the income that does not meet the income test requirements. We also may decide to retain net capital gains we earn from the sale or other disposition of our property and pay U.S. federal income tax directly on such income. In that event, our stockholders would be treated as if they earned that income and paid the tax on it directly. However, stockholders that are tax-exempt, such as charities or qualified pension plans, would have no benefit from their deemed payment of such tax liability unless they file U.S. federal income tax returns and seek a refund of such tax. We also will be subject to corporate tax on any undistributed REIT taxable income. We also may be subject to state and local taxes on our income or property, including franchise, payroll and transfer taxes, either directly or at the level of the OP or at the level of the other companies through which we indirectly own our assets, such as any TRSs, which are subject to full U.S. federal, state, local and foreign corporate-level income taxes. Any taxes we pay directly or indirectly will reduce our cash flow.
To qualify as a REIT, we must meet annual distribution requirements, which may force us to forgo otherwise attractive opportunities or borrow funds during unfavorable market conditions. This could delay or hinder our ability to meet our investment objectives and reduce our stockholders’ overall return.
In order to qualify as a REIT, we must distribute annually to our stockholders at least 90% of our REIT taxable income (which does not equal net income as calculated in accordance with GAAP), determined without regard to the deduction for dividends paid and excluding net capital gain. We will be subject to U.S. federal income tax on our undistributed REIT taxable income and net capital gain and to a 4% nondeductible excise tax on any amount by which distributions we make with respect to any calendar year are less than the sum of (a) 85% of our ordinary income, (b) 95% of our capital gain net income and (c) 100% of our undistributed income from prior years. These requirements could cause us to distribute amounts that otherwise would be spent on investments in real estate assets and it is possible that we might be required to borrow funds, possibly at unfavorable rates, or sell assets to fund these distributions. Although we intend to make distributions sufficient to meet the annual distribution requirements and to avoid U.S. federal income and excise taxes on our earnings while we qualify as a REIT, it is possible that we might not always be able to do so.
Recharacterization of sale-leaseback transactions may cause us to lose our REIT status.
We will use commercially reasonable efforts to structure any sale-leaseback transaction we enter into so that the lease will be characterized as a “true lease” for U.S. federal income tax purposes, thereby allowing us to be treated as the owner of the property for U.S. federal income tax purposes. However, the IRS may challenge this characterization. In the event that any sale-leaseback transaction is challenged and recharacterized as a financing transaction or loan for U.S. federal income tax purposes, deductions for depreciation and cost recovery relating to the property would be disallowed. If a sale-leaseback transaction were so recharacterized, we might fail to continue to satisfy the REIT qualification asset tests or income tests and, consequently, lose our REIT status effective with the year of recharacterization. Alternatively, the amount of our REIT taxable income could be recalculated which might also cause us to fail to meet the distribution requirement for a taxable year.
Certain of our business activities are potentially subject to the prohibited transaction tax.
For so long as we qualify as a REIT, our ability to dispose of property during the first few years following acquisition may be restricted to a substantial extent as a result of our REIT qualification. Under applicable provisions of the Code regarding prohibited transactions by REITs, while we qualify as a REIT and provided we do not meet a safe harbor available under the Code, we will be subject to a 100% penalty tax on the net income from the sale or other disposition of any property (other than
43

foreclosure property) that we own, directly or indirectly through any subsidiary entity, including the OP, but generally excluding TRSs, that is deemed to be inventory or property held primarily for sale to customers in the ordinary course of a trade or business. Whether property is inventory or otherwise held primarily for sale to customers in the ordinary course of a trade or business depends on the particular facts and circumstances surrounding each property. We intend to avoid the 100% prohibited transaction tax by (a) conducting activities that may otherwise be considered prohibited transactions through a TRS (but such TRS will incur corporate rate income taxes with respect to any income or gain recognized by it), (b) conducting our operations in such a manner so that no sale or other disposition of an asset we own, directly or indirectly through any subsidiary, will be treated as a prohibited transaction, and (c) structuring certain dispositions of our properties to comply with the requirements of the prohibited transaction safe harbor available under the Code for properties that, among other requirements, have been held for at least two years. Despite our present intention, no assurance can be given that any particular property we own, directly or through any subsidiary entity, including the OP, but generally excluding TRSs, will not be treated as inventory or property held primarily for sale to customers in the ordinary course of a trade or business.
TRSs are subject to corporate-level taxes and our dealings with TRSs may be subject to a 100% excise tax.
A REIT may own up to 100% of the stock of one or more TRSs. Both the subsidiary and the REIT must jointly elect to treat the subsidiary as a TRS. A corporation of which a TRS directly or indirectly owns more than 35% of the voting power or value of the stock will automatically be treated as a TRS. Overall, no more than 20% (25% for taxable years beginning prior to January 1, 2018) of the gross value of a REIT’s assets may consist of stock or securities of one or more TRSs. A TRS may hold assets and earn income that would not be qualifying assets or income if held or earned directly by a REIT, including gross income from operations pursuant to management contracts. We may lease some of our seniors housing properties that are “qualified health care properties” to one or more TRSs which, in turn, contract with independent third-party management companies to operate those qualified health care properties on behalf of those TRSs. In addition, we may use one or more TRSs generally to hold properties for sale in the ordinary course of a trade or business or to hold assets or conduct activities that we cannot conduct directly as a REIT. A TRS is subject to applicable U.S. federal, state, local and foreign income tax on its taxable income, as well as limitations on the deductibility of its interest expenses. In addition, the Code imposes a 100% excise tax on certain transactions between a TRS and its parent REIT that are not conducted on an arm’s-length basis.
If the OP failed to qualify as a partnership or is not otherwise disregarded for U.S. federal income tax purposes, we would cease to qualify as a REIT.
If the IRS were to successfully challenge the status of the OP as a partnership or disregarded entity for U.S. federal income tax purposes, the OP would be taxable as a corporation. In such event, this would reduce the amount of distributions that the OP could make to us. This also would result in our failing to qualify as a REIT, and we would become subject to a corporate-level tax on our income. This substantially would reduce our cash available to pay dividends and other distributions to our stockholders. In addition, if any of the partnerships or limited liability companies through which the OP owns its properties, in whole or in part, loses its characterization as a partnership and is otherwise not disregarded for U.S. federal income tax purposes, the partnership or limited liability company would be subject to taxation as a corporation, thereby reducing distributions to the OP. Such a recharacterization of an underlying property owner could also threaten our ability to maintain our REIT qualification.
If our qualified health care properties are not properly leased to a TRS or the managers of those qualified health care properties do not qualify as “eligible independent contractors,” we could fail to qualify as a REIT.
In general, under the REIT rules, we cannot directly operate any of our seniors housing properties that are qualified health care properties and can only indirectly participate in the operation of qualified health care properties on an after-tax basis by leasing those properties to independent health care facility operators or to TRSs. A qualified health care property is any real property (and any personal property incident to that real property), which is, or is necessary or incidental to the use of, a hospital, nursing facility, assisted living facilities, congregate care facility, qualified continuing care facility, or other licensed facility which extends medical or nursing or ancillary services to patients and is operated by a provider of those services that is eligible for participation in the Medicare program with respect to that facility. Furthermore, rent paid by a lessee of a qualified health care property that is a “related party tenant” of ours will not be qualifying income for purposes of the two gross income tests applicable to REITs. However, a TRS that leases qualified health care properties from us will not be treated as a related party tenant with respect to our qualified health care properties that are managed by an eligible independent contractor.
An eligible independent contractor is an independent contractor that, at the time such contractor enters into a management or other agreement with a TRS to operate a qualified health care property, is actively engaged in the trade or business of operating qualified health care properties for any person not related to us or the TRS. Among other requirements to qualify as an independent contractor, a manager must not own, directly or applying attribution provisions of the Code, more than 35% of the shares of our outstanding stock (by value), and no person or group of persons can own more than 35% of the shares of our outstanding stock and 35% of the ownership interests of the manager (taking into account only owners of more than 5% of our shares and, with respect to ownership interest in such managers that are publicly traded, only holders of more than 5% of such ownership interests). The ownership attribution rules that apply for purposes of the 35% thresholds are complex. There can be no assurance that the levels of ownership of our shares by our managers and their owners will not be exceeded.
44

If our leases with TRSs are not respected as true leases for U.S. federal income tax purposes, we likely would fail to qualify as a REIT.
To qualify as a REIT, we must satisfy two gross income tests, under which specified percentages of our gross income must be derived from certain sources, such as “rents from real property.” Rent paid by TRSs to the OP pursuant to the lease of our qualified healthcare properties will constitute a substantial portion of our gross income. For that rent to qualify as rents from real property for purposes of the REIT gross income tests, the leases must be respected as true leases for U.S. federal income tax purposes and not be treated as service contracts, joint ventures or some other type of arrangement. If our leases are not respected as true leases for U.S. federal income tax purposes, we may fail to qualify as a REIT.
We may choose to make distributions in shares of our common stock, in which case our stockholders may be required to pay U.S. federal income taxes in excess of the cash portion of distributions they receive.
In connection with our qualification as a REIT, we are required to distribute annually to our stockholders at least 90% of our REIT taxable income (which does not equal net income as calculated in accordance with GAAP), determined without regard to the deduction for dividends paid and excluding net capital gain. In order to satisfy this requirement, as much as 80% of the aggregate distributions may be in shares of our common stock. Taxable stockholders receiving such distributions will be required to include the full amount of such distributions as ordinary dividend income to the extent of our current or accumulated earnings and profits, as determined for U.S. federal income tax purposes. As a result, U.S. stockholders may be required to pay U.S. federal income taxes with respect to such distributions in excess of the cash portion of the distribution received.
Accordingly, U.S. stockholders receiving a distribution of shares of our common stock may be required to sell shares received in such distribution or may be required to sell other stock or assets owned by them, at a time that may be disadvantageous, in order to satisfy any tax imposed on such distribution. If a U.S. stockholder sells the shares that it receives as part of the distribution in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the distribution, depending on the value of the shares at the time of the sale. Furthermore, with respect to certain non-U.S. stockholders, we may be required to withhold U.S. tax with respect to such distribution, including in respect of all or a portion of such distribution that is payable in stock, by withholding or disposing of part of the shares included in such distribution and using the proceeds of such disposition to satisfy the withholding tax imposed. Because there is no established trading market for shares of our common stock, stockholders may not be able to sell shares of our common stock to pay taxes owed on dividend income.
The taxation of distributions can be complex; however, distributions to stockholders that are treated as dividends for U.S. federal income tax purposes generally will be taxable as ordinary income, which may reduce our stockholders’ after-tax anticipated return from an investment in us.
Amounts that we pay to our taxable stockholders out of current and accumulated earnings and profits (and not designated as capital gain dividends or qualified dividend income) generally will be treated as dividends for U.S. federal income tax purposes and will be taxable as ordinary income. Noncorporate stockholders are entitled to a 20% deduction with respect to these ordinary REIT dividends which would, if allowed in full, result in a maximum effective U.S. federal income tax rate on these ordinary REIT dividends of 29.6% (or 33.4% including the 3.8% surtax on net investment income); however, the 20% deduction will end after December 31, 2025.
However, a portion of the amounts that we pay to our stockholders generally may (a) be designated by us as capital gain dividends taxable as long-term capital gain to the extent that such portion is attributable to net capital gain recognized by us, (b) be designated by us as qualified dividend income, taxable at capital gains rates, to the extent that such portion is attributable to dividends we receive from TRSs, or (c) constitute a return of capital to the extent that such portion exceeds our accumulated earnings and profits as determined for U.S. federal income tax purposes. With respect to qualified dividend income, the current maximum U.S federal tax rate applicable to U.S. noncorporate stockholders is 20% (or 23.8% including the 3.8% surtax on net investment income). Dividends payable by REITs, however, generally are not eligible for this reduced rate and, as described above, through December 31, 2025, will be subject to an effective rate of 29.6% (or 33.4% including the 3.8% surtax on net investment income). Although this does not adversely affect the taxation of REITs or dividends payable by REITs, the more favorable rates applicable to regular corporate qualified dividends could cause investors who are individuals, trusts and estates to perceive investments in REITs to be relatively less attractive than investments in the stock of non-REIT corporations that pay dividends, which could adversely affect the value of the stock of REITs, including shares of our stock. Tax rates could be changed in future legislation. A return of capital is not taxable but has the effect of reducing the tax basis of a stockholder’s investment in shares of our stock. Amounts paid to our stockholders that exceed our current and accumulated earnings and profits and a stockholder’s tax basis in shares of our stock generally will be taxable as capital gain.
45

Our stockholders may have tax liability on distributions that they elect to reinvest in shares of our common stock, but they would not receive the cash from such distributions to pay such tax liability.
Stockholders who participate in the DRIP will be deemed to have received, and for U.S. federal income tax purposes will be taxed on, the distributions reinvested in shares of our common stock to the extent the distributions were not a tax-free return of capital. In addition, our stockholders will be treated for tax purposes as having received an additional distribution to the extent the shares are purchased at a discount to fair market value. As a result, unless a stockholder is a tax-exempt entity, it may have to use funds from other sources to pay its tax liability on the distributions reinvested in shares of our common stock pursuant to the DRIP.
Complying with REIT requirements may limit our ability to hedge our liabilities effectively and may cause us to incur tax liabilities.
The REIT provisions of the Code may limit our ability to hedge our liabilities. Any income from a hedging transaction we enter into to manage the risk of interest rate changes, price changes or currency fluctuations with respect to borrowings made or to be made to acquire or carry real estate assets, or in certain cases to hedge previously acquired hedges entered into to manage risks associated with property that has been disposed of or liabilities that have been extinguished, if properly identified under applicable Treasury Regulations, does not constitute “gross income” for purposes of the 75% or 95% gross income tests. To the extent that we enter into other types of hedging transactions, the income from those transactions will likely be treated as non-qualifying income for purposes of both of the gross income tests. As a result of these rules, we may need to limit our use of advantageous hedging techniques or implement those hedges through a TRS. This could increase the cost of our hedging activities because the TRS would be subject to tax on gains or expose us to greater risks associated with changes in interest rates than we would otherwise want to bear. In addition, losses in a TRS generally will not provide any tax benefit, except for being carried forward against future taxable income of the TRS.
Complying with REIT requirements may force us to forgo or liquidate otherwise attractive investment opportunities.
To maintain our qualification as a REIT, we must ensure that we meet the REIT gross income tests annually and that at the end of each calendar quarter, at least 75% of the value of our assets consists of cash, cash items, government securities and qualified REIT real estate assets, including certain mortgage loans and certain kinds of mortgage-related securities. The remainder of our investment in securities (other than securities that qualify for the 75% asset test and securities of qualified REIT subsidiaries and TRSs) generally cannot exceed 10% of the outstanding voting securities of any one issuer, 10% of the total value of the outstanding securities of any one issuer, or 5% of the value of our assets as to any one issuer. In addition, no more than 20% of the value of our total assets may consist of stock or securities of one or more TRSs and no more than 25% of our assets may consist of publicly offered REIT debt instruments that do not otherwise qualify under the 75% asset test. If we fail to comply with these requirements at the end of any calendar quarter, we must correct the failure within 30 days after the end of the calendar quarter or qualify for certain statutory relief provisions to avoid losing our REIT qualification and suffering adverse tax consequences. As a result, we may be required to liquidate assets from our portfolio or not make otherwise attractive investments in order to maintain our qualification as a REIT.
The ability of the Board to revoke our REIT qualification without stockholder approval may subject us to U.S. federal income tax and reduce distributions to our stockholders.
Our charter provides that the Board may revoke or otherwise terminate our REIT election, without the approval of our stockholders, if it determines that it is no longer in our best interests to continue to qualify as a REIT. While we intend to maintain our qualification as a REIT, we may terminate our REIT election if we determine that qualifying as a REIT is no longer in our best interests. If we cease to be a REIT, we would become subject to corporate-level U.S. federal income tax on our taxable income (as well as any applicable state and local corporate tax) and would no longer be required to distribute most of our taxable income to our stockholders, which may have adverse consequences on our total return to our stockholders and on the value of shares of our stock.
We may be subject to adverse legislative or regulatory tax changes that could increase our tax liability, reduce our operating flexibility, and reduce the value of shares of our stock.
Changes to the tax laws may occur, and any such changes could have an adverse effect on an investment in shares of our stock or on the market value or the resale potential of our assets. Our stockholders are urged to consult with an independent tax advisor with respect to the status of legislative, regulatory or administrative developments and proposals and their potential effect on an investment in shares of our stock.
Although REITs generally receive better tax treatment than entities taxed as non-REIT “C corporations,” it is possible that future legislation would result in a REIT having fewer tax advantages, and it could become more advantageous for a company that invests in real estate to elect to be treated for U.S. federal income tax purposes as a non-REIT “C corporation.” As a result, our charter provides the Board with the power, under certain circumstances, to revoke or otherwise terminate our REIT election and cause us to be taxed as a non-REIT “C corporation,” without the vote of our stockholders. The Board has duties to us and could only cause such changes in our tax treatment if it determines that such changes are in our best interests.
46

The share ownership restrictions for REITs and the 9.8% share ownership limit in our charter may inhibit market activity in shares of our stock and restrict our business combination opportunities.
In order to qualify as a REIT, five or fewer individuals, as defined in the Code, may not own, actually or constructively, more than 50% in value of the issued and outstanding shares of our stock at any time during the last half of each taxable year, other than the first year for which a REIT election is made. Attribution rules in the Code determine if any individual or entity actually or constructively owns shares of our stock under this requirement. Additionally, at least 100 persons must beneficially own shares of our stock during at least 335 days of a taxable year for each taxable year, other than the first year for which a REIT election is made. To help ensure that we meet these tests, among other purposes, our charter restricts the acquisition and ownership of shares of our stock.
Our charter, with certain exceptions, authorizes our directors to take such actions as are necessary and desirable to preserve our qualification as a REIT while we so qualify. Unless exempted by the Board, for so long as we qualify as a REIT, our charter prohibits, among other limitations on ownership and transfer of shares of our stock, any person from beneficially or constructively owning (applying certain attribution rules under the Code) more than 9.8% in value of the aggregate outstanding shares of our stock and more than 9.8% (in value or in number of shares, whichever is more restrictive) of any class or series of the outstanding shares of our stock. The Board may not grant an exemption from these restrictions to any proposed transferee whose ownership in excess of the 9.8% ownership limit would result in the termination of our qualification as a REIT. These restrictions on transferability and ownership will not apply, however, if the Board determines that it is no longer in our best interests to continue to qualify as a REIT or that compliance with the restrictions is no longer required in order for us to continue to so qualify as a REIT.
These ownership limits could delay or prevent a transaction or a change in control that might involve a premium price for shares of our stock or otherwise be in the best interests of the stockholders.
Non-U.S. stockholders will be subject to U.S. federal withholding tax and may be subject to U.S. federal income tax on dividends and other distributions received from us and upon the disposition of shares of our stock.
Subject to certain exceptions, amounts paid to non-U.S. stockholders will be treated as dividends for U.S. federal income tax purposes to the extent of our current or accumulated earnings and profits. Such dividends ordinarily will be subject to U.S. withholding tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty, unless the dividends are treated as “effectively connected” with the conduct by the non-U.S. stockholder of a U.S. trade or business. Capital gain distributions attributable to sales or exchanges of “U.S. real property interests” (“USRPIs”), generally will be taxed to a non-U.S. stockholder (other than a “qualified foreign pension fund,” certain entities wholly owned by a qualified foreign pension fund and certain foreign publicly-traded entities) as if such gain were effectively connected with a U.S. trade or business. However, a capital gain distribution will not be treated as effectively connected income if (a) the distribution is received with respect to a class of stock that is regularly traded on an established securities market located in the U.S. and (b) the non-U.S. stockholder does not own more than 10% of any class of our stock at any time during the one-year period ending on the date the distribution is received.
Gain recognized by a non-U.S. stockholder upon the sale or exchange of shares of our stock generally will not be subject to U.S. federal income taxation unless such stock constitutes a USRPI . Shares of our stock will not constitute a USRPI so long as we are a “domestically-controlled qualified investment entity.” A domestically-controlled qualified investment entity includes a REIT if at all times during a specified testing period, less than 50% in value of such REIT’s stock is held directly or indirectly by non-U.S. stockholders. Recently proposed regulations would apply special look-through rules to certain U.S. corporate stockholders in determining whether a REIT is domestically controlled. We believe, but there can be no assurance, that we will be a domestically-controlled qualified investment entity.
Even if we do not qualify as a domestically-controlled qualified investment entity at the time a non-U.S. stockholder sells or exchanges shares of our stock, gain arising from such a sale or exchange would not be subject to U.S. taxation as a sale of a USRPI if (a) the shares are of a class of our stock that is “regularly traded,” as defined by applicable Treasury regulations, on an established securities market, and (b) such non-U.S. stockholder owned, actually and constructively, 10% or less of the outstanding shares of our stock of that class at any time during the five-year period ending on the date of the sale.
Potential characterization of dividends and other distributions or gain on sale may be treated as unrelated business taxable income to tax-exempt investors.
If (a) we are a “pension-held REIT,” (b) a tax-exempt stockholder has incurred (or is deemed to have incurred) debt to purchase or hold shares of our stock, or (c) a holder of shares of our stock is a certain type of tax-exempt stockholder, dividends on, and gains recognized on the sale of, shares of our stock by such tax-exempt stockholder may be subject to U.S. federal income tax as unrelated business taxable income under the Code.
Item 1B. Unresolved Staff Comments.
None.
47

Item 2. Properties
The following table presents certain additional information about the properties we owned as of December 31, 2022:
PortfolioNumber
of Properties
Rentable
Square Feet
Percent Leased (1)
Weighted Average Remaining Lease Term (2)
Gross Asset Value (3)
(In thousands)
Medical Office and Other Healthcare Related Buildings1505,090,957 90.4%4.9$1,423,804 
Seniors Housing — Operating Properties52(4)4,030,413 75.1%(5)N/A1,140,608 
Total Portfolio2029,121,370 $2,564,412 
_______________
(1)Inclusive of leases signed but not yet commenced as of December 31, 2022.
(2)Weighted-average remaining lease term in years is calculated based on square feet as of December 31, 2022.
(3)Gross asset value represents total real estate investments, at cost ($2.6 billion total as of December 31, 2022), net of gross market lease intangible liabilities ($23.5 million total as of December 31, 2022). Impairment charges are already reflected within gross asset value.
(4)Includes two parcels of land.
(5)Weighted by unit count as of December 31, 2022. As of December 31, 2022, we had 4,374 rentable units in our SHOP segment. Excludes land parcels.
N/A    Not applicable.

48

The following table details the geographic distribution, by state, of our portfolio as of December 31, 2022:
StateNumber of Properties
Annualized Rental Income (1)
Annualized Rental Income as a Percentage of the Total PortfolioRentable Square FeetPercentage of Portfolio
Rentable Square Feet
Rentable Units in SHOP Segment
(In thousands)
Alabama1$176 0.1 %5,564 0.1 %
Arizona149,743 3.1 %509,534 5.6 %
Arkansas314,615 4.7 %248,783 2.7 %299
California818,580 5.9 %446,723 4.9 %247
Colorado31,727 0.6 %67,016 0.7 %
Florida2360,216 19.2 %1,099,729 12.1 %812
Georgia1627,439 8.7 %802,691 8.8 %624
Idaho13,959 1.3 %55,846 0.6 %95
Illinois2124,855 7.9 %858,036 9.4 %356
Indiana84,693 1.5 %208,672 2.3 %
Iowa1429,185 9.3 %585,667 6.4 %679
Kansas14,309 1.4 %49,360 0.5 %71
Kentucky23,952 1.3 %92,875 1.0 %114
Louisiana1656 0.2 %17,830 0.2 %
Maryland11,046 0.3 %36,260 0.4 %
Massachusetts3846 0.3 %36,563 0.4 %
Michigan1114,705 4.7 %420,298 4.6 %311
Minnesota11,098 0.4 %36,375 0.4 %
Mississippi31,716 0.5 %73,859 0.8 %
Missouri27,715 2.5 %96,016 1.1 %146
Nevada23,270 1.0 %86,342 0.9 %
New Jersey1773 0.2 %25,164 0.3 %
New York42,598 0.8 %119,602 1.3 %
North Carolina31,555 0.5 %90,650 1.0 %
Ohio57,863 2.5 %172,085 1.9 %
Oklahoma21,092 0.3 %47,407 0.5 %
Oregon27,551 2.4 %267,748 2.9 %252
Pennsylvania1731,195 9.9 %1,442,824 15.8 %289
South Carolina21,103 0.4 %52,527 0.6 %
Tennessee33,219 1.0 %177,489 1.9 %
Texas96,693 2.1 %403,369 4.4 %
Virginia11,633 0.3 %62,165 0.7 %
Washington12,031 0.6 %52,900 0.6 %
Wisconsin1311,810 3.8 %373,401 4.1 %79
Total202$313,617 100 %9,121,370 100 %4,374
49

__________
(1)Annualized rental income on a straight-line basis for the leases in place in the property portfolio as of December 31, 2022, which includes tenant concessions such as free rent, as applicable, as well as annualized gross revenue from our SHOPs based off the fourth quarter of 2022.
Future Minimum Lease Payments
The following table presents future minimum base rental cash payments due to us (excluding our SHOP segment) over the next ten years and thereafter as of December 31, 2022. The SHOP segment is excluded as the leases of units with residents are generally for annual periods or month to month. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to performance thresholds and increases in annual rent based on exceeding certain economic indexes, among other items.
(In thousands)Future Minimum
Base Rent Payments
2023$106,009 
202499,507 
202588,452 
202680,462 
202762,175 
202845,274 
202938,165 
203034,468 
203129,247 
203222,472 
Thereafter45,649 
$651,880 
Future Lease Expirations Table
The following is a summary of lease expirations for the next ten years at the properties we owned (excluding our SHOP segment) as of December 31, 2022:
Year of Expiration
Number of Leases Expiring
Annualized Rental Income (1)
Annualized Rental Income as a Percentage of the Total Portfolio
Leased Rentable Square Feet
Percent of Portfolio Rentable Square Feet Expiring
(In thousands)
202370$6,249 5.8%272,362 5.9%
20249912,069 11.2%543,459 11.9%
2025717,788 7.3%326,401 7.1%
20268217,801 16.6%1,000,453 21.8%
20279515,701 14.6%815,793 17.8%
20283410,457 9.7%397,495 8.7%
2029203,191 3.0%140,652 3.1%
2030234,498 4.2%182,801 4.0%
2031154,820 4.5%174,374 3.8%
20322913,049 12.2%435,838 9.5%
Total538$95,623 89.1%4,289,628 93.6%
_____________
(1)Annualized rental income on a straight-line basis for the leases in place in the property portfolio as of December 31, 2022, which includes tenant concessions such as free rent, as applicable.
Tenant Concentration
As of December 31, 2022, we did not have any tenants (including for this purpose, all affiliates of such tenants) whose annualized rental income on a straight-line basis represented 10% or more of total annualized rental income on a straight-line basis for our portfolio.
Significant Portfolio Properties
As of December 31, 2022, the rentable square feet or annualized rental income on a straight-line basis of one property represented 5% or more of our total portfolio’s rentable square feet or annualized rental income on a straight-line basis:
50

Wellington at Hershey’s Mill - West Chester, PA
In December 2014, we purchased Wellington at Hershey’s Mill, a seniors housing property located in West Chester, Pennsylvania. Wellington at Hershey’s Mill, which is leased to our TRS and operated and managed on our behalf by a third-party operator in our SHOP segment, contains 491,710 rentable square feet and consists of 193 units dedicated to independent living patients, 64 units dedicated to assisted living patients and 32 units dedicated to memory care patients. As of December 31, 2022, this property represented 5.4% of our total rentable square feet and 4.8% of our total annualized rental income on a straight-line basis.
Property Financings
See Note 4 — Mortgage Notes Payable, Net and Note 5 — Credit Facilities to our consolidated financial statements in this Annual Report on Form 10-K for property financings as of December 31, 2022 and 2021.

Item 3. Legal Proceedings.
We are not a party to, and none of our properties are subject to, any material pending legal proceedings.
Item 4. Mine Safety Disclosures.
Not applicable.
51

PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Market Information
No established public market currently exists for our shares of common stock. Until our shares are listed on a national exchange, if ever, our stockholders may not sell their shares unless the buyer meets the applicable suitability and minimum purchase requirements.
Estimated Per-Share Net Asset Value
Overview
On March 28, 2022, the independent directors of the Board, who comprise a majority of the Board, unanimously approved an estimated per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2021 (the “Valuation Date”) equal to $15.00. The Estimated Per-Share NAV of $15.00 fell within the range of the values reported by Kroll, LLC ("Kroll"), an independent third-party real estate advisory firm engaged by us. The range of values provided by Kroll was based on the estimated fair value of our assets less the estimated fair value of our liabilities and the liquidation value of our Series A Preferred Stock and the liquidation value of our Series B Preferred Stock, divided by 99,717,390 shares of common stock outstanding as of December 31, 2021. The common stock outstanding amount used to calculate the Estimated Per-Share NAV as of December 31, 2021 included the dividends declared and issued entirely in shares of our common stock through December 31, 2021, but did not include any other dividend declared and payable in whole or in part in shares of our common stock subsequent to December 31, 2021.
In determining the Estimated Per-Share NAV of $15.00, the independent directors of the Board considered various factors, including the information provided by Kroll, the impact of the stock dividend that was issued in January 2022, the fact that properties held for sale or under contract for sale at December 31, 2021 were valued based on their contract sale prices and without giving consideration to the reinvestment of the sale proceeds, and the impact of the COVID-19 pandemic.
The Estimated Per-Share NAV has not been adjusted for any stock dividend(s) issued subsequent to December 31, 2021 and will not be until a new Estimated Per-Share NAV is published. We intend to publish an Estimated Per-Share NAV as of December 31, 2022 in early April 2023.
Process
Consistent with our valuation guidelines, we engaged Kroll to perform appraisals of our real estate assets (each asset individually, a “Real Estate Asset” and collectively, the “Real Estate Assets”) as of the Valuation Date and provided a valuation range for each Real Estate Asset. In addition, Kroll was engaged to review, and incorporate in its report, our market value estimate regarding other assets, liabilities, and the liquidation value of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock as of the Valuation Date. Kroll has extensive experience estimating the fair value of commercial real estate.
The method used by Kroll to appraise the Real Estate Assets in the report furnished to the Advisor and the Board by Kroll (the “Kroll Report”) complies with the Institute of Portfolio Alternatives (formerly known as the Investment Program Association) Practice Guideline 2013-01 titled “Valuations of Publicly Registered Non-Listed REITs,” issued April 29, 2013. Also, Kroll advised that the scope of work performed was conducted in conformity with the requirements of the Code of Professional Ethics and Standards of Professional Practice of the Appraisal Institute. We have engaged Kroll for the past six years to assist in determining our Estimated Per-Share NAV. For preparing the Kroll Report, we paid Kroll a customary fee for services of this nature, no part of which was contingent relating to the provision of services or specific findings. Other than its engagement as described herein and its engagements to provide certain purchase price allocation and other real estate valuation services, Kroll does not have any direct interests in any transaction with us.
Potential conflicts of interest between Kroll, on one hand, and us or the Advisor, on the other hand, may arise as a result of (1) the impact of the findings of Kroll in relation to our Real Estate Assets, or the assets of real estate investment programs sponsored by affiliates of the Advisor, on the value of ownership interests owned by, or incentive compensation payable to, directors, officers or affiliates of us and the Advisor, or (2) Kroll performing valuation services for other programs sponsored by affiliates of the Advisor, as well as other services for us. While we and other programs sponsored by affiliates of the Advisor have engaged and may engage Kroll or its affiliates in the future for valuations and real estate-related services of various kinds, we believe that there are no material conflicts of interest with respect to our engagement of Kroll.
52

Valuation Methodology
Kroll performed a full valuation of our Real Estate Assets utilizing an income capitalization approach consisting of the Direct Capitalization Method or the Discounted Cash Flow Method and certain other approaches, including the acquisition price, disposition price, and sales comparison approach. These approaches are commonly used in the commercial real estate industry.
The Estimated Per-Share NAV is generally comprised of (i) the sum of (A) the estimated value of the Real Estate Assets and (B) the estimated value of the other assets, minus (ii) the sum of (C) the estimated value of debt and other liabilities (D) the estimate of the aggregate incentive fees, participations and limited partnership interests held by or allocable to the Advisor, our management or any of the respective affiliates based on our aggregate net asset value and payable in our hypothetical liquidation as of the Valuation Date (which was zero as of December 31, 2021), and (E) the liquidation value of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock, divided by (iii) the number of shares of common stock outstanding as of the Valuation Date, which was 99,717,390. In determining the Estimated Per-Share NAV, the independent directors of the Board also considered the impact of other factors described herein that were not specifically quantified. Shares of common stock outstanding for these purposes is the sum of shares of common stock outstanding, including vested and unvested restricted shares, and partnership units of our operating partnership designated as “Common OP Units,” excluding performance-based restricted partnership units of our operating partnership designated as “Class B Units” because the Advisor concluded that, in a hypothetical liquidation at such Estimated Per-Share NAV, it may not be entitled to any incentive fees or Class B Units. The Advisor determined the Estimated Per-Share NAV in a manner consistent with the definition of fair value under U.S. generally accepted accounting principles set forth in FASB’s Topic ASC 820, Fair Value Measurements and Disclosures.
Limitations of the Estimated Per-Share NAV
The Estimated Per-Share NAV does not represent the: (i) the price at which shares of our common stock would trade at on a national securities exchange or a third party would pay for them, (ii) the amount stockholders would obtain if they tried to sell their shares of common stock or (iii) the amount stockholders would receive if we liquidated our assets and distributed the proceeds after paying all of our expenses and liabilities. Also, there is no assurance that the methodology used to establish the Estimated Per-Share NAV would be acceptable to the Financial Industry Regulatory Authority for use on customer account statements, or that the Estimated Per-Share NAV will satisfy the applicable annual valuation requirements under the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) and the Internal Revenue Code of 1986, as amended (the “Code”) with respect to employee benefit plans subject to ERISA and other retirement plans or accounts subject to Section 4975 of the Code. Further, the Estimated Per-Share NAV was calculated as of a specific date, and the value of shares of common stock will fluctuate over time as a result of, among other things, developments related to individual assets, changes in the real estate and capital markets, acquisitions or dispositions of assets and the distribution of proceeds from the sale of real estate to stockholders.
Conclusion
The Estimated Per-Share NAV as of December 31, 2021 of $15.00, a value within the range determined by Kroll, was unanimously adopted by the independent directors of the Board, who comprise a majority of the Board, with Mr. Weil abstaining, on March 28, 2022. The independent directors of the Board based their conclusions on their review of the Advisor’s analysis and recommendation, the Kroll Report, estimates and calculations and the fundamentals of the Real Estate Assets. The Board is ultimately and solely responsible for the Estimated Per-Share NAV. Estimated Per-Share NAV was determined at a moment in time and will likely change over time as a result of changes to the value of individual assets as well as changes and developments in the real estate and capital markets, including changes in interest rates.
Holders
As of March 14, 2023 we had 106,566,638 shares of common stock outstanding held by a total of 44,527 stockholders of record.
Dividends and Other Distributions
We elected to be taxed as a REIT for U.S. federal income tax purposes commencing with our taxable year ended December 31, 2013. As a REIT, we are required to distribute annually to our stockholders at least 90% of our REIT taxable income (which does not equal net income as calculated in accordance with GAAP), determined without regard for the deduction for dividends paid and excluding net capital gains.
53

The amount of dividends and other distributions payable to our stockholders is determined by the Board and is dependent on a number of factors, including funds available for dividends and other distribution, financial condition, provisions in our Credit Facility or other agreements that may restrict our ability to pay dividends and other distributions, capital expenditure requirements, as applicable, and annual dividends and other distribution requirements needed to maintain our status as a REIT under the Code. Under our Credit Facility, we may not pay cash distributions on our common stock until we have a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million (giving effect to the aggregate amount of distributions projected to be paid by us during the quarter in which we have elected to commence paying cash distributions on common stock) and our ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5%. As of December 31, 2022, our ratio of consolidated total indebtedness to consolidated total asset value for these purposes was 63.2%. Thus, we did not satisfy these conditions as of December 31, 2022, and our ability to make future cash distributions on our common stock will depend on our future cash flows and indebtedness and may further depend on our ability to obtain additional liquidity, which may not be available on favorable terms, or at all. Dividends and other distribution payments are not assured. Any accrued and unpaid dividends payable with respect to our Series A Preferred Stock must be paid upon redemption of those shares. For further information on provisions in our Credit Facility that restrict the payment of dividends and other distributions, see Note 5 — Credit Facility, Net to our consolidated financial statements included in this Annual Report on Form 10-K and Item 1A “Risk Factors. — We have not paid our distributions on our common stock in cash since 2020, and there can be no assurance we will pay distributions on our common stock in cash in the future.”
Distributions to Common Stockholders
From March 1, 2018 until June 30, 2020, we generally paid distributions on our common stock on a monthly basis at a rate equivalent of $0.85 per annum, per share of common stock. Distributions were generally paid by the 5th day following each month end to stockholders of record at the close of business each day during the prior month.
On August 13, 2020, the Board changed our common stock distribution policy in order to preserve our liquidity and maintain additional financial flexibility. Under the revised policy, distributions authorized by the Board on our shares of common stock, if and when declared, are paid on a quarterly basis in arrears in shares of our common stock valued at our estimated per share net asset value of common stock in effect on the applicable date, based on a single record date to be specified at the beginning of each quarter.
The following table details each stock dividend issued since October 1, 2020. The Board may further change our common stock distribution policy at any time, further reduce the amount of distributions paid or suspend distribution payments at any time, and therefore distribution payments are not assured.
Stock Dividend Declaration DateStock Dividend Issue DateDividend Basis (per share)Applicable NAV (per share)Quarterly Stock Dividend Rate (per share)
October 1, 2020October 15, 2020$0.85 $15.75 0.013492
January 4, 2021January 15, 2021$0.85 $15.75 0.013492
April 2, 2021April 15, 2021$0.85 $14.50 0.014655
July 1, 2021July 15, 2021$0.85 $14.50 0.014655
October 1, 2021October 15, 2021$0.85 $14.50 0.014655
January 3, 2022January 15, 2022$0.85 $14.50 0.014655
April 1, 2022April 18, 2022$0.85 $15.00 0.014167
July 1, 2022July 15, 2022$0.85 $15.00 0.014167
October 3, 2022October 17, 2022$0.85 $15.00 0.014167
January 3, 2023January 18, 2023$0.85 $15.00 0.014167
Dividends to Series A Preferred Stockholders
Dividends on our Series A Preferred Stock are declared quarterly in an amount equal to $1.84 per share each year ($0.46 per share per quarter) to Series A Preferred Stockholders, which is equivalent to 7.375% per annum on the $25.00 liquidation preference per share of Series A Preferred Stock. Dividends on the Series A Preferred Stock are cumulative and payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the next succeeding business day to holders of record on the close of business on the record date set by our board of directors and declared by us.
Dividends to Series B Preferred Stockholders
54

Dividends on our Series B Preferred Stock are declared quarterly in an amount equal to $1.78 per share each year ($0.45 per share per quarter) to Series B Preferred Stockholders, which is equivalent to 7.125% per annum on the $25.00 liquidation preference per share of Series B Preferred Stock. Dividends on the Series B Preferred Stock are cumulative and payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the next succeeding business day to holders of record on the close of business on the record date set by our board of directors and declared by us.
Tax Characteristics of Dividends
All common dividends in the years ended December 31, 2022 and 2021, and a portion of common dividends issued in the year ended December 31, 2020, were issued as stock dividends, which do not represent taxable dividends to shareholders for U.S. federal income tax purposes. The cash distributions paid to holders of common stock in the first half of the year ended December 31, 2020 were considered 100% return of capital. All dividends paid on the Series A Preferred Stock and Series B Preferred Stock (first payment was made in January 2022) were considered 100% return of capital for income for tax purposes for the years ended December 31, 2022, 2021 and 2020.
Sales of Unregistered Securities
None.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
In light of the amendment to the Credit Facility on August 10, 2020, which provides that we may not repurchase shares of our common stock until the Commencement Quarter, the Board suspended repurchases under the SRP effective August 14, 2020. No further repurchase requests under the SRP may be made unless and until the SRP is reactivated. For additional information on the SRP, see Note 8 — Stockholders’ Equity to our consolidated financial statements included in this Annual Report on Form 10-K.
The following table summarizes our SRP activity for the period presented.
Number of Common Shares RepurchasedAverage Price per Share
Cumulative repurchases as of December 31, 20214,896,620 $20.60 
Year ended December 31, 2022
— — 
Cumulative repurchases as of December 31, 20224,896,620 20.60 
Item 6. [Reserved].
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with the accompanying consolidated financial statements. The following information contains forward-looking statements, which are subject to risks and uncertainties. Should one or more of these risks or uncertainties materialize, actual results may differ materially from those expressed or implied by the forward-looking statements. Please see “Forward-Looking Statements” elsewhere in this Annual Report on Form 10-K for a description of these risks and uncertainties.
Overview
We are an externally managed real estate investment trust for U.S. federal income tax purposes (“REIT”) that focuses on acquiring and managing a diversified portfolio of healthcare-related real estate focused on medical office and other healthcare-related buildings and senior housing operating properties. Prior to December 31, 2021, we had three reportable segments 1) Former MOBs, 2) Former NNN and 3) SHOPs. As a result of strategic property divestitures in our Former NNN segment, and transitions of certain properties reported in our Former NNN segment into our SHOP segment, we have combined the properties in our Former NNN segment with the properties in our Former MOB segment to form a single set of MOBs. As a result, effective December 31, 2021 we have determined that we have two reportable segments, with activities related to investing in MOBs and SHOPs. All prior periods presented in this Annual Report on Form 10-K have been conformed to the presentation of our new reportable segment structure. As of December 31, 2022, we owned 202 properties located in 34 states and comprised of 9.1 million rentable square feet.
55

Substantially all of our business is conducted through the OP, a Delaware limited partnership, and its wholly owned subsidiaries. Our Advisor manages our day-to-day business with the assistance of our Property Manager. Our Advisor and Property Manager are under common control with AR Global and these related parties receive compensation and fees for providing services to us. We also reimburse these entities for certain expenses they incur in providing these services to us. The Special Limited Partner, which is also under common control with AR Global, also has an interest in us through ownership of interests in our OP.
We operate in two reportable business segments for management and financial reporting purposes: MOBs and SHOPs. In our MOB operating segment, we own, manage, and lease single and multi-tenant MOBs where tenants are required to pay their pro rata share of property operating expenses, which may be subject to expense exclusions and floors, in addition to base rent. Our Property Manager or third party managers manage our MOBs. In our SHOP segment, we invest in seniors housing properties using the RIDEA structure. As of December 31, 2022, we had four eligible independent contractors operating 52 SHOPs (including two land parcels). All of our properties across both business segments are located throughout the United States.
We have declared quarterly dividends entirely in shares of our common stock since October 2020 in order to preserve our liquidity in response to the COVID-19 pandemic.
Management Update on the Impacts of the COVID-19 Pandemic
The COVID-19 global pandemic created several risks and uncertainties that have had and may continue to have an impact on our business, including our financial condition, future results of operations and our liquidity. The extent to which the ongoing global COVID-19 pandemic, including the outbreaks that have occurred and may occur in markets where we own properties, impacts our operations and those of our tenants and third-party operators, will continue to depend on future developments, including the scope, severity and duration of the pandemic, and the actions taken to contain the COVID-19 pandemic or treat its impact, among others, which are highly uncertain and cannot be predicted with confidence, but could be material.
As of December 31, 2022, our MOB segment had an occupancy of 90.4% with a weighted-average remaining lease term of 4.9 years, (based on annualized straight-line rent as of December 31, 2022), and our SHOP segment had an occupancy of 75.1% weighted by unit count. Since the second quarter of 2021, we experienced relative stability in occupancy and operating costs in our SHOP portfolio, however, during the year ended December 31, 2022, it became necessary to increase our use of temporary contract labor and agencies, and the amount we pay for wages, including overtime wages, and bonuses, in response to a shortage of workers, largely due to, among other things, the spread of more transmissible COVID-19 variants, increased inflation raising the cost of labor generally and lack of qualified personnel that we are able to employ on a permanent basis. Utilization of contract labor and agencies for care providers increased operating costs in our SHOP segment for the year ended December 31, 2022, by $6.1 million as compared to the year ended December 31, 2021. Future developments in the course of the pandemic, inflation increases, labor shortages and supply chain disruptions may cause further adverse impacts on our occupancy and cost levels. Occupancy and operating costs in our MOB segment were relatively stable during these quarters.
The negative impact of the pandemic on our results of operations and cash flows has impacted and could continue to impact our ability to comply with covenants in our Credit Facility, and the amount available for future borrowings thereunder. For example, we would have been in default of a covenant contained in the Credit Facility requiring us to maintain a certain minimum fixed charge coverage ratio for the fiscal quarter ended June 30, 2022 of 1.50 to 1.00. As a result, we entered into the Fourth Amendment to our Credit Facility on August 11, 2022, in which the lenders agreed to reduce this covenant to permit us to avoid any Default or Event of Default. Specifically, this covenant was reduced to (a) 1.20 to 1.00 for the period commencing with the quarter ended June 30, 2022 through the quarter ending June 30, 2023, (b) 1.35 to 1.00 for the period commencing with the quarter ending September 30, 2023 through the quarter ending December 31, 2023 and (c) 1.45 to 1.00 for the period commencing with the quarter ending March 31, 2024 and continuing thereafter, among other changes (see Liquidity and Capital Resources section below and see Note 5 — Credit Facilities, Net to our consolidated financial statements included in this Annual Report on Form 10-K for additional information).
Prospectively, based upon our current expectations, we believe our operating results through June 30, 2023 will allow us to comply with these covenants. However, we believe our operating results may not be sufficient to comply with the increased Fixed Charge Coverage Ratio, which increases from 1.20:1.00 to 1.35:1.00 commencing with the quarter ending September 30, 2023 and thereafter. Absent a waiver or modification from the lender group, failure to comply with the Fixed Charge Coverage Ratio would constitute an Event of Default and the balance of the Credit Facility would be due and payable. We have obtained such waivers and modifications from the lender group in the past, but there can be no assurance that such a waiver or modification will be granted in future periods. Additionally, we are exploring long-term secured financing opportunities, utilizing some or all of our properties as collateral, the proceeds from which we believe will be sufficient to repay all amounts outstanding under the Credit Facility, which was $180.0 million as of December 31, 2022 ($200.0 million including the $20.0 million drawn subsequent to December 31, 2022, see Note 17 — Subsequent Events for details). There can be no assurance these opportunities will result in definitive agreements on favorable terms, or at all.
56

For additional information on the risks and uncertainties associated with the COVID-19 pandemic, please see Item 1A. “Risk Factors — We are subject to risks associated with a pandemic, epidemic or outbreak of a contagious disease, such as the ongoing global COVID-19 pandemic” included in this Annual Report on Form 10-K for the year ended December 31, 2022.
Rent Collections
We experienced delays in rent collection in the second, third and fourth quarters of 2020 and the first quarter of 2021. We took several steps to mitigate the impact of the pandemic on our business. We were in direct contact with our tenants and operators when the crisis began, cultivating open dialogue and deepening the fundamental relationships that we have carefully developed through prior transactions and historic operations. We achieved mutually agreeable solutions with our MOB tenants and in some cases, during the year ended December 31, 2020, we executed lease amendments wherein we agreed to defer payment. Based on this approach and the overall financial strength and creditworthiness of our tenants, we believe that we have had positive results in our cash rent collections during this pandemic. During the years ended December 31, 2022 and 2021, we did not enter into any rent deferral agreements with any of our tenants and all amounts previously deferred under prior rent deferral agreements have been collected.
We collected approximately 100% of the original cash rent due for the fourth quarter of 2020 and throughout 2021 and 2022 in our MOB segment. Cash rental payments for our 52 SHOPs is primarily paid by the residents through private payer insurance or directly, and to a lesser extent, by government reimbursement programs such as Medicaid and Medicare, therefore we have not provided the amount of quarterly cash rent collected for our SHOP segment.
“Original cash rent” refers to contractual rents on a cash basis due from tenants as stipulated in their original executed lease agreement at inception or as amended, prior to any rent deferral agreement. We calculate “original cash rent collections” by comparing the total amount of rent collected during the period to the original cash rent due. Total rent collected during the period includes both original cash rent due and payments made by tenants pursuant to rent deferral agreements. Eliminating the impact of deferred rent paid, we collected nearly 100% of original cash rent due for each quarter of 2021 and 2022.
A deferral agreement is an executed or approved amendment to an existing lease to defer a certain portion of cash rent due to a future period. During the year ended December 31, 2020, we granted rent deferrals for an aggregate of $0.4 million or less than 1% of original cash rent due for the year. No additional rent was deferred during the years ended December 31, 2022 and 2021.
We have also granted rent concessions which serve to reduce revenue in our SHOP segment. We offered $3.3 million, $2.4 million, and $0.4 million of rent concessions during the years ended December 31, 2022, 2021 and 2020, respectively.
Seniors Housing Properties
During the year ended December 31, 2022, we experienced a significant increase in labor costs in our SHOP segment, largely due to, among other things, increased inflation raising the cost of labor generally and a lack of qualified personnel that we are able to employ on a permanent basis. As a result, our third party operators were forced to increase their use of temporary contract labor and agencies in our SHOP segment. In our SHOP segment, we recorded $6.1 million in temporary contract labor and agency-related costs for care providers for the year ended December 31, 2022, as compared to almost no temporary contract labor and agency-related costs for care providers for the year ended December 31, 2021. Using temporary contract labor and agencies is typically more costly than internal staffing supplied by our third party operators. As a result of the increased use of temporary contract labor and agencies, as well as the continuing impact of the national labor shortage, the amounts we incurred for salaries, wages, overtime and bonuses to meet our third parties’ labor needs in our SHOP segment continued to increase during the year ended December 31, 2022 as compared to the year ended December 31, 2021. Because occupancy levels have not yet recovered to their pre-pandemic rates (as noted in the table below) and resident fees have not increased enough to counteract these lower occupancy rates, our results of operations in our SHOP segment have been significantly adversely affected by the increase in labor costs. There is no guarantee the occupancy levels in our SHOP segment will increase and return to their pre-pandemic levels, that we will be able to raise resident fee levels at rates that are commensurate with these increases in labor costs or that we will reduce our reliance on contract labor.
Beginning in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect us in a number of ways. Occupancy in our SHOP portfolio has trended lower since December 31, 2019 to a low of 72.0% as of March 31, 2021 and has subsequently begun to stabilize. As of December 31, 2022, occupancy in our SHOP segment reached 75.1%. We have also continued to experience lower inquiry volumes and reduced in-person tours. These and other impacts of the COVID-19 pandemic have affected and could continue to affect our ability to fill vacancies. The below table presents SHOP occupancy since the onset of the COVID-19 pandemic in March 2020:
57

As of
Number of Properties (1)
Rentable UnitsPercentage Leased
December 31, 2019594,926 85.1%
March 31, 2020635,198 84.4%
June 30, 2020635,198 79.2%
September 30, 2020675,350 77.4%
December 31, 2020594,878 74.5%
March 31, 2021554,682 72.0%
June 30, 2021544,530 73.2%
September 30, 2021544,494 74.3%
December 31, 2021544,494 74.1%
March 31, 2022504,378 75.9%
June 30, 2022504,374 76.3%
September 30, 2022504,374 75.8%
December 31, 2022504,374 75.1%
________
(1) Exclusive of two land parcels.
The declines in revenue we experienced during the years ended December 31, 2022 and 2021, as compared to the year ended December 31, 2020, were primarily attributable to the decline in occupancy in or SHOP segment, as noted in the table above, and our SHOP disposals which reduced the average number of rentable units over the periods, partially offset by recovering occupancy and increased rental rates on some of our properties which were effective January 1, 2022. In addition, although operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies as early as March 2020, during the year ended December 31, 2022, these trends became more prominent as our third party operators relied more on the use of contract labor and agencies and had to increase the amounts we incur for salaries, wages, overtime and bonuses, as noted above. At the SHOPs, we generally bear these cost increases, which were partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), and to a lesser extent, cost recoveries for personal protective equipment from residents. See below for additional information on the CARES Act. There can be no assurance, however, that future developments in the course of the pandemic, inflation increases, labor shortages and supply disruptions will not cause further adverse impacts to our occupancy, revenues and cost levels, and these trends may continue to impact us and have a material adverse effect on our revenues and net income in future quarters. We believe that our vaccination participation achieved in 2021 for both residents and staff populations have mitigated certain adverse impacts of COVID-19. Furthermore, as infections decline and more vaccinations and boosters are administered during 2023, our occupancy may further increase. However, there can be no assurance as to when or if we will be able to approach pre-pandemic levels of occupancy.
The pandemic raised the risk of an elevated level of resident exposure to illness and restrictions on move-ins at our SHOPs, and increased the general level of frailty for our incoming residents, which has and could also continue to adversely impact resident length of stay, occupancy and revenues, as well as increase costs. We believe that the actions we have taken help reduce, but do not eliminate, the incidences of COVID-19 at our properties. Any incidences, or the perception that outbreaks may occur, could materially and adversely affect our revenues and net income, as well as cause reputational harm to us and our tenants, managers and operators.
The extent to which the global COVID-19 pandemic, including the outbreaks that have occurred and may occur in markets where we own properties, impacts our operations and those of our tenants and third-party operators, will continue to depend on future developments, including the scope, severity and duration of the pandemic, and the actions taken to contain the COVID-19 or treat its impact, among others, which are highly uncertain and cannot be predicted with confidence, but could be material.
On March 27, 2020, the CARES Act was signed into law providing, among other things, funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. During the years ended December 31, 2022, 2021, and 2020, we received $4.5 million, $5.1 million and $3.6 million, respectively, from CARES Act grants. For accounting purposes, we treat the funds as grant contributions from the government and the full amounts were recognized as reductions of property operating and maintenance expenses in our consolidated statement of operations during the years ended December 31, 2022, 2021 and 2020.
58

We do not anticipate that any further funds under the CARES Act will be received, and there can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.
Significant Accounting Estimates and Critical Accounting Policies
Set forth below is a summary of the significant accounting estimates and critical accounting policies that management believes are important to the preparation of our consolidated financial statements. Certain of our accounting estimates are particularly important for an understanding of our financial position and results of operations and require the application of significant judgment by our management. As a result, these estimates are subject to a degree of uncertainty. These significant accounting estimates and critical accounting policies include:
Impacts of the COVID-19 Pandemic
As discussed above we took a proactive approach to achieve mutually agreeable solutions with our tenants and in some cases, in the year ended December 31, 2020, we executed lease amendments providing for deferral of rent.
For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases were modified, the FASB and SEC provided relief that allowed companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. For COVID-19 relief qualified changes, there are two methods to potentially account for such rent deferrals or abatements under the relief, (1) as if the changes were originally contemplated in the lease contract or (2) as if the deferred payments are variable lease payments contained in the lease contract.
For all other lease changes that did not qualify for FASB relief, we would be required to apply modification accounting including assessing classification under ASC 842. Some, but not all of our lease modifications qualified for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, we elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there would be no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact would be recognized ratably over the remaining life of the lease. For leases not qualified for this relief, we applied modification accounting and determined that there were no changes in the current classification of our leases impacted by negotiations with our tenants.
Revenue Recognition
Our revenues, which are derived primarily from lease contracts, include rent received from tenants in our MOB segment. As of December 31, 2022 these leases had a weighted average remaining lease term of 4.9 years. Rent from tenants in our MOB segment (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires us to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that we will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When we acquire a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. We defer the revenue related to lease payments received from tenants in advance of their due dates. Pursuant to certain of our lease agreements, tenants are required to reimburse us for certain property operating expenses, in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating costs of the respective properties. Under ASC 842, we have elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, we have reflected them on a net basis.
Our revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOP segment, held using a structure permitted under RIDEA and to a lesser extent, fees for ancillary services performed for SHOP residents, which are generally variable in nature. Rental income from residents in our SHOP segment is recognized as earned when services are provided. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of the leases are short term in nature, primarily month-to-month. Fees for ancillary services are recorded in the period in which the services are performed.
59

We defer the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of our lease agreements, tenants are required to reimburse us for certain property operating and maintenance expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating and maintenance costs of the respective properties.
We continually review receivables related to rent and unbilled rents receivable and determine collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards, we are required to assess, based on credit risk only, if it is probable that we will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If we determine that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e. straight-line). However, if we determine it is not probable that we will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants in accordance with accounting rules, on the accompanying consolidated statements of operations and comprehensive income (loss) in the period the related costs are incurred, as applicable.
Under ASC 842, which was adopted effective on January 1, 2019, uncollectable amounts are reflected as reductions in revenue. Under ASC 840, we recorded such amounts as bad debt expense as part of property operating expenses. During the years ended December 31, 2022, 2021 and 2020 such amounts were $3.2 million, $1.1 million and $2.7 million, respectively. Approximately $1.3 million and $1.0 million in the years ended December 31, 2022 and 2020, respectively, related to previously disposed properties. There were no significant write-off’s related to previously disposed properties during the year ended December 31, 2021.
Investments in Real Estate
Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.
At the time an asset is acquired, we evaluate the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “Purchase Price Allocation” section below for a discussion of the initial accounting for investments in real estate.
Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on our operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the years ended December 31, 2022, 2021 or 2020. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. We evaluate probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were no real estate investments held for sale as of December 31, 2022 or December 31, 2021.
Purchase Price Allocation
In both a business combination and an asset acquisition, we allocate the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as if vacant basis. Intangible assets may include the value of in-place leases and above-and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In allocating the fair value to any assumed or issued non-controlling interests, amounts are recorded at their fair value at the close of business on the acquisition date. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets. All acquisitions during the years ended December 31, 2022, 2021 and 2020 were accounted for as asset acquisitions. We acquired four properties during the year ended December 31, 2022.
60

For acquired properties with leases classified as operating leases, we allocate the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, we utilize a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. We also consider information obtained about each property as a result of our pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.
Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. We utilize various estimates, processes and information to determine the as-if vacant property value. We estimate the fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates and land values per square foot.
Identifiable intangible assets include amounts allocated to acquired leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, we include real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from six to 24 months. We also estimate costs to execute similar leases including leasing commissions, legal and other related expenses.
Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.
The aggregate value of intangible assets related to customer relationship, as applicable, is measured based on our evaluation of the specific characteristics of each tenant’s lease and our overall relationship with the tenant. Characteristics considered by us in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. We did not record any intangible asset amounts related to customer relationships during the years ended December 31, 2022 and 2021.
Accounting for Leases
Lessor Accounting
In accordance with the lease accounting standard, all of our leases as lessor prior to adoption were accounted for as operating leases. We evaluate new leases originated after the adoption date (by us or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than a major part of the remaining economic useful life of the asset (e.g., equal to or greater than 75%), the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or the asset is so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. As of December 31, 2022 and 2021, we did not have any leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.
As a lessor of real estate, we elected, by class of underlying assets, to account for lease and non-lease components (such as tenant reimbursements of property operating and maintenance expenses) as a single lease component as an operating lease because (a) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (b) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under the accounting guidance. Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed.
Lessee Accounting
We are also the lessee under certain land leases which will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the consolidated balance sheets as of December 31, 2022 and 2021, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022, 2021 and 2020.
For lessees, the accounting standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a
61

right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction. For additional information and disclosures related to our operating leases, see Note 16Commitments and Contingencies to the consolidated financial statements included in this Annual Report on Form 10-K.
Impairment of Long-Lived Assets
When circumstances indicate the carrying value of a property may not be recoverable, we review the property for impairment. This review is based on an estimate of the future undiscounted cash flows expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, we would recognize an impairment loss in the consolidated statement of operations and comprehensive (loss) to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held and used. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.
Depreciation and Amortization
Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests.
Construction in progress, including capitalized interest, insurance and real estate taxes, is not depreciated until the development has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).
The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.
The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.
Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.
Above-and Below-Market Lease Amortization
Capitalized above-market lease values are amortized as a reduction of revenue from tenants over the remaining terms of the respective leases and the capitalized below-market lease values are amortized as an increase to revenue from tenants over the remaining initial terms plus the terms of any below-market fixed rate renewal options of the respective leases. If a tenant with a below-market rent renewal does not renew, any remaining unamortized amount will be taken into income at that time.
Capitalized above-market ground lease values are amortized as a reduction of property operating expense over the remaining terms of the respective leases. Capitalized below-market ground lease values are amortized as an increase to property operating expense over the remaining terms of the respective leases and expected below-market renewal option periods.
Equity-Based Compensation
The Company has a stock-based incentive award program for its directors, which is accounted for under the guidance of share based payments. The cost of services received in exchange for these stock awards is measured at the grant date fair value of the award and the expense for such awards is included in general and administrative expenses and is recognized over the service period (i.e., vesting) required or when the requirements for exercise of the award have been met.
CARES Act Grants
On March 27, 2020, the CARES Act was signed into law and it provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. During the years ended December 31, 2022, 2021 and 2020 we received $4.5 million, $5.1 million and $3.6 million in funding from CARES Act grants, respectively. For accounting purposes, the CARES Act funds are treated as a grant contribution from the government. The funding we received was recognized as a reduction of property operating and maintenance expenses in our consolidated statements of operations to offset the negative impacts of COVID-19. We do not anticipate that any further funds under the CARES Act will be received, and there can be no
62

assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.
Recently Issued Accounting Pronouncements
See Note 2 — Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements to the consolidated financial statements included in this Annual Report on Form 10-K for further discussion.
Results of Operations
Below is a discussion of our results of operations for the years ended December 31, 2022 and 2021. Please see the “Results of Operations” section located on page 60 under Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021 for a discussion of our results of operations for the year ended December 31, 2020 and year-to-date comparisons between December 31, 2021 and 2020.
Same Store Properties
Information based on Same Store Properties, Acquired Properties and Disposed Properties (as each are defined below) allows us to evaluate the performance of our portfolio based on a consistent population of properties owned for the entire period of time covered. As of December 31, 2022, we owned 202 properties. There were 181 properties (our “Same Store Properties”) owned for the entire years ended December 31, 2022 and 2021, including two land parcels. Since January 1, 2021 and through December 31, 2022, we acquired 21 properties (our “Acquired Properties”) and disposed of 12 properties (our “Disposed Properties”).
The following table presents a roll-forward of our properties owned from January 1, 2021 to December 31, 2022:

MOBSHOPTotal
Number of properties, December 31, 2020
132 61 193 
Acquisition activity during the year ended December 31, 2021
17 — 17 
Disposition activity during the year ended December 31, 2021
(3)(5)(8)
Number of properties, December 31, 2021
146 56 202 
Acquisition activity during the year ended December 31, 2022
44
Disposition activity during the year ended December 31, 2022
— (4)(4)
Number of properties, December 31, 2022
150 52 202 
Number of Same Store Properties (1)
129 52 181 
Number of Acquired Properties21  21 
Number of Disposed Properties3 9 12 
_______________
(1)Includes the acquisition of a land parcel adjacent to an existing property which is not considered an Acquisition.
63

Comparison of the Years Ended December 31, 2022 and 2021
Net loss attributable to common stockholders was $93.3 million and $92.9 million for the years ended December 31, 2022 and 2021, respectively. The following table shows our results of operations for the years ended December 31, 2022 and 2021 and the year to year change by line item of the consolidated statements of operations:
 Year Ended December 31,Increase (Decrease)
(Dollar amounts in thousands)20222021$
Revenue from tenants$335,846 $329,355 $6,491 
Operating expenses:  
Property operating and maintenance213,444 205,813 7,631 
Impairment charges27,630 40,951 (13,321)
Operating fees to related parties25,353 24,206 1,147 
Acquisition and transaction related1,484 2,714 (1,230)
General and administrative17,287 16,828 459 
Depreciation and amortization82,064 79,926 2,138 
Total expenses
367,262 370,438 (3,176)
Operating loss before gain on sale of real estate investments(31,416)(41,083)9,667 
Gain (loss) on sale of real estate investments(125)3,648 (3,773)
Operating loss
(31,541)(37,435)5,894 
Other income (expense):
Interest expense(51,740)(47,900)(3,840)
Interest and other income
27 61 (34)
Gain on non-designated derivatives3,834 37 3,797 
Total other expenses
(47,879)(47,802)(77)
Loss before income taxes(79,420)(85,237)5,817 
Income tax expense(201)(203)
Net loss(79,621)(85,440)5,819 
Net loss attributable to non-controlling interests135 260 (125)
Allocation for preferred stock(13,799)(7,762)(6,037)
Net loss attributable to common stockholders$(93,285)$(92,942)$(343)
64

Net Operating Income
NOI is a non-GAAP financial measure used by us to evaluate the operating performance of our real estate portfolio. NOI is equal to revenue from tenants less property operating and maintenance expenses. NOI excludes all other financial statement amounts included in net income (loss) attributable to common stockholders. We believe NOI provides useful and relevant information because it reflects only those income and expense items that are incurred at the property level and presents such items on an unlevered basis. See “Non-GAAP Financial Measures” below for additional disclosure and a reconciliation, in the aggregate, of the NOI for the segments presented below to our net loss attributable to common stockholders.
Segment Results — Medical Office Buildings
The following table presents the components of NOI and the period to period change within our MOB segment for the years ended December 31, 2022 and 2021:
Segment Same Store(1)
Acquisitions(2)
Dispositions(3)
Segment Total(4)
 Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)
(Dollar amounts in thousands)20222021$20222021$20222021$20222021$
Revenue from tenants
$114,860 $113,342 $1,518 $16,576 $5,592 $10,984 $$3,933 $(3,924)$131,445 $122,867 $8,578 
Less: Property operating and maintenance
32,484 30,659 1,825 3,482 1,291 2,191 (20)2,530 (2,550)35,946 34,480 1,466 
NOI
$82,376 $82,683 $(307)$13,094 $4,301 $8,793 $29 $1,403 $(1,374)$95,499 $88,387 $7,112 
_______________
(1)Our MOB segment included 129 Same Store Properties.
(2)Our MOB segment included 21 Acquired Properties.
(3)Our MOB segment included three Disposed Properties.
(4)Our MOB segment consisted of 150 properties.
Revenue from tenants primarily reflects contractual rent received from tenants in our MOBs and operating expense reimbursements. These reimbursements generally increase in proportion with the increase in property operating and maintenance expenses in our MOB segment. Pursuant to many of our lease agreements in our MOBs, tenants are required to pay their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors, in addition to base rent.
Revenue from Tenants
During the year ended December 31, 2022, revenue from tenants increased by $8.6 million in our MOB segment as compared to the year ended December 31, 2021, primarily as a result of increased revenue from tenants of $11.0 million generated from our Acquired Properties and increased revenue from tenants of $1.5 million from our Same Store Properties, partially offset by a decrease in revenue from tenants of $3.9 million from our Disposed Properties. The increase in revenue from our Same Store Properties was primarily attributable from increased operating expense reimbursement revenue from increased property, operating and maintenance expenses, partially offset by non-recoverable amounts from marginally lower occupancy in the year ended December 31, 2022 as compared to December 31, 2021.
Property Operating and Maintenance
Property operating and maintenance relates to the costs associated with our properties, including real estate taxes, utilities, repairs, maintenance, and unaffiliated third party property management fees. During the year ended December 31, 2022, property operating and maintenance costs in our MOB segment increased by $1.5 million as compared to the year ended December 31, 2021, primarily as a result of increased costs from our Acquired Properties of $2.2 million and increased costs from our Same Store Properties of $1.8 million. These increases were partially offset by decreased costs from our Disposed Properties of $2.6 million. The increase in property operating and maintenance expenses from our Same Store properties is primarily the result of the impacts of inflation on utility and maintenance costs, which are largely reimbursed by tenants.
Segment Results — Seniors Housing Operating Properties
The following table presents the revenue and property operating and maintenance expense and the period to period change within our SHOP segment for the years ended December 31, 2022 and 2021:
65

Segment Same Store (1)
Acquisitions (2)
Dispositions (3)
Segment Total
 Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)
(Dollar amounts in thousands)20222021$20222021$20222021$20222021$
Revenue from tenants
$204,443 $195,652 $8,791 $— $— $— $(41)$10,836 $(10,877)$204,402 $206,488 $(2,086)
Less: Property operating and maintenance
174,516 159,432 15,084 — — — 2,983 11,901 (8,918)177,499 171,333 6,166 
NOI
$29,927 $36,220 $(6,293)$— $— $— $(3,024)$(1,065)$(1,959)$26,903 $35,155 $(8,252)
__________
(1)Our SHOP segment included 52 Same Store Properties, including two land parcels.
(2)Our SHOP segment included zero Acquired Properties.
(3)Our SHOP segment included nine Disposed Properties.
(4)Our SHOP segment included 52 properties, including two land parcels.
Revenues from tenants within our SHOP segment are generated in connection with rent and services offered to residents depending on the level of care required, as well as fees associated with other ancillary services. Property operating and maintenance expenses relates to the costs associated with staffing to provide care for the residents in our SHOPs, as well as food, marketing, real estate taxes, management fees paid to our third party operators, and costs associated with maintaining the physical site.
Revenue from Tenants
During the year ended December 31, 2022, revenue from tenants decreased by $2.1 million in our SHOP segment as compared to the year ended December 31, 2021, which was primarily driven by a decrease in revenue from tenants of $10.9 million due to our Disposed Properties, partially offset by an increase in revenue from tenants of $8.8 million from our Same Store Properties.
The increase to our Same Store Properties revenue from tenants was primarily driven by higher monthly leasing rates in the year ended December 31, 2022, as compared to the year ended December 31, 2021. Our revenue from tenants also improved due to higher and recovering occupancy in the year ended December 31, 2022 as compared to lower and declining occupancy in the year ended December 31, 2021. For our Same Store Properties, average quarterly occupancy was 75.7% and 74.4% in the years ended December 31, 2022 and 2021, respectively. These increases were partially offset by an increase in rent concessions offered during the year ended December 31, 2022 of $3.2 million, as compared to $2.0 million in the year ended December 31, 2021.
We also previously generated a portion of our SHOP revenue from SNFs (which include ancillary revenue from non-residents) at two of our Same Store SHOPs and two of our Disposition SHOPs. This revenue was $3.5 million during the year ended December 31, 2021 and was not significant during the year ended December 31, 2022 as a result of transitioning our SNF units to other types of units at our Same Store Properties, as well as from disposing of our SNF in Wellington, Florida in May 2021. This property’s results are presented in Disposed Properties in the table above. As a result of these unit transitions and dispositions, we do not expect ancillary revenue to be a significant source of revenue in future periods. Additionally, during the years ended December 31, 2022 and 2021, we recorded reductions in revenue related to bad debt of $3.2 million and $1.1 million, respectively. Approximately $1.3 million of bad debt expense recorded in the years ended December 31, 2022 was related to our Disposed Properties. There were no significant write-off’s related to previously disposed properties during the year ended December 31, 2021.
Property Operating and Maintenance
During the year ended December 31, 2022, property operating and maintenance expenses increased $6.2 million in our SHOP segment as compared to the year ended December 31, 2021, primarily due to an increase in property operating and maintenance expenses of $15.1 million from our Same Store Properties, partially offset by a decrease in property operating and maintenance expenses of $8.9 million from our Disposed Properties.
Our Same Store properties operating and maintenance expenses increased significantly in the year ended December 31, 2022 compared to the year ended December 31, 2021, primarily from increased amounts incurred from contract labor and agencies, as well as amounts incurred for wages, including overtime and bonus amounts, paid to employees of our third-party operators. Contract labor and agency costs at our Same Store Properties increased $6.0 million, and amounts our third party operators pay for overtime wages and bonuses, as well as overall inflation on utilities and supplies increased our property maintenance and operating costs by $8.5 million in the year ended December 31, 2022. For additional information on the risks and uncertainties associated with increases in inflation and labor costs, see the Inflation section below and Part 1 — Item 1A. Risk Factors section of this Annual Report on Form 10-K.
66

The total increase in Same Store Properties operating and maintenance expenses was also impacted by the receipt of $4.5 million of funds through the CARES Act in the year ended December 31, 2022, as compared to $5.1 million during the year ended December 31, 2021, which offset costs incurred from the COVID-19 pandemic. Of the $4.5 million of CARES Act funds received by us in the year ended December 31, 2022, $3.9 million was recognized as a reduction to our Same Store Property operating and maintenance expenses in the table above, with the remainder attributable to our Disposed properties. Of the $5.1 million of CARES Act funds received in the year ended December 31, 2021, $4.5 million was attributable to our Same Store Property operating and maintenance expenses with the remainder attributable to our Disposed properties. There can be no assurance that the program will be extended or any further amounts received. See the “Overview — Management Update on the Impacts of the COVID-19 Pandemic” section above for additional information on the risks and uncertainties associated with the COVID-19 pandemic and management’s actions taken in response.
Other Results of Operations
Impairment Charges
We incurred $27.6 million of impairment charges for the year ended December 31, 2022, of which $10.6 million related to seven skilled nursing facilities in our MOB segment located in Illinois, $15.1 million related to six held for use SHOP properties of eight total properties that we are actively marketing for sale and $1.8 million related to an MOB property located in Pennsylvania which we began marketing for sale in the fourth quarter of 2022. All of these impairment charges were recorded to reduce the carrying value of the properties to their fair values, respectively, as determined by estimated discounted cash flows over our intended holding periods.
We incurred $41.0 million of impairment charges for the year ended December 31, 2021. The impairment charges for the year ended December 31, 2021 related to a $0.9 million impairment on our Wellington property, which was recorded to adjust the carrying value to its fair value as determined by its purchase and sale agreement, a $6.1 million impairment related to an MOB property located in Sun City, Arizona, and $34.0 million related to our LaSalle properties.
See Note 3 — Real Estate Investments to our consolidated financial statements in this Annual Report on Form 10-K for additional information on impairment charges.
Operating Fees to Related Parties
Operating fees to related parties increased $1.1 million to $25.4 million for the year ended December 31, 2022 from $24.2 million for the year ended December 31, 2021.
Our Advisor and Property Manager are paid for asset management and property management services for managing our properties on a day-to-day basis. We pay a fixed base management fee equal to $1.6 million per month, while the variable portion of the base management fee is equal, per month, to one twelfth of 1.25% of the cumulative net proceeds of any equity raised subsequent to February 17, 2017. Asset management fees increased $1.1 million to $21.8 million for the year ended December 31, 2022 from $20.7 million for the year ended December 31, 2021. The increase in the variable portion of the base management fee was a result of a full year of fees in 2022 for preferred equity offerings completed in May and October 2021, which increased the variable asset management fee in the year ended December 31, 2022 relative to the year ended December 31, 2021. There are no fees earned for stock dividend issuances. Variable asset management fees will further increase if we issue additional equity securities in the future. There were no incentive fees incurred in either of the years ended December 31, 2022 or 2021.
Property management fees increased $0.5 million to $4.2 million during the year ended December 31, 2022 from $3.7 million for the year ended December 31, 2021. Property management fees increase or decrease in direct correlation with gross revenues of the properties managed and depending on the mix of properties managed, as the fee payable for different types of properties varies.
See Note 9 — Related Party Transactions and Arrangements to our consolidated financial statements found in this Annual Report on Form 10-K which provides detail on our asset and property management fees.
Acquisition and Transaction Related Expenses
Acquisition and transaction related expenses were $1.5 million for the year ended December 31, 2022 and $2.7 million for the year ended December 31, 2021. This decrease was due to certain transactions that occurred in the year ended December 31, 2021 which did not occur in the year ended December 31, 2022.
The acquisition and transaction related expenses incurred during the year ended December 31, 2022 consist of: (i) dead deal costs of $0.8 million, (ii) legal fees related to terminated SHOP operators of $0.5 million and (iii) mortgage repayment penalties of $0.2 million.
67

The acquisition and transaction related expenses incurred during the year ended December 31, 2021 consisted of: (i) the write-off of offering costs relating to the Preferred Stock Equity Line of $1.2 million (see Note 8 — Stockholder’s Equity for additional information), (ii) $0.8 million of litigation costs related to our Michigan dispositions which occurred in the first quarter of 2021, (iii) $0.5 million of dead deal and other miscellaneous costs and (iv) $0.2 million of settlement charges related to our Jupiter, Florida disposition which occurred in the second quarter of 2021.
General and Administrative Expenses
General and administrative expenses increased $0.5 million to $17.3 million for the year ended December 31, 2022 compared to $16.8 million for the year ended December 31, 2021, which includes $8.8 million and $8.4 million (net of a professional fee credit discussed below) for the years ended December 31, 2022 and 2021, respectively, incurred in expense reimbursements. The increase in general and administrative expenses was primarily driven by a professional fee credit of $1.0 million during the year ended December 31, 2021 related to an adjustment for 2020 bonuses. See Note 9 – Related Party Transactions and Arrangements to our consolidated financial statements included in this Annual Report on Form 10-K for additional information.
Depreciation and Amortization Expenses
Depreciation and amortization expense increased $2.1 million to $82.1 million for the year ended December 31, 2022 from $79.9 million for the year ended December 31, 2021. The increase was due to our acquisitions of approximately $4.7 million, partially offset by a decrease in Same Store depreciation and amortization of $0.9 million primarily due to several intangible assets becoming fully amortized and a decrease due to dispositions of $2.0 million. The decrease in our Same Store depreciation and amortization was partially offset by $1.3 million of accelerated depreciation we recorded in the year ended December 31, 2022 on one MOB property in Florida which incurred damages as a result of Hurricane Ian as well as 15 SHOPs across the Midwest which suffered cold weather-related damages.
Gain on Sale of Real Estate Investments
During the third quarter of 2021, we began to actively market the LaSalle Properties for sale, and a non-binding letter of intent was signed in the fourth quarter of 2021 for an aggregate contract sales price of $12.4 million. We completed the sale of the LaSalle Properties in the first quarter of 2022 and, as a result, we recorded a loss on sale of $0.3 million for the year ended December 31, 2022. We had previously recorded $34.0 million of impairment charges on the LaSalle Properties in the year ended December 31, 2021. We also recorded a gain on sale of $0.2 million in the year ended December 31, 2022 related to the settlement of a lien on formerly disposed properties.
During the year ended December 31, 2021, we disposed of eight properties. The properties were sold for an aggregate contract price of $133.6 million, which resulted in an aggregate gain on sale of $3.6 million.
See Note 3 — Real Estate Investments, Net to our consolidated financial statements in this Annual Report on Form 10-K for additional information on the dispositions noted above.
Interest Expense
Interest expense increased by $3.8 million to $51.7 million for the year ended December 31, 2022 from $47.9 million for the year ended December 31, 2021. The increase in interest expense resulted from higher average interest rates of amounts outstanding under our Revolving Credit Facility during 2022, as compared to 2021. As of December 31, 2022 we had total borrowings of $1.1 billion, at a weighted average interest rate of 4.83% per year. As of December 31, 2021, we had total borrowings of $1.1 billion, at a weighted average interest rate of 3.44% per year.
Our interest expense in future periods will vary based on our level of future borrowings and the cost of borrowings (including current market rates) among other factors. Market interest rates have continued to increase throughout the year ended December 31, 2022 and subsequently thereafter. Our weighted average interest rate as of December 31, 2022 was higher than that as of December 31, 2021. We anticipate that interest expense for the year ended December 31, 2023 will exceed the $51.7 million expense recorded for the year ended December 31, 2022 if interest rates maintain current levels or continue to increase.
Interest and Other Income
Interest and other income includes income from our investment securities and interest income earned on cash and cash equivalents held during the period. Interest and other income was approximately $27,000 for the year ended December 31, 2022. Interest and other income was approximately $61,000 for the year ended December 31, 2021.
68

Gain on Non-Designated Derivatives
Gain on non-designated derivative instruments for the years ended December 31, 2022 and 2021 related to interest rate caps that are designed to protect us from adverse interest rate changes in connection with our Fannie Mae Master Credit Facilities, which have floating interest rates. The gain recorded in the year ended December 31, 2022 was due to significant increases in interest rates during the period and represents the change in value as well as $0.3 million of cash received from these interest rate caps. In prior years, these interest rate caps were not limiting interest expense and did not have significant changes in value, nor was any cash received.
Income Tax Expense
Income taxes generally relate to our SHOPs, which are leased to our TRS. We recorded income tax expense of $0.2 million and $0.2 million for the years ended December 31, 2022 and 2021, respectively
Because of our TRS’s recent operating history of losses and the impacts of the COVID-19 pandemic on the results of operations of our SHOP assets, in the third quarter of 2020, we were not able to conclude that it is more likely than not we will realize the future benefit of our deferred tax assets and recorded a full valuation allowance. Since that time, our TRS’s operating performance has not significantly improved and thus we have recorded a 100% valuation allowance on our net deferred tax assets through December 31, 2022. If and when we believe it is more likely than not that we will recover our deferred tax assets, we will reverse the valuation allowance as an income tax benefit in our consolidated statements of comprehensive income (loss).
Net Loss Attributable to Non-Controlling Interests
Net loss attributable to non-controlling interests was $0.1 million and $0.3 million for the years ended December 31, 2022 and 2021, respectively. These amounts represent the portion of our net income that is related to the Series A Preferred Units held by third parties (issued in connection with a property acquisition in September, 2021), Common OP Units held by third parties, and other non-controlling interest holders in our subsidiaries that own certain properties.
Allocation for Preferred Stock
Allocation for preferred stock was $13.8 million and $7.8 million for the years ended December 31, 2022 and 2021, respectively. These amounts represent the allocation of our net income that is related to holders of Series A Preferred Stock and holders of Series B Preferred Stock. The increase in the allocation for preferred stock is the result of additional shares of Series A Preferred Stock and Series B Preferred Stock issued in the year ended December 31, 2021, which were outstanding for a partial year in the year ended December 31, 2021 but which were outstanding for a full year in the year ended December 31, 2022.
69

Cash Flows from Operating Activities
During the year ended December 31, 2022, net cash provided by operating activities was $28.3 million. The level of cash flows provided by operating activities is affected by, among other things, the number of properties owned, the performance of those properties, the timing of interest payments and the amount of borrowings outstanding during the period, as well as the receipt of scheduled rent payments and the level of operating expenses. Cash inflows include non-cash items of $38.5 million (net loss of $79.6 million adjusted for non-cash items including depreciation and amortization of tangible and identifiable intangible real estate assets, deferred financing costs and mortgage premiums and discounts, bad debt expense, equity-based compensation, gain on non-designated derivatives and impairment charges) and a decrease in prepaid expenses and other assets of $3.0 million. These cash inflows were partially offset by a decrease in accounts payable and accrued expenses of $2.9 million related to timing of payments for real estate taxes, property operating expenses and professional and legal fees, a decrease in deferred rent and other liabilities of $2.7 million and by a net increase in unbilled receivables recorded in accordance with straight-line basis accounting of $1.5 million.
During the year ended December 31, 2021, net cash provided by operating activities was $38.9 million. The level of cash flows provided by operating activities is affected by, among other things, the number of properties owned, the performance of those properties, the timing of interest payments and the amount of borrowings outstanding during the period, as well as the receipt of scheduled rent payments and the level of operating expenses. Cash inflows include non-cash items of $38.8 million (net loss of $85.4 million adjusted for non-cash items including depreciation and amortization of tangible and identifiable intangible real estate assets, deferred financing costs and mortgage premiums and discounts, bad debt expense, equity-based compensation, gain on non-designated derivatives and impairment charges). In addition, cash provided by operating activities was impacted by an increase in accounts payable and accrued expenses of $1.3 million related to higher accrued real estate taxes, property operating expenses and professional and legal fees, a net decrease in prepaid expenses and other assets of $2.1 million, and by an increase in deferred rent of $1.7 million. These cash inflows were partially offset by a net increase in unbilled receivables recorded in accordance with straight-line basis accounting of $0.8 million.
Cash Flows from Investing Activities
Net cash used in investing activities during the year ended December 31, 2022 was $41.8 million. The cash used in investing activities included $25.5 million for the acquisition of four properties and $28.0 million in capital expenditures. These cash outflows were partially offset by $11.7 million in proceeds from the sale of the four LaSalle Properties.
Net cash used in investing activities during the year ended December 31, 2021 was $47.9 million. The cash used in investing activities included $159.3 million for the acquisition of 17 properties and $19.1 million in capital expenditures. These cash outflows were partially offset by proceeds from the sale of real estate of $130.4 million.
Cash Flows from Financing Activities
Net cash provided by financing activities of $4.6 million during the year ended December 31, 2022 was comprised of cash inflows of $30.0 million from borrowings under our Revolving Credit facility, partially offset by outflows of payments on our Credit Facilities of $3.0 million, payments of deferred financing costs of $1.7 million, dividends paid to holders of Series A Preferred Stock of $7.3 million, dividends paid to holders of Series B Preferred Stock of $6.5 million and principal payments on mortgages of $6.7 million.
Net cash provided by financing activities of $4.1 million during the year ended December 31, 2021 related to net proceeds from the issuance of Series A preferred stock of $56.3 million, net proceeds from the issuance of Series B preferred stock of $86.9 million and proceeds from a mortgage note payable of $42.8 million. These cash inflows were partially offset by net repayments under our Revolving Credit Facility of $173.8 million, payment for deferred financing costs of $1.5 million and payments of preferred stock dividends of $5.1 million.
Liquidity and Capital Resources
Our existing principal demands for cash are to fund acquisitions, capital expenditures, the payment of our operating and administrative expenses, debt service obligations (including principal repayment), and dividends to holders of our Series A Preferred Stock and holders of our Series B Preferred Stock. We closely monitor our current and anticipated liquidity position relative to our current and anticipated demands for cash and believe that we have sufficient current liquidity and access to additional liquidity to meet our financial obligations for at least the next 12 months. Our future liquidity requirements, and available liquidity, however, depend on many factors, such as the impact of COVID-19 on our tenants and operators. Further, recent and continuing increases in inflation brought about by labor shortages, supply chain disruptions and increases in interest rates may adversely impact our results of operations and thus ultimately our liquidity. Moreover, these increases in the rate of inflation, the ongoing war in Ukraine and related sanctions, supply chain disruptions and increases in interest rates, may also impact our tenant and residents’ ability to pay rent and thus our cash flows. For more information about the risks and uncertainties associated with inflation, the ongoing war in Ukraine and related sanctions, and labor shortages and labor costs, please see the Inflation section below and Part I – Item 1A. Risk Factors section of this Annual Report on Form 10-K.
70

We expect to fund our future short-term operating liquidity requirements, including dividends to holders of Series A Preferred Stock and holders of Series B Preferred Stock, through a combination of current cash on hand, net cash provided by our property operations and draws on the Revolving Credit Facility, which may include additional borrowings following the repayments we were or are required to make thereunder.
As of December 31, 2022 and 2021, we had $53.7 million and $59.7 million of cash and cash equivalents, respectively, and our ability to use this cash on hand is restricted. Under our Credit Facility, we are required to maintain a combination of cash, cash equivalents and availability for future borrowings under our Revolving Credit Facility totaling at least $50.0 million. As of December 31, 2022, $203.4 million was available for future borrowings under our Revolving Credit Facility, of which $90.0 million was available for general corporate purposes and acquisitions, with the remainder available to repay other existing debt obligations.
Certain other restrictions and conditions described below, including those on paying cash dividends on our common stock, will no longer apply starting in the “Commencement Quarter” which is a quarter in which we make an election and, as of the day prior to the commencement of the applicable quarter we have a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million, giving effect to the aggregate amount of distributions projected to be paid by us during the applicable quarter, our ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5%, and our Fixed Charge Coverage Ratio is not less than 1.50 to 1.00 for the most recently ended four fiscal quarters. The fiscal quarter ended June 30, 2021 was the first quarter that could have been the Commencement Quarter. We did not satisfy the conditions during the quarter ended December 31, 2022 in order to elect the quarter ending March 31, 2023 as the Commencement Quarter. There can be no assurance as to if, or when, we will, or will be able to, elect the Commencement Quarter, including to the extent we may be unable to satisfy these conditions in future periods. We may not pay distributions to holders of common stock in cash or any other cash distributions (including repurchases of shares of our common stock) on our common stock until the Commencement Quarter. Moreover, beginning in the Commencement Quarter, we may only pay cash distributions provided that the aggregate distributions (as defined in the Credit Facility and including dividends on Series A Preferred Stock, Series B Preferred Stock or any other class of preferred stock that may be issued) for any period of four fiscal quarters that do not exceed 95% of Modified FFO (as defined in the Credit Facility) for the same period based only on fiscal quarters after the Commencement Quarter.
Our Credit Facility also restricts our uses of liquidity. Until the first day of the Commencement Quarter, we must use all of the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to repay amounts outstanding under the Revolving Credit Facility, to the extent there are any such amounts outstanding. We may borrow additional amounts if all relevant conditions are met, including sufficient availability for future borrowings. There can be no assurance these conditions will be met. The availability for future borrowings under the Credit Facility is calculated using the adjusted net operating income of the real estate assets comprising the borrowing base, and availability has been, and may continue to be, adversely affected by the increases in operating costs, primarily costs arising from the use of contract labor for care providers and, to a lesser extent, the amount we pay in overtime wages and bonuses, that have resulted from the effects of the COVID-19 pandemic and may persist for some time.
Financings
As of December 31, 2022, our total debt leverage ratio (net debt divided by gross asset value) was approximately 41.5%. Net debt totaled $1.1 billion, which represents gross debt ($1.1 billion) less cash and cash equivalents ($53.7 million). Gross asset value totaled $2.6 billion, which represents total real estate investments, at cost ($2.6 billion), net of gross market lease intangible liabilities ($23.5 million). Cumulative impairment charges are already reflected within gross asset value.
As of December 31, 2022, we had total gross borrowings of $1.1 billion, at a weighted average interest rate of 4.83%. As of December 31, 2021, we had total gross borrowings of $1.1 billion at a weighted average interest rate of 3.44%. As of December 31, 2022, the carrying value of our real estate investments, at cost was $2.6 billion, with $0.9 billion of this amount pledged as collateral for mortgage notes payable, $0.6 billion of this amount pledged to secure advances under the Fannie Mae Master Credit Facilities and $0.9 billion of this amount comprising the borrowing base of the Credit Facility. These real estate assets are not available to satisfy other debts and obligations, or to serve as collateral with respect to new indebtedness, as applicable, unless the existing indebtedness associated with the property is satisfied or the property is removed from the borrowing base of the Credit Facility, which would impact availability thereunder.
We expect to utilize proceeds from our Credit Facility to fund future property acquisitions, as well as, subject to the terms of our Credit Facility, other sources of funds that may be available to us. These actions may require us to add some or all of our unencumbered properties to the borrowing base under our Credit Facility. Unencumbered real estate investments, at cost as of December 31, 2022 was $0.1 billion. There can be no assurance as to the amount of liquidity we would be able to generate from adding any of the unencumbered assets we own to the borrowing base of our Credit Facility. Pursuant to the Credit Facility, any resulting net proceeds from dispositions prior to the Commencement Quarter must be used to repay amounts outstanding under the Revolving Credit Facility, to the extent there are any such amounts outstanding.

71

Mortgage Notes Payable
As of December 31, 2022, we had $585.2 million in gross mortgage notes payable outstanding. Future scheduled principal payments on our mortgage notes payable for 2023 are $1.1 million.
Credit Facility
Our Credit Facility consists of two components, the Revolving Credit Facility and our Term Loan. The Revolving Credit Facility is interest-only and matures on March 13, 2023, subject to a one one-year extension at our option. Our Term Loan is interest-only and matures on March 13, 2024. Loans under our Credit Facility may be prepaid at any time, in whole or in part, without premium or penalty, subject to customary breakage costs. Any amounts repaid under our Term Loan may not be re-borrowed.
The total commitments under the Credit Facility are $655.0 million, including $505.0 million under the Revolving Credit Facility. The Credit Facility includes an uncommitted “accordion feature” that may, subject to conditions, be used to increase the commitments under either component of the Credit Facility by up to an additional $370.0 million to a total of $1.0 billion. As of December 31, 2022, $150.0 million was outstanding under the Term Loan, and $30.0 million amounts were outstanding under the Revolving Credit Facility. The unused borrowing availability under the Credit Facility was $203.4 million, of which $90.0 million was available for general corporate purposes and acquisitions, with the remainder available to repay other existing debt obligations. The amount available for future borrowings under the Credit Facility is based on either the value of the pool of eligible unencumbered real estate assets comprising the borrowing base, or a minimum debt service coverage ratio with respect to the borrowing base. Both of these amounts are calculated using the adjusted net operating income of the real estate assets comprising the borrowing base, and, therefore, availability under our Credit Facility has been adversely affected by the increases in operating costs, primarily costs arising from the use of contract labor for care providers and, to a lesser extent, the amount we pay in overtime wages and bonuses, due to the effects of the COVID-19 pandemic, and may continue to be adversely affected. See also the discussion above regarding the need to maintain certain levels of liquidity until the Commencement Quarter.
The equity interests and related rights in our wholly-owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Revolving Credit Facility are pledged for the benefit of the lenders thereunder. The Credit Facility also contains a subfacility for letters of credit of up to $25.0 million. The applicable margin used to determine the interest rate under both the Term Loan and Revolving Credit Facility components of the Credit Facility varies based on our leverage. As of December 31, 2022, the Term Loan had an effective interest rate per annum equal to 5.11%. Under the Credit Facility, we must comply with covenants governing the maximum ratio of consolidated total indebtedness to consolidated total asset value, and requiring us to maintain a minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges (the “Fixed Charge Coverage Ratio”) on a quarterly basis, a minimum consolidated tangible net worth and a minimum debt service coverage ratio. We entered into the Fourth Amendment to the Credit Facility on August 11, 2022. As described above, pursuant to the Fourth Amendment, the Fixed Charge Coverage Ratio we must satisfy, based on the four most recently ended fiscal quarters, is (a) 1.20 to 1.00 for the period commencing with the quarter ended June 30, 2022 through the quarter ending June 30, 2023, (b) 1.35 to 1.00 for the period commencing with the quarter ending September 30, 2023 through the quarter ending December 31, 2023 and (c) 1.45 to 1.00 for the period commencing with the quarter ending March 31, 2024 and continuing thereafter, provided, however, that from and after the Commencement Quarter, we must satisfy a minimum Fixed Charge Coverage Ratio of 1.50 to 1.00.
Without the Fourth Amendment, we would have been in default of the pre-amendment Fixed Charge Coverage Ratio for the four fiscal quarter period ended June 30, 2022. However, we were in compliance with the new covenants under the Credit Facility for the five fiscal quarter periods ended December 31, 2022.
Prospectively, based upon our current expectations, we believe our operating results through June 30, 2023 will allow us to comply with these covenants. However, we believe our operating results may not be sufficient to comply with the increased Fixed Charge Coverage Ratio, which increases from 1.20:1.00 to 1.35:1.00 commencing with the quarter ending September 30, 2023 and thereafter. Absent a waiver or modification from the lender group, failure to comply with the Fixed Charge Coverage Ratio would constitute an Event of Default and the balance of the Credit Facility would be due and payable. We have obtained such waivers and modifications from the lender group in the past, but there can be no assurance that such a waiver or modification will be granted in future periods. Additionally, we are exploring long-term secured financing opportunities, utilizing some or all of our properties as collateral, the proceeds from which we believe will be sufficient to repay all amounts outstanding under the Credit Facility, which was $180.0 million as of December 31, 2022 (including the $20.0 million drawn subsequent to December 31, 2022, see Note 17 — Subsequent Events for details). There can be no assurance these opportunities will result in definitive agreements on favorable terms, or at all.
See Note 5 — Credit Facilities, Net to our consolidated financial statements in this Annual Report on Form 10-K for additional information on the Credit Facility, its related covenants, and the Fourth Amendment.
Fannie Mae Master Credit Facilities
As of December 31, 2022, $352.0 million was outstanding under the Fannie Mae Master Credit Facilities. We may request future advances under the Fannie Mae Master Credit Facilities by adding eligible properties to the collateral pool subject to
72

customary conditions, including satisfaction of minimum debt service coverage and maximum loan-to-value tests. We do not expect to draw any further amounts on the Fannie Mae Master Credit Facilities. Borrowings under the Fannie Mae Master Credit Facilities bear annual interest at a rate that varies on a monthly basis and is equal to the sum of the current LIBOR for one month U.S. dollar-denominated deposits and 2.62%, with a combined floor of 2.62%. The Fannie Mae Master Credit Facilities mature on November 1, 2026. Future scheduled principal payments on our Fannie Mae Master Credit Facilities for 2023 are $5.8 million.
Capital Expenditures
During the year ended December 31, 2022, our capital expenditures were $28.0 million, of which approximately $10.5 million related our MOB segment and $17.5 million related to our SHOP segment. We anticipate this rate of capital expenditures will be similar for the MOB and SHOP segments throughout 2023, however, the economic uncertainty created by the COVID-19 global pandemic will continue to impact our decisions on the amount and timing of future capital expenditures.
Acquisitions — Year Ended December 31, 2022
During the year ended December 31, 2022, we acquired one multi-tenant MOB and three single-tenant MOBs for an aggregate contract purchase price of $25.3 million. These acquisitions were funded with cash on hand.
Acquisitions — Subsequent Year Ended December 31, 2022
We acquired four single-tenant MOB properties subsequent to December 31, 2022 for a contract purchase price of $20.0 million, which was funded with borrowings from our Revolving Credit Facility. We have entered into one purchase and sale agreement to acquire one MOB property for a contract purchase price of $5.2 million. There can be no assurance we will complete this acquisition on its contemplated terms, or at all. We anticipate primarily using proceeds from borrowings under our Revolving Credit Facility to fund the consideration required to complete this acquisition.
Dispositions — Year Ended December 31, 2022
During the year ended December 31, 2022, we completed the sale of the LaSalle Properties for an aggregate contract sales price of $12.4 million. We had previously recorded $34.0 million of impairment charges on the LaSalle Properties in the year ended December 31, 2021.
Dispositions — Subsequent to December 31, 2022
Subsequent to December 31, 2022, we did not dispose of any properties. We have entered into five purchase and sale agreements to dispose of five SHOPs for an aggregate contract sales price of $26.1 million. Pursuant to the terms of the Credit Facility, the net proceeds from these dispositions will be used to repay amounts outstanding under the Revolving Credit Facility. There can be no assurance that we will complete these dispositions on their contemplated terms, or at all.
Share Repurchase Program
Under the Credit Facility, we are restricted from repurchasing shares until the Commencement Quarter. Thus, the Board suspended repurchases under the SRP effective August 14, 2020. No further repurchase requests under the SRP may be made unless and until the SRP is reactivated. There can be no assurance, however, as to whether our SRP will be reactivated or on what terms. Beginning in the Commencement Quarter, we will be permitted to repurchase up to $50.0 million of shares of our common stock (including amounts previously repurchased during the term of the Revolving Credit Facility) if, after giving effect to the repurchases, we maintain cash and cash equivalents of at least $30.0 million and our ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 55.0%.
No assurances can be made as to when or if our SRP will be reactivated.
Non-GAAP Financial Measures
This section discusses the non-GAAP financial measures we use to evaluate our performance including Funds from Operations (“FFO”), Modified Funds from Operations (“MFFO”) and NOI. While NOI is a property-level measure, MFFO is based on our total performance as a company and therefore reflects the impact of other items not specifically associated with NOI such as, interest expense, general and administrative expenses and operating fees to related parties. Additionally, NOI as defined herein, includes straight-line rent which is excluded from MFFO. A description of these non-GAAP financial measures and reconciliations to the most directly comparable GAAP measure, which is net income, are provided below:
Funds from Operations and Modified Funds from Operations
The historical accounting convention used for real estate assets requires straight-line depreciation of buildings, improvements, and straight-line amortization of intangibles, which implies that the value of a real estate asset diminishes predictably over time. We believe that, because real estate values historically rise and fall with market conditions, including, but not limited to, inflation, interest rates, the business cycle, unemployment and consumer spending, presentations of operating results for a REIT using the historical accounting convention for depreciation and certain other items may be less informative.
73

Because of these factors, the National Association of Real Estate Investment Trusts (“NAREIT”), an industry trade group, has published a standardized measure of performance known as FFO, which is used in the REIT industry as a supplemental performance measure. We believe FFO, which excludes certain items such as real estate-related depreciation and amortization, is an appropriate supplemental measure of a REIT’s operating performance. FFO is not equivalent to our net income or loss as determined under GAAP.
We calculate FFO, a non-GAAP measure, consistent with the standards established over time by the Board of Governors of NAREIT, as restated in a White Paper approved by the Board of Governors of NAREIT effective in December 2018 (the “White Paper”). The White Paper defines FFO as net income or loss computed in accordance with GAAP, excluding depreciation and amortization related to real estate, gains and losses from the sale of certain real estate assets, gains and losses from change in control and impairment write-downs of certain real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity. Adjustments for unconsolidated partnerships and joint ventures are calculated to reflect our proportionate share of FFO attributable to our stockholders. Our FFO calculation complies with NAREIT’s definition.
We believe that the use of FFO provides a more complete understanding of our operating performance to investors and to management, and reflects the impact on our operations from trends in occupancy rates, rental rates, operating costs, general and administrative expenses, and interest costs, which may not be immediately apparent from net income.
Changes in the accounting and reporting promulgations under GAAP that were put into effect in 2009 subsequent to the establishment of NAREIT’s definition of FFO, such as the change to expense as incurred rather than capitalize and depreciate acquisition fees and expenses incurred for business combinations, have prompted an increase in cash-settled expenses, specifically acquisition fees and expenses, as items that are expensed under GAAP across all industries. These changes had a particularly significant impact on publicly registered, non-listed REITs, which typically have a significant amount of acquisition activity in the early part of their existence, particularly during the period when they are raising capital through ongoing initial public offerings.
Because of these factors, the Institute of Portfolio Alternatives (“IPA”), an industry trade group, has published a standardized measure of performance known as MFFO, which the IPA has recommended as a supplemental measure for publicly registered, non-listed REITs. MFFO is designed to be reflective of the ongoing operating performance of publicly registered, non-listed REITs by adjusting for those costs that are more reflective of acquisitions and investment activity, along with other items the IPA believes are not indicative of the ongoing operating performance of a publicly registered, non-listed REIT, such as straight-lining of rents as required by GAAP. We believe it is appropriate to use MFFO as a supplemental measure of operating performance because we believe that, when compared year-over-year, both before and after we have deployed all of our offering proceeds and are no longer incurring a significant amount of acquisition fees or other related costs, it reflects the impact on our operations from trends in occupancy rates, rental rates, operating costs, general and administrative expenses, and interest costs, which may not be immediately apparent from net income. MFFO is not equivalent to our net income or loss as determined under GAAP.
We calculate MFFO, a non-GAAP measure, consistent with the IPA’s Guideline 2010-01, Supplemental Performance Measure for Publicly Registered, Non-Listed REITs: Modified Funds from Operations (the “Practice Guideline”) issued by the IPA in November 2010, except that we adjust for deferred tax asset allowances based on management’s determination. The Practice Guideline defines MFFO as FFO further adjusted for acquisition fees and expenses and other items. In calculating MFFO, we follow the Practice Guideline (with the added adjustment for deferred tax asset allowances based on management’s determination as noted above) and exclude acquisition fees and expenses, amortization of above and below market and other intangible lease assets and liabilities, amounts relating to straight-line rent adjustments (in order to reflect such payments from a GAAP accrual basis to a cash basis of disclosing the lease and rental payments), contingent purchase price consideration, accretion of discounts and amortization of premiums on debt investments, mark-to-market adjustments included in net income, gains or losses included in net income from the extinguishment or sale of debt, hedges, foreign exchange, derivatives or securities holdings where trading of such holdings is not a fundamental attribute of the business plan, unrealized gains or losses resulting from consolidation from, or deconsolidation to, equity accounting, and adjustments for unconsolidated partnerships and joint ventures, with such adjustments calculated to reflect MFFO on the same basis. We also exclude other non-operating items in calculating MFFO, such as transaction-related fees and expenses and capitalized interest. In addition, because we currently believe that concessions granted to our tenants as a result of the COVID-19 pandemic are collectable (see Accounting Treatment of Rent Deferrals below), we have excluded from the increase in straight-line rent for MFFO purposes the amounts recognized under GAAP relating to these deferrals, which is not considered by the Practice Guideline.
We believe that, because MFFO excludes costs that we consider more reflective of acquisition activities and other non-operating items, MFFO can provide, on a going-forward basis, an indication of the sustainability (that is, the capacity to continue to be maintained) of our operating performance. Our Modified FFO (as defined in our Credit Facility) is similar but not identical to MFFO as discussed in this Quarterly Report on Form 10-Q. We also believe that MFFO is a recognized measure of sustainable operating performance by the non-listed REIT industry and allows for an evaluation of our performance against other publicly registered, non-listed REITs.
74

Not all REITs, including publicly registered, non-listed REITs, calculate FFO and MFFO the same way. Accordingly, comparisons with other REITs, including publicly registered, non-listed REITs, may not be meaningful. Furthermore, FFO and MFFO are not indicative of cash flow available to fund cash needs and should not be considered as an alternative to net income (loss) or income (loss) from continuing operations as determined under GAAP as an indication of our performance, as an alternative to cash flows from operations as an indication of our liquidity, or indicative of funds available to fund our cash needs including our ability to pay dividends and other distributions to our stockholders. FFO and MFFO should be reviewed in conjunction with GAAP measurements as an indication of our performance. The methods utilized to evaluate the performance of a publicly registered, non-listed REIT under GAAP should be construed as more relevant measures of operational performance and considered more prominently than the non-GAAP measures, FFO and MFFO, and the adjustments to GAAP in calculating FFO and MFFO.
Neither the SEC, NAREIT, the IPA nor any other regulatory body or industry trade group has passed judgment on the acceptability of the adjustments that we use to calculate FFO or MFFO. In the future, updates to the White Paper or the Practice Guideline may be published or the SEC or another regulatory body could standardize the allowable adjustments across the publicly registered, non-listed REIT industry and we would have to adjust our calculation and characterization of FFO or MFFO accordingly.
Accounting Treatment of Rent Deferrals
All of the concessions granted to our tenants as a result of the COVID-19 pandemic are rent deferrals with the original lease term unchanged and collection of deferred rent deemed probable (see the “Overview - Management Update on the Impacts of the COVID-19 Pandemic” section of this Management’s Discussion and Analysis of Financial Condition and Results of Operations for additional information). As a result of relief granted by the FASB and SEC related to lease modification accounting, rental revenue used to calculate Net Income and NAREIT FFO has not been, and we do not expect it to be, significantly impacted by these types of deferrals. As of December 31, 2022, all deferred amounts have been collected and we have not deferred any additional amounts since the year ended December 31, 2020. For a detailed discussion of our revenue recognition policy, including details related to the relief granted by the FASB and SEC, see Note 2 — Significant Accounting Polices to our consolidated financial statements included in this Annual Report on Form 10-K.
The table below reflects the items deducted from or added to net loss attributable to common stockholders in our calculation of FFO and MFFO for the periods indicated. In calculating our FFO and MFFO, we exclude the impact of amounts attributable to our non-controlling interests.
Year Ended December 31,
(In thousands)202220212020
Net loss attributable to common stockholders (in accordance with GAAP)
$(93,285)$(92,942)$(78,781)
Depreciation and amortization (1)
80,063 78,115 79,643 
Impairment charges
27,630 40,951 36,446 
Loss (gain) on sale of real estate investments125 (3,648)(5,230)
Adjustments for non-controlling interests (2)
(490)(529)(526)
FFO (as defined by NAREIT) attributable to common stockholders
14,043 21,947 31,552 
Acquisition and transaction related
1,484 2,714 173 
(Accretion) amortization of market lease and other lease intangibles, net
(625)(198)(80)
Straight-line rent adjustments
(1,523)(780)(2,405)
Straight-line rent (rent deferral agreements) (3)
— (280)280 
Amortization of mortgage premiums and discounts, net
51 55 60 
(Gain) loss on non-designated derivatives(3,834)(37)102 
Cash received from non-designated derivatives286 — — 
Deferred tax asset valuation allowance (4)
2,750 (482)4,641 
Adjustments for non-controlling interests (2)
10 (9)
MFFO attributable to common stockholders
$12,642 $22,940 $34,314 
________
(1)Net of non-real estate depreciation and amortization.
(2)Represents the portion of the adjustments allocable to non-controlling interests.
(3)Represents the amount of deferred rent pursuant to lease negotiations which qualify for FASB relief for which rent was deferred but not reduced. These amounts are included in the straight-line rent receivable on our consolidated balance sheet but are considered to be earned revenue attributed to the current period for purposes of MFFO as they are expected to be collected.
(4)This is a non-cash item and is added back as it is not considered a part of operating performance.
75

Net Operating Income
NOI is a non-GAAP financial measure used by us to evaluate the operating performance of our real estate portfolio. NOI is equal to revenue from tenants less property operating and maintenance expenses. NOI excludes all other items of expense and income included in the financial statements in calculating net income (loss).
We believe NOI provides useful and relevant information because it reflects only those income and expense items that are incurred at the property level and presents such items on an unlevered basis. We use NOI to assess and compare property level performance and to make decisions concerning the operation of the properties. Further, we believe NOI is useful to investors as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating expenses and acquisition activity on an unleveraged basis, providing perspective not immediately apparent from net income (loss).
NOI excludes certain components from net income (loss) in order to provide results that are more closely related to a property’s results of operations. For example, interest expense is not necessarily linked to the operating performance of a real estate asset and is often incurred at the corporate level. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property level. NOI presented by us may not be comparable to NOI reported by other REITs that define NOI differently. We believe that in order to facilitate a clear understanding of our operating results, NOI should be examined in conjunction with net income (loss) as presented in our consolidated financial statements. NOI should not be considered as an alternative to net income (loss) as an indication of our performance or to cash flows as a measure of our liquidity or ability to pay distributions.
The following table reflects the items deducted from or added to net loss attributable to common stockholders in our calculation of Same Store, Acquisitions and Dispositions NOI for the year ended December 31, 2022:
Same StoreAcquisitionsDispositionsNon-Property SpecificTotal
(In thousands)MOBSHOPMOBSHOPMOBSHOP
Net (loss) income attributable to common stockholders (in accordance with GAAP)$27,224 $(18,432)$5,447 $— $38 $(3,491)$(104,071)$(93,285)
Impairment charges12,488 15,142 — — — — — 27,630 
Operating fees to related parties— — — — — — 25,353 25,353 
Acquisition and transaction related212 — — — — 1,271 1,484 
General and administrative84 13 — — — — 17,190 17,287 
Depreciation and amortization42,257 31,819 7,646 — — 342 — 82,064 
Interest expense116 1,386 — — — — 50,238 51,740 
Interest and other income(5)(1)— — (9)— (12)(27)
Gain on non-designated derivative instruments— — — — — — (3,834)(3,834)
Loss on sale of real estate investments— — — — — 125 — 125 
Income tax expense— — — — — — 201 201 
Net loss attributable to non-controlling interests— — — — — — (135)(135)
Allocation for preferred stock— — — — — — 13,799 13,799 
NOI$82,376 $29,927 $13,094 $— $29 $(3,024)$— $122,402 
76

The following table reflects the items deducted from or added to net loss attributable to common stockholders in our calculation of Same Store, Acquisitions and Dispositions NOI for the year ended December 31, 2021:
Same StoreAcquisitionsDispositionsNon-Property SpecificTotal
(In thousands)MOBSHOPMOBSHOPMOBSHOP
Net income (loss) attributable to common stockholders (in accordance with GAAP)$33,017 $4,557 $1,395 $— $3,131 $(37,632)$(97,410)$(92,942)
Impairment charges6,082 — — — — 34,869 — 40,951 
Operating fees to related parties— — — — — — 24,206 24,206 
Acquisition and transaction related— — — — — 2,711 2,714 
General and administrative92 22 — — — 21 16,693 16,828 
Depreciation and amortization43,187 30,235 2,907 — 1,978 1,619 — 79,926 
Interest expense322 1,404 — — — — 46,174 47,900 
Interest and other income(18)(1)— — — — (42)(61)
Gain on non-designated derivative instruments— — — — — — (37)(37)
Gain on sale of real estate investments— — — — (3,706)58 — (3,648)
Income tax expense— — — — — — 203 203 
Net loss attributable to non-controlling interests— — — — — — (260)(260)
Allocation for preferred stock— — — — — — 7,762 7,762 
NOI$82,682 $36,220 $4,302 $— $1,403 $(1,065)$— $123,542 
Refer to Note 15 — Segment Reporting to our consolidated financial statements found in this Annual Report on Form 10-K for a reconciliation of NOI to net loss attributable to stockholders by reportable segment.
77

Dividends and Other Distributions
Dividends on our Series A Preferred Stock are declared quarterly in an amount equal to $1.84375 per share each year ($0.460938 per share per quarter) to Series A Preferred Stock holders, which is equivalent to 7.375% per annum on the $25.00 liquidation preference per share of Series A Preferred Stock. Dividends on the Series A Preferred Stock are cumulative and payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the next succeeding business day to holders of record on the close of business on the record date set by our board of directors and declared by us.
Dividends on our Series B Preferred Stock are declare quarterly in an amount equal to $1.78125 per share each year ($0.445313 per share per quarter) to Series B Preferred Stock holders, which is equivalent to 7.125% of per annum in the $25.00 liquidation preference per share of Series B Preferred Stock. Dividends on the Series B Preferred Stock are cumulative and payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the next succeeding business day to holders of record on the close of business on the record date set by our board of directors and declared by us. The first dividend on the Series B Preferred Stock was paid in January 2022.
On February 20, 2018, the Board authorized the rate at which we pay monthly distributions to stockholders, effective as of March 1, 2018, which is $0.85 per annum, per share of common stock. Also, on August 13, 2020, the Board changed our common stock distribution policy in order to preserve our liquidity and maintain additional financial flexibility in light of the COVID-19 pandemic and to comply with the Credit Facility at the time. Under this distribution policy, distributions authorized by the Board on shares of our common stock, if and when declared, are now paid on a quarterly basis in arrears in shares of our common stock valued at the estimated per share asset value in effect on the applicable date, based on a single record date to be specified at the beginning of each quarter.
Under our Credit Facility we may not pay distributions to holders of common stock in cash or make any other cash distributions (including repurchases of shares of our common stock), subject to certain exceptions. These exceptions include paying cash dividends on the Series A Preferred Stock and the Series B Preferred Stock or any other preferred stock we may issue and paying any cash distributions necessary to maintain our status as a REIT. We may not pay any cash distributions (including dividends on Series A Preferred Stock and Series B Preferred Stock) if a default or event of default exists or would result therefrom. The restrictions on paying cash distributions will no longer apply starting in the quarter in which we make an election and, as of the day prior to the commencement of the applicable quarter, we have a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million, giving effect to the aggregate amount of distributions projected to be paid by us during the applicable quarter, our ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5% and our Fixed Charge Coverage Ratio is not less than 1.50 to 1.00 for the most recently ended four fiscal quarters. There can be no assurance as to if, or when, we will be able to satisfy these conditions. We may only pay cash distributions on our common stock beginning in the Commencement Quarter and the aggregate distributions (as defined in the Credit Facility and including dividends on Series A Preferred Stock, Series B Preferred Stock or any other class of preferred stock that may be issued) for any period of four fiscal quarters do not exceed 95% of Modified FFO (as defined in the Credit Facility) for the same period based only on fiscal quarters after the Commencement Quarter. In addition, our ability to pay cash distributions may be limited by financial covenants in the Credit Facility, including our requirement to maintain a minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges and a minimum debt service coverage ratio. Until four full fiscal quarters have elapsed after the commencement of the Commencement Quarter, the aggregate amount of permitted distributions and Modified FFO will be determined by using only the fiscal quarters that have elapsed from and after the Commencement Quarter and annualizing those amounts.
Subject to the restrictions in our Credit Facility, the amount of dividends and other distributions payable to our stockholders is determined by the Board and is dependent on a number of factors, including funds available for distribution, our financial condition, capital expenditure requirements, as applicable, requirements of Maryland law and annual distribution requirements needed to maintain our status as a REIT under the Internal Revenue Code of 1986 (the “Code”). Distribution payments are dependent on the availability of funds. The Board may reduce the amount of dividends or distributions paid or suspend dividend or distribution payments at any time and therefore dividend and distribution payments are not assured. Any accrued and unpaid dividends payable with respect to the Series A Preferred Stock or Series B Preferred Stock become part of the liquidation preference thereof.
The following table shows the sources for the payment of distributions to common stockholders and preferred stockholders, including distributions on restricted shares and Common OP Units, but excluding distributions related to Class B Units because these distributions are recorded as an expense in our consolidated statement of operations and comprehensive loss, for the periods indicated. No cash distributions were made to common stockholders, restricted shareholders, holders of Common OP Units or holders of Class B Units in the year ended December 31, 2022.
78

Three Months EndedYear Ended
March 31, 2022June 30, 2022September 30, 2022December 31, 2022December 31, 2022
(In thousands)Percentage of DistributionsPercentage of DistributionsPercentage of DistributionsPercentage of DistributionsPercentage of Distributions
Distributions:
Dividends paid to holders of Series A Preferred Stock$1,833 52.4%$1,833 52.4%$1,834 52.5%$1,833 52.4%$7,333 52.4%
Dividends paid to holders of Series B Preferred Stock1,616 46.2%1,617 46.3%1,616 46.2%1,617 46.3%6,466 46.2%
Distributions paid to holders of Series A Preferred Units46 1.3%46 1.3%46 1.3%46 1.3%184 1.3%
Total cash distributions$3,495 100.0%$3,496 100.0%$3,496 100.0%$3,496 100.0%$13,983 100.0%
Source of distribution coverage:
Cash flows provided by operations (1)
$3,495 100.0 %$3,496 100.0 %$3,496 100.0 %$3,496 100.0 %$13,983 100.0 %
Total source of distribution coverage
$3,495 100.0 %$3,496 100.0 %$3,496 100.0 %$3,496 100.0 %$13,983 100.0 %
Cash flows provided by operations (in accordance with GAAP)
$5,882 $7,855 $7,358 $7,200 $28,295 
Net loss (in accordance with GAAP)$(2,340)$(17,635)$(19,875)$(39,771)$(79,621)
_______
(1)Assumes the use of available cash flows from operations before any other sources.

For the year ended December 31, 2022, cash flows provided by operations were $28.3 million. We had not historically generated sufficient cash flows from operations to fund the payment of dividends and other distributions at the current rate prior to switching from paying cash dividends to stock dividends on our common stock. As shown in the table above, we funded dividends to holders of Series A Preferred Stock, Series B Preferred Stock and Series A Preferred Units with cash flows provided by operations. Because shares of common stock are only offered and sold pursuant to the DRIP in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as we pay distributions in stock instead of cash.
Our ability to pay dividends on our Series A Preferred Stock, Series B Preferred Stock and Series A Preferred Units and, starting with the Commencement Quarter, other distributions and maintain compliance with the restrictions on the payment of distributions in our Credit Facility depends on our ability to increase the amount of cash we generate from property operations which in turn depends on a variety of factors, including the duration and scope of the COVID-19 pandemic and its impact on our tenants and properties, our ability to complete acquisitions of new properties and our ability to improve operations at our existing properties. There can be no assurance that we will complete acquisitions on a timely basis or on acceptable terms and conditions, if at all. Our ability to improve operations at our existing properties is also subject to a variety of risks and uncertainties, many of which are beyond our control, and there can be no assurance we will be successful in achieving this objective.
We may still pay any cash distributions necessary to maintain its status as a REIT and may not pay any cash distributions (including dividends on Series A Preferred Stock and Series B Preferred Stock) if a default or event of default exists or would result therefrom under the Credit Facility.
79

Loan Obligations
The payment terms of our mortgage notes payable generally require principal and interest amounts payable monthly with all unpaid principal and interest due at maturity. The payment terms of our Credit Facility require interest only amounts payable monthly with all unpaid principal and interest due at maturity. The payment terms of our Fannie Mae Master Credit Facilities required interest only payments through November 2021 and principal and interest payments thereafter. Our loan agreements require us to comply with specific financial and reporting covenants. Pursuant to the terms of the Fourth Amendment entered into on August 11, 2022, as described above, the prior Fixed Charge Coverage Ratio, based on the four most recently ended fiscal quarters, of 1.50 to 1.00 was reduced to (a) 1.20 to 1.00 for the period commencing with the quarter ended June 30, 2022 through the quarter ending June 30, 2023, (b) 1.35 to 1.00 for the period commencing with the quarter ending September 30, 2023 through the quarter ending December 31, 2023 and (c) 1.45 to 1.00 for the period commencing with the quarter ending March 31, 2024 and continuing thereafter; provided, however, that from and after the Commencement Quarter, we must satisfy a minimum Fixed Charge Coverage Ratio of 1.50 to 1.00. Prospectively, based upon our current expectations, we believe our operating results through June 30, 2023 will allow us to comply with these covenants. However, we believe our operating results may not be sufficient to comply with the increased Fixed Charge Coverage Ratio, which increases from 1.20:1.00 to 1.35:1.00 commencing with the quarter ending September 30, 2023 and thereafter. Absent a waiver or modification from the lender group, failure to comply with the Fixed Charge Coverage Ratio would constitute an Event of Default and the balance of the Credit Facility would be due and payable. We have obtained such waivers and modifications from the lender group in the past, but there can be no assurance that such a waiver or modification will be granted in future periods. See Note 5 — Credit Facilities, Net for additional information on the Fourth Amendment.
Under our Credit Facility, until the first day of the Commencement Quarter, we must use all the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to repay amounts outstanding under the Revolving Credit Facility, to the extent there are any such amounts outstanding. We may borrow additional amounts if all relevant conditions are met, including sufficient availability for future borrowings. There can be no assurance these conditions will be met.
Election as a REIT 
We elected to be taxed as a REIT under Sections 856 through 860 of the Code, effective for our taxable year ended December 31, 2013. Commencing with that taxable year, we have been organized and operated in a manner so that we qualify as a REIT under the Code. We intend to continue to operate in such a manner but can provide no assurances that we will operate in a manner so as to remain qualified for taxation as a REIT. To continue to qualify as a REIT, we must distribute annually at least 90% of our REIT taxable income (which does not equal net income as calculated in accordance with GAAP) determined without regard to the deduction for dividends paid and excluding net capital gains, and comply with a number of other organizational and operational requirements. If we continue to qualify as a REIT, we generally will not be subject to U.S. federal corporate income tax on the portion of our REIT taxable income that we distribute to our stockholders. Even if we continue to qualify for taxation as a REIT, we may be subject to certain state and local taxes on our income and properties as well as U.S. federal income and excise taxes on our undistributed income.
Inflation
We may be adversely impacted by inflation on the leases with tenants in our MOB segment that do not contain indexed escalation provisions, or those leases which have escalations at rates which do not exceed or approximate current inflation rates. As of December 31, 2022, the increase to the 12-month CPI for all items, as published by the Bureau of Labor Statistics, was 6.5%. To help mitigate the adverse impact of inflation, approximately 90% of our leases with our tenants in our MOB segment contain rent escalation provisions which average 2.3% per year. These provisions generally increase rental rates during the terms of the leases either at fixed rates or indexed escalations (based on the Consumer Price Index or other measures). Approximately 85.9% are fixed-rate, 4.1% are based on the Consumer Price Index and 10% do not contain any escalation provisions.
In addition to base rent, depending on the specific lease, MOB tenants are generally required to pay either (i) their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors or (ii) their share of increases in property operating and maintenance expenses to the extent they exceed the properties’ expenses for the base year of the respective leases. Property operating and maintenance expenses include common area maintenance costs, real estate taxes and insurance. Increased operating costs paid by our tenants under these net leases could have an adverse impact on our tenants if increases in their operating expenses exceed increases in their revenue, which may adversely affect our tenants’ ability to pay rent owed to us or property expenses to be paid, or reimbursed to us, by our tenants. Renewals of leases or future leases for our net lease properties may not be negotiated on a triple-net basis or on a basis requiring the tenants to pay all or some of such expenses, in which event we may have to pay those costs. If we are unable to lease properties on a triple-net basis or on a basis requiring the tenants to pay all or some of such expenses, or if tenants fail to pay required tax, utility and other impositions, we could be required to pay those costs.
80


Leases with residents at our SHOPs typically do not have rent escalations, however, we are able to renew leases at market rates as they mature due to their short-term nature. As inflation rates increase or persist at high levels, the cost of providing medical care at our SHOPs, particularly labor costs, will increase. If we are unable to admit new residents or renew resident leases at market rates, while bearing these increased costs from providing services to our residents, our results of operations may be affected.
Related-Party Transactions and Agreements
Please see Note 9 — Related Party Transactions and Arrangements to our consolidated financial statements included in this Annual Report on Form 10-K for a discussion of the various related party transactions, agreements and fees.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
The market risk associated with financial instruments and derivative financial instruments is the risk of loss from adverse changes in market prices or interest rates. Our long-term debt, which consists of secured financings, our Credit Facility (which includes a Revolving Credit Facility and a Term Loan) and the Fannie Mae Master Credit Facilities, bear interest at fixed rates and variable rates. Our interest rate risk management objectives are to limit the impact of interest rate changes on earnings and cash flows and to lower our overall borrowing costs. To achieve these objectives, from time to time, we may enter into interest rate hedge contracts such as swaps, collars, and treasury lock agreements in order to mitigate our interest rate risk with respect to various debt instruments. We will not hold or issue these derivative contracts for trading or speculative purposes. As of December 31, 2022, we had entered into seven non-designated interest rate caps with a current notional amount of approximately $354.6 million (of which six caps were active as of December 31, 2022 and one has a forward start date as of April 2023), two LIBOR-based designated interest rate swaps with a notional amount of $50.0 million and seven SOFR-based designated interest rate swaps with a notional amount of $528.5 million. Subsequent to December 31, 2022, we terminated our two LIBOR-based designated interest rate swaps with a notional amount of $50.0 million (see Note 17 — Subsequent Events to our consolidated financial statements). We do not have any foreign operations and thus we are generally not directly exposed to foreign currency fluctuations.
Mortgage Notes Payable
As of December 31, 2022, all of our mortgages are either fixed-rate ($206.7 million) or variable-rate ($378.5 million), before consideration of interest rate swaps. Our mortgages had a gross aggregate carrying value of $585.2 million and a fair value of $550.6 million as of December 31, 2022.
Credit Facilities
Our Credit Facilities are variable-rate, before consideration of interest rate swaps, and are comprised of our Revolving Credit Facility, our Term Loan and our Fannie Mae Master Credit Facilities. Our Credit Facilities had a gross aggregate carrying amount of $532.0 million and a fair value of $532.5 million as of December 31, 2022.
Sensitivity Analysis - Interest Expense
Interest rate volatility associated with all of our variable-rate borrowings affects interest expense incurred and cash flow to the extent they are not fixed via interest rate swap or capped via interest rate cap contracts.
Interest Rate Swaps
As noted above, we have two LIBOR-based designated interest rate swaps with a notional amount of $50.0 million and seven SOFR-based designated interest rate swaps with a notional amount of $528.5 million, which effectively create a fixed interest rate for a portion of our variable-rate debt. These interest rate swaps effectively hedge all of our variable rate debt with the exception of our Fannie Mae Master Credit Facilities discussed below.
Interest Rate Caps
We also have entered into seven non-designated interest rate cap contracts with a current notional amount of $354.6 million as of December 31, 2022 (of which six caps were active as of December 31, 2022 and one has a forward start date as of April 2023), which limits 30-day LIBOR exposure on our Fannie Mae Master Credit Facilities to 3.50%. The active caps began limiting 30-day LIBOR during the fourth quarter of 2022 as 30-day LIBOR rates exceeded the strike price of 3.50% and we are receiving monthly cash payments on these contracts. Because these are non-designated derivatives, the amounts received are included in gain on non-designated derivatives in our statement of operations and comprehensive loss.
Sensitivity


As of December 31, 2022, we are not currently negatively exposed to rising interest rates. Assuming all other variables besides interest rates remain constant, a 100 basis point increase in variable interest rates would not impact our interest expense due to our interest rate swaps and effective interest rate caps as of December 31, 2022. Assuming all other variables besides interest rates remain constant, a 100 basis point decrease in variable interest rates would also not impact our swapped debt, and based on the SOFR/LIBOR rate as of December 31, 2022, a 100 basis point decrease would not have a material impact on our net interest payments (inclusive of cash received from our non-designated derivatives included in gain on non-designated derivatives).
Sensitivity Analysis - Fair Value of Debt
Changes in market interest rates on our debt instruments impacts their fair value, even if it has no impact on interest due on them. For instance, if interest rates rise 100 basis points and the balances on our debt instruments remain constant, we expect the fair value of our obligations to decrease, the same way the price of a bond declines as interest rates rise. The sensitivity analysis related to our debt assumes an immediate 100 basis point move in interest rates from their December 31, 2022 levels, with all other variables held constant. A 100 basis point increase in market interest rates would result in a decrease in the fair value of our debt by $10.4 million. A 100 basis point decrease in market interest rates would result in an increase in the fair value of our debt by $11.5 million. A 100 basis point increase in market interest rates would result in an increase in the fair value of our nine designated interest rate swaps by $14.6 million. A 100 basis point decrease in market interest rates would result in a decrease in the fair value of our nine designated interest rate swaps by $15.3 million.
These amounts were determined by considering the impact of hypothetical interest rate changes on our borrowing costs, and assuming no other changes in our capital structure. The information presented above includes only those exposures that existed as of December 31, 2022 and does not consider exposures or positions arising after that date. The information represented herein has limited predictive value. Future actual realized gains or losses with respect to interest rate fluctuations will depend on cumulative exposures, hedging strategies employed and the magnitude of the fluctuations.
Item 8. Financial Statements and Supplementary Data.
The information required by this Item 8 is hereby incorporated by reference to our Consolidated Financial Statements beginning on page F-1 of this Annual Report on Form 10-K.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
None.
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
In accordance with Rules 13a-15(b) and 15d-15(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our disclosure controls and procedures include internal controls and other procedures designed to provide reasonable assurance that information required to be disclosed in this and other reports filed under the Exchange Act is recorded, processed, summarized and reported within the required time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures. It should be noted that no system of controls can provide complete assurance of achieving a company’s objectives and that future events may impact the effectiveness of a system of controls.
Our Chief Executive Officer and Chief Financial Officer, carried out an evaluation, together with other members of our management, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective as of December 31, 2022 at a reasonable level of assurance.
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) or 15d-15(f) promulgated under the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.
Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding
82

prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate.
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In making that assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013). Based on its assessment, our management concluded that, as of December 31, 2022, our internal control over financial reporting was effective based on those criteria.
This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. The effectiveness of our internal control over financial reporting has not been audited by our independent registered public accounting firm because we are a “non-accelerated filer” as defined under SEC rules.
Changes in Internal Control Over Financial Reporting
During the three months ended December 31, 2022, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item 9B. Other Information.
None.
Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections
Not Applicable.
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
We have adopted a Code of Business Conduct and Ethics that applies to all of our executive officers and directors, including but not limited to, our principal executive officer and principal financial officer. A copy of our code of ethics may be obtained, free of charge, by sending a written request to our executive office: 650 Fifth Avenue - 30th Floor, New York, NY 10019, Attention: Chief Financial Officer. Our Code of Business Conduct and Ethics is also publicly available on our website at www.healthcaretrustinc.com. If we make any substantive amendments to the code of ethics or grant any waiver, including any implicit waiver, from a provision of the Code of Business Conduct and Ethics to our chief executive officer, chief financial officer, chief accounting officer or controller or persons performing similar functions, we will disclose the nature of the amendment or waiver on that website or in a report on Form 8-K.
The information required by this Item will be set forth in our definitive proxy statement with respect to our 2023 annual meeting of stockholders to be filed not later than 120 days after the end of the 2022 fiscal year, and is incorporated herein by reference.
Item 11. Executive Compensation.
The information required by this Item will be set forth in our definitive proxy statement with respect to our 2023 annual meeting of stockholders to be filed not later than 120 days after the end of the 2022 fiscal year, and is incorporated herein by reference.

83


Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Securities Authorized for Issuance Under Equity Compensation Plans
Restricted Share Plan
We have an employee and director incentive restricted share plan (as amended from time to time, the “RSP”), which provides us with the ability to grant awards of restricted shares to our directors, officers and employees (if we ever have employees), and, among other eligible persons, employees of the Advisor and its affiliates who provide services to us. For additional information, see Note 11 — Equity-Based Compensation to our consolidated financial statements included in this Annual Report on Form 10-K.
The following table sets forth information regarding securities authorized for issuance under the RSP as of December 31, 2022:
Plan Category
Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights
Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights
Number of Securities Remaining Available For Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a) )
(a)
(b)
(c)
Equity Compensation Plans approved by security holders
3,419,100 
(1)
Equity Compensation Plans not approved by security holders
Total
3,419,100 
(1)
________
(1)The total number of shares of common stock that may be subject to awards granted under the RSP may not exceed 5.0% of our outstanding shares of common stock on a fully diluted basis at any time and in any event will not exceed 3,861,194 shares (as such number may be further adjusted for stock splits, stock dividends, combinations and similar events). As of December 31, 2022, we had 105,080,531 shares of common stock issued and outstanding and 442,094 shares of common stock that were subject to awards granted under the RSP. For additional information on the RSP, please see Note 11 — Equity-Based Compensation to our consolidated financial statements included in this Annual Report on Form 10-K.
The other information required by this Item will be set forth in our definitive proxy statement with respect to our 2023 annual meeting of stockholders to be filed not later than 120 days after the end of the 2022 fiscal year, and is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
The information required by this Item will be set forth in our definitive proxy statement with respect to our 2023 annual meeting of stockholders to be filed not later than 120 days after the end of the 2022 fiscal year, and is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services.
The information required by this Item will be set forth in our definitive proxy statement with respect to our 2023 annual meeting of stockholders to be filed not later than 120 days after the end of the 2022 fiscal year, and is incorporated herein by reference.
PART IV
Item 15. Exhibit and Financial Statement Schedules.
(a) Financial Statements and Financial Statement Schedules
1.    Financial Statements:
        See the Index to Consolidated Financial Statements at page F-1 of this Annual Report on Form 10-K.
2.    Financial Statement Schedules:
The following financial statement schedule is included herein at page F-42 of this Annual Report on Form 10-K: Schedule III — Real Estate and Accumulated Depreciation

(b) Exhibits
See Exhibit Index below.



EXHIBIT INDEX

The following exhibits are included, or incorporated by reference, in this Annual Report on Form 10-K for the year ended December 31, 2022 (and are numbered in accordance with Item 601 of Regulation S-K):
Exhibit No.  Description
 3.1 (1)
Articles of Amendment and Restatement for Healthcare Trust, Inc.
3.2 (2)
Articles Supplementary of Healthcare Trust, Inc. relating to election to be subject to Section 3-803 of the Maryland General Corporation Law, dated November 9, 2017
3.3 (3)
Articles Supplementary relating to the designation of shares of 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, dated December 6, 2019
3.4 (6)
Articles Supplementary designating additional shares of 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, dated September 15, 2020
3.5 (28)
Articles Supplementary relating to the designation of shares of 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, dated October 4, 2021
3.6 (30)
Articles Supplementary designating additional shares of 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, dated May 10, 2021
3.7 (4)
Amended and Restated Bylaws of Healthcare Trust, Inc.
3.8 (5)
Amendment to Amended and Restated Bylaws of Healthcare Trust, Inc.
3.9 (29)
Second Amendment to Amended and Restated Bylaws of Healthcare Trust, Inc.
4.1 (7)
Agreement of Limited Partnership of Healthcare Trust Operating Partnership, L.P. (f/k/a American Realty Capital Healthcare Trust II Operating Partnership, L.P.), dated as of February 14, 2013
4.2 (8)
First Amendment, dated December 31, 2013, to the Agreement of Limited Partnership of American Realty Capital Healthcare Trust II, L.P., dated February 14, 2013
4.3 (1)
Second Amendment, dated April 15, 2015, to the Agreement of Limited Partnership of American Realty Capital Healthcare Trust II, L.P., dated as of February 14, 2013
4.4 (10)
Third Amendment, dated December 6, 2019, to the Agreement of Limited Partnership of Healthcare Trust Operating Partnership, L.P., dated February 14, 2013
4.5 (6)
Fourth Amendment, dated September 15, 2020, to the Agreement of Limited Partnership of Healthcare Trust Operating Partnership, L.P., dated February 14, 2013
4.6 (30)
Fifth Amendment, dated May 7, 2021, to the Agreement of Limited Partnership of Healthcare Trust Operating Partnership, L.P., dated February 14, 2013
4.7 (28)
Sixth Amendment, dated October 4, 2021, to the Agreement of Limited Partnership of Healthcare Trust Operating Partnership, L.P., dated February 14, 2013
4.8 (5)
Rights Agreement, dated May 18, 2020, between Healthcare Trust, Inc.,and Computershare Trust Company, N.A., as Rights Agent
4.9 *
Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
10.1 (9)
Second Amended and Restated Advisory Agreement, dated as of February 17, 2017, by and among the Company, Healthcare Trust Operating Partnership, L.P. and Healthcare Trust Advisors, LLC
10.2 (11)
Amendment No. 1, dated as of July 25, 2019, to the Second Amended and Restated Advisory Agreement, by and among Healthcare Trust, Inc., Healthcare Trust Operating Partnership, L.P. and Healthcare Trust Advisors, LLC

10.3 (9)

Amended and Restated Property Management and Leasing Agreement, dated as of February 17, 2017, by and among the Company, Healthcare Trust Operating Partnership, L.P. and Healthcare Trust Properties, LLC
10.4 (12)
First Amendment, dated as of April 9, 2018, to Amended and Restated Property Management and Leasing Agreement, by and among Healthcare Trust, Inc., Healthcare Trust Operating Partnership, L.P., and Healthcare Trust Properties, LLC
10.5 (32)
Second Amendment, dated as of November 11, 2021, to Amended and Restated Property Management and Leasing Agreement, by and among Healthcare Trust, Inc., Healthcare Trust Operating Partnership, L.P., and Healthcare Trust Properties, LLC
10.6 (13)
Indemnification Agreement, dated as of December 31, 2014, with Directors, Officers, Advisor and Dealer Manager
10.7 (13)
Indemnification Agreement, dated April 14, 2015, with Mr. Randolph C. Read
10.8 (14)
Form of Restricted Stock Award Agreement Pursuant to the Employee and Director Incentive Restricted Share Plan of Healthcare Trust, Inc.
10.9 (15)
Master Credit Facility Agreement, dated as of October 31, 2016, by and among the borrowers party thereto and KeyBank National Association
85

Exhibit No.  Description
10.10 (4)
First Amendment to Master Credit Facility, dated April 26, 2017, by among the borrowers party thereto and KeyBank National Association

10.11 (4)
Reaffirmation, Joinder and Second Amendment to Master Credit Facility, dated October 26, 2017, by among the borrowers party thereto and KeyBank National Association

10.12 (15)
Master Credit Facility Agreement, dated as of October 31, 2016, by and among the borrowers party thereto and Capital One Multifamily Finance, LLC
10.13 (4)
Reaffirmation, Joinder and First Amendment to Master Credit Facility, dated March 30, 2017, by among the borrowers party thereto and Capital One Multifamily Finance, LLC

10.14 (4)
Second Amendment to Master Credit Facility, dated October 26, 2017, by among the borrowers party thereto and Capital One Multifamily Finance, LLC

10.15 (4)
Third Amendment to Master Credit Facility, dated March 2, 2018, by among the borrowers party thereto and Capital One Multifamily Finance, LLC

10.16 (16)
Amended and Restated Loan Agreement, dated as of December 20, 2019, by and among the borrower entities party thereto, Capital One, National Association and the other lenders party thereto

10.17 (16)
Amended and Restated Guaranty of Recourse Obligations, dated as of December 20, 2019, by Healthcare Trust Operating Partnership, L.P. in favor of Capital One, National Association

10.18 (16)
Amended and Restated Hazardous Materials Indemnity Agreement, dated as of December 20, 2019, by Healthcare Trust Operating Partnership, L.P. and the borrower entities party thereto, for the benefit of Capital One, National Association

10.19 (2)
Amended and Restated Employee and Director Incentive Restricted Share Plan of Healthcare Trust, Inc., effective as of August 31, 2017
10.20 (2)
Form of Restricted Stock Award Agreement Pursuant to the Amended and Restated Employee and Director Incentive Restricted Share Plan of Healthcare Trust, Inc.
10.21 (17)
Loan Agreement, dated as of December 28, 2017, among the borrower entities party thereto and Capital One, National Association
10.22 (17)
Guaranty of Recourse Obligation, dated as of December 28, 2017, by Healthcare Trust Operating Partnership, L.P. in favor of Capital One, National Association
10.23 (17)
Hazardous Materials Indemnity Agreement, dated as of December 28, 2017, by Healthcare Trust Operating Partnership, L.P. and the borrower entities party thereto, for the benefit of Capital One, National Association
10.24 (12)
 Loan Agreement, dated as of April 10, 2018, by and among the borrowers party thereto, and KeyBank National Association, as lender
10.25 (12)
Promissory Note A -1, dated as of April 10, 2018, by the borrowers party thereto in favor of KeyBank National
Association, as lender
10.26 (12)
 Promissory Note A-2, dated as of April 10, 2018, by the borrowers party thereto in favor of KeyBank National
Association, as lender
10.27 (12)
Guarantee Agreement, dated as of April 10, 2018, by Healthcare Trust Operating Partnership, L.P. in favor of KeyBank National Association, as lender
10.28 (12)
Environmental Indemnity Agreement, dated as of April 10, 2018, by the borrowers party thereto and Healthcare Trust Operating Partnership, L.P. in favor of KeyBank National Association, as indemnitee
10.29 (18)
Form of Indemnification Agreement
10.30 (19)
Amended and Restated Senior Secured Revolving Credit Agreement dated as of March 13, 2019 by and among Healthcare Trust Operating Partnership, L.P., KeyBank National Association and the other lender parties thereto

10.31 (20)
First Amendment to Amended and Restated Senior Secured Revolving Credit Agreement entered into as of March 13, 2019 by and among Healthcare Trust Operating Partnership, L.P., KeyBank National Association and the other lender parties thereto
10.32 (21)
Second Amendment to First Amended and Restated Senior Secured Credit Agreement, entered into as of August 10, 2020, among Healthcare Trust Operating Partnership, L.P., Healthcare Trust, Inc., the other guarantor parties thereto, Keybank National Association and the other lenders party thereto
10.33 (32)
Third Amendment to First Amended and Restated Senior Secured Credit Agreement, entered into as of November 12, 2021, among Healthcare Trust Operating Partnership, L.P., Healthcare Trust, Inc., the other guarantor parties thereto, Keybank National Association and the other lenders party thereto
10.34 (31)
Fourth Amendment to First Amended and Restated Senior Credit Agreement, entered into as of August 11, 2022, among Healthcare Trust Operating Partnership, L.P., Healthcare Trust, Inc., the other guarantor parties thereto, Keybank National Association and the other lenders party thereto
List of Subsidiaries of Healthcare Trust, Inc.
86

Exhibit No.  Description
Consent of PricewaterhouseCoopers LLP
Certification of the Principal Executive Officer of the Company pursuant to Securities Exchange Act Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of the Principal Financial Officer of the Company pursuant to Securities Exchange Act Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32 *
Written statements of the Principal Executive Officer and Principal Financial Officer of the Company pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
99.1 (22)
Second Amended and Restated Share Repurchase Program of Healthcare Trust, Inc.
99.2 (23)
Amendment to Second Amended and Restated Share Repurchase Program of Healthcare Trust, Inc.
99.3 (24)
Second Amendment to Second Amended and Restated Share Repurchase Program

99.4 (25)
Third Amendment to Second Amended and Restated Share Repurchase Program

99.5 (26)
Fourth Amendment to Second Amended and Restated Share Repurchase Program

99.6 (27)
Fifth Amendment to Second Amended and Restated Share Repurchase Program

101.INS *
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL
tags are embedded within the Inline XBRL document.

101.SCH *XBRL Taxonomy Extension Schema Document
101.CAL *XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF *XBRL Taxonomy Extension Definition Linkbase Document
101.LAB *XBRL Taxonomy Extension Label Linkbase Document
101.PRE *XBRL Taxonomy Extension Presentation Linkbase Document
104 *Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
________
87

*    Filed herewith

(1)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 6, 2016.
(2)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 filed with the Securities and Exchange Commission on November 14, 2017.
(3)Filed as an exhibit to the Company’s Registration Statement on Form 8-A filed with the Securities and Exchange Commission on December 6, 2019.
(4)Filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission on March 20, 2018.
(5)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 19, 2020.
(6)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 15, 2020.
(7)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 filed with the Securities and Exchange Commission on May 14, 2013.
(8)Filed as an exhibit to the Company’s Quarterly Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission on March 7, 2014.
(9)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 17, 2017.
(10)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2019.
(11)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 25, 2019.
(12)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 16, 2018.
(13)Filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission on April 15, 2015.
(14)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 filed with the Securities and Exchange Commission on August 15, 2016.
(15)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 filed with the Securities and Exchange Commission on November 10, 2016.
(16)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 27, 2019.
(17)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 4, 2018.
(18)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended May 31, 2018 filed with the Securities and Exchange Commission on August 3, 2018.
(19)Filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on March 14, 2019.
(20)Filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on March 24, 2020.
(21)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 13, 2020.
(22)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 14, 2017.
(23)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 29, 2019.
(24)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 27, 2019.
(25)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 23, 2019.
(26)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 21, 2019.
(27)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 9, 2020.
(28)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 4, 2021, and incorporated by reference herein.
(29)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 19, 2022, and incorporated by reference herein.
(30)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 10, 2021.
(31)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the Securities and Exchange Commission on August 12, 2022.
(32)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 filed with the Securities and Exchange Commission on November 12, 2021.
Item 16. Form 10-K Summary.
Not applicable.
88

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized this 17th day of March, 2023.

 HEALTHCARE TRUST, INC. 
 By/s/ Edward M. Weil, Jr.
Edward M. Weil, Jr.
Chief Executive Officer and President
(Principal Executive Officer)


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
NameCapacityDate
/s/ Leslie D. MichelsonNon-Executive Chairman of the Board of Directors, Independent DirectorMarch 17, 2023
Leslie D. Michelson
/s/ Scott M. Lappetito Chief Financial Officer, Treasurer and SecretaryMarch 17, 2023
Scott M. Lappetito(Principal Financial Officer and Principal Accounting Officer)
/s/ Edward M. Weil, Jr.Chief Executive Officer, President and Director March 17, 2023
Edward M. Weil, Jr.(Principal Executive Officer)
/s/ Elizabeth K. TuppenyIndependent DirectorMarch 17, 2023
Elizabeth K. Tuppeny
/s/ Edward G. RendellIndependent DirectorMarch 17, 2023
Edward G. Rendell
/s/ B.J. PennIndependent DirectorMarch 17, 2023
B.J. Penn
89

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

F-1

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Healthcare Trust, Inc.

Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Healthcare Trust, Inc. and its subsidiaries (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of operations and comprehensive loss, of changes in equity and of cash flows for each of the three years in the period ended December 31, 2022, including the related notes and financial statement schedule listed in the accompanying index (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Purchase Price Allocations for Property Acquisitions
As described in Note 3 to the consolidated financial statements, during the year ended December 31, 2022, the Company completed real estate acquisitions, net of below market lease liabilities assumed, of $25.5 million. For acquired properties with leases classified as operating leases, management allocated the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed based on their respective fair values. Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. Management utilizes various estimates, processes and information to determine the as-if vacant property value. Management estimates fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot. Identifiable intangible assets include amounts allocated to acquire leases for above- and below-market lease rates and the value of in-place leases. Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below- market fixed rate renewal options for below-market leases.
The principal considerations for our determination that performing procedures relating to purchase price allocations for property acquisitions is a critical audit matter are (i) the significant judgment by management when developing the fair value estimates of tangible and intangible assets acquired and liabilities assumed; (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management’s significant assumptions related to capitalization rates, fair market lease
F-2

Report of Independent Registered Public Accounting Firm
rates, discount rates and land values per square foot; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others (i) reading the purchase agreements and lease documents; (ii) testing the completeness and accuracy of underlying data used by management in the fair value estimates, and (iii) testing management’s process for estimating the fair value of tangible and intangible assets acquired and liabilities assumed, including testing management’s projected cash flows and evaluating the accuracy of valuation outputs. Testing management’s process included evaluating the appropriateness of the valuation methods and reasonableness of the significant assumptions related to capitalization rates, fair market lease rates, discount rates and land values per square foot. Evaluating the reasonableness of the significant assumptions included considering whether these assumptions were consistent with external market data, comparable transactions, and evidence obtained in other areas of the audit. In conjunction with certain purchase price allocations, professionals with specialized skill and knowledge were used to assist in evaluating the reasonableness of certain assumptions utilized by management related to capitalization rates, fair market lease rates, discount rates and land values per square foot.

/s/ PricewaterhouseCoopers LLP
New York, New York
March 17, 2023
We have served as the Company's auditor since 2019.
F-3

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)

December 31,
20222021
ASSETS 
Real estate investments, at cost:
Land
$206,454 $206,392 
Buildings, fixtures and improvements
2,089,133 2,117,896 
Acquired intangible assets
292,034 288,372 
Total real estate investments, at cost
2,587,621 2,612,660 
Less: accumulated depreciation and amortization
(609,324)(562,733)
Total real estate investments, net
1,978,297 2,049,927 
Cash and cash equivalents53,654 59,738 
Restricted cash22,884 25,644 
Derivative assets, at fair value40,647 174 
Straight-line rent receivable, net
25,276 23,858 
Operating lease right-of-use assets
7,814 7,914 
Prepaid expenses and other assets (including $929 due from related parties as of December 31, 2021)
34,554 32,564 
Deferred costs17,223 14,581 
Total assets
$2,180,349 $2,214,400 
LIABILITIES AND EQUITY  
Mortgage notes payable, net$578,700 $584,239 
Credit facilities, net530,297 502,051 
Market lease intangible liabilities, net9,407 10,943 
Derivative liabilities, at fair value 13,903 
Accounts payable and accrued expenses (including $47 due to related parties as of December 31, 2022 and 2021)
45,247 42,709 
Operating lease liabilities8,087 8,130 
Deferred rent5,925 8,619 
Distributions payable
3,496 3,406 
Total liabilities
1,181,159 1,174,000 
Stockholders’ Equity
7.375% Series A cumulative redeemable perpetual preferred stock, $0.01 par value, 4,740,000 authorized as of December 31, 2022 and 2021; 3,977,144 issued and outstanding as of December 31, 2022 and 2021
40 40 
7.125% Series B cumulative redeemable perpetual preferred stock, $0.01 par value, 3,680,000 authorized; 3,630,000 issued and outstanding as of December 31, 2022 and 2021
36 36 
Common stock, $0.01 par value, 300,000,000 shares authorized, 105,080,531 shares and 99,281,754 shares issued and outstanding as of December 31, 2022 and 2021, respectively
1,051 993 
Additional paid-in capital2,417,059 2,329,839 
Accumulated other comprehensive income (loss)36,910 (14,341)
Distributions in excess of accumulated earnings(1,462,457)(1,282,871)
Total stockholders’ equity
992,639 1,033,696 
Non-controlling interests6,551 6,704 
Total equity
999,190 1,040,400 
Total liabilities and equity
$2,180,349 $2,214,400 

The accompanying notes are an integral part of these consolidated financial statements.
F-4

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
 Year Ended December 31,
202220212020
Revenue from tenants$335,846 $329,355 $381,612 
Operating expenses:  
Property operating and maintenance213,444 205,813 243,548 
Impairment charges27,630 40,951 36,446 
Operating fees to related parties25,353 24,206 23,922 
Acquisition and transaction related1,484 2,714 173 
General and administrative17,287 16,828 21,572 
Depreciation and amortization82,064 79,926 81,053 
Total expenses
367,262 370,438 406,714 
Operating loss before gain on sale of real estate investments(31,416)(41,083)(25,102)
Gain (loss) on sale of real estate investments(125)3,648 5,230 
Operating loss
(31,541)(37,435)(19,872)
Other income (expense):
Interest expense(51,740)(47,900)(51,519)
Interest and other income
27 61 44 
Gain (loss) on non-designated derivatives3,834 37 (102)
Total other expenses
(47,879)(47,802)(51,577)
Loss before income taxes(79,420)(85,237)(71,449)
Income tax expense(201)(203)(4,061)
Net loss(79,621)(85,440)(75,510)
Net loss (income) attributable to non-controlling interests135 260 (303)
Allocation for preferred stock(13,799)(7,762)(2,968)
Net loss attributable to common stockholders(93,285)(92,942)(78,781)
Other comprehensive income (loss):
Unrealized gain (loss) on designated derivatives51,251 25,332 (32,630)
Comprehensive loss attributable to common stockholders$(42,034)$(67,610)$(111,411)
Weighted-average common shares outstanding — Basic and Diluted (1)
106,428,154 106,354,994 106,119,937 
Net loss per common share attributable to common stockholders — Basic and Diluted (1)
$(0.88)$(0.87)$(0.74)
_____
(1)Retroactively adjusted for the effects of the Stock Dividends (see Note 1 — Organization for details).



The accompanying notes are an integral part of these consolidated financial statements.
F-5

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
Years Ended December 31, 2022, 2021 and 2020
(In thousands, except share data)
Series A Preferred StockSeries B Preferred StockCommon StockAccumulated Other Comprehensive Income (Loss)
Number of
Shares
Par ValueNumber of
Shares
Par ValueNumber of
Shares
Par ValueAdditional
Paid-in
Capital
Distributions in Excess of Accumulated EarningsTotal Stockholders’ EquityNon-controlling InterestsTotal Equity
Balance, December 31, 20191,610,000 $16  $ 92,356,664 $923 $2,078,628 $(7,043)$(971,190)$1,101,334 $5,410 $1,106,744 
Issuance of Series A Preferred Stock, net— — — — — — (59)— — (59)— (59)
Common stock issued through distribution reinvestment plan— — — — 875,986 9 14,595 — — 14,604 — 14,604 
Common stock repurchases— — — — (705,101)(7)(10,539)— — (10,546)— (10,546)
Share-based compensation, net— — — — — — 1,345 — — 1,345 — 1,345 
Distributions declared in common stock,
$0.21 per share
— — — — 1,248,197 13 19,646 — (19,659) —  
Distributions declared in cash on common stock, $0.42 per share
— — — — — — — — (38,839)(38,839)— (38,839)
Dividends declared on Series A Preferred Stock, $1.84 per share
— — — — — — — — (2,968)(2,968)— (2,968)
Distributions to non-controlling interest holders— — — — — — — — — — (201)(201)
Buyout of non-controlling interest— — — — — — — — (88)(88)(495)(583)
Net loss— — — — — — — — (75,813)(75,813)303 (75,510)
Unrealized loss on designated derivative— — — — — — — (32,615)— (32,615)— (32,615)
Rebalancing of ownership percentage— — — — — — 645 (15)— 630 (630) 
Balance, December 31, 20201,610,000 16   93,775,746 938 2,104,261 (39,673)(1,108,557)956,985 4,387 961,372 
Issuance of Series A Preferred Stock, net2,367,144 24 — — — — 56,241 — — 56,265 — 56,265 
Issuance of Series B Preferred Stock, net— — 3,630,000 36 — — 86,783 — — 86,819 — 86,819 
Share-based compensation, net— — — — — — 1,329 — — 1,329 — 1,329 
Distributions declared in common stock, $0.85 per share
— — — — 5,506,008 55 81,316 — (81,371) —  
Dividends declared on Series A Preferred Stock, $1.57 per share
— — — — — — — — (6,236)(6,236)— (6,236)
Dividends declared on Series B Preferred Stock, $0.42 per share
— — — — — — — — (1,527)(1,527)— (1,527)
Distributions to non-controlling interest holders— — — — — — — — — — (92)(92)
Issuance of Series A Preferred OP Units— — — — — — — — — — 2,578 2,578 
Net loss— — — — — — — — (85,180)(85,180)(260)(85,440)
Unrealized loss on designated derivative— — — — — — — 25,332 — 25,332 — 25,332 
Rebalancing of ownership percentage— — — — — — (91)— — (91)91  
Balance, December 31, 20213,977,144 40 3,630,000 36 99,281,754 993 2,329,839 (14,341)(1,282,871)1,033,696 6,704 1,040,400 
Issuance of Series A Preferred Stock, net— — — — — — — — —  —  
Issuance of Series B Preferred Stock, net— — — — — — (42)— — (42)— (42)
Share-based compensation, net— — — — — — 1,185 — — 1,185 — 1,185 
Distributions declared in common stock, $0.85 per share
— — — — 5,798,777 58 86,243 — (86,301) —  
Dividends declared Series A Preferred Stock, $1.84 per share
— — — — — — — — (7,333)(7,333)— (7,333)
Dividends declared on Series B Preferred Stock, $1.78 per share
— — — — — — — — (6,466)(6,466)— (6,466)
Distributions to non-controlling interest holders— — — — — — — — — — (184)(184)
Net loss— — — — — — — — (79,486)(79,486)(135)(79,621)
Unrealized loss on designated derivative— — — — — — — 51,251 — 51,251 — 51,251 
Rebalancing of ownership percentage— — — — — — (166)— — (166)166  
Balance, December 31, 20223,977,144 $40 3,630,000 $36 105,080,531 $1,051 $2,417,059 $36,910 $(1,462,457)$992,639 $6,551 $999,190 


The accompanying notes are an integral part of these consolidated financial statements.
F-6

HEALTHCARE TRUST, INC. AND SUBSIDIARIES
  
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Year Ended December 31,
202220212020
Cash flows from operating activities:  
Net loss$(79,621)$(85,440)$(75,510)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization82,064 79,926 81,053 
Amortization (including write-offs) of deferred financing costs4,879 4,427 4,059 
Amortization of terminated swap423 846 846 
Amortization of mortgage premiums and discounts, net51 55 60 
(Accretion) amortization of market lease and other intangibles, net
(625)(198)(80)
Bad debt expense3,159 1,094 2,708 
Equity-based compensation1,185 1,329 1,345 
(Gain) loss on non-designated derivative instruments(3,834)(37)102 
Cash received from non-designated derivative instruments286   
(Gain) loss on sales of real estate investments, net125 (3,648)(5,230)
Impairment charges27,630 40,951 36,446 
Deferred tax valuation allowance2,750 (483)4,641 
Changes in assets and liabilities:
Straight-line rent receivable(1,523)(761)(2,409)
Prepaid expenses and other assets(3,036)(2,139)(63)
Accounts payable, accrued expenses and other liabilities(2,924)1,252 (4,554)
Deferred rent(2,694)1,705 (1,607)
Net cash provided by operating activities28,295 38,879 41,807 
Cash flows from investing activities:
Property acquisitions and development costs(25,538)(159,300)(94,984)
Capital expenditures and other assets acquired(27,993)(19,071)(21,892)
Proceeds from sales of real estate investments11,749 130,449 34,385 
Net cash used in investing activities(41,782)(47,922)(82,491)
Cash flows from financing activities: 
Payments on credit facilities(2,998)(298,804)(26,091)
Proceeds from credit facilities30,000 125,000 95,000 
Proceeds from mortgage notes payable 42,750  
Payments on mortgage notes payable(6,662)(1,264)(1,048)
Payments for non-designated derivative instruments (85)(97)
Payments of deferred financing costs(1,672)(1,490)(2,241)
Proceeds from issuance of Series A Preferred Stock, net 56,265 (1,016)
Proceeds from issuance of Series B Preferred Stock, net(42)86,897  
Common stock repurchases  (10,539)
Distributions paid on common stock  (31,354)
Dividends paid on Series A Preferred stock(7,333)(5,144)(2,399)
Dividends paid on Series B Preferred stock(6,466)  
Buyout of non-controlling interest holders  (583)
Distributions to non-controlling interest holders(184)(46)(201)
Net cash provided by financing activities4,643 4,079 19,431 
Net change in cash, cash equivalents and restricted cash(8,844)(4,964)(21,253)
Cash, cash equivalents and restricted cash, beginning of year85,382 90,346 111,599 
Cash, cash equivalents and restricted cash, end of year$76,538 $85,382 $90,346 
F-7

HEALTHCARE TRUST, INC. AND SUBSIDIARIES
  
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Year Ended December 31,
202220212020
Cash, cash equivalents, end of period$53,654 $59,738 $72,357 
Restricted cash, end of period22,884 25,644 17,989 
Cash, cash equivalents and restricted cash, end of period$76,538 $85,382 $90,346 
Supplemental disclosures of cash flow information:
Cash paid for interest$45,042 $42,815 $47,878 
Cash paid for income taxes 566 311 315 
Non-cash investing and financing activities:
Common stock issued through distribution reinvestment plan
$ $ $14,604 
Common stock issued through stock dividends86,301 81,371 19,659 
Accrued capital expenditures  1,287 
Accrued offering costs on Series B Preferred Stock 78  
Mortgage assumed in acquisition   13,883 

The accompanying notes are an integral part of these consolidated financial statements.
F-8


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022


Note 1 — Organization
Healthcare Trust, Inc. (including, as required by context, Healthcare Trust Operating Partnership, L.P. (the “OP”) and its subsidiaries, the “Company”), is an externally managed real estate investment trust for U.S. federal income tax purposes (“REIT”) that focuses on acquiring and managing a diversified portfolio of healthcare-related real estate, focused on medical office and other healthcare-related buildings (“MOBs”), and senior housing operating properties (“SHOPs”).
As of December 31, 2022, the Company owned 202 properties located in 34 states and comprised of 9.1 million rentable square feet.
Substantially all of the Company’s business is conducted through the OP and its wholly owned subsidiaries, including taxable REIT subsidiaries. The Company’s advisor, Healthcare Trust Advisors, LLC (the “Advisor”) manages our day-to-day business with the assistance of our property manager, Healthcare Trust Properties, LLC (the “Property Manager”). The Company’s Advisor and Property Manager are under common control with AR Global Investments, LLC (“AR Global”), and these related parties receive compensation and fees for providing services to the Company. The Company also reimburses these entities for certain expenses they incur in providing these services to the Company. Healthcare Trust Special Limited Partnership, LLC (the “Special Limited Partner”), which is also under common control with AR Global, also has an interest in the Company through ownership of interests in the OP. As of December 31, 2022, the Company owned 52 seniors housing properties under the REIT Investment Diversification and Empowerment Act of 2007 (“RIDEA”) structure in its SHOP segment. Under RIDEA, a REIT may lease qualified healthcare properties on an arm’s length basis to a taxable REIT subsidiary (“TRS”) if the property is operated on behalf of such subsidiary by a person who qualifies as an eligible independent contractor.
The Company operates in two reportable business segments for management and internal financial reporting purposes: MOBs and SHOPs. In its MOB operating segment, the Company owns, manages, and leases single and multi-tenant MOBs where tenants are required to pay their pro rata share of property operating expenses, which may be subject to expense exclusions and floors, in addition to base rent. The Property Manager or third party managers manage the Company’s MOBs. In its SHOP segment, the Company invests in seniors housing properties using the RIDEA structure. As of December 31, 2022, the Company had four eligible independent contractors operating 52 SHOPs (including two land parcels). All of the Company’s properties across both business segments are located throughout the United States.
The Company has declared quarterly dividends entirely in shares of its common stock since October 2020 in order to preserve its liquidity in response to the COVID-19 pandemic. Dividends payable entirely in shares of common stock are treated in a fashion similar to a stock split for accounting purposes specifically related to per-share calculations for the current and prior periods. Since October 2020, the Company has issued an aggregate of approximately 12.6 million shares in respect to the Stock Dividends. No other additional shares of common stock were issued during the years ended December 31, 2022 or 2021. References made to weighted-average shares and per-share amounts in the accompanying consolidated statements of operations and comprehensive income have been retroactively adjusted to reflect the cumulative increase in shares outstanding resulting from the Stock Dividends since October 2020 and through January 2023, and are noted as such throughout the accompanying financial statements and notes. Any future issuances of stock dividends will also result in retroactive adjustments. Please see Note 8 — Stockholder’s Equity for additional information on the stock dividends.
On April 1, 2022, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2021. The Company’s previous Estimated Per-Share NAV was as of December 31, 2020. The Estimated Per-Share NAV published on April 1, 2022 has not been adjusted since publication and will not be adjusted until the board of directors (the “Board”) determines a new Estimated Per-Share NAV. Issuing dividends in additional shares of common stock will, all things equal, cause the value of each share to decline because the number of shares outstanding increases when shares of common stock are issued in respect of a Stock Dividend; however, because each stockholder will receive the same number of new shares, the total value of a common stockholder’s investment, all things equal, will not change assuming no sales or other transfers. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually unless the Company lists its common stock.
Note 2 — Summary of Significant Accounting Policies
Basis of Accounting
    The accompanying consolidated financial statements of the Company are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“GAAP”).
Principles of Consolidation and Basis of Presentation
F-9


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.
Out-of-Period Adjustment
During the year ended December 31, 2019, the Company did not record quarterly interest expense related to borrowings under the Revolving Credit Facility (as defined below) that were borrowed and repaid during the fourth quarter of 2019. The amount of interest expense and related payable that should have been recorded was $0.3 million. In 2020, the Company identified that the cumulative interest payable balance was understated, and as a result a true up entry was recorded to record the payable and related expense, resulting in an out of period adjustment. The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and adjusted the amounts on a cumulative basis in 2020.
Impacts of the COVID-19 Pandemic
During the first quarter of 2020, the global COVID-19 pandemic that has spread around the world and to every state in the United States commenced. The COVID-19 pandemic has had, and could continue to have, an adverse impact on economic conditions, including a global economic slowdown and recession that may continue for some time. The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of COVID-19 on economic and market conditions. The COVID-19 pandemic had, and another pandemic in the future could have, impacts across many sectors and areas of the global economy and financial markets, leading to significant adverse impacts on economic activity including volatility in financial markets. The Company’s MOB tenants and SHOP properties operate businesses that require in-person interactions with their patients and residents, and concern regarding the transmission of COVID-19 impacted the willingness of persons to, among other things, live in or use facilities at the Company’s properties, and impact the revenues generated by the Company’s tenants.
The Company’s ability to lease space and negotiate and maintain favorable rents and the results of operations at its SHOPs could also continue to be negatively impacted by a prolonged recession in the U.S. economy. Moreover, the demand for leasing space at the Company’s MOB properties could decline, which could negatively impacting occupancy percentage, revenue and net income. Additionally, downturns or stagnation the U.S. housing market as a result of an economic downturn could adversely affect the ability, or perceived ability, of seniors to afford the resident fees and services at the Company’s SHOPs. Further, recent and continuing increases in inflation brought about by the labor shortages, supply chain disruptions and increases in interest rates have adversely impacted, and may continue to impact, the Company’s results of operations. Moreover, these increases in the rate of inflation, the ongoing war in Ukraine and related sanctions, supply chain disruptions and increases in interest rates may also impact the ability of the Company’s tenants and residents to pay rent and hence the Company’s results of operations and liquidity.
Starting in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways that vary by operating segment:
COVID-19 Impact — MOB Segment
The financial stability and overall health of the Company’s MOB tenants is critical to its business. The Company took a proactive approach to achieve mutually agreeable solutions with its MOB tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent. Since the year ended December 31, 2020, the Company has not entered into any rent deferral agreements with any of its MOB tenants, and all amounts previously deferred under prior rent deferral agreements have been collected.
F-10


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases are being modified, the FASB and SEC have provided relief that allows companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. For COVID-19 relief qualified changes, there are two methods to potentially account for such rent deferrals or abatements under the relief, (1) as if the changes were originally contemplated in the lease contract or (2) as if the deferred payments are variable lease payments contained in the lease contract.
For all other lease changes that did not qualify for FASB relief, the Company is required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualify for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company has elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there would be no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact would be recognized ratably over the remaining life of the lease. For leases not qualifying for this relief, the Company has applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.
COVID-19 Impact — SHOP Segment
In the Company’s SHOP segment, occupancy trended downward from March 2020 until June 2021 and has since stabilized, however, SHOP occupancy remains substantially below pre-pandemic levels. Further, the Company has continued to experience lower inquiry volumes and reduced in-person tours since the onset of the pandemic. In addition, starting in mid-March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOPs, the Company generally bears these cost increases, which were partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), and to a lesser extent, cost recoveries for personal protective equipment from residents. See below for additional information on the CARES Act. These cost increases became more prominent throughout the year ended December 31, 2022 from a combination of factors: firstly, the Company was impacted by rising inflation which generally increased the costs of services and supplies, secondly, the Company relied more on the use of temporary contract labor and agencies due to a shortage of qualified personnel and lastly, the amounts the Company paid to third party providers for wages, including overtime wages, and bonuses increased. Future developments in the course of the pandemic, increases to inflation, labor shortages and supply chain disruptions may cause further adverse impacts to the Company’s occupancy and cost levels, and these trends may continue to impact the Company and have material adverse effects on its revenues, operating costs and net income in future periods.
The financial impact of the COVID-19 pandemic on the Company has been partially offset by funds received under the CARES Act. The Company received $4.5 million, $5.1 million and $3.6 million in these funds during the years ended December 31, 2022, 2021 and 2020, respectively. The Company considers these funds to be grant contributions from the government. The full amounts received were recognized as reductions of property operating expenses in the Company’s consolidated statement of operations for the years ended December 31, 2022, 2021 and 2020, respectively, to partially offset incurred COVID-19 expenses. The Company does not anticipate that any further funds under the CARES Act will be received, and there can be no assurance that the CARES Act program will be extended or any further amounts received under currently effective or potential future government programs.
Revenue Recognition
The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in its MOB segment. As of December 31, 2022, these leases had a weighted average remaining lease term of 4.9 years. Rent from tenants in the Company’s MOB operating segment (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is
F-11


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Tenant revenue also includes operating expense reimbursements which generally increase with the increase in property operating and maintenance expenses in our MOB segment. In addition to base rent, dependent on the specific lease, tenants are generally required to pay either (i) their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors or (ii) the their share of increases in property operating and maintenance expenses to the extent they exceed the properties’ expenses for the base year of the respective leases. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.
The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOP segment, held using a structure permitted under RIDEA, and to a lesser extent, fees for ancillary services performed for SHOP residents, which are generally variable in nature. Rental income from residents in the Company’s SHOP segment is recognized as earned when services are provided. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of the leases are short term in nature, primarily month-to-month. The Company did not record material amounts of ancillary revenue from non-residents during the year ended December 31, 2022. The Company recorded ancillary revenue from non-residents of $3.5 million and $13.3 million for the years ended December 31, 2021 and 2020, respectively. Fees for ancillary services are recorded in the period in which the services are performed. The decline in ancillary revenue since the year ended December 31, 2020 is primarily due to the Company’s dispositions of its SNF properties in Lutz and Wellington, Florida, which were sold in November 2020 and May 2021, respectively.
The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating and maintenance expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating and maintenance costs of the respective properties.
The following table presents future base rent payments on a cash basis due to the Company as of December 31, 2022 over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short-term in nature.
(In thousands)Future 
Base Rent Payments
2023$106,009 
202499,507 
202588,452 
202680,462 
202762,175 
Thereafter215,275 
Total$651,880 
The Company continually reviews receivables related to rent and unbilled rents receivable and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards, the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants in accordance
F-12


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
with accounting rules, on the accompanying consolidated statements of operations and comprehensive income (loss) in the period the related costs are incurred, as applicable.
During the years ended December 31, 2022, 2021 and 2020, the Company recorded reductions in revenue of $3.2 million, $1.1 million and $2.7 million, respectively. Approximately $1.3 million and $1.0 million of bad debt expense recorded in the years ended December 31, 2022 and 2020, respectively, related to previously disposed properties. There were no significant write-off’s related to previously disposed properties during the year ended December 31, 2021.
Investments in Real Estate
Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.
At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “Purchase Price Allocation” section in this Note for a discussion of the initial accounting for investments in real estate.
Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the years ended December 31, 2022, 2021 and 2020. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were no real estate investments held for sale as of December 31, 2022 or December 31, 2021.
The Company generally determines the value of construction in progress based upon the replacement cost. During the construction period, the Company capitalizes interest, insurance and real estate taxes until the development has reached substantial completion.
Purchase Price Allocation
In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In allocating the fair value to any assumed or issued non-controlling interests, amounts are recorded at their fair value at the close of business on the acquisition date. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets.
For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.
Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates the fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.
F-13


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Identifiable intangible assets include amounts allocated to acquire leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from six to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.
Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.
The aggregate value of intangible assets related to customer relationship, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the years ended December 31, 2022, 2021 and 2020.
Accounting for Leases
Lessor Accounting
In accordance with the lease accounting standard, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than a major part of the remaining economic useful life of the asset (e.g., equal to or greater than 75%), the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or the asset is so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. As of December 31, 2022 and 2021, the Company had no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.
As a lessor of real estate, the Company has elected, by class of underlying assets, to account for lease and non-lease components (such as tenant reimbursements of property operating and maintenance expenses) as a single lease component as an operating lease because (a) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (b) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under the accounting guidance. Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed.
Lessee Accounting
The Company is also the lessee under certain land leases which will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the consolidated balance sheets as of December 31, 2022 and 2021, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022, 2021 and 2020.
For lessees, the accounting standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction. For additional information and disclosures related to the Company’s operating leases, see Note 16Commitments and Contingencies.
F-14


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Gain on Dispositions of Real Estate Investments
Gains on sales of rental real estate are not considered sales to customers and will generally be recognized pursuant to the provisions included in ASC 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets (“ASC 610-20”).
Impairment of Long-Lived Assets
When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statement of operations and comprehensive (loss) to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held and used. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.
Reportable Segments
The Company has determined that it has two reportable segments, with activities related to investing in MOBs and SHOPs. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level. For additional information see Note 15 — Segment Reporting.
Depreciation and Amortization
Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests.
Construction in progress, including capitalized interest, insurance and real estate taxes, is not depreciated until the development has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).
The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.
The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.
Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.
Above and Below-Market Lease Amortization
Capitalized above-market lease values are amortized as a reduction of revenue from tenants over the remaining terms of the respective leases and the capitalized below-market lease values are amortized as an increase to revenue from tenants over the remaining initial terms plus the terms of any below-market fixed rate renewal options of the respective leases. If a tenant with a below-market rent renewal does not renew, any remaining unamortized amount will be taken into income at that time.
Capitalized above-market ground lease values are amortized as a reduction of property operating expense over the remaining terms of the respective leases. Capitalized below-market ground lease values are amortized as an increase to property operating expense over the remaining terms of the respective leases and expected below-market renewal option periods.
Derivative Instruments
The Company may use derivative financial instruments to hedge all or a portion of the interest rate risk associated with its borrowings. Certain of the techniques used to hedge exposure to interest rate fluctuations may also be used to protect against declines in the market value of assets that result from general trends in debt markets. The principal objective of such agreements is to minimize the risks and costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions.
The Company records all derivatives on the balance sheet at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair value of an
F-15


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply, or the Company elects not to apply hedge accounting.
The accounting for subsequent changes in the fair value of these derivatives depends on whether each has been designated and qualifies for hedge accounting treatment. If the Company elects not to apply hedge accounting treatment, any change in the fair value of these derivative instruments is recognized immediately in gains (losses) on derivative instruments in the accompanying consolidated statements of operations and comprehensive loss prior to the adoption of ASU 2017-2 on January 1, 2019. If the derivative is designated and qualifies for hedge accounting treatment, the change in the estimated fair value of the derivative is recorded in other comprehensive income (loss) to the extent that it is effective, with any ineffective portion of a derivative’s change in fair value immediately recognized in earnings. After the adoption of ASU 2017-2, if the derivative qualifies for hedge accounting, all of the change in value is recorded in other comprehensive income (loss).
Non-controlling Interests
The non-controlling interests represent the portion of the common and preferred equity in the OP that is not owned by the Company as well as certain investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Non-controlling interests are presented as a separate component of equity on the consolidated balance sheets and presented as net loss attributable to non-controlling interests on the consolidated statements of operations and comprehensive loss. Non-controlling interests are allocated a share of net income or loss based on their share of equity ownership, including any preferential amounts. See Note 13 — Non-Controlling Interests for additional information.
Cash and Cash Equivalents
Cash and cash equivalents includes cash in bank accounts as well as investments in highly-liquid money market funds with original maturities of three months or less. The Company did not have any cash invested in money market funds at December 31, 2022 or 2021.
The Company deposits cash with high quality financial institutions. These deposits are guaranteed by the Federal Deposit Insurance Company (“FDIC”) up to an insurance limit. At December 31, 2022 and 2021, the Company had deposits of $53.7 million and $59.7 million, of which $43.6 million and $46.2 million, respectively, were in excess of the amount insured by the FDIC. Although the Company bears risk to amounts in excess of those insured by the FDIC, it does not anticipate any losses as a result.
Deferred Costs
Deferred costs, net, consists of deferred financing costs related to the Credit Facility (as defined in Note 5 — Credit Facilities) Fannie Mae Master Credit Facilities (as defined in Note 5 — Credit Facilities), and deferred leasing costs. Deferred financing costs relating to mortgage notes payable (see Note 4 — Mortgage Notes Payable, Net) are reflected net of the related financing in the mortgage notes payable, net line item of the Company’s consolidated balance sheet.
Deferred financing costs associated with the Credit Facility and Fannie Mae Master Credit Facilities and mortgage notes payable represent commitment fees, legal fees, and other costs associated with obtaining commitments for financing. These costs are amortized over the term of the financing agreement using the effective interest method for the Credit Facility and Fannie Mae Master Credit Facilities and using the effective interest method over the expected term for the mortgage notes payable.
Unamortized deferred financing costs are expensed if the associated debt is refinanced or paid down before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.
Deferred leasing costs, consisting primarily of lease commissions and professional fees incurred in connection with new leases, are deferred and amortized over the term of the lease.
F-16


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Equity-Based Compensation
The Company has a stock-based incentive award program for its directors, which is accounted for under the guidance of share- based payments. The cost of services received in exchange for these stock awards is measured at the grant date fair value of the award and the expense for such awards is included in general and administrative expenses and is recognized over the service period (i.e., vesting) required or when the requirements for exercise of the award have been met (see Note 11Equity-Based Compensation).
Income Taxes
The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986 (the “Code”), as amended, commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.
If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and local income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2022, 2021 and 2020. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income.
Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties. Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS. Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.
As of December 31, 2022, the Company owned 52 seniors housing properties (including two land parcels) which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of December 31, 2022 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the ongoing COVID-19 pandemic. These abatements were extended through December 31, 2022 and may continue to be extended for future periods.
Because of the Company’s TRS's recent operating history of taxable losses and the impacts of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $6.9 million and $4.2 million as of December 31, 2022 and 2021, respectively. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive income (loss). As of December 31, 2022, the Company’s consolidated TRS had net operating loss carryforwards for federal income tax purposes of approximately $24.4 million at December 31, 2022 (of which $7.6 million were incurred prior to January 1, 2018). Carryforwards from losses incurred prior to January 1, 2018, if unused, these will begin to expire in 2035. For net operating losses incurred subsequent to December 31, 2017, there is no expiration date. As of December 31, 2022, the Company had a deferred tax asset of $6.9 million with a full valuation allowance. As of December 31, 2021, the Company had a deferred tax asset of $4.2 million with a full valuation allowance.
F-17


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2022, 2021 and 2020, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately 0.0%, 0.0% and (105.8)% for the years ended December 31, 2022, 2021 and 2020, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.
Year Ended December 31,
202220212020
(In thousands)CurrentDeferredCurrentDeferredCurrentDeferred
Federal (expense) benefit $ $2,145 $ $(319)$726 $ 
State (expense) benefit(201)604 (203)(163)(196)50 
Deferred tax asset valuation allowance— (2,749)— 482 — (4,641)
Total income tax benefit (expense)$(201)$ $(203)$ $530 $(4,591)
As of December 31, 2022 and 2021, the Company had no material uncertain income tax positions. The tax years subsequent to and including the fiscal year ended December 31, 2017 remain open to examination by the major taxing jurisdictions to which the Company is subject.
Per Share Data
Net income (loss) per basic share of common stock is calculated by dividing net income (loss) by the weighted-average number of shares (retroactively adjusted for the Stock Dividends) of common stock issued and outstanding during such period. Diluted net income (loss) per share of common stock considers the effect of potentially dilutive shares of common stock outstanding during the period.
CARES Act Grants
On March 27, 2020, the CARES Ac) was signed into law and it provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. During the years ended December 31, 2022, 2021 and 2020 the Company received $4.5 million, $5.1 million and $3.6 million in funding from CARES Act grants, respectively. For accounting purposes, the CARES Act funds are treated as a grant contribution from the government. The funding the Company received was recognized as a reduction of property operating and maintenance expenses in the Company’s consolidated statements of operations to offset the negative impacts of COVID-19. There can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.
Recently Issued Accounting Pronouncements
Adopted as of January 1, 2020:
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. The objective of ASU 2018-13 is to improve the effectiveness of disclosures in the notes to the financial statements by removing, modifying, and adding certain fair value disclosure requirements to facilitate clear communication of the information required by generally accepted accounting principles. The amended guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which changes how entities measure credit losses for financial assets carried at amortized cost. The update eliminates the requirement that a credit loss must be probable before it can be recognized and instead requires an entity to recognize the current estimate of all expected credit losses. Additionally, the amended standard requires credit losses on available-for-sale debt securities to be carried as an allowance rather than as a direct write-down of the asset. On July 25, 2018, the FASB proposed an amendment to ASU 2016-13 to clarify that operating lease receivables recorded by lessors (including unbilled straight-line rent) are explicitly excluded from the scope of ASU 2016-13. The new guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.
Adopted as of January 1, 2021:
F-18


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2021 and determined it did not have a material impact on its consolidated financial statements.
Adopted as of January 1, 2022:
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption was permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2022 and determined it did not have a material impact on its consolidated financial statements.
Not yet Fully Adopted as of December 31, 2022
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period from March 12, 2020 through June 30, 2023 as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that the Company’s hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of the Company’s derivatives, which will be consistent with the Company’s past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur.
Note 3 — Real Estate Investments, Net
Property Acquisitions
The Company invests in healthcare-related facilities, primarily MOBs and seniors housing properties which expand and diversify its portfolio and revenue base. The Company owned 202 properties as of December 31, 2022. During the year ended December 31, 2022, the Company, through wholly-owned subsidiaries of the OP, completed its acquisitions of one multi-tenant MOBs and three single tenant MOBs for an aggregate contract purchase price of $25.3 million. All acquisitions in 2022, 2021 and 2020 were considered asset acquisitions for accounting purposes.
The following table presents the allocation of the assets acquired and liabilities assumed during the years ended December 31, 2022, 2021 and 2020:
F-19


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Year Ended December 31,
(In thousands)202220212020
Real estate investments, at cost:
Land$4,933 $12,848 $7,665 
Buildings, fixtures and improvements16,606 121,376 90,699 
Total tangible assets21,539 134,224 98,364 
Acquired intangibles:
In-place leases and other intangible assets (1)
3,763 28,499 10,369 
Market lease and other intangible assets (1)
268 794 496 
Market lease liabilities (1)
(32)(1,639)(362)
Total intangible assets and liabilities
3,999 27,654 10,503 
Mortgage notes payable assumed, net  (13,883)
Issuance of Preferred OP Units (2)
 (2,578) 
Cash paid for real estate investments, including acquisitions$25,538 $159,300 $94,984 
Number of properties purchased4 17 9 
_______________
(1)Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 8.9 years, 9.3 years and 12.1 years, respectively, as of December 31, 2022. Weighted-average remaining amortization periods for in-place leases and above-market leases acquired were 11.2 years, 10.2 years and 8.5 years, respectively, as of December 31, 2021. Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 1.7 years, 7.7 years and 7.4 years, respectively, as of December 31, 2020.
(2)See Note 8 — Stockholders’ Equity for additional information.
Significant Tenants
As of December 31, 2022, 2021 and 2020, the Company did not have any tenants (including for this purpose, all affiliates of such tenants) whose annualized rental income on a straight-line basis represented 10% or greater of total annualized rental income on a straight-line basis for the portfolio. The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of December 31, 2022, 2021 and 2020:
December 31,
State202220212020
Florida (1)
19.2%17.7%20.6%
Pennsylvania**10.4%
_______________
*    State’s annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income for all portfolio properties as of the period specified.
(1)In May 2021, the Company’s skilled nursing facility in Wellington, Florida, and the Company’s development property in Jupiter, Florida were sold. In December 2020, the Company’s skilled nursing facility in Lutz, Florida was sold.

Intangible Assets and Liabilities
Acquired intangible assets and liabilities consisted of the following as of the periods presented:
F-20


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
December 31, 2022December 31, 2021
(In thousands)Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Intangible assets:
In-place leases$268,135 $198,138 $69,997 $264,741 $183,073 $81,668 
Market lease assets14,432 12,042 2,390 14,164 11,212 2,952 
Other intangible assets9,467 1,165 8,302 9,467 1,006 8,461 
Total acquired intangible assets
$292,034 $211,345 $80,689 $288,372 $195,291 $93,081 
Intangible liabilities:
Market lease liabilities $23,504 $14,097 $9,407 $23,472 $12,529 $10,943 
The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above-and below-market lease assets and liabilities, net and the amortization of above-and below-market ground leases, for the periods presented:
Year Ended December 31,
(In thousands)202220212020
Amortization of in-place leases and other intangible assets (1)
$15,076 $15,071 $15,121 
Accretion of above-and below-market leases, net (2)
$(795)$(422)$(257)
Amortization of above-and below-market ground leases, net (3)
$159 $214 $178 
________
(1)Reflected within depreciation and amortization expense.
(2)Reflected within revenue from tenants.
(3)Reflected within property operating and maintenance expense.
The following table provides the projected amortization and adjustments to revenue from tenants for the next five years:
(In thousands)20232024202520262027
In-place lease assets$13,208 $11,287 $9,700 $8,454 $4,958 
Other intangible assets10 10 10 10 10 
Total to be added to amortization expense$13,218 $11,297 $9,710 $8,464 $4,968 
Above-market lease assets$(495)$(416)$(363)$(329)$(240)
Below-market lease liabilities1,512 1,294 1,103 941 623 
Total to be added to revenue from tenants$1,017 $878 $740 $612 $383 
Dispositions
F-21


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
The following table summarizes the properties sold during the years ended December 31, 2022, 2021 and 2020:
(In thousands)Disposition DateContract Sale PriceGain (Loss)
on Sale, of Real Estate Investments
2022 Dispositions:
LaSalle properties (four properties) (1)
March 2, 2022$12,400 $(303)
Lien settlement on formerly disposed propertiesN/AN/A178 
Totals$12,400 $(125)
2021 Dispositions:
Hampton River Portfolio (two properties)
December 21, 2021$37,800 $1,323 
NuVista Jupiter (2)
May 14, 202165,000 2,383 
Wellington Green (3)
May 14, 202130,750 114 
Michigan SHOPs (four properties) (4)
January 15, 2021 (172)
Totals$133,550 $3,648 
2020 Dispositions:
Lutz (5)
December 15, 2020$20,000 $3,832 
Michigan SHOPs (seven properties) (4)
November 2, 202011,750 (908)
Cape GirardeauMarch 19, 20208,600 2,306 
Totals$40,350 $5,230 
______
(1)Impairment charges of $34.0 million were recorded during the year ended December 31, 2021.
(2)Impairment charges of $14.6 million and $19.8 million were recorded during the years ended December 31, 2020 and 2019, respectively.
(3)Impairment charges of $0.9 million, $2.3 million and $9.9 million were recorded during the years ended December 31, 2021, 2020 and 2019, respectively.
(4)Impairment charges of $19.6 million and $22.6 million were recorded during the years ended December 31, 2020 and 2019, respectively. The contract sales price for all 11 properties was received in November of 2020. Loss on sale amounts relate to the properties transferred at the respective dates.
(5)Impairment charges of $3.6 million were recorded during the year ended December 31, 2019.

The sales of the properties noted above did not represent a strategic shift that has a major effect on the Company’s operations and financial results. Accordingly, the results of operations of these properties remain classified within continuing operations for all periods presented until the respective sale dates.
Assets Held for Sale
When assets are identified by management as held for sale, the Company reflects them separately on its balance sheet and stops recognizing depreciation and amortization expense on the identified assets and estimates the sales price, net of costs to sell, of those assets. If the carrying amount of the assets classified as held for sale exceeds the estimated net sales price, the Company records an impairment charge equal to the amount by which the carrying amount of the assets exceeds the Company’s estimate of the net sales price of the assets. For held-for-sale properties, the Company predominately uses the contract sale price as fair market value.
There were no assets held for sale as of December 31, 2022 or December 31, 2021.
Assets Held for Use
When circumstances indicate the carrying value of a property classified as held for use may not be recoverable, the Company reviews the property for impairment. For the Company, the most common triggering events are (i) concerns regarding the tenant (i.e., credit or expirations) in the Company’s single-tenant properties or significant vacancy in the Company’s multi-tenant properties and (ii) changes to the Company’s expected holding period as a result of business decisions or non-recourse debt maturities. If a triggering event is identified, the Company considers the projected cash flows due to various performance indicators, and where appropriate, the Company evaluates the impact on its ability to recover the carrying value of the properties based on the expected cash flows on an undiscounted basis over its intended holding period. The Company makes certain assumptions in this approach including, among others, the market and economic conditions, expected cash flow projections, intended holding periods and assessments of terminal values. Where more than one possible scenario exists, the Company uses a probability weighted approach in estimating cash flows. As these factors are difficult to predict and
F-22


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in its impairment analysis may not be achieved, and actual losses for impairment may be realized in the future. If the undiscounted cash flows over the expected hold period are less than the carrying value, the Company reflects an impairment charge to write the asset down to its fair value.
Impairment Charges
The following table presents impairment charges by segment recorded during the years ended December 31, 2022, 2021 and 2020:
Year Ended December 31,
(In thousands)202220212020
MOB Segment:
Illinois skilled nursing facilities (1) (7)
$10,644 $ $ 
Sassafras MOB (2) (7)
1,844   
Sun City MOB (3) (7)
 6,082  
Total MOB impairment charges12,488 6,082  
SHOP Segment:
Various held for use SHOPs (4) (7)
15,142   
LaSalle Properties (5) (7)
 34,000  
Wellington, Florida skilled nursing facility (6) (7)
 869 2,276 
Michigan properties (8)
  19,570 
NuVista Jupiter (7) (9)
  14,600 
Total SHOP impairment charges15,142 34,869 36,446 
Total impairment charges$27,630 $40,951 $36,446 
(1)These seven properties were impaired after the Company received an offer by the tenant to purchase all seven properties, which caused the Company to reassess its expected holding period for these properties. As of December 31, 2022, these properties were not disposed nor are under contract for disposal.
(2)The Company began marketing this property for sale in the fourth quarter of 2022. As of December 31, 2022 this property was not disposed nor under contract for disposal.
(3)This property has been actively marketed for sale since September 2021. As of December 31, 2022 this property was not disposed nor under contract for disposal.
(4)Consists of eight properties actively marketed for sale. Of the eight properties, six properties were impaired in year ended December 31, 2022. As of December 31, 2022, these properties were not disposed, but five of these properties are under contract for disposal.
(5)These four properties were disposed in the year ended December 31, 2022.
(6)This property was disposed in the year ended December 31, 2021. The Company recorded this impairment charge in the year ended December 31, 2021 to reduce the carrying value of the property to its estimated fair value as determined by an amendment to its purchase and sale agreement. The Company had previously recorded $2.3 million of impairment charges on this property in the year ended December 31, 2020.
(7)These properties were impaired to reduce their carrying values to their estimated fair values, respectively, as determined by the Assets Held for Use approach described above.
(8)These properties were disposed in the first quarter of 2021 and the fourth quarter of 2020.
(9)This property was disposed in the second quarter of 2021.
F-23


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Note 4 — Mortgage Notes Payable, Net
The following table reflects the Company’s mortgage notes payable as of December 31, 2022 and 2021:
PortfolioEncumbered PropertiesOutstanding Loan Amount as of December 31,
Effective Interest Rate (1) as of December 31,
Interest Rate
2022202120222021Maturity
(In thousands)(In thousands)
Palm Valley Medical Plaza - Goodyear, AZ$ $2,879  %4.15%FixedJun. 2023
Medical Center V - Peoria, AZ 2,684  %4.75%FixedSep. 2023
Fox Ridge Bryant - Bryant, AR16,817 6,977 3.98 %3.98%FixedMay 2047
Fox Ridge Chenal - Little Rock, AR115,639 16,024 2.95 %2.95%FixedMay 2049
Fox Ridge North Little Rock - North Little Rock, AR19,704 9,943 2.95 %2.95%FixedMay 2049
Capital One MOB Loan41378,500 378,500 3.73 %3.71%Fixed(2)Dec. 2026
Multi-Property CMBS Loan21118,700 118,700 4.60 %4.60%FixedMay 2028
Shiloh - Illinois
113,071 13,384 4.34 %4.34%FixedJan. 2025
BMO CMBS942,750 42,750 2.89 %2.89%FixedDec. 2031
Gross mortgage notes payable75585,181 591,841 3.83 %3.82%
Deferred financing costs, net of accumulated amortization (3)
(5,117)(6,186)
Mortgage premiums and discounts, net(1,364)(1,416)
Mortgage notes payable, net$578,700 $584,239 
__________
(1)Calculated on a weighted average basis for all mortgages outstanding as of December 31, 2022 and December 31, 2021. For the SOFR/LIBOR based loans, SOFR/LIBOR in effect at the balance sheet date was utilized. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See Note 7 — Derivatives and Hedging Activities for additional details.
(2)Variable rate loan, based on daily SOFR as of December 31, 2022 and based on 30-day LIBOR as of December 31, 2021, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. The Company allocated $378.5 million of its “pay-fixed” interest rate swaps to this mortgage consistently as of December 31, 2022 and 2021.
(3)Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.

As of December 31, 2022, the Company had pledged $0.9 billion in real estate investments, at cost, as collateral for its $585.2 million of gross mortgage notes payable. This real estate is not available to satisfy other debts and obligations unless first satisfying the mortgage notes payable secured by these properties. The Company makes payments of principal and interest, or interest only, depending upon the specific requirements of each mortgage note, on a monthly basis.
Some of the Company’s mortgage note agreements require compliance with certain property-level financial covenants including debt service coverage ratios. As of December 31, 2022, the Company was in compliance with these financial covenants.
See Note 5 Credit Facilities - Future Principal Payments and LIBOR Transition for a schedule of principal payment requirements of the Company’s Mortgage Notes and Credit Facilities and a discussion of the expected cessation of LIBOR publication.
BMO MOB Loan
On November 15, 2021, the Company, entered into a $42.8 million loan agreement (the “BMO MOB Loan”) with Bank of Montreal (“BMO”).
The BMO MOB Loan requires monthly interest-only payments, with the principal balance due on the maturity date. The BMO MOB Loan permits BMO to securitize the entire BMO MOB Loan or any portion thereof.
F-24


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
At the closing of the BMO MOB Loan, the net proceeds after accrued interest and closing costs were used to (i) repay approximately $37.0 million of indebtedness under the Revolving Credit Facility, under which nine of the properties were included as part of the borrowing base prior to the BMO MOB Loan, (ii) fund approximately $2.5 million in deposits required to be made at closing into reserve accounts required under the loan agreement. The remaining $2.4 million net proceeds available to the Company were used for general corporate purposes and acquisitions.
Note 5 — Credit Facilities, Net
The Company had the following credit facilities outstanding as of December 31, 2022 and 2021:
Outstanding Facility Amount as of December 31,
Effective Interest Rate as of December 31,(9) (10)
Credit Facility
Encumbered Properties (1)
2022202120222021Interest RateMaturity
(In thousands)(In thousands)
Credit Facility:
Revolving Credit Facility
$30,000 $ 7.26 % %VariableMar. 2024(8)
Term Loan
150,000 150,000 5.11 %4.11 %Fixed(6)Mar. 2024
Deferred financing costs
(1,750)(2,994)
Term Loan, net
148,250 147,006 
Total Credit Facility
98(2)$178,250 $147,006 
Fannie Mae Master Credit Facilities:
Capital One Facility11(3)$210,483 $212,417 5.90 %2.51 %Variable(7)Nov. 2026
KeyBank Facility10(4)141,564 142,628 6.60 %2.56 %Variable(7)Nov. 2026
Total Fannie Mae Master Credit Facilities
21$352,047 $355,045 
Total Credit Facilities119$530,297 $502,051 5.94 %(5)3.00 %(5)
_______
(1)Encumbered properties are as of December 31, 2022.
(2)The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below) have been pledged for the benefit of the lenders thereunder.
(3)Secured by first-priority mortgages on 11 of the Company’s seniors housing properties located in Florida, Georgia, Iowa and Michigan as of December 31, 2022 with a carrying value of $348.9 million.
(4)Secured by first-priority mortgages on ten of the Company’s seniors housing properties located in, Missouri, Kansas, California, Florida, Georgia and Iowa as of December 31, 2022 with carrying value of $261.0 million.
(5)Calculated on a weighted average basis for all credit facilities outstanding as of December 31, 2022 and 2021, respectively.
(6)Variable rate loan, based on SOFR, all of which was economically fixed as a result of entering into “pay-fixed” interest rate swap agreements (the Company designates its SOFR “pay-fixed” interest rate swaps against all 30-day SOFR debt, see Note 7 — Derivatives and Hedging Activities for additional details).
(7)The effective rates above only include the impact of designated hedging instruments. The Company also has seven non-designated interest rate cap agreements with an aggregate notional amount of $354.6 million which limits 30-day LIBOR to 3.50%. The Company did not designate these derivatives as hedges and accordingly, the changes in value and any cash received from these derivatives are presented within gain (loss) on derivative instruments on the consolidated statements of operations and comprehensive income (see discussion below and Note 7 — Derivatives and Hedging Activities for additional details). Inclusive of the impact of these interest rate caps on these non-designated derivatives, the economic interest rate on the Capital One Fannie Mae Facility was 5.26%, and the economic interest rate on the KeyBank Fannie Mae Facility was 5.96% as of December 31, 2022.
(8)During the year ended December 31, 2022, the Company exercised its option to extend the maturity one year to March 2024.
(9)Effective interest rate below for variable rate debt gives effect to any “pay-fixed” swap entered into by the Company allocated to the loan for presentation purposes. If no “pay-fixed” swaps are allocated, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of December 31, 2022 and 2021. Interest rate caps are not considered unless the caps, if any, are currently in effect.
(10)The Company has interest “pay-fixed” swaps which are designated as cash flow hedges on LIBOR- or SOFR-based outstanding combined borrowings. Prior to the Fourth Amendment (as defined below) which, among other things, changed the reference rate on the Credit Facility from LIBOR to SOFR, to present average rates in the table above, the Company historically allocated the notional amount of a “pay-fixed” swap to the outstanding amounts of its Credit Facility (both the Revolving Credit Facility and the Term Loan) with any remaining notional amounts applied to its Capital One Fannie Mae Facility. During the three months ended September 30, 2022, the Company converted $150.0 million of its “pay-fixed” swaps from LIBOR to SOFR. As of December 31, 2022, the Company allocated the $150.0 million SOFR-based “pay-fixed” swaps to the Term Loan, which were also allocated to the
F-25


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Term Loan as of December 31, 2021 when the Term Loan and swaps were LIBOR-based. As of December 31, 2022 and 2021, $50.0 million of LIBOR-based “pay-fixed” swaps were allocated to the Capital One Fannie Mae Facility because there were no LIBOR-based amounts outstanding under the Revolving Credit Facility in either period. The $50.0 million of LIBOR-based “pay-fixed” swaps were terminated subsequent to December 31, 2022. See Note 17 — Subsequent Events for additional information.
As of December 31, 2022, the carrying value of our real estate investments, at cost was $2.6 billion, with $0.9 billion of this amount pledged as collateral for mortgage notes payable, $0.6 billion of this amount pledged to secure advances under the Fannie Mae Master Credit Facilities and $0.9 billion of this amount comprising the borrowing base of the Credit Facility. All of the real estate assets pledged to secure debt or comprising the borrowing base of are not available to satisfy other debts and obligations, or to serve as collateral with respect to new indebtedness, unless, as applicable, the existing indebtedness associated with the property is satisfied or the property is removed from the borrowing base of the Credit Facility, which would impact availability thereunder.
Unencumbered real estate investments, at cost as of December 31, 2022 was $0.1 billion, although there can be no assurance as to the amount of liquidity the Company would be able to generate from using these unencumbered assets as collateral for mortgage loans or adding them to the borrowing base of the Company’s Credit Facility. Currently, any properties that the Company acquires must be added to the borrowing base of the Credit Facility, and any net proceeds from the dispositions of any unencumbered properties must be used to repay amounts outstanding under the Revolving Credit Facility (as defined below).
Credit Facility
The amended and restated senior secured credit facility (the “Credit Facility”), consists of two components, a revolving credit facility (the “Revolving Credit Facility”) and a term loan (the “Term Loan”).
The Revolving Credit Facility is interest-only and matures on March 13, 2023, subject to a one-year extension at the Company’s option. The Term Loan is interest-only and matures on March 13, 2024. The total commitments under the Credit Facility are $655.0 million, including $505.0 million under the Revolving Credit Facility. The Credit Facility includes an uncommitted “accordion feature” that may be used to increase the commitments under either component of the Credit Facility by up to an additional $370.0 million to a total of $1.0 billion.
The amount available for future borrowings under the Revolving Credit Facility is based on either the value of the pool of eligible unencumbered real estate assets comprising the borrowing base, or satisfying a minimum debt service coverage ratio with respect to the borrowing base. The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Revolving Credit Facility have been pledged for the benefit of the lenders thereunder.
As of December 31, 2022, $150.0 million was outstanding under the Term Loan, and $30.0 million was outstanding under the Revolving Credit Facility. The unused borrowing availability under the Revolving Credit Facility was $203.4 million based on the borrowing base as of December 31, 2022.
On August 11, 2022, the Company, the OP, KeyBank National Association individually and as agent for the lenders and the lenders from time to time a party under the Credit Facility, among others, entered into the fourth amendment to the Credit Facility (the “Fourth Amendment”). Without the Fourth Amendment, the Company would have been in default of the reamendment Fixed Charge Coverage Ratio covenant (defined below) for the four fiscal quarter period ended June 30, 2022. Pursuant to the Fourth Amendment, the lenders agreed to reduce the minimum required Fixed Charge Coverage Ratio covenant to permit the Company to avoid any Default or Events of Default through the amendment date. The Fourth Amendment also eliminated the LIBOR-based rate option, among other changes. The terms described below represent the terms pursuant to the Fourth Amendment.
The Company is required to maintain a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $50.0 million. Certain other restrictions and conditions described below will no longer apply beginning in the quarter in which the Company makes an election and, as of the day prior to the commencement of the applicable quarter, the Company has a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million, giving effect to the aggregate amount of distributions projected to be paid by the Company during the applicable quarter, the Company’s ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5% and the Company’s Fixed Charge Coverage Ratio (as defined below) for the most recently ended four fiscal quarters is not less than 1.50 to 1.00 (the “Commencement Quarter”). The fiscal quarter ended June 30, 2021 was the first quarter that could have been the Commencement Quarter. The Company did not satisfy the conditions during the quarter ended December 31, 2022 in order to elect the quarter ending March 31, 2023 as the Commencement Quarter.
F-26


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Until the first day of the Commencement Quarter, the Company must use all the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to prepay amounts outstanding under the Revolving Credit Facility, to the extent there are any such amounts outstanding. The Company may borrow additional amounts if all relevant conditions are met, including sufficient availability for future borrowings. There can be no assurance these conditions will be met at the time of any particular borrowing.
Until the Commencement Quarter, the Company may not pay distributions to holders of common stock in cash or any other cash distributions (including repurchases of shares of the Company’s common stock), subject to certain exceptions. These exceptions include paying dividends on the 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (“Series A Preferred Stock”), the 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (“Series B Preferred Stock”) or any other class of preferred stock that the Company may issue and paying any cash distributions necessary to maintain its status as a REIT. The Company may not pay any cash distributions (including dividends on Series A Preferred Stock or Series B Preferred Stock or any other preferred stock) if a default or event of default exists or would result therefrom. Beginning in the Commencement Quarter, the Company will be able to pay cash distributions to holders of common stock, subject to the restrictions described below and the aggregate distributions (as defined in the Credit Facility and including dividends on Series A Preferred Stock, Series B Preferred Stock or any other class of preferred stock that may be issued) for any period of four fiscal quarters may not exceed 95% of Modified FFO (as defined in the Credit Facility) for the same period based only on fiscal quarters after the Commencement Quarter. In addition, beginning in the Commencement Quarter, the Company will be permitted to repurchase up to $50.0 million of shares of its common stock (including amounts previously repurchased during the term of the Revolving Credit Facility) if, after giving effect to the repurchases, the Company maintains cash and cash equivalents of at least $30.0 million and the Company’s ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 55.0%.
Under the Credit Facility, the Company must comply with covenants governing the maximum ratio of consolidated total indebtedness to consolidated total asset value, and requiring the Company to maintain a minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges, a minimum consolidated tangible net worth and a minimum debt service coverage ratio. Specifically, the maximum ratio of consolidated total indebtedness to consolidated total asset value is presently 65% unless and until the Commencement Quarter, following which the ratio will be 62.5%. The minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges (the “Fixed Charge Coverage Ratio”) that the Company must satisfy based on the four most recently ended fiscal quarters is (a) 1.20 to 1.00 for the period commencing with the quarter ended June 30, 2022 through the quarter ending June 30, 2023, (b) 1.35 to 1.00 for the period commencing with the quarter ending September 30, 2023 through the quarter ending December 31, 2023 and (c) 1.45 to 1.00 for the period commencing with the quarter ending March 31, 2024 and continuing thereafter; provided, however, that from and after the Commencement Quarter, the Company must satisfy a minimum Fixed Charge Coverage Ratio of 1.50 to 1.00. The minimum consolidated tangible net worth is the sum of (i) $1.2 billion, plus (ii) 75% of any net offering proceeds (as defined in the Credit Facility) since the Credit Facility closed in March 2019. As of December 31, 2022, the Company had a consolidated tangible net worth of $1.5 billion. The minimum debt service coverage ratio (calculated similar to the calculation of the Fixed Charge Coverage Ratio but excluding dividends on Series A Preferred Stock, Series B Preferred Stock or any other class of preferred stock that may be issued) that the Company must satisfy based on the four most recently ended fiscal quarters is (a) 1.50:1.00 for the period commencing with the quarter ended June 30, 2022 through the quarter ending June 30, 2023, (b) 1.65:1.00 for the period commencing with the quarter ending September 30, 2023 through the quarter ending December 31, 2023 and (c) 1.75:1.00 for the period commencing with the quarter ending March 31, 2024 and continuing thereafter until the Company elects the Commencement Quarter, after which the debt service coverage ratio covenant will no longer apply. Additionally, the borrowing base advance rate is 52.5% until the Company elects the Commencement Quarter, after which the borrowing base advance rate will be 55%.
In addition, as of December 31, 2022, the Company had the option to have amounts outstanding under the Revolving Credit Facility bear interest at an annual rate equal to either: (i) SOFR (as defined below), plus an applicable margin that ranges, depending on the Company’s leverage, from 2.10% to 2.85%; or (ii) the Base Rate (as defined in the Credit Facility), plus an applicable margin that ranges, depending on the Company’s leverage, from 0.85% to 1.60%. Commencing on the first day of the Commencement Quarter, the Company will have the option to have amounts outstanding under the Revolving Credit Facility bear interest at an annual rate equal to either: (a) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.60% to 2.35%, plus an additional spread adjustment depending on the length of the interest period; or (b) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.35% to 1.10%. As of December 31, 2022 the Company had elected to use the SOFR option for all of its borrowings under the Revolving Credit Facility, to the extent there are any such amounts outstanding.
F-27


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Further, as of December 31, 2022, the Company has the option to have amounts outstanding under the Term Loan bear interest at an annual rate equal to either: (i) SOFR, plus an applicable margin that ranges, depending on the Company’s leverage, from 2.05% to 2.80%; or (ii) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.80% to 1.55%. Commencing on the first day of the Commencement Quarter, the Company will have the option to have amounts outstanding under the Term Loan bear interest at an annual rate equal to either: (a) SOFR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.55% to 2.30%, plus an additional spread adjustment depending on the length of the interest period; or (b) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.30% to 1.05%. Pursuant to the terms of the Company’s Credit Facility, the “floor” on SOFR-based rates is 0.25%. As of December 31, 2022, the Company had elected to use the SOFR option for all of its borrowings under the Term Loan.
As of December 31, 2022, the Company was in compliance with the financial covenants under the Credit Facility.
As discussed in Note 2 — Summary of Significant Accounting Policies, the Company has experienced, and continues to experience, negative impacts from rising operating costs, particularly in its SHOP segment, as well as rising variable interest rates. The Company’s Credit Facility matures in March 2024 and contains various operating covenants (described above) which the Company was in compliance with through December 31, 2022. Prospectively, based upon the Company’s current expectations, the Company believes its operating results through June 30, 2023 will allow it to comply with these covenants. However, the Company believes its operating results may not be sufficient to comply with the increased Fixed Charge Coverage Ratio, which increases from 1.20:1.00 to 1.35:1.00 commencing with the quarter ending September 30, 2023 and thereafter. Absent a waiver or modification from the lender group, failure to comply with the Fixed Charge Coverage Ratio would constitute an Event of Default and the balance of the Credit Facility would be due and payable. The Company has obtained such waivers and modifications from the lender group in the past, but there can be no assurance that such a waiver or modification will be granted in future periods. Additionally, the Company is exploring long-term secured financing opportunities, utilizing some or all of the Company’s properties as collateral, the proceeds from which the Company believes will be sufficient to repay all amounts outstanding under the Credit Facility, which was $180.0 million as of December 31, 2022 ($200.0 million including the $20.0 million drawn subsequent to December 31, 2022, see Note 17 — Subsequent Events for details).
Fannie Mae Master Credit Facilities
On October 31, 2016, the Company, through wholly-owned subsidiaries of the OP, entered into a master credit facility agreement relating to a secured credit facility with KeyBank (the “KeyBank Facility”) and a master credit facility agreement with Capital One for a secured credit facility with Capital One Multifamily Finance LLC, an affiliate of Capital One (the “Capital One Facility”; the Capital One Facility and the KeyBank Facility are referred to herein individually as “Fannie Mae Master Credit Facility” and together as the “Fannie Mae Master Credit Facilities”). Advances made under these agreements are assigned by Capital One and KeyBank to Fannie Mae at closing for inclusion in Fannie Mae’s Multifamily MBS program.
In connection with the Fannie Mae Master Credit Facilities, the Company was required to enter into interest rate cap agreements. Periodically, the Company renews these interest rate cap agreements upon their expiration. As of December 31, 2022, the Company had seven interest rate cap agreements (of which six caps were active as of December 31, 2022 and one has a forward start date as of April 2023) with an aggregate current effective notional amount of $354.6 million which caps LIBOR at 3.50% with terms through April 2024. The Company does not apply hedge accounting to these agreements and changes in value as well as any cash received are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive income (see Note 7 — Derivatives and Hedging Activities for additional disclosure regarding the Company’s derivatives).
In November 2020, in conjunction with the sale and transfer of four of the Michigan SHOPs, one of which was encumbered under the Fannie Mae Master Credit Facility with Capital One, $4.2 million was repaid to Capitol One upon the release of the property.
The Company may request future advances under the Fannie Mae Master Credit Facilities by adding eligible properties to the collateral pool, subject to customary conditions, including satisfaction of minimum debt service coverage and maximum loan-to-value tests.
F-28


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Future Principal Payments
The following table summarizes the scheduled aggregate principal payments for the five years subsequent to December 31, 2022 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities):
Future Principal
Payments
(In thousands)Mortgage Notes PayableCredit FacilitiesTotal
2023$1,139 $5,769 $6,908 
20241,178 185,769 186,947 
202513,270 5,769 19,039 
2026379,393 334,740 714,133 
2027922  922 
Thereafter189,279  189,279 
Total$585,181 $532,047 $1,117,228 
LIBOR Transition
In July 2017, the Financial Conduct Authority (which regulates LIBOR) announced it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee, which identified the Secured Overnight Financing Rate (“SOFR”) as its preferred alternative to LIBOR in derivatives and other financial contracts. On March 5, 2021, the Financial Conduct Authority confirmed a partial extension of this deadline announcing that it will cease the publication of the one-week and two-month USD LIBOR settings immediately following December 31, 2021. The remaining USD LIBOR settings will continue to be published through June 30, 2023. The Company is not able to predict when there will be sufficient liquidity in the SOFR market. The Company is monitoring and evaluating the risks related to changes in LIBOR availability, which include potential changes in interest paid on debt and amounts received and paid on interest rate swaps. In addition, the value of debt or derivative instruments tied to LIBOR will also be impacted as LIBOR is limited and discontinued and contracts must be transitioned to a new alternative rate. While the Company currently expects LIBOR to be available in substantially its current form until at least through June 30, 2023 for the USD LIBOR rates currently relevant to the Company, it is possible that LIBOR will become unavailable prior to that time. This could occur, for example, if a sufficient number of banks decline to make submissions to the LIBOR administrator. Pursuant to the Fourth Amendment, the Credit Agreement was updated and provisions were added to transition the Credit Facility from using a benchmark rate of LIBOR to using a benchmark rate of SOFR, and the Company will either utilize the Base Rate (as defined in the Credit Facility) or the updated SOFR-based rates. During the year ended December 31, 2022, the Company converted $150.0 million of its “pay-fixed” swaps on its Credit Facility from LIBOR to SOFR, and the Company additionally converted its $378.5 million Capital One MOB Loan and related “pay-fixed” swap from LIBOR to SOFR, however, the Company still has mortgages, credit facilities (namely, the Capital One Facility and the KeyBank Facility) and derivative agreements that have terms that are based on LIBOR. Certain of those agreements have alternative rates already contained in the agreements while others do not. The Company anticipates that it will either utilize the alternative rates contained in the agreements or negotiate a replacement reference rate for LIBOR with the lenders and derivative counterparties.
As of December 31, 2022, the Company had $558.7 million of LIBOR-based borrowings ($352.0 million of which is variable-rate) and $50.0 million of LIBOR-based “pay-fixed” swaps. The Company terminated its remaining $50.0 million of “pay-fixed” swaps subsequent to December 31, 2022. See Note 17 — Subsequent Events for additional information.
Note 6 — Fair Value of Financial Instruments
GAAP establishes a hierarchy of valuation techniques based on the observability of inputs used in measuring asset and liabilities at fair value. GAAP establishes market-based or observable inputs as the preferred source of values, followed by valuation models using management assumptions in the absence of market inputs. The three levels of the hierarchy are described below:
F-29


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Level 1 — Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset and liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.
Level 3 — Unobservable inputs that reflect the entity’s own assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.
The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. However, the Company expects that changes in classifications between levels will be rare.
Financial Instruments Measured at Fair Value on a Recurring Basis
Derivative Instruments
Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with those derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and its counterparties. However, as of December 31, 2022 and 2021, the Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of the Company’s derivatives. As a result, the Company has determined that its derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.
The valuation of derivative instruments is determined using a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, as well as observable market-based inputs, including interest rate curves and implied volatilities. In addition, credit valuation adjustments, are incorporated into the fair values to account for the Company’s potential nonperformance risk and the performance risk of the counterparties.
The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2022 and 2021, aggregated by the level in the fair value hierarchy within which those instruments fall.
(In thousands)Quoted Prices in Active Markets
Level 1
Significant
Other Observable Inputs
Level 2
Significant Unobservable Inputs
Level 3
Total
December 31, 2022
Derivative assets, at fair value (non-designated)$ $3,737 $ $3,737 
Derivative assets, at fair value (designated) 36,910  36,910 
Derivative liabilities, at fair value    
Total$ $40,647 $ $40,647 
December 31, 2021
Derivative assets, at fair value (non-designated)$ $174 $ $174 
Derivative liabilities, at fair value (designated)(13,903)(13,903)
Total$ $(13,729)$ $(13,729)
A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the type of inputs may result in a reclassification for certain assets. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the year ended December 31, 2022.
F-30


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Real Estate Investments Measured at Fair Value on a Non-Recurring Basis
Real Estate Investments — Held for Use
The Company also had impaired real estate investments held for use, which were carried at fair value on a non-recurring basis on the consolidated balance sheet as of December 31, 2022 and 2021.
As of December 31, 2022, the Company owned 17 held for use properties (nine MOBs and eight SHOPs) for which the Company had reconsidered its expected holding period, of which 10 properties (two MOBs and eight SHOPs) are being marketed for sale. As a result, the Company evaluated the impact on its ability to recover the carrying value of the properties and recorded impairment charges to write these properties down to their estimated fair values. The Company had also previously written down other held for use properties which have subsequently been sold.
As of December 31, 2021, the Company owned five held for use properties (one MOB and four SHOPs) for which the Company had reconsidered their expected holding periods and which were being marketed for sale. As a result, the Company evaluated the impact on its ability to recover the carrying values of the respective properties and recorded impairment charges to write these properties down to their estimated fair values during 2021. The four SHOPs were sold in the first quarter of 2022.
See Note 3 — Real Estate investments, Net - “Assets Held for Use and Related Impairments” for additional details.
Real Estate Investments — Held for Sale
Real estate investments held for sale are carried at net realizable value on a non-recurring basis and are generally classified in Level 3 of the fair value hierarchy. The Company did not have any real estate investments classified as held for sale as of December 31, 2022 and 2021.
Financial Instruments Not Measured at Fair Value
The Company is required to disclose the fair value of financial instruments for which it is practicable to estimate that value. The fair values of short-term financial instruments such as cash and cash equivalents, restricted cash, straight-line rent receivable, net, prepaid expenses and other assets, deferred costs, net, accounts payable and accrued expenses, deferred rent and distributions payable approximate their carrying value on the consolidated balance sheets due to their short-term nature.
The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:
December 31, 2022December 31, 2021
(In thousands)Level
Carrying Amount 
Fair Value
Carrying Amount 
Fair Value
Gross mortgage notes payable and mortgage
premium and discounts, net
3$583,817 $550,626 $590,425 $594,348 
Credit Facility
3$180,000 $179,496 $150,000 $148,817 
Fannie Mae Master Credit Facilities
3$352,047 $353,034 $355,045 $350,710 
The fair value of the mortgage notes payable is estimated using a discounted cash flow analysis, based on the Advisor’s experience with similar types of borrowing arrangements, excluding the value of derivatives.
Note 7 — Derivatives and Hedging Activities
Risk Management Objective of Using Derivatives
The Company may use derivative financial instruments, including interest rate swaps, caps, collars, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings.
The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. Additionally, in using interest rate derivatives, the Company aims to add stability to interest expense and to manage its exposure to interest rate movements. The Company does not intend to utilize derivatives for speculative purposes or purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company, and its affiliates, may also have other financial relationships. The Company does not anticipate that any of its counterparties will fail to meet their obligations.
F-31


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
    The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of December 31, 2022 and 2021:
December 31,
(In thousands)Balance Sheet Location20222021
Derivatives designated as hedging instruments:
Interest rate “pay-fixed” swapsDerivative assets, at fair value$36,910 $ 
Interest rate “pay-fixed” swapsDerivative liabilities, at fair value$ $13,903 
Derivatives not designated as hedging instruments:
Interest rate capsDerivative assets, at fair value$3,737 $174 
Cash Flow Hedges of Interest Rate Risk
The Company currently has nine interest rate swaps that are designated as cash flow hedges. The interest rate swaps are used as part of the Company’s interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. During the years ended December 31, 2022 and 2021, such derivatives were used to hedge the variable cash flows associated with variable-rate debt. The interest rate “pay-fixed” swaps have base interest rates between 1.39% and 2.32% with expirations varying through December 2026.
The changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive (loss) income and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings.
In connection with the refinancing of the $250.0 million loan made by Capital One, National Association and certain other lenders to certain subsidiaries of the OP on June 30, 2017 (the “MOB Loan”), during the fourth quarter of 2019, the Company terminated two interest rate swaps with an aggregate notional amount of $250.0 million for a payment of approximately $2.2 million. Following these terminations, $2.2 million was recorded in AOCI and was being recorded as an adjustment to interest expense over the original term of the two terminated swaps and the MOB Loan prior to its refinancing. For the years ended December 31, 2022, 2021 and 2020, the Company reclassified $0.4 million, $0.9 million and $0.9 million, respectively, from AOCI as increases to interest expense. No amounts remained in AOCI related to these previously terminated swaps as of December 31, 2022.
During the year ended December 31, 2022, the Company converted $150.0 million of the “pay-fixed” swaps on its Credit Facility and $378.5 million of the “pay-fixed” swaps on its mortgages from LIBOR to SOFR.
Amounts reported in accumulated other comprehensive (loss) income related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. During the next 12 months, from January 1, 2023 through December 31, 2023, the Company estimates that $17.4 million will be reclassified from other comprehensive income as a decrease to interest expense relating to the “pay-fixed” swaps designated as derivatives.
As of December 31, 2022 and 2021, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:
December 31, 2022December 31, 2021
Interest Rate DerivativeNumber of InstrumentsNotional AmountNumber of InstrumentsNotional Amount
(In thousands)(In thousands)
SOFR-based interest rate “pay-fixed” swaps7 $528,500  $ 
LIBOR-based interest rate “pay-fixed” swaps2 50,000 9 578,500 
Total interest rate “pay-fixed” swaps9 $578,500 9 $578,500 
The table below details the location in the financial statements of the loss recognized on interest rate derivatives designated as cash flow hedges for the periods ended December 31, 2022 and 2021:
F-32


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Year Ended December 31,
(In thousands)202220212020
Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives$50,098 $14,322 $(40,614)
Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense$(1,153)$(11,010)$(7,999)
Total amount of interest expense presented in the
consolidated statements of operations and comprehensive loss
$51,740 $47,900 $51,519 
Non-Designated Derivatives
These derivatives are used to manage the Company’s exposure to interest rate movements, but the Company has not elected to apply hedge accounting. As of December 31, 2022, we have entered into seven LIBOR interest rate caps with a notional amount of $354.6 million (of which six caps were active as of December 31, 2022 and one has a forward start date as of April 2023) which limit 30-day LIBOR borrowings to 3.50% and have varying expiration dates through April 2024. Beginning in the fourth quarter of 2022, LIBOR exceeded 3.50% and the Company began receiving payments under these interest rate caps. While the Company does not apply hedge accounting for these interest rate caps, they are economically hedging the Capital One Facility and KeyBank Facility. Changes in the fair value of, and any cash received from, derivatives not designated as hedges under a qualifying hedging relationship are recorded directly to net income (loss) and are presented within gain (loss) on non-designated derivatives in our consolidated statements of operations and comprehensive loss. For the years ended December 31, 2022, 2021 and 2020, gain (loss) on non-designated derivatives were a gain of $3.8 million (including cash received of $0.3 million), a gain of $37,000 and a loss of $0.1 million, respectively.
The Company had the following outstanding interest rate derivatives that were not designated as a hedges in qualifying hedging relationships as of as of December 31, 2022 and 2021:
December 31, 2022December 31, 2021
Interest Rate DerivativesNumber of Instruments
Notional Amount (1)
Number of Instruments
Notional Amount (1)
(In thousands)(In thousands)
Interest rate caps (2)
7 $354,624 9 $355,175 
(1)Notional amount represents the currently active interest cap contract and excludes one and three inactive cap agreements (included in the instrument count) with aggregate notional amounts of $52.6 million and $140.8 million as of December 31, 2022 and 2021, respectively, which take effect upon the expiration of similar caps included above and effectively extend the term for the same notional amount.
(2)All of the Company’s interest rate cap agreements limit 30-day LIBOR to 3.50% with terms through April 2024. The actual 30-day LIBOR rates during the fourth quarter of 2022 exceeded the strike price rate of 3.50% and the Company is currently receiving payments under these agreements. Changes in the fair market value of these non-designated derivatives, as well as any cash received, are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive income.
Offsetting Derivatives
The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2022 and 2021. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheets.
F-33


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Gross Amounts Not Offset in the Consolidated Balance Sheet
(In thousands)Gross Amounts of Recognized AssetsGross Amounts of Recognized (Liabilities)Gross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets presented in the Consolidated Balance SheetFinancial InstrumentsCash Collateral ReceivedNet Amount
December 31, 2022
$40,647 —  $40,647   $40,647 
December 31, 2021
$174 —  $174   $174 
December 31, 2021
$— (13,903) $(13,903)  $(13,903)
Credit-risk-related Contingent Features
The Company has agreements in place with each of its derivative counterparties that contain a provision where if the Company either defaults or is capable of being declared in default on any of its indebtedness, then the Company could also be declared in default on its derivative obligations.
As of December 31, 2022 there were no derivatives in a net liability position. The Company is not required to post any collateral related to these agreements and was not in breach of any agreement provisions.
Note 8 — Stockholders’ Equity
Common Stock
As of December 31, 2022 and 2021, the Company had 105,080,531 and 99,281,754 shares of common stock outstanding, respectively, including unvested restricted shares, shares issued pursuant to the Company’s distribution reinvestment plan (“DRIP”), net of share repurchases, and shares issued as stock dividends since October 2020. Since October 2020, the Company has issued an aggregate of approximately 12.6 million shares in respect to the stock dividends. No other additional shares of common stock were issued during the years ended December 31, 2022 or 2021. References made to weighted-average shares and per-share amounts in the consolidated statements of operations and comprehensive income have been retroactively adjusted to reflect the cumulative increase in shares outstanding due to the stock dividends (including the January 2023 stock dividend), and are noted as such throughout the accompanying financial statements and notes. Any future issuances of stock dividends will also result in retroactive adjustments. See Note 1 — Organization for additional information.
On April 1, 2022, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2021, which was approved by the Board on March 28, 2022. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually unless the Company lists its common stock.
Tender Offers
On January 9, 2020, the Company announced a tender offer (the “2020 Tender Offer”) to purchase up to 200,000 shares of its common stock for cash at a purchase price equal to $8.50 per share with the proration period and withdrawal rights expiring February 7, 2020. The Company made the 2020 Tender Offer in response to an unsolicited offer to stockholders commenced on December 31, 2019. The 2020 Tender Offer expired in accordance with the terms on February 7, 2020. In accordance with the 2020 Tender Offer, the Company accepted for purchase 200,000 shares for a total cost of approximately $1.7 million, which was funded with available cash.
Share Repurchase Program
Under the Company’s share repurchase program (the “SRP”), as amended from time to time, qualifying stockholders are able to sell their shares to the Company in limited circumstances. The SRP permits investors to sell their shares back to the Company after they have held them for at least one year, subject to significant conditions and limitations. Repurchases of shares of the Company’s common stock, when requested, are at the sole discretion of the Board.
Under the SRP, subject to certain conditions, only repurchase requests made following the death or qualifying disability of stockholders that purchased shares of the Company’s common stock or received their shares from the Company (directly or indirectly) through one or more non-cash transactions are considered for repurchase. Additionally, pursuant to the SRP, the
F-34


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
repurchase price per share equals 100% of the Estimated Per-Share NAV in effect on the last day of the fiscal semester, or the six-month period ending June 30 or December 31.
On February 26, 2020, the Company repurchased 505,101 shares of common stock for approximately $8.8 million, at an average price per share of $17.50 pursuant to the SRP. The repurchases reflect all repurchase requests made in good order following the death or qualifying disability of stockholders during the period commencing July 1, 2019 up to and including December 31, 2019.
Pursuant to the SRP, repurchases were to be made in respect of requests made during the periods when the SRP was active during the active periods under the SRP during the six months ending June 30, 2020 - the period from January 1, 2020 to January 8, 2020 and the period from February 26, 2020 up to and including June 30, 2020 - no later than July 31, 2020.
On February 26, 2020, the Company repurchased 505,101 shares of common stock for approximately $8.8 million, at an average price per share of $17.50 pursuant to the SRP. The repurchases reflect all repurchase requests made in good order following the death or qualifying disability of stockholders during the period commencing July 1, 2019 up to and including December 31, 2019.
Pursuant to the SRP, repurchases were to be made in respect of requests made during the periods when the SRP was active during the active periods under the SRP during the six months ending June 30, 2020 - the period from January 1, 2020 to January 8, 2020 and the period from February 26, 2020 up to and including June 30, 2020 - no later than July 31, 2020.
On August 13, 2020, in order to strategically maintain the Company’s liquidity in light of the continued impact of COVID-19 pandemic and to comply with an amendment to the Credit Facility described in Note 5 — Credit Facilities, Net, which restricts the Company from repurchasing shares until no earlier than the Commencement Quarter (which has not yet occurred), the Board determined that, effective on August 14, 2020, repurchases under the SRP would be suspended. The Board also rejected all repurchase requests made during the period from January 1, 2020 until the effectiveness of the suspension of the SRP. No further repurchase requests under the SRP may be made unless and until the SRP is reactivated. No assurances can be made as to when or if the SRP will be reactivated.
When a stockholder requests redemption and redemption is approved by the Board, the Company will reclassify such obligation from equity to a liability based on the settlement value of the obligation. Shares repurchased under the SRP have the status of authorized but unissued shares.
The table below reflects the number of shares repurchased and the average price per share (retroactively adjusted for the Stock Dividends), under the SRP and does not include any repurchases under tender offers (see above), cumulatively through December 31, 2022:
Number of Shares RepurchasedAverage Price per Share
Cumulative repurchases as of December 31, 2021
4,896,620 $20.60 
Year ended December 31, 2022
  
Cumulative repurchases as of December 31, 2022
4,896,620 20.60 
Distribution Reinvestment Plan
Pursuant to the DRIP, stockholders may elect to reinvest distributions paid in cash by the Company into shares of common stock. No dealer manager fees or selling commissions are paid with respect to shares purchased under the DRIP. The shares purchased pursuant to the DRIP have the same rights and are treated in the same manner as all of the other shares of outstanding common stock. The Board may designate that certain cash or other distributions be excluded from reinvestment pursuant to the DRIP. The Company has the right to amend the DRIP or terminate the DRIP with ten days’ notice to participants. Shares issued under the DRIP are recorded as equity in the accompanying consolidated balance sheet in the period distributions are declared. During the years ended December 31, 2022 and 2021, the Company did not issue any shares of common stock pursuant to the DRIP. During the year ended December 31, 2020, the Company issued 0.9 million shares of common stock pursuant to the DRIP, generating aggregate proceeds of $14.6 million. Because shares of common stock are only offered and sold pursuant to the DRIP in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as the Company pays distributions in stock instead of cash.
Stockholder Rights Plan
F-35


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
In May 2020, the Company announced that the Board had approved a stockholder rights plan. In December 2020, the Company issued a dividend of one common share purchase right for each share of its common stock outstanding as authorized by its board of directors in its discretion.
Preferred Stock
The Company is authorized to issue up to 50,000,000 shares of preferred stock. In connection with an underwritten offering in December 2019 (see details below), the Company classified and designated 1,610,000 shares of its authorized preferred stock as authorized shares of its Series A Preferred Stock as of December 31, 2022. In September 2020, the Board authorized the classification of 600,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the Preferred Stock Equity Line (as defined below) and in May 2021, the Board authorized the classification of 2,530,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the offering in May 2021 (described below). The Company had 3,977,144 shares of Series A Preferred Stock issued and outstanding, as of December 31, 2022 and 2021.
In connection with an underwritten offering in October 2021, the Company classified and designated 3,680,000 shares of its authorized preferred stock on October 4, 2021 as authorized shares of its 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (“Series B Preferred Stock”). As a result of an underwritten offering in October 2021, the Company had 3,630,000 shares of Series B Preferred Stock issued and outstanding as of December 31, 2022 and 2021.
Series A Preferred Stock
Series A Preferred Stock — Terms
Holders of Series A Preferred Stock are entitled to cumulative dividends in the amount of $1.84375 per share each year, which is equivalent to the rate of 7.375% of the $25.00 liquidation preference per share per annum. The Series A Preferred Stock has no stated maturity and will remain outstanding indefinitely unless redeemed, converted or otherwise repurchased. On and after December 11, 2024, at any time and from time to time, the Series A Preferred Stock will be redeemable in whole or in part, at the Company’s option, at a cash redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. In addition, upon the occurrence of a Delisting Event or a Change of Control (each as defined in the articles supplementary governing the terms of the Series A Preferred Stock (the “Series A Articles Supplementary”)), the Company may, subject to certain conditions, at its option, redeem the Series A Preferred Stock, in whole or in part, after the first date on which the Delisting Event occurred or within 120 days after the first date on which the Change of Control occurred, as applicable, by paying the liquidation preference of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. Upon the occurrence of a Change of Control during a continuing Delisting Event, unless the Company has elected to exercise its redemption right, holders of the Series A Preferred Stock will have certain rights to convert Series A Preferred Stock into shares of Company’s common stock. In addition, upon the occurrence of a Delisting Event, the dividend rate will be increased on the day after the occurrence of the Delisting Event by 2.00% per annum to the rate of 9.375% of the $25.00 liquidation preference per share per annum (equivalent to $2.34375 per share each year) from and after the date of the Delisting Event. Following the cure of such Delisting Event, the dividend rate will revert to the rate of 7.375% of the $25.00 liquidation preference per share per annum. The necessary conditions to convert the Series A Preferred Stock into common stock have not been met as of December 31, 2022. Therefore, Series A Preferred Stock did not impact Company’s earnings per share calculations for the year ended December 31, 2022, 2021 and 2020.
The Series A Preferred Stock ranks senior to common stock, with respect to dividend rights and rights upon the Company’s voluntary or involuntary liquidation, dissolution or winding up.
Voting rights for holders of Series A Preferred Stock exist primarily with respect to the ability to elect two additional directors to the board of directors if six or more quarterly dividends (whether or not authorized or declared or consecutive) payable on the Series A Preferred Stock are in arrears, and with respect to voting on amendments to the Company’s charter (which includes the Series A Articles Supplementary) that materially and adversely affect the rights of the Series A Preferred Stock or create additional classes or series of shares of the Company’s capital stock that are senior to the Series A Preferred Stock. Other than the limited circumstances described above and in the Series A Articles Supplementary, holders of Series A Preferred Stock do not have any voting rights.
Series A Preferred Stock Add-On Offering
F-36


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
On May 11, 2021, the Company completed an underwritten public offering of 2,352,144 shares (which includes 152,144 shares issued and sold pursuant to the underwriters’ exercise of their option to purchase additional shares) of its Series A Preferred Stock for net proceeds of $56.0 million after deducting the underwriters’ discount, structuring fee and other offering costs aggregating to $2.9 million. Pursuant to the terms of the Credit Facility, all proceeds were used to repay amounts outstanding under the Credit Facility.
Series A Preferred Units
In September 2021, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 100,000 partnership units in the OP designated as “Series A Preferred Units”. These were recorded at fair value on the date of the acquisition at $2.6 million and were included as part of the consideration paid for the acquisition. Additionally, these are considered a non-controlling interest for the Company and were recorded as an increase in non-controlling interests on the consolidated balance sheet (see Note 13 — Non-controlling Interests for additional information).
Preferred Stock Equity Line with B. Riley Principal Capital, LLC
On September 15, 2020, the Company entered into a preferred stock purchase agreement and registration rights agreement with B. Riley Principal Capital, LLC (“B. Riley”), pursuant to which the Company has the right from time to time to sell up to an aggregate of $15 million of shares of its Series A Preferred Stock to B. Riley until December 31, 2023, on the terms and subject to the conditions set forth in the purchase agreement. This arrangement is also referred to as the “Preferred Stock Equity Line.” The Company controls the timing and amount of any sales to B. Riley under the Preferred Stock Equity Line, and B. Riley is obligated to make purchases of up to 3,500 shares of Series A Preferred Stock each time (as may be increased by mutual agreement by the parties) in accordance with the purchase agreement, upon certain terms and conditions being met. The Company sold 15,000 shares under the Preferred Stock Equity Line during the year ended December 31, 2021, resulting in gross proceeds of $0.4 million and net proceeds of $0.3 million after fees and commissions.
In total, the Company incurred $1.2 million in costs related to establishing the Preferred Stock Equity Line which were all initially recorded in prepaid expenses and other assets on our consolidated balance sheet. Upon receiving proceeds under the Preferred Stock Equity Line in the third quarter of 2021, the Company reclassified $30,000 of these prepaid costs to additional paid in capital in the Company’s consolidated statement of changes in equity as a reduction of the gross proceeds received under the Preferred Stock Equity Line.
In the fourth quarter of 2021, the Company determined that it was not probable that additional proceeds would be received from the Preferred Stock Equity Line and later terminated the Preferred Stock Equity Line. As a result, the Company expensed the remaining balance of prepaid costs, which totaled $1.2 million, within acquisition and transaction related costs on the consolidated statement of operations and comprehensive income during the year ended December 31, 2021.
The Company did not sell any Series A Preferred Stock under the Preferred Stock Equity Line during the year ended December 31, 2020 or through its termination in the year ended December 31, 2021.
Series B Preferred Stock
Series B Preferred Stock — Terms
Holders of Series B Preferred Stock are entitled to cumulative dividends in the amount of $1.78125 per share each year, which is equivalent to the rate of 7.125% of the $25.00 liquidation preference per share per annum. The Series B Preferred Stock has no stated maturity and will remain outstanding indefinitely unless redeemed, converted or otherwise repurchased. On and after October 6, 2026, at any time and from time to time, the Series B Preferred Stock will be redeemable in whole or in part, at the Company’s option, at a cash redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. In addition, upon the occurrence of a Delisting Event or a Change of Control (each as defined in the articles supplementary governing the terms of the Series B Preferred Stock (the “Series B Articles Supplementary”)), the Company may, subject to certain conditions, at its option, redeem the Series B Preferred Stock, in whole or in part, after the first date on which the Delisting Event occurred or within 120 days after the first date on which the Change of Control occurred, as applicable, by paying the liquidation preference of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. Upon the occurrence of a Change of Control during a continuing Delisting Event, unless the Company has elected to exercise its redemption right, holders of the Series B Preferred Stock will have certain rights to convert Series B Preferred Stock into shares of Company’s common stock. In addition, upon the occurrence of a Delisting Event, the dividend rate will be increased on the day after the occurrence of the Delisting Event by 2.00% per annum to the rate of 9.125% of the $25.00 liquidation preference per share per annum (equivalent to $2.28125 per share each year) from and after
F-37


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
the date of the Delisting Event. Following the cure of such Delisting Event, the dividend rate will revert to the rate of 7.125% of the $25.00 liquidation preference per share per annum. The necessary conditions to convert the Series B Preferred Stock into common stock have not been met as of December 31, 2022. Therefore, Series B Preferred Stock did not impact Company’s earnings per share calculations for the year ended December 31, 2022 and 2021.
The Series B Preferred Stock ranks on parity with the Company’s Series A Preferred Stock, and senior to its common stock, with respect to dividend rights and rights upon the Company’s voluntary or involuntary liquidation, dissolution or winding up.
Voting rights for holders of Series B Preferred Stock exist primarily with respect to the ability to elect two additional directors to the board of directors if six or more quarterly dividends (whether or not authorized or declared or consecutive) payable on the Series B Preferred Stock are in arrears, and with respect to voting on amendments to the Company’s charter (which includes the Series B Articles Supplementary) that materially and adversely affect the rights of the Series B Preferred Stock or create additional classes or series of shares of the Company’s capital stock that are senior to the Series B Preferred Stock. Other than the limited circumstances described above and in the Series B Articles Supplementary, holders of Series B Preferred Stock do not have any voting rights.
Underwritten Offering — Series B Preferred Stock
On October 6, 2021, the Company completed the initial issuance and sale of 3,630,000 shares (which includes 430,000 shares issued and sold pursuant to the underwriters’ exercise of their option to purchase additional shares) of its 7.125% Series B Preferred Stock in an underwritten public offering at a public offering price equal to the liquidation preference of $25.00 per share. The offering generated gross proceeds of $90.8 million and net proceeds of $86.8 million, after deducting underwriting discounts, structuring fees and other costs.
Pursuant to the terms of the Credit Facility, all proceeds were used to repay amounts outstanding under the Credit Facility. Subject to the terms and conditions set forth in the Credit Facility, the Company may then draw on the Credit Facility to borrow any amounts so repaid.
Distributions and Dividends
Common Stock
In April 2013, the Board authorized, and the Company began paying distributions on a monthly basis at a rate equivalent to $1.70 per annum, per share of common stock, which began in May 2013. In March 2017, the Board authorized a decrease in the rate at which the Company pays monthly distributions to stockholders, effective as of April 1, 2017, to a rate equivalent to $1.45 per annum per share of common stock. On February 20, 2018, the Board authorized a further decrease in the rate at which the Company pays monthly distributions to stockholders, effective as of March 1, 2018, to a rate equivalent to $0.85 per annum per share of common stock.
From March 1, 2018 until June 30, 2020, the Company paid monthly distributions to stockholders at a rate equivalent to $0.85 per annum per share of common stock. Distributions were payable by the 5th day following each month end to stockholders of record at the close of business each day during the prior month.
On August 13, 2020, the Board changed the Company’s common stock distribution policy in order to preserve the Company’s liquidity and maintain additional financial flexibility in light of the continued COVID-19 pandemic and to comply with an amendment to the Credit Facility (see Note 5 — Credit Facility, Net for additional information) which restricts the Company from paying distributions on common stock until no earlier than the quarter ending June 30, 2021. Under the new policy, distributions authorized by the Board on the Company’s shares of common stock, if and when declared, are now paid on a quarterly basis in arrears in shares of the Company’s common stock valued at the Company’s estimated per share net asset value of common stock in effect on the applicable date, based on a single record date to be specified at the beginning of each quarter. The following table details these stock dividends:
F-38


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Stock Dividend Declaration DateStock Dividend Issue DateQuarterly Stock Dividend Rate (per share)
October 1, 2020October 15, 20200.013492
January 4, 2021January 15, 20210.013492
April 2, 2021April 15, 20210.014655
July 1, 2021July 15, 20210.014655
October 1, 2021October 15, 20210.014655
January 3, 2022January 15, 20220.014655
April 1, 2022April 18, 20220.014167
July 1, 2022July 15, 20220.014167
October 3, 2022October 17, 20220.014167
January 3, 2023January 18, 20230.014167
Tax Characteristics of Dividends
The following table details from a tax perspective the portion of distributions classified as a return of capital, capital gain dividend income and ordinary dividend income, per share per annum, for the year ended December 31, 2020. All common dividends in the years ended December 31, 2022 and 2021, and a portion of common dividends issued in the year ended December 31, 2020, were issued as stock dividends, which do not represent taxable dividends to shareholders for U.S. federal income tax purposes. The cash distributions paid to holders of common stock in the first half of the year ended December 31, 2020 were considered 100% return of capital. All dividends paid on the Series A Preferred Stock and Series B Preferred Stock were considered 100% return of capital for tax purposes for the years ended December 31, 2022, 2021 and 2020.
Note 9 — Related Party Transactions and Arrangements
As of December 31, 2022 and 2021, the Special Limited Partner owned 10,094 and 9,537 shares, respectively, of the Company’s outstanding common stock. The Advisor and its affiliates may incur and pay costs and fees on behalf of the Company. As of December 31, 2022 and 2021, the Advisor held 90 partnership units in the OP designated as “Common OP Units.”
The limited partnership agreement of the OP (as amended from time to time, the “LPA”) allows for the special allocation, solely for tax purposes, of excess depreciation deductions of up to $10.0 million to the Advisor, a limited partner of the OP. In connection with this special allocation, the Advisor has agreed to restore a deficit balance in its capital account in the event of a liquidation of the OP and has agreed to provide a guaranty or indemnity of indebtedness of the OP.
Fees Incurred in Connection with the Operations of the Company
The Second Amended and Restated Advisory Agreement by and among the Company, the OP and the Advisor (as amended, the “Second A&R Advisory Agreement”) took effect on February 17, 2017, and is automatically renewable for another ten-year term upon each ten-year anniversary unless the Second A&R Advisory Agreement is terminated (i) with notice of an election not to renew at least 365 days prior to the applicable tenth anniversary, (ii) in accordance with a change of control (as defined in the Second A&R Advisory Agreement) or a transition to self-management, (iii) by 67% of the independent directors of the Board for cause, without penalty, with 45 days’ notice or (iv) with 60 days prior written notice by the Advisor for (a) a failure to obtain a satisfactory agreement for any successor to the Company to assume and agree to perform obligations under the Second A&R Advisory Agreement or (b) any material breach of the Second A&R Advisory Agreement of any nature whatsoever by the Company.
On July 25, 2019, the Company entered into Amendment No. 1 to the Second A&R Advisory Agreement (the “Advisory Agreement Amendment”) among the Company, the OP, and the Advisor. The Advisory Agreement Amendment was unanimously approved by the Company’s independent directors. Additional information on the Advisory Agreement Amendment is included later in this footnote under “Professional Fees and Other Reimbursements.”
Acquisition Expense Reimbursements
The Advisor may be reimbursed for services provided for which it incurs investment-related expenses, or insourced expenses. The amount reimbursed for insourced expenses may not exceed 0.5% of the contract purchase price of each acquired property or 0.5% of the amount advanced for a loan or other investment. Additionally, the Company reimburses the Advisor for
F-39


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
third party acquisition expenses. Under the Second A&R Advisory Agreement, total acquisition expenses may not exceed 4.5% of the contract purchase price of the Company’s portfolio or 4.5% of the amount advanced for all loans or other investments. This threshold has not been exceeded through December 31, 2022.
Asset Management Fees and Variable Management/Incentive Fees
Under the LPA and the advisory agreement that was superseded by the 0riginal amended and restated advisory agreement and until March 31, 2015, for its asset management services, the Company issued the Advisor an asset management subordinated participation by causing the OP to issue (subject to periodic approval by the Board) to the Advisor partnership units of the OP designated as “Class B Units” (“Class B Units”). The Class B Units were intended to be profit interests and vest, and no longer are subject to forfeiture, at such time as: (x) the value of the OP’s assets plus all distributions made equals or exceeds the total amount of capital contributed by investors plus a 6.0% cumulative, pre-tax, non-compounded annual return thereon (the “Economic Hurdle”); (y) any one of the following occurs: (1) a listing; (2) another liquidity event or (3) the termination of the advisory agreement by an affirmative vote of a majority of the Company’s independent directors without cause; and (z) the Advisor is still providing advisory services to the Company (the “Performance Condition”).
Unvested Class B Units will be forfeited immediately if: (a) the advisory agreement is terminated for any reason other than a termination without cause; or (b) the advisory agreement is terminated by an affirmative vote of a majority of the Company’s independent directors without cause before the Economic Hurdle has been met.
Subject to approval by the Board, the Class B Units were issued to the Advisor quarterly in arrears pursuant to the terms of the LPA. The number of Class B Units issued in any quarter was equal to: (i) the excess of (A) the product of (y) the cost of assets multiplied by (z) 0.1875% over (B) any amounts payable as an oversight fee (as described below) for such calendar quarter; divided by (ii) the value of one share of common stock as of the last day of such calendar quarter, which was initially equal to $22.50 (the price in the Company’s initial public offering of common stock minus the selling commissions and dealer manager fees). The value of issued Class B Units will be determined and expensed when the Company deems the achievement of the Performance Condition to be probable. As of December 31, 2022, the Company determined that achieving the Performance Condition was not yet considered probable for accounting purposes. The Advisor receives cash distributions on each issued Class B Unit equivalent to the cash distribution paid, if any on the Company’s common stock. These cash distributions on Class B Units are included in general and administrative expenses in the consolidated statement of operations and comprehensive loss until the Performance Condition is considered probable to occur. Stock Dividends do not cause the OP to issue additional Class OP Units, rather, the redemption ratio to common stock is adjusted. The Board has previously approved the issuance of 359,250 Class B Units to the Advisor in connection with this arrangement. The Board determined in February 2018 that Economic Hurdle had been satisfied, however none of the events have occurred, including a listing of the Company’s common stock on a national securities exchange, which would have satisfied the other vesting requirement of the Class B Units. Therefore, no expense has ever been recognized in connection with the Class B Units.
On May 12, 2015, the Company, the OP and the Advisor entered into an amendment to the then-current advisory agreement, which, among other things, provided that the Company would cease causing the OP to issue Class B Units to the Advisor with respect to any period ending after March 31, 2015.
Effective February 17, 2017, the Second A&R Advisory Agreement requires the Company to pay the Advisor a base management fee, which is payable on the first business day of each month. The fixed portion of the base management fee is equal to $1.625 million per month, while the variable portion of the base management fee is equal to one-twelfth of 1.25% of the cumulative net proceeds of any equity (including convertible equity and certain convertible debt but excluding proceeds from the DRIP) issued by the Company and its subsidiaries subsequent to February 17, 2017 per month. There are no variable management fees earned from the issuance of common stock dividends. The base management fee is payable to the Advisor or its assignees in cash, Common OP Units or shares, or a combination thereof, the form of payment to be determined at the discretion of the Advisor and the value of any Common OP Unit or share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate.
In addition, the Second A&R Advisory Agreement requires the Company to pay the Advisor a variable management/incentive fee quarterly in arrears equal to (1) the product of fully diluted shares common stock outstanding multiplied by (2) (x) 15.0% of the applicable prior quarter’s Core Earnings (as defined below) per share in excess of $0.375 per share plus (y) 10.0% of the applicable prior quarter’s Core Earnings per share in excess of $0.47 per share. Core Earnings is defined as, for the applicable period, net income or loss, computed in accordance with GAAP, excluding non-cash equity compensation expense, the variable management/incentive fee, acquisition and transaction related fees and expenses, financing related fees and expenses, depreciation and amortization, realized gains and losses on the sale of assets, any unrealized gains or losses or other non-cash items recorded in net income or loss for the applicable period, regardless of whether such items are included in
F-40


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
other comprehensive income or loss, or in net income, one-time events pursuant to changes in GAAP and certain non-cash charges, impairment losses on real estate related investments and other than temporary impairments of securities, amortization of deferred financing costs, amortization of tenant inducements, amortization of straight-line rent and any associated bad debt reserves, amortization of market lease intangibles, provision for loss loans, and other non-recurring revenue and expenses (in each case after discussions between the Advisor and the independent directors and approved by a majority of the independent directors). The variable management/incentive fee is payable to the Advisor or its assignees in cash or shares, or a combination of both, the form of payment to be determined in the sole discretion of the Advisor and the value of any share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate. No variable management incentive fee was incurred for the years ended December 31, 2022, 2021 and 2020.
Property Management Fees
Unless the Company contracts with a third party, the Company pays the Property Manager a property management fee on a monthly basis, equal to 1.5% of gross revenues from the Company’s stand-alone single-tenant net leased properties managed and 2.5% of gross revenues from all other types of properties managed, plus market-based leasing commissions applicable to the geographic location of the property. The Company also reimburses the Property Manager for property level expenses incurred by the Property Manager. The Property Manager may charge a separate fee for the one-time initial rent-up or leasing-up of newly constructed properties in an amount not to exceed the fee customarily charged in arm’s length transactions by others rendering similar services in the same geographic area for similar properties, and the Property Manager is allowed to receive a higher property management fee in certain cases if approved by the Company’s Board of Directors (including a majority of the independent directors).
If the Company contracts directly with third parties for such services, the Company will pay the third party customary market fees and will pay the Property Manager an oversight fee of 1.0% of the gross revenues of the property managed by the third party. In no event will the Company pay the Property Manager or any affiliate of the Property Manager both a property management fee and an oversight fee with respect to any particular property. If the Property Manager provides services other than those specified in the Property Management Agreement, the Company will pay the Property Manager a monthly fee equal to no more than that which the Company would pay to a third party that is not an affiliate of the Company or the Property Manager to provide the services.
On February 17, 2017, the Company entered into the Amended and Restated Property Management and Leasing Agreement (the “A&R Property Management Agreement”) with the OP and the Property Manager. The A&R Property Management Agreement automatically renews for successive one-year terms unless any party provides written notice of its intention to terminate the A&R Property Management Agreement at least 90 days prior to the end of the term. Neither party has provided notice of intent to terminate. The current term of the A&R Property Management Agreement expires February 17, 2023. The Property Manager may assign the A&R Property Management Agreement to any party with expertise in commercial real estate which has, together with its affiliates, over $100.0 million in assets under management.
On April 10, 2018, in connection with the Multi-Property CMBS Loan, the Company and the OP entered into a further amendment to the A&R Property Management Agreement confirming, consistent with the intent of the parties, that the borrowers under the Multi-Property CMBS Loan and other subsidiaries of the OP that own or lease the Company’s properties are the direct obligors under the arrangements pursuant to which the Company’s properties are managed by either the Property Manager or a third party overseen by the Property Manager pursuant to the A&R Property Management Agreement. See the Mortgage Notes Payable table included in Note 4 — Mortgage Notes Payable, Net for additional information on the Multi- Property CMBS Loan.
Professional Fees and Other Reimbursements
The Company reimburses the Advisor’s costs of providing administrative services including personnel costs, except for costs to the extent that the employees perform services for which the Advisor receives a separate fee. This reimbursement includes reasonable overhead expenses for employees of the Advisor or its affiliates directly involved in the performance of services on behalf of the Company, including the reimbursement of rent expense at certain properties that are both occupied by employees of the Advisor or its affiliates and owned by affiliates of the Advisor. During the year ended December 31, 2022, 2021 and 2020, the Company incurred $8.8 million, $9.4 million and $12.1 million, respectively, of reimbursement expenses from the Advisor for providing administrative services. These reimbursement expenses are included in general and administrative expense on the consolidated statements of operations and comprehensive income (loss). In September 2022, the Advisor terminated certain of its employees who provided services to the Company and for which the Company reimbursed the
F-41


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Advisor for salaries and benefits. In connection with the termination, the Company recognized a compensation charge, net of adjustments for previously accrued bonuses, of $0.3 million in the third quarter of 2022.
On July 25, 2019, the Company entered into the Advisory Agreement Amendment. Under the Advisory Agreement Amendment, including prior to the Advisory Agreement Amendment, the Company has been required to reimburse the Advisor for, among other things, reasonable salaries and wages, benefits and overhead of all employees of the Advisor or its affiliates, except for costs of employees to the extent that the employees perform services for which the Advisor receives a separate fee.
The Advisory Agreement Amendment clarifies that, with respect to executive officers of the Advisor, the Company is required to reimburse the Advisor or its affiliates for the reasonable salaries and wages, benefits and overhead of the Company’s executive officers, other than for any executive officer that is also a partner, member or equity owner of AR Global, an affiliate of the Advisor.
Further, under the Advisory Agreement Amendment, the aggregate amount of expenses relating to salaries, wages and benefits, including for executive officers and all other employees of the Advisor or its affiliates (the “Capped Reimbursement Amount”), is limited to the greater of: (a) a fixed component (the “Fixed Component”) and (b) a variable component (the “Variable Component”).
Both the Fixed Component and the Variable Component increase by an annual cost of living adjustment equal to the greater of (x) 3.0% and (y) the CPI, as defined in the Advisory Agreement Amendment for the prior year ended December 31st. Initially, for the year ended December 31, 2020; (a) the Fixed Component was equal to $6.8 million and (b) the Variable Component was equal to (i) the sum of the total real estate investments, at cost as recorded on the balance sheet dated as of the last day of each fiscal quarter (the “Real Estate Cost”) in the year divided by four, which amount is then (ii) multiplied by 0.29%.
If the Company sells real estate investments aggregating an amount equal to or more than 25.0% of Real Estate Cost, in one or a series of related dispositions in which the proceeds of the disposition(s) are not reinvested in Investments (as defined in the Advisory Agreement Amendment), then within 12 months following the disposition(s), the Advisory Agreement Amendment requires the Advisor and the Company to negotiate in good faith to reset the Fixed Component; provided that if the proceeds of the disposition(s) are paid to shareholders of the Company as a special distribution or used to repay loans with no intent of subsequently re-financing and re-investing the proceeds thereof in Investments, the Advisory Agreement amendment requires these negotiations within 90 days thereof, in each case taking into account reasonable projections of reimbursable costs in light of the Company’s reduced assets.
The Company paid approximately $2.5 million in 2019 to the Advisor or its affiliates as reimbursement for bonuses of employees of the Advisor or its affiliates who provided administrative services during the calendar year 2019, prorated for the time spent working on matters relating to the Company. The Company does not reimburse the Advisor or its affiliates for any bonus amounts relating to time dedicated to the Company by Edward M. Weil, Jr., the Company’s Chief Executive Officer. The Advisor formally awarded 2019 bonuses to employees of the Advisor or its affiliates in September 2020 (the “2019 Bonus Awards”). The original estimate for bonuses recorded and paid to the Advisor in 2019 exceeded the cash portion of the 2019 Bonus Awards to be paid to employees of the Advisor or its affiliates and to be reimbursed by the Company by $1.2 million. As a result, during the three months ended September 30, 2020, the Company recorded a receivable from the Advisor of $1.2 million in prepaid expenses and other assets on the consolidated balance sheet and a corresponding reduction in general and administrative expenses. Pursuant to authorization by the independent members of the Company’s board of directors, the $1.2 million receivable was being paid back to the Company over a 10-month period from January 2021 through October 2021. As of December 31, 2021, all of this amount had been repaid by the Advisor.
During the second quarter of 2021, the Advisor finalized the amounts and form of the 2020 bonuses previously estimated (the “2020 Bonus Awards”) to be paid to the employees of the Advisor or its affiliates who provided administrative services during such calendar year, prorated for the time spent working on matters relating to the Company. The 2020 Bonus Awards are being paid by the Advisor over a ten-month period from June 2021 to April 2022. The final amounts exceeded the amounts previously paid by the Company to the Advisor for estimated 2020 bonuses by approximately $1.0 million for the following reasons (i) forfeitures of bonuses related to employees of the Advisor or its affiliates who were terminated or resigned prior to payment (including the Company’s former chief financial officer) and (ii) a general reduction in final bonuses for remaining personnel due to on-going negative impacts of the COVID-19 pandemic. As a result, during the second quarter of 2021, the Company recorded a receivable from the Advisor of $1.0 million, which is recorded in prepaid expenses and other assets on the consolidated balance sheet and a corresponding reduction in general administrative expenses. Pursuant to authorization by the independent members of the Company’s board of directors, the $1.0 million receivable is required to be repaid to the Company
F-42


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
on a pro rata basis over a six-month period from November 2021 through April 2022. As of December 31, 2022, the entire amount has been repaid by the Advisor.
Reimbursements for the cash portion of 2021 bonuses paid by the Advisor to employees of the Advisor or its affiliates were expensed and reimbursed on a monthly basis during 2021, and 2022 bonuses were expensed and reimbursed on a monthly basis during 2022 in accordance with estimates provided by the Advisor. Generally, prior to the 2019 Bonus Awards, employee bonuses have been formally awarded to employees of the Advisor or its affiliates in March as an all - cash award and paid out by the Advisor in the year subsequent to the year in which services were rendered to the Company.
In December 2020, after mediation on October 27, 2020, the Advisor agreed to a settlement with the Company’s former chief executive officer for severance claims related to his termination in 2018. Pursuant to the settlement, among other parties, the Advisor advised the Company that the Company and its directors and officers were released from any and all actions or claims the former chief executive officer now has or may ever have against them. Prior to the agreement, the Advisor did not believe any settlement was probable. In consideration of the release, among other things, and upon the recommendation of its nominating and corporate governance committee, which determined that the reimbursement was advisable and fair to, and in the best interest of, the Company, the Company’s board of directors approved the reimbursement by the Company to the Advisor of severance payments and legal costs relating to this settlement and determined that the reimbursement for those payments and costs would not be subject to (and therefore would not be aggregated with other reimbursements that are subject to) the Capped Reimbursement Amount. The Company recorded approximately $2.2 million of expenses for the reimbursement which is included in general and administrative expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.
Summary of fees, expenses and related payables
The following table details amounts incurred and payable in connection with the Company’s operations-related services described above as of and for the periods presented:
Year Ended December 31,Payable (Receivable) as of
 202220212020December 31,
(In thousands)
Incurred
Incurred
Incurred20222021
One-time fees and reimbursements:
Acquisition cost reimbursements$23 $90 $81 $5 $23 
Ongoing fees and reimbursements:
Asset management fees 21,831 20,710 19,987   
Property management fees (4)
4,200 3,749 4,197 3 24 
Professional fees and other reimbursements (1) (3)
8,820 

9,386 12,102 39 (70)
Professional fees credit due from Advisor (1,030)(1,217) (859)(2)
Distributions on Class B Units   178   
Total related party operation fees and reimbursements$34,874 $32,905 $35,328 $47 $(882)
_________
(1)Included in general and administrative expenses in the consolidated statements of operations. Includes $6.0 million, $6.2 million and $5.6 million subject to the Capped Reimbursement Amount for the years ended December 31, 2022, 2021 and 2020, respectively.
(2)Balance as of December 31, 2021 includes a receivable of $0.9 million from the Advisor related to the overpayment of 2020 Bonus Awards, which, pursuant to authorization by the independent members of the Company’s board of directors, was required to be repaid to the Company on a pro rata basis over a six-month period from November 2021 through April 2022.
(3)During the year ended December 31, 2020 the Company recorded approximately $2.2 million of expense reimbursements to the Advisor for severance payments and related legal costs relating to the termination of its former Chief Executive Officer.
(4)Inclusive of $0.7 million and $0.3 million of leasing commissions which are included in prepaid expenses and other assets on the consolidated balance sheet as of December 31, 2022 and 2021.
Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company’s Real Estate Assets
Fees Incurred in Connection with a Listing
If the common stock of the Company is listed on a national exchange, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive a subordinated incentive listing distribution from the OP equal to 15.0% of the amount by which the market value of all issued and outstanding shares of common stock plus distributions
F-43


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
exceeds the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax non-compounded annual return to investors in the Company’s initial public offering of common stock. No such distribution was incurred during the years ended December 31, 2022, 2021 and 2020. If the Special Limited Partner or any of its affiliates receives the subordinated incentive listing distribution the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive termination distribution described below.
Subordinated Participation in Net Sales Proceeds
Upon a liquidation or sale of all or substantially all of the Company’s assets, including through a merger or sale of stock, the Special Limited Partner will be entitled to receive a subordinated participation in the net sales proceeds of the sale of real estate assets from the OP equal to 15.0% of remaining net sale proceeds after return of capital contributions to investors in the Company’s initial public offering of common stock plus payment to investors of a 6.0% cumulative, pre-tax non-compounded annual return on the capital contributed by investors. No such participation in net sales proceeds became due and payable during the years ended December 31, 2022, 2021 and 2020. Any amount of net sales proceeds paid to the Special Limited Partner or any of its affiliates prior to the Company’s listing or termination or non-renewal of the advisory agreement with the Advisor, as applicable, will reduce dollar for dollar the amount of the subordinated incentive listing distribution described above and subordinated incentive termination distribution described below.
Termination Fees
Under the operating partnership agreement of the OP, upon termination or non-renewal of the advisory agreement with the Advisor, with or without cause, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive subordinated termination distributions from the OP equal to 15.0% of the amount by which the sum of the Company’s market value plus distributions exceeds the sum of the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax, non-compounded annual return to investors in the Company’s initial public offering of common stock. The Special Limited Partner is able to elect to defer its right to receive a subordinated distribution upon termination until either a listing on a national securities exchange or other liquidity event occurs. If the Special Limited Partner or any of its affiliates receives the subordinated incentive termination distribution, the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive listing distribution described above.
Under the Advisory Agreement Amendment, upon the termination or non-renewal of the agreement, the Advisor is entitled to receive from the Company all amounts due to the Advisor, including any change of control fee and transition fee (both described below), as well as the then-present fair market value of the Advisor’s interest in the Company. All fees will be due within 30 days after the effective date of the termination of the Advisory Agreement Amendment.
Upon a termination by either party in connection with a change of control (as defined in the Advisory Agreement Amendment), the Company would be required to pay the Advisor a change of control fee equal to the product of four and the “Subject Fees” described below.
Upon a termination by the Company in connection with a transition to self-management, the Company would be required to pay the Advisor a transition fee equal to (i) $15.0 million plus (ii) the product of four multiplied by the Subject Fees, provided that the transition fee shall not exceed an amount equal to 4.5 multiplied by the Subject Fees.
The Subject Fees are equal to (i) the product of four multiplied by the actual base management fee plus (ii) the product of four multiplied by the actual variable management/incentive fee, in each of clauses (i) and (ii), payable for the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated, plus (iii) without duplication, the annual increase in the base management fee resulting from the cumulative net proceeds of any equity raised (but excluding proceeds from the DRIP) in respect to the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated.
Note 10 — Economic Dependency
Under various agreements, the Company has engaged or will engage the Advisor, its affiliates and entities under common control with the Advisor to provide certain services that are essential to the Company, including asset management services, supervision of the management and leasing of properties owned by the Company and asset acquisition and disposition decisions, as well as other administrative responsibilities for the Company including accounting services and investor relations.
As a result of these relationships, the Company is dependent upon the Advisor and its affiliates. In the event that the Advisor and its affiliates are unable to provide the Company with the respective services, the Company will be required to find alternative providers of these services.
F-44


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Note 11 — Equity-Based Compensation
Restricted Share Plan
The Company has adopted an employee and director incentive restricted share plan (as amended from time to time, the “RSP”), which provides the Company with the ability to grant awards of restricted shares of common stock (“restricted shares”) to the Company’s directors, officers and employees (if the Company ever has employees), employees of the Advisor and its affiliates, employees of entities that provide services to the Company, directors of the Advisor or of entities that provide services to the Company, certain consultants to the Company and the Advisor and its affiliates or to entities that provide services to the Company. The total number of shares of common stock that may be subject to awards granted under the RSP may not exceed 5.0% of the Company’s outstanding shares of common stock on a fully diluted basis at any time and in any event will not exceed 3.6 million shares (as such number may be further adjusted for stock splits, stock dividends, combinations and similar events).
Restricted shares vest on a straight-line basis over periods of three to five years and may not, in general, be sold or otherwise transferred until restrictions are removed and the shares have vested. Holders of restricted shares may receive cash distributions prior to the time that the restrictions on the restricted shares have lapsed. Any distributions payable in shares of common stock are subject to the same restrictions as the underlying restricted shares.
The following table reflects the amount of restricted shares outstanding as of December 31, 2022 and activity for the period presented:
Number of Common Shares Weighted-Average Issue Price
Unvested, December 31, 2019277,241 $21.18 
Stock dividend2,878 15.75 
Granted  
Vested(64,735)21.18 
Forfeitures  
Unvested, December 31, 2020
215,384 21.11 
Stock Dividend12,646 14.79 
Granted 
Vested(68,603)19.72 
Forfeitures  
Unvested, December 31, 2021
159,427 21.21 
Stock dividend8,313 14.86 
Granted  
Vested(70,397)23.67 
Forfeitures  
Unvested, December 31, 2022
97,343 18.89 
As of December 31, 2022, the Company had $1.5 million of unrecognized compensation cost related to unvested restricted share awards granted under the RSP. That cost is expected to be recognized over a weighted-average period of 1.6 years. Compensation expense related to restricted shares was $1.2 million, $1.3 million and $1.3 million during the years ended December 31, 2022, 2021 and 2020, respectively.
Other Share-Based Compensation
The Company may issue common stock in lieu of cash to pay fees earned by the Company’s directors at the respective director’s election. There are no restrictions on shares issued in lieu of cash compensation since these payments in lieu of cash relate to fees earned for services performed. No such shares were issued during the years ended December 31, 2022, 2021 and 2020.
F-45


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Note 12 — Accumulated Other Comprehensive Income (Loss)
The following table illustrates the changes in accumulated other comprehensive income (loss) as of and for the periods presented:
(In thousands)Unrealized Gains (Losses) on Designated Derivative
Balance, December 31, 2019$(7,043)
Other comprehensive loss, before reclassifications(40,614)
Amount of loss reclassified from accumulated other comprehensive income (loss) 7,999 
Rebalancing of ownership percentage(15)
Balance, December 31, 2020
(39,673)
Other comprehensive income, before reclassifications14,322 
Amount of loss reclassified from accumulated other comprehensive income (loss)11,010 
Balance, December 31, 2021
(14,341)
Other comprehensive income, before reclassifications50,098 
Amount of loss reclassified from accumulated other comprehensive income (loss)1,153 
Balance, December 31, 2022
$36,910 

Accumulated other comprehensive income (loss) predominately relates to the unrealized gains (losses) on designated derivatives, however, as previously discussed in Note 7 — Derivatives and Hedging, a previously designated hedge was terminated and the termination costs are being amortized over the term of the hedged item. The unamortized portion of the terminated swap still remaining in accumulated other comprehensive (loss) income was $0.4 million as of December 31, 2021. The terminated swap was fully amortized within the year ending December 31, 2022.
Note 13 — Non-Controlling Interests
Non-controlling interests on the Company’s consolidated balance sheet is comprised of the following:
Balance as of December 31,
(In thousands)20222021
Series A Preferred Units held by third parties$2,578 $2,578 
Common OP Units held by third parties3,584 3,758 
Total Non-controlling Interests in the OP6,162 6,336 
Non-controlling interests in property owning subsidiaries389 368 
Total Non-controlling Interests$6,551 $6,704 
Non-Controlling Interests in the Operating Partnership
For preferred and common shares issued by the Company, the Company typically issues mirror securities with substantially equivalent economic rights between the Company and the OP. The securities held by the Company are eliminated in consolidation.
Series A Preferred OP Units
The Company is the sole general partner and holds substantially all of the Series A Preferred Units.
In September 2021, the Company partially funded the purchase of a MOB from an unaffiliated third party by causing the OP to issue 100,000 Series A Preferred Units, with a face value of $25.00 per unit, which were recorded at issuance at a then fair value of $2.6 million, or $25.78 per unit, to the unaffiliated third party.
A holder of Series A Preferred Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s Series A Preferred Stock. After holding the Series A Preferred Units for a period of one year, a holder of Series A Preferred Units has the right to redeem Series A Preferred Units for, at the option of the OP, the corresponding number of shares of the Company’s Series A Preferred Stock, or the cash equivalent. The remaining rights of the limited partners in the
F-46


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During the year ended December 31, 2022 and 2021, Series A Preferred Unit holders were paid distributions of $0.2 million and $46,000, respectively.
Common OP Units
The Company is the sole general partner and holds substantially all of the Common OP Units. As of December 31, 2022 and 2021, the Advisor held 90 Common OP Units, which represents a nominal percentage of the aggregate ownership in the OP.
In November 2014, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 405,908 Common OP Units, with an initial value of $10.1 million, or $25.00 per unit, to the unaffiliated third party.
A holder of Common OP Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s common stock in an amount retroactively adjusted to reflect the Stock Dividends, other stock dividends and other similar events. After holding the Common OP Units for a period of one year, a holder of Common OP Units has the right to redeem Common OP Units for, at the option of the OP, the corresponding number of shares of the Company’s common stock, as retroactively adjusted for the Stock Dividends, other stock dividends and other similar events, or the cash equivalent. The remaining rights of the limited partners in the OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During the years ended December 31, 2022 and 2021, Common OP Unit non-controlling interest holders were not paid any cash distributions. During the year ended December 31, 2020, Common OP Unit non-controlling interest holders were paid distributions of $0.2 million.
Stock Dividends do not cause the OP to issue additional Common OP Units, rather, the redemption ratio to common stock is adjusted. The 405,908 Common OP Units outstanding as of December 31, 2022 would be redeemable for 467,498 shares of common stock, giving effect to adjustments for the impact of the Stock Dividends through January 2023.
Non-Controlling Interests in Property Owning Subsidiaries
The Company also has investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Upon disposition of a property subject to non-controlling interest, the investor will receive a proportionate share of the net proceeds from the sale of the property. The investor has no recourse to any other assets of the Company. Due to the nature of the Company’s involvement with these arrangements and the significance of its investment in relation to the investment of the third party, the Company has determined that it controls each entity in these arrangements and therefore the entities related to these arrangements are consolidated within the Company’s financial statements. A non-controlling interest is recorded for the investor’s ownership interest in the properties.
On November 4, 2020, the Company purchased all of the outstanding the membership interests in the joint venture that owns the UnityPoint Clinics in Muscatine, Iowa and Moline, Illinois for approximately $0.6 million, funded with cash on hand. Following this transaction, the properties were wholly owned by the Company and added to the borrowing base under the Credit Facility.
The following table summarizes the activity related to investment arrangements with unaffiliated third parties.
Third Party Net Investment AmountNon-Controlling Ownership PercentageNet Real Estate Assets Subject to Investment ArrangementDistributions
Property NameAs of December 31,As of December 31,As of December 31,Year Ended December 31,
(Dollar amounts in thousands)
Investment Date2022202220222021202220212020
Plaza Del Rio Medical Office Campus Portfolio(1)
May 2015$389 2.5 %$12,455 $12,925 $ $ $ 
_____________
(1)One property within the Plaza Del Rio Medical Office Campus Portfolio was mortgaged as part of the Multi-Property CMBS Loan. See Note 4 - Mortgage Notes Payable for additional information.
F-47


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Note 14 — Net Loss Per Share
The following is a summary of the basic and diluted net loss per share computation for the years ended December 31, 2022, 2021 and 2020 and has been retroactively adjusted to reflect the stock dividends (see Note 1 — Organization for additional details):
Year Ended December 31,
202220212020
Net loss attributable to stockholders (in thousands)
$(93,285)$(92,942)$(78,781)
Basic and diluted weighted-average shares outstanding (1)
106,428,154 106,354,994 106,119,937 
Basic and diluted net loss per share (1)
$(0.88)$(0.87)$(0.74)
(1)Retroactively adjusted for the effects of the stock dividends. See Note 1 — Organization and Note 8 — Stockholder’s Equity for additional information.
Diluted net loss per share assumes the conversion of all common stock equivalents into an equivalent number of shares of common stock, unless the effect is antidilutive. The Company considers unvested restricted shares, Common OP Units and Class B Units to be common share equivalents. The Company had the following common stock equivalents on a weighted-average basis that were excluded from the calculation of diluted net loss per share attributable to stockholders as their effect would have been antidilutive. The amounts in the table below have been retroactively adjusted to reflect the stock dividends (see Note 1 — Organization for additional details):
December 31,
202220212020
Unvested restricted shares (1)
141,364 214,520 288,965 
Common OP Units (2)
467,602 467,602 467,602 
Class B Units (3)
413,760 413,760 413,760 
Total weighted average antidilutive common share equivalents1,022,726 1,095,882 1,170,327 
________
(1)Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. There were 97,343, 159,427 and 215,384 unvested restricted shares outstanding as of December 31, 2022, 2021 and 2020, respectively.
(2)Weighted average number of antidilutive Common OP Units presented as shares outstanding for the periods presented, at the current conversion rate as retroactively adjusted for the effects of the stock dividends. There were 405,998 Common OP Units outstanding as of December 31, 2022, 2021 and 2020.
(3)Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current conversion rate as retroactively adjusted for the effects of the stock dividends. There were 359,250 Class B Units outstanding as of December 31, 2022, 2021 and 2020.
Note 15 — Segment Reporting
The disclosures below for the years ended December 31, 2022, 2021 and 2020, are presented for the Company’s two reportable business segments for management and internal financial reporting purposes: MOBs and SHOPs. Prior to December 31, 2021, the Company had three reportable segments 1) medical office and outpatient buildings (“Former MOBs”), 2) triple net-leased healthcare properties (“Former NNN”) and 3) SHOPs. Culminating in the year ended December 31, 2021, the Company has completed several strategic property divestitures from the Company’s Former NNN segment and transitioned certain properties previously reported in the Company’s Former NNN segment into the Company’s SHOP segment. The remaining Former NNN properties are similar in nature, cash flows, and risk structure with the Former MOB segment and are managed operationally and reported collectively by the Company’s management. Accordingly, in the fourth quarter of 2021, the Company reevaluated its segments and concluded that it had two reportable segments. The Company combined the properties in its Former NNN segment with the properties in its Former MOB segment for segment reporting. All prior periods presented in the tables below have been conformed to the presentation of the Company’s new reportable segment structure.
The Company evaluates performance and makes resource allocations based on its two business segments. The medical office building segment primarily consists of MOBs leased to healthcare-related tenants under long-term leases, which may require such tenants to pay a pro rata share of property-related expenses as well as seniors housing properties, hospitals, inpatient rehabilitation facilities and skilled nursing facilities under long-term leases, under which tenants are generally responsible to directly pay property-related expenses. The SHOP segment consists of direct investments in seniors housing properties, primarily providing assisted living, independent living and memory care services, which are operated through engaging independent third-party operators.
F-48


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Net Operating Income
The Company evaluates the performance of the combined properties in each segment based on net operating income (“NOI”). NOI is defined as total revenues from tenants, less property operating and maintenance expense. NOI excludes all other items of expense and income included in the financial statements in calculating net income (loss). The Company uses NOI to assess and compare property level performance and to make decisions concerning the operation of the properties. The Company believes that NOI is useful as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating expenses and acquisition activity on an unleveraged basis, providing perspective not immediately apparent from net income (loss).
NOI excludes certain components from net income (loss) in order to provide results that are more closely related to a property’s results of operations. For example, interest expense is not necessarily linked to the operating performance of a real estate asset and is often incurred at the corporate level. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property level. NOI presented by the Company may not be comparable to NOI reported by other REITs that define NOI differently. The Company believes that in order to facilitate a clear understanding of the Company’s operating results, NOI should be examined in conjunction with net income (loss) as presented in the Company’s consolidated financial statements. NOI should not be considered as an alternative to net income (loss) as an indication of the Company’s performance or to cash flows as a measure of the Company’s liquidity or ability to pay distributions.
The following tables reconcile the segment activity to consolidated net loss for the years ended December 31, 2022, 2021 and 2020:
Year Ended December 31, 2022
(In thousands)Medical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants$131,444 $204,402 $335,846 
Property operating and maintenance35,945 177,499 213,444 
NOI$95,499 $26,903 122,402 
Impairment charges(27,630)
Operating fees to related parties(25,353)
Acquisition and transaction related(1,484)
General and administrative(17,287)
Depreciation and amortization(82,064)
Loss on sale of real estate investments(125)
Interest expense(51,740)
Interest and other income 27 
Gain on non designated derivatives3,834 
Income tax expense(201)
Net loss attributable to non-controlling interests135 
Allocation for preferred stock(13,799)
Net loss attributable to common stockholders$(93,285)

F-49


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
Year Ended December 31, 2021
(In thousands)Medical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants$122,867 $206,488 $329,355 
Property operating and maintenance34,480 171,333 205,813 
NOI88,387 35,155 123,542 
Impairment charges(40,951)
Operating fees to related parties(24,206)
Acquisition and transaction related(2,714)
General and administrative(16,828)
Depreciation and amortization(79,926)
Gain on sale of real estate investments3,648 
Interest expense(47,900)
Interest and other income61 
Gain on non-designated derivatives37 
Income tax expense(203)
Net loss attributable to non-controlling interests260 
Allocation for preferred stock(7,762)
Net loss attributable to common stockholders$(92,942)

Year Ended December 31, 2020
(In thousands)Medical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants$119,824 $261,788 $381,612 
Property operating and maintenance32,812 210,736 243,548 
NOI87,012 51,052 138,064 
Impairment charges(36,446)
Operating fees to related parties(23,922)
Acquisition and transaction related(173)
General and administrative(21,572)
Depreciation and amortization(81,053)
Gain on sale of real estate investment 5,230 
Interest expense(51,519)
Interest and other income 44 
Loss on non-designated derivatives (102)
Income tax expense(4,061)
Net income attributable to non-controlling interests(303)
Allocation for preferred stock(2,968)
Net loss attributable to common stockholders$(78,781)

F-50


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
The following table reconciles the segment activity to consolidated total assets as of the periods presented:
December 31,
(In thousands)20222021
ASSETS
Investments in real estate, net:
Medical office and other healthcare-related buildings$1,121,857 $1,149,241 
Seniors housing — operating properties856,440 900,686 
Total investments in real estate, net
1,978,297 2,049,927 
Cash and cash equivalents53,654 59,738 
Restricted cash22,884 25,644 
Derivative assets, at fair value40,647 174 
Straight-line rent receivable, net25,276 23,858 
Operating lease right-of-use asset7,814 7,914 
Prepaid expenses and other assets34,554 32,564 
Deferred costs, net17,223 14,581 
Total assets$2,180,349 $2,214,400 

The following table reconciles capital expenditures by reportable business segments, excluding corporate non-real estate expenditures, for the periods presented:
Year Ended December 31,
(In thousands)202220212020
Medical office and other healthcare-related buildings$10,542 $6,152 $8,561 
Seniors housing — operating properties17,451 12,919 12,833 
Total capital expenditures$27,993 $19,071 $21,394 
Note 16 — Commitments and Contingencies
As of December 31, 2022, the Company has seven operating and six direct financing lease agreements related to certain acquisitions under leasehold interests arrangements. The seven operating leases have durations, including assumed renewals, ranging from 19.9 to 84.7 years, excluding an adjacent parking lot lease with a term of 1.8 years as of December 31, 2022. The Company did not enter into any additional ground leases during the year ended December 31, 2022. The classification of these leases were grandfathered in adoption of ASU 842, whereby they will continue to be classified as operating leases unless modified.
As of December 31, 2022, the Company’s balance sheet included ROU assets and liabilities of $7.8 million and $8.1 million, respectively, which are included in operating lease right-of-use assets and operating lease liabilities, respectively, on the Company’s consolidated balance sheet. In determining operating ROU assets and lease liabilities for the Company’s existing operating leases upon the adoption of the lease guidance issued in 2019, as well as for new operating leases since adoption, the Company was required to estimate an appropriate incremental borrowing rate on a fully-collateralized basis for the terms of the leases. Because the terms of the Company’s ground leases are significantly longer than the terms of borrowings available to the Company on a fully-collateralized basis, the Company’s estimate of this rate required significant judgment. During the year ended December 31, 2021, the Company sold a property which included a prepaid ground lease. Upon disposition, the carrying value of the ROU asset was $5.7 million, and was recorded as a reduction of the gain on sale for that property.
The Company’s ground operating leases have a weighted-average remaining lease term, including assumed renewals, of 34.1 years and a weighted-average discount rate of 7.36% as of December 31, 2022. For the years ended December 31, 2022, 2021 and 2020, the Company paid cash of $0.7 million, $0.8 million and $0.8 million for amounts included in the measurement of lease liabilities and recorded total rental expense from operating leases of $0.9 million, $0.9 million and $0.9 million, on a straight-line basis in accordance with the standard, during the years ended December 31, 2022, 2021 and 2020, respectively.
F-51


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022
The lease expense is recorded in property operating expenses in the consolidated statements of operations and comprehensive loss.
Future Base Rent Payments
(In thousands)Operating Leases
Direct Financing Leases (1)
2023$645 $88 
2024632 90 
2025588 93 
2026599 95 
2027617 97 
Thereafter21,942 7,215 
Total minimum lease payments25,023 7,678 
Less: amounts representing interest(16,936)(2,841)
Total present value of minimum lease payments$8,087 $4,837 
_______
(1)The Direct Finance Lease liability is included in Accounts Payable and accrued expenses on the balance sheet as of December 31, 2022. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.
Litigation and Regulatory Matters
In the ordinary course of business, the Company may become subject to litigation, claims and regulatory matters. There are no material legal or regulatory proceedings pending or known to be contemplated against the Company or its properties.
Environmental Matters
In connection with the ownership and operation of real estate, the Company may potentially be liable for costs and damages related to environmental matters. As of December 31, 2022, the Company had not been notified by any governmental authority of any non-compliance, liability or other claim, and is not aware of any other environmental condition that it believes will have a material adverse effect on the results of operations.
Note 17 — Subsequent Events
The Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K and determined that there have not been any events that have occurred that would require adjustments to disclosures in the consolidated financial statements except the following disclosures:
Stock Dividend
On January 3, 2023, the Company declared a quarterly stock dividend of 0.014167 shares of the Company’s common stock on each share of the Company’s outstanding common stock. The stock dividend was payable on January 18, 2023 to holders of record of the Company’s common stock at the close of business on January 13, 2023.
Swap Terminations
Subsequent to December 31, 2022, the Company terminated two LIBOR-based interest rate swap agreements with an aggregate notional amount of $50.0 million. The swaps were terminated in an asset position with a fair value of $2.0 million. The funds were received in February 2023. This amount will remain in AOCI and will amortize into net loss as a reduction to interest expense through March 2024.
Credit Facility Borrowings
Subsequent to December 31, 2022, the Company drew $20.0 million on its Revolving Credit Facility.
Acquisitions
Subsequent to December 31, 2022, the Company acquired four single-tenant MOB properties for a contract purchase price of $20.0 million, which was funded with borrowings from the Revolving Credit Facility.
F-52

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2022
(In thousands)
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Fresenius Medical Care - Winfield, AL(5)AL5/10/2013$ $152 $1,568 $ $ $1,720 $445 
Adena Health Center - Jackson, OH(5),(11)OH6/28/2013 242 4,494  (25)4,711 1,100 
Ouachita Community Hospital - West Monroe, LA(5)LA7/12/2013 633 5,304   5,937 1,329 
CareMeridian - Littleton, CO(5)CO8/8/2013 976 8,900  111 9,987 3,037 
Oak Lawn Medical Center - Oak Lawn, ILIL8/21/20135,343 835 7,217  25 8,077 1,994 
Surgery Center of Temple - Temple, TX(5)TX8/30/2013 225 5,208  432 5,865 1,379 
Greenville Health System - Greenville, SC(5), (9)SC10/10/2013 720 3,045  389 4,154 759 
Stockbridge Family Medical - Stockbridge, GAGA2/21/20141,781 823 1,799  177 2,799 542 
Arrowhead Medical Plaza II - Glendale, AZAZ2/21/20147,540  9,758  2,076 11,834 3,261 
Village Center Parkway - Stockbridge, GAGA2/21/20142,434 1,135 2,299  372 3,806 809 
Creekside MOB - Douglasville, GAGA4/30/20148,814 2,709 5,320  791 8,820 1,858 
Bowie Gateway Medical Center - Bowie, MDMD5/7/20149,153 983 10,321  334 11,638 2,489 
Campus at Crooks & Auburn Building D - Rochester Mills, MIMI5/19/20143,627 640 4,166  145 4,951 1,120 
Berwyn Medical Center - Berwyn, IL(5)IL5/29/2014 1,305 7,559   8,864 1,693 
Countryside Medical Arts - Safety Harbor, FLFL5/30/20146,983 915 7,663  74 8,652 1,862 
St. Andrews Medical Park - Venice, FLFL5/30/201411,119 1,666 10,005 2 399 12,072 3,027 
Campus at Crooks & Auburn Building C - Rochester Mills, MIMI6/3/20143,831 609 3,893  178 4,680 1,081 
Laguna Professional Center - Elk Grove, CACA7/15/20148,887 1,811 14,598  318 16,727 3,709 
UC Davis MOB - Elk Grove, CACA7/15/20148,136 1,138 7,242  294 8,674 1,951 
Estate at Hyde Park - Tampa, FL(7)FL7/31/2014 1,777 20,308  1,079 23,164 5,133 
Autumn Ridge of Clarkston - Clarkston, MI(7)MI8/12/2014 655 19,967  1,584 22,206 4,884 
Sunnybrook of Burlington - Burlington, IA(6)IA8/26/2014 518 16,739  429 17,686 4,438 
Sunnybrook of Carroll - Carroll, IA(6)IA8/26/2014 473 11,263  51 11,787 2,686 
Prairie Hills at Cedar Rapids - Cedar Rapids, IA(7)IA8/26/2014 195 8,595  182 8,972 2,096 
Prairie Hills at Clinton - Clinton, IA(6)IA8/26/2014 890 18,882  86 19,858 4,781 
Prairie Hills at Des Moines - Des Moines, IA(6)IA8/26/2014 647 13,745  57 14,449 3,593 
Sunnybrook of Fairfield - Fairfield, IA(5)IA8/26/2014 340 14,115  291 14,746 3,635 
Sunnybrook of Ft. Madison - Ft. Madison, IA(5),(11)IA8/26/2014 263 3,931 (54)(1,177)2,963 (21)
Prairie Hills at Independence - Independence, IA(5)IA8/26/2014 473 10,600  179 11,252 2,519 
Sunnybrook of Mt. Pleasant - Mt. Pleasant, IA(5)IA8/26/2014 205 10,935  359 11,499 2,575 
Sunnybrook of Muscatine - Muscatine, IA(6)IA8/26/2014 302 13,840  172 14,314 3,364 
Prairie Hills at Ottumwa - Ottumwa, IA(5),(11)IA8/26/2014 538 9,186 (376)(7,088)2,260 47 
Prairie Hills at Tipton - Tipton, IA(5)IA8/26/2014 306 10,409  78 10,793 2,405 
F-53

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2022
(In thousands)
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Liberty Court - Dixon, IL(5)IL8/29/2014 119 1,998  59 2,176 541 
Lakeside Vista - Holland, MI(6)MI8/29/2014 378 12,196  1,878 14,452 3,057 
The Atrium - Rockford, IL(5)IL8/29/2014 164 1,746  295 2,205 369 
Arrowhead Medical Plaza I - Glendale, AZAZ9/10/20144,571  6,447  1,410 7,857 1,886 
Sunnybrook of Burlington - Land - Burlington, IAMO9/23/2014 620    620  
Community Health MOB - Harrisburg, PA(10)PA9/26/20145,424  6,170   6,170 1,315 
Brady MOB - Harrisburg, PA(10)PA9/26/201419,661  22,485   22,485 4,680 
Landis Memorial - Harrisburg, PA(5), (10)PA9/26/2014  32,484   32,484 6,782 
FOC II - Mechanicsburg, PA(10)PA9/26/201416,136  16,473  142 16,615 3,960 
FOC Clinical - Mechanicsburg, PA(10)PA9/26/201417,695  19,634   19,634 4,616 
FOC I - Mechanicsburg, PA(10)PA9/26/20148,204  8,923  368 9,291 2,308 
Copper Springs Senior Living - Meridian, ID(5),(11)ID9/29/2014 498 7,130 (14)(2,052)5,562 48 
Addington Place of Brunswick - Brunswick, GA(5)GA9/30/2014 1,509 14,402  489 16,400 3,747 
Addington Place of Dublin - Dublin, GA(5)GA9/30/2014 403 9,281  182 9,866 2,541 
Allegro at Elizabethtown - Elizabethtown, KY(5),(11)KY9/30/2014 317 7,290 (76)(3,175)4,356 13 
Addington Place of Johns Creek - Johns Creek, GA(7)GA9/30/2014 997 11,943  448 13,388 3,174 
Allegro at Jupiter - Jupiter, FL(6)FL9/30/2014 3,741 49,534  674 53,949 12,027 
Addington Place of Lee's Summit - Lee's Summit, MO(7)MO9/30/2014 2,734 25,008  391 28,133 6,149 
Addington Place at Mills - Roswell, GA(5)GA9/30/2014 1,000 8,611  2,575 12,186 3,310 
Addington Place of College Harbour - St Petersburg, FL(5)FL9/30/2014 3,791 8,684  2,117 14,592 3,430 
Allegro at Stuart - Stuart, FL(6)FL9/30/2014 5,018 60,575  969 66,562 15,029 
Allegro at Tarpon - Tarpon Springs, FL(7)FL9/30/2014 2,360 13,728  3,107 19,195 4,430 
Addington Place of Titusville - Titusville, FL(6)FL9/30/2014 1,379 13,976  720 16,075 4,034 
Allegro at St. Petersburg - Land - St. Petersburg, FLFL9/30/2014 3,045    3,045  
Gateway MOB - Clarksville, TN(9)TN10/3/201417,560  16,367  1,011 17,378 4,335 
Dyer Building - Dyer, IN(5)IN10/17/20146,143 601 8,992  191 9,784 1,971 
757 Building - Munster, IN(5)IN10/17/2014 645 7,885  31 8,561 1,685 
761 Building - Munster, ININ10/17/20146,797 1,436 8,616  90 10,142 1,974 
759 Building - Munster, ININ10/17/20148,271 1,101 8,899  31 10,031 1,955 
Schererville Building - Schererville, ININ10/17/2014 1,260 935  88 2,283 381 
Meadowbrook Senior Living - Agoura Hills, CA(7)CA11/25/2014 8,821 48,682  2,485 59,988 11,659 
Mount Vernon Medical Office Building - Mount Vernon, WA(9)WA11/25/201415,797  18,519  3 18,522 4,095 
F-54

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2022
(In thousands)
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Wellington at Hershey's Mill - West Chester, PA(5)PA12/3/2014 8,531 80,734  5,364 94,629 18,754 
Eye Specialty Group Medical Building - Memphis, TNTN12/5/20148,475 775 7,223   7,998 1,533 
Addington Place of Alpharetta - Alpharetta, GAGA12/10/2014 1,604 26,069  462 28,135 6,296 
Addington Place of Prairie Village - Prairie Village, KS(7)KS12/10/2014 1,782 21,869  451 24,102 5,466 
Bloom MOB - Harrisburg, PA(10)PA12/15/201415,322  15,928  517 16,445 3,535 
Medical Sciences Pavilion - Harrisburg, PA(10)PA12/15/201418,272  22,309   22,309 4,569 
Wood Glen Nursing and Rehab Center - West Chicago, IL(5),(11)IL12/16/2014 1,896 16,107 (367)(6,436)11,200 228 
Pinnacle Center - Southaven, MSMS12/16/20147,085 1,378 6,547  1,560 9,485 1,952 
Paradise Valley Medical Plaza - Phoenix, AZAZ12/29/201413,085  25,194  1,703 26,897 6,019 
Victory Medical Center at Craig Ranch - McKinney, TXTX12/30/2014 1,596 40,475  1,199 43,270 8,801 
Rivershores Healthcare & Rehab Centre - Marseilles, IL(5),(11)IL12/31/2014 1,276 6,868 (247)(2,837)5,060 105 
Morton Terrace Healthcare & Rehab Centre - Morton, IL(5),(11)IL12/31/2014 709 5,649 (137)(2,520)3,701 77 
Morton Villa Healthcare & Rehab Centre - Morton, IL(5),(11)IL12/31/2014 645 3,687 (125)(1,546)2,661 57 
The Heights Healthcare & Rehab Centre - Peoria Heights, IL(5),(11)IL12/31/2014 214 7,952 (41)(3,369)4,756 127 
Colonial Healthcare & Rehab Centre - Princeton, IL(5),(11)IL12/31/2014 173 5,871 (33)(2,622)3,389 92 
Capitol Healthcare & Rehab Centre - Springfield, IL(5),(11)IL12/31/2014 603 21,699 (117)(8,560)13,625 311 
Acuity Specialty Hospital - Mesa, AZ(5)AZ1/14/2015 1,977 16,203  543 18,723 3,660 
Acuity Specialty Hospital - Sun City, AZ(11)AZ1/14/2015 2,329 15,795 (909)(7,715)9,500 658 
Addington Place of Shoal Creek - Kansas City, MO(7)MO2/2/2015 3,723 22,259  704 26,686 5,404 
Aurora Healthcare Center - Green Bay, WI(5)WI3/18/2015 1,130 1,678   2,808 420 
Aurora Healthcare Center - Greenville, WI(5)WI3/18/2015 259 958   1,217 256 
Aurora Healthcare Center - Kiel, WI(5)WI3/18/2015 676 2,214   2,890 494 
Aurora Healthcare Center - Plymouth, WIWI3/18/201517,038 2,891 24,224   27,115 5,430 
Aurora Healthcare Center - Waterford, WI(5)WI3/18/2015 590 6,452   7,042 1,395 
Aurora Healthcare Center - Wautoma, WI(5)WI3/18/2015 1,955 4,361   6,316 983 
Arbor View Assisted Living and Memory Care - Burlington, WI(5)WI3/31/2015 367 7,815  71 8,253 2,080 
Advanced Orthopedic Medical Center - Richmond, VAVA4/7/201515,390 1,523 19,229  493 21,245 3,970 
Palm Valley Medical Plaza - Goodyear, AZ(5)AZ4/7/2015 1,890 4,940  367 7,197 1,267 
Physicians Plaza of Roane County - Harriman, TNTN4/27/20156,293 1,746 7,842  182 9,770 1,737 
Adventist Health Lacey Medical Plaza - Hanford, CACA4/29/201511,526 328 13,302  98 13,728 2,620 
Medical Center I - Peoria, AZAZ5/15/20153,085 807 1,115  1,545 3,467 1,190 
Medical Center II - Peoria, AZAZ5/15/2015 945 1,330  5,036 7,311 1,836 
Commercial Center - Peoria, AZAZ5/15/20153,254 959 1,110  710 2,779 571 
F-55

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2022
(In thousands)
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Medical Center III - Peoria, AZAZ5/15/20152,137 673 1,651  1,047 3,371 932 
Morrow Medical Center - Morrow, GAGA6/24/20154,334 1,155 5,674  493 7,322 1,451 
Belmar Medical Building -Lakewood, COCO6/29/20153,770 819 4,287  596 5,702 1,114 
Addington Place - Northville, MI(7)MI6/30/2015 440 14,975  1,007 16,422 3,403 
Conroe Medical Arts and Surgery Center - Conroe, TXTX7/10/201513,221 1,965 12,198  744 14,907 2,842 
Medical Center V - Peoria, AZ(5)AZ7/10/2015 1,089 3,200  879 5,168 804 
Legacy Medical Village - Plano, TXTX7/10/201523,662 3,755 31,097  1,430 36,282 6,634 
Scripps Cedar Medical Center - Vista, CACA8/6/201514,983 1,213 14,596  1,673 17,482 2,981 
Ramsey Woods Memory Care - Cudahy, WI(5)WI10/2/2015 930 4,990  122 6,042 1,188 
East Coast Square West - Cedar Point, NCNC10/15/20155,254 1,535 4,803  6 6,344 962 
East Coast Square North - Morehead City, NCNC10/15/20153,933 899 4,761  144 5,804 917 
Eastside Cancer Institute - Greenville, SC(5)SC10/22/2015 1,498 6,637  639 8,774 1,379 
Sassafras Medical Building - Erie, PA(11)PA10/22/20152,315 928 4,629 (364)(2,333)2,860  
Sky Lakes Klamath Medical Clinic - Klamath Falls, OR(5)OR10/22/2015 433 2,623   3,056 508 
Courtyard Fountains - Gresham, OR(5)OR12/1/2015 2,476 50,601  2,255 55,332 10,764 
Presence Healing Arts Pavilion - New Lenox, IL(9)IL12/4/20155,966  6,768  76 6,844 1,383 
Mainland Medical Arts Pavilion - Texas City, TXTX12/4/20156,174 320 7,923  321 8,564 1,756 
Renaissance on Peachtree - Atlanta, GA(6)GA12/15/2015 4,535 68,895  3,246 76,676 13,856 
Fox Ridge Senior Living at Bryant - Bryant, AR(11)AR12/29/20156,817 1,687 12,936 (557)(6,326)7,740 40 
Fox Ridge Senior Living at Chenal - Little Rock, ARAR12/29/201515,639 6,896 20,579  364 27,839 4,917 
Fox Ridge North Little Rock - North Little Rock, AR(9)AR12/29/20159,704  19,265  263 19,528 4,211 
High Desert Medical Group Medical Office Building - Lancaster, CACA4/7/20177,480 1,459 9,300   10,759 1,749 
Northside Hospital - Canton, GAGA7/13/20178,014 3,408 8,191  438 12,037 1,249 
West Michigan Surgery Center - Big Rapids, MI(5)MI8/18/2017 258 5,677   5,935 803 
Camellia Walk Assisted Living and Memory Care - Evans, GA(6)GA9/28/2017 1,854 17,372  1,232 20,458 3,426 
Cedarhurst of Collinsville - Collinsville, IL(5), (8)IL12/22/2017 1,228 8,652  264 10,144 1,393 
Arcadian Cove Assisted Living - Richmond, KY(5), (8),(11)KY12/22/2017 481 3,923 (425)(3,536)443 14 
Beaumont Medical Center - Warren, MI(5), (8)MI12/22/2017 1,078 9,525  19 10,622 1,328 
DaVita Dialysis - Hudson, FL(5), (8)FL12/22/2017 226 1,979  121 2,326 273 
DaVita Bay Breeze Dialysis Center - Largo, FL(5), (8)FL12/22/2017 399 896  48 1,343 150 
Greenfield Medical Plaza - Gilbert, AZ(5), (8)AZ12/22/2017 1,476 4,144  277 5,897 633 
RAI Care Center - Clearwater, FL(5), (8)FL12/22/2017 624 3,156   3,780 420 
F-56

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2022
(In thousands)
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Illinois CancerCare - Galesburg, IL(8)IL12/22/20172,323 290 2,457   2,747 368 
UnityPoint Clinic - Muscatine, IA(5), (8)IA12/22/2017 570 4,541  34 5,145 649 
Lee Memorial Health System Outpatient Center - Ft. Myers(5), (8)FL12/22/2017 439 4,374  710 5,523 688 
Decatur Medical Office Building - Decatur, GA(5), (8), (9)GA12/22/2017 695 3,273  261 4,229 507 
Madison Medical Plaza - Joliet, IL(8), (9)IL12/22/201712,477  16,855  37 16,892 2,111 
Woodlake Office Center - Woodbury, MN(8)MN12/22/20178,638 1,017 10,688  1,297 13,002 1,652 
Rockwall Medical Plaza - Rockwall, TX(5), (8)MN12/22/2017 1,097 4,582  214 5,893 709 
MetroHealth Buckeye Health Center - Cleveland, OH(5), (8)OH12/22/2017 389 4,367  255 5,011 648 
UnityPoint Clinic - Moline, IL(5), (8)IL12/22/2017 396 2,880  5 3,281 411 
VA Outpatient Clinic - Galesberg, IL(5), (8)IL12/22/2017 359 1,852   2,211 302 
Philip Professional Center - Lawrenceville, GAGA12/22/20175,780 1,285 6,714  264 8,263 1,045 
Texas Children’s Hospital - Houston, TX
TX3/5/20184,590 1,368 4,428  116 5,912 790 
Florida Medical Heartcare - Tampa, FL
(5)FL3/29/2018 586 1,902   2,488 322 
Florida Medical Somerset - Tampa, FL
(5)FL3/29/2018 61 1,366   1,427 204 
Florida Medical Tampa Palms - Tampa, FL
(5)FL3/29/2018 141 1,402   1,543 215 
Florida Medical Wesley Chapel - Tampa, FL
(5)FL3/29/2018 485 1,987   2,472 345 
Aurora Health Center - Milwaukee, WI
WI4/17/20183,984 1,014 4,041  224 5,279 788 
Vascular Surgery Associates - Tallahassee, FL
(5)FL5/11/2018 902 5,383   6,285 856 
Glendale MOB - Farmington Hills, MI
(5)MI8/28/2018 504 12,332   12,836 1,542 
Crittenton Washington MOB - Washington Township, MI
(5)MI9/12/2018 640 4,090  283 5,013 592 
Crittenton Sterling Heights MOB - Sterling Heights, MI
(5)MI9/12/2018 1,398 2,695  258 4,351 492 
Advocate Aurora MOB - Elkhorn, WI
WI9/24/20187,184 181 9,452   9,633 1,280 
Pulmonary & Critical Care Med - Lemoyne, PA
PA11/13/20184,271 621 3,805   4,426 661 
Dignity Emerus Blue Diamond - Las Vegas, NV
NV11/15/201813,966 2,182 16,594   18,776 1,864 
Dignity Emerus Craig Rd - North Las Vegas, NV
NV11/15/201818,780 3,807 22,803   26,610 2,584 
Greenfield MOB - Greenfield, WI
WI1/17/20197,526 1,552 8,333  246 10,131 1,199 
Milwaukee MOB - South Milwaukee, WI
WI1/17/20194,136 410 5,041   5,451 544 
St. Francis WI MOB - St. Francis, WI
WI1/17/20199,088 865 11,355  251 12,471 1,353 
Lancaster Medical Arts MOB - Lancaster, PA
(5)PA6/20/2019 85 4,417   4,502 569 
Women’s Healthcare Group MOB - York, PA
(5)PA6/21/2019 624 2,161   2,785 403 
Pioneer Spine Sports - Northampton, MA
(5)MA7/22/2019 435 1,858   2,293 192 
F-57

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2022
(In thousands)
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Pioneer Spine Sport - Springfield, MA
(5)MA7/22/2019 333 2,530   2,863 252 
Pioneer Spine Sports - West Springfield, MA
(5)MA7/22/2019 374 4,295   4,669 417 
Felicita Vida - Escondido, CA
(5)CA9/3/2019 1,677 28,953  396 31,026 2,785 
Cedarhurst of Edwardsville - Edwardsville, IL(5)IL1/10/2020 321 9,032  56 9,409 805 
UMPC Sir Thomas Court - Harrisburg, PA(5)PA1/17/2020 745 6,272   7,017 498 
UMPC Fisher Road - Mechanicsburg, PA(5)PA1/17/2020 747 3,844   4,591 333 
Swedish American MOB - Roscoe, IL(5)IL1/22/2020 599 5,862   6,461 588 
Cedarhurst of Sparta - Sparta, IL(5)IL1/31/2020 381 13,807  63 14,251 1,225 
UMPC Chambers Hill - Harrisburg, PA(5)PA2/3/2020 498 4,238   4,736 329 
Cedarhurst of Shiloh - Shiloh, ILIL3/13/202013,071 376 28,299  65 28,740 2,085 
Bayshore Naples Memory Care - Naples, FL(5)FL3/20/2020 3,231 17,112  54 20,397 1,306 
Circleville MOB - Circleville, OHOH12/7/20203,556 765 4,011  71 4,847 243 
Kingwood Executive Center - Kingwood, TX(5)TX1/6/2021 1,522 4,166  34 5,722 251 
OrthoOne Hilliard - Hilliard, OH(5)OH5/28/2021 760 3,118  77 3,955 206 
South Douglas MOB - Midwest City, OK(5)OK6/23/2021 628 3,863   4,491 193 
Fort Wayne Opthomology Engle - Fort Wayne, ININ6/29/20213,923 516 6,124   6,640 260 
Fort Wayne Opthomology Dupont - Fort Wayne, ININ6/29/20211,924 597 2,653   3,250 138 
St. Peters Albany 2 Palisades - Albany, NY(5)NY6/30/2021 516 4,342   4,858 202 
Hefner Pointe Medical Center - Oklahoma City, OKOK6/30/20213,831 678 4,819  31 5,528 222 
St. Peters Troy 2 New Hampshire - Troy, NY(5)NY6/30/2021 330 2,444  19 2,793 113 
St Peters - Albany, NY - 4 Palisades(5)NY7/30/2021 542 2,416   2,958 113 
St Peters - Albany, NY - 5 Palisades(5)NY7/30/2021 593 5,359   5,952 221 
St Lukes Heart Vascular Center - East Stroudsburg(5)PA8/31/2021 363 3,224   3,587 113 
Metropolitan Eye Lakeshore Surgery - St. Clair, MI(5)MI8/31/2021 203 4,632   4,835 164 
Naidu Clinic - Odessa, TX(5)TX9/1/2021 730 2,409   3,139 93 
Belpre V Cancer Center - Belpre, OH(5)OH9/30/2021 1,153 63,894   65,047 2,072 
Center for Advanced Dermatology - Lakewood, CO(5)CO12/1/2021 1,034 1,874   2,908 59 
Florida Medical Clinic - Tampa, FL(5)FL12/1/2021 1,104 1,137  124 2,365 44 
Pensacola Nephrology MOB - Pensacola, FL(5)FL12/29/2021 1,578 5,123   6,701 135 
Millennium Eye Care - Freehold, NJ(5)NJ5/26/2022 635 6,014   6,649 125 
Atlanta Gastroenterology Associates - Lawrenceville, GA(5)GA6/29/2022 2,639 2,263   4,902 24 
Bone and Joint Specialists - Merrillville, IN(5)IN6/29/2022 1,014 2,499   3,513 29 
F-58

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2022
(In thousands)
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Eastern Carolina ENT - Greenville, NC(5)NC12/21/2022 664 5,826   6,490  
Fannie Mae Master Credit Facilities (6)(7)
352,047 
Total
$937,230 $210,294 $2,075,880 $(3,840)$13,253 $2,295,587 $397,982 
______________
(1)Acquired intangible lease assets allocated to individual properties in the amount of $292.0 million are not reflected in the table above.
(2)The tax basis of aggregate land, buildings and improvements as of December 31, 2022 is $2.1 billion.
(3)The accumulated depreciation column excludes $211.3 million of accumulated amortization associated with acquired intangible lease assets.
(4)Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements and 5 years for fixtures.
(5)These unencumbered properties were part of the borrowing base of the Credit Facility, which had $180.0 million of outstanding borrowings as of December 31, 2022. The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the real estate assets comprising the borrowing base have been pledged for the benefit of the lenders thereunder (see Note 5 Credit Facilities, Net for additional details).
(6)These properties collateralize the Capital One Facility, which had $210.5 million of outstanding borrowings as of December 31, 2022.
(7)These properties collateralize the KeyBank Facility, which had $141.6 million of outstanding borrowings as of December 31, 2022.
(8)These properties were acquired from American Realty Capital Healthcare Trust III, Inc. in 2017, which was a related party to the Company’s Advisor.
(9)Some or all of the land underlying this property is subject to an operating land lease. The related right-of-use assets are separately recorded. See Note 16 — Commitments and Contingencies for additional information.
(10)The building amount represents combined direct financing lease for the total asset as the land element was not required to be bifurcated under ASU 840. See Note 16 — Commitments and Contingencies for additional information.
(11)The property has been impaired as of December 31, 2022. See Note 3 — Real Estate Investments, Net “Assets Held for Use and Related Impairments” for additional information.

F-59

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2022
(In thousands)
A summary of activity for real estate and accumulated depreciation for the years ended December 31, 2022, 2021 and 2020:
December 31,
(In thousands)202220212020
Real estate investments, at cost (1):
 
Balance at beginning of year$2,345,708 $2,211,451 $2,296,627 
Additions-acquisitions and capital expenditures44,926 98,364 80,980 
Disposals, impairments and reclasses (2)
(95,047)35,893 (166,156)
Balance at end of the year$2,295,587 $2,345,708 $2,211,451 
  
Accumulated depreciation (1):
 
Balance at beginning of year$328,095 $260,399 $226,167 
Depreciation expense63,143 63,393 64,731 
Disposals, impairments and reclasses (2)
6,744 4,303 (30,499)
Balance at end of the year$397,982 $328,095 $260,399 
__________
(1)Acquired intangible lease assets and related accumulated depreciation are not reflected in the table above.
(2)Includes amounts relating to dispositions and impairment charges on assets for the years ended December 31, 2022, 2021 and 2020. Amounts for the year ended December 31, 2020 include the reclassification of approximately $49.4 million and $8.7 million of assets and accumulated depreciation, respectively, that were previously classified as held-for-sale as of December 31, 2019 to real estate investments, at cost and accumulated depreciation during the year ended December 31, 2020. For additional information on this reclassification during the year ended December 31, 2020, see Note 3 — Real Estate Investments.
F-60
EX-4.9 2 ex49htidescriptionofsecuri.htm EX-4.9 DESCRIPTION OF SECURITES Document

EXHIBIT 4.9

DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO
SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
The following is a description of securities of Healthcare Trust, Inc. registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of December 31, 2022 and certain provisions of the Maryland General Corporation Law (the “MGCL”) and our charter and our bylaws. The description is a summary, does not purport to be complete and is subject to and qualified in its entirety by reference to Maryland law and to our charter (including any applicable articles supplementary classifying a class or series of preferred stock) and bylaws, copies of which are filed as exhibits to our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and are incorporated by reference herein.
As used herein, the terms “Company,” “we,” “our” and “us” refer to Healthcare Trust, Inc., a Maryland corporation. Capitalized terms used but not defined herein shall have the meaning ascribed to such terms under our charter (including any applicable articles supplementary classifying a class or series of preferred stock).
General
Our charter authorizes us to issue up to 350,000,000 shares of stock, consisting of 300,000,000 shares of common stock, par value $0.01 per share, and 50,000,000 shares of preferred stock, par value $0.01 per share. As of December 31, 2022, we had the following stock issued and outstanding: (i) 105,080,531 shares of common stock; (ii) 3,977,144 shares of our 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, par value $0.01 per share (the “Series A Preferred Stock”), and (iii) 3,630,000 shares of our 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (the “Series B Preferred Stock”).
Our board of directors, with the approval of a majority of the entire board of directors and without any action taken by our stockholders, may amend our charter from time to time to increase or decrease the aggregate number of authorized shares of our stock or the number of shares of stock of any class or series that we have authority to issue. Under Maryland law, stockholders are not generally liable for our debts or obligations solely as a result of their status as stockholders.
The transfer agent and registrar for our common stock, Series A Preferred Stock and Series B Preferred Stock is Computershare Trust Company, N.A., which also serves as the rights agent for the rights to purchase from the Company one share of common stock that are attached to all shares of our common stock (the “Rights”).
Our Series A Preferred Stock is listed on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “HTIA,” and our Series B Preferred Stock is listed on Nasdaq under the symbol “HTIBP.” Our common stock and the Rights are registered under Section 12(g) of the Exchange Act but are not listed for trading on any national securities exchange.
Common Stock
Subject to the preferential rights, if any, of holders of any other class or series of our stock and to the provisions of our charter relating to the restrictions on ownership and transfer of our stock, the holders of our common stock:
•have the right to receive ratably any distributions from funds legally available therefor, when, as and if authorized by our board of directors and declared by us; and
•are entitled to share ratably in all of our assets available for distribution to holders of our common stock upon liquidation, dissolution or winding up of our affairs.
Upon issuance for full payment therefor, all common stock issued by us will be fully paid and non-assessable. There are no redemption, sinking fund, conversion or preemptive rights with respect to the shares of our common stock. Holders of our common stock generally will have no appraisal rights.

Subject to the provisions of our charter relating to the restrictions on ownership and transfer of our stock and except as may otherwise be provided in the charter, holders of our common stock are entitled to one vote per





image_5.jpg

share on all matters on which holders of our common stock are entitled to vote at all meetings of our stockholders. The holders of our common stock do not have cumulative voting rights.
Preferred Stock
General
Under our charter, our board of directors, without stockholder approval, is authorized to cause us to issue shares of preferred stock in one or more classes or series, to establish the number of shares in each class or series and to fix the terms preferences, conversions or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications and terms and conditions of redemption for each class or series. Our board of directors could authorize the issuance of additional shares of preferred stock with terms and conditions that could have the effect of discouraging a takeover or other transaction that holders of common stock might believe to be in their best interests or in which holders of some, or a majority, of the shares of common stock might receive a premium for their shares over the then market price of such shares of common stock.
Some of the rights, preferences, privileges and restrictions of the shares of preferred stock of a class or series may include the following:
•distribution rights;
•conversion rights;
•voting rights;
•redemption rights and terms of redemptions; and
•liquidation preferences.
Series A Preferred Stock
As of December 31, 2022, 4,740,000 shares of preferred stock were classified and designated as Series A Preferred Stock pursuant to our charter.
Ranking
The Series A Preferred Stock ranks, with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding-up:
•senior to our common stock and to all other equity securities, the terms of which expressly provide that such securities rank junior to the Series A Preferred Stock;
•on parity with the Series B Preferred Stock and all other equity securities, the terms of which expressly provide that such securities rank on parity with the Series A Preferred Stock; and
•junior to any class or series of equity securities, the terms of which expressly provide that such securities rank senior to the Series A Preferred Stock.
The authorization or issuance of equity securities ranking senior to the Series A Preferred Stock requires the affirmative vote of the holders of at least two-thirds of the outstanding shares of Series A Preferred Stock and of any other similarly-affected classes and series of preferred stock ranking on parity with the Series A Preferred Stock, including the Series B Preferred Stock, and upon which like voting rights have been conferred and are exercisable. Any convertible debt securities that we may issue will not be considered to be “equity securities” for these purposes prior to the time of conversion. The Series A Preferred Stock ranks junior to all our existing and future indebtedness. The terms of the Series A Preferred Stock do not limit our ability to (i) incur indebtedness or (ii) issue additional equity securities that rank junior to or on parity with the Series A Preferred Stock, including the Series B Preferred



Stock, with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up.
2

image_5.jpg

Dividends
Holders of Series A Preferred Stock are entitled to receive, when, as and if authorized by our board of directors and declared by us, out of funds legally available for the payment of dividends, cumulative cash dividends in the amount of  $1.84375 per share each year, which is equivalent to the rate of 7.375% of the $25.00 liquidation preference per share per annum. Dividends are payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the next succeeding business day. A dividend period is the respective quarterly period commencing on and including the 1st day of January, April, July and October of each year and ending on and including the day preceding the first day of the next succeeding dividend period to all holders of record on the applicable record date, when and as authorized by our board of directors and declared by us. Holders of record of all shares of Series A Preferred Stock issued and outstanding at the close of business on the record date fixed by our board of directors for any dividend will be entitled to receive the full dividend paid on the applicable dividend payment date even if such shares were not issued and outstanding for the full dividend period.
Any dividend, including any dividend payable on the Series A Preferred Stock for any partial dividend period, is computed on the basis of a 360-day year consisting of twelve 30-day months. Dividends are payable to holders of record of Series A Preferred Stock as they appear in the transfer agent’s records at the close of business on the applicable record date, which will be the date that our board of directors sets as the record date for the payment of a dividend that is not more than 30 nor fewer than 10 days prior to the applicable dividend payment date.
Our board of directors will not authorize, and we will not pay or declare and set apart for payment, any dividend on the Series A Preferred Stock at any time that:
•the terms and conditions of any of our agreements, including our credit facility or any other agreement relating to our indebtedness, prohibit the authorization, payment or setting apart for payment;
•the terms and conditions of any of our agreements, including our credit facility or any other agreement relating to our indebtedness, provide that the authorization, payment or setting apart for payment would constitute a breach of, or a default under, the agreement; or
•the law restricts or prohibits the authorization, payment or setting apart for payment.
Notwithstanding the foregoing, dividends on the Series A Preferred Stock accrue whether or not the dividends are authorized by our board of directors and declared by us.
Accrued and unpaid dividends on the Series A Preferred Stock do not bear interest.
We will not pay or declare and set apart for payment any dividends (other than a dividend paid in common stock or other stock ranking junior to the Series A Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up) or declare and make any other distribution of cash or other property, directly or indirectly, on or with respect to common stock or other equity securities that rank junior to or on parity with the Series A Preferred Stock, including the Series B Preferred Stock, or redeem or otherwise acquire common stock or other stock that ranks junior to or on parity with the Series A Preferred Stock, including the Series B Preferred Stock (except (i) by conversion into or exchange for common stock or other shares of equity securities ranking junior to the Series A Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up, (ii) for the acquisition of shares of our stock pursuant to the provisions of our charter relating to the restrictions upon ownership and transfer of our stock and (iii) for a purchase or acquisition of equity securities pursuant to a purchase or exchange offer made on the same terms to holders of all outstanding shares of Series A Preferred Stock and any other stock that ranks on parity with the Series A Preferred Stock, including the Series B Preferred Stock, with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up), unless we also have either paid or contemporaneously declared and set apart for payment full cumulative dividends on the Series A Preferred Stock for all past dividend periods.



Notwithstanding the foregoing, if we do not either pay or declare and set apart for payment full cumulative dividends on the Series A Preferred Stock and all stock that ranks on parity with the Series A Preferred Stock, including the Series B Preferred Stock, with respect to dividends, the amount which we have declared will be allocated pro rata to the holders of Series A Preferred Stock and to each equally ranked class or series of stock, including the Series B Preferred Stock, so that the amount declared for each share of Series A Preferred Stock and for each share of each equally ranked class or series of stock, including the Series B Preferred Stock, is proportionate to the accrued and unpaid dividends on those shares. Any dividend payment made on the Series A Preferred Stock will first be credited against the earliest accrued and unpaid dividend.
3

image_5.jpg

If, for any taxable year, we elect to designate as “capital gain dividends” (as defined in Section 857 of the Internal Revenue Code of 1986, as amended (the “Code”)) a portion (the “Capital Gains Amount”) of the dividends not in excess of our earnings and profits that are paid or made available for the year to the holders of all classes or series of stock (the “Total Dividends”), then the portion of the Capital Gains Amount that will be allocable to the holders of Series A Preferred Stock will be in the same proportion that the Total Dividends paid or made available to the holders of Series A Preferred Stock for the taxable year bears to the Total Dividends for the taxable year made with respect to all classes or series of stock outstanding.
Holders of shares of Series A Preferred Stock are not entitled to any dividend, whether payable in cash, property or shares of capital stock, in excess of full cumulative dividends on the Series A Preferred Stock as described above.
Liquidation Preference
Upon any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of Series A Preferred Stock are entitled to be paid out of our assets legally available for distribution to our stockholders a liquidation preference of  $25.00 per share, plus an amount equal to any accrued and unpaid dividends (whether or not authorized or declared) to, but not including, the date of payment, after payment of or provision for our debts and liabilities and any other class or series of our capital stock ranking senior to the Series A Preferred Stock with respect to liquidation rights before any distribution or payment may be made to holders of common stock or any other class or series of our equity stock ranking junior to the Series A Preferred Stock with respect to liquidation rights. If, upon our voluntary or involuntary liquidation, dissolution or winding up, our available assets are insufficient to pay the full amount of the liquidating distributions on all outstanding shares of Series A Preferred Stock and the corresponding amounts payable on all shares of each other class or series of stock ranking on parity with the Series A Preferred Stock, including the Series B Preferred Stock, with respect to liquidation rights, then the holders of Series A Preferred Stock and any other class or series of stock ranking on parity with the Series A Preferred Stock, including the Series B Preferred Stock, with respect to liquidation rights will share ratably in any distribution of assets in proportion to the full liquidating distributions to which they would otherwise be respectively entitled. Holders of Series A Preferred Stock are entitled to written notice of any voluntary or involuntary liquidation, dissolution or winding up at least 20 days before the payment date of the liquidating distribution. After the holders of Series A Preferred Stock have received the full amount of the liquidating distributions to which they are entitled, they will have no right or claim to any of our remaining assets.
In determining whether any distribution (other than upon voluntary or involuntary dissolution) by dividend, redemption or other acquisition of shares of stock of the Company or otherwise is permitted under the MGCL, amounts that would be needed, if the Company were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of the holders of Series A Preferred Stock will not be added to the Company’s total liabilities.
Our consolidation, conversion or merger with or into any other person or entity or the sale, lease, transfer or conveyance of all or substantially all of our property or business, whether in connection with a Change of Control (as defined below) or otherwise, will not be deemed to constitute our liquidation, dissolution or winding up.
Optional Redemption
The Series A Preferred Stock is not redeemable prior to December 11, 2024, except in the circumstances described in this section, in the section below titled “- Special Optional Redemption,” or pursuant to certain provisions of our charter. See “Certain Provisions of the Maryland General Corporation Law and our Charter and Bylaws - Restrictions on Transfer and Ownership of Stock” below.



Notwithstanding any other provision relating to redemption or repurchase of the Series A Preferred Stock, we may redeem any or all of the Series A Preferred Stock at any time, whether before or after December 11, 2024 at a redemption price of  $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), pursuant to the restrictions on ownership and transfer of our stock set forth in our charter or if our board of directors otherwise determines that redemption is necessary for us to preserve our status as a real estate investment trust for federal income tax purposes (“REIT”).
On and after December 11, 2024, the Series A Preferred Stock may be redeemed at our option, in whole or in part, at any time or from time to time, at a redemption price of  $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date (unless the redemption date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend will be included in the redemption price), without interest, upon the giving of notice, as provided below.
4

image_5.jpg

If less than all of the outstanding shares of Series A Preferred Stock are to be redeemed, the shares to be redeemed will be determined pro rata (as nearly as may be practicable without creating fractional shares) or by lot. If the redemption is to be by lot, and if as a result of the redemption any holder of Series A Preferred Stock would own, or be deemed by virtue of certain attribution provisions of the Code to own, more than 9.8% in value of the aggregate of the outstanding shares of our stock (which includes the Series A Preferred Stock) or 9.8% in value or in number of shares (whichever is more restrictive) of the outstanding shares of any class or series of our stock or violate any of the other restrictions on ownership and transfer of our stock set forth in our charter, then, except in certain instances, we will redeem the requisite number of shares of Series A Preferred Stock of that holder so that the holder will not own or be deemed by virtue of certain attribution provisions of the Code to own, subsequent to the redemption, more than 9.8% in value of the aggregate of the outstanding shares of our stock or 9.8% in value or in number of shares (whichever is more restrictive) of the outstanding shares of any class or series of our stock or violate any of the other restrictions on ownership and transfer set forth in our charter.
We will mail to record holders of the Series A Preferred Stock, a notice of redemption no less than 30 days nor more than 60 days prior to the redemption date. We will send the notice to the record holder’s address, as shown on our share transfer books. A failure to give notice of redemption or any defect in the notice or in its mailing will not affect the validity of the redemption of any Series A Preferred Stock except as to shares held by any holder to whom notice was defective or not given. Each notice will state the following:
•the redemption date;
•the redemption price;
•the total number of shares of Series A Preferred Stock to be redeemed (and, if less than all the shares held by any holder are to be redeemed, the number of shares to be redeemed from the holder);
•the place or places where the shares of Series A Preferred Stock are to be surrendered for payment, together with the certificates, if any, representing the shares (duly endorsed for transfer) and any other documents we require in connection with redemption; and
•that dividends on the Series A Preferred Stock will cease to accrue on the redemption date.
We are not required to provide such notice in the event we redeem Series A Preferred Stock in order to maintain our status as a REIT.
Unless full cumulative dividends on all shares of Series A Preferred Stock have been or contemporaneously are declared and paid or declared and a sum sufficient for the payment thereof set apart for payment for all past dividend periods, no shares of Series A Preferred Stock may be redeemed unless all outstanding shares of Series A Preferred Stock are simultaneously redeemed. In addition, unless full cumulative dividends on all shares of Series A Preferred Stock have been or contemporaneously are declared and paid or declared and a sum sufficient for the payment thereof set apart for payment for all past dividend periods, we will not purchase or otherwise acquire directly or indirectly any Series A Preferred Stock (except (i) by exchange for our equity securities ranking junior to the Series A Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up, (ii) pursuant to the provisions of our charter relating to restrictions on ownership and



transfer of our stock and (iii) the purchase or acquisition of the Series A Preferred Stock pursuant to a purchase or exchange offer made on the same terms to the holders of all outstanding shares of Series A Preferred Stock and any other stock that ranks on parity with the Series A Preferred Stock, including the Series B Preferred Stock, with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up). So long as no dividends on Series A Preferred Stock for any past dividend period are in arrears, we are entitled at any time and from time to time to repurchase Series A Preferred Stock in open-market transactions duly authorized by our board of directors and effected in compliance with applicable laws and these requirements will not prevent our purchase or acquisition of Series A Preferred Stock pursuant to a purchase or exchange offer made on the same terms to holders of all outstanding shares of Series A Preferred Stock and any other stock that ranks on parity with the Series A Preferred Stock, including the Series B Preferred Stock, with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up or our redemption of Series A Preferred Stock pursuant to the provisions of our charter relating to the restrictions on ownership and transfer of our stock.
Special Optional Redemption
During any period of time (whether before or after December 11, 2024) that the Series A Preferred Stock is not listed on the Nasdaq Stock Market, the NYSE or the NYSE American LLC, or listed or quoted on an exchange or quotation system that is a successor to the Nasdaq Stock Market, the NYSE or the NYSE American LLC (a
5

image_5.jpg

“Delisting Event”), we have the option to redeem the outstanding shares of Series A Preferred Stock, in whole or in part, after the occurrence of the Delisting Event, for a redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date (unless the redemption date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend payable on the payment date will be included in the redemption price), upon the giving of notice, as provided below.
In addition to the foregoing, upon the occurrence of a Delisting Event, the dividend rate specified shall be increased on the day after the occurrence of the Delisting Event by 2.00% per annum to the rate of 9.375% of the $25.00 per share stated liquidation preference per annum (equivalent to $2.34375 per annum per share) from and after the date of the Delisting Event. Following the cure of a Delisting Event, the dividend rate shall revert to the rate of 7.375% of the $25.00 per share stated liquidation preference per annum.
In addition, upon the occurrence of a Change of Control, we may, at our option, redeem the Series A Preferred Stock, in whole or in part, within 120 days after the first date on which the Change of Control occurred, by paying $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date (unless the redemption date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend payable on the payment date will be included in the redemption price). If, prior to the Conversion Date (as defined below), we provide notice of redemption with respect to the Series A Preferred Stock (whether pursuant to our optional redemption right or our special optional redemption rights), holders of Series A Preferred Stock will not have the conversion right described below under “- Change of Control Conversion Right.”
We will mail to record holders of the Series A Preferred Stock, a notice of redemption no less than 30 days nor more than 60 days prior to the redemption date. We will send the notice to the record holder’s address, as shown on our share transfer books. A failure to give notice of redemption or any defect in the notice or in its mailing with not affect the validity of the redemption of any Series A Preferred Stock except as to the holder to whom notice was defective or not given. Each notice will state the following:
•the redemption date;
•the redemption price;
•the total number of shares of Series A Preferred Stock to be redeemed;
•the place or places where the shares of Series A Preferred Stock are to be surrendered for payment, together with the certificates, if any, representing the shares (duly endorsed for transfer) and any other documents we require in connection with the redemption;



•that the Series A Preferred Stock is being redeemed pursuant to our special optional redemption right in connection with the occurrence of a Change of Control or a Delisting Event, as applicable, and a brief description of the transaction or transactions constituting the Change of Control or Delisting Event, as applicable;
•that holders of Series A Preferred Stock to which the notice relates will not be able to tender the Series A Preferred Stock for conversion in connection with a Change of Control during a continuous Delisting Event, and each share of Series A Preferred Stock tendered for conversion that is selected, prior to the Conversion Date, for redemption will be redeemed on the related redemption date instead of converted on the Conversion Date; and
•that dividends on the Series A Preferred Stock to be redeemed will cease to accrue on the redemption date.
A “Change of Control” occurs when, after the original issuance of the Series A Preferred Stock, the following has occurred and is continuing:
•the acquisition by any person, including any syndicate or group deemed to be a “person” under Section 13(d)(3) of the Exchange Act, of beneficial ownership, directly or indirectly, through a purchase, merger, conversion or other acquisition transaction or series of purchases, mergers, conversions or other acquisition transactions, of shares of our stock entitling that person to exercise more than 50% of the total voting power of all outstanding shares of our stock entitled to vote generally in the election of directors (except that the person will be deemed to have beneficial ownership of all securities that the
6

image_5.jpg

person has the right to acquire, whether the right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition); and
•following the closing of any transaction referred to in the bullet point above, neither we nor the acquiring or surviving entity, including any parent of the Company or the acquiring or surviving entity, has a class of common equity securities listed on the Nasdaq Stock Market, the NYSE or the NYSE American LLC, or listed or quoted on an exchange or quotation system that is a successor to the Nasdaq Stock Market, the NYSE or the NYSE American LLC.
Additional Provisions Relating to Optional Redemption and Special Optional Redemption
If  (i) we have given a notice of redemption, (ii) we have set apart sufficient funds for the redemption of the shares of Series A Preferred Stock called for redemption and (iii) irrevocable instructions have been given to pay the redemption price and an amount equal to all accrued and unpaid dividends to, but not including, the redemption date, then from and after the redemption date, those shares of Series A Preferred Stock so called for redemption will no longer be outstanding, no further dividends will accrue and all other rights of the holders of those shares of Series A Preferred Stock will terminate, except the right to receive the redemption price, without interest. The holders of those shares of Series A Preferred Stock will retain their right to receive the redemption price for their shares and any accrued and unpaid dividends payable upon redemption, without interest.
The holders of Series A Preferred Stock at the close of business on a dividend record date will be entitled to receive the dividend payable with respect to the Series A Preferred Stock on the corresponding dividend payment date notwithstanding the redemption of the Series A Preferred Stock between such record date and the corresponding dividend payment date. There is no restriction on the redemption of shares of Series A Preferred Stock by us while there is any arrearage in the payment of dividends.
All shares of Series A Preferred Stock that we redeem or reacquire in any manner will return to the status of authorized but unissued shares of preferred stock, without further designation as to series or class and may thereafter be classified, reclassified or issued as any series or class of preferred stock.
Change of Control Conversion Right
Upon the occurrence of a Change of Control during a continuing Delisting Event, each holder of Series A Preferred Stock has the right, unless, prior to the Conversion Date, we have provided or provide notice of our election to redeem the shares of Series A Preferred Stock as described under “- Optional Redemption” or “- Special



Optional Redemption,” to convert some of or all the shares of Series A Preferred Stock held by the holder (the “Change of Control Conversion Right”) on the Conversion Date into a number of shares of common stock per share of Series A Preferred Stock (the “Common Stock Conversion Consideration”), which is equal to the lesser of:
•the quotient obtained by dividing (i) the sum of the $25.00 liquidation preference per share of Series A Preferred Stock to be converted plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared) on the Series A Preferred Stock to, but not including, the Conversion Date (as defined below) (unless the Conversion Date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend payable on the payment date will be included in this sum), by (ii) the Common Stock Price (as defined below); and
•2.8571 (the “Share Cap”).
The Share Cap is subject to pro rata adjustments for any stock splits (including those effected pursuant to a common stock dividend), subdivisions or combinations (in each case, a “Stock Split”) with respect to shares of our common stock as follows: the adjusted Share Cap as the result of a Stock Split will be the number of shares of our common stock that is equivalent to the product of  (i) the Share Cap in effect immediately prior to the Stock Split, multiplied by (ii) a fraction, the numerator of which is the number of shares of our common stock outstanding after giving effect to the Stock Split and the denominator of which is the number of shares of our common stock outstanding immediately prior to the Stock Split.
If a Change of Control occurs during a continuing Delisting Event, pursuant to or in connection with which shares of our common stock will be converted into cash, securities or other property or assets (including any combination thereof) (the “Alternative Form Consideration”), a holder of shares of Series A Preferred Stock will receive upon conversion of the shares of Series A Preferred Stock the kind and amount of Alternative Form Consideration which the holder would have owned or been entitled to receive had the holder held a number of shares of our common stock equal to the Common Stock Conversion Consideration immediately prior to the effective time
7

image_5.jpg

of the Change of Control (the “Alternative Conversion Consideration,” and the Common Stock Conversion Consideration or the Alternative Conversion Consideration, as may be applicable to a Change of Control during a continuing Delisting Event, is referred to as the “Conversion Consideration”).
If the holders of shares of our common stock have the opportunity to elect the form of consideration to be received in connection with the Change of Control during a continuing Delisting Event, the Conversion Consideration that holders of Series A Preferred Stock will receive will be the form of consideration elected by the holders of a plurality of the shares of common stock held by stockholders who participate in the election and will be subject to any limitations to which all holders of shares of common stock are subject, including, without limitation, pro rata reductions applicable to any portion of the consideration payable in connection with the Change of Control during a continuing Delisting Event.
We will not issue fractional shares of common stock upon the conversion of the Series A Preferred Stock. Instead, we will pay the cash value of any fractional shares based on the Common Stock Price.
Within 15 days following the occurrence of a Change of Control during a continuing Delisting Event, unless we have provided notice of our election to redeem the shares of Series A Preferred Stock as described under “- Optional Redemption” or “- Special Optional Redemption,” we will provide to holders of record of outstanding shares of Series A Preferred Stock a notice of occurrence of both the Change of Control and Delisting Event that describes the resulting Change of Control Conversion Right. A failure to give notice of conversion or any defect in the notice or in its mailing will not affect the validity of the proceedings for the conversion of any Series A Preferred Stock except as to the holder to whom this notice was defective or not given. This notice will state the following:
•the events constituting the Change of Control during a continuing Delisting Event;
•the date of the Change of Control during a continuing Delisting Event;
•the last date on which the holders of shares of Series A Preferred Stock may exercise their Change of Control Conversion Right;



•the method and period for calculating the Common Stock Price;
•the “Conversion Date,” which will be a business day fixed by our board of directors that is not fewer than 20 and not more than 35 days following the date of the notice;
•that if, prior to the Conversion Date we provide notice of our election to redeem all or any portion of the shares of Series A Preferred Stock, holders of Series A Preferred Stock will not be able to convert the shares of Series A Preferred Stock so called for redemption and the shares of Series A Preferred Stock will be redeemed on the related redemption date, even if they have already been tendered for conversion pursuant to the Change of Control Conversion Right;
•if applicable, the type and amount of Alternative Conversion Consideration entitled to be received per share of Series A Preferred Stock;
•the name and address of the paying agent and the conversion agent; and
•the procedures that the holders of shares of Series A Preferred Stock must follow to exercise the Change of Control Conversion Right.
We will issue a press release for publication on the Dow Jones & Company, Inc., Business Wire, PR Newswire or Bloomberg Business News (or, if these organizations are not in existence at the time of issuance of the press release, another news or press organization as is reasonably calculated to broadly disseminate the relevant information to the public) containing the information stated in the notice, and post the notice on our website, in any event prior to the opening of business on the first business day following any date on which we provide the notice described above to the holders of record of Series A Preferred Stock.
To exercise the Change of Control Conversion Right, a holder of record of Series A Preferred Stock will be required to deliver, on or before the close of business on the Conversion Date, the certificates, if any, representing any certificated shares of Series A Preferred Stock to be converted, duly endorsed for transfer, together with a completed written conversion notice and any other documents we reasonably require in connection with the conversion, to our conversion agent. The conversion notice must state:
8

image_5.jpg

•the Conversion Date; and
•the number of shares of Series A Preferred Stock to be converted.
The “Common Stock Price” for any Change of Control will be (i) if the consideration to be received in the Change of Control during a continuing Delisting Event by holders of shares of our common stock is solely cash, the amount of cash consideration per share of common stock, and (ii) if the consideration to be received in the Change of Control during a continuing Delisting Event by holders of shares of our common stock is other than solely cash, (x) the Non-traded Common Stock Price, if the common stock is not listed on a national exchange on the effective date of any Change in Control or (y) the Traded Common Stock Price, if the common stock is listed on a national securities exchange on the effective date of any Change in Control.
The “Non-traded Common Stock Price” is the currently applicable repurchase price for shares of common stock pursuant to our share repurchase program (our “SRP”) immediately prior to the effective date of the Change of Control. The “Traded Common Stock Price” is the average of the closing price per share of our common stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the Change of Control.
Holders of Series A Preferred Stock may withdraw any notice of exercise of a Change of Control Conversion Right (in whole or in part) by a written notice of withdrawal delivered to our conversion agent prior to the close of business on the business day prior to the Conversion Date. The notice of withdrawal must state:
•the number of withdrawn shares of Series A Preferred Stock;
•if certificated shares of Series A Preferred Stock have been tendered for conversion and withdrawn, the certificate numbers of the withdrawn certificated shares of Series A Preferred Stock; and



•the number of shares of Series A Preferred Stock, if any, which remain subject to the conversion notice.
Notwithstanding the foregoing, if the Series A Preferred Stock is held in global form, the conversion notice and/or the notice of withdrawal, as applicable, must comply with applicable procedures of the Depository Trust Company (the “DTC”).
Shares of Series A Preferred Stock as to which the Change of Control Conversion Right have been properly exercised and for which the conversion notice has not been properly withdrawn will be converted into the applicable Conversion Consideration on the applicable Conversion Date, unless prior thereto we provide notice of our election to redeem those shares of Series A Preferred Stock, whether pursuant to our optional redemption right or our special optional redemption right. If we elect to redeem shares of Series A Preferred Stock that would otherwise be converted into the applicable Conversion Consideration on a Conversion Date, the shares of Series A Preferred Stock will not be so converted and the holders of the shares will be entitled to receive on the applicable redemption date the redemption price for the shares.
We will deliver the Conversion Consideration no later than the third business day following the Conversion Date.
In connection with the exercise of any Change of Control Conversion Right, we will comply with all U.S. federal and state securities laws and stock exchange rules in connection with any conversion of shares of Series A Preferred Stock into shares of common stock. Notwithstanding any other provision of the Series A Preferred Stock, no holder of Series A Preferred Stock will be entitled to convert shares of Series A Preferred Stock for shares of our common stock to the extent that receipt of the shares of common stock would cause the holder (or any other person) to violate the restrictions on ownership and transfer of our stock contained in our charter. See “Certain Provisions of the Maryland General Corporation Law and our Charter and Bylaws-Restrictions on Transfer and Ownership of Stock” below.
These Change of Control conversion and redemption features may make it more difficult for or discourage a party from pursuing a takeover or other transaction that holders of common stock might believe to be in their best interests or in which holders of some, or a majority, of the shares of common stock might receive a premium for their shares over the then market price of such shares of common stock.
Except as provided above in connection with the occurrence of a Change of Control during a Delisting Event and in our charter, the Series A Preferred Stock is not convertible into or exchangeable for any other property or securities.
9

image_5.jpg

Voting Rights
Except as described below, holders of Series A Preferred Stock generally have no voting rights. On any matter in which the Series A Preferred Stock may vote (as expressly provided in our charter), each share of Series A Preferred Stock entitles the holder thereof to cast one vote, except that, when voting together as a single class with shares of any other class or series of voting preferred stock, shares of different classes or series will vote in proportion to the liquidation preference of the shares.
Whenever dividends on the Series A Preferred Stock are in arrears, whether or not authorized or declared, for six or more quarterly periods, whether or not these quarterly periods are consecutive, holders of Series A Preferred Stock and any other class or series of preferred stock ranking on parity with the Series A Preferred Stock, including the Series B Preferred Stock, with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up and upon which like voting rights have been conferred and are exercisable, which we refer to as “voting preferred stock,” and with which the holders of Series A Preferred Stock are entitled to vote together as a single class, will have the exclusive power, voting together as a single class, to elect, at any special meeting called by our secretary at the written request of holders of record of at least 10% of the outstanding shares of Series A Preferred Stock and any other class or series of voting preferred stock (unless the request is received more than 45 days and less than 90 days before our next annual meeting of stockholders at which the vote would occur) and at each subsequent annual meeting of stockholders, two additional directors to serve on our board of directors. The right of holders of Series A Preferred Stock to vote in the election of directors will terminate when all dividends accrued and unpaid on the outstanding shares of Series A Preferred Stock for all past dividend periods have been fully paid. Unless the number of our directors has previously been increased pursuant to the terms of any other class or series of voting preferred stock with which the holders of Series A Preferred Stock are entitled to vote



together as a single class in the election of directors, the number of our directors will automatically increase by two at the time as holders of Series A Preferred Stock become entitled to vote in the election of two additional directors. The term of office of these directors will terminate, and the number of our directors will automatically decrease by two, when all dividends accrued and unpaid for all past dividend periods on the Series A Preferred Stock have been fully paid, unless shares of voting preferred stock remain outstanding and entitled to vote in the election of directors. If the right of holders of Series A Preferred Stock to elect the two additional directors terminates after the record date for determining holders of shares of Series A Preferred Stock entitled to vote in any election of directors but before the closing of the polls in the election, holders of Series A Preferred Stock outstanding as of the applicable record date will not be entitled to vote in the election of directors. The right of the holders of Series A Preferred Stock to elect the additional directors will again vest if and whenever dividends are in arrears for six quarterly periods, as described above. In no event will the holders of Series A Preferred Stock be entitled to nominate or elect an individual as a director, and no individual will be qualified to be nominated for election or to serve as a director, if the individual’s service as a director would cause us to fail to satisfy a requirement relating to director independence of any national securities exchange on which any class or series of our stock is listed or otherwise conflict with our charter or bylaws.
The additional directors will be elected by a plurality of the votes cast in the election of preferred stock directors, and each of these directors will serve until the next annual meeting of our stockholders and until his or her successor is duly elected and qualifies, or until the director’s term of office terminates as described above. Any director elected by the holders of Series A Preferred Stock and any other class or series of voting preferred stock, voting together as a single class, may be removed, with or without cause, only by a vote of the holders of a majority of the outstanding shares of Series A Preferred Stock and all classes or series of voting preferred stock with which the holders of Series A Preferred Stock are entitled to vote together as a single class in the election of directors, voting together as a single class. At any time that the holders of Series A Preferred Stock are entitled to vote in the election of the two additional preferred stock directors, holders of Series A Preferred Stock will be entitled to vote in the election of a successor to fill any vacancy on our board of directors that results from the removal of the director.
At any time that holders of Series A Preferred Stock have the right to elect two additional preferred stock directors as described above but these directors have not been elected, our secretary must call a special meeting for the purpose of electing the additional directors upon the written request of the holders of record of 10% of the outstanding shares of Series A Preferred Stock and any other class or series of voting preferred stock with which the holders of Series A Preferred Stock are entitled to vote together as a single class with respect to the election of directors, unless the request is received more than 45 days and less than 90 days before the date fixed for the next annual meeting of our stockholders at which the vote would occur, in which case, the additional directors may be elected either at the annual meeting or at a separate special meeting of our stockholders at our discretion.
So long as any shares of Series A Preferred Stock are outstanding, the approval of the holders of at least two-thirds of the outstanding shares of Series A Preferred Stock and each other equally affected class or series of voting preferred stock, including the Series B Preferred Stock, with which the holders of Series A Preferred Stock are entitled to vote as a single class on such matter (voting together as a single class), is required to authorize (a) any amendment,
10

image_5.jpg

alteration, repeal or other change to any provision of our charter, including the articles supplementary setting forth the terms of the Series A Preferred Stock (whether by merger, conversion, consolidation, transfer or conveyance of all or substantially all of our assets or otherwise), that would materially and adversely affect the rights, preferences, privileges or voting powers of the Series A Preferred Stock, or (b) the creation, issuance or increase in the number of authorized shares of any class or series of stock ranking senior to the Series A Preferred Stock (or any equity securities convertible into or exchangeable for any such shares, but not including debt securities convertible into or exchangeable for any such shares prior to the time of conversion) with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up. Notwithstanding the foregoing, holders of voting preferred stock will not be entitled to vote together as a class with the holders of Series A Preferred Stock on any amendment, alteration, repeal or other change to any provision of our charter unless the action affects the holders of Series A Preferred Stock and the voting preferred stock equally.
The following actions will not be deemed to materially and adversely affect the rights, preferences, privileges or voting powers of the Series A Preferred Stock:
•any increase or decrease in the number of authorized shares of common stock or preferred stock of any other class or series, any increase in the number of shares of Series A Preferred Stock or the



classification or reclassification of any unissued shares, or the creation or issuance of equity securities, of any class or series ranking junior to or on parity with the Series A Preferred Stock, including the Series B Preferred Stock, with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up, provided that such action does not decrease the number of authorized shares of common stock below the number (after giving effect to all other outstanding shares of capital stock) necessary to permit the Series A Preferred Stock to be converted in full in accordance with the terms hereof;
•any amendment, alteration or repeal or other change to any provision of our charter, including the articles supplementary setting forth the terms of the Series A Preferred Stock, as a result of a merger, conversion, consolidation, transfer or conveyance of all or substantially all of our assets or other business combination, whether or not we are the surviving entity, if the Series A Preferred Stock (or stock into which the Series A Preferred Stock has been converted in any successor person or entity to us) remains outstanding with the terms thereof unchanged in all material respects or is exchanged for stock of the successor person or entity with substantially identical rights; or
•any amendment, alteration or repeal or other change to any provision of our charter, including the articles supplementary setting forth the terms of the Series A Preferred Stock, as a result of a merger, conversion, consolidation, transfer or conveyance of all or substantially all of our assets or other business combination, if the holders of Series A Preferred Stock receive the $25.00 liquidation preference per share of Series A Preferred Stock, plus an amount equal to accrued and unpaid dividends to, but not including, the date of the event.
The voting provisions above will not apply if, at or prior to the time when the act with respect to which the vote would otherwise be required would occur, we have redeemed or called for redemption all outstanding shares of Series A Preferred Stock.
No Maturity, Sinking Fund or Mandatory Redemption
The Series A Preferred Stock has no stated maturity date and is not subject to any sinking fund or mandatory redemption provisions.
Conversion
The Series A Preferred Stock is not convertible into any other property or securities, except as provided under “- Change of Control Conversion Right.”
Information Rights
During any period in which we are not subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act and any shares of Series A Preferred Stock are outstanding, we will (i) transmit by mail or other permissible means under the Exchange Act to all holders of Series A Preferred Stock as their names and addresses appear in our record books and without cost to the holders, copies of the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we would have been required to file with the Securities and Exchange Commission (the “SEC”) pursuant to Section 13 or 15(d) of the Exchange Act if we were subject thereto (other than any exhibits that would have been required) within 15 days after the respective dates by which we would have been required to file these reports with the SEC if we were subject to Section 13 or 15(d) of the Exchange Act and (ii) within 15 days following written request, supply copies of these reports to any prospective holder of Series A Preferred Stock.
11

image_5.jpg

Preemptive Rights
No holders of Series A Preferred Stock will, as a result of his, her or its status as such holder, have any preemptive rights to purchase or subscribe for shares of our common stock or any of our other securities.
Series B Preferred Stock



As of December 31, 2022, 3,680,000 shares of preferred stock were classified and designated as Series B Preferred Stock pursuant to our charter.
Ranking
The Series B Preferred Stock ranks, with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding-up:
•senior to our common stock and to all other equity securities, the terms of which expressly provide that such securities rank junior to the Series B Preferred Stock;
•on parity with the Series A Preferred Stock and all other equity securities, the terms of which expressly provide that such securities rank on parity with the Series B Preferred Stock; and
•junior to any class or series of equity securities, the terms of which expressly provide that such securities rank senior to the Series B Preferred Stock.
The authorization or issuance of equity securities ranking senior to the Series B Preferred Stock requires the affirmative vote of the holders of at least two-thirds of the outstanding shares of Series B Preferred Stock and of any other similarly-affected classes and series of preferred stock ranking on parity with the Series B Preferred Stock and upon which like voting rights have been conferred and are exercisable, including the Series A Preferred Stock. Any convertible debt securities that we may issue will not be considered to be “equity securities” for these purposes prior to the time of conversion. The Series B Preferred Stock ranks junior to all our existing and future indebtedness. The terms of the Series B Preferred Stock do not limit our ability to (i) incur indebtedness or (ii) issue additional equity securities that rank junior to or on parity with the Series B Preferred Stock, including the Series A Preferred Stock, with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up.

Dividends
Holders of Series B Preferred Stock are entitled to receive, when, as and if authorized by our board of directors and declared by us, out of funds legally available for the payment of dividends, cumulative cash dividends in the amount of  $1.78125 per share each year, which is equivalent to the rate of 7.125% of the $25.00 liquidation preference per share per annum. Dividends are payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the next succeeding business day. A dividend period is the respective quarterly period commencing on and including the 1st day of January, April, July and October of each year and ending on and including the day preceding the first day of the next succeeding dividend period to all holders of record on the applicable record date, when and as authorized by our board of directors and declared by us. Holders of record of all shares of Series B Preferred Stock issued and outstanding at the close of business on the record date fixed by our board of directors for any dividend will be entitled to receive the full dividend paid on the applicable dividend payment date even if such shares were not issued and outstanding for the full dividend period.
Any dividend, including any dividend payable on the Series B Preferred Stock for any partial dividend period, is computed on the basis of a 360-day year consisting of twelve 30-day months. Dividends are payable to holders of record of Series B Preferred Stock as they appear in the transfer agent’s records at the close of business on the applicable record date, which will be the date that our board of directors sets as the record date for the payment of a dividend that is not more than 30 nor fewer than 10 days prior to the applicable dividend payment date.
Our board of directors will not authorize, and we will not pay or declare and set apart for payment, any dividend on the Series B Preferred Stock at any time that:
•the terms and conditions of any of our agreements, including our credit facility or any other agreement relating to our indebtedness, prohibit the authorization, payment or setting apart for payment;
12

image_5.jpg

•the terms and conditions of any of our agreements, including our credit facility or any other agreement relating to our indebtedness, provide that the authorization, payment or setting apart for payment would constitute a breach of, or a default under, the agreement; or
•the law restricts or prohibits the authorization, payment or setting apart for payment.



Notwithstanding the foregoing, dividends on the Series B Preferred Stock accrue whether or not the dividends are authorized by our board and declared by us.
Accrued and unpaid dividends on the Series B Preferred Stock do not bear interest.
We will not pay or declare and set apart for payment any dividends (other than a dividend paid in common stock or other stock ranking junior to the Series B Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up) or declare and make any other distribution of cash or other property, directly or indirectly, on or with respect to common stock or other equity securities that rank junior to or on parity with the Series B Preferred Stock or redeem or otherwise acquire common stock or other stock that ranks junior to or on parity with the Series B Preferred Stock, including the Series A Preferred Stock (except (i) by conversion into or exchange for common stock or other shares of equity securities ranking junior to the Series B Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up, (ii) for the acquisition of shares of our stock pursuant to the provisions of our charter relating to the restrictions upon ownership and transfer of our stock and (iii) for a purchase or acquisition of equity securities pursuant to a purchase or exchange offer made on the same terms to holders of all outstanding shares of Series B Preferred Stock and any other stock that ranks on parity with the Series B Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up, including the Series A Preferred Stock), unless we also have either paid or declared and set apart for payment full cumulative dividends on the Series B Preferred Stock for all past dividend periods.
Notwithstanding the foregoing, if we do not either pay or declare and set apart for payment full cumulative dividends on the Series B Preferred Stock and all stock that ranks on parity with the Series B Preferred Stock with respect to dividends, including the Series A Preferred Stock, the amount which we have declared will be allocated pro rata to the holders of Series B Preferred Stock and to each equally ranked class or series of stock, including the Series A Preferred Stock, so that the amount declared for each share of Series B Preferred Stock and for each share of each equally ranked class or series of stock, including the Series A Preferred Stock, is proportionate to the accrued and unpaid dividends on those shares. Any dividend payment made on the Series B Preferred Stock will first be credited against the earliest accrued and unpaid dividend.
If, for any taxable year, we elect to designate as “capital gain dividends” (as defined in Section 857 of the Code) a portion (the “Capital Gains Amount”) of the dividends not in excess of our earnings and profits that are paid or made available for the year to the holders of all classes or series of stock (the “Total Dividends”), then the portion of the Capital Gains Amount that will be allocable to the holders of Series B Preferred Stock will be in the same proportion that the Total Dividends paid or made available to the holders of Series B Preferred Stock for the taxable year bears to the Total Dividends for the taxable year made with respect to all classes or series of stock outstanding.
Holders of shares of Series B Preferred Stock are not entitled to any dividend, whether payable in cash, property or shares of capital stock, in excess of full cumulative dividends on the Series B Preferred Stock as described above.
Liquidation Preference
Upon any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of Series B Preferred Stock are entitled to be paid out of our assets legally available for distribution to our stockholders a liquidation preference of  $25.00 per share, plus an amount equal to any accrued and unpaid dividends (whether or not authorized or declared) to, but not including, the date of payment, after payment of or provision for our debts and liabilities and any other class or series of our capital stock ranking senior to the Series B Preferred Stock with respect to liquidation rights before any distribution or payment may be made to holders of common stock or any other class or series of our equity stock ranking junior to the Series B Preferred Stock with respect to liquidation rights. If, upon our voluntary or involuntary liquidation, dissolution or winding up, our available assets are insufficient to pay the full amount of the liquidating distributions on all outstanding shares of Series B Preferred Stock and the corresponding amounts payable on all shares of each other class or series of stock ranking on parity with the Series B Preferred Stock with respect to liquidation rights, including the Series A Preferred Stock, then the holders of Series B Preferred Stock and any other class or series of stock ranking on parity with the Series B Preferred Stock with respect to liquidation rights, including the Series A Preferred Stock, will share ratably in any distribution of assets in proportion to the full liquidating distributions to which they would otherwise be respectively
13

image_5.jpg




entitled. Holders of Series B Preferred Stock are entitled to written notice of any voluntary or involuntary liquidation, dissolution or winding up at least 20 days before the payment date of the liquidating distribution. After the holders of Series B Preferred Stock have received the full amount of the liquidating distributions to which they are entitled, they will have no right or claim to any of our remaining assets.
In determining whether any distribution (other than upon voluntary or involuntary dissolution) by dividend, redemption or other acquisition of shares of stock of the Company or otherwise is permitted under the MGCL, amounts that would be needed, if the Company were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of the holders of Series B Preferred Stock will not be added to the Company’s total liabilities.
Our consolidation, conversion or merger with or into any other person or entity or the sale, lease, transfer or conveyance of all or substantially all of our property or business, whether in connection with a Change of Control (as defined below) or otherwise, will not be deemed to constitute our liquidation, dissolution or winding up.
Optional Redemption
The Series B Preferred Stock is not redeemable prior to October 6, 2026, except in the circumstances described in this section, in the section below titled “- Special Optional Redemption,” or pursuant to certain provisions of our charter. See “Certain Provisions of the Maryland General Corporation Law and our Charter and Bylaws - Restrictions on Transfer and Ownership of Stock” below.
Notwithstanding any other provision relating to redemption or repurchase of the Series B Preferred Stock, we may redeem any or all of the Series B Preferred Stock at any time, whether before or after October 6, 2026 at a redemption price of  $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), pursuant to the restrictions on ownership and transfer of our stock set forth in our charter or if our board of directors otherwise determines that redemption is necessary for us to preserve our status as a REIT.
On and after October 6, 2026, the Series B Preferred Stock may be redeemed at our option, in whole or in part, at any time or from time to time, at a redemption price of  $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date (unless the redemption date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend will be included in the redemption price), without interest, upon the giving of notice, as provided below.
If less than all of the outstanding shares of Series B Preferred Stock are to be redeemed, the shares to be redeemed will be determined pro rata (as nearly as may be practicable without creating fractional shares) or by lot. If the redemption is to be by lot, and if as a result of the redemption any holder of Series B Preferred Stock would own, or be deemed by virtue of certain attribution provisions of the Code to own, more than 9.8% in value of the aggregate of the outstanding shares of our stock (which includes the Series B Preferred Stock) or 9.8% in value or in number of shares (whichever is more restrictive) of the outstanding shares of any class or series of our stock or violate any of the other restrictions on ownership and transfer of our stock set forth in our charter, then, except in certain instances, we will redeem the requisite number of shares of Series B Preferred Stock of that holder so that the holder will not own or be deemed by virtue of certain attribution provisions of the Code to own, subsequent to the redemption, more than 9.8% in value of the aggregate of the outstanding shares of our stock or 9.8% in value or in number of shares (whichever is more restrictive) of the outstanding shares of any class or series of our stock or violate any of the other restrictions on ownership and transfer set forth in our charter.
We will mail to record holders of the Series B Preferred Stock, a notice of redemption no less than 30 days nor more than 60 days prior to the redemption date. We will send the notice to the record holder’s address, as shown on our share transfer books. A failure to give notice of redemption or any defect in the notice or in its mailing will not affect the validity of the redemption of any Series B Preferred Stock except as to shares held by any holder to whom notice was defective or not given. Each notice will state the following:
•the redemption date;
•the redemption price;
•the total number of shares of Series B Preferred Stock to be redeemed (and, if less than all the shares held by any holder are to be redeemed, the number of shares to be redeemed from the holder);
14




image_5.jpg

•the place or places where the shares of Series B Preferred Stock are to be surrendered for payment, together with the certificates, if any, representing the shares (duly endorsed for transfer) and any other documents we require in connection with redemption; and
•that dividends on the Series B Preferred Stock will cease to accrue on the redemption date.
We are not required to provide such notice in the event we redeem Series B Preferred Stock in order to maintain our status as a REIT.
Unless full cumulative dividends on all shares of Series B Preferred Stock have been or contemporaneously are declared and paid or declared and a sum sufficient for the payment thereof set apart for payment for all past dividend periods, no shares of Series B Preferred Stock may be redeemed unless all outstanding shares of Series B Preferred Stock are simultaneously redeemed. In addition, unless full cumulative dividends on all shares of Series B Preferred Stock have been or contemporaneously are declared and paid or declared and a sum sufficient for the payment thereof set apart for payment for all past dividend periods, we will not purchase or otherwise acquire directly or indirectly any Series B Preferred Stock (except (i) by exchange for our equity securities ranking junior to the Series B Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up, (ii) pursuant to the provisions of our charter relating to restrictions on ownership and transfer of our stock and (iii) the purchase or acquisition of the Series B Preferred Stock pursuant to a purchase or exchange offer made on the same terms to the holders of all outstanding shares of Series B Preferred Stock and any other stock that ranks on parity with the Series B Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up). So long as no dividends on Series B Preferred Stock for any past dividend period are in arrears, we are entitled at any time and from time to time to repurchase Series B Preferred Stock in open-market transactions duly authorized by our board of directors and effected in compliance with applicable laws and these requirements will not prevent our purchase or acquisition of Series B Preferred Stock pursuant to a purchase or exchange offer made on the same terms to holders of all outstanding shares of Series B Preferred Stock and any other stock that ranks on parity with the Series B Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up or our redemption of Series B Preferred Stock pursuant to the provisions of our charter relating to the restrictions on ownership and transfer of our stock.
Special Optional Redemption
During any period of time (whether before or after October 6, 2026) that the Series B Preferred Stock is not listed on the Nasdaq Stock Market, the NYSE or the NYSE American LLC, or listed or quoted on an exchange or quotation system that is a successor to the Nasdaq Stock Market, the NYSE or the NYSE American LLC (a “Delisting Event”), we have the option to redeem the outstanding shares of Series B Preferred Stock, in whole or in part, after the occurrence of the Delisting Event, for a redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date (unless the redemption date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend payable on the payment date will be included in the redemption price), upon the giving of notice, as provided below.
In addition to the foregoing, upon the occurrence of a Delisting Event, the dividend rate specified shall be increased on the day after the occurrence of the Delisting Event by 2.00% per annum to the rate of 9.125% of the $25.00 per share stated liquidation preference per annum (equivalent to $2.28125 per annum per share) from and after the date of the Delisting Event. Following the cure of a Delisting Event, the dividend rate shall revert to the rate of 7.125% of the $25.00 per share stated liquidation preference per annum.
In addition, upon the occurrence of a Change of Control, we may, at our option, redeem the Series B Preferred Stock, in whole or in part, within 120 days after the first date on which the Change of Control occurred, by paying $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date (unless the redemption date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend payable on the payment date will be included in the redemption price). If, prior to the Conversion Date (as defined below), we provide notice of redemption with respect to the Series B Preferred Stock (whether pursuant to our optional redemption right or our special optional redemption rights), holders of Series B Preferred Stock will not have the conversion right described below under “- Change of Control Conversion Right.”



We will mail to record holders of the Series B Preferred Stock, a notice of redemption no less than 30 days nor more than 60 days prior to the redemption date. We will send the notice to the record holder’s address, as shown on our share transfer books. A failure to give notice of redemption or any defect in the notice or in its mailing with not affect the validity of the redemption of any Series B Preferred Stock except as to the holder to whom notice was defective or not given. Each notice will state the following:
15

image_5.jpg

•the redemption date;
•the redemption price;
•the total number of shares of Series B Preferred Stock to be redeemed;
•the place or places where the shares of Series B Preferred Stock are to be surrendered for payment, together with the certificates, if any, representing the shares (duly endorsed for transfer) and any other documents we require in connection with the redemption;
•that the Series B Preferred Stock is being redeemed pursuant to our special optional redemption right in connection with the occurrence of a Change of Control or a Delisting Event, as applicable, and a brief description of the transaction or transactions constituting the Change of Control or Delisting Event, as applicable;
•that holders of Series B Preferred Stock to which the notice relates will not be able to tender the Series B Preferred Stock for conversion in connection with a Change of Control during a continuous Delisting Event, and each share of Series B Preferred Stock tendered for conversion that is selected, prior to the Conversion Date, for redemption will be redeemed on the related redemption date instead of converted on the Conversion Date; and
•that dividends on the Series B Preferred Stock to be redeemed will cease to accrue on the redemption date.
A “Change of Control” occurs when, after the original issuance of the Series B Preferred Stock, the following has occurred and is continuing:
•the acquisition by any person, including any syndicate or group deemed to be a “person” under Section 13(d)(3) of the Exchange Act, of beneficial ownership, directly or indirectly, through a purchase, merger, conversion or other acquisition transaction or series of purchases, mergers, conversions or other acquisition transactions, of shares of our stock entitling that person to exercise more than 50% of the total voting power of all outstanding shares of our stock entitled to vote generally in the election of directors (except that the person will be deemed to have beneficial ownership of all securities that the person has the right to acquire, whether the right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition); and
•following the closing of any transaction referred to in the bullet point above, neither we nor the acquiring or surviving entity, including any parent of the Company or the acquiring or surviving entity, has a class of common equity securities listed on the Nasdaq Stock Market, the NYSE or the NYSE American LLC, or listed or quoted on an exchange or quotation system that is a successor to the Nasdaq Stock Market, the NYSE or the NYSE American LLC.
Additional Provisions Relating to Optional Redemption and Special Optional Redemption
If  (i) we have given a notice of redemption, (ii) we have set apart sufficient funds for the redemption of the shares of Series B Preferred Stock called for redemption and (iii) irrevocable instructions have been given to pay the redemption price and an amount equal to all accrued and unpaid dividends to, but not including, the redemption date, then from and after the redemption date, those shares of Series B Preferred Stock so called for redemption will no longer be outstanding, no further dividends will accrue and all other rights of the holders of those shares of Series B Preferred Stock will terminate, except the right to receive the redemption price, without interest. The holders of those shares of Series B Preferred Stock will retain their right to receive the redemption price for their shares and any accrued and unpaid dividends payable upon redemption, without interest.



The holders of Series B Preferred Stock at the close of business on a dividend record date will be entitled to receive the dividend payable with respect to the Series B Preferred Stock on the corresponding dividend payment date notwithstanding the redemption of the Series B Preferred Stock between such record date and the corresponding dividend payment date. There is no restriction on the redemption of shares of Series B Preferred Stock by us while there is any arrearage in the payment of dividends.
All shares of Series B Preferred Stock that we redeem or reacquire in any manner will return to the status of authorized but unissued shares of preferred stock, without further designation as to series or class and may thereafter be classified, reclassified or issued as any series or class of preferred stock.
16

image_5.jpg

Change of Control Conversion Right
Upon the occurrence of a Change of Control during a continuing Delisting Event, each holder of Series B Preferred Stock has the right, unless, prior to the Conversion Date, we have provided or provide notice of our election to redeem the shares of Series B Preferred Stock as described under “- Optional Redemption” or “- Special Optional Redemption,” to convert some of or all the shares of Series B Preferred Stock held by the holder (the “Change of Control Conversion Right”) on the Conversion Date into a number of shares of common stock per share of Series B Preferred Stock (the “Common Stock Conversion Consideration”), which is equal to the lesser of:
•the quotient obtained by dividing (i) the sum of the $25.00 liquidation preference per share of Series B Preferred Stock to be converted plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared) on the Series B Preferred Stock to, but not including, the Conversion Date (as defined below) (unless the Conversion Date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend payable on the payment date will be included in this sum), by (ii) the Common Stock Price (as defined below); and
•3.4483 (the “Share Cap”).
The Share Cap is subject to pro rata adjustments for any stock splits (including those effected pursuant to a common stock dividend), subdivisions or combinations (in each case, a “Stock Split”) with respect to shares of our common stock as follows: the adjusted Share Cap as the result of a Stock Split will be the number of shares of our common stock that is equivalent to the product of  (i) the Share Cap in effect immediately prior to the Stock Split, multiplied by (ii) a fraction, the numerator of which is the number of shares of our common stock outstanding after giving effect to the Stock Split and the denominator of which is the number of shares of our common stock outstanding immediately prior to the Stock Split.
If a Change of Control occurs during a continuing Delisting Event, pursuant to or in connection with which shares of our common stock will be converted into cash, securities or other property or assets (including any combination thereof) (the “Alternative Form Consideration”), a holder of shares of Series B Preferred Stock will receive upon conversion of the shares of Series B Preferred Stock the kind and amount of Alternative Form Consideration which the holder would have owned or been entitled to receive had the holder held a number of shares of our common stock equal to the Common Stock Conversion Consideration immediately prior to the effective time of the Change of Control (the “Alternative Conversion Consideration,” and the Common Stock Conversion Consideration or the Alternative Conversion Consideration, as may be applicable to a Change of Control during a continuing Delisting Event, is referred to as the “Conversion Consideration”).
If the holders of shares of our common stock have the opportunity to elect the form of consideration to be received in connection with the Change of Control during a continuing Delisting Event, the Conversion Consideration that holders of Series B Preferred Stock will receive will be the form of consideration elected by the holders of a plurality of the shares of common stock held by stockholders who participate in the election and will be subject to any limitations to which all holders of shares of common stock are subject, including, without limitation, pro rata reductions applicable to any portion of the consideration payable in connection with the Change of Control during a continuing Delisting Event.
We will not issue fractional shares of common stock upon the conversion of the Series B Preferred Stock. Instead, we will pay the cash value of any fractional shares based on the Common Stock Price.



Within 15 days following the occurrence of a Change of Control during a continuing Delisting Event, unless we have provided notice of our election to redeem the shares of Series B Preferred Stock as described under “- Optional Redemption” or “- Special Optional Redemption,” we will provide to holders of record of outstanding shares of Series B Preferred Stock a notice of occurrence of both the Change of Control and Delisting Event that describes the resulting Change of Control Conversion Right. A failure to give notice of conversion or any defect in the notice or in its mailing will not affect the validity of the proceedings for the conversion of any Series B Preferred Stock except as to the holder to whom this notice was defective or not given. This notice will state the following:
•the events constituting the Change of Control during a continuing Delisting Event;
•the date of the Change of Control during a continuing Delisting Event;
•the last date on which the holders of shares of Series B Preferred Stock may exercise their Change of Control Conversion Right;
17

image_5.jpg

•the method and period for calculating the Common Stock Price;
•the “Conversion Date,” which will be a business day fixed by our board of directors that is not fewer than 20 and not more than 35 days following the date of the notice;
•that if, prior to the Conversion Date we provide notice of our election to redeem all or any portion of the shares of Series B Preferred Stock, holders of Series B Preferred Stock will not be able to convert the shares of Series B Preferred Stock so called for redemption and the shares of Series B Preferred Stock will be redeemed on the related redemption date, even if they have already been tendered for conversion pursuant to the Change of Control Conversion Right;
•if applicable, the type and amount of Alternative Conversion Consideration entitled to be received per share of Series B Preferred Stock;
•the name and address of the paying agent and the conversion agent; and
•the procedures that the holders of shares of Series B Preferred Stock must follow to exercise the Change of Control Conversion Right.
We will issue a press release for publication on the Dow Jones & Company, Inc., Business Wire, PR Newswire or Bloomberg Business News (or, if these organizations are not in existence at the time of issuance of the press release, another news or press organization as is reasonably calculated to broadly disseminate the relevant information to the public) containing the information stated in the notice, and post the notice on our website, in any event prior to the opening of business on the first business day following any date on which we provide the notice described above to the holders of record of Series B Preferred Stock.
To exercise the Change of Control Conversion Right, a holder of record of Series B Preferred Stock will be required to deliver, on or before the close of business on the Conversion Date, the certificates, if any, representing any certificated shares of Series B Preferred Stock to be converted, duly endorsed for transfer, together with a completed written conversion notice and any other documents we reasonably require in connection with the conversion, to our conversion agent. The conversion notice must state:
•the Conversion Date; and
•the number of shares of Series B Preferred Stock to be converted.
The “Common Stock Price” for any Change of Control will be (i) if the consideration to be received in the Change of Control during a continuing Delisting Event by holders of shares of our common stock is solely cash, the amount of cash consideration per share of common stock, and (ii) if the consideration to be received in the Change of Control during a continuing Delisting Event by holders of shares of our common stock is other than solely cash, (x) the Non-traded Common Stock Price, if the common stock is not listed on a national exchange on the effective date of any Change in Control or (y) the Traded Common Stock Price, if the common stock is listed on a national securities exchange on the effective date of any Change in Control.



The “Non-traded Common Stock Price” is the currently applicable repurchase price for shares of common stock pursuant to our SRP immediately prior to the effective date of the Change of Control, or, if our SRP has been terminated prior to that date, 100% of the Estimated Per-Share NAV applicable immediately prior to the effective date of the Change of Control. The “Traded Common Stock Price” is the average of the closing price per share of our common stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the Change of Control.
Holders of Series B Preferred Stock may withdraw any notice of exercise of a Change of Control Conversion Right (in whole or in part) by a written notice of withdrawal delivered to our conversion agent prior to the close of business on the business day prior to the Conversion Date. The notice of withdrawal must state:
•the number of withdrawn shares of Series B Preferred Stock;
•if certificated shares of Series B Preferred Stock have been tendered for conversion and withdrawn, the certificate numbers of the withdrawn certificated shares of Series B Preferred Stock; and
18

image_5.jpg

•the number of shares of Series B Preferred Stock, if any, which remain subject to the conversion notice.
Notwithstanding the foregoing, if the Series B Preferred Stock is held in global form, the conversion notice and/or the notice of withdrawal, as applicable, must comply with applicable procedures of DTC.
Shares of Series B Preferred Stock as to which the Change of Control Conversion Right have been properly exercised and for which the conversion notice has not been properly withdrawn will be converted into the applicable Conversion Consideration on the applicable Conversion Date, unless prior thereto we provide notice of our election to redeem those shares of Series B Preferred Stock, whether pursuant to our optional redemption right or our special optional redemption right. If we elect to redeem shares of Series B Preferred Stock that would otherwise be converted into the applicable Conversion Consideration on a Conversion Date, the shares of Series B Preferred Stock will not be so converted and the holders of the shares will be entitled to receive on the applicable redemption date the redemption price for the shares.
We will deliver the Conversion Consideration no later than the third business day following the Conversion Date.
In connection with the exercise of any Change of Control Conversion Right, we will comply with all U.S. federal and state securities laws and stock exchange rules in connection with any conversion of shares of Series B Preferred Stock into shares of common stock. Notwithstanding any other provision of the Series B Preferred Stock, no holder of Series B Preferred Stock will be entitled to convert shares of Series B Preferred Stock for shares of our common stock to the extent that receipt of the shares of common stock would cause the holder (or any other person) to violate the restrictions on ownership and transfer of our stock contained in our charter. See “Certain Provisions of the Maryland General Corporation Law and our Charter and Bylaws-Restrictions on Transfer and Ownership of Stock” below.
These Change of Control conversion and redemption features may make it more difficult for or discourage a party from pursuing a takeover or other transaction that holders of common stock might believe to be in their best interests or in which holders of some, or a majority, of the shares of common stock might receive a premium for their shares over the then market price of such shares of common stock.
Except as provided above in connection with the occurrence of a Change of Control during a Delisting Event and in our charter, the Series B Preferred Stock is not convertible into or exchangeable for any other property or securities.
Voting Rights
Except as described below, holders of Series B Preferred Stock generally have no voting rights. On any matter in which the Series B Preferred Stock may vote (as expressly provided in our charter), each share of Series B Preferred Stock entitles the holder thereof to cast one vote, except that, when voting together as a single class with shares of any other class or series of voting preferred stock, shares of different classes or series will vote in proportion to the liquidation preference of the shares.



Whenever dividends on the Series B Preferred Stock are in arrears, whether or not authorized or declared, for six or more quarterly periods, whether or not these quarterly periods are consecutive, holders of Series B Preferred Stock and any other class or series of preferred stock ranking on parity with the Series B Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up and upon which like voting rights have been conferred and are exercisable, including the Series A Preferred Stock, which we refer to as “voting preferred stock,” and with which the holders of Series B Preferred Stock are entitled to vote together as a single class, will have the exclusive power, voting together as a single class, to elect, at any special meeting called by our secretary at the written request of stockholders of record entitled to cast at least 10% of the votes entitled to be cast collectively by the holders of the outstanding shares of Series B Preferred Stock and any other class or series of voting preferred stock (unless the request is received more than 45 days and less than 90 days before our next annual meeting of stockholders at which the vote would occur) and at each subsequent annual meeting of stockholders, two additional directors to serve on our board. The right of holders of Series B Preferred Stock to vote in the election of directors will terminate when all dividends accrued and unpaid on the outstanding shares of Series B Preferred Stock for all past dividend periods have been fully paid. Unless the number of our directors has previously been increased pursuant to the terms of any other class or series of voting preferred stock with which the holders of Series B Preferred Stock are entitled to vote together as a single class in the election of directors, the number of our directors will automatically increase by two at the time as holders of Series B Preferred Stock become entitled to vote in the election of two additional directors. The term of office of these directors will terminate, and the number of our directors will automatically decrease by two, when all dividends accrued and unpaid for all past dividend periods on the Series B Preferred Stock have been fully paid, unless shares of voting
19

image_5.jpg

preferred stock remain outstanding and entitled to vote in the election of directors. If the right of holders of Series B Preferred Stock to elect the two additional directors terminates after the record date for determining holders of shares of Series B Preferred Stock entitled to vote in any election of directors but before the closing of the polls in the election, holders of Series B Preferred Stock outstanding as of the applicable record date will not be entitled to vote in the election of directors. The right of the holders of Series B Preferred Stock to elect the additional directors will again vest if and whenever dividends are in arrears for six quarterly periods, as described above. In no event will the holders of Series B Preferred Stock be entitled to nominate or elect an individual as a director, and no individual will be qualified to be nominated for election or to serve as a director, if the individual’s service as a director would cause us to fail to satisfy a requirement relating to director independence of any national securities exchange on which any class or series of our stock is listed or otherwise conflict with our charter or bylaws.
The additional directors will be elected by a plurality of the votes cast in the election of preferred stock directors, and each of these directors will serve until the next annual meeting of our stockholders and until his or her successor is duly elected and qualifies, or until the director’s term of office terminates as described above. Any director elected by the holders of Series B Preferred Stock and any other class or series of voting preferred stock, voting together as a single class, may be removed, with or without cause, only by a majority of the votes entitled to be cast collectively by the holders of the outstanding shares of Series B Preferred Stock and all classes or series of voting preferred stock with which the holders of Series B Preferred Stock are entitled to vote together as a single class in the election of directors, voting together as a single class. At any time that the holders of Series B Preferred Stock are entitled to vote in the election of the two additional preferred stock directors, holders of Series B Preferred Stock will be entitled to vote in the election of a successor to fill any vacancy on our board that results from the removal of the director.
At any time that holders of Series B Preferred Stock, and any other class or series of voting preferred stock with which the holders of Series B Preferred Stock will be entitled to vote as a single class in the election of directors, have the right to elect two additional preferred stock directors as described above but these directors have not been elected, our secretary must call a special meeting for the purpose of electing the additional directors upon the written request of stockholders of record entitled to cast at least 10% of the votes entitled to be cast collectively by the holders of the outstanding shares of Series B Preferred Stock and any other class or series of voting preferred stock with which the holders of Series B Preferred Stock are entitled to vote together as a single class with respect to the election of directors, unless the request is received more than 45 days and less than 90 days before the date fixed for the next annual meeting of our stockholders at which the vote would occur, in which case, the additional directors may be elected either at the annual meeting or at a separate special meeting of our stockholders at our discretion.
So long as any shares of Series B Preferred Stock are outstanding, the approval of at least two-thirds of the votes entitled to be cast collectively by the holders of the outstanding shares of Series B Preferred Stock and each other equally affected class or series of voting preferred stock, including the Series A Preferred Stock, with which the holders of Series B Preferred Stock are entitled to vote as a single class on such matter (voting together as a



single class), is required to authorize (a) any amendment, alteration, repeal or other change to any provision of our charter, including the articles supplementary setting forth the terms of the Series B Preferred Stock (whether by merger, conversion, consolidation, transfer or conveyance of all or substantially all of our assets or otherwise), that would materially and adversely affect the rights, preferences, privileges or voting powers of the Series B Preferred Stock, or (b) the creation, issuance or increase in the number of authorized shares of any class or series of stock ranking senior to the Series B Preferred Stock (or any equity securities convertible into or exchangeable for any such shares, but not including debt securities convertible into or exchangeable for any such shares prior to the time of conversion) with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up. Notwithstanding the foregoing, holders of voting preferred stock will not be entitled to vote together as a class with the holders of Series B Preferred Stock on any amendment, alteration, repeal or other change to any provision of our charter unless the action affects the holders of Series B Preferred Stock and the voting preferred stock equally.
The following actions will not be deemed to materially and adversely affect the rights, preferences, privileges or voting powers of the Series B Preferred Stock:
•any increase or decrease in the number of authorized shares of common stock or preferred stock of any other class or series, any increase in the number of shares of Series B Preferred Stock or the classification or reclassification of any unissued shares, or the creation or issuance of equity securities, of any class or series ranking junior to or on parity with the Series B Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up, including the Series A Preferred Stock, provided that such action does not decrease the number of authorized shares of common stock below the number (after giving effect to all other outstanding shares of capital stock) necessary to permit the Series B Preferred Stock to be converted in full in accordance with the terms hereof;
•any amendment, alteration or repeal or other change to any provision of our charter, including the articles supplementary setting forth the terms of the Series B Preferred Stock, as a result of a merger, conversion, consolidation, transfer or conveyance of all or substantially all of our assets or other
20

image_5.jpg

business combination, whether or not we are the surviving entity, if the Series B Preferred Stock (or stock into which the Series B Preferred Stock has been converted in any successor person or entity to us) remains outstanding with the terms thereof unchanged in all material respects or is exchanged for stock of the successor person or entity with substantially identical rights; or
•any amendment, alteration or repeal or other change to any provision of our charter, including the articles supplementary setting forth the terms of the Series B Preferred Stock, as a result of a merger, conversion, consolidation, transfer or conveyance of all or substantially all of our assets or other business combination, if the holders of Series B Preferred Stock receive the $25.00 liquidation preference per share of Series B Preferred Stock, plus an amount equal to accrued and unpaid dividends to, but not including, the date of the event.
The voting provisions above will not apply if, at or prior to the time when the act with respect to which the vote would otherwise be required would occur, we have redeemed or called for redemption all outstanding shares of Series B Preferred Stock.
No Maturity, Sinking Fund or Mandatory Redemption
The Series B Preferred Stock has no stated maturity date and is not subject to any sinking fund or mandatory redemption provisions.
Conversion
The Series B Preferred Stock is not convertible into any other property or securities, except as provided under “- Change of Control Conversion Rights.”
Information Rights



During any period in which we are not subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act and any shares of Series B Preferred Stock are outstanding, we will (i) transmit by mail or other permissible means under the Exchange Act to all holders of Series B Preferred Stock as their names and addresses appear in our record books and without cost to the holders, copies of the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we would have been required to file with the SEC pursuant to Section 13 or 15(d) of the Exchange Act if we were subject thereto (other than any exhibits that would have been required) within 15 days after the respective dates by which we would have been required to file these reports with the SEC if we were subject to Section 13 or 15(d) of the Exchange Act and (ii) within 15 days following written request, supply copies of these reports to any prospective holder of Series B Preferred Stock.
Preemptive Rights
No holders of Series B Preferred Stock will, as a result of his, her or its status as such holder, have any preemptive rights to purchase or subscribe for shares of our common stock or any of our other securities.
Common Stock Purchase Rights
On December 8, 2020, following authorization by our board of directors, we declared a dividend of one Right for each share of our common stock outstanding on the close of business on December 18, 2020 to the stockholders of record on that date payable on that date. Initially, the Rights will be attached to all shares of common stock, and no separate certificates representing the Rights (“Right Certificates”) will be issued. Until the Distribution Date (as defined below), the Rights will be inseparable from the shares of common stock, and the Company will issue one Right with respect to each new share of common stock so that all shares of common stock will have Rights attached.
The Rights are in all respects subject to and governed by the provisions of the rights agreement (the “Rights Agreement”) the Company entered into with Computershare Trust Company, N.A., as rights agent, on May 18, 2020.
Distribution Date
On the Distribution Date, the Rights will separate from the shares of our common stock. As soon as practicable after the Distribution Date, unless the Rights are recorded in book-entry or another uncertificated form,
21

image_5.jpg

the Company will prepare and cause the Right Certificates to be delivered to each record holder of shares of our common stock as of the Distribution Date (other than any Acquiring Person (as defined below), its affiliates and associates).
The “Distribution Date” generally means the close of business on the 10th business day after the earlier of the date of the public announcement by the Company or a person or entity that results in the person or entity being an Acquiring Person (as defined below) or the date that a majority of our board of directors becomes aware that a person or entity has become an Acquiring Person. Our board of directors may determine to delay the occurrence of the Distribution Date under certain limited circumstances, including, among other things, to preserve the Company’s status as a real estate investment trust for U.S. federal income tax purposes.
In addition, on the Distribution Date, proper provision will be made by the Company to provide each holder (other than the Company) of limited partnership units of the Company’s operating partnership, Healthcare Trust Operating Partnership, L.P. (the “OP”), designated as “OP Units” (“OP Units”) with the number of Rights that would have been issued to the holder as if the Company had redeemed all of the holder’s OP Units for shares of our common stock pursuant to and subject to the terms and conditions of the agreement of limited partnership of the OP immediately prior to the Distribution Date.
Exercisability
The Rights will not be exercisable until the Distribution Date. After the Distribution Date, each Right will be exercisable to purchase one share of our common stock for $31.50 (the “Purchase Price”). Prior to exercising their Rights, holders of the Rights, in that capacity, have no rights as a stockholder of the Company.



Acquiring Person
An “Acquiring Person” generally means any person or entity that or which, together with its affiliates and associates, is or becomes on or after the date of the adoption of the Rights Agreement the Beneficial Owner (as described below) of 2.0% or more of the shares of our common stock then outstanding, but does not include:
•the Company or any of its subsidiaries;
•any employee benefit plan of the Company or any of its subsidiaries or the Company’s advisor, Healthcare Trust Advisors, LLC (the “Advisor”);
•any entity or trustee holding shares of our common stock for or pursuant to the terms of any employee benefit plan or for the purpose of funding any plan or other benefits for employees of the Company or of any of its subsidiaries or the Advisor;
•any passive investor, which generally means any person or entity Beneficially Owning shares of our common stock without a plan or an intent to seek control of or influence the control of the Company, but excluding any person or entity that makes a tender offer, mini or otherwise;
•any person or entity that our board of directors, or a committee thereof, has permitted to Beneficially Own a specified percentage of 2.0% or more of shares of our common stock then outstanding but only for so long as the person or entity does not acquire, without the prior approval of our board of directors, Beneficial Ownership of any additional shares of our common stock above the specified percentage; and
•any person or entity that would otherwise be deemed an Acquiring Person as of the date of the adoption of the Rights Agreement, but only for so long as the person or entity does not acquire, without the prior approval of our board of directors, Beneficial Ownership of any additional shares of our common stock.
The Rights Agreement also provides that our board of directors may exempt any person or entity from being an Acquiring Person prior to the person or entity becoming an Acquiring Person, subject to the right of our board of directors to revoke the exemption. In the event the shares of our common stock are listed on the New York Stock Exchange, Inc. or The NASDAQ Stock Market LLC, the 2.0% threshold will increase to a threshold of 4.9% effective upon the commencement of trading.
Securities “Beneficial Owned” by a person, together with its affiliates and associates, include:
22

image_5.jpg

•any securities beneficially owned, directly or indirectly, within the meaning of Rule 13d-3 of the Exchange Act;
•except under limited circumstances, securities with respect to which the person, or any of its affiliates or associates, has the right or obligation to acquire or vote pursuant to any agreement, arrangement or understanding;
•any securities which are Beneficially Owned, directly or indirectly, by any other person with which the person, or any of its affiliates or associates, has any agreement, arrangement or understanding, whether or not in writing, for the purpose of acquiring, holding, voting or disposing of any voting securities of the Company, and which the person or entity, or any of its affiliates or associates, is acting in concert towards a common goal relating to (i) acquiring, holding, voting or disposing of voting securities of the Company or (ii) changing or influencing the control of the Company; and
•any securities which are the subject of, or the reference securities for, or that underlie, any derivative securities (as defined under Rule 16a-1 under the Exchange Act) that increase in value as the value of the underlying equity increases.
With limited exception, from and after a person or entity becoming an Acquiring Person, all Rights that are, or, under certain circumstances specified in the Rights Agreement, were, Beneficially Owned by any Acquiring



Person (or by certain related parties) will be null and void. In addition, on and after the Distribution Date, any Right, the exercise or exchange of which would cause a Person to become an Acquiring Person, will become null and void.
Consequences of Any Person or Entity Becoming an Acquiring Person
Flip In. If any person or entity becomes an Acquiring Person (other than pursuant to a Permitted Offer or a transaction described below under “-Flip Over”), each Right will entitle the holder thereof (other than Rights that have become null and void) to purchase at the Purchase Price a number of shares of our common stock having an estimated market value of twice the Purchase Price. However, these Rights will not be exercisable until the Rights are no longer redeemable by the Company as described below under “-Redemption” and are subject to the Company’s right to exchange described below under “-Exchange.” If shares of our common stock are not listed on a national securities exchange, the Company’s estimated net asset value per share of common stock in effect as of the applicable date, subject to adjustments and certain exceptions, will be deemed to be the market price of the shares of common stock.
A “Permitted Offer” is a tender or exchange offer for all outstanding shares of our common stock at a price and on terms which a majority of our board of directors has previously determined are fair to the Company’s stockholders and not inadequate and otherwise in the best interests of the Company.
Exchange. If any person or entity becomes an Acquiring Person (but before the completion of a transaction described below under “-Flip Over,”), the Company, upon the authorization and direction of our board of directors, may exchange the Rights (other than Rights that have become null and void), in whole or in part, for shares of our common stock on a one-for-one basis. To the extent prohibited by Maryland law, our board of directors will not authorize an exchange after an Acquiring Person becomes the Beneficial Owner of a majority of the outstanding shares of our common stock.
Flip Over. If, after the date a majority of our board of directors becomes aware (pursuant to a public announcement or otherwise) that a person or entity has become an Acquiring Person, (i) the Company completes a merger or other business combination in which the Company is not the surviving entity or in which the Company is the surviving entity and shares of our common stock are or will be exchanged for securities of any other person or entity or other assets, or (ii) 50% or more of the Company's assets or Earning Power (as defined in the Rights Agreement) is sold or transferred, each Right will entitle the holder thereof (other than Rights that have become null and void) to purchase at the Purchase Price a number of shares of common stock of the acquiring company having a market value of twice the Purchase Price.
Expiration
23

image_5.jpg

The Rights will expire, unless earlier exercised, exchanged, amended or redeemed, on the earlier of May 18, 2023 or if shares of our common stock are listed on the New York Stock Exchange, Inc., or The NASDAQ Stock Market LLC, 364 days from the commencement of trading.
Redemption
At any time before the earlier of (i) the close of business on the 5th business day following the Distribution Date, or (ii) the expiration of the Rights by their terms, the Company, upon the authorization and direction of our board of directors, may redeem the Rights in whole, but not in part, at a price of $0.000001 per Right. If Continuing Directors no longer comprise a majority of our board of directors, then, for a period of 180 days, the Rights cannot be redeemed unless there are Continuing Directors and a majority of the Continuing Directors concur with the decision of our board of directors to redeem the Rights. Immediately upon the action of our board of directors ordering redemption of the Rights (with, if required, the concurrence of a majority of the Continuing Directors), or at a later time as our board of directors may establish for the effectiveness of the redemption, the Rights will terminate and the only right of the holders of Rights will be to receive the $0.000001 per Right redemption price.
The “Continuing Directors” include any current member of our board of directors and any person subsequently elected to our board of directors upon recommendation or approval of a majority of those directors (or



directors recommended or approved by them), and exclude an Acquiring Person, its affiliates and associates, or any of their respective representatives or nominees.
Amendment
The terms of the Rights may be amended by our board of directors without the consent of the holders of the Rights, except that from and after the Distribution Date no such amendment may adversely affect the interests of the holders of the Rights (other than the Acquiring Person and its affiliates and associates).
Adjustment
The Purchase Price payable, and the number of shares of common stock or other securities or property issuable, upon exercise of the Rights is subject to adjustment in connection with various events from time to time to prevent dilution, including:
•if the Company declares a dividend on shares of our common stock payable in shares of common stock or effects a subdivision, combination or reclassification of shares of our common stock;
•if the holders of shares of our common stock are granted rights, options or warrants to subscribe for or purchase shares of our common stock (or shares having the same rights, privileges and preferences as shares of our common stock) or convertible securities at a price less than the then current per share market price of shares of our common stock; or
•upon the distribution to all holders of shares of our common stock of evidences of indebtedness or assets (excluding regular periodic cash dividends, if any, or dividends payable in shares of our common stock) or subscription rights or warrants (other than those referred to above).
With certain exceptions, no adjustment in the Purchase Price payable upon exercise of the Rights will be required until cumulative adjustments amount to at least 1% of the Purchase Price.
The number of outstanding Rights and the number of shares of our common stock issuable upon exercise of each Right are also subject to adjustment in the event of a stock split of our common stock or a stock dividend on our common stock payable in shares of our common stock or subdivisions, consolidations or combinations of shares of our common stock occurring, in any such case, prior to the Distribution Date.
Certain Provisions of the Maryland General Corporation Law and our Charter and Bylaws
Power to Reclassify Shares of Our Stock
Our board of directors may classify any unissued shares of preferred stock, and reclassify any unissued shares of common stock or any previously classified but unissued shares of preferred stock, into other classes or series of stock, including one or more classes or series of stock that have priority over our common stock with respect to voting rights, distributions or upon liquidation, and authorize us to issue the newly classified shares. Prior
24

image_5.jpg

to the issuance of shares of each class or series, our board of directors is required by the MGCL and our charter to set, subject to the provisions of our charter regarding the restrictions on ownership and transfer of our stock, the preferences, conversion or other rights, voting powers, restrictions, limitations as to dividends and other distributions, qualifications and terms and conditions of redemption for each such class or series. These actions can be taken without stockholder approval, unless stockholder approval is required by applicable law, the terms of any other class or series of our stock or the rules of any stock exchange or automated quotation system on which our securities may be listed or traded.
Restrictions on Transfer and Ownership of Stock
In order for us to qualify as a REIT under  the Internal Revenue Code of 1986, as amended (the “Code”), shares of our stock must be owned by 100 or more persons during at least 335 days of a taxable year of 12 months (other than the first year for which an election to be taxed as a REIT has been made) or during a proportionate part



of a shorter taxable year. Also, under Section 856(h) of the Code, a REIT cannot be “closely held.” In this regard, not more than 50% of the value of the outstanding shares of stock may be owned, directly or indirectly, by five or fewer individuals (as defined in the Code to include certain entities) during the last half of a taxable year (other than the first year for which an election to be a REIT has been made).
Our charter contains restrictions on the ownership and transfer of shares of our common stock and other outstanding shares of stock. The relevant sections of our charter provide that, subject to the exceptions described below, no person or entity may own, or be deemed to own, by virtue of the applicable constructive ownership provisions of the Code, more than 9.8% in value of the aggregate of the outstanding shares of our stock or more than 9.8% (in value or in number of shares, whichever is more restrictive) of the outstanding shares of any class or series of our stock; we refer to these limitations as the “ownership limits.”
The constructive ownership rules under the Code are complex and may cause shares of stock owned actually or constructively by a group of related individuals or entities to be owned constructively by one individual or entity. As a result, the acquisition of less than 9.8% in value of the aggregate of the outstanding shares of our stock or 9.8% (in value or in number of shares, whichever is more restrictive) of the outstanding shares of any class or series of our stock (or the acquisition of an interest in an entity that owns, actually or constructively, shares of our stock by an individual or entity), could, nevertheless, cause that individual or entity, or another individual or entity, to violate the ownership limits.
Our board of directors may, upon receipt of certain representations, undertakings and agreements and in its sole discretion, exempt (prospectively or retroactively) any person from the ownership limits and establish a different limit, or excepted holder limit, for a particular person if the person’s ownership in excess of the ownership limits will not then or in the future result in our being “closely held” under Section 856(h) of the Code (without regard to whether the person’s interest is held during the last half of a taxable year) or otherwise cause us to fail to qualify as a REIT. In order to be considered by our board of directors for exemption, a person also must not own, actually or constructively, an interest in one of our tenants (or a tenant of any entity which we own or control) that would cause us to own, actually or constructively, more than a 9.9% interest in the tenant unless the revenue derived by us from such tenant is sufficiently small that, in the opinion of our board of directors, rent from such tenant would not adversely affect our ability to qualify as a REIT. The person seeking an exemption must provide such representations and undertakings to the satisfaction of our board of directors that it will not violate these two restrictions. The person also must agree that any violation or attempted violation of these restrictions will result in the automatic transfer to a charitable trust of the shares of stock causing the violation. As a condition of granting an exemption or creating an excepted holder limit, our board of directors may, but is not required to, obtain an opinion of counsel or Internal Revenue Service ruling satisfactory to our board of directors with respect to our qualification as a REIT and may impose such other conditions or restrictions as it deems appropriate.
Our board of directors may increase or decrease the ownership limits. Any decrease in the ownership limits will not be effective for any person whose percentage ownership of shares of our stock is in excess of such decreased limits until such person’s percentage ownership of shares of our stock equals or falls below such decreased limits, but any further acquisition of shares of our stock in excess of such percentage ownership will be in violation of the applicable decreased limits. Our board of directors may not increase or decrease the ownership limits if, after giving effect to such increase or decrease, five or fewer persons could beneficially own or constructively own in the aggregate more than 49.9% in value of the shares of our stock then outstanding.
Our charter further prohibits:
25

image_5.jpg

•any person from beneficially or constructively owning, applying certain attribution rules of the Code, shares of our stock that would result in our being “closely held” under Section 856(h) of the Code (without regard to whether the stockholder’s interest is held during the last half of a taxable year) or otherwise cause us to fail to qualify as a REIT; and
•any person from transferring shares of our stock if such transfer would result in shares of our stock being beneficially owned by fewer than 100 persons (determined without reference to any rules of attribution).
Any person who acquires or attempts or intends to acquire beneficial or constructive ownership of shares of our stock that will or may violate the ownership limits or any of the other foregoing restrictions on ownership and transfer of our stock will be required to immediately give written notice to us or, in the case of a proposed or



attempted transaction, give, at least 15 days prior written notice to us, and provide us with such other information as we may request in order to determine the effect of such transfer on our qualification as a REIT. The ownership limits and the other restrictions on ownership and transfer of our stock will not apply if our board of directors determines that it is no longer in our best interests to continue to qualify as a REIT or that compliance with the restrictions on ownership and transfer of our stock is no longer required in order for us to qualify as a REIT.
If any transfer of shares of our stock would result in shares of our stock being beneficially owned by fewer than 100 persons, such transfer will be void from the time of such purported transfer and the intended transferee will acquire no rights in such shares. In addition, if any purported transfer of shares of our stock or any other event would otherwise result in:
•any person violating the ownership limits or such other limit established by our board of directors; or
•us being “closely held” under Section 856(h) of the Code (without regard to whether the stockholder’s interest is held during the last half of a taxable year) or otherwise failing to qualify as a REIT,
then that number of shares (rounded up to the nearest whole share) that would cause us to violate such restrictions will automatically be transferred to, and held by, a charitable trust for the exclusive benefit of one or more charitable beneficiaries selected by us, and the intended transferee will acquire no rights in such shares. The transfer will be deemed to be effective as of the close of business on the business day prior to the date of the violative transfer or other event that results in the transfer to the charitable trust. A person who, but for the transfer of the shares to the charitable trust, would have beneficially or constructively owned the shares so transferred is referred to as a “prohibited owner,” which, if appropriate in the context, also means any person who would have been the record owner of the shares that the prohibited owner would have so owned. If the transfer to the charitable trust as described above would not be effective, for any reason, to prevent violation of the applicable restriction on ownership and transfer contained in our charter, then our charter provides that the transfer of the shares will be void from the time of such purported transfer.
Shares of stock transferred to a charitable trustee are deemed offered for sale to us, or our designee, at a price per share equal to the lesser of (1) the price paid per share in the transaction that resulted in such transfer to the charitable trust (or, if the event that resulted in the transfer to the charitable trust did not involve a purchase of such shares of stock, at market price, defined generally as the last reported sales price reported on the principal national securities exchange on which the shares are listed and admitted to trading, per share of such stock on the day of the event which resulted in the transfer of such shares of stock to the charitable trust) and (2) the market price on the date we, or our designee, accept such offer. We may reduce the amount payable to the prohibited owner by the amount of dividends and other distributions which have been paid to the prohibited owner and are owed by the prohibited owner to the charitable trustee as described below. We may pay the amount of such reduction to the charitable trustee for the benefit of the charitable beneficiary. We have the right to accept such offer until the trustee of the charitable trust has sold the shares held in the charitable trust as discussed below. Upon a sale to us, the interest of the charitable beneficiary in the shares sold terminates, and the charitable trustee must distribute the net proceeds of the sale to the prohibited owner.
Within 20 days of receiving notice from us of the transfer of the shares to the charitable trust, the charitable trustee will sell the shares to a person or entity designated by the charitable trustee who could own the shares without violating the ownership limits or the other restrictions on ownership and transfer of our stock described above. After that, the charitable trustee must distribute to the prohibited owner an amount equal to the lesser of (1) the price paid by the prohibited owner for the shares in the transaction that resulted in the transfer to the charitable trust (or, if the event that resulted in the transfer to the charitable trust did not involve a purchase of such shares, at market price per share of such stock on the day of the event that resulted in the transfer to the charitable trust) and (2) the price per share received by the charitable trustee for the shares. The charitable trustee may reduce the amount payable to the prohibited owner by the
26

image_5.jpg

amount of dividends and other distributions which have been paid to the prohibited owner and are owed by the prohibited owner to the charitable trustee. Any net sales proceeds in excess of the amount payable to the prohibited owner will be immediately paid to the charitable beneficiary. In addition, if, prior to discovery by us that shares of stock have been transferred to a charitable trust, such shares of stock are sold by a prohibited owner, then such shares will be deemed to have been sold on behalf of the charitable trust and to the extent that the prohibited owner received an amount for or in respect of such shares that exceeds the amount that such prohibited owner was entitled



to receive, such excess amount will be paid to the charitable trustee upon demand. The prohibited owner will have no rights in the shares held by the charitable trustee.
The charitable trustee will be designated by us and will be unaffiliated with us and with any prohibited owner. Prior to the sale of any shares by the charitable trust, the charitable trustee will receive, in trust for the charitable beneficiary, all rights to dividends and other distributions made by us with respect to such shares and may also exercise all voting rights with respect to such shares. Any dividend or other distribution paid prior to our discovery that shares of stock have been transferred to the charitable trust will be paid by the recipient to the charitable trustee upon demand. These rights will be exercised for the exclusive benefit of the charitable beneficiary.
Subject to Maryland law, effective as of the date that the shares have been transferred to the charitable trustee, the charitable trustee will have the authority, at the charitable trustee’s sole discretion:
•to rescind as void any vote cast by a prohibited owner prior to our discovery that the shares have been transferred to the charitable trustee; and
•to recast the vote in accordance with the desires of the charitable trustee acting for the benefit of the charitable beneficiary.
However, if we have already taken irreversible corporate action, then the charitable trustee may not rescind and recast the vote.
If our board of directors determines that a transfer or other event has taken place or that a proposed transfer would violate the restrictions on ownership and transfer of our stock set forth in our charter, our board of directors may take such action as it deems advisable to refuse to give effect to or to prevent such transfer, including, but not limited to, causing us to redeem shares of stock, refusing to give effect to the transfer on our books or instituting proceedings to enjoin the transfer.
Every owner of more than 5% (or such lower percentage as required by the Code or the regulations promulgated thereunder) of the outstanding shares of all classes or series of our stock, including common stock, will be required to give written notice to us within 30 days after the end of each taxable year stating the name and address of such owner, the number of shares of each class and series of our stock that the person beneficially owns and a description of the manner in which such shares are held. Each such owner will be required to provide to us such additional information as we may request in order to determine the effect, if any, of such beneficial ownership on our qualification as a REIT and to ensure compliance with the ownership limits. In addition, each stockholder will, upon demand, be required to provide to us such information as we may request in order to determine our qualification as a REIT and to comply with the requirements of any taxing authority or governmental authority or to determine such compliance.
Any certificates representing shares of our stock, or any written statements of information delivered in lieu of certificates, will bear a legend referring to the restrictions described above.
Number of Directors; Vacancies; Removal
We presently have six directors. This number may be increased or decreased from time to time pursuant to the bylaws, but may never be less than one or, unless our bylaws are amended, more than fifteen. Our board of directors is divided into three classes of directors serving staggered three-year terms. At each annual meeting, directors of one class are elected to serve until the annual meeting of stockholders held in the third year following the year of their election and until their successors are duly elected and qualify. At any time that the number of directors comprising the board of directors is less than five, one director must be a managing director. A “managing director” means an individual identified by the Advisor or, in the absence of such designation, the individual then serving as chief executive officer. At any time that the number of directors comprising the board of directors if five or more, up to two directors shall be managing directors; provided, however, that, if only one managing director is identified by the Advisor, the board will include one managing director. To qualify for nomination or election as a director, an individual at the time of nomination and election must meet the qualifications of an independent director or managing director, as the case may be, depending on the position for which such individual may be nominated or elected. An “independent director” means an individual who meets the qualifications of an independent director set forth in our corporate governance guidelines, as amended from time to time.
We have elected by a provision of our charter to be subject to a provision of Maryland law requiring that, except as otherwise provided in the terms of any class or series of preferred stock, vacancies on our board of directors, other than those resulting from the unexpired term of another director, may be filled only by the



affirmative vote of a majority of the remaining directors in office, even if the remaining directors do not constitute a quorum, and that any individual elected to fill a vacancy will serve for the remainder of the full term of the directorship in which the vacancy occurred and until his or her successor is duly elected and qualifies. Any director may resign at any time by delivering his or her notice to the board of directors, the chairman of the board of directors or the Company’s secretary.
27

image_5.jpg

Our charter provides that, subject to the rights of holders of one or more classes or series of preferred stock, any or all directors may be removed from office at any time, but only for “cause,” and then only by the affirmative vote of the stockholders, entitled to cast at least two-thirds of the votes entitled to be cast generally in the election of directors. For the purpose of this provision of our charter, “cause” means, with respect to any particular director, conviction of a felony or a final judgment of a court of competent jurisdiction holding that such director caused demonstrable, material harm to us through bad faith or active and deliberate dishonesty.
Action by Stockholders
Under the MGCL, common stockholder action can be taken only at an annual or special meeting of stockholders or by unanimous consent in lieu of a meeting (unless the charter provides for a lesser percentage, which our charter does not). These provisions, combined with the requirements of our charter and bylaws regarding the calling of a stockholder-requested special meeting of stockholders discussed below, may have the effect of delaying consideration of a stockholder proposal until the next annual meeting.
Meetings and Special Voting Requirements
Subject to our charter restrictions on ownership and transfer of our stock and the terms of each class or series of stock, including with respect to the vote by the stockholders for the election of the directors, each holder of common stock is entitled at each meeting of stockholders to one vote per share owned by such stockholder on all matters submitted to a vote of stockholders. There is no cumulative voting in the election of our board of directors, which means that the holders of a majority of shares of our outstanding common stock can elect all the directors then standing for election and the holders of the remaining shares of common stock will not be able to elect any directors.
Under Maryland law, a Maryland corporation generally cannot dissolve, amend its charter, merge, convert, sell all or substantially all of its assets, engage in a share exchange or engage in similar transactions outside the ordinary course of business, unless declared advisable by the board of directors and approved by the affirmative vote of stockholders entitled to cast at least two-thirds of the votes entitled to be cast on the matter. However, a Maryland corporation may provide in its charter for approval of these matters by a lesser percentage, but not less than a majority of all the votes entitled to be cast on the matter. Our charter provides for approval of these matters by the affirmative vote of stockholders entitled to cast a majority of all the votes entitled to be cast on the matter (except for certain charter amendments relating to director resignation and removal and the vote required for certain amendments). However, our operating assets are held by our subsidiaries and these subsidiaries may be able to merge or sell all or substantially all of their assets without the approval of our stockholders.
Pursuant to our bylaws, an annual meeting of our stockholders for the purpose of the election of directors and the transaction of any business will be held on a date and at the time and place set by our board of directors. Special meetings of stockholders to act on any matter that may properly be considered at a meeting of stockholders may be called by the board of directors, the chairman of the board of directors, the president or the chief executive officer and, subject to the satisfaction of certain procedural requirements, must be called by our secretary to act on any matter that may properly be considered at a meeting of stockholders upon the written request of stockholders entitled to cast not less than a majority of all the votes entitled to be cast on the matter at the meeting. The presence of stockholders entitled to cast at least a majority of all the votes entitled to be cast at such meeting on any matter, either in person or by proxy, will constitute a quorum.
Our board of directors has the exclusive power to adopt, alter or repeal any provision of our bylaws and to make new bylaws.
No Appraisal Rights
As permitted by the MGCL, our charter provides that stockholders will not be entitled to exercise appraisal rights unless a majority of our board of directors determines that appraisal rights apply, with respect to all or any



classes or series of stock, to one or more transactions occurring after the date of such determination in connection with which stockholders would otherwise be entitled to exercise appraisal rights.
Dissolution
Our dissolution must be declared advisable by a majority of our entire board of directors and approved by the affirmative vote of stockholders entitled to cast not less than a majority of the votes entitled to be cast on such matter.
Business Combinations
28

image_5.jpg

Under the MGCL, certain “business combinations,” including a merger, consolidation, share exchange or, in certain circumstances, an asset transfer or issuance or reclassification of equity securities, between a Maryland corporation and an “interested stockholder,” defined generally as any person who beneficially owns, directly or indirectly, 10% or more of the voting power of the corporation’s outstanding voting stock or an affiliate or associate of the corporation who, at any time within the two-year period prior to the date in question, was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then outstanding stock of the corporation, or an affiliate of such an interested stockholder, are prohibited for five years after the most recent date on which the interested stockholder becomes an interested stockholder. Thereafter, any such business combination between the Maryland corporation and an interested stockholder or an affiliate of an interested stockholder generally must be recommended by the board of directors of such corporation and approved by the affirmative vote of at least (1) 80% of the votes entitled to be cast by holders of outstanding shares of voting stock of the corporation and (2) two-thirds of the votes entitled to be cast by holders of voting stock of the corporation other than shares held by the interested stockholder with whom (or with whose affiliate) the business combination is to be effected or held by an affiliate or associate of the interested stockholder. The super-majority vote requirements do not apply if the corporation’s common stockholders receive a minimum price (as defined in the MGCL) for their shares of common stock and the consideration is received in cash or in the same form as previously paid by the interested stockholder for its shares of common stock. Under the MGCL, a person is not an “interested stockholder” if the board of directors approved in advance the transaction by which the person otherwise would have become an interested stockholder. A corporation’s board of directors may provide that its approval is subject to compliance with any terms and conditions determined by it.
These provisions of the MGCL do not apply, however, to business combinations that are approved or exempted by a board of directors prior to the time that the interested stockholder becomes an interested stockholder. As permitted by the MGCL, our board of directors has by resolution exempted business combinations between us and our Advisor or any affiliate of our Advisor. Consequently, the five-year prohibition and the supermajority vote requirements and other provisions of the statute will not apply to such business combinations. As a result, our Advisor or any affiliate of our Advisor may be able to enter into business combinations with us that may not be in the best interest of our stockholders. This resolution, however, may be altered or repealed in whole or in part at any time by our board of directors.
Control Share Acquisitions
The MGCL provides that “control shares” of a Maryland corporation acquired in a “control share acquisition” have no voting rights except to the extent approved by the affirmative vote of stockholders entitled to cast at least two-thirds of the votes entitled to be cast on the matter, excluding shares of stock in respect of which any of the following persons is entitled to exercise or direct the exercise of the voting power of such shares in the election of directors: (1) the acquirer, (2) an officer of the corporation or (3) an employee of the corporation who is also a director of the corporation. “Control shares” are shares of voting stock which, if aggregated with all other such shares of stock owned by the acquirer, or in respect of which the acquirer is able to exercise or direct the exercise of voting power (except solely by virtue of a revocable proxy), would entitle the acquirer to exercise voting power in electing directors within one of the following ranges of voting power: (A) one-tenth or more but less than one-third, (B) one-third or more but less than a majority or (C) a majority or more of all voting power. Control shares do not include shares of stock that the acquirer is then entitled to vote as a result of having previously obtained stockholder approval or shares acquired directly from the corporation. A “control share acquisition” means the acquisition of issued and outstanding control shares, subject to certain exceptions.
A person who has made or proposes to make a control share acquisition, upon satisfaction of certain conditions (including an undertaking to pay expenses and making an “acquiring person statement” as described in



MGCL), may compel the board of directors to call a special meeting of stockholders to be held within 50 days of demand to consider the voting rights of the shares. If no request for a meeting is made, the corporation may itself present the question at any stockholders’ meeting.
If voting rights are not approved at the meeting or if the acquirer does not deliver an “acquiring person statement” as required by the statute, then, subject to certain conditions and limitations, the corporation may redeem any or all of the control shares (except those for which voting rights have previously been approved) for fair value determined, without regard to the absence of voting rights for the control shares, as of the date of any meeting of stockholders at which the voting rights of such shares of stock are considered and not approved, or, if no such meeting is held, as of the date of the last control share acquisition by the acquirer. If voting rights for control shares are approved at a stockholders’ meeting and the acquirer becomes entitled to vote a majority of the shares of stock entitled to vote, all other stockholders may exercise appraisal rights, unless the corporation’s charter provides otherwise. The fair value of the shares as determined for purposes of such appraisal rights may not be less than the highest price per share paid by the acquirer in the control share acquisition.
29

image_5.jpg

The control share acquisition statute does not apply to (1) shares of stock acquired in a merger, consolidation or statutory share exchange if the corporation is a party to the transaction or (2) acquisitions approved or exempted by the charter or bylaws of the corporation.
Our bylaws contain a provision exempting from the control share acquisition statute any and all acquisitions by any person of our stock. This bylaw provision may be amended or eliminated at any time in the future.
Subtitle 8
Subtitle 8 of Title 3 of the MGCL permits the board of directors of a Maryland corporation with a class of equity securities registered under the Exchange Act and at least three independent directors to elect to be subject, by provision in its charter or bylaws or a resolution of its board of directors and notwithstanding any contrary provision in the charter or bylaws, to any or all of five provisions:
•a classified board of directors;
•a two-thirds vote requirement for removing a director;
•a requirement that the number of directors be fixed only by vote of the directors;
•a requirement that a vacancy on the board of directors be filled only by the remaining directors and, if the board of directors is classified, for the remainder of the full term of the class of directors in which the vacancy occurred; and
•a majority requirement for the calling of a stockholder-requested special meeting of stockholders.
We have elected to be subject to the provisions of Subtitle 8 relating to a classified board of directors and the filling of vacancies on our board of directors. Through provisions in our charter and bylaws unrelated to Subtitle 8, we already (1) require a two-thirds vote for the removal of any director from the board of directors, which removal will be allowed only for cause, (2) vest in the board of directors the exclusive power to fix the number of directorships, and (3) require, unless called by the chairman of our board of directors, our president, our chief executive officer or our board of directors, the written request of stockholders entitled to cast not less than a majority of all votes entitled to be cast on any matter that may properly be considered at a meeting of stockholders in order to call a special meeting to act on such matter.
Advance Notice of Director Nominations and New Business
Our bylaws provide that nominations of individuals for election to the board of directors or proposals of other business may be made at an annual meeting (1) pursuant to our notice of meeting, (2) by or at the direction of our board of directors, or (3) by any stockholder of record at the record date set by the board of directors for the purpose of determining stockholders entitled to vote at the annual meeting, at the time of giving of notice pursuant to the bylaws and at the time of the annual meeting (and any postponement of adjournment thereof), who is entitled to



vote at the meeting in the election of each individual so nominated or on any such other business and who has complied with the advance notice procedures set forth in our bylaws. Our bylaws currently require the stockholder to provide notice to the secretary containing the information required by our bylaws not earlier than the 150th day nor later than 5:00 p.m., Eastern Time, on the 120th day prior to the first anniversary of the date of our proxy statement for the preceding year’s annual meeting.
With respect to special meetings of stockholders, only the business specified in our notice of meeting may be brought before the meeting. Nominations of individuals for election to the board of directors may be made at a special meeting, (1) by or at the direction of the board of directors, or (2) provided that the special meeting has been called in accordance with our bylaws for the purpose of electing directors, by any stockholder who is a holder of record at the record date set by the board of directors for the purpose of determining stockholders entitled to vote at the special meeting, at the time of giving of notice and at the time of the special meeting (and any postponement or adjournment thereof), who is entitled to vote at the meeting in the election of each individual so nominated and who complies with the notice procedures set forth in our bylaws. Such stockholder may nominate one or more individuals, as the case may be, for election as a director if the stockholder’s notice containing the information required by our bylaws is delivered to the secretary not earlier than the 120th day prior to such special meeting and not later than 5:00 p.m., Eastern Time, on the later of  (1) the 90th day prior to such special meeting or (2) the tenth day following the day on which public announcement is first made of the date of the special meeting and the proposed nominees of our board of directors to be elected at the meeting.
Indemnification and Limitation of Directors’ and Officers’ Liability
30

image_5.jpg

Maryland law permits a Maryland corporation to include in its charter a provision eliminating the liability of its directors and officers to the corporation and its stockholders for money damages except for liability resulting from (1) actual receipt of an improper benefit or profit in money, property or services or (2) active and deliberate dishonesty established by a final judgment as being material to the cause of action. Our charter contains a provision that eliminates such liability to the maximum extent permitted by Maryland law. This provision does not reduce the exposure of directors and officers to liability under federal or state securities laws, nor does it limit the stockholders’ ability to obtain injunctive relief or other equitable remedies for a violation of a director’s or an officer’s duties to us, although the equitable remedies may not be an effective remedy in some circumstances.
The MGCL requires a Maryland corporation (unless its charter provides otherwise, which our charter does not) to indemnify a director or officer who has been successful, on the merits or otherwise, in the defense of any proceeding to which he or she is made or threatened to be made a party by reason of his or her service in that capacity against reasonable expenses actually incurred in the proceeding in which the director or officer was successful. The MGCL permits a Maryland corporation to indemnify its present and former directors and officers, among others, against judgments, penalties, fines, settlements and reasonable expenses actually incurred by them in connection with any proceeding to which they may be made or threatened to be made a party by reason of their service in those or other capacities unless it is established that (1) the act or omission of the director or officer was material to the matter giving rise to the proceeding and (A) was committed in bad faith or (B) was the result of active and deliberate dishonesty, (2) the director or officer actually received an improper personal benefit in money, property or services, or (3) in the case of any criminal proceeding, the director or officer had reasonable cause to believe that the act or omission was unlawful. However, under the MGCL, a Maryland corporation may not indemnify a director or officer for an adverse judgment in a suit by or in the right of the corporation or for a judgment of liability on the basis that a personal benefit was improperly received. A court may order indemnification if it determines that the director or officer is fairly and reasonably entitled to indemnification, even though the director or officer did not meet the prescribed standard of conduct or was adjudged liable on the basis that personal benefit was improperly received. However, indemnification for an adverse judgment in a suit by us or in our right, or for a judgment of liability on the basis that personal benefit was improperly received, is limited to expenses. In addition, the MGCL permits a corporation to advance reasonable expenses to a director or officer upon the corporation’s receipt of  (1) a written affirmation by the director or officer of his or her good faith belief that he or she has met the standard of conduct necessary for indemnification by the corporation and (2) a written undertaking by him or her or on his or her behalf to repay the amount paid or reimbursed by the corporation if it is ultimately determined that the appropriate standard of conduct was not met.
Our charter authorizes us to obligate ourselves and our bylaws obligate us, to the maximum extent permitted by Maryland law in effect from time to time, to indemnify and, without requiring a preliminary determination of the ultimate entitlement to indemnification, pay or reimburse reasonable expenses in advance of final disposition of a proceeding to:



•any present or former director or officer who is made or threatened to be made a party to or witness in the proceeding by reason of his or her service in that capacity;
•any individual who, while our director or officer and at our request, serves or has served as a director, officer, partner, member, manager or trustee of another corporation, real estate investment trust, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise and who is made or threatened to be made a party to or witness in the proceeding by reason of his or her service in that capacity; and
•our Advisor and its affiliates from and against any claim, liability or expense to which they may become subject or which they may incur by reason of their service as our Advisor.
Our charter and bylaws also permit us, with the approval of our board of directors, to indemnify and advance expenses to any person who served a predecessor of ours in any of the capacities described above and to any employee or agent of us, a predecessor of us or our Advisor.
We have entered into an indemnification agreement with each of our directors and officers, and certain former directors and officers, providing for indemnification of such directors and officers. The indemnification agreements provide that each indemnitee is entitled to indemnification unless it is established that (1) the act or omission of an indemnitee was material to the matter giving rise to the proceeding and (i) was committed in bad faith or (ii) was the result of active and deliberate dishonesty, (2) such indemnitee actually received an improper personal benefit in money, property or services or (3) in the case of any criminal proceeding, such indemnitee had reasonable cause to believe that his or her conduct was unlawful. The indemnification agreements further limit each indemnitee’s entitlement to indemnification in cases where (1) the proceeding was one by or in the right of us and such indemnitee was adjudged to be liable to us, (2) such indemnitee was adjudged to be liable on the basis that personal benefit was improperly received in any proceeding charging improper personal benefit to such indemnitee or (3) the proceeding was brought by such indemnitee, except in certain circumstances.
31

image_5.jpg

Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended (the “Securities Act”), may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
Exclusive Forum
Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Circuit Court for Baltimore City, Maryland, or, if that court does not have jurisdiction, the United States District Court for the District of Maryland, Northern Division, is the sole and exclusive forum for (a) any derivative action or proceeding brought on our behalf, other than actions arising under federal securities laws, (b) any Internal Corporate Claim, as such term is defined in the MGCL, or any successor provision thereof, including, without limitation, (i) any action asserting a claim of breach of any duty owed by any of our directors, officers or other employees to us or to our stockholders or (ii) any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the MGCL, our charter or our bylaws, or (c) any other action asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine.
Our bylaws also provide that, unless we consent in writing, none of the foregoing actions, claims or proceedings may be brought in any court sitting outside the State of Maryland and the federal district courts are, to the fullest extent permitted by law, the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.
32


EX-21.1 3 ex211htisubsidiarylist1231.htm EX-21.1 SUBSIDIARY LISTING Document
Exhibit 21.1
Subsidiaries of Healthcare Trust, Inc.
NameJurisdiction of Formation/Incorporation
Healthcare Trust Operating Partnership, L.P.Delaware
Advantage Senior Care, LLCDelaware
ARHC AAEKHWI01, LLCDelaware
ARHC ACRICKY01 TRS, LLCDelaware
ARHC ACRICKY01, LLCDelaware
ARHC AHGBYWI01, LLCDelaware
ARHC AHGVLWI01, LLCDelaware
ARHC AHHFDCA01, LLCDelaware
ARHC AHJACOH01, LLCDelaware
ARHC AHKIEWI01, LLCDelaware
ARHC AHMLWWI01, LLCDelaware
ARHC AHPLYWI01, LLCDelaware
ARHC AHWTFWI01, LLCDelaware
ARHC AHWTMWI01, LLCDelaware
ARHC ALALPGA01 TRS, LLCDelaware
ARHC ALALPGA01, LLCDelaware
ARHC ALCFBTX01, LLCDelaware
ARHC ALCLKTX01, LLCDelaware
ARHC ALELIKY01 TRS, LLCDelaware
ARHC ALELIKY01, LLCDelaware
ARHC ALJUPFL01 TRS, LLCDelaware
ARHC ALJUPFL01, LLCDelaware
ARHC ALMEYTX01, LLCDelaware
ARHC ALSPGFL01 TRS, LLCDelaware
ARHC ALSPGFL01, LLCDelaware
ARHC ALSTUFL01 TRS, LLCDelaware
ARHC ALSTUFL01, LLCDelaware
ARHC ALTSPFL01 TRS, LLCDelaware
ARHC ALTSPFL01, LLCDelaware
ARHC ALWOOTX01, LLCDelaware
ARHC AMGLNAZ01, LLCDelaware
ARHC AMGLNAZ02, LLCDelaware
ARHC AORMDVA01, LLCDelaware
ARHC APNVLMI01 TRS, LLCDelaware
ARHC APNVLMI01, LLCDelaware
ARHC ARCLRMI01 TRS, LLCDelaware
ARHC ARCLRMI01, LLCDelaware
ARHC ATROCIL01 TRS, LLCDelaware
ARHC ATROCIL01, LLCDelaware
ARHC AVBURWI01 TRS, LLCDelaware
ARHC AVBURWI01, LLCDelaware
ARHC BCKNGNY01, LLCDelaware
ARHC BGBOWMD01, LLCDelaware
ARHC BLHBGPA01, LLCDelaware
ARHC BMBUCMI01, LLC (f/k/a ARHC CO Borrower 5, LLC)Delaware
ARHC BMBWNIL01, LLCDelaware



ARHC BMLKWCO01, LLCDelaware
ARHC BMWRNMI01, LLCDelaware
ARHC BPBUFMO01, LLCDelaware
ARHC BRHBGPA01, LLCDelaware
ARHC BSHUMMO01, LLCDelaware
ARHC BSNPLFL01 TRS, LLCDelaware
ARHC BSNPLFL01, LLCDelaware
ARHC BWBRUGA01 TRS, LLCDelaware
ARHC BWBRUGA01, LLCDelaware
ARHC CALEWMO01, LLCDelaware
ARHC CAROCMI01, LLCDelaware
ARHC CAROCMI02, LLCDelaware
ARHC CCCGRMO01, LLCDelaware
ARHC CCGBGIL01, LLCDelaware
ARHC CCSCNNY01, LLCDelaware
ARHC CFGREOR01 TRS, LLCDelaware
ARHC CFGREOR01, LLCDelaware
ARHC CHCASMO01, LLCDelaware
ARHC CHCOLIL01 TRS, LLCDelaware
ARHC CHCOLIL01, LLCDelaware
ARHC CHEVLIL01 TRS, LLCDelaware
ARHC CHEVLIL01, LLCDelaware
ARHC CHHBGPA01, LLCDelaware
ARHC CHPTNIL01, LLCDelaware
ARHC CHSGDIL01, LLCDelaware
ARHC CHSLOIL01 TRS, LLCDelaware
ARHC CHSLOIL01, LLCDelaware
ARHC CHSLOIL02, LLCDelaware
ARHC CHSPTIL01 TRS, LLCDelaware
ARHC CHSPTIL01, LLCDelaware
ARHC CMCNRTX01, LLCDelaware
ARHC CMLITCO01, LLCDelaware
ARHC CMSHTMI001, LLCDelaware
ARHC CMWTSMI001, LLCDelaware
ARHC CO BORROWER 11, LLCDelaware
ARHC CO BORROWER 12, LLCDelaware
ARHC CO BORROWER 13, LLCDelaware
ARHC CO BORROWER 14, LLCDelaware
ARHC CO BORROWER 15, LLCDelaware
ARHC CO SPE Member, LLCDelaware
ARHC CPCIROH01, LLCDelaware
ARHC CPHAMVA01, LLCDelaware
ARHC CSCLWFL01, LLCDelaware
ARHC CSDOUGA01, LLCDelaware
ARHC CSKENMI01, LLCDelaware
ARHC CWEVAGA01 TRS, LLCDelaware
ARHC CWEVAGA01, LLC (f/k/a ARHC CO Borrower 6, LLC)Delaware
ARHC DBDUBGA01 TRS, LLCDelaware
ARHC DBDUBGA01, LLCDelaware



ARHC DDHUDFL01, LLCDelaware
ARHC DDLARFL01, LLCDelaware
ARHC DELVSNV01, LLCDelaware
ARHC DELVSNV02, LLCDelaware
ARHC DFDYRIN01, LLCDelaware
ARHC DMDCRGA01, LLCDelaware
ARHC DVMERID01 TRS, LLCDelaware
ARHC DVMERID01, LLCDelaware
ARHC ECCPTNC01, LLCDelaware
ARHC ECGVLSC01, LLCDelaware
ARHC ECMCYNC01, LLCDelaware
ARHC EMRAYMO01, LLCDelaware
ARHC ESMEMTN01, LLCDelaware
ARHC FMMUNIN01, LLCDelaware
ARHC FMMUNIN02, LLCDelaware
ARHC FMMUNIN03, LLCDelaware
ARHC FMWEDAL01, LLCDelaware
ARHC FOMBGPA01, LLCDelaware
ARHC FOMBGPA01, LLCDelaware
ARHC Fox Ridge MT, LLCDelaware
ARHC FRBRYAR01 TRS, LLCDelaware
ARHC FRBRYAR01, LLCDelaware
ARHC FRLTRAR01 TRS, LLCDelaware
ARHC FRLTRAR01, LLCDelaware
ARHC FRNLRAR01 TRS, LLCDelaware
ARHC FRNLRAR01, LLCDelaware
ARHC FVECOCA01 Trs, LLCDelaware
ARHC FVECOCA01, LLCDelaware
ARHC GDFMHMI01, LLCDelaware
ARHC GFGBTAZ01, LLCDelaware
ARHC GGPOTMO01, LLCDelaware
ARHC GHGVLSC01, LLCDelaware
ARHC GMCLKTN01, LLCDelaware
ARHC GOFENMI01, LLCDelaware
ARHC GYHSVMO01, LLCDelaware
ARHC HBTPAFL01 TRS, LLCDelaware
ARHC HBTPAFL01, LLCDelaware
ARHC HCTMPFL01, LLCDelaware
ARHC HDLANCA01, LLCDelaware
ARHC HHPEOIL01, LLCDelaware
ARHC HRHAMVA01, LLCDelaware
ARHC JCCRKGA01 TRS, LLCDelaware
ARHC JCCRKGA01, LLCDelaware
ARHC KB BORROWER 1, LLCDelaware
ARHC KB BORROWER 10, LLCDelaware
ARHC KB BORROWER 11, LLCDelaware
ARHC KB BORROWER 12, LLCDelaware
ARHC KB BORROWER 13, LLCDelaware
ARHC KB BORROWER 14, LLCDelaware



ARHC KB BORROWER 15, LLCDelaware
ARHC KB BORROWER 2, LLCDelaware
ARHC KB BORROWER 3, LLCDelaware
ARHC KB BORROWER 4, LLCDelaware
ARHC KB BORROWER 5, LLCDelaware
ARHC KB BORROWER 6, LLCDelaware
ARHC KB BORROWER 7, LLCDelaware
ARHC KB BORROWER 8, LLCDelaware
ARHC KB BORROWER 9, LLCDelaware
ARHC KB SPE Member, LLCDelaware
ARHC KEKWDTX01, LLCDelaware
ARHC LCDIXIL01 TRS, LLCDelaware
ARHC LCDIXIL01, LLCDelaware
ARHC LDSPGFL01, LLCDelaware
ARHC LHPTVPA01, LLCDelaware
ARHC LMFMYFL01, LLCDelaware
ARHC LMHBGPA01, LLCDelaware
ARHC LMLANPA01, LLCDelaware
ARHC LMPLNTX01, LLCDelaware
ARHC LPELKCA01, LLCDelaware
ARHC LSSMTMO01 TRS, LLCDelaware
ARHC LSSMTMO01, LLCDelaware
ARHC LVHLDMI01, LLC (f/k/a ARHC CO Borrower 7, LLC)Delaware
ARHC MBAGHCA01 TRS, LLCDelaware
ARHC MBAGHCA01, LLCDelaware
ARHC MCMSHMO01, LLCDelaware
ARHC MCNWDNY01, LLCDelaware
ARHC MHCLVOH01, LLCDelaware
ARHC MMJLTIL01, LLCDelaware
ARHC MMTCTTX01, LLCDelaware
ARHC MRMRWGA01, LLCDelaware
ARHC MSHBGPA01, LLCDelaware
ARHC MTMTNIL01, LLCDelaware
ARHC MVMTNIL01, LLCDelaware
ARHC MVMVNWA01, LLCDelaware
ARHC NHCANGA01, LLCDelaware
ARHC NVJUPFL01 TRS, LLCDelaware
ARHC NVJUPFL01, LLCDelaware
ARHC NVLTZFL01 TRS, LLCDelaware
ARHC NVLTZFL01, LLCDelaware
ARHC NVWELFL01 TRS, LLCDelaware
ARHC NVWELFL01, LLCDelaware
ARHC OCWMNLA01, LLCDelaware
ARHC OLOLNIL01, LLCDelaware
ARHC OOHLDOH001, LLCDelaware
ARHC OPBROOR01 TRS, LLCDelaware
ARHC OPBROOR01, LLCDelaware
ARHC PCCHEMI01, LLCDelaware
ARHC PCLMYPA01, LLCDelaware



ARHC PCPLSMI01, LLCDelaware
ARHC PCSHVMS01, LLCDelaware
ARHC PHCRPIA01 TRS, LLCDelaware
ARHC PHCRPIA01, LLCDelaware
ARHC PHCTNIA01 TRS, LLCDelaware
ARHC PHCTNIA01, LLC (f/k/a ARHC CO Borrower 8, LLC)Delaware
ARHC PHDESIA01 TRS, LLCDelaware
ARHC PHDESIA01, LLC (f/k/a ARHC CO BORROWER 2, LLC)Delaware
ARHC PHNLXIL01, LLCDelaware
ARHC PHOTTIA01 TRS, LLCDelaware
ARHC PHOTTIA01, LLCDelaware
ARHC PHTIPIA01 TRS, LLCDelaware
ARHC PHTIPIA01, LLCDelaware
ARHC Plaza Del Rio Medical Office Campus Member 1, LLCDelaware
ARHC Plaza Del Rio Medical Office Campus Member 2, LLCDelaware
ARHC PMCPKNY01, LLCDelaware
ARHC PMPEOAZ01, LLCDelaware
ARHC PPCLRMI01, LLCDelaware
ARHC PPDWTMI01 TRS, LLCDelaware
ARHC PPDWTMI01, LLCDelaware
ARHC PPDWTMI01, LLCDelaware
ARHC PPGBLMI01, LLCDelaware
ARHC PPHRNTN01, LLCDelaware
ARHC PPLVLGA01, LLCDelaware
ARHC PRPEOAZ01, LLCDelaware
ARHC PRPEOAZ02, LLCDelaware
ARHC PRPEOAZ03, LLCDelaware
ARHC PRPEOAZ04, LLCDelaware
ARHC PRPEOAZ05 TRS, LLCDelaware
ARHC PSINDIA01 TRS, LLCDelaware
ARHC PSINDIA01, LLCDelaware
ARHC PSNHTMA01, LLCDelaware
ARHC PSSGDMA01, LLCDelaware
ARHC PSWSGMA01, LLCDelaware
ARHC PVGYRAZ01, LLCDelaware
ARHC PVPHXAZ01, LLCDelaware
ARHC PVVLGKS01 TRS, LLCDelaware
ARHC PVVLGKS01, LLCDelaware
ARHC PWHLTMI01, LLCDelaware
ARHC Quad Cities Portfolio Member, LLCDelaware
ARHC RACLWFL01, LLCDelaware
ARHC RHMARIL01, LLCDelaware
ARHC RHMESAZ01, LLCDelaware
ARHC RHSUNAZ01, LLCDelaware
ARHC RMRWLTX01, LLCDelaware
ARHC RPATLGA01 TRS, LLCDelaware
ARHC RPATLGA01, LLC (f/k/a ARHC CO BORROWER 3, LLC)Delaware
ARHC RWCUDWI01 TRS, LLCDelaware
ARHC RWCUDWI01, LLCDelaware



ARHC RWROSGA01 TRS, LLCDelaware
ARHC RWROSGA01, LLCDelaware
ARHC SARCOIL01, LLCDelaware
ARHC SAVENFL01, LLCDelaware
ARHC SBBURIA01 TRS, LLCDelaware
ARHC SBBURIA01, LLC (f/k/a ARHC CO BORROWER 1, LLC)Delaware
ARHC SCBTHNY01, LLCDelaware
ARHC SCBTHNY02, LLCDelaware
ARHC SCCRLIA01 TRS, LLCDelaware
ARHC SCCRLIA01, LLC (f/k/a ARHC CO Borrower 9, LLC)Delaware
ARHC SCKCYMO01 TRS, LLCDelaware
ARHC SCKCYMO01, LLCDelaware
ARHC SCTEMTX01, LLCDelaware
ARHC SCVSTCA01, LLCDelaware
ARHC SFFLDIA01 TRS, LLCDelaware
ARHC SFFLDIA01, LLCDelaware
ARHC SFSCHIN01, LLCDelaware
ARHC SFSTOGA01, LLCDelaware
ARHC SLKLAOR01, LLCDelaware
ARHC SMERIPA01, LLCDelaware
ARHC SMMDSIA01 TRS, LLCDelaware
ARHC SMMDSIA01, LLCDelaware
ARHC SMMTEIA01 TRS, LLCDelaware
ARHC SMMTEIA01, LLC (f/k/a ARHC CO Borrower 10, LLC)Delaware
ARHC SPPLSIA01 TRS, LLCDelaware
ARHC SPPLSIA01, LLCDelaware
ARHC SSTMPFL01, LLCDelaware
ARHC TCHOUTX01, LLCDelaware
ARHC TPTMPFL01, LLCDelaware
ARHC TRS HOLDCO II, LLCDelaware
ARHC TVTITFL01 TRS, LLCDelaware
ARHC TVTITFL01, LLC (f/k/a ARHC CO BORROWER 4, LLC)Delaware
ARHC UCELKCA01, LLCDelaware
ARHC UPHBGPA01, LLCDelaware
ARHC UPHBGPA02, LLCDelaware
ARHC UPMOLIL01, LLCDelaware
ARHC UPMUSIA01, LLCDelaware
ARHC VAGBGIL01, LLCDelaware
ARHC VCSTOGA01, LLCDelaware
ARHC VSMCKTX01, LLCDelaware
ARHC VSTALFL01, LLCDelaware
ARHC WCWCHFL01, LLCDelaware
ARHC WGWCHIL01, LLCDelaware
ARHC WHWCHPA01 TRS, LLCDelaware
ARHC WHWCHPA01, LLCDelaware
ARHC WHYRKPA01, LLCDelaware
ARHC WIGNFWI01, LLCDelaware
ARHC WISMLWI01, LLCDelaware
ARHC WISTFWI01, LLCDelaware



ARHC WLWBYMN01, LLCDelaware
ARHC WMBRPMI01, LLCDelaware
ARHC WWGDRMI01, LLCDelaware
ARHC WWWYGMI01, LLCDelaware
LEISURE LIVING MANAGEMENT OF BUCHANAN, LLCMichigan
LEISURE LIVING MANAGEMENT OF GRAND RAPIDS, INC.Michigan
LEISURE LIVING MANAGEMENT OF HOLLAND, INC.Michigan
LEISURE LIVING MANAGEMENT OF LANSING, INC.Michigan
LIFEHOUSE - CRYSTAL MANOR OPERATIONS, LLCMichigan
LIFEHOUSE - GOLDEN ACRES OPERATIONS, LLCMichigan
LIFEHOUSE - WALDON WOODS OPERATIONS, LLCMichigan
LIFEHOUSE CLARE OPERATIONS, LLCMichigan
LIFEHOUSE GRAND BLANC OPERATIONS, LLCMichigan
LIFEHOUSE MT. PLEASANT OPERATIONS, LLCMichigan
LIFEHOUSE PRESTIGE COMMONS OPERATIONS, LLCMichigan
LIFEHOUSE PRESTIGE WAY OPERATIONS, LLCMichigan
NuVista Living at Jupiter, LLCFlorida
ARHC PNPENFL01, LLCDelaware
ARHC SDGMDWOK01, LLCDelaware
ARHC OPFWNIN01, LLCDelaware
ARHC OPFWNIN02, LLCDelaware
ARHC SPABYNY01, LLCDelaware
ARHC SPABYNY02, LLCDelaware
ARHC SPABYNY03, LLCDelaware
ARHC SPTRYNY01, LLCDelaware
ARHC HPOKCOK01, LLCDelaware
ARHC SLESTPA01, LLCDelaware
ARHC MESCSMI01, LLCDelaware
ARHC NCODSTX01, LLCDelaware
ARHC BPBLPOH01, LLCDelaware
ARHC FMTPAFL01, LLCDelaware
ARHC ADERLCO01, LLCDelaware


EX-23.1 4 ex231hti12312022.htm EX-23.1 CONSENT OF PWC Document

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We hereby consent to the incorporation by reference in the Registration Statement on Form S-3D (No. 333-197802) of Healthcare Trust, Inc. of our report dated March 17, 2023 relating to the financial statements and financial statement schedule, which appears in this Form 10‑K.

/s/ PricewaterhouseCoopers LLP
New York, New York
March 17, 2023

EX-31.1 5 ex311hti12312022.htm EX-31.1 CEO 302 CERTIFICATION Document
Exhibit 31.1
CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a) UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
I, Edward M. Weil, Jr., certify that:
1.I have reviewed this Annual Report on Form 10-K of Healthcare Trust, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Dated this 17th day of March, 2023/s/ Edward M. Weil, Jr.
Edward M. Weil, Jr.
Chief Executive Officer and President
(Principal Executive Officer)



EX-31.2 6 ex312hti12312022.htm EX-31.2 CFO 302 CERTIFICATION Document
Exhibit 31.2
CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a) UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
I, Scott M. Lappetito, certify that:
1.I have reviewed this Annual Report on Form 10-K of Healthcare Trust, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Dated this 17th day of March, 2023/s/ Scott M. Lappetito
Scott M. Lappetito
Chief Financial Officer, Treasurer and Secretary
(Principal Financial Officer and Principal Accounting Officer)




EX-32 7 ex32hti12312022.htm EX-32 CEO AND CFO 906 CERTIFICATION Document

Exhibit 32
SECTION 1350 CERTIFICATIONS
This Certificate is being delivered pursuant to the requirements of Section 1350 of Chapter 63 (Mail Fraud) of Title 18 (Crimes and Criminal Procedures) of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
The undersigned, who are the Chief Executive Officer and Chief Financial Officer of Healthcare Trust, Inc. (the “Company”), each hereby certify as follows:
The Annual Report on Form 10-K of the Company, which accompanies this Certificate, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and all information contained in this annual report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated this 17th day of March, 2023
/s/ Edward M. Weil, Jr.
Edward M. Weil, Jr.
Chief Executive Officer and President
(Principal Executive Officer)
/s/ Scott M. Lappetito
Scott M. Lappetito
Chief Financial Officer, Treasurer and Secretary
(Principal Financial Officer and Principal Accounting Officer)


EX-101.SCH 8 hct-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Real Estate Investments, Net link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Mortgage Notes Payable, Net link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Credit Facilities, Net link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Derivatives and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Related Party Transactions and Arrangements link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Economic Dependency link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Equity-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Non-Controlling Interests link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Real Estate and Accumulated Depreciation Schedule III link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Real Estate Investments, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Mortgage Notes Payable, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Credit Facilities, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Derivatives and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Related Party Transactions and Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Equity-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Non-Controlling Interests (Tables) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Organization (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Summary of Significant Accounting Policies (Future Base Rent Payments on a Cash Basis) (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Summary of Significant Accounting Policies (Income Taxes) (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Real Estate Investments, Net (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Real Estate Investments, Net (Acquired Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Real Estate Investments, Net (Geographic Concentrations) (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Real Estate Investments, Net (Summary of Intangible Lease Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Real Estate Investments, Net (Summary of Amortization and Accretion Recognized) (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Real Estate Investments, Net (Summary of Intangible Assets and Liabilities Future Amortization Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Real Estate Investments, Net (Real Estate Sales) (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Real Estate Investments, Net (Impairments) (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Mortgage Notes Payable, Net (Mortgage Notes) (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Mortgage Notes Payable, Net (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Credit Facilities, Net (Summary of Credit Facilities) (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Credit Facilities, Net (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Credit Facilities, Net (Future Principal Payments of Outstanding Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Fair Value of Financial Instruments (Assets Measured at Fair Value) (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Fair Value of Financial Instruments (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Fair Value of Financial Instruments (Level 3 Inputs) (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Derivatives and Hedging Activities (Balance Sheet Location) (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Derivatives and Hedging Activities (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Derivatives and Hedging Activities (Summary of Derivative Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Derivatives and Hedging Activities (Derivatives Included in AOCI) (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Derivatives and Hedging Activities (Offsetting Derivatives) (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Stockholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Stockholders' Equity (Stock Redemption) (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - Stockholders' Equity (Stock Dividends) (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - Related Party Transactions and Arrangements (Ownership) (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - Related Party Transactions and Arrangements (Fees Incurred in Connection with the Operations of the Company) (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - Related Party Transactions and Arrangements (Fees, Expenses and Related Payables) (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - Related Party Transactions and Arrangements (Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company’s Real Estate Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - Equity-Based Compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - Equity-Based Compensation (Summary of Share-based Compensation Awards) (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - Non-controlling Interests - Balance Sheet Breakdown (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - Non-controlling Interests (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000079 - Disclosure - Non-controlling Interests (Summary of Non-controlling Interests) (Details) link:presentationLink link:calculationLink link:definitionLink 0000080 - Disclosure - Net Loss Per Share (Summary of Basic and Diluted Net Loss Per Share Computation) (Details) link:presentationLink link:calculationLink link:definitionLink 0000081 - Disclosure - Net Loss Per Share (Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 0000082 - Disclosure - Segment Reporting (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000083 - Disclosure - Segment Reporting (Reconciliation of Segment Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 0000084 - Disclosure - Segment Reporting (Reconciliation of Segment Activity to Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 0000085 - Disclosure - Segment Reporting (Reconciliation of Capital Expenditures by Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 0000086 - Disclosure - Commitments and Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000087 - Disclosure - Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details) link:presentationLink link:calculationLink link:definitionLink 0000087 - Disclosure - Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details) link:presentationLink link:calculationLink link:definitionLink 0000088 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 0000089 - Disclosure - Real Estate and Accumulated Depreciation Schedule III (Summary of Real Estate Properties) (Details) link:presentationLink link:calculationLink link:definitionLink 0000090 - Disclosure - Real Estate and Accumulated Depreciation Schedule III (Changes in Accumulated Depreciation) (Details) link:presentationLink link:calculationLink link:definitionLink 0000091 - Disclosure - Real Estate and Accumulated Depreciation Schedule III (Changes in Accumulated Depreciation Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 hct-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 hct-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 hct-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Geographic Concentration Risk Geographic Concentration Risk [Member] FOC II - Mechanicsburg, PA FOC II - Mechanicsburg [Member] FOC II - Mechanicsburg [Member] Business Acquisition [Axis] Business Acquisition [Axis] Revision of Prior Period [Axis] Revision of Prior Period [Axis] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Bad debt expense Accounts Receivable, Credit Loss Expense (Reversal) Tender Offer Tender Offer [Member] Tender Offer [Member] Outstanding loan amount Total Long-Term Debt, Gross Public Offering Public Offering [Member] Public Offering Sale and transfer of SHOPs Number Of Senior Housing Operating Properties Sold And Transferred Number Of Senior Housing Operating Properties Sold And Transferred MetroHealth Buckeye Health Center - Cleveland, OH MetroHealthBuckeyeHealthCenterCleveland [Member] MetroHealthBuckeyeHealthCenterCleveland [Member] Preferred stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Preferred Stock, Shares Outstanding Aurora Healthcare Center - Green Bay, WI Aurora Health Center - Green Bay [Member] Aurora Health Center - Green Bay [Member] Aurora Healthcare Center - Wautoma, WI Aurora Healthcare Center, Wautoma, WI [Member] Aurora Healthcare Center, Wautoma, WI [Member] Economic Dependency [Abstract] Economic Dependency [Abstract] Economic Dependency [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Total present value of minimum lease payments Finance Lease, Liability Distributions paid on common stock Payments of Ordinary Dividends, Common Stock Total real estate investments, at cost Real estate investments, at cost Real Estate Investment Property, at Cost Class B units (in shares) Common Share Equivalents, Shares Outstanding Common Share Equivalents, Shares Outstanding Campus at Crooks & Auburn Building D - Rochester Mills, MI Campus at Crooks & Auburn Building D - Rochester Hills [Member] Campus at Crooks & Auburn Building D - Rochester Hills [Member] Debt, fair value disclosure Debt Instrument, Fair Value Disclosure Cash received from derivatives Proceeds from Derivative Instrument, Financing Activities Below market leases, amortization income, 2025 Below Market Lease, Amortization Income, Year Three Real estate investments, at cost: SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross [Abstract] Real Estate Investments, Net Real Estate Disclosure [Text Block] Limited partner units (in shares) Limited Partners' Capital Account, Units Outstanding Other income (expense): Other Income and Expenses [Abstract] Additional paid-in capital Additional Paid in Capital CareMeridian - Littleton, CO CareMeridian - Littleton, CO. [Member] CareMeridian - Littleton, CO. [Member] Renaissance on Peachtree - Atlanta, GA Renaissance on Peachtree - Atlanta [Member] Renaissance on Peachtree - Atlanta [Member] Allegro at Elizabethtown - Elizabethtown, KY Allegro at Elizabethtown - Elizabethtown - September [Member] Allegro at Elizabethtown - Elizabethtown - September [Member] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Variable rate Debt Instrument, Basis Spread on Variable Rate 2026 Finance Lease, Liability, to be Paid, Year Four Below market leases Below Market Leases [Member] Below Market Leases Weighted average discount rate, percent Operating Lease, Weighted Average Discount Rate, Percent Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Deferred tax asset valuation allowance Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability Number of independent contractors Number Of Independent Contractors Number Of Independent Contractors Allocation for preferred stock Dividends, Preferred Stock State (expense) benefit Current State and Local Tax Expense (Benefit) Cash paid for income taxes Income Taxes Paid Encumbrances SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Amount of Encumbrances 2025 Finance Lease, Liability, to be Paid, Year Three Schedule of Impairments Recorded Details of Impairment of Long-Lived Assets Held and Used by Asset [Table Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Change in Control Fee Change in Control Fee [Member] Change in Control Fee [Member] Document Information [Line Items] Document Information [Line Items] Gross Carrying Amount Below Market Lease, Gross Adena Health Center - Jackson, OH Adena Health Center - Jackson, OH [Member] Adena Health Center - Jackson, OH [Member] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Number of states properties are located in Number of States in which Entity Operates Non-controlling Interests Non-controlling Interest Policy [Policy Text Block] Non-controlling Interest Policy [Policy Text Block] Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Interest Expense Interest Expense [Member] Secured Debt Secured Debt [Member] UMPC Chambers Hill - Harrisburg, PA UMPC Chambers Hill - Harrisburg [Member] UMPC Chambers Hill - Harrisburg Ownership [Axis] Ownership [Axis] Payments of deferred financing costs Payments of Financing Costs Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Limited Partners' Capital Account, Class [Domain] Limited Partners' Capital Account, Class [Domain] Related Party [Domain] Related Party [Domain] Shares approved for issuance (in shares) Common Share Equivalents, Shares Approved for Issuance Common Share Equivalents, Shares Approved for Issuance Share price, net (in dollars per share) Share Price, Equity Instruments, Net of Selling Commissions and Dealer Fees Share Price, Equity Instruments, Net of Selling Commissions and Dealer Fees Hedging Designation [Domain] Hedging Designation [Domain] SOFR-based interest rate “pay-fixed” swaps SOFR Based Interest Rate Swap [Member] SOFR Based Interest Rate Swap Gross Revenue, Stand-alone Single-tenant Net Leased Properties Gross Revenue, Stand-alone Single-tenant Net Leased Properties [Member] Gross Revenue, Stand-alone Single-tenant Net Leased Properties [Member] Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Deferred Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract] Revision of Prior Period, Reclassification, Adjustment Revision of Prior Period, Reclassification, Adjustment [Member] Plan Name [Domain] Plan Name [Domain] Financing advance fees as a percentage of benchmark, expected third party costs Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Third Party Acquisition Costs Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Third Party Acquisition Costs Credit facilities, net Outstanding balance Long-Term Line of Credit Entity Address, State or Province Entity Address, State or Province American Realty Capital Healthcare II Special Limited Partnership, LLC American Realty Capital Healthcare II Special Limited Partnership, LLC [Member] American Realty Capital Healthcare II Special Limited Partnership, LLC [Member] Wellington at Hershey's Mill - West Chester, PA Wellington at Hershey's Mill - West Chester [Member] Wellington at Hershey's Mill - West Chester [Member] Amortization of terminated swap Amortization of Terminated Swap Payment Amortization of Terminated Swap Payment Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Variable Management - Incentive Fee Variable Management - Incentive Fee [Member] Variable Management - Incentive Fee [Member] Reduction of real estate cost percent Related Party Transaction Reduction of Real Estate Cost Percent Related Party Transaction Reduction of Real Estate Cost Percent Reclassification, Type [Axis] Reclassification, Type [Axis] Award Type [Axis] Award Type [Axis] Capped Reimbursement Amount Capped Reimbursement Amount [Member] Capped Reimbursement Amount [Member] Subordinated performance fee as a percentage of benchmark Related Party Transaction, Subordinated Performance Fee Earned by Related Party, Percentage of Benchmark Related Party Transaction, Subordinated Performance Fee Earned by Related Party, Percentage of Benchmark Monthly Base Management Fee Monthly Base Management Fee [Member] Monthly Base Management Fee [Member] Disposals, impairments and reclasses Assets Other Real Estate, Disposals And Reclasses Other Real Estate, Disposals And Reclasses Market lease and other intangible assets Above-market lease assets Above Market Leases [Member] Pensacola Nephrology MOB - Pensacola, FL Pensacola Nephrology MOB - Pensacola, FL [Member] Pensacola Nephrology MOB - Pensacola, FL Addington Place of Brunswick - Brunswick, GA Addington Place of Brunswick - Brunswick - September [Member] Addington Place of Brunswick - Brunswick - September [Member] Lender Name [Axis] Lender Name [Axis] Total liabilities Liabilities Remaining lease term Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Straight-line rent receivable, net Deferred Rent Receivables, Net, Noncurrent Revolving Credit Facility Revolving Credit Facility [Member] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Document Type Document Type Encumbered Properties Number of Real Estate Properties, Encumbered Number of Real Estate Properties, Encumbered Useful life Property, Plant and Equipment, Useful Life Surgery Center of Temple - Temple, TX Surgery Center of Temple - Temple, TX. [Member] Surgery Center of Temple - Temple, TX. [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Eastside Cancer Institute - Greenville, SC Eastside Cancer institute - Greenville - October [Member] Eastside Cancer institute - Greenville - October [Member] Severance costs Severance Costs Beginning balance (usd per share) Ending balance (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value American Realty Capital Healthcare Advisors, LLC American Realty Capital Healthcare Advisors, LLC [Member] American Realty Capital Healthcare Advisors, LLC [Member] Prairie Hills at Tipton - Tipton, IA Prairie Hills at Tipton - Tipton - August [Member] Prairie Hills at Tipton - Tipton - August [Member] Asset Acquisition [Axis] Asset Acquisition [Axis] Total income tax benefit (expense) Deferred Income Tax Expense (Benefit) Payments for non-designated derivative instruments Payments for (Proceeds from) Derivative Instrument, Financing Activities UMPC Fisher Road - Mechanicsburg, PA UMPC Fisher Road - Mechanicsburg [Member] UMPC Fisher Road - Mechanicsburg Addington Place of Alpharetta - Alpharetta, GA Addington Place of Alpharetta - Alpharetta [Member] Addington Place of Alpharetta - Alpharetta [Member] Costs capitalized subsequent to acquisition, buildings and improvements SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Cost Capitalized Subsequent to Acquisition, Building and Improvements Line of credit facility, increase limit Line of Credit Facility, Accordion Feature, Increase Limit Line of Credit Facility, Accordion Feature, Increase Limit APIC, stock issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Covenant Period August 11, 2022 Until Commencement Quarter Covenant Period August 11, 2022 Until Commencement Quarter [Member] Covenant Period August 11, 2022 Until Commencement Quarter Sunnybrook of Carroll - Carroll, IA Sunnybrook of Carroll - Carroll - August26 [Member] Sunnybrook of Carroll - Carroll - August26 [Member] Acuity Specialty Hospital - Mesa, AZ AcuitySpecialtyHospitalMesa [Member] AcuitySpecialtyHospitalMesa [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Brady MOB - Harrisburg, PA Brady MOB - Harrisburg [Member] Brady MOB - Harrisburg [Member] Operating lease impairment loss Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal) Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal) Dignity Emerus Blue Diamond - Las Vegas, NV Dignity Emerus Blue Diamond Road - Las Vegas [Member] Dignity Emerus Blue Diamond Road - Las Vegas [Member] Interest and other income Interest and Other Income Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Additions-acquisitions and capital expenditures Real Estate Investment Property, at Cost, Acquisitions Real Estate Investment Property, at Cost, Acquisitions Credit Facilities Revolving Credit Facility Line of Credit [Member] Stockholders’ Equity Stockholders' Equity Attributable to Parent [Abstract] Proceeds from loans Proceeds from Loans Florida Medical Somerset - Tampa, FL Florida Medical - Somerset [Member] Florida Medical - Somerset [Member] Schedule of Restricted Share Award Activity Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Preferred stock distributions declared per share (in usd per share) Preferred Stock, Dividends Per Share, Declared Buyout of non-controlling interest Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Related Party Transaction [Line Items] Related Party Transaction [Line Items] Schedule of Components of Income Tax Benefit (Expense) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] St Peters - Albany, NY - 5 Palisades St Peters - Albany, NY - 5 Palisades [Member] St Peters - Albany, NY - 5 Palisades Nonvested awards, compensation cost not yet recognized, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Other comprehensive loss, before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Schedule of Fair Value by Balance Sheet Fair Value, by Balance Sheet Grouping [Table Text Block] Preferred Stock Equity Line Preferred Stock Equity Line [Member] Preferred Stock Equity Line Derivative Contract [Domain] Derivative Contract [Domain] NOI Gross Profit Entity Registrant Name Entity Registrant Name Swedish American MOB - Roscoe, IL Swedish American MOB - Roscoe [Member] Swedish American MOB - Roscoe Commencement Quarter Commencement Quarter [Member] Commencement Quarter Real estate investments pledged as collateral Real Estate Investment, At Cost Relating to Notes Payable Real Estate Investment, At Cost Relating to Notes Payable Reimbursed fees to related party, capped reimbursement amount Related Party Transaction, Reimbursed Fees to Related Party, Capped Reimbursement Amount Related Party Transaction, Reimbursed Fees to Related Party, Capped Reimbursement Amount Subsequent Events Subsequent Events [Text Block] UnityPoint Clinic - Moline, IL UnityPoint Clinic - Moline [Member] UnityPoint Clinic - Moline [Member] Proceeds from sales of real estate investments Proceeds from Sale of Real Estate Held-for-investment Accounts payable and accrued expenses (including $47 due to related parties as of December 31, 2022 and 2021) Accounts Payable and Accrued Liabilities Consideration received on transaction, gross Sale of Stock, Consideration Received on Transaction, Gross Sale of Stock, Consideration Received on Transaction, Gross Business acquisitions Series of Individually Immaterial Business Acquisitions [Member] Multi-tenant MOB Multi-tenant MOB [Member] Multi-tenant MOB [Member] Real estate investments Real Estate Properties [Line Items] Leases [Abstract] Leases [Abstract] Felicita Vida - Escondido, CA FelicitaVidaEscondido [Member] FelicitaVidaEscondido [Member] Total equity Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Ouachita Community Hospital - West Monroe, LA Ouachita Community Hospital - West Monroe, LA [Member] Ouachita Community Hospital - West Monroe, LA [Member] Discount on offering Sale Of Stock, Discount On Offering Sale Of Stock, Discount On Offering Principles of Consolidation and Basis of Presentation Consolidation, Policy [Policy Text Block] Buildings, fixtures and improvements Buildings, Fixtures and Improvements Buildings, Fixtures and Improvements Quarterly asset management fee Related Party Transaction, Quarterly Asset Management Fee Earned By Related Party, Percentage of Benchmark Related Party Transaction, Quarterly Asset Management Fee Earned By Related Party, Percentage of Benchmark Minimum Minimum [Member] Market lease assets Intangible Market Lease Assets [Member] Intangible Market Lease Assets [Member] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Allegro at Tarpon - Tarpon Springs, FL Allegro at Tarpon - Tarpon Springs - September [Member] Allegro at Tarpon - Tarpon Springs - September [Member] Proceeds from mortgage notes payable Proceeds from Issuance of Secured Debt Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Distributions to non-controlling interest holders Distributions to non-controlling interest holders Payments of Ordinary Dividends, Noncontrolling Interest Trading Symbol Trading Symbol Entity File Number Entity File Number Net offering proceeds, percent Debt Instrument, Covenants, Percent Of Net Offering Proceeds Debt Instrument, Covenants, Percent Of Net Offering Proceeds Weighted-average price per share (in usd per share) Treasury Stock Acquired, Average Cost Per Share Eastern Carolina ENT - Greenville, NC Eastern Carolina ENT - Greenville, NC [Member] Eastern Carolina ENT - Greenville, NC Fee payment period Related Party Transaction, Fee Payment Period Related Party Transaction, Fee Payment Period Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Finite-lived intangible asset, amortization expense, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Accumulated depreciation SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Investment in Real Estate Sold 757 Building - Munster, IN 757 Building - Munster - October [Member] 757 Building - Munster - October [Member] Title of Individual [Axis] Title of Individual [Axis] Derivative Instruments Derivatives, Policy [Policy Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Advance on Loan or Other Investment Advance on Loan or Other Investment [Member] Advance on Loan or Other Investment [Member] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Schedule of Credit Facilities Schedule of Line of Credit Facilities [Table Text Block] Economic interest rate Debt Instrument, Interest Rate, Economic Percentage Debt Instrument, Interest Rate, Economic Percentage Proceeds from credit facilities Proceeds from Lines of Credit Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] In-place leases and other intangible assets In-place leases In-place lease assets Leases, Acquired-in-Place [Member] Palm Valley Medical Plaza - Goodyear, AZ Palm Valley Medical Plaza AZ [Member] Palm Valley Medical Plaza AZ [Member] Distributions declared in common stock Stock Issued During Period, Value, Stock Dividend LIBOR Based Variable Rate LIBOR Based Variable Rate [Member] LIBOR Based Variable Rate Professional fees credit due from Advisor Related Party Transaction, Other Revenues from Transactions with Related Party Concentration risk, percentage Concentration Risk, Percentage Contract Purchase Price Contract Purchase Price [Member] Contract Purchase Price [Member] Circleville MOB - Circleville, OH Circleville MOB - Circleville [Member] Circleville MOB - Circleville Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Atlanta Gastroenterology Associates - Lawrenceville, GA Atlanta Gastroenterology Associates - Lawrenceville, GA [Member] Atlanta Gastroenterology Associates - Lawrenceville, GA Accounts payable and accrued expenses, due to related parties Due to Related Parties Credit Facility [Domain] Credit Facility [Domain] Reclassification From Held-For-Sale To Real Estate Investments Reclassification From Held-For-Sale To Real Estate Investments [Member] Reclassification From Held-For-Sale To Real Estate Investments KeyBank Facility KeyBank Facility [Member] KeyBank Facility [Member] Net loss per common share attributable to common stockholders - Basic (in usd per share) Basic net loss per share (in usd per share) Earnings Per Share, Basic Lancaster Medical Arts MOB - Lancaster, PA LancasterMedicalArtsMOBLancaster [Member] LancasterMedicalArtsMOBLancaster [Member] Disposed properties reduction in revenue Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal), Formerly Disposed Properties Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal), Formerly Disposed Properties Sky Lakes Klamath Medical Clinic - Klamath Falls, OR Sky Lakes Klamath Medical Clinic - Klamath Falls [Member] Sky Lakes Klamath Medical Clinic - Klamath Falls [Member] Payable (receivable) Related Party Transaction, Due from (to) Related Party Third Amended And Restated Advisory Agreement Third Amended And Restated Advisory Agreement [Member] Third Amended And Restated Advisory Agreement [Member] Debt Covenant Period [Domain] Debt Covenant Period [Domain] Debt Covenant Period Buyout of non-controlling interest holders Payments to noncontrolling interests Payments to Noncontrolling Interests RAI Care Center - Clearwater, FL RAI Clearwater [Member] RAI Clearwater [Member] Proceeds from issuance of preferred stock Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants Ownership [Domain] Ownership [Domain] Preferred unit, face value (in usd per share) Preferred Unit, Face Value, Share Price Preferred Unit, Face Value, Share Price Entity Interactive Data Current Entity Interactive Data Current Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] 2023 Lessor, Operating Lease, Payment to be Received, Year One Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Special allocation for tax purposes excess depreciation deductions maximum Related Party Transaction, Special Allocation for Tax Purposes, Excess Depreciation Deductions Maximum Related Party Transaction, Special Allocation for Tax Purposes, Excess Depreciation Deductions Maximum Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] 2027 Finance Lease, Liability, to be Paid, Year Five Audit Information [Abstract] Audit Information Share-based compensation, net Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Greenfield Medical Plaza - Gilbert, AZ Greenfield Medical Plaza - Gilbert [Member] Greenfield Medical Plaza - Gilbert [Member] Common stock repurchases Payments for Repurchase of Common Stock Pioneer Spine Sports - Northampton, MA PioneerSpineSportsNorthampton [Member] PioneerSpineSportsNorthampton [Member] Class of Stock [Axis] Class of Stock [Axis] Thereafter Long-Term Debt, Maturity, after Year Five Income Taxes Income Tax, Policy [Policy Text Block] Below market leases, amortization income, 2026 Below Market Lease, Amortization Income, Year Four Lee Memorial Health System Outpatient Center - Ft. Myers Lee Memorial Health System Outpatient Center - Fort Meyers [Member] Lee Memorial Health System Outpatient Center - Fort Meyers [Member] Increase in preferred stock, dividend rate, percentage Increase (Decrease) Preferred Stock, Dividend Rate, Percentage Increase (Decrease) Preferred Stock, Dividend Rate, Percentage Current Current Federal, State and Local, Tax Expense (Benefit) [Abstract] Common stock issued through distribution reinvestment plan Common stock issued through distribution reinvestment plan Stock Issued During Period, Value, Dividend Reinvestment Plan Florida FLORIDA Asset Acquisition [Domain] Asset Acquisition [Domain] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Distributions in excess of accumulated earnings Retained Earnings (Accumulated Deficit) Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Valuation allowance percentage Deferred Tax Asset, Valuation Allowance, Percentage Deferred Tax Asset, Valuation Allowance, Percentage Economic Dependency Economic Dependency [Text Block] Matters related to services provided by affiliate. Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Financial Instruments Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Security Not Offset Related Party Transactions and Arrangements Related Party Transactions Disclosure [Text Block] Accrued offering costs on Series B Preferred Stock Stock Issuance Costs Incurred But Not Yet Paid Stock Issuance Costs Incurred But Not Yet Paid Rental Income Rental Income [Member] Rental Income [Member] Addington Place of College Harbour - St Petersburg, FL AddingtonPlaceofCollegeHarbourStPetersburgSeptember [Member] AddingtonPlaceofCollegeHarbourStPetersburgSeptember [Member] Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Stock dividend (usd per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend, Weighted Average Grant Date Fair Value Ancillary revenue Ancillary Fee Income Generated by Servicing Financial Assets, Amount Derivative liabilities, at fair value Derivative Financial Instruments, Liabilities [Member] Contract Sale Price Disposal Group, Including Discontinued Operation, Consideration Severance Payments Severance Payments [Member] Severance Payments Deferred Costs Deferred Charges, Policy [Policy Text Block] Lease intangibles, lease-up period Lease Intangibles, Lease-up Period Lease Intangibles, Lease-up Period Interest rate cap Derivative, Cap Interest Rate Illinois CancerCare - Galesburg, IL Illinois Cancer Care - Galesburg [Member] Illinois Cancer Care - Galesburg [Member] Real Estate Cost Real Estate Cost [Member] Real Estate Cost [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Acuity Specialty Hospital - Sun City, AZ AcuitySpecialtyHospitalSunCity [Member] AcuitySpecialtyHospitalSunCity [Member] Stock dividend (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend Number of instruments held, not active Derivative, Number Of Instruments Held, Not Active Derivative, Number Of Instruments Held, Not Active Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Transition Fee Transition Fee [Member] Transition Fee [Member] Number of securities called by share purchase right (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Property operating and maintenance Property operating and maintenance Operating Lease, Expense East Coast Square West - Cedar Point, NC East Coast Square West - Cedar Point - October [Member] East Coast Square West - Cedar Point - October [Member] Addington Place of Johns Creek - Johns Creek, GA Addington Place of Johns Creek - Johns Creek - September [Member] Addington Place of Johns Creek - Johns Creek - September [Member] Mortgage premiums and discounts, net Debt Instrument, Unamortized Discount (Premium), Net Capital One MOB Loan MOB Loan [Member] MOB Loan [Member] Consumer Price Index Consumer Price Index [Member] Consumer Price Index [Member] Document Information [Table] Document Information [Table] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common stock held by related party (in shares) Common Stock, Shares, Outstanding Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Interest rate cap agreements excluded Derivative, Notional Amount, Not Yet In Effect Derivative, Notional Amount, Not Yet In Effect Issuance of Series A Preferred OP Units Noncontrolling Interest, Increase from Subsidiary Equity Issuance Common OP Unit Common Operating Partnership Unit [Member] Common Operating Partnership Unit In-place leases and other intangible assets In-place Leases and Other Intangible Assets [Member] In-place Leases and Other Intangible Assets [Member] Number of properties held-for-use Disposal Group Including Discontinued Operation, Number Of Properties Held For Use Disposal Group Including Discontinued Operation, Number Of Properties Held For Use Income tax expense Income Tax Expense (Benefit) Preferred units, issued (in shares) Preferred Units, Issued Geographical [Domain] Geographical [Domain] Entity Public Float Entity Public Float VA Outpatient Clinic - Galesberg, IL VA Outpatient Clinic - Galesburg [Member] VA Outpatient Clinic - Galesburg [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Above- and below-market leases, net Above and Below Market Leases [Member] Above and Below Market Leases [Member] Fannie Mae Master Credit Facilities Master Credit Facility Master Credit Facility [Member] Master Credit Facility [Member] Derivative liabilities, at fair value Net Amounts of Assets presented in the Consolidated Balance Sheet Derivative Liability Schererville Building - Schererville, IN Schererville Building - Schererville [Member] Schererville Building - Schererville [Member] Gross Amounts of Recognized (Liabilities) Derivative Liability, Subject to Master Netting Arrangement, before Offset Preferred stock, dividend rate (in usd per share) Preferred Stock, Dividend Rate, Per-Dollar-Amount Lien settlement on formerly disposed properties Lien settlement on formerly disposed properties [Member] Lien settlement on formerly disposed properties New Credit Facilities New Credit Facilities [Member] New Credit Facilities [Member] Contingent good faith negotiations of fixed component, term Related Party Transaction, Contingent Good Faith Negotiations Of Fixed Component, Term Related Party Transaction, Contingent Good Faith Negotiations Of Fixed Component, Term Common stock, $0.01 par value, 300,000,000 shares authorized, 105,080,531 shares and 99,281,754 shares issued and outstanding as of December 31, 2022 and 2021, respectively Common Stock, Value, Issued Day Prior to Commencement Quarter Day Prior to Commencement Quarter [Member] [Member] Day Prior to Commencement Quarter [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Preferred Stock Preferred Stock [Member] Capital One Facility Capital One Facility [Member] Capital One Facility [Member] LIBOR-based interest rate “pay-fixed” swaps LIBOR Based Interest Rate Swap [Member] LIBOR Based Interest Rate Swap Seniors Housing — Operating Properties Seniors Housing Communities [Member] Seniors Housing Communities [Member] Second Amended and Restated Advisory Agreement Second Amended and Restated Advisory Agreement [Member] Second Amended and Restated Advisory Agreement [Member] Number of properties under contract for disposal Disposal Group Including Discontinued Operation, Number Of Properties Under Disposal Contract Disposal Group Including Discontinued Operation, Number Of Properties Under Disposal Contract Issuance of Preferred OP Units Equity Instrument Consideration, Preferred Units Issued Equity Instrument Consideration, Preferred Units Issued Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Preferred stock, additional shares authorized (in shares) Preferred Stock, Additional Shares Authorized Preferred Stock, Additional Shares Authorized Schedule of Derivatives Included in AOCI Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Allegro at Jupiter - Jupiter, FL Allegro at Jupiter - Jupiter - September [Member] Allegro at Jupiter - Jupiter - September [Member] Cash, cash equivalents and restricted cash, beginning of year Cash, cash equivalents and restricted cash, end of year Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Glendale MOB - Farmington Hills, MI Glendale MOB - Farmington Hills MI [Member] Glendale MOB - Farmington Hills MI [Member] Professional fees and other reimbursements Transfer Agent and Other Professional Fees [Member] Transfer Agent and other professional fees [Member] St Lukes Heart Vascular Center - East Stroudsburg St Lukes Heart Vascular Center - East Stroudsburg [Member] St Lukes Heart Vascular Center - East Stroudsburg Adventist Health Lacey Medical Plaza - Hanford, CA Adventist Health Lacey Medical Plaza - Hanford [Member] Adventist Health Lacey Medical Plaza - Hanford [Member] Fresenius Medical Care - Winfield, AL Fresenius Medical Care - Winfield, AL [Member] Fresenius Medical Care - Winfield, AL [Member] Total Stockholders’ Equity Parent [Member] Income Statement Location [Domain] Income Statement Location [Domain] Amendment Flag Amendment Flag Period of notice of termination Related Party Transaction, Period of Notice for Termination Related Party Transaction, Period of Notice for Termination Operating lease costs Operating Lease, Cost Percent distribution in excess of modified funds from operations Debt Instrument, Covenants, Distribution In Excess Of Modified Funds From Operations, Percent Debt Instrument, Covenants, Distribution In Excess Of Modified Funds From Operations, Percent Weighted-average remaining amortization periods Finite-Lived Intangible Assets, Remaining Amortization Period Unrealized loss on designated derivative Other Comprehensive Income (Loss), Net of Tax Acquired intangibles Real Estate Investments, Acquired Intangible Assets, Total Real Estate Investments, Acquired Intangible Assets, Total Fox Ridge Chenal - Little Rock, AR Fox Ridge Senior Living at Chenal - Little Rock [Member] Fox Ridge Senior Living at Chenal - Little Rock [Member] St. Andrews Medical Park - Venice, FL St. Andrews Medical Park - Venice [Member] St. Andrews Medical Park - Venice [Member] Capital expenditures and other assets acquired Payments to Acquire Other Property, Plant, and Equipment Florida Medical Heartcare - Tampa, FL Florida Medical - Heartcare [Member] Florida Medical - Heartcare [Member] Proceeds from sale of interest rate cash flow hedge Proceeds From Sale of Interest Rate Cash Flow Hedge Proceeds From Sale of Interest Rate Cash Flow Hedge Depreciation and amortization Depreciation, Depletion and Amortization Bowie Gateway Medical Center - Bowie, MD Bowie Gateway Medical Center - Bowie [Member] Bowie Gateway Medical Center - Bowie [Member] Lutz, Florida Lutz, Florida [Member] Lutz, Florida [Member] Scripps Cedar Medical Center - Vista, CA Scripps Cedar Medical Center - Vista - August [Member] Scripps Cedar Medical Center - Vista - August [Member] Sassafras Medical Building - Erie, PA Sassafras Medical Building - Erie [Member] Sassafras Medical Building - Erie [Member] Counterparty Name [Axis] Counterparty Name [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Prepaid Expenses and Other Assets Prepaid Expenses And Other Assets [Member] Prepaid Expenses And Other Assets East Coast Square North - Morehead City, NC East Coast Square North - Morehead City - October [Member] East Coast Square North - Morehead City - October [Member] Number of instruments Number of Instruments Derivative, Number of Instruments Held Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Net Amount Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Arrowhead Medical Plaza I - Glendale, AZ Arrowhead Medical Plaza I - Glendale [Member] Arrowhead Medical Plaza I - Glendale [Member] Operating lease payments Operating Lease, Payments Schedule of Stock Dividends Dividends Declared [Table Text Block] Asset position with fair value Derivative Instruments in Hedges, Assets, at Fair Value Derivative liabilities, at fair value Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral Michigan MICHIGAN St. Francis WI MOB - St. Francis, WI StFrancisWIMOBStFrancis [Member] StFrancisWIMOBStFrancis [Member] Total intangible assets and liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired in Period, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired in Period, Net Pioneer Spine Sport - Springfield, MA PioneerSpineSportsSpringfield [Member] PioneerSpineSportsSpringfield [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Total expenses Operating Expenses Maximum Maximum [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Victory Medical Center at Craig Ranch - McKinney, TX VictoryMedicalCenteratCraigRanchMcKinney [Member] VictoryMedicalCenteratCraigRanchMcKinney [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Basis of core earnings, percent Related Party Transaction, Basis of Core Earnings, Percent Related Party Transaction, Basis of Core Earnings, Percent Dividends Payable [Line Items] Dividends Payable [Line Items] Crittenton Sterling Heights MOB - Sterling Heights, MI Crittenton Sterling Heights MOB [Member] Crittenton Sterling Heights MOB [Member] Measurement Frequency [Domain] Measurement Frequency [Domain] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Schedule of Shares Repurchased [Table] Schedule of Shares Repurchased [Table] Schedule of Shares Repurchased [Table] Line of Credit Facility [Table] Line of Credit Facility [Table] Aurora Health Center - Milwaukee, WI AuroraHealthCenterMilwaukeeApril [Member] AuroraHealthCenterMilwaukeeApril [Member] Addington Place of Titusville - Titusville, FL Addington Place of Titusville - Titusville [Member] Addington Place of Titusville - Titusville [Member] Mortgage notes payable assumed, net Business Combination, Assets and Liabilities Assumed, Mortgage Proceeds Business Combination, Assets and Liabilities Assumed, Mortgage Proceeds Straight-line rent receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-Controlling Ownership Percentage Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Number of dividends in arrears required for voting rights Preferred Stock, Number Of Additional Directors, Quarterly Dividends In Arrears Requirement Preferred Stock, Number Of Additional Directors, Quarterly Dividends In Arrears Requirement Subsequent Event [Line Items] Subsequent Event [Line Items] Payments on credit facilities Repayments of credit facility borrowings Repayments of Lines of Credit Cedarhurst of Edwardsville - Edwardsville, IL Cedarhurst Of Edwardsville - Edwardsville [Member] Cedarhurst Of Edwardsville - Edwardsville Term of lease excluded Lessee, Operating Lease, Renewal Term, Excluded Lessee, Operating Lease, Renewal Term, Excluded Segment Reporting Segment Reporting Disclosure [Text Block] Interest and other income Other Nonoperating Income Advanced Orthopedic Medical Center - Richmond, VA Advanced Orthopaedic Medical Center - Richmond - April [Member] Advanced Orthopaedic Medical Center - Richmond - April [Member] Northside Hospital - Canton, GA Northside Hospital Medical Office Building - Canton [Member] Northside Hospital Medical Office Building - Canton [Member] Cash in excess of FDIC limit Cash, Uninsured Amount LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Fair Value Estimate of Fair Value Measurement [Member] Investments in Real Estate Real Estate, Policy [Policy Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Pulmonary & Critical Care Med - Lemoyne, PA Pulmonary & Critical Care Medicine Accoc - Lemoyne [Member] Pulmonary & Critical Care Medicine Accoc - Lemoyne [Member] Number of properties purchased Number of Businesses Acquired Income Tax Authority [Axis] Income Tax Authority [Axis] Fox Ridge Senior Living at Chenal - Little Rock, AR Fox Ridge Senior Living at Chenal - Little Rock - December [Member] Fox Ridge Senior Living at Chenal - Little Rock - December [Member] Proceeds from government assistance Proceeds From Government Assistance, CARES Act Proceeds From Government Assistance, CARES Act Weighted-average common shares outstanding - Basic (in shares) Basic weighted-average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Debt instrument, collateral amount Debt Instrument, Collateral Amount Woodlake Office Center - Woodbury, MN Woodlake Office Center [Member] Woodlake Office Center [Member] Board of directors voting percentage Related Party Transaction, Voting Percentage Required to Alter Agreement Related Party Transaction, Voting Percentage Required to Alter Agreement Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Skilled Nursing Facilities Skilled Nursing Facilities [Member] Skilled Nursing Facilities [Member] Number of senior housing communities Number of Senior Housing Communities Number of Senior Housing Communities Rivershores Healthcare & Rehab Centre - Marseilles, IL Rivershores Healthcare & Rehab Centre - Marseilles - December [Member] Rivershores Healthcare & Rehab Centre - Marseilles - December [Member] Notional Amount Derivative, Notional Amount Cumulative redeemable perpetual preferred stock Preferred Stock, Value, Issued Unvested Restricted Shares Restricted Stock [Member] Deferred costs Deferred Costs Operating fees to related parties Costs and Expenses, Related Party Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases and Lessee Accounting Lessee, Leases [Policy Text Block] Significant Unobservable Inputs Level 3 Fair Value, Inputs, Level 3 [Member] Floor interest rate Debt Instrument, Floor Interest Rate Debt Instrument, Floor Interest Rate Maximum authorized amount as a percentage of shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Equity-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of core earnings (in usd per share) Related Party Transaction, Basis of Core Earnings, Per Share Basis Related Party Transaction, Basis of Core Earnings, Per Share Basis Operating fees to related parties Affiliate Costs Authorized preferred stock offering, value Preferred Stock Offering, Authorized Value Preferred Stock Offering, Authorized Value Addington Place - Northville, MI Addington Place - Northville [Member] Addington Place - Northville Number of properties disposed Disposal Group Including Discontinued Operation, Number Of Properties Disposed Disposal Group Including Discontinued Operation, Number Of Properties Disposed Center for Advanced Dermatology - Lakewood, CO Center for Advanced Dermatology - Lakewood, CO [Member] Center for Advanced Dermatology - Lakewood, CO 2024 Lessor, Operating Lease, Payment to be Received, Year Two Non-controlling Interests Noncontrolling Interest [Member] High Desert Medical Group Medical Office Building - Lancaster, CA High Desert Medical Group Medical Office Building - Lancaster [Member] High Desert Medical Group Medical Office Building - Lancaster [Member] Mount Vernon Medical Office Building - Mount Vernon, WA Mount Vernon Medical Office Building - Mount Vernon - November [Member] Mount Vernon Medical Office Building - Mount Vernon - November [Member] Property management fees Property Management and Leasing Fees [Member] Property Management and Leasing Fees [Member] Debt service coverage ratio Debt Instrument, Covenants, Debt Service Coverage Ratio Debt Instrument, Covenants, Debt Service Coverage Ratio Pennsylvania PENNSYLVANIA Commercial Center - Peoria, AZ Commercial Center - Peoria - May [Member] Commercial Center - Peoria - May [Member] Addington Place of Lee's Summit - Lee's Summit, MO Addington Place of Lee's Summit - Lee's Summit - September [Member] Addington Place of Lee's Summit - Lee's Summit - September [Member] Related Party [Axis] Related Party [Axis] Land Land [Member] Renewal term Related Party Agreement, Term of Agreement, Renewal Period Related Party Agreement, Term of Agreement, Renewal Period Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Disposal Group Name [Domain] Disposal Group Name [Domain] Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Significant Other Observable Inputs Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Mainland Medical Arts Pavilion - Texas City, TX Mainland Medical Arts Pavilion - Texas City [Member] Mainland Medical Arts Pavilion - Texas City [Member] Milwaukee MOB - South Milwaukee, WI MilwaukeeMOBSouthMilwaukee [Member] MilwaukeeMOBSouthMilwaukee [Member] Net Carrying Amount Intangible Assets, Net (Excluding Goodwill) Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Assets held for sale Disposal Group, Including Discontinued Operation, Assets Mortgage assumed in acquisition Noncash, or Part Noncash, Mortgage Notes Payable Secured In Connection With The Acquisition Of Real Estate Noncash, or Part Noncash, Mortgage notes secured simultaneously with the acquisition of real estate assets, which includes land, buildings, fixtures, and land and building improvements. Naidu Clinic - Odessa, TX Naidu Clinic - Odessa, TX [Member] Naidu Clinic - Odessa, TX Accumulated Amortization Below Market Lease, Accumulated Amortization Concentration Risk Type [Axis] Concentration Risk Type [Axis] American Realty Capital Healthcare III Advisors, LLC American Realty Capital Healthcare III Advisors, LLC [Member] American Realty Capital Healthcare III Advisors, LLC [Member] Sunnybrook of Burlington - Burlington, IA Sunnybrook of Burlington - Burlington [Member] Sunnybrook of Burlington - Burlington [Member] Healthcare Trust Special Limited Partnership, LLC Healthcare Trust Special Limited Partnership, LLC [Member] Healthcare Trust Special Limited Partnership, LLC [Member] Paradise Valley Medical Plaza - Phoenix, AZ Paradise Valley Medical Plaza - Phoenix - December [Member] Paradise Valley Medical Plaza - Phoenix - December [Member] Number of finance lease contracts Lessee, Finance Lease, Number Of Contracts Lessee, Finance Lease, Number Of Contracts Stock issued during period, issued for services (in shares) Stock Issued During Period, Shares, Issued for Services Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Proceeds from common stock issued through distribution reinvestment plan Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan Remaining lease term Lease, Remaining Lease Term Lease, Remaining Lease Term Physicians Plaza of Roane County - Harriman, TN Physicians Plaza of Roane County - Harriman [Member] Physicians Plaza of Roane County - Harriman [Member] Reimbursements of Employee Bonuses of the Advisor Reimbursements of Employee Bonuses of the Advisor [Member] Reimbursements of Employee Bonuses of the Advisor Net Amount Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Income Tax Authority [Domain] Income Tax Authority [Domain] Average variable interest rate Derivative, Average Variable Interest Rate Colonial Healthcare & Rehab Centre - Princeton, IL Colonial Healthcare & Rehab Centre - Princeton - December [Member] Colonial Healthcare & Rehab Centre - Princeton - December [Member] Over-Allotment Option Over-Allotment Option [Member] Cash Collateral Received Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset DRIP, period of notice to alter agreement DRIP, Period of Notice to Alter Agreement DRIP, Period of Notice to Alter Agreement Deferred tax valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Units issued to purchase building Common Unit, Issuance Value Credit Facility [Axis] Credit Facility [Axis] Transaction amount Related Party Transaction, Amounts of Transaction Michigan properties Michigan Properties [Member] Michigan Properties Landis Memorial - Harrisburg, PA Landis Memorial - Harrisburg - September [Member] Landis Memorial - Harrisburg - September [Member] Equity [Abstract] Equity [Abstract] Subsequent Event [Table] Subsequent Event [Table] Creekside MOB - Douglasville, GA Creekside MOB - Douglasville [Member] Creekside MOB - Douglasville [Member] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Beginning balance (in shares) Ending balance (in shares) Unvested restricted stock (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Hampton River Portfolio (two properties) Hampton River Portolio [Member] Hampton River Portolio Prairie Hills at Clinton - Clinton, IA Prairie Hills at Clinton - Clinton - August [Member] Prairie Hills at Clinton - Clinton - August [Member] NuVista Jupiter NuVista Jupiter [Member] NuVista Jupiter Covenant Period after June 30 2021 Covenant Period after June 30 2021 [Member] Covenant Period after June 30 2021 Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Market lease liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities Acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities Acquired Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Real Estate [Abstract] Real Estate [Abstract] Healthcare Trust Operating Partnership, L.P. Healthcare Trust Operating Partnership, L.P. [Member] Healthcare Trust Operating Partnership, L.P. [Member] Payments on mortgage notes payable Repayments of Secured Debt Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Real estate investments, at cost: Investments in real estate, net: Real Estate Investment Property, at Cost [Abstract] Pioneer Spine Sports - West Springfield, MA PioneerSpineSportsWestSpringfield [Member] PioneerSpineSportsWestSpringfield [Member] Entity [Domain] Entity [Domain] Related Party Fees, by Benchmark [Axis] Related Party Fees, by Benchmark [Axis] Related Party Fees, by Benchmark [Axis] City Area Code City Area Code ASSETS Assets [Abstract] Plaza Del Rio Medical Office Campus Portfolio AZ Plaza Del Rio Medical Office Campus Portfolio AZ [Member] Plaza Del Rio Medical Office Campus Portfolio AZ [Member] Revision of Prior Period, Adjustment Revision of Prior Period, Adjustment [Member] Quarterly Variable Management Fee, Benchmark One Quarterly Variable Management Fee, Benchmark One [Member] Quarterly Variable Management Fee, Benchmark One [Member] Distributions declared in common stock (in shares) Common Stock Dividends, Shares Sale of Stock [Axis] Sale of Stock [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Per Share Data Earnings Per Share, Policy [Policy Text Block] Preferred units, redemption period Preferred Units, Redemption Period Preferred Units, Redemption Period 2023 Long-Term Debt, Maturity, Year One Equity-based compensation Share-Based Payment Arrangement, Noncash Expense The Heights Healthcare & Rehab Centre - Peoria Heights, IL The Heights Healthcare & rehab Centre - Peoria Heights - December [Member] The Heights Healthcare & rehab Centre - Peoria Heights - December [Member] Preferred units issued (in usd per share) Preferred Unit, Issuance Value, Share Price Preferred Unit, Issuance Value, Share Price Variable Rate [Axis] Variable Rate [Axis] Interest rate contract Interest Rate Contract [Member] Sunnybrook of Muscatine - Muscatine, IA Sunnybrook of Muscatine - Muscatine - August26 [Member] Sunnybrook of Muscatine - Muscatine - August26 [Member] Deferred rent Increase (Decrease) in Other Operating Liabilities Special Limited Partner Special Limited Partner [Member] Special Limited Partner [Member] West Michigan Surgery Center - Big Rapids, MI West Michigan Surgery Center - Big Rapids [Member] West Michigan Surgery Center - Big Rapids [Member] Total capital expenditures Payments to Acquire Property, Plant, and Equipment Finite-lived intangible asset, amortization expense, 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Aurora Healthcare Center - Plymouth, WI Aurora Healthcare Center Plymouth, WI [Member] Aurora Healthcare Center Plymouth, WI [Member] Thereafter Finance Lease, Liability, to be Paid, after Year Five Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] TEXAS TEXAS Below-market lease liabilities Below Market Lease [Member] Below Market Lease [Member] Covenant Period From July 1, 2021 through Commencement Quarter Covenant Period From July 1, 2021 through Commencement Quarter [Member] Covenant Period From July 1, 2021 through Commencement Quarter [Member] Real Estate [Domain] Real Estate [Domain] Number of instruments terminated Derivative, Number of Instruments Terminated Derivative, Number of Instruments Terminated Schedule of Offsetting Assets Offsetting Assets [Table Text Block] Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties [Member] Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties [Member] Morrow Medical Center - Morrow, GA Morrow Medical Center - Morrow - June [Member] Morrow Medical Center - Morrow - June [Member] UC Davis MOB - Elk Grove, CA UC Davis MOB - Elk Grove [Member] UC Davis MOB - Elk Grove [Member] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table] Amount of loss reclassified from accumulated other comprehensive income (loss) Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Covenant Period Quarter Ending June 30, 2022 Through June 30, 2023 Covenant Period Quarter Ending June 30, 2022 Through June 30, 2023 [Member] Covenant Period Quarter Ending June 30, 2022 Through June 30, 2023 Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Fort Wayne Opthomology Engle - Fort Wayne, IN Fort Wayne Opthomology Engle - Fort Wayne, IN [Member] Fort Wayne Opthomology Engle - Fort Wayne, IN Entity Address, Postal Zip Code Entity Address, Postal Zip Code Area of real estate property Area of Real Estate Property Base management fee of net proceeds Related Party Transaction, Base Management Fee of Net Proceeds, Percent Related Party Transaction, Base Management Fee of Net Proceeds, Percent Market lease intangible liabilities, net Off-Market Lease, Unfavorable 2024 Long-Term Debt, Maturity, Year Two Subordinated participation fees as a percentage of benchmark Related Party Transaction, Subordinated Incentive Listing Distribution, Percentage of Benchmark Related Party Transaction, Subordinated Incentive Listing Distribution, Percentage of Benchmark Preferred stock, dividend rate, percentage Preferred Stock, Dividend Rate, Percentage Common stock issued through distribution reinvestment plan (in shares) Stock Issued During Period, Shares, Dividend Reinvestment Plan Expenses incurred Related Party Transaction, Expenses from Transactions with Related Party Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Rockwall Medical Plaza - Rockwall, TX Rockwall Medical Plaza [Member] Rockwall Medical Plaza [Member] Cash received from non-designated derivative instruments Derivative Instruments Not Designated As Hedging Instruments, Cash Received Derivative Instruments Not Designated As Hedging Instruments, Cash Received Pinnacle Center - Southaven, MS Pinnacle Center - Southaven - December [Member] Pinnacle Center - Southaven - December [Member] Oversight fees earned by related party Related Party Transaction, Oversight Fees Earned by Related Party, Percentage of Benchmark Related Party Transaction, Oversight Fees Earned by Related Party, Percentage of Benchmark Multi-Property CMBS Loan Multi-Property CMBS Loan [Member] Multi-Property CMBS Loan [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Units issued to fund purchase of A Building (in usd per share) Common Unit, Issuance Value Share Price Common Unit, Issuance Value Share Price Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] UnityPoint Clinic Portfolio UnityPoint Clinic Portfolio [Member] UnityPoint Clinic Portfolio [Member] Aurora Healthcare Center - Kiel, WI Aura Sheboyan Clinic - Kiel - March [Member] Aura Sheboyan Clinic - Kiel - March [Member] Asset management fees Asset Management Fees [Member] Asset Management Fees [Member] Beaumont Medical Center - Warren, MI Beaumont Medical Center - Warren [Member] Beaumont Medical Center - Warren [Member] Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Domestic Tax Authority Domestic Tax Authority [Member] Distributions payable Dividends Payable Total Fair Value, Net Asset (Liability) Decatur Medical Office Building - Decatur, GA Decatur Medical Office Building [Member] Decatur Medical Office Building [Member] Stock repurchase, value Treasury Stock, Value, Acquired, Cost Method (Accretion) amortization of market lease and other intangibles, net Accretion of above- and below-market leases, net Accretion of Below-Market Lease Liabilities and Amortization of Above-Market Lease Assets, Net Adjustment for noncash decrease (increase) in rental revenue related to assets (liabilities) associated with the acquisition of an off-market lease when the terms of the lease are favorable (unfavorable) to the market terms for the lease at the date of acquisition. Advisor And Company Advisor And Company [Member] Advisor And Company [Member] Deferred rent Deferred Rent Credit Other intangible assets Other Intangible Assets [Member] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Mortgage notes payable, net Secured debt Secured Debt Subsequent Event Type [Axis] Subsequent Event Type [Axis] Property Operating and Maintenance Expense Property Operating and Maintenance Expense [Member] Property Operating and Maintenance Expense [Member] Property management fees Related Party Transaction, Property Management Fees Earned by Related Party, Percentage of Benchmark Related Party Transaction, Property Management Fees Earned by Related Party, Percentage of Benchmark Non-controlling interests in property owning subsidiaries Noncontrolling Interests In Property Owning Subsidiaries Noncontrolling Interests In Property Owning Subsidiaries Commitments and Contingencies Lessee, Operating Leases [Text Block] Net Carrying Amount Below Market Lease, Net Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital [Member] Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital [Member] Plan Name [Axis] Plan Name [Axis] Direct Financing Leases Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Real Estate [Line Items] Real Estate [Line Items] Number of intercompany leases modified Number Of Intercompany Leases Modified Number Of Intercompany Leases Modified Intangible assets: Finite-Lived Intangible Assets, Net [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Four Single-Tenant MOB Properties Four Single-Tenant MOB Properties [Member] Four Single-Tenant MOB Properties Noncontrolling Interest [Abstract] Noncontrolling Interest [Abstract] Bone and Joint Specialists - Merrillville, IN Bone and Joint Specialists - Merrillville, IN [Member] Bone and Joint Specialists - Merrillville, IN Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Quoted Prices in Active Markets Level 1 Fair Value, Inputs, Level 1 [Member] Disposals, impairments and reclasses SEC Schedule, 12-28, Real Estate Companies, Investment In Real Estate, Accumulated Depreciation, Disposals, Impairments And Reclassifications SEC Schedule, 12-28, Real Estate Companies, Investment In Real Estate, Accumulated Depreciation, Disposals, Impairments And Reclassifications Sunnybrook of Mt. Pleasant - Mt. Pleasant, IA Sunnybrook of MT. Pleasant - Mt. Pleasant - August26 [Member] Sunnybrook of MT. Pleasant - Mt. Pleasant - August26 [Member] Stock dividends (in shares) Stock Dividends, Shares Gain (loss) on sale of real estate investments (Gain) loss on sales of real estate investments, net Gains (Losses) on Sales of Investment Real Estate Maximum shares per preferred stock offering (in shares) Preferred Stock Offering, Maximum Shares per Offer Preferred Stock Offering, Maximum Shares per Offer Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Derivative assets, at fair value Net Amounts of Assets presented in the Consolidated Balance Sheet Derivative Asset Reclassification, Type [Domain] Reclassification, Type [Domain] Cedarhurst of Shiloh - Shiloh, IL Cedarhurst Of Shiloh - Shiloh [Member] Cedarhurst Of Shiloh - Shiloh Related Party Transaction [Domain] Related Party Transaction [Domain] Cash flow hedge reclassification in next twelve months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Document Annual Report Document Annual Report Wellington Wellington [Member] Wellington Legal Entity [Axis] Legal Entity [Axis] Costs capitalized subsequent to acquisition, land SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Cost Capitalized Subsequent to Acquisition, Land Illinois skilled nursing facilities M O B Property Illinois Skilled Nursing Facilities [Member] M O B Property Illinois Skilled Nursing Facilities [Member] DaVita Dialysis - Hudson, FL DaVita Hudson [Member] DaVita Hudson [Member] Belmar Medical Building -Lakewood, CO Belmar Medical Building - Lakewood - June [Member] Belmar Medical Building - Lakewood - June [Member] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items] Geographical [Axis] Geographical [Axis] Bayshore Naples Memory Care - Naples, FL Bayshore Naples Memory Care - Naples [Member] Bayshore Naples Memory Care - Naples Legacy Medical Village - Plano, TX Legacy Medical Village - Plano [Member] Legacy Medical Village - Plano [Member] Issuance of preferred stock, net Stock Issued During Period, Value, New Issues Due from affiliates Due from Affiliates Florida Medical Wesley Chapel - Tampa, FL Florida Medical - Wesley Chapel [Member] Florida Medical - Wesley Chapel [Member] Fee multiplier Related Party Transaction, Fee Multiplier Related Party Transaction, Fee Multiplier St. Peters Albany 2 Palisades - Albany, NY St. Peters Albany 2 Palisades - Albany, NY [Member] St. Peters Albany 2 Palisades - Albany, NY Real Estate [Table] Real Estate [Table] Total tangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired During Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired During Period Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Related Party Fees, Benchmark [Domain] Related Party Fees, Benchmark [Domain] Related Party Fees, Benchmark [Domain] Disposal Group, Held-for-use, Not Discontinued Operations Disposal Group, Held-for-use, Not Discontinued Operations [Member] Disposal Group, Held-for-use, Not Discontinued Operations [Member] Number of Common Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] 2020 Bonus Awards 2020 Bonus Awards [Member] 2020 Bonus Awards Fixed charge coverage ratio Debt Instrument, Covenants, Fixed Charge Coverage Ratio Debt Instrument, Covenants, Fixed Charge Coverage Ratio Segments [Axis] Segments [Axis] Credit Facilities, Net Debt Disclosure [Text Block] Total real estate investments, net Net Real Estate Assets Subject to Investment Arrangement Real Estate Investment Property, Net Entity Shell Company Entity Shell Company Financing advance fees as a percentage of benchmark, expected company portfolio cost Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Company's Portfolio Costs Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Company's Portfolio Costs Concentration Risk [Table] Concentration Risk [Table] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Tax Depreciation Deduction Tax Depreciation Deduction [Member] Tax Depreciation Deduction [Member] Women’s Healthcare Group MOB - York, PA WomensHealthcareGroupMOBYork [Member] WomensHealthcareGroupMOBYork [Member] 2025 Long-Term Debt, Maturity, Year Three Gateway MOB - Clarksville, TN Gateway Medical Office Building - Clarksville - October [Member] Gateway Medical Office Building - Clarksville - October [Member] Affiliated Entity Affiliated Entity [Member] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Autumn Ridge of Clarkston - Clarkston, MI Autumn Ridge Of Clarkston - Clarkston - August [Member] Autumn Ridge Of Clarkston - Clarkston - August Consolidation Items [Domain] Consolidation Items [Domain] Subsequent Event Subsequent Event [Member] Sales Revenue, Net Revenue Benchmark [Member] Fort Wayne Opthomology Dupont - Fort Wayne, IN Fort Wayne Opthomology Dupont - Fort Wayne, IN [Member] Fort Wayne Opthomology Dupont - Fort Wayne, IN Document Period End Date Document Period End Date 2027 Lessor, Operating Lease, Payment to be Received, Year Five Payments for deposits Payments for Deposits on Real Estate Acquisitions Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items] Ancillary Fee Income, Servicing Financial Asset, Statement of Income or Comprehensive Income [Extensible Enumeration] Ancillary Fee Income, Servicing Financial Asset, Statement of Income or Comprehensive Income [Extensible Enumeration] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Assets FOC I - Mechanicsburg, PA FOC I - Mechanicsburg [Member] FOC I - Mechanicsburg [Member] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Cedarhurst of Collinsville - Collinsville, IL Cedarhurst of Collinsville [Member] Cedarhurst of Collinsville [Member] Schedule of Recurring Fair Value Measurements Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Buildings, fixtures and improvements Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Building, Fixtures and Improvements, Capital Leases, Acquired in Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Building, Fixtures and Improvements, Capital Leases, Acquired in Period Total interest rate “pay-fixed” swaps Interest Rate Swap [Member] Single Tenant MOB Single Tenant MOB [Member] Single Tenant MOB [Member] UnityPoint Clinic - Muscatine, IA UnityPoint Clinic - Muscatine [Member] UnityPoint Clinic - Muscatine [Member] Preferred stock, liquidation preference (in usd per share) Preferred Stock, Liquidation Preference Per Share 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Stock repurchased, authorized amount Stock Repurchase Program, Authorized Amount Fox Ridge Senior Living at Bryant - Bryant, AR Fox Ridge Senior Living at Bryant - Bryant - December [Member] Fox Ridge Senior Living at Bryant - Bryant - December [Member] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Sunnybrook of Ft. Madison - Ft. Madison, IA Sunnybrook of Ft. Madison - Ft. Madison - August26 [Member] Sunnybrook of Ft. Madison - Ft. Madison - August26 [Member] Segments [Domain] Segments [Domain] Dividend paid on Preferred stock Payments of Ordinary Dividends, Preferred Stock and Preference Stock Countryside Medical Arts - Safety Harbor, FL Countryside Medical Arts - Safety Harbor [Member] Countryside Medical Arts - Safety Harbor [Member] Net Loss Per Share Earnings Per Share [Text Block] Non-Controlling Interests Noncontrolling Interest Disclosure [Text Block] Restricted Share Plan Restricted Share Plan [Member] Restricted Share Plan [Member] Distributions on Class B Units Distributions On Class B Units [Member] Distributions On Class B Units [Member] Interest rate caps Interest Rate Cap [Member] Disposed by sale Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Below market leases, amortization income, 2024 Below Market Lease, Amortization Income, Year Two Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Derivative assets, at fair value Derivative Financial Instruments, Assets [Member] Award Type [Domain] Award Type [Domain] Accounting for Leases, Lessor Accounting Lessor, Leases [Policy Text Block] Intangible liabilities: Below Market Lease, Net [Abstract] Schedule of Balance Sheet Location Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Addington Place of Prairie Village - Prairie Village, KS Addington Place of Prairie Village - Prairie Village [Member] Addington Place of Prairie Village - Prairie Village [Member] Subject Fees (Transition Fee Not in Excess of the Product) Subject Fees (Transition Fee Not in Excess of the Product) [Member] Subject Fees (Transition Fee Not in Excess of the Product) [Member] Issuance of preferred stock, net (in shares) Stock Issued During Period, Shares, New Issues Limited partner units, redemption period Limited Partners' Capital Account, Units, Redemption Period Limited Partners' Capital Account, Units, Redemption Period Cost of living percent multiplier Related Party Transaction Basis Cost Of Living Percent Related Party Transaction Basis Cost Of Living Percent Medical Center V - Peoria, AZ Medical Center V - Peoria, AZ Medical Center V - Peoria, AZ [Member] Medical Center V - Peoria, AZ [Member] Medical Center III - Peoria, AZ Medical Center III - Peoria [Member] Medical Center III - Peoria [Member] Prairie Hills at Des Moines - Des Moines, IA Prairie Hills at Des Moines - Des Moines - August [Member] Prairie Hills at Des Moines - Des Moines - August [Member] Mortgage Notes Payable Mortgages [Member] Fannie Credit Facility Fannie Credit Facility [Member] Fannie Credit Facility [Member] Entity Address, City or Town Entity Address, City or Town Florida Medical Tampa Palms - Tampa, FL Florida Medical - Tampa Palms [Member] Florida Medical - Tampa Palms [Member] Depreciation expense SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Depreciation Expense Gross Revenue, Managed Properties Gross Revenue, Managed Properties [Member] Gross Revenue, Managed Properties [Member] Operating expenses: Operating Expenses [Abstract] Term of agreement Related Party Transaction, Term of Agreement Related Party Transaction, Term of Agreement Class B units Class B Units [Member] Class B Units [Member] 759 Building - Munster, IN 759 Building - Munster - October [Member] 759 Building - Munster - October [Member] Non-controlling interests Total Non-controlling Interests Third Party Net Investment Amount Stockholders' Equity Attributable to Noncontrolling Interest In-place and market leases Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Acquired During The Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Acquired During The Period Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] 2026 Lessor, Operating Lease, Payment to be Received, Year Four Cash flow hedge reclassification current Unamortized portion remaining in accumulated other comprehensive (loss) income Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net Deferred financing costs, net of accumulated amortization Deferred financing costs Debt Issuance Costs, Net Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Auditor Name Auditor Name Aurora Healthcare Center - Greenville, WI Aurora Healthcare Center, Greenville,WI [Member] Aurora Healthcare Center, Greenville,WI [Member] Below market leases, amortization income, 2023 Below Market Lease, Amortization Income, Year One Operating loss carryforwards Operating Loss Carryforwards Unencumbered Properties Unencumbered Properties [Member] Unencumbered Properties [Member] Advocate Aurora MOB - Elkhorn, WI Advocate Aurora MOB - Elkhorn WI [Member] Advocate Aurora MOB - Elkhorn WI [Member] Interest rate cap agreements excluded Number Of Interest Rate Derivatives Not Yet In Effect Number Of Interest Rate Derivatives Not Yet In Effect Disposal Group Classification [Axis] Disposal Group Classification [Axis] Restricted cash Restricted Cash and Cash Equivalents Schedule of Noncontrolling Interest on Balance Sheet Noncontrolling Interest [Table Text Block] Noncontrolling Interest Land SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Land Preferred unit issuance value Preferred Unit, Issuance Value Preferred Unit, Issuance Value Sunnybrook of Fairfield - Fairfield, IA Sunnybrook of Fairfield - Fairfield - August26 [Member] Sunnybrook of Fairfield - Fairfield - August26 [Member] Belpre V Cancer Center - Belpre, OH Belpre V Cancer Center - Belpre, OH [Member] Belpre V Cancer Center - Belpre, OH Subsequent Events [Abstract] Subsequent Events [Abstract] Revenue from tenants Revenues Unrealized gain (loss) on designated derivatives Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Covenant Period Quarter Ending March 31, 2024 And Thereafter Covenant Period Quarter Ending March 31, 2024 And Thereafter [Member] Covenant Period Quarter Ending March 31, 2024 And Thereafter Useful life SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation Cedarhurst of Sparta - Sparta, IL Cedarhurst Of Sparta - Sparta [Member] Cedarhurst Of Sparta - Sparta State (expense) benefit Deferred State and Local Income Tax Expense (Benefit) OrthoOne Hilliard - Hilliard, OH OrthoOne Hilliard - Hilliard, OH [Member] OrthoOne Hilliard - Hilliard, OH Amortization/accretion of market least intangibles Amortization of Intangible Assets Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Distributions declared in common stock (in usd per share) Common Stock, Stock Dividends, Per Share, Declared Common Stock, Stock Dividends, Per Share, Declared 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Arbor View Assisted Living and Memory Care - Burlington, WI Arbor View Assisted Living and Memory Care - Burlington - March [Member] Arbor View Assisted Living and Memory Care - Burlington - March [Member] Public Stock Offering Public Stock Offering [Member] Public Stock Offering [Member] Land Improvements Land Improvements [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders’ equity Stockholders' Equity Attributable to Parent Derivatives and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Director Director [Member] Morton Villa Healthcare & Rehab Centre - Morton, IL Morton Villa Healthcare & Rehab Centre - Morton [Member] Morton Villa Healthcare & Rehab Centre - Morton [Member] Forfeitures (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Campus at Crooks & Auburn Building C - Rochester Mills, MI Campus at Crooks & Auburn Building C - Rochester Hills - June [Member] Campus at Crooks & Auburn Building C - Rochester Hills - June [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Preferred stock, number of shares issued in public offering Sale of Stock, Number of Shares Issued in Transaction Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Finite-lived intangible asset, amortization expense, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three 2027 Long-Term Debt, Maturity, Year Five Distributions in Excess of Accumulated Earnings Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] 2025 Lessor, Operating Lease, Payment to be Received, Year Three Sun City MOB MOB Property, Sun City, Arizona [Member] MOB Property, Sun City, Arizona Common Stock Common Stock [Member] Prairie Hills at Cedar Rapids - Cedar Rapids, IA Prairie Hills at Cedar Rapids - Cedar Rapids - August [Member] Prairie Hills at Cedar Rapids - Cedar Rapids - August [Member] Money market funds Money Market Funds, at Carrying Value Medical Center I - Peoria, AZ Medical Center I - Peoria - May [Member] Medical Center I - Peoria - May [Member] Number of reportable segments Number of Reportable Segments CARES Act Grants Revenue [Policy Text Block] Redeemable amount of shares (in shares) Limited Partners' Capital Account, Potentially Redeemable Amount Limited Partners' Capital Account, Potentially Redeemable Amount Statement [Table] Statement [Table] Schedule of Properties Sold Disposal Groups, Including Discontinued Operations [Table Text Block] Vested (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Effective Interest Rate Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Depreciation and Amortization Expense Depreciation and Amortization Expense [Member] Depreciation and Amortization Expense [Member] Palm Valley Medical Plaza - Goodyear, AZ Palm Valley Medical Plaza - Goodyear - April [Member] Palm Valley Medical Plaza - Goodyear - April [Member] Fixtures and improvements Furniture and Fixtures [Member] BMO CMBS BMO MOB Loan BMO MOB Loan [Member] BMO MOB Loan Schedule of Class of Treasury Stock Class of Treasury Stock [Table Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Arcadian Cove Assisted Living - Richmond, KY Arcadian Cove Assisted Living [Member] Arcadian Cove Assisted Living [Member] Number of shares repurchased (in shares) Number of shares repurchased (in shares) Treasury Stock, Shares, Acquired Related Party Transaction [Axis] Related Party Transaction [Axis] Disposal Group Name [Axis] Disposal Group Name [Axis] Equity Components [Axis] Equity Components [Axis] Term Loan Term Loan [Member] Term Loan [Member] Kingwood Executive Center - Kingwood, TX Kingwood Executive Center - Kingwood, TX [Member] Kingwood Executive Center - Kingwood, TX Dividends Payable [Table] Dividends Payable [Table] Reportable Segments Segment Reporting, Policy [Policy Text Block] St. Peters Troy 2 New Hampshire - Troy, NY St. Peters Troy 2 New Hampshire - Troy, NY [Member] St. Peters Troy 2 New Hampshire - Troy, NY Revision of Prior Period [Domain] Revision of Prior Period [Domain] Schedule of Acquired Finite-Lived Intangible Assets by Major Class Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Vascular Surgery Associates - Tallahassee, FL Vascular Surgery Associates [Member] Vascular Surgery Associates [Member] Statement [Line Items] Statement [Line Items] Dignity Emerus Craig Rd - North Las Vegas, NV Dignity Emerus Craig Road - North Las Vegas [Member] Dignity Emerus Craig Road - North Las Vegas [Member] Prairie Hills at Ottumwa - Ottumwa, IA Prairie Hills at Ottumwa - Ottumwa - August [Member] Prairie Hills at Ottumwa - Ottumwa - August [Member] Total other expenses Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Number of additional directors Preferred Stock, Number Of Additional Directors Preferred Stock, Number Of Additional Directors Gross Carrying Amount Finite-Lived Intangible Assets, Gross Subject Fees Subject Fees [Member] Subject Fees [Member] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Common stock repurchases Stock Repurchased During Period, Value Accumulated Other Comprehensive Income (Loss) Unrealized Gains (Losses) on Designated Derivative AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Medical Office Buildings MOB Segment: Medical Office Buildings [Member] Medical Office Buildings [Member] Rebalancing of ownership percentage Adjustments to Additional Paid in Capital, Rebalancing Of Ownership Percentage Adjustments to Additional Paid in Capital, Rebalancing Of Ownership Percentage Auditor Firm ID Auditor Firm ID Land Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Acquired in Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Acquired in Period Base management fee of net proceeds, variable portion factor, percent Related Party Transaction, Base Management Fee Of Net Proceeds, Variable Portion Factor, Percent Related Party Transaction, Base Management Fee Of Net Proceeds, Variable Portion Factor, Percent Document Transition Report Document Transition Report Local Phone Number Local Phone Number Operating loss Operating Income (Loss) Number of operating lease contracts Lessee, Operating Lease, Number Of Contracts Lessee, Operating Lease, Number Of Contracts Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Schedule of Real Estate Properties [Table] Schedule of Real Estate Properties [Table] Cash paid for real estate investments, including acquisitions Business Acquisition Cost Of Acquired Entity Cash Paid In Period Business Acquisition Cost Of Acquired Entity Cash Paid In Period Depreciation and Amortization Depreciation, Depletion, and Amortization [Policy Text Block] The Atrium - Rockford, IL The Atrium - Rockford [Member] The Atrium - Rockford [Member] Quarterly Variable Management Fee, Benchmark Two Quarterly Variable Management Fee, Benchmark Two [Member] Quarterly Variable Management Fee, Benchmark Two [Member] Common stock repurchases (in shares) Stock Repurchased During Period, Shares Camellia Walk Assisted Living and Memory Care - Evans, GA Camellia Walk Assisted Living And Memory Care - Evans [Member] Camellia Walk Assisted Living And Memory Care - Evans [Member] Name of Property [Domain] Name of Property [Domain] Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Total income tax benefit (expense) Current Federal, State and Local, Tax Expense (Benefit) Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Series A Preferred Stock Series A Cumulative Redeemable Perpetual Preferred Stock [Member] Series A Cumulative Redeemable Perpetual Preferred Stock 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Wellington Green Wellington, Florida skilled nursing facility Wellington Green [Member] Wellington Green Federal (expense) benefit Deferred Federal Income Tax Expense (Benefit) Additional Paid-in Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Prairie Hills at Independence - Independence, IA Prairie Hills at Independence - Independence [Member] Prairie Hills at Independence - Independence [Member] Fox Ridge Bryant - Bryant, AR Fox Ridge Senior Living at Bryant - Bryant [Member] Fox Ridge Senior Living at Bryant - Bryant [Member] Advisor Advisor [Member] Advisor [Member] Medical Sciences Pavilion - Harrisburg, PA Medical Sciences Pavilion - Harrisburg - December [Member] Medical Sciences Pavilion - Harrisburg - December [Member] Derivative [Line Items] Derivative [Line Items] Weighted-average common shares outstanding - Diluted (in shares) Diluted weighted-average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Conroe Medical Arts and Surgery Center - Conroe, TX Conroe Medical Arts and Surgery Center - Conroe [Member] Conroe Medical Arts and Surgery Center - Conroe [Member] Community Health MOB - Harrisburg, PA Community Health MOB - Harrisburg [Member] Community Health MOB - Harrisburg [Member] Sunnybrook of Burlington - Land - Burlington, IA Sunnybrook of Burlington - Land - Burlington - August [Member] Sunnybrook of Burlington - Land - Burlington - August [Member] Laguna Professional Center - Elk Grove, CA Laguna Professional Center - Elk Grove [Member] Laguna Professional Center - Elk Grove [Member] Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return [Member] Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return [Member] Term Loan, net Long-term Line of Credit, Including Financing Costs Long-term Line of Credit, Including Financing Costs ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Base Rate Base Rate [Member] Carrying Amount  Reported Value Measurement [Member] Pre-tax Non-compounded Return on Capital Contribution Pre-tax Non-compounded Return on Capital Contribution [Member] Pre-tax Non-compounded Return on Capital Contribution [Member] Operating Segments Operating Segments [Member] Professional fees credit due from Advisor Professional Fees Credit Due From Advisor [Member] Professional Fees Credit Due From Advisor Extension term Long Term Line Of Credit, Maturity, Extension Term Long Term Line Of Credit, Maturity, Extension Term Covenant Period Quarter Ending September 30, 2023 Through December 31, 2023 Covenant Period Quarter Ending September 30, 2023 Through December 31, 2023 [Member] Covenant Period Quarter Ending September 30, 2023 Through December 31, 2023 Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Madison Medical Plaza - Joliet, IL Madison Medical Plaza - Joliet [Member] Madison Medical Plaza - Joliet [Member] Net loss (income) attributable to non-controlling interests Net Income (Loss) Attributable to Noncontrolling Interest Net loss attributable to common stockholders Net loss attributable to stockholders Net Income (Loss) Available to Common Stockholders, Basic Texas Children’s Hospital - Houston, TX Texas Children's Hospital - Houston [Member] Texas Children's Hospital - Houston [Member] Common stock, shares issued (in shares) Common Stock, Shares, Issued Concentration Risk [Line Items] Concentration Risk [Line Items] Village Center Parkway - Stockbridge, GA Village Center Parkway - Stockbridge [Member] Village Center Parkway - Stockbridge [Member] Number of properties held for sale Disposal Group Including Discontinued Operation, Number Of Properties Held For Sale Disposal Group Including Discontinued Operation, Number Of Properties Held For Sale Meadowbrook Senior Living - Agoura Hills, CA Meadowbrook Senior Living - Agoura Hills - November [Member] Meadowbrook Senior Living - Agoura Hills - November [Member] Greenfield MOB - Greenfield, WI GreenfieldMOBGreenfield [Member] GreenfieldMOBGreenfield [Member] Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Acquisition and transaction related Acquisition and transaction related Business Combination, Acquisition Related Costs Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Minimum net worth required for compliance Banking Regulation, Mortgage Banking, Net Worth, Minimum Fox Ridge North Little Rock - North Little Rock, AR Fox Ridge North Little Rock - North Little Rock, AR Fox Ridge Senior Living at Parkstone - North Little Rock [Member] Fox Ridge Senior Living at Parkstone - North Little Rock [Member] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Debt instrument, face amount Debt Instrument, Face Amount Comprehensive loss attributable to common stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Segment Reporting Schedule of Segment Reporting Information, by Segment [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Impairment charges Impairment charges Impairment of Real Estate Series B Preferred Stock Series B Cumulative Redeemable Perpetual Preferred Stock [Member] Series B Cumulative Redeemable Perpetual Preferred Stock Real estate cost percent multiplier Related Party Transaction Basis of Real Estate Cost Percent Related Party Transaction Basis of Real Estate Cost Percent 2019 Bonus Awards 2019 Bonus Awards [Member] 2019 Bonus Awards LIBOR-Based Borrowings LIBOR-Based Borrowings [Member] LIBOR-Based Borrowings Addington Place at Mills - Roswell, GA AddingtonPlaceatMillsRosewell [Member] AddingtonPlaceatMillsRosewell [Member] 2023 Finance Lease, Liability, to be Paid, Year One Above-market ground leases Above Market Ground Lease [Member] Above Market Ground Lease [Member] Derivative [Table] Derivative [Table] Derivative assets, at fair value (non-designated) Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Florida Medical Clinic - Tampa, FL Florida Medical Clinic - Tampa, FL [Member] Florida Medical Clinic - Tampa, FL 2024 Finance Lease, Liability, to be Paid, Year Two Basis of Accounting and Out-of-Period Adjustment Basis of Accounting, Policy [Policy Text Block] Operating Leases Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Number of land parcels Number Of Land Parcels Number Of Land Parcels Title of Individual [Domain] Title of Individual [Domain] Accumulated Depreciation Balance at beginning of year Balance at end of the year SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation Distributions declared in cash on common stock Dividends Operating loss before gain on sale of real estate investments Operating Income (Loss) Before Gain (Loss) on Sale of Real Estate Investments Operating Income (Loss) Before Gain (Loss) on Sale of Real Estate Investments Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Forfeitures (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Mortgage notes payable, net Long-Term Debt Balance Sheet Location [Axis] Balance Sheet Location [Axis] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Accumulated depreciation: SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation [Roll Forward] Gain (loss) on non-designated derivatives (Gain) loss on non-designated derivative instruments Gain on non designated derivatives Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Presence Healing Arts Pavilion - New Lenox, IL Presence Healing Arts Pavilion - New Lenox - December [Member] Presence Healing Arts Pavilion - New Lenox - December [Member] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Number of instruments held, active Derivative, Number Of Instruments Held, Active Derivative, Number Of Instruments Held, Active Addington Place of Dublin - Dublin, GA Addington Place of Dublin - Dublin - September [Member] Addington Place of Dublin - Dublin - September [Member] Eye Specialty Group Medical Building - Memphis, TN Eye Specialty Group Medical Building - Memphis - December [Member] Eye Specialty Group Medical Building - Memphis - December [Member] Sassafras MOB MOB Property, Sassafras [Member] MOB Property, Sassafras Hefner Pointe Medical Center - Oklahoma City, OK Hefner Pointe Medical Center - Oklahoma City, OK [Member] Hefner Pointe Medical Center - Oklahoma City, OK Oak Lawn Medical Center - Oak Lawn, IL Oak Lawn Medical Center - Oak Lawn, IL. [Member] Oak Lawn Medical Center - Oak Lawn, IL. [Member] Delisting Delisting [Member] Delisting [Member] Entity Small Business Entity Small Business Measurement Basis [Axis] Measurement Basis [Axis] Shares outstanding (in shares) Shares, Outstanding Liberty Court - Dixon, IL Liberty Court - Dixon [Member] Liberty Court - Dixon [Member] LaSalle Properties LaSalle Properties [Member] LaSalle Properties Distributions declared per share (in usd per share) Common Stock, Dividends, Per Share, Declared Series A Preferred Unit Series A Preferred Unit [Member] Series A Preferred Unit Acquired intangible assets Finite-Lived Intangible Assets, Net Philip Professional Center - Lawrenceville, GA Philip Professional Center - Lawrenceville, GA [Member] Philip Professional Center - Lawrenceville, GA [Member] Estate at Hyde Park - Tampa, FL Estate at Hyde Park - Tampa - July [Member] Estate at Hyde Park - Tampa - July [Member] Distributions to non-controlling interest holders Distributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Restricted cash Restricted Cash Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Nonvested awards, compensation cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Amortization of mortgage premiums and discounts, net Amortization of Debt Discount (Premium) Federal income taxes SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Federal Income Tax Basis Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Number of real estate properties Number of properties Number of Real Estate Properties Gross Amount Balance at beginning of year Balance at end of the year SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross Number of properties acquired Asset Acquisition, Number Of Properties Acquired Asset Acquisition, Number Of Properties Acquired Schedule of Shares Repurchased [Line Items] Schedule of Shares Repurchased [Line Items] [Line Items] for Schedule of Shares Repurchased [Table] Reimbursements of Administrative Services Reimbursements of Administrative Services [Member] Reimbursements of Administrative Services [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services [Table Text Block] Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services [Table Text Block] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Operating lease liabilities Operating Lease, Liability Property acquisitions and development costs Payments to acquire property Payments to Acquire Real Estate Equity-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Land Land Total minimum lease payments Finance Lease, Liability, to be Paid Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member] Schedule of Finance Lease, Liability, Maturity Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] Non-cash investing and financing activities: Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract] Noncontrolling Interest [Table] Noncontrolling Interest [Table] Finite-lived intangible asset, amortization expense, 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Total Lessor, Operating Lease, Payments to be Received Granted (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Covenant Period After Commencement Quarter Covenant Period After Commencement Quarter [Member] Covenant Period After Commencement Quarter Accumulated amortization Finite-Lived Intangible Assets and Liabilities, Accumulated Amortization Finite-Lived Intangible Assets and Liabilities, Accumulated Amortization 761 Building - Munster, IN 761 Building - Munster - October [Member] 761 Building - Munster - October [Member] Sale of stock, net proceeds Sale of Stock, Consideration Received on Transaction Crittenton Washington MOB - Washington Township, MI Crittenton Washington MOB [Member] Crittenton Washington MOB [Member] Morton Terrace Healthcare & Rehab Centre - Morton, IL Morton Terrace Healthcare& Rehab Centre - Morton - December [Member] Morton Terrace Healthcare& Rehab Centre - Morton - December [Member] Current borrowing capacity, base percent Debt Instrument, Covenants, Current Borrowing Capacity Base Percent Debt Instrument, Covenants, Current Borrowing Capacity Base Percent Dyer Building - Dyer, IN Dyer Building - Dyer - October [Member] Dyer Building - Dyer - October [Member] 2026 Long-Term Debt, Maturity, Year Four Hedging Designation [Axis] Hedging Designation [Axis] Various held for use SHOPs Various Seniors Housing Communities [Member] Various Seniors Housing Communities [Member] Auditor Location Auditor Location Minimum cash, cash equivalents, and borrowing capacity Debt Instrument, Covenants, Minimum Cash, Cash Equivalents, and Borrowing Capacity Debt Instrument, Covenants, Minimum Cash, Cash Equivalents, and Borrowing Capacity Entity Filer Category Entity Filer Category Gross amounts of recognized liabilities Gross Amounts Offset in the Consolidated Balance Sheet Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Schedule Related to Investment Arrangements with Unaffiliated Third Party Redeemable Noncontrolling Interest [Table Text Block] Federal (expense) benefit Current Federal Tax Expense (Benefit) Arrowhead Medical Plaza II - Glendale, AZ Arrowhead Medical Plaza II - Glendale [Member] Arrowhead Medical Plaza II - Glendale [Member] Total Non-controlling Interests in the OP Noncontrolling Interest in Operating Partnerships Shiloh - Illinois Shiloh - Illinois [Member] Shiloh - Illinois [Member] DaVita Bay Breeze Dialysis Center - Largo, FL DaVita Bay Breeze [Member] DaVita Bay Breeze [Member] Berwyn Medical Center - Berwyn, IL Berwyn Medical Center - Berwyn [Member] Berwyn Medical Center - Berwyn [Member] Consideration transferred Asset Acquisition, Consideration Transferred Period of notice Related Party Transaction, Period of Notice to Alter Agreement Related Party Transaction, Period of Notice to Alter Agreement Share-based compensation expense Share-Based Payment Arrangement, Expense Security Exchange Name Security Exchange Name Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Common stock issued through stock dividends Stock Issued Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Common OP Unit Common OP Unit [Member] Common OP Unit Prepaid expenses and other assets (including $929 due from related parties as of December 31, 2021) Prepaid expenses and other assets Prepaid Expense and Other Assets Addington Place of Shoal Creek - Kansas City, MO Addington Place of Shoal Creek - Kansas City [Member] Addington Place of Shoal Creek - Kansas City [Member] OP Units Common OP Units OP Units [Member] OP Units [Member] Below market leases, amortization income, 2027 Below Market Lease, Amortization Income, Year Five Cover [Abstract] Cover [Abstract] Entity Voluntary Filers Entity Voluntary Filers Number of properties marketed for sale Disposal Group Including Discontinued Operation, Number Of Properties Marketed For Sale Disposal Group Including Discontinued Operation, Number Of Properties Marketed For Sale Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Less: accumulated depreciation and amortization Real Estate Investment Property, Accumulated Depreciation Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Covenant Period From And After Commencement Quarter Covenant Period From And After Commencement Quarter [Member] Covenant Period From And After Commencement Quarter Segment Reporting [Abstract] Segment Reporting [Abstract] Courtyard Fountains - Gresham, OR Courtyard Fountains - Gresham, OR [Member] Courtyard Fountains - Gresham, OR [Member] Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Total liabilities and equity Liabilities and Equity Amortization (including write-offs) of deferred financing costs Amortization of Debt Issuance Costs Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Greenville Health System - Greenville, SC Greenville Health System - Greenville, SC [Member] Greenville Health System - Greenville, SC [Member] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Less: amounts representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Net loss per common share attributable to common stockholders - Diluted (in usd per share) Diluted net loss per share (in usd per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period Purchase Price Allocation Purchase Price Allocation Policy [Policy Text Block] Purchase Price Allocation Policy [Policy Text Block] St Peters - Albany, NY - 4 Palisades St Peters - Albany, NY - 4 Palisades [Member] St Peters - Albany, NY - 4 Palisades Restricted share vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Mortgage Notes Payable, Net Mortgage Notes Payable Disclosure [Text Block] Consolidation Items [Axis] Consolidation Items [Axis] FOC Clinical - Mechanicsburg, PA FOC Clinical - Mechanicsburg [Member] FOC Clinical - Mechanicsburg [Member] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Lakeside Vista - Holland, MI Lakeside Vista - Holland [Member] Lakeside Vista - Holland Metropolitan Eye Lakeshore Surgery - St. Clair, MI Metropolitan Eye Lakeshore Surgery - St. Clair, MI [Member] Metropolitan Eye Lakeshore Surgery - St. Clair, MI Deferred tax asset, net Deferred Tax Assets, Net of Valuation Allowance Repurchase price per share, percentage of estimated per-share NAV Stock Repurchase Program, Share Price, Percentage Of Estimated Per-Share NAV Stock Repurchase Program, Share Price, Percentage Of Estimated Per-Share NAV Thereafter Lessor, Operating Lease, Payment to be Received, after Year Five Amended and Restated Property Management and Leasing Agreement Amended and Restated Property Management and Leasing Agreement [Member] Amended and Restated Property Management and Leasing Agreement [Member] Schedule of Future Base Rent Payments on a Cash Basis Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block] Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Share Repurchase Program [Axis] Share Repurchase Program [Axis] Prepaid expenses and other assets, due from related parties Due from Related Parties Limited Partners' Capital Account by Class [Axis] Limited Partners' Capital Account by Class [Axis] Proceeds from issuance of Preferred Stock, net Proceeds from Issuance of Preferred Stock and Preference Stock Gross amounts of recognized assets Derivative Asset, Subject to Master Netting Arrangement, before Offset Schedule of Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Aurora Healthcare Center - Waterford, WI Aurora Healthcare Center, Waterford, WI [Member] Aurora Healthcare Center, Waterford, WI [Member] Class of Stock [Domain] Class of Stock [Domain] Bloom MOB - Harrisburg, PA Bloom MOB - Harrisburg - December [Member] Bloom MOB - Harrisburg - December [Member] Wood Glen Nursing and Rehab Center - West Chicago, IL Wood Glen Nursing and Rehab Center - West Chicago - December [Member] Wood Glen Nursing and Rehab Center - West Chicago - December [Member] Interest expense Interest expense Total amount of interest expense presented in the consolidated statements of operations and comprehensive loss Interest Expense Allegro at Stuart - Stuart, FL Allegro at Stuart - Stuart - September [Member] Allegro at Stuart - Stuart - September [Member] Acquisition cost reimbursements Acquisition Costs Reimbursements [Member] Acquisition Costs Reimbursements [Member] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Building Building [Member] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table] UMPC Sir Thomas Court - Harrisburg, PA UMPC Sir Thomas Court - Harrisburg [Member] UMPC Sir Thomas Court - Harrisburg Number of real estate properties, failed to recover carrying value Number Of Real Estate Properties, Failed To Recover Carrying Value Number Of Real Estate Properties, Failed To Recover Carrying Value Building and Improvements SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Building and Improvements Stock issuance costs Sale Of Stock, Stock Issuance Cost Sale Of Stock, Stock Issuance Cost Allegro at St. Petersburg - Land - St. Petersburg, FL Allegro at St Petersburg - Land - St Petersburg - September [Member] Allegro at St Petersburg - Land - St Petersburg - September [Member] Capitol Healthcare & Rehab Centre - Springfield, IL Capitol Healthcare & Rehab Centre - Springfield - December [Member] Capitol Healthcare & Rehab Centre - Springfield - December [Member] Cumulative capital investment return to investors as a percentage of benchmark Related Party Transaction, Cumulative Capital Investment Return, as a Percentage of Benchmark Related Party Transaction, Cumulative Capital Investment Return, as a Percentage of Benchmark Finite-lived intangible asset, amortization expense, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Annual Targeted Investor Return Annual Targeted Investor Return [Member] Annual Targeted Investor Return [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Copper Springs Senior Living - Meridian, ID Copper Springs Senior Living - Meridian - September [Member] Copper Springs Senior Living - Meridian - September [Member] Weighted-Average Issue Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Consolidated tangible net worth Banking Regulation, Mortgage Banking, Net Worth, Actual Name of Property [Axis] Name of Property [Axis] Renewal term Lessee, Lease, Renewal Term Lessee, Lease, Renewal Term Millennium Eye Care - Freehold, NJ Millennium Eye Care - Freehold, NJ [Member] Millennium Eye Care - Freehold, NJ Shares authorized for repurchase (in shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased Gain on Dispositions of Real Estate Investments Gain on Dispositions of Real Estate Investments Policy [Policy Text Block] Gain on Dispositions of Real Estate Investments Policy [Policy Text Block] Asset threshold for assignment of agreement Related Party Transaction, Asset Threshold Qualifying Management Related Party Transaction, Asset Threshold Qualifying Management General and administrative General and administrative General and Administrative Expense Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Real Estate and Accumulated Depreciation Schedule III SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Text Block] Less: amounts representing interest Finance Lease, Liability, Undiscounted Excess Amount Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Ramsey Woods Memory Care - Cudahy, WI Ramsey Woods - Cudahy [Member] Ramsey Woods - Cudahy [Member] Impairment charges Asset Impairment Charges Extension period Line of Credit Facility, Extension Period Line of Credit Facility, Extension Period South Douglas MOB - Midwest City, OK South Douglas MOB - Midwest City, OK [Member] South Douglas MOB - Midwest City, OK Stockbridge Family Medical - Stockbridge, GA Stockbridge Family Medical - Stockbridge [Member] Stockbridge Family Medical - Stockbridge [Member] Medical Center II - Peoria, AZ Medical Center II - Peoria - May [Member] Medical Center II - Peoria - May [Member] Amortization Expense Amortization Expense [Member] Amortization Expense [Member] EX-101.PRE 12 hct-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 hct-20221231_g1.jpg begin 644 hct-20221231_g1.jpg M_]C_X 02D9)1@ ! 0$!+ $L #_X1""17AI9@ 34T *@ @ ! $[ ( M % (2H=I 0 ! (4)R= $ * 0<.H< < @, /@ M FMC.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z M;65T82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \ M/WAP86-K970@96YD/2=W)S\^_]L 0P " 0$" 0$" @(" @(" @,% P,# P,& M! 0#!0<&!P<'!@<'" D+"0@("@@'!PH-"@H+# P,# <)#@\-# X+# P,_]L M0P$" @(# P,& P,&# @'" P,# P,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,_\ $0@$S0EM P$B (1 0,1 ?_$ !\ M $% 0$! 0$! ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ M !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?( MR;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! M 0$ ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ _?RBBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHSBC- !11FB@ HHHH **** M"BBC- !11FC- !11FB@ HHHH **** "BBB@ HHSBC.: "BC.*,T %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1106Q0 449XH!S0 4449H **,YHH **,T9 MH **,T;J "BC-&<4 %%,:XC3[SJ/J:Y[Q%\8O"7A#=_:WBCP_I>WK]KU"*'' M_?3"KC3G+X4V9RK4X_%)+YG29IK$YKQ_Q'_P4&^!?A1F%]\8/AK"Z]4'B*UD MD'_ %CZ>)_R:"W^17Q;K?\ P7^_9CTE6\CQEJNI8[6^@WBY^GF1I7%Z MY_P?Y=#XJT?O/T&! MSW_6C/%?F?JW_!SS\)X<_8? 7Q"N/3SQ:0Y^N)6KE]8_X.CO#,1/V'X2ZY<> MGGZU%#G\HGK:/#69O:D_P_S.>7%65K_E\G]Y^K/-+TK\@=1_X.FKF3<+7X*P MQ^AE\5;OT%H/YUAW_P#P=&>+&S]E^$^@0^GFZQ+)_P"@QK71'A3,VO@MZM'/ M+C#*U]N_R/V:HK\2K_\ X.?OB=(Q^S_#SP/#Z"22YD_DXK,N?^#G3XS-_J?! M7PTC/;?;7K?^W K1<'YE_*OO1C+C;*U]I_8]E]Y/^O66=Y?-<C8?:/ OPZD]?+CO$_G.:E\&YE_*O MO1:XXRM_:?W'[A4'FOQ4M/\ @Z$^(BG]_P##7P?)Z[+NX3/ZFM>P_P"#I#Q) M&ZFZ^$>BS#N(=6/_ &H?%(?]#:C^==-I/_!T3X*EQ]N^%OB>'U\C4H)+,K?_+U+[S]2R?Q_&C=CTK\V=)_X.;8.?P58_>CZ1S17 ME_AG]MGX.^, /[+^*OPZU!FZ+;^([21A[8$F?PKO-#\::/XFA\S3=5T_4(_[ MUM<)*/S4FN>5"K'XHO[F=4<51E\,U]Z-2BFK,K=&4_C3LUEL;*2>P449HS0, M**,T9H **,\T4 %%&<49H ***,T %%&:,YH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M***,T %%&ZC/- !11F@G% !11G%&: "BC.*-W- !37ZTV:[CMT+22*BJ,DDX MQ7DOQ1_;S^"_P8,J^)/B?X*TN>'A[9M5BDN0?^N*%I/_ !VM*=&I-VIQ;]$8 MU,12IK]Y)+U9ZYT'^--WX%?#OQ*_X.$_V;_ 9E73M:\1>+I$.-FDZ/(H)]FN M/)4_4$U\]_$K_@Z+TN R)X1^$]]==H[C5]76WV^YBBC?\@]>I0X?S"M\-)_/ M0\?$<39;1TE57RU/UH#?2C.1_A7X,_$;_@Y'^/?BL/'HNG^!_"\1/[LVFGR7 M,P^K3R,A^NP?2O"/B)_P5P_:0^)WF+J'Q:\46JOU72W33 /;_1UC/ZU[%'@G M'3_B.,?G<\:OQY@(.U-2E\K']*]YJ=OIUNTLUQ##&@RSR.%51[DUY?X[_;E^ M#?PRW_V]\4O .F21]89=F8[ MB^H:A+K1X#C_R]J_/^-O^#FGX+Z-N M31/"7Q!UJ9.C26UK:PM_P(S,W_CM?AK17IT>"/HWEE_P!:\Q\5?\%*OC_XR+?;?C!\0E5^ MJ6NMSVJG_@,;**\0HKT*>5X.GI&DON1Y]3-L94^.J_O9U'BGXV^,O'!?^VO% MGB75O,^]]LU.:?/_ 'TQ_G7,^:S=68_B3^/:FT5T1HTHZ15CDE6J2^*3?W@3 MGU_Q_*@-116JTV,OF%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH *,[EHHH 4$CIQ^/6I;?4)[257AFEBD7D,CL"/QS_ %J& MBH<8O=%1J26S.X\-?M-_$GP8RG1_B!XVTDI]TV6MW,&SZ;)%KTSPA_P5=_:, M\$;?L?Q?\8S>7P/M]W]N'_D=7_E7SW16$\#AI_%33^2.BGC\1#X:C^]GVKX/ M_P"#@/\ :8\,%?M7BK1M<5?X;[0[5=WU,*H?Y&O4_!__ HQ^6C/0I\19E3^&K+[S]A/!/_ M =(Z7<,B^(_A'?VN/OR:=KJSY^B/"GY;OQKV#P3_P ')7P!\2%%U+3_ !]X M>;^)KK3(IHU^AAF=B/\ @.>.E?@W17GU.#\MGM%KT9ZE'C3,X;S3]5^I_2+X M&_X+1_LS_$!E6U^*FDV4C_PZE:7-@%/NTT:K^.<5[9X _:;^'/Q3V?\ ",^/ M?!OB R?=&G:S;W+'\$I M1\0,0OXE)/T;1_7.)5D^ZV?H:=NQC^M?RG^ ?VH?B5\*@G_"-?$#QIH"Q\*F MGZS<6Z@>F%8#\Q7N'P]_X+7_ +3'PY=!!\2[[5((\ Q:I9VU[O\ J\B%_P 0 MU>76X%Q,=:51/UNCUJ/B!A7I5IM>FI_2 S8':@'(K\._AO\ \'-?Q!_$D*=7MUN-/GD]R=\B9^B"O?_AK_ ,'0'@'4UC3Q;\-?%FBL?OMI=Y!J M*@_1S#Q],UY%?A7,J>U/F]&>SA^,,KJ;U.7U5C]0\\4Z,Y6OCOX9?\%VOV:? MB6\<;^.9O#MS)C$.L:9<6^WZR*C1C_ONOHSX8_M+_#SXR(#X3\<>$_$A8;@N MFZM!=.![JCDC\0*\BM@,32TJ0:^1[-#,L+6UI5$_F=U134E5_NL#]#3LURG< MG?5!11G-&: "B@'(HH **,T4 %%&/=+^2U\?_ !G_ M .#E3X-^"#-#X/T#Q9XWNE)\N7RDTVSDZ_\ +20F4?C%_P#6[\-E.-Q#_7B\YP6'_BU$OF?HTG#4COM7)88_WNM?AE\:/^#E?XQ>.!-#X0\.>$O!=K M,?EE>-]2NXQ_OR;8R>G6'']/DWXP_P#!17XX_'AYO^$F^*'BZ\AF_P!9;07S M6=JX/8PP[(\>VVOHL+P3C:GO56H_BSYO%<=X"GI2BY?@C^CSXM_M_M32<^@]AT%>[A>!< M-'6O)R]'8^=Q7'V+EI0A&*[[L_6/XL_\'1&K77G0^!_A;I]IC_5W6N:F]QN_ MWH8E3'X2&OF3XK_\%Y/VDOB?YB0^+['PO:R]8-%TR&$ >TD@DE&/9A]:^-Z* M^@P_#V7T?AI)^;U?XGSN)XDS&N_?K-+LM$=Q\2_VF?B+\9W8^+O'?BWQ('.Y MEU/5I[E/H%9B!]!Q7$,S.P^8\?=))X_"DHKUJ=&%-6@DOD>14K5*CO.3?S#_ M "****T,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** _EZ&GPW#6[*T;-&5.5(8_+]/2F44I)-6 M8U)K5'K?PP_;T^-'P9,:^&_B?XUTVWAX6U_M666UXZ?N7+1_^.FOI+X3?\'$ MG[1'P]\M=8O/"_C2%>&_M72EAE(]FMC%S[D'_=KX2HKSJV4X.M_$I)_(]'#Y MQC*+_=U6OF?L9\)/^#HC0;ORXO'7POU?3^SW.B:C'>;_ '$4JQ;?^^S7T]\) M?^"Z7[-OQ5,<9\=/X9NY<8@URPFM-G^]* T(^OF=J_G5H/7_ #Q]*\/$\%Y? M5UC>/H_T/H,-QSF-*RE:2\U^J/ZQ/AS\9_"/Q=TO[9X5\4>'_$EGC=YVF:A% M=H![F-B*Z;=TK^2/P_XDU+PIJ<=]I=_>Z9>PG*3VL[0R1'U!4YS],5]%?!O_ M (+ _M%_!(Q)I_Q,UO5+.,8-MK>S54=1T4F<,ZC_ '6!YKP<1P)77\"HGZGT M6%\0*+TQ%-KT/Z4AS_\ KHW>]?BY\&O^#GKQKHAAA\>?#KP[KT> KW&CWDNG MR_[VV02J3[90?2OKGX*?\'"G[/?Q3\J/6-2U[P->28!36=.9H=W&<26YD&/= M]O3M7S^*X;S&AJZ=UW6I])A.*,MKZ1J6?9Z'W6M**XOX4_M#^!/CCIWVKP;X MP\->)X0H9CIFI0W)C&/X@C$K]" :[0,"*\6=.4':2L>Y3J0FKP:?H%%&: ..?NVZ9E;H?NJ:TIT9U'RTTV_ M(RJUZ=)GKG_2-3OH[6,GT!=@"?8_'C_@X0_9]^$AFM]%U#6O'U]&2NS1 MK(K;AAZS3F-2OO'OK\$_&?CW7?B-KLNJ>(M9U37M3N.9+O4;N2ZN&.3U>0LQ MZ^IK)_R3CK7U.#X%HQUQ$V_38^3QG'V(GIAX**\]S],OCI_PS*P^M?&OQN_X**_&_P#:':9?%GQ*\47U MK<$E[."Z-I9L#G@P0>7'[S?HF*6 M9SRQW*<@L<_4T@Z445ZJC;3\CR=]?S"BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH"X4444 %%%% !1110 449HSF@+A11G)H MSS0 44'BCM0 44#D4#F@ HHS10 44=:* "BC-&>: "BC-&* "BBC.: "BC%% M !11T-&,4 %%&:* "BB@#)H **,8HS0 449YHH **** "BBB@ HHHHU"X444 M4 %%%% !1110 4#_ /5Z444>H;EK1M;O/#VH0W6GWEU8W5N=T4UO*T!+J'AR[:/ M'N+: M%[ACF0Z;?20)-_UT0,$<<=&##VK[4^ /_!Q[\:OAHT%OXRT_P_\ $*Q0J'DG MA_L^^<#KB6']V#]8CGUKY?&<$8JGK0DI>6S/K,%Q[A)Z8B+CY[H_>'S.?O"G M+TK\_P#]GS_@XL^!GQ5:"U\51Z[\/=2DP':_MC=V6X]A-#EL>[QH*^U_A;\: M_"'QI\/KJGA'Q/H/B73VY^T:9?1W,8SS@E"=IYZ'!KY?%9;B<,[5H->O]6/K M,)FF%Q*O1J)G5449S2!P>XKC/0%HHSFC- !11FB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BDW4N: "BC-(75>X]: %IK'#4[- M>./#_A^15+I:RW DO)1_L0)F5O\ @*FO@3]H[_@YK\(^''N++X7>"=2\37*Y M5-2UJ3[#:9[.L*YDD'3AC$:_&K5-5NMZ\,Z3-G&G>'%.G1J",8,JYF8$<$.["OEN^OIM2O);BXFDN+B4EWED)D M=V.,G1\CB,=7Q$N:M-R]0/7T_'-%%%=)RA1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 9'X9H MH **!R* <_AUH *.U+M.>AXK=\'?"WQ-\0;E8]!\.ZYK4C'&VPL);EC[8136 M_>!_^"6?[0_Q%$?]G_!_QM'OY4ZA8FP4 M_C<; /K7LG@7_@WH_:2\7E?MVB^&O#>_^+4]:B;;]?L_FG].U<%;-\!2^.JO MO.ZADN.J_!2?W'P[WHQ7ZC>"?^#7GQY?JO\ PD7Q.\*Z7W;^S]/GOL'V#F&O M5_!W_!KKX,M O]O_ !2\3:A_>_L_3(+//TWF7%>=4XKRV&CJ?82?O24 M?G<_F_ +=*>D$DA 6-V+= %ZU_4;X6_8,^"?@M%_LSX2_#FU9/NNOAVU:0?\ M"*%OUKO_ ]\-M \)KC2=#TC31V^RV<<'_H*BN*7'E/[%*_JST*?A[5?\2LO MDC^5KPY\"O&_C#;_ &3X.\4ZIO\ N_9-+GFW?3:IKOO#G_!.7X^>+2IL_@[\ M1F5NCS:!<0H?HTBJ*_I_6V4?PJ/P_P#K4JIY?_ZJXI\=5OL4DO5W.ZGX?45\ M=5OY'\W>A?\ !%?]ISQ&B^1\*=50-T^TZC96V/J))5KL-#_X-_OVF]6"_:/" M.DZ?G_GYUZT;;_W[D?\ 2OZ%B>* ,"N6?&^.E\*BOD=D. L OBE)_,_!;1O^ M#;/]H/5 /.OOAWIO?_2-5F('_?NW>NMT3_@V&^+5SM.I>/?A[:]S]G-U/CZ; MH4_I7[>8Y_\ K4NW-S2]$=$.!\LCJU)^K/QLT[_@UN\22A6O/BYHL M+'[WE:')+CZ9F%;EC_P:R9.ZZ^-A]UC\*?U-W_2OUVV4?=K&7%69/_EY^".F M/!^5K>G^+/RET_\ X-;_ Z@_P!*^+FM3>OE:'''G\Y6K:T[_@U\^'*/BK)_O:I9?TM*L1_P#!M/\ &(_-KGQ M,D^NJVO]+:OT.HJ?]8,Q_P"?TOO*_P!6\L_Y\Q/SW_XAL?V?2O\ R$OB-GU_ MM6W_ /D>HV_X-J/@ XXUCXD+]-5MOZVYK]#**7]OYC_S^E]X_P#5O+/^?,3\ M[9/^#9[X!O\ \S#\4%^FJ6?];4U5NO\ @V1^!*,R7_+W\%_D92X1RM_\ +K\6?C/JG_!KGXNA#?8?BQX>G/I-I$L( M/Y.]ZQT^T37D.?RMWK]PME!'^<5O'B[,E]N_R M1C+@S+']AKT9^">L?\&W7[0FF@^3<^ -0QT%OJ\JY^F^%?Z5Q_B+_@@)^T[H MV?L_@K2]4]K;7K/_ -J2+_*OZ&\X-+C=6\>-,P6KY7\O^"W,OF?S6 MZ[_P1R_:6\-!OM'PE\02;?\ GUEMKG_T6[9_"N)\0?\ !/;X[^& S7WP=^)4 M:+]YT\.W375#CK%+XH1_$Y)>'^$^Q4:^YG\G?B7X-^ M+O!F[^V/"WB+2]G4WFG30X_[Z45SK1,O56';D5_7(]LI'W%]^.M<_P"(_@]X M4\8AAJ_AG0=4#<,+O3XILC_@2FNVGQ[+:=)?)G%4\/>L*WWH_DYHQFOZ@_%7 M_!.KX$>-%;^T/A!\.I&;K)'H-O#+_P!]HH;]:\P\6_\ !#7]F/QAN:3X:PV$ MK='L=5O8-OT43;/_ !VNRGQWAK^_3:^YG#5X Q:^"HG^!_.7G-&*_>;Q;_P; M9_L_^(-S66H?$#1&/W1:ZI#(J_A+ Y_6O*/&O_!K?X>NB[>'?BUK.GC/RKJ& MBQ7>?J4DB_\ 0:[Z?&672W;7JO\ (\^IP5FD/ABGZ,_'"@\?RK],O&O_ ;" M_%/3BQ\/^/O ^JJOW1?1W-DS#Z(DF/SKR'QS_P &_P!^TOX.+&U\+:/X@5>K M:;K=NN1])FC8_EFO0I\09=/:JOZ]3RZO#N94_BI/[KGQ7C-&>?IUKV[QU_P3 M6^/OPXW'5OA#X\6&/(>6VTB2]B7ZO$K #WS7D?B+P=K'@VZ^SZQI>I:7<+P8 M[NW>%A^# &O2IXNA4UA)/YH\ZKA*\/C@U\F9M%#?*<'@^]%="UV.9IK<**", M49H **",44 %%%% !1110 4444 '7U'(P1V/J*VO 7Q&\0?"WQ!%JOAG7-6\ M.ZE 08[O3;N2UF3GLR'_ .M6+14RBI*TE=%0G*+YHNS/N;]G+_@X)^/7P5%O M:^(+[2_B'I<6$\O68-MTJ@]KB+8Q/^U+YAYZ=*^^/V;/^#C7X,_%EX+/QI8: MU\.=2DPK/<*;_3]Q[":-=X[\O$H [U^$- Z_K^/;VKY_'<+9?B-7#D?DSZ/ M\69AADH\_.O-']8GPO\ C'X3^-'AR/5_"'B30O$NER#Y;G3;R.XC^A*$@$>A MY%=*&^?M7\FWPV^*_B?X.^(HM7\)^(=:\-ZI"1MN]-NY+688:I:.*CR/NM4?O,'R?O#\*5#D5\4_LO?\%W?@)^T4;>T MU+6I_A[KTVT/9^( L-N6_P!FZ&8L=@7*$XZ5]F:#K=GXBTN&]T^[M[ZSN%\R M*>"421R*>A5AP0?45\EB,#7PTN6M!Q]3[/"X_#XE:A=);PQ_5G(&?09K\]_VM?^#CSX;?"S M[5IGPQTF[^(>L)N1;^;=9:5"?4,R^;+TZ!5!!&'].[!Y9B<7*U&#?Y?>>=CL MVPN#5Z\TOS^X_22658UW,V%')STKY;_:K_X+$? G]DZ2XM-4\60^(_$%OE3I M'A\+?7"L.JNP81Q$=Q(ZMZ U^)/[5G_!5_XX?M>O<6_B+Q==$T7-A M8[?[KJAWRCVF>0?2OG')/7K[]:^VR_@;[>+G\H_JSX/,N/OL82'S?^7^9^CW M[4O_ N-C$=F)Z? OQ0 M^,7BSXV>)IM9\8>(M8\2ZI,1NNM2O'N'QU !8G &3A1@#/3K7-T5]G@\IPF% MCRT()>?7[SX?&9QC,7+FKS;\N@'DY]?UHHHKT?0\P**** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHS1GK_L]?:BX!11GF@#-&X!CBCK71> /A%X MK^*VIBS\+^&?$'B*\S@1:7I\MU)GZ1@G]*^E/A-_P0__ &E/BV8Y5\ 2^';. M;&;C7;R&RV_[T18S#_OV:XZ^/PU%7JU%'YG90R[%5OX5-OY'R2.:#P:_5+X2 M_P#!KUXJU,QR>./B=H>EKP7@T73Y+XGV#RF(+]=I^E?3WPK_ .#O6O$K\7Y=3T4G)^2_4][#<&YG55W% M17F_T/P/VDG&.?2NF^'_ ,%_&/Q9N5@\*^%?$GB28M@1Z7IT]TV?^V8)K^E; MX8_\$V_@1\'A&V@?"GP7;S18V7%QIJ7=PN/^FDP=_P!:]GT_2[?2;-8+6WAM MX8QM2.- J(/0 <"O$K<>17\*E][_ ,CWL/X>R>M:K;T5_P S^<;X8_\ !%'] MI3XI-#)#\-;[1[9^6GUFYM['R_?,!VHP2><_A7BUN-\_#W_@@A^S3X"\M MKCP;J'B2:/I+JVL7,G/J4C=(S_WS7V:>!_C1C->36S[,*OQU7\M/R/;P_#N7 M4?@I+YZ_F>4?#S]AGX-_"I(SX>^%_@72YH>%FAT2W\X?]M"FX_4DUZ?::7#8 M0+'##'#&HP$10J@?0<58/%*.E>;4Q%2;O*3?JSTJ>%HPTA%+T0P+AZ?0!BBL MSH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &M&"#[ M^U4M8\.V.OVK07UE;7D#C#1SQB16'T.:OTC4U)IZ.Q,J<9?$KGB?Q"_X)R_ MOXI"3^VOA/X&GDD^]-!I45K.W_;2(*_ZUX5\0_\ @WP_9M\;&0V7A_Q%X7DD MY+Z5K4S$'V6X\U1^5?<(&12,N6KKI9EBJ?P5)?>SSZV48*K_ !*47\C\J?B+ M_P &NWA:^5V\(_%37M+YRL>K:5#?9]BT3P_GBO /B3_P;3_&[PP)9/#_ (@\ M#^)K<'Y46[GL[EO^ R1E!_W\K]U0M!!%>OA^+,QI?;OZI'CXC@[*ZFO);T=C M^:GXD_\ !(']I'X5&1M0^$_B*\C4_?T<1ZEN'J!;.[?F,UX+XR^'/B'X=ZD; M/Q!H6L:'=@X,.H6SU73[/4K208>&Z MA6:-OJK @UZ]#CJLM*M-/S3:/%Q'A_1>M"JUY-)G\DHYHSFOZ9/BC_P2C_9Y M^,'F-K'PG\)1RS'=)+IMJ=,D8^I:V*$GW-?-OQ7_ .#:GX*^+5ED\,ZYXV\( MW#?ZN,74=]:I]4D3S#]/-'3ZU[6'XVP4M*D7%]]SP\1P'CXZTI*7SLS\+2<" M@G;UXK]./BO_ ,&Q'Q(\.-))X,^('A3Q)$I)$>HV\VF32#TPGFH3]6 KYD^* M_P#P1Q_:0^#@DDOOACK6J6T?W9]$>/4MX]=D#,X'L5%>]A\^P%;X*BOV>A\_ MBN'\PH/]Y3=NZU/F*BM+Q1X,UCP1JTECK6E:EI-]%_K+>]MGMY4[I?L M[_MK?%3]E/4EN/ /CC7= B5PS6:3^=8S?[]O(#&Q]V7CUZ5Y;16=:C2JJU2* M:\S:C7JT7S4Y-/R/UF_95_X.9[VS-OIOQ@\&QW4?"MK/AP[)!V)>VE(!)ZY2 M0 =EZ9_23]F?]O#X2_MI0WEC=7%G=6S>9%-#(T/X-PE9N5!\C\ MMOZ]#Z[+N.,90M&O[Z\]S^N(."M /%?SW_LH_P#!>KXY?LYO:V.N:G#\1] C MPK6VNDO>*H_N78_>;L#&9?-'L*_3O]DG_@NI\#_VGC:Z?JFK-\//$=QA#I^O MNL=L[GM'=#]TP/0;]C$]%Z5\/F'#&-PMW;FCW6OX;GW^6\58'%I+FY9=G_GL M?:B\]J>#D57L+R+4+6.:":.:&8!D>-@RN#T((ZBIE(%?/ZK1GTB::NF.HH#9 MHS0,**"<"@'- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4449H ** +M'\-6[ ^2EU-FXN2.T4*@R2' MV121Z5^8W[8'_!R[)-;U37M8O6W37E_ M#,+0M+$_O)?=U\=?VFO'W[3/B=M8\>>+-9\37P M;=']LG9X;?/.(H\A(QR>$51ST%<+T_S_ )_F:**^NIT8TTHQ5O):'QE2M.I) MRF[W[ZA1116AF%%%% !1110 4444 %%%% !1110 4444 %%% &30 448XSV/ M2CI^'7VH **W? /PP\2_%77%TSPOX?UKQ%J38(M=.LI;J7![[8P6_I7UK\#/ M^"!_[1?QG$,U]X=TWP3I\P#>?X@OEA?'_7&+S)5;V917'B,RPU!7J32]6=N' MRW%8AVI4W+T1\6DXHQ7[,_ W_@V#\*:,8;CXB?$+6M;D W/9Z):16,8/=3+( M)&8>X5#]*^Q_@=_P2A_9_P#V>Q#)H'PST"XOH<8O=5C;4K@,/XE:X+[#_N!: M^;QG&F!IZ4DY/R5E]Y]/@^!E"[%'/5F KZQ^#'_!NS^T%\2A#-KT'AKP/:GD_VIJ(GN # MCE4MQ(,^S,O3M7[XVFGPZ="D<$,<4<8"JJ#:H [ 581<#_ZW6OG<1QQC)_P8 MJ*\U=GTV%X!P<-:\G+T=D?ES\&/^#8;P+H!AF\=_$+Q)XBD49:VTBWCTV$^J MDN96(Z\C:?I7UE\&O^"1/[.WP,6%M*^%WA_4+F/_ )>-81M4D)_O?Z0753_N M@5]+ 8I",GK7SN*SS'5_XE1V[+1?@?387A_+\/\ PZ2OW>OYE#0O#FG^&-.C MM-.L+6PM8AM2&VA6*.,>@48 J]'P/QH(_P FE7I7EN3;O+<]:,5%6BA:***" M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8X^;\*?36&3_] M:@#!\#/"4*_7RS7R1 M\:/^"!G[1WPA,LEEX;TSQE90DYET'44D8K[12B.0GV5">>]?T-8^E-96)_SB MO>PO%^8TM&U)>:/G\7P7EM;5)Q?DS^3[XD_!3QC\&M4^P^+?"OB'PS=[BJQ: MGITUHSGV\P#/X5S!X-?UL>(_"&F^,-)FT_5M.LM4L+@;9;>[A6:&4>C*P(/X MBOF3XX?\$5?V=/CCYTEQ\/[3P[?2GB[\/2MIK1YZD11XA[]XS]*^BPO'4'_O M$&O-'S.*\/ZL=<-4379G\X6.: V:_7KXX_\ !KU"XFG^&_Q*DB'_ "RL/$5D M&!')PUQ!C_T3ZU\8_'G_ ((L_M%_ 0SR77@6\\4:?"3B\\.R#4E8>OE(?/ ^ ML8%?2X7B++\1;VA\OC.&\PPVM6%_-:GRG15O6_#]_X8U*:RU*RN]/O+ M=MLT%S"89(CZ,K $'Z\U4 R<=_2O:C.,E>+N>'*$HZ35F%% Y&:*9(4 [3G) M'&#R>?P__7]***EV>X]5L>[?LI_\%)?C%^QM=PKX-\87RZ1&PW:+?L;O39!Z M>4Y(CZ=8]C?[0K]2/V/?^#CWX?\ Q1%KI/Q6TJ7P#K4@"'5+4/=:3*W') !E MAR>Q5U Y+@5^(-'4_3WQC\>WY5XN9YEO$F-P6E.=X]GJ?U MH> ?B!H?Q.\+6NM>'-8TW7-(OEWP7MA=)<02CU5U)!_.MD_6OY7?V=?VM_B1 M^R?XG_M;X?>+M5\.S.ZM-#!,6M;L#M+ P\MQQ_$AQ^5?J'^QC_P:U)Z$S6V3(G3.Z,R9_N*!7P&9<'XK#WG1?/'\3]& MROC;"8BT:ZY)>>Q^L#'BE4Y%N:^4E"47RR5F?94ZD9KF@[KNAU% ;-&:DL** M"V#1F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T%@#36;)- !G' M?%&>>O;KFO/_ -H?]IWP#^RSX)D\0^/O$^E^'=-0%8S<2?OKEAR4BB7,DK=/ ME12?:OR5_;A_X.._%'CQ[S0?@QIA,47,4(]"Q=\8^ MXP('J9;DN+QLOW,=.[V/%S3/L)@(WK2U[+<_4O\ :L_;D^&/[&/AK^TO'WBB MQTR61"UMIZ-Y^H7G7'E0+EF&01N.%&.2*_)K]M/_ (.,?'OQ9^V:+\)M-_X0 M#07W1C4Y]EQK%POJO6*#/HN]O1P>!^=WC3QQK/Q(\3WFL^(-5U#6]8OG,D][ M>SM-/.QZEI&);T_#CM65^OX8K]&ROA#"X>TZW[R7X+Y'YGFO&6+Q/N8?]W#[ MV_F:/BSQ;JGCOQ#N9+F[NYVN)YV/4L[G)[>_;M6=G-%%?61C M&*M!61\?*3D^9N["BBBJ)"BBB@ HHHH **** "BBB@ HHHH ****/( HHQ@T M8X'OT]Z>P!1G]*]<_9[_ &"_B_\ M3S0GP/X!\0:Q9S' U V_P!GL/QN)=L7 M'LQ//2OO+]G+_@V0\5^(1;WOQ0\ M1C,[P6%TJU-?O_(]C!9'C<7K2INW?8_+''S8[GM7J/P(_8I^*_[34T:^!_ / MB3Q!!(VT7<5F4LU/O/)B%>HZL*_>_P#9T_X(S_L__LW"":Q\#VOB35H0I_M' MQ"?[1E9A_$(W'DHPZY1%//TKZBLM.ATRVCAMH([>&)0J1QJ%50.@ '8>E?)X MSCJ-[8:%_-Z?@C[# >'\]\5.WDM?Q/Q*^ /_ ;/?$[QIY%W\0/%GA_P3:MA MFM;-3JE\OJIV[(E^HD?Z5]N_ '_@W[_9]^#/D7&K:/JWCW4H.1+KMWN@#=\0 M1!(V!]) _7Z5]OQ_\"_&E49%?*XOB7'XG>I9=EH?78/A;+L/JJ=WWEJ<_P" M/A;X;^%.A1Z7X9\/Z+X>TV+[EKIUE':PKP!PL8 [#MVKH(Q@4$8[4J]*\.4G M)WE=L^@A3C!6BDD+11104%%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,DSG^'\:?2 M%#?#GBB%5*Q_VCI\5PT.>I1F4LA]U(-?&/[0/_ M ;D_!#XI1SW'A.X\0?#W4)/F5+2X-]8[N?O0S$N1[+(HK]!NE-P=WM79A?BLIP>)7[ZFG\C\&?V@?^#%[LDA5U*PEMQ-UY1F #C@\ MJ2.*_JX[_=_2LWQ9X-TGQSHTVFZUI>GZQI]R-LUK>VR3PS#T9&!!_$5]3@^. M,5'2M%27W,^3QG >%G[V&DX>3U1_)3FC./PZ^U?T+?M%?\$%?V??CKY]QI_A MV\\!ZI+D_:/#MQ]GA)/K;N'B 'HB(3ZBO@W]HS_@VK^*7P^BFO/A_P"(M%\> M6\J9].U?68/B[+Z_P ;Y7YK^D?&X[@W,WK7T=*I"<>:#NN]SYFI1J0ERS5GVMJ%!YX]\_CV_*CH:*TU,SN/@-^TE MX[_9A\7QZ]X#\4:MX;U)2/,:TE*QW !SMEB.8Y%SGAP0.3CFOU*_8K_X.3[7 M5&M-#^-VAK83';&/$>BQ.\/8%I[;)9?7=$6]HP*_'VCK^?KC/X_Y%>3F&28/ M&K][#7NMSV,MS[&8*2]A/3L]C^L/X2_%_P +_&_P7:^(/"'B#2?$6BW@S'=Z M?FBYD@R>Z^8G4DH*_.\TX0Q6&7/0]^/XH_2LIXTPN):IUUR2_!GZ MD$;L4X5C^#/&>D>/_#-GJ^A:I8:SI.H)YUM>6=PD\$Z'NKJ2K#Z&M<-7R+33 MM+1]C[6,E)76PM%&>:,T#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 449I"X'<4 *6Q3= MV:;,ZJ"Q/"@Y/H.]?#__ 4!_P""X_PU_8_^W>'O#( MKBZL8I"]GI%L/(TVPS_<@!(W#^^Y=SQES@ >,DY8G]?7_/O7Z+E'!M*G^\QO MO2[+;YGYAG''%6M^[P7NQZM[_P# .L^,OQT\8?M#>-KCQ%XV\1:IXDUJXZSW MLYD\D9)"H,%409.$3"C)P!7)]#_@,445]O3IPA%1@K)=CX6=24VY2=[]]0HH MHJS,**** "BBB@ HHHH **** "BBB@ HHSBB@-4!.*,9JQI.EW6M:C#:V5O/ M=W5TVR*&&,O).>R@+DD^@ YK[(_99_X(/?'C]HW[/>ZEHL/P^T&;:_VSQ"## M<,IYRELH,I.#T<1@_P!_J!R8K'X?#1YJ\U'\_N.S!Y?B<5+EH0#]>\476=L@L;1Y(X?^NCXV(.>KLH'K7[>?LM?\&] M7P5^!8M;_P 6+J'Q,UR##;M4_<:"&E ]*_ M0S]FS_@B]\ /V9?L]U9^#X?%6M0D$ZGXC8:A*6'1A&P$*$=BL8(]>E?5B&6Z3PRCT9&!!_$5\;_M*_P#! OX!_'C[1>:/H]Y\/=9FRWVC M0)=EN6/K;N&C"^T8C)]:^W&7CBD 8FNG#8_$8=WH3:^9PXK+L-B5:O!/\_O/ MP8_::_X-U?C1\'A<7W@NZTOXD:/'DA;1Q8ZB%'K;R'8WT21V)SQ7PU\0?AAX MD^$WB.71_%&@ZQX=U2#[]GJ-G):S)R1]UP#C@\@8K^LHY+8_I7*?%OX%>#OC MQX=DT?QIX7T/Q1IL@/[C4K)+A4R,97-L13]W$Q4O-:,^-Q M_ >'J7EA9.+[/5'\H>>/UH[?K7[@?M2_\&V'PW^(8N-0^&.O:IX"U-\LME=9 MU+36/H-["9/3.]P !A?7\WOVI?\ @CY\>/V4FN+K5O!MQK^A6Y)_M?P_G4+9 M5'5W50)HQ[R(![U]M@>),#BDN65I=GH?#YAPSF&$OS0O'NM3Y@H ^@/K_D&E MD&QL,-O)'/7CK25[?3R/ L[VZGM7[(7_ 4"^*7[$GB5;SP+XDN;73Y) ]WH MUT6N--NQP,-"Q !( &]-K@8Y S7[%_L)?\%[/AC^T^+'0?&GD_#?QE-B)8KR M<'2[V0\ 17!P%).?DDV^@9^M?@51W[8/!R,Y'TZ'\>E>%FG#N$QRYI1M+^9' MOY3Q)B\ U&G+FCU3U_X8_KDM[A)XE:-E96^Z0?E;W%3!\9[5_.K^P/\ \%G? MBE^Q0;/1;JX;QMX#A(1M$U*:#?D0:C:'O\F2)$'&7C++SR0<@?F>:\.XO N\U> M/='ZMD_$V$QZM%\L^J?Z/J?06:*:C*J]AW_QI0P/>O!/HA:*,T YH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M IK'!_"G;J@O;R*RMVFFD2*&-2S.[!54#J23Q@4+71";25V29P?Z^E>4_M5_ MMG_#O]C/P,WB#Q_X@M=+A8,+2R4B2]U%Q_!#"/F<^_09R2!S7Q+_ ,%&_P#@ MX'\-?!DWWA/X.?8?%_BI=T$^NO\ /I.F'H?+QG[1(, _+^['JY!2OQP^,?QN M\6?M!^.[SQ-XTU_4O$6MWQ_>7-[.7.W_ )YJ.B(,\(H"CD# X'U^2\)5L3^] MQ/N1_%_Y'Q&><94<+>EA;3GWZ+_,^P/^"@?_ 72^(W[64M[X?\ !\EW\/? MWY4BC _P#K?SI: M_3<%E^'PM/V="-OZZGY;CLPKXN?M*\FW^'R"BBBNPX0HHHH **** "BBB@ H MHHH **** "BC/Z=?:@#)Q0]-PUZ!_CC\:,=/]KI[U]$_LB?\$L_C-^VA-;W' MA?PO/8^'9B VNZL6LM/*]]CD;IOI&K8[^WZC_LE_\&X_PO\ A(+;4_B1J5Y\ M1]:3:[6I!L]*C8=C&A\R7'3YWVD=4[5X68\1X'!Z2ES2[(]_+.&<;C/>A!Q7 M=_Y'XV_ 3]EOXA?M0>)AI/@'PCK7B:Z! E:TMR8+8>LLK8CC'/5R*_27]DG_ M (-G-0U#[+JGQD\5KI\.56E%17EH+11169L% M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %12Q[Y/PZ5+32,F@32>Y\W?M6?\$H M_@E^U[]INO$?@^TT_P 07&6_MS1L6-^7/\3LHV2G_KJC]*_,_P#:M_X-M?B- M\.!<:E\+]H:/.<;?7]P@,>E,>/-L8^92#[U^;_[7/_!M#H7B W6J?!OQ1+H%PX9UT/7'>XL\ M]ECN%S,@]G$A.>2!T^XR_C3#5;1Q,>1^6J/S_,N!<51O+"OGCVV?_!/QKZU? M\+^*M4\$>(;35M%U"^TG5-/E$UM=VD[0SV[CHZ.I!5AG\?P->C_M-_L2?%+] MD#7?L/Q!\'ZIHL?_!Q->:#]A\*?'B.34+/Y88?%EE!FXB'&#=PJ M/W@'>2,%N.4;)8?K;\-OB7H'Q:\(6.O^&-8T[7M#U*/S;6]LIUFAF7V921QT MQU!&*_DT.Y2/S_'L3W_*O:?V-OV_/B9^PWXP&I>!]>ECT^XD#WNCW9:73=1_ MZZ1$X#'&/,7:P&,$#.?C/O+S/X?O9AFX8#+-:R' F7J<8#@ MEE P3]=1L #SWK\WQ.%JX>?LZT>5GZE@\91Q5/VE"7,OZW'T49HS7.=04444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111N% 6VCFFL M^/\ ]=-E8+\WH.OM7P?_ ,%,_P#@MYX/_8XAOO"?@O[#XS^)$8:)X5D+Z?HC M],W#J07<<_ND(;@[BG&>K!X&MBJBI45=_P!;G'CLPH82DZM>5E_6Q]/?M9?M MB?#_ /8T^'$GB3Q]KL.EVV"+6UC(DO-1D'/EP19#.W3GA5R"Q4X\%_#MBR)H]I-BXU%3R&NY1@.#_P \Q^[&1G>1N/S9 M\??VB?&?[3WQ%N_%7CG7]0\0:S=D_O9Y,)"F3^ZB082)!DX5% Y/7-<3^7X" MOU+)>%><68C&OV>']R'XOU#.:***^LTW/C_ ""BBB@ MHHHH **** "BBB@ HHHH *,\_7I1_AFE5=S8Q]XA>>G/K]/ZT.RW"-W\(A.! M2HC2L%4;LD*!C.">,U]A_L4?\$2_C+^UV;/5+K3F\!>$9]K_ -K:U%)'+<1^ ML%MQ(YP<@G8G)^?/ _7;]BK_ ((W_!O]C-+/4+71?^$L\76X!_MW6XTGEA;C M)@CQYY^/_ .QW_P $ M5?C=^UJUGJ+:(?!'A>XPW]K:\CP-(GK% ,2R9'(. AS]\'-?JQ^QY_P0J^"W M[+:6NH:IIK?$3Q/;X;[?KD*O:Q..LZ=9ZMI ME[&8KBTNX%F@G0]5='!5@?0@BOS_ /VO_P#@W7^%OQH%UJGPYNIOAOKT@+BU MB0W&DS-SP83\T?U1MJXX0]*_1)1F@#-=F#S#$867-AYM'GX[*\+BX\N(@G^? MWG\R7[7_ /P3*^,'[%%],_C#PM/-H2OMBUW3(ICK@GK]WEO&T)6AC(V?=; M?-'Y[FG _R9^!VG:E&!"D M$8/''.,?I]_P3E_X.$-8\ QZ?X0^.37.OZ'A8(/%,<9EU"S7H/M*=;A!U+@^ M9UR)">/D+]LK_@EU\8/V'[V:;Q5X=:^\.A\1^(-*W7&G2#G&]]H>$MZ2!23T MR,$_/&0'_P!KKD<$GZ^V>]?4XC#8'-**U4E;=;H^3P^*S#*J_6,NJ>S/ZS_A MW\1-#^*G@W3]?\.:M8:WHVJ1":UO+.<313*>X8'GN/4$$8&,5MJ< U_,U^P= M_P %*OB1^P#XO%QX9OSJ7ANYD#ZCX>OI&:RO!P&91R89<# D3!^5=RNH*G]X M?V$O^"D7PW_;W\&+=>%M0^P:_9QA]2\/WKA+ZP/0G:.)(LD8=?EY&=IRH_,< MZX2S,Q '/7_]?#?M7?M=>!?V-_AC<^+/'.L1 M:?9Q*RVULA#W>HR@<0P19!=SQW 7.6*C)'X$_P#!1O\ X*K^._\ @H!XHDM9 MYI/#_@&SESI_A^WE)C?!XDN6P#+(<=P53L O6'P3X=F;28Y-ESK=]F MWTRU(QG,I!W,N<[(PS_,#CT_8?\ 87_X()_"W]E_[%K?C.)/B5XPA"R>;J$ M_LRSD&/]5;'(<@]'EW'@$!#7@YIQ)A,%[LGS2[+^M#Z'*N&<;CFI1CRQ[L_+ M+]AW_@CY\7OVVYK74K'2_P#A%/!DS!V\0:O&\<,B^L$?WIS@G!0!+[M1K,\+CDF"+_5PC/0@%P.-YKZVM(%M MX5CC18U3A55< < 8]JD P:_-LTXFQF,;C%\L>R_5]3]0RGA3!8).?#7:ZU9[KC3+P MCH%E ^4D#A'". !\N,$^6_#;XF^(/@[XWT_Q'X7UB^T+7-*D$MI>60< M*@&:^_ROC*E67LL=%*_7=/U70_.F/2 MOY5?VAOV8_'W[*OCF3P_X_\ #>I>'=43=Y)N(\PW2@@;H91N25<_Q(Q *C.# MP/NK_@EC_P %V=:^ T^G>!/B_>7NO>",I!8ZV^9K[14/ $O4S0#CG)=0#C<- MJ#CSCA:%2+Q>6M..[C_EY>1V9'Q94IR6$S--2V3_ ,_/S/W#!R/6EK(\$^,] M)^(/A2QUK0]2L]6T?4X5N+2\M)A-#<1L,JRL."#6L&S7P/*T[/<_1XR4ES1U M0M%!:B@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4UF^?KVZ4XMBHY&4'/6@ + =Z^8_ M^"D'_!3WP3_P3[\"%K^:/7/&FH1%M*\/P2@2R=0)ICSY4(((W$$L00H;!V^8 M?\%7O^"R>@_L0Z5<^$?![6?B+XH74>/))\RUT%".)9]O63NL7!(^9L#:'_"# MXG?$_P 0?&;QYJ'B;Q5JUYKFO:K,9[J\NGWN['TQP% P HP% %?8GYTJ*SNNWYFS\H/\ >Z#G\?Y5]_?\$\O^""OCS]J!+'Q)\0OMW@#P M--B1(Y(=NK:G&?\ GG$P_*_CWXYM/#7@WP_JGB+7+X_N[6Q@,DFT=7;H%5>[,R MJO.2 37ZV?L!_P#!N9I/A5;+Q+\N>E?FF<<7U\1^[PON1[]7_ )'ZEDO!=##?O,7[\OP1F^$/!NE^ M ?#MGI.BZ;9:3I=A&(;:TLX$MX($'1510%4#T Q6JM(!S2U\Y!+6]Y#NV/C ='X:-P"<.A##L17Y'_M]?\&Z& MN> EO?$OP1NI_$FEINFD\.WKJ-0MQR3]GDP%FP,X5MLF!@%V-?M(>M,E'.<= M!Z=:]++LXQ.!E>C+3MT9X^9Y'A,=%^VCKWZH_G5_X)^?\%.OB/\ \$S/B-/X M;UBSU*_\'_:C'K/A?40\4UC(<;I8 XS%,!U7[K#A@,*R_O5^S)^T_P""_P!K M?X46/C'P/K$.K:3>#9(OW;BRE !:":/K'(N1D'J"""5(8^<_MK_\$S/A;^W= MH+Q^+-$6S\01QE+3Q!IZK;ZA;=P&8#$R9YV29 ZC:W-?E?XE_9L_:(_X(1?& M-O''A>1O%7P]FD6.]N[:-CI^HP Y$5[",M;N 2%DR0"?E=LLI^BQ$L%G*YZ= MJ=?MTE_P3YO#+'Y(U"M>K0[K>*]#]U@VX_I3U.?SKPG]A3]OKP+^WM\+%U_P MK=F'4K4*FK:+FJM*7-%[,=11G(H!S69L%%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37.*<6%0R,,[NP') M]![4>@>H2^_/KZ5^:W_!7S_@MA;?L\+J7PS^%%Y;WWCI@UOJFL(5D@\/9R&C MCZA[D=#U6,]0S J.8_X+)?\ !; ?#EM5^%/P?U17\0KNM->\16TF5TL]&M[9 MAR9NH>1?]7C"_/EH_P ;+B=[F=Y)&:221B69CDL>Y)[Y]3UK[SAOA?VEL5C% MITC^K/SGBCBSV;>$P;U^U+MY(GUO6[SQ+K%UJ&H75Q?7U]*T]Q1CE MG9F))8DY)/)/-5:**_2XQ27*EL?EKDY.[^_N%%%%, HHHH **** "BBB@ HS MQ].OM0!D_B!^)Z?R-$?[UEV99F.%P>N>./\ ZW6AV6K'&[=D%>K?LG_L7?$7 M]M#QZNA> ?#]SJ4D;*UW?O\ NK+35/1YIB-J]R!RS8PH.2#]@?\ !-G_ ((( M^*OVB_[/\7?%1=0\&^"I-LT&G!?*U;5TX(X(!MXV_O,"Y'10"''[3?!GX'^% M/V>_ %EX7\&Z#IWAW0M/7$-K9Q;5SQEV)^9W/!+L2S'DDGFOC$.W5GR5_P3R_X(??#O]CA;+Q%XDCM?'?Q B4/]ONH/ M]"TR3O\ 9H6S@@Y_>/E_[OECBON* ;4Q[TB@[/Q]*D7I7YGB\;6Q53VM:5V? MJV!P%#"4U2H127];A1117*=@4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %5=4TZ'5+66WN(8[BWN$,4LL0_#GQ]8LTLNANVW1=8 M4D,\)7GRU?&"G,9XXC(#K]!?L;_MHQ_M&6UYX;\4Z'=>!/BKX;C']O>%[\;9 M8L':+JW).)K5V^[(I.,@$]"?=I!\W ^O^?SKB?BQ\ ] ^+=YINH7D$]AX@T- MS+I.MV!$.H:8^.?+DPT MPNB>\>GKY'=1-N7V-*HQ5+PW;WUIH\,>I2V]Q>1C;)-"AC28C^+8<[<]=N2! MZFKV:\_9GJ+;4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHH)Q0 4USBEW#-1S$%OPH 23!Y^HSZ?_7K\I_\ @M-_ MP6?_ .$+75OA#\(]45M:(>T\0>(+63/V#.0]K;./^6W4/)_ <@?/DIM?\%KO M^"Q@^#5EJ7PC^%VIY\77"-;^(-:MI<_V&A&#;PLO_+R>C-_RS&0/G.8_Q9EE M::1F=BS,26)ZD]S^/\J^^X7X:Y[8O%+3HOU/SCBOBI1O@L(]=I2[>2"20RR, MQ9F+$G+=3_G^>:;117Z4HV1^7ZO<****!!1110 4444 %%%!X&>W2BS */Z4 M'BOJ;_@G7_P2D^('_!0#Q#'>6D,GAWP':S;+WQ#=PDQG!^:.V3@S2]B 0J_Q M,,@'FQ6,I8:FZM9V7];'5A,'6Q-14J*;9XA^S_\ LY^,OVHOB1:>$_ ^AWFN M:S>9S'$N([>,$;I)G)"QQC(RS<-OLGC MCXAQ@2I+)'NT_2'Z_P"CQO\ ?D7H)7&00"JI7TO^R+^Q/X!_8E^&D?AKP)HZ MV2L%>]U&;$E]JDH!_>3RX!8\DA0 B9PJJ.*];A!$>,;<<8K\LSSBJMB_W6'] MV'XL_6LAX1HX2U;$VE/\%Z#DR%]/2G4TGFG U\F?:!1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %-?DTZD)Q]*0$;-@\X^GK7Y]?\%I_P#@K7#^R/X4N/AWX"OX9_B5 MKEOBYN8G#?\ ".6[C'F'MY[ _(I^Z/G(QM#>G?\ !6G_ (*7Z5^P#\'_ "=. MDMK_ .(WB2%X]$T]L.+8<@W/QIXSU;XB^+=1U[7-0N MM5UC5[A[N\O+ER\MS*YW,[$\DDFOM.%^'OK,EB:Z]Q;>;/@^+>)/JT?J>&?O MOXGV10O;Z;4[R6XN9I+BXG.@)^G6OVS_P""4W_!#+2_V>_[ M-^(7Q:MK/7?'B[;BPTA@LUGH#\$,Q^[+<#UY2,CY=Q <>/FV<8?+Z?-5=Y/9 M'LY+DN)S&IRTE:*W9\\?\$JO^"#%_P#%J'3OB!\:K.[T?PS(%N-.\-',-UJ8 M."LEP>&BBZ848=\Y)50-_P"S7@[PCIG@3PW9Z/H^GV6E:7IL2P6MI:0K%#;Q MJ,*B*H XP*O1Q_+TZ=JE6OR+-,XQ&/J^TK/Y+9'[/E&2X;+Z?)1CKU;W8H MHHHKS#V HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "C-%(W(H 0G'H*\=_;D_;)\-?L M.? /5/''B&996A0P:;IZ.%FU6[8$QPIGIG!);D*@9B#BO1OB'X]T?X7^#-6\ M1>(+^#2]%T6UDN[R[F.(X(D!+$]^W0#]%=[3P]I;M@6T&[YI9,''G2[0S$9Q\B9PF3[W#^2RQ]?7X([O]#YO MB3/(9?0M'XY;+]3RC]I+]HWQ1^U;\9-:\<>+[YK[6-9E+,JL5AMHNB0Q*3\D M:K@ =>N23R>$[>OT% Z#VXSZT5^S4Z,:4%3@K);(_#ZM6I4FZE1W@VXU'Q)J$:'6=?F M0"YU!Q_".OEQ*>%C!X')+,23\YGO$%++X\L/>J/IV\V?3\/\-U#H=2NUM?$/Q(U"'&H:VT>5MAK\BQ6*JXFHZM9W;/V?!X.CA:2HT(V2' M4445SG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 444$XH *BN/O?=W<=/7_/^>E2; MU]:^(_\ @MG_ ,%'H_V*?@+_ ,(_X$J8FLJ-):LY,=C*>%HRKU7I$^)/\ @OO_ ,%-&^+_ (RN/@KX M*O\ S/"_ARY_XJ&[B;Y-4OHSQ;@YR8X&!#9^](._EC/YED\]_P 33IYGN)FD MD+-(YRS,:;7[?EN7T\%0C1IK;=]WW/P+-,RJ8[$2Q%1[[+LNP44 M45Z!YX4444 %%%% !111_7B@-PKV#]BK]BOQK^W+\9+7PGX/M&&PK-J.I2 B MUTF#.#+*P'U"H/F<\#H(H8&'LJ6M1_AYL^LX:X:J8^7M*NE-?CY%3]B?\ 8B\& M?L,?!RS\)^$;,9^674M1F1?M.JW &#-(1Z=%4'" XY.:]GA.4Z$>QI"IV]>] M.48K\CK5IU9NI4=Y/<_9L/0IT8*E25HK86BBBLS8**** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHS0 4U^M.W5'*I?L>?LA>+_VV_C7IW@KP=:^;2 _9M,M@0)+B4C^%=PP.K,0J MY) KG_V?_@'XH_:=^+.C^"O!^FR:IKFM2B.*/'[I%'+22MT2-5RS.>@'?-?T M;?\ !/#]@#PS_P $_?@C!X;T<+J.NWP2?7=:=,3:G<@8^JQKN8(F> 2>69C7 MS?$&?0P%/DIZU)+3R\SZCAOAVIF-7GJ:4UOY^1T'[$W[%G@_]AKX*6/@_P ) MVNYEQ+J6I2(/M6K7) WS2$>IZ*.%4 #IS[$@PM-"87NOH/2I!7X[4K3JS=2H M[R>Y^UT*$*--4J:M%;!1114FH4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'K M12'GB@!"?I7S9_P5/_;>:5BTDLC$LS,3R26)))[FJ]#')_B_&BOVM144HQV1 M^%N4G[T]WOZA1110(**** "BBB@ SBM#PKX3U/QWXFL=$T:QN-2U?59TM+.U M@CWRSRN0$10.22Q48'?%9Z@LZA?O]!\V,G\.1]??ZU^VW_!"'_@E8/@7X5M/ MC)X\TW;XOUNV#>']/GCPVC6Y_\$E_^"8>F_L"_"3[=JT=M>?$KQ)"K:S?+AA8J2&%G M">?W:M@L1P[ $Y"KC[ @.4[]<E?BN*Q57$U76K.[9^[8/! MTL+25&BK)"T445SG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36.*= M3)7VCZSR1^U?SL.6+G=U]?6OK_\ X+:?M@M^UA^VWK4.GWGVCPKX%8Z!I:HV8I#& MY^T3#LV^;< PZHB=J^/UX'OW/K7[)POEJPF#BY?'/5_HC\/XKS;Z[C6H_!#1 M?JPHHHKZ0^7"BBB@ HHHH *,]?S_ *?X4$[17N7_ 3X_8DUW]O/]HW2_!FE M^9:Z7'_I>MZCM^33;)6 D;W=LA$'=B,X7<1CB,13HTW5J.R6IOA\/4KU%1I* M\GL?4/\ P0I_X)>_\--_$"/XI>.-.6;P#X7N@NGVDZ9CUV^0@X*GAH8B 6SP MSX3D"0#]UH$V)W_&N<^$'PIT'X'_ TT7PCX9T^'3-#T&U2TL[>, !$4=3_> M8G+,QY9B22223TPK\3SG-)X[$NI+9:)=D?N^0Y/#+\*J2^)_$^["BBBO)/:" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HQS11F@ )Q7S7_P5D_:S/[' MO[$OBKQ'97'V?Q#JD?\ 8NAE#^\6[G#*)$_VHD$DH_ZY8KZ2D/'\Z_#?_@Y$ M_:L/Q/\ VF='^&.GW&[2_A_:B:^4-\LE_M>UP_E_P!; MQL(/X5J_1'@\29C]3P,IKXGHO5GYORS-<2-(QW,Q))R3G\3S^?--HZ_YZ45^ MW?4**** "BBB@ HS10?F*C(!SQGH,]3^%'6P="YX?T*^\4 M:[9Z9IMK/>ZCJ-PEK:V\"%Y;B9SM1$ Y+$G Y)(]*_HX_X)1_\ !/RR_8)_ M9NM=-NH89/&WB/9?>(KM,-F7!V0*W>.($J.Q8NW\0KX+_P"#=O\ X)Y?\)IX MHD^.OBNQ9M+T:22T\+PS+D7-UC;+=X/\,0)5(/%6L3?9])\-Z=/J=V_I%$A=L>IPO [DU_*[\:/BIJ7QQ^+GB7QCK#[ M]3\3:E/J=QSD(TKE]H]EW8'H !VK]Q/^#BW]HL?"?]B*#PE:W CU+XB:G%8L MBMML]GBKXD0QRVOF+\]II8^:$9Q_P MCB4X_A\D?PFO%X@S18'" MNB]3WN'>:5ND:*"S$^P /-%F]$*4K*[/P?_P"# MB_X_-\4/VYX_"=O-OT[X>Z3#9F/=N3[5.!<2M]=CPJ?>,CM7P#C'I^%=I^T9 M\7+KX]_'SQEXTO-WG^)]8NM1*L>8A)*S*GT52%'L!7%U^\Y3A/JV$A1ZI(_G MC-L6\5BZE?NV%%%%=YYX4444 % &3]>!11C=\O7=Q@C@\@?UY_"@#Z(_X)K6IC\3?$X MQZFQD7]Y!8*"+5.G\09I3CC$J#^&OO=/NU^-\49H\7B^6/PPT7ZL_;>$EJ_3HA:**"VT9+J/HJ,W48_Y:+^='VR+_GHOYTNK=?JX%-1D]D'MJ?\R^\M45''>0S+E9$8$9!!ZTX MR*#U%39HN,D]AU%&[FC.:!A1110 4444 %%%% !1110 4444 %%%% !1106" M]30 45&]U'']Z15^IJ$:W9EMOVJWW>GF"J49/9&;JP3LVBU14(OX6'$L9_&G M?;(?^>B_G1ROL'MH=U]Y)14?VR+_ )Z+^='VF/\ OK^=+E8_:0[HDHIGVB/^ M^OYTOG+_ 'E_.BS'SQ[CJ*:)5/\ $*<&S2*N@HHS1F@ HHW49S0 449Q1F@ MHHW4TRJ#]Y?SH%S);CJ*;YZ?WE_.D^T1X^^OYT[,7M(]Q]%1_;(O^>B_G1]L MA_YZ+^=/E9/M8=U]Y)15>75K6 ?/<0I_O.!3HK^&< I-&P;H0V3,(8,@]5$LB,1Q\JGFM*-*56I&G'=NR,,36 MC1I2JRVBKGIUQ\3O#MCXI71)M>T:+6& 9;!KV,7)!Y!\O=NY^E;0D#D8-?R3 M^)_&&J>-O$=]K6L:A>:IJVJ3-OV:/^"J M_P =?V5#;6_AOQUJ-]HUN JZ1K#'4;'8/X%63YHA_P!E43 MEV9\%0\0*+J6JTW%=.I_2_T]*4/D=?SK\D?@=_P=!6C6T=O\1OAG=1R* )+S MP[>JX<^UO,1M[_\ +9J^G_A=_P %Z_V;?B48XY_%U_X7N),8AUK3)XL'T,D: MO$/J7Q7S>(R#,*/Q4V_-:_D?3X;B3+L0O3T9]HYHSFO%?"O_ 43^ WB MP*+'XP?#EV;[J2Z_;0R-]%=U/Z5Z)X9^,OA'Q@%_L?Q1X=U0-T^R:E#/G_OE MC7FRPM:/QQ:^3/5CBZ$OAFG\T=-14:7D4@^616^AIRRJW1E/XUERLV52+V8Z MB@-FC-(H***"<4 %%&ZC=0 44;J-U !11NHW4 %%&ZC=0 44;J-U !11NHW4 M %%&ZC=0 44;J-U !11NHW4 %%&ZC=0 44;J-U !11NHW4 %%&ZC=0 44;J- MU !11NHW4 %%&ZC=0 449I"P% "TC4AG0?Q+^=4-:\5:7X?@\W4-2LK&,=7G MG6-?S)%5&,F[)&],A3:F/?BI!7B1V/>"BBBJ **** "BC-(7"]2!WH 6BF-<1IU=1]34/] MLV>_;]J@W>F\9JE&3V1#J06[19HJ(7L)_P"6B?G2_:XA_P M%_.CE8O:P[HD MHJ/[5&?XU_.E$Z'^)?SI697M(]Q]%-\Y/[R_G2JZL."*6HR%[:FMY+[RU1 M4<=U', 5D5@>F#UJ0L!4V:W+C)/5!10#FC.:!A1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?-?_!7?XR_\*._X)W_$ M_5(Y?)NM0TEM&MB#\^^[86V5]U65FX_NU]*9P:_,7_@YY^*G]@_LU^ ?"$S?\$^_V7;C]L3]KKP9X%6.1 MM/O[P7&JNO2*QBP]P2>Q* JN>K.!UKQD]?U]B>V?SS^%?LY_P;1_LE?\(Q\, M?$WQAU2U_P!,\32G1M%=UY6TA;,\B^SS )Z@VY]:\?/LP^J8*=1;[+U9[?#V M7/&XZ%'IN_1'ZC:3I5OHNEV]G:P1V]K:QK#%%&NU(D4 !5 Z 8 ]!5H<"H_ MN\8IP; ]*_#]6[L_>XV2LAU4]9U.WT2PN+V\FBM;2SA:>::5@J1(HRS$G@ # M)R> *MEU4>E? G_ <(?MB-^SY^R.G@O2+KR?$?Q,E?3SL;#Q:>@!N6 MXY&_='#[B9\(/!WQ&\=>%?"LEV;?1[#2M;NK&W2UB^2-S&CJ \@'F-D9W.1T QYE#_ M ,%%?CY ?E^-'Q//^]XEO&_G(:\:'0GR/<(/^"EW[04'W?C)\1C_ +VNW#?S:K'_ ]!_:&\ MO;_PN'Q]C_L*R9_]")KP>BK_ +/PW\D?N7^1G_:&)_Y^2^]GN$W_ 4O_:"F M!W?&3XC?\!URX7^3"JD__!13X^72X;XS_$\?[OB6\C_E)7C5%']GX5;4U]R# M^T,3UJ2^]GJTW[=WQONA^]^,7Q2D'??XJOC_ .U*H77[8OQJ-Q\<_&MY_K?%_BF3_ ']5F.?_ !XURM!.!1]7I;:]K4@[[[V1OYM5.7Q1J4W^LU"];/]Z9N?_'JH@9->P_!W_@G]\:OC MW'#-X3^&7B_5+6Y&8KPV#VMI*/:XEVQ?FV*QJ2PM)?O.6/K8TIQQ59VI-6C;5(?!_A&-N M6&HZMYTB#Z6R2 GV)Q7LV@_\&M_B:YA!U3XN:-9R8Y%KHCP_G%57C"7S9^7?A_QMK7A6[CN-+U?4M/GA8.DMM7PWX%T^XC2\<37]_>RF>\U&0#:&D; & .BJ%49) MQDDGY?B+/LMQ&&]E05Y=^6WXGU?#7#^9X?%*KB':/76_X'L:MN_K[4Y#34&$ MZ-4@&*_/S]*"BBB@ HHHH **** "BBB@ HHHH **** "OSB_X.'/VU?B!^R[ M\./ WA_P'JEYX9"^" VTD88,ISR#Q7H977 MHT<5"I75XIZH\W-\/7KX2=+#NTFM&?S#^*/B1X@\;W\ESK.O:SJUQ+R\MY>2 M3N^>>2Q+'J?3Z5C^>^/O-7[">+O^#6[1[JYD?0_C!J=E"S$I%>^'TN64=@66 M>,'C'11]!7/77_!K-J:QGR?C-92-V#^&60?F+DU^H4^)LH:T:2Z)H_)I<*YR MGJFWUU_(_)Y;J5#Q)(OH=YJ1-:O(FVK=72M_LRM_C7Z:^(_^#7WXD6D+'2?B M1X-OI.RW5K<6RGZE5D/Y"O'/BI_P;[_M(?#B!Y++0_#_ (NBC&3_ &-JR94< M]$N/*8GV4$UTT\[RJH[*:_KU.*KD.;T]90E^)\:P>+]5@.Z/4]00^JW#?T:K MD/Q/\2VW^K\0:U&>VR]E&/\ QZKWQ5^!OC/X&:W_ &;XR\*Z_P"%[XD[8M3L M);4R8ZE=X&X>XR/>N5)VCGCJ?RZUZ].G1FKQ2:[Z'D5*E>G+EDW%]G-K4_N_%_BB/_J[;_M*_$:U/[KQ]XRCQ_.FWQ#=_\ QRKUO^W)\:K3_5_%SXG1 MD=-OB>]'_M2O+:*7U2ANX+[D4L97V4Y?>SV&W_X*$_'JT^[\:/BG_P "\57K M?^U*N1?\%)_C_%]WXR_$K_@6OW+?S?M"W'WOC'\0E_P!W5Y5_DU>$T4?V M=A?^?Q/6I+[V>FW'[:GQCO/]=\ M5_B1+GKN\2WAS^#]YXT\62>N[5[@Y_-ZH7'Q6\478_?>(]>ESUWW\K?S M8U@9Q_.@#)QWSC%5]7I+517W(/K5;^=_>S0F\6:KA_!C]C?XJ?M$"-_!?P_P#%?B*UD)5;NUTYS:@].9F41+]2 MPKZ6^'7_ ;V?M)>.%C:^T;PYX55^K:IK4;X'N+?S3^@K@KX[+Z+_>SBON._ M#X',:^M&$G]Y\0I<,<_.WO@YJUI?B"^T>=9+.]O+5UY#0S%&_,'^5?IYX<_X M->?'=U;Q_P!K?$[PK92?Q+:Z?<72K]"YCS^0KM/#?_!K1;QRJVL?&6:50>8[ M3PRJ'_OIKEOT7\^E>=4XDRA/6:^Z_P"AZE/AG.)-6B_F['DO_!"+]OWXJW/[ M87A_X9:OXDUKQ5X1\3072/;:E=27;:8T-K+,DD3N2R+F+:5X4AR<%@N/W'@& MV/IBOF+]A'_@E-\,?^"?TMQJ7AFVU+6/$][ +6XUO591)A1XNNRXN': M9S[9B,'Y5]%PKA_;9E#^[=_?GAV_P _C11THK]E/P_3 M<*,^WXT44P#=@_3\?Z4[S74?>8?\#--HJ91B]RHRDNIIZ3XTUC0&S8ZIJ5GZ M&"Y:/'Y$5U&E_M1_$O0D"V/Q"\;V87IY.N7,?\GKA**S^K4GK9?SU2U_;I^-EC@0_&#XH1;>FSQ3>K^@E-:EK_P %&?C]9_<^,_Q./^_XDNW_ M )O7B]%9O!8>6\(_SWS_AZ5^T1_T6 M'QS_ .#-_P#Z]'_#TK]HC_HL7CG_ ,&3_P"%>!T4?V;A/^?:^Y#_ +0Q7_/R M7WL]\_X>E?M$?]%B\<_^#)_\*/\ AZ5^T1_T6+QS_P"#)_\ "O Z*/[-PG_/ MM?<@_M#%?\_)?>SWS_AZ5^T1_P!%B\<_^#)_\*/^'I7[1'_18O'/_@R?_"O MZ*/[-PG_ #[7W(/[0Q7_ #\E][/?/^'I7[1'_18O'/\ X,G_ ,*/^'I7[1'_ M $6+QS_X,G_PKP.BC^S<)_S[7W(/[0Q7_/R7WL]\_P"'I7[1'_18O'/_ (,G M_P */^'I7[1'_18O'/\ X,G_ ,*\#HH_LW"?\^U]R#^T,5_S\E][/?/^'I7[ M1'_18O'/_@R?_"C_ (>E?M$?]%B\<_\ @R?_ KP.BC^S<)_S[7W(/[0Q7_/ MR7WL]\_X>E?M$?\ 18O'/_@R?_"C_AZ5^T1_T6+QS_X,G_PKP.BC^S<)_P ^ MU]R#^T,5_P _)?>SWS_AZ5^T1_T6+QS_ .#)_P#"C_AZ5^T1_P!%B\<_^#)_ M\*\#HH_LW"?\^U]R#^T,5_S\E][/?/\ AZ5^T1_T6+QS_P"#)_\ "C_AZ5^T M1_T6+QS_ .#)_P#"O Z*/[-PG_/M?<@_M#%?\_)?>SWS_AZ5^T1_T6+QS_X, MG_PH_P"'I7[1'_18O'/_ (,G_P *\#HH_LW"?\^U]R#^T,5_S\E][/?/^'I7 M[1'_ $6+QS_X,G_PH_X>E?M$?]%B\<_^#)_\*\#HH_LW"?\ /M?<@_M#%?\ M/R7WL]\_X>E?M$?]%B\<_P#@R?\ PH_X>E?M$?\ 18O'/_@R?_"O Z*/[-PG M_/M?<@_M#%?\_)?>SWS_ (>E?M$?]%B\<_\ @R?_ H_X>E?M$?]%B\<_P#@ MR?\ PKP.BC^S<)_S[7W(/[0Q7_/R7WL]\_X>E?M$?]%B\<_^#)_\*/\ AZ5^ MT1_T6+QS_P"#)_\ "O Z*/[-PG_/M?<@_M#%?\_)?>SWS_AZ5^T1_P!%B\<_ M^#)_\*/^'I7[1'_18O'/_@R?_"O Z*/[-PG_ #[7W(/[0Q7_ #\E][/?/^'I M7[1'_18O'/\ X,G_ ,*1O^"H_P"T0ZX_X7#XZ^HU)_\ $&O!**/[.PG_ #[7 MW(/[2Q2_Y>2^]GN%S_P4P_:"NC\WQD^(O_ -;G7^3"LS5/V__CIK*%+CXQ_$ MZ2,]5_X2:\"G\/,Q7D5%..7X9.ZIK[D+^T,2U_$E][.TU?\ :0^(?B(-_:'C MOQC>ANOVC6;B;=^!:N2OM5N=3N#+<7$\TC;_$.2V3AN<\_SZT#@8]***M66B,&V]PKZ;_X(W:U)H/\ P4O^$\T3M&TN MIR6S;3]Y9;>6,C\FKYDKZ2_X)!0?:/\ @I/\)%ZXU@O^4,A_I7#FBO@ZO^%G MH92VL;2M_,OS/Z6.@'UIPIIX-.'2OP8_H@**** "BBB@ ZU^6?\ P<._MT_% M#]G7Q'X-\%^!]>OO">E^(-/EOKW4=/;2]5T^18[O3W8 ,%+*RLC;5W(P(. MU3PRJP]+*<10H8J-3$QYH]CR-;J2XUC7]:U M6XE.Z26\O99GD)Y))+9)R2>?6L7SI.3YDGJ>:_7G7O\ @UGM9+AO[+^,MQ;P MY^6.Y\,K*P'NZW"Y_*N>UG_@UL\101;M.^+NCW,@Z"YT&2$?FLSG]*_3H\29 M0]I)?]NV/R>?"^<+[+?_ &]<_*N.]F3!2:9<]-K$5/'XDU"#'EW]XGIME(_D M:^^_B+_P;9_'CPLDDNC:GX&\31]1'!J$MO,W_ 98U7GW?%?+/QV_X)^_&C]F MJ&:?QG\.?$VCV4)P]Z+;[58Q_6>'=%VZ[J]'#YGE]?2G*+?RN>?B,KS+#O\ M>1DE\_T/-[;XC>(++B'7-8A(_N7DJX_\>%7H/C=XTM#^Z\7>)H\?W=3F_P#B MJY?;@8"D;>WI1G(KT?846K\J^Y'F_6*R=N9_>SMK?]I?XC6;?N?'WC2/_$?N17UW$+_ )>2^]GMT/\ P4H_: @^[\9/B/\ 0Z]<'_V:K<7_ 5 M_:&A7CXQ>/OQU:0_^S5X-14?V?AGO"/W+_(?]H8E?\O)?>SW6;_@IU^T) M^,7Q"'^[K$J_R:J=Q_P4<^/UQ][XS?$P?[OB.Z7^3BO%J*%E^%_Y]Q^Y#_M# M$_\ /R7WL];N/V^?CI= ^9\9OBHX/4'Q7?8_+S*H7'[9_P 8+P'SOBK\2)?7 M=XDO#G\Y*\SHK2.#H+10C]R,_KF)O?GE][_S.[N?VH_B9>_ZWXA^.)?7?KMR M?YR&J%Q\>O'-W_K?&7BJ3_>U:<_^S&N3H S5?5:*^PON0OK5:_Q2^]F]<_%# MQ)>?ZWQ#KDGKNOY6_K5"7Q5J=P,R:A?R>[3L?ZU0[X[^E>L?!K]A3XQ?M +! M+X/^&_B[6K2X_P!7>1Z=)%9O_P!O#A8OS;%8U'AJ2O4Y8^MC6G]:K:4N:7I< M\MEU&XF/SW$[?[SD_P S4?G/C.^3'NQK[K^&G_!NO^T7XY,;:I:^$_",;O1X>S>JE)0E\W;\S\Q/"?Q,\1> =0CO=#U_6M%NH3E+BQO9+>1 M/<,K _CGBOVA_P"#>/\ ;4^)/[3?A;QYX>\>:U>>*+?PA]ADL-2O&\VZ03^> M&BDEP&E'[D,&?+";6[\NZF^U7]]>2>;=ZC,%"[Y&P!PH "J HYP M,DD_+<1YYEN(PWLJ&LN_+;\3ZOAG(G*-M?GT;VU/TH6BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH ***1FQ0 UF^:OP[_ .#FKXF/XA_:\\'^&8Y-]OX;\-"Y89^Y M/_ M9?\ @A8_LV_L^^$? NF[6MO#&F0V)D"[?M$BJ/,E(]7D+.?=C7X7_P#!O_\ MLY+\V4FMR[ERC7'$5NI[;@[^8/\ K@?>OZ"H_N_C7YCQ MOCN>M'#1^SJ_5_\ /U;@'+_ &=">*EO+1>B'4UUS3J:YXKX4_0M]".=EC!/ MI\U?S??\%A_VM6_:Y_;B\3:A:W'G>'/"[C0-&7.4:*!B'D';$LQDD!_N%!VK M]N_^"JO[4/\ PR1^P]XT\46]Q]GUJZMCI.C%6P_VRY!C1E_VHU+2X](C7\T# MN7=B>6SSSGGO^M?H' ^7W<\7+T7ZGYKQ]F32C@X^K_03/']?7THHHK](\C\Q M"BBB@ HHHH **** #_#-=Q^SE^SSXH_:F^,FB^"/!]BU]KFM2[(^2L=N@Y>6 M1@/EC5O(SS,OJ6$=;KLO5GLY#E?U_%QH/;=^B/?OV$O M^",GPG_8Z\.V-Y?Z38^./'" -/K>K6PF2&0?\^T+%EA4=B,OZMC 'V)!$L:8 M4;0.GTIJ)_>Y/O4D??K7XMB<96Q$_:5Y7?X?(_=,'@J&&A[.A%17X_,G6G4UNM# P?'OPYT#XG^'[C2/$FB:7KVEW0_>VE_:)AZ_H\QANK.X3;(AZ@\$@JRX8,I(((()'-<[7[T?\%[_P!@.Q_: M*_9NO/B-HMBJ^-?A[:M=R21J/,O].7)FC?\ O&-=TBD\@!P,EJ_!?/\ L[<< M8]/\^_-?L.19M',,/[1;K==O^ S\5X@R>678GV?V7L^X4445[)X84444 %%% M% !1110 4449H#3J6] \/WWBO7;/3--M9[[4-0G2WMK>&+S)+B5V"HBJ.69F M( 'O[C_ /!-?_@@YX-^!/A'3O%'Q8TNP\8>.[I!/_9MTJW&F:)GD1>7 MC9/(/XF;*@C"# #-\?\ _!N9^R;:_&?]J;5OB!J]JUQIGPUMDDLU="8XXY6]F\L]0*_=:,;5XW#V]*_..+\\JQJ_4J$K"\@I3I/&X MF/-S;7[%?3]-ATFSBM[6&&WM[=!'''&NU44< #H!V XJU%]VC;2J,5^?7OK M<_2HQ25D+1110,**** "BBB@ HHHH *",BBFOTH ;(WEK[*,U_,7_P %,?BM M_P +J_;W^*GB!9/.@D\07%G;/G(:&V/V:,CV*1*?QK^DCX^?$:/X/_ _QAXL MGV^7X:T6\U1@YP&\F%Y,?CMQ^-?RDZC?2ZIJ$]U-(TTUQ(TKR-]Z1B_X(S0?:/\ @II\)U]-1G?_ +YM9C_2OF&OJS_@B':_:_\ M@J)\*U_NW%])_P!\Z?=-_2O.S?\ W*K_ (6>ED^N-I?XE^9_1]W_ !%*M)3A MTK\(/Z&"BBB@ HHHH **** "BBB@ J"[MUN%V,NY6&"",CFIZ:QYHU6PI)-6 M9\/_ +>O_!#KX6?M9:1?:MX8L++X>^.MK2Q7^G6XCLKV3D[;FW7"D,2"_&6FR:7KFDR;9$)W1RH>5EC;)#1L.01]."" M*_JR=&+K[O_ <*_L66WQK_ &7/^%E:79K_ ,)1\.<2RR(/GN-, M9@)E;U\IBLH)^ZHEQRU?9<,\15:-58?$/FB]->A\+Q5PS0K47B<.N6:[=>]S M\(Z*._I[>GX]_K17ZM8_(E\*"BBB@ HHHH **** "BBB@ Q74?!3X,^(OVA/ MBEHO@[PGITFJ:]KURMM:VZ 8)M+T_Q]X\"B6XU#4H/.L[ M.7KBV@?**%.?WC N3D_)G:/M>TMUMX0B(%51M"J, < 4X# Z-UZ8Z4]:_%< M5CJ^*FZM>3;?W?(_=L'@,/A::I4(I)??\Q11117,=@4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4T_>IU-/WZ M &R\#\*_EI_;?\6?\)U^V5\5=8W^8NH>+=3FC.5 M9^2/S?Q"J?NZ,/-E&BBBOTH_+PHHHH *"=O/MG\1T_G13K>W>[NHHHU9Y)'" M(JC+,QX 'XXI2:2NPLWHC]R?^#;/]GP?#_\ 9&U[QW<0[;[Q_JS) ^.MG:%H M5P?^NQN3[X'I7Z/Q#"UYE^QG\%5_9W_94\ >"UC6.;P_H=M;76/X[C8&G;_@ M4I=OQKT]>E?A&:XJ6)QE2L^K/Z&R?!K#8.G171(*9)][\.GK3Z:XR?YUYYZ1 M^,__ TX/2ORM MP!]*]_\ ^"I_CK5/B%_P4.^+UYJ[;KBT\276FQ 9VK;VS_9X0!V_=QH2/4FO M *_I_/\ Q!C'BLPJ5.SM]V@4445ZQXX4444 %%%% !11 M11TU!;@%W,._;\_\FOZBO^"??PM'P8_8F^%_ASR1#-8^'+-KI=N/](DB668X M]Y7<_C7\P7AO2)/$'B/3[&+_ %M[<1P)Q_$[!1_.OZU="LH],T:UMXEVQ6\2 MQHH_A"@ #]*_/N/*S4:5+S;/TCP]HISJU?)(M4445^<'Z@%%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-8X-.II&3 M0!4UW2;?7='NK&ZACN+6\A>&:*0925&!#*1W!!(_&OY5?VD/A:WP/_:!\;># M6+,/"^N7FEHQ_C2&=T5OQ4 _C7]6C]1_G%?S=?\ !:7PPOA+_@IO\5+:.,1I M/>VU[P,9,]G!,Q_%G-?<<"UFL1.EW7Y'Y_X@8=/#4ZO5,^6Z***_4#\G"BBB M@ HHHH **** "CKW_"BC^@S1U#;4_>__ (-R_A6O@?\ X)]C7&A"S>,]?O-0 M\S;AGBCVVRC/H&AD(]W-??<8PM?-?_!(3PQ_PB'_ 38^$=KMV^=HHO,8Z^? M+)-_[4-?2J=*_!\WK.ICJLW_ #,_H3):*HX&E272*%HHHKSSU HHHH **** M"BBB@ HHHH *1J6F2G H ^1_^"Y/Q3_X5=_P37\?&*3R[SQ MMHMO@_>\^9! M(/QA$M?SG?3IDX_.OV@_X.@OBC_9?P2^&G@V.3YM:UFXU>10V/EM8!&-WMF[ M)'NE?B_G/_ZJ_6N"Z')E_/\ S-_Y'XSQQB/:9C[/^5)??J%%'7^5 .?\_A7U MWJ?&[[!1G@_[/7VKZ(_9!_X):?&7]M9H;KPGX8>S\.R/M;7=7S::>,'#;7(+ MRX/&(E?!R#BOT6^ W_!L5X/T2WM[CXD>/M MO("'GM7BXWB+ X3W:E1-]DKL]S+^&L?BUS4J=EW;LC\83Q2A2QP 21UXK^D? MX9?\$9?V;?A=M^R_"[1M4D4#=)K$LVH^:?5DG9D_("O:O"'[,OPY\ 0)'H?@ M+P;HL%+X_KY5?U'^4 > M%6E$=9RX[K]*:^]FT?#VAUJO[D?R_P!K_P $W_C]=8V?!GXE+_O^';I/YH*T MK?\ X);_ +0]X1M^#WCH?[^F.G_H6*_INQCUHQ[FLY<=8I_\NX_B:+P_PO\ MS\?W(_FBMO\ @D?^TA=8V?"/Q5_P.-$_FPK1MO\ @C3^TU>M\OPGUH?[]W:K M_P"A2BOZ3<4AXJ/]>,7T@OQ*7A_A%O4E^!_.';_\$0/VH[O&WX67([?/K&G+ M_P"A7%:5I_P0?_:DN/O_ WBA_W_ !#IG])S7]%1HV\5$N.,<_LQ^[_@FL> M\#UE(_GEMO\ @@#^TY?]I.8_-HOAF'_ ']< MBX_+-?T$X(I:Q_UTS#M'[O\ @FBX#R]=9?>?@-:?\&YG[15Q]Z/P5#_OZR?Z M1FM&V_X-K_V@)\"34OAQ%W_>:K<-_*W;]*_>?RC_'WX+:M^SI\9/$7@?7IK*XUCPO>/874EI(TD#NO4H656Q]0 M*X^OH+_@JS_RD7^,'_8QW']*^?:_4L'6E5H0J3W:3T\S\CQE*-*O.G#9-K[F M%%%%=1RA1110 4444 %%%%&Z#7H>E_LC_LK>)/VT/CEIOP_\*W.DVFM:G%// M!+J4TD5NOE1M(V61'8?*IZ+Z5]=W'_!M;^T!']S5/AS(HZ!-6NS/P-F_X-P_VB(!\O\ P@LGLFKN,_G$*HW'_!NS^T? /ET_PE+_ +FM M*,_FHK^@#'^<4HR!7SW^NF8+M]W_ 3Z/_47+?[WWG\^$W_!O=^TM /E\.^' MY/9--\??51^[_@DO@+ =)2^\_F]F_X(H?M/6X^; MX4ZD?]W4K%OY3&J,_P#P1P_:7M1\WPEUYN_R36S?RDK^E T;# MHF;6/A?\0M+51DM=^'KR$ ?5HQ7!:GH=]HEP8;RSNK24<%)HF1A^!%?UO&$% MONCZU1USPMIWB*T:WU"PL]0@<8,=Q"LB,/<,#75#CRIM.DODSEJ>'M/>%5_< M?R2_Q;>_I1G]*_IT^)'_ 3+^ ?Q8W?VS\)O!;22??EM-.2RE8^I>#8Q/OFO ME_XX_P#!MC\&?'ZSS^#M8\5> [Q\F.%9QJ5C$?\ KG+^]/\ W^[5ZF&XVP"->NM)UK3K[2=4L9#%<6E["\,\#_ -UT M7G?^X5O\+/5R/7'TO\2/Z'!POZ4ZCM17X4NY_084444P"BBB@ MHHHH **** "BBB@ K!^)O@FQ^)?@#6_#NIQ"?3=>T^>PNHR,B2*5"CC\F-;U M1RC&3C/%5&3BTT34@IQ<'UT^\_DM\>^$;GP!XXUG0KP8O-%OI["<8Q^\BD:- MOU4_2LFO=_\ @I[X37P5_P %"/C!8H@C1O%%Y=JH'"B>0S#'_?RO"*_?L'5= M6A&H^J7Y'\XXJFJ=:=-=&U]S"BBBN@YPHHHH **** "BBBC2VHUN ..^W'(/ M^?K_ #K^F+_@DW\+%^#_ /P3O^%.E>3Y,MSH<6J3*1AO,N\W3;O<>;CGL!7\ MS\63(N.N:_K$^#'AH>#/A#X7T<+M&DZ3:V8&.GEPHG]*^"X[K-4:4.[;/T+P M]I*5:K4[*WXG34445^:'ZJ%%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !2-V^M+2-_6DP.4^.VKGP]\%? M&&H [38Z+>7 /IL@=OZ5_*#(3X5U-\_2TE-?R ML-]XU^C\!1_=U7YH_+?$*7[VDO)_F)1117Z$?G(4444 %>Y?\$T/A#_PO7]O M3X6^&VA^T6\^O07MS&1E7M[;-S,"/0QQ,/QKPVOT2_X-K/A2OB_]MC7/$T\8 MDA\(^'9GA;'W+B>1(D_.(SBO+SK$.A@:M5=G^.AZF2X;ZQCZ5)]9(_=A!\BT MJC%(#\O'K2JNZ MYC']:_JRA&V,5_+C^P#I7]M_MS_!VUV[EE\::0&'JHO82?T!K^I =*_,^.Y7 MK4E_=?YGZIX>QM0JOS7Y!1117P9^B!1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !0310>E)[ ,8\U_/)_P7YL/L?\ MP4Y\:28Q]JLM-EZ=<64*?^RU_0X1S^-?@!_P<36/V3_@H[?2=/M6@Z?+]<*Z M?^R5]?P5_P C%_X7^A\5QTKY1\*44&BOUH_' HHHH **** "BBB@ H(W M#\A^>:*='Q(OUSCUI2=DV-*[L?U&?L#Z-_PC_P"PY\'[/;M:W\&:2KC'\7V. M(M^N:]<0<5Q7[-FG#2OV>/ MJJX6V\/V$0'LMO&/Z5VXK^?L3*]:3\W^9_1^ M#C:A!>2_)!1116)T!1110 4444 %%%% !1110 4V3K]13J9+S\OYT">Q^%O_ M *^EO^"PGQ M*_X6G_P4D^*VH+)YD-CJPTB,9R$^R1);,![;HF/XU\TU^YY'1=' 4J=NE_O/ MY_S[$*MF%6H^]ON#&Y@,_>R!D9QZ_P#U_P *_63_ (([?\$0K7Q?H6D_%;XS M:6UQ9W2QW>@^&KI] #1VPR,%5!#R#G*E%(Q)D?O]:VZP6X51A5 MX48QM'85\IQ5Q!*F_J>&EK]I_H?7<'\-QJKZYBH^[]E=_,CT?2[?1M-@M;2" M.UM;9!%##$@2.) ,!54< < #BK6:0#%"C%?F^K=S]2BDE9"T444#"BBB@ H MHHH **** "BBB@ HHHH **** "FOUIU-?K0!_,O_ ,%6?^4B_P 8/^QCN/Z5 M\^U]!?\ !5G_ )2+_&#_ +&.X_I7S[7[UEO^Z4_\*_(_G7,O][J_XG^84445 MW'"%%%% !1110 4444 ?:'_! /\ Y2=>"_\ KQU/_P!(Y:_H;3[M?SR?\$ _ M^4G7@O\ Z\=3_P#2.6OZ&T^[7Y+QI_OZ_P */V+@/_D7/_$_T%HHHKY$^V"B MBB@ HHHH **** "BBB@ HHHH **** &NNX5XW^U?^P7\+OVT/#;6/CSPO9ZE M=1QF.VU.$>3J-EG.#'.N& !).QLH>ZFO9J:RUI1K5*4N>G*S75&-;#TZT>2J MDUYG\[__ 4F_P""-GCC]@V6?Q%IGZ5_6UXF\-6/C'0KS2=4LK74--U&![:ZMKF(213Q. MI5D93PRD$@@]037\[W_!8+_@G-+^P/\ M +_ &1'))X \8&6\T)V+,;(@YEL MV)ZM&74JVNU^T?\%*M ;_GCI&HO_Y *_\ LU?$!.2>^><^N>:^\/\ @W2M M/M'_ 47MW_Y]_#U^_T_U:_UKWL^_P"1?6_PL^>X?_Y&-'_$C]^C]RE7^E)U M2E']*_##]_ZBT444QA1110 4444 %%%% !1110 4UCAJ=36^]0!_-O\ \%H; M/[#_ ,%-_BLF,;KZVD_[ZLX&_K7R[7UM_P %S[?[-_P5,^**]F?37_/3+0_S M-?)-?NV42YL%2?\ =7Y'\\YQ'EQU5>;_ #"BBBO2/-"BBB@ HHHH **** -3 MP-HW_"1>-M'T_O?7T%N!Z[G"_P!17]:=D-MI'QCY17\J?[+NGC5OVEOA[:L- MRW'B33XB#W#7,8K^JVW&(U^@_E7YMQY+WZ*\I?FC]0\/5^[K/T_(DHHHKX _ M2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH ***#0!YO^V-;&\_9'^*$(Y,GA+5$&.^;.45_*XWWC]?SK M^K7]I.U^W_L\^/+?&?.\/7Z?G;2"OY2Y1B1O8XK](X#?[NJO-?D?EOB%'][2 M?D_S&T445^@'YR%%%%&K6@ #@&OV8_X->_AI]@^$?Q0\7-'_ ,A75[328W*] M/LT+2L ?^WI<_05^,^,G]:_H)_X-Z?!0\+?\$U]"OA'L/B+5M0U \8+XF^SY M/X6X_*OD^,JSAEW(NK1]AP30]IF7,]DF?<*#Y?H:<* 3_P4*MF_P">GA:Q?_R)<#^E?O?_ !?A7X.?\'*D/E_M_P"D M-C_6>#[)O_)F[']*^LX+_P"1C\F?&\<_\BQ_XD?GN**!17ZX?C(4444 %%%% M !1110 4Z'_7)_O"FTZ$XE7ZYJ*GP/T-*/QKU7YG]8WP?M?L/PE\,P]/)TJV M3'TB45TE97@B#[+X,TN/_GG:1+^2 5JU_/U;^(_5G]'X?^%'T7Y!11169J%% M%% !1110 4444 %%%% !5?5+B.RLIKB1ECCA0N[$X"@T^! MGC*2U!:YCT.\>(#^^('Q^N*NG'FFH]VC*O+EIREV3/Y9/BYXTD^)'Q5\3>(I MF9IM>U6ZU"0MU+2RLY_]"JK\/_!&I?$SQSH_AW1K>2[U;7+V&PLX4/S2S2NJ M1@>AW'K62X8R8ZMG''K7Z"?\&Z'[,J?&#]L>\\;W]OYVE?#>P^TQ,PRGVZXW M10\>R"9P>S(IK]SQV+6#PU'VVX1-OVV[?YIYCW^:0L0#R%VKVKUA!@4B#Y>!CF MGBOPRK5G5FZD]WJ_4_?L/1A2IJG3V2L@HHHJ#8**** "BBB@ HHHH **** " MBBB@ HHHH **** "FOUIU-?K0!_,O_P59_Y2+_&#_L8[C^E?/M?07_!5G_E( MO\8/^QCN/Z5\^U^]9;_NE/\ PK\C^=?A2^;_R+;C^M? MY"UM=R1NI5XW*,",$$'%?H-_P;40>;^W[K+?\\_!M MZW_DS:#^M?LF?2OEM62_E/P_A^+6:T4_YC]X/X6^M.'2F[LJ?K3ATK\/1^^! M1115 %%%% !1110 4444 %%%% !36^]^%.H-#V _G5_X+S0^5_P5'^(C?\]( M=+;_ ,IML/Z5\>U]F?\ !?6/9_P4\\<'^]9Z8?\ R1A']*^,Z_<\C_W"C_A1 M_/F>?[_5_P 3"BBBO5/*"BBB@ HHHH **** /3OV*;7[;^V-\)X?^>WC#24Q MZYO(A7]3J?=K^6_]@.'[1^W7\&(_[WCG11^=]"*_J04U^9\=R_?TEY/\S]4\ M/(VP]5_WE^0M%%%?!GZ(%%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !0>E%!Z4 9?B_1X_$/A74M/E_U= M]:R6[@],,I4_SK^2V_MGLKZ:&0;9(9&1ACH02#7]<5PNZ)O<8K^4O]I'PV?! MO[0_CS1RGEG2_$-_9E2,;3'_8IT#_A%?V//A7IFW:=/\):7;L,8Y6TB4_J*^%X\J6H4H>?Z'Z%X>T[XF MK4_NK\STZBBBOS$_5@II^]3J:?OT ?S>_P#!;)=O_!3_ .*O_7U9G_R0MJ^5 MZ^K?^"W:[/\ @J%\5/\ KXL?_3?;5\I5^\93_N=/T7Y'\\YQ_OM7U?YA1117 MH'FA1110 4444 %%%%'1AU/I/_@C_;_:O^"E/PD7TU@O^*PR'^E?TL@Y%?S6 M_P#!&\9_X*8?"7_L*2'_ ,EY:_I2'2ORSCC_ 'R'^$_6_#__ '*?^+] HHHK MXH^]"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@!#P:_"C_@YFA\G]O3PRW_/3P/:-_P"3M^/Z5^Z[?TK\,/\ M@YRB_P",Y/"#?WO!%LO_ )/7W^-?5<&_\C)>C_(^0XX_Y%;_ ,43\X^]% .1 M17Z\?BP4444 %%%% !1110 4Z'_6K]<4VI+9=]S$O]Y@/Y5G6^!^C-:'\2/J MC^MSP^GE:':+_=A0?H*N5#IZ[+*(>BBIJ_GV;O)L_H^C_#CZ(****DT"BBB@ M HHHH **** "BBB@ JGK.FPZSI\]I^/'P]^-FJZ-X2\'S>+O#$UXW]DZI;WELD(KDZGKLT#; MHXY-H6.W0]UC08ST+LY'!%?4VSF@+D5[V8<18O%X>.'J6LM^[]3Y_+>&<)@\ M3+$T[MOOT] #=*=0!BBO!/H@HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "FOUIU-?K0!_,O_P %6?\ E(O\8/\ L8[C^E?/M?07_!5G_E(O\8/^ MQCN/Z5\^U^]9;_NE/_"OR/YUS+_>ZO\ B?YA1117<<(4444 %%%% !1110!] MH?\ ! /_ )2=>"_^O'4__2.6OZ&T^[7\\G_! /\ Y2=>"_\ KQU/_P!(Y:_H M;3[M?DO&G^_K_"C]BX#_ .1<_P#$_P!!:***^1/M@HHHH **** "BBB@ HHH MH **** "BBB@ HHHH *CG/R,/45)39!GW]L4 U=6/Y6_VO\ P%)\+/VJ_B1X M=DB\D:/XDO[6-2,?NUN'"$>Q4 CU!S7WA_P;#?#JXU+]I[X@>*O+D^RZ-X:7 M3&?'RA[JYCD7GUVVK?G7UY_P44_X(4^&?VX/B])X\T7Q5<^!?$FHQI'JA_LT M7UMJ!10BRE/,C*2;5"E@Q#!5X!R3[K_P3F_X)[>'?^"=OP:G\,Z-J%QKFI:K M=?;=5U6:W$#7DH4*H6,%MD:J.%+-RS'/.!^@9EQ-AZV5^PBWSR2B_EN?FN5\ M+XJAFWMYI>SBVUZL^@57C\M?NF1_P#(OH_X4?S_ )]_O]7_ !,****]0\<**** "BBB M@ HHHH ]E_X)V1>;^WM\&/;QMH[?E>1'^E?U"H,"OY@?^";<7G_M_?!M?^IP MTP_^3,=?T_K_ %K\OXZ_WFG_ (?U/U;P]_W6KZK\A:***^'/T(**** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "FN:=37ZT !&!7\T/_!6_P-_PKS_@I!\7-/">6+C7&U$+C'_'U&ES^OFY M_&OZ73G%?@9_P<:_#MO!_P#P4,;5O+VQ>*_#]E?[\?>:/S+8_B! N?0$5]AP M16Y<$8,;?)T:S3'T@05_)_!Q,I[ Y^M?UH?#:-8?AYH*K]U=/@ ^@C6OS MWCS:DO7]#](\/(^]5?DC:HHHK\Y/U *0]:6D/6@#^P_]-UK7RA7U?_P7!_Y2C?%/_KO8?^FZUKY0K]XRG_/VTO!;_P![P; OY7MW_C7[D'I7X??\ M'/,>/VO_ *_][PBJ_E>7/\ C7U'!_\ R,H^C/D>-O\ D5OU1^:@^Z/I10:* M_8#\5"BBB@ HHHH **** "K&DKOU:U'_ $U7^8JO5K05WZY9C_ING\ZSK? _ M1FM#^)'U1_6Y:?\ 'FG^[4U16G_'G'_NU+7\]O<_H^C\"]$%%%%!H%%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %-?K3J:_6@#^9?_ (*L_P#*1?XP?]C'LM_W2G_A7Y'\ZYE_O=7_$_P PHHHKN.$**** "BBB M@ HHHH ^T/\ @@'_ ,I.O!?_ %XZG_Z1RU_0VGW:_GD_X(!_\I.O!?\ UXZG M_P"DJ>2%%%% !1110 4 M444UN![E_P $S5W?\%!?@W_V-NGG_P CK7]/0Z5_,1_P3'7=_P %!_@Y_P!C M78?^CEK^G<=*_+N.O]ZI_P"%_F?K'A]_NU7_ !+\@HHHKX<_0 HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** FOR0_X.COAAOTGX5>-(8N8);[1KF3'W@ZQS1+GVV3D#W-?K?7Q7 M_P %^/@X?BQ_P3D\2WD49DNO!MY:Z_$ .R.89#G_ &89Y6_"O8X?Q'L'Q)AO;Y=5AY7^X_GG_S]:*#17[AY'X'YA1110]@6Z'1#]XOUQ7]8WP: MO/[1^$7A>X!W";2;60$=\Q*:_DX0X8>QS^5?U2?L>:P/$/[)?PPU -O%]X4T MN<-G.=]I$W]:_/\ CR/NTGYO]#]&\.Y?O*R\D>CT445^;GZD%(>M+2'K0!_. M'_P7!_Y2C?%/_KO8?^FZUKY0KZO_ ."X/_*4;XI_]=[#_P!-UK7RA7[QE/\ MN5+T7Y'\\YQ_OU7U?YA1117H'FA1110 4444 %%%% =3ZB_X(O#=_P %-_A/ M_P!A"X/_ ))SU_22O"U_-O\ \$6O^4G/PI_Z_P"X_P#2.>OZ2$/RU^5\\-./_)F6OIN$?^1E'T?Y'R?&G_(KEZH_,?O1 M1G-%?L1^)] HHHH **** "BBB@ J]X:7=XCT_P#Z^8__ $(51K0\)#=XITT? M]/<7_H:UG6^!^C-:'\2/JC^M>T_X\X_]VI:BM/\ CSC_ -VI:_GM[G]'T?@7 MH@HHHH- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ IK]:=37ZT ?S+_\ !5G_ )2+_&#_ +&. MX_I7S[7T%_P59_Y2+_&#_L8[C^E?/M?O66_[I3_PK\C^=*O\ L&Z;_P"DJ5\4'K7[GD?^X4?\*/Y]S[_D85?\3"BB MBO5/)"BBB@ HHHH **** />/^"8(W?\ !0OX._\ 8U67_HT5_3FOW17\QW_! M+M=W_!0SX._]C39G_P B5_3BOW:_+>./]ZI_X?U/UCP__P!VJ>J_(6BBBOB3 M] "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH *Y/XZ?#BV^,GP;\5^$;S;]G\3:1X%=93)$YS^=5"3C)270BI!3@XOJC^2+Q#H=SX8UZ\TV\B:"[T^=[::- MNL;HQ5@??(/':J=?5W_!:SX ?\,__P#!1+QS;P0F'3?%$J^)+'C 9;G)EP/0 M7"SJ,=E%?*(.17[Y@<1[>A"M_,DS^=L?A7AL1.A+[+:"BBBNHXP_S^HK^FK_ M ()4^*?^$O\ ^"=GPANBV[R?#EM9YS_SP!@_3R\?A7\RH&2/Q_'I_C7]"W_! MOYXX_P"$M_X)G^$[1GWR>'[_ %#37.?^GEYU'_?,RC\*^)XXIWPD)]I?H?=\ M U.7&RAWC^I]K44 \4 YK\M/UT*0]:6D/6@#^P_] M-UK7RA7U?_P7!_Y2C?%/_KO8?^FZUKY0K]XRG_OVRK\3_\ @Z$7/[2?PX_[%N3_ -*F MKZ;A+_D91]'^1\KQG_R+)>J/S#/6BBBOV'J?B(4444P"BBB@ HHHH *T?!__ M "-VE_\ 7W%_Z&*SJT?!_P#R-VE_]?<7_H8K*M_#EZ&M#^)'U1_6O9_\>L?^ MZ*DJ.S_X]8_]T5)7\^=3^CZ/P+T04444&@4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U^M.I MK]: /YE_^"K/_*1?XP?]C'.I M_P#I'+7]#:?=K^>3_@@'_P I.O!?_7CJ?_I'+7]#:?=K\EXT_P!_7^%'[%P' M_P BY_XG^@M%%%?(GVP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4UNHIU-;J* /Y[/\ @X'_ M .4F7BK_ +!NF_\ I*E?%!ZU]K_\' __ "DR\5?]@W3?_25*^*#UK]SR/_<* M/^%'\^Y]_P C"K_B84445ZIY(4444 %%%% !1111U ]\_P""6W_*0_X/?]C/ M9_\ HP5_3>O?ZU_,A_P2V_Y2'_![_L9[/_T8*_IO7O\ 6ORWCC_>X?X?U/UG MP_\ ]UJ?XE^0M%%%?$GWX4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !37.#^5.IKG!H _*/_@YW M_9Z;5O OP_\ BA9V^YM)N9= U.11\WE3#S8"?]E7249/>4#O7XXYR3ZYY'I7 M]1'[?G[.W[U$S[9'>OY>[NUDL; MJ2&:.2*:%BCHXPR,#@@CL%9)/+A\4>'#<1C_ )Z3VLR%1C_KG-,?P-?. M\54?:9;4\K/[F?2<)8CV6:4WWT^\_<8')^M.48IBC"?2I AK0_B1]4?UKV?_ !ZQ_P"Z*DJ.S_X]8_\ =%25_/G4_H^C M\"]$%%%%!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %-?K3J:_6@#^9?_@JS_P I%_C!_P!C M'3_ ((! M_P#*3KP7_P!>.I_^DJ>2%%%% !1110 4444=0/?/^"6W_*0_P"#W_8SV?\ Z,%?TWKW^M?S(?\ M!+;_ )2'_![_ +&>S_\ 1@K^F]>_UK\MXX_WN'^']3]9\/\ _=:G^)?D+111 M7Q)]^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4V04ZD89- $3C.[_ &CBOYS?^"UG[+3_ ++G M[>7BA;6W\G0?&3?\)'IA PF)V8S(.PVSK* O9=A[BOZ-L<&OSW_X.)_V4A\: M?V0[;QUI]JTFM_#2Z-S(R#]X^GS[8[A?^ L(I,]%6-SQDU])PKF2PV/C?X9: M/]#Y3B[+7BLO;C\4-5^I^#IX8T4 Y';GGCH/I17[(?B5K.P5]#?\$HOC"OP. M_P""AGPLUR23R[:;6!I=P2<*L=VC6I+?[(\[=[; :^>:L:7J4VCZC;W=O(\- MQ:RK-%(IPT3J$_\ MD8Q]&?*\9_\ (LEZH_+P44#I17[&?B/0**** "BBB@ HHHH *T?!_P#R-VE_ M]?<7_H8K.K1\'_\ (W:7_P!?<7_H8K*M_#EZ&M#^)'U1_6O9_P#'K'_NBI*C ML_\ CUC_ -T5)7\^=3^CZ/P+T04444&@4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U^M.IK] M: /YE_\ @JS_ ,I%_C!_V,=Q_2OGVOH+_@JS_P I%_C!_P!C'3_@@'_RDZ\%_P#7CJ?_ *1RU_0VGW:_)>-/]_7^ M%'[%P'_R+G_B?Z"T445\B?;!1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36ZBG4UNHH _GL_X M.!_^4F7BK_L&Z;_Z2I7Q0>M?:_\ P<#_ /*3+Q5_V#=-_P#25*^*#UK]SR/_ M '"C_A1_/N??\C"K_B84445ZIY(4444 %%%% !1111U ]\_X);?\I#_@]_V, M]G_Z,%?TWKW^M?S(?\$MO^4A_P 'O^QGL_\ T8*_IO7O]:_+>./][A_A_4_6 M?#__ '6I_B7Y"T445\2??A1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61XY\)Z?X^\(ZI MH>K6L5YI>L6DME>02#*S0R(4=3[%216O4UL[L\6_;< M_>;_ (-S?CZOQ1_8;N/"-S,)-0^'^K2V@0MN86LY-Q"Q]M[3J/:.OT$B^[7X M(_\ !NS^T2/A+^V])X3O+CR=-^(FF26**S;5^V0_OH6/;)43(.^9 *_>Z/[M M?B_$^!>&S":Z2U^\_\?=?R'4AZTM(>M?/GTQ_.'_P7!_Y2C?%/ M_KO8?^FZUKY0KZO_ ."X/_*4;XI_]=[#_P!-UK7RA7[QE/\ N5+T7Y'\\YQ_ MOU7U?YA1117H'FA1110 4444 %%%% 'U'_P1;_Y2OZ1TX%? MS3_@@'_RDZ\%_P#7CJ?_ *1RU_0VGW:_)>-/]_7^%'[%P'_R+G_B?Z"T M445\B?;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !36ZBG4UNHH _GL_X.!_^4F7BK_L&Z;_Z M2I7Q0>M?:_\ P<#_ /*3+Q5_V#=-_P#25*^*#UK]SR/_ '"C_A1_/N??\C"K M_B84445ZIY(4444 %%%% !1111U ]\_X);?\I#_@]_V,]G_Z,%?TWKW^M?S( M?\$MO^4A_P 'O^QGL_\ T8*_IO7O]:_+>./][A_A_4_6?#__ '6I_B7Y"T44 M5\2??A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !0>1110!SOQ3^'FD_%SX>ZUX7UVS2^T M?7K*6PO+=QE9(I%*,/R.0>H(!'2OY@OVQ/V9M7_9 _:-\4> =861I="NRMM< ML,+>VK?-!,/]^,J2.S;AU!K^IN0?-QZ>G%?FS_P M(O ,/EZJL2G?=Z86)+G'),#,6]HWE/85]5PGFWU3%>RJ?#/3Y]#XWC+)_K>& M]M3^*'Y=3\/>A_2BC&SY>FW@CTH[U^O[R\C\9U:O8Z#X4_$;4OA!\3/#_BO1 MI/)U;PYJ$&I6DF?NRQ2*Z9]5R,$=QFOZI/@I\4]-^-OPC\->,-'D$FF>)M-M M]2M^ZF'CB8[Q?X,^^X M%S!4L5+#2VDOQ1^E5(>M /%!/-?ER/UH_G#_ ."X/_*4;XI_]=[#_P!-UK7R MA7U?_P %P?\ E*-\4_\ KO8?^FZUKY0K]YRG_C]ER[L(I9OB)<6OYU:*\G_ %&PG\\OP_R/8_U^ MQW\D?Q/Z*O\ A_!^RQ_T4R3_ ,)W5/\ Y'H_X?P?LL?]%,D_\)W5/_D>OYU: M*/\ 4;"?SR_#_(/]?L=_)'\3^BK_ (?P?LL?]%,D_P#"=U3_ .1Z/^'\'[+' M_13)/_"=U3_Y'K^=6BC_ %&PG\\OP_R#_7['?R1_$_HJ_P"'\'[+'_13)/\ MPG=4_P#D>C_A_!^RQ_T4R3_PG=4_^1Z_G5HH_P!1L)_/+\/\@_U^QW\D?Q/Z M*O\ A_!^RQ_T4R3_ ,)W5/\ Y'H_X?P?LL?]%,D_\)W5/_D>OYU:*/\ 4;"? MSR_#_(/]?L=_)'\3^BK_ (?P?LL?]%,D_P#"=U3_ .1Z/^'\'[+'_13)/_"= MU3_Y'K^=6BC_ %&PG\\OP_R#_7['?R1_$_HJ_P"'\'[+'_13)/\ PG=4_P#D M>C_A_!^RQ_T4R3_PG=4_^1Z_G5HH_P!1L)_/+\/\@_U^QW\D?Q/Z*O\ A_!^ MRQ_T4R3_ ,)W5/\ Y'H_X?P?LL?]%,D_\)W5/_D>OYU:*/\ 4;"?SR_#_(/] M?L=_)'\3^BK_ (?P?LL?]%,D_P#"=U3_ .1Z/^'\'[+'_13)/_"=U3_Y'K^= M6BC_ %&PG\\OP_R#_7['?R1_$_HJ_P"'\'[+'_13)/\ PG=4_P#D>C_A_!^R MQ_T4R3_PG=4_^1Z_G5HH_P!1L)_/+\/\@_U^QW\D?Q/Z*O\ A_!^RQ_T4R3_ M ,)W5/\ Y'H_X?P?LL?]%,D_\)W5/_D>OYU:*/\ 4;"?SR_#_(/]?L=_)'\3 M^BK_ (?P?LL?]%,D_P#"=U3_ .1Z/^'\'[+'_13)/_"=U3_Y'K^=6BC_ %&P MG\\OP_R#_7['?R1_$_HJ_P"'\'[+'_13)/\ PG=4_P#D>C_A_!^RQ_T4R3_P MG=4_^1Z_G5HH_P!1L)_/+\/\@_U^QW\D?Q/Z*O\ A_!^RQ_T4R3_ ,)W5/\ MY'I1_P %X?V6!_S4QO\ PG=4_P#D:OYU**/]1L)_/+\/\@_U^QW\D?Q/Z*G_ M ."\/[+.>/B8WK_R+NJ?_(U?E'_P6S_;R\(_MU?M&Z'>>!6O+KPWX7TL6,5[ M<6[6_P!LE:1Y'=$;#A,% -P!R#QTKXQHKT,LX7PV"K>WIMM^9YN:<68O'4?J M]1)+?1=@'US]:***^F/EEH%%%% PHHHH **** "M'P?_ ,C=I?\ U]Q?^ABL MZM'P?_R-VE_]?<7_ *&*RK?PY>AK0_B1]4?UKV?_ !ZQ_P"Z*DJ.S_X]8_\ M=%25_/G4_H^C\"]$%%%%!H%%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-?K3J:_6@#^9?_@JS M_P I%_C!_P!C'3_ ((!_P#*3KP7_P!>.I_^DJ>2%%%% !1110 4444=0/?/^"6W_*0_P"#W_8SV?\ Z,%? MTWKW^M?S(?\ !+;_ )2'_![_ +&>S_\ 1@K^F]>_UK\MXX_WN'^']3]9\/\ M_=:G^)?D+1117Q)]^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+7=*MM>TVXL; MRWANK6[B:&:&5-Z2HP*LI!X(()!!Z@D5=IK#.?I1JM4*235F?S3_ /!5#]AR MZ_82_:LU;P[;PS?\(GK1.I>')WRV^T=B/*+=WB;*'O@*Q^^*^;0<_P">M?TE M?\%7_P!@RS_;S_9COM&MX81XQT -J/AVXX[=!^Q\,9LL;AN63] M^.C_ ,S\0XJR=X'%>XO?EYR.WK^=>]BB"BBB@T"BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "FOUIU-?K0!_,O\ \%6?^4B_Q@_[&.X_I7S[7T%_P59_Y2+_ !@_[&.X M_I7S[7[UEO\ NE/_ K\C^=_P"QGL__ $8*_IO7O]:_F0_X);?\I#_@]_V,]G_Z,%?TWKW^M?EO M''^]P_P_J?K/A_\ [K4_Q+\A:***^)/OPHHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH *:V:=36&30!'.GF$?+NW#!R.W>OQG_ .#A?_@G%)X.\5M\=/"-B_\ 9.L2 M)!XI@@7;]DNFPB7F /NR<(Y_OX/_ "TK]G/SK%^('@+2?BAX,U3P]KEC#J>C MZU:O:7EK.NZ.>)QM8'\#U&".HYP:]'*3G65PQ^%=":UZ/S M/Y+\Y&?Y#C_(Z?AZ45]"_P#!2S]A#5OV!?VD=0\+SK<77AK4B;SP]J#@_P"E MVA. K'&/-C/R.!WPV '6OGK]:_<<+B(8FDJ]+:6Q^"8K#3PU5T:V\=SZN_X( MY_MJM^QC^V)I-SJ5T;?PCXOVZ+KFY\1PH[#RKDCI^YDP2>NQG ZU_1S&5,6X M$88D\=*_D8ZC&2,\5_01_P $*_VZO^&L_P!E&#P[K5YYGC/X=K%IE[YC?O+R MT(/V6XYY)**8V[[H\G[U? \;97>V.I+RE_F?HO >;-7P-7UC_D?E-_P7!_Y2 MC?%3_KO8?^FZUKY0KZN_X+?_ /*4/XI8Z":P ]M.M17RC7V>4O_ &.DO[J/ MAB>:%%%% !1110 4444 !.**]6_8?_9UA_:R_:O\ !/P] MNKZ;3;/Q)J'DW5Q 98X41I7V9XW%8V"D@@$@D$5^U&E_P#!NW^SA:V,<4VE M^*[J2,!6FDUIU:0^IVA1^0KP\TX@PN FJ=:[;UT/>RCAO%YA!SHV27<_ &BO MZ!O^(>']FS_H"^)O_!Y-1_Q#P_LV?] 7Q-_X/)J\O_7; =I?<>Q_J'F/>/WG M\_-%?T#?\0\/[-G_ $!?$W_@\FH_XAX?V;/^@+XF_P#!Y-1_KM@.TON#_4/, M>\?O/Y^:*_H&_P"(>']FS_H"^)O_ >34?\ $/#^S9_T!?$W_@\FH_UVP':7 MW!_J'F/>/WG\_-%?T#?\0\/[-G_0%\3?^#R:C_B'A_9L_P"@+XF_\'DU'^NV M [2^X/\ 4/,>\?O/Y^:*_H&_XAX?V;/^@+XF_P#!Y-1_Q#P_LV?] 7Q-_P"# MR:C_ %VP':7W!_J'F/>/WG\_-%?T#?\ $/#^S9_T!?$W_@\FH_XAX?V;/^@+ MXF_\'DU'^NV [2^X/]0\Q[Q^\_GYHK^@;_B'A_9L_P"@+XF_\'DU'_$/#^S9 M_P! 7Q-_X/)J/]=L!VE]P?ZAYCWC]Y_/S17] W_$/#^S9_T!?$W_ (/)J/\ MB'A_9L_Z OB;_P 'DU'^NV [2^X/]0\Q[Q^\_GYHK^@;_B'A_9L_Z OB;_P> M34?\0\/[-G_0%\3?^#R:C_7; =I?<'^H>8]X_>?S\T5_0-_Q#P_LV?\ 0%\3 M?^#R:C_B'A_9L_Z OB;_ ,'DU'^NV [2^X/]0\Q[Q^\_GYHK^@;_ (AX?V;/ M^@+XF_\ !Y-1_P 0\/[-G_0%\3?^#R:C_7; =I?<'^H>8]X_>?S\T5_0-_Q# MP_LV?] 7Q-_X/)J/^(>']FS_ * OB;_P>34?Z[8#M+[@_P!0\Q[Q^\_GYHK^ M@;_B'A_9L_Z OB;_ ,'DU'_$/#^S9_T!?$W_ (/)J/\ 7; =I?<'^H>8]X_> M?S\T5_0-_P 0\/[-G_0%\3?^#R:C_B'A_9L_Z OB;_P>34?Z[8#M+[A?ZAYC MWC]Y_/S1T_+-?T"-_P &\O[-P(VZ'XG_ !UN; _7\_PK\N/^"QW_ 3YT'_@ MG[^T#H^E^$[_ %&\\-^)M-_M&VBOW5Y[-U=HWB+J!N7A2"0#\V#D@L>_+>)L M)C:OL:5^;S78\[-.%<9@:/MZMN7R=SY"Z44#@?YYHKZ$^;"BBB@ HHHH *** M* "M'P?_ ,C=I?\ U]Q?^ABLZM'P?_R-VE_]?<7_ *&*RK?PY>AK0_B1]4?U MKV?_ !ZQ_P"Z*DJ.S_X]8_\ =%25_/G4_H^C\"]$%%%%!H%%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %-?K3J:_6@#^9?_@JS_P I%_C!_P!C'3_ ((!_P#*3KP7_P!>.I_^DJ>2%%%% !1110 4444=0/? M/^"6W_*0_P"#W_8SV?\ Z,%?TWKW^M?S(?\ !+;_ )2'_![_ +&>S_\ 1@K^ MF]>_UK\MXX_WN'^']3]9\/\ _=:G^)?D+1117Q)]^%%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4$X%%(_2@#P#_@HY^PGH/[?7[/M]X5U'R;/7+0-=Z#JC M+EM/NPO'3DQN!M<=PO:#=-:7EO(,% M67N#T92N"K#AE((R""?ZQ2-V>M?GQ_P7$_X)9?\ #5_@'_A9'@?3@WQ$\+VY M%S;0)\^OV:_,8\#EIX^2F,ELLO4J5^PX5S[ZK4^K5G[DMO)_\$^'XOX=^MP^ MM4%[\=_-?\ _![->Z?\ !.K]LW4OV&/VHM#\:6_G3:.Q-AKEFC<7EC(1YBXZ M%EP)$[;XP"0#7ALT3P2M'(&5U8J01@YS_/V]:;T_ETSG(_IP?PK]0Q&'A7HR MHSUC)'Y/AZU7#UHUJ>DHL^G/^"QOB_3O'_\ P47^(&N:1>0ZAI6KIIEY9W41 MW)<0R:9:.CJ?0J017S'4EQ=2WDF^:221PJH"[%B%4!5&3V"@ #L,#M4=&%H* MC2C27V5;_(6*Q'MZLJO=W"BBBN@P"BBB@ HHHH **** /J/_ ((M_P#*3CX4 M_P#7]<_^D<]?TCIP*_FX_P""+?\ RDX^%/\ U_7/_I'/7](Z=*_*^./]\C_A M1^N\ _[E/_$QU%%%?%GW84444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %?BS_P="_\E^^&?_8!G_\ 2BOVFK\6 M?^#H7_DOWPS_ .P#/_Z45]+PG_R,8^C/E>,_^19+U1^7(HH%%?L9^(] HHHH M **** "BBB@ K1\'_P#(W:7_ -?<7_H8K.K1\'_\C=I?_7W%_P"ABLJW\.7H M:T/XD?5']:]G_P >L?\ NBI*CL_^/6/_ '14E?SYU/Z/H_ O1!1110:!1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !37ZTZFOUH _F7_X*L_\ *1?XP?\ 8QW']*^?:^@O^"K/ M_*1?XP?]C'_P"Q MGL__ $8*_IO7O]:_+>./][A_A_4_6?#_ /W6I_B7Y"T445\2??A1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !44XRWMC'%2TC<]J/0/4_&[_@O/_P2 MB_X1.ZU#XY?#W3=NFW3&;Q;IEJG_ !YR'.;^-0/N-_RU &0S;\89ROY2D$'[ MNW'!&,8_S_G/6OZX-8TNWUK3KBTN[>*ZM;B-HIH94#QRHPVLK*//!%G+-\,=>N/FA5=Q\.W#'_ %#'D^2W.QS_ +C' M.PM^D\*<1AK0_B1]4?UKV?_ M !ZQ_P"Z*DJ.S_X]8_\ =%25_/G4_H^C\"]$%%%%!H%%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %-?K3J:_6@#^9?_@JS_P I%_C!_P!C'3_ ((!_P#*3KP7_P!>.I_^DJ>2%%%% !1110 4444=0/?/^"6 MW_*0_P"#W_8SV?\ Z,%?TWKW^M?S(?\ !+;_ )2'_![_ +&>S_\ 1@K^F]>_ MUK\MXX_WN'^']3]9\/\ _=:G^)?D+1117Q)]^%%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !6'\1/A]H_Q5\&ZGX=U_3K75M&UFV>TO+2Y3=% M<1.,%6'XY&,$'D$5N4A^]3C)Q:E%V9,HJ2Y9*Z9_.?\ \%8/^"6NN?\ !/\ M^)SW^FQ76K?#37IV_L?42N]K-SEOL=P>@D7G:_ D"Y !#*OR(PVD\L<';D^M M?UA?&CX/>'?C[\-=6\(^+-)M]:T#6H&M[JUG3BN 6 &2J_JO M#/$<<7%8?$.U1=?YO^"?D'%7#,L)+ZSAU>F]_P"[_P ^7**"PQN^7;G&1PO MX?D:.]?9'Q 4444 %%%% !1110!]1_\ !%O_ )2L?^Z*DJ.S_ ./6/_=%25_/G4_H^C\"]$%%%%!H%%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%-?K3J:_6@#^9?\ X*L_\I%_C!_V,=Q_2OGVOH+_ (*KG_C8M\8/^QDN/YBO MGVOWK+?]TI_X5^1_.N9?[W5_Q/\ ,****[CA"BBB@ HHHH **** /M#_ ((! MG_C9UX+_ .O'4O\ TCEK^AM/NU_/%_P0$_Y2=^"_^O+4O_2.:OZ'5^[7Y+QI M_P C!?X4?L/ 7_(N?^)BT445\B?;A1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36ZBG4UNHH M_GL_X.!_^4F7BK_L&Z;_ .DJ5\4'K7VM_P ' QS_ ,%,_%G_ &#=-_\ 25*^ M*3UK]SR/_<*/^%'\^Y]_R,*O^)A1117JGDA1110 4444 %%%%'4#WS_@EL?^ M-A_P>_[&>S_]&"OZ;U[_ %K^8_\ X)5 =9D9=%UM5Y(//V:<@?),JCV5PI*X^8#Y;7]X&_C[\.M4\)^+M'M=(PJO3?3^7_ (!\@ Y%%#G!;GOC)^O%!&#B MOLM3X:(4444#"BBB@:W/J'_@B[_RDZ^$_P#U_P!Q_P"D=Q7])2?=K^;7_@B^ MOZ2D^[7Y7QQ_OL?\*/UO@#_%_^1DT_P#Z^(__ $(5G6^!^C-:'\2/JC^MFT_X\X_] MVI:BM/\ CSC_ -VI:_GM[G]'T?@7H@HHHH- HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK]? MPIU-?K^% '\RO_!5+_E(I\8/^QEN?_0J^?Z]^_X*GG/_ 42^,'_ &,MU_Z% M7@-?O66_[K3]%^1_.N9?[W5_Q/\ ,****[CA"BBB@ HHHH **** >Q]F?\$" M&V_\%/? _P#M6FI?^D,]?T0"OYV_^"!S[?\ @J!X#_VK74Q_Y(SU_1(*_)>- M/]_7^%'[#P%_R+W_ (F%%%%?(GVX4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C=:6D(H _GH M_P"#@(_\;,O%G_8.TW_TECKXK/6OM/\ X. #G_@IIXN_[!^F_P#I)'7Q8>M? MN>1_[A1_PH_G_/?]_K?XF%%%%>J>.%%%% !1110 4444 >]_\$NCC_@H9\'? M^QHL_P#T,5_3C7\QG_!+XX_X*%_!W_L:;+_T8*_ISK\MXX_WJG_A_4_6?#__ M '6I_B7Y!1117Q)]^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1106Q0 44@8'N*7.: "L/XB?#_1?BKX.U'P[XBTRSUC1=7@:WO+.ZC$D5 MQ&W56!__ %CJ,$"MS-!&:(R:::)E%27+)71^!/\ P5E_X(Q:U^QCJ5[XX\!0 M7FN?#":0R2+_ *RY\.%C]R7^]!SA9>WW7.=I;X)^Z,#@+QCD;?3@]/IVZ5_7 M#JNEV^M6,]I=017-K=1M#-%(@=)$((*LI!# @XP>,$U^-_\ P5C_ ."#UUX& M;4OB-\$=-DO-%^>XU3PK"K236&>6DLQRS1=S$#E /D!7*K^D\/\ %:FEAL:] M=E+OY,_+>).#W3;Q6!6G6/8_*ZBG/&R.0593G&",$'_/T_+%-!R*^_NGHM3\ M[VT>C"BBBA[!U/I[_@C.^S_@IE\*#_U$I1^=M-7])PK^:S_@CB^S_@IA\)?? M59!_Y+RU_2F.E?EG''^^0_P_J?K?A_\ [E/_ !?H%%%%?%'WH4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %? MBG_P="G_ (R,^&O_ &+LW_I2:_:ROQ1_X.@S_P 9(?#?_L79?_2EJ^FX2_Y& M4?1_D?*\9_\ (LEZH_,$=** ,"BOV'J?B(4444P"BBB@ HHHH *N^'#M\0V/ M_7Q'_P"A"J57- .-=LO^NZ?^A"LZWP/T9K0_B1]4?UM6?_'E'_NBIJALO^/- M/]T5-7\]O<_H^C\$?1!1110:!1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37Z_A3J;)W^E'4# M^9'_ (*E'_C8A\8/^QFNA_X]7@=>]_\ !4+5/_3;./]ZI_X?U/U MCP^_W:K_ (E^0M%%%?$GZ %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !49<:(YL;8--:YQ\O=XNAZ@AL@_J3\+OB;H'QB\ Z9XF\,ZM9ZUH> ML0BXM+RVDWQS(?Y$="#@@@@@$8K^=K_@M8?-_P""GGQ7]#>6HZ_].5L1].E2 M?\$T/^"J/C#_ ()\^-A;K]HU_P"'VJ3AM4T%I,>43@&>V)XCF X^[(!M8 A M67]$QW"\,5@J>(PJM/E5UWT_,_,8Y%R,JW/(/(()[T,*_ M/9TY0ER3T:/TNG4C4BIP=TQ:BF 9L>W?D5+NIIY/X5)9^<'_ 55_P""&>D? MM+-J'C[X5P6'A_QXX:XOM*VK%8Z\PR2W]V&=CDE@-LC'_$6EWVC:WI5R2I&2#]ED M?%53#6H8EWAWZH^#XBX0AB;XC!JT^JZ,_FV!R**]:_; _8G^('[$'Q(D\.^. MM(DM&D+M9:A#F2QU6,'F2&7&&Z@LI^=2?F )KR7&#COZ5^H8?$4ZT(U*3NF? ME.(HU*-5PJJS73M_F?2G_!'U_+_X*4_"5O\ J,,/_($M?TKKTK^:3_@D0VW_ M (*2?",_]1G_ -I25_2VIXK\SXX_WN'^']3]5\/_ /OVPK\3?^#H(Y_:8^'?\ V+,O M_I3)7TW"7_(RCZ/\CY7C/_D62]4?F+GFBC_&BOV'J?B(4444P"BBB@ HHHH M*M:*<:Q:G_ILG\ZJU8TIMNIVY_Z:+_,5G6^!^C-:'\2/JC^M^T_X]$_W:EJ* MTYM(_P#=J6OY[>Y_1]'X%Z(****#0**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9)_2GTV3H? MI0!_,?\ \%1#G_@H;\8O^QIO/_1AKP6O>/\ @J <_P#!0SXQ?]C5>_\ HTUX M/7[YE_\ NM/_ K\D?SKF7^]U?\ $_S"BBBNPX0HHHH **** "BBB@:/K[_@ M@^^W_@J3\-_]I-4'_E,NJ_HN'2OYS?\ @A(V/^"IWPQ]QJG_ *:KROZ,A7Y/ MQM_O\?\ "OU/U_@/_<9?XF%%%%?'GW 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4$44AH8'\ M\7_!?@Y_X*=>-/\ KRTW_P!(H:^,:^S/^"^QS_P4\\;?]>>F_P#I##7QG7[G MD?\ N%'_ H_GS//]_J_XF%%%%>J>4%%%% !1110 4444UN![G_P3+./^"@_ MP;_[&RP_]'+7]/(K^87_ ()G?\I!?@W_ -C=IW_H]:_IZ!S7Y=QU_O-/_"_S M/UCP^_W6K_B7Y!1117PY^@!1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4UCAA3J:WW@: /YLO^"R\_VC_@IE\6&]-1A7\K6 ?TKYB!P??J". M"#VKZ2_X*]S_ &C_ (*2_%MO36=OY11C^E?-M?O.5_[G2]%^1_.^;?[[5]7^ M9[A^PS^WWXZ_8(^**:]X3O/M&FW15-5T2X=OL6I1 ]&'\$@R=LB_,I)ZJS*? MZ"/V'/V^O 7[>?PN37O"-Z(M0M0JZKHUP5%YI'^)ZN7OVSJ01D\]17X8_P#!2W_@B9XT_8MN M+[Q/X3CO/&GPTW-+]KCC#7VCH>=MU&HP5' \]5*G&65,XK^@FJ][:K=1M&Z+ M)'(-K*PW*P/4$>F*]G)\\Q& G^[=X]4]F>#G7#V&SȄ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end GRAPHIC 14 image_5.jpg GRAPHIC 2 begin 644 image_5.jpg MB5!.1PT*&@H -24A$4@ #+( +" ( !>-])% F4E$051X7NW( M,0T ( #L$G'.?QS,-*>S0$ . CZ0 &!9.@ M %B6#@ ):E P @&7I 8%DZ M 6)8. EJ4# " 9>D !@62X > ?>8K\:T?LK5PV $E%3D2N0F"" end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover Page - USD ($)
12 Months Ended
Dec. 31, 2022
Mar. 14, 2023
Jun. 30, 2022
Document Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-39153    
Entity Registrant Name Healthcare Trust, Inc.    
Entity Incorporation, State or Country Code MD    
Entity Tax Identification Number 38-3888962    
Entity Address, Address Line One 650 Fifth Ave.    
Entity Address, Address Line Two 30th Floor    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10019    
City Area Code 212    
Local Phone Number 415-6500    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 0
Entity Common Stock, Shares Outstanding   106,566,638  
Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement to be delivered to stockholders in connection with the registrant’s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K. The registrant intends to file its proxy statement within 120 days after its fiscal year end.    
Entity Central Index Key 0001561032    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Amendment Flag false    
Series A Preferred Stock      
Document Information [Line Items]      
Title of 12(b) Security 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share    
Trading Symbol HTIA    
Security Exchange Name NASDAQ    
Series B Preferred Stock      
Document Information [Line Items]      
Title of 12(b) Security 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share    
Trading Symbol HTIB    
Security Exchange Name NASDAQ    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Audit Information
12 Months Ended
Dec. 31, 2022
Audit Information [Abstract]  
Auditor Firm ID 238
Auditor Name PricewaterhouseCoopers LLP
Auditor Location New York, New York
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Real estate investments, at cost:    
Land $ 206,454 $ 206,392
Buildings, fixtures and improvements 2,089,133 2,117,896
Acquired intangible assets 292,034 288,372
Total real estate investments, at cost 2,587,621 2,612,660
Less: accumulated depreciation and amortization (609,324) (562,733)
Total real estate investments, net 1,978,297 2,049,927
Cash and cash equivalents 53,654 59,738
Restricted cash 22,884 25,644
Derivative assets, at fair value 40,647 174
Straight-line rent receivable, net 25,276 23,858
Operating lease right-of-use assets 7,814 7,914
Prepaid expenses and other assets (including $929 due from related parties as of December 31, 2021) 34,554 32,564
Deferred costs 17,223 14,581
Total assets 2,180,349 2,214,400
LIABILITIES AND EQUITY    
Mortgage notes payable, net 578,700 584,239
Credit facilities, net 530,297 502,051
Market lease intangible liabilities, net 9,407 10,943
Derivative liabilities, at fair value 0 13,903
Accounts payable and accrued expenses (including $47 due to related parties as of December 31, 2022 and 2021) 45,247 42,709
Operating lease liabilities 8,087 8,130
Deferred rent 5,925 8,619
Distributions payable 3,496 3,406
Total liabilities 1,181,159 1,174,000
Stockholders’ Equity    
Common stock, $0.01 par value, 300,000,000 shares authorized, 105,080,531 shares and 99,281,754 shares issued and outstanding as of December 31, 2022 and 2021, respectively 1,051 993
Additional paid-in capital 2,417,059 2,329,839
Accumulated other comprehensive income (loss) 36,910 (14,341)
Distributions in excess of accumulated earnings (1,462,457) (1,282,871)
Total stockholders’ equity 992,639 1,033,696
Non-controlling interests 6,551 6,704
Total equity 999,190 1,040,400
Total liabilities and equity 2,180,349 2,214,400
Series A Preferred Stock    
Stockholders’ Equity    
Cumulative redeemable perpetual preferred stock 40 40
Series B Preferred Stock    
Stockholders’ Equity    
Cumulative redeemable perpetual preferred stock $ 36 $ 36
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Prepaid expenses and other assets, due from related parties   $ 929
Accounts payable and accrued expenses, due to related parties $ 47 $ 47
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 300,000,000 300,000,000
Common stock, shares issued (in shares) 105,080,531 99,281,754
Common stock, shares outstanding (in shares) 105,080,531 99,281,754
Series A Preferred Stock    
Preferred stock, dividend rate, percentage 7.375%  
Preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 4,740,000 4,740,000
Preferred stock, shares issued (in shares) 3,977,144 3,977,144
Preferred stock, shares outstanding (in shares) 3,977,144 3,977,144
Series B Preferred Stock    
Preferred stock, dividend rate, percentage 7.125%  
Preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 3,680,000 3,680,000
Preferred stock, shares issued (in shares) 3,630,000 3,630,000
Preferred stock, shares outstanding (in shares) 3,630,000 3,630,000
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]      
Revenue from tenants $ 335,846 $ 329,355 $ 381,612
Operating expenses:      
Property operating and maintenance 213,444 205,813 243,548
Impairment charges 27,630 40,951 36,446
Operating fees to related parties 25,353 24,206 23,922
Acquisition and transaction related 1,484 2,714 173
General and administrative 17,287 16,828 21,572
Depreciation and amortization 82,064 79,926 81,053
Total expenses 367,262 370,438 406,714
Operating loss before gain on sale of real estate investments (31,416) (41,083) (25,102)
Gain (loss) on sale of real estate investments (125) 3,648 5,230
Operating loss (31,541) (37,435) (19,872)
Other income (expense):      
Interest expense (51,740) (47,900) (51,519)
Interest and other income 27 61 44
Gain (loss) on non-designated derivatives 3,834 37 (102)
Total other expenses (47,879) (47,802) (51,577)
Loss before income taxes (79,420) (85,237) (71,449)
Income tax expense (201) (203) (4,061)
Net loss (79,621) (85,440) (75,510)
Net loss (income) attributable to non-controlling interests 135 260 (303)
Allocation for preferred stock (13,799) (7,762) (2,968)
Net loss attributable to common stockholders (93,285) (92,942) (78,781)
Other comprehensive income (loss):      
Unrealized gain (loss) on designated derivatives 51,251 25,332 (32,630)
Comprehensive loss attributable to common stockholders $ (42,034) $ (67,610) $ (111,411)
Weighted-average common shares outstanding - Basic (in shares) [1] 106,428,154 106,354,994 106,119,937
Weighted-average common shares outstanding - Diluted (in shares) [1] 106,428,154 106,354,994 106,119,937
Net loss per common share attributable to common stockholders - Basic (in usd per share) [1] $ (0.88) $ (0.87) $ (0.74)
Net loss per common share attributable to common stockholders - Diluted (in usd per share) [1] $ (0.88) $ (0.87) $ (0.74)
[1] Retroactively adjusted for the effects of the Stock Dividends (see Note 1 — Organization for details).
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)
$ in Thousands
Total
Series A Preferred Stock
Series B Preferred Stock
Total Stockholders’ Equity
Total Stockholders’ Equity
Series A Preferred Stock
Total Stockholders’ Equity
Series B Preferred Stock
Preferred Stock
Series A Preferred Stock
Preferred Stock
Series B Preferred Stock
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Series A Preferred Stock
Additional Paid-in Capital
Series B Preferred Stock
Accumulated Other Comprehensive Income (Loss)
Distributions in Excess of Accumulated Earnings
Distributions in Excess of Accumulated Earnings
Series A Preferred Stock
Distributions in Excess of Accumulated Earnings
Series B Preferred Stock
Non-controlling Interests
Beginning balance (in shares) at Dec. 31, 2019             1,610,000 0                  
Beginning balance at Dec. 31, 2019 $ 1,106,744     $ 1,101,334     $ 16 $ 0 $ 923 $ 2,078,628     $ (7,043) $ (971,190)     $ 5,410
Beginning balance (in shares) at Dec. 31, 2019                 92,356,664                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Issuance of preferred stock, net   $ (59)     $ (59)           $ (59)            
Common stock issued through distribution reinvestment plan (in shares) 900,000               875,986                
Common stock issued through distribution reinvestment plan $ 14,604     14,604         $ 9 14,595              
Common stock repurchases (in shares)                 (705,101)                
Common stock repurchases (10,546)     (10,546)         $ (7) (10,539)              
Share-based compensation, net 1,345     1,345           1,345              
Distributions declared in common stock (in shares)                 1,248,197                
Distributions declared in common stock 0     0         $ 13 19,646       (19,659)      
Distributions declared in cash on common stock (38,839)     (38,839)                   (38,839)      
Allocation for preferred stock (2,968)     (2,968)                   (2,968)      
Distributions to non-controlling interest holders (201)                               (201)
Buyout of non-controlling interest (583)     (88)                   (88)     (495)
Net loss (75,510)     (75,813)                   (75,813)     303
Unrealized loss on designated derivative (32,615)     (32,615)                 (32,615)        
Rebalancing of ownership percentage 0     630           645     (15)       (630)
Ending balance (in shares) at Dec. 31, 2020             1,610,000 0                  
Ending balance at Dec. 31, 2020 $ 961,372     956,985     $ 16 $ 0 $ 938 2,104,261     (39,673) (1,108,557)     4,387
Ending balance (in shares) at Dec. 31, 2020                 93,775,746                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Issuance of preferred stock, net (in shares) 0           2,367,144 3,630,000                  
Issuance of preferred stock, net   56,265 $ 86,819   56,265 $ 86,819 $ 24 $ 36     $ 56,241 $ 86,783          
Common stock issued through distribution reinvestment plan (in shares) 0                                
Common stock issued through distribution reinvestment plan $ 0                                
Share-based compensation, net 1,329     1,329           1,329              
Distributions declared in common stock (in shares)                 5,506,008                
Distributions declared in common stock 0     0         $ 55 81,316       (81,371)      
Allocation for preferred stock (7,762) $ (6,236) $ (1,527)   (6,236) (1,527)                 $ (6,236) $ (1,527)  
Distributions to non-controlling interest holders (92)                               (92)
Issuance of Series A Preferred OP Units 2,578                               2,578
Net loss (85,440)     (85,180)                   (85,180)     (260)
Unrealized loss on designated derivative 25,332     25,332                 25,332        
Rebalancing of ownership percentage 0     (91)           (91)             91
Ending balance (in shares) at Dec. 31, 2021   3,977,144 3,630,000       3,977,144 3,630,000                  
Ending balance at Dec. 31, 2021 $ 1,040,400     1,033,696     $ 40 $ 36 $ 993 2,329,839     (14,341) (1,282,871)     6,704
Ending balance (in shares) at Dec. 31, 2021 99,281,754               99,281,754                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Issuance of preferred stock, net (in shares) 0                                
Issuance of preferred stock, net   $ 0 $ (42)   0 (42)           $ (42)          
Common stock issued through distribution reinvestment plan (in shares) 0                                
Common stock issued through distribution reinvestment plan $ 0                                
Share-based compensation, net 1,185     1,185           1,185              
Distributions declared in common stock (in shares)                 5,798,777                
Distributions declared in common stock 0     0         $ 58 86,243       (86,301)      
Allocation for preferred stock (13,799) $ (7,333) $ (6,466)   $ (7,333) $ (6,466)                 $ (7,333) $ (6,466)  
Distributions to non-controlling interest holders (184)                               (184)
Net loss (79,621)     (79,486)                   (79,486)     (135)
Unrealized loss on designated derivative 51,251     51,251                 51,251        
Rebalancing of ownership percentage 0     (166)           (166)             166
Ending balance (in shares) at Dec. 31, 2022   3,977,144 3,630,000       3,977,144 3,630,000                  
Ending balance at Dec. 31, 2022 $ 999,190     $ 992,639     $ 40 $ 36 $ 1,051 $ 2,417,059     $ 36,910 $ (1,462,457)     $ 6,551
Ending balance (in shares) at Dec. 31, 2022 105,080,531               105,080,531                
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Distributions declared in common stock (in usd per share) $ 0.85 $ 0.85 $ 0.21
Distributions declared per share (in usd per share)     0.42
Preferred stock distributions declared per share (in usd per share)     $ 1.84
Series A Preferred Stock      
Preferred stock distributions declared per share (in usd per share) 1.84 1.57  
Series B Preferred Stock      
Preferred stock distributions declared per share (in usd per share) $ 1.78 $ 0.42  
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:      
Net loss $ (79,621) $ (85,440) $ (75,510)
Adjustments to reconcile net loss to net cash provided by operating activities:      
Depreciation and amortization 82,064 79,926 81,053
Amortization (including write-offs) of deferred financing costs 4,879 4,427 4,059
Amortization of terminated swap 423 846 846
Amortization of mortgage premiums and discounts, net 51 55 60
(Accretion) amortization of market lease and other intangibles, net (625) (198) (80)
Bad debt expense 3,159 1,094 2,708
Equity-based compensation 1,185 1,329 1,345
(Gain) loss on non-designated derivative instruments (3,834) (37) 102
Cash received from non-designated derivative instruments 286 0 0
(Gain) loss on sales of real estate investments, net 125 (3,648) (5,230)
Impairment charges 27,630 40,951 36,446
Deferred tax valuation allowance 2,750 (483) 4,641
Changes in assets and liabilities:      
Straight-line rent receivable (1,523) (761) (2,409)
Prepaid expenses and other assets (3,036) (2,139) (63)
Accounts payable, accrued expenses and other liabilities (2,924) 1,252 (4,554)
Deferred rent (2,694) 1,705 (1,607)
Net cash provided by operating activities 28,295 38,879 41,807
Cash flows from investing activities:      
Property acquisitions and development costs (25,538) (159,300) (94,984)
Capital expenditures and other assets acquired (27,993) (19,071) (21,892)
Proceeds from sales of real estate investments 11,749 130,449 34,385
Net cash used in investing activities (41,782) (47,922) (82,491)
Cash flows from financing activities:      
Payments on credit facilities (2,998) (298,804) (26,091)
Proceeds from credit facilities 30,000 125,000 95,000
Proceeds from mortgage notes payable 0 42,750 0
Payments on mortgage notes payable (6,662) (1,264) (1,048)
Payments for non-designated derivative instruments 0 (85) (97)
Payments of deferred financing costs (1,672) (1,490) (2,241)
Common stock repurchases 0 0 (10,539)
Distributions paid on common stock 0 0 (31,354)
Buyout of non-controlling interest holders 0 0 (583)
Distributions to non-controlling interest holders (184) (46) (201)
Net cash provided by financing activities 4,643 4,079 19,431
Net change in cash, cash equivalents and restricted cash (8,844) (4,964) (21,253)
Cash, cash equivalents and restricted cash, beginning of year 85,382 90,346 111,599
Cash, cash equivalents and restricted cash, end of year 76,538 85,382 90,346
Cash and cash equivalents 53,654 59,738 72,357
Restricted cash 22,884 25,644 17,989
Cash, cash equivalents and restricted cash, end of period 76,538 85,382 90,346
Supplemental disclosures of cash flow information:      
Cash paid for interest 45,042 42,815 47,878
Cash paid for income taxes 566 311 315
Non-cash investing and financing activities:      
Common stock issued through distribution reinvestment plan 0 0 14,604
Common stock issued through stock dividends 86,301 81,371 19,659
Accrued capital expenditures 0 0 1,287
Accrued offering costs on Series B Preferred Stock 0 78 0
Mortgage assumed in acquisition 0 0 13,883
Series A Preferred Stock      
Cash flows from financing activities:      
Proceeds from issuance of Preferred Stock, net 0 56,265 (1,016)
Dividend paid on Preferred stock (7,333) (5,144) (2,399)
Series B Preferred Stock      
Cash flows from financing activities:      
Proceeds from issuance of Preferred Stock, net (42) 86,897 0
Dividend paid on Preferred stock $ (6,466) $ 0 $ 0
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Organization
12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
Healthcare Trust, Inc. (including, as required by context, Healthcare Trust Operating Partnership, L.P. (the “OP”) and its subsidiaries, the “Company”), is an externally managed real estate investment trust for U.S. federal income tax purposes (“REIT”) that focuses on acquiring and managing a diversified portfolio of healthcare-related real estate, focused on medical office and other healthcare-related buildings (“MOBs”), and senior housing operating properties (“SHOPs”).
As of December 31, 2022, the Company owned 202 properties located in 34 states and comprised of 9.1 million rentable square feet.
Substantially all of the Company’s business is conducted through the OP and its wholly owned subsidiaries, including taxable REIT subsidiaries. The Company’s advisor, Healthcare Trust Advisors, LLC (the “Advisor”) manages our day-to-day business with the assistance of our property manager, Healthcare Trust Properties, LLC (the “Property Manager”). The Company’s Advisor and Property Manager are under common control with AR Global Investments, LLC (“AR Global”), and these related parties receive compensation and fees for providing services to the Company. The Company also reimburses these entities for certain expenses they incur in providing these services to the Company. Healthcare Trust Special Limited Partnership, LLC (the “Special Limited Partner”), which is also under common control with AR Global, also has an interest in the Company through ownership of interests in the OP. As of December 31, 2022, the Company owned 52 seniors housing properties under the REIT Investment Diversification and Empowerment Act of 2007 (“RIDEA”) structure in its SHOP segment. Under RIDEA, a REIT may lease qualified healthcare properties on an arm’s length basis to a taxable REIT subsidiary (“TRS”) if the property is operated on behalf of such subsidiary by a person who qualifies as an eligible independent contractor.
The Company operates in two reportable business segments for management and internal financial reporting purposes: MOBs and SHOPs. In its MOB operating segment, the Company owns, manages, and leases single and multi-tenant MOBs where tenants are required to pay their pro rata share of property operating expenses, which may be subject to expense exclusions and floors, in addition to base rent. The Property Manager or third party managers manage the Company’s MOBs. In its SHOP segment, the Company invests in seniors housing properties using the RIDEA structure. As of December 31, 2022, the Company had four eligible independent contractors operating 52 SHOPs (including two land parcels). All of the Company’s properties across both business segments are located throughout the United States.
The Company has declared quarterly dividends entirely in shares of its common stock since October 2020 in order to preserve its liquidity in response to the COVID-19 pandemic. Dividends payable entirely in shares of common stock are treated in a fashion similar to a stock split for accounting purposes specifically related to per-share calculations for the current and prior periods. Since October 2020, the Company has issued an aggregate of approximately 12.6 million shares in respect to the Stock Dividends. No other additional shares of common stock were issued during the years ended December 31, 2022 or 2021. References made to weighted-average shares and per-share amounts in the accompanying consolidated statements of operations and comprehensive income have been retroactively adjusted to reflect the cumulative increase in shares outstanding resulting from the Stock Dividends since October 2020 and through January 2023, and are noted as such throughout the accompanying financial statements and notes. Any future issuances of stock dividends will also result in retroactive adjustments. Please see Note 8 — Stockholder’s Equity for additional information on the stock dividends.
On April 1, 2022, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2021. The Company’s previous Estimated Per-Share NAV was as of December 31, 2020. The Estimated Per-Share NAV published on April 1, 2022 has not been adjusted since publication and will not be adjusted until the board of directors (the “Board”) determines a new Estimated Per-Share NAV. Issuing dividends in additional shares of common stock will, all things equal, cause the value of each share to decline because the number of shares outstanding increases when shares of common stock are issued in respect of a Stock Dividend; however, because each stockholder will receive the same number of new shares, the total value of a common stockholder’s investment, all things equal, will not change assuming no sales or other transfers. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually unless the Company lists its common stock.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Accounting
    The accompanying consolidated financial statements of the Company are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“GAAP”).
Principles of Consolidation and Basis of Presentation
The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.
Out-of-Period Adjustment
During the year ended December 31, 2019, the Company did not record quarterly interest expense related to borrowings under the Revolving Credit Facility (as defined below) that were borrowed and repaid during the fourth quarter of 2019. The amount of interest expense and related payable that should have been recorded was $0.3 million. In 2020, the Company identified that the cumulative interest payable balance was understated, and as a result a true up entry was recorded to record the payable and related expense, resulting in an out of period adjustment. The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and adjusted the amounts on a cumulative basis in 2020.
Impacts of the COVID-19 Pandemic
During the first quarter of 2020, the global COVID-19 pandemic that has spread around the world and to every state in the United States commenced. The COVID-19 pandemic has had, and could continue to have, an adverse impact on economic conditions, including a global economic slowdown and recession that may continue for some time. The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of COVID-19 on economic and market conditions. The COVID-19 pandemic had, and another pandemic in the future could have, impacts across many sectors and areas of the global economy and financial markets, leading to significant adverse impacts on economic activity including volatility in financial markets. The Company’s MOB tenants and SHOP properties operate businesses that require in-person interactions with their patients and residents, and concern regarding the transmission of COVID-19 impacted the willingness of persons to, among other things, live in or use facilities at the Company’s properties, and impact the revenues generated by the Company’s tenants.
The Company’s ability to lease space and negotiate and maintain favorable rents and the results of operations at its SHOPs could also continue to be negatively impacted by a prolonged recession in the U.S. economy. Moreover, the demand for leasing space at the Company’s MOB properties could decline, which could negatively impacting occupancy percentage, revenue and net income. Additionally, downturns or stagnation the U.S. housing market as a result of an economic downturn could adversely affect the ability, or perceived ability, of seniors to afford the resident fees and services at the Company’s SHOPs. Further, recent and continuing increases in inflation brought about by the labor shortages, supply chain disruptions and increases in interest rates have adversely impacted, and may continue to impact, the Company’s results of operations. Moreover, these increases in the rate of inflation, the ongoing war in Ukraine and related sanctions, supply chain disruptions and increases in interest rates may also impact the ability of the Company’s tenants and residents to pay rent and hence the Company’s results of operations and liquidity.
Starting in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways that vary by operating segment:
COVID-19 Impact — MOB Segment
The financial stability and overall health of the Company’s MOB tenants is critical to its business. The Company took a proactive approach to achieve mutually agreeable solutions with its MOB tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent. Since the year ended December 31, 2020, the Company has not entered into any rent deferral agreements with any of its MOB tenants, and all amounts previously deferred under prior rent deferral agreements have been collected.
For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases are being modified, the FASB and SEC have provided relief that allows companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. For COVID-19 relief qualified changes, there are two methods to potentially account for such rent deferrals or abatements under the relief, (1) as if the changes were originally contemplated in the lease contract or (2) as if the deferred payments are variable lease payments contained in the lease contract.
For all other lease changes that did not qualify for FASB relief, the Company is required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualify for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company has elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there would be no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact would be recognized ratably over the remaining life of the lease. For leases not qualifying for this relief, the Company has applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.
COVID-19 Impact — SHOP Segment
In the Company’s SHOP segment, occupancy trended downward from March 2020 until June 2021 and has since stabilized, however, SHOP occupancy remains substantially below pre-pandemic levels. Further, the Company has continued to experience lower inquiry volumes and reduced in-person tours since the onset of the pandemic. In addition, starting in mid-March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOPs, the Company generally bears these cost increases, which were partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), and to a lesser extent, cost recoveries for personal protective equipment from residents. See below for additional information on the CARES Act. These cost increases became more prominent throughout the year ended December 31, 2022 from a combination of factors: firstly, the Company was impacted by rising inflation which generally increased the costs of services and supplies, secondly, the Company relied more on the use of temporary contract labor and agencies due to a shortage of qualified personnel and lastly, the amounts the Company paid to third party providers for wages, including overtime wages, and bonuses increased. Future developments in the course of the pandemic, increases to inflation, labor shortages and supply chain disruptions may cause further adverse impacts to the Company’s occupancy and cost levels, and these trends may continue to impact the Company and have material adverse effects on its revenues, operating costs and net income in future periods.
The financial impact of the COVID-19 pandemic on the Company has been partially offset by funds received under the CARES Act. The Company received $4.5 million, $5.1 million and $3.6 million in these funds during the years ended December 31, 2022, 2021 and 2020, respectively. The Company considers these funds to be grant contributions from the government. The full amounts received were recognized as reductions of property operating expenses in the Company’s consolidated statement of operations for the years ended December 31, 2022, 2021 and 2020, respectively, to partially offset incurred COVID-19 expenses. The Company does not anticipate that any further funds under the CARES Act will be received, and there can be no assurance that the CARES Act program will be extended or any further amounts received under currently effective or potential future government programs.
Revenue Recognition
The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in its MOB segment. As of December 31, 2022, these leases had a weighted average remaining lease term of 4.9 years. Rent from tenants in the Company’s MOB operating segment (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is
considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Tenant revenue also includes operating expense reimbursements which generally increase with the increase in property operating and maintenance expenses in our MOB segment. In addition to base rent, dependent on the specific lease, tenants are generally required to pay either (i) their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors or (ii) the their share of increases in property operating and maintenance expenses to the extent they exceed the properties’ expenses for the base year of the respective leases. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.
The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOP segment, held using a structure permitted under RIDEA, and to a lesser extent, fees for ancillary services performed for SHOP residents, which are generally variable in nature. Rental income from residents in the Company’s SHOP segment is recognized as earned when services are provided. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of the leases are short term in nature, primarily month-to-month. The Company did not record material amounts of ancillary revenue from non-residents during the year ended December 31, 2022. The Company recorded ancillary revenue from non-residents of $3.5 million and $13.3 million for the years ended December 31, 2021 and 2020, respectively. Fees for ancillary services are recorded in the period in which the services are performed. The decline in ancillary revenue since the year ended December 31, 2020 is primarily due to the Company’s dispositions of its SNF properties in Lutz and Wellington, Florida, which were sold in November 2020 and May 2021, respectively.
The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating and maintenance expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating and maintenance costs of the respective properties.
The following table presents future base rent payments on a cash basis due to the Company as of December 31, 2022 over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short-term in nature.
(In thousands)Future 
Base Rent Payments
2023$106,009 
202499,507 
202588,452 
202680,462 
202762,175 
Thereafter215,275 
Total$651,880 
The Company continually reviews receivables related to rent and unbilled rents receivable and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards, the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants in accordance
with accounting rules, on the accompanying consolidated statements of operations and comprehensive income (loss) in the period the related costs are incurred, as applicable.
During the years ended December 31, 2022, 2021 and 2020, the Company recorded reductions in revenue of $3.2 million, $1.1 million and $2.7 million, respectively. Approximately $1.3 million and $1.0 million of bad debt expense recorded in the years ended December 31, 2022 and 2020, respectively, related to previously disposed properties. There were no significant write-off’s related to previously disposed properties during the year ended December 31, 2021.
Investments in Real Estate
Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.
At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “Purchase Price Allocation” section in this Note for a discussion of the initial accounting for investments in real estate.
Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the years ended December 31, 2022, 2021 and 2020. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were no real estate investments held for sale as of December 31, 2022 or December 31, 2021.
The Company generally determines the value of construction in progress based upon the replacement cost. During the construction period, the Company capitalizes interest, insurance and real estate taxes until the development has reached substantial completion.
Purchase Price Allocation
In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In allocating the fair value to any assumed or issued non-controlling interests, amounts are recorded at their fair value at the close of business on the acquisition date. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets.
For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.
Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates the fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.
Identifiable intangible assets include amounts allocated to acquire leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from six to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.
Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.
The aggregate value of intangible assets related to customer relationship, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the years ended December 31, 2022, 2021 and 2020.
Accounting for Leases
Lessor Accounting
In accordance with the lease accounting standard, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than a major part of the remaining economic useful life of the asset (e.g., equal to or greater than 75%), the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or the asset is so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. As of December 31, 2022 and 2021, the Company had no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.
As a lessor of real estate, the Company has elected, by class of underlying assets, to account for lease and non-lease components (such as tenant reimbursements of property operating and maintenance expenses) as a single lease component as an operating lease because (a) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (b) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under the accounting guidance. Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed.
Lessee Accounting
The Company is also the lessee under certain land leases which will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the consolidated balance sheets as of December 31, 2022 and 2021, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022, 2021 and 2020.
For lessees, the accounting standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction. For additional information and disclosures related to the Company’s operating leases, see Note 16Commitments and Contingencies.
Gain on Dispositions of Real Estate Investments
Gains on sales of rental real estate are not considered sales to customers and will generally be recognized pursuant to the provisions included in ASC 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets (“ASC 610-20”).
Impairment of Long-Lived Assets
When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statement of operations and comprehensive (loss) to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held and used. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.
Reportable Segments
The Company has determined that it has two reportable segments, with activities related to investing in MOBs and SHOPs. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level. For additional information see Note 15 — Segment Reporting.
Depreciation and Amortization
Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests.
Construction in progress, including capitalized interest, insurance and real estate taxes, is not depreciated until the development has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).
The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.
The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.
Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.
Above and Below-Market Lease Amortization
Capitalized above-market lease values are amortized as a reduction of revenue from tenants over the remaining terms of the respective leases and the capitalized below-market lease values are amortized as an increase to revenue from tenants over the remaining initial terms plus the terms of any below-market fixed rate renewal options of the respective leases. If a tenant with a below-market rent renewal does not renew, any remaining unamortized amount will be taken into income at that time.
Capitalized above-market ground lease values are amortized as a reduction of property operating expense over the remaining terms of the respective leases. Capitalized below-market ground lease values are amortized as an increase to property operating expense over the remaining terms of the respective leases and expected below-market renewal option periods.
Derivative Instruments
The Company may use derivative financial instruments to hedge all or a portion of the interest rate risk associated with its borrowings. Certain of the techniques used to hedge exposure to interest rate fluctuations may also be used to protect against declines in the market value of assets that result from general trends in debt markets. The principal objective of such agreements is to minimize the risks and costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions.
The Company records all derivatives on the balance sheet at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair value of an
asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply, or the Company elects not to apply hedge accounting.
The accounting for subsequent changes in the fair value of these derivatives depends on whether each has been designated and qualifies for hedge accounting treatment. If the Company elects not to apply hedge accounting treatment, any change in the fair value of these derivative instruments is recognized immediately in gains (losses) on derivative instruments in the accompanying consolidated statements of operations and comprehensive loss prior to the adoption of ASU 2017-2 on January 1, 2019. If the derivative is designated and qualifies for hedge accounting treatment, the change in the estimated fair value of the derivative is recorded in other comprehensive income (loss) to the extent that it is effective, with any ineffective portion of a derivative’s change in fair value immediately recognized in earnings. After the adoption of ASU 2017-2, if the derivative qualifies for hedge accounting, all of the change in value is recorded in other comprehensive income (loss).
Non-controlling Interests
The non-controlling interests represent the portion of the common and preferred equity in the OP that is not owned by the Company as well as certain investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Non-controlling interests are presented as a separate component of equity on the consolidated balance sheets and presented as net loss attributable to non-controlling interests on the consolidated statements of operations and comprehensive loss. Non-controlling interests are allocated a share of net income or loss based on their share of equity ownership, including any preferential amounts. See Note 13 — Non-Controlling Interests for additional information.
Cash and Cash Equivalents
Cash and cash equivalents includes cash in bank accounts as well as investments in highly-liquid money market funds with original maturities of three months or less. The Company did not have any cash invested in money market funds at December 31, 2022 or 2021.
The Company deposits cash with high quality financial institutions. These deposits are guaranteed by the Federal Deposit Insurance Company (“FDIC”) up to an insurance limit. At December 31, 2022 and 2021, the Company had deposits of $53.7 million and $59.7 million, of which $43.6 million and $46.2 million, respectively, were in excess of the amount insured by the FDIC. Although the Company bears risk to amounts in excess of those insured by the FDIC, it does not anticipate any losses as a result.
Deferred Costs
Deferred costs, net, consists of deferred financing costs related to the Credit Facility (as defined in Note 5 — Credit Facilities) Fannie Mae Master Credit Facilities (as defined in Note 5 — Credit Facilities), and deferred leasing costs. Deferred financing costs relating to mortgage notes payable (see Note 4 — Mortgage Notes Payable, Net) are reflected net of the related financing in the mortgage notes payable, net line item of the Company’s consolidated balance sheet.
Deferred financing costs associated with the Credit Facility and Fannie Mae Master Credit Facilities and mortgage notes payable represent commitment fees, legal fees, and other costs associated with obtaining commitments for financing. These costs are amortized over the term of the financing agreement using the effective interest method for the Credit Facility and Fannie Mae Master Credit Facilities and using the effective interest method over the expected term for the mortgage notes payable.
Unamortized deferred financing costs are expensed if the associated debt is refinanced or paid down before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.
Deferred leasing costs, consisting primarily of lease commissions and professional fees incurred in connection with new leases, are deferred and amortized over the term of the lease.
Equity-Based Compensation
The Company has a stock-based incentive award program for its directors, which is accounted for under the guidance of share- based payments. The cost of services received in exchange for these stock awards is measured at the grant date fair value of the award and the expense for such awards is included in general and administrative expenses and is recognized over the service period (i.e., vesting) required or when the requirements for exercise of the award have been met (see Note 11Equity-Based Compensation).
Income Taxes
The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986 (the “Code”), as amended, commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.
If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and local income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2022, 2021 and 2020. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income.
Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties. Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS. Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.
As of December 31, 2022, the Company owned 52 seniors housing properties (including two land parcels) which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of December 31, 2022 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the ongoing COVID-19 pandemic. These abatements were extended through December 31, 2022 and may continue to be extended for future periods.
Because of the Company’s TRS's recent operating history of taxable losses and the impacts of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $6.9 million and $4.2 million as of December 31, 2022 and 2021, respectively. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive income (loss). As of December 31, 2022, the Company’s consolidated TRS had net operating loss carryforwards for federal income tax purposes of approximately $24.4 million at December 31, 2022 (of which $7.6 million were incurred prior to January 1, 2018). Carryforwards from losses incurred prior to January 1, 2018, if unused, these will begin to expire in 2035. For net operating losses incurred subsequent to December 31, 2017, there is no expiration date. As of December 31, 2022, the Company had a deferred tax asset of $6.9 million with a full valuation allowance. As of December 31, 2021, the Company had a deferred tax asset of $4.2 million with a full valuation allowance.
The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2022, 2021 and 2020, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately 0.0%, 0.0% and (105.8)% for the years ended December 31, 2022, 2021 and 2020, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.
Year Ended December 31,
202220212020
(In thousands)CurrentDeferredCurrentDeferredCurrentDeferred
Federal (expense) benefit $— $2,145 $— $(319)$726 $— 
State (expense) benefit(201)604 (203)(163)(196)50 
Deferred tax asset valuation allowance— (2,749)— 482 — (4,641)
Total income tax benefit (expense)$(201)$— $(203)$— $530 $(4,591)
As of December 31, 2022 and 2021, the Company had no material uncertain income tax positions. The tax years subsequent to and including the fiscal year ended December 31, 2017 remain open to examination by the major taxing jurisdictions to which the Company is subject.
Per Share Data
Net income (loss) per basic share of common stock is calculated by dividing net income (loss) by the weighted-average number of shares (retroactively adjusted for the Stock Dividends) of common stock issued and outstanding during such period. Diluted net income (loss) per share of common stock considers the effect of potentially dilutive shares of common stock outstanding during the period.
CARES Act Grants
On March 27, 2020, the CARES Ac) was signed into law and it provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. During the years ended December 31, 2022, 2021 and 2020 the Company received $4.5 million, $5.1 million and $3.6 million in funding from CARES Act grants, respectively. For accounting purposes, the CARES Act funds are treated as a grant contribution from the government. The funding the Company received was recognized as a reduction of property operating and maintenance expenses in the Company’s consolidated statements of operations to offset the negative impacts of COVID-19. There can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.
Recently Issued Accounting Pronouncements
Adopted as of January 1, 2020:
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. The objective of ASU 2018-13 is to improve the effectiveness of disclosures in the notes to the financial statements by removing, modifying, and adding certain fair value disclosure requirements to facilitate clear communication of the information required by generally accepted accounting principles. The amended guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which changes how entities measure credit losses for financial assets carried at amortized cost. The update eliminates the requirement that a credit loss must be probable before it can be recognized and instead requires an entity to recognize the current estimate of all expected credit losses. Additionally, the amended standard requires credit losses on available-for-sale debt securities to be carried as an allowance rather than as a direct write-down of the asset. On July 25, 2018, the FASB proposed an amendment to ASU 2016-13 to clarify that operating lease receivables recorded by lessors (including unbilled straight-line rent) are explicitly excluded from the scope of ASU 2016-13. The new guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.
Adopted as of January 1, 2021:
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2021 and determined it did not have a material impact on its consolidated financial statements.
Adopted as of January 1, 2022:
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption was permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2022 and determined it did not have a material impact on its consolidated financial statements.
Not yet Fully Adopted as of December 31, 2022
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period from March 12, 2020 through June 30, 2023 as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that the Company’s hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of the Company’s derivatives, which will be consistent with the Company’s past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate Investments, Net
12 Months Ended
Dec. 31, 2022
Real Estate [Abstract]  
Real Estate Investments, Net Real Estate Investments, Net
Property Acquisitions
The Company invests in healthcare-related facilities, primarily MOBs and seniors housing properties which expand and diversify its portfolio and revenue base. The Company owned 202 properties as of December 31, 2022. During the year ended December 31, 2022, the Company, through wholly-owned subsidiaries of the OP, completed its acquisitions of one multi-tenant MOBs and three single tenant MOBs for an aggregate contract purchase price of $25.3 million. All acquisitions in 2022, 2021 and 2020 were considered asset acquisitions for accounting purposes.
The following table presents the allocation of the assets acquired and liabilities assumed during the years ended December 31, 2022, 2021 and 2020:
Year Ended December 31,
(In thousands)202220212020
Real estate investments, at cost:
Land$4,933 $12,848 $7,665 
Buildings, fixtures and improvements16,606 121,376 90,699 
Total tangible assets21,539 134,224 98,364 
Acquired intangibles:
In-place leases and other intangible assets (1)
3,763 28,499 10,369 
Market lease and other intangible assets (1)
268 794 496 
Market lease liabilities (1)
(32)(1,639)(362)
Total intangible assets and liabilities
3,999 27,654 10,503 
Mortgage notes payable assumed, net— — (13,883)
Issuance of Preferred OP Units (2)
— (2,578)— 
Cash paid for real estate investments, including acquisitions$25,538 $159,300 $94,984 
Number of properties purchased17 
_______________
(1)Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 8.9 years, 9.3 years and 12.1 years, respectively, as of December 31, 2022. Weighted-average remaining amortization periods for in-place leases and above-market leases acquired were 11.2 years, 10.2 years and 8.5 years, respectively, as of December 31, 2021. Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 1.7 years, 7.7 years and 7.4 years, respectively, as of December 31, 2020.
(2)See Note 8 — Stockholders’ Equity for additional information.
Significant Tenants
As of December 31, 2022, 2021 and 2020, the Company did not have any tenants (including for this purpose, all affiliates of such tenants) whose annualized rental income on a straight-line basis represented 10% or greater of total annualized rental income on a straight-line basis for the portfolio. The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of December 31, 2022, 2021 and 2020:
December 31,
State202220212020
Florida (1)
19.2%17.7%20.6%
Pennsylvania**10.4%
_______________
*    State’s annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income for all portfolio properties as of the period specified.
(1)In May 2021, the Company’s skilled nursing facility in Wellington, Florida, and the Company’s development property in Jupiter, Florida were sold. In December 2020, the Company’s skilled nursing facility in Lutz, Florida was sold.

Intangible Assets and Liabilities
Acquired intangible assets and liabilities consisted of the following as of the periods presented:
December 31, 2022December 31, 2021
(In thousands)Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Intangible assets:
In-place leases$268,135 $198,138 $69,997 $264,741 $183,073 $81,668 
Market lease assets14,432 12,042 2,390 14,164 11,212 2,952 
Other intangible assets9,467 1,165 8,302 9,467 1,006 8,461 
Total acquired intangible assets
$292,034 $211,345 $80,689 $288,372 $195,291 $93,081 
Intangible liabilities:
Market lease liabilities $23,504 $14,097 $9,407 $23,472 $12,529 $10,943 
The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above-and below-market lease assets and liabilities, net and the amortization of above-and below-market ground leases, for the periods presented:
Year Ended December 31,
(In thousands)202220212020
Amortization of in-place leases and other intangible assets (1)
$15,076 $15,071 $15,121 
Accretion of above-and below-market leases, net (2)
$(795)$(422)$(257)
Amortization of above-and below-market ground leases, net (3)
$159 $214 $178 
________
(1)Reflected within depreciation and amortization expense.
(2)Reflected within revenue from tenants.
(3)Reflected within property operating and maintenance expense.
The following table provides the projected amortization and adjustments to revenue from tenants for the next five years:
(In thousands)20232024202520262027
In-place lease assets$13,208 $11,287 $9,700 $8,454 $4,958 
Other intangible assets10 10 10 10 10 
Total to be added to amortization expense$13,218 $11,297 $9,710 $8,464 $4,968 
Above-market lease assets$(495)$(416)$(363)$(329)$(240)
Below-market lease liabilities1,512 1,294 1,103 941 623 
Total to be added to revenue from tenants$1,017 $878 $740 $612 $383 
Dispositions
The following table summarizes the properties sold during the years ended December 31, 2022, 2021 and 2020:
(In thousands)Disposition DateContract Sale PriceGain (Loss)
on Sale, of Real Estate Investments
2022 Dispositions:
LaSalle properties (four properties) (1)
March 2, 2022$12,400 $(303)
Lien settlement on formerly disposed propertiesN/AN/A178 
Totals$12,400 $(125)
2021 Dispositions:
Hampton River Portfolio (two properties)
December 21, 2021$37,800 $1,323 
NuVista Jupiter (2)
May 14, 202165,000 2,383 
Wellington Green (3)
May 14, 202130,750 114 
Michigan SHOPs (four properties) (4)
January 15, 2021— (172)
Totals$133,550 $3,648 
2020 Dispositions:
Lutz (5)
December 15, 2020$20,000 $3,832 
Michigan SHOPs (seven properties) (4)
November 2, 202011,750 (908)
Cape GirardeauMarch 19, 20208,600 2,306 
Totals$40,350 $5,230 
______
(1)Impairment charges of $34.0 million were recorded during the year ended December 31, 2021.
(2)Impairment charges of $14.6 million and $19.8 million were recorded during the years ended December 31, 2020 and 2019, respectively.
(3)Impairment charges of $0.9 million, $2.3 million and $9.9 million were recorded during the years ended December 31, 2021, 2020 and 2019, respectively.
(4)Impairment charges of $19.6 million and $22.6 million were recorded during the years ended December 31, 2020 and 2019, respectively. The contract sales price for all 11 properties was received in November of 2020. Loss on sale amounts relate to the properties transferred at the respective dates.
(5)Impairment charges of $3.6 million were recorded during the year ended December 31, 2019.

The sales of the properties noted above did not represent a strategic shift that has a major effect on the Company’s operations and financial results. Accordingly, the results of operations of these properties remain classified within continuing operations for all periods presented until the respective sale dates.
Assets Held for Sale
When assets are identified by management as held for sale, the Company reflects them separately on its balance sheet and stops recognizing depreciation and amortization expense on the identified assets and estimates the sales price, net of costs to sell, of those assets. If the carrying amount of the assets classified as held for sale exceeds the estimated net sales price, the Company records an impairment charge equal to the amount by which the carrying amount of the assets exceeds the Company’s estimate of the net sales price of the assets. For held-for-sale properties, the Company predominately uses the contract sale price as fair market value.
There were no assets held for sale as of December 31, 2022 or December 31, 2021.
Assets Held for Use
When circumstances indicate the carrying value of a property classified as held for use may not be recoverable, the Company reviews the property for impairment. For the Company, the most common triggering events are (i) concerns regarding the tenant (i.e., credit or expirations) in the Company’s single-tenant properties or significant vacancy in the Company’s multi-tenant properties and (ii) changes to the Company’s expected holding period as a result of business decisions or non-recourse debt maturities. If a triggering event is identified, the Company considers the projected cash flows due to various performance indicators, and where appropriate, the Company evaluates the impact on its ability to recover the carrying value of the properties based on the expected cash flows on an undiscounted basis over its intended holding period. The Company makes certain assumptions in this approach including, among others, the market and economic conditions, expected cash flow projections, intended holding periods and assessments of terminal values. Where more than one possible scenario exists, the Company uses a probability weighted approach in estimating cash flows. As these factors are difficult to predict and
are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in its impairment analysis may not be achieved, and actual losses for impairment may be realized in the future. If the undiscounted cash flows over the expected hold period are less than the carrying value, the Company reflects an impairment charge to write the asset down to its fair value.
Impairment Charges
The following table presents impairment charges by segment recorded during the years ended December 31, 2022, 2021 and 2020:
Year Ended December 31,
(In thousands)202220212020
MOB Segment:
Illinois skilled nursing facilities (1) (7)
$10,644 $— $— 
Sassafras MOB (2) (7)
1,844 — — 
Sun City MOB (3) (7)
— 6,082 — 
Total MOB impairment charges12,488 6,082 — 
SHOP Segment:
Various held for use SHOPs (4) (7)
15,142 — — 
LaSalle Properties (5) (7)
— 34,000 — 
Wellington, Florida skilled nursing facility (6) (7)
— 869 2,276 
Michigan properties (8)
— — 19,570 
NuVista Jupiter (7) (9)
— — 14,600 
Total SHOP impairment charges15,142 34,869 36,446 
Total impairment charges$27,630 $40,951 $36,446 
(1)These seven properties were impaired after the Company received an offer by the tenant to purchase all seven properties, which caused the Company to reassess its expected holding period for these properties. As of December 31, 2022, these properties were not disposed nor are under contract for disposal.
(2)The Company began marketing this property for sale in the fourth quarter of 2022. As of December 31, 2022 this property was not disposed nor under contract for disposal.
(3)This property has been actively marketed for sale since September 2021. As of December 31, 2022 this property was not disposed nor under contract for disposal.
(4)Consists of eight properties actively marketed for sale. Of the eight properties, six properties were impaired in year ended December 31, 2022. As of December 31, 2022, these properties were not disposed, but five of these properties are under contract for disposal.
(5)These four properties were disposed in the year ended December 31, 2022.
(6)This property was disposed in the year ended December 31, 2021. The Company recorded this impairment charge in the year ended December 31, 2021 to reduce the carrying value of the property to its estimated fair value as determined by an amendment to its purchase and sale agreement. The Company had previously recorded $2.3 million of impairment charges on this property in the year ended December 31, 2020.
(7)These properties were impaired to reduce their carrying values to their estimated fair values, respectively, as determined by the Assets Held for Use approach described above.
(8)These properties were disposed in the first quarter of 2021 and the fourth quarter of 2020.
(9)This property was disposed in the second quarter of 2021.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Mortgage Notes Payable, Net
12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Mortgage Notes Payable, Net Mortgage Notes Payable, Net
The following table reflects the Company’s mortgage notes payable as of December 31, 2022 and 2021:
PortfolioEncumbered PropertiesOutstanding Loan Amount as of December 31,
Effective Interest Rate (1) as of December 31,
Interest Rate
2022202120222021Maturity
(In thousands)(In thousands)
Palm Valley Medical Plaza - Goodyear, AZ$— $2,879 — %4.15%FixedJun. 2023
Medical Center V - Peoria, AZ— 2,684 — %4.75%FixedSep. 2023
Fox Ridge Bryant - Bryant, AR16,817 6,977 3.98 %3.98%FixedMay 2047
Fox Ridge Chenal - Little Rock, AR115,639 16,024 2.95 %2.95%FixedMay 2049
Fox Ridge North Little Rock - North Little Rock, AR19,704 9,943 2.95 %2.95%FixedMay 2049
Capital One MOB Loan41378,500 378,500 3.73 %3.71%Fixed(2)Dec. 2026
Multi-Property CMBS Loan21118,700 118,700 4.60 %4.60%FixedMay 2028
Shiloh - Illinois
113,071 13,384 4.34 %4.34%FixedJan. 2025
BMO CMBS942,750 42,750 2.89 %2.89%FixedDec. 2031
Gross mortgage notes payable75585,181 591,841 3.83 %3.82%
Deferred financing costs, net of accumulated amortization (3)
(5,117)(6,186)
Mortgage premiums and discounts, net(1,364)(1,416)
Mortgage notes payable, net$578,700 $584,239 
__________
(1)Calculated on a weighted average basis for all mortgages outstanding as of December 31, 2022 and December 31, 2021. For the SOFR/LIBOR based loans, SOFR/LIBOR in effect at the balance sheet date was utilized. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See Note 7 — Derivatives and Hedging Activities for additional details.
(2)Variable rate loan, based on daily SOFR as of December 31, 2022 and based on 30-day LIBOR as of December 31, 2021, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. The Company allocated $378.5 million of its “pay-fixed” interest rate swaps to this mortgage consistently as of December 31, 2022 and 2021.
(3)Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.

As of December 31, 2022, the Company had pledged $0.9 billion in real estate investments, at cost, as collateral for its $585.2 million of gross mortgage notes payable. This real estate is not available to satisfy other debts and obligations unless first satisfying the mortgage notes payable secured by these properties. The Company makes payments of principal and interest, or interest only, depending upon the specific requirements of each mortgage note, on a monthly basis.
Some of the Company’s mortgage note agreements require compliance with certain property-level financial covenants including debt service coverage ratios. As of December 31, 2022, the Company was in compliance with these financial covenants.
See Note 5 Credit Facilities - Future Principal Payments and LIBOR Transition for a schedule of principal payment requirements of the Company’s Mortgage Notes and Credit Facilities and a discussion of the expected cessation of LIBOR publication.
BMO MOB Loan
On November 15, 2021, the Company, entered into a $42.8 million loan agreement (the “BMO MOB Loan”) with Bank of Montreal (“BMO”).
The BMO MOB Loan requires monthly interest-only payments, with the principal balance due on the maturity date. The BMO MOB Loan permits BMO to securitize the entire BMO MOB Loan or any portion thereof.
At the closing of the BMO MOB Loan, the net proceeds after accrued interest and closing costs were used to (i) repay approximately $37.0 million of indebtedness under the Revolving Credit Facility, under which nine of the properties were included as part of the borrowing base prior to the BMO MOB Loan, (ii) fund approximately $2.5 million in deposits required to be made at closing into reserve accounts required under the loan agreement. The remaining $2.4 million net proceeds available to the Company were used for general corporate purposes and acquisitions.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Credit Facilities, Net
12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Credit Facilities, Net Credit Facilities, Net
The Company had the following credit facilities outstanding as of December 31, 2022 and 2021:
Outstanding Facility Amount as of December 31,
Effective Interest Rate as of December 31,(9) (10)
Credit Facility
Encumbered Properties (1)
2022202120222021Interest RateMaturity
(In thousands)(In thousands)
Credit Facility:
Revolving Credit Facility
$30,000 $— 7.26 %— %VariableMar. 2024(8)
Term Loan
150,000 150,000 5.11 %4.11 %Fixed(6)Mar. 2024
Deferred financing costs
(1,750)(2,994)
Term Loan, net
148,250 147,006 
Total Credit Facility
98(2)$178,250 $147,006 
Fannie Mae Master Credit Facilities:
Capital One Facility11(3)$210,483 $212,417 5.90 %2.51 %Variable(7)Nov. 2026
KeyBank Facility10(4)141,564 142,628 6.60 %2.56 %Variable(7)Nov. 2026
Total Fannie Mae Master Credit Facilities
21$352,047 $355,045 
Total Credit Facilities119$530,297 $502,051 5.94 %(5)3.00 %(5)
_______
(1)Encumbered properties are as of December 31, 2022.
(2)The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below) have been pledged for the benefit of the lenders thereunder.
(3)Secured by first-priority mortgages on 11 of the Company’s seniors housing properties located in Florida, Georgia, Iowa and Michigan as of December 31, 2022 with a carrying value of $348.9 million.
(4)Secured by first-priority mortgages on ten of the Company’s seniors housing properties located in, Missouri, Kansas, California, Florida, Georgia and Iowa as of December 31, 2022 with carrying value of $261.0 million.
(5)Calculated on a weighted average basis for all credit facilities outstanding as of December 31, 2022 and 2021, respectively.
(6)Variable rate loan, based on SOFR, all of which was economically fixed as a result of entering into “pay-fixed” interest rate swap agreements (the Company designates its SOFR “pay-fixed” interest rate swaps against all 30-day SOFR debt, see Note 7 — Derivatives and Hedging Activities for additional details).
(7)The effective rates above only include the impact of designated hedging instruments. The Company also has seven non-designated interest rate cap agreements with an aggregate notional amount of $354.6 million which limits 30-day LIBOR to 3.50%. The Company did not designate these derivatives as hedges and accordingly, the changes in value and any cash received from these derivatives are presented within gain (loss) on derivative instruments on the consolidated statements of operations and comprehensive income (see discussion below and Note 7 — Derivatives and Hedging Activities for additional details). Inclusive of the impact of these interest rate caps on these non-designated derivatives, the economic interest rate on the Capital One Fannie Mae Facility was 5.26%, and the economic interest rate on the KeyBank Fannie Mae Facility was 5.96% as of December 31, 2022.
(8)During the year ended December 31, 2022, the Company exercised its option to extend the maturity one year to March 2024.
(9)Effective interest rate below for variable rate debt gives effect to any “pay-fixed” swap entered into by the Company allocated to the loan for presentation purposes. If no “pay-fixed” swaps are allocated, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of December 31, 2022 and 2021. Interest rate caps are not considered unless the caps, if any, are currently in effect.
(10)The Company has interest “pay-fixed” swaps which are designated as cash flow hedges on LIBOR- or SOFR-based outstanding combined borrowings. Prior to the Fourth Amendment (as defined below) which, among other things, changed the reference rate on the Credit Facility from LIBOR to SOFR, to present average rates in the table above, the Company historically allocated the notional amount of a “pay-fixed” swap to the outstanding amounts of its Credit Facility (both the Revolving Credit Facility and the Term Loan) with any remaining notional amounts applied to its Capital One Fannie Mae Facility. During the three months ended September 30, 2022, the Company converted $150.0 million of its “pay-fixed” swaps from LIBOR to SOFR. As of December 31, 2022, the Company allocated the $150.0 million SOFR-based “pay-fixed” swaps to the Term Loan, which were also allocated to the
Term Loan as of December 31, 2021 when the Term Loan and swaps were LIBOR-based. As of December 31, 2022 and 2021, $50.0 million of LIBOR-based “pay-fixed” swaps were allocated to the Capital One Fannie Mae Facility because there were no LIBOR-based amounts outstanding under the Revolving Credit Facility in either period. The $50.0 million of LIBOR-based “pay-fixed” swaps were terminated subsequent to December 31, 2022. See Note 17 — Subsequent Events for additional information.
As of December 31, 2022, the carrying value of our real estate investments, at cost was $2.6 billion, with $0.9 billion of this amount pledged as collateral for mortgage notes payable, $0.6 billion of this amount pledged to secure advances under the Fannie Mae Master Credit Facilities and $0.9 billion of this amount comprising the borrowing base of the Credit Facility. All of the real estate assets pledged to secure debt or comprising the borrowing base of are not available to satisfy other debts and obligations, or to serve as collateral with respect to new indebtedness, unless, as applicable, the existing indebtedness associated with the property is satisfied or the property is removed from the borrowing base of the Credit Facility, which would impact availability thereunder.
Unencumbered real estate investments, at cost as of December 31, 2022 was $0.1 billion, although there can be no assurance as to the amount of liquidity the Company would be able to generate from using these unencumbered assets as collateral for mortgage loans or adding them to the borrowing base of the Company’s Credit Facility. Currently, any properties that the Company acquires must be added to the borrowing base of the Credit Facility, and any net proceeds from the dispositions of any unencumbered properties must be used to repay amounts outstanding under the Revolving Credit Facility (as defined below).
Credit Facility
The amended and restated senior secured credit facility (the “Credit Facility”), consists of two components, a revolving credit facility (the “Revolving Credit Facility”) and a term loan (the “Term Loan”).
The Revolving Credit Facility is interest-only and matures on March 13, 2023, subject to a one-year extension at the Company’s option. The Term Loan is interest-only and matures on March 13, 2024. The total commitments under the Credit Facility are $655.0 million, including $505.0 million under the Revolving Credit Facility. The Credit Facility includes an uncommitted “accordion feature” that may be used to increase the commitments under either component of the Credit Facility by up to an additional $370.0 million to a total of $1.0 billion.
The amount available for future borrowings under the Revolving Credit Facility is based on either the value of the pool of eligible unencumbered real estate assets comprising the borrowing base, or satisfying a minimum debt service coverage ratio with respect to the borrowing base. The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Revolving Credit Facility have been pledged for the benefit of the lenders thereunder.
As of December 31, 2022, $150.0 million was outstanding under the Term Loan, and $30.0 million was outstanding under the Revolving Credit Facility. The unused borrowing availability under the Revolving Credit Facility was $203.4 million based on the borrowing base as of December 31, 2022.
On August 11, 2022, the Company, the OP, KeyBank National Association individually and as agent for the lenders and the lenders from time to time a party under the Credit Facility, among others, entered into the fourth amendment to the Credit Facility (the “Fourth Amendment”). Without the Fourth Amendment, the Company would have been in default of the reamendment Fixed Charge Coverage Ratio covenant (defined below) for the four fiscal quarter period ended June 30, 2022. Pursuant to the Fourth Amendment, the lenders agreed to reduce the minimum required Fixed Charge Coverage Ratio covenant to permit the Company to avoid any Default or Events of Default through the amendment date. The Fourth Amendment also eliminated the LIBOR-based rate option, among other changes. The terms described below represent the terms pursuant to the Fourth Amendment.
The Company is required to maintain a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $50.0 million. Certain other restrictions and conditions described below will no longer apply beginning in the quarter in which the Company makes an election and, as of the day prior to the commencement of the applicable quarter, the Company has a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million, giving effect to the aggregate amount of distributions projected to be paid by the Company during the applicable quarter, the Company’s ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5% and the Company’s Fixed Charge Coverage Ratio (as defined below) for the most recently ended four fiscal quarters is not less than 1.50 to 1.00 (the “Commencement Quarter”). The fiscal quarter ended June 30, 2021 was the first quarter that could have been the Commencement Quarter. The Company did not satisfy the conditions during the quarter ended December 31, 2022 in order to elect the quarter ending March 31, 2023 as the Commencement Quarter.
Until the first day of the Commencement Quarter, the Company must use all the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to prepay amounts outstanding under the Revolving Credit Facility, to the extent there are any such amounts outstanding. The Company may borrow additional amounts if all relevant conditions are met, including sufficient availability for future borrowings. There can be no assurance these conditions will be met at the time of any particular borrowing.
Until the Commencement Quarter, the Company may not pay distributions to holders of common stock in cash or any other cash distributions (including repurchases of shares of the Company’s common stock), subject to certain exceptions. These exceptions include paying dividends on the 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (“Series A Preferred Stock”), the 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (“Series B Preferred Stock”) or any other class of preferred stock that the Company may issue and paying any cash distributions necessary to maintain its status as a REIT. The Company may not pay any cash distributions (including dividends on Series A Preferred Stock or Series B Preferred Stock or any other preferred stock) if a default or event of default exists or would result therefrom. Beginning in the Commencement Quarter, the Company will be able to pay cash distributions to holders of common stock, subject to the restrictions described below and the aggregate distributions (as defined in the Credit Facility and including dividends on Series A Preferred Stock, Series B Preferred Stock or any other class of preferred stock that may be issued) for any period of four fiscal quarters may not exceed 95% of Modified FFO (as defined in the Credit Facility) for the same period based only on fiscal quarters after the Commencement Quarter. In addition, beginning in the Commencement Quarter, the Company will be permitted to repurchase up to $50.0 million of shares of its common stock (including amounts previously repurchased during the term of the Revolving Credit Facility) if, after giving effect to the repurchases, the Company maintains cash and cash equivalents of at least $30.0 million and the Company’s ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 55.0%.
Under the Credit Facility, the Company must comply with covenants governing the maximum ratio of consolidated total indebtedness to consolidated total asset value, and requiring the Company to maintain a minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges, a minimum consolidated tangible net worth and a minimum debt service coverage ratio. Specifically, the maximum ratio of consolidated total indebtedness to consolidated total asset value is presently 65% unless and until the Commencement Quarter, following which the ratio will be 62.5%. The minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges (the “Fixed Charge Coverage Ratio”) that the Company must satisfy based on the four most recently ended fiscal quarters is (a) 1.20 to 1.00 for the period commencing with the quarter ended June 30, 2022 through the quarter ending June 30, 2023, (b) 1.35 to 1.00 for the period commencing with the quarter ending September 30, 2023 through the quarter ending December 31, 2023 and (c) 1.45 to 1.00 for the period commencing with the quarter ending March 31, 2024 and continuing thereafter; provided, however, that from and after the Commencement Quarter, the Company must satisfy a minimum Fixed Charge Coverage Ratio of 1.50 to 1.00. The minimum consolidated tangible net worth is the sum of (i) $1.2 billion, plus (ii) 75% of any net offering proceeds (as defined in the Credit Facility) since the Credit Facility closed in March 2019. As of December 31, 2022, the Company had a consolidated tangible net worth of $1.5 billion. The minimum debt service coverage ratio (calculated similar to the calculation of the Fixed Charge Coverage Ratio but excluding dividends on Series A Preferred Stock, Series B Preferred Stock or any other class of preferred stock that may be issued) that the Company must satisfy based on the four most recently ended fiscal quarters is (a) 1.50:1.00 for the period commencing with the quarter ended June 30, 2022 through the quarter ending June 30, 2023, (b) 1.65:1.00 for the period commencing with the quarter ending September 30, 2023 through the quarter ending December 31, 2023 and (c) 1.75:1.00 for the period commencing with the quarter ending March 31, 2024 and continuing thereafter until the Company elects the Commencement Quarter, after which the debt service coverage ratio covenant will no longer apply. Additionally, the borrowing base advance rate is 52.5% until the Company elects the Commencement Quarter, after which the borrowing base advance rate will be 55%.
In addition, as of December 31, 2022, the Company had the option to have amounts outstanding under the Revolving Credit Facility bear interest at an annual rate equal to either: (i) SOFR (as defined below), plus an applicable margin that ranges, depending on the Company’s leverage, from 2.10% to 2.85%; or (ii) the Base Rate (as defined in the Credit Facility), plus an applicable margin that ranges, depending on the Company’s leverage, from 0.85% to 1.60%. Commencing on the first day of the Commencement Quarter, the Company will have the option to have amounts outstanding under the Revolving Credit Facility bear interest at an annual rate equal to either: (a) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.60% to 2.35%, plus an additional spread adjustment depending on the length of the interest period; or (b) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.35% to 1.10%. As of December 31, 2022 the Company had elected to use the SOFR option for all of its borrowings under the Revolving Credit Facility, to the extent there are any such amounts outstanding.
Further, as of December 31, 2022, the Company has the option to have amounts outstanding under the Term Loan bear interest at an annual rate equal to either: (i) SOFR, plus an applicable margin that ranges, depending on the Company’s leverage, from 2.05% to 2.80%; or (ii) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.80% to 1.55%. Commencing on the first day of the Commencement Quarter, the Company will have the option to have amounts outstanding under the Term Loan bear interest at an annual rate equal to either: (a) SOFR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.55% to 2.30%, plus an additional spread adjustment depending on the length of the interest period; or (b) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.30% to 1.05%. Pursuant to the terms of the Company’s Credit Facility, the “floor” on SOFR-based rates is 0.25%. As of December 31, 2022, the Company had elected to use the SOFR option for all of its borrowings under the Term Loan.
As of December 31, 2022, the Company was in compliance with the financial covenants under the Credit Facility.
As discussed in Note 2 — Summary of Significant Accounting Policies, the Company has experienced, and continues to experience, negative impacts from rising operating costs, particularly in its SHOP segment, as well as rising variable interest rates. The Company’s Credit Facility matures in March 2024 and contains various operating covenants (described above) which the Company was in compliance with through December 31, 2022. Prospectively, based upon the Company’s current expectations, the Company believes its operating results through June 30, 2023 will allow it to comply with these covenants. However, the Company believes its operating results may not be sufficient to comply with the increased Fixed Charge Coverage Ratio, which increases from 1.20:1.00 to 1.35:1.00 commencing with the quarter ending September 30, 2023 and thereafter. Absent a waiver or modification from the lender group, failure to comply with the Fixed Charge Coverage Ratio would constitute an Event of Default and the balance of the Credit Facility would be due and payable. The Company has obtained such waivers and modifications from the lender group in the past, but there can be no assurance that such a waiver or modification will be granted in future periods. Additionally, the Company is exploring long-term secured financing opportunities, utilizing some or all of the Company’s properties as collateral, the proceeds from which the Company believes will be sufficient to repay all amounts outstanding under the Credit Facility, which was $180.0 million as of December 31, 2022 ($200.0 million including the $20.0 million drawn subsequent to December 31, 2022, see Note 17 — Subsequent Events for details).
Fannie Mae Master Credit Facilities
On October 31, 2016, the Company, through wholly-owned subsidiaries of the OP, entered into a master credit facility agreement relating to a secured credit facility with KeyBank (the “KeyBank Facility”) and a master credit facility agreement with Capital One for a secured credit facility with Capital One Multifamily Finance LLC, an affiliate of Capital One (the “Capital One Facility”; the Capital One Facility and the KeyBank Facility are referred to herein individually as “Fannie Mae Master Credit Facility” and together as the “Fannie Mae Master Credit Facilities”). Advances made under these agreements are assigned by Capital One and KeyBank to Fannie Mae at closing for inclusion in Fannie Mae’s Multifamily MBS program.
In connection with the Fannie Mae Master Credit Facilities, the Company was required to enter into interest rate cap agreements. Periodically, the Company renews these interest rate cap agreements upon their expiration. As of December 31, 2022, the Company had seven interest rate cap agreements (of which six caps were active as of December 31, 2022 and one has a forward start date as of April 2023) with an aggregate current effective notional amount of $354.6 million which caps LIBOR at 3.50% with terms through April 2024. The Company does not apply hedge accounting to these agreements and changes in value as well as any cash received are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive income (see Note 7 — Derivatives and Hedging Activities for additional disclosure regarding the Company’s derivatives).
In November 2020, in conjunction with the sale and transfer of four of the Michigan SHOPs, one of which was encumbered under the Fannie Mae Master Credit Facility with Capital One, $4.2 million was repaid to Capitol One upon the release of the property.
The Company may request future advances under the Fannie Mae Master Credit Facilities by adding eligible properties to the collateral pool, subject to customary conditions, including satisfaction of minimum debt service coverage and maximum loan-to-value tests.
Future Principal Payments
The following table summarizes the scheduled aggregate principal payments for the five years subsequent to December 31, 2022 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities):
Future Principal
Payments
(In thousands)Mortgage Notes PayableCredit FacilitiesTotal
2023$1,139 $5,769 $6,908 
20241,178 185,769 186,947 
202513,270 5,769 19,039 
2026379,393 334,740 714,133 
2027922 — 922 
Thereafter189,279 — 189,279 
Total$585,181 $532,047 $1,117,228 
LIBOR Transition
In July 2017, the Financial Conduct Authority (which regulates LIBOR) announced it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee, which identified the Secured Overnight Financing Rate (“SOFR”) as its preferred alternative to LIBOR in derivatives and other financial contracts. On March 5, 2021, the Financial Conduct Authority confirmed a partial extension of this deadline announcing that it will cease the publication of the one-week and two-month USD LIBOR settings immediately following December 31, 2021. The remaining USD LIBOR settings will continue to be published through June 30, 2023. The Company is not able to predict when there will be sufficient liquidity in the SOFR market. The Company is monitoring and evaluating the risks related to changes in LIBOR availability, which include potential changes in interest paid on debt and amounts received and paid on interest rate swaps. In addition, the value of debt or derivative instruments tied to LIBOR will also be impacted as LIBOR is limited and discontinued and contracts must be transitioned to a new alternative rate. While the Company currently expects LIBOR to be available in substantially its current form until at least through June 30, 2023 for the USD LIBOR rates currently relevant to the Company, it is possible that LIBOR will become unavailable prior to that time. This could occur, for example, if a sufficient number of banks decline to make submissions to the LIBOR administrator. Pursuant to the Fourth Amendment, the Credit Agreement was updated and provisions were added to transition the Credit Facility from using a benchmark rate of LIBOR to using a benchmark rate of SOFR, and the Company will either utilize the Base Rate (as defined in the Credit Facility) or the updated SOFR-based rates. During the year ended December 31, 2022, the Company converted $150.0 million of its “pay-fixed” swaps on its Credit Facility from LIBOR to SOFR, and the Company additionally converted its $378.5 million Capital One MOB Loan and related “pay-fixed” swap from LIBOR to SOFR, however, the Company still has mortgages, credit facilities (namely, the Capital One Facility and the KeyBank Facility) and derivative agreements that have terms that are based on LIBOR. Certain of those agreements have alternative rates already contained in the agreements while others do not. The Company anticipates that it will either utilize the alternative rates contained in the agreements or negotiate a replacement reference rate for LIBOR with the lenders and derivative counterparties.
As of December 31, 2022, the Company had $558.7 million of LIBOR-based borrowings ($352.0 million of which is variable-rate) and $50.0 million of LIBOR-based “pay-fixed” swaps. The Company terminated its remaining $50.0 million of “pay-fixed” swaps subsequent to December 31, 2022. See Note 17 — Subsequent Events for additional information.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value of Financial Instruments
12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments GAAP establishes a hierarchy of valuation techniques based on the observability of inputs used in measuring asset and liabilities at fair value. GAAP establishes market-based or observable inputs as the preferred source of values, followed by valuation models using management assumptions in the absence of market inputs. The three levels of the hierarchy are described below:
Level 1 — Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset and liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.
Level 3 — Unobservable inputs that reflect the entity’s own assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.
The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. However, the Company expects that changes in classifications between levels will be rare.
Financial Instruments Measured at Fair Value on a Recurring Basis
Derivative Instruments
Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with those derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and its counterparties. However, as of December 31, 2022 and 2021, the Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of the Company’s derivatives. As a result, the Company has determined that its derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.
The valuation of derivative instruments is determined using a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, as well as observable market-based inputs, including interest rate curves and implied volatilities. In addition, credit valuation adjustments, are incorporated into the fair values to account for the Company’s potential nonperformance risk and the performance risk of the counterparties.
The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2022 and 2021, aggregated by the level in the fair value hierarchy within which those instruments fall.
(In thousands)Quoted Prices in Active Markets
Level 1
Significant
Other Observable Inputs
Level 2
Significant Unobservable Inputs
Level 3
Total
December 31, 2022
Derivative assets, at fair value (non-designated)$— $3,737 $— $3,737 
Derivative assets, at fair value (designated)— 36,910 — 36,910 
Derivative liabilities, at fair value— — — — 
Total$— $40,647 $— $40,647 
December 31, 2021
Derivative assets, at fair value (non-designated)$— $174 $— $174 
Derivative liabilities, at fair value (designated)(13,903)(13,903)
Total$— $(13,729)$— $(13,729)
A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the type of inputs may result in a reclassification for certain assets. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the year ended December 31, 2022.
Real Estate Investments Measured at Fair Value on a Non-Recurring Basis
Real Estate Investments — Held for Use
The Company also had impaired real estate investments held for use, which were carried at fair value on a non-recurring basis on the consolidated balance sheet as of December 31, 2022 and 2021.
As of December 31, 2022, the Company owned 17 held for use properties (nine MOBs and eight SHOPs) for which the Company had reconsidered its expected holding period, of which 10 properties (two MOBs and eight SHOPs) are being marketed for sale. As a result, the Company evaluated the impact on its ability to recover the carrying value of the properties and recorded impairment charges to write these properties down to their estimated fair values. The Company had also previously written down other held for use properties which have subsequently been sold.
As of December 31, 2021, the Company owned five held for use properties (one MOB and four SHOPs) for which the Company had reconsidered their expected holding periods and which were being marketed for sale. As a result, the Company evaluated the impact on its ability to recover the carrying values of the respective properties and recorded impairment charges to write these properties down to their estimated fair values during 2021. The four SHOPs were sold in the first quarter of 2022.
See Note 3 — Real Estate investments, Net - “Assets Held for Use and Related Impairments” for additional details.
Real Estate Investments — Held for Sale
Real estate investments held for sale are carried at net realizable value on a non-recurring basis and are generally classified in Level 3 of the fair value hierarchy. The Company did not have any real estate investments classified as held for sale as of December 31, 2022 and 2021.
Financial Instruments Not Measured at Fair Value
The Company is required to disclose the fair value of financial instruments for which it is practicable to estimate that value. The fair values of short-term financial instruments such as cash and cash equivalents, restricted cash, straight-line rent receivable, net, prepaid expenses and other assets, deferred costs, net, accounts payable and accrued expenses, deferred rent and distributions payable approximate their carrying value on the consolidated balance sheets due to their short-term nature.
The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:
December 31, 2022December 31, 2021
(In thousands)Level
Carrying Amount 
Fair Value
Carrying Amount 
Fair Value
Gross mortgage notes payable and mortgage
premium and discounts, net
3$583,817 $550,626 $590,425 $594,348 
Credit Facility
3$180,000 $179,496 $150,000 $148,817 
Fannie Mae Master Credit Facilities
3$352,047 $353,034 $355,045 $350,710 
The fair value of the mortgage notes payable is estimated using a discounted cash flow analysis, based on the Advisor’s experience with similar types of borrowing arrangements, excluding the value of derivatives.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Derivatives and Hedging Activities
12 Months Ended
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivatives and Hedging Activities Derivatives and Hedging Activities
Risk Management Objective of Using Derivatives
The Company may use derivative financial instruments, including interest rate swaps, caps, collars, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings.
The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. Additionally, in using interest rate derivatives, the Company aims to add stability to interest expense and to manage its exposure to interest rate movements. The Company does not intend to utilize derivatives for speculative purposes or purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company, and its affiliates, may also have other financial relationships. The Company does not anticipate that any of its counterparties will fail to meet their obligations.
    The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of December 31, 2022 and 2021:
December 31,
(In thousands)Balance Sheet Location20222021
Derivatives designated as hedging instruments:
Interest rate “pay-fixed” swapsDerivative assets, at fair value$36,910 $— 
Interest rate “pay-fixed” swapsDerivative liabilities, at fair value$— $13,903 
Derivatives not designated as hedging instruments:
Interest rate capsDerivative assets, at fair value$3,737 $174 
Cash Flow Hedges of Interest Rate Risk
The Company currently has nine interest rate swaps that are designated as cash flow hedges. The interest rate swaps are used as part of the Company’s interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. During the years ended December 31, 2022 and 2021, such derivatives were used to hedge the variable cash flows associated with variable-rate debt. The interest rate “pay-fixed” swaps have base interest rates between 1.39% and 2.32% with expirations varying through December 2026.
The changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive (loss) income and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings.
In connection with the refinancing of the $250.0 million loan made by Capital One, National Association and certain other lenders to certain subsidiaries of the OP on June 30, 2017 (the “MOB Loan”), during the fourth quarter of 2019, the Company terminated two interest rate swaps with an aggregate notional amount of $250.0 million for a payment of approximately $2.2 million. Following these terminations, $2.2 million was recorded in AOCI and was being recorded as an adjustment to interest expense over the original term of the two terminated swaps and the MOB Loan prior to its refinancing. For the years ended December 31, 2022, 2021 and 2020, the Company reclassified $0.4 million, $0.9 million and $0.9 million, respectively, from AOCI as increases to interest expense. No amounts remained in AOCI related to these previously terminated swaps as of December 31, 2022.
During the year ended December 31, 2022, the Company converted $150.0 million of the “pay-fixed” swaps on its Credit Facility and $378.5 million of the “pay-fixed” swaps on its mortgages from LIBOR to SOFR.
Amounts reported in accumulated other comprehensive (loss) income related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. During the next 12 months, from January 1, 2023 through December 31, 2023, the Company estimates that $17.4 million will be reclassified from other comprehensive income as a decrease to interest expense relating to the “pay-fixed” swaps designated as derivatives.
As of December 31, 2022 and 2021, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:
December 31, 2022December 31, 2021
Interest Rate DerivativeNumber of InstrumentsNotional AmountNumber of InstrumentsNotional Amount
(In thousands)(In thousands)
SOFR-based interest rate “pay-fixed” swaps$528,500 — $— 
LIBOR-based interest rate “pay-fixed” swaps50,000 578,500 
Total interest rate “pay-fixed” swaps$578,500 $578,500 
The table below details the location in the financial statements of the loss recognized on interest rate derivatives designated as cash flow hedges for the periods ended December 31, 2022 and 2021:
Year Ended December 31,
(In thousands)202220212020
Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives$50,098 $14,322 $(40,614)
Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense$(1,153)$(11,010)$(7,999)
Total amount of interest expense presented in the
consolidated statements of operations and comprehensive loss
$51,740 $47,900 $51,519 
Non-Designated Derivatives
These derivatives are used to manage the Company’s exposure to interest rate movements, but the Company has not elected to apply hedge accounting. As of December 31, 2022, we have entered into seven LIBOR interest rate caps with a notional amount of $354.6 million (of which six caps were active as of December 31, 2022 and one has a forward start date as of April 2023) which limit 30-day LIBOR borrowings to 3.50% and have varying expiration dates through April 2024. Beginning in the fourth quarter of 2022, LIBOR exceeded 3.50% and the Company began receiving payments under these interest rate caps. While the Company does not apply hedge accounting for these interest rate caps, they are economically hedging the Capital One Facility and KeyBank Facility. Changes in the fair value of, and any cash received from, derivatives not designated as hedges under a qualifying hedging relationship are recorded directly to net income (loss) and are presented within gain (loss) on non-designated derivatives in our consolidated statements of operations and comprehensive loss. For the years ended December 31, 2022, 2021 and 2020, gain (loss) on non-designated derivatives were a gain of $3.8 million (including cash received of $0.3 million), a gain of $37,000 and a loss of $0.1 million, respectively.
The Company had the following outstanding interest rate derivatives that were not designated as a hedges in qualifying hedging relationships as of as of December 31, 2022 and 2021:
December 31, 2022December 31, 2021
Interest Rate DerivativesNumber of Instruments
Notional Amount (1)
Number of Instruments
Notional Amount (1)
(In thousands)(In thousands)
Interest rate caps (2)
$354,624 $355,175 
(1)Notional amount represents the currently active interest cap contract and excludes one and three inactive cap agreements (included in the instrument count) with aggregate notional amounts of $52.6 million and $140.8 million as of December 31, 2022 and 2021, respectively, which take effect upon the expiration of similar caps included above and effectively extend the term for the same notional amount.
(2)All of the Company’s interest rate cap agreements limit 30-day LIBOR to 3.50% with terms through April 2024. The actual 30-day LIBOR rates during the fourth quarter of 2022 exceeded the strike price rate of 3.50% and the Company is currently receiving payments under these agreements. Changes in the fair market value of these non-designated derivatives, as well as any cash received, are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive income.
Offsetting Derivatives
The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2022 and 2021. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheets.
Gross Amounts Not Offset in the Consolidated Balance Sheet
(In thousands)Gross Amounts of Recognized AssetsGross Amounts of Recognized (Liabilities)Gross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets presented in the Consolidated Balance SheetFinancial InstrumentsCash Collateral ReceivedNet Amount
December 31, 2022
$40,647 — — $40,647 — — $40,647 
December 31, 2021
$174 — — $174 — — $174 
December 31, 2021
$— (13,903)— $(13,903)— — $(13,903)
Credit-risk-related Contingent Features
The Company has agreements in place with each of its derivative counterparties that contain a provision where if the Company either defaults or is capable of being declared in default on any of its indebtedness, then the Company could also be declared in default on its derivative obligations.
As of December 31, 2022 there were no derivatives in a net liability position. The Company is not required to post any collateral related to these agreements and was not in breach of any agreement provisions.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Stockholders' Equity Stockholders’ Equity
Common Stock
As of December 31, 2022 and 2021, the Company had 105,080,531 and 99,281,754 shares of common stock outstanding, respectively, including unvested restricted shares, shares issued pursuant to the Company’s distribution reinvestment plan (“DRIP”), net of share repurchases, and shares issued as stock dividends since October 2020. Since October 2020, the Company has issued an aggregate of approximately 12.6 million shares in respect to the stock dividends. No other additional shares of common stock were issued during the years ended December 31, 2022 or 2021. References made to weighted-average shares and per-share amounts in the consolidated statements of operations and comprehensive income have been retroactively adjusted to reflect the cumulative increase in shares outstanding due to the stock dividends (including the January 2023 stock dividend), and are noted as such throughout the accompanying financial statements and notes. Any future issuances of stock dividends will also result in retroactive adjustments. See Note 1 — Organization for additional information.
On April 1, 2022, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2021, which was approved by the Board on March 28, 2022. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually unless the Company lists its common stock.
Tender Offers
On January 9, 2020, the Company announced a tender offer (the “2020 Tender Offer”) to purchase up to 200,000 shares of its common stock for cash at a purchase price equal to $8.50 per share with the proration period and withdrawal rights expiring February 7, 2020. The Company made the 2020 Tender Offer in response to an unsolicited offer to stockholders commenced on December 31, 2019. The 2020 Tender Offer expired in accordance with the terms on February 7, 2020. In accordance with the 2020 Tender Offer, the Company accepted for purchase 200,000 shares for a total cost of approximately $1.7 million, which was funded with available cash.
Share Repurchase Program
Under the Company’s share repurchase program (the “SRP”), as amended from time to time, qualifying stockholders are able to sell their shares to the Company in limited circumstances. The SRP permits investors to sell their shares back to the Company after they have held them for at least one year, subject to significant conditions and limitations. Repurchases of shares of the Company’s common stock, when requested, are at the sole discretion of the Board.
Under the SRP, subject to certain conditions, only repurchase requests made following the death or qualifying disability of stockholders that purchased shares of the Company’s common stock or received their shares from the Company (directly or indirectly) through one or more non-cash transactions are considered for repurchase. Additionally, pursuant to the SRP, the
repurchase price per share equals 100% of the Estimated Per-Share NAV in effect on the last day of the fiscal semester, or the six-month period ending June 30 or December 31.
On February 26, 2020, the Company repurchased 505,101 shares of common stock for approximately $8.8 million, at an average price per share of $17.50 pursuant to the SRP. The repurchases reflect all repurchase requests made in good order following the death or qualifying disability of stockholders during the period commencing July 1, 2019 up to and including December 31, 2019.
Pursuant to the SRP, repurchases were to be made in respect of requests made during the periods when the SRP was active during the active periods under the SRP during the six months ending June 30, 2020 - the period from January 1, 2020 to January 8, 2020 and the period from February 26, 2020 up to and including June 30, 2020 - no later than July 31, 2020.
On February 26, 2020, the Company repurchased 505,101 shares of common stock for approximately $8.8 million, at an average price per share of $17.50 pursuant to the SRP. The repurchases reflect all repurchase requests made in good order following the death or qualifying disability of stockholders during the period commencing July 1, 2019 up to and including December 31, 2019.
Pursuant to the SRP, repurchases were to be made in respect of requests made during the periods when the SRP was active during the active periods under the SRP during the six months ending June 30, 2020 - the period from January 1, 2020 to January 8, 2020 and the period from February 26, 2020 up to and including June 30, 2020 - no later than July 31, 2020.
On August 13, 2020, in order to strategically maintain the Company’s liquidity in light of the continued impact of COVID-19 pandemic and to comply with an amendment to the Credit Facility described in Note 5 — Credit Facilities, Net, which restricts the Company from repurchasing shares until no earlier than the Commencement Quarter (which has not yet occurred), the Board determined that, effective on August 14, 2020, repurchases under the SRP would be suspended. The Board also rejected all repurchase requests made during the period from January 1, 2020 until the effectiveness of the suspension of the SRP. No further repurchase requests under the SRP may be made unless and until the SRP is reactivated. No assurances can be made as to when or if the SRP will be reactivated.
When a stockholder requests redemption and redemption is approved by the Board, the Company will reclassify such obligation from equity to a liability based on the settlement value of the obligation. Shares repurchased under the SRP have the status of authorized but unissued shares.
The table below reflects the number of shares repurchased and the average price per share (retroactively adjusted for the Stock Dividends), under the SRP and does not include any repurchases under tender offers (see above), cumulatively through December 31, 2022:
Number of Shares RepurchasedAverage Price per Share
Cumulative repurchases as of December 31, 2021
4,896,620 $20.60 
Year ended December 31, 2022
— — 
Cumulative repurchases as of December 31, 2022
4,896,620 20.60 
Distribution Reinvestment Plan
Pursuant to the DRIP, stockholders may elect to reinvest distributions paid in cash by the Company into shares of common stock. No dealer manager fees or selling commissions are paid with respect to shares purchased under the DRIP. The shares purchased pursuant to the DRIP have the same rights and are treated in the same manner as all of the other shares of outstanding common stock. The Board may designate that certain cash or other distributions be excluded from reinvestment pursuant to the DRIP. The Company has the right to amend the DRIP or terminate the DRIP with ten days’ notice to participants. Shares issued under the DRIP are recorded as equity in the accompanying consolidated balance sheet in the period distributions are declared. During the years ended December 31, 2022 and 2021, the Company did not issue any shares of common stock pursuant to the DRIP. During the year ended December 31, 2020, the Company issued 0.9 million shares of common stock pursuant to the DRIP, generating aggregate proceeds of $14.6 million. Because shares of common stock are only offered and sold pursuant to the DRIP in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as the Company pays distributions in stock instead of cash.
Stockholder Rights Plan
In May 2020, the Company announced that the Board had approved a stockholder rights plan. In December 2020, the Company issued a dividend of one common share purchase right for each share of its common stock outstanding as authorized by its board of directors in its discretion.
Preferred Stock
The Company is authorized to issue up to 50,000,000 shares of preferred stock. In connection with an underwritten offering in December 2019 (see details below), the Company classified and designated 1,610,000 shares of its authorized preferred stock as authorized shares of its Series A Preferred Stock as of December 31, 2022. In September 2020, the Board authorized the classification of 600,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the Preferred Stock Equity Line (as defined below) and in May 2021, the Board authorized the classification of 2,530,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the offering in May 2021 (described below). The Company had 3,977,144 shares of Series A Preferred Stock issued and outstanding, as of December 31, 2022 and 2021.
In connection with an underwritten offering in October 2021, the Company classified and designated 3,680,000 shares of its authorized preferred stock on October 4, 2021 as authorized shares of its 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (“Series B Preferred Stock”). As a result of an underwritten offering in October 2021, the Company had 3,630,000 shares of Series B Preferred Stock issued and outstanding as of December 31, 2022 and 2021.
Series A Preferred Stock
Series A Preferred Stock — Terms
Holders of Series A Preferred Stock are entitled to cumulative dividends in the amount of $1.84375 per share each year, which is equivalent to the rate of 7.375% of the $25.00 liquidation preference per share per annum. The Series A Preferred Stock has no stated maturity and will remain outstanding indefinitely unless redeemed, converted or otherwise repurchased. On and after December 11, 2024, at any time and from time to time, the Series A Preferred Stock will be redeemable in whole or in part, at the Company’s option, at a cash redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. In addition, upon the occurrence of a Delisting Event or a Change of Control (each as defined in the articles supplementary governing the terms of the Series A Preferred Stock (the “Series A Articles Supplementary”)), the Company may, subject to certain conditions, at its option, redeem the Series A Preferred Stock, in whole or in part, after the first date on which the Delisting Event occurred or within 120 days after the first date on which the Change of Control occurred, as applicable, by paying the liquidation preference of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. Upon the occurrence of a Change of Control during a continuing Delisting Event, unless the Company has elected to exercise its redemption right, holders of the Series A Preferred Stock will have certain rights to convert Series A Preferred Stock into shares of Company’s common stock. In addition, upon the occurrence of a Delisting Event, the dividend rate will be increased on the day after the occurrence of the Delisting Event by 2.00% per annum to the rate of 9.375% of the $25.00 liquidation preference per share per annum (equivalent to $2.34375 per share each year) from and after the date of the Delisting Event. Following the cure of such Delisting Event, the dividend rate will revert to the rate of 7.375% of the $25.00 liquidation preference per share per annum. The necessary conditions to convert the Series A Preferred Stock into common stock have not been met as of December 31, 2022. Therefore, Series A Preferred Stock did not impact Company’s earnings per share calculations for the year ended December 31, 2022, 2021 and 2020.
The Series A Preferred Stock ranks senior to common stock, with respect to dividend rights and rights upon the Company’s voluntary or involuntary liquidation, dissolution or winding up.
Voting rights for holders of Series A Preferred Stock exist primarily with respect to the ability to elect two additional directors to the board of directors if six or more quarterly dividends (whether or not authorized or declared or consecutive) payable on the Series A Preferred Stock are in arrears, and with respect to voting on amendments to the Company’s charter (which includes the Series A Articles Supplementary) that materially and adversely affect the rights of the Series A Preferred Stock or create additional classes or series of shares of the Company’s capital stock that are senior to the Series A Preferred Stock. Other than the limited circumstances described above and in the Series A Articles Supplementary, holders of Series A Preferred Stock do not have any voting rights.
Series A Preferred Stock Add-On Offering
On May 11, 2021, the Company completed an underwritten public offering of 2,352,144 shares (which includes 152,144 shares issued and sold pursuant to the underwriters’ exercise of their option to purchase additional shares) of its Series A Preferred Stock for net proceeds of $56.0 million after deducting the underwriters’ discount, structuring fee and other offering costs aggregating to $2.9 million. Pursuant to the terms of the Credit Facility, all proceeds were used to repay amounts outstanding under the Credit Facility.
Series A Preferred Units
In September 2021, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 100,000 partnership units in the OP designated as “Series A Preferred Units”. These were recorded at fair value on the date of the acquisition at $2.6 million and were included as part of the consideration paid for the acquisition. Additionally, these are considered a non-controlling interest for the Company and were recorded as an increase in non-controlling interests on the consolidated balance sheet (see Note 13 — Non-controlling Interests for additional information).
Preferred Stock Equity Line with B. Riley Principal Capital, LLC
On September 15, 2020, the Company entered into a preferred stock purchase agreement and registration rights agreement with B. Riley Principal Capital, LLC (“B. Riley”), pursuant to which the Company has the right from time to time to sell up to an aggregate of $15 million of shares of its Series A Preferred Stock to B. Riley until December 31, 2023, on the terms and subject to the conditions set forth in the purchase agreement. This arrangement is also referred to as the “Preferred Stock Equity Line.” The Company controls the timing and amount of any sales to B. Riley under the Preferred Stock Equity Line, and B. Riley is obligated to make purchases of up to 3,500 shares of Series A Preferred Stock each time (as may be increased by mutual agreement by the parties) in accordance with the purchase agreement, upon certain terms and conditions being met. The Company sold 15,000 shares under the Preferred Stock Equity Line during the year ended December 31, 2021, resulting in gross proceeds of $0.4 million and net proceeds of $0.3 million after fees and commissions.
In total, the Company incurred $1.2 million in costs related to establishing the Preferred Stock Equity Line which were all initially recorded in prepaid expenses and other assets on our consolidated balance sheet. Upon receiving proceeds under the Preferred Stock Equity Line in the third quarter of 2021, the Company reclassified $30,000 of these prepaid costs to additional paid in capital in the Company’s consolidated statement of changes in equity as a reduction of the gross proceeds received under the Preferred Stock Equity Line.
In the fourth quarter of 2021, the Company determined that it was not probable that additional proceeds would be received from the Preferred Stock Equity Line and later terminated the Preferred Stock Equity Line. As a result, the Company expensed the remaining balance of prepaid costs, which totaled $1.2 million, within acquisition and transaction related costs on the consolidated statement of operations and comprehensive income during the year ended December 31, 2021.
The Company did not sell any Series A Preferred Stock under the Preferred Stock Equity Line during the year ended December 31, 2020 or through its termination in the year ended December 31, 2021.
Series B Preferred Stock
Series B Preferred Stock — Terms
Holders of Series B Preferred Stock are entitled to cumulative dividends in the amount of $1.78125 per share each year, which is equivalent to the rate of 7.125% of the $25.00 liquidation preference per share per annum. The Series B Preferred Stock has no stated maturity and will remain outstanding indefinitely unless redeemed, converted or otherwise repurchased. On and after October 6, 2026, at any time and from time to time, the Series B Preferred Stock will be redeemable in whole or in part, at the Company’s option, at a cash redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. In addition, upon the occurrence of a Delisting Event or a Change of Control (each as defined in the articles supplementary governing the terms of the Series B Preferred Stock (the “Series B Articles Supplementary”)), the Company may, subject to certain conditions, at its option, redeem the Series B Preferred Stock, in whole or in part, after the first date on which the Delisting Event occurred or within 120 days after the first date on which the Change of Control occurred, as applicable, by paying the liquidation preference of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. Upon the occurrence of a Change of Control during a continuing Delisting Event, unless the Company has elected to exercise its redemption right, holders of the Series B Preferred Stock will have certain rights to convert Series B Preferred Stock into shares of Company’s common stock. In addition, upon the occurrence of a Delisting Event, the dividend rate will be increased on the day after the occurrence of the Delisting Event by 2.00% per annum to the rate of 9.125% of the $25.00 liquidation preference per share per annum (equivalent to $2.28125 per share each year) from and after
the date of the Delisting Event. Following the cure of such Delisting Event, the dividend rate will revert to the rate of 7.125% of the $25.00 liquidation preference per share per annum. The necessary conditions to convert the Series B Preferred Stock into common stock have not been met as of December 31, 2022. Therefore, Series B Preferred Stock did not impact Company’s earnings per share calculations for the year ended December 31, 2022 and 2021.
The Series B Preferred Stock ranks on parity with the Company’s Series A Preferred Stock, and senior to its common stock, with respect to dividend rights and rights upon the Company’s voluntary or involuntary liquidation, dissolution or winding up.
Voting rights for holders of Series B Preferred Stock exist primarily with respect to the ability to elect two additional directors to the board of directors if six or more quarterly dividends (whether or not authorized or declared or consecutive) payable on the Series B Preferred Stock are in arrears, and with respect to voting on amendments to the Company’s charter (which includes the Series B Articles Supplementary) that materially and adversely affect the rights of the Series B Preferred Stock or create additional classes or series of shares of the Company’s capital stock that are senior to the Series B Preferred Stock. Other than the limited circumstances described above and in the Series B Articles Supplementary, holders of Series B Preferred Stock do not have any voting rights.
Underwritten Offering — Series B Preferred Stock
On October 6, 2021, the Company completed the initial issuance and sale of 3,630,000 shares (which includes 430,000 shares issued and sold pursuant to the underwriters’ exercise of their option to purchase additional shares) of its 7.125% Series B Preferred Stock in an underwritten public offering at a public offering price equal to the liquidation preference of $25.00 per share. The offering generated gross proceeds of $90.8 million and net proceeds of $86.8 million, after deducting underwriting discounts, structuring fees and other costs.
Pursuant to the terms of the Credit Facility, all proceeds were used to repay amounts outstanding under the Credit Facility. Subject to the terms and conditions set forth in the Credit Facility, the Company may then draw on the Credit Facility to borrow any amounts so repaid.
Distributions and Dividends
Common Stock
In April 2013, the Board authorized, and the Company began paying distributions on a monthly basis at a rate equivalent to $1.70 per annum, per share of common stock, which began in May 2013. In March 2017, the Board authorized a decrease in the rate at which the Company pays monthly distributions to stockholders, effective as of April 1, 2017, to a rate equivalent to $1.45 per annum per share of common stock. On February 20, 2018, the Board authorized a further decrease in the rate at which the Company pays monthly distributions to stockholders, effective as of March 1, 2018, to a rate equivalent to $0.85 per annum per share of common stock.
From March 1, 2018 until June 30, 2020, the Company paid monthly distributions to stockholders at a rate equivalent to $0.85 per annum per share of common stock. Distributions were payable by the 5th day following each month end to stockholders of record at the close of business each day during the prior month.
On August 13, 2020, the Board changed the Company’s common stock distribution policy in order to preserve the Company’s liquidity and maintain additional financial flexibility in light of the continued COVID-19 pandemic and to comply with an amendment to the Credit Facility (see Note 5 — Credit Facility, Net for additional information) which restricts the Company from paying distributions on common stock until no earlier than the quarter ending June 30, 2021. Under the new policy, distributions authorized by the Board on the Company’s shares of common stock, if and when declared, are now paid on a quarterly basis in arrears in shares of the Company’s common stock valued at the Company’s estimated per share net asset value of common stock in effect on the applicable date, based on a single record date to be specified at the beginning of each quarter. The following table details these stock dividends:
Stock Dividend Declaration DateStock Dividend Issue DateQuarterly Stock Dividend Rate (per share)
October 1, 2020October 15, 20200.013492
January 4, 2021January 15, 20210.013492
April 2, 2021April 15, 20210.014655
July 1, 2021July 15, 20210.014655
October 1, 2021October 15, 20210.014655
January 3, 2022January 15, 20220.014655
April 1, 2022April 18, 20220.014167
July 1, 2022July 15, 20220.014167
October 3, 2022October 17, 20220.014167
January 3, 2023January 18, 20230.014167
Tax Characteristics of Dividends
The following table details from a tax perspective the portion of distributions classified as a return of capital, capital gain dividend income and ordinary dividend income, per share per annum, for the year ended December 31, 2020. All common dividends in the years ended December 31, 2022 and 2021, and a portion of common dividends issued in the year ended December 31, 2020, were issued as stock dividends, which do not represent taxable dividends to shareholders for U.S. federal income tax purposes. The cash distributions paid to holders of common stock in the first half of the year ended December 31, 2020 were considered 100% return of capital. All dividends paid on the Series A Preferred Stock and Series B Preferred Stock were considered 100% return of capital for tax purposes for the years ended December 31, 2022, 2021 and 2020.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions and Arrangements
12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
Related Party Transactions and Arrangements Related Party Transactions and Arrangements
As of December 31, 2022 and 2021, the Special Limited Partner owned 10,094 and 9,537 shares, respectively, of the Company’s outstanding common stock. The Advisor and its affiliates may incur and pay costs and fees on behalf of the Company. As of December 31, 2022 and 2021, the Advisor held 90 partnership units in the OP designated as “Common OP Units.”
The limited partnership agreement of the OP (as amended from time to time, the “LPA”) allows for the special allocation, solely for tax purposes, of excess depreciation deductions of up to $10.0 million to the Advisor, a limited partner of the OP. In connection with this special allocation, the Advisor has agreed to restore a deficit balance in its capital account in the event of a liquidation of the OP and has agreed to provide a guaranty or indemnity of indebtedness of the OP.
Fees Incurred in Connection with the Operations of the Company
The Second Amended and Restated Advisory Agreement by and among the Company, the OP and the Advisor (as amended, the “Second A&R Advisory Agreement”) took effect on February 17, 2017, and is automatically renewable for another ten-year term upon each ten-year anniversary unless the Second A&R Advisory Agreement is terminated (i) with notice of an election not to renew at least 365 days prior to the applicable tenth anniversary, (ii) in accordance with a change of control (as defined in the Second A&R Advisory Agreement) or a transition to self-management, (iii) by 67% of the independent directors of the Board for cause, without penalty, with 45 days’ notice or (iv) with 60 days prior written notice by the Advisor for (a) a failure to obtain a satisfactory agreement for any successor to the Company to assume and agree to perform obligations under the Second A&R Advisory Agreement or (b) any material breach of the Second A&R Advisory Agreement of any nature whatsoever by the Company.
On July 25, 2019, the Company entered into Amendment No. 1 to the Second A&R Advisory Agreement (the “Advisory Agreement Amendment”) among the Company, the OP, and the Advisor. The Advisory Agreement Amendment was unanimously approved by the Company’s independent directors. Additional information on the Advisory Agreement Amendment is included later in this footnote under “Professional Fees and Other Reimbursements.”
Acquisition Expense Reimbursements
The Advisor may be reimbursed for services provided for which it incurs investment-related expenses, or insourced expenses. The amount reimbursed for insourced expenses may not exceed 0.5% of the contract purchase price of each acquired property or 0.5% of the amount advanced for a loan or other investment. Additionally, the Company reimburses the Advisor for
third party acquisition expenses. Under the Second A&R Advisory Agreement, total acquisition expenses may not exceed 4.5% of the contract purchase price of the Company’s portfolio or 4.5% of the amount advanced for all loans or other investments. This threshold has not been exceeded through December 31, 2022.
Asset Management Fees and Variable Management/Incentive Fees
Under the LPA and the advisory agreement that was superseded by the 0riginal amended and restated advisory agreement and until March 31, 2015, for its asset management services, the Company issued the Advisor an asset management subordinated participation by causing the OP to issue (subject to periodic approval by the Board) to the Advisor partnership units of the OP designated as “Class B Units” (“Class B Units”). The Class B Units were intended to be profit interests and vest, and no longer are subject to forfeiture, at such time as: (x) the value of the OP’s assets plus all distributions made equals or exceeds the total amount of capital contributed by investors plus a 6.0% cumulative, pre-tax, non-compounded annual return thereon (the “Economic Hurdle”); (y) any one of the following occurs: (1) a listing; (2) another liquidity event or (3) the termination of the advisory agreement by an affirmative vote of a majority of the Company’s independent directors without cause; and (z) the Advisor is still providing advisory services to the Company (the “Performance Condition”).
Unvested Class B Units will be forfeited immediately if: (a) the advisory agreement is terminated for any reason other than a termination without cause; or (b) the advisory agreement is terminated by an affirmative vote of a majority of the Company’s independent directors without cause before the Economic Hurdle has been met.
Subject to approval by the Board, the Class B Units were issued to the Advisor quarterly in arrears pursuant to the terms of the LPA. The number of Class B Units issued in any quarter was equal to: (i) the excess of (A) the product of (y) the cost of assets multiplied by (z) 0.1875% over (B) any amounts payable as an oversight fee (as described below) for such calendar quarter; divided by (ii) the value of one share of common stock as of the last day of such calendar quarter, which was initially equal to $22.50 (the price in the Company’s initial public offering of common stock minus the selling commissions and dealer manager fees). The value of issued Class B Units will be determined and expensed when the Company deems the achievement of the Performance Condition to be probable. As of December 31, 2022, the Company determined that achieving the Performance Condition was not yet considered probable for accounting purposes. The Advisor receives cash distributions on each issued Class B Unit equivalent to the cash distribution paid, if any on the Company’s common stock. These cash distributions on Class B Units are included in general and administrative expenses in the consolidated statement of operations and comprehensive loss until the Performance Condition is considered probable to occur. Stock Dividends do not cause the OP to issue additional Class OP Units, rather, the redemption ratio to common stock is adjusted. The Board has previously approved the issuance of 359,250 Class B Units to the Advisor in connection with this arrangement. The Board determined in February 2018 that Economic Hurdle had been satisfied, however none of the events have occurred, including a listing of the Company’s common stock on a national securities exchange, which would have satisfied the other vesting requirement of the Class B Units. Therefore, no expense has ever been recognized in connection with the Class B Units.
On May 12, 2015, the Company, the OP and the Advisor entered into an amendment to the then-current advisory agreement, which, among other things, provided that the Company would cease causing the OP to issue Class B Units to the Advisor with respect to any period ending after March 31, 2015.
Effective February 17, 2017, the Second A&R Advisory Agreement requires the Company to pay the Advisor a base management fee, which is payable on the first business day of each month. The fixed portion of the base management fee is equal to $1.625 million per month, while the variable portion of the base management fee is equal to one-twelfth of 1.25% of the cumulative net proceeds of any equity (including convertible equity and certain convertible debt but excluding proceeds from the DRIP) issued by the Company and its subsidiaries subsequent to February 17, 2017 per month. There are no variable management fees earned from the issuance of common stock dividends. The base management fee is payable to the Advisor or its assignees in cash, Common OP Units or shares, or a combination thereof, the form of payment to be determined at the discretion of the Advisor and the value of any Common OP Unit or share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate.
In addition, the Second A&R Advisory Agreement requires the Company to pay the Advisor a variable management/incentive fee quarterly in arrears equal to (1) the product of fully diluted shares common stock outstanding multiplied by (2) (x) 15.0% of the applicable prior quarter’s Core Earnings (as defined below) per share in excess of $0.375 per share plus (y) 10.0% of the applicable prior quarter’s Core Earnings per share in excess of $0.47 per share. Core Earnings is defined as, for the applicable period, net income or loss, computed in accordance with GAAP, excluding non-cash equity compensation expense, the variable management/incentive fee, acquisition and transaction related fees and expenses, financing related fees and expenses, depreciation and amortization, realized gains and losses on the sale of assets, any unrealized gains or losses or other non-cash items recorded in net income or loss for the applicable period, regardless of whether such items are included in
other comprehensive income or loss, or in net income, one-time events pursuant to changes in GAAP and certain non-cash charges, impairment losses on real estate related investments and other than temporary impairments of securities, amortization of deferred financing costs, amortization of tenant inducements, amortization of straight-line rent and any associated bad debt reserves, amortization of market lease intangibles, provision for loss loans, and other non-recurring revenue and expenses (in each case after discussions between the Advisor and the independent directors and approved by a majority of the independent directors). The variable management/incentive fee is payable to the Advisor or its assignees in cash or shares, or a combination of both, the form of payment to be determined in the sole discretion of the Advisor and the value of any share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate. No variable management incentive fee was incurred for the years ended December 31, 2022, 2021 and 2020.
Property Management Fees
Unless the Company contracts with a third party, the Company pays the Property Manager a property management fee on a monthly basis, equal to 1.5% of gross revenues from the Company’s stand-alone single-tenant net leased properties managed and 2.5% of gross revenues from all other types of properties managed, plus market-based leasing commissions applicable to the geographic location of the property. The Company also reimburses the Property Manager for property level expenses incurred by the Property Manager. The Property Manager may charge a separate fee for the one-time initial rent-up or leasing-up of newly constructed properties in an amount not to exceed the fee customarily charged in arm’s length transactions by others rendering similar services in the same geographic area for similar properties, and the Property Manager is allowed to receive a higher property management fee in certain cases if approved by the Company’s Board of Directors (including a majority of the independent directors).
If the Company contracts directly with third parties for such services, the Company will pay the third party customary market fees and will pay the Property Manager an oversight fee of 1.0% of the gross revenues of the property managed by the third party. In no event will the Company pay the Property Manager or any affiliate of the Property Manager both a property management fee and an oversight fee with respect to any particular property. If the Property Manager provides services other than those specified in the Property Management Agreement, the Company will pay the Property Manager a monthly fee equal to no more than that which the Company would pay to a third party that is not an affiliate of the Company or the Property Manager to provide the services.
On February 17, 2017, the Company entered into the Amended and Restated Property Management and Leasing Agreement (the “A&R Property Management Agreement”) with the OP and the Property Manager. The A&R Property Management Agreement automatically renews for successive one-year terms unless any party provides written notice of its intention to terminate the A&R Property Management Agreement at least 90 days prior to the end of the term. Neither party has provided notice of intent to terminate. The current term of the A&R Property Management Agreement expires February 17, 2023. The Property Manager may assign the A&R Property Management Agreement to any party with expertise in commercial real estate which has, together with its affiliates, over $100.0 million in assets under management.
On April 10, 2018, in connection with the Multi-Property CMBS Loan, the Company and the OP entered into a further amendment to the A&R Property Management Agreement confirming, consistent with the intent of the parties, that the borrowers under the Multi-Property CMBS Loan and other subsidiaries of the OP that own or lease the Company’s properties are the direct obligors under the arrangements pursuant to which the Company’s properties are managed by either the Property Manager or a third party overseen by the Property Manager pursuant to the A&R Property Management Agreement. See the Mortgage Notes Payable table included in Note 4 — Mortgage Notes Payable, Net for additional information on the Multi- Property CMBS Loan.
Professional Fees and Other Reimbursements
The Company reimburses the Advisor’s costs of providing administrative services including personnel costs, except for costs to the extent that the employees perform services for which the Advisor receives a separate fee. This reimbursement includes reasonable overhead expenses for employees of the Advisor or its affiliates directly involved in the performance of services on behalf of the Company, including the reimbursement of rent expense at certain properties that are both occupied by employees of the Advisor or its affiliates and owned by affiliates of the Advisor. During the year ended December 31, 2022, 2021 and 2020, the Company incurred $8.8 million, $9.4 million and $12.1 million, respectively, of reimbursement expenses from the Advisor for providing administrative services. These reimbursement expenses are included in general and administrative expense on the consolidated statements of operations and comprehensive income (loss). In September 2022, the Advisor terminated certain of its employees who provided services to the Company and for which the Company reimbursed the
Advisor for salaries and benefits. In connection with the termination, the Company recognized a compensation charge, net of adjustments for previously accrued bonuses, of $0.3 million in the third quarter of 2022.
On July 25, 2019, the Company entered into the Advisory Agreement Amendment. Under the Advisory Agreement Amendment, including prior to the Advisory Agreement Amendment, the Company has been required to reimburse the Advisor for, among other things, reasonable salaries and wages, benefits and overhead of all employees of the Advisor or its affiliates, except for costs of employees to the extent that the employees perform services for which the Advisor receives a separate fee.
The Advisory Agreement Amendment clarifies that, with respect to executive officers of the Advisor, the Company is required to reimburse the Advisor or its affiliates for the reasonable salaries and wages, benefits and overhead of the Company’s executive officers, other than for any executive officer that is also a partner, member or equity owner of AR Global, an affiliate of the Advisor.
Further, under the Advisory Agreement Amendment, the aggregate amount of expenses relating to salaries, wages and benefits, including for executive officers and all other employees of the Advisor or its affiliates (the “Capped Reimbursement Amount”), is limited to the greater of: (a) a fixed component (the “Fixed Component”) and (b) a variable component (the “Variable Component”).
Both the Fixed Component and the Variable Component increase by an annual cost of living adjustment equal to the greater of (x) 3.0% and (y) the CPI, as defined in the Advisory Agreement Amendment for the prior year ended December 31st. Initially, for the year ended December 31, 2020; (a) the Fixed Component was equal to $6.8 million and (b) the Variable Component was equal to (i) the sum of the total real estate investments, at cost as recorded on the balance sheet dated as of the last day of each fiscal quarter (the “Real Estate Cost”) in the year divided by four, which amount is then (ii) multiplied by 0.29%.
If the Company sells real estate investments aggregating an amount equal to or more than 25.0% of Real Estate Cost, in one or a series of related dispositions in which the proceeds of the disposition(s) are not reinvested in Investments (as defined in the Advisory Agreement Amendment), then within 12 months following the disposition(s), the Advisory Agreement Amendment requires the Advisor and the Company to negotiate in good faith to reset the Fixed Component; provided that if the proceeds of the disposition(s) are paid to shareholders of the Company as a special distribution or used to repay loans with no intent of subsequently re-financing and re-investing the proceeds thereof in Investments, the Advisory Agreement amendment requires these negotiations within 90 days thereof, in each case taking into account reasonable projections of reimbursable costs in light of the Company’s reduced assets.
The Company paid approximately $2.5 million in 2019 to the Advisor or its affiliates as reimbursement for bonuses of employees of the Advisor or its affiliates who provided administrative services during the calendar year 2019, prorated for the time spent working on matters relating to the Company. The Company does not reimburse the Advisor or its affiliates for any bonus amounts relating to time dedicated to the Company by Edward M. Weil, Jr., the Company’s Chief Executive Officer. The Advisor formally awarded 2019 bonuses to employees of the Advisor or its affiliates in September 2020 (the “2019 Bonus Awards”). The original estimate for bonuses recorded and paid to the Advisor in 2019 exceeded the cash portion of the 2019 Bonus Awards to be paid to employees of the Advisor or its affiliates and to be reimbursed by the Company by $1.2 million. As a result, during the three months ended September 30, 2020, the Company recorded a receivable from the Advisor of $1.2 million in prepaid expenses and other assets on the consolidated balance sheet and a corresponding reduction in general and administrative expenses. Pursuant to authorization by the independent members of the Company’s board of directors, the $1.2 million receivable was being paid back to the Company over a 10-month period from January 2021 through October 2021. As of December 31, 2021, all of this amount had been repaid by the Advisor.
During the second quarter of 2021, the Advisor finalized the amounts and form of the 2020 bonuses previously estimated (the “2020 Bonus Awards”) to be paid to the employees of the Advisor or its affiliates who provided administrative services during such calendar year, prorated for the time spent working on matters relating to the Company. The 2020 Bonus Awards are being paid by the Advisor over a ten-month period from June 2021 to April 2022. The final amounts exceeded the amounts previously paid by the Company to the Advisor for estimated 2020 bonuses by approximately $1.0 million for the following reasons (i) forfeitures of bonuses related to employees of the Advisor or its affiliates who were terminated or resigned prior to payment (including the Company’s former chief financial officer) and (ii) a general reduction in final bonuses for remaining personnel due to on-going negative impacts of the COVID-19 pandemic. As a result, during the second quarter of 2021, the Company recorded a receivable from the Advisor of $1.0 million, which is recorded in prepaid expenses and other assets on the consolidated balance sheet and a corresponding reduction in general administrative expenses. Pursuant to authorization by the independent members of the Company’s board of directors, the $1.0 million receivable is required to be repaid to the Company
on a pro rata basis over a six-month period from November 2021 through April 2022. As of December 31, 2022, the entire amount has been repaid by the Advisor.
Reimbursements for the cash portion of 2021 bonuses paid by the Advisor to employees of the Advisor or its affiliates were expensed and reimbursed on a monthly basis during 2021, and 2022 bonuses were expensed and reimbursed on a monthly basis during 2022 in accordance with estimates provided by the Advisor. Generally, prior to the 2019 Bonus Awards, employee bonuses have been formally awarded to employees of the Advisor or its affiliates in March as an all - cash award and paid out by the Advisor in the year subsequent to the year in which services were rendered to the Company.
In December 2020, after mediation on October 27, 2020, the Advisor agreed to a settlement with the Company’s former chief executive officer for severance claims related to his termination in 2018. Pursuant to the settlement, among other parties, the Advisor advised the Company that the Company and its directors and officers were released from any and all actions or claims the former chief executive officer now has or may ever have against them. Prior to the agreement, the Advisor did not believe any settlement was probable. In consideration of the release, among other things, and upon the recommendation of its nominating and corporate governance committee, which determined that the reimbursement was advisable and fair to, and in the best interest of, the Company, the Company’s board of directors approved the reimbursement by the Company to the Advisor of severance payments and legal costs relating to this settlement and determined that the reimbursement for those payments and costs would not be subject to (and therefore would not be aggregated with other reimbursements that are subject to) the Capped Reimbursement Amount. The Company recorded approximately $2.2 million of expenses for the reimbursement which is included in general and administrative expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.
Summary of fees, expenses and related payables
The following table details amounts incurred and payable in connection with the Company’s operations-related services described above as of and for the periods presented:
Year Ended December 31,Payable (Receivable) as of
 202220212020December 31,
(In thousands)
Incurred
Incurred
Incurred20222021
One-time fees and reimbursements:
Acquisition cost reimbursements$23 $90 $81 $$23 
Ongoing fees and reimbursements:
Asset management fees 21,831 20,710 19,987 — — 
Property management fees (4)
4,200 3,749 4,197 24 
Professional fees and other reimbursements (1) (3)
8,820 

9,386 12,102 39 (70)
Professional fees credit due from Advisor— (1,030)(1,217)— (859)(2)
Distributions on Class B Units — — 178 — — 
Total related party operation fees and reimbursements$34,874 $32,905 $35,328 $47 $(882)
_________
(1)Included in general and administrative expenses in the consolidated statements of operations. Includes $6.0 million, $6.2 million and $5.6 million subject to the Capped Reimbursement Amount for the years ended December 31, 2022, 2021 and 2020, respectively.
(2)Balance as of December 31, 2021 includes a receivable of $0.9 million from the Advisor related to the overpayment of 2020 Bonus Awards, which, pursuant to authorization by the independent members of the Company’s board of directors, was required to be repaid to the Company on a pro rata basis over a six-month period from November 2021 through April 2022.
(3)During the year ended December 31, 2020 the Company recorded approximately $2.2 million of expense reimbursements to the Advisor for severance payments and related legal costs relating to the termination of its former Chief Executive Officer.
(4)Inclusive of $0.7 million and $0.3 million of leasing commissions which are included in prepaid expenses and other assets on the consolidated balance sheet as of December 31, 2022 and 2021.
Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company’s Real Estate Assets
Fees Incurred in Connection with a Listing
If the common stock of the Company is listed on a national exchange, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive a subordinated incentive listing distribution from the OP equal to 15.0% of the amount by which the market value of all issued and outstanding shares of common stock plus distributions
exceeds the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax non-compounded annual return to investors in the Company’s initial public offering of common stock. No such distribution was incurred during the years ended December 31, 2022, 2021 and 2020. If the Special Limited Partner or any of its affiliates receives the subordinated incentive listing distribution the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive termination distribution described below.
Subordinated Participation in Net Sales Proceeds
Upon a liquidation or sale of all or substantially all of the Company’s assets, including through a merger or sale of stock, the Special Limited Partner will be entitled to receive a subordinated participation in the net sales proceeds of the sale of real estate assets from the OP equal to 15.0% of remaining net sale proceeds after return of capital contributions to investors in the Company’s initial public offering of common stock plus payment to investors of a 6.0% cumulative, pre-tax non-compounded annual return on the capital contributed by investors. No such participation in net sales proceeds became due and payable during the years ended December 31, 2022, 2021 and 2020. Any amount of net sales proceeds paid to the Special Limited Partner or any of its affiliates prior to the Company’s listing or termination or non-renewal of the advisory agreement with the Advisor, as applicable, will reduce dollar for dollar the amount of the subordinated incentive listing distribution described above and subordinated incentive termination distribution described below.
Termination Fees
Under the operating partnership agreement of the OP, upon termination or non-renewal of the advisory agreement with the Advisor, with or without cause, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive subordinated termination distributions from the OP equal to 15.0% of the amount by which the sum of the Company’s market value plus distributions exceeds the sum of the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax, non-compounded annual return to investors in the Company’s initial public offering of common stock. The Special Limited Partner is able to elect to defer its right to receive a subordinated distribution upon termination until either a listing on a national securities exchange or other liquidity event occurs. If the Special Limited Partner or any of its affiliates receives the subordinated incentive termination distribution, the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive listing distribution described above.
Under the Advisory Agreement Amendment, upon the termination or non-renewal of the agreement, the Advisor is entitled to receive from the Company all amounts due to the Advisor, including any change of control fee and transition fee (both described below), as well as the then-present fair market value of the Advisor’s interest in the Company. All fees will be due within 30 days after the effective date of the termination of the Advisory Agreement Amendment.
Upon a termination by either party in connection with a change of control (as defined in the Advisory Agreement Amendment), the Company would be required to pay the Advisor a change of control fee equal to the product of four and the “Subject Fees” described below.
Upon a termination by the Company in connection with a transition to self-management, the Company would be required to pay the Advisor a transition fee equal to (i) $15.0 million plus (ii) the product of four multiplied by the Subject Fees, provided that the transition fee shall not exceed an amount equal to 4.5 multiplied by the Subject Fees.
The Subject Fees are equal to (i) the product of four multiplied by the actual base management fee plus (ii) the product of four multiplied by the actual variable management/incentive fee, in each of clauses (i) and (ii), payable for the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated, plus (iii) without duplication, the annual increase in the base management fee resulting from the cumulative net proceeds of any equity raised (but excluding proceeds from the DRIP) in respect to the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Economic Dependency
12 Months Ended
Dec. 31, 2022
Economic Dependency [Abstract]  
Economic Dependency Economic Dependency
Under various agreements, the Company has engaged or will engage the Advisor, its affiliates and entities under common control with the Advisor to provide certain services that are essential to the Company, including asset management services, supervision of the management and leasing of properties owned by the Company and asset acquisition and disposition decisions, as well as other administrative responsibilities for the Company including accounting services and investor relations.
As a result of these relationships, the Company is dependent upon the Advisor and its affiliates. In the event that the Advisor and its affiliates are unable to provide the Company with the respective services, the Company will be required to find alternative providers of these services.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Equity-Based Compensation
12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Equity-Based Compensation Equity-Based Compensation
Restricted Share Plan
The Company has adopted an employee and director incentive restricted share plan (as amended from time to time, the “RSP”), which provides the Company with the ability to grant awards of restricted shares of common stock (“restricted shares”) to the Company’s directors, officers and employees (if the Company ever has employees), employees of the Advisor and its affiliates, employees of entities that provide services to the Company, directors of the Advisor or of entities that provide services to the Company, certain consultants to the Company and the Advisor and its affiliates or to entities that provide services to the Company. The total number of shares of common stock that may be subject to awards granted under the RSP may not exceed 5.0% of the Company’s outstanding shares of common stock on a fully diluted basis at any time and in any event will not exceed 3.6 million shares (as such number may be further adjusted for stock splits, stock dividends, combinations and similar events).
Restricted shares vest on a straight-line basis over periods of three to five years and may not, in general, be sold or otherwise transferred until restrictions are removed and the shares have vested. Holders of restricted shares may receive cash distributions prior to the time that the restrictions on the restricted shares have lapsed. Any distributions payable in shares of common stock are subject to the same restrictions as the underlying restricted shares.
The following table reflects the amount of restricted shares outstanding as of December 31, 2022 and activity for the period presented:
Number of Common Shares Weighted-Average Issue Price
Unvested, December 31, 2019277,241 $21.18 
Stock dividend2,878 15.75 
Granted— — 
Vested(64,735)21.18 
Forfeitures— — 
Unvested, December 31, 2020
215,384 21.11 
Stock Dividend12,646 14.79 
Granted— 
Vested(68,603)19.72 
Forfeitures— — 
Unvested, December 31, 2021
159,427 21.21 
Stock dividend8,313 14.86 
Granted— — 
Vested(70,397)23.67 
Forfeitures— — 
Unvested, December 31, 2022
97,343 18.89 
As of December 31, 2022, the Company had $1.5 million of unrecognized compensation cost related to unvested restricted share awards granted under the RSP. That cost is expected to be recognized over a weighted-average period of 1.6 years. Compensation expense related to restricted shares was $1.2 million, $1.3 million and $1.3 million during the years ended December 31, 2022, 2021 and 2020, respectively.
Other Share-Based Compensation
The Company may issue common stock in lieu of cash to pay fees earned by the Company’s directors at the respective director’s election. There are no restrictions on shares issued in lieu of cash compensation since these payments in lieu of cash relate to fees earned for services performed. No such shares were issued during the years ended December 31, 2022, 2021 and 2020.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Accumulated Other Comprehensive Income (Loss)
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)
The following table illustrates the changes in accumulated other comprehensive income (loss) as of and for the periods presented:
(In thousands)Unrealized Gains (Losses) on Designated Derivative
Balance, December 31, 2019$(7,043)
Other comprehensive loss, before reclassifications(40,614)
Amount of loss reclassified from accumulated other comprehensive income (loss) 7,999 
Rebalancing of ownership percentage(15)
Balance, December 31, 2020
(39,673)
Other comprehensive income, before reclassifications14,322 
Amount of loss reclassified from accumulated other comprehensive income (loss)11,010 
Balance, December 31, 2021
(14,341)
Other comprehensive income, before reclassifications50,098 
Amount of loss reclassified from accumulated other comprehensive income (loss)1,153 
Balance, December 31, 2022
$36,910 

Accumulated other comprehensive income (loss) predominately relates to the unrealized gains (losses) on designated derivatives, however, as previously discussed in Note 7 — Derivatives and Hedging, a previously designated hedge was terminated and the termination costs are being amortized over the term of the hedged item. The unamortized portion of the terminated swap still remaining in accumulated other comprehensive (loss) income was $0.4 million as of December 31, 2021. The terminated swap was fully amortized within the year ending December 31, 2022.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Non-Controlling Interests
12 Months Ended
Dec. 31, 2022
Noncontrolling Interest [Abstract]  
Non-Controlling Interests Non-Controlling Interests
Non-controlling interests on the Company’s consolidated balance sheet is comprised of the following:
Balance as of December 31,
(In thousands)20222021
Series A Preferred Units held by third parties$2,578 $2,578 
Common OP Units held by third parties3,584 3,758 
Total Non-controlling Interests in the OP6,162 6,336 
Non-controlling interests in property owning subsidiaries389 368 
Total Non-controlling Interests$6,551 $6,704 
Non-Controlling Interests in the Operating Partnership
For preferred and common shares issued by the Company, the Company typically issues mirror securities with substantially equivalent economic rights between the Company and the OP. The securities held by the Company are eliminated in consolidation.
Series A Preferred OP Units
The Company is the sole general partner and holds substantially all of the Series A Preferred Units.
In September 2021, the Company partially funded the purchase of a MOB from an unaffiliated third party by causing the OP to issue 100,000 Series A Preferred Units, with a face value of $25.00 per unit, which were recorded at issuance at a then fair value of $2.6 million, or $25.78 per unit, to the unaffiliated third party.
A holder of Series A Preferred Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s Series A Preferred Stock. After holding the Series A Preferred Units for a period of one year, a holder of Series A Preferred Units has the right to redeem Series A Preferred Units for, at the option of the OP, the corresponding number of shares of the Company’s Series A Preferred Stock, or the cash equivalent. The remaining rights of the limited partners in the
OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During the year ended December 31, 2022 and 2021, Series A Preferred Unit holders were paid distributions of $0.2 million and $46,000, respectively.
Common OP Units
The Company is the sole general partner and holds substantially all of the Common OP Units. As of December 31, 2022 and 2021, the Advisor held 90 Common OP Units, which represents a nominal percentage of the aggregate ownership in the OP.
In November 2014, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 405,908 Common OP Units, with an initial value of $10.1 million, or $25.00 per unit, to the unaffiliated third party.
A holder of Common OP Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s common stock in an amount retroactively adjusted to reflect the Stock Dividends, other stock dividends and other similar events. After holding the Common OP Units for a period of one year, a holder of Common OP Units has the right to redeem Common OP Units for, at the option of the OP, the corresponding number of shares of the Company’s common stock, as retroactively adjusted for the Stock Dividends, other stock dividends and other similar events, or the cash equivalent. The remaining rights of the limited partners in the OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During the years ended December 31, 2022 and 2021, Common OP Unit non-controlling interest holders were not paid any cash distributions. During the year ended December 31, 2020, Common OP Unit non-controlling interest holders were paid distributions of $0.2 million.
Stock Dividends do not cause the OP to issue additional Common OP Units, rather, the redemption ratio to common stock is adjusted. The 405,908 Common OP Units outstanding as of December 31, 2022 would be redeemable for 467,498 shares of common stock, giving effect to adjustments for the impact of the Stock Dividends through January 2023.
Non-Controlling Interests in Property Owning Subsidiaries
The Company also has investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Upon disposition of a property subject to non-controlling interest, the investor will receive a proportionate share of the net proceeds from the sale of the property. The investor has no recourse to any other assets of the Company. Due to the nature of the Company’s involvement with these arrangements and the significance of its investment in relation to the investment of the third party, the Company has determined that it controls each entity in these arrangements and therefore the entities related to these arrangements are consolidated within the Company’s financial statements. A non-controlling interest is recorded for the investor’s ownership interest in the properties.
On November 4, 2020, the Company purchased all of the outstanding the membership interests in the joint venture that owns the UnityPoint Clinics in Muscatine, Iowa and Moline, Illinois for approximately $0.6 million, funded with cash on hand. Following this transaction, the properties were wholly owned by the Company and added to the borrowing base under the Credit Facility.
The following table summarizes the activity related to investment arrangements with unaffiliated third parties.
Third Party Net Investment AmountNon-Controlling Ownership PercentageNet Real Estate Assets Subject to Investment ArrangementDistributions
Property NameAs of December 31,As of December 31,As of December 31,Year Ended December 31,
(Dollar amounts in thousands)
Investment Date2022202220222021202220212020
Plaza Del Rio Medical Office Campus Portfolio(1)
May 2015$389 2.5 %$12,455 $12,925 $— $— $— 
_____________
(1)One property within the Plaza Del Rio Medical Office Campus Portfolio was mortgaged as part of the Multi-Property CMBS Loan. See Note 4 - Mortgage Notes Payable for additional information.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Net Loss Per Share
12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Net Loss Per Share Net Loss Per Share
The following is a summary of the basic and diluted net loss per share computation for the years ended December 31, 2022, 2021 and 2020 and has been retroactively adjusted to reflect the stock dividends (see Note 1 — Organization for additional details):
Year Ended December 31,
202220212020
Net loss attributable to stockholders (in thousands)
$(93,285)$(92,942)$(78,781)
Basic and diluted weighted-average shares outstanding (1)
106,428,154 106,354,994 106,119,937 
Basic and diluted net loss per share (1)
$(0.88)$(0.87)$(0.74)
(1)Retroactively adjusted for the effects of the stock dividends. See Note 1 — Organization and Note 8 — Stockholder’s Equity for additional information.
Diluted net loss per share assumes the conversion of all common stock equivalents into an equivalent number of shares of common stock, unless the effect is antidilutive. The Company considers unvested restricted shares, Common OP Units and Class B Units to be common share equivalents. The Company had the following common stock equivalents on a weighted-average basis that were excluded from the calculation of diluted net loss per share attributable to stockholders as their effect would have been antidilutive. The amounts in the table below have been retroactively adjusted to reflect the stock dividends (see Note 1 — Organization for additional details):
December 31,
202220212020
Unvested restricted shares (1)
141,364 214,520 288,965 
Common OP Units (2)
467,602 467,602 467,602 
Class B Units (3)
413,760 413,760 413,760 
Total weighted average antidilutive common share equivalents1,022,726 1,095,882 1,170,327 
________
(1)Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. There were 97,343, 159,427 and 215,384 unvested restricted shares outstanding as of December 31, 2022, 2021 and 2020, respectively.
(2)Weighted average number of antidilutive Common OP Units presented as shares outstanding for the periods presented, at the current conversion rate as retroactively adjusted for the effects of the stock dividends. There were 405,998 Common OP Units outstanding as of December 31, 2022, 2021 and 2020.
(3)Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current conversion rate as retroactively adjusted for the effects of the stock dividends. There were 359,250 Class B Units outstanding as of December 31, 2022, 2021 and 2020.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting
12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The disclosures below for the years ended December 31, 2022, 2021 and 2020, are presented for the Company’s two reportable business segments for management and internal financial reporting purposes: MOBs and SHOPs. Prior to December 31, 2021, the Company had three reportable segments 1) medical office and outpatient buildings (“Former MOBs”), 2) triple net-leased healthcare properties (“Former NNN”) and 3) SHOPs. Culminating in the year ended December 31, 2021, the Company has completed several strategic property divestitures from the Company’s Former NNN segment and transitioned certain properties previously reported in the Company’s Former NNN segment into the Company’s SHOP segment. The remaining Former NNN properties are similar in nature, cash flows, and risk structure with the Former MOB segment and are managed operationally and reported collectively by the Company’s management. Accordingly, in the fourth quarter of 2021, the Company reevaluated its segments and concluded that it had two reportable segments. The Company combined the properties in its Former NNN segment with the properties in its Former MOB segment for segment reporting. All prior periods presented in the tables below have been conformed to the presentation of the Company’s new reportable segment structure.
The Company evaluates performance and makes resource allocations based on its two business segments. The medical office building segment primarily consists of MOBs leased to healthcare-related tenants under long-term leases, which may require such tenants to pay a pro rata share of property-related expenses as well as seniors housing properties, hospitals, inpatient rehabilitation facilities and skilled nursing facilities under long-term leases, under which tenants are generally responsible to directly pay property-related expenses. The SHOP segment consists of direct investments in seniors housing properties, primarily providing assisted living, independent living and memory care services, which are operated through engaging independent third-party operators.
Net Operating Income
The Company evaluates the performance of the combined properties in each segment based on net operating income (“NOI”). NOI is defined as total revenues from tenants, less property operating and maintenance expense. NOI excludes all other items of expense and income included in the financial statements in calculating net income (loss). The Company uses NOI to assess and compare property level performance and to make decisions concerning the operation of the properties. The Company believes that NOI is useful as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating expenses and acquisition activity on an unleveraged basis, providing perspective not immediately apparent from net income (loss).
NOI excludes certain components from net income (loss) in order to provide results that are more closely related to a property’s results of operations. For example, interest expense is not necessarily linked to the operating performance of a real estate asset and is often incurred at the corporate level. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property level. NOI presented by the Company may not be comparable to NOI reported by other REITs that define NOI differently. The Company believes that in order to facilitate a clear understanding of the Company’s operating results, NOI should be examined in conjunction with net income (loss) as presented in the Company’s consolidated financial statements. NOI should not be considered as an alternative to net income (loss) as an indication of the Company’s performance or to cash flows as a measure of the Company’s liquidity or ability to pay distributions.
The following tables reconcile the segment activity to consolidated net loss for the years ended December 31, 2022, 2021 and 2020:
Year Ended December 31, 2022
(In thousands)Medical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants$131,444 $204,402 $335,846 
Property operating and maintenance35,945 177,499 213,444 
NOI$95,499 $26,903 122,402 
Impairment charges(27,630)
Operating fees to related parties(25,353)
Acquisition and transaction related(1,484)
General and administrative(17,287)
Depreciation and amortization(82,064)
Loss on sale of real estate investments(125)
Interest expense(51,740)
Interest and other income 27 
Gain on non designated derivatives3,834 
Income tax expense(201)
Net loss attributable to non-controlling interests135 
Allocation for preferred stock(13,799)
Net loss attributable to common stockholders$(93,285)
Year Ended December 31, 2021
(In thousands)Medical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants$122,867 $206,488 $329,355 
Property operating and maintenance34,480 171,333 205,813 
NOI88,387 35,155 123,542 
Impairment charges(40,951)
Operating fees to related parties(24,206)
Acquisition and transaction related(2,714)
General and administrative(16,828)
Depreciation and amortization(79,926)
Gain on sale of real estate investments3,648 
Interest expense(47,900)
Interest and other income61 
Gain on non-designated derivatives37 
Income tax expense(203)
Net loss attributable to non-controlling interests260 
Allocation for preferred stock(7,762)
Net loss attributable to common stockholders$(92,942)

Year Ended December 31, 2020
(In thousands)Medical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants$119,824 $261,788 $381,612 
Property operating and maintenance32,812 210,736 243,548 
NOI87,012 51,052 138,064 
Impairment charges(36,446)
Operating fees to related parties(23,922)
Acquisition and transaction related(173)
General and administrative(21,572)
Depreciation and amortization(81,053)
Gain on sale of real estate investment 5,230 
Interest expense(51,519)
Interest and other income 44 
Loss on non-designated derivatives (102)
Income tax expense(4,061)
Net income attributable to non-controlling interests(303)
Allocation for preferred stock(2,968)
Net loss attributable to common stockholders$(78,781)
The following table reconciles the segment activity to consolidated total assets as of the periods presented:
December 31,
(In thousands)20222021
ASSETS
Investments in real estate, net:
Medical office and other healthcare-related buildings$1,121,857 $1,149,241 
Seniors housing — operating properties856,440 900,686 
Total investments in real estate, net
1,978,297 2,049,927 
Cash and cash equivalents53,654 59,738 
Restricted cash22,884 25,644 
Derivative assets, at fair value40,647 174 
Straight-line rent receivable, net25,276 23,858 
Operating lease right-of-use asset7,814 7,914 
Prepaid expenses and other assets34,554 32,564 
Deferred costs, net17,223 14,581 
Total assets$2,180,349 $2,214,400 

The following table reconciles capital expenditures by reportable business segments, excluding corporate non-real estate expenditures, for the periods presented:
Year Ended December 31,
(In thousands)202220212020
Medical office and other healthcare-related buildings$10,542 $6,152 $8,561 
Seniors housing — operating properties17,451 12,919 12,833 
Total capital expenditures$27,993 $19,071 $21,394 
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies
12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Commitments and Contingencies Commitments and Contingencies
As of December 31, 2022, the Company has seven operating and six direct financing lease agreements related to certain acquisitions under leasehold interests arrangements. The seven operating leases have durations, including assumed renewals, ranging from 19.9 to 84.7 years, excluding an adjacent parking lot lease with a term of 1.8 years as of December 31, 2022. The Company did not enter into any additional ground leases during the year ended December 31, 2022. The classification of these leases were grandfathered in adoption of ASU 842, whereby they will continue to be classified as operating leases unless modified.
As of December 31, 2022, the Company’s balance sheet included ROU assets and liabilities of $7.8 million and $8.1 million, respectively, which are included in operating lease right-of-use assets and operating lease liabilities, respectively, on the Company’s consolidated balance sheet. In determining operating ROU assets and lease liabilities for the Company’s existing operating leases upon the adoption of the lease guidance issued in 2019, as well as for new operating leases since adoption, the Company was required to estimate an appropriate incremental borrowing rate on a fully-collateralized basis for the terms of the leases. Because the terms of the Company’s ground leases are significantly longer than the terms of borrowings available to the Company on a fully-collateralized basis, the Company’s estimate of this rate required significant judgment. During the year ended December 31, 2021, the Company sold a property which included a prepaid ground lease. Upon disposition, the carrying value of the ROU asset was $5.7 million, and was recorded as a reduction of the gain on sale for that property.
The Company’s ground operating leases have a weighted-average remaining lease term, including assumed renewals, of 34.1 years and a weighted-average discount rate of 7.36% as of December 31, 2022. For the years ended December 31, 2022, 2021 and 2020, the Company paid cash of $0.7 million, $0.8 million and $0.8 million for amounts included in the measurement of lease liabilities and recorded total rental expense from operating leases of $0.9 million, $0.9 million and $0.9 million, on a straight-line basis in accordance with the standard, during the years ended December 31, 2022, 2021 and 2020, respectively.
The lease expense is recorded in property operating expenses in the consolidated statements of operations and comprehensive loss.
Future Base Rent Payments
(In thousands)Operating Leases
Direct Financing Leases (1)
2023$645 $88 
2024632 90 
2025588 93 
2026599 95 
2027617 97 
Thereafter21,942 7,215 
Total minimum lease payments25,023 7,678 
Less: amounts representing interest(16,936)(2,841)
Total present value of minimum lease payments$8,087 $4,837 
_______
(1)The Direct Finance Lease liability is included in Accounts Payable and accrued expenses on the balance sheet as of December 31, 2022. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.
Litigation and Regulatory Matters
In the ordinary course of business, the Company may become subject to litigation, claims and regulatory matters. There are no material legal or regulatory proceedings pending or known to be contemplated against the Company or its properties.
Environmental Matters
In connection with the ownership and operation of real estate, the Company may potentially be liable for costs and damages related to environmental matters. As of December 31, 2022, the Company had not been notified by any governmental authority of any non-compliance, liability or other claim, and is not aware of any other environmental condition that it believes will have a material adverse effect on the results of operations.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent Events
12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
The Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K and determined that there have not been any events that have occurred that would require adjustments to disclosures in the consolidated financial statements except the following disclosures:
Stock Dividend
On January 3, 2023, the Company declared a quarterly stock dividend of 0.014167 shares of the Company’s common stock on each share of the Company’s outstanding common stock. The stock dividend was payable on January 18, 2023 to holders of record of the Company’s common stock at the close of business on January 13, 2023.
Swap Terminations
Subsequent to December 31, 2022, the Company terminated two LIBOR-based interest rate swap agreements with an aggregate notional amount of $50.0 million. The swaps were terminated in an asset position with a fair value of $2.0 million. The funds were received in February 2023. This amount will remain in AOCI and will amortize into net loss as a reduction to interest expense through March 2024.
Credit Facility Borrowings
Subsequent to December 31, 2022, the Company drew $20.0 million on its Revolving Credit Facility.
Acquisitions
Subsequent to December 31, 2022, the Company acquired four single-tenant MOB properties for a contract purchase price of $20.0 million, which was funded with borrowings from the Revolving Credit Facility.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate and Accumulated Depreciation Schedule III
12 Months Ended
Dec. 31, 2022
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]  
Real Estate and Accumulated Depreciation Schedule III
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Fresenius Medical Care - Winfield, AL(5)AL5/10/2013$— $152 $1,568 $— $— $1,720 $445 
Adena Health Center - Jackson, OH(5),(11)OH6/28/2013— 242 4,494 — (25)4,711 1,100 
Ouachita Community Hospital - West Monroe, LA(5)LA7/12/2013— 633 5,304 — — 5,937 1,329 
CareMeridian - Littleton, CO(5)CO8/8/2013— 976 8,900 — 111 9,987 3,037 
Oak Lawn Medical Center - Oak Lawn, ILIL8/21/20135,343 835 7,217 — 25 8,077 1,994 
Surgery Center of Temple - Temple, TX(5)TX8/30/2013— 225 5,208 — 432 5,865 1,379 
Greenville Health System - Greenville, SC(5), (9)SC10/10/2013— 720 3,045 — 389 4,154 759 
Stockbridge Family Medical - Stockbridge, GAGA2/21/20141,781 823 1,799 — 177 2,799 542 
Arrowhead Medical Plaza II - Glendale, AZAZ2/21/20147,540 — 9,758 — 2,076 11,834 3,261 
Village Center Parkway - Stockbridge, GAGA2/21/20142,434 1,135 2,299 — 372 3,806 809 
Creekside MOB - Douglasville, GAGA4/30/20148,814 2,709 5,320 — 791 8,820 1,858 
Bowie Gateway Medical Center - Bowie, MDMD5/7/20149,153 983 10,321 — 334 11,638 2,489 
Campus at Crooks & Auburn Building D - Rochester Mills, MIMI5/19/20143,627 640 4,166 — 145 4,951 1,120 
Berwyn Medical Center - Berwyn, IL(5)IL5/29/2014— 1,305 7,559 — — 8,864 1,693 
Countryside Medical Arts - Safety Harbor, FLFL5/30/20146,983 915 7,663 — 74 8,652 1,862 
St. Andrews Medical Park - Venice, FLFL5/30/201411,119 1,666 10,005 399 12,072 3,027 
Campus at Crooks & Auburn Building C - Rochester Mills, MIMI6/3/20143,831 609 3,893 — 178 4,680 1,081 
Laguna Professional Center - Elk Grove, CACA7/15/20148,887 1,811 14,598 — 318 16,727 3,709 
UC Davis MOB - Elk Grove, CACA7/15/20148,136 1,138 7,242 — 294 8,674 1,951 
Estate at Hyde Park - Tampa, FL(7)FL7/31/2014— 1,777 20,308 — 1,079 23,164 5,133 
Autumn Ridge of Clarkston - Clarkston, MI(7)MI8/12/2014— 655 19,967 — 1,584 22,206 4,884 
Sunnybrook of Burlington - Burlington, IA(6)IA8/26/2014— 518 16,739 — 429 17,686 4,438 
Sunnybrook of Carroll - Carroll, IA(6)IA8/26/2014— 473 11,263 — 51 11,787 2,686 
Prairie Hills at Cedar Rapids - Cedar Rapids, IA(7)IA8/26/2014— 195 8,595 — 182 8,972 2,096 
Prairie Hills at Clinton - Clinton, IA(6)IA8/26/2014— 890 18,882 — 86 19,858 4,781 
Prairie Hills at Des Moines - Des Moines, IA(6)IA8/26/2014— 647 13,745 — 57 14,449 3,593 
Sunnybrook of Fairfield - Fairfield, IA(5)IA8/26/2014— 340 14,115 — 291 14,746 3,635 
Sunnybrook of Ft. Madison - Ft. Madison, IA(5),(11)IA8/26/2014— 263 3,931 (54)(1,177)2,963 (21)
Prairie Hills at Independence - Independence, IA(5)IA8/26/2014— 473 10,600 — 179 11,252 2,519 
Sunnybrook of Mt. Pleasant - Mt. Pleasant, IA(5)IA8/26/2014— 205 10,935 — 359 11,499 2,575 
Sunnybrook of Muscatine - Muscatine, IA(6)IA8/26/2014— 302 13,840 — 172 14,314 3,364 
Prairie Hills at Ottumwa - Ottumwa, IA(5),(11)IA8/26/2014— 538 9,186 (376)(7,088)2,260 47 
Prairie Hills at Tipton - Tipton, IA(5)IA8/26/2014— 306 10,409 — 78 10,793 2,405 
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Liberty Court - Dixon, IL(5)IL8/29/2014— 119 1,998 — 59 2,176 541 
Lakeside Vista - Holland, MI(6)MI8/29/2014— 378 12,196 — 1,878 14,452 3,057 
The Atrium - Rockford, IL(5)IL8/29/2014— 164 1,746 — 295 2,205 369 
Arrowhead Medical Plaza I - Glendale, AZAZ9/10/20144,571 — 6,447 — 1,410 7,857 1,886 
Sunnybrook of Burlington - Land - Burlington, IAMO9/23/2014— 620 — — — 620 — 
Community Health MOB - Harrisburg, PA(10)PA9/26/20145,424 — 6,170 — — 6,170 1,315 
Brady MOB - Harrisburg, PA(10)PA9/26/201419,661 — 22,485 — — 22,485 4,680 
Landis Memorial - Harrisburg, PA(5), (10)PA9/26/2014— — 32,484 — — 32,484 6,782 
FOC II - Mechanicsburg, PA(10)PA9/26/201416,136 — 16,473 — 142 16,615 3,960 
FOC Clinical - Mechanicsburg, PA(10)PA9/26/201417,695 — 19,634 — — 19,634 4,616 
FOC I - Mechanicsburg, PA(10)PA9/26/20148,204 — 8,923 — 368 9,291 2,308 
Copper Springs Senior Living - Meridian, ID(5),(11)ID9/29/2014— 498 7,130 (14)(2,052)5,562 48 
Addington Place of Brunswick - Brunswick, GA(5)GA9/30/2014— 1,509 14,402 — 489 16,400 3,747 
Addington Place of Dublin - Dublin, GA(5)GA9/30/2014— 403 9,281 — 182 9,866 2,541 
Allegro at Elizabethtown - Elizabethtown, KY(5),(11)KY9/30/2014— 317 7,290 (76)(3,175)4,356 13 
Addington Place of Johns Creek - Johns Creek, GA(7)GA9/30/2014— 997 11,943 — 448 13,388 3,174 
Allegro at Jupiter - Jupiter, FL(6)FL9/30/2014— 3,741 49,534 — 674 53,949 12,027 
Addington Place of Lee's Summit - Lee's Summit, MO(7)MO9/30/2014— 2,734 25,008 — 391 28,133 6,149 
Addington Place at Mills - Roswell, GA(5)GA9/30/2014— 1,000 8,611 — 2,575 12,186 3,310 
Addington Place of College Harbour - St Petersburg, FL(5)FL9/30/2014— 3,791 8,684 — 2,117 14,592 3,430 
Allegro at Stuart - Stuart, FL(6)FL9/30/2014— 5,018 60,575 — 969 66,562 15,029 
Allegro at Tarpon - Tarpon Springs, FL(7)FL9/30/2014— 2,360 13,728 — 3,107 19,195 4,430 
Addington Place of Titusville - Titusville, FL(6)FL9/30/2014— 1,379 13,976 — 720 16,075 4,034 
Allegro at St. Petersburg - Land - St. Petersburg, FLFL9/30/2014— 3,045 — — — 3,045 — 
Gateway MOB - Clarksville, TN(9)TN10/3/201417,560 — 16,367 — 1,011 17,378 4,335 
Dyer Building - Dyer, IN(5)IN10/17/20146,143 601 8,992 — 191 9,784 1,971 
757 Building - Munster, IN(5)IN10/17/2014— 645 7,885 — 31 8,561 1,685 
761 Building - Munster, ININ10/17/20146,797 1,436 8,616 — 90 10,142 1,974 
759 Building - Munster, ININ10/17/20148,271 1,101 8,899 — 31 10,031 1,955 
Schererville Building - Schererville, ININ10/17/2014— 1,260 935 — 88 2,283 381 
Meadowbrook Senior Living - Agoura Hills, CA(7)CA11/25/2014— 8,821 48,682 — 2,485 59,988 11,659 
Mount Vernon Medical Office Building - Mount Vernon, WA(9)WA11/25/201415,797 — 18,519 — 18,522 4,095 
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Wellington at Hershey's Mill - West Chester, PA(5)PA12/3/2014— 8,531 80,734 — 5,364 94,629 18,754 
Eye Specialty Group Medical Building - Memphis, TNTN12/5/20148,475 775 7,223 — — 7,998 1,533 
Addington Place of Alpharetta - Alpharetta, GAGA12/10/2014— 1,604 26,069 — 462 28,135 6,296 
Addington Place of Prairie Village - Prairie Village, KS(7)KS12/10/2014— 1,782 21,869 — 451 24,102 5,466 
Bloom MOB - Harrisburg, PA(10)PA12/15/201415,322 — 15,928 — 517 16,445 3,535 
Medical Sciences Pavilion - Harrisburg, PA(10)PA12/15/201418,272 — 22,309 — — 22,309 4,569 
Wood Glen Nursing and Rehab Center - West Chicago, IL(5),(11)IL12/16/2014— 1,896 16,107 (367)(6,436)11,200 228 
Pinnacle Center - Southaven, MSMS12/16/20147,085 1,378 6,547 — 1,560 9,485 1,952 
Paradise Valley Medical Plaza - Phoenix, AZAZ12/29/201413,085 — 25,194 — 1,703 26,897 6,019 
Victory Medical Center at Craig Ranch - McKinney, TXTX12/30/2014— 1,596 40,475 — 1,199 43,270 8,801 
Rivershores Healthcare & Rehab Centre - Marseilles, IL(5),(11)IL12/31/2014— 1,276 6,868 (247)(2,837)5,060 105 
Morton Terrace Healthcare & Rehab Centre - Morton, IL(5),(11)IL12/31/2014— 709 5,649 (137)(2,520)3,701 77 
Morton Villa Healthcare & Rehab Centre - Morton, IL(5),(11)IL12/31/2014— 645 3,687 (125)(1,546)2,661 57 
The Heights Healthcare & Rehab Centre - Peoria Heights, IL(5),(11)IL12/31/2014— 214 7,952 (41)(3,369)4,756 127 
Colonial Healthcare & Rehab Centre - Princeton, IL(5),(11)IL12/31/2014— 173 5,871 (33)(2,622)3,389 92 
Capitol Healthcare & Rehab Centre - Springfield, IL(5),(11)IL12/31/2014— 603 21,699 (117)(8,560)13,625 311 
Acuity Specialty Hospital - Mesa, AZ(5)AZ1/14/2015— 1,977 16,203 — 543 18,723 3,660 
Acuity Specialty Hospital - Sun City, AZ(11)AZ1/14/2015— 2,329 15,795 (909)(7,715)9,500 658 
Addington Place of Shoal Creek - Kansas City, MO(7)MO2/2/2015— 3,723 22,259 — 704 26,686 5,404 
Aurora Healthcare Center - Green Bay, WI(5)WI3/18/2015— 1,130 1,678 — — 2,808 420 
Aurora Healthcare Center - Greenville, WI(5)WI3/18/2015— 259 958 — — 1,217 256 
Aurora Healthcare Center - Kiel, WI(5)WI3/18/2015— 676 2,214 — — 2,890 494 
Aurora Healthcare Center - Plymouth, WIWI3/18/201517,038 2,891 24,224 — — 27,115 5,430 
Aurora Healthcare Center - Waterford, WI(5)WI3/18/2015— 590 6,452 — — 7,042 1,395 
Aurora Healthcare Center - Wautoma, WI(5)WI3/18/2015— 1,955 4,361 — — 6,316 983 
Arbor View Assisted Living and Memory Care - Burlington, WI(5)WI3/31/2015— 367 7,815 — 71 8,253 2,080 
Advanced Orthopedic Medical Center - Richmond, VAVA4/7/201515,390 1,523 19,229 — 493 21,245 3,970 
Palm Valley Medical Plaza - Goodyear, AZ(5)AZ4/7/2015— 1,890 4,940 — 367 7,197 1,267 
Physicians Plaza of Roane County - Harriman, TNTN4/27/20156,293 1,746 7,842 — 182 9,770 1,737 
Adventist Health Lacey Medical Plaza - Hanford, CACA4/29/201511,526 328 13,302 — 98 13,728 2,620 
Medical Center I - Peoria, AZAZ5/15/20153,085 807 1,115 — 1,545 3,467 1,190 
Medical Center II - Peoria, AZAZ5/15/2015— 945 1,330 — 5,036 7,311 1,836 
Commercial Center - Peoria, AZAZ5/15/20153,254 959 1,110 — 710 2,779 571 
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Medical Center III - Peoria, AZAZ5/15/20152,137 673 1,651 — 1,047 3,371 932 
Morrow Medical Center - Morrow, GAGA6/24/20154,334 1,155 5,674 — 493 7,322 1,451 
Belmar Medical Building -Lakewood, COCO6/29/20153,770 819 4,287 — 596 5,702 1,114 
Addington Place - Northville, MI(7)MI6/30/2015— 440 14,975 — 1,007 16,422 3,403 
Conroe Medical Arts and Surgery Center - Conroe, TXTX7/10/201513,221 1,965 12,198 — 744 14,907 2,842 
Medical Center V - Peoria, AZ(5)AZ7/10/2015— 1,089 3,200 — 879 5,168 804 
Legacy Medical Village - Plano, TXTX7/10/201523,662 3,755 31,097 — 1,430 36,282 6,634 
Scripps Cedar Medical Center - Vista, CACA8/6/201514,983 1,213 14,596 — 1,673 17,482 2,981 
Ramsey Woods Memory Care - Cudahy, WI(5)WI10/2/2015— 930 4,990 — 122 6,042 1,188 
East Coast Square West - Cedar Point, NCNC10/15/20155,254 1,535 4,803 — 6,344 962 
East Coast Square North - Morehead City, NCNC10/15/20153,933 899 4,761 — 144 5,804 917 
Eastside Cancer Institute - Greenville, SC(5)SC10/22/2015— 1,498 6,637 — 639 8,774 1,379 
Sassafras Medical Building - Erie, PA(11)PA10/22/20152,315 928 4,629 (364)(2,333)2,860 — 
Sky Lakes Klamath Medical Clinic - Klamath Falls, OR(5)OR10/22/2015— 433 2,623 — — 3,056 508 
Courtyard Fountains - Gresham, OR(5)OR12/1/2015— 2,476 50,601 — 2,255 55,332 10,764 
Presence Healing Arts Pavilion - New Lenox, IL(9)IL12/4/20155,966 — 6,768 — 76 6,844 1,383 
Mainland Medical Arts Pavilion - Texas City, TXTX12/4/20156,174 320 7,923 — 321 8,564 1,756 
Renaissance on Peachtree - Atlanta, GA(6)GA12/15/2015— 4,535 68,895 — 3,246 76,676 13,856 
Fox Ridge Senior Living at Bryant - Bryant, AR(11)AR12/29/20156,817 1,687 12,936 (557)(6,326)7,740 40 
Fox Ridge Senior Living at Chenal - Little Rock, ARAR12/29/201515,639 6,896 20,579 — 364 27,839 4,917 
Fox Ridge North Little Rock - North Little Rock, AR(9)AR12/29/20159,704 — 19,265 — 263 19,528 4,211 
High Desert Medical Group Medical Office Building - Lancaster, CACA4/7/20177,480 1,459 9,300 — — 10,759 1,749 
Northside Hospital - Canton, GAGA7/13/20178,014 3,408 8,191 — 438 12,037 1,249 
West Michigan Surgery Center - Big Rapids, MI(5)MI8/18/2017— 258 5,677 — — 5,935 803 
Camellia Walk Assisted Living and Memory Care - Evans, GA(6)GA9/28/2017— 1,854 17,372 — 1,232 20,458 3,426 
Cedarhurst of Collinsville - Collinsville, IL(5), (8)IL12/22/2017— 1,228 8,652 — 264 10,144 1,393 
Arcadian Cove Assisted Living - Richmond, KY(5), (8),(11)KY12/22/2017— 481 3,923 (425)(3,536)443 14 
Beaumont Medical Center - Warren, MI(5), (8)MI12/22/2017— 1,078 9,525 — 19 10,622 1,328 
DaVita Dialysis - Hudson, FL(5), (8)FL12/22/2017— 226 1,979 — 121 2,326 273 
DaVita Bay Breeze Dialysis Center - Largo, FL(5), (8)FL12/22/2017— 399 896 — 48 1,343 150 
Greenfield Medical Plaza - Gilbert, AZ(5), (8)AZ12/22/2017— 1,476 4,144 — 277 5,897 633 
RAI Care Center - Clearwater, FL(5), (8)FL12/22/2017— 624 3,156 — — 3,780 420 
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Illinois CancerCare - Galesburg, IL(8)IL12/22/20172,323 290 2,457 — — 2,747 368 
UnityPoint Clinic - Muscatine, IA(5), (8)IA12/22/2017— 570 4,541 — 34 5,145 649 
Lee Memorial Health System Outpatient Center - Ft. Myers(5), (8)FL12/22/2017— 439 4,374 — 710 5,523 688 
Decatur Medical Office Building - Decatur, GA(5), (8), (9)GA12/22/2017— 695 3,273 — 261 4,229 507 
Madison Medical Plaza - Joliet, IL(8), (9)IL12/22/201712,477 — 16,855 — 37 16,892 2,111 
Woodlake Office Center - Woodbury, MN(8)MN12/22/20178,638 1,017 10,688 — 1,297 13,002 1,652 
Rockwall Medical Plaza - Rockwall, TX(5), (8)MN12/22/2017— 1,097 4,582 — 214 5,893 709 
MetroHealth Buckeye Health Center - Cleveland, OH(5), (8)OH12/22/2017— 389 4,367 — 255 5,011 648 
UnityPoint Clinic - Moline, IL(5), (8)IL12/22/2017— 396 2,880 — 3,281 411 
VA Outpatient Clinic - Galesberg, IL(5), (8)IL12/22/2017— 359 1,852 — — 2,211 302 
Philip Professional Center - Lawrenceville, GAGA12/22/20175,780 1,285 6,714 — 264 8,263 1,045 
Texas Children’s Hospital - Houston, TX
TX3/5/20184,590 1,368 4,428 — 116 5,912 790 
Florida Medical Heartcare - Tampa, FL
(5)FL3/29/2018— 586 1,902 — — 2,488 322 
Florida Medical Somerset - Tampa, FL
(5)FL3/29/2018— 61 1,366 — — 1,427 204 
Florida Medical Tampa Palms - Tampa, FL
(5)FL3/29/2018— 141 1,402 — — 1,543 215 
Florida Medical Wesley Chapel - Tampa, FL
(5)FL3/29/2018— 485 1,987 — — 2,472 345 
Aurora Health Center - Milwaukee, WI
WI4/17/20183,984 1,014 4,041 — 224 5,279 788 
Vascular Surgery Associates - Tallahassee, FL
(5)FL5/11/2018— 902 5,383 — — 6,285 856 
Glendale MOB - Farmington Hills, MI
(5)MI8/28/2018— 504 12,332 — — 12,836 1,542 
Crittenton Washington MOB - Washington Township, MI
(5)MI9/12/2018— 640 4,090 — 283 5,013 592 
Crittenton Sterling Heights MOB - Sterling Heights, MI
(5)MI9/12/2018— 1,398 2,695 — 258 4,351 492 
Advocate Aurora MOB - Elkhorn, WI
WI9/24/20187,184 181 9,452 — — 9,633 1,280 
Pulmonary & Critical Care Med - Lemoyne, PA
PA11/13/20184,271 621 3,805 — — 4,426 661 
Dignity Emerus Blue Diamond - Las Vegas, NV
NV11/15/201813,966 2,182 16,594 — — 18,776 1,864 
Dignity Emerus Craig Rd - North Las Vegas, NV
NV11/15/201818,780 3,807 22,803 — — 26,610 2,584 
Greenfield MOB - Greenfield, WI
WI1/17/20197,526 1,552 8,333 — 246 10,131 1,199 
Milwaukee MOB - South Milwaukee, WI
WI1/17/20194,136 410 5,041 — — 5,451 544 
St. Francis WI MOB - St. Francis, WI
WI1/17/20199,088 865 11,355 — 251 12,471 1,353 
Lancaster Medical Arts MOB - Lancaster, PA
(5)PA6/20/2019— 85 4,417 — — 4,502 569 
Women’s Healthcare Group MOB - York, PA
(5)PA6/21/2019— 624 2,161 — — 2,785 403 
Pioneer Spine Sports - Northampton, MA
(5)MA7/22/2019— 435 1,858 — — 2,293 192 
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Pioneer Spine Sport - Springfield, MA
(5)MA7/22/2019— 333 2,530 — — 2,863 252 
Pioneer Spine Sports - West Springfield, MA
(5)MA7/22/2019— 374 4,295 — — 4,669 417 
Felicita Vida - Escondido, CA
(5)CA9/3/2019— 1,677 28,953 — 396 31,026 2,785 
Cedarhurst of Edwardsville - Edwardsville, IL(5)IL1/10/2020— 321 9,032 — 56 9,409 805 
UMPC Sir Thomas Court - Harrisburg, PA(5)PA1/17/2020— 745 6,272 — — 7,017 498 
UMPC Fisher Road - Mechanicsburg, PA(5)PA1/17/2020— 747 3,844 — — 4,591 333 
Swedish American MOB - Roscoe, IL(5)IL1/22/2020— 599 5,862 — — 6,461 588 
Cedarhurst of Sparta - Sparta, IL(5)IL1/31/2020— 381 13,807 — 63 14,251 1,225 
UMPC Chambers Hill - Harrisburg, PA(5)PA2/3/2020— 498 4,238 — — 4,736 329 
Cedarhurst of Shiloh - Shiloh, ILIL3/13/202013,071 376 28,299 — 65 28,740 2,085 
Bayshore Naples Memory Care - Naples, FL(5)FL3/20/2020— 3,231 17,112 — 54 20,397 1,306 
Circleville MOB - Circleville, OHOH12/7/20203,556 765 4,011 — 71 4,847 243 
Kingwood Executive Center - Kingwood, TX(5)TX1/6/2021— 1,522 4,166 — 34 5,722 251 
OrthoOne Hilliard - Hilliard, OH(5)OH5/28/2021— 760 3,118 — 77 3,955 206 
South Douglas MOB - Midwest City, OK(5)OK6/23/2021— 628 3,863 — — 4,491 193 
Fort Wayne Opthomology Engle - Fort Wayne, ININ6/29/20213,923 516 6,124 — — 6,640 260 
Fort Wayne Opthomology Dupont - Fort Wayne, ININ6/29/20211,924 597 2,653 — — 3,250 138 
St. Peters Albany 2 Palisades - Albany, NY(5)NY6/30/2021— 516 4,342 — — 4,858 202 
Hefner Pointe Medical Center - Oklahoma City, OKOK6/30/20213,831 678 4,819 — 31 5,528 222 
St. Peters Troy 2 New Hampshire - Troy, NY(5)NY6/30/2021— 330 2,444 — 19 2,793 113 
St Peters - Albany, NY - 4 Palisades(5)NY7/30/2021— 542 2,416 — — 2,958 113 
St Peters - Albany, NY - 5 Palisades(5)NY7/30/2021— 593 5,359 — — 5,952 221 
St Lukes Heart Vascular Center - East Stroudsburg(5)PA8/31/2021— 363 3,224 — — 3,587 113 
Metropolitan Eye Lakeshore Surgery - St. Clair, MI(5)MI8/31/2021— 203 4,632 — — 4,835 164 
Naidu Clinic - Odessa, TX(5)TX9/1/2021— 730 2,409 — — 3,139 93 
Belpre V Cancer Center - Belpre, OH(5)OH9/30/2021— 1,153 63,894 — — 65,047 2,072 
Center for Advanced Dermatology - Lakewood, CO(5)CO12/1/2021— 1,034 1,874 — — 2,908 59 
Florida Medical Clinic - Tampa, FL(5)FL12/1/2021— 1,104 1,137 — 124 2,365 44 
Pensacola Nephrology MOB - Pensacola, FL(5)FL12/29/2021— 1,578 5,123 — — 6,701 135 
Millennium Eye Care - Freehold, NJ(5)NJ5/26/2022— 635 6,014 — — 6,649 125 
Atlanta Gastroenterology Associates - Lawrenceville, GA(5)GA6/29/2022— 2,639 2,263 — — 4,902 24 
Bone and Joint Specialists - Merrillville, IN(5)IN6/29/2022— 1,014 2,499 — — 3,513 29 
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2022
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31, 2022(1) (2)
Accumulated
Depreciation(3) (4)
Eastern Carolina ENT - Greenville, NC(5)NC12/21/2022— 664 5,826 — — 6,490 — 
Fannie Mae Master Credit Facilities (6)(7)
352,047 
Total
$937,230 $210,294 $2,075,880 $(3,840)$13,253 $2,295,587 $397,982 
______________
(1)Acquired intangible lease assets allocated to individual properties in the amount of $292.0 million are not reflected in the table above.
(2)The tax basis of aggregate land, buildings and improvements as of December 31, 2022 is $2.1 billion.
(3)The accumulated depreciation column excludes $211.3 million of accumulated amortization associated with acquired intangible lease assets.
(4)Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements and 5 years for fixtures.
(5)These unencumbered properties were part of the borrowing base of the Credit Facility, which had $180.0 million of outstanding borrowings as of December 31, 2022. The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the real estate assets comprising the borrowing base have been pledged for the benefit of the lenders thereunder (see Note 5 Credit Facilities, Net for additional details).
(6)These properties collateralize the Capital One Facility, which had $210.5 million of outstanding borrowings as of December 31, 2022.
(7)These properties collateralize the KeyBank Facility, which had $141.6 million of outstanding borrowings as of December 31, 2022.
(8)These properties were acquired from American Realty Capital Healthcare Trust III, Inc. in 2017, which was a related party to the Company’s Advisor.
(9)Some or all of the land underlying this property is subject to an operating land lease. The related right-of-use assets are separately recorded. See Note 16 — Commitments and Contingencies for additional information.
(10)The building amount represents combined direct financing lease for the total asset as the land element was not required to be bifurcated under ASU 840. See Note 16 — Commitments and Contingencies for additional information.
(11)The property has been impaired as of December 31, 2022. See Note 3 — Real Estate Investments, Net “Assets Held for Use and Related Impairments” for additional information.
A summary of activity for real estate and accumulated depreciation for the years ended December 31, 2022, 2021 and 2020:
December 31,
(In thousands)202220212020
Real estate investments, at cost (1):
 
Balance at beginning of year$2,345,708 $2,211,451 $2,296,627 
Additions-acquisitions and capital expenditures44,926 98,364 80,980 
Disposals, impairments and reclasses (2)
(95,047)35,893 (166,156)
Balance at end of the year$2,295,587 $2,345,708 $2,211,451 
  
Accumulated depreciation (1):
 
Balance at beginning of year$328,095 $260,399 $226,167 
Depreciation expense63,143 63,393 64,731 
Disposals, impairments and reclasses (2)
6,744 4,303 (30,499)
Balance at end of the year$397,982 $328,095 $260,399 
__________
(1)Acquired intangible lease assets and related accumulated depreciation are not reflected in the table above.
(2)Includes amounts relating to dispositions and impairment charges on assets for the years ended December 31, 2022, 2021 and 2020. Amounts for the year ended December 31, 2020 include the reclassification of approximately $49.4 million and $8.7 million of assets and accumulated depreciation, respectively, that were previously classified as held-for-sale as of December 31, 2019 to real estate investments, at cost and accumulated depreciation during the year ended December 31, 2020. For additional information on this reclassification during the year ended December 31, 2020, see Note 3 — Real Estate Investments.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of Accounting and Out-of-Period Adjustment Basis of Accounting     The accompanying consolidated financial statements of the Company are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“GAAP”).
Out-of-Period Adjustment
During the year ended December 31, 2019, the Company did not record quarterly interest expense related to borrowings under the Revolving Credit Facility (as defined below) that were borrowed and repaid during the fourth quarter of 2019. The amount of interest expense and related payable that should have been recorded was $0.3 million. In 2020, the Company identified that the cumulative interest payable balance was understated, and as a result a true up entry was recorded to record the payable and related expense, resulting in an out of period adjustment. The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and adjusted the amounts on a cumulative basis in 2020.
Impacts of the COVID-19 Pandemic
During the first quarter of 2020, the global COVID-19 pandemic that has spread around the world and to every state in the United States commenced. The COVID-19 pandemic has had, and could continue to have, an adverse impact on economic conditions, including a global economic slowdown and recession that may continue for some time. The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of COVID-19 on economic and market conditions. The COVID-19 pandemic had, and another pandemic in the future could have, impacts across many sectors and areas of the global economy and financial markets, leading to significant adverse impacts on economic activity including volatility in financial markets. The Company’s MOB tenants and SHOP properties operate businesses that require in-person interactions with their patients and residents, and concern regarding the transmission of COVID-19 impacted the willingness of persons to, among other things, live in or use facilities at the Company’s properties, and impact the revenues generated by the Company’s tenants.
The Company’s ability to lease space and negotiate and maintain favorable rents and the results of operations at its SHOPs could also continue to be negatively impacted by a prolonged recession in the U.S. economy. Moreover, the demand for leasing space at the Company’s MOB properties could decline, which could negatively impacting occupancy percentage, revenue and net income. Additionally, downturns or stagnation the U.S. housing market as a result of an economic downturn could adversely affect the ability, or perceived ability, of seniors to afford the resident fees and services at the Company’s SHOPs. Further, recent and continuing increases in inflation brought about by the labor shortages, supply chain disruptions and increases in interest rates have adversely impacted, and may continue to impact, the Company’s results of operations. Moreover, these increases in the rate of inflation, the ongoing war in Ukraine and related sanctions, supply chain disruptions and increases in interest rates may also impact the ability of the Company’s tenants and residents to pay rent and hence the Company’s results of operations and liquidity.
Starting in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways that vary by operating segment:
COVID-19 Impact — MOB Segment
The financial stability and overall health of the Company’s MOB tenants is critical to its business. The Company took a proactive approach to achieve mutually agreeable solutions with its MOB tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent. Since the year ended December 31, 2020, the Company has not entered into any rent deferral agreements with any of its MOB tenants, and all amounts previously deferred under prior rent deferral agreements have been collected.
COVID-19 Impact — SHOP Segment
In the Company’s SHOP segment, occupancy trended downward from March 2020 until June 2021 and has since stabilized, however, SHOP occupancy remains substantially below pre-pandemic levels. Further, the Company has continued to experience lower inquiry volumes and reduced in-person tours since the onset of the pandemic. In addition, starting in mid-March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOPs, the Company generally bears these cost increases, which were partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), and to a lesser extent, cost recoveries for personal protective equipment from residents. See below for additional information on the CARES Act. These cost increases became more prominent throughout the year ended December 31, 2022 from a combination of factors: firstly, the Company was impacted by rising inflation which generally increased the costs of services and supplies, secondly, the Company relied more on the use of temporary contract labor and agencies due to a shortage of qualified personnel and lastly, the amounts the Company paid to third party providers for wages, including overtime wages, and bonuses increased. Future developments in the course of the pandemic, increases to inflation, labor shortages and supply chain disruptions may cause further adverse impacts to the Company’s occupancy and cost levels, and these trends may continue to impact the Company and have material adverse effects on its revenues, operating costs and net income in future periods.
The financial impact of the COVID-19 pandemic on the Company has been partially offset by funds received under the CARES Act. The Company received $4.5 million, $5.1 million and $3.6 million in these funds during the years ended December 31, 2022, 2021 and 2020, respectively. The Company considers these funds to be grant contributions from the government. The full amounts received were recognized as reductions of property operating expenses in the Company’s consolidated statement of operations for the years ended December 31, 2022, 2021 and 2020, respectively, to partially offset incurred COVID-19 expenses. The Company does not anticipate that any further funds under the CARES Act will be received, and there can be no assurance that the CARES Act program will be extended or any further amounts received under currently effective or potential future government programs.
Principles of Consolidation and Basis of Presentation Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.
Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.
Leases and Lessee Accounting
For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases are being modified, the FASB and SEC have provided relief that allows companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. For COVID-19 relief qualified changes, there are two methods to potentially account for such rent deferrals or abatements under the relief, (1) as if the changes were originally contemplated in the lease contract or (2) as if the deferred payments are variable lease payments contained in the lease contract.
For all other lease changes that did not qualify for FASB relief, the Company is required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualify for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company has elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there would be no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact would be recognized ratably over the remaining life of the lease. For leases not qualifying for this relief, the Company has applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.
Lessee Accounting
The Company is also the lessee under certain land leases which will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the consolidated balance sheets as of December 31, 2022 and 2021, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022, 2021 and 2020.
For lessees, the accounting standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction. For additional information and disclosures related to the Company’s operating leases, see Note 16Commitments and Contingencies.
Revenue Recognition
Revenue Recognition
The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in its MOB segment. As of December 31, 2022, these leases had a weighted average remaining lease term of 4.9 years. Rent from tenants in the Company’s MOB operating segment (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is
considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Tenant revenue also includes operating expense reimbursements which generally increase with the increase in property operating and maintenance expenses in our MOB segment. In addition to base rent, dependent on the specific lease, tenants are generally required to pay either (i) their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors or (ii) the their share of increases in property operating and maintenance expenses to the extent they exceed the properties’ expenses for the base year of the respective leases. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.
The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOP segment, held using a structure permitted under RIDEA, and to a lesser extent, fees for ancillary services performed for SHOP residents, which are generally variable in nature. Rental income from residents in the Company’s SHOP segment is recognized as earned when services are provided. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of the leases are short term in nature, primarily month-to-month. The Company did not record material amounts of ancillary revenue from non-residents during the year ended December 31, 2022. The Company recorded ancillary revenue from non-residents of $3.5 million and $13.3 million for the years ended December 31, 2021 and 2020, respectively. Fees for ancillary services are recorded in the period in which the services are performed. The decline in ancillary revenue since the year ended December 31, 2020 is primarily due to the Company’s dispositions of its SNF properties in Lutz and Wellington, Florida, which were sold in November 2020 and May 2021, respectively.
The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating and maintenance expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating and maintenance costs of the respective properties.
The Company continually reviews receivables related to rent and unbilled rents receivable and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards, the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants in accordance with accounting rules, on the accompanying consolidated statements of operations and comprehensive income (loss) in the period the related costs are incurred, as applicable.
Investments in Real Estate
Investments in Real Estate
Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.
At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “Purchase Price Allocation” section in this Note for a discussion of the initial accounting for investments in real estate.
Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the years ended December 31, 2022, 2021 and 2020. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were no real estate investments held for sale as of December 31, 2022 or December 31, 2021.
The Company generally determines the value of construction in progress based upon the replacement cost. During the construction period, the Company capitalizes interest, insurance and real estate taxes until the development has reached substantial completion.
Purchase Price Allocation
Purchase Price Allocation
In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In allocating the fair value to any assumed or issued non-controlling interests, amounts are recorded at their fair value at the close of business on the acquisition date. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets.
For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.
Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates the fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.
Identifiable intangible assets include amounts allocated to acquire leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from six to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.
Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.
The aggregate value of intangible assets related to customer relationship, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the years ended December 31, 2022, 2021 and 2020.
Accounting for Leases, Lessor Accounting
Accounting for Leases
Lessor Accounting
In accordance with the lease accounting standard, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than a major part of the remaining economic useful life of the asset (e.g., equal to or greater than 75%), the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or the asset is so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. As of December 31, 2022 and 2021, the Company had no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.
As a lessor of real estate, the Company has elected, by class of underlying assets, to account for lease and non-lease components (such as tenant reimbursements of property operating and maintenance expenses) as a single lease component as an operating lease because (a) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (b) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under the accounting guidance. Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed.
Gain on Dispositions of Real Estate Investments
Gain on Dispositions of Real Estate Investments
Gains on sales of rental real estate are not considered sales to customers and will generally be recognized pursuant to the provisions included in ASC 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets (“ASC 610-20”).
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statement of operations and comprehensive (loss) to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held and used. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.
Reportable Segments
Reportable Segments
The Company has determined that it has two reportable segments, with activities related to investing in MOBs and SHOPs. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level. For additional information see Note 15 — Segment Reporting.
Depreciation and Amortization
Depreciation and Amortization
Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests.
Construction in progress, including capitalized interest, insurance and real estate taxes, is not depreciated until the development has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).
The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.
The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.
Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.
Above and Below-Market Lease Amortization
Capitalized above-market lease values are amortized as a reduction of revenue from tenants over the remaining terms of the respective leases and the capitalized below-market lease values are amortized as an increase to revenue from tenants over the remaining initial terms plus the terms of any below-market fixed rate renewal options of the respective leases. If a tenant with a below-market rent renewal does not renew, any remaining unamortized amount will be taken into income at that time.
Capitalized above-market ground lease values are amortized as a reduction of property operating expense over the remaining terms of the respective leases. Capitalized below-market ground lease values are amortized as an increase to property operating expense over the remaining terms of the respective leases and expected below-market renewal option periods.
Derivative Instruments
Derivative Instruments
The Company may use derivative financial instruments to hedge all or a portion of the interest rate risk associated with its borrowings. Certain of the techniques used to hedge exposure to interest rate fluctuations may also be used to protect against declines in the market value of assets that result from general trends in debt markets. The principal objective of such agreements is to minimize the risks and costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions.
The Company records all derivatives on the balance sheet at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair value of an
asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply, or the Company elects not to apply hedge accounting.The accounting for subsequent changes in the fair value of these derivatives depends on whether each has been designated and qualifies for hedge accounting treatment. If the Company elects not to apply hedge accounting treatment, any change in the fair value of these derivative instruments is recognized immediately in gains (losses) on derivative instruments in the accompanying consolidated statements of operations and comprehensive loss prior to the adoption of ASU 2017-2 on January 1, 2019. If the derivative is designated and qualifies for hedge accounting treatment, the change in the estimated fair value of the derivative is recorded in other comprehensive income (loss) to the extent that it is effective, with any ineffective portion of a derivative’s change in fair value immediately recognized in earnings. After the adoption of ASU 2017-2, if the derivative qualifies for hedge accounting, all of the change in value is recorded in other comprehensive income (loss).
Non-controlling Interests Non-controlling InterestsThe non-controlling interests represent the portion of the common and preferred equity in the OP that is not owned by the Company as well as certain investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Non-controlling interests are presented as a separate component of equity on the consolidated balance sheets and presented as net loss attributable to non-controlling interests on the consolidated statements of operations and comprehensive loss. Non-controlling interests are allocated a share of net income or loss based on their share of equity ownership, including any preferential amounts. See Note 13 — Non-Controlling Interests for additional information.
Cash and Cash Equivalents Cash and Cash EquivalentsCash and cash equivalents includes cash in bank accounts as well as investments in highly-liquid money market funds with original maturities of three months or less.
Deferred Costs
Deferred Costs
Deferred costs, net, consists of deferred financing costs related to the Credit Facility (as defined in Note 5 — Credit Facilities) Fannie Mae Master Credit Facilities (as defined in Note 5 — Credit Facilities), and deferred leasing costs. Deferred financing costs relating to mortgage notes payable (see Note 4 — Mortgage Notes Payable, Net) are reflected net of the related financing in the mortgage notes payable, net line item of the Company’s consolidated balance sheet.
Deferred financing costs associated with the Credit Facility and Fannie Mae Master Credit Facilities and mortgage notes payable represent commitment fees, legal fees, and other costs associated with obtaining commitments for financing. These costs are amortized over the term of the financing agreement using the effective interest method for the Credit Facility and Fannie Mae Master Credit Facilities and using the effective interest method over the expected term for the mortgage notes payable.
Unamortized deferred financing costs are expensed if the associated debt is refinanced or paid down before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.
Deferred leasing costs, consisting primarily of lease commissions and professional fees incurred in connection with new leases, are deferred and amortized over the term of the lease.
Equity-Based Compensation Equity-Based CompensationThe Company has a stock-based incentive award program for its directors, which is accounted for under the guidance of share- based payments. The cost of services received in exchange for these stock awards is measured at the grant date fair value of the award and the expense for such awards is included in general and administrative expenses and is recognized over the service period (i.e., vesting) required or when the requirements for exercise of the award have been met (see Note 11Equity-Based Compensation).
Income Taxes
Income Taxes
The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986 (the “Code”), as amended, commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.
If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and local income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2022, 2021 and 2020. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income.
Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties. Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS. Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.
As of December 31, 2022, the Company owned 52 seniors housing properties (including two land parcels) which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of December 31, 2022 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the ongoing COVID-19 pandemic. These abatements were extended through December 31, 2022 and may continue to be extended for future periods.
Because of the Company’s TRS's recent operating history of taxable losses and the impacts of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $6.9 million and $4.2 million as of December 31, 2022 and 2021, respectively. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive income (loss). As of December 31, 2022, the Company’s consolidated TRS had net operating loss carryforwards for federal income tax purposes of approximately $24.4 million at December 31, 2022 (of which $7.6 million were incurred prior to January 1, 2018). Carryforwards from losses incurred prior to January 1, 2018, if unused, these will begin to expire in 2035. For net operating losses incurred subsequent to December 31, 2017, there is no expiration date. As of December 31, 2022, the Company had a deferred tax asset of $6.9 million with a full valuation allowance. As of December 31, 2021, the Company had a deferred tax asset of $4.2 million with a full valuation allowance.
The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2022, 2021 and 2020, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately 0.0%, 0.0% and (105.8)% for the years ended December 31, 2022, 2021 and 2020, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.The tax years subsequent to and including the fiscal year ended December 31, 2017 remain open to examination by the major taxing jurisdictions to which the Company is subject.
Per Share Data
Per Share Data
Net income (loss) per basic share of common stock is calculated by dividing net income (loss) by the weighted-average number of shares (retroactively adjusted for the Stock Dividends) of common stock issued and outstanding during such period. Diluted net income (loss) per share of common stock considers the effect of potentially dilutive shares of common stock outstanding during the period.
CARES Act Grants
CARES Act Grants
On March 27, 2020, the CARES Ac) was signed into law and it provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. During the years ended December 31, 2022, 2021 and 2020 the Company received $4.5 million, $5.1 million and $3.6 million in funding from CARES Act grants, respectively. For accounting purposes, the CARES Act funds are treated as a grant contribution from the government. The funding the Company received was recognized as a reduction of property operating and maintenance expenses in the Company’s consolidated statements of operations to offset the negative impacts of COVID-19. There can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
Adopted as of January 1, 2020:
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. The objective of ASU 2018-13 is to improve the effectiveness of disclosures in the notes to the financial statements by removing, modifying, and adding certain fair value disclosure requirements to facilitate clear communication of the information required by generally accepted accounting principles. The amended guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which changes how entities measure credit losses for financial assets carried at amortized cost. The update eliminates the requirement that a credit loss must be probable before it can be recognized and instead requires an entity to recognize the current estimate of all expected credit losses. Additionally, the amended standard requires credit losses on available-for-sale debt securities to be carried as an allowance rather than as a direct write-down of the asset. On July 25, 2018, the FASB proposed an amendment to ASU 2016-13 to clarify that operating lease receivables recorded by lessors (including unbilled straight-line rent) are explicitly excluded from the scope of ASU 2016-13. The new guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.
Adopted as of January 1, 2021:
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2021 and determined it did not have a material impact on its consolidated financial statements.
Adopted as of January 1, 2022:
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption was permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2022 and determined it did not have a material impact on its consolidated financial statements.
Not yet Fully Adopted as of December 31, 2022
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period from March 12, 2020 through June 30, 2023 as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that the Company’s hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of the Company’s derivatives, which will be consistent with the Company’s past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Schedule of Future Base Rent Payments on a Cash Basis
The following table presents future base rent payments on a cash basis due to the Company as of December 31, 2022 over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short-term in nature.
(In thousands)Future 
Base Rent Payments
2023$106,009 
202499,507 
202588,452 
202680,462 
202762,175 
Thereafter215,275 
Total$651,880 
Schedule of Components of Income Tax Benefit (Expense)
The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2022, 2021 and 2020, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately 0.0%, 0.0% and (105.8)% for the years ended December 31, 2022, 2021 and 2020, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.
Year Ended December 31,
202220212020
(In thousands)CurrentDeferredCurrentDeferredCurrentDeferred
Federal (expense) benefit $— $2,145 $— $(319)$726 $— 
State (expense) benefit(201)604 (203)(163)(196)50 
Deferred tax asset valuation allowance— (2,749)— 482 — (4,641)
Total income tax benefit (expense)$(201)$— $(203)$— $530 $(4,591)
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate Investments, Net (Tables)
12 Months Ended
Dec. 31, 2022
Real Estate [Abstract]  
Schedule of Business Acquisitions, by Acquisition The following table presents the allocation of the assets acquired and liabilities assumed during the years ended December 31, 2022, 2021 and 2020:
Year Ended December 31,
(In thousands)202220212020
Real estate investments, at cost:
Land$4,933 $12,848 $7,665 
Buildings, fixtures and improvements16,606 121,376 90,699 
Total tangible assets21,539 134,224 98,364 
Acquired intangibles:
In-place leases and other intangible assets (1)
3,763 28,499 10,369 
Market lease and other intangible assets (1)
268 794 496 
Market lease liabilities (1)
(32)(1,639)(362)
Total intangible assets and liabilities
3,999 27,654 10,503 
Mortgage notes payable assumed, net— — (13,883)
Issuance of Preferred OP Units (2)
— (2,578)— 
Cash paid for real estate investments, including acquisitions$25,538 $159,300 $94,984 
Number of properties purchased17 
_______________
(1)Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 8.9 years, 9.3 years and 12.1 years, respectively, as of December 31, 2022. Weighted-average remaining amortization periods for in-place leases and above-market leases acquired were 11.2 years, 10.2 years and 8.5 years, respectively, as of December 31, 2021. Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 1.7 years, 7.7 years and 7.4 years, respectively, as of December 31, 2020.
(2)See Note 8 — Stockholders’ Equity for additional information.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of December 31, 2022, 2021 and 2020:
December 31,
State202220212020
Florida (1)
19.2%17.7%20.6%
Pennsylvania**10.4%
_______________
*    State’s annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income for all portfolio properties as of the period specified.
(1)In May 2021, the Company’s skilled nursing facility in Wellington, Florida, and the Company’s development property in Jupiter, Florida were sold. In December 2020, the Company’s skilled nursing facility in Lutz, Florida was sold.
Schedule of Acquired Finite-Lived Intangible Assets by Major Class Acquired intangible assets and liabilities consisted of the following as of the periods presented:
December 31, 2022December 31, 2021
(In thousands)Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Intangible assets:
In-place leases$268,135 $198,138 $69,997 $264,741 $183,073 $81,668 
Market lease assets14,432 12,042 2,390 14,164 11,212 2,952 
Other intangible assets9,467 1,165 8,302 9,467 1,006 8,461 
Total acquired intangible assets
$292,034 $211,345 $80,689 $288,372 $195,291 $93,081 
Intangible liabilities:
Market lease liabilities $23,504 $14,097 $9,407 $23,472 $12,529 $10,943 
Schedule of Finite-Lived Intangible Assets
The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above-and below-market lease assets and liabilities, net and the amortization of above-and below-market ground leases, for the periods presented:
Year Ended December 31,
(In thousands)202220212020
Amortization of in-place leases and other intangible assets (1)
$15,076 $15,071 $15,121 
Accretion of above-and below-market leases, net (2)
$(795)$(422)$(257)
Amortization of above-and below-market ground leases, net (3)
$159 $214 $178 
________
(1)Reflected within depreciation and amortization expense.
(2)Reflected within revenue from tenants.
(3)Reflected within property operating and maintenance expense.
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
The following table provides the projected amortization and adjustments to revenue from tenants for the next five years:
(In thousands)20232024202520262027
In-place lease assets$13,208 $11,287 $9,700 $8,454 $4,958 
Other intangible assets10 10 10 10 10 
Total to be added to amortization expense$13,218 $11,297 $9,710 $8,464 $4,968 
Above-market lease assets$(495)$(416)$(363)$(329)$(240)
Below-market lease liabilities1,512 1,294 1,103 941 623 
Total to be added to revenue from tenants$1,017 $878 $740 $612 $383 
Schedule of Properties Sold
The following table summarizes the properties sold during the years ended December 31, 2022, 2021 and 2020:
(In thousands)Disposition DateContract Sale PriceGain (Loss)
on Sale, of Real Estate Investments
2022 Dispositions:
LaSalle properties (four properties) (1)
March 2, 2022$12,400 $(303)
Lien settlement on formerly disposed propertiesN/AN/A178 
Totals$12,400 $(125)
2021 Dispositions:
Hampton River Portfolio (two properties)
December 21, 2021$37,800 $1,323 
NuVista Jupiter (2)
May 14, 202165,000 2,383 
Wellington Green (3)
May 14, 202130,750 114 
Michigan SHOPs (four properties) (4)
January 15, 2021— (172)
Totals$133,550 $3,648 
2020 Dispositions:
Lutz (5)
December 15, 2020$20,000 $3,832 
Michigan SHOPs (seven properties) (4)
November 2, 202011,750 (908)
Cape GirardeauMarch 19, 20208,600 2,306 
Totals$40,350 $5,230 
______
(1)Impairment charges of $34.0 million were recorded during the year ended December 31, 2021.
(2)Impairment charges of $14.6 million and $19.8 million were recorded during the years ended December 31, 2020 and 2019, respectively.
(3)Impairment charges of $0.9 million, $2.3 million and $9.9 million were recorded during the years ended December 31, 2021, 2020 and 2019, respectively.
(4)Impairment charges of $19.6 million and $22.6 million were recorded during the years ended December 31, 2020 and 2019, respectively. The contract sales price for all 11 properties was received in November of 2020. Loss on sale amounts relate to the properties transferred at the respective dates.
(5)Impairment charges of $3.6 million were recorded during the year ended December 31, 2019.
Schedule of Impairments Recorded
The following table presents impairment charges by segment recorded during the years ended December 31, 2022, 2021 and 2020:
Year Ended December 31,
(In thousands)202220212020
MOB Segment:
Illinois skilled nursing facilities (1) (7)
$10,644 $— $— 
Sassafras MOB (2) (7)
1,844 — — 
Sun City MOB (3) (7)
— 6,082 — 
Total MOB impairment charges12,488 6,082 — 
SHOP Segment:
Various held for use SHOPs (4) (7)
15,142 — — 
LaSalle Properties (5) (7)
— 34,000 — 
Wellington, Florida skilled nursing facility (6) (7)
— 869 2,276 
Michigan properties (8)
— — 19,570 
NuVista Jupiter (7) (9)
— — 14,600 
Total SHOP impairment charges15,142 34,869 36,446 
Total impairment charges$27,630 $40,951 $36,446 
(1)These seven properties were impaired after the Company received an offer by the tenant to purchase all seven properties, which caused the Company to reassess its expected holding period for these properties. As of December 31, 2022, these properties were not disposed nor are under contract for disposal.
(2)The Company began marketing this property for sale in the fourth quarter of 2022. As of December 31, 2022 this property was not disposed nor under contract for disposal.
(3)This property has been actively marketed for sale since September 2021. As of December 31, 2022 this property was not disposed nor under contract for disposal.
(4)Consists of eight properties actively marketed for sale. Of the eight properties, six properties were impaired in year ended December 31, 2022. As of December 31, 2022, these properties were not disposed, but five of these properties are under contract for disposal.
(5)These four properties were disposed in the year ended December 31, 2022.
(6)This property was disposed in the year ended December 31, 2021. The Company recorded this impairment charge in the year ended December 31, 2021 to reduce the carrying value of the property to its estimated fair value as determined by an amendment to its purchase and sale agreement. The Company had previously recorded $2.3 million of impairment charges on this property in the year ended December 31, 2020.
(7)These properties were impaired to reduce their carrying values to their estimated fair values, respectively, as determined by the Assets Held for Use approach described above.
(8)These properties were disposed in the first quarter of 2021 and the fourth quarter of 2020.
(9)This property was disposed in the second quarter of 2021.
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Mortgage Notes Payable, Net (Tables)
12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments
The following table reflects the Company’s mortgage notes payable as of December 31, 2022 and 2021:
PortfolioEncumbered PropertiesOutstanding Loan Amount as of December 31,
Effective Interest Rate (1) as of December 31,
Interest Rate
2022202120222021Maturity
(In thousands)(In thousands)
Palm Valley Medical Plaza - Goodyear, AZ$— $2,879 — %4.15%FixedJun. 2023
Medical Center V - Peoria, AZ— 2,684 — %4.75%FixedSep. 2023
Fox Ridge Bryant - Bryant, AR16,817 6,977 3.98 %3.98%FixedMay 2047
Fox Ridge Chenal - Little Rock, AR115,639 16,024 2.95 %2.95%FixedMay 2049
Fox Ridge North Little Rock - North Little Rock, AR19,704 9,943 2.95 %2.95%FixedMay 2049
Capital One MOB Loan41378,500 378,500 3.73 %3.71%Fixed(2)Dec. 2026
Multi-Property CMBS Loan21118,700 118,700 4.60 %4.60%FixedMay 2028
Shiloh - Illinois
113,071 13,384 4.34 %4.34%FixedJan. 2025
BMO CMBS942,750 42,750 2.89 %2.89%FixedDec. 2031
Gross mortgage notes payable75585,181 591,841 3.83 %3.82%
Deferred financing costs, net of accumulated amortization (3)
(5,117)(6,186)
Mortgage premiums and discounts, net(1,364)(1,416)
Mortgage notes payable, net$578,700 $584,239 
__________
(1)Calculated on a weighted average basis for all mortgages outstanding as of December 31, 2022 and December 31, 2021. For the SOFR/LIBOR based loans, SOFR/LIBOR in effect at the balance sheet date was utilized. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See Note 7 — Derivatives and Hedging Activities for additional details.
(2)Variable rate loan, based on daily SOFR as of December 31, 2022 and based on 30-day LIBOR as of December 31, 2021, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. The Company allocated $378.5 million of its “pay-fixed” interest rate swaps to this mortgage consistently as of December 31, 2022 and 2021.
(3)Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Credit Facilities, Net (Tables)
12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Schedule of Credit Facilities
The Company had the following credit facilities outstanding as of December 31, 2022 and 2021:
Outstanding Facility Amount as of December 31,
Effective Interest Rate as of December 31,(9) (10)
Credit Facility
Encumbered Properties (1)
2022202120222021Interest RateMaturity
(In thousands)(In thousands)
Credit Facility:
Revolving Credit Facility
$30,000 $— 7.26 %— %VariableMar. 2024(8)
Term Loan
150,000 150,000 5.11 %4.11 %Fixed(6)Mar. 2024
Deferred financing costs
(1,750)(2,994)
Term Loan, net
148,250 147,006 
Total Credit Facility
98(2)$178,250 $147,006 
Fannie Mae Master Credit Facilities:
Capital One Facility11(3)$210,483 $212,417 5.90 %2.51 %Variable(7)Nov. 2026
KeyBank Facility10(4)141,564 142,628 6.60 %2.56 %Variable(7)Nov. 2026
Total Fannie Mae Master Credit Facilities
21$352,047 $355,045 
Total Credit Facilities119$530,297 $502,051 5.94 %(5)3.00 %(5)
_______
(1)Encumbered properties are as of December 31, 2022.
(2)The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below) have been pledged for the benefit of the lenders thereunder.
(3)Secured by first-priority mortgages on 11 of the Company’s seniors housing properties located in Florida, Georgia, Iowa and Michigan as of December 31, 2022 with a carrying value of $348.9 million.
(4)Secured by first-priority mortgages on ten of the Company’s seniors housing properties located in, Missouri, Kansas, California, Florida, Georgia and Iowa as of December 31, 2022 with carrying value of $261.0 million.
(5)Calculated on a weighted average basis for all credit facilities outstanding as of December 31, 2022 and 2021, respectively.
(6)Variable rate loan, based on SOFR, all of which was economically fixed as a result of entering into “pay-fixed” interest rate swap agreements (the Company designates its SOFR “pay-fixed” interest rate swaps against all 30-day SOFR debt, see Note 7 — Derivatives and Hedging Activities for additional details).
(7)The effective rates above only include the impact of designated hedging instruments. The Company also has seven non-designated interest rate cap agreements with an aggregate notional amount of $354.6 million which limits 30-day LIBOR to 3.50%. The Company did not designate these derivatives as hedges and accordingly, the changes in value and any cash received from these derivatives are presented within gain (loss) on derivative instruments on the consolidated statements of operations and comprehensive income (see discussion below and Note 7 — Derivatives and Hedging Activities for additional details). Inclusive of the impact of these interest rate caps on these non-designated derivatives, the economic interest rate on the Capital One Fannie Mae Facility was 5.26%, and the economic interest rate on the KeyBank Fannie Mae Facility was 5.96% as of December 31, 2022.
(8)During the year ended December 31, 2022, the Company exercised its option to extend the maturity one year to March 2024.
(9)Effective interest rate below for variable rate debt gives effect to any “pay-fixed” swap entered into by the Company allocated to the loan for presentation purposes. If no “pay-fixed” swaps are allocated, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of December 31, 2022 and 2021. Interest rate caps are not considered unless the caps, if any, are currently in effect.
(10)The Company has interest “pay-fixed” swaps which are designated as cash flow hedges on LIBOR- or SOFR-based outstanding combined borrowings. Prior to the Fourth Amendment (as defined below) which, among other things, changed the reference rate on the Credit Facility from LIBOR to SOFR, to present average rates in the table above, the Company historically allocated the notional amount of a “pay-fixed” swap to the outstanding amounts of its Credit Facility (both the Revolving Credit Facility and the Term Loan) with any remaining notional amounts applied to its Capital One Fannie Mae Facility. During the three months ended September 30, 2022, the Company converted $150.0 million of its “pay-fixed” swaps from LIBOR to SOFR. As of December 31, 2022, the Company allocated the $150.0 million SOFR-based “pay-fixed” swaps to the Term Loan, which were also allocated to the
Term Loan as of December 31, 2021 when the Term Loan and swaps were LIBOR-based. As of December 31, 2022 and 2021, $50.0 million of LIBOR-based “pay-fixed” swaps were allocated to the Capital One Fannie Mae Facility because there were no LIBOR-based amounts outstanding under the Revolving Credit Facility in either period. The $50.0 million of LIBOR-based “pay-fixed” swaps were terminated subsequent to December 31, 2022. See Note 17 — Subsequent Events for additional information.
Schedule of Maturities of Long-term Debt
The following table summarizes the scheduled aggregate principal payments for the five years subsequent to December 31, 2022 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities):
Future Principal
Payments
(In thousands)Mortgage Notes PayableCredit FacilitiesTotal
2023$1,139 $5,769 $6,908 
20241,178 185,769 186,947 
202513,270 5,769 19,039 
2026379,393 334,740 714,133 
2027922 — 922 
Thereafter189,279 — 189,279 
Total$585,181 $532,047 $1,117,228 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value of Financial Instruments (Tables)
12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of Recurring Fair Value Measurements
The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2022 and 2021, aggregated by the level in the fair value hierarchy within which those instruments fall.
(In thousands)Quoted Prices in Active Markets
Level 1
Significant
Other Observable Inputs
Level 2
Significant Unobservable Inputs
Level 3
Total
December 31, 2022
Derivative assets, at fair value (non-designated)$— $3,737 $— $3,737 
Derivative assets, at fair value (designated)— 36,910 — 36,910 
Derivative liabilities, at fair value— — — — 
Total$— $40,647 $— $40,647 
December 31, 2021
Derivative assets, at fair value (non-designated)$— $174 $— $174 
Derivative liabilities, at fair value (designated)(13,903)(13,903)
Total$— $(13,729)$— $(13,729)
Schedule of Fair Value by Balance Sheet
The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:
December 31, 2022December 31, 2021
(In thousands)Level
Carrying Amount 
Fair Value
Carrying Amount 
Fair Value
Gross mortgage notes payable and mortgage
premium and discounts, net
3$583,817 $550,626 $590,425 $594,348 
Credit Facility
3$180,000 $179,496 $150,000 $148,817 
Fannie Mae Master Credit Facilities
3$352,047 $353,034 $355,045 $350,710 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Derivatives and Hedging Activities (Tables)
12 Months Ended
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Balance Sheet Location The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of December 31, 2022 and 2021:
December 31,
(In thousands)Balance Sheet Location20222021
Derivatives designated as hedging instruments:
Interest rate “pay-fixed” swapsDerivative assets, at fair value$36,910 $— 
Interest rate “pay-fixed” swapsDerivative liabilities, at fair value$— $13,903 
Derivatives not designated as hedging instruments:
Interest rate capsDerivative assets, at fair value$3,737 $174 
Schedule of Derivative Instruments
As of December 31, 2022 and 2021, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:
December 31, 2022December 31, 2021
Interest Rate DerivativeNumber of InstrumentsNotional AmountNumber of InstrumentsNotional Amount
(In thousands)(In thousands)
SOFR-based interest rate “pay-fixed” swaps$528,500 — $— 
LIBOR-based interest rate “pay-fixed” swaps50,000 578,500 
Total interest rate “pay-fixed” swaps$578,500 $578,500 
The Company had the following outstanding interest rate derivatives that were not designated as a hedges in qualifying hedging relationships as of as of December 31, 2022 and 2021:
December 31, 2022December 31, 2021
Interest Rate DerivativesNumber of Instruments
Notional Amount (1)
Number of Instruments
Notional Amount (1)
(In thousands)(In thousands)
Interest rate caps (2)
$354,624 $355,175 
(1)Notional amount represents the currently active interest cap contract and excludes one and three inactive cap agreements (included in the instrument count) with aggregate notional amounts of $52.6 million and $140.8 million as of December 31, 2022 and 2021, respectively, which take effect upon the expiration of similar caps included above and effectively extend the term for the same notional amount.
(2)All of the Company’s interest rate cap agreements limit 30-day LIBOR to 3.50% with terms through April 2024. The actual 30-day LIBOR rates during the fourth quarter of 2022 exceeded the strike price rate of 3.50% and the Company is currently receiving payments under these agreements. Changes in the fair market value of these non-designated derivatives, as well as any cash received, are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive income.
Schedule of Derivatives Included in AOCI The table below details the location in the financial statements of the loss recognized on interest rate derivatives designated as cash flow hedges for the periods ended December 31, 2022 and 2021:
Year Ended December 31,
(In thousands)202220212020
Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives$50,098 $14,322 $(40,614)
Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense$(1,153)$(11,010)$(7,999)
Total amount of interest expense presented in the
consolidated statements of operations and comprehensive loss
$51,740 $47,900 $51,519 
Schedule of Offsetting Assets The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2022 and 2021. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheets.
Gross Amounts Not Offset in the Consolidated Balance Sheet
(In thousands)Gross Amounts of Recognized AssetsGross Amounts of Recognized (Liabilities)Gross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets presented in the Consolidated Balance SheetFinancial InstrumentsCash Collateral ReceivedNet Amount
December 31, 2022
$40,647 — — $40,647 — — $40,647 
December 31, 2021
$174 — — $174 — — $174 
December 31, 2021
$— (13,903)— $(13,903)— — $(13,903)
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Schedule of Class of Treasury Stock
The table below reflects the number of shares repurchased and the average price per share (retroactively adjusted for the Stock Dividends), under the SRP and does not include any repurchases under tender offers (see above), cumulatively through December 31, 2022:
Number of Shares RepurchasedAverage Price per Share
Cumulative repurchases as of December 31, 2021
4,896,620 $20.60 
Year ended December 31, 2022
— — 
Cumulative repurchases as of December 31, 2022
4,896,620 20.60 
Schedule of Stock Dividends The following table details these stock dividends:
Stock Dividend Declaration DateStock Dividend Issue DateQuarterly Stock Dividend Rate (per share)
October 1, 2020October 15, 20200.013492
January 4, 2021January 15, 20210.013492
April 2, 2021April 15, 20210.014655
July 1, 2021July 15, 20210.014655
October 1, 2021October 15, 20210.014655
January 3, 2022January 15, 20220.014655
April 1, 2022April 18, 20220.014167
July 1, 2022July 15, 20220.014167
October 3, 2022October 17, 20220.014167
January 3, 2023January 18, 20230.014167
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions and Arrangements (Tables)
12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services
The following table details amounts incurred and payable in connection with the Company’s operations-related services described above as of and for the periods presented:
Year Ended December 31,Payable (Receivable) as of
 202220212020December 31,
(In thousands)
Incurred
Incurred
Incurred20222021
One-time fees and reimbursements:
Acquisition cost reimbursements$23 $90 $81 $$23 
Ongoing fees and reimbursements:
Asset management fees 21,831 20,710 19,987 — — 
Property management fees (4)
4,200 3,749 4,197 24 
Professional fees and other reimbursements (1) (3)
8,820 

9,386 12,102 39 (70)
Professional fees credit due from Advisor— (1,030)(1,217)— (859)(2)
Distributions on Class B Units — — 178 — — 
Total related party operation fees and reimbursements$34,874 $32,905 $35,328 $47 $(882)
_________
(1)Included in general and administrative expenses in the consolidated statements of operations. Includes $6.0 million, $6.2 million and $5.6 million subject to the Capped Reimbursement Amount for the years ended December 31, 2022, 2021 and 2020, respectively.
(2)Balance as of December 31, 2021 includes a receivable of $0.9 million from the Advisor related to the overpayment of 2020 Bonus Awards, which, pursuant to authorization by the independent members of the Company’s board of directors, was required to be repaid to the Company on a pro rata basis over a six-month period from November 2021 through April 2022.
(3)During the year ended December 31, 2020 the Company recorded approximately $2.2 million of expense reimbursements to the Advisor for severance payments and related legal costs relating to the termination of its former Chief Executive Officer.
(4)Inclusive of $0.7 million and $0.3 million of leasing commissions which are included in prepaid expenses and other assets on the consolidated balance sheet as of December 31, 2022 and 2021.
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Equity-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Restricted Share Award Activity
The following table reflects the amount of restricted shares outstanding as of December 31, 2022 and activity for the period presented:
Number of Common Shares Weighted-Average Issue Price
Unvested, December 31, 2019277,241 $21.18 
Stock dividend2,878 15.75 
Granted— — 
Vested(64,735)21.18 
Forfeitures— — 
Unvested, December 31, 2020
215,384 21.11 
Stock Dividend12,646 14.79 
Granted— 
Vested(68,603)19.72 
Forfeitures— — 
Unvested, December 31, 2021
159,427 21.21 
Stock dividend8,313 14.86 
Granted— — 
Vested(70,397)23.67 
Forfeitures— — 
Unvested, December 31, 2022
97,343 18.89 
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Accumulated Other Comprehensive Income (Loss) (Tables)
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The following table illustrates the changes in accumulated other comprehensive income (loss) as of and for the periods presented:
(In thousands)Unrealized Gains (Losses) on Designated Derivative
Balance, December 31, 2019$(7,043)
Other comprehensive loss, before reclassifications(40,614)
Amount of loss reclassified from accumulated other comprehensive income (loss) 7,999 
Rebalancing of ownership percentage(15)
Balance, December 31, 2020
(39,673)
Other comprehensive income, before reclassifications14,322 
Amount of loss reclassified from accumulated other comprehensive income (loss)11,010 
Balance, December 31, 2021
(14,341)
Other comprehensive income, before reclassifications50,098 
Amount of loss reclassified from accumulated other comprehensive income (loss)1,153 
Balance, December 31, 2022
$36,910 
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Non-Controlling Interests (Tables)
12 Months Ended
Dec. 31, 2022
Noncontrolling Interest [Abstract]  
Schedule of Noncontrolling Interest on Balance Sheet
Non-controlling interests on the Company’s consolidated balance sheet is comprised of the following:
Balance as of December 31,
(In thousands)20222021
Series A Preferred Units held by third parties$2,578 $2,578 
Common OP Units held by third parties3,584 3,758 
Total Non-controlling Interests in the OP6,162 6,336 
Non-controlling interests in property owning subsidiaries389 368 
Total Non-controlling Interests$6,551 $6,704 
Schedule Related to Investment Arrangements with Unaffiliated Third Party
The following table summarizes the activity related to investment arrangements with unaffiliated third parties.
Third Party Net Investment AmountNon-Controlling Ownership PercentageNet Real Estate Assets Subject to Investment ArrangementDistributions
Property NameAs of December 31,As of December 31,As of December 31,Year Ended December 31,
(Dollar amounts in thousands)
Investment Date2022202220222021202220212020
Plaza Del Rio Medical Office Campus Portfolio(1)
May 2015$389 2.5 %$12,455 $12,925 $— $— $— 
_____________
(1)One property within the Plaza Del Rio Medical Office Campus Portfolio was mortgaged as part of the Multi-Property CMBS Loan. See Note 4 - Mortgage Notes Payable for additional information.
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Net Loss Per Share (Tables)
12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following is a summary of the basic and diluted net loss per share computation for the years ended December 31, 2022, 2021 and 2020 and has been retroactively adjusted to reflect the stock dividends (see Note 1 — Organization for additional details):
Year Ended December 31,
202220212020
Net loss attributable to stockholders (in thousands)
$(93,285)$(92,942)$(78,781)
Basic and diluted weighted-average shares outstanding (1)
106,428,154 106,354,994 106,119,937 
Basic and diluted net loss per share (1)
$(0.88)$(0.87)$(0.74)
(1)Retroactively adjusted for the effects of the stock dividends. See Note 1 — Organization and Note 8 — Stockholder’s Equity for additional information.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share The amounts in the table below have been retroactively adjusted to reflect the stock dividends (see Note 1 — Organization for additional details):
December 31,
202220212020
Unvested restricted shares (1)
141,364 214,520 288,965 
Common OP Units (2)
467,602 467,602 467,602 
Class B Units (3)
413,760 413,760 413,760 
Total weighted average antidilutive common share equivalents1,022,726 1,095,882 1,170,327 
________
(1)Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. There were 97,343, 159,427 and 215,384 unvested restricted shares outstanding as of December 31, 2022, 2021 and 2020, respectively.
(2)Weighted average number of antidilutive Common OP Units presented as shares outstanding for the periods presented, at the current conversion rate as retroactively adjusted for the effects of the stock dividends. There were 405,998 Common OP Units outstanding as of December 31, 2022, 2021 and 2020.
(3)Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current conversion rate as retroactively adjusted for the effects of the stock dividends. There were 359,250 Class B Units outstanding as of December 31, 2022, 2021 and 2020.
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Schedule of Segment Reporting
The following tables reconcile the segment activity to consolidated net loss for the years ended December 31, 2022, 2021 and 2020:
Year Ended December 31, 2022
(In thousands)Medical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants$131,444 $204,402 $335,846 
Property operating and maintenance35,945 177,499 213,444 
NOI$95,499 $26,903 122,402 
Impairment charges(27,630)
Operating fees to related parties(25,353)
Acquisition and transaction related(1,484)
General and administrative(17,287)
Depreciation and amortization(82,064)
Loss on sale of real estate investments(125)
Interest expense(51,740)
Interest and other income 27 
Gain on non designated derivatives3,834 
Income tax expense(201)
Net loss attributable to non-controlling interests135 
Allocation for preferred stock(13,799)
Net loss attributable to common stockholders$(93,285)
Year Ended December 31, 2021
(In thousands)Medical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants$122,867 $206,488 $329,355 
Property operating and maintenance34,480 171,333 205,813 
NOI88,387 35,155 123,542 
Impairment charges(40,951)
Operating fees to related parties(24,206)
Acquisition and transaction related(2,714)
General and administrative(16,828)
Depreciation and amortization(79,926)
Gain on sale of real estate investments3,648 
Interest expense(47,900)
Interest and other income61 
Gain on non-designated derivatives37 
Income tax expense(203)
Net loss attributable to non-controlling interests260 
Allocation for preferred stock(7,762)
Net loss attributable to common stockholders$(92,942)

Year Ended December 31, 2020
(In thousands)Medical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants$119,824 $261,788 $381,612 
Property operating and maintenance32,812 210,736 243,548 
NOI87,012 51,052 138,064 
Impairment charges(36,446)
Operating fees to related parties(23,922)
Acquisition and transaction related(173)
General and administrative(21,572)
Depreciation and amortization(81,053)
Gain on sale of real estate investment 5,230 
Interest expense(51,519)
Interest and other income 44 
Loss on non-designated derivatives (102)
Income tax expense(4,061)
Net income attributable to non-controlling interests(303)
Allocation for preferred stock(2,968)
Net loss attributable to common stockholders$(78,781)
The following table reconciles the segment activity to consolidated total assets as of the periods presented:
December 31,
(In thousands)20222021
ASSETS
Investments in real estate, net:
Medical office and other healthcare-related buildings$1,121,857 $1,149,241 
Seniors housing — operating properties856,440 900,686 
Total investments in real estate, net
1,978,297 2,049,927 
Cash and cash equivalents53,654 59,738 
Restricted cash22,884 25,644 
Derivative assets, at fair value40,647 174 
Straight-line rent receivable, net25,276 23,858 
Operating lease right-of-use asset7,814 7,914 
Prepaid expenses and other assets34,554 32,564 
Deferred costs, net17,223 14,581 
Total assets$2,180,349 $2,214,400 

The following table reconciles capital expenditures by reportable business segments, excluding corporate non-real estate expenditures, for the periods presented:
Year Ended December 31,
(In thousands)202220212020
Medical office and other healthcare-related buildings$10,542 $6,152 $8,561 
Seniors housing — operating properties17,451 12,919 12,833 
Total capital expenditures$27,993 $19,071 $21,394 
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Schedule of Operating Lease, Liability, Maturity
Future Base Rent Payments
(In thousands)Operating Leases
Direct Financing Leases (1)
2023$645 $88 
2024632 90 
2025588 93 
2026599 95 
2027617 97 
Thereafter21,942 7,215 
Total minimum lease payments25,023 7,678 
Less: amounts representing interest(16,936)(2,841)
Total present value of minimum lease payments$8,087 $4,837 
_______
(1)The Direct Finance Lease liability is included in Accounts Payable and accrued expenses on the balance sheet as of December 31, 2022. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.
Schedule of Finance Lease, Liability, Maturity
Future Base Rent Payments
(In thousands)Operating Leases
Direct Financing Leases (1)
2023$645 $88 
2024632 90 
2025588 93 
2026599 95 
2027617 97 
Thereafter21,942 7,215 
Total minimum lease payments25,023 7,678 
Less: amounts representing interest(16,936)(2,841)
Total present value of minimum lease payments$8,087 $4,837 
_______
(1)The Direct Finance Lease liability is included in Accounts Payable and accrued expenses on the balance sheet as of December 31, 2022. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Organization (Narrative) (Details)
ft² in Millions
3 Months Ended 12 Months Ended 27 Months Ended
Dec. 31, 2021
segment
Dec. 31, 2022
land_parcel
property
contractor
segment
shares
Dec. 31, 2021
segment
shares
Dec. 31, 2022
property
shares
Dec. 31, 2022
state
Dec. 31, 2022
ft²
Dec. 31, 2022
encumberedProperty
Organization, Consolidation and Presentation of Financial Statements [Abstract]              
Number of real estate properties   202   202     119
Number of states properties are located in | state         34    
Area of real estate property | ft²           9.1  
Number of senior housing communities | property   52   52      
Number of reportable segments | segment 2 2 3        
Number of independent contractors | contractor   4          
Number of land parcels | land_parcel   2          
Distributions declared in common stock (in shares)       12,600,000      
Issuance of preferred stock, net (in shares)   0 0        
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Narrative) (Details)
3 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
segment
Dec. 31, 2022
USD ($)
land_parcel
property
segment
Dec. 31, 2021
USD ($)
segment
Dec. 31, 2020
USD ($)
lease
Dec. 31, 2019
USD ($)
Jan. 01, 2018
USD ($)
Schedule of Shares Repurchased [Line Items]            
Interest expense   $ 51,740,000 $ 47,900,000 $ 51,519,000    
Proceeds from government assistance   $ 4,500,000 $ 5,100,000 $ 3,600,000    
Remaining lease term   4 years 10 months 24 days        
Ancillary Fee Income, Servicing Financial Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]     Revenue from tenants Revenue from tenants    
Operating lease impairment loss   $ 3,200,000 $ 1,100,000 $ 2,700,000    
Disposed properties reduction in revenue   1,300,000 0 1,000,000    
Assets held for sale $ 0 $ 0 $ 0      
Number of reportable segments | segment 2 2 3      
Money market funds $ 0 $ 0 $ 0      
Cash and cash equivalents 59,738,000 53,654,000 59,738,000 $ 72,357,000    
Cash in excess of FDIC limit 46,200,000 $ 43,600,000 46,200,000      
Number of senior housing communities | property   52        
Number of land parcels | land_parcel   2        
Number of intercompany leases modified | lease       25    
Valuation allowance percentage   100.00%        
Deferred tax asset, net $ 4,200,000 $ 6,900,000 $ 4,200,000      
Effective income tax rate   0.00% 0.00% (105.80%)    
Domestic Tax Authority            
Schedule of Shares Repurchased [Line Items]            
Operating loss carryforwards   $ 24,400,000       $ 7,600,000
Credit Facilities            
Schedule of Shares Repurchased [Line Items]            
Interest expense         $ 0  
Credit Facilities | Revision of Prior Period, Adjustment            
Schedule of Shares Repurchased [Line Items]            
Interest expense         $ 300,000  
Minimum            
Schedule of Shares Repurchased [Line Items]            
Lease intangibles, lease-up period   6 months        
Maximum            
Schedule of Shares Repurchased [Line Items]            
Lease intangibles, lease-up period   24 months        
Building            
Schedule of Shares Repurchased [Line Items]            
Useful life   40 years        
Land Improvements            
Schedule of Shares Repurchased [Line Items]            
Useful life   15 years        
Fixtures and improvements | Minimum            
Schedule of Shares Repurchased [Line Items]            
Useful life   7 years        
Fixtures and improvements | Maximum            
Schedule of Shares Repurchased [Line Items]            
Useful life   10 years        
Seniors Housing — Operating Properties            
Schedule of Shares Repurchased [Line Items]            
Ancillary revenue   $ 0 $ 3,500,000 $ 13,300,000    
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Future Base Rent Payments on a Cash Basis) (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Accounting Policies [Abstract]  
2023 $ 106,009
2024 99,507
2025 88,452
2026 80,462
2027 62,175
Thereafter 215,275
Total $ 651,880
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Income Taxes) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Current      
Federal (expense) benefit $ 0 $ 0 $ 726
State (expense) benefit (201) (203) (196)
Total income tax benefit (expense) (201) (203) 530
Deferred      
Federal (expense) benefit 2,145 (319) 0
State (expense) benefit 604 (163) 50
Deferred tax asset valuation allowance (2,749) 482 (4,641)
Total income tax benefit (expense) $ 0 $ 0 $ (4,591)
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate Investments, Net (Narrative) (Details)
12 Months Ended
Dec. 31, 2022
USD ($)
property
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Real Estate [Line Items]      
Number of properties purchased | property 202    
Payments to acquire property | $ $ 25,538,000 $ 159,300,000 $ 94,984,000
Assets held for sale | $ $ 0 $ 0  
Multi-tenant MOB      
Real Estate [Line Items]      
Number of properties purchased | property 1    
Single Tenant MOB      
Real Estate [Line Items]      
Number of properties purchased | property 3    
Medical Office Buildings      
Real Estate [Line Items]      
Payments to acquire property | $ $ 25,300,000    
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate Investments, Net (Acquired Assets) (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2022
USD ($)
property
Dec. 31, 2021
USD ($)
property
Dec. 31, 2020
USD ($)
property
Real estate investments, at cost:      
Issuance of Preferred OP Units $ 0 $ (2,578) $ 0
Number of properties purchased | property 202    
In-place leases and other intangible assets      
Real estate investments, at cost:      
Weighted-average remaining amortization periods 8 years 10 months 24 days 11 years 2 months 12 days 1 year 8 months 12 days
Market lease and other intangible assets      
Real estate investments, at cost:      
Weighted-average remaining amortization periods 9 years 3 months 18 days 10 years 2 months 12 days 7 years 8 months 12 days
Below market leases      
Real estate investments, at cost:      
Weighted-average remaining amortization periods 12 years 1 month 6 days 8 years 6 months 7 years 4 months 24 days
Business acquisitions      
Real estate investments, at cost:      
Land $ 4,933 $ 12,848 $ 7,665
Buildings, fixtures and improvements 16,606 121,376 90,699
Total tangible assets 21,539 134,224 98,364
Market lease liabilities (32) (1,639) (362)
Total intangible assets and liabilities 3,999 27,654 10,503
Mortgage notes payable assumed, net 0 0 (13,883)
Cash paid for real estate investments, including acquisitions $ 25,538 $ 159,300 $ 94,984
Number of properties purchased | property 4 17 9
Business acquisitions | In-place leases and other intangible assets      
Real estate investments, at cost:      
In-place and market leases $ 3,763 $ 28,499 $ 10,369
Business acquisitions | Market lease and other intangible assets      
Real estate investments, at cost:      
In-place and market leases $ 268 $ 794 $ 496
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate Investments, Net (Geographic Concentrations) (Details) - Geographic Concentration Risk - Sales Revenue, Net
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Florida      
Concentration Risk [Line Items]      
Concentration risk, percentage 19.20% 17.70% 20.60%
Pennsylvania      
Concentration Risk [Line Items]      
Concentration risk, percentage     10.40%
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate Investments, Net (Summary of Intangible Lease Assets and Liabilities) (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Intangible assets:    
Gross Carrying Amount $ 292,034 $ 288,372
Accumulated Amortization 211,345 195,291
Net Carrying Amount 80,689 93,081
Intangible liabilities:    
Gross Carrying Amount 23,504 23,472
Accumulated Amortization 14,097 12,529
Net Carrying Amount 9,407 10,943
In-place leases    
Intangible assets:    
Gross Carrying Amount 268,135 264,741
Accumulated Amortization 198,138 183,073
Net Carrying Amount 69,997 81,668
Market lease assets    
Intangible assets:    
Gross Carrying Amount 14,432 14,164
Accumulated Amortization 12,042 11,212
Net Carrying Amount 2,390 2,952
Other intangible assets    
Intangible assets:    
Gross Carrying Amount 9,467 9,467
Accumulated Amortization 1,165 1,006
Net Carrying Amount $ 8,302 $ 8,461
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate Investments, Net (Summary of Amortization and Accretion Recognized) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]      
Accretion of above- and below-market leases, net $ (625) $ (198) $ (80)
Depreciation and Amortization Expense | In-place leases and other intangible assets      
Finite-Lived Intangible Assets [Line Items]      
Amortization/accretion of market least intangibles 15,076 15,071 15,121
Rental Income | Above- and below-market leases, net      
Finite-Lived Intangible Assets [Line Items]      
Accretion of above- and below-market leases, net (795) (422) (257)
Property Operating and Maintenance Expense | Above-market ground leases      
Finite-Lived Intangible Assets [Line Items]      
Amortization/accretion of market least intangibles $ 159 $ 214 $ 178
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate Investments, Net (Summary of Intangible Assets and Liabilities Future Amortization Expense) (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Amortization Expense  
Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible asset, amortization expense, 2023 $ 13,218
Finite-lived intangible asset, amortization expense, 2024 11,297
Finite-lived intangible asset, amortization expense, 2025 9,710
Finite-lived intangible asset, amortization expense, 2026 8,464
Finite-lived intangible asset, amortization expense, 2027 4,968
Rental Income  
Finite-Lived Intangible Assets [Line Items]  
Below market leases, amortization income, 2023 1,017
Below market leases, amortization income, 2024 878
Below market leases, amortization income, 2025 740
Below market leases, amortization income, 2026 612
Below market leases, amortization income, 2027 383
In-place lease assets | Amortization Expense  
Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible asset, amortization expense, 2023 13,208
Finite-lived intangible asset, amortization expense, 2024 11,287
Finite-lived intangible asset, amortization expense, 2025 9,700
Finite-lived intangible asset, amortization expense, 2026 8,454
Finite-lived intangible asset, amortization expense, 2027 4,958
Other intangible assets | Amortization Expense  
Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible asset, amortization expense, 2023 10
Finite-lived intangible asset, amortization expense, 2024 10
Finite-lived intangible asset, amortization expense, 2025 10
Finite-lived intangible asset, amortization expense, 2026 10
Finite-lived intangible asset, amortization expense, 2027 10
Above-market lease assets | Rental Income  
Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible asset, amortization expense, 2023 (495)
Finite-lived intangible asset, amortization expense, 2024 (416)
Finite-lived intangible asset, amortization expense, 2025 (363)
Finite-lived intangible asset, amortization expense, 2026 (329)
Finite-lived intangible asset, amortization expense, 2027 (240)
Below-market lease liabilities | Rental Income  
Finite-Lived Intangible Assets [Line Items]  
Below market leases, amortization income, 2023 1,512
Below market leases, amortization income, 2024 1,294
Below market leases, amortization income, 2025 1,103
Below market leases, amortization income, 2026 941
Below market leases, amortization income, 2027 $ 623
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate Investments, Net (Real Estate Sales) (Details)
$ in Thousands
12 Months Ended
Mar. 02, 2022
USD ($)
property
Dec. 21, 2021
USD ($)
property
May 14, 2021
USD ($)
Jan. 15, 2021
USD ($)
property
Dec. 15, 2020
USD ($)
Nov. 02, 2020
USD ($)
property
Mar. 19, 2020
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Nov. 30, 2020
property
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Gain (loss) on sale of real estate investments               $ (125) $ 3,648 $ 5,230    
Impairment charges               27,630 40,951 36,446    
Disposed by sale                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Contract Sale Price               12,400 133,550 40,350    
Gain (loss) on sale of real estate investments               (125) 3,648 5,230    
Disposed by sale | Seniors Housing — Operating Properties | Michigan                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Number of properties disposed | property       4   7            
Contract Sale Price       $ 0   $ 11,750            
Gain (loss) on sale of real estate investments       $ (172)   $ (908)            
Impairment charges                   19,600 $ 22,600  
Number of properties held for sale | property                       11
Disposed by sale | Skilled Nursing Facilities | Lutz, Florida                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Contract Sale Price         $ 20,000              
Gain (loss) on sale of real estate investments         $ 3,832              
Impairment charges                     3,600  
Disposed by sale | Medical Office Buildings                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Contract Sale Price             $ 8,600          
Gain (loss) on sale of real estate investments             $ 2,306          
Disposed by sale | LaSalle Properties                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Number of properties disposed | property 4                      
Contract Sale Price $ 12,400                      
Gain (loss) on sale of real estate investments $ (303)                      
Impairment charges                 34,000      
Disposed by sale | Lien settlement on formerly disposed properties                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Gain (loss) on sale of real estate investments               $ 178        
Disposed by sale | Hampton River Portfolio (two properties)                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Number of properties disposed | property   2                    
Contract Sale Price   $ 37,800                    
Gain (loss) on sale of real estate investments   $ 1,323                    
Disposed by sale | NuVista Jupiter                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Contract Sale Price     $ 65,000                  
Gain (loss) on sale of real estate investments     2,383                  
Impairment charges                   14,600 19,800  
Disposed by sale | Wellington Green                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Contract Sale Price     30,750                  
Gain (loss) on sale of real estate investments     $ 114                  
Impairment charges                 $ 900 $ 2,300 $ 9,900  
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate Investments, Net (Impairments) (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2022
USD ($)
property
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2022
encumberedProperty
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges $ 27,630 $ 40,951 $ 36,446  
Number of real estate properties 202     119
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges $ 27,630 40,951 36,446  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | MOB Segment:        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges 12,488 6,082 0  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Seniors Housing — Operating Properties        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges $ 15,142 34,869 36,446  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Illinois skilled nursing facilities        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of real estate properties, failed to recover carrying value | property 7      
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Illinois skilled nursing facilities | MOB Segment:        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges $ 10,644 0 0  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Sassafras MOB | MOB Segment:        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges 1,844 0 0  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Sun City MOB | MOB Segment:        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges $ 0 6,082 0  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Various held for use SHOPs | Seniors Housing — Operating Properties        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of real estate properties, failed to recover carrying value | property 6      
Number of real estate properties | property 8      
Number of properties under contract for disposal | property 5      
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Various held for use SHOPs | Seniors Housing — Operating Properties        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges $ 15,142 0 0  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | LaSalle Properties | Seniors Housing — Operating Properties        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of properties disposed | property 4      
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | LaSalle Properties | Seniors Housing — Operating Properties        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges $ 0 34,000 0  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Wellington, Florida skilled nursing facility | Wellington        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges     2,300  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Wellington, Florida skilled nursing facility | Seniors Housing — Operating Properties        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges 0 869 2,276  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Michigan properties | Seniors Housing — Operating Properties        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges 0 0 19,570  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | NuVista Jupiter | Seniors Housing — Operating Properties        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges $ 0 $ 0 $ 14,600  
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Mortgage Notes Payable, Net (Mortgage Notes) (Details)
Dec. 31, 2022
USD ($)
property
Dec. 31, 2021
USD ($)
Jun. 30, 2017
USD ($)
Debt Instrument [Line Items]      
Outstanding loan amount $ 1,117,228,000    
Effective Interest Rate 5.94% 3.00%  
Capital One MOB Loan | LIBOR-based interest rate “pay-fixed” swaps      
Debt Instrument [Line Items]      
Notional Amount $ 378,500,000 $ 378,500,000  
Mortgage Notes Payable      
Debt Instrument [Line Items]      
Encumbered Properties | property 75    
Outstanding loan amount $ 585,181,000 $ 591,841,000  
Effective Interest Rate 3.83% 3.82%  
Deferred financing costs, net of accumulated amortization $ (5,117,000) $ (6,186,000)  
Mortgage premiums and discounts, net (1,364,000) (1,416,000)  
Mortgage notes payable, net $ 578,700,000 584,239,000  
Mortgage Notes Payable | Capital One MOB Loan      
Debt Instrument [Line Items]      
Encumbered Properties | property 41    
Outstanding loan amount $ 378,500,000 $ 378,500,000 $ 250,000,000
Effective Interest Rate 3.73% 3.71%  
Mortgage Notes Payable | Multi-Property CMBS Loan      
Debt Instrument [Line Items]      
Encumbered Properties | property 21    
Outstanding loan amount $ 118,700,000 $ 118,700,000  
Effective Interest Rate 4.60% 4.60%  
Mortgage Notes Payable | Shiloh - Illinois      
Debt Instrument [Line Items]      
Encumbered Properties | property 1    
Outstanding loan amount $ 13,071,000 $ 13,384,000  
Effective Interest Rate 4.34% 4.34%  
Mortgage Notes Payable | BMO CMBS      
Debt Instrument [Line Items]      
Encumbered Properties | property 9    
Outstanding loan amount $ 42,750,000 $ 42,750,000  
Effective Interest Rate 2.89% 2.89%  
Palm Valley Medical Plaza - Goodyear, AZ | Mortgage Notes Payable      
Debt Instrument [Line Items]      
Encumbered Properties | property 0    
Outstanding loan amount $ 0 $ 2,879,000  
Effective Interest Rate 0.00% 4.15%  
Medical Center V - Peoria, AZ | Mortgage Notes Payable      
Debt Instrument [Line Items]      
Encumbered Properties | property 0    
Outstanding loan amount $ 0 $ 2,684,000  
Effective Interest Rate 0.00% 4.75%  
Fox Ridge Bryant - Bryant, AR | Mortgage Notes Payable      
Debt Instrument [Line Items]      
Encumbered Properties | property 1    
Outstanding loan amount $ 6,817,000 $ 6,977,000  
Effective Interest Rate 3.98% 3.98%  
Fox Ridge Chenal - Little Rock, AR | Mortgage Notes Payable      
Debt Instrument [Line Items]      
Encumbered Properties | property 1    
Outstanding loan amount $ 15,639,000 $ 16,024,000  
Effective Interest Rate 2.95% 2.95%  
Fox Ridge North Little Rock - North Little Rock, AR | Mortgage Notes Payable      
Debt Instrument [Line Items]      
Encumbered Properties | property 1    
Outstanding loan amount $ 9,704,000 $ 9,943,000  
Effective Interest Rate 2.95% 2.95%  
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Mortgage Notes Payable, Net (Narrative) (Details)
$ in Thousands
12 Months Ended
Nov. 15, 2021
USD ($)
property
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2022
property
Dec. 31, 2022
encumberedProperty
Debt Instrument [Line Items]            
Real estate investments pledged as collateral   $ 900,000        
Outstanding loan amount   1,117,228        
Repayments of credit facility borrowings   2,998 $ 298,804 $ 26,091    
Number of real estate properties         202 119
Mortgage Notes Payable            
Debt Instrument [Line Items]            
Outstanding loan amount   585,181 591,841      
Mortgage Notes Payable | Fox Ridge Chenal - Little Rock, AR            
Debt Instrument [Line Items]            
Outstanding loan amount   15,639 16,024      
Mortgage Notes Payable | Fox Ridge North Little Rock - North Little Rock, AR            
Debt Instrument [Line Items]            
Outstanding loan amount   9,704 9,943      
Mortgage Notes Payable | BMO MOB Loan            
Debt Instrument [Line Items]            
Outstanding loan amount   $ 42,750 $ 42,750      
Debt instrument, face amount $ 42,800          
Mortgage Notes Payable | BMO MOB Loan | Revolving Credit Facility            
Debt Instrument [Line Items]            
Repayments of credit facility borrowings $ 37,000          
Number of real estate properties | property 9          
Payments for deposits $ 2,500          
Proceeds from loans $ 2,400          
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.22.4
Credit Facilities, Net (Summary of Credit Facilities) (Details)
12 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2022
property
Dec. 31, 2022
Dec. 31, 2022
encumberedProperty
Dec. 31, 2022
instrument
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
instrument
Line of Credit Facility [Line Items]              
Number of properties   202   119      
Outstanding balance $ 530,297,000           $ 502,051,000
Effective interest rate     5.94%       3.00%
Interest rate caps | Not Designated as Hedging Instrument              
Line of Credit Facility [Line Items]              
Number of instruments | instrument         7   9
Notional Amount 354,624,000           $ 355,175,000
Credit Facilities              
Line of Credit Facility [Line Items]              
Outstanding balance 178,250,000           147,006,000
Fannie Mae Master Credit Facilities | Interest rate caps              
Line of Credit Facility [Line Items]              
Interest rate cap     3.50%        
Notional Amount 354,600,000            
Fannie Mae Master Credit Facilities | Credit Facilities              
Line of Credit Facility [Line Items]              
Number of properties | property   21          
Outstanding balance 352,047,000           355,045,000
Fannie Mae Master Credit Facilities | Capital One Facility | Interest rate caps              
Line of Credit Facility [Line Items]              
Economic interest rate     5.26%        
Fannie Mae Master Credit Facilities | Capital One Facility | Credit Facilities              
Line of Credit Facility [Line Items]              
Number of properties | property   11          
Outstanding balance 210,483,000           $ 212,417,000
Effective interest rate     5.90%       2.51%
Debt instrument, collateral amount 348,900,000            
Fannie Mae Master Credit Facilities | KeyBank Facility | Interest rate caps              
Line of Credit Facility [Line Items]              
Economic interest rate     5.96%        
Fannie Mae Master Credit Facilities | KeyBank Facility | Credit Facilities              
Line of Credit Facility [Line Items]              
Number of properties | property   10          
Outstanding balance 141,564,000           $ 142,628,000
Effective interest rate     6.60%       2.56%
Debt instrument, collateral amount 261,000,000            
Credit Facilities              
Line of Credit Facility [Line Items]              
Outstanding balance 180,000,000            
Credit Facilities | LIBOR-based interest rate “pay-fixed” swaps              
Line of Credit Facility [Line Items]              
Notional Amount 50,000,000           $ 50,000,000
Credit Facilities | Revolving Credit Facility              
Line of Credit Facility [Line Items]              
Number of properties | property   98          
Outstanding balance 30,000,000           $ 0
Effective interest rate     7.26%       0.00%
Term Loan | SOFR-based interest rate “pay-fixed” swaps              
Line of Credit Facility [Line Items]              
Notional Amount $ 150,000,000         $ 150,000,000  
Term Loan | Revolving Credit Facility              
Line of Credit Facility [Line Items]              
Extension term 1 year            
Term Loan | Credit Facilities              
Line of Credit Facility [Line Items]              
Outstanding balance $ 150,000,000           $ 150,000,000
Deferred financing costs (1,750,000)           (2,994,000)
Term Loan, net $ 148,250,000           $ 147,006,000
Effective interest rate     5.11%       4.11%
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.22.4
Credit Facilities, Net (Narrative) (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 06, 2021
Oct. 04, 2021
$ / shares
Nov. 30, 2020
USD ($)
property
Mar. 17, 2023
USD ($)
Dec. 31, 2022
USD ($)
instrument
derivative
$ / shares
Dec. 31, 2021
USD ($)
instrument
$ / shares
Dec. 31, 2020
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2017
USD ($)
Debt Instrument [Line Items]                  
Real estate investments, at cost         $ 2,587,621,000 $ 2,612,660,000      
Real estate investments pledged as collateral         900,000,000        
Credit facilities, net         530,297,000 502,051,000      
Minimum cash, cash equivalents, and borrowing capacity         $ 50,000,000        
Percent distribution in excess of modified funds from operations         95.00%        
Stock repurchased, authorized amount         $ 50,000,000        
Proceeds from credit facilities         30,000,000 125,000,000 $ 95,000,000    
Sale and transfer of SHOPs | property     4            
Repayments of credit facility borrowings         2,998,000 $ 298,804,000 $ 26,091,000    
Outstanding loan amount         $ 1,117,228,000        
Interest rate caps | Not Designated as Hedging Instrument                  
Debt Instrument [Line Items]                  
Number of instruments | instrument         7 9      
Notional Amount         $ 354,624,000 $ 355,175,000      
SOFR-based interest rate “pay-fixed” swaps | Designated as Hedging Instrument                  
Debt Instrument [Line Items]                  
Number of instruments | instrument         7 0      
Notional Amount         $ 528,500,000 $ 0      
LIBOR-Based Borrowings | Designated as Hedging Instrument                  
Debt Instrument [Line Items]                  
Notional Amount         558,700,000        
LIBOR Based Variable Rate | Designated as Hedging Instrument                  
Debt Instrument [Line Items]                  
Notional Amount         $ 352,000,000        
LIBOR-based interest rate “pay-fixed” swaps | Designated as Hedging Instrument                  
Debt Instrument [Line Items]                  
Number of instruments | instrument         2 9      
Notional Amount         $ 50,000,000 $ 578,500,000      
Subsequent Event | LIBOR-based interest rate “pay-fixed” swaps                  
Debt Instrument [Line Items]                  
Notional Amount       $ 50,000,000          
Series A Preferred Stock                  
Debt Instrument [Line Items]                  
Preferred stock, dividend rate, percentage         7.375%        
Preferred stock, par value (in usd per share) | $ / shares         $ 0.01 $ 0.01      
Series B Preferred Stock                  
Debt Instrument [Line Items]                  
Preferred stock, dividend rate, percentage 7.125% 7.125%     7.125%        
Preferred stock, par value (in usd per share) | $ / shares   $ 0.01     $ 0.01 $ 0.01      
Commencement Quarter                  
Debt Instrument [Line Items]                  
Current borrowing capacity, base percent         62.50%        
Covenant Period From July 1, 2021 through Commencement Quarter                  
Debt Instrument [Line Items]                  
Current borrowing capacity, base percent         65.00%        
Covenant Period After Commencement Quarter                  
Debt Instrument [Line Items]                  
Current borrowing capacity, base percent         62.50%        
Secured Overnight Financing Rate (SOFR) | Commencement Quarter                  
Debt Instrument [Line Items]                  
Floor interest rate         0.25%        
Minimum | Covenant Period after June 30 2021                  
Debt Instrument [Line Items]                  
Fixed charge coverage ratio         1.50        
Term Loan                  
Debt Instrument [Line Items]                  
Extension period         1 year        
Maximum borrowing capacity         $ 505,000,000        
Term Loan | SOFR-based interest rate “pay-fixed” swaps                  
Debt Instrument [Line Items]                  
Notional Amount         $ 150,000,000     $ 150,000,000  
Term Loan | Minimum | Base Rate | Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         0.30%        
Term Loan | Minimum | Base Rate | Covenant Period August 11, 2022 Until Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         0.80%        
Term Loan | Minimum | Secured Overnight Financing Rate (SOFR) | Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         1.55%        
Term Loan | Minimum | Secured Overnight Financing Rate (SOFR) | Covenant Period August 11, 2022 Until Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         2.05%        
Term Loan | Maximum | Base Rate | Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         1.05%        
Term Loan | Maximum | Base Rate | Covenant Period August 11, 2022 Until Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         1.55%        
Term Loan | Maximum | Secured Overnight Financing Rate (SOFR) | Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         2.30%        
Term Loan | Maximum | Secured Overnight Financing Rate (SOFR) | Covenant Period August 11, 2022 Until Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         2.80%        
Credit Facilities                  
Debt Instrument [Line Items]                  
Credit facilities, net         $ 180,000,000        
Consolidated tangible net worth         1,500,000,000        
Credit Facilities | LIBOR-based interest rate “pay-fixed” swaps                  
Debt Instrument [Line Items]                  
Notional Amount         50,000,000 $ 50,000,000      
Credit Facilities | Subsequent Event                  
Debt Instrument [Line Items]                  
Credit facilities, net       200,000,000          
Mortgage Notes Payable                  
Debt Instrument [Line Items]                  
Outstanding loan amount         585,181,000 591,841,000      
Unencumbered Properties                  
Debt Instrument [Line Items]                  
Real estate investments, at cost         100,000,000        
Revolving Credit Facility | Credit Facilities                  
Debt Instrument [Line Items]                  
Maximum borrowing capacity         655,000,000        
Credit facilities, net         30,000,000 0      
Minimum net worth required for compliance         $ 1,200,000,000        
Net offering proceeds, percent         75.00%        
Revolving Credit Facility | Credit Facilities | Subsequent Event                  
Debt Instrument [Line Items]                  
Proceeds from credit facilities       $ 20,000,000          
Revolving Credit Facility | Credit Facilities | Covenant Period Quarter Ending June 30, 2022 Through June 30, 2023                  
Debt Instrument [Line Items]                  
Fixed charge coverage ratio         1.20        
Debt service coverage ratio         1.50        
Revolving Credit Facility | Credit Facilities | Covenant Period Quarter Ending September 30, 2023 Through December 31, 2023                  
Debt Instrument [Line Items]                  
Fixed charge coverage ratio         1.35        
Debt service coverage ratio         1.65        
Revolving Credit Facility | Credit Facilities | Covenant Period Quarter Ending March 31, 2024 And Thereafter                  
Debt Instrument [Line Items]                  
Fixed charge coverage ratio         1.45        
Debt service coverage ratio         1.75        
Revolving Credit Facility | Credit Facilities | Covenant Period From And After Commencement Quarter                  
Debt Instrument [Line Items]                  
Fixed charge coverage ratio         1.50        
Revolving Credit Facility | Credit Facilities | Minimum | Base Rate                  
Debt Instrument [Line Items]                  
Variable rate         52.50%        
Revolving Credit Facility | Credit Facilities | Minimum | Base Rate | Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         0.35%        
Revolving Credit Facility | Credit Facilities | Minimum | Base Rate | Covenant Period August 11, 2022 Until Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         0.85%        
Revolving Credit Facility | Credit Facilities | Minimum | Secured Overnight Financing Rate (SOFR) | Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         1.60%        
Revolving Credit Facility | Credit Facilities | Minimum | Secured Overnight Financing Rate (SOFR) | Covenant Period August 11, 2022 Until Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         2.10%        
Revolving Credit Facility | Credit Facilities | Maximum | Base Rate                  
Debt Instrument [Line Items]                  
Variable rate         55.00%        
Revolving Credit Facility | Credit Facilities | Maximum | Base Rate | Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         1.10%        
Revolving Credit Facility | Credit Facilities | Maximum | Base Rate | Covenant Period August 11, 2022 Until Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         1.60%        
Revolving Credit Facility | Credit Facilities | Maximum | Secured Overnight Financing Rate (SOFR) | Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         2.35%        
Revolving Credit Facility | Credit Facilities | Maximum | Secured Overnight Financing Rate (SOFR) | Covenant Period August 11, 2022 Until Commencement Quarter                  
Debt Instrument [Line Items]                  
Variable rate         2.85%        
Secured Debt                  
Debt Instrument [Line Items]                  
Remaining borrowing capacity         $ 203,400,000        
Secured Debt | Minimum                  
Debt Instrument [Line Items]                  
Line of credit facility, increase limit         370,000,000        
Secured Debt | Maximum                  
Debt Instrument [Line Items]                  
Line of credit facility, increase limit         1,000,000,000        
Credit Facilities                  
Debt Instrument [Line Items]                  
Credit facilities, net         178,250,000 147,006,000      
Outstanding loan amount         532,047,000        
Credit Facilities | Term Loan                  
Debt Instrument [Line Items]                  
Credit facilities, net         150,000,000 150,000,000      
Fannie Mae Master Credit Facilities                  
Debt Instrument [Line Items]                  
Real estate investments, at cost         $ 600,000,000        
Repayments of credit facility borrowings     $ 4,200,000            
Fannie Mae Master Credit Facilities | Interest rate caps                  
Debt Instrument [Line Items]                  
Number of instruments held, active | derivative         6        
Number of instruments held, not active | derivative         1        
Notional Amount         $ 354,600,000        
Interest rate cap         3.50%        
Fannie Mae Master Credit Facilities | Credit Facilities                  
Debt Instrument [Line Items]                  
Credit facilities, net         $ 352,047,000 355,045,000      
New Credit Facilities                  
Debt Instrument [Line Items]                  
Real estate investments, at cost         900,000,000        
New Credit Facilities | Day Prior to Commencement Quarter                  
Debt Instrument [Line Items]                  
Minimum cash, cash equivalents, and borrowing capacity         100,000,000        
New Credit Facilities | Commencement Quarter                  
Debt Instrument [Line Items]                  
Minimum cash, cash equivalents, and borrowing capacity         $ 30,000,000        
New Credit Facilities | Minimum | Commencement Quarter                  
Debt Instrument [Line Items]                  
Current borrowing capacity, base percent         55.00%        
Capital One MOB Loan | LIBOR-based interest rate “pay-fixed” swaps                  
Debt Instrument [Line Items]                  
Notional Amount         $ 378,500,000 378,500,000      
Capital One MOB Loan | Mortgage Notes Payable                  
Debt Instrument [Line Items]                  
Outstanding loan amount         378,500,000 $ 378,500,000     $ 250,000,000
Capital One MOB Loan | Mortgage Notes Payable | SOFR-based interest rate “pay-fixed” swaps                  
Debt Instrument [Line Items]                  
Notional Amount         $ 378,500,000        
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.22.4
Credit Facilities, Net (Future Principal Payments of Outstanding Debt) (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
2023 $ 6,908  
2024 186,947  
2025 19,039  
2026 714,133  
2027 922  
Thereafter 189,279  
Total 1,117,228  
Credit Facilities    
Debt Instrument [Line Items]    
2023 5,769  
2024 185,769  
2025 5,769  
2026 334,740  
2027 0  
Thereafter 0  
Total 532,047  
Mortgage Notes Payable    
Debt Instrument [Line Items]    
2023 1,139  
2024 1,178  
2025 13,270  
2026 379,393  
2027 922  
Thereafter 189,279  
Total $ 585,181 $ 591,841
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value of Financial Instruments (Assets Measured at Fair Value) (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities, at fair value $ 0  
Total 40,647 $ (13,729)
Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value (non-designated) 3,737  
Derivative liabilities, at fair value   (13,903)
Not Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value (non-designated) 36,910 174
Quoted Prices in Active Markets Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities, at fair value 0  
Total 0 0
Quoted Prices in Active Markets Level 1 | Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value (non-designated) 0  
Derivative liabilities, at fair value  
Quoted Prices in Active Markets Level 1 | Not Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value (non-designated) 0 0
Significant Other Observable Inputs Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities, at fair value 0  
Total 40,647 (13,729)
Significant Other Observable Inputs Level 2 | Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value (non-designated) 3,737  
Derivative liabilities, at fair value   (13,903)
Significant Other Observable Inputs Level 2 | Not Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value (non-designated) 36,910 174
Significant Unobservable Inputs Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities, at fair value 0  
Total 0 0
Significant Unobservable Inputs Level 3 | Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value (non-designated) 0  
Derivative liabilities, at fair value  
Significant Unobservable Inputs Level 3 | Not Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value (non-designated) $ 0 $ 0
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value of Financial Instruments (Narrative) (Details) - TEXAS - property
3 Months Ended
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Disposal Group, Held-for-use, Not Discontinued Operations      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Number of properties held-for-use   17 5
Number of properties marketed for sale   10  
Disposal Group, Held-for-use, Not Discontinued Operations | Medical Office Buildings      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Number of properties held-for-use   9 1
Number of properties marketed for sale   2  
Disposal Group, Held-for-use, Not Discontinued Operations | Seniors Housing — Operating Properties      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Number of properties held-for-use   8 4
Number of properties marketed for sale   8  
Disposed by sale | Seniors Housing — Operating Properties      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Number of properties disposed 4    
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value of Financial Instruments (Level 3 Inputs) (Details) - Significant Unobservable Inputs Level 3 - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Mortgage Notes Payable | Carrying Amount     
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt, fair value disclosure $ 583,817 $ 590,425
Mortgage Notes Payable | Fair Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt, fair value disclosure 550,626 594,348
Revolving Credit Facility | Carrying Amount     
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt, fair value disclosure 180,000 150,000
Revolving Credit Facility | Fair Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt, fair value disclosure 179,496 148,817
Fannie Credit Facility | Revolving Credit Facility | Carrying Amount     
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt, fair value disclosure 352,047 355,045
Fannie Credit Facility | Revolving Credit Facility | Fair Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt, fair value disclosure $ 353,034 $ 350,710
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.22.4
Derivatives and Hedging Activities (Balance Sheet Location) (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Derivative [Line Items]    
Gross amounts of recognized assets $ 40,647 $ 174
Gross amounts of recognized liabilities 0 0
Derivative assets, at fair value | Designated as Hedging Instrument | Total interest rate “pay-fixed” swaps    
Derivative [Line Items]    
Gross amounts of recognized assets 36,910 0
Derivative assets, at fair value | Not Designated as Hedging Instrument | Interest rate caps    
Derivative [Line Items]    
Gross amounts of recognized assets 3,737 174
Derivative liabilities, at fair value | Designated as Hedging Instrument | Total interest rate “pay-fixed” swaps    
Derivative [Line Items]    
Gross amounts of recognized liabilities $ 0 $ 13,903
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.22.4
Derivatives and Hedging Activities (Narrative) (Details)
3 Months Ended 12 Months Ended
Dec. 31, 2019
USD ($)
instrument
Dec. 31, 2022
USD ($)
instrument
derivative
Dec. 31, 2021
USD ($)
instrument
Dec. 31, 2020
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2017
USD ($)
Derivative [Line Items]            
Outstanding loan amount   $ 1,117,228,000        
Gain (loss) on non-designated derivatives   3,834,000 $ 37,000 $ (102,000)    
Cash received from derivatives   300,000        
Mortgage Notes Payable            
Derivative [Line Items]            
Outstanding loan amount   585,181,000 $ 591,841,000      
SOFR-based interest rate “pay-fixed” swaps | Term Loan            
Derivative [Line Items]            
Notional Amount   $ 150,000,000     $ 150,000,000  
Designated as Hedging Instrument | Total interest rate “pay-fixed” swaps            
Derivative [Line Items]            
Number of instruments | instrument   9 9      
Number of instruments terminated | instrument 2          
Notional Amount   $ 578,500,000 $ 578,500,000      
Proceeds from sale of interest rate cash flow hedge $ 2,200,000          
Designated as Hedging Instrument | Total interest rate “pay-fixed” swaps | Minimum            
Derivative [Line Items]            
Average variable interest rate   1.39%        
Designated as Hedging Instrument | Total interest rate “pay-fixed” swaps | Maximum            
Derivative [Line Items]            
Average variable interest rate   2.32%        
Designated as Hedging Instrument | Interest rate contract            
Derivative [Line Items]            
Cash flow hedge reclassification current   $ 0 $ 400,000      
Designated as Hedging Instrument | SOFR-based interest rate “pay-fixed” swaps            
Derivative [Line Items]            
Number of instruments | instrument   7 0      
Notional Amount   $ 528,500,000 $ 0      
Not Designated as Hedging Instrument | Interest rate caps            
Derivative [Line Items]            
Number of instruments | instrument   7 9      
Notional Amount   $ 354,624,000 $ 355,175,000      
Interest Expense | Designated as Hedging Instrument | Interest rate contract            
Derivative [Line Items]            
Cash flow hedge reclassification current   400,000 900,000 $ 900,000    
Cash flow hedge reclassification in next twelve months   17,400,000        
Capital One MOB Loan | Mortgage Notes Payable            
Derivative [Line Items]            
Outstanding loan amount   378,500,000 $ 378,500,000     $ 250,000,000
Capital One MOB Loan | SOFR-based interest rate “pay-fixed” swaps | Mortgage Notes Payable            
Derivative [Line Items]            
Notional Amount   378,500,000        
Capital One MOB Loan | Designated as Hedging Instrument | Total interest rate “pay-fixed” swaps            
Derivative [Line Items]            
Notional Amount 250,000,000          
Capital One MOB Loan | Interest Expense | Designated as Hedging Instrument | Interest rate contract            
Derivative [Line Items]            
Cash flow hedge reclassification current $ 2,200,000          
Fannie Mae Master Credit Facilities | Interest rate caps            
Derivative [Line Items]            
Notional Amount   $ 354,600,000        
Number of instruments held, active | derivative   6        
Number of instruments held, not active | derivative   1        
Interest rate cap   3.50%        
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.22.4
Derivatives and Hedging Activities (Summary of Derivative Instruments) (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
instrument
derivative
Dec. 31, 2021
USD ($)
instrument
derivative
Derivative [Line Items]    
Interest rate cap agreements excluded | derivative 1 3
Interest rate cap agreements excluded $ 52,600 $ 140,800
Interest rate caps | Fannie Mae Master Credit Facilities    
Derivative [Line Items]    
Notional Amount $ 354,600  
Interest rate cap 3.50%  
Designated as Hedging Instrument | Total interest rate “pay-fixed” swaps    
Derivative [Line Items]    
Number of Instruments | instrument 9 9
Notional Amount $ 578,500 $ 578,500
Designated as Hedging Instrument | SOFR-based interest rate “pay-fixed” swaps    
Derivative [Line Items]    
Number of Instruments | instrument 7 0
Notional Amount $ 528,500 $ 0
Designated as Hedging Instrument | LIBOR-based interest rate “pay-fixed” swaps    
Derivative [Line Items]    
Number of Instruments | instrument 2 9
Notional Amount $ 50,000 $ 578,500
Not Designated as Hedging Instrument | Interest rate caps    
Derivative [Line Items]    
Number of Instruments | instrument 7 9
Notional Amount $ 354,624 $ 355,175
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.22.4
Derivatives and Hedging Activities (Derivatives Included in AOCI) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Derivative [Line Items]      
Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives $ 51,251 $ 25,332 $ (32,630)
Total amount of interest expense presented in the consolidated statements of operations and comprehensive loss 51,740 47,900 51,519
Designated as Hedging Instrument | Total interest rate “pay-fixed” swaps      
Derivative [Line Items]      
Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives 50,098 14,322 (40,614)
Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense $ (1,153) $ (11,010) $ (7,999)
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.22.4
Derivatives and Hedging Activities (Offsetting Derivatives) (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Gross amounts of recognized assets $ 40,647 $ 174
Gross Amounts of Recognized (Liabilities)   (13,903)
Gross Amounts Offset in the Consolidated Balance Sheet 0 0
Net Amounts of Assets presented in the Consolidated Balance Sheet 40,647 174
Net Amounts of Assets presented in the Consolidated Balance Sheet 0 (13,903)
Financial Instruments 0 0
Cash Collateral Received 0 0
Net Amount $ 40,647 174
Net Amount   $ (13,903)
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity (Narrative) (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 27 Months Ended 111 Months Ended 123 Months Ended
Oct. 03, 2022
shares
Jul. 01, 2022
shares
Apr. 01, 2022
shares
Jan. 03, 2022
shares
Oct. 06, 2021
USD ($)
$ / shares
shares
Oct. 04, 2021
$ / shares
shares
Oct. 01, 2021
shares
Jul. 01, 2021
shares
May 11, 2021
USD ($)
shares
Apr. 02, 2021
shares
Jan. 04, 2021
shares
Oct. 01, 2020
shares
Feb. 26, 2020
USD ($)
$ / shares
shares
Jan. 09, 2020
USD ($)
$ / shares
shares
Mar. 01, 2018
$ / shares
Apr. 01, 2017
$ / shares
Apr. 30, 2013
$ / shares
Sep. 30, 2021
USD ($)
shares
Dec. 31, 2022
USD ($)
director
dividend
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
May 31, 2021
shares
Sep. 30, 2020
shares
Sep. 15, 2020
USD ($)
shares
Class of Stock [Line Items]                                                      
Distributions declared in common stock (in shares)                                           12,600,000          
Issuance of preferred stock, net (in shares)                                     0 0              
Stock dividends (in shares) 0.014167 0.014167 0.014167 0.014655     0.014655 0.014655   0.014655 0.013492 0.013492                              
Weighted-average price per share (in usd per share) | $ / shares                         $ 17.50           $ 0       $ 20.60 $ 20.60      
Stock repurchase, value | $                         $ 8,800 $ 1,700                          
Repurchase price per share, percentage of estimated per-share NAV                                     100.00%                
Number of shares repurchased (in shares)                         505,101           0       4,896,620 4,896,620      
DRIP, period of notice to alter agreement                                     10 days                
Common stock issued through distribution reinvestment plan (in shares)                                     0 0 900,000            
Proceeds from common stock issued through distribution reinvestment plan | $                                         $ 14,600            
Number of securities called by share purchase right (in shares)                                         1            
Number of additional directors | director                                     2                
Number of dividends in arrears required for voting rights | dividend                                     6                
Distributions declared per share (in usd per share) | $ / shares                             $ 0.85 $ 1.45 $ 1.70       $ 0.42            
Public Stock Offering                                                      
Class of Stock [Line Items]                                                      
Preferred stock, liquidation preference (in usd per share) | $ / shares         $ 25.00                                            
Preferred stock, number of shares issued in public offering         3,630,000                                            
Consideration received on transaction, gross | $         $ 90,800                                            
Issuance of preferred stock, net | $         $ 86,800                                            
Public Offering                                                      
Class of Stock [Line Items]                                                      
Preferred stock, number of shares issued in public offering                 2,352,144                                    
Sale of stock, net proceeds | $                 $ 56,000                                    
Discount on offering | $                 $ 2,900                                    
Preferred Stock Equity Line                                                      
Class of Stock [Line Items]                                                      
Issuance of preferred stock, net (in shares)                                       15,000              
Sale of stock, net proceeds | $                                       $ 300              
Authorized preferred stock offering, value | $                                                     $ 15,000
Maximum shares per preferred stock offering (in shares)                                                     3,500
Proceeds from issuance of preferred stock | $                                       400              
Stock issuance costs | $                                       $ 1,200     $ 1,200        
APIC, stock issuance costs | $                                   $ 30                  
Over-Allotment Option                                                      
Class of Stock [Line Items]                                                      
Preferred stock, number of shares issued in public offering         430,000       152,144                                    
Series A Preferred Stock                                                      
Class of Stock [Line Items]                                                      
Preferred stock, shares authorized (in shares)                                     4,740,000 4,740,000   4,740,000 4,740,000 4,740,000      
Preferred stock, additional shares authorized (in shares)                                                   600,000  
Preferred stock, shares issued (in shares)                                     3,977,144 3,977,144   3,977,144 3,977,144 3,977,144      
Preferred stock, dividend rate, percentage                                     7.375%                
Preferred stock, par value (in usd per share) | $ / shares                                     $ 0.01 $ 0.01   $ 0.01 $ 0.01 $ 0.01      
Preferred stock, shares outstanding (in shares)                                     3,977,144 3,977,144   3,977,144 3,977,144 3,977,144      
Preferred stock, dividend rate (in usd per share) | $ / shares                                     $ 1.84375                
Preferred stock, liquidation preference (in usd per share) | $ / shares                                     $ 25.00     $ 25.00   $ 25.00      
Issuance of preferred stock, net | $                                     $ 0 $ 56,265 $ (59)            
Series A Preferred Stock | Public Stock Offering                                                      
Class of Stock [Line Items]                                                      
Preferred stock, shares authorized (in shares)                                     1,610,000     1,610,000   1,610,000 2,530,000    
Preferred stock, liquidation preference (in usd per share) | $ / shares                                     $ 25.00     $ 25.00   $ 25.00      
Series A Preferred Stock | Delisting                                                      
Class of Stock [Line Items]                                                      
Preferred stock, dividend rate, percentage                                     9.375%                
Preferred stock, dividend rate (in usd per share) | $ / shares                                     $ 2.34375                
Increase in preferred stock, dividend rate, percentage                                     2.00%                
Series A Preferred Stock | Maximum                                                      
Class of Stock [Line Items]                                                      
Preferred stock, shares authorized (in shares)                                     50,000,000     50,000,000   50,000,000      
Series B Preferred Stock                                                      
Class of Stock [Line Items]                                                      
Preferred stock, shares authorized (in shares)                                     3,680,000 3,680,000   3,680,000 3,680,000 3,680,000      
Preferred stock, shares issued (in shares)                                     3,630,000 3,630,000   3,630,000 3,630,000 3,630,000      
Preferred stock, dividend rate, percentage         7.125% 7.125%                         7.125%                
Preferred stock, par value (in usd per share) | $ / shares           $ 0.01                         $ 0.01 $ 0.01   $ 0.01 $ 0.01 $ 0.01      
Preferred stock, shares outstanding (in shares)                                     3,630,000 3,630,000   3,630,000 3,630,000 3,630,000      
Preferred stock, dividend rate (in usd per share) | $ / shares                                     $ 1.78125                
Preferred stock, liquidation preference (in usd per share) | $ / shares                                     $ 25.00     $ 25.00   $ 25.00      
Issuance of preferred stock, net | $                                     $ (42) $ 86,819              
Series B Preferred Stock | Public Stock Offering                                                      
Class of Stock [Line Items]                                                      
Preferred stock, shares authorized (in shares)           3,680,000                                          
Preferred stock, liquidation preference (in usd per share) | $ / shares                                     $ 25.00     $ 25.00   $ 25.00      
Series B Preferred Stock | Delisting                                                      
Class of Stock [Line Items]                                                      
Preferred stock, dividend rate, percentage                                     9.125%                
Preferred stock, dividend rate (in usd per share) | $ / shares                                     $ 2.28125                
Increase in preferred stock, dividend rate, percentage                                     2.00%                
Tender Offer                                                      
Class of Stock [Line Items]                                                      
Shares authorized for repurchase (in shares)                           200,000                          
Weighted-average price per share (in usd per share) | $ / shares                           $ 8.50                          
Common Stock                                                      
Class of Stock [Line Items]                                                      
Shares outstanding (in shares)                                     105,080,531 99,281,754   105,080,531 99,281,754 105,080,531      
Distributions declared in common stock (in shares)                                     5,798,777 5,506,008 1,248,197            
Common stock issued through distribution reinvestment plan (in shares)                                         875,986            
Non-controlling Interests                                                      
Class of Stock [Line Items]                                                      
Preferred units, issued (in shares)                                   100,000                  
Preferred unit issuance value | $                                   $ 2,600                  
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity (Stock Redemption) (Details) - $ / shares
12 Months Ended 111 Months Ended 123 Months Ended
Feb. 26, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Equity [Abstract]        
Number of shares repurchased (in shares) 505,101 0 4,896,620 4,896,620
Weighted-average price per share (in usd per share) $ 17.50 $ 0 $ 20.60 $ 20.60
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity (Stock Dividends) (Details) - shares
Jan. 03, 2023
Oct. 03, 2022
Jul. 01, 2022
Apr. 01, 2022
Jan. 03, 2022
Oct. 01, 2021
Jul. 01, 2021
Apr. 02, 2021
Jan. 04, 2021
Oct. 01, 2020
Dividends Payable [Line Items]                    
Stock dividends (in shares)   0.014167 0.014167 0.014167 0.014655 0.014655 0.014655 0.014655 0.013492 0.013492
Subsequent Event                    
Dividends Payable [Line Items]                    
Stock dividends (in shares) 0.014167                  
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions and Arrangements (Ownership) (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Related Party Transaction [Line Items]    
Common stock held by related party (in shares) 105,080,531 99,281,754
Limited partner units (in shares) 90 90
Tax Depreciation Deduction | Advisor    
Related Party Transaction [Line Items]    
Special allocation for tax purposes excess depreciation deductions maximum $ 10.0  
American Realty Capital Healthcare II Special Limited Partnership, LLC | Special Limited Partner    
Related Party Transaction [Line Items]    
Common stock held by related party (in shares) 10,094 9,537
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions and Arrangements (Fees Incurred in Connection with the Operations of the Company) (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Jul. 25, 2019
USD ($)
Feb. 17, 2017
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2020
USD ($)
Related Party Transaction [Line Items]                  
Renewal term   10 years              
Board of directors voting percentage   67.00%              
Period of notice   45 days              
Share price, net (in dollars per share) | $ / shares         $ 22.50        
Asset threshold for assignment of agreement         $ 100,000        
Payable (receivable)         $ 47 $ (882)      
Advisor                  
Related Party Transaction [Line Items]                  
Shares approved for issuance (in shares) | shares         359,250        
Capped Reimbursement Amount                  
Related Party Transaction [Line Items]                  
Reimbursed fees to related party, capped reimbursement amount         $ 6,000 6,200 $ 5,600    
American Realty Capital Healthcare Advisors, LLC | Advance on Loan or Other Investment | Advisor                  
Related Party Transaction [Line Items]                  
Financing advance fees as a percentage of benchmark, expected third party costs         0.50%        
Financing advance fees as a percentage of benchmark, expected company portfolio cost         4.50%        
American Realty Capital Healthcare Advisors, LLC | Contract Purchase Price | Advisor                  
Related Party Transaction [Line Items]                  
Quarterly asset management fee         0.1875%        
American Realty Capital Healthcare Advisors, LLC | Gross Revenue, Stand-alone Single-tenant Net Leased Properties | Advisor                  
Related Party Transaction [Line Items]                  
Property management fees         1.50%        
American Realty Capital Healthcare Advisors, LLC | Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties | Advisor                  
Related Party Transaction [Line Items]                  
Property management fees         2.50%        
American Realty Capital Healthcare Advisors, LLC                  
Related Party Transaction [Line Items]                  
Period of notice   60 days              
Second Amended and Restated Advisory Agreement                  
Related Party Transaction [Line Items]                  
Period of notice of termination   365 days              
Annual Targeted Investor Return | Healthcare Trust Special Limited Partnership, LLC | Pre-tax Non-compounded Return on Capital Contribution | Special Limited Partner                  
Related Party Transaction [Line Items]                  
Cumulative capital investment return to investors as a percentage of benchmark         6.00%        
Monthly Base Management Fee | American Realty Capital Healthcare Advisors, LLC                  
Related Party Transaction [Line Items]                  
Transaction amount   $ 1,625              
Base management fee of net proceeds, variable portion factor, percent   8.33%              
Base management fee of net proceeds   1.25%              
Quarterly Variable Management Fee, Benchmark One | American Realty Capital Healthcare Advisors, LLC                  
Related Party Transaction [Line Items]                  
Basis of core earnings, percent         15.00%        
Basis of core earnings (in usd per share) | $ / shares         $ 0.375        
Quarterly Variable Management Fee, Benchmark Two | American Realty Capital Healthcare Advisors, LLC                  
Related Party Transaction [Line Items]                  
Basis of core earnings, percent         10.00%        
Basis of core earnings (in usd per share) | $ / shares         $ 0.47        
Amended and Restated Property Management and Leasing Agreement                  
Related Party Transaction [Line Items]                  
Renewal term   1 year              
Period of notice of termination   90 days              
Reimbursements of Administrative Services | American Realty Capital Healthcare Advisors, LLC                  
Related Party Transaction [Line Items]                  
Transaction amount         $ 8,800 $ 9,400 12,100    
Severance costs     $ 300            
Third Amended And Restated Advisory Agreement | American Realty Capital Healthcare Advisors, LLC | Advisor                  
Related Party Transaction [Line Items]                  
Contingent good faith negotiations of fixed component, term 12 months                
Third Amended And Restated Advisory Agreement | American Realty Capital Healthcare Advisors, LLC | Advisor And Company                  
Related Party Transaction [Line Items]                  
Contingent good faith negotiations of fixed component, term 90 days                
Third Amended And Restated Advisory Agreement | American Realty Capital Healthcare Advisors, LLC | Capped Reimbursement Amount                  
Related Party Transaction [Line Items]                  
Reimbursed fees to related party, capped reimbursement amount $ 6,800                
Third Amended And Restated Advisory Agreement | American Realty Capital Healthcare Advisors, LLC | Real Estate Cost                  
Related Party Transaction [Line Items]                  
Fee multiplier 4                
Real estate cost percent multiplier 0.0029                
Reduction of real estate cost percent 0.250                
Third Amended And Restated Advisory Agreement | American Realty Capital Healthcare Advisors, LLC | Consumer Price Index                  
Related Party Transaction [Line Items]                  
Cost of living percent multiplier 0.030                
Reimbursements of Employee Bonuses of the Advisor | American Realty Capital Healthcare Advisors, LLC                  
Related Party Transaction [Line Items]                  
Transaction amount               $ 2,500  
2019 Bonus Awards                  
Related Party Transaction [Line Items]                  
Payable (receivable)         $ 1,200     $ 1,200 $ 1,200
Term of agreement         10 months        
2020 Bonus Awards                  
Related Party Transaction [Line Items]                  
Term of agreement       10 months          
2020 Bonus Awards | Advisor                  
Related Party Transaction [Line Items]                  
Transaction amount       $ 1,000          
Term of agreement       6 months          
Severance Payments                  
Related Party Transaction [Line Items]                  
Payable (receivable)             $ 2,200    
Maximum | American Realty Capital Healthcare Advisors, LLC | Gross Revenue, Managed Properties | Advisor                  
Related Party Transaction [Line Items]                  
Oversight fees earned by related party         1.00%        
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions and Arrangements (Fees, Expenses and Related Payables) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Related Party Transaction [Line Items]      
Expenses incurred $ 34,874 $ 32,905 $ 35,328
Payable (receivable) 47 (882)  
Acquisition cost reimbursements      
Related Party Transaction [Line Items]      
Expenses incurred 23 90 81
Payable (receivable) 5 23  
Asset management fees      
Related Party Transaction [Line Items]      
Expenses incurred 21,831 20,710 19,987
Payable (receivable) 0 0  
Property management fees      
Related Party Transaction [Line Items]      
Expenses incurred 4,200 3,749 4,197
Payable (receivable) 3 24  
Property management fees | Prepaid Expenses and Other Assets      
Related Party Transaction [Line Items]      
Expenses incurred 700 300  
Professional fees and other reimbursements      
Related Party Transaction [Line Items]      
Expenses incurred 8,820 9,386 12,102
Payable (receivable) 39 (70)  
Professional fees credit due from Advisor      
Related Party Transaction [Line Items]      
Professional fees credit due from Advisor 0 (1,030) (1,217)
Payable (receivable) 0 (859)  
Distributions on Class B Units      
Related Party Transaction [Line Items]      
Expenses incurred 0 0 178
Payable (receivable) 0 0  
Severance Payments      
Related Party Transaction [Line Items]      
Payable (receivable)     2,200
Advisor | 2020 Bonus Awards      
Related Party Transaction [Line Items]      
Due from affiliates   900  
Capped Reimbursement Amount      
Related Party Transaction [Line Items]      
Reimbursed fees to related party, capped reimbursement amount $ 6,000 $ 6,200 $ 5,600
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions and Arrangements (Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company’s Real Estate Assets) (Details)
$ in Millions
12 Months Ended
Dec. 31, 2022
USD ($)
Healthcare Trust Special Limited Partnership, LLC | Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital | Special Limited Partner  
Related Party Transaction [Line Items]  
Subordinated participation fees as a percentage of benchmark 15.00%
Healthcare Trust Special Limited Partnership, LLC | Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return | Special Limited Partner  
Related Party Transaction [Line Items]  
Subordinated performance fee as a percentage of benchmark 15.00%
Annual Targeted Investor Return | Healthcare Trust Special Limited Partnership, LLC | Pre-tax Non-compounded Return on Capital Contribution | Special Limited Partner  
Related Party Transaction [Line Items]  
Cumulative capital investment return to investors as a percentage of benchmark 6.00%
Second Amended and Restated Advisory Agreement | Affiliated Entity | Advisor  
Related Party Transaction [Line Items]  
Fee payment period 30 days
Asset management fees  
Related Party Transaction [Line Items]  
Fee multiplier 4
Transition Fee  
Related Party Transaction [Line Items]  
Transaction amount $ 15.0
Subject Fees (Transition Fee Not in Excess of the Product)  
Related Party Transaction [Line Items]  
Fee multiplier 4
Subject Fees  
Related Party Transaction [Line Items]  
Fee multiplier 4.5
Change in Control Fee  
Related Party Transaction [Line Items]  
Fee multiplier 4
Variable Management - Incentive Fee  
Related Party Transaction [Line Items]  
Fee multiplier 4
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.22.4
Equity-Based Compensation (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Restricted Share Plan | Unvested Restricted Shares      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Maximum authorized amount as a percentage of shares authorized 5.00%    
Number of shares authorized (in shares) 3,600,000    
Nonvested awards, compensation cost not yet recognized $ 1.5    
Nonvested awards, compensation cost not yet recognized, period for recognition 1 year 7 months 6 days    
Share-based compensation expense $ 1.2 $ 1.3 $ 1.3
Restricted Share Plan | Unvested Restricted Shares | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Restricted share vesting period 3 years    
Restricted Share Plan | Unvested Restricted Shares | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Restricted share vesting period 5 years    
Director      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock issued during period, issued for services (in shares) 0 0 0
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.22.4
Equity-Based Compensation (Summary of Share-based Compensation Awards) (Details) - Unvested Restricted Shares - $ / shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Number of Common Shares      
Beginning balance (in shares) 159,427 215,384  
Ending balance (in shares) 97,343 159,427 215,384
Restricted Share Plan      
Number of Common Shares      
Beginning balance (in shares) 159,427 215,384 277,241
Stock dividend (in shares) 8,313 12,646 2,878
Granted (in shares) 0 0 0
Vested (in shares) (70,397) (68,603) (64,735)
Forfeitures (in shares) 0 0 0
Ending balance (in shares) 97,343 159,427 215,384
Weighted-Average Issue Price      
Beginning balance (usd per share) $ 21.21 $ 21.11 $ 21.18
Stock dividend (usd per share) 14.86 14.79 15.75
Granted (usd per share) 0 0
Vested (usd per share) 23.67 19.72 21.18
Forfeitures (usd per share) 0 0 0
Ending balance (usd per share) $ 18.89 $ 21.21 $ 21.11
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.22.4
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Beginning balance $ 1,040,400,000 $ 961,372,000 $ 1,106,744,000
Rebalancing of ownership percentage 0 0 0
Ending balance 999,190,000 1,040,400,000 961,372,000
Interest rate contract | Designated as Hedging Instrument      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Unamortized portion remaining in accumulated other comprehensive (loss) income 0 400,000  
Unrealized Gains (Losses) on Designated Derivative      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Beginning balance (14,341,000) (39,673,000) (7,043,000)
Other comprehensive loss, before reclassifications 50,098,000 14,322,000 (40,614,000)
Amount of loss reclassified from accumulated other comprehensive income (loss) 1,153,000 11,010,000 7,999,000
Rebalancing of ownership percentage     (15,000)
Ending balance $ 36,910,000 $ (14,341,000) $ (39,673,000)
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.22.4
Non-controlling Interests - Balance Sheet Breakdown (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Noncontrolling Interest [Line Items]    
Total Non-controlling Interests in the OP $ 6,162 $ 6,336
Non-controlling interests in property owning subsidiaries 389 368
Total Non-controlling Interests 6,551 6,704
Series A Preferred Unit    
Noncontrolling Interest [Line Items]    
Total Non-controlling Interests in the OP 2,578 2,578
Common OP Unit    
Noncontrolling Interest [Line Items]    
Total Non-controlling Interests in the OP $ 3,584 $ 3,758
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.22.4
Non-controlling Interests (Narrative) (Details) - USD ($)
12 Months Ended
Nov. 04, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Sep. 30, 2021
Nov. 30, 2014
Noncontrolling Interest [Line Items]            
Distributions to non-controlling interest holders   $ 184,000 $ 46,000 $ 201,000    
Limited partner units (in shares)   90 90      
Payments to noncontrolling interests   $ 0 $ 0 583,000    
Series A Preferred Unit            
Noncontrolling Interest [Line Items]            
Distributions to non-controlling interest holders   200,000 46,000      
Common OP Unit            
Noncontrolling Interest [Line Items]            
Distributions to non-controlling interest holders   $ 0 $ 0 $ 200,000    
OP Units            
Noncontrolling Interest [Line Items]            
Redeemable amount of shares (in shares)   467,498        
UnityPoint Clinic Portfolio            
Noncontrolling Interest [Line Items]            
Payments to noncontrolling interests $ 600,000          
Non-controlling Interests            
Noncontrolling Interest [Line Items]            
Preferred units, issued (in shares)         100,000  
Preferred unit, face value (in usd per share)         $ 25.00  
Preferred unit issuance value         $ 2,600,000  
Preferred units issued (in usd per share)         $ 25.78  
Preferred units, redemption period   1 year        
Limited partner units (in shares)   405,908       405,908
Units issued to purchase building           $ 10,100,000
Units issued to fund purchase of A Building (in usd per share)           $ 25.00
Limited partner units, redemption period   1 year        
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.22.4
Non-controlling Interests (Summary of Non-controlling Interests) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Noncontrolling Interest [Line Items]      
Third Party Net Investment Amount $ 6,551 $ 6,704  
Net Real Estate Assets Subject to Investment Arrangement 1,978,297 2,049,927  
Distributions 184 92 $ 201
Non-controlling Interests      
Noncontrolling Interest [Line Items]      
Distributions 184 92 201
Plaza Del Rio Medical Office Campus Portfolio AZ | Non-controlling Interests      
Noncontrolling Interest [Line Items]      
Third Party Net Investment Amount 389    
Net Real Estate Assets Subject to Investment Arrangement 12,455 12,925  
Distributions $ 0 $ 0 $ 0
Plaza Del Rio Medical Office Campus Portfolio AZ | Non-controlling Interests | Healthcare Trust Operating Partnership, L.P.      
Noncontrolling Interest [Line Items]      
Non-Controlling Ownership Percentage 2.50%    
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.22.4
Net Loss Per Share (Summary of Basic and Diluted Net Loss Per Share Computation) (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Earnings Per Share [Abstract]      
Net loss attributable to stockholders $ (93,285) $ (92,942) $ (78,781)
Basic weighted-average shares outstanding (in shares) [1] 106,428,154 106,354,994 106,119,937
Diluted weighted-average shares outstanding (in shares) [1] 106,428,154 106,354,994 106,119,937
Basic net loss per share (in usd per share) [1] $ (0.88) $ (0.87) $ (0.74)
Diluted net loss per share (in usd per share) [1] $ (0.88) $ (0.87) $ (0.74)
[1] Retroactively adjusted for the effects of the Stock Dividends (see Note 1 — Organization for details).
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.22.4
Net Loss Per Share (Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) - shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 1,022,726 1,095,882 1,170,327
Limited partner units (in shares) 90 90  
Class B units (in shares) 359,250 359,250 359,250
Unvested Restricted Shares      
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 141,364 214,520 288,965
Common OP Units      
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 467,602 467,602 467,602
Class B units      
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 413,760 413,760 413,760
Unvested Restricted Shares      
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]      
Unvested restricted stock (in shares) 97,343 159,427 215,384
American Realty Capital Healthcare III Advisors, LLC | Advisor      
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]      
Limited partner units (in shares) 405,998 405,998 405,998
XML 96 R82.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting (Narrative) (Details) - segment
3 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Segment Reporting [Abstract]      
Number of reportable segments 2 2 3
XML 97 R83.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting (Reconciliation of Segment Activity) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Segment Reporting Information [Line Items]      
Revenue from tenants $ 335,846 $ 329,355 $ 381,612
Property operating and maintenance 213,444 205,813 243,548
NOI 122,402 123,542 138,064
Impairment charges (27,630) (40,951) (36,446)
Operating fees to related parties (25,353) (24,206) (23,922)
Acquisition and transaction related (1,484) (2,714) (173)
General and administrative (17,287) (16,828) (21,572)
Depreciation and amortization (82,064) (79,926) (81,053)
Gain (loss) on sale of real estate investments (125) 3,648 5,230
Interest expense (51,740) (47,900) (51,519)
Interest and other income 27 61 44
Gain on non designated derivatives 3,834 37 (102)
Income tax expense (201) (203) (4,061)
Net loss (income) attributable to non-controlling interests 135 260 (303)
Allocation for preferred stock (13,799) (7,762) (2,968)
Net loss attributable to common stockholders (93,285) (92,942) (78,781)
Medical Office Buildings      
Segment Reporting Information [Line Items]      
Revenue from tenants 131,444 122,867 119,824
Property operating and maintenance 35,945 34,480 32,812
NOI 95,499 88,387 87,012
Seniors Housing — Operating Properties      
Segment Reporting Information [Line Items]      
Revenue from tenants 204,402 206,488 261,788
Property operating and maintenance 177,499 171,333 210,736
NOI $ 26,903 $ 35,155 $ 51,052
XML 98 R84.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting (Reconciliation of Segment Activity to Assets) (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Investments in real estate, net:      
Net Real Estate Assets Subject to Investment Arrangement $ 1,978,297 $ 2,049,927  
Cash and cash equivalents 53,654 59,738 $ 72,357
Restricted cash 22,884 25,644  
Derivative assets, at fair value 40,647 174  
Straight-line rent receivable, net 25,276 23,858  
Operating lease right-of-use assets 7,814 7,914  
Prepaid expenses and other assets 34,554 32,564  
Deferred costs 17,223 14,581  
Total assets 2,180,349 2,214,400  
Medical Office Buildings      
Investments in real estate, net:      
Net Real Estate Assets Subject to Investment Arrangement 1,121,857 1,149,241  
Seniors Housing — Operating Properties      
Investments in real estate, net:      
Net Real Estate Assets Subject to Investment Arrangement $ 856,440 $ 900,686  
XML 99 R85.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting (Reconciliation of Capital Expenditures by Segment) (Details) - Operating Segments - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Segment Reporting Information [Line Items]      
Total capital expenditures $ 27,993 $ 19,071 $ 21,394
Medical Office Buildings      
Segment Reporting Information [Line Items]      
Total capital expenditures 10,542 6,152 8,561
Seniors Housing — Operating Properties      
Segment Reporting Information [Line Items]      
Total capital expenditures $ 17,451 $ 12,919 $ 12,833
XML 100 R86.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies (Narrative) (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2022
USD ($)
lease
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Lessee, Lease, Description [Line Items]      
Number of operating lease contracts | lease 7    
Number of finance lease contracts | lease 6    
Term of lease excluded 1 year 9 months 18 days    
Operating lease right-of-use assets $ 7,814 $ 7,914  
Operating lease liabilities $ 8,087 8,130  
Remaining lease term 34 years 1 month 6 days    
Weighted average discount rate, percent 7.36%    
Operating lease payments $ 700 800 $ 800
Operating lease costs $ 900 900 $ 900
Land      
Lessee, Lease, Description [Line Items]      
Operating lease right-of-use assets   $ 5,700  
Minimum      
Lessee, Lease, Description [Line Items]      
Renewal term 19 years 10 months 24 days    
Maximum      
Lessee, Lease, Description [Line Items]      
Renewal term 84 years 8 months 12 days    
XML 101 R87.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Operating Leases    
2023 $ 645  
2024 632  
2025 588  
2026 599  
2027 617  
Thereafter 21,942  
Total minimum lease payments 25,023  
Less: amounts representing interest (16,936)  
Operating lease liabilities 8,087 $ 8,130
Direct Financing Leases    
2023 88  
2024 90  
2025 93  
2026 95  
2027 97  
Thereafter 7,215  
Total minimum lease payments 7,678  
Less: amounts representing interest (2,841)  
Total present value of minimum lease payments $ 4,837  
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Accounts payable and accrued expenses (including $47 due to related parties as of December 31, 2022 and 2021)  
XML 102 R88.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent Events (Details)
3 Months Ended 12 Months Ended
Jan. 03, 2023
shares
Oct. 03, 2022
shares
Jul. 01, 2022
shares
Apr. 01, 2022
shares
Jan. 03, 2022
shares
Oct. 01, 2021
shares
Jul. 01, 2021
shares
Apr. 02, 2021
shares
Jan. 04, 2021
shares
Oct. 01, 2020
shares
Mar. 17, 2023
USD ($)
instrument
property
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Subsequent Event [Line Items]                            
Stock dividends (in shares) | shares   0.014167 0.014167 0.014167 0.014655 0.014655 0.014655 0.014655 0.013492 0.013492        
Proceeds from credit facilities                       $ 30,000,000 $ 125,000,000 $ 95,000,000
LIBOR-based interest rate “pay-fixed” swaps | Credit Facilities                            
Subsequent Event [Line Items]                            
Notional Amount                       $ 50,000,000 $ 50,000,000  
Subsequent Event                            
Subsequent Event [Line Items]                            
Stock dividends (in shares) | shares 0.014167                          
Subsequent Event | Four Single-Tenant MOB Properties                            
Subsequent Event [Line Items]                            
Number of properties acquired | property                     4      
Consideration transferred                     $ 20,000,000      
Subsequent Event | Credit Facilities | Revolving Credit Facility                            
Subsequent Event [Line Items]                            
Proceeds from credit facilities                     $ 20,000,000      
Subsequent Event | LIBOR-based interest rate “pay-fixed” swaps                            
Subsequent Event [Line Items]                            
Number of instruments terminated | instrument                     2      
Notional Amount                     $ 50,000,000      
Asset position with fair value                     $ 2,000,000      
XML 103 R89.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate and Accumulated Depreciation Schedule III (Summary of Real Estate Properties) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances $ 937,230      
Land 210,294      
Building and Improvements 2,075,880      
Costs capitalized subsequent to acquisition, land (3,840)      
Costs capitalized subsequent to acquisition, buildings and improvements 13,253      
Gross Amount 2,295,587 $ 2,345,708 $ 2,211,451 $ 2,296,627
Accumulated Depreciation 397,982 328,095 $ 260,399 $ 226,167
Acquired intangibles 292,000      
Federal income taxes 2,100,000      
Accumulated amortization 211,300      
Credit facilities, net 530,297 502,051    
Secured debt 578,700 584,239    
Credit Facilities        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Credit facilities, net $ 180,000      
Building        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Useful life 40 years      
Land Improvements        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Useful life 15 years      
Fixtures and improvements        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Useful life 5 years      
Fresenius Medical Care - Winfield, AL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances $ 0      
Land 152      
Building and Improvements 1,568      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 1,720      
Accumulated Depreciation 445      
Adena Health Center - Jackson, OH        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 242      
Building and Improvements 4,494      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements (25)      
Gross Amount 4,711      
Accumulated Depreciation 1,100      
Ouachita Community Hospital - West Monroe, LA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 633      
Building and Improvements 5,304      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 5,937      
Accumulated Depreciation 1,329      
CareMeridian - Littleton, CO        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 976      
Building and Improvements 8,900      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 111      
Gross Amount 9,987      
Accumulated Depreciation 3,037      
Oak Lawn Medical Center - Oak Lawn, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 5,343      
Land 835      
Building and Improvements 7,217      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 25      
Gross Amount 8,077      
Accumulated Depreciation 1,994      
Surgery Center of Temple - Temple, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 225      
Building and Improvements 5,208      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 432      
Gross Amount 5,865      
Accumulated Depreciation 1,379      
Greenville Health System - Greenville, SC        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 720      
Building and Improvements 3,045      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 389      
Gross Amount 4,154      
Accumulated Depreciation 759      
Stockbridge Family Medical - Stockbridge, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 1,781      
Land 823      
Building and Improvements 1,799      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 177      
Gross Amount 2,799      
Accumulated Depreciation 542      
Arrowhead Medical Plaza II - Glendale, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 7,540      
Land 0      
Building and Improvements 9,758      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 2,076      
Gross Amount 11,834      
Accumulated Depreciation 3,261      
Village Center Parkway - Stockbridge, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 2,434      
Land 1,135      
Building and Improvements 2,299      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 372      
Gross Amount 3,806      
Accumulated Depreciation 809      
Creekside MOB - Douglasville, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,814      
Land 2,709      
Building and Improvements 5,320      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 791      
Gross Amount 8,820      
Accumulated Depreciation 1,858      
Bowie Gateway Medical Center - Bowie, MD        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 9,153      
Land 983      
Building and Improvements 10,321      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 334      
Gross Amount 11,638      
Accumulated Depreciation 2,489      
Campus at Crooks & Auburn Building D - Rochester Mills, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,627      
Land 640      
Building and Improvements 4,166      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 145      
Gross Amount 4,951      
Accumulated Depreciation 1,120      
Berwyn Medical Center - Berwyn, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,305      
Building and Improvements 7,559      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 8,864      
Accumulated Depreciation 1,693      
Countryside Medical Arts - Safety Harbor, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 6,983      
Land 915      
Building and Improvements 7,663      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 74      
Gross Amount 8,652      
Accumulated Depreciation 1,862      
St. Andrews Medical Park - Venice, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 11,119      
Land 1,666      
Building and Improvements 10,005      
Costs capitalized subsequent to acquisition, land 2      
Costs capitalized subsequent to acquisition, buildings and improvements 399      
Gross Amount 12,072      
Accumulated Depreciation 3,027      
Campus at Crooks & Auburn Building C - Rochester Mills, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,831      
Land 609      
Building and Improvements 3,893      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 178      
Gross Amount 4,680      
Accumulated Depreciation 1,081      
Laguna Professional Center - Elk Grove, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,887      
Land 1,811      
Building and Improvements 14,598      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 318      
Gross Amount 16,727      
Accumulated Depreciation 3,709      
UC Davis MOB - Elk Grove, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,136      
Land 1,138      
Building and Improvements 7,242      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 294      
Gross Amount 8,674      
Accumulated Depreciation 1,951      
Estate at Hyde Park - Tampa, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,777      
Building and Improvements 20,308      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,079      
Gross Amount 23,164      
Accumulated Depreciation 5,133      
Autumn Ridge of Clarkston - Clarkston, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 655      
Building and Improvements 19,967      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,584      
Gross Amount 22,206      
Accumulated Depreciation 4,884      
Sunnybrook of Burlington - Burlington, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 518      
Building and Improvements 16,739      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 429      
Gross Amount 17,686      
Accumulated Depreciation 4,438      
Sunnybrook of Carroll - Carroll, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 473      
Building and Improvements 11,263      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 51      
Gross Amount 11,787      
Accumulated Depreciation 2,686      
Prairie Hills at Cedar Rapids - Cedar Rapids, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 195      
Building and Improvements 8,595      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 182      
Gross Amount 8,972      
Accumulated Depreciation 2,096      
Prairie Hills at Clinton - Clinton, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 890      
Building and Improvements 18,882      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 86      
Gross Amount 19,858      
Accumulated Depreciation 4,781      
Prairie Hills at Des Moines - Des Moines, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 647      
Building and Improvements 13,745      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 57      
Gross Amount 14,449      
Accumulated Depreciation 3,593      
Sunnybrook of Fairfield - Fairfield, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 340      
Building and Improvements 14,115      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 291      
Gross Amount 14,746      
Accumulated Depreciation 3,635      
Sunnybrook of Ft. Madison - Ft. Madison, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 263      
Building and Improvements 3,931      
Costs capitalized subsequent to acquisition, land (54)      
Costs capitalized subsequent to acquisition, buildings and improvements (1,177)      
Gross Amount 2,963      
Accumulated Depreciation (21)      
Prairie Hills at Independence - Independence, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 473      
Building and Improvements 10,600      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 179      
Gross Amount 11,252      
Accumulated Depreciation 2,519      
Sunnybrook of Mt. Pleasant - Mt. Pleasant, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 205      
Building and Improvements 10,935      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 359      
Gross Amount 11,499      
Accumulated Depreciation 2,575      
Sunnybrook of Muscatine - Muscatine, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 302      
Building and Improvements 13,840      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 172      
Gross Amount 14,314      
Accumulated Depreciation 3,364      
Prairie Hills at Ottumwa - Ottumwa, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 538      
Building and Improvements 9,186      
Costs capitalized subsequent to acquisition, land (376)      
Costs capitalized subsequent to acquisition, buildings and improvements (7,088)      
Gross Amount 2,260      
Accumulated Depreciation 47      
Prairie Hills at Tipton - Tipton, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 306      
Building and Improvements 10,409      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 78      
Gross Amount 10,793      
Accumulated Depreciation 2,405      
Liberty Court - Dixon, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 119      
Building and Improvements 1,998      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 59      
Gross Amount 2,176      
Accumulated Depreciation 541      
Lakeside Vista - Holland, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 378      
Building and Improvements 12,196      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,878      
Gross Amount 14,452      
Accumulated Depreciation 3,057      
The Atrium - Rockford, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 164      
Building and Improvements 1,746      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 295      
Gross Amount 2,205      
Accumulated Depreciation 369      
Arrowhead Medical Plaza I - Glendale, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 4,571      
Land 0      
Building and Improvements 6,447      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,410      
Gross Amount 7,857      
Accumulated Depreciation 1,886      
Sunnybrook of Burlington - Land - Burlington, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 620      
Building and Improvements 0      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 620      
Accumulated Depreciation 0      
Community Health MOB - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 5,424      
Land 0      
Building and Improvements 6,170      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,170      
Accumulated Depreciation 1,315      
Brady MOB - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 19,661      
Land 0      
Building and Improvements 22,485      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 22,485      
Accumulated Depreciation 4,680      
Landis Memorial - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 0      
Building and Improvements 32,484      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 32,484      
Accumulated Depreciation 6,782      
FOC II - Mechanicsburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 16,136      
Land 0      
Building and Improvements 16,473      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 142      
Gross Amount 16,615      
Accumulated Depreciation 3,960      
FOC Clinical - Mechanicsburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 17,695      
Land 0      
Building and Improvements 19,634      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 19,634      
Accumulated Depreciation 4,616      
FOC I - Mechanicsburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,204      
Land 0      
Building and Improvements 8,923      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 368      
Gross Amount 9,291      
Accumulated Depreciation 2,308      
Copper Springs Senior Living - Meridian, ID        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 498      
Building and Improvements 7,130      
Costs capitalized subsequent to acquisition, land (14)      
Costs capitalized subsequent to acquisition, buildings and improvements (2,052)      
Gross Amount 5,562      
Accumulated Depreciation 48      
Addington Place of Brunswick - Brunswick, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,509      
Building and Improvements 14,402      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 489      
Gross Amount 16,400      
Accumulated Depreciation 3,747      
Addington Place of Dublin - Dublin, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 403      
Building and Improvements 9,281      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 182      
Gross Amount 9,866      
Accumulated Depreciation 2,541      
Allegro at Elizabethtown - Elizabethtown, KY        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 317      
Building and Improvements 7,290      
Costs capitalized subsequent to acquisition, land (76)      
Costs capitalized subsequent to acquisition, buildings and improvements (3,175)      
Gross Amount 4,356      
Accumulated Depreciation 13      
Addington Place of Johns Creek - Johns Creek, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 997      
Building and Improvements 11,943      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 448      
Gross Amount 13,388      
Accumulated Depreciation 3,174      
Allegro at Jupiter - Jupiter, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 3,741      
Building and Improvements 49,534      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 674      
Gross Amount 53,949      
Accumulated Depreciation 12,027      
Addington Place of Lee's Summit - Lee's Summit, MO        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 2,734      
Building and Improvements 25,008      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 391      
Gross Amount 28,133      
Accumulated Depreciation 6,149      
Addington Place at Mills - Roswell, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,000      
Building and Improvements 8,611      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 2,575      
Gross Amount 12,186      
Accumulated Depreciation 3,310      
Addington Place of College Harbour - St Petersburg, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 3,791      
Building and Improvements 8,684      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 2,117      
Gross Amount 14,592      
Accumulated Depreciation 3,430      
Allegro at Stuart - Stuart, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 5,018      
Building and Improvements 60,575      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 969      
Gross Amount 66,562      
Accumulated Depreciation 15,029      
Allegro at Tarpon - Tarpon Springs, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 2,360      
Building and Improvements 13,728      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 3,107      
Gross Amount 19,195      
Accumulated Depreciation 4,430      
Addington Place of Titusville - Titusville, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,379      
Building and Improvements 13,976      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 720      
Gross Amount 16,075      
Accumulated Depreciation 4,034      
Allegro at St. Petersburg - Land - St. Petersburg, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 3,045      
Building and Improvements 0      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 3,045      
Accumulated Depreciation 0      
Gateway MOB - Clarksville, TN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 17,560      
Land 0      
Building and Improvements 16,367      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,011      
Gross Amount 17,378      
Accumulated Depreciation 4,335      
Dyer Building - Dyer, IN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 6,143      
Land 601      
Building and Improvements 8,992      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 191      
Gross Amount 9,784      
Accumulated Depreciation 1,971      
757 Building - Munster, IN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 645      
Building and Improvements 7,885      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 31      
Gross Amount 8,561      
Accumulated Depreciation 1,685      
761 Building - Munster, IN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 6,797      
Land 1,436      
Building and Improvements 8,616      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 90      
Gross Amount 10,142      
Accumulated Depreciation 1,974      
759 Building - Munster, IN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,271      
Land 1,101      
Building and Improvements 8,899      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 31      
Gross Amount 10,031      
Accumulated Depreciation 1,955      
Schererville Building - Schererville, IN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,260      
Building and Improvements 935      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 88      
Gross Amount 2,283      
Accumulated Depreciation 381      
Meadowbrook Senior Living - Agoura Hills, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 8,821      
Building and Improvements 48,682      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 2,485      
Gross Amount 59,988      
Accumulated Depreciation 11,659      
Mount Vernon Medical Office Building - Mount Vernon, WA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 15,797      
Land 0      
Building and Improvements 18,519      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 3      
Gross Amount 18,522      
Accumulated Depreciation 4,095      
Wellington at Hershey's Mill - West Chester, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 8,531      
Building and Improvements 80,734      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 5,364      
Gross Amount 94,629      
Accumulated Depreciation 18,754      
Eye Specialty Group Medical Building - Memphis, TN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,475      
Land 775      
Building and Improvements 7,223      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 7,998      
Accumulated Depreciation 1,533      
Addington Place of Alpharetta - Alpharetta, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,604      
Building and Improvements 26,069      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 462      
Gross Amount 28,135      
Accumulated Depreciation 6,296      
Addington Place of Prairie Village - Prairie Village, KS        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,782      
Building and Improvements 21,869      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 451      
Gross Amount 24,102      
Accumulated Depreciation 5,466      
Bloom MOB - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 15,322      
Land 0      
Building and Improvements 15,928      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 517      
Gross Amount 16,445      
Accumulated Depreciation 3,535      
Medical Sciences Pavilion - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 18,272      
Land 0      
Building and Improvements 22,309      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 22,309      
Accumulated Depreciation 4,569      
Wood Glen Nursing and Rehab Center - West Chicago, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,896      
Building and Improvements 16,107      
Costs capitalized subsequent to acquisition, land (367)      
Costs capitalized subsequent to acquisition, buildings and improvements (6,436)      
Gross Amount 11,200      
Accumulated Depreciation 228      
Pinnacle Center - Southaven, MS        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 7,085      
Land 1,378      
Building and Improvements 6,547      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,560      
Gross Amount 9,485      
Accumulated Depreciation 1,952      
Paradise Valley Medical Plaza - Phoenix, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 13,085      
Land 0      
Building and Improvements 25,194      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,703      
Gross Amount 26,897      
Accumulated Depreciation 6,019      
Victory Medical Center at Craig Ranch - McKinney, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,596      
Building and Improvements 40,475      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,199      
Gross Amount 43,270      
Accumulated Depreciation 8,801      
Rivershores Healthcare & Rehab Centre - Marseilles, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,276      
Building and Improvements 6,868      
Costs capitalized subsequent to acquisition, land (247)      
Costs capitalized subsequent to acquisition, buildings and improvements (2,837)      
Gross Amount 5,060      
Accumulated Depreciation 105      
Morton Terrace Healthcare & Rehab Centre - Morton, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 709      
Building and Improvements 5,649      
Costs capitalized subsequent to acquisition, land (137)      
Costs capitalized subsequent to acquisition, buildings and improvements (2,520)      
Gross Amount 3,701      
Accumulated Depreciation 77      
Morton Villa Healthcare & Rehab Centre - Morton, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 645      
Building and Improvements 3,687      
Costs capitalized subsequent to acquisition, land (125)      
Costs capitalized subsequent to acquisition, buildings and improvements (1,546)      
Gross Amount 2,661      
Accumulated Depreciation 57      
The Heights Healthcare & Rehab Centre - Peoria Heights, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 214      
Building and Improvements 7,952      
Costs capitalized subsequent to acquisition, land (41)      
Costs capitalized subsequent to acquisition, buildings and improvements (3,369)      
Gross Amount 4,756      
Accumulated Depreciation 127      
Colonial Healthcare & Rehab Centre - Princeton, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 173      
Building and Improvements 5,871      
Costs capitalized subsequent to acquisition, land (33)      
Costs capitalized subsequent to acquisition, buildings and improvements (2,622)      
Gross Amount 3,389      
Accumulated Depreciation 92      
Capitol Healthcare & Rehab Centre - Springfield, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 603      
Building and Improvements 21,699      
Costs capitalized subsequent to acquisition, land (117)      
Costs capitalized subsequent to acquisition, buildings and improvements (8,560)      
Gross Amount 13,625      
Accumulated Depreciation 311      
Acuity Specialty Hospital - Mesa, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,977      
Building and Improvements 16,203      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 543      
Gross Amount 18,723      
Accumulated Depreciation 3,660      
Acuity Specialty Hospital - Sun City, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 2,329      
Building and Improvements 15,795      
Costs capitalized subsequent to acquisition, land (909)      
Costs capitalized subsequent to acquisition, buildings and improvements (7,715)      
Gross Amount 9,500      
Accumulated Depreciation 658      
Addington Place of Shoal Creek - Kansas City, MO        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 3,723      
Building and Improvements 22,259      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 704      
Gross Amount 26,686      
Accumulated Depreciation 5,404      
Aurora Healthcare Center - Green Bay, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,130      
Building and Improvements 1,678      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,808      
Accumulated Depreciation 420      
Aurora Healthcare Center - Greenville, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 259      
Building and Improvements 958      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 1,217      
Accumulated Depreciation 256      
Aurora Healthcare Center - Kiel, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 676      
Building and Improvements 2,214      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,890      
Accumulated Depreciation 494      
Aurora Healthcare Center - Plymouth, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 17,038      
Land 2,891      
Building and Improvements 24,224      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 27,115      
Accumulated Depreciation 5,430      
Aurora Healthcare Center - Waterford, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 590      
Building and Improvements 6,452      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 7,042      
Accumulated Depreciation 1,395      
Aurora Healthcare Center - Wautoma, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,955      
Building and Improvements 4,361      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,316      
Accumulated Depreciation 983      
Arbor View Assisted Living and Memory Care - Burlington, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 367      
Building and Improvements 7,815      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 71      
Gross Amount 8,253      
Accumulated Depreciation 2,080      
Advanced Orthopedic Medical Center - Richmond, VA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 15,390      
Land 1,523      
Building and Improvements 19,229      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 493      
Gross Amount 21,245      
Accumulated Depreciation 3,970      
Palm Valley Medical Plaza - Goodyear, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,890      
Building and Improvements 4,940      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 367      
Gross Amount 7,197      
Accumulated Depreciation 1,267      
Physicians Plaza of Roane County - Harriman, TN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 6,293      
Land 1,746      
Building and Improvements 7,842      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 182      
Gross Amount 9,770      
Accumulated Depreciation 1,737      
Adventist Health Lacey Medical Plaza - Hanford, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 11,526      
Land 328      
Building and Improvements 13,302      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 98      
Gross Amount 13,728      
Accumulated Depreciation 2,620      
Medical Center I - Peoria, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,085      
Land 807      
Building and Improvements 1,115      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,545      
Gross Amount 3,467      
Accumulated Depreciation 1,190      
Medical Center II - Peoria, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 945      
Building and Improvements 1,330      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 5,036      
Gross Amount 7,311      
Accumulated Depreciation 1,836      
Commercial Center - Peoria, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,254      
Land 959      
Building and Improvements 1,110      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 710      
Gross Amount 2,779      
Accumulated Depreciation 571      
Medical Center III - Peoria, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 2,137      
Land 673      
Building and Improvements 1,651      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,047      
Gross Amount 3,371      
Accumulated Depreciation 932      
Morrow Medical Center - Morrow, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 4,334      
Land 1,155      
Building and Improvements 5,674      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 493      
Gross Amount 7,322      
Accumulated Depreciation 1,451      
Belmar Medical Building -Lakewood, CO        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,770      
Land 819      
Building and Improvements 4,287      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 596      
Gross Amount 5,702      
Accumulated Depreciation 1,114      
Addington Place - Northville, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 440      
Building and Improvements 14,975      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,007      
Gross Amount 16,422      
Accumulated Depreciation 3,403      
Conroe Medical Arts and Surgery Center - Conroe, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 13,221      
Land 1,965      
Building and Improvements 12,198      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 744      
Gross Amount 14,907      
Accumulated Depreciation 2,842      
Medical Center V - Peoria, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,089      
Building and Improvements 3,200      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 879      
Gross Amount 5,168      
Accumulated Depreciation 804      
Legacy Medical Village - Plano, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 23,662      
Land 3,755      
Building and Improvements 31,097      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,430      
Gross Amount 36,282      
Accumulated Depreciation 6,634      
Scripps Cedar Medical Center - Vista, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 14,983      
Land 1,213      
Building and Improvements 14,596      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,673      
Gross Amount 17,482      
Accumulated Depreciation 2,981      
Ramsey Woods Memory Care - Cudahy, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 930      
Building and Improvements 4,990      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 122      
Gross Amount 6,042      
Accumulated Depreciation 1,188      
East Coast Square West - Cedar Point, NC        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 5,254      
Land 1,535      
Building and Improvements 4,803      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 6      
Gross Amount 6,344      
Accumulated Depreciation 962      
East Coast Square North - Morehead City, NC        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,933      
Land 899      
Building and Improvements 4,761      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 144      
Gross Amount 5,804      
Accumulated Depreciation 917      
Eastside Cancer Institute - Greenville, SC        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,498      
Building and Improvements 6,637      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 639      
Gross Amount 8,774      
Accumulated Depreciation 1,379      
Sassafras Medical Building - Erie, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 2,315      
Land 928      
Building and Improvements 4,629      
Costs capitalized subsequent to acquisition, land (364)      
Costs capitalized subsequent to acquisition, buildings and improvements (2,333)      
Gross Amount 2,860      
Accumulated Depreciation 0      
Sky Lakes Klamath Medical Clinic - Klamath Falls, OR        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 433      
Building and Improvements 2,623      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 3,056      
Accumulated Depreciation 508      
Courtyard Fountains - Gresham, OR        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 2,476      
Building and Improvements 50,601      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 2,255      
Gross Amount 55,332      
Accumulated Depreciation 10,764      
Presence Healing Arts Pavilion - New Lenox, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 5,966      
Land 0      
Building and Improvements 6,768      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 76      
Gross Amount 6,844      
Accumulated Depreciation 1,383      
Mainland Medical Arts Pavilion - Texas City, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 6,174      
Land 320      
Building and Improvements 7,923      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 321      
Gross Amount 8,564      
Accumulated Depreciation 1,756      
Renaissance on Peachtree - Atlanta, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 4,535      
Building and Improvements 68,895      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 3,246      
Gross Amount 76,676      
Accumulated Depreciation 13,856      
Fox Ridge Senior Living at Bryant - Bryant, AR        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 6,817      
Land 1,687      
Building and Improvements 12,936      
Costs capitalized subsequent to acquisition, land (557)      
Costs capitalized subsequent to acquisition, buildings and improvements (6,326)      
Gross Amount 7,740      
Accumulated Depreciation 40      
Fox Ridge Senior Living at Chenal - Little Rock, AR        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 15,639      
Land 6,896      
Building and Improvements 20,579      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 364      
Gross Amount 27,839      
Accumulated Depreciation 4,917      
Fox Ridge North Little Rock - North Little Rock, AR        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 9,704      
Land 0      
Building and Improvements 19,265      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 263      
Gross Amount 19,528      
Accumulated Depreciation 4,211      
High Desert Medical Group Medical Office Building - Lancaster, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 7,480      
Land 1,459      
Building and Improvements 9,300      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 10,759      
Accumulated Depreciation 1,749      
Northside Hospital - Canton, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,014      
Land 3,408      
Building and Improvements 8,191      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 438      
Gross Amount 12,037      
Accumulated Depreciation 1,249      
West Michigan Surgery Center - Big Rapids, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 258      
Building and Improvements 5,677      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 5,935      
Accumulated Depreciation 803      
Camellia Walk Assisted Living and Memory Care - Evans, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,854      
Building and Improvements 17,372      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,232      
Gross Amount 20,458      
Accumulated Depreciation 3,426      
Cedarhurst of Collinsville - Collinsville, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,228      
Building and Improvements 8,652      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 264      
Gross Amount 10,144      
Accumulated Depreciation 1,393      
Arcadian Cove Assisted Living - Richmond, KY        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 481      
Building and Improvements 3,923      
Costs capitalized subsequent to acquisition, land (425)      
Costs capitalized subsequent to acquisition, buildings and improvements (3,536)      
Gross Amount 443      
Accumulated Depreciation 14      
Beaumont Medical Center - Warren, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,078      
Building and Improvements 9,525      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 19      
Gross Amount 10,622      
Accumulated Depreciation 1,328      
DaVita Dialysis - Hudson, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 226      
Building and Improvements 1,979      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 121      
Gross Amount 2,326      
Accumulated Depreciation 273      
DaVita Bay Breeze Dialysis Center - Largo, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 399      
Building and Improvements 896      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 48      
Gross Amount 1,343      
Accumulated Depreciation 150      
Greenfield Medical Plaza - Gilbert, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,476      
Building and Improvements 4,144      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 277      
Gross Amount 5,897      
Accumulated Depreciation 633      
RAI Care Center - Clearwater, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 624      
Building and Improvements 3,156      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 3,780      
Accumulated Depreciation 420      
Illinois CancerCare - Galesburg, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 2,323      
Land 290      
Building and Improvements 2,457      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,747      
Accumulated Depreciation 368      
UnityPoint Clinic - Muscatine, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 570      
Building and Improvements 4,541      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 34      
Gross Amount 5,145      
Accumulated Depreciation 649      
Lee Memorial Health System Outpatient Center - Ft. Myers        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 439      
Building and Improvements 4,374      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 710      
Gross Amount 5,523      
Accumulated Depreciation 688      
Decatur Medical Office Building - Decatur, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 695      
Building and Improvements 3,273      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 261      
Gross Amount 4,229      
Accumulated Depreciation 507      
Madison Medical Plaza - Joliet, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 12,477      
Land 0      
Building and Improvements 16,855      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 37      
Gross Amount 16,892      
Accumulated Depreciation 2,111      
Woodlake Office Center - Woodbury, MN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,638      
Land 1,017      
Building and Improvements 10,688      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,297      
Gross Amount 13,002      
Accumulated Depreciation 1,652      
Rockwall Medical Plaza - Rockwall, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,097      
Building and Improvements 4,582      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 214      
Gross Amount 5,893      
Accumulated Depreciation 709      
MetroHealth Buckeye Health Center - Cleveland, OH        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 389      
Building and Improvements 4,367      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 255      
Gross Amount 5,011      
Accumulated Depreciation 648      
UnityPoint Clinic - Moline, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 396      
Building and Improvements 2,880      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 5      
Gross Amount 3,281      
Accumulated Depreciation 411      
VA Outpatient Clinic - Galesberg, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 359      
Building and Improvements 1,852      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,211      
Accumulated Depreciation 302      
Philip Professional Center - Lawrenceville, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 5,780      
Land 1,285      
Building and Improvements 6,714      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 264      
Gross Amount 8,263      
Accumulated Depreciation 1,045      
Texas Children’s Hospital - Houston, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 4,590      
Land 1,368      
Building and Improvements 4,428      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 116      
Gross Amount 5,912      
Accumulated Depreciation 790      
Florida Medical Heartcare - Tampa, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 586      
Building and Improvements 1,902      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,488      
Accumulated Depreciation 322      
Florida Medical Somerset - Tampa, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 61      
Building and Improvements 1,366      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 1,427      
Accumulated Depreciation 204      
Florida Medical Tampa Palms - Tampa, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 141      
Building and Improvements 1,402      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 1,543      
Accumulated Depreciation 215      
Florida Medical Wesley Chapel - Tampa, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 485      
Building and Improvements 1,987      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,472      
Accumulated Depreciation 345      
Aurora Health Center - Milwaukee, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,984      
Land 1,014      
Building and Improvements 4,041      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 224      
Gross Amount 5,279      
Accumulated Depreciation 788      
Vascular Surgery Associates - Tallahassee, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 902      
Building and Improvements 5,383      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,285      
Accumulated Depreciation 856      
Glendale MOB - Farmington Hills, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 504      
Building and Improvements 12,332      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 12,836      
Accumulated Depreciation 1,542      
Crittenton Washington MOB - Washington Township, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 640      
Building and Improvements 4,090      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 283      
Gross Amount 5,013      
Accumulated Depreciation 592      
Crittenton Sterling Heights MOB - Sterling Heights, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,398      
Building and Improvements 2,695      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 258      
Gross Amount 4,351      
Accumulated Depreciation 492      
Advocate Aurora MOB - Elkhorn, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 7,184      
Land 181      
Building and Improvements 9,452      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 9,633      
Accumulated Depreciation 1,280      
Pulmonary & Critical Care Med - Lemoyne, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 4,271      
Land 621      
Building and Improvements 3,805      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,426      
Accumulated Depreciation 661      
Dignity Emerus Blue Diamond - Las Vegas, NV        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 13,966      
Land 2,182      
Building and Improvements 16,594      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 18,776      
Accumulated Depreciation 1,864      
Dignity Emerus Craig Rd - North Las Vegas, NV        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 18,780      
Land 3,807      
Building and Improvements 22,803      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 26,610      
Accumulated Depreciation 2,584      
Greenfield MOB - Greenfield, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 7,526      
Land 1,552      
Building and Improvements 8,333      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 246      
Gross Amount 10,131      
Accumulated Depreciation 1,199      
Milwaukee MOB - South Milwaukee, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 4,136      
Land 410      
Building and Improvements 5,041      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 5,451      
Accumulated Depreciation 544      
St. Francis WI MOB - St. Francis, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 9,088      
Land 865      
Building and Improvements 11,355      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 251      
Gross Amount 12,471      
Accumulated Depreciation 1,353      
Lancaster Medical Arts MOB - Lancaster, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 85      
Building and Improvements 4,417      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,502      
Accumulated Depreciation 569      
Women’s Healthcare Group MOB - York, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 624      
Building and Improvements 2,161      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,785      
Accumulated Depreciation 403      
Pioneer Spine Sports - Northampton, MA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 435      
Building and Improvements 1,858      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,293      
Accumulated Depreciation 192      
Pioneer Spine Sport - Springfield, MA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 333      
Building and Improvements 2,530      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,863      
Accumulated Depreciation 252      
Pioneer Spine Sports - West Springfield, MA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 374      
Building and Improvements 4,295      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,669      
Accumulated Depreciation 417      
Felicita Vida - Escondido, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,677      
Building and Improvements 28,953      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 396      
Gross Amount 31,026      
Accumulated Depreciation 2,785      
Cedarhurst of Edwardsville - Edwardsville, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 321      
Building and Improvements 9,032      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 56      
Gross Amount 9,409      
Accumulated Depreciation 805      
UMPC Sir Thomas Court - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 745      
Building and Improvements 6,272      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 7,017      
Accumulated Depreciation 498      
UMPC Fisher Road - Mechanicsburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 747      
Building and Improvements 3,844      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,591      
Accumulated Depreciation 333      
Swedish American MOB - Roscoe, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 599      
Building and Improvements 5,862      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,461      
Accumulated Depreciation 588      
Cedarhurst of Sparta - Sparta, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 381      
Building and Improvements 13,807      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 63      
Gross Amount 14,251      
Accumulated Depreciation 1,225      
UMPC Chambers Hill - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 498      
Building and Improvements 4,238      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,736      
Accumulated Depreciation 329      
Cedarhurst of Shiloh - Shiloh, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 13,071      
Land 376      
Building and Improvements 28,299      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 65      
Gross Amount 28,740      
Accumulated Depreciation 2,085      
Bayshore Naples Memory Care - Naples, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 3,231      
Building and Improvements 17,112      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 54      
Gross Amount 20,397      
Accumulated Depreciation 1,306      
Circleville MOB - Circleville, OH        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,556      
Land 765      
Building and Improvements 4,011      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 71      
Gross Amount 4,847      
Accumulated Depreciation 243      
Kingwood Executive Center - Kingwood, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,522      
Building and Improvements 4,166      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 34      
Gross Amount 5,722      
Accumulated Depreciation 251      
OrthoOne Hilliard - Hilliard, OH        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 760      
Building and Improvements 3,118      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 77      
Gross Amount 3,955      
Accumulated Depreciation 206      
South Douglas MOB - Midwest City, OK        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 628      
Building and Improvements 3,863      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,491      
Accumulated Depreciation 193      
Fort Wayne Opthomology Engle - Fort Wayne, IN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,923      
Land 516      
Building and Improvements 6,124      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,640      
Accumulated Depreciation 260      
Fort Wayne Opthomology Dupont - Fort Wayne, IN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 1,924      
Land 597      
Building and Improvements 2,653      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 3,250      
Accumulated Depreciation 138      
St. Peters Albany 2 Palisades - Albany, NY        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 516      
Building and Improvements 4,342      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,858      
Accumulated Depreciation 202      
Hefner Pointe Medical Center - Oklahoma City, OK        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,831      
Land 678      
Building and Improvements 4,819      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 31      
Gross Amount 5,528      
Accumulated Depreciation 222      
St. Peters Troy 2 New Hampshire - Troy, NY        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 330      
Building and Improvements 2,444      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 19      
Gross Amount 2,793      
Accumulated Depreciation 113      
St Peters - Albany, NY - 4 Palisades        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 542      
Building and Improvements 2,416      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,958      
Accumulated Depreciation 113      
St Peters - Albany, NY - 5 Palisades        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 593      
Building and Improvements 5,359      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 5,952      
Accumulated Depreciation 221      
St Lukes Heart Vascular Center - East Stroudsburg        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 363      
Building and Improvements 3,224      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 3,587      
Accumulated Depreciation 113      
Metropolitan Eye Lakeshore Surgery - St. Clair, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 203      
Building and Improvements 4,632      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,835      
Accumulated Depreciation 164      
Naidu Clinic - Odessa, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 730      
Building and Improvements 2,409      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 3,139      
Accumulated Depreciation 93      
Belpre V Cancer Center - Belpre, OH        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,153      
Building and Improvements 63,894      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 65,047      
Accumulated Depreciation 2,072      
Center for Advanced Dermatology - Lakewood, CO        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,034      
Building and Improvements 1,874      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,908      
Accumulated Depreciation 59      
Florida Medical Clinic - Tampa, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,104      
Building and Improvements 1,137      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 124      
Gross Amount 2,365      
Accumulated Depreciation 44      
Pensacola Nephrology MOB - Pensacola, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,578      
Building and Improvements 5,123      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,701      
Accumulated Depreciation 135      
Millennium Eye Care - Freehold, NJ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 635      
Building and Improvements 6,014      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,649      
Accumulated Depreciation 125      
Atlanta Gastroenterology Associates - Lawrenceville, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 2,639      
Building and Improvements 2,263      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,902      
Accumulated Depreciation 24      
Bone and Joint Specialists - Merrillville, IN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,014      
Building and Improvements 2,499      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 3,513      
Accumulated Depreciation 29      
Eastern Carolina ENT - Greenville, NC        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 664      
Building and Improvements 5,826      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,490      
Accumulated Depreciation 0      
Credit Facilities        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Credit facilities, net 178,250 147,006    
Credit Facilities | Master Credit Facility        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Credit facilities, net 352,047 355,045    
Capital One Facility | Credit Facilities | Master Credit Facility        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Credit facilities, net 210,483 212,417    
Secured debt 210,500      
KeyBank Facility | Credit Facilities | Master Credit Facility        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Credit facilities, net 141,564 $ 142,628    
Secured debt $ 141,600      
XML 104 R90.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate and Accumulated Depreciation Schedule III (Changes in Accumulated Depreciation) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Real estate investments, at cost:      
Balance at beginning of year $ 2,345,708 $ 2,211,451 $ 2,296,627
Additions-acquisitions and capital expenditures 44,926 98,364 80,980
Disposals, impairments and reclasses (95,047) 35,893 (166,156)
Balance at end of the year 2,295,587 2,345,708 2,211,451
Accumulated depreciation:      
Balance at beginning of year 328,095 260,399 226,167
Depreciation expense 63,143 63,393 64,731
Disposals, impairments and reclasses 6,744 4,303 (30,499)
Balance at end of the year $ 397,982 $ 328,095 $ 260,399
XML 105 R91.htm IDEA: XBRL DOCUMENT v3.22.4
Real Estate and Accumulated Depreciation Schedule III (Changes in Accumulated Depreciation Additional Information) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]      
Assets $ 95,047 $ (35,893) $ 166,156
Reclassification From Held-For-Sale To Real Estate Investments | Revision of Prior Period, Reclassification, Adjustment      
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]      
Assets     49,400
Accumulated depreciation     $ 8,700
XML 106 hct-20221231_htm.xml IDEA: XBRL DOCUMENT 0001561032 2022-01-01 2022-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2022-01-01 2022-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2022-01-01 2022-12-31 0001561032 2022-06-30 0001561032 2023-03-14 0001561032 2022-12-31 0001561032 2021-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2022-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2021-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2021-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2022-12-31 0001561032 2021-01-01 2021-12-31 0001561032 2020-01-01 2020-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001561032 us-gaap:CommonStockMember 2019-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001561032 us-gaap:RetainedEarningsMember 2019-12-31 0001561032 us-gaap:ParentMember 2019-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2019-12-31 0001561032 2019-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:ParentMember 2020-01-01 2020-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2020-01-01 2020-12-31 0001561032 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001561032 us-gaap:ParentMember 2020-01-01 2020-12-31 0001561032 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001561032 us-gaap:CommonStockMember 2020-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001561032 us-gaap:RetainedEarningsMember 2020-12-31 0001561032 us-gaap:ParentMember 2020-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2020-12-31 0001561032 2020-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:ParentMember 2021-01-01 2021-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2021-01-01 2021-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:ParentMember 2021-01-01 2021-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2021-01-01 2021-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001561032 us-gaap:ParentMember 2021-01-01 2021-12-31 0001561032 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001561032 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001561032 us-gaap:CommonStockMember 2021-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001561032 us-gaap:RetainedEarningsMember 2021-12-31 0001561032 us-gaap:ParentMember 2021-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2021-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:ParentMember 2022-01-01 2022-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:ParentMember 2022-01-01 2022-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001561032 us-gaap:ParentMember 2022-01-01 2022-12-31 0001561032 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001561032 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001561032 us-gaap:CommonStockMember 2022-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001561032 us-gaap:RetainedEarningsMember 2022-12-31 0001561032 us-gaap:ParentMember 2022-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2022-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2020-01-01 2020-12-31 0001561032 2020-10-01 2022-12-31 0001561032 us-gaap:LineOfCreditMember 2019-01-01 2019-12-31 0001561032 srt:RestatementAdjustmentMember us-gaap:LineOfCreditMember 2019-01-01 2019-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2021-01-01 2021-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2020-01-01 2020-12-31 0001561032 srt:MinimumMember 2022-01-01 2022-12-31 0001561032 srt:MaximumMember 2022-01-01 2022-12-31 0001561032 us-gaap:BuildingMember 2022-01-01 2022-12-31 0001561032 us-gaap:LandImprovementsMember 2022-01-01 2022-12-31 0001561032 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001561032 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001561032 us-gaap:DomesticCountryMember 2022-12-31 0001561032 us-gaap:DomesticCountryMember 2018-01-01 0001561032 hct:MultitenantMOBMember 2022-01-01 2022-12-31 0001561032 hct:SingleTenantMOBMember 2022-01-01 2022-12-31 0001561032 hct:MedicalOfficeBuildingsMember 2022-01-01 2022-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2022-01-01 2022-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-01-01 2021-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2020-01-01 2020-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:LeasesAcquiredInPlaceMember 2022-01-01 2022-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:LeasesAcquiredInPlaceMember 2021-01-01 2021-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:LeasesAcquiredInPlaceMember 2020-01-01 2020-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:AboveMarketLeasesMember 2022-01-01 2022-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:AboveMarketLeasesMember 2021-01-01 2021-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:AboveMarketLeasesMember 2020-01-01 2020-12-31 0001561032 us-gaap:LeasesAcquiredInPlaceMember 2022-01-01 2022-12-31 0001561032 us-gaap:AboveMarketLeasesMember 2022-01-01 2022-12-31 0001561032 hct:BelowMarketLeasesMember 2022-01-01 2022-12-31 0001561032 us-gaap:LeasesAcquiredInPlaceMember 2021-01-01 2021-12-31 0001561032 us-gaap:AboveMarketLeasesMember 2021-01-01 2021-12-31 0001561032 hct:BelowMarketLeasesMember 2021-01-01 2021-12-31 0001561032 us-gaap:LeasesAcquiredInPlaceMember 2020-01-01 2020-12-31 0001561032 us-gaap:AboveMarketLeasesMember 2020-01-01 2020-12-31 0001561032 hct:BelowMarketLeasesMember 2020-01-01 2020-12-31 0001561032 stpr:FL us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0001561032 stpr:FL us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0001561032 stpr:FL us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-12-31 0001561032 stpr:PA us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-12-31 0001561032 us-gaap:LeasesAcquiredInPlaceMember 2022-12-31 0001561032 us-gaap:LeasesAcquiredInPlaceMember 2021-12-31 0001561032 hct:IntangibleMarketLeaseAssetsMember 2022-12-31 0001561032 hct:IntangibleMarketLeaseAssetsMember 2021-12-31 0001561032 us-gaap:OtherIntangibleAssetsMember 2022-12-31 0001561032 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0001561032 hct:InplaceLeasesandOtherIntangibleAssetsMember hct:DepreciationandAmortizationExpenseMember 2022-01-01 2022-12-31 0001561032 hct:InplaceLeasesandOtherIntangibleAssetsMember hct:DepreciationandAmortizationExpenseMember 2021-01-01 2021-12-31 0001561032 hct:InplaceLeasesandOtherIntangibleAssetsMember hct:DepreciationandAmortizationExpenseMember 2020-01-01 2020-12-31 0001561032 hct:AboveandBelowMarketLeasesMember hct:RentalIncomeMember 2022-01-01 2022-12-31 0001561032 hct:AboveandBelowMarketLeasesMember hct:RentalIncomeMember 2021-01-01 2021-12-31 0001561032 hct:AboveandBelowMarketLeasesMember hct:RentalIncomeMember 2020-01-01 2020-12-31 0001561032 hct:AboveMarketGroundLeaseMember hct:PropertyOperatingandMaintenanceExpenseMember 2022-01-01 2022-12-31 0001561032 hct:AboveMarketGroundLeaseMember hct:PropertyOperatingandMaintenanceExpenseMember 2021-01-01 2021-12-31 0001561032 hct:AboveMarketGroundLeaseMember hct:PropertyOperatingandMaintenanceExpenseMember 2020-01-01 2020-12-31 0001561032 us-gaap:LeasesAcquiredInPlaceMember hct:AmortizationExpenseMember 2022-12-31 0001561032 us-gaap:OtherIntangibleAssetsMember hct:AmortizationExpenseMember 2022-12-31 0001561032 hct:AmortizationExpenseMember 2022-12-31 0001561032 us-gaap:AboveMarketLeasesMember hct:RentalIncomeMember 2022-12-31 0001561032 hct:BelowMarketLeaseMember hct:RentalIncomeMember 2022-12-31 0001561032 hct:RentalIncomeMember 2022-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:LaSallePropertiesMember 2022-03-02 2022-03-02 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:LaSallePropertiesMember 2022-03-02 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:LienSettlementOnFormerlyDisposedPropertiesMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2022-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:HamptonRiverPortolioMember 2021-12-21 2021-12-21 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:HamptonRiverPortolioMember 2021-12-21 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:NuVistaJupiterMember 2021-05-14 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:NuVistaJupiterMember 2021-05-14 2021-05-14 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:WellingtonGreenMember 2021-05-14 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:WellingtonGreenMember 2021-05-14 2021-05-14 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-01-15 2021-01-15 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-01-15 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-01-01 2021-12-31 0001561032 hct:SkilledNursingFacilitiesMember hct:LutzFloridaMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-12-15 0001561032 hct:SkilledNursingFacilitiesMember hct:LutzFloridaMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-12-15 2020-12-15 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-11-02 2020-11-02 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-11-02 0001561032 hct:MedicalOfficeBuildingsMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-03-19 0001561032 hct:MedicalOfficeBuildingsMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-03-19 2020-03-19 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:LaSallePropertiesMember 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:NuVistaJupiterMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:NuVistaJupiterMember 2019-01-01 2019-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:WellingtonGreenMember 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:WellingtonGreenMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:WellingtonGreenMember 2019-01-01 2019-12-31 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-01-01 2020-12-31 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2019-01-01 2019-12-31 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-11-30 0001561032 hct:SkilledNursingFacilitiesMember hct:LutzFloridaMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2019-01-01 2019-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MOBPropertyIllinoisSkilledNursingFacilitiesMember hct:MedicalOfficeBuildingsMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MOBPropertyIllinoisSkilledNursingFacilitiesMember hct:MedicalOfficeBuildingsMember 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MOBPropertyIllinoisSkilledNursingFacilitiesMember hct:MedicalOfficeBuildingsMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MOBPropertySassafrasMember hct:MedicalOfficeBuildingsMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MOBPropertySassafrasMember hct:MedicalOfficeBuildingsMember 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MOBPropertySassafrasMember hct:MedicalOfficeBuildingsMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MOBPropertySunCityArizonaMember hct:MedicalOfficeBuildingsMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MOBPropertySunCityArizonaMember hct:MedicalOfficeBuildingsMember 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MOBPropertySunCityArizonaMember hct:MedicalOfficeBuildingsMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MedicalOfficeBuildingsMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MedicalOfficeBuildingsMember 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MedicalOfficeBuildingsMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:VariousSeniorsHousingCommunitiesMember hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:VariousSeniorsHousingCommunitiesMember hct:SeniorsHousingCommunitiesMember 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:VariousSeniorsHousingCommunitiesMember hct:SeniorsHousingCommunitiesMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:LaSallePropertiesMember hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:LaSallePropertiesMember hct:SeniorsHousingCommunitiesMember 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:LaSallePropertiesMember hct:SeniorsHousingCommunitiesMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:WellingtonGreenMember hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:WellingtonGreenMember hct:SeniorsHousingCommunitiesMember 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:WellingtonGreenMember hct:SeniorsHousingCommunitiesMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MichiganPropertiesMember hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MichiganPropertiesMember hct:SeniorsHousingCommunitiesMember 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MichiganPropertiesMember hct:SeniorsHousingCommunitiesMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:NuVistaJupiterMember hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:NuVistaJupiterMember hct:SeniorsHousingCommunitiesMember 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:NuVistaJupiterMember hct:SeniorsHousingCommunitiesMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MOBPropertyIllinoisSkilledNursingFacilitiesMember 2022-12-31 0001561032 hct:SeniorsHousingCommunitiesMember us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:VariousSeniorsHousingCommunitiesMember 2022-12-31 0001561032 hct:SeniorsHousingCommunitiesMember us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:VariousSeniorsHousingCommunitiesMember 2022-01-01 2022-12-31 0001561032 hct:SeniorsHousingCommunitiesMember us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:LaSallePropertiesMember 2022-01-01 2022-12-31 0001561032 hct:WellingtonMember us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:WellingtonGreenMember 2020-01-01 2020-12-31 0001561032 hct:PalmValleyMedicalPlazaAZMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:PalmValleyMedicalPlazaAZMember us-gaap:MortgagesMember 2021-12-31 0001561032 hct:MedicalCenterVPeoriaAZMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:MedicalCenterVPeoriaAZMember us-gaap:MortgagesMember 2021-12-31 0001561032 hct:FoxRidgeSeniorLivingatBryantBryantMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:FoxRidgeSeniorLivingatBryantBryantMember us-gaap:MortgagesMember 2021-12-31 0001561032 hct:FoxRidgeSeniorLivingatChenalLittleRockMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:FoxRidgeSeniorLivingatChenalLittleRockMember us-gaap:MortgagesMember 2021-12-31 0001561032 hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember us-gaap:MortgagesMember 2021-12-31 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember 2021-12-31 0001561032 hct:MultiPropertyCMBSLoanMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:MultiPropertyCMBSLoanMember us-gaap:MortgagesMember 2021-12-31 0001561032 hct:ShilohIllinoisMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:ShilohIllinoisMember us-gaap:MortgagesMember 2021-12-31 0001561032 hct:BMOMOBLoanMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:BMOMOBLoanMember us-gaap:MortgagesMember 2021-12-31 0001561032 us-gaap:MortgagesMember 2022-12-31 0001561032 us-gaap:MortgagesMember 2021-12-31 0001561032 hct:MOBLoanMember hct:LIBORBasedInterestRateSwapMember 2022-12-31 0001561032 hct:MOBLoanMember hct:LIBORBasedInterestRateSwapMember 2021-12-31 0001561032 hct:BMOMOBLoanMember us-gaap:MortgagesMember 2021-11-15 0001561032 us-gaap:RevolvingCreditFacilityMember hct:BMOMOBLoanMember us-gaap:MortgagesMember 2021-11-15 2021-11-15 0001561032 us-gaap:RevolvingCreditFacilityMember hct:BMOMOBLoanMember us-gaap:MortgagesMember 2021-11-15 0001561032 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-12-31 0001561032 us-gaap:LineOfCreditMember hct:TermLoanMember 2022-12-31 0001561032 us-gaap:LineOfCreditMember hct:TermLoanMember 2021-12-31 0001561032 us-gaap:LineOfCreditMember 2022-12-31 0001561032 us-gaap:LineOfCreditMember 2021-12-31 0001561032 us-gaap:LineOfCreditMember hct:MasterCreditFacilityMember hct:CapitalOneFacilityMember 2022-12-31 0001561032 us-gaap:LineOfCreditMember hct:MasterCreditFacilityMember hct:CapitalOneFacilityMember 2021-12-31 0001561032 us-gaap:LineOfCreditMember hct:MasterCreditFacilityMember hct:KeyBankFacilityMember 2022-12-31 0001561032 us-gaap:LineOfCreditMember hct:MasterCreditFacilityMember hct:KeyBankFacilityMember 2021-12-31 0001561032 us-gaap:LineOfCreditMember hct:MasterCreditFacilityMember 2022-12-31 0001561032 us-gaap:LineOfCreditMember hct:MasterCreditFacilityMember 2021-12-31 0001561032 us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2022-12-31 0001561032 hct:MasterCreditFacilityMember us-gaap:InterestRateCapMember 2022-12-31 0001561032 hct:MasterCreditFacilityMember us-gaap:InterestRateCapMember hct:CapitalOneFacilityMember 2022-12-31 0001561032 hct:MasterCreditFacilityMember us-gaap:InterestRateCapMember hct:KeyBankFacilityMember 2022-12-31 0001561032 us-gaap:RevolvingCreditFacilityMember hct:TermLoanMember 2022-01-01 2022-12-31 0001561032 hct:SOFRBasedInterestRateSwapMember hct:TermLoanMember 2022-09-30 0001561032 hct:SOFRBasedInterestRateSwapMember hct:TermLoanMember 2022-12-31 0001561032 hct:LIBORBasedInterestRateSwapMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 hct:LIBORBasedInterestRateSwapMember us-gaap:LineOfCreditMember 2021-12-31 0001561032 hct:MasterCreditFacilityMember 2022-12-31 0001561032 hct:NewCreditFacilitiesMember 2022-12-31 0001561032 hct:UnencumberedPropertiesMember 2022-12-31 0001561032 hct:TermLoanMember 2022-01-01 2022-12-31 0001561032 hct:TermLoanMember 2022-12-31 0001561032 srt:MinimumMember us-gaap:SecuredDebtMember 2022-12-31 0001561032 srt:MaximumMember us-gaap:SecuredDebtMember 2022-12-31 0001561032 us-gaap:SecuredDebtMember 2022-12-31 0001561032 hct:NewCreditFacilitiesMember hct:DayPriortoCommencementQuarterMemberMember 2022-12-31 0001561032 hct:CommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MinimumMember hct:CovenantPeriodAfterJune302021Member 2022-01-01 2022-12-31 0001561032 hct:NewCreditFacilitiesMember hct:CommencementQuarterMember 2022-12-31 0001561032 srt:MinimumMember hct:NewCreditFacilitiesMember hct:CommencementQuarterMember 2022-01-01 2022-12-31 0001561032 hct:CovenantPeriodFromJuly12021throughCommencementQuarterMember 2022-01-01 2022-12-31 0001561032 hct:CovenantPeriodAfterCommencementQuarterMember 2022-01-01 2022-12-31 0001561032 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember hct:CovenantPeriodQuarterEndingJune302022ThroughJune302023Member 2022-01-01 2022-12-31 0001561032 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember hct:CovenantPeriodQuarterEndingSeptember302023ThroughDecember312023Member 2022-01-01 2022-12-31 0001561032 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember hct:CovenantPeriodQuarterEndingMarch312024AndThereafterMember 2022-01-01 2022-12-31 0001561032 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember hct:CovenantPeriodFromAndAfterCommencementQuarterMember 2022-01-01 2022-12-31 0001561032 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-01-01 2022-12-31 0001561032 us-gaap:LineOfCreditMember 2022-12-31 0001561032 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-01-01 2022-12-31 0001561032 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-01-01 2022-12-31 0001561032 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember hct:SecuredOvernightFinancingRateSOFRMember hct:CovenantPeriodAugust112022UntilCommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember hct:SecuredOvernightFinancingRateSOFRMember hct:CovenantPeriodAugust112022UntilCommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember hct:CovenantPeriodAugust112022UntilCommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember hct:CovenantPeriodAugust112022UntilCommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember hct:SecuredOvernightFinancingRateSOFRMember hct:CommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember hct:SecuredOvernightFinancingRateSOFRMember hct:CommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember hct:CommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember hct:CommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MinimumMember hct:TermLoanMember hct:SecuredOvernightFinancingRateSOFRMember hct:CovenantPeriodAugust112022UntilCommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MaximumMember hct:TermLoanMember hct:SecuredOvernightFinancingRateSOFRMember hct:CovenantPeriodAugust112022UntilCommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MinimumMember hct:TermLoanMember us-gaap:BaseRateMember hct:CovenantPeriodAugust112022UntilCommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MaximumMember hct:TermLoanMember us-gaap:BaseRateMember hct:CovenantPeriodAugust112022UntilCommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MinimumMember hct:TermLoanMember hct:SecuredOvernightFinancingRateSOFRMember hct:CommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MaximumMember hct:TermLoanMember hct:SecuredOvernightFinancingRateSOFRMember hct:CommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MinimumMember hct:TermLoanMember us-gaap:BaseRateMember hct:CommencementQuarterMember 2022-01-01 2022-12-31 0001561032 srt:MaximumMember hct:TermLoanMember us-gaap:BaseRateMember hct:CommencementQuarterMember 2022-01-01 2022-12-31 0001561032 hct:SecuredOvernightFinancingRateSOFRMember hct:CommencementQuarterMember 2022-12-31 0001561032 us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-03-17 0001561032 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-01-01 2023-03-17 0001561032 2020-11-01 2020-11-30 0001561032 hct:MasterCreditFacilityMember 2020-11-01 2020-11-30 0001561032 hct:LIBORBasedBorrowingsMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 hct:LIBORBasedVariableRateMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 hct:LIBORBasedInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2022-12-31 0001561032 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001561032 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2021-12-31 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2021-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2021-12-31 0001561032 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2021-12-31 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001561032 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001561032 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001561032 stpr:TX hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember 2022-12-31 0001561032 stpr:TX hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember hct:MedicalOfficeBuildingsMember 2022-12-31 0001561032 stpr:TX hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2022-12-31 0001561032 stpr:TX hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember 2021-12-31 0001561032 stpr:TX hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember hct:MedicalOfficeBuildingsMember 2021-12-31 0001561032 stpr:TX hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2021-12-31 0001561032 stpr:TX us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-03-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgagesMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgagesMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgagesMember 2021-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgagesMember 2021-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2021-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2021-12-31 0001561032 hct:FannieCreditFacilityMember us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 hct:FannieCreditFacilityMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 hct:FannieCreditFacilityMember us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2021-12-31 0001561032 hct:FannieCreditFacilityMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2021-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsAssetsMember us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2022-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsAssetsMember us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2021-12-31 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 srt:MinimumMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 srt:MaximumMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember 2017-06-30 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-10-01 2019-12-31 0001561032 hct:MOBLoanMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001561032 hct:MOBLoanMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-10-01 2019-12-31 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-12-31 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0001561032 hct:MOBLoanMember hct:SOFRBasedInterestRateSwapMember us-gaap:MortgagesMember 2022-12-31 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-12-31 0001561032 hct:SOFRBasedInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 hct:SOFRBasedInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001561032 hct:LIBORBasedInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-12-31 0001561032 us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2021-12-31 0001561032 hct:TenderOfferMember 2020-01-09 0001561032 hct:TenderOfferMember 2020-01-09 2020-01-09 0001561032 2020-01-09 2020-01-09 0001561032 2020-02-26 2020-02-26 0001561032 2012-10-15 2021-12-31 0001561032 2012-10-15 2022-12-31 0001561032 srt:MaximumMember hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2022-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember hct:PublicStockOfferingMember 2022-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2020-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember hct:PublicStockOfferingMember 2021-05-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember hct:PublicStockOfferingMember 2021-10-04 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2021-10-04 2021-10-04 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2021-10-04 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember hct:DelistingMember 2022-01-01 2022-12-31 0001561032 hct:PublicOfferingMember 2021-05-11 2021-05-11 0001561032 us-gaap:OverAllotmentOptionMember 2021-05-11 2021-05-11 0001561032 us-gaap:NoncontrollingInterestMember 2021-09-30 0001561032 hct:PreferredStockEquityLineMember 2020-09-15 0001561032 hct:PreferredStockEquityLineMember 2021-01-01 2021-12-31 0001561032 hct:PreferredStockEquityLineMember 2021-12-31 0001561032 hct:PreferredStockEquityLineMember 2021-07-01 2021-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember hct:PublicStockOfferingMember 2022-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember hct:DelistingMember 2022-01-01 2022-12-31 0001561032 hct:PublicStockOfferingMember 2021-10-06 2021-10-06 0001561032 us-gaap:OverAllotmentOptionMember 2021-10-06 2021-10-06 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2021-10-06 2021-10-06 0001561032 hct:PublicStockOfferingMember 2021-10-06 0001561032 2013-04-01 2013-04-30 0001561032 2017-04-01 2017-04-01 0001561032 2018-03-01 2018-03-01 0001561032 2020-10-01 2020-10-01 0001561032 2021-01-04 2021-01-04 0001561032 2021-04-02 2021-04-02 0001561032 2021-07-01 2021-07-01 0001561032 2021-10-01 2021-10-01 0001561032 2022-01-03 2022-01-03 0001561032 2022-04-01 2022-04-01 0001561032 2022-07-01 2022-07-01 0001561032 2022-10-03 2022-10-03 0001561032 us-gaap:SubsequentEventMember 2023-01-03 2023-01-03 0001561032 hct:SpecialLimitedPartnerMember hct:AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember 2022-12-31 0001561032 hct:SpecialLimitedPartnerMember hct:AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember 2021-12-31 0001561032 hct:TaxDepreciationDeductionMember hct:AdvisorMember 2022-12-31 0001561032 2017-02-17 2017-02-17 0001561032 hct:SecondAmendedandRestatedAdvisoryAgreementMember 2017-02-17 2017-02-17 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2017-02-17 2017-02-17 0001561032 hct:AdvisorMember hct:AdvanceOnLoanOrOtherInvestmentMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2022-12-31 0001561032 hct:AnnualTargetedInvestorReturnMember hct:SpecialLimitedPartnerMember hct:PreTaxNonCompoundedReturnOnCapitalContributionMember hct:HealthcareTrustSpecialLimitedPartnershipLLCMember 2022-12-31 0001561032 hct:AdvisorMember hct:ContractPurchasePriceMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2022-12-31 0001561032 hct:AdvisorMember 2022-01-01 2022-12-31 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:MonthlyBaseManagementFeeMember 2017-02-17 2017-02-17 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:QuarterlyVariableManagementFeeBenchmarkOneMember 2022-01-01 2022-12-31 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:QuarterlyVariableManagementFeeBenchmarkTwoMember 2022-01-01 2022-12-31 0001561032 hct:AdvisorMember hct:GrossRevenueStandAloneSingleTenantNetLeasedPropertiesMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2022-12-31 0001561032 hct:AdvisorMember hct:GrossRevenueExcludingStandAloneSingleTenantNetLeasedPropertiesMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2022-12-31 0001561032 srt:MaximumMember hct:AdvisorMember hct:GrossRevenueManagedPropertiesMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2022-12-31 0001561032 hct:AmendedandRestatedPropertyManagementandLeasingAgreementMember 2017-02-17 2017-02-17 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ReimbursementsofAdministrativeServicesMember 2022-01-01 2022-12-31 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ReimbursementsofAdministrativeServicesMember 2021-01-01 2021-12-31 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ReimbursementsofAdministrativeServicesMember 2020-01-01 2020-12-31 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ReimbursementsofAdministrativeServicesMember 2022-07-01 2022-09-30 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember hct:ConsumerPriceIndexMember 2019-07-25 2019-07-25 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember hct:CappedReimbursementAmountMember 2019-07-25 2019-07-25 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember hct:RealEstateCostMember 2019-07-25 2019-07-25 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember hct:AdvisorMember 2019-07-25 2019-07-25 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember hct:AdvisorAndCompanyMember 2019-07-25 2019-07-25 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ReimbursementsOfEmployeeBonusesOfTheAdvisorMember 2019-01-01 2019-12-31 0001561032 hct:A2019BonusAwardsMember 2019-12-31 0001561032 hct:A2019BonusAwardsMember 2020-09-30 0001561032 hct:A2019BonusAwardsMember 2022-12-31 0001561032 hct:A2019BonusAwardsMember 2022-01-01 2022-12-31 0001561032 hct:A2020BonusAwardsMember 2021-04-01 2021-06-30 0001561032 hct:A2020BonusAwardsMember hct:AdvisorMember 2021-04-01 2021-06-30 0001561032 hct:SeverancePaymentsMember 2020-12-31 0001561032 hct:AcquisitionCostsReimbursementsMember 2022-01-01 2022-12-31 0001561032 hct:AcquisitionCostsReimbursementsMember 2021-01-01 2021-12-31 0001561032 hct:AcquisitionCostsReimbursementsMember 2020-01-01 2020-12-31 0001561032 hct:AcquisitionCostsReimbursementsMember 2022-12-31 0001561032 hct:AcquisitionCostsReimbursementsMember 2021-12-31 0001561032 hct:AssetManagementFeesMember 2022-01-01 2022-12-31 0001561032 hct:AssetManagementFeesMember 2021-01-01 2021-12-31 0001561032 hct:AssetManagementFeesMember 2020-01-01 2020-12-31 0001561032 hct:AssetManagementFeesMember 2022-12-31 0001561032 hct:AssetManagementFeesMember 2021-12-31 0001561032 hct:PropertyManagementAndLeasingFeesMember 2022-01-01 2022-12-31 0001561032 hct:PropertyManagementAndLeasingFeesMember 2021-01-01 2021-12-31 0001561032 hct:PropertyManagementAndLeasingFeesMember 2020-01-01 2020-12-31 0001561032 hct:PropertyManagementAndLeasingFeesMember 2022-12-31 0001561032 hct:PropertyManagementAndLeasingFeesMember 2021-12-31 0001561032 hct:TransferAgentandOtherProfessionalFeesMember 2022-01-01 2022-12-31 0001561032 hct:TransferAgentandOtherProfessionalFeesMember 2021-01-01 2021-12-31 0001561032 hct:TransferAgentandOtherProfessionalFeesMember 2020-01-01 2020-12-31 0001561032 hct:TransferAgentandOtherProfessionalFeesMember 2022-12-31 0001561032 hct:TransferAgentandOtherProfessionalFeesMember 2021-12-31 0001561032 hct:ProfessionalFeesCreditDueFromAdvisorMember 2022-01-01 2022-12-31 0001561032 hct:ProfessionalFeesCreditDueFromAdvisorMember 2021-01-01 2021-12-31 0001561032 hct:ProfessionalFeesCreditDueFromAdvisorMember 2020-01-01 2020-12-31 0001561032 hct:ProfessionalFeesCreditDueFromAdvisorMember 2022-12-31 0001561032 hct:ProfessionalFeesCreditDueFromAdvisorMember 2021-12-31 0001561032 hct:DistributionsOnClassBUnitsMember 2022-01-01 2022-12-31 0001561032 hct:DistributionsOnClassBUnitsMember 2021-01-01 2021-12-31 0001561032 hct:DistributionsOnClassBUnitsMember 2020-01-01 2020-12-31 0001561032 hct:DistributionsOnClassBUnitsMember 2022-12-31 0001561032 hct:DistributionsOnClassBUnitsMember 2021-12-31 0001561032 hct:CappedReimbursementAmountMember 2022-01-01 2022-12-31 0001561032 hct:CappedReimbursementAmountMember 2021-01-01 2021-12-31 0001561032 hct:CappedReimbursementAmountMember 2020-01-01 2020-12-31 0001561032 hct:A2020BonusAwardsMember hct:AdvisorMember 2021-12-31 0001561032 hct:PrepaidExpensesAndOtherAssetsMember hct:PropertyManagementAndLeasingFeesMember 2022-01-01 2022-12-31 0001561032 hct:PrepaidExpensesAndOtherAssetsMember hct:PropertyManagementAndLeasingFeesMember 2021-01-01 2021-12-31 0001561032 hct:SpecialLimitedPartnerMember hct:ExcessOfAdjustedMarketValueOfRealEstateAssetsPlusDistributionsOverAggregateContributedInvestorCapitalMember hct:HealthcareTrustSpecialLimitedPartnershipLLCMember 2022-12-31 0001561032 hct:SpecialLimitedPartnerMember hct:NetSaleProceedsAfterReturnOfCapitalContributionsAndAnnualTargetedInvestorReturnMember hct:HealthcareTrustSpecialLimitedPartnershipLLCMember 2022-12-31 0001561032 hct:AdvisorMember hct:SecondAmendedandRestatedAdvisoryAgreementMember srt:AffiliatedEntityMember 2022-01-01 2022-12-31 0001561032 hct:TransitionFeeMember 2022-01-01 2022-12-31 0001561032 hct:SubjectFeesTransitionFeeNotinExcessoftheProductMember 2022-01-01 2022-12-31 0001561032 hct:SubjectFeesMember 2022-01-01 2022-12-31 0001561032 hct:ChangeinControlFeeMember 2022-01-01 2022-12-31 0001561032 hct:VariableManagementIncentiveFeeMember 2022-01-01 2022-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2022-01-01 2022-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2022-12-31 0001561032 srt:MinimumMember us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2022-01-01 2022-12-31 0001561032 srt:MaximumMember us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2022-01-01 2022-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2019-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2020-01-01 2020-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2020-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2021-01-01 2021-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2021-12-31 0001561032 srt:DirectorMember 2020-01-01 2020-12-31 0001561032 srt:DirectorMember 2022-01-01 2022-12-31 0001561032 srt:DirectorMember 2021-01-01 2021-12-31 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0001561032 hct:SeriesAPreferredUnitMember 2022-12-31 0001561032 hct:SeriesAPreferredUnitMember 2021-12-31 0001561032 hct:CommonOperatingPartnershipUnitMember 2022-12-31 0001561032 hct:CommonOperatingPartnershipUnitMember 2021-12-31 0001561032 hct:SeriesAPreferredUnitMember 2022-01-01 2022-12-31 0001561032 hct:SeriesAPreferredUnitMember 2021-01-01 2021-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2014-11-30 0001561032 hct:CommonOPUnitMember 2022-01-01 2022-12-31 0001561032 hct:CommonOPUnitMember 2021-01-01 2021-12-31 0001561032 hct:CommonOPUnitMember 2020-01-01 2020-12-31 0001561032 hct:OpUnitsMember 2022-01-01 2022-12-31 0001561032 hct:UnityPointClinicPortfolioMember 2020-11-04 2020-11-04 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2022-12-31 0001561032 hct:HealthcareTrustOperatingPartnershipL.P.Member hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2022-12-31 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2021-12-31 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001561032 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001561032 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001561032 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001561032 hct:OpUnitsMember 2021-01-01 2021-12-31 0001561032 hct:OpUnitsMember 2020-01-01 2020-12-31 0001561032 hct:ClassBUnitsMember 2022-01-01 2022-12-31 0001561032 hct:ClassBUnitsMember 2021-01-01 2021-12-31 0001561032 hct:ClassBUnitsMember 2020-01-01 2020-12-31 0001561032 us-gaap:RestrictedStockMember 2022-12-31 0001561032 us-gaap:RestrictedStockMember 2021-12-31 0001561032 us-gaap:RestrictedStockMember 2020-12-31 0001561032 hct:AdvisorMember hct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember 2022-12-31 0001561032 hct:AdvisorMember hct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember 2021-12-31 0001561032 hct:AdvisorMember hct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember 2020-12-31 0001561032 2021-10-01 2021-12-31 0001561032 hct:MedicalOfficeBuildingsMember 2022-01-01 2022-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-12-31 0001561032 hct:MedicalOfficeBuildingsMember 2021-01-01 2021-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2021-01-01 2021-12-31 0001561032 hct:MedicalOfficeBuildingsMember 2020-01-01 2020-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2020-01-01 2020-12-31 0001561032 hct:MedicalOfficeBuildingsMember 2022-12-31 0001561032 hct:MedicalOfficeBuildingsMember 2021-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2022-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2021-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:MedicalOfficeBuildingsMember 2022-01-01 2022-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:MedicalOfficeBuildingsMember 2021-01-01 2021-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:MedicalOfficeBuildingsMember 2020-01-01 2020-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:SeniorsHousingCommunitiesMember 2021-01-01 2021-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:SeniorsHousingCommunitiesMember 2020-01-01 2020-12-31 0001561032 us-gaap:OperatingSegmentsMember 2022-01-01 2022-12-31 0001561032 us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0001561032 us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0001561032 us-gaap:LandMember 2021-12-31 0001561032 hct:LIBORBasedInterestRateSwapMember us-gaap:SubsequentEventMember 2023-01-01 2023-03-17 0001561032 hct:LIBORBasedInterestRateSwapMember us-gaap:SubsequentEventMember 2023-03-17 0001561032 hct:FourSingleTenantMOBPropertiesMember us-gaap:SubsequentEventMember 2023-01-01 2023-03-17 0001561032 hct:FreseniusMedicalCareWinfieldALMember 2022-12-31 0001561032 hct:AdenaHealthCenterJacksonOHMember 2022-12-31 0001561032 hct:OuachitaCommunityHospitalWestMonroeLAMember 2022-12-31 0001561032 hct:CareMeridianLittletonCO.Member 2022-12-31 0001561032 hct:OakLawnMedicalCenterOakLawnIL.Member 2022-12-31 0001561032 hct:SurgeryCenterofTempleTempleTX.Member 2022-12-31 0001561032 hct:GreenvilleHealthSystemGreenvilleSCMember 2022-12-31 0001561032 hct:StockbridgeFamilyMedicalStockbridgeMember 2022-12-31 0001561032 hct:ArrowheadMedicalPlazaIIGlendaleMember 2022-12-31 0001561032 hct:VillageCenterParkwayStockbridgeMember 2022-12-31 0001561032 hct:CreeksideMOBDouglasvilleMember 2022-12-31 0001561032 hct:BowieGatewayMedicalCenterBowieMember 2022-12-31 0001561032 hct:CampusatCrooksAuburnBuildingDRochesterHillsMember 2022-12-31 0001561032 hct:BerwynMedicalCenterBerwynMember 2022-12-31 0001561032 hct:CountrysideMedicalArtsSafetyHarborMember 2022-12-31 0001561032 hct:St.AndrewsMedicalParkVeniceMember 2022-12-31 0001561032 hct:CampusatCrooksAuburnBuildingCRochesterHillsJuneMember 2022-12-31 0001561032 hct:LagunaProfessionalCenterElkGroveMember 2022-12-31 0001561032 hct:UCDavisMOBElkGroveMember 2022-12-31 0001561032 hct:EstateatHydeParkTampaJulyMember 2022-12-31 0001561032 hct:AutumnRidgeOfClarkstonClarkstonAugustMember 2022-12-31 0001561032 hct:SunnybrookofBurlingtonBurlingtonMember 2022-12-31 0001561032 hct:SunnybrookofCarrollCarrollAugust26Member 2022-12-31 0001561032 hct:PrairieHillsatCedarRapidsCedarRapidsAugustMember 2022-12-31 0001561032 hct:PrairieHillsatClintonClintonAugustMember 2022-12-31 0001561032 hct:PrairieHillsatDesMoinesDesMoinesAugustMember 2022-12-31 0001561032 hct:SunnybrookofFairfieldFairfieldAugust26Member 2022-12-31 0001561032 hct:SunnybrookofFt.MadisonFt.MadisonAugust26Member 2022-12-31 0001561032 hct:PrairieHillsatIndependenceIndependenceMember 2022-12-31 0001561032 hct:SunnybrookofMT.PleasantMt.PleasantAugust26Member 2022-12-31 0001561032 hct:SunnybrookofMuscatineMuscatineAugust26Member 2022-12-31 0001561032 hct:PrairieHillsatOttumwaOttumwaAugustMember 2022-12-31 0001561032 hct:PrairieHillsatTiptonTiptonAugustMember 2022-12-31 0001561032 hct:LibertyCourtDixonMember 2022-12-31 0001561032 hct:LakesideVistaHollandMember 2022-12-31 0001561032 hct:TheAtriumRockfordMember 2022-12-31 0001561032 hct:ArrowheadMedicalPlazaIGlendaleMember 2022-12-31 0001561032 hct:SunnybrookofBurlingtonLandBurlingtonAugustMember 2022-12-31 0001561032 hct:CommunityHealthMOBHarrisburgMember 2022-12-31 0001561032 hct:BradyMOBHarrisburgMember 2022-12-31 0001561032 hct:LandisMemorialHarrisburgSeptemberMember 2022-12-31 0001561032 hct:FOCIIMechanicsburgMember 2022-12-31 0001561032 hct:FOCClinicalMechanicsburgMember 2022-12-31 0001561032 hct:FOCIMechanicsburgMember 2022-12-31 0001561032 hct:CopperSpringsSeniorLivingMeridianSeptemberMember 2022-12-31 0001561032 hct:AddingtonPlaceofBrunswickBrunswickSeptemberMember 2022-12-31 0001561032 hct:AddingtonPlaceofDublinDublinSeptemberMember 2022-12-31 0001561032 hct:AllegroatElizabethtownElizabethtownSeptemberMember 2022-12-31 0001561032 hct:AddingtonPlaceofJohnsCreekJohnsCreekSeptemberMember 2022-12-31 0001561032 hct:AllegroatJupiterJupiterSeptemberMember 2022-12-31 0001561032 hct:AddingtonPlaceofLeesSummitLeesSummitSeptemberMember 2022-12-31 0001561032 hct:AddingtonPlaceatMillsRosewellMember 2022-12-31 0001561032 hct:AddingtonPlaceofCollegeHarbourStPetersburgSeptemberMember 2022-12-31 0001561032 hct:AllegroatStuartStuartSeptemberMember 2022-12-31 0001561032 hct:AllegroatTarponTarponSpringsSeptemberMember 2022-12-31 0001561032 hct:AddingtonPlaceofTitusvilleTitusvilleMember 2022-12-31 0001561032 hct:AllegroatStPetersburgLandStPetersburgSeptemberMember 2022-12-31 0001561032 hct:GatewayMedicalOfficeBuildingClarksvilleOctoberMember 2022-12-31 0001561032 hct:DyerBuildingDyerOctoberMember 2022-12-31 0001561032 hct:A757BuildingMunsterOctoberMember 2022-12-31 0001561032 hct:A761BuildingMunsterOctoberMember 2022-12-31 0001561032 hct:A759BuildingMunsterOctoberMember 2022-12-31 0001561032 hct:ScherervilleBuildingScherervilleMember 2022-12-31 0001561032 hct:MeadowbrookSeniorLivingAgouraHillsNovemberMember 2022-12-31 0001561032 hct:MountVernonMedicalOfficeBuildingMountVernonNovemberMember 2022-12-31 0001561032 hct:WellingtonatHersheysMillWestChesterMember 2022-12-31 0001561032 hct:EyeSpecialtyGroupMedicalBuildingMemphisDecemberMember 2022-12-31 0001561032 hct:AddingtonPlaceofAlpharettaAlpharettaMember 2022-12-31 0001561032 hct:AddingtonPlaceofPrairieVillagePrairieVillageMember 2022-12-31 0001561032 hct:BloomMOBHarrisburgDecemberMember 2022-12-31 0001561032 hct:MedicalSciencesPavilionHarrisburgDecemberMember 2022-12-31 0001561032 hct:WoodGlenNursingandRehabCenterWestChicagoDecemberMember 2022-12-31 0001561032 hct:PinnacleCenterSouthavenDecemberMember 2022-12-31 0001561032 hct:ParadiseValleyMedicalPlazaPhoenixDecemberMember 2022-12-31 0001561032 hct:VictoryMedicalCenteratCraigRanchMcKinneyMember 2022-12-31 0001561032 hct:RivershoresHealthcareRehabCentreMarseillesDecemberMember 2022-12-31 0001561032 hct:MortonTerraceHealthcareRehabCentreMortonDecemberMember 2022-12-31 0001561032 hct:MortonVillaHealthcareRehabCentreMortonMember 2022-12-31 0001561032 hct:TheHeightsHealthcarerehabCentrePeoriaHeightsDecemberMember 2022-12-31 0001561032 hct:ColonialHealthcareRehabCentrePrincetonDecemberMember 2022-12-31 0001561032 hct:CapitolHealthcareRehabCentreSpringfieldDecemberMember 2022-12-31 0001561032 hct:AcuitySpecialtyHospitalMesaMember 2022-12-31 0001561032 hct:AcuitySpecialtyHospitalSunCityMember 2022-12-31 0001561032 hct:AddingtonPlaceofShoalCreekKansasCityMember 2022-12-31 0001561032 hct:AuroraHealthCenterGreenBayMember 2022-12-31 0001561032 hct:AuroraHealthcareCenterGreenvilleWIMember 2022-12-31 0001561032 hct:AuraSheboyanClinicKielMarchMember 2022-12-31 0001561032 hct:AuroraHealthcareCenterPlymouthWIMember 2022-12-31 0001561032 hct:AuroraHealthcareCenterWaterfordWIMember 2022-12-31 0001561032 hct:AuroraHealthcareCenterWautomaWIMember 2022-12-31 0001561032 hct:ArborViewAssistedLivingandMemoryCareBurlingtonMarchMember 2022-12-31 0001561032 hct:AdvancedOrthopaedicMedicalCenterRichmondAprilMember 2022-12-31 0001561032 hct:PalmValleyMedicalPlazaGoodyearAprilMember 2022-12-31 0001561032 hct:PhysiciansPlazaofRoaneCountyHarrimanMember 2022-12-31 0001561032 hct:AdventistHealthLaceyMedicalPlazaHanfordMember 2022-12-31 0001561032 hct:MedicalCenterIPeoriaMayMember 2022-12-31 0001561032 hct:MedicalCenterIIPeoriaMayMember 2022-12-31 0001561032 hct:CommercialCenterPeoriaMayMember 2022-12-31 0001561032 hct:MedicalCenterIIIPeoriaMember 2022-12-31 0001561032 hct:MorrowMedicalCenterMorrowJuneMember 2022-12-31 0001561032 hct:BelmarMedicalBuildingLakewoodJuneMember 2022-12-31 0001561032 hct:AddingtonPlaceNorthvilleMember 2022-12-31 0001561032 hct:ConroeMedicalArtsandSurgeryCenterConroeMember 2022-12-31 0001561032 hct:MedicalCenterVPeoriaAZMember 2022-12-31 0001561032 hct:LegacyMedicalVillagePlanoMember 2022-12-31 0001561032 hct:ScrippsCedarMedicalCenterVistaAugustMember 2022-12-31 0001561032 hct:RamseyWoodsCudahyMember 2022-12-31 0001561032 hct:EastCoastSquareWestCedarPointOctoberMember 2022-12-31 0001561032 hct:EastCoastSquareNorthMoreheadCityOctoberMember 2022-12-31 0001561032 hct:EastsideCancerinstituteGreenvilleOctoberMember 2022-12-31 0001561032 hct:SassafrasMedicalBuildingErieMember 2022-12-31 0001561032 hct:SkyLakesKlamathMedicalClinicKlamathFallsMember 2022-12-31 0001561032 hct:CourtyardFountainsGreshamORMember 2022-12-31 0001561032 hct:PresenceHealingArtsPavilionNewLenoxDecemberMember 2022-12-31 0001561032 hct:MainlandMedicalArtsPavilionTexasCityMember 2022-12-31 0001561032 hct:RenaissanceonPeachtreeAtlantaMember 2022-12-31 0001561032 hct:FoxRidgeSeniorLivingatBryantBryantDecemberMember 2022-12-31 0001561032 hct:FoxRidgeSeniorLivingatChenalLittleRockDecemberMember 2022-12-31 0001561032 hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember 2022-12-31 0001561032 hct:HighDesertMedicalGroupMedicalOfficeBuildingLancasterMember 2022-12-31 0001561032 hct:NorthsideHospitalMedicalOfficeBuildingCantonMember 2022-12-31 0001561032 hct:WestMichiganSurgeryCenterBigRapidsMember 2022-12-31 0001561032 hct:CamelliaWalkAssistedLivingAndMemoryCareEvansMember 2022-12-31 0001561032 hct:CedarhurstofCollinsvilleMember 2022-12-31 0001561032 hct:ArcadianCoveAssistedLivingMember 2022-12-31 0001561032 hct:BeaumontMedicalCenterWarrenMember 2022-12-31 0001561032 hct:DaVitaHudsonMember 2022-12-31 0001561032 hct:DaVitaBayBreezeMember 2022-12-31 0001561032 hct:GreenfieldMedicalPlazaGilbertMember 2022-12-31 0001561032 hct:RAIClearwaterMember 2022-12-31 0001561032 hct:IllinoisCancerCareGalesburgMember 2022-12-31 0001561032 hct:UnityPointClinicMuscatineMember 2022-12-31 0001561032 hct:LeeMemorialHealthSystemOutpatientCenterFortMeyersMember 2022-12-31 0001561032 hct:DecaturMedicalOfficeBuildingMember 2022-12-31 0001561032 hct:MadisonMedicalPlazaJolietMember 2022-12-31 0001561032 hct:WoodlakeOfficeCenterMember 2022-12-31 0001561032 hct:RockwallMedicalPlazaMember 2022-12-31 0001561032 hct:MetroHealthBuckeyeHealthCenterClevelandMember 2022-12-31 0001561032 hct:UnityPointClinicMolineMember 2022-12-31 0001561032 hct:VAOutpatientClinicGalesburgMember 2022-12-31 0001561032 hct:PhilipProfessionalCenterLawrencevilleGAMember 2022-12-31 0001561032 hct:TexasChildrensHospitalHoustonMember 2022-12-31 0001561032 hct:FloridaMedicalHeartcareMember 2022-12-31 0001561032 hct:FloridaMedicalSomersetMember 2022-12-31 0001561032 hct:FloridaMedicalTampaPalmsMember 2022-12-31 0001561032 hct:FloridaMedicalWesleyChapelMember 2022-12-31 0001561032 hct:AuroraHealthCenterMilwaukeeAprilMember 2022-12-31 0001561032 hct:VascularSurgeryAssociatesMember 2022-12-31 0001561032 hct:GlendaleMOBFarmingtonHillsMIMember 2022-12-31 0001561032 hct:CrittentonWashingtonMOBMember 2022-12-31 0001561032 hct:CrittentonSterlingHeightsMOBMember 2022-12-31 0001561032 hct:AdvocateAuroraMOBElkhornWIMember 2022-12-31 0001561032 hct:PulmonaryCriticalCareMedicineAccocLemoyneMember 2022-12-31 0001561032 hct:DignityEmerusBlueDiamondRoadLasVegasMember 2022-12-31 0001561032 hct:DignityEmerusCraigRoadNorthLasVegasMember 2022-12-31 0001561032 hct:GreenfieldMOBGreenfieldMember 2022-12-31 0001561032 hct:MilwaukeeMOBSouthMilwaukeeMember 2022-12-31 0001561032 hct:StFrancisWIMOBStFrancisMember 2022-12-31 0001561032 hct:LancasterMedicalArtsMOBLancasterMember 2022-12-31 0001561032 hct:WomensHealthcareGroupMOBYorkMember 2022-12-31 0001561032 hct:PioneerSpineSportsNorthamptonMember 2022-12-31 0001561032 hct:PioneerSpineSportsSpringfieldMember 2022-12-31 0001561032 hct:PioneerSpineSportsWestSpringfieldMember 2022-12-31 0001561032 hct:FelicitaVidaEscondidoMember 2022-12-31 0001561032 hct:CedarhurstOfEdwardsvilleEdwardsvilleMember 2022-12-31 0001561032 hct:UMPCSirThomasCourtHarrisburgMember 2022-12-31 0001561032 hct:UMPCFisherRoadMechanicsburgMember 2022-12-31 0001561032 hct:SwedishAmericanMOBRoscoeMember 2022-12-31 0001561032 hct:CedarhurstOfSpartaSpartaMember 2022-12-31 0001561032 hct:UMPCChambersHillHarrisburgMember 2022-12-31 0001561032 hct:CedarhurstOfShilohShilohMember 2022-12-31 0001561032 hct:BayshoreNaplesMemoryCareNaplesMember 2022-12-31 0001561032 hct:CirclevilleMOBCirclevilleMember 2022-12-31 0001561032 hct:KingwoodExecutiveCenterKingwoodTXMember 2022-12-31 0001561032 hct:OrthoOneHilliardHilliardOHMember 2022-12-31 0001561032 hct:SouthDouglasMOBMidwestCityOKMember 2022-12-31 0001561032 hct:FortWayneOpthomologyEngleFortWayneINMember 2022-12-31 0001561032 hct:FortWayneOpthomologyDupontFortWayneINMember 2022-12-31 0001561032 hct:StPetersAlbany2PalisadesAlbanyNYMember 2022-12-31 0001561032 hct:HefnerPointeMedicalCenterOklahomaCityOKMember 2022-12-31 0001561032 hct:StPetersTroy2NewHampshireTroyNYMember 2022-12-31 0001561032 hct:StPetersAlbanyNY4PalisadesMember 2022-12-31 0001561032 hct:StPetersAlbanyNY5PalisadesMember 2022-12-31 0001561032 hct:StLukesHeartVascularCenterEastStroudsburgMember 2022-12-31 0001561032 hct:MetropolitanEyeLakeshoreSurgeryStClairMIMember 2022-12-31 0001561032 hct:NaiduClinicOdessaTXMember 2022-12-31 0001561032 hct:BelpreVCancerCenterBelpreOHMember 2022-12-31 0001561032 hct:CenterForAdvancedDermatologyLakewoodCOMember 2022-12-31 0001561032 hct:FloridaMedicalClinicTampaFLMember 2022-12-31 0001561032 hct:PensacolaNephrologyMOBPensacolaFLMember 2022-12-31 0001561032 hct:MillenniumEyeCareFreeholdNJMember 2022-12-31 0001561032 hct:AtlantaGastroenterologyAssociatesLawrencevilleGAMember 2022-12-31 0001561032 hct:BoneAndJointSpecialistsMerrillvilleINMember 2022-12-31 0001561032 hct:EasternCarolinaENTGreenvilleNCMember 2022-12-31 0001561032 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001561032 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember hct:ReclassificationFromHeldForSaleToRealEstateInvestmentsMember 2020-01-01 2020-12-31 iso4217:USD shares pure iso4217:USD shares hct:property hct:state utr:sqft hct:segment hct:contractor hct:land_parcel hct:lease hct:encumberedProperty hct:instrument hct:derivative hct:director hct:dividend 0001561032 2022 FY false http://fasb.org/us-gaap/2022#Revenues http://fasb.org/us-gaap/2022#Revenues P6M 0.0833 P3Y http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent 10-K true 2022-12-31 --12-31 false 001-39153 Healthcare Trust, Inc. MD 38-3888962 650 Fifth Ave. 30th Floor New York NY 10019 212 415-6500 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share HTIA NASDAQ 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share HTIB NASDAQ No No Yes Yes Non-accelerated Filer false false false false 0 106566638 Portions of the registrant’s definitive proxy statement to be delivered to stockholders in connection with the registrant’s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K. The registrant intends to file its proxy statement within 120 days after its fiscal year end. 238 PricewaterhouseCoopers LLP New York, New York 206454000 206392000 2089133000 2117896000 292034000 288372000 2587621000 2612660000 609324000 562733000 1978297000 2049927000 53654000 59738000 22884000 25644000 40647000 174000 25276000 23858000 7814000 7914000 929000 34554000 32564000 17223000 14581000 2180349000 2214400000 578700000 584239000 530297000 502051000 9407000 10943000 0 13903000 47000 47000 45247000 42709000 8087000 8130000 5925000 8619000 3496000 3406000 1181159000 1174000000 0.07375 0.01 0.01 4740000 4740000 3977144 3977144 3977144 3977144 40000 40000 0.07125 0.01 0.01 3680000 3680000 3630000 3630000 3630000 3630000 36000 36000 0.01 0.01 300000000 300000000 105080531 105080531 99281754 99281754 1051000 993000 2417059000 2329839000 36910000 -14341000 -1462457000 -1282871000 992639000 1033696000 6551000 6704000 999190000 1040400000 2180349000 2214400000 335846000 329355000 381612000 213444000 205813000 243548000 27630000 40951000 36446000 25353000 24206000 23922000 1484000 2714000 173000 17287000 16828000 21572000 82064000 79926000 81053000 367262000 370438000 406714000 -31416000 -41083000 -25102000 -125000 3648000 5230000 -31541000 -37435000 -19872000 51740000 47900000 51519000 27000 61000 44000 3834000 37000 -102000 -47879000 -47802000 -51577000 -79420000 -85237000 -71449000 201000 203000 4061000 -79621000 -85440000 -75510000 -135000 -260000 303000 13799000 7762000 2968000 -93285000 -92942000 -78781000 51251000 25332000 -32630000 -42034000 -67610000 -111411000 106428154 106428154 106354994 106354994 106119937 106119937 -0.88 -0.88 -0.87 -0.87 -0.74 -0.74 1610000 16000 0 0 92356664 923000 2078628000 -7043000 -971190000 1101334000 5410000 1106744000 -59000 -59000 -59000 875986 9000 14595000 14604000 14604000 705101 7000 10539000 10546000 10546000 1345000 1345000 1345000 0.21 1248197 13000 19646000 -19659000 0 0 0.42 38839000 38839000 38839000 1.84 2968000 2968000 2968000 201000 201000 88000 88000 495000 583000 -75813000 -75813000 303000 -75510000 -32615000 -32615000 -32615000 645000 -15000 630000 -630000 0 1610000 16000 0 0 93775746 938000 2104261000 -39673000 -1108557000 956985000 4387000 961372000 2367144 24000 56241000 56265000 56265000 3630000 36000 86783000 86819000 86819000 1329000 1329000 1329000 0.85 5506008 55000 81316000 -81371000 0 0 1.57 6236000 6236000 6236000 0.42 1527000 1527000 1527000 92000 92000 2578000 2578000 -85180000 -85180000 -260000 -85440000 25332000 25332000 25332000 -91000 -91000 91000 0 3977144 40000 3630000 36000 99281754 993000 2329839000 -14341000 -1282871000 1033696000 6704000 1040400000 0 0 -42000 -42000 -42000 1185000 1185000 1185000 0.85 5798777 58000 86243000 -86301000 0 0 1.84 7333000 7333000 7333000 1.78 6466000 6466000 6466000 184000 184000 -79486000 -79486000 -135000 -79621000 51251000 51251000 51251000 -166000 -166000 166000 0 3977144 40000 3630000 36000 105080531 1051000 2417059000 36910000 -1462457000 992639000 6551000 999190000 -79621000 -85440000 -75510000 82064000 79926000 81053000 4879000 4427000 4059000 423000 846000 846000 51000 55000 60000 -625000 -198000 -80000 3159000 1094000 2708000 1185000 1329000 1345000 3834000 37000 -102000 286000 0 0 -125000 3648000 5230000 27630000 40951000 36446000 -2750000 483000 -4641000 1523000 761000 2409000 3036000 2139000 63000 -2924000 1252000 -4554000 -2694000 1705000 -1607000 28295000 38879000 41807000 25538000 159300000 94984000 27993000 19071000 21892000 11749000 130449000 34385000 -41782000 -47922000 -82491000 2998000 298804000 26091000 30000000 125000000 95000000 0 42750000 0 6662000 1264000 1048000 0 85000 97000 1672000 1490000 2241000 0 56265000 -1016000 -42000 86897000 0 0 0 10539000 0 0 31354000 7333000 5144000 2399000 6466000 0 0 0 0 583000 184000 46000 201000 4643000 4079000 19431000 -8844000 -4964000 -21253000 85382000 90346000 111599000 76538000 85382000 90346000 53654000 59738000 72357000 22884000 25644000 17989000 76538000 85382000 90346000 45042000 42815000 47878000 566000 311000 315000 0 0 14604000 86301000 81371000 19659000 0 0 1287000 0 78000 0 0 0 13883000 Organization <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare Trust, Inc. (including, as required by context, Healthcare Trust Operating Partnership, L.P. (the “OP”) and its subsidiaries, the “Company”), is an externally managed real estate investment trust for U.S. federal income tax purposes (“REIT”) that focuses on acquiring and managing a diversified portfolio of healthcare-related real estate, focused on medical office and other healthcare-related buildings (“MOBs”), and senior housing operating properties (“SHOPs”). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company owned 202 properties located in 34 states and comprised of 9.1 million rentable square feet.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company’s business is conducted through the OP and its wholly owned subsidiaries, including taxable REIT subsidiaries. The Company’s advisor, Healthcare Trust Advisors, LLC (the “Advisor”) manages our day-to-day business with the assistance of our property manager, Healthcare Trust Properties, LLC (the “Property Manager”). The Company’s Advisor and Property Manager are under common control with AR Global Investments, LLC (“AR Global”), and these related parties receive compensation and fees for providing services to the Company. The Company also reimburses these entities for certain expenses they incur in providing these services to the Company. Healthcare Trust Special Limited Partnership, LLC (the “Special Limited Partner”), which is also under common control with AR Global, also has an interest in the Company through ownership of interests in the OP. As of December 31, 2022, the Company owned 52 seniors housing properties under the REIT Investment Diversification and Empowerment Act of 2007 (“RIDEA”) structure in its SHOP segment. Under RIDEA, a REIT may lease qualified healthcare properties on an arm’s length basis to a taxable REIT subsidiary (“TRS”) if the property is operated on behalf of such subsidiary by a person who qualifies as an eligible independent contractor.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in two reportable business segments for management and internal financial reporting purposes: MOBs and SHOPs. In its MOB operating segment, the Company owns, manages, and leases single and multi-tenant MOBs where tenants are required to pay their pro rata share of property operating expenses, which may be subject to expense exclusions and floors, in addition to base rent. The Property Manager or third party managers manage the Company’s MOBs. In its SHOP segment, the Company invests in seniors housing properties using the RIDEA structure. As of December 31, 2022, the Company had four eligible independent contractors operating 52 SHOPs (including two land parcels). All of the Company’s properties across both business segments are located throughout the United States.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has declared quarterly dividends entirely in shares of its common stock since October 2020 in order to preserve its liquidity in response to the COVID-19 pandemic. Dividends payable entirely in shares of common stock are treated in a fashion similar to a stock split for accounting purposes specifically related to per-share calculations for the current and prior periods. Since October 2020, the Company has issued an aggregate of approximately 12.6 million shares in respect to the Stock Dividends. No other additional shares of common stock were issued during the years ended December 31, 2022 or 2021. References made to weighted-average shares and per-share amounts in the accompanying consolidated statements of operations and comprehensive income have been retroactively adjusted to reflect the cumulative increase in shares outstanding resulting from the Stock Dividends since October 2020 and through January 2023, and are noted as such throughout the accompanying financial statements and notes. Any future issuances of stock dividends will also result in retroactive adjustments. Please see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_193" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">No</a><a href="#i287ff37c25f74b1a844547bcd3a52b7a_193" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">te 8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Stockholder’s Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on the stock dividends.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2021. The Company’s previous Estimated Per-Share NAV was as of December 31, 2020. The Estimated Per-Share NAV published on April 1, 2022 has not been adjusted since publication and will not be adjusted until the board of directors (the “Board”) determines a new Estimated Per-Share NAV. Issuing dividends in additional shares of common stock will, all things equal, cause the value of each share to decline because the number of shares outstanding increases when shares of common stock are issued in respect of a Stock Dividend; however, because each stockholder will receive the same number of new shares, the total value of a common stockholder’s investment, all things equal, will not change assuming no sales or other transfers. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually unless the Company lists its common stock.</span></div> 202 34 9100000 52 2 4 52 2 12600000 0 0 Summary of Significant Accounting Policies<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Accounting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of the Company are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“GAAP”). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation and Basis of Presentation </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Period Adjustment</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company did not record quarterly interest expense related to borrowings under the Revolving Credit Facility (as defined below) that were borrowed and repaid during the fourth quarter of 2019. The amount of interest expense and related payable that should have been recorded was $0.3 million. In 2020, the Company identified that the cumulative interest payable balance was understated, and as a result a true up entry was recorded to record the payable and related expense, resulting in an out of period adjustment. The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and adjusted the amounts on a cumulative basis in 2020.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impacts of the COVID-19 Pandemic</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2020, the global COVID-19 pandemic that has spread around the world and to every state in the United States commenced. The COVID-19 pandemic has had, and could continue to have, an adverse impact on economic conditions, including a global economic slowdown and recession that may continue for some time. The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of COVID-19 on economic and market conditions. The COVID-19 pandemic had, and another pandemic in the future could have, impacts across many sectors and areas of the global economy and financial markets, leading to significant adverse impacts on economic activity including volatility in financial markets. The Company’s MOB tenants and SHOP properties operate businesses that require in-person interactions with their patients and residents, and concern regarding the transmission of COVID-19 impacted the willingness of persons to, among other things, live in or use facilities at the Company’s properties, and impact the revenues generated by the Company’s tenants.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to lease space and negotiate and maintain favorable rents and the results of operations at its SHOPs could also continue to be negatively impacted by a prolonged recession in the U.S. economy. Moreover, the demand for leasing space at the Company’s MOB properties could decline, which could negatively impacting occupancy percentage, revenue and net income. Additionally, downturns or stagnation the U.S. housing market as a result of an economic downturn could adversely affect the ability, or perceived ability, of seniors to afford the resident fees and services at the Company’s SHOPs. Further, recent and continuing increases in inflation brought about by the labor shortages, supply chain disruptions and increases in interest rates have adversely impacted, and may continue to impact, the Company’s results of operations. Moreover, these increases in the rate of inflation, the ongoing war in Ukraine and related sanctions, supply chain disruptions and increases in interest rates may also impact the ability of the Company’s tenants and residents to pay rent and hence the Company’s results of operations and liquidity.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways that vary by operating segment:</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Impact — MOB Segment</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial stability and overall health of the Company’s MOB tenants is critical to its business. The Company took a proactive approach to achieve mutually agreeable solutions with its MOB tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent. Since the year ended December 31, 2020, the Company has not entered into any rent deferral agreements with any of its MOB tenants, and all amounts previously deferred under prior rent deferral agreements have been collected.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases are being modified, the FASB and SEC have provided relief that allows companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. For COVID-19 relief qualified changes, there are two methods to potentially account for such rent deferrals or abatements under the relief, (1) as if the changes were originally contemplated in the lease contract or (2) as if the deferred payments are variable lease payments contained in the lease contract.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all other lease changes that did not qualify for FASB relief, the Company is required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualify for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company has elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there would be no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact would be recognized ratably over the remaining life of the lease. For leases not qualifying for this relief, the Company has applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Impact — SHOP Segment</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company’s SHOP segment, occupancy trended downward from March 2020 until June 2021 and has since stabilized, however, SHOP occupancy remains substantially below pre-pandemic levels. Further, the Company has continued to experience lower inquiry volumes and reduced in-person tours since the onset of the pandemic. In addition, starting in mid-March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOPs, the Company generally bears these cost increases, which were partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), and to a lesser extent, cost recoveries for personal protective equipment from residents. See below for additional information on the CARES Act. These cost increases became more prominent throughout the year ended December 31, 2022 from a combination of factors: firstly, the Company was impacted by rising inflation which generally increased the costs of services and supplies, secondly, the Company relied more on the use of temporary contract labor and agencies due to a shortage of qualified personnel and lastly, the amounts the Company paid to third party providers for wages, including overtime wages, and bonuses increased. Future developments in the course of the pandemic, increases to inflation, labor shortages and supply chain disruptions may cause further adverse impacts to the Company’s occupancy and cost levels, and these trends may continue to impact the Company and have material adverse effects on its revenues, operating costs and net income in future periods.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial impact of the COVID-19 pandemic on the Company has been partially offset by funds received under the CARES Act. The Company received $4.5 million, $5.1 million and $3.6 million in these funds during the years ended December 31, 2022, 2021 and 2020, respectively. The Company considers these funds to be grant contributions from the government. The full amounts received were recognized as reductions of property operating expenses in the Company’s consolidated statement of operations for the years ended December 31, 2022, 2021 and 2020, respectively, to partially offset incurred COVID-19 expenses. The Company does not anticipate that any further funds under the CARES Act will be received, and there can be no assurance that the CARES Act program will be extended or any further amounts received under currently effective or potential future government programs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in its MOB segment. As of December 31, 2022, these leases had a weighted average remaining lease term of 4.9 years. Rent from tenants in the Company’s MOB operating segment (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Tenant revenue also includes operating expense reimbursements which generally increase with the increase in property operating and maintenance expenses in our MOB segment. In addition to base rent, dependent on the specific lease, tenants are generally required to pay either (i) their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors or (ii) the their share of increases in property operating and maintenance expenses to the extent they exceed the properties’ expenses for the base year of the respective leases. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “<span style="-sec-ix-hidden:f-568"><span style="-sec-ix-hidden:f-569">Revenue from tenants</span></span>.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOP segment, held using a structure permitted under RIDEA, and to a lesser extent, fees for ancillary services performed for SHOP residents, which are generally variable in nature. Rental income from residents in the Company’s SHOP segment is recognized as earned when services are provided. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the leases are short term in nature, primarily month-to-month. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record material amounts of ancillary revenue from non-residents during the year ended December 31, 2022. </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded ancillary revenue from non-residents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $3.5 million and $13.3 million for the years ended December 31, 2021 and 2020, respectively. Fees for ancillary services are recorded in the period in which the services are performed. The decline in ancillary revenue since the year ended December 31, 2020 is primarily due to the Company’s dispositions of its SNF properties in Lutz and Wellington, Florida, which were sold in November 2020 and May 2021, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating and maintenance expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating and maintenance costs of the respective properties.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future base rent payments on a cash basis due to the Company as of December 31, 2022 over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short-term in nature.</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:78.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future <br/>Base Rent Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,880 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually reviews receivables related to rent and unbilled rents receivable and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards, the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants in accordance </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with accounting rules, on the accompanying consolidated statements of operations and comprehensive income (loss) in the period the related costs are incurred, as applicable.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022, 2021 and 2020, the Company recorded reductions in revenue of $3.2 million, $1.1 million and $2.7 million, respectively. Approximately $1.3 million and $1.0 million of bad debt expense recorded in the years ended December 31, 2022 and 2020, respectively, related to previously disposed properties. There were no significant write-off’s related to previously disposed properties during the year ended December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Real Estate</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation” </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section in this Note for a discussion of the initial accounting for investments in real estate.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the years ended December 31, 2022, 2021 and 2020. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were no real estate investments held for sale as of December 31, 2022 or December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally determines the value of construction in progress based upon the replacement cost. During the construction period, the Company capitalizes interest, insurance and real estate taxes until the development has reached substantial completion.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Allocation</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In allocating the fair value to any assumed or issued non-controlling interests, amounts are recorded at their fair value at the close of business on the acquisition date. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates the fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifiable intangible assets include amounts allocated to acquire leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from <span style="-sec-ix-hidden:f-591">six</span> to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate value of intangible assets related to customer relationship, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the years ended December 31, 2022, 2021 and 2020.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Leases</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessor Accounting</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the lease accounting standard, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than a major part of the remaining economic useful life of the asset (e.g., equal to or greater than 75%), the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or the asset is so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. As of December 31, 2022 and 2021, the Company had no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessor of real estate, the Company has elected, by class of underlying assets, to account for lease and non-lease components (such as tenant reimbursements of property operating and maintenance expenses) as a single lease component as an operating lease because (a) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (b) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under the accounting guidance. Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessee Accounting</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also the lessee under certain land leases which will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the consolidated balance sheets as of December 31, 2022 and 2021, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022, 2021 and 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lessees, the accounting standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction. For additional information and disclosures related to the Company’s operating leases, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_217" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Dispositions of Real Estate Investments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains on sales of rental real estate are not considered sales to customers and will generally be recognized pursuant to the provisions included in ASC 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets (“ASC 610-20”).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statement of operations and comprehensive (loss) to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held and used. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it has two reportable segments, with activities related to investing in MOBs and SHOPs. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level. For additional information see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_214" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 15</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress, including capitalized interest, insurance and real estate taxes, is not depreciated until the development has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Above and Below-Market Lease Amortization</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized above-market lease values are amortized as a reduction of revenue from tenants over the remaining terms of the respective leases and the capitalized below-market lease values are amortized as an increase to revenue from tenants over the remaining initial terms plus the terms of any below-market fixed rate renewal options of the respective leases. If a tenant with a below-market rent renewal does not renew, any remaining unamortized amount will be taken into income at that time.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized above-market ground lease values are amortized as a reduction of property operating expense over the remaining terms of the respective leases. Capitalized below-market ground lease values are amortized as an increase to property operating expense over the remaining terms of the respective leases and expected below-market renewal option periods.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use derivative financial instruments to hedge all or a portion of the interest rate risk associated with its borrowings. Certain of the techniques used to hedge exposure to interest rate fluctuations may also be used to protect against declines in the market value of assets that result from general trends in debt markets. The principal objective of such agreements is to minimize the risks and costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records all derivatives on the balance sheet at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair value of an </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply, or the Company elects not to apply hedge accounting.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for subsequent changes in the fair value of these derivatives depends on whether each has been designated and qualifies for hedge accounting treatment. If the Company elects not to apply hedge accounting treatment, any change in the fair value of these derivative instruments is recognized immediately in gains (losses) on derivative instruments in the accompanying consolidated statements of operations and comprehensive loss prior to the adoption of ASU 2017-2 on January 1, 2019. If the derivative is designated and qualifies for hedge accounting treatment, the change in the estimated fair value of the derivative is recorded in other comprehensive income (loss) to the extent that it is effective, with any ineffective portion of a derivative’s change in fair value immediately recognized in earnings. After the adoption of ASU 2017-2, if the derivative qualifies for hedge accounting, all of the change in value is recorded in other comprehensive income (loss). </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling Interests</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-controlling interests represent the portion of the common and preferred equity in the OP that is not owned by the Company as well as certain investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Non-controlling interests are presented as a separate component of equity on the consolidated balance sheets and presented as net loss attributable to non-controlling interests on the consolidated statements of operations and comprehensive loss. Non-controlling interests are allocated a share of net income or loss based on their share of equity ownership, including any preferential amounts. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Non-Controlling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents includes cash in bank accounts as well as investments in highly-liquid money market funds with original maturities of three months or less. The Company did not have any cash invested in money market funds at December 31, 2022 or 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company deposits cash with high quality financial institutions. These deposits are guaranteed by the Federal Deposit Insurance Company (“FDIC”) up to an insurance limit. At December 31, 2022 and 2021, the Company had deposits of $53.7 million and $59.7 million, of which $43.6 million and $46.2 million, respectively, were in excess of the amount insured by the FDIC. Although the Company bears risk to amounts in excess of those insured by the FDIC, it does not anticipate any losses as a result.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Costs</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs, net, consists of deferred financing costs related to the Credit Facility (as defined in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facilities)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fannie Mae Master Credit Facilities (as defined in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facilities)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and deferred leasing costs. Deferred financing costs relating to mortgage notes payable (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_181" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Mortgage Notes Payable, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) are reflected net of the related financing in the mortgage notes payable, net line item of the Company’s consolidated balance sheet.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs associated with the Credit Facility and Fannie Mae Master Credit Facilities and mortgage notes payable represent commitment fees, legal fees, and other costs associated with obtaining commitments for financing. These costs are amortized over the term of the financing agreement using the effective interest method for the Credit Facility and Fannie Mae Master Credit Facilities and using the effective interest method over the expected term for the mortgage notes payable. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized deferred financing costs are expensed if the associated debt is refinanced or paid down before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred leasing costs, consisting primarily of lease commissions and professional fees incurred in connection with new leases, are deferred and amortized over the term of the lease.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive award program for its directors, which is accounted for under the guidance of share- based payments. The cost of services received in exchange for these stock awards is measured at the grant date fair value of the award and the expense for such awards is included in general and administrative expenses and is recognized over the service period (i.e., vesting) required or when the requirements for exercise of the award have been met (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986 (the “Code”), as amended, commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and local income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2022, 2021 and 2020. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties. Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS. Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company owned 52 seniors housing properties (including two land parcels) which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of December 31, 2022 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the ongoing COVID-19 pandemic. These abatements were extended through December 31, 2022 and may continue to be extended for future periods.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the Company’s TRS's recent operating history of taxable losses and the impacts of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $6.9 million and $4.2 million as of December 31, 2022 and 2021, respectively. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive income (loss). As of December 31, 2022, the Company’s consolidated TRS had net operating loss carryforwards for federal income tax purposes of approximately $24.4 million at December 31, 2022 (of which $7.6 million were incurred prior to January 1, 2018). Carryforwards from losses incurred prior to January 1, 2018, if unused, these will begin to expire in 2035. For net operating losses incurred subsequent to December 31, 2017, there is no expiration date. As of December 31, 2022, the Company had a deferred tax asset of $6.9 million with a full valuation allowance. As of December 31, 2021, the Company had a deferred tax asset of $4.2 million with a full valuation allowance.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2022, 2021 and 2020, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately 0.0%, 0.0% and (105.8)% for the years ended December 31, 2022, 2021 and 2020, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal (expense) benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(319)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State (expense) benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,749)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,591)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had no material uncertain income tax positions. The tax years subsequent to and including the fiscal year ended December 31, 2017 remain open to examination by the major taxing jurisdictions to which the Company is subject.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Per Share Data</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per basic share of common stock is calculated by dividing net income (loss) by the weighted-average number of shares (retroactively adjusted for the Stock Dividends) of common stock issued and outstanding during such period. Diluted net income (loss) per share of common stock considers the effect of potentially dilutive shares of common stock outstanding during the period.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CARES Act Grants</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Ac) was signed into law and it provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. During the years ended December 31, 2022, 2021 and 2020 the Company received $4.5 million, $5.1 million and $3.6 million in funding from CARES Act grants, respectively. For accounting purposes, the CARES Act funds are treated as a grant contribution from the government. The funding the Company received was recognized as a reduction of property operating and maintenance expenses in the Company’s consolidated statements of operations to offset the negative impacts of COVID-19. There can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The objective of ASU 2018-13 is to improve the effectiveness of disclosures in the notes to the financial statements by removing, modifying, and adding certain fair value disclosure requirements to facilitate clear communication of the information required by generally accepted accounting principles. The amended guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which changes how entities measure credit losses for financial assets carried at amortized cost. The update eliminates the requirement that a credit loss must be probable before it can be recognized and instead requires an entity to recognize the current estimate of all expected credit losses. Additionally, the amended standard requires credit losses on available-for-sale debt securities to be carried as an allowance rather than as a direct write-down of the asset. On July 25, 2018, the FASB proposed an amendment to ASU 2016-13 to clarify that operating lease receivables recorded by lessors (including unbilled straight-line rent) are explicitly excluded from the scope of ASU 2016-13. The new guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2021 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2022:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption was permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2022 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not yet Fully Adopted as of December 31, 2022</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period from March 12, 2020 through June 30, 2023 as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that the Company’s hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of the Company’s derivatives, which will be consistent with the Company’s past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur.</span></div> Basis of Accounting     The accompanying consolidated financial statements of the Company are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“GAAP”).<div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Period Adjustment</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company did not record quarterly interest expense related to borrowings under the Revolving Credit Facility (as defined below) that were borrowed and repaid during the fourth quarter of 2019. The amount of interest expense and related payable that should have been recorded was $0.3 million. In 2020, the Company identified that the cumulative interest payable balance was understated, and as a result a true up entry was recorded to record the payable and related expense, resulting in an out of period adjustment. The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and adjusted the amounts on a cumulative basis in 2020.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impacts of the COVID-19 Pandemic</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2020, the global COVID-19 pandemic that has spread around the world and to every state in the United States commenced. The COVID-19 pandemic has had, and could continue to have, an adverse impact on economic conditions, including a global economic slowdown and recession that may continue for some time. The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of COVID-19 on economic and market conditions. The COVID-19 pandemic had, and another pandemic in the future could have, impacts across many sectors and areas of the global economy and financial markets, leading to significant adverse impacts on economic activity including volatility in financial markets. The Company’s MOB tenants and SHOP properties operate businesses that require in-person interactions with their patients and residents, and concern regarding the transmission of COVID-19 impacted the willingness of persons to, among other things, live in or use facilities at the Company’s properties, and impact the revenues generated by the Company’s tenants.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to lease space and negotiate and maintain favorable rents and the results of operations at its SHOPs could also continue to be negatively impacted by a prolonged recession in the U.S. economy. Moreover, the demand for leasing space at the Company’s MOB properties could decline, which could negatively impacting occupancy percentage, revenue and net income. Additionally, downturns or stagnation the U.S. housing market as a result of an economic downturn could adversely affect the ability, or perceived ability, of seniors to afford the resident fees and services at the Company’s SHOPs. Further, recent and continuing increases in inflation brought about by the labor shortages, supply chain disruptions and increases in interest rates have adversely impacted, and may continue to impact, the Company’s results of operations. Moreover, these increases in the rate of inflation, the ongoing war in Ukraine and related sanctions, supply chain disruptions and increases in interest rates may also impact the ability of the Company’s tenants and residents to pay rent and hence the Company’s results of operations and liquidity.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways that vary by operating segment:</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Impact — MOB Segment</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial stability and overall health of the Company’s MOB tenants is critical to its business. The Company took a proactive approach to achieve mutually agreeable solutions with its MOB tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent. Since the year ended December 31, 2020, the Company has not entered into any rent deferral agreements with any of its MOB tenants, and all amounts previously deferred under prior rent deferral agreements have been collected.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Impact — SHOP Segment</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company’s SHOP segment, occupancy trended downward from March 2020 until June 2021 and has since stabilized, however, SHOP occupancy remains substantially below pre-pandemic levels. Further, the Company has continued to experience lower inquiry volumes and reduced in-person tours since the onset of the pandemic. In addition, starting in mid-March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOPs, the Company generally bears these cost increases, which were partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), and to a lesser extent, cost recoveries for personal protective equipment from residents. See below for additional information on the CARES Act. These cost increases became more prominent throughout the year ended December 31, 2022 from a combination of factors: firstly, the Company was impacted by rising inflation which generally increased the costs of services and supplies, secondly, the Company relied more on the use of temporary contract labor and agencies due to a shortage of qualified personnel and lastly, the amounts the Company paid to third party providers for wages, including overtime wages, and bonuses increased. Future developments in the course of the pandemic, increases to inflation, labor shortages and supply chain disruptions may cause further adverse impacts to the Company’s occupancy and cost levels, and these trends may continue to impact the Company and have material adverse effects on its revenues, operating costs and net income in future periods.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial impact of the COVID-19 pandemic on the Company has been partially offset by funds received under the CARES Act. The Company received $4.5 million, $5.1 million and $3.6 million in these funds during the years ended December 31, 2022, 2021 and 2020, respectively. The Company considers these funds to be grant contributions from the government. The full amounts received were recognized as reductions of property operating expenses in the Company’s consolidated statement of operations for the years ended December 31, 2022, 2021 and 2020, respectively, to partially offset incurred COVID-19 expenses. The Company does not anticipate that any further funds under the CARES Act will be received, and there can be no assurance that the CARES Act program will be extended or any further amounts received under currently effective or potential future government programs.</span></div> Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP. <div style="margin-bottom:5pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.</span></div> 0 300000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases are being modified, the FASB and SEC have provided relief that allows companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. For COVID-19 relief qualified changes, there are two methods to potentially account for such rent deferrals or abatements under the relief, (1) as if the changes were originally contemplated in the lease contract or (2) as if the deferred payments are variable lease payments contained in the lease contract.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all other lease changes that did not qualify for FASB relief, the Company is required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualify for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company has elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there would be no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact would be recognized ratably over the remaining life of the lease. For leases not qualifying for this relief, the Company has applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessee Accounting</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also the lessee under certain land leases which will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the consolidated balance sheets as of December 31, 2022 and 2021, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022, 2021 and 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lessees, the accounting standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction. For additional information and disclosures related to the Company’s operating leases, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_217" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> 4500000 5100000 3600000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in its MOB segment. As of December 31, 2022, these leases had a weighted average remaining lease term of 4.9 years. Rent from tenants in the Company’s MOB operating segment (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Tenant revenue also includes operating expense reimbursements which generally increase with the increase in property operating and maintenance expenses in our MOB segment. In addition to base rent, dependent on the specific lease, tenants are generally required to pay either (i) their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors or (ii) the their share of increases in property operating and maintenance expenses to the extent they exceed the properties’ expenses for the base year of the respective leases. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “<span style="-sec-ix-hidden:f-568"><span style="-sec-ix-hidden:f-569">Revenue from tenants</span></span>.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOP segment, held using a structure permitted under RIDEA, and to a lesser extent, fees for ancillary services performed for SHOP residents, which are generally variable in nature. Rental income from residents in the Company’s SHOP segment is recognized as earned when services are provided. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the leases are short term in nature, primarily month-to-month. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record material amounts of ancillary revenue from non-residents during the year ended December 31, 2022. </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded ancillary revenue from non-residents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $3.5 million and $13.3 million for the years ended December 31, 2021 and 2020, respectively. Fees for ancillary services are recorded in the period in which the services are performed. The decline in ancillary revenue since the year ended December 31, 2020 is primarily due to the Company’s dispositions of its SNF properties in Lutz and Wellington, Florida, which were sold in November 2020 and May 2021, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating and maintenance expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating and maintenance costs of the respective properties.</span></div>The Company continually reviews receivables related to rent and unbilled rents receivable and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards, the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants in accordance with accounting rules, on the accompanying consolidated statements of operations and comprehensive income (loss) in the period the related costs are incurred, as applicable. P4Y10M24D 0 3500000 13300000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future base rent payments on a cash basis due to the Company as of December 31, 2022 over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short-term in nature.</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:78.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future <br/>Base Rent Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,880 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 106009000 99507000 88452000 80462000 62175000 215275000 651880000 3200000 1100000 2700000 1300000 1000000 0 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Real Estate</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation” </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section in this Note for a discussion of the initial accounting for investments in real estate.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the years ended December 31, 2022, 2021 and 2020. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were no real estate investments held for sale as of December 31, 2022 or December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally determines the value of construction in progress based upon the replacement cost. During the construction period, the Company capitalizes interest, insurance and real estate taxes until the development has reached substantial completion.</span></div> 0 0 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Allocation</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In allocating the fair value to any assumed or issued non-controlling interests, amounts are recorded at their fair value at the close of business on the acquisition date. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates the fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifiable intangible assets include amounts allocated to acquire leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from <span style="-sec-ix-hidden:f-591">six</span> to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate value of intangible assets related to customer relationship, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the years ended December 31, 2022, 2021 and 2020.</span></div> P24M <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Leases</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessor Accounting</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the lease accounting standard, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than a major part of the remaining economic useful life of the asset (e.g., equal to or greater than 75%), the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or the asset is so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. As of December 31, 2022 and 2021, the Company had no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessor of real estate, the Company has elected, by class of underlying assets, to account for lease and non-lease components (such as tenant reimbursements of property operating and maintenance expenses) as a single lease component as an operating lease because (a) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (b) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under the accounting guidance. Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed.</span></div> <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Dispositions of Real Estate Investments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains on sales of rental real estate are not considered sales to customers and will generally be recognized pursuant to the provisions included in ASC 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets (“ASC 610-20”).</span></div> <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statement of operations and comprehensive (loss) to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held and used. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.</span></div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it has two reportable segments, with activities related to investing in MOBs and SHOPs. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level. For additional information see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_214" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 15</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> 2 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress, including capitalized interest, insurance and real estate taxes, is not depreciated until the development has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Above and Below-Market Lease Amortization</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized above-market lease values are amortized as a reduction of revenue from tenants over the remaining terms of the respective leases and the capitalized below-market lease values are amortized as an increase to revenue from tenants over the remaining initial terms plus the terms of any below-market fixed rate renewal options of the respective leases. If a tenant with a below-market rent renewal does not renew, any remaining unamortized amount will be taken into income at that time.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized above-market ground lease values are amortized as a reduction of property operating expense over the remaining terms of the respective leases. Capitalized below-market ground lease values are amortized as an increase to property operating expense over the remaining terms of the respective leases and expected below-market renewal option periods.</span></div> P40Y P15Y P7Y P10Y <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use derivative financial instruments to hedge all or a portion of the interest rate risk associated with its borrowings. Certain of the techniques used to hedge exposure to interest rate fluctuations may also be used to protect against declines in the market value of assets that result from general trends in debt markets. The principal objective of such agreements is to minimize the risks and costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records all derivatives on the balance sheet at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair value of an </span></div>asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply, or the Company elects not to apply hedge accounting.The accounting for subsequent changes in the fair value of these derivatives depends on whether each has been designated and qualifies for hedge accounting treatment. If the Company elects not to apply hedge accounting treatment, any change in the fair value of these derivative instruments is recognized immediately in gains (losses) on derivative instruments in the accompanying consolidated statements of operations and comprehensive loss prior to the adoption of ASU 2017-2 on January 1, 2019. If the derivative is designated and qualifies for hedge accounting treatment, the change in the estimated fair value of the derivative is recorded in other comprehensive income (loss) to the extent that it is effective, with any ineffective portion of a derivative’s change in fair value immediately recognized in earnings. After the adoption of ASU 2017-2, if the derivative qualifies for hedge accounting, all of the change in value is recorded in other comprehensive income (loss). Non-controlling Interests<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-controlling interests represent the portion of the common and preferred equity in the OP that is not owned by the Company as well as certain investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Non-controlling interests are presented as a separate component of equity on the consolidated balance sheets and presented as net loss attributable to non-controlling interests on the consolidated statements of operations and comprehensive loss. Non-controlling interests are allocated a share of net income or loss based on their share of equity ownership, including any preferential amounts. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Non-Controlling Interests</span> for additional information. Cash and Cash EquivalentsCash and cash equivalents includes cash in bank accounts as well as investments in highly-liquid money market funds with original maturities of three months or less. 0 0 53700000 59700000 43600000 46200000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Costs</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs, net, consists of deferred financing costs related to the Credit Facility (as defined in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facilities)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fannie Mae Master Credit Facilities (as defined in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facilities)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and deferred leasing costs. Deferred financing costs relating to mortgage notes payable (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_181" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Mortgage Notes Payable, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) are reflected net of the related financing in the mortgage notes payable, net line item of the Company’s consolidated balance sheet.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs associated with the Credit Facility and Fannie Mae Master Credit Facilities and mortgage notes payable represent commitment fees, legal fees, and other costs associated with obtaining commitments for financing. These costs are amortized over the term of the financing agreement using the effective interest method for the Credit Facility and Fannie Mae Master Credit Facilities and using the effective interest method over the expected term for the mortgage notes payable. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized deferred financing costs are expensed if the associated debt is refinanced or paid down before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred leasing costs, consisting primarily of lease commissions and professional fees incurred in connection with new leases, are deferred and amortized over the term of the lease.</span></div> Equity-Based Compensation<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive award program for its directors, which is accounted for under the guidance of share- based payments. The cost of services received in exchange for these stock awards is measured at the grant date fair value of the award and the expense for such awards is included in general and administrative expenses and is recognized over the service period (i.e., vesting) required or when the requirements for exercise of the award have been met (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-Based Compensation</span>). <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986 (the “Code”), as amended, commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and local income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2022, 2021 and 2020. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties. Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS. Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company owned 52 seniors housing properties (including two land parcels) which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of December 31, 2022 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the ongoing COVID-19 pandemic. These abatements were extended through December 31, 2022 and may continue to be extended for future periods.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the Company’s TRS's recent operating history of taxable losses and the impacts of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $6.9 million and $4.2 million as of December 31, 2022 and 2021, respectively. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive income (loss). As of December 31, 2022, the Company’s consolidated TRS had net operating loss carryforwards for federal income tax purposes of approximately $24.4 million at December 31, 2022 (of which $7.6 million were incurred prior to January 1, 2018). Carryforwards from losses incurred prior to January 1, 2018, if unused, these will begin to expire in 2035. For net operating losses incurred subsequent to December 31, 2017, there is no expiration date. As of December 31, 2022, the Company had a deferred tax asset of $6.9 million with a full valuation allowance. As of December 31, 2021, the Company had a deferred tax asset of $4.2 million with a full valuation allowance.</span></div>The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2022, 2021 and 2020, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately 0.0%, 0.0% and (105.8)% for the years ended December 31, 2022, 2021 and 2020, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.The tax years subsequent to and including the fiscal year ended December 31, 2017 remain open to examination by the major taxing jurisdictions to which the Company is subject. 52 2 25 1 6900000 4200000 24400000 7600000 6900000 4200000 <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2022, 2021 and 2020, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately 0.0%, 0.0% and (105.8)% for the years ended December 31, 2022, 2021 and 2020, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal (expense) benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(319)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State (expense) benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,749)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,591)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.000 0.000 -1.058 0 -2145000 0 319000 -726000 0 201000 -604000 203000 163000 196000 -50000 2749000 -482000 4641000 201000 0 203000 0 -530000 4591000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Per Share Data</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per basic share of common stock is calculated by dividing net income (loss) by the weighted-average number of shares (retroactively adjusted for the Stock Dividends) of common stock issued and outstanding during such period. Diluted net income (loss) per share of common stock considers the effect of potentially dilutive shares of common stock outstanding during the period.</span></div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CARES Act Grants</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Ac) was signed into law and it provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. During the years ended December 31, 2022, 2021 and 2020 the Company received $4.5 million, $5.1 million and $3.6 million in funding from CARES Act grants, respectively. For accounting purposes, the CARES Act funds are treated as a grant contribution from the government. The funding the Company received was recognized as a reduction of property operating and maintenance expenses in the Company’s consolidated statements of operations to offset the negative impacts of COVID-19. There can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.</span></div> 4500000 5100000 3600000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The objective of ASU 2018-13 is to improve the effectiveness of disclosures in the notes to the financial statements by removing, modifying, and adding certain fair value disclosure requirements to facilitate clear communication of the information required by generally accepted accounting principles. The amended guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which changes how entities measure credit losses for financial assets carried at amortized cost. The update eliminates the requirement that a credit loss must be probable before it can be recognized and instead requires an entity to recognize the current estimate of all expected credit losses. Additionally, the amended standard requires credit losses on available-for-sale debt securities to be carried as an allowance rather than as a direct write-down of the asset. On July 25, 2018, the FASB proposed an amendment to ASU 2016-13 to clarify that operating lease receivables recorded by lessors (including unbilled straight-line rent) are explicitly excluded from the scope of ASU 2016-13. The new guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2021 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2022:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption was permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2022 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not yet Fully Adopted as of December 31, 2022</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period from March 12, 2020 through June 30, 2023 as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that the Company’s hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of the Company’s derivatives, which will be consistent with the Company’s past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur.</span></div> Real Estate Investments, Net <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property Acquisitions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in healthcare-related facilities, primarily MOBs and seniors housing properties which expand and diversify its portfolio and revenue base. The Company owned 202 properties as of December 31, 2022. During the year ended December 31, 2022, the Company, through wholly-owned subsidiaries of the OP, completed its acquisitions of one multi-tenant MOBs and three single tenant MOBs for an aggregate contract purchase price of $25.3 million. All acquisitions in 2022, 2021 and 2020 were considered asset acquisitions for accounting purposes.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the allocation of the assets acquired and liabilities assumed during the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, at cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings, fixtures and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,539 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,224 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,364 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place leases and other intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease and other intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,639)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets and liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,654 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage notes payable assumed, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,883)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Preferred OP Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for real estate investments, including acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,538 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,300 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,984 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of properties purchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">_______________</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:11.94pt">Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 8.9 years, 9.3 years and 12.1 years, respectively, as of December 31, 2022. Weighted-average remaining amortization periods for in-place leases and above-market leases acquired were 11.2 years, 10.2 years and 8.5 years, respectively, as of December 31, 2021. Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 1.7 years, 7.7 years and 7.4 years, respectively, as of December 31, 2020.</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:11.94pt">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_193" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Note 8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> — Stockholders’ Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">for additional information.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Significant Tenants</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, 2021 and 2020, the Company did not have any tenants (including for this purpose, all affiliates of such tenants) whose annualized rental income on a straight-line basis represented 10% or greater of total annualized rental income on a straight-line basis for the portfolio. The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of December 31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*    State’s annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income for all portfolio properties as of the period specified.</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:11.94pt">In May 2021, the Company’s skilled nursing facility in Wellington, Florida, and the Company’s development property in Jupiter, Florida were sold. In December 2020, the Company’s skilled nursing facility in Lutz, Florida was sold.</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Liabilities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangible assets and liabilities consisted of the following as of the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.434%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,390 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquired intangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,689 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,504 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,097 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,407 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,472 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,529 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,943 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above-and below-market lease assets and liabilities, net and the amortization of above-and below-market ground leases, for the periods presented:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:58.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of in-place leases and other intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,071 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,121 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of above-and below-market leases, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(795)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of above-and below-market ground leases, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflected within depreciation and amortization expense.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflected within revenue from tenants.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflected within property operating and maintenance expense.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the projected amortization and adjustments to revenue from tenants for the next five years: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:51.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,208 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total to be added to amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,297 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,710 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,464 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Above-market lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below-market lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total to be added to revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dispositions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the properties sold during the years ended December 31, 2022, 2021 and 2020:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:39.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Disposition Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contract Sale Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) <br/>on Sale, of Real Estate Investments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">2022 Dispositions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LaSalle properties (four properties) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lien settlement on formerly disposed properties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Totals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,400 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">2021 Dispositions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hampton River Portfolio (two properties)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 21, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NuVista Jupiter </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 14, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wellington Green </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 14, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan SHOPs (four properties) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 15, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Totals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,648 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">2020 Dispositions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lutz </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan SHOPs (seven properties) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cape Girardeau</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 19, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Totals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,230 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">______</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Impairment charges of $34.0 million were recorded during the year ended December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Impairment charges of $14.6 million and $19.8 million were recorded during the years ended December 31, 2020 and 2019, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Impairment charges of $0.9 million, $2.3 million and $9.9 million were recorded during the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Impairment charges of $19.6 million and $22.6 million were recorded during the years ended December 31, 2020 and 2019, respectively. The contract sales price for all 11 properties was received in November of 2020. Loss on sale amounts relate to the properties transferred at the respective dates.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Impairment charges of $3.6 million were recorded during the year ended December 31, 2019.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales of the properties noted above did not represent a strategic shift that has a major effect on the Company’s operations and financial results. Accordingly, the results of operations of these properties remain classified within continuing operations for all periods presented until the respective sale dates.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held for Sale</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When assets are identified by management as held for sale, the Company reflects them separately on its balance sheet and stops recognizing depreciation and amortization expense on the identified assets and estimates the sales price, net of costs to sell, of those assets. If the carrying amount of the assets classified as held for sale exceeds the estimated net sales price, the Company records an impairment charge equal to the amount by which the carrying amount of the assets exceeds the Company’s estimate of the net sales price of the assets. For held-for-sale properties, the Company predominately uses the contract sale price as fair market value.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no assets held for sale as of December 31, 2022 or December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held for Use</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When circumstances indicate the carrying value of a property classified as held for use may not be recoverable, the Company reviews the property for impairment. For the Company, the most common triggering events are (i) concerns regarding the tenant (i.e., credit or expirations) in the Company’s single-tenant properties or significant vacancy in the Company’s multi-tenant properties and (ii) changes to the Company’s expected holding period as a result of business decisions or non-recourse debt maturities. If a triggering event is identified, the Company considers the projected cash flows due to various performance indicators, and where appropriate, the Company evaluates the impact on its ability to recover the carrying value of the properties based on the expected cash flows on an undiscounted basis over its intended holding period. The Company makes certain assumptions in this approach including, among others, the market and economic conditions, expected cash flow projections, intended holding periods and assessments of terminal values. Where more than one possible scenario exists, the Company uses a probability weighted approach in estimating cash flows. As these factors are difficult to predict and </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in its impairment analysis may not be achieved, and actual losses for impairment may be realized in the future. If the undiscounted cash flows over the expected hold period are less than the carrying value, the Company reflects an impairment charge to write the asset down to its fair value.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Charges</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents impairment charges by segment recorded during the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MOB Segment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Illinois skilled nursing facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) (7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sassafras MOB </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2) (7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sun City MOB </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3) (7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total MOB impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,488 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,082 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SHOP Segment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various held for use SHOPs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4) (7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LaSalle Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5) (7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wellington, Florida skilled nursing facility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6) (7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(8) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NuVista Jupiter </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total SHOP impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,630 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,951 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,446 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">These seven properties were impaired after the Company received an offer by the tenant to purchase all seven properties, which caused the Company to reassess its expected holding period for these properties. As of December 31, 2022, these properties were not disposed nor are under contract for disposal.</span></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The Company began marketing this property for sale in the fourth quarter of 2022. As of December 31, 2022 this property was not disposed nor under contract for disposal.</span></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">This property has been actively marketed for sale since September 2021. As of December 31, 2022 this property was not disposed nor under contract for disposal.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Consists of eight properties actively marketed for sale. Of the eight properties, six properties were impaired in year ended December 31, 2022. As of December 31, 2022, these properties were not disposed, but five of these properties are under contract for disposal.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">These four properties were disposed in the year ended December 31, 2022.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">This property was disposed in the year ended December 31, 2021. The Company recorded this impairment charge in the year ended December 31, 2021 to reduce the carrying value of the property to its estimated fair value as determined by an amendment to its purchase and sale agreement. The Company had previously recorded $2.3 million of impairment charges on this property in the year ended December 31, 2020.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">These properties were impaired to reduce their carrying values to their estimated fair values, respectively, as determined by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Assets Held for Use</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> approach described above.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">These properties were disposed in the first quarter of 2021 and the fourth quarter of 2020.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">This property was disposed in the second quarter of 2021.</span></div> 202 1 3 25300000 The following table presents the allocation of the assets acquired and liabilities assumed during the years ended December 31, 2022, 2021 and 2020:<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, at cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings, fixtures and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,539 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,224 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,364 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place leases and other intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease and other intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,639)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets and liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,654 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage notes payable assumed, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,883)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Preferred OP Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for real estate investments, including acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,538 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,300 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,984 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of properties purchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">_______________</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:11.94pt">Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 8.9 years, 9.3 years and 12.1 years, respectively, as of December 31, 2022. Weighted-average remaining amortization periods for in-place leases and above-market leases acquired were 11.2 years, 10.2 years and 8.5 years, respectively, as of December 31, 2021. Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 1.7 years, 7.7 years and 7.4 years, respectively, as of December 31, 2020.</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:11.94pt">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_193" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Note 8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> — Stockholders’ Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">for additional information.</span></div> 4933000 12848000 7665000 16606000 121376000 90699000 21539000 134224000 98364000 3763000 28499000 10369000 268000 794000 496000 32000 1639000 362000 3999000 27654000 10503000 0 0 13883000 0 2578000 0 25538000 159300000 94984000 4 17 9 P8Y10M24D P9Y3M18D P12Y1M6D P11Y2M12D P10Y2M12D P8Y6M P1Y8M12D P7Y8M12D P7Y4M24D The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of December 31, 2022, 2021 and 2020:<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*    State’s annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income for all portfolio properties as of the period specified.</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:11.94pt">In May 2021, the Company’s skilled nursing facility in Wellington, Florida, and the Company’s development property in Jupiter, Florida were sold. In December 2020, the Company’s skilled nursing facility in Lutz, Florida was sold.</span></div> 0.192 0.177 0.206 0.104 Acquired intangible assets and liabilities consisted of the following as of the periods presented:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.434%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,390 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquired intangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,689 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,504 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,097 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,407 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,472 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,529 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,943 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 268135000 198138000 69997000 264741000 183073000 81668000 14432000 12042000 2390000 14164000 11212000 2952000 9467000 1165000 8302000 9467000 1006000 8461000 292034000 211345000 80689000 288372000 195291000 93081000 23504000 14097000 9407000 23472000 12529000 10943000 <div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above-and below-market lease assets and liabilities, net and the amortization of above-and below-market ground leases, for the periods presented:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:58.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of in-place leases and other intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,071 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,121 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of above-and below-market leases, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(795)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of above-and below-market ground leases, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflected within depreciation and amortization expense.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflected within revenue from tenants.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflected within property operating and maintenance expense.</span></div> 15076000 15071000 15121000 -795000 -422000 -257000 159000 214000 178000 <div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the projected amortization and adjustments to revenue from tenants for the next five years: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:51.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,208 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total to be added to amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,297 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,710 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,464 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Above-market lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below-market lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total to be added to revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 13208000 11287000 9700000 8454000 4958000 10000 10000 10000 10000 10000 13218000 11297000 9710000 8464000 4968000 -495000 -416000 -363000 -329000 -240000 1512000 1294000 1103000 941000 623000 1017000 878000 740000 612000 383000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the properties sold during the years ended December 31, 2022, 2021 and 2020:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:39.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Disposition Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contract Sale Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) <br/>on Sale, of Real Estate Investments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">2022 Dispositions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LaSalle properties (four properties) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lien settlement on formerly disposed properties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Totals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,400 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">2021 Dispositions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hampton River Portfolio (two properties)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 21, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NuVista Jupiter </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 14, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wellington Green </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 14, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan SHOPs (four properties) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 15, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Totals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,648 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">2020 Dispositions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lutz </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan SHOPs (seven properties) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cape Girardeau</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 19, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Totals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,230 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">______</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Impairment charges of $34.0 million were recorded during the year ended December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Impairment charges of $14.6 million and $19.8 million were recorded during the years ended December 31, 2020 and 2019, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Impairment charges of $0.9 million, $2.3 million and $9.9 million were recorded during the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Impairment charges of $19.6 million and $22.6 million were recorded during the years ended December 31, 2020 and 2019, respectively. The contract sales price for all 11 properties was received in November of 2020. Loss on sale amounts relate to the properties transferred at the respective dates.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Impairment charges of $3.6 million were recorded during the year ended December 31, 2019.</span></div> 4 12400000 -303000 178000 12400000 -125000 2 37800000 1323000 65000000 2383000 30750000 114000 4 0 -172000 133550000 3648000 20000000 3832000 7 11750000 -908000 8600000 2306000 40350000 5230000 34000000 14600000 19800000 900000 2300000 9900000 19600000 22600000 11 3600000 0 0 <div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents impairment charges by segment recorded during the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MOB Segment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Illinois skilled nursing facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) (7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sassafras MOB </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2) (7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sun City MOB </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3) (7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total MOB impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,488 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,082 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SHOP Segment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various held for use SHOPs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4) (7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LaSalle Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5) (7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wellington, Florida skilled nursing facility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6) (7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(8) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NuVista Jupiter </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total SHOP impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,630 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,951 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,446 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">These seven properties were impaired after the Company received an offer by the tenant to purchase all seven properties, which caused the Company to reassess its expected holding period for these properties. As of December 31, 2022, these properties were not disposed nor are under contract for disposal.</span></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The Company began marketing this property for sale in the fourth quarter of 2022. As of December 31, 2022 this property was not disposed nor under contract for disposal.</span></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">This property has been actively marketed for sale since September 2021. As of December 31, 2022 this property was not disposed nor under contract for disposal.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Consists of eight properties actively marketed for sale. Of the eight properties, six properties were impaired in year ended December 31, 2022. As of December 31, 2022, these properties were not disposed, but five of these properties are under contract for disposal.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">These four properties were disposed in the year ended December 31, 2022.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">This property was disposed in the year ended December 31, 2021. The Company recorded this impairment charge in the year ended December 31, 2021 to reduce the carrying value of the property to its estimated fair value as determined by an amendment to its purchase and sale agreement. The Company had previously recorded $2.3 million of impairment charges on this property in the year ended December 31, 2020.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">These properties were impaired to reduce their carrying values to their estimated fair values, respectively, as determined by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Assets Held for Use</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> approach described above.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">These properties were disposed in the first quarter of 2021 and the fourth quarter of 2020.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">This property was disposed in the second quarter of 2021.</span></div> 10644000 0 0 1844000 0 0 0 6082000 0 12488000 6082000 0 15142000 0 0 0 34000000 0 0 869000 2276000 0 0 19570000 0 0 14600000 15142000 34869000 36446000 27630000 40951000 36446000 7 7 8 8 6 5 4 2300000 Mortgage Notes Payable, Net<div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s mortgage notes payable as of December 31, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:25.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.725%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Portfolio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbered Properties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding Loan Amount as of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Interest Rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> as of December 31, </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palm Valley Medical Plaza - Goodyear, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jun. 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Center V - Peoria, AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sep. 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Bryant - Bryant, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,977 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Chenal - Little Rock, AR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge North Little Rock - North Little Rock, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,943 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital One MOB Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.71%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec. 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multi-Property CMBS Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shiloh - Illinois</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,384 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.34%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan. 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BMO CMBS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.89%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec. 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross mortgage notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585,181 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591,841 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.83 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.82%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred financing costs, net of accumulated amortization </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage premiums and discounts, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage notes payable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578,700 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584,239 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Calculated on a weighted average basis for all mortgages outstanding as of December 31, 2022 and December 31, 2021. For the SOFR/LIBOR based loans, SOFR/LIBOR in effect at the balance sheet date was utilized. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan, based on daily SOFR as of December 31, 2022 and based on 30-day LIBOR as of December 31, 2021, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. The Company allocated $378.5 million of its “pay-fixed” interest rate swaps to this mortgage consistently as of December 31, 2022 and 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had pledged $0.9 billion in real estate investments, at cost, as collateral for its $585.2 million of gross mortgage notes payable. This real estate is not available to satisfy other debts and obligations unless first satisfying the mortgage notes payable secured by these properties. The Company makes payments of principal and interest, or interest only, depending upon the specific requirements of each mortgage note, on a monthly basis.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company’s mortgage note agreements require compliance with certain property-level financial covenants including debt service coverage ratios. As of December 31, 2022, the Company was in compliance with these financial covenants.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Principal Payments and LIBOR Transition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a schedule of principal payment requirements of the Company’s Mortgage Notes and Credit Facilities and a discussion of the expected cessation of LIBOR publication.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BMO MOB Loan</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, the Company, entered into a $42.8 million loan agreement (the “BMO MOB Loan”) with Bank of Montreal (“BMO”).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BMO MOB Loan requires monthly interest-only payments, with the principal balance due on the maturity date. The BMO MOB Loan permits BMO to securitize the entire BMO MOB Loan or any portion thereof.</span></div>At the closing of the BMO MOB Loan, the net proceeds after accrued interest and closing costs were used to (i) repay approximately $37.0 million of indebtedness under the Revolving Credit Facility, under which nine of the properties were included as part of the borrowing base prior to the BMO MOB Loan, (ii) fund approximately $2.5 million in deposits required to be made at closing into reserve accounts required under the loan agreement. The remaining $2.4 million net proceeds available to the Company were used for general corporate purposes and acquisitions. <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s mortgage notes payable as of December 31, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:25.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.725%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Portfolio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbered Properties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding Loan Amount as of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Interest Rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> as of December 31, </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palm Valley Medical Plaza - Goodyear, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jun. 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Center V - Peoria, AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sep. 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Bryant - Bryant, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,977 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Chenal - Little Rock, AR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge North Little Rock - North Little Rock, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,943 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital One MOB Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.71%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec. 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multi-Property CMBS Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shiloh - Illinois</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,384 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.34%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan. 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BMO CMBS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.89%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec. 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross mortgage notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585,181 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591,841 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.83 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.82%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred financing costs, net of accumulated amortization </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage premiums and discounts, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage notes payable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578,700 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584,239 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Calculated on a weighted average basis for all mortgages outstanding as of December 31, 2022 and December 31, 2021. For the SOFR/LIBOR based loans, SOFR/LIBOR in effect at the balance sheet date was utilized. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan, based on daily SOFR as of December 31, 2022 and based on 30-day LIBOR as of December 31, 2021, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. The Company allocated $378.5 million of its “pay-fixed” interest rate swaps to this mortgage consistently as of December 31, 2022 and 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.</span></div> 0 0 2879000 0 0.0415 0 0 2684000 0 0.0475 1 6817000 6977000 0.0398 0.0398 1 15639000 16024000 0.0295 0.0295 1 9704000 9943000 0.0295 0.0295 41 378500000 378500000 0.0373 0.0371 21 118700000 118700000 0.0460 0.0460 1 13071000 13384000 0.0434 0.0434 9 42750000 42750000 0.0289 0.0289 75 585181000 591841000 0.0383 0.0382 5117000 6186000 1364000 1416000 578700000 584239000 378500000 378500000 900000000 585200000 42800000 37000000 9 2500000 2400000 Credit Facilities, Net <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following credit facilities outstanding as of December 31, 2022 and 2021:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Facility Amount as of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate as of December 31,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(9) (10)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encumbered Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Facility:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mar. 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(8)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mar. 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred financing costs </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan, net </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,006 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Credit Facility </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fannie Mae Master Credit Facilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital One Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210,483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov. 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KeyBank Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov. 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fannie Mae Master Credit Facilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352,047</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">355,045</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">530,297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">502,051</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.94</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Encumbered properties are as of December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below) have been pledged for the benefit of the lenders thereunder.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Secured by first-priority mortgages on 11 of the Company’s seniors housing properties located in Florida, Georgia, Iowa and Michigan as of December 31, 2022 with a carrying value of $348.9 million.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Secured by first-priority mortgages on ten of the Company’s seniors housing properties located in, Missouri, Kansas, California, Florida, Georgia and Iowa as of December 31, 2022 with carrying value of $261.0 million.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Calculated on a weighted average basis for all credit facilities outstanding as of December 31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan, based on SOFR, all of which was economically fixed as a result of entering into “pay-fixed” interest rate swap agreements (the Company designates its SOFR “pay-fixed” interest rate swaps against all 30-day SOFR debt, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details).</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The effective rates above only include the impact of designated hedging instruments. The Company also has seven non-designated interest rate cap agreements with an aggregate notional amount of $354.6 million which limits 30-day LIBOR to 3.50%. The Company did not designate these derivatives as hedges and accordingly, the changes in value and any cash received from these derivatives are presented within gain (loss) on derivative instruments on the consolidated statements of operations and comprehensive income (see discussion below and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details). Inclusive of the impact of these interest rate caps on these non-designated derivatives, the economic interest rate on the Capital One Fannie Mae Facility was 5.26%, and the economic interest rate on the KeyBank Fannie Mae Facility was 5.96% as of December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">During the year ended December 31, 2022, the Company exercised its option to extend the maturity one year to March 2024.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Effective interest rate below for variable rate debt gives effect to any “pay-fixed” swap entered into by the Company allocated to the loan for presentation purposes. If no “pay-fixed” swaps are allocated, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of December 31, 2022 and 2021. Interest rate caps are not considered unless the caps, if any, are currently in effect.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.34pt">The Company has interest “pay-fixed” swaps which are designated as cash flow hedges on LIBOR- or SOFR-based outstanding combined borrowings. Prior to the Fourth Amendment (as defined below) which, among other things, changed the reference rate on the Credit Facility from LIBOR to SOFR, to present average rates in the table above, the Company historically allocated the notional amount of a “pay-fixed” swap to the outstanding amounts of its Credit Facility (both the Revolving Credit Facility and the Term Loan) with any remaining notional amounts applied to its Capital One Fannie Mae Facility. During the three months ended September 30, 2022, the Company converted $150.0 million of its “pay-fixed” swaps from LIBOR to SOFR. As of December 31, 2022, the Company allocated the $150.0 million SOFR-based “pay-fixed” swaps to the Term Loan, which were also allocated to the </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Term Loan as of December 31, 2021 when the Term Loan and swaps were LIBOR-based. As of December 31, 2022 and 2021, $50.0 million of LIBOR-based “pay-fixed” swaps were allocated to the Capital One Fannie Mae Facility because there were no LIBOR-based amounts outstanding under the Revolving Credit Facility in either period. The $50.0 million of LIBOR-based “pay-fixed” swaps were terminated subsequent to December 31, 2022. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_220" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 17</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the carrying value of our real estate investments, at cost was $2.6 billion, with $0.9 billion of this amount pledged as collateral for mortgage notes payable, $0.6 billion of this amount pledged to secure advances under the Fannie Mae Master Credit Facilities and $0.9 billion of this amount comprising the borrowing base of the Credit Facility. All of the real estate assets pledged to secure debt or comprising the borrowing base of are not available to satisfy other debts and obligations, or to serve as collateral with respect to new indebtedness, unless, as applicable, the existing indebtedness associated with the property is satisfied or the property is removed from the borrowing base of the Credit Facility, which would impact availability thereunder.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unencumbered real estate investments, at cost as of December 31, 2022 was $0.1 billion, although there can be no assurance as to the amount of liquidity the Company would be able to generate from using these unencumbered assets as collateral for mortgage loans or adding them to the borrowing base of the Company’s Credit Facility. Currently, any properties that the Company acquires must be added to the borrowing base of the Credit Facility, and any net proceeds from the dispositions of any unencumbered properties must be used to repay amounts outstanding under the Revolving Credit Facility (as defined below).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amended and restated senior secured credit facility (the “Credit Facility”), consists of two components, a revolving credit facility (the “Revolving Credit Facility”) and a term loan (the “Term Loan”).</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is interest-only and matures on March 13, 2023, subject to a one-year extension at the Company’s option. The Term Loan is interest-only and matures on March 13, 2024. The total commitments under the Credit Facility are $655.0 million, including $505.0 million under the Revolving Credit Facility. The Credit Facility includes an uncommitted “accordion feature” that may be used to increase the commitments under either component of the Credit Facility by up to an additional $370.0 million to a total of $1.0 billion.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount available for future borrowings under the Revolving Credit Facility is based on either the value of the pool of eligible unencumbered real estate assets comprising the borrowing base, or satisfying a minimum debt service coverage ratio with respect to the borrowing base. The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Revolving Credit Facility have been pledged for the benefit of the lenders thereunder.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, $150.0 million was outstanding under the Term Loan, and $30.0 million was outstanding under the Revolving Credit Facility. The unused borrowing availability under the Revolving Credit Facility was $203.4 million based on the borrowing base as of December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, the Company, the OP, KeyBank National Association individually and as agent for the lenders and the lenders from time to time a party under the Credit Facility, among others, entered into the fourth amendment to the Credit Facility (the “Fourth Amendment”). Without the Fourth Amendment, the Company would have been in default of the reamendment Fixed Charge Coverage Ratio covenant (defined below) for the four fiscal quarter period ended June 30, 2022. Pursuant to the Fourth Amendment, the lenders agreed to reduce the minimum required Fixed Charge Coverage Ratio covenant to permit the Company to avoid any Default or Events of Default through the amendment date. The Fourth Amendment also eliminated the LIBOR-based rate option, among other changes. The terms described below represent the terms pursuant to the Fourth Amendment.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to maintain a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $50.0 million. Certain other restrictions and conditions described below will no longer apply beginning in the quarter in which the Company makes an election and, as of the day prior to the commencement of the applicable quarter, the Company has a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million, giving effect to the aggregate amount of distributions projected to be paid by the Company during the applicable quarter, the Company’s ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5% and the Company’s Fixed Charge Coverage Ratio (as defined below) for the most recently ended four fiscal quarters is not less than 1.50 to 1.00 (the “Commencement Quarter”). The fiscal quarter ended June 30, 2021 was the first quarter that could have been the Commencement Quarter. The Company did not satisfy the conditions during the quarter ended December 31, 2022 in order to elect the quarter ending March 31, 2023 as the Commencement Quarter.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the first day of the Commencement Quarter, the Company must use all the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to prepay amounts outstanding under the Revolving Credit Facility, to the extent there are any such amounts outstanding. The Company may borrow additional amounts if all relevant conditions are met, including sufficient availability for future borrowings. There can be no assurance these conditions will be met at the time of any particular borrowing.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the Commencement Quarter, the Company may not pay distributions to holders of common stock in cash or any other cash distributions (including repurchases of shares of the Company’s common stock), subject to certain exceptions. These exceptions include paying dividends on the 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (“Series A Preferred Stock”), the 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (“Series B Preferred Stock”) or any other class of preferred stock that the Company may issue and paying any cash distributions necessary to maintain its status as a REIT. The Company may not pay any cash distributions (including dividends on Series A Preferred Stock or Series B Preferred Stock or any other preferred stock) if a default or event of default exists or would result therefrom. Beginning in the Commencement Quarter, the Company will be able to pay cash distributions to holders of common stock, subject to the restrictions described below and the aggregate distributions (as defined in the Credit Facility and including dividends on Series A Preferred Stock, Series B Preferred Stock or any other class of preferred stock that may be issued) for any period of four fiscal quarters may not exceed 95% of Modified FFO (as defined in the Credit Facility) for the same period based only on fiscal quarters after the Commencement Quarter. In addition, beginning in the Commencement Quarter, the Company will be permitted to repurchase up to $50.0 million of shares of its common stock (including amounts previously repurchased during the term of the Revolving Credit Facility) if, after giving effect to the repurchases, the Company maintains cash and cash equivalents of at least $30.0 million and the Company’s ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 55.0%.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Credit Facility, the Company must comply with covenants governing the maximum ratio of consolidated total indebtedness to consolidated total asset value, and requiring the Company to maintain a minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges, a minimum consolidated tangible net worth and a minimum debt service coverage ratio. Specifically, the maximum ratio of consolidated total indebtedness to consolidated total asset value is presently 65% unless and until the Commencement Quarter, following which the ratio will be 62.5%. The minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges (the “Fixed Charge Coverage Ratio”) that the Company must satisfy based on the four most recently ended fiscal quarters is (a) 1.20 to 1.00 for the period commencing with the quarter ended June 30, 2022 through the quarter ending June 30, 2023, (b) 1.35 to 1.00 for the period commencing with the quarter ending September 30, 2023 through the quarter ending December 31, 2023 and (c) 1.45 to 1.00 for the period commencing with the quarter ending March 31, 2024 and continuing thereafter; provided, however, that from and after the Commencement Quarter, the Company must satisfy a minimum Fixed Charge Coverage Ratio of 1.50 to 1.00. The minimum consolidated tangible net worth is the sum of (i) $1.2 billion, plus (ii) 75% of any net offering proceeds (as defined in the Credit Facility) since the Credit Facility closed in March 2019. As of December 31, 2022, the Company had a consolidated tangible net worth of $1.5 billion. The minimum debt service coverage ratio (calculated similar to the calculation of the Fixed Charge Coverage Ratio but excluding dividends on Series A Preferred Stock, Series B Preferred Stock or any other class of preferred stock that may be issued) that the Company must satisfy based on the four most recently ended fiscal quarters is (a) 1.50:1.00 for the period commencing with the quarter ended June 30, 2022 through the quarter ending June 30, 2023, (b) 1.65:1.00 for the period commencing with the quarter ending September 30, 2023 through the quarter ending December 31, 2023 and (c) 1.75:1.00 for the period commencing with the quarter ending March 31, 2024 and continuing thereafter until the Company elects the Commencement Quarter, after which the debt service coverage ratio covenant will no longer apply. Additionally, the borrowing base advance rate is 52.5% until the Company elects the Commencement Quarter, after which the borrowing base advance rate will be 55%.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2022, the Company had the option to have amounts outstanding under the Revolving Credit Facility bear interest at an annual rate equal to either: (i) SOFR (as defined below), plus an applicable margin that ranges, depending on the Company’s leverage, from 2.10% to 2.85%; or (ii) the Base Rate (as defined in the Credit Facility), plus an applicable margin that ranges, depending on the Company’s leverage, from 0.85% to 1.60%. Commencing on the first day of the Commencement Quarter, the Company will have the option to have amounts outstanding under the Revolving Credit Facility bear interest at an annual rate equal to either: (a) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.60% to 2.35%, plus an additional spread adjustment depending on the length of the interest period; or (b) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.35% to 1.10%. As of December 31, 2022 the Company had elected to use the SOFR option for all of its borrowings under the Revolving Credit Facility, to the extent there are any such amounts outstanding.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, as of December 31, 2022, the Company has the option to have amounts outstanding under the Term Loan bear interest at an annual rate equal to either: (i) SOFR, plus an applicable margin that ranges, depending on the Company’s leverage, from 2.05% to 2.80%; or (ii) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.80% to 1.55%. Commencing on the first day of the Commencement Quarter, the Company will have the option to have amounts outstanding under the Term Loan bear interest at an annual rate equal to either: (a) SOFR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.55% to 2.30%, plus an additional spread adjustment depending on the length of the interest period; or (b) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.30% to 1.05%. Pursuant to the terms of the Company’s Credit Facility, the “floor” on SOFR-based rates is 0.25%. As of December 31, 2022, the Company had elected to use the SOFR option for all of its borrowings under the Term Loan.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company was in compliance with the financial covenants under the Credit Facility. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_175" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">N</a><a href="#i287ff37c25f74b1a844547bcd3a52b7a_175" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">o</a><a href="#i287ff37c25f74b1a844547bcd3a52b7a_175" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">te 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has experienced, and continues to experience, negative impacts from rising operating costs, particularly in its SHOP segment, as well as rising variable interest rates. The Company’s Credit Facility matures in March 2024 and contains various operating covenants (described above) which the Company was in compliance with through December 31, 2022. Prospectively, based upon the Company’s current expectations, the Company believes its operating results through June 30, 2023 will allow it to comply with these covenants. However, the Company believes its operating results may not be sufficient to comply with the increased Fixed Charge Coverage Ratio, which increases from 1.20:1.00 to 1.35:1.00 commencing with the quarter ending September 30, 2023 and thereafter. Absent a waiver or modification from the lender group, failure to comply with the Fixed Charge Coverage Ratio would constitute an Event of Default and the balance of the Credit Facility would be due and payable. The Company has obtained such waivers and modifications from the lender group in the past, but there can be no assurance that such a waiver or modification will be granted in future periods. Additionally, the Company is exploring long-term secured financing opportunities, utilizing some or all of the Company’s properties as collateral, the proceeds from which the Company believes will be sufficient to repay all amounts outstanding under the Credit Facility, which was $180.0 million as of December 31, 2022 ($200.0 million including the $20.0 million drawn subsequent to December 31, 2022, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_220" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 17</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Subsequent Events </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for details).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fannie Mae Master Credit Facilities</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2016, the Company, through wholly-owned subsidiaries of the OP, entered into a master credit facility agreement relating to a secured credit facility with KeyBank (the “KeyBank Facility”) and a master credit facility agreement with Capital One for a secured credit facility with Capital One Multifamily Finance LLC, an affiliate of Capital One (the “Capital One Facility”; the Capital One Facility and the KeyBank Facility are referred to herein individually as “Fannie Mae Master Credit Facility” and together as the “Fannie Mae Master Credit Facilities”). Advances made under these agreements are assigned by Capital One and KeyBank to Fannie Mae at closing for inclusion in Fannie Mae’s Multifamily MBS program. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Fannie Mae Master Credit Facilities, the Company was required to enter into interest rate cap agreements. Periodically, the Company renews these interest rate cap agreements upon their expiration. As of December 31, 2022, the Company had seven interest rate cap agreements (of which six caps were active as of December 31, 2022 and one has a forward start date as of April 2023) with an aggregate current effective notional amount of $354.6 million which caps LIBOR at 3.50% with terms through April 2024. The Company does not apply hedge accounting to these agreements and changes in value as well as any cash received are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive income (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional disclosure regarding the Company’s derivatives).</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, in conjunction with the sale and transfer of four of the Michigan SHOPs, one of which was encumbered under the Fannie Mae Master Credit Facility with Capital One, $4.2 million was repaid to Capitol One upon the release of the property.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may request future advances under the Fannie Mae Master Credit Facilities by adding eligible properties to the collateral pool, subject to customary conditions, including satisfaction of minimum debt service coverage and maximum loan-to-value tests. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Principal Payments </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled aggregate principal payments for the five years subsequent to December 31, 2022 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities): </span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Principal<br/>Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mortgage Notes Payable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Facilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,769 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,908 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,181 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532,047 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,228 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LIBOR Transition</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the Financial Conduct Authority (which regulates LIBOR) announced it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee, which identified the Secured Overnight Financing Rate (“SOFR”) as its preferred alternative to LIBOR in derivatives and other financial contracts. On March 5, 2021, the Financial Conduct Authority confirmed a partial extension of this deadline announcing that it will cease the publication of the one-week and two-month USD LIBOR settings immediately following December 31, 2021. The remaining USD LIBOR settings will continue to be published through June 30, 2023. The Company is not able to predict when there will be sufficient liquidity in the SOFR market. The Company is monitoring and evaluating the risks related to changes in LIBOR availability, which include potential changes in interest paid on debt and amounts received and paid on interest rate swaps. In addition, the value of debt or derivative instruments tied to LIBOR will also be impacted as LIBOR is limited and discontinued and contracts must be transitioned to a new alternative rate. While the Company currently expects LIBOR to be available in substantially its current form until at least through June 30, 2023 for the USD LIBOR rates currently relevant to the Company, it is possible that LIBOR will become unavailable prior to that time. This could occur, for example, if a sufficient number of banks decline to make submissions to the LIBOR administrator. Pursuant to the Fourth Amendment, the Credit Agreement was updated and provisions were added to transition the Credit Facility from using a benchmark rate of LIBOR to using a benchmark rate of SOFR, and the Company will either utilize the Base Rate (as defined in the Credit Facility) or the updated SOFR-based rates. During the year ended December 31, 2022, the Company converted $150.0 million of its “pay-fixed” swaps on its Credit Facility from LIBOR to SOFR, and the Company additionally converted its $378.5 million Capital One MOB Loan and related “pay-fixed” swap from LIBOR to SOFR, however, the Company still has mortgages, credit facilities (namely, the Capital One Facility and the KeyBank Facility) and derivative agreements that have terms that are based on LIBOR. Certain of those agreements have alternative rates already contained in the agreements while others do not. The Company anticipates that it will either utilize the alternative rates contained in the agreements or negotiate a replacement reference rate for LIBOR with the lenders and derivative counterparties.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had $558.7 million of LIBOR-based borrowings ($352.0 million of which is variable-rate) and $50.0 million of LIBOR-based “pay-fixed” swaps. The Company terminated its remaining $50.0 million of “pay-fixed” swaps subsequent to December 31, 2022. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_220" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 17</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following credit facilities outstanding as of December 31, 2022 and 2021:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Facility Amount as of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate as of December 31,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(9) (10)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encumbered Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Facility:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mar. 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(8)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mar. 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred financing costs </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan, net </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,006 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Credit Facility </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fannie Mae Master Credit Facilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital One Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210,483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov. 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KeyBank Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov. 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fannie Mae Master Credit Facilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352,047</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">355,045</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">530,297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">502,051</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.94</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Encumbered properties are as of December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below) have been pledged for the benefit of the lenders thereunder.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Secured by first-priority mortgages on 11 of the Company’s seniors housing properties located in Florida, Georgia, Iowa and Michigan as of December 31, 2022 with a carrying value of $348.9 million.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Secured by first-priority mortgages on ten of the Company’s seniors housing properties located in, Missouri, Kansas, California, Florida, Georgia and Iowa as of December 31, 2022 with carrying value of $261.0 million.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Calculated on a weighted average basis for all credit facilities outstanding as of December 31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan, based on SOFR, all of which was economically fixed as a result of entering into “pay-fixed” interest rate swap agreements (the Company designates its SOFR “pay-fixed” interest rate swaps against all 30-day SOFR debt, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details).</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The effective rates above only include the impact of designated hedging instruments. The Company also has seven non-designated interest rate cap agreements with an aggregate notional amount of $354.6 million which limits 30-day LIBOR to 3.50%. The Company did not designate these derivatives as hedges and accordingly, the changes in value and any cash received from these derivatives are presented within gain (loss) on derivative instruments on the consolidated statements of operations and comprehensive income (see discussion below and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details). Inclusive of the impact of these interest rate caps on these non-designated derivatives, the economic interest rate on the Capital One Fannie Mae Facility was 5.26%, and the economic interest rate on the KeyBank Fannie Mae Facility was 5.96% as of December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">During the year ended December 31, 2022, the Company exercised its option to extend the maturity one year to March 2024.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Effective interest rate below for variable rate debt gives effect to any “pay-fixed” swap entered into by the Company allocated to the loan for presentation purposes. If no “pay-fixed” swaps are allocated, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of December 31, 2022 and 2021. Interest rate caps are not considered unless the caps, if any, are currently in effect.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.34pt">The Company has interest “pay-fixed” swaps which are designated as cash flow hedges on LIBOR- or SOFR-based outstanding combined borrowings. Prior to the Fourth Amendment (as defined below) which, among other things, changed the reference rate on the Credit Facility from LIBOR to SOFR, to present average rates in the table above, the Company historically allocated the notional amount of a “pay-fixed” swap to the outstanding amounts of its Credit Facility (both the Revolving Credit Facility and the Term Loan) with any remaining notional amounts applied to its Capital One Fannie Mae Facility. During the three months ended September 30, 2022, the Company converted $150.0 million of its “pay-fixed” swaps from LIBOR to SOFR. As of December 31, 2022, the Company allocated the $150.0 million SOFR-based “pay-fixed” swaps to the Term Loan, which were also allocated to the </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Term Loan as of December 31, 2021 when the Term Loan and swaps were LIBOR-based. As of December 31, 2022 and 2021, $50.0 million of LIBOR-based “pay-fixed” swaps were allocated to the Capital One Fannie Mae Facility because there were no LIBOR-based amounts outstanding under the Revolving Credit Facility in either period. The $50.0 million of LIBOR-based “pay-fixed” swaps were terminated subsequent to December 31, 2022. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_220" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 17</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional information.</span> 30000000 0 0.0726 0 150000000 150000000 0.0511 0.0411 1750000 2994000 148250000 147006000 98 178250000 147006000 11 210483000 212417000 0.0590 0.0251 10 141564000 142628000 0.0660 0.0256 21 352047000 355045000 119 530297000 502051000 0.0594 0.0300 11 348900000 10 261000000 7 354600000 0.0350 0.0526 0.0596 P1Y 150000000 150000000 50000000 50000000 50000000 2600000000 900000000 600000000 900000000 100000000 P1Y 655000000 505000000 370000000 1000000000 150000000 30000000 203400000 50000000 100000000 0.625 1.50 0.07375 0.01 0.07125 0.01 0.95 50000000 30000000 0.550 0.65 0.625 1.20 1.35 1.45 1.50 1200000000 0.75 1500000000 1.50 1.65 1.75 0.525 0.55 0.0210 0.0285 0.0085 0.0160 0.0160 0.0235 0.0035 0.0110 0.0205 0.0280 0.0080 0.0155 0.0155 0.0230 0.0030 0.0105 0.0025 1.20 1.35 180000000 200000000 20000000 7 6 1 354600000 0.0350 4 4200000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled aggregate principal payments for the five years subsequent to December 31, 2022 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities): </span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Principal<br/>Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mortgage Notes Payable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Facilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,769 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,908 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,181 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532,047 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,228 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1139000 5769000 6908000 1178000 185769000 186947000 13270000 5769000 19039000 379393000 334740000 714133000 922000 0 922000 189279000 0 189279000 585181000 532047000 1117228000 150000000 378500000 558700000 352000000 50000000 50000000 Fair Value of Financial Instruments GAAP establishes a hierarchy of valuation techniques based on the observability of inputs used in measuring asset and liabilities at fair value. GAAP establishes market-based or observable inputs as the preferred source of values, followed by valuation models using management assumptions in the absence of market inputs. The three levels of the hierarchy are described below: <div style="margin-bottom:5pt;margin-top:5pt;padding-left:63pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:63pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Inputs other than quoted prices included within Level 1 that are observable for the asset and liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:63pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Unobservable inputs that reflect the entity’s own assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. However, the Company expects that changes in classifications between levels will be rare.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with those derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and its counterparties. However, as of December 31, 2022 and 2021, the Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of the Company’s derivatives. As a result, the Company has determined that its derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of derivative instruments is determined using a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, as well as observable market-based inputs, including interest rate curves and implied volatilities. In addition, credit valuation adjustments, are incorporated into the fair values to account for the Company’s potential nonperformance risk and the performance risk of the counterparties.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2022 and 2021, aggregated by the level in the fair value hierarchy within which those instruments fall.</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets<br/>Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value (non-designated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value (designated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value (non-designated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities, at fair value (designated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,903)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,903)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,729)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,729)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the type of inputs may result in a reclassification for certain assets. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the year ended December 31, 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Investments Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Investments — Held for Use</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also had impaired real estate investments held for use, which were carried at fair value on a non-recurring basis on the consolidated balance sheet as of December 31, 2022 and 2021. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company owned 17 held for use properties (nine MOBs and eight SHOPs) for which the Company had reconsidered its expected holding period, of which 10 properties (two MOBs and eight SHOPs) are being marketed for sale. As a result, the Company evaluated the impact on its ability to recover the carrying value of the properties and recorded impairment charges to write these properties down to their estimated fair values. The Company had also previously written down other held for use properties which have subsequently been sold. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company owned five held for use properties (one MOB and four SHOPs) for which the Company had reconsidered their expected holding periods and which were being marketed for sale. As a result, the Company evaluated the impact on its ability to recover the carrying values of the respective properties and recorded impairment charges to write these properties down to their estimated fair values during 2021. The four SHOPs were sold in the first quarter of 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_178" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Real Estate investments, Net - “Assets Held for Use and Related Impairments”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Investments — Held for Sale</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate investments held for sale are carried at net realizable value on a non-recurring basis and are generally classified in Level 3 of the fair value hierarchy. The Company did not have any real estate investments classified as held for sale as of December 31, 2022 and 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Not Measured at Fair Value</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to disclose the fair value of financial instruments for which it is practicable to estimate that value. The fair values of short-term financial instruments such as cash and cash equivalents, restricted cash, straight-line rent receivable, net, prepaid expenses and other assets, deferred costs, net, accounts payable and accrued expenses, deferred rent and distributions payable approximate their carrying value on the consolidated balance sheets due to their short-term nature.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross mortgage notes payable and mortgage <br/>premium and discounts, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,817 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Facility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,496 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,817 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fannie Mae Master Credit Facilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,047 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353,034 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,045 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,710 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the mortgage notes payable is estimated using a discounted cash flow analysis, based on the Advisor’s experience with similar types of borrowing arrangements, excluding the value of derivatives.</span></div> <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2022 and 2021, aggregated by the level in the fair value hierarchy within which those instruments fall.</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets<br/>Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value (non-designated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value (designated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value (non-designated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities, at fair value (designated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,903)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,903)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,729)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,729)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 3737000 0 3737000 0 36910000 0 36910000 0 0 0 0 0 40647000 0 40647000 0 174000 0 174000 13903000 13903000 0 -13729000 0 -13729000 17 9 8 10 2 8 5 1 4 4 <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross mortgage notes payable and mortgage <br/>premium and discounts, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,817 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Facility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,496 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,817 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fannie Mae Master Credit Facilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,047 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353,034 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,045 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,710 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 583817000 550626000 590425000 594348000 180000000 179496000 150000000 148817000 352047000 353034000 355045000 350710000 Derivatives and Hedging Activities <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Management Objective of Using Derivatives</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use derivative financial instruments, including interest rate swaps, caps, collars, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. Additionally, in using interest rate derivatives, the Company aims to add stability to interest expense and to manage its exposure to interest rate movements. The Company does not intend to utilize derivatives for speculative purposes or purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company, and its affiliates, may also have other financial relationships. The Company does not anticipate that any of its counterparties will fail to meet their obligations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of December 31, 2022 and 2021:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.970%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.425%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,903 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedges of Interest Rate Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has nine interest rate swaps that are designated as cash flow hedges. The interest rate swaps are used as part of the Company’s interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. During the years ended December 31, 2022 and 2021, such derivatives were used to hedge the variable cash flows associated with variable-rate debt. The interest rate “pay-fixed” swaps have base interest rates between 1.39% and 2.32% with expirations varying through December 2026.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive (loss) income and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the refinancing of the $250.0 million loan made by Capital One, National Association and certain other lenders to certain subsidiaries of the OP on June 30, 2017 (the “MOB Loan”), during the fourth quarter of 2019, the Company terminated two interest rate swaps with an aggregate notional amount of $250.0 million for a payment of approximately $2.2 million. Following these terminations, $2.2 million was recorded in AOCI and was being recorded as an adjustment to interest expense over the original term of the two terminated swaps and the MOB Loan prior to its refinancing. For the years ended December 31, 2022, 2021 and 2020, the Company reclassified $0.4 million, $0.9 million and $0.9 million, respectively, from AOCI as increases to interest expense. No amounts remained in AOCI related to these previously terminated swaps as of December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company converted $150.0 million of the “pay-fixed” swaps on its Credit Facility and $378.5 million of the “pay-fixed” swaps on its mortgages from LIBOR to SOFR.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in accumulated other comprehensive (loss) income related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. During the next 12 months, from January 1, 2023 through December 31, 2023, the Company estimates that $17.4 million will be reclassified from other comprehensive income as a decrease to interest expense relating to the “pay-fixed” swaps designated as derivatives.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SOFR-based interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR-based interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below details the location in the financial statements of the loss recognized on interest rate derivatives designated as cash flow hedges for the periods ended December 31, 2022 and 2021:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,322 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,614)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,153)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,010)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,999)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount of interest expense presented in the<br/>consolidated statements of operations and comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,740 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,900 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,519 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Designated Derivatives</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These derivatives are used to manage the Company’s exposure to interest rate movements, but the Company has not elected to apply hedge accounting. As of December 31, 2022, we have entered into seven LIBOR interest rate caps with a notional amount of $354.6 million (of which six caps were active as of December 31, 2022 and one has a forward start date as of April 2023) which limit 30-day LIBOR borrowings to 3.50% and have varying expiration dates through April 2024. Beginning in the fourth quarter of 2022, LIBOR exceeded 3.50% and the Company began receiving payments under these interest rate caps. While the Company does not apply hedge accounting for these interest rate caps, they are economically hedging the Capital One Facility and KeyBank Facility. Changes in the fair value of, and any cash received from, derivatives not designated as hedges under a qualifying hedging relationship are recorded directly to net income (loss) and are presented within gain (loss) on non-designated derivatives in our consolidated statements of operations and comprehensive loss. For the years ended December 31, 2022, 2021 and 2020, gain (loss) on non-designated derivatives were a gain of $3.8 million (including cash received of $0.3 million), a gain of $37,000 and a loss of $0.1 million, respectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following outstanding interest rate derivatives that were not designated as a hedges in qualifying hedging relationships as of as of December 31, 2022 and 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate caps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,624 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Notional amount represents the currently active interest cap contract and excludes one and three inactive cap agreements (included in the instrument count) with aggregate notional amounts of $52.6 million and $140.8 million as of December 31, 2022 and 2021, respectively, which take effect upon the expiration of similar caps included above and effectively extend the term for the same notional amount.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">All of the Company’s interest rate cap agreements limit 30-day LIBOR to 3.50% with terms through April 2024. The actual 30-day LIBOR rates during the fourth quarter of 2022 exceeded the strike price rate of 3.50% and the Company is currently receiving payments under these agreements. Changes in the fair market value of these non-designated derivatives, as well as any cash received, are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive income.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Offsetting Derivatives</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2022 and 2021. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheets.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:18.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts Not Offset in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts of Recognized (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts Offset in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Amounts of Assets presented in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Collateral Received</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,903)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,903)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,903)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit-risk-related Contingent Features</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements in place with each of its derivative counterparties that contain a provision where if the Company either defaults or is capable of being declared in default on any of its indebtedness, then the Company could also be declared in default on its derivative obligations.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 there were no derivatives in a net liability position. The Company is not required to post any collateral related to these agreements and was not in breach of any agreement provisions.</span></div> The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of December 31, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.970%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.425%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,903 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 36910000 0 0 13903000 3737000 174000 9 0.0139 0.0232 250000000 2 250000000 2200000 -2200000 2 -400000 -900000 -900000 0 150000000 378500000 -17400000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SOFR-based interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR-based interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following outstanding interest rate derivatives that were not designated as a hedges in qualifying hedging relationships as of as of December 31, 2022 and 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate caps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,624 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Notional amount represents the currently active interest cap contract and excludes one and three inactive cap agreements (included in the instrument count) with aggregate notional amounts of $52.6 million and $140.8 million as of December 31, 2022 and 2021, respectively, which take effect upon the expiration of similar caps included above and effectively extend the term for the same notional amount.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">All of the Company’s interest rate cap agreements limit 30-day LIBOR to 3.50% with terms through April 2024. The actual 30-day LIBOR rates during the fourth quarter of 2022 exceeded the strike price rate of 3.50% and the Company is currently receiving payments under these agreements. Changes in the fair market value of these non-designated derivatives, as well as any cash received, are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive income.</span></div> 7 528500000 0 0 2 50000000 9 578500000 9 578500000 9 578500000 The table below details the location in the financial statements of the loss recognized on interest rate derivatives designated as cash flow hedges for the periods ended December 31, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,322 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,614)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,153)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,010)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,999)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount of interest expense presented in the<br/>consolidated statements of operations and comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,740 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,900 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,519 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 50098000 14322000 -40614000 -1153000 -11010000 -7999000 51740000 47900000 51519000 7 354600000 6 1 0.0350 0.0350 3800000 300000 37000 -100000 7 354624000 9 355175000 1 3 52600000 140800000 0.0350 0.0350 The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2022 and 2021. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:18.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts Not Offset in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts of Recognized (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts Offset in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Amounts of Assets presented in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Collateral Received</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,903)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,903)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,903)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 40647000 0 40647000 0 0 40647000 174000 0 174000 0 0 174000 13903000 0 13903000 0 0 13903000 Stockholders’ Equity <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had 105,080,531 and 99,281,754 shares of common stock outstanding, respectively, including unvested restricted shares, shares issued pursuant to the Company’s distribution reinvestment plan (“DRIP”), net of share repurchases, and shares issued as stock dividends since October 2020. Since October 2020, the Company has issued an aggregate of approximately 12.6 million shares in respect to the stock dividends. No other additional shares of common stock were issued during the years ended December 31, 2022 or 2021. References made to weighted-average shares and per-share amounts in the consolidated statements of operations and comprehensive income have been retroactively adjusted to reflect the cumulative increase in shares outstanding due to the stock dividends (including the January 2023 stock dividend), and are noted as such throughout the accompanying financial statements and notes. Any future issuances of stock dividends will also result in retroactive adjustments. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2021, which was approved by the Board on March 28, 2022. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually unless the Company lists its common stock.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tender Offers</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, the Company announced a tender offer (the “2020 Tender Offer”) to purchase up to 200,000 shares of its common stock for cash at a purchase price equal to $8.50 per share with the proration period and withdrawal rights expiring February 7, 2020. The Company made the 2020 Tender Offer in response to an unsolicited offer to stockholders commenced on December 31, 2019. The 2020 Tender Offer expired in accordance with the terms on February 7, 2020. In accordance with the 2020 Tender Offer, the Company accepted for purchase 200,000 shares for a total cost of approximately $1.7 million, which was funded with available cash.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company’s share repurchase program (the “SRP”), as amended from time to time, qualifying stockholders are able to sell their shares to the Company in limited circumstances. The SRP permits investors to sell their shares back to the Company after they have held them for at least one year, subject to significant conditions and limitations. Repurchases of shares of the Company’s common stock, when requested, are at the sole discretion of the Board.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the SRP, subject to certain conditions, only repurchase requests made following the death or qualifying disability of stockholders that purchased shares of the Company’s common stock or received their shares from the Company (directly or indirectly) through one or more non-cash transactions are considered for repurchase. Additionally, pursuant to the SRP, the </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">repurchase price per share equals 100% of the Estimated Per-Share NAV in effect on the last day of the fiscal semester, or the six-month period ending June 30 or December 31.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2020, the Company repurchased 505,101 shares of common stock for approximately $8.8 million, at an average price per share of $17.50 pursuant to the SRP. The repurchases reflect all repurchase requests made in good order following the death or qualifying disability of stockholders during the period commencing July 1, 2019 up to and including December 31, 2019.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the SRP, repurchases were to be made in respect of requests made during the periods when the SRP was active during the active periods under the SRP during the six months ending June 30, 2020 - the period from January 1, 2020 to January 8, 2020 and the period from February 26, 2020 up to and including June 30, 2020 - no later than July 31, 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2020, the Company repurchased 505,101 shares of common stock for approximately $8.8 million, at an average price per share of $17.50 pursuant to the SRP. The repurchases reflect all repurchase requests made in good order following the death or qualifying disability of stockholders during the period commencing July 1, 2019 up to and including December 31, 2019.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the SRP, repurchases were to be ma</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">de in respect of requests made during the periods when the SRP was active during the active periods under the SRP during the six months ending June 30, 2020 - the period from January 1, 2020 to January 8, 2020 and the period from February 26, 2020 up to and including June 30, 2020 - no later than July 31, 2020.</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2020, in order to strategically maintain the Company’s liquidity in light of the continued impact of COVID-19 pandemic and to comply with an amendment to the Credit Facility described in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facilities, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which restricts the Company from repurchasing shares until no earlier than the Commencement Quarter (which has not yet occurred), the Board determined that, effective on August 14, 2020, repurchases under the SRP would be suspended. The Board also rejected all repurchase requests made during the period from January 1, 2020 until the effectiveness of the suspension of the SRP. No further repurchase requests under the SRP may be made unless and until the SRP is reactivated. No assurances can be made as to when or if the SRP will be reactivated. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a stockholder requests redemption and redemption is approved by the Board, the Company will reclassify such obligation from equity to a liability based on the settlement value of the obligation. Shares repurchased under the SRP have the status of authorized but unissued shares.</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reflects the number of shares repurchased and the average price per share (retroactively adjusted for the Stock Dividends), under the SRP and does not include any repurchases under tender offers (see above), cumulatively through December 31, 2022:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares Repurchased</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative repurchases as of December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896,620 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative repurchases as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896,620 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Reinvestment Plan</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the DRIP, stockholders may elect to reinvest distributions paid in cash by the Company into shares of common stock. No dealer manager fees or selling commissions are paid with respect to shares purchased under the DRIP. The shares purchased pursuant to the DRIP have the same rights and are treated in the same manner as all of the other shares of outstanding common stock. The Board may designate that certain cash or other distributions be excluded from reinvestment pursuant to the DRIP. The Company has the right to amend the DRIP or terminate the DRIP with ten days’ notice to participants. Shares issued under the DRIP are recorded as equity in the accompanying consolidated balance sheet in the period distributions are declared. During the years ended December 31, 2022 and 2021, the Company did not issue any shares of common stock pursuant to the DRIP. During the year ended December 31, 2020, the Company issued 0.9 million shares of common stock pursuant to the DRIP, generating aggregate proceeds of $14.6 million. Because shares of common stock are only offered and sold pursuant to the DRIP in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as the Company pays distributions in stock instead of cash.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Rights Plan</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company announced that the Board had approved a stockholder rights plan. In December 2020, the Company issued a dividend of one common share purchase right for each share of its common stock outstanding as authorized by its board of directors in its discretion.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 50,000,000 shares of preferred stock. In connection with an underwritten offering in December 2019 (see details below), the Company classified and designated 1,610,000 shares of its authorized preferred stock as authorized shares of its Series A Preferred Stock as of December 31, 2022. In September 2020, the Board authorized the classification of 600,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the Preferred Stock Equity Line (as defined below) and in May 2021, the Board authorized the classification of 2,530,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the offering in May 2021 (described below). The Company had 3,977,144 shares of Series A Preferred Stock issued and outstanding, as of December 31, 2022 and 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with an underwritten offering in October 2021, the Company classified and designated 3,680,000 shares of its authorized preferred stock on October 4, 2021 as authorized shares of its 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (“Series B Preferred Stock”). As a result of an underwritten offering in October 2021, the Company had 3,630,000 shares of Series B Preferred Stock issued and outstanding as of December 31, 2022 and 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Preferred Stock — Terms</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are entitled to cumulative dividends in the amount of $1.84375 per share each year, which is equivalent to the rate of 7.375% of the $25.00 liquidation preference per share per annum. The Series A Preferred Stock has no stated maturity and will remain outstanding indefinitely unless redeemed, converted or otherwise repurchased. On and after December 11, 2024, at any time and from time to time, the Series A Preferred Stock will be redeemable in whole or in part, at the Company’s option, at a cash redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. In addition, upon the occurrence of a Delisting Event or a Change of Control (each as defined in the articles supplementary governing the terms of the Series A Preferred Stock (the “Series A Articles Supplementary”)), the Company may, subject to certain conditions, at its option, redeem the Series A Preferred Stock, in whole or in part, after the first date on which the Delisting Event occurred or within 120 days after the first date on which the Change of Control occurred, as applicable, by paying the liquidation preference of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. Upon the occurrence of a Change of Control during a continuing Delisting Event, unless the Company has elected to exercise its redemption right, holders of the Series A Preferred Stock will have certain rights to convert Series A Preferred Stock into shares of Company’s common stock. In addition, upon the occurrence of a Delisting Event, the dividend rate will be increased on the day after the occurrence of the Delisting Event by 2.00% per annum to the rate of 9.375% of the $25.00 liquidation preference per share per annum (equivalent to $2.34375 per share each year) from and after the date of the Delisting Event. Following the cure of such Delisting Event, the dividend rate will revert to the rate of 7.375% of the $25.00 liquidation preference per share per annum. The necessary conditions to convert the Series A Preferred Stock into common stock have not been met as of December 31, 2022. Therefore, Series A Preferred Stock did not impact Company’s earnings per share calculations for the year ended December 31, 2022, 2021 and 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock ranks senior to common stock, with respect to dividend rights and rights upon the Company’s voluntary or involuntary liquidation, dissolution or winding up.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Voting rights for holders of Series A Preferred Stock exist primarily with respect to the ability to elect two additional directors to the board of directors if six or more quarterly dividends (whether or not authorized or declared or consecutive) payable on the Series A Preferred Stock are in arrears, and with respect to voting on amendments to the Company’s charter (which includes the Series A Articles Supplementary) that materially and adversely affect the rights of the Series A Preferred Stock or create additional classes or series of shares of the Company’s capital stock that are senior to the Series A Preferred Stock. Other than the limited circumstances described above and in the Series A Articles Supplementary, holders of Series A Preferred Stock do not have any voting rights.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Preferred Stock Add-On Offering</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 11, 2021, the Company completed an underwritten public offering of 2,352,144 shares (which includes 152,144 shares issued and sold pursuant to the underwriters’ exercise of their option to purchase additional shares) of its Series A Preferred Stock for net proceeds of $56.0 million after deducting the underwriters’ discount, structuring fee and other offering costs aggregating to $2.9 million. Pursuant to the terms of the Credit Facility, all proceeds were used to repay amounts outstanding under the Credit Facility.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Preferred Units</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 100,000 partnership units in the OP designated as “Series A Preferred Units”. These were recorded at fair value on the date of the acquisition at $2.6 million and were included as part of the consideration paid for the acquisition. Additionally, these are considered a non-controlling interest for the Company and were recorded as an increase in non-controlling interests on the consolidated balance sheet (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Non-controlling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock Equity Line with B. Riley Principal Capital, LLC</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2020, the Company entered into a preferred stock purchase agreement and registration rights agreement with B. Riley Principal Capital, LLC (“B. Riley”), pursuant to which the Company has the right from time to time to sell up to an aggregate of $15 million of shares of its Series A Preferred Stock to B. Riley until December 31, 2023, on the terms and subject to the conditions set forth in the purchase agreement. This arrangement is also referred to as the “Preferred Stock Equity Line.” The Company controls the timing and amount of any sales to B. Riley under the Preferred Stock Equity Line, and B. Riley is obligated to make purchases of up to 3,500 shares of Series A Preferred Stock each time (as may be increased by mutual agreement by the parties) in accordance with the purchase agreement, upon certain terms and conditions being met. The Company sold 15,000 shares under the Preferred Stock Equity Line during the year ended December 31, 2021, resulting in gross proceeds of $0.4 million and net proceeds of $0.3 million after fees and commissions.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company incurred $1.2 million in costs related to establishing the Preferred Stock Equity Line which were all initially recorded in prepaid expenses and other assets on our consolidated balance sheet. Upon receiving proceeds under the Preferred Stock Equity Line in the third quarter of 2021, the Company reclassified $30,000 of these prepaid costs to additional paid in capital in the Company’s consolidated statement of changes in equity as a reduction of the gross proceeds received under the Preferred Stock Equity Line.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, the Company determined that it was not probable that additional proceeds would be received from the Preferred Stock Equity Line and later terminated the Preferred Stock Equity Line. As a result, the Company expensed the remaining balance of prepaid costs, which totaled $1.2 million, within acquisition and transaction related costs on the consolidated statement of operations and comprehensive income during the year ended December 31, 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not sell any Series A Preferred Stock under the Preferred Stock Equity Line during the year ended December 31, 2020 or through its termination in the year ended December 31, 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Series B Preferred Stock — Terms</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series B Preferred Stock are entitled to cumulative dividends in the amount of $1.78125 per share each year, which is equivalent to the rate of 7.125% of the $25.00 liquidation preference per share per annum. The Series B Preferred Stock has no stated maturity and will remain outstanding indefinitely unless redeemed, converted or otherwise repurchased. On and after October 6, 2026, at any time and from time to time, the Series B Preferred Stock will be redeemable in whole or in part, at the Company’s option, at a cash redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. In addition, upon the occurrence of a Delisting Event or a Change of Control (each as defined in the articles supplementary governing the terms of the Series B Preferred Stock (the “Series B Articles Supplementary”)), the Company may, subject to certain conditions, at its option, redeem the Series B Preferred Stock, in whole or in part, after the first date on which the Delisting Event occurred or within 120 days after the first date on which the Change of Control occurred, as applicable, by paying the liquidation preference of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. Upon the occurrence of a Change of Control during a continuing Delisting Event, unless the Company has elected to exercise its redemption right, holders of the Series B Preferred Stock will have certain rights to convert Series B Preferred Stock into shares of Company’s common stock. In addition, upon the occurrence of a Delisting Event, the dividend rate will be increased on the day after the occurrence of the Delisting Event by 2.00% per annum to the rate of 9.125% of the $25.00 liquidation preference per share per annum (equivalent to $2.28125 per share each year) from and after </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the date of the Delisting Event. Following the cure of such Delisting Event, the dividend rate will revert to the rate of 7.125% of the $25.00 liquidation preference per share per annum. The necessary conditions to convert the Series B Preferred Stock into common stock have not been met as of December 31, 2022. Therefore, Series B Preferred Stock did not impact Company’s earnings per share calculations for the year ended December 31, 2022 and 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series B Preferred Stock ranks on parity with the Company’s Series A Preferred Stock, and senior to its common stock, with respect to dividend rights and rights upon the Company’s voluntary or involuntary liquidation, dissolution or winding up.</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Voting rights for holders of Series B Preferred Stock exist primarily with respect to the ability to elect two additional directors to the board of directors if six or more quarterly dividends (whether or not authorized or declared or consecutive) payable on the Series B Preferred Stock are in arrears, and with respect to voting on amendments to the Company’s charter (which includes the Series B Articles Supplementary) that materially and adversely affect the rights of the Series B Preferred Stock or create additional classes or series of shares of the Company’s capital stock that are senior to the Series B Preferred Stock. Other than the limited circumstances described above and in the Series B Articles Supplementary, holders of Series B Preferred Stock do not have any voting rights.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Underwritten Offering — Series B Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2021, the Company completed the initial issuance and sale of 3,630,000 shares (which includes 430,000 shares issued and sold pursuant to the underwriters’ exercise of their option to purchase additional shares) of its 7.125% Series B Preferred Stock in an underwritten public offering at a public offering price equal to the liquidation preference of $25.00 per share. The offering generated gross proceeds of $90.8 million and net proceeds of $86.8 million, after deducting underwriting discounts, structuring fees and other costs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Credit Facility, all proceeds were used to repay amounts outstanding under the Credit Facility. Subject to the terms and conditions set forth in the Credit Facility, the Company may then draw on the Credit Facility to borrow any amounts so repaid.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributions and Dividends</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2013, the Board authorized, and the Company began paying distributions on a monthly basis at a rate equivalent to $1.70 per annum, per share of common stock, which began in May 2013. In March 2017, the Board authorized a decrease in the rate at which the Company pays monthly distributions to stockholders, effective as of April 1, 2017, to a rate equivalent to $1.45 per annum per share of common stock. On February 20, 2018, the Board authorized a further decrease in the rate at which the Company pays monthly distributions to stockholders, effective as of March 1, 2018, to a rate equivalent to $0.85 per annum per share of common stock. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From March 1, 2018 until June 30, 2020, the Company paid monthly distributions to stockholders at a rate equivalent to $0.85 per annum per share of common stock. Distributions were payable by the 5th day following each month end to stockholders of record at the close of business each day during the prior month.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2020, the Board changed the Company’s common stock distribution policy in order to preserve the Company’s liquidity and maintain additional financial flexibility in light of the continued COVID-19 pandemic and to comply with an amendment to the Credit Facility (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facility, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information) which restricts the Company from paying distributions on common stock until no earlier than the quarter ending June 30, 2021. Under the new policy, distributions authorized by the Board on the Company’s shares of common stock, if and when declared, are now paid on a quarterly basis in arrears in shares of the Company’s common stock valued at the Company’s estimated per share net asset value of common stock in effect on the applicable date, based on a single record date to be specified at the beginning of each quarter. The following table details these stock dividends:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Dividend Declaration Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Dividend Issue Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarterly Stock Dividend Rate (per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 15, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.013492</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 15, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.013492</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 15, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 18, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 17, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 18, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Characteristics of Dividends</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details from a tax perspective the portion of distributions classified as a return of capital, capital gain dividend income and ordinary dividend income, per share per annum, for the year ended December 31, 2020. All common dividends in the years ended December 31, 2022 and 2021, and a portion of common dividends issued in the year ended December 31, 2020, were issued as stock dividends, which do not represent taxable dividends to shareholders for U.S. federal income tax purposes. The cash distributions paid to holders of common stock in the first half of the year ended December 31, 2020 were considered 100% return of capital. All dividends paid on the Series A Preferred Stock and Series B Preferred Stock were considered 100% return of capital for tax purposes for the years ended December 31, 2022, 2021 and 2020.</span></div> 105080531 99281754 12600000 0 0 200000 8.50 200000 1700000 1 505101 8800000 17.50 505101 8800000 17.50 <div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reflects the number of shares repurchased and the average price per share (retroactively adjusted for the Stock Dividends), under the SRP and does not include any repurchases under tender offers (see above), cumulatively through December 31, 2022:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares Repurchased</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative repurchases as of December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896,620 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative repurchases as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896,620 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4896620 20.60 0 0 4896620 20.60 P10D 0 0 900000 14600000 1 50000000 1610000 600000 2530000 3977144 3977144 3680000 0.07125 0.01 3630000 3630000 1.84375 0.07375 25.00 25.00 25.00 0.0200 0.09375 25.00 2.34375 0.07375 25.00 2352144 152144 56000000 2900000 100000 2600000 15000000 3500 15000 400000 300000 1200000 30000 1200000 1.78125 0.07125 25.00 25.00 25.00 0.0200 0.09125 25.00 2.28125 0.07125 25.00 2 6 3630000 430000 0.07125 25.00 90800000 86800000 1.70 1.45 0.85 0.85 The following table details these stock dividends:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Dividend Declaration Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Dividend Issue Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarterly Stock Dividend Rate (per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 15, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.013492</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 15, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.013492</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 15, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 18, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 17, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 18, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr></table> 0.013492 0.013492 0.014655 0.014655 0.014655 0.014655 0.014167 0.014167 0.014167 0.014167 Related Party Transactions and Arrangements <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Special Limited Partner owned 10,094 and 9,537 shares, respectively, of the Company’s outstanding common stock. The Advisor and its affiliates may incur and pay costs and fees on behalf of the Company. As of December 31, 2022 and 2021, the Advisor held 90 partnership units in the OP designated as “Common OP Units.”</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The limited partnership agreement of the OP (as amended from time to time, the “LPA”) allows for the special allocation, solely for tax purposes, of excess depreciation deductions of up to $10.0 million to the Advisor, a limited partner of the OP. In connection with this special allocation, the Advisor has agreed to restore a deficit balance in its capital account in the event of a liquidation of the OP and has agreed to provide a guaranty or indemnity of indebtedness of the OP.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fees Incurred in Connection with the Operations of the Company</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second Amended and Restated Advisory Agreement by and among the Company, the OP and the Advisor (as amended, the “Second A&amp;R Advisory Agreement”) took effect on February 17, 2017, and is automatically renewable for another ten-year term upon each ten-year anniversary unless the Second A&amp;R Advisory Agreement is terminated (i) with notice of an election not to renew at least 365 days prior to the applicable tenth anniversary, (ii) in accordance with a change of control (as defined in the Second A&amp;R Advisory Agreement) or a transition to self-management, (iii) by 67% of the independent directors of the Board for cause, without penalty, with 45 days’ notice or (iv) with 60 days prior written notice by the Advisor for (a) a failure to obtain a satisfactory agreement for any successor to the Company to assume and agree to perform obligations under the Second A&amp;R Advisory Agreement or (b) any material breach of the Second A&amp;R Advisory Agreement of any nature whatsoever by the Company.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2019, the Company entered into Amendment No. 1 to the Second A&amp;R Advisory Agreement (the “Advisory Agreement Amendment”) among the Company, the OP, and the Advisor. The Advisory Agreement Amendment was unanimously approved by the Company’s independent directors. Additional information on the Advisory Agreement Amendment is included later in this footnote under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“Professional Fees and Other Reimbursements.”</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition Expense Reimbursements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advisor may be reimbursed for services provided for which it incurs investment-related expenses, or insourced expenses. The amount reimbursed for insourced expenses may not exceed 0.5% of the contract purchase price of each acquired property or 0.5% of the amount advanced for a loan or other investment. Additionally, the Company reimburses the Advisor for </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third party acquisition expenses. Under the Second A&amp;R Advisory Agreement, total acquisition expenses may not exceed 4.5% of the contract purchase price of the Company’s portfolio or 4.5% of the amount advanced for all loans or other investments. This threshold has not been exceeded through December 31, 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Asset Management Fees and Variable Management/Incentive Fees</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LPA and the advisory agreement that was superseded by the 0riginal amended and restated advisory agreement and until March 31, 2015, for its asset management services, the Company issued the Advisor an asset management subordinated participation by causing the OP to issue (subject to periodic approval by the Board) to the Advisor partnership units of the OP designated as “Class B Units” (“Class B Units”). The Class B Units were intended to be profit interests and vest, and no longer are subject to forfeiture, at such time as: (x) the value of the OP’s assets plus all distributions made equals or exceeds the total amount of capital contributed by investors plus a 6.0% cumulative, pre-tax, non-compounded annual return thereon (the “Economic Hurdle”); (y) any one of the following occurs: (1) a listing; (2) another liquidity event or (3) the termination of the advisory agreement by an affirmative vote of a majority of the Company’s independent directors without cause; and (z) the Advisor is still providing advisory services to the Company (the “Performance Condition”).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unvested Class B Units will be forfeited immediately if: (a) the advisory agreement is terminated for any reason other than a termination without cause; or (b) the advisory agreement is terminated by an affirmative vote of a majority of the Company’s independent directors without cause before the Economic Hurdle has been met.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to approval by the Board, the Class B Units were issued to the Advisor quarterly in arrears pursuant to the terms of the LPA. The number of Class B Units issued in any quarter was equal to: (i) the excess of (A) the product of (y) the cost of assets multiplied by (z) 0.1875% over (B) any amounts payable as an oversight fee (as described below) for such calendar quarter; divided by (ii) the value of one share of common stock as of the last day of such calendar quarter, which was initially equal to $22.50 (the price in the Company’s initial public offering of common stock minus the selling commissions and dealer manager fees). The value of issued Class B Units will be determined and expensed when the Company deems the achievement of the Performance Condition to be probable. As of December 31, 2022, the Company determined that achieving the Performance Condition was not yet considered probable for accounting purposes. The Advisor receives cash distributions on each issued Class B Unit equivalent to the cash distribution paid, if any on the Company’s common stock. These cash distributions on Class B Units are included in general and administrative expenses in the consolidated statement of operations and comprehensive loss until the Performance Condition is considered probable to occur. Stock Dividends do not cause the OP to issue additional Class OP Units, rather, the redemption ratio to common stock is adjusted. The Board has previously approved the issuance of 359,250 Class B Units to the Advisor in connection with this arrangement. The Board determined in February 2018 that Economic Hurdle had been satisfied, however none of the events have occurred, including a listing of the Company’s common stock on a national securities exchange, which would have satisfied the other vesting requirement of the Class B Units. Therefore, no expense has ever been recognized in connection with the Class B Units. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2015, the Company, the OP and the Advisor entered into an amendment to the then-current advisory agreement, which, among other things, provided that the Company would cease causing the OP to issue Class B Units to the Advisor with respect to any period ending after March 31, 2015.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 17, 2017, the Second A&amp;R Advisory Agreement requires the Company to pay the Advisor a base management fee, which is payable on the first business day of each month. The fixed portion of the base management fee is equal to $1.625 million per month, while the variable portion of the base management fee is equal to one-twelfth of 1.25% of the cumulative net proceeds of any equity (including convertible equity and certain convertible debt but excluding proceeds from the DRIP) issued by the Company and its subsidiaries subsequent to February 17, 2017 per month. There are no variable management fees earned from the issuance of common stock dividends. The base management fee is payable to the Advisor or its assignees in cash, Common OP Units or shares, or a combination thereof, the form of payment to be determined at the discretion of the Advisor and the value of any Common OP Unit or share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Second A&amp;R Advisory Agreement requires the Company to pay the Advisor a variable management/incentive fee quarterly in arrears equal to (1) the product of fully diluted shares common stock outstanding multiplied by (2) (x) 15.0% of the applicable prior quarter’s Core Earnings (as defined below) per share in excess of $0.375 per share plus (y) 10.0% of the applicable prior quarter’s Core Earnings per share in excess of $0.47 per share. Core Earnings is defined as, for the applicable period, net income or loss, computed in accordance with GAAP, excluding non-cash equity compensation expense, the variable management/incentive fee, acquisition and transaction related fees and expenses, financing related fees and expenses, depreciation and amortization, realized gains and losses on the sale of assets, any unrealized gains or losses or other non-cash items recorded in net income or loss for the applicable period, regardless of whether such items are included in </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other comprehensive income or loss, or in net income, one-time events pursuant to changes in GAAP and certain non-cash charges, impairment losses on real estate related investments and other than temporary impairments of securities, amortization of deferred financing costs, amortization of tenant inducements, amortization of straight-line rent and any associated bad debt reserves, amortization of market lease intangibles, provision for loss loans, and other non-recurring revenue and expenses (in each case after discussions between the Advisor and the independent directors and approved by a majority of the independent directors). The variable management/incentive fee is payable to the Advisor or its assignees in cash or shares, or a combination of both, the form of payment to be determined in the sole discretion of the Advisor and the value of any share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate. No variable management incentive fee was incurred for the years ended December 31, 2022, 2021 and 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property Management Fees</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the Company contracts with a third party, the Company pays the Property Manager a property management fee on a monthly basis, equal to 1.5% of gross revenues from the Company’s stand-alone single-tenant net leased properties managed and 2.5% of gross revenues from all other types of properties managed, plus market-based leasing commissions applicable to the geographic location of the property. The Company also reimburses the Property Manager for property level expenses incurred by the Property Manager. The Property Manager may charge a separate fee for the one-time initial rent-up or leasing-up of newly constructed properties in an amount not to exceed the fee customarily charged in arm’s length transactions by others rendering similar services in the same geographic area for similar properties, and the Property Manager is allowed to receive a higher property management fee in certain cases if approved by the Company’s Board of Directors (including a majority of the independent directors).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company contracts directly with third parties for such services, the Company will pay the third party customary market fees and will pay the Property Manager an oversight fee of 1.0% of the gross revenues of the property managed by the third party. In no event will the Company pay the Property Manager or any affiliate of the Property Manager both a property management fee and an oversight fee with respect to any particular property. If the Property Manager provides services other than those specified in the Property Management Agreement, the Company will pay the Property Manager a monthly fee equal to no more than that which the Company would pay to a third party that is not an affiliate of the Company or the Property Manager to provide the services.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2017, the Company entered into the Amended and Restated Property Management and Leasing Agreement (the “A&amp;R Property Management Agreement”) with the OP and the Property Manager. The A&amp;R Property Management Agreement automatically renews for successive one-year terms unless any party provides written notice of its intention to terminate the A&amp;R Property Management Agreement at least 90 days prior to the end of the term. Neither party has provided notice of intent to terminate. The current term of the A&amp;R Property Management Agreement expires February 17, 2023. The Property Manager may assign the A&amp;R Property Management Agreement to any party with expertise in commercial real estate which has, together with its affiliates, over $100.0 million in assets under management. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2018, in connection with the Multi-Property CMBS Loan, the Company and the OP entered into a further amendment to the A&amp;R Property Management Agreement confirming, consistent with the intent of the parties, that the borrowers under the Multi-Property CMBS Loan and other subsidiaries of the OP that own or lease the Company’s properties are the direct obligors under the arrangements pursuant to which the Company’s properties are managed by either the Property Manager or a third party overseen by the Property Manager pursuant to the A&amp;R Property Management Agreement. See the Mortgage Notes Payable table included in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_181" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Mortgage Notes Payable, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on the Multi- Property CMBS Loan.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Professional Fees and Other Reimbursements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reimburses the Advisor’s costs of providing administrative services including personnel costs, except for costs to the extent that the employees perform services for which the Advisor receives a separate fee. This reimbursement includes reasonable overhead expenses for employees of the Advisor or its affiliates directly involved in the performance of services on behalf of the Company, including the reimbursement of rent expense at certain properties that are both occupied by employees of the Advisor or its affiliates and owned by affiliates of the Advisor. During the year ended December 31, 2022, 2021 and 2020, the Company incurred $8.8 million, $9.4 million and $12.1 million, respectively, of reimbursement expenses from the Advisor for providing administrative services. These reimbursement expenses are included in general and administrative expense on the consolidated statements of operations and comprehensive income (loss). In September 2022, the Advisor terminated certain of its employees who provided services to the Company and for which the Company reimbursed the </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advisor for salaries and benefits. In connection with the termination, the Company recognized a compensation charge, net of adjustments for previously accrued bonuses, of $0.3 million in the third quarter of 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2019, the Company entered into the Advisory Agreement Amendment. Under the Advisory Agreement Amendment, including prior to the Advisory Agreement Amendment, the Company has been required to reimburse the Advisor for, among other things, reasonable salaries and wages, benefits and overhead of all employees of the Advisor or its affiliates, except for costs of employees to the extent that the employees perform services for which the Advisor receives a separate fee.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advisory Agreement Amendment clarifies that, with respect to executive officers of the Advisor, the Company is required to reimburse the Advisor or its affiliates for the reasonable salaries and wages, benefits and overhead of the Company’s executive officers, other than for any executive officer that is also a partner, member or equity owner of AR Global, an affiliate of the Advisor.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under the Advisory Agreement Amendment, the aggregate amount of expenses relating to salaries, wages and benefits, including for executive officers and all other employees of the Advisor or its affiliates (the “Capped Reimbursement Amount”), is limited to the greater of: (a) a fixed component (the “Fixed Component”) and (b) a variable component (the “Variable Component”). </span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the Fixed Component and the Variable Component increase by an annual cost of living adjustment equal to the greater of (x) 3.0% and (y) the CPI, as defined in the Advisory Agreement Amendment for the prior year ended December 31st. Initially, for the year ended December 31, 2020; (a) the Fixed Component was equal to $6.8 million and (b) the Variable Component was equal to (i) the sum of the total real estate investments, at cost as recorded on the balance sheet dated as of the last day of each fiscal quarter (the “Real Estate Cost”) in the year divided by four, which amount is then (ii) multiplied by 0.29%. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company sells real estate investments aggregating an amount equal to or more than 25.0% of Real Estate Cost, in one or a series of related dispositions in which the proceeds of the disposition(s) are not reinvested in Investments (as defined in the Advisory Agreement Amendment), then within 12 months following the disposition(s), the Advisory Agreement Amendment requires the Advisor and the Company to negotiate in good faith to reset the Fixed Component; provided that if the proceeds of the disposition(s) are paid to shareholders of the Company as a special distribution or used to repay loans with no intent of subsequently re-financing and re-investing the proceeds thereof in Investments, the Advisory Agreement amendment requires these negotiations within 90 days thereof, in each case taking into account reasonable projections of reimbursable costs in light of the Company’s reduced assets.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid approximately $2.5 million in 2019 to the Advisor or its affiliates as reimbursement for bonuses of employees of the Advisor or its affiliates who provided administrative services during the calendar year 2019, prorated for the time spent working on matters relating to the Company. The Company does not reimburse the Advisor or its affiliates for any bonus amounts relating to time dedicated to the Company by Edward M. Weil, Jr., the Company’s Chief Executive Officer. The Advisor formally awarded 2019 bonuses to employees of the Advisor or its affiliates in September 2020 (the “2019 Bonus Awards”). The original estimate for bonuses recorded and paid to the Advisor in 2019 exceeded the cash portion of the 2019 Bonus Awards to be paid to employees of the Advisor or its affiliates and to be reimbursed by the Company by $1.2 million. As a result, during the three months ended September 30, 2020, the Company recorded a receivable from the Advisor of $1.2 million in prepaid expenses and other assets on the consolidated balance sheet and a corresponding reduction in general and administrative expenses. Pursuant to authorization by the independent members of the Company’s board of directors, the $1.2 million receivable was being paid back to the Company over a 10-month period from January 2021 through October 2021. As of December 31, 2021, all of this amount had been repaid by the Advisor.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, the Advisor finalized the amounts and form of the 2020 bonuses previously estimated (the “2020 Bonus Awards”) to be paid to the employees of the Advisor or its affiliates who provided administrative services during such calendar year, prorated for the time spent working on matters relating to the Company. The 2020 Bonus Awards are being paid by the Advisor over a ten-month period from June 2021 to April 2022. The final amounts exceeded the amounts previously paid by the Company to the Advisor for estimated 2020 bonuses by approximately $1.0 million for the following reasons (i) forfeitures of bonuses related to employees of the Advisor or its affiliates who were terminated or resigned prior to payment (including the Company’s former chief financial officer) and (ii) a general reduction in final bonuses for remaining personnel due to on-going negative impacts of the COVID-19 pandemic. As a result, during the second quarter of 2021, the Company recorded a receivable from the Advisor of $1.0 million, which is recorded in prepaid expenses and other assets on the consolidated balance sheet and a corresponding reduction in general administrative expenses. Pursuant to authorization by the independent members of the Company’s board of directors, the $1.0 million receivable is required to be repaid to the Company </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a pro rata basis over a six-month period from November 2021 through April 2022. As of December 31, 2022, the entire amount has been repaid by the Advisor.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursements for the cash portion of 2021 bonuses paid by the Advisor to employees of the Advisor or its affiliates were expensed and reimbursed on a monthly basis during 2021, and 2022 bonuses were expensed and reimbursed on a monthly basis during 2022 in accordance with estimates provided by the Advisor. Generally, prior to the 2019 Bonus Awards, employee bonuses have been formally awarded to employees of the Advisor or its affiliates in March as an all - cash award and paid out by the Advisor in the year subsequent to the year in which services were rendered to the Company.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, after mediation on October 27, 2020, the Advisor agreed to a settlement with the Company’s former chief executive officer for severance claims related to his termination in 2018. Pursuant to the settlement, among other parties, the Advisor advised the Company that the Company and its directors and officers were released from any and all actions or claims the former chief executive officer now has or may ever have against them. Prior to the agreement, the Advisor did not believe any settlement was probable. In consideration of the release, among other things, and upon the recommendation of its nominating and corporate governance committee, which determined that the reimbursement was advisable and fair to, and in the best interest of, the Company, the Company’s board of directors approved the reimbursement by the Company to the Advisor of severance payments and legal costs relating to this settlement and determined that the reimbursement for those payments and costs would not be subject to (and therefore would not be aggregated with other reimbursements that are subject to) the Capped Reimbursement Amount. The Company recorded approximately $2.2 million of expenses for the reimbursement which is included in general and administrative expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of fees, expenses and related payables</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details amounts incurred and payable in connection with the Company’s operations-related services described above as of and for the periods presented:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.584%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payable (Receivable) as of</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">One-time fees and reimbursements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition cost reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ongoing fees and reimbursements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset management fees </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property management fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees and other reimbursements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1) (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees credit due from Advisor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions on Class B Units </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related party operation fees and reimbursements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,874 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,905 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,328 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(882)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Included in general and administrative expenses in the consolidated statements of operations. Includes $6.0 million, $6.2 million and $5.6 million subject to the Capped Reimbursement Amount for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Balance as of December 31, 2021 includes a receivable of $0.9 million from the Advisor related to the overpayment of 2020 Bonus Awards, which, pursuant to authorization by the independent members of the Company’s board of directors, was required to be repaid to the Company on a pro rata basis over a six-month period from November 2021 through April 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">During the year ended December 31, 2020 the Company recorded approximately $2.2 million of expense reimbursements to the Advisor for severance payments and related legal costs relating to the termination of its former Chief Executive Officer.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Inclusive of $0.7 million and $0.3 million of leasing commissions which are included in prepaid expenses and other assets on the consolidated balance sheet as of December 31, 2022 and 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company’s Real Estate Assets</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fees Incurred in Connection with a Listing</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the common stock of the Company is listed on a national exchange, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive a subordinated incentive listing distribution from the OP equal to 15.0% of the amount by which the market value of all issued and outstanding shares of common stock plus distributions </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exceeds the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax non-compounded annual return to investors in the Company’s initial public offering of common stock. No such distribution was incurred during the years ended December 31, 2022, 2021 and 2020. If the Special Limited Partner or any of its affiliates receives the subordinated incentive listing distribution the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive termination distribution described below.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Subordinated Participation in Net Sales Proceeds </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a liquidation or sale of all or substantially all of the Company’s assets, including through a merger or sale of stock, the Special Limited Partner will be entitled to receive a subordinated participation in the net sales proceeds of the sale of real estate assets from the OP equal to 15.0% of remaining net sale proceeds after return of capital contributions to investors in the Company’s initial public offering of common stock plus payment to investors of a 6.0% cumulative, pre-tax non-compounded annual return on the capital contributed by investors. No such participation in net sales proceeds became due and payable during the years ended December 31, 2022, 2021 and 2020. Any amount of net sales proceeds paid to the Special Limited Partner or any of its affiliates prior to the Company’s listing or termination or non-renewal of the advisory agreement with the Advisor, as applicable, will reduce dollar for dollar the amount of the subordinated incentive listing distribution described above and subordinated incentive termination distribution described below.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Fees</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the operating partnership agreement of the OP, upon termination or non-renewal of the advisory agreement with the Advisor, wi</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">th or without cause, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive subordinated termination dist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ributions from the OP equal to 15.0% of the amount by which the sum of the Company’s market value plus distributions exceeds the sum of the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax, non-compounded annual return to investors in the Company’s initial public offering of common stock. The Special Limited Partner is able to elect to defer its right to receive a subordinated distribution upon termination until either a listing on a national securities exchange or other liquidity event occurs. If the Special Limited Partner or any of its affiliates receives the subordinated incentive termination distribution, the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive listing distribution described above.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advisory Agreement Amendment, upon the termination or non-renewal of the agreement, the Advisor is entitled to receive from the Company all amounts due to the Advisor, including any change of control fee and transition fee (both described below), as well as the then-present fair market value of the Advisor’s interest in the Company. All fees will be due within 30 days after the effective date of the termination of the Advisory Agreement Amendment.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a termination by either party in connection with a change of control (as defined in the Advisory Agreement Amendment), the Company would be required to pay the Advisor a change of control fee equal to the product of four and the “Subject Fees” described below.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a termination by the Company in connection with a transition to self-management, the Company would be required to pay the Advisor a transition fee equal to (i) $15.0 million plus (ii) the product of four multiplied by the Subject Fees, provided that the transition fee shall not exceed an amount equal to 4.5 multiplied by the Subject Fees. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Subject Fees are equal to (i) the product of four multiplied by the actual base management fee plus (ii) the product of four multiplied by the actual variable management/incentive fee, in each of clauses (i) and (ii), payable for the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated, plus (iii) without duplication, the annual increase in the base management fee resulting from the cumulative net proceeds of any equity raised (but excluding proceeds from the DRIP) in respect to the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated.</span></div> 10094 9537 90 90 10000000 P10Y P10Y P365D 0.67 P45D P60D 0.005 0.005 0.045 0.045 0.060 0.001875 22.50 359250 1625000 0.0125 0.150 0.375 0.100 0.47 0.015 0.025 0.010 P1Y P90D 100000000 8800000 9400000 12100000 300000 0.030 6800000 4 0.0029 0.250 P12M P90D 2500000 1200000 1200000 1200000 P10M P10M 1000000 1000000 1000000 P6M 2200000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details amounts incurred and payable in connection with the Company’s operations-related services described above as of and for the periods presented:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.584%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payable (Receivable) as of</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">One-time fees and reimbursements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition cost reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ongoing fees and reimbursements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset management fees </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property management fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees and other reimbursements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1) (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees credit due from Advisor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions on Class B Units </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related party operation fees and reimbursements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,874 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,905 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,328 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(882)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Included in general and administrative expenses in the consolidated statements of operations. Includes $6.0 million, $6.2 million and $5.6 million subject to the Capped Reimbursement Amount for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Balance as of December 31, 2021 includes a receivable of $0.9 million from the Advisor related to the overpayment of 2020 Bonus Awards, which, pursuant to authorization by the independent members of the Company’s board of directors, was required to be repaid to the Company on a pro rata basis over a six-month period from November 2021 through April 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">During the year ended December 31, 2020 the Company recorded approximately $2.2 million of expense reimbursements to the Advisor for severance payments and related legal costs relating to the termination of its former Chief Executive Officer.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Inclusive of $0.7 million and $0.3 million of leasing commissions which are included in prepaid expenses and other assets on the consolidated balance sheet as of December 31, 2022 and 2021.</span></div> 23000 90000 81000 5000 23000 21831000 20710000 19987000 0 0 4200000 3749000 4197000 3000 24000 8820000 9386000 12102000 39000 -70000 0 1030000 1217000 0 -859000 0 0 178000 0 0 34874000 32905000 35328000 47000 -882000 6000000 6200000 5600000 900000 2200000 700000 300000 0.150 0.060 0.150 0.060 0.150 0.060 P30D 4 15000000 4 4.5 4 4 Economic Dependency<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under various agreements, the Company has engaged or will engage the Advisor, its affiliates and entities under common control with the Advisor to provide certain services that are essential to the Company, including asset management services, supervision of the management and leasing of properties owned by the Company and asset acquisition and disposition decisions, as well as other administrative responsibilities for the Company including accounting services and investor relations.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these relationships, the Company is dependent upon the Advisor and its affiliates. In the event that the Advisor and its affiliates are unable to provide the Company with the respective services, the Company will be required to find alternative providers of these services.</span></div> Equity-Based Compensation <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Share Plan</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted an employee and director incentive restricted share plan (as amended from time to time, the “RSP”), which provides the Company with the ability to grant awards of restricted shares of common stock (“restricted shares”) to the Company’s directors, officers and employees (if the Company ever has employees), employees of the Advisor and its affiliates, employees of entities that provide services to the Company, directors of the Advisor or of entities that provide services to the Company, certain consultants to the Company and the Advisor and its affiliates or to entities that provide services to the Company. The total number of shares of common stock that may be subject to awards granted under the RSP may not exceed 5.0% of the Company’s outstanding shares of common stock on a fully diluted basis at any time and in any event will not exceed 3.6 million shares (as such number may be further adjusted for stock splits, stock dividends, combinations and similar events).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Restricted shares vest on a straight-line basis over periods of <span style="-sec-ix-hidden:f-1430">three</span> to five years and may not, in general, be sold or otherwise transferred until restrictions are removed and the shares have vested. Holders of restricted shares may receive cash distributions prior to the time that the restrictions on the restricted shares have lapsed. Any distributions payable in shares of common stock are subject to the same restrictions as the underlying restricted shares.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the amount of restricted shares outstanding as of December 31, 2022 and activity for the period presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Common Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Issue Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock dividend</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,384 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Dividend</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock dividend</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,313 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,343 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had $1.5 million of unrecognized compensation cost related to unvested restricted share awards granted under the RSP. That cost is expected to be recognized over a weighted-average period of 1.6 years. Compensation expense related to restricted shares was $1.2 million, $1.3 million and $1.3 million during the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Share-Based Compensation</span></div>The Company may issue common stock in lieu of cash to pay fees earned by the Company’s directors at the respective director’s election. There are no restrictions on shares issued in lieu of cash compensation since these payments in lieu of cash relate to fees earned for services performed. No such shares were issued during the years ended December 31, 2022, 2021 and 2020. 0.050 3600000 P5Y <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the amount of restricted shares outstanding as of December 31, 2022 and activity for the period presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Common Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Issue Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock dividend</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,384 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Dividend</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock dividend</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,313 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,343 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 277241 21.18 2878 15.75 0 0 64735 21.18 0 0 215384 21.11 12646 14.79 0 68603 19.72 0 0 159427 21.21 8313 14.86 0 0 70397 23.67 0 0 97343 18.89 1500000 P1Y7M6D 1200000 1300000 1300000 0 0 0 Accumulated Other Comprehensive Income (Loss) <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the changes in accumulated other comprehensive income (loss) as of and for the periods presented: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.463%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Designated Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,043)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,614)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income (loss) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebalancing of ownership percentage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,673)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,322 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,341)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36,910</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss) predominately relates to the unrealized gains (losses) on designated derivatives, however, as previously discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a previously designated hedge was terminated and the termination costs are being amortized over the term of the hedged item. The unamortized portion of the terminated swap still remaining in accumulated other comprehensive (loss) income was $0.4 million as of December 31, 2021. The terminated swap was fully amortized within the year ending December 31, 2022.</span></div> <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the changes in accumulated other comprehensive income (loss) as of and for the periods presented: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.463%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Designated Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,043)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,614)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income (loss) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebalancing of ownership percentage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,673)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,322 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,341)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36,910</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -7043000 -40614000 -7999000 -15000 -39673000 14322000 -11010000 -14341000 50098000 -1153000 36910000 -400000 Non-Controlling Interests <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interests on the Company’s consolidated balance sheet is comprised of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred Units held by third parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common OP Units held by third parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Non-controlling Interests in the OP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests in property owning subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Non-controlling Interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,551 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,704 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling Interests in the Operating Partnership</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For preferred and common shares issued by the Company, the Company typically issues mirror securities with substantially equivalent economic rights between the Company and the OP. The securities held by the Company are eliminated in consolidation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Series A Preferred OP Units</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the sole general partner and holds substantially all of the Series A Preferred Units.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company partially funded the purchase of a MOB from an unaffiliated third party by causing the OP to issue 100,000 Series A Preferred Units, with a face value of $25.00 per unit, which were recorded at issuance at a then fair value of $2.6 million, or $25.78 per unit, to the unaffiliated third party.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder of Series A Preferred Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s Series A Preferred Stock. After holding the Series A Preferred Units for a period of one year, a holder of Series A Preferred Units has the right to redeem Series A Preferred Units for, at the option of the OP, the corresponding number of shares of the Company’s Series A Preferred Stock, or the cash equivalent. The remaining rights of the limited partners in the </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During the year ended December 31, 2022 and 2021, Series A Preferred Unit holders were paid distributions of $0.2 million and $46,000, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Common OP Units</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the sole general partner and holds substantially all of the Common OP Units. As of December 31, 2022 and 2021, the Advisor held 90 Common OP Units, which represents a nominal percentage of the aggregate ownership in the OP. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 405,908 Common OP Units, with an initial value of $10.1 million, or $25.00 per unit, to the unaffiliated third party.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder of Common OP Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s common stock in an amount retroactively adjusted to reflect the Stock Dividends, other stock dividends and other similar events. After holding the Common OP Units for a period of one year, a holder of Common OP Units has the right to redeem Common OP Units for, at the option of the OP, the corresponding number of shares of the Company’s common stock, as retroactively adjusted for the Stock Dividends, other stock dividends and other similar events, or the cash equivalent. The remaining rights of the limited partners in the OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During the years ended December 31, 2022 and 2021, Common OP Unit non-controlling interest holders were not paid any cash distributions. During the year ended December 31, 2020, Common OP Unit non-controlling interest holders were paid distributions of $0.2 million.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock Dividends do not cause the OP to issue additional Common OP Units, rather, the redemption ratio to common stock is adjusted. The 405,908 Common OP Units outstanding as of December 31, 2022 would be redeemable for 467,498 shares of common stock, giving effect to adjustments for the impact of the Stock Dividends through January 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling Interests in Property Owning Subsidiaries</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Upon disposition of a property subject to non-controlling interest, the investor will receive a proportionate share of the net proceeds from the sale of the property. The investor has no recourse to any other assets of the Company. Due to the nature of the Company’s involvement with these arrangements and the significance of its investment in relation to the investment of the third party, the Company has determined that it controls each entity in these arrangements and therefore the entities related to these arrangements are consolidated within the Company’s financial statements. A non-controlling interest is recorded for the investor’s ownership interest in the properties.</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2020, the Company purchased all of the outstanding the membership interests in the joint venture that owns the UnityPoint Clinics in Muscatine, Iowa and Moline, Illinois for approximately $0.6 million, funded with cash on hand. Following this transaction, the properties were wholly owned by the Company and added to the borrowing base under the Credit Facility.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to investment arrangements with unaffiliated third parties. </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Third Party Net Investment Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Ownership Percentage</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Real Estate Assets Subject to Investment Arrangement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Distributions </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollar amounts in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investment Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plaza Del Rio Medical Office Campus Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 10pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_____________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">One property within the Plaza Del Rio Medical Office Campus Portfolio was mortgaged as part of the Multi-Property CMBS Loan. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_181" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Mortgage Notes Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional information.</span></div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interests on the Company’s consolidated balance sheet is comprised of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred Units held by third parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common OP Units held by third parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Non-controlling Interests in the OP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests in property owning subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Non-controlling Interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,551 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,704 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2578000 2578000 3584000 3758000 6162000 6336000 389000 368000 6551000 6704000 100000 25.00 2600000 25.78 P1Y 200000 46000 90 90 405908 10100000 25.00 P1Y 0 0 200000 405908 467498 600000 <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to investment arrangements with unaffiliated third parties. </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Third Party Net Investment Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Ownership Percentage</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Real Estate Assets Subject to Investment Arrangement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Distributions </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollar amounts in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investment Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plaza Del Rio Medical Office Campus Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 10pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_____________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">One property within the Plaza Del Rio Medical Office Campus Portfolio was mortgaged as part of the Multi-Property CMBS Loan. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_181" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Mortgage Notes Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional information.</span></div> 389000 0.025 12455000 12925000 0 0 0 Net Loss Per Share<div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the basic and diluted net loss per share computation for the years ended December 31, 2022, 2021 and 2020 and has been retroactively adjusted to reflect the stock dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,285)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,942)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average shares outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,428,154 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,354,994 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,119,937 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.88)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.87)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Retroactively adjusted for the effects of the stock dividends. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and Note 8 — Stockholder’s Equity for additional information.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share assumes the conversion of all common stock equivalents into an equivalent number of shares of common stock, unless the effect is antidilutive. The Company considers unvested restricted shares, Common OP Units and Class B Units to be common share equivalents. The Company had the following common stock equivalents on a weighted-average basis that were excluded from the calculation of diluted net loss per share attributable to stockholders as their effect would have been antidilutive. The amounts in the table below have been retroactively adjusted to reflect the stock dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,520 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,965 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common OP Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total weighted average antidilutive common share equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095,882 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170,327 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. There were 97,343, 159,427 and 215,384 unvested restricted shares outstanding as of December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Weighted average number of antidilutive Common OP Units presented as shares outstanding for the periods presented, at the current conversion rate as retroactively adjusted for the effects of the stock dividends. There were 405,998 Common OP Units outstanding as of December 31, 2022, 2021 and 2020.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current conversion rate as retroactively adjusted for the effects of the stock dividends. There were 359,250 Class B Units outstanding as of December 31, 2022, 2021 and 2020.</span></div> <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the basic and diluted net loss per share computation for the years ended December 31, 2022, 2021 and 2020 and has been retroactively adjusted to reflect the stock dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,285)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,942)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average shares outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,428,154 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,354,994 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,119,937 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.88)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.87)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Retroactively adjusted for the effects of the stock dividends. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and Note 8 — Stockholder’s Equity for additional information.</span></div> -93285000 -92942000 -78781000 106428154 106428154 106354994 106354994 106119937 106119937 -0.88 -0.88 -0.87 -0.87 -0.74 -0.74 The amounts in the table below have been retroactively adjusted to reflect the stock dividends (see <span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,520 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,965 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common OP Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total weighted average antidilutive common share equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095,882 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170,327 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. There were 97,343, 159,427 and 215,384 unvested restricted shares outstanding as of December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Weighted average number of antidilutive Common OP Units presented as shares outstanding for the periods presented, at the current conversion rate as retroactively adjusted for the effects of the stock dividends. There were 405,998 Common OP Units outstanding as of December 31, 2022, 2021 and 2020.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current conversion rate as retroactively adjusted for the effects of the stock dividends. There were 359,250 Class B Units outstanding as of December 31, 2022, 2021 and 2020.</span></div> 141364 214520 288965 467602 467602 467602 413760 413760 413760 1022726 1095882 1170327 97343 159427 215384 405998 405998 405998 359250 359250 359250 Segment Reporting<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosures below for the years ended December 31, 2022, 2021 and 2020, are presented for the Company’s two reportable business segments for management and internal financial reporting purposes: MOBs and SHOPs. Prior to December 31, 2021, the Company had three reportable segments 1) medical office and outpatient buildings (“Former MOBs”), 2) triple net-leased healthcare properties (“Former NNN”) and 3) SHOPs. Culminating in the year ended December 31, 2021, the Company has completed several strategic property divestitures from the Company’s Former NNN segment and transitioned certain properties previously reported in the Company’s Former NNN segment into the Company’s SHOP segment. The remaining Former NNN properties are similar in nature, cash flows, and risk structure with the Former MOB segment and are managed operationally and reported collectively by the Company’s management. Accordingly, in the fourth quarter of 2021, the Company reevaluated its segments and concluded that it had two reportable segments. The Company combined the properties in its Former NNN segment with the properties in its Former MOB segment for segment reporting. All prior periods presented in the tables below have been conformed to the presentation of the Company’s new reportable segment structure.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates performance and makes resource allocations based on its two business segments. The medical office building segment primarily consists of MOBs leased to healthcare-related tenants under long-term leases, which may require such tenants to pay a pro rata share of property-related expenses as well as seniors housing properties, hospitals, inpatient rehabilitation facilities and skilled nursing facilities under long-term leases, under which tenants are generally responsible to directly pay property-related expenses. The SHOP segment consists of direct investments in seniors housing properties, primarily providing assisted living, independent living and memory care services, which are operated through engaging independent third-party operators. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Operating Income</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the performance of the combined properties in each segment based on net operating income (“NOI”). NOI is defined as total revenues from tenants, less property operating and maintenance expense. NOI excludes all other items of expense and income included in the financial statements in calculating net income (loss). The Company uses NOI to assess and compare property level performance and to make decisions concerning the operation of the properties. The Company believes that NOI is useful as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating expenses and acquisition activity on an unleveraged basis, providing perspective not immediately apparent from net income (loss). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOI excludes certain components from net income (loss) in order to provide results that are more closely related to a property’s results of operations. For example, interest expense is not necessarily linked to the operating performance of a real estate asset and is often incurred at the corporate level. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property level. NOI presented by the Company may not be comparable to NOI reported by other REITs that define NOI differently. The Company believes that in order to facilitate a clear understanding of the Company’s operating results, NOI should be examined in conjunction with net income (loss) as presented in the Company’s consolidated financial statements. NOI should not be considered as an alternative to net income (loss) as an indication of the Company’s performance or to cash flows as a measure of the Company’s liquidity or ability to pay distributions. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reconcile the segment activity to consolidated net loss for the years ended December 31, 2022, 2021 and 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335,846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property operating and maintenance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,499 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,630)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating fees to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,484)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82,064)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on sale of real estate investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on non designated derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation for preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(93,285)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,867 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206,488 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property operating and maintenance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,951)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating fees to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79,926)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of real estate investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,648 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on non-designated derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation for preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(92,942)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,824 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,612 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property operating and maintenance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,446)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating fees to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,572)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81,053)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of real estate investment </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on non-designated derivatives </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation for preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(78,781)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the segment activity to consolidated total assets as of the periods presented:</span></div><div style="margin-bottom:3pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in real estate, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical office and other healthcare-related buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121,857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149,241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seniors housing — operating properties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900,686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments in real estate, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978,297 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,654 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,738 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,884 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,180,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:8pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles capital expenditures by reportable business segments, excluding corporate non-real estate expenditures, for the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical office and other healthcare-related buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seniors housing — operating properties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,993 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,071 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,394 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2 3 2 2 <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reconcile the segment activity to consolidated net loss for the years ended December 31, 2022, 2021 and 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335,846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property operating and maintenance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,499 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,630)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating fees to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,484)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82,064)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on sale of real estate investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on non designated derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation for preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(93,285)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,867 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206,488 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property operating and maintenance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,951)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating fees to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79,926)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of real estate investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,648 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on non-designated derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation for preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(92,942)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,824 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,612 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property operating and maintenance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,446)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating fees to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,572)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81,053)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of real estate investment </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on non-designated derivatives </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation for preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(78,781)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the segment activity to consolidated total assets as of the periods presented:</span></div><div style="margin-bottom:3pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in real estate, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical office and other healthcare-related buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121,857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149,241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seniors housing — operating properties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900,686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments in real estate, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978,297 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,654 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,738 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,884 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,180,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:8pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles capital expenditures by reportable business segments, excluding corporate non-real estate expenditures, for the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical office and other healthcare-related buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seniors housing — operating properties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,993 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,071 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,394 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 131444000 204402000 335846000 35945000 177499000 213444000 95499000 26903000 122402000 27630000 25353000 1484000 17287000 82064000 -125000 51740000 27000 3834000 201000 -135000 13799000 -93285000 122867000 206488000 329355000 34480000 171333000 205813000 88387000 35155000 123542000 40951000 24206000 2714000 16828000 79926000 3648000 47900000 61000 37000 203000 -260000 7762000 -92942000 119824000 261788000 381612000 32812000 210736000 243548000 87012000 51052000 138064000 36446000 23922000 173000 21572000 81053000 5230000 51519000 44000 -102000 4061000 303000 2968000 -78781000 1121857000 1149241000 856440000 900686000 1978297000 2049927000 53654000 59738000 22884000 25644000 40647000 174000 25276000 23858000 7814000 7914000 34554000 32564000 17223000 14581000 2180349000 2214400000 10542000 6152000 8561000 17451000 12919000 12833000 27993000 19071000 21394000 Commitments and Contingencies <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December 31, 2022, the Company has seven operating and six direct financing lease agreements related to certain acquisitions under leasehold interests arrangements. The seven operating leases have durations, including assumed renewals, ranging from 19.9 to 84.7 years, excluding an adjacent parking lot lease with a term of 1.8 years as of December 31, 2022. The Company did not enter into any additional ground leases during the year ended December 31, 2022. The classification of these leases were grandfathered in adoption of ASU 842, whereby they will continue to be classified as operating leases unless modified.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company’s balance sheet included ROU assets and liabilities of $7.8 million and $8.1 million, respectively, which are included in operating lease right-of-use assets and operating lease liabilities, respectively, on the Company’s consolidated balance sheet. In determining operating ROU assets and lease liabilities for the Company’s existing operating leases upon the adoption of the lease guidance issued in 2019, as well as for new operating leases since adoption, the Company was required to estimate an appropriate incremental borrowing rate on a fully-collateralized basis for the terms of the leases. Because the terms of the Company’s ground leases are significantly longer than the terms of borrowings available to the Company on a fully-collateralized basis, the Company’s estimate of this rate required significant judgment. During the year ended December 31, 2021, the Company sold a property which included a prepaid ground lease. Upon disposition, the carrying value of the ROU asset was $5.7 million, and was recorded as a reduction of the gain on sale for that property.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ground operating leases have a weighted-average remaining lease term, including assumed renewals, of 34.1 years and a weighted-average discount rate of 7.36% as of December 31, 2022. For the years ended December 31, 2022, 2021 and 2020, the Company paid cash of $0.7 million, $0.8 million and $0.8 million for amounts included in the measurement of lease liabilities and recorded total rental expense from operating leases of $0.9 million, $0.9 million and $0.9 million, on a straight-line basis in accordance with the standard, during the years ended December 31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease expense is recorded in property operating expenses in the consolidated statements of operations and comprehensive loss. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Base Rent Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Direct Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,023 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,936)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,087 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The Direct Finance Lease liability is included in <span style="-sec-ix-hidden:f-1706">Accounts Payable and accrued expenses</span> on the balance sheet as of December 31, 2022. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Matters</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may become subject to litigation, claims and regulatory matters. There are no material legal or regulatory proceedings pending or known to be contemplated against the Company or its properties.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the ownership and operation of real estate, the Company may potentially be liable for costs and damages related to environmental matters. As of December 31, 2022, the Company had not been notified by any governmental authority of any non-compliance, liability or other claim, and is not aware of any other environmental condition that it believes will have a material adverse effect on the results of operations.</span></div> 7 6 7 P19Y10M24D P84Y8M12D P1Y9M18D 7800000 8100000 5700000 P34Y1M6D 0.0736 700000 800000 800000 900000 900000 900000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Base Rent Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Direct Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,023 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,936)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,087 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div>(1)The Direct Finance Lease liability is included in <span style="-sec-ix-hidden:f-1706">Accounts Payable and accrued expenses</span> on the balance sheet as of December 31, 2022. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840. <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Base Rent Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Direct Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,023 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,936)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,087 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div>(1)The Direct Finance Lease liability is included in <span style="-sec-ix-hidden:f-1706">Accounts Payable and accrued expenses</span> on the balance sheet as of December 31, 2022. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840. 645000 88000 632000 90000 588000 93000 599000 95000 617000 97000 21942000 7215000 25023000 7678000 16936000 2841000 8087000 4837000 Subsequent Events<div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K and determined that there have not been any events that have occurred that would require adjustments to disclosures in the consolidated financial statements except the following disclosures:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Dividend</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2023, the Company declared a quarterly stock dividend of 0.014167 shares of the Company’s common stock on each share of the Company’s outstanding common stock. The stock dividend was payable on January 18, 2023 to holders of record of the Company’s common stock at the close of business on January 13, 2023.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Swap Terminations</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2022, the Company terminated two LIBOR-based interest rate swap agreements with an aggregate notional amount of $50.0 million. The swaps were terminated in an asset position with a fair value of $2.0 million. The funds were received in February 2023. This amount will remain in AOCI and will amortize into net loss as a reduction to interest expense through March 2024.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility Borrowings</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2022, the Company drew $20.0 million on its Revolving Credit Facility.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2022, the Company acquired four single-tenant MOB properties for a contract purchase price of $20.0 million, which was funded with borrowings from the Revolving Credit Facility.</span></div> 0.014167 2 50000000 2000000 20000000 4 20000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subsequent to Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbrances at <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Amount at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fresenius Medical Care - Winfield, AL</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/10/2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,568 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adena Health Center - Jackson, OH</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5),(11)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/28/2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ouachita Community Hospital - West Monroe, LA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/12/2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CareMeridian - Littleton, CO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/8/2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oak Lawn Medical Center - Oak Lawn, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/21/2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">835 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,077 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,994 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgery Center of Temple - Temple, TX</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/30/2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Greenville Health System - Greenville, SC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (9)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/10/2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockbridge Family Medical - Stockbridge, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/21/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,781 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arrowhead Medical Plaza II - Glendale, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/21/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,076 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Village Center Parkway - Stockbridge, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/21/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,806 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Creekside MOB - Douglasville, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,709 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bowie Gateway Medical Center - Bowie, MD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/7/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,638 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Campus at Crooks &amp; Auburn Building D - Rochester Mills, MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/19/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,627 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,951 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Berwyn Medical Center - Berwyn, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/29/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Countryside Medical Arts - Safety Harbor, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">St. Andrews Medical Park - Venice, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,072 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Campus at Crooks &amp; Auburn Building C - Rochester Mills, MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/3/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laguna Professional Center - Elk Grove, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/15/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,811 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,709 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UC Davis MOB - Elk Grove, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/15/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,951 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estate at Hyde Park - Tampa, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/31/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Autumn Ridge of Clarkston - Clarkston, MI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/12/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,884 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Burlington - Burlington, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Carroll - Carroll, IA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prairie Hills at Cedar Rapids - Cedar Rapids, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prairie Hills at Clinton - Clinton, IA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prairie Hills at Des Moines - Des Moines, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Fairfield - Fairfield, IA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Ft. Madison - Ft. Madison, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5),(11)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prairie Hills at Independence - Independence, IA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Mt. Pleasant - Mt. Pleasant, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Muscatine - Muscatine, IA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prairie Hills at Ottumwa - Ottumwa, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5),(11)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,088)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prairie Hills at Tipton - Tipton, IA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,793 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subsequent to Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbrances at <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Amount at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liberty Court - Dixon, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/29/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lakeside Vista - Holland, MI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/29/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,057 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The Atrium - Rockford, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/29/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arrowhead Medical Plaza I - Glendale, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/10/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,447 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Burlington - Land - Burlington, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/23/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Community Health MOB - Harrisburg, PA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,424 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brady MOB - Harrisburg, PA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Landis Memorial - Harrisburg, PA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (10)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,782 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FOC II - Mechanicsburg, PA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FOC Clinical - Mechanicsburg, PA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FOC I - Mechanicsburg, PA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,923 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Copper Springs Senior Living - Meridian, ID</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5),(11)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ID</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/29/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,052)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Brunswick - Brunswick, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,402 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Dublin - Dublin, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,866 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allegro at Elizabethtown - Elizabethtown, KY</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5),(11)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Johns Creek - Johns Creek, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,943 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allegro at Jupiter - Jupiter, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,534 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Lee's Summit - Lee's Summit, MO</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place at Mills - Roswell, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of College Harbour - St Petersburg, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allegro at Stuart - Stuart, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allegro at Tarpon - Tarpon Springs, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Titusville - Titusville, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,034 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allegro at St. Petersburg - Land - St. Petersburg, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gateway MOB - Clarksville, TN</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/3/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dyer Building - Dyer, IN</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/17/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">757 Building - Munster, IN</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/17/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">645 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761 Building - Munster, IN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/17/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759 Building - Munster, IN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/17/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,955 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Schererville Building - Schererville, IN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/17/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Meadowbrook Senior Living - Agoura Hills, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/25/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mount Vernon Medical Office Building - Mount Vernon, WA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/25/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subsequent to Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbrances at <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Amount at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Wellington at Hershey's Mill - West Chester, PA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/3/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eye Specialty Group Medical Building - Memphis, TN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/5/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,475 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,533 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Alpharetta - Alpharetta, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/10/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Prairie Village - Prairie Village, KS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/10/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,782 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bloom MOB - Harrisburg, PA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/15/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Sciences Pavilion - Harrisburg, PA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/15/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,309 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,309 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,569 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Wood Glen Nursing and Rehab Center - West Chicago, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5),(11)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/16/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,436)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pinnacle Center - Southaven, MS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/16/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,952 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Paradise Valley Medical Plaza - Phoenix, AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/29/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,085 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,019 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Victory Medical Center at Craig Ranch - McKinney, TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,475 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,270 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rivershores Healthcare &amp; Rehab Centre - Marseilles, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5),(11)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Morton Terrace Healthcare &amp; Rehab Centre - Morton, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5),(11)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">709 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,701 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Morton Villa Healthcare &amp; Rehab Centre - Morton, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5),(11)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">645 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The Heights Healthcare &amp; Rehab Centre - Peoria Heights, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5),(11)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,952 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Colonial Healthcare &amp; Rehab Centre - Princeton, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5),(11)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,622)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitol Healthcare &amp; Rehab Centre - Springfield, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5),(11)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acuity Specialty Hospital - Mesa, AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/14/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acuity Specialty Hospital - Sun City, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/14/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Shoal Creek - Kansas City, MO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/2/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Healthcare Center - Green Bay, WI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Healthcare Center - Greenville, WI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Healthcare Center - Kiel, WI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Healthcare Center - Plymouth, WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Healthcare Center - Waterford, WI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Healthcare Center - Wautoma, WI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,955 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arbor View Assisted Living and Memory Care - Burlington, WI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/31/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,815 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Advanced Orthopedic Medical Center - Richmond, VA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/7/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palm Valley Medical Plaza - Goodyear, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/7/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Physicians Plaza of Roane County - Harriman, TN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/27/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adventist Health Lacey Medical Plaza - Hanford, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/29/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Center I - Peoria, AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/15/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,085 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Center II - Peoria, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/15/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial Center - Peoria, AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/15/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subsequent to Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbrances at <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Amount at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Center III - Peoria, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/15/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Morrow Medical Center - Morrow, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/24/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Belmar Medical Building -Lakewood, CO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/29/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place - Northville, MI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/30/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conroe Medical Arts and Surgery Center - Conroe, TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/10/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Center V - Peoria, AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/10/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legacy Medical Village - Plano, TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/10/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Scripps Cedar Medical Center - Vista, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,482 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ramsey Woods Memory Care - Cudahy, WI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/2/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">East Coast Square West - Cedar Point, NC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/15/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">East Coast Square North - Morehead City, NC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/15/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,933 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,804 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eastside Cancer Institute - Greenville, SC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/22/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sassafras Medical Building - Erie, PA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/22/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,860 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sky Lakes Klamath Medical Clinic - Klamath Falls, OR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/22/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Courtyard Fountains - Gresham, OR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/1/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Presence Healing Arts Pavilion - New Lenox, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/4/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,768 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mainland Medical Arts Pavilion - Texas City, TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/4/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Renaissance on Peachtree - Atlanta, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/15/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Senior Living at Bryant - Bryant, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/29/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Senior Living at Chenal - Little Rock, AR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/29/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,917 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge North Little Rock - North Little Rock, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/29/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">High Desert Medical Group Medical Office Building - Lancaster, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/7/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,459 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Northside Hospital - Canton, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/13/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">West Michigan Surgery Center - Big Rapids, MI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/18/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Camellia Walk Assisted Living and Memory Care - Evans, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/28/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,372 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cedarhurst of Collinsville - Collinsville, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arcadian Cove Assisted Living - Richmond, KY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8),(11)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beaumont Medical Center - Warren, MI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DaVita Dialysis - Hudson, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,979 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DaVita Bay Breeze Dialysis Center - Largo, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Greenfield Medical Plaza - Gilbert, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RAI Care Center - Clearwater, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subsequent to Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbrances at <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Amount at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Illinois CancerCare - Galesburg, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UnityPoint Clinic - Muscatine, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lee Memorial Health System Outpatient Center - Ft. Myers</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">710 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decatur Medical Office Building - Decatur, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8), (9)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Madison Medical Plaza - Joliet, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8), (9)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Woodlake Office Center - Woodbury, MN</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,638 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,688 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,002 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rockwall Medical Plaza - Rockwall, TX</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">709 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MetroHealth Buckeye Health Center - Cleveland, OH</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">648 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UnityPoint Clinic - Moline, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,880 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">411 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VA Outpatient Clinic - Galesberg, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Philip Professional Center - Lawrenceville, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,780 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,285 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,714 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Texas Children’s Hospital - Houston, TX</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/5/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida Medical Heartcare - Tampa, FL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/29/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida Medical Somerset - Tampa, FL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/29/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida Medical Tampa Palms - Tampa, FL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/29/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida Medical Wesley Chapel - Tampa, FL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/29/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Health Center - Milwaukee, WI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/17/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vascular Surgery Associates - Tallahassee, FL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/11/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Glendale MOB - Farmington Hills, MI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/28/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crittenton Washington MOB - Washington Township, MI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/12/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crittenton Sterling Heights MOB - Sterling Heights, MI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/12/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Advocate Aurora MOB - Elkhorn, WI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/24/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,633 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pulmonary &amp; Critical Care Med - Lemoyne, PA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/13/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dignity Emerus Blue Diamond - Las Vegas, NV</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/15/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dignity Emerus Craig Rd - North Las Vegas, NV</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/15/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,780 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Greenfield MOB - Greenfield, WI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/17/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milwaukee MOB - South Milwaukee, WI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/17/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">St. Francis WI MOB - St. Francis, WI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/17/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,088 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lancaster Medical Arts MOB - Lancaster, PA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/20/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">569 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Women’s Healthcare Group MOB - York, PA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/21/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pioneer Spine Sports - Northampton, MA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/22/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subsequent to Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbrances at <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Amount at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pioneer Spine Sport - Springfield, MA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/22/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pioneer Spine Sports - West Springfield, MA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/22/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,295 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Felicita Vida - Escondido, CA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/3/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cedarhurst of Edwardsville - Edwardsville, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/10/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,032 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UMPC Sir Thomas Court - Harrisburg, PA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/17/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UMPC Fisher Road - Mechanicsburg, PA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/17/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swedish American MOB - Roscoe, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/22/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cedarhurst of Sparta - Sparta, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/31/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UMPC Chambers Hill - Harrisburg, PA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/3/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cedarhurst of Shiloh - Shiloh, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/13/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bayshore Naples Memory Care - Naples, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/20/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Circleville MOB - Circleville, OH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/7/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kingwood Executive Center - Kingwood, TX</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/6/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OrthoOne Hilliard - Hilliard, OH</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/28/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">South Douglas MOB - Midwest City, OK</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OK</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/23/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fort Wayne Opthomology Engle - Fort Wayne, IN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/29/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fort Wayne Opthomology Dupont - Fort Wayne, IN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/29/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">St. Peters Albany 2 Palisades - Albany, NY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/30/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hefner Pointe Medical Center - Oklahoma City, OK</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OK</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/30/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">St. Peters Troy 2 New Hampshire - Troy, NY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/30/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,793 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">St Peters - Albany, NY - 4 Palisades</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/30/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,958 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">St Peters - Albany, NY - 5 Palisades</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/30/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,952 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">St Lukes Heart Vascular Center - East Stroudsburg</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/31/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Metropolitan Eye Lakeshore Surgery - St. Clair, MI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/31/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,835 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Naidu Clinic - Odessa, TX</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/1/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Belpre V Cancer Center - Belpre, OH</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,894 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,047 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Center for Advanced Dermatology - Lakewood, CO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/1/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,034 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,874 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida Medical Clinic - Tampa, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/1/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pensacola Nephrology MOB - Pensacola, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/29/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Millennium Eye Care - Freehold, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/26/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Atlanta Gastroenterology Associates - Lawrenceville, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/29/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bone and Joint Specialists - Merrillville, IN</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/29/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subsequent to Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbrances at <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Amount at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eastern Carolina ENT - Greenville, NC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/21/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fannie Mae Master Credit Facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352,047 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">937,230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">210,294</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,075,880</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,840)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,295,587</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">397,982</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Acquired intangible lease assets allocated to individual properties in the amount of $292.0 million are not reflected in the table above.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">The tax basis of aggregate land, buildings and improvements as of December 31, 2022 is $2.1 billion.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">The accumulated depreciation column excludes $211.3 million of accumulated amortization associated with acquired intangible lease assets.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements and 5 years for fixtures.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">These unencumbered properties were part of the borrowing base of the Credit Facility, which had $180.0 million of outstanding borrowings as of December 31, 2022. The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the real estate assets comprising the borrowing base have been pledged for the benefit of the lenders thereunder (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Credit Facilities, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional details).</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">These properties collateralize the Capital One Facility, which had $210.5 million of outstanding borrowings as of December 31, 2022.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">These properties collateralize the KeyBank Facility, which had $141.6 million of outstanding borrowings as of December 31, 2022.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">These properties were acquired from American Realty Capital Healthcare Trust III, Inc. in 2017, which was a related party to the Company’s Advisor.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Some or all of the land underlying this property is subject to an operating land lease. The related right-of-use assets are separately recorded. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_217" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> — Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information. </span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.28pt">The building amount represents combined direct financing lease for the total asset as the land element was not required to be bifurcated under ASU 840. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_217" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> — Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information. </span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.28pt">The property has been impaired as of December 31, 2022. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_178" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">— Real Estate Investments, Net “Assets Held for Use and Related Impairments”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity for real estate and accumulated depreciation for the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:55.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.663%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Real estate investments, at cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,211,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,296,627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions-acquisitions and capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals, impairments and reclasses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,047)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,295,587 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345,708 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,211,451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated depreciation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,095 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals, impairments and reclasses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,982 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,095 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,399 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Acquired intangible lease assets and related accumulated depreciation are not reflected in the table above.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes amounts relating to dispositions and impairment charges on assets for the years ended December 31, 2022, 2021 and 2020. Amounts for the year ended December 31, 2020 include the reclassification of approximately $49.4 million and $8.7 million of assets and accumulated depreciation, respectively, that were previously classified as held-for-sale as of December 31, 2019 to real estate investments, at cost and accumulated depreciation during the year ended December 31, 2020. For additional information on this reclassification during the year ended December 31, 2020, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i287ff37c25f74b1a844547bcd3a52b7a_178" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">— Real Estate Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div> 0 152000 1568000 0 0 1720000 445000 0 242000 4494000 0 -25000 4711000 1100000 0 633000 5304000 0 0 5937000 1329000 0 976000 8900000 0 111000 9987000 3037000 5343000 835000 7217000 0 25000 8077000 1994000 0 225000 5208000 0 432000 5865000 1379000 0 720000 3045000 0 389000 4154000 759000 1781000 823000 1799000 0 177000 2799000 542000 7540000 0 9758000 0 2076000 11834000 3261000 2434000 1135000 2299000 0 372000 3806000 809000 8814000 2709000 5320000 0 791000 8820000 1858000 9153000 983000 10321000 0 334000 11638000 2489000 3627000 640000 4166000 0 145000 4951000 1120000 0 1305000 7559000 0 0 8864000 1693000 6983000 915000 7663000 0 74000 8652000 1862000 11119000 1666000 10005000 2000 399000 12072000 3027000 3831000 609000 3893000 0 178000 4680000 1081000 8887000 1811000 14598000 0 318000 16727000 3709000 8136000 1138000 7242000 0 294000 8674000 1951000 0 1777000 20308000 0 1079000 23164000 5133000 0 655000 19967000 0 1584000 22206000 4884000 0 518000 16739000 0 429000 17686000 4438000 0 473000 11263000 0 51000 11787000 2686000 0 195000 8595000 0 182000 8972000 2096000 0 890000 18882000 0 86000 19858000 4781000 0 647000 13745000 0 57000 14449000 3593000 0 340000 14115000 0 291000 14746000 3635000 0 263000 3931000 -54000 -1177000 2963000 -21000 0 473000 10600000 0 179000 11252000 2519000 0 205000 10935000 0 359000 11499000 2575000 0 302000 13840000 0 172000 14314000 3364000 0 538000 9186000 -376000 -7088000 2260000 47000 0 306000 10409000 0 78000 10793000 2405000 0 119000 1998000 0 59000 2176000 541000 0 378000 12196000 0 1878000 14452000 3057000 0 164000 1746000 0 295000 2205000 369000 4571000 0 6447000 0 1410000 7857000 1886000 0 620000 0 0 0 620000 0 5424000 0 6170000 0 0 6170000 1315000 19661000 0 22485000 0 0 22485000 4680000 0 0 32484000 0 0 32484000 6782000 16136000 0 16473000 0 142000 16615000 3960000 17695000 0 19634000 0 0 19634000 4616000 8204000 0 8923000 0 368000 9291000 2308000 0 498000 7130000 -14000 -2052000 5562000 48000 0 1509000 14402000 0 489000 16400000 3747000 0 403000 9281000 0 182000 9866000 2541000 0 317000 7290000 -76000 -3175000 4356000 13000 0 997000 11943000 0 448000 13388000 3174000 0 3741000 49534000 0 674000 53949000 12027000 0 2734000 25008000 0 391000 28133000 6149000 0 1000000 8611000 0 2575000 12186000 3310000 0 3791000 8684000 0 2117000 14592000 3430000 0 5018000 60575000 0 969000 66562000 15029000 0 2360000 13728000 0 3107000 19195000 4430000 0 1379000 13976000 0 720000 16075000 4034000 0 3045000 0 0 0 3045000 0 17560000 0 16367000 0 1011000 17378000 4335000 6143000 601000 8992000 0 191000 9784000 1971000 0 645000 7885000 0 31000 8561000 1685000 6797000 1436000 8616000 0 90000 10142000 1974000 8271000 1101000 8899000 0 31000 10031000 1955000 0 1260000 935000 0 88000 2283000 381000 0 8821000 48682000 0 2485000 59988000 11659000 15797000 0 18519000 0 3000 18522000 4095000 0 8531000 80734000 0 5364000 94629000 18754000 8475000 775000 7223000 0 0 7998000 1533000 0 1604000 26069000 0 462000 28135000 6296000 0 1782000 21869000 0 451000 24102000 5466000 15322000 0 15928000 0 517000 16445000 3535000 18272000 0 22309000 0 0 22309000 4569000 0 1896000 16107000 -367000 -6436000 11200000 228000 7085000 1378000 6547000 0 1560000 9485000 1952000 13085000 0 25194000 0 1703000 26897000 6019000 0 1596000 40475000 0 1199000 43270000 8801000 0 1276000 6868000 -247000 -2837000 5060000 105000 0 709000 5649000 -137000 -2520000 3701000 77000 0 645000 3687000 -125000 -1546000 2661000 57000 0 214000 7952000 -41000 -3369000 4756000 127000 0 173000 5871000 -33000 -2622000 3389000 92000 0 603000 21699000 -117000 -8560000 13625000 311000 0 1977000 16203000 0 543000 18723000 3660000 0 2329000 15795000 -909000 -7715000 9500000 658000 0 3723000 22259000 0 704000 26686000 5404000 0 1130000 1678000 0 0 2808000 420000 0 259000 958000 0 0 1217000 256000 0 676000 2214000 0 0 2890000 494000 17038000 2891000 24224000 0 0 27115000 5430000 0 590000 6452000 0 0 7042000 1395000 0 1955000 4361000 0 0 6316000 983000 0 367000 7815000 0 71000 8253000 2080000 15390000 1523000 19229000 0 493000 21245000 3970000 0 1890000 4940000 0 367000 7197000 1267000 6293000 1746000 7842000 0 182000 9770000 1737000 11526000 328000 13302000 0 98000 13728000 2620000 3085000 807000 1115000 0 1545000 3467000 1190000 0 945000 1330000 0 5036000 7311000 1836000 3254000 959000 1110000 0 710000 2779000 571000 2137000 673000 1651000 0 1047000 3371000 932000 4334000 1155000 5674000 0 493000 7322000 1451000 3770000 819000 4287000 0 596000 5702000 1114000 0 440000 14975000 0 1007000 16422000 3403000 13221000 1965000 12198000 0 744000 14907000 2842000 0 1089000 3200000 0 879000 5168000 804000 23662000 3755000 31097000 0 1430000 36282000 6634000 14983000 1213000 14596000 0 1673000 17482000 2981000 0 930000 4990000 0 122000 6042000 1188000 5254000 1535000 4803000 0 6000 6344000 962000 3933000 899000 4761000 0 144000 5804000 917000 0 1498000 6637000 0 639000 8774000 1379000 2315000 928000 4629000 -364000 -2333000 2860000 0 0 433000 2623000 0 0 3056000 508000 0 2476000 50601000 0 2255000 55332000 10764000 5966000 0 6768000 0 76000 6844000 1383000 6174000 320000 7923000 0 321000 8564000 1756000 0 4535000 68895000 0 3246000 76676000 13856000 6817000 1687000 12936000 -557000 -6326000 7740000 40000 15639000 6896000 20579000 0 364000 27839000 4917000 9704000 0 19265000 0 263000 19528000 4211000 7480000 1459000 9300000 0 0 10759000 1749000 8014000 3408000 8191000 0 438000 12037000 1249000 0 258000 5677000 0 0 5935000 803000 0 1854000 17372000 0 1232000 20458000 3426000 0 1228000 8652000 0 264000 10144000 1393000 0 481000 3923000 -425000 -3536000 443000 14000 0 1078000 9525000 0 19000 10622000 1328000 0 226000 1979000 0 121000 2326000 273000 0 399000 896000 0 48000 1343000 150000 0 1476000 4144000 0 277000 5897000 633000 0 624000 3156000 0 0 3780000 420000 2323000 290000 2457000 0 0 2747000 368000 0 570000 4541000 0 34000 5145000 649000 0 439000 4374000 0 710000 5523000 688000 0 695000 3273000 0 261000 4229000 507000 12477000 0 16855000 0 37000 16892000 2111000 8638000 1017000 10688000 0 1297000 13002000 1652000 0 1097000 4582000 0 214000 5893000 709000 0 389000 4367000 0 255000 5011000 648000 0 396000 2880000 0 5000 3281000 411000 0 359000 1852000 0 0 2211000 302000 5780000 1285000 6714000 0 264000 8263000 1045000 4590000 1368000 4428000 0 116000 5912000 790000 0 586000 1902000 0 0 2488000 322000 0 61000 1366000 0 0 1427000 204000 0 141000 1402000 0 0 1543000 215000 0 485000 1987000 0 0 2472000 345000 3984000 1014000 4041000 0 224000 5279000 788000 0 902000 5383000 0 0 6285000 856000 0 504000 12332000 0 0 12836000 1542000 0 640000 4090000 0 283000 5013000 592000 0 1398000 2695000 0 258000 4351000 492000 7184000 181000 9452000 0 0 9633000 1280000 4271000 621000 3805000 0 0 4426000 661000 13966000 2182000 16594000 0 0 18776000 1864000 18780000 3807000 22803000 0 0 26610000 2584000 7526000 1552000 8333000 0 246000 10131000 1199000 4136000 410000 5041000 0 0 5451000 544000 9088000 865000 11355000 0 251000 12471000 1353000 0 85000 4417000 0 0 4502000 569000 0 624000 2161000 0 0 2785000 403000 0 435000 1858000 0 0 2293000 192000 0 333000 2530000 0 0 2863000 252000 0 374000 4295000 0 0 4669000 417000 0 1677000 28953000 0 396000 31026000 2785000 0 321000 9032000 0 56000 9409000 805000 0 745000 6272000 0 0 7017000 498000 0 747000 3844000 0 0 4591000 333000 0 599000 5862000 0 0 6461000 588000 0 381000 13807000 0 63000 14251000 1225000 0 498000 4238000 0 0 4736000 329000 13071000 376000 28299000 0 65000 28740000 2085000 0 3231000 17112000 0 54000 20397000 1306000 3556000 765000 4011000 0 71000 4847000 243000 0 1522000 4166000 0 34000 5722000 251000 0 760000 3118000 0 77000 3955000 206000 0 628000 3863000 0 0 4491000 193000 3923000 516000 6124000 0 0 6640000 260000 1924000 597000 2653000 0 0 3250000 138000 0 516000 4342000 0 0 4858000 202000 3831000 678000 4819000 0 31000 5528000 222000 0 330000 2444000 0 19000 2793000 113000 0 542000 2416000 0 0 2958000 113000 0 593000 5359000 0 0 5952000 221000 0 363000 3224000 0 0 3587000 113000 0 203000 4632000 0 0 4835000 164000 0 730000 2409000 0 0 3139000 93000 0 1153000 63894000 0 0 65047000 2072000 0 1034000 1874000 0 0 2908000 59000 0 1104000 1137000 0 124000 2365000 44000 0 1578000 5123000 0 0 6701000 135000 0 635000 6014000 0 0 6649000 125000 0 2639000 2263000 0 0 4902000 24000 0 1014000 2499000 0 0 3513000 29000 0 664000 5826000 0 0 6490000 0 352047000 937230000 210294000 2075880000 -3840000 13253000 2295587000 397982000 292000000 2100000000 211300000 P40Y P15Y P5Y 180000000 210500000 141600000 2345708000 2211451000 2296627000 44926000 98364000 80980000 95047000 -35893000 166156000 2295587000 2345708000 2211451000 328095000 260399000 226167000 63143000 63393000 64731000 -6744000 -4303000 30499000 397982000 328095000 260399000 49400000 8700000 Retroactively adjusted for the effects of the Stock Dividends (see Note 1 — Organization for details). EXCEL 107 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�RG=HR S5F)B6I.Q>-:,1G51 MS9.,0^LA!Y)M6@E/,IRZ<.$\E!PO31T:U?F<.#]CG[["/GZEW8F!/K%&XK,. M9-NIZG!LFD)M38:V+T>U0M(+0Q^/CDR_ZFH-K;M:XWNG7^3=WA>H-D4U&]4< M5'-1S4,U']4"K5W3,-%'(W,DUGF$:-P(U6)42U M1;4,U7)4*RBMF7GKVI+J MQ[W_YSP"X1",2L2D-D4U&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+4.U'-4* M2FLFZ[JR1>NN;'GMJ0BO+2>AM>^?;WWM@M:XH)J-:@ZJN:CF209*TZV1*C[N MT9=LJ%MZ^R)E@+8O1+4(U6)42U M1;4,U7)4*RBMF2GK.A>-?WY,-WGRY+5] ML[EI:99P+7"JM9\",K;&JE#N::-M<_JUS>W7-D^RF=;*4^UM=$M,46@Y"*I% MDO971\P0+E3&TB,V$N_J3]"VI:B6H5J.:@6E-9-*7>BA_7\]CT5KWZ;=FIBA ME2"H9J.:@VHNJGFHYJ-:@&HAJD6H%J-:@FHIJF6HEJ-:06G-;%S7H&A_YC-< MM/:C.EH9&"U8034;U1Q4O;N8Y^UK M?^NOEG)<=,<^.9&BQ3FO-]]! [JHYJ&:CVK!06M\ 62*B;%]^,>J+MX^'Z$- MBU$M0;54EIM% MN54^*MGSO"[-E,^KQ4Z>1XU6@S1S)#ZFH#O^R8F4U&Q4QZ-U5+-^S#*W>KO'03%UOG76C3VE!-;M?%QPTJ(MJ'JKYJ!:@6HAJ$:K% MJ);T>UFF:- ,U7)4*RBMF27KLAR]NRSGC6O0ZJ_7W'0'/CDYHC4WDN8/)JJ8 M&M%2&E3S4,U'M0#5PCY#%:$A8U1+4"U%M0S5]&[ZU[Z MKY6F2M,>>0?ZA2YY_,)DU%ZH8"K;4+90@8VVST$U%]6\OL?.[WOL K1](:I% MJ!:C6H)J*:IEJ):C6D%IS4Q8UY_HW?4GWU>1-=IE%^+9L1]M- MGCP-UEO7R82L/95L,C"$VQILM%6.T;[%7FB5*]FDU2H/;96/:@&JA:@6H5K< MYP64H"%35,M0+4>U@M*:&:PN6ZE^[,I@?]SBMX? G?/)SK:=/)\D-1O5'%1S M45!;U_\UFB7 MF;2N J"/P$$U^_7F.VA %]4\5/-1+3#:#TG7-K=?VSRT;3ZJ!:@6HEJ$:C&J):B6HEK6[]6; M]WOU%E3;&@G(K*N%S%.>Y/+&U6_-=IW'0!V+]4+=+3EU:H5J-JHYJ.:BFH=J M/JH%J!:B6H1J,:HEJ):B6H9J.:H5K^6M9DZM:X7,[J>S=*W::$H>&#&:6)HJ M)DNTI@?5;'D?C+%8G(U&=5'-0S4?U0)4"U$M0K48U1)42WN^RC,T:HYJA:P/ MJFX>27!:G>"ZZVN^9]5&LUU;8ZJ:VU -7"7F,5H3%C5$M0+46U#-5R5"LD(_]RX)L9KZZ@ MJ7[LRGC]EQ[2I)FO4S_UEIB#]OK"C;(-I0LWHNUS4,U%-:_OL?/['KL ;5^( M:A&JQ:B6H%J*:AFJY:A64%HS$];5*V9W]4KWPHWR[-$T-K%X:.JM2VMH 0:JV:CFH)J+:AZJ^:@6]'\QA6C@"-5B5$M0+46U#-5R M5"LH[3&OGF]ORG(WG>UF'][=S:[+>+:Y7JRVRK+\4O'#'T=57MXLKF^>?]FM M[]Z?J6?*+^O=;GW[\.--.;LJ-_L-JG__LE[OGGXYK_QOZ\VO#S$^_!]02P,$ M% @ UD%Q5FE5>C(C P K@P !@ !X;"]W;W)KPDI$!#!!52WY#8N?N?[^>+N70VA#ZQ ("CYSA*6%<).%]>JRKS H@QJY$E M).+)G- 8)%^ "?UQ.J!BIA8H?QI"PD"2(PKRK]/1KIRWM M4X-?(6S8SCV2F9*#D=]5-+D@B,#C4@&+RQH&$$522"SC;ZZI%"&EX^[] M5OTFS5WD,L,,!B3Z'?H\Z"HM!?DPQZN(/Y#-+>3Y-*2>1R*6_J)-9FN9"O)6 MC),X=Q8KB,,DN^+GG,..@]X\XF#D#L:AP[$(]=RA?JJ#F3N8*9DLE92#@SFV M.Y1L$)760DW>I#!3;Y%^F,AM=SD53T/AQ^W!_=B]_S%R>M.A@]RIN-P-QU,7 MW=^@P6UO_'WHHM$8#7\^CJ9_T-4$4TAX #STQ7.*D5-F)'&M2U(UBU3- MMZ1:I'1BDI5!Y %ZS9;8@ZXB3D@&= V*_>F#WM2^E=7*)<6<3*R]!\TTRJ$U M"FB-2F@3<4("E9RR0O O [$RZ+D0+RGF-%Y5GEYKF>40FP7$9B5$%V@(#/70 M"TU7TBPC4ZET+IE+BCD7$MLC:!4$K?75/Z6\*I7.+:]+BCD7$MLCV"X(MM^CO-HE9XG5.BBOUT9[IW8&IW+Y MY\)1=SJY&.@B[8B9^,-?)3SK@XK9HNGNI;WFP7Q?-.-9[_PBDW7R=Y@N0H$N M@KF0U&J6.%9IUAUG TZ6:;\X(UQTG^EM(#XH@$H#\7Q."-\.9(#B$\7^#U!+ M P04 " #607%6=.3AW*T+ !Y/@ & 'AL+W=OQ\5F3:UE:6 M/)*<-/OKEY1LTR(/:3O0?FEMY]6Q7NKP\.&1?/E>M]W-5E,W59-FV MZ_<7%TVVY*NT^;5:\U+\95[5J[05;^O%1;.N>3KK#EH5%]CW@XM5FI>3Z\ON ML_OZ^K+:M$5>\OO::S:K55J_W/*B>KZ:H,GN@V_Y8MG*#RZN+]?I@C_P]L_U M?2W>7>RCS/(5+YN\*KV:SZ\F-^A]$A!Y0*?X=\Z?FX/7GK3R6%4_Y)M/LZN) M+\^(%SQK98A4_/?$[WA1R$CB//[>!IWLOU,>>/AZ%_UC9UZ8>4P;?E<5?^6S M=GDUB2;>C,_33=%^JYY_YUM#3,;+JJ+I_O6>MUI_XF6;IJU6VX/%&:SRLO\_ M_;D=B(,#4& Y &\/P/H!U'( V1Y 3CV ;@^@WOEFH1 M3;[H!K,[6MC/2WG=']I:_#47Q[77=U^_/'S]XU-R\_U#XCU\%_]]_O#E^X/W M]:-W=_/PN_?QCZ]_/7A3[\^'Q'OSRUOO%R\OO>_+:M.DY:RYO&C%. =PYNL3-BPK-?/8+>>=C'&#BA MN],/1\#AR>F'^PXW9'\]2!>/V*Y'VBR]N9B-C3>OJY4G)GB=MGFYZ&=(WN:\ M>0\->Q^6PF%E]7C?K-.,7TU$>6AX_<0GU__\!PK\?T%#-F:P9*1@@^&D^^&D MKNC77T3E+*H&3-3^2-8=*7 MT[.'C9D]8P9+1@HV&/U@/_J!,WL2+H)F>=JO4.7,2U=5W>;_[3Z AK$/%QPD M083]@&H99:K".,:!EE! +.0S N=3N'<4.AW='!CPWN1E5FQF,CV>Z[SETVH^ M;]YZU5PNG+RN10[-\S(5"2<46=6TX#0*C?.D41AKE@$1Q:'F&!#Y+(8-1WO# MT>F&A;.6UV(535OAK7E.UY"AR#P-3#0_IB:B^@5T:P9NXKV;^"PW\NU"X)DG M\G25;U9-EZ6SO,FJC2@9[V1I@"S&QJDQO>P!$J89-"6!I=PA7^&([W3XYB;+ M:B[]O1W,MLYM6O^098\+SNN,5NV2UP)(VK1?NOAN4X#K!FZ@U0H MCC3;D"JR&3_@,.0T?IN*"\K.5R&VMPIB@RK@J@(CC6_4 JRBQ^%(XA M)YY]DNMR,*R*J)T_I7+G(K*P:>M-MU*#5HF9-"0B M^M( RO0Z"8B0CRU.%2DA-RIUY"F6.R[39$.54[)T*^Q2Y[26'F53 KBBF:DH :)060,4QL M7A6_(#? ?%JMT[R6/KQLF=8+#E\M$S5P&!!?]V+*J!_K"T<"R(1CV\J'%+D@ M-[HD.R9ITY_>4UILMEA6B,V28!2X8)I(@4-F&#-54QH1W1> )P%%%EN*3U#D MWO MQ>(E,E!LJ].FX6V_A!=Y^I@7=EY'3NHY%]A'C9:,%6TXH J1D)N1Q.M4 M-GNF\@]B5HO<[ZM:*@@!'$N38Z:(&<@'R<+ R'Y A<4T@=,$*R[";BZZK[F8 MRK,='30'_-.G#>0, Z1"?*(78DB&$=%76$@66/8C6'$/=G./X+V.5;UU^B*O MT#NQ5M'DP+T*_)-%,<8WV1!62BN83$W0 MA4DR4QSH '<'R%#HZXP.!1-3+;2X4%R$W5ST9=MS\(ZU&T"')L#@",?ZX@G( M2&3L+1- 1E%DM:B "-.S6G$]%)S03,%.T#JW.(\:+1DKVG!,%7QA-WS=US)' MVAV$U>=^DZ;R50RB(VR]M-#=3L?A1JO0V^]6IRU!2'<:RO2Y .Q7ZHKTQ@ M/!3%EHT#5F"&W6 FKFG&^6P[2X[Q-&C51"N$0JIO;"$9\:FN2P =H22R[ 6Q M0C7L[B7M:]Y&;FX%L$$5 ?1GMH*F%(41U@U"NC#&QM($Z"),8PN,8L5..#ZK MY*GVW[&2YV2RLTO>F-&2L:(-[^M]X\S1P40R < MB_4VU!TLBR)?[_2 PL"W90M1Z$;S'M57V M0\##>E-GR[2QE!&398SK=%22 )*IO,5FV:P3143D2*LJ%UF6/VYZNNWV[;+X M'Q@$39G88I@Z*DD R90@8MNW$D4_Q$T_MYN7:M/*W)/3*ZO*MJZ*0B9>7K9< MK)RMMZP*,=?@*V8BBV'NJ"0!)%,667H01&$/<;>,AM=+WE%_C4.HC13INW9( M9=PYA$38M\PPJDB$NDD$W+-#B <^+6%2! VHOAF!5+ZQ8P=4**;$9E !"74# M26>PZZ=*.I=6W_6&N=AF/8F-2;EMK\IK6>>97!SDWT&_0/LGBJA^/2$9C8UE M#Y)A@326U*6*5*B;5.Y.-OG.>^2+O"SEI1:3^(6G->C;!(](;+#UQ0*0Q3XQ M,AF0(21VXI822Q7+4#?+G..;RVVWP[&))&%@]A0 &3 P"2 ;#LS0\,"?< MGI/V=,^@)9,_& F8D;R + YUYPD@"S%A%IZABF>HFV>^G3 +3=C .#*J*B1C M@3Y9$T"&PCBR):-"%WJLV7-V,JX%DU9@WX<"CP=!Z0@\'P2EHRESI:-"'!HZ M.P4/F_6ZX!)'TZ)[X*2HFJ[');QENRZ"J,+]D\EB707;!M3)4>>V#4:-EHP5 M;3C "K>H&[>Z^=ZAH]S1[ $'$3@@27F4Z-B0\\U14C?ND"R, HM&S2J&(NZ M&4OW(VB8RUNY%MH 'C\*]/M6@(@@O>T)BBRM0*90BOG.]/\B 5$Z.F@!EK/3 M^V7,26IG/W Y9K1DK&C#H540Q]P0-]@'YDTC;P6VR[K:+):RT.Q!7916U5;V MUD4*/F+$3/#2]QW')0D@033P+7LJINB-':$WA]?^PUDN2=WRJ#T#6"T@OOXH M'R1#Q+A! ,A0'-@>P&0*U9@;U6ZV]W,SX)8(Z,HD*..2'94D@ 3AR,(L3&$8 MK'^WWGV]Z\T\V+;Z['B?"9"$.I@YPPP-'CQP M[H:RS[O&8"K2<=7?YSBX60>Z,;'*<'-4D@ 21"+;YIXI.&-N.-M>EYN3KHLS MU-EE>_5MX;8J(PW:K1DK&C#,56,Q]R,-[S-(.N_?)!- M(K26J]:'$-GQMAH@80$.=.X#9%/D(\M&@2GN8\=Z:_T"MF^#*FO63BB#'K4B M1&\V03*&C%T?),/$UH((% ,&[G;:.07?'>K<23!JM&2L:,-A5+P7H/]/80F< M''GVF(X9+1DKVG!,%5<&Y]R_?$UA"8#GQHPM)2"*@BC6GU<'9!9,"114!FZH M?$U9V88<_$8OH,:V$I#IK.*4](XN#GZ3N^+UHOMM<^-U#SOV/V[=?[K__?1- M]ZMA[?-;]#[I?P6MPO0_ROZ2X'X^[RJVMT;^07[7YM?_P]02P,$% @ UD%Q5A0LS8/* M"0 '!D !@ !X;"]W;W)KZK8-]F2)_MB M2=VL8EU.G2K2IQOGOX="J2@>2F/#V:B(L7I_>!BR0I4R3%RE+-ZLG"]EQ$^_ M/@R55S)GH=(!'JLI3^\4(9MSD;34?M M@UN]+B(].#P_K>1:W:GXM5IX_#KLM.2Z5#9H9X57J[/1?/K^XA6MYP7?M-J$ MP7=!GBR=^TX_KO.ST1$9I(S*(FF0^+A7'Y0QI AF_-7H''5;DN#P>ZO]-_8= MOBQE4!^<^9?.8W$V>C<2N5K)VL1;M_FH&G]>D[[,FS0261VB*QMA M6%!JFS[E0Q.''Q&8-0(SMCMMQ%9>RBC/3[W;"$^KH8V^L*LL#>.TI:3<18^W M&G+Q_,:OI=7_E12BT\,(C?3\,&ND+Y+T;(_T="8^.QN+(*YLKO)M!8#^/=\&:('@/ZS*T3)@%>[#:"B>A\JF:FS445[ M^7LU.O_YI^F;HY,7W'O5N??J)>U_F[X?EQ8?E32QR*17XHL'\,;BVB(7OVB; MF3K7=CT6,J ._ZJU5[E8/HH,J5(H2JQ@0J%0D)-D.V_./T0.GO%!KS1LJ9R/ M*T#.$;B*+DX'7AF8MV7KN%&>D_)2Y3K#*[=:Z4SQ#@[!\+MT+&MM*$&]W9]O M+D(?*!(&R#4\+UP=R$C7):CR]#WJ@==W'V\6G?A$S /9CL)4Y1(&M,69DM-D M1;B-A25X/E1H7,8&:BN.7PEV,K UB'CE-;NZ$K].IF V8Q+-HQ:71H&=:X+3 M"KPV$7? 1)0V:DXS_I#88'>R=?KV)" 2\$Z%0-@ .O,ZH^UCX5V]+ECB9M$A M;5,X4INU%+A\/HCO 1^_;1L?DBPQ!4UR #\2#EC>Q;TMAEQV++CW/+5FTXI^3 M>(^!7;XV=C&@:3 W$@C%F3_$1\Y:U9!.%)^Y>H2:,P$ I0 ME4ELWY/ST'"V"!51=J5CE%TCYA@G-0-"[N&9Q\[<+[=WG;$ZD5]7[-"1^#RU MCJ4JI%F1PZ%&Z@?*T+.EP,J 56"_SO @4K*5T6M-5FCX"U3G%#Q&"68?Y[=+ MI-DRY7I#U4*]CIWHJ*H)8"J8Q$F<$*9@FQJW6'4C5U+!:6\Z\7M!K8S7: M(.V<'SP>-+%FGV>8 JL)8>V#@DT2T4Y^1/'$E+8K, G6@X= M=9*W*^.X62"X,L\UPQJKZ0#"33+EXAGM.BH0[1,S=FT@-%]V]DQRN@OK$/;; MT4R#%&?[I1H-#>.E8NGKZ@=YH)!PG3K9WT Q#&(,UF!L#$95!J2A."(.F3*! MQIC]8\/ 9EY!^ N'97G,QA3HMNAIF% ''19YU?+_,NGANWA@*DT5YF1A"&: M:P!\#!X8$S7!NHK;&^,KH-'W++'.UW2ISO$4;(_ZFB:SM[N23 M\@>IOO JJPWS>Z(3<@2]UK=\@H&2^KS"1XX$W#T+UE.DT908:NQ#Y+Q>>[6F M P-\E!4 \:!QY"?WI[/)FVX^;0+1Q+0I85)[QTYV49R(/UPSL+?E"W[;$\8- M$4YC2U[[MH(>E?2$#1RLGY<-53H^IQ-QJU:0MS1:E#+G'&_X+D+E!Q)]D>J^ MV9C#U$54EI2&KE=36C@TM'_6'91I-NY/PC1GIL)KB8I'>570-0U!+QVF"FP, MGE,4)HP8Z>J%1O?\3TPX*;5>K0P'D/-8'*>N0,&PCLR2(?7,)[6]%9J^70WB0FI(!1(_ M![A6=9HED%/)F:%FS&;V1;\!I-HYDWQ*H.JBU<2*U4_$(DT:02D"%F#ZC@? MZ>PDN8^C3)ZF/B:T*Q0_2I^KK8>?MND2CZ\Z4M*?)-U;,44E&[*3GJEX: M'0J*E+!J0P=7+A/N?AVPK(IT-L'?>VEJU\=K_YA_ZZ\ =G:( MZ>[3!T!WK]& Q!ZM8B/#'HU'2>,^P=Y)]R083!I(=Y')%5I&2V]'' 3E":8^SP03Q M @7!V#&?K#$^T$V"HMEP#-:M0QH;4BHAIR0-E;PCJICZ&NR"D_U26W.T"?// M"[BM;QZT7NPL#2,.N):X^4FYGV *V:A[.NJV)B0#^ZI(F6B/B(QZ60ZMI( F M.Q+:HXN(5.>PW#+M2:7U]TN[PM=A("ND7?.)O2XI"M;!"$..^Z9-8+"Q 4S^ M9':@*9FR2+TPX7(_;KGU-3U4)N;*=4"XV\M->L+ &C?'4QYCL)1)KRWFAIH M6^XG>$WD@^A;OH@">](&M34T&@W9 =91.WDRMDQV77,>#FZL2^77?"]/&PO=V]R:W-H965T'I===_]!OGANS3MFG]LZ/-,.R^NW?/EQNW+?RBV[D6/EEU_;88X-=^ M?<_O>E=4]-"VN7=Q=O;HWK:HVZ/G3^EO[_KG3[MQ:.K6O>LS/VZW17_SPC7= M];.C\R/]P_MZO1GP#_>>/]T5:_?!#;_MWO7PV[VP2E5O7>OKKLUZMWIV='G^ MW8L'^'WZPK]J=^W-SQF>9-EU'_&7M]6SHS,$R#6N''"% OZY'=RZ[Y=UT-FV='3XZRRJV*L1G>=]?_='*>A[A> MV36>_I]=\W!@BV=OBTAN>&YQ_X,K)NE7VHUVV]JLNB M';++LNS&=JC;=?:N:^JR=O[IO0'VPZ?NE;+V"U[[XL#:YQ?93UT[;'SVNJU< ME2YP#P -T%XHM"\N;EWQE2L7V?WS/+LXN[BX9;W[X?3W:;W[!]:;.6;V/Y=+ M/_1 +?\[=V)>[\'\>LA!W_E=4;IG1\ BWO57[NCY/_YV_NCL^UN@?1"@?7#; MZG_QKOY3:V- P8KN^VN:&_P#V77>GB@*@979:NZ+=JR+IK, M#_ 'X.F!%AC@J9?\3%;T+@.<[>#?*@-V'7C%?H2GEKIC$7>L6_JMKV!E!TPS M;.RGN[Z<-@+MVK>N+IKG!S]T.X:EY^=_:&G_[@##Y[/@??WMR<7'V_0^7 ME^_HQ_/O3Q;9N[@0[/\RG(HD2EM%9+S#^VX'_N0KT ';-&/E]-QXD"F.T<0T?^W'IZZHN>KB617;9-+#*X/K34G&JZ^ #0-.M+T@6>L*V:VH0*(4@ MI+1'6V1O6Y!ML!9\ ^&_WCC8NT]N;%/ .OC[I^-G0613-(*$8,OA>/0 2MD4+ZH(>PV?JRO4^6\') MNAY14@(AP$/7<.M^4^\"*'E6C,.FZV$-W&Y;?'1PQ++VC! BHX"ZR#)X>^( MW@&X -1&!G0Y /GO"B*O'F5]N)Z.4(/?P#VSKL^V;KO$'P&0:U X]*_!()\D MJQ%_5W![Q;)Q$67RJ=+CO]Z^5G+,0 G#0C44M#2@LN;(EP LCC=L?,0M17K%9@2 CA[KH>]RZV@4(/'1%^KVI?-IU'TF?@ MD81PYT//\"[$"(+0SY\X,M4^;+T#UAL%&O<)[#D/OU1CCZ0<'R*YZ?JZJT"6 M,!< JL"Z\;#_V.!! =]MNJ[+3S6>8.S1?93Q"BB$SC1J)&(V]ZMB[XB'F*H MX-^R@V\BJO-L-_8ED"D1'(AUH*FN+.06.OIJC]+J"A8,-PVV:(,[P/IY5@/E MU3U]EH-0J'M@L 9VV;H";R B"^1MMP5)4WQR\$T49;L=*#ADQ47VRSB<=JO3 M=X2-[++Z?>3]LE<1:3>NZ(%7P;#)P"PAAA?3Y/S;/.&AJJZRMAL4_#]&D!2N M!Y:)+,^7 M]HZ(KAK,NN!_, -O/9")NPX'COKKKF"B%X"6JR'K(W18ED ]*" M>'M%C+U$4_N$R?8:-I"UD"C@X,A+ )"Y_E4W]L A A=2#)Z!90>3$?YM#UA> MC '>%3(^6+*@,43/@"UWEB(,1#HP MR:HF(27L4([;$?9"61P@T5V71<-60"'((F*H[(BT$LJ?X&+2<>;4SFX&- 30!UX M.\L.3DO3F&3=["@V]:EY815#0A/R4=O=-UT<#GQ\9T^3AA MA<2^).@" (LA!#>N85*%&P$A ?=$]SEOM@$7 Z9+5PFN]W;"33:%$ ,+,I;! M0 BP 5(I?@98@JV K&LZ.>('B*'M< GXMR(!!9*"[30\>J&G"]_SP'<56!Y" M-*7SY+O26;?%3=P7;]23^ $'EP'OBQUR)9RWZ78D:W"153."@3?<\#W4*%5! M,),B!+P1-7FY=9 'XNB2K$1,(8TB%>V=;17Q9,^).X*:_^@&<^3#>%4&:]4 MDD_DGE8CF7ME$ :Y[ \0EWWG20O#W3JVW&@IH(5 E2Z1@E@AL-,I?,,#:"31U#8G56R.\@&6ZL161?T# M.&:IBQ)F!)RN6.D86V6*F8@$AE7HCFT-,4;8+T.(Q/R;+B*HG<<]FTMDR0,% M %#D=M-FK5MW8),.3N@9D%O@I19774\BO9]83&SC ![XPM@?&,C#PBM5\Z=H M?)>(CJ7#O4A\HC)7!,-Q"L1 XAT5@ZH_%I\6"A5@]W4]0[$?L_R$AB(Z!PP MCY#BVEU9CK!>>8,D4*+[NB;MQI89 M(W,04PF,PHI% IK[>8:"#AB\)8<'!/2Z9;D4C@A6 !U )(K5PV@P&X;4I131 MS+OH4T2C6RX\SUBYE0[.4IF_KD"0M#4*$K@9>$[UN')-MG)B 6-8!HS+@\1+ M=[[(WJ!1A/>"%RCB6&Z?%7^)PLJ1SJS;5<.G7X(> ]\0=3G8!$+9#?S6HUG4 M(X*!)_P(QB;H@PT2)O@'_2BNAEBF=F6Q=7K2=F131?PHS>5"ZC<)??*G^>PA M9ZE^0HTH/BTLA$[Q2L*)>7D@]8[B!& 3PS=_^]C#R5+CR0.=B0[]ZN/C"8D- MC4!127# ][0".DA0Q X8>"0)Z),-FA!W1Y3X;'^P6P*VM4+)R0+".T7)K1S+^T& )$0BN4&O8@+# 4'/ELB?XG.!#S M#.-/8O0CI=4@E@&1O!9LP=XE>PT'=XF^7-DUF%%!>_L->APFYCKVNXX0/1.; MO?SP,GORX.*[[$?'E]%B3H5N---PY35)_V6(#)(#@$$2CZJ#\;_M*C+Q6-5T M,9Z5U4R3,U\3?W2)UI$C642ZR'-021\A@EDA]O/T<7/$ "$%"]"A)0W+?U:S M+AZ(/$HY /FP#?P2%^XLQ,?1&&U8_*7!/KZ@R0I\=XS;,_%FT=CA(V)$4C<) M:3!$*4E?=G++CZ"1R 8D^Q.Y%;W<2LS.IJ&XP;C3B'S5[11VN5(U,ZK.^59$ MP:![='H8C*4"?F!5^#.CUU4GB^R?L#[I&Z"9!J.J>QZG=2MX)W(;9%V,(2X= MF1FR*#/4F\L/+]@H?_V2J9?9E0PRN#J)*=,!O5Q8S>*8HH$@D##?<1,1QVZ5 M">/>,#E%2%73[4D*(C?:7^Q "0.(3@6N/"5KGLW$ IBOY5!:KE9J[X :7$ZR M88X5R"Q"KX\@BE05@& 8[",4>\'(1R^VK ;3 ;#ID7(4H1OP1A%9VQ'T,7S? M)^%?W-/#=AF9KD3PJ,$H3,BT*TYI/"E+$+L7WLL?(.@Y]@/V04OF$B& KGJX MAON!&\#0!FK.;G A_LQLRKXU9@$28496:K$,\=(84^-M\^SX_ 21)&)$]N9H M3-?7ZYK,7K*OW';7%":/Q*C6[ %N='QAUPJB%DP.(0A8- 3^^?'P&:[#+#R[ MO(A=#+83(:K-\KVP)U*F*A ^Y;N'EV-^HJH @[@=ZX4E^T8 M-1,YDF#C@=C\3<@715BXGIP0E8(2@\"&$]KF1IDJ:+2V,Y$O-?<0*DH#1(=P M)6'&P$O!N)#81C66A!U^D!,LI-/996.$RE9&XU,2X$\4SP58GG!DA$%N%'UX MNJ-ZY1*MR4&9ZWB M;$[T63(\?)/]]P@6%?Q^SMX1QFG)FA6OX$^\QXVJ;MHK;L'WY2?Z@9(2I.J" M0F\PV&D][>D-J3/+D>!/&-,F/PV-$O0S46S=8.QNW#KU\)C\8FAMZ,9>H6=/ MU;M@9"@H+$TDO)'C*8,[MZVK4^O21>>J[#PZ->JI]37*+XG9(X-%84DJ2:(. MN40#$%H&$?@$F'U@7L]0%L?X+\MX\I=KR5/-W38#Q<$/]*;0@P*E2S&P,J3/ M9!?C!E-, Y31NL:(PB*[9&E&$9#T.F(5Q1*<&2_R$U$0'7:U!(D]*&%.#W2K M%:(:ZI@X+L$-C!?1J("PA:E#172$AL8-]^!<0< 5V@S9P30B8Q M&.)A& ZA&C'B=^%(!8SG&Z.$@7^1<)!C,U^@ENL^S:D8-4 M@A^48Y3P,#F!3^P/1 5X6[34)2_A"OYU$9LQH"H12LP[TLL]1$V8W8"%OW!5=- M#7V]E.B9E'/ ATCF;4Q;KT83.0J')>%NS#6*.8#2Y<4HD$#I"!N&##4G];RQ MDI2WA**62V#>5DQP+#OJ"[95-#T1E@#,P@5NPU*DUQ -8I('[I_>&<,C MYBFB.@(GWX@*\C]4ZLWFYR-JL2 H2B#V!P45D-0! M-)?ZM4'@ 'GOF,*@%K;P-T+,[9LN#Z%Z(U^B:9 MM1*+#W4C9=&48R.!/W2:6W<=8AXKK-LQ.^8'5CX$0ZC9%00.A$"I#%844![; M..QS<9:OV'(FW@_/:-9F(L(Q!.(EJ*#5AZ'B;A*'.RB P*@A3N5SU3V9IQ57 M0?[*" @!$\I5ME*GLZ<0X7OU=HF6H>1R#MC>42B$O]3MG*(-!0\(1ND2Q0L6 M:"HWC,HSPFV5!=!'!M'!&SJZXF=71(< MKIQ3(D/4[?Q_'XLE+Z3]W/8/WQS"QT7XL_U-B/)E<8AXTHZ(*$E)7X^ MM52<<37T]+S^3G402,CQ7B7B,T?]8$N#:5,'?Y/*]'Y^8\O@ (P?Q^%/0L>_ M'94Z#FC5O&FZ'KS,)$X)CB<=]&>@>0*(@,$G?P+>0*S>YFS_!RR*M##I,_;% M.S 6QD(:IN"T& JZ-:$6:SA2K6UU=;!"$AV#Y*);?(EN-.='(B=A)9TNQY;. MYNS[$ZX=,58)( ]W,\;)-;K,6N@?D6"2H@5]\ZG"-2!1?B8WJ=7:A]TL^*>0\W M>GTM**QLA0"Q? BA!3+M-0"M@H_LI"I8ZQ,C--8YKMF3,L!.&F7R+)2V4_V M5 ;QE>K-*/:7%$2FPG5-S5I:\07[:H"P#;#D3"U@T;:CYA3#8FQV40!1]@M5 MI340"#?WF)+F>G!;/T4(63&*%2)844%1BY,B.DT5T2([INP;J#4 UI]H !CN MYG[V379^]B@_._L6?WV0??MM_O#L,?[\,'OR)'_P\ )_?I0]./ M+O+SQP\1-KFX[.+\87Z!?Z)LZC?9HX?G^9,G9]-X'P9EQ0*_PK;UQ/V=FEJ( MU\193M+.2=+3ZYUJ*2#6LQ8?.6$@+9OHF<7"7[[L6 ?.=).!!SITO;BV,7H; MF@R4L_CQ/%0*FC8$54UPJZ/'WIU$.0DI2\6]=+KMMV_H(MAGD"X0)!QP(/6< MH6K[+<3Q0C'V "L7?>5O+Z*@XH@\4FG)W5I][3]*]KU&Q<4ZKUO&UJF],(5< M0'95]UH!&6LH)OJE&(+I/'6CN6.82W=L%#^4ITTNF@T + ?CTAXER' B#!^L MN)<#Y47=E^,6D4,& H<7Q69*SFZO&;09QV(S:97W7,6T<;:ZGQHQ0SI1TW?< M+]Z"BL4B^S[:]>#6IGWEAI@)PQ.LU\.7X_DX\!$BFBJV@)R,NCC)S6.R?-(V M(&$R\1W(X)LTNQ_7"[>8Q-B2I/RY>4EK8^CW=%^*)]AF 7D_K!22.=G(BRET5Z] 5@:)+T36PO MZL*)U7C1 )B-/MX^;!%)%1E[9:FIP. MRF$D!I\I!K+=9]<]V!FGW6IE(B9W7/:.[N8YQN^2-NCWV ;]FCLEWQ[LD$[= M/6(>/U"[9X\.D&DVVS5%J7^@'-6N!B.$H@S7$L:^D1249O2![Z5&J\?,+*ZH MRI7(Y8J6*4K3KD&> 7.I]*IC_[;?,\!I8 5?-$4YE,Y#S0KEYU&,>DKJ>0VM M5Y-R?FP')Q.!C8G=B&(. "RY08^*;L8!_YR &):;+3HWLS5XGH(Q8$QQ1F_7 M8A>6]!5)_QCOU\H&*1R>6RM/V-]N'T5!O&5/W5;")J$BX>M$$HJBSP/=[I_T M+B#'6)DE-YW%$>0_J K@%?PH>$ )]:UB"J6G\WNGU3OX@88[W^FP@7[C7GSM)KQ2:T9M)^QB-@%\]/*P 9#*QO_:,1!ZUSTA5I3B2 MDOT:W!JC;YMZ-1BU%>L]45=SJQ@PT>\ !6=\)^40_^6G5QU-?T M:^50P&OWB) 019FIN@^\5Z6:;N;H.J& !G6%SD.)-N-4D*+OR5+0>0N]'5Y! M]?0Z0P,;&'G<#O--%,9;'.(64C78?84!S[E;2^#&=A>PD8S^(IM?8,1O)!8S MFCU(;1,\!X"D.Q"Q."QME<4$@\(H9R,AQ.04@JMN\OQ M!KZ+R9!M4;E$ W-\%?NA 5\EA9$X8C3DGU23WO#.ZF1L A M+DX>.AS/Z>?TO,5O%)")7^.$4&0X#J4[1'!1"0?2#R,_=/(8!2\V@+$0DT78 MWDS5:!3//HL#ENI6JU?8A(BXH#$K4EM,Z5LSYV!#)41%N7&5K1DFO=,X5I(' M135F,9<=&N+S.I<'%!S21B' QNL)+B=#:&CNF$A (Z4P1E>TZUJC)CJT1(Q) M>B"$0\PA\AC%M/N0E;I$1]AMZW%+*"4M.B:Q6+;.V;0(UTFI[0!>[/S2O(DI M)Y%XEVF]DJ0_S[*!WY/+3]NY[W#:+[N& [@(.#>+ZU2AIN.RW'!UP7U/ZV\8 MUEML<1Z.1>T)2S=<.RGTF0ZT$LUE($'^L2S0NC@93,4.5K0P7JU1O^ZZBFN9 M>O$4BGY-Z1K=%']CR ^*P -PV_,SZ*9!U1KG>X;\R5\XI,KA2C,@=-725J-F M/+<=[PMDBL>(>$E5=@SK--*H<&?A_X52/OHE_+S?U+)61PBX#MX(LWC8_I$RX"PH:2H/6;S;<:G6\:N MMA(K\"4(I]5*EHC0HF7O G,QAQ)I-T8QB,P [BM2(T@'L4B9<])[H1#Q_ TJ MG8Q+IQ-(YI*FV)^4L#ZF7@%?:V(0S"[Q;[4-N0QY4G=5? &71W&B46FB,>XE!J,2=S"#(7DKXR+U@")(A4V9( MI X>#;*1,=$SJN@@U@+2#Q30+.:MZ%Z%QW?8_863U3#NT&&@[G;YHQ02,YM& MH KMV?D"MUII!J;;S#U$'H_P,I6:FFA3E(<@B7W4'," 'IC,)9XQ>[O&X\> M5AGZ[4_'G4;&R0RQG)\G64NU5E2O[$T\"]TPGJL+J904+GY;-T4?#OTV$08I MF)/LH!: [GE$4Y>)B7*F<8+RF581-)TT#5.%U1#;I_C.[H FM>:&FYWD^7KN M9B7V\O6G[)*(0\[QCAP@OUB.U-W0Z0U(63$#E69 MQL&R0:=8:CX@!R+) H*X,D5TL-TEUZE!$O$KB\(E)W0A2@=5S%-P9X=M<8V]S%_IT93U#&C*[7.,=N2*3,5+B9 M' I/QB=[F(O:<=3S7G4*R)V L83DIFI?PE8FFGO(KPP-&9-*AT@&<^O'?OH( MK>WTX'3XR\E61IRF(_)0NMKIW -5LP@K6@^=ZU18>G"MLA3,N4^X!Q96J4-C M0?-3V/)LW7?7PR9,)? R\XBB.+@.U@.$M?:>GBD-D;( 2AN(V<>2J@B5?<(@ M3$>3.A[I^X06XBEHO6"$",<;PTY4"P4Q<4H")RS"2'DNU]QGX%_3":TD M?L#J7LU/U1RXOH&S92-0(#Q5LC^]8J]LJ >,74UW_\\.]2 M##,;94+YM1VUXM\4RH:Z2;\W8_YS6WY[]O>31-L%@R0R2QH(4EL4WPX19BF% M(^*5=JP/).01"@!#88V4UGMJX6P E):'*F.[G9"SD.!Q,M!)BF.D8H5:\+B1 MDU8/8;#X_(EAN'BO9H0&N2&&54/UC3)RI>]:0,V2CK,*WP7T8'$@<@IWCRR+ M\N/D!1(8))V*DNC@)]_5*9AT@H/]FBI SZ>M+A4E:8)X"]S,J4Z%V2A++!>: M,+E/X@]:/#PY(!7P$'QACS0Q>[ ))\-Z22#,97&*L]A_6[$0B2,)^^P>;SK"E)E J M,MYR'PZ7AX=R3W8"M;[91#UCA[?1TZJMT#><76@F3(:LVO6QE5MN7..4-=G8 MN1ESIT4P"S(HG)N^A<>4I%+H(N29W:1BGL(,29WS7*7B[8%4Q0/>,@?,=%P> M?D1IZ]G!?UJ ;3I]Q+6+-OJM^?//BI#HR;2Q0HS*=,TVG^FEMHKSKQ?-?-4 M ^V7Q?OS^93@U#!,>ZW% U)O!CQIU)3"4>EH*AVUFNL'DU%HDG2(UQZD:+B[ MB2LO;TNBP;2B6[#9N+-#"3&;H1,(: "H+%E%<\:H#.<6;$*':Z3"TRDEIGUP MG[_8XB%!0MJ])B=.=PKGQ[A5F*L0$ET<8+QE6WQOD^]RO6,NT0[K8\": MCM"M3E$@B]4EY2?O?_DMO!J(*V\9> TFWX3.%N5S*ED-0"1VT_D%=]/I.UH: M&0[/>8J4<(S!$=H\K,87.-4+?-$M@^3DCJ>GQE,W;18B@\> M3)ZYIP:1A(;"PMK!"8W6]NGY<6%F3XT,2)F#:-B MWC227-;\&"GJQ BO#DH05Z2%D8%IR2EBS9AHTNT3?6\&AS20'35F M.6WJ()H^(EO#C0W3C\[/3K&TE\'#E7_L*%$1AMV\<[Y&,7UIZ/E(1E<@-C4,8JP[N"K3-[R%/07P MR !<-9]G)G+-GG>,#>I4J]!\B7#03>3VI6T4/]?95:M@S?%;&CCOY(8ZL.LD M-,5%LO$Z..I&@\B#6PGQ21[.=)$Y)-RZJ6\EHXZE3S.FG\HNE:E!7% M6CM@.)IQ=ZONC:KS89RZ*@,7WH>7Y2U MBTC-J$J 2ZY,YS\DG]8\99Q>)<"PDL61F*A38S%28PC 7;&6'7>(_P=GXDQ0 M;B7F_@'J^/>9,H''^/"Y?3BI%DB_K)X4=<"Z,+!DTNZ1!@Z-YT3VW$SY0? ^ M-]R +R5<"WK'ZEP!JZU-L:[XGH"D"S) M?N8;;)W4S457E)YL-_E$'2>)/ZP<(W>R D^032;R,XVH5KE6*60 MDPGPDWQ^KH-TKL(*40?=FA+>6PB#$.$49E+/S&QG?6'=X7DX*<+G88$N[8HN%!@:0KK# PM0G[F4TS/"AB1,F4 MRX/B=>HULH$19FZ14"?J"M.F636.;3P^B2[;LY)DL24BC@; Y]!+\HS,/XM3 M#)ZF]:D'"E!3^N9879AM14/HI+^0UC=]'C M5& M#2C+$SY-_/LOS?P?9FE+P!*;2!:567Z\7!C 27_(A4L58$OETD2C+O>\TOI?RB6S\\_O3+[SX%+<',W4!+[_X_"9I)V$]!2Z\_ M3NY]A3.^V(9]2RI^WSY%OQ@DAT99P:GZ;LQ5-M,VJP3%C19S*3!'X MI0L+Z 3V I.W?M"Y24&[" :CNF7U(#V T:\67:]>+)6#++62352EQ&+Q(FA2 MGJASMD?BFYUJ?N<-)F+1>:3+#MEOZWZ7 @=]@F-@F/T"^/7 M\^15[P#ZTWO#\Z?W:@__*^$_H#?X/\'XJAB*YT]!S:[=2T -O;^Q'9X=G1^9 MOV+*XMG1Y?EWEQ=']^#)^/7G3W>@V4"-K3'*U;@5/'JV>/SPB&/&^LO0[7!) M;),"G4X_;EP! .,7X',L+-5?<(/KKO](X#W_/U!+ P04 " #607%6Q9O, M7+ 1 #N- &0 'AL+W=O/2F;.E>%O*F$;K;; MI'IX+O/R_NF9=]9^\8M:;VKZXO+9DUVREK>R_G5W4^'39469$ M+RUSS7_%O;G7C\]$VNBZW-K%X&"K"O.:?+1ZZ"U8N"<6^':!SWR;C9C+ETF= M/'M2E?>BHKM!C=ZPJ+P:S*F"C');5[BJL*Y^]HM,II?;<4/-/4/-\\:8LZHT6/Q:9S(8$+L%:QY_?\O?<_R3% MES*=BL!SA._Z_B?H!9V\ =,+OD#>_[U>ZKJ"7_S[F*2&3GB<#L7*E=XEJ7QZ MAF#0LKJ39\_^_CI?;95OIR9N*@1X53^(Z_3/1FE%L:+% M^XT4+\KM+BD>A.(E&J]B TKU)DTJ>5')'/0RL4I2E6.5!+U=I1#9*G\0;]X] MUR(I,J%EHR:*1'('3 7OE?0$VX!Y]VHD6Y4K >>1V*:O.@:;B95,1&S4(/,BD M$I+\]/!&A^^P6]"'JFS6&[!]&*][=."+%JER2;DB, MI*]6W%464FR1,M1%+8NDJ/>JPB92"M)2+D7_(E(O;A#)>EW)-1DQ18R1WXI= M4Z4;:(0TGTHB_\B?30,DBAR**Z;B.L^'',"(1C[\]7A;O''%O:R8+ 3".YA# M:_C&8"5SD:9E4]1LR*;:E5IJ8PP8"NF=-9LL<^(',0$?8Z4DN)8FG(2MFIB\ MU0UO!SYRE2RM)]'U9HOOLZ&U]&ES#<2Y$O]#MOWQ\.;)JP+4X(NX59_S6K.4 MM<"!(DV@J'Z@)#64H^LK\9JV>"1")PX"O'J^LP@7>#-WHF@FGCT"?87(OMCE2$@BE_ (LW$)S56]VUJZ$^](&S6 3GXA7N2@H3*S< +(B1;Z[$;\6%*T3\-:M\9W9?+'__"+1 M&^RF,@Z%ZI2OJ"+-&_*"8?@\$OX,QB1G\6:Q$[@NWL5PI$4HWC;LH&"IE\+: MV,X$))^+6/QG^ ^K]G=&'3*[2) Z22>5)"3&NV^A)_67B3L0565F@E@-'07> MO81S7FQ[)C2&6!)D$Z/O6]_CC+&8QB8P'1$C[9@8I:6>/_7:*XB"G63PE2.5 MGLS,WT$4WOJH- .N/6_JM\QY;ON>%R^FLZ]AV_LN;/\W%O"F\Y;A>?N6E\ZG MX==(XD[9]V]1@=XBK,2B<_O;NDP_H.ZA,&C^;OZ#^!$L #)P2<@R]G .9],D M<.6Y5>M"K51*5>P]%S,MKH_;?I2]![47H""C0!<;Z%?0%[4E-MD'&O%1;Y1N MBY)#)4XHDER]92 :BL(&Y)M M+PA/$?# !I6TE0U+//>QP,8HRMB#H[?FK/;U5 W_<@]YCA?57&E;43GM$((B M%^AK:Y-D5,9320"APQP#T$5+OHO@\&Y.HP0;P'3&=*+Y[ZCY%*I_/'N#B-'HL;613Z(;]+"I6(?^!?9(/P\4&B M_8>A;9U??X.,]Y"(G+CUE7H#/,=J_*S3=.KIX/"!HMAU.+T("G1$G0+]R&P D<6Z+@NGU:-C@>HAH0SX/"]W M5 -;!IG(OYJ=@L0=!9.UX"_@$-QU%CP(_"]B\753_]4C#76TE#M@<;T'%J][ MP.((ACJ%01@6:W)NJ^M]7([UKT47)5>'_GM8/L9X])]5J36 1E4]$/GK+:%M M\)HV:!DXOJ[[-87ZM_'-WX'$J[%*#L'E(T)_CA?,",[$](Z 310#KLWY8NC, M0X\N+@+'G1-67@ C$.(:;1N! 3FG9#1*\3Q"Y]YP'K>IZ#*H3OXIDO MWIU H[$31G/A8<%, "*C%6R_<8&T@7 CSR+.Y+39P74,!H*0WF';("3A%H#G MBYB^6H#RW&=Y9XX?DW Q9%MX?7WU_.;J-"@&M0!0EG:"F"ZK#!R[?: M2D&.3\UK)3(!HN/X:\3+8,S7,Q(+4TKV9(R$*@#/0,P M="(R#=1O,]*8MQ,$U^CDB8Q%7EWI/8S?;^LAK[]=19RRJ3U Q$3M&\^\0;M( M0?QE^K*:(4#W2$SF\8Q?0]]\]F?S\P,VOTQ;3#4P3')0>.S#\X48="6_R!5- M7?<^F!%Z2%7/]/WMY<<=_$T:!'JPMIW\K*IRVP*X*7-Q<&M7>*Q34X;&9H3' M>2<.UU?&I1WJE,&HR%#W\8ZH>.F_W1V'Z/HN(8AYUC%?)C+5843(S&KXZX M3T!_0OHSHS\1_9F/4NX^2Z&3]5UN(Y$:%R9US+F;1**;A68Z,5N<3):>._C/ M#AY*V)VP_)$XMRJS6WOMUC9KS3V[=62W1HZ_/FAG]NQ/PM8=O8A?@R@PKWYL MW#-TS\7SPQS03Z">,T-1("9"2OMN@$[:$Q$T>52*DT>HG>/'3L+>8< ZFV\Y<6EA$(^?;9UGR(EP1Q7[33O]L$ M7-SPY.^?<'$Q>8UT;1-2GWL:6^'>?,#C9%4V5>^+#"3*^5+ 0,6>=<0 CP4LLGJYP:-=H1$O8V>7MYS?]3AF#+Z %-SY^=&^F' M[/Z<;'> G>(7&@B+FP[Y3NK[9[XU*-VH-)'_[\[N; MHQH-S\6_$@#[ZH%RN"&P'TG-VT&8"6M @AGQ'3A1N##%9&1%H%TQF?7$MD1I M%>"SZYKE"V"I,6^:0N" N;B!_/E(T3Y+UP&G7D>7:++G#Q91N>BEC7QBIIHC]:,47I!"/N-&YW M=<0C?S^C-US%^\O?QM1G60M/ZR@>Z\CW>]]\9QV]W_3.+S0RF+:'%VVCZWF# M>47"F%9B-8'VO<>"^2_9HI&U'F-WDJQN]V.%"+=>@3V5XI D4+!Q 9-3K@*&!/BT!G4@]-JAZZ,6@7# MN1[P;@:?(LU1ZWD&T<(R,K:Q_;T_\LGSVVARI:[7E(5_=N0O'B0'A M/';3!GYJU"S'6*3LD-94O#+.E;;-O0F-T0EUS\[8KUOVVB4C)H>4IN(GB$BR M7D#6"Y9U[\9#@6#'K-PB3-@%&FWM,4A@=@_H;P6)VVG]79(WILV +W*F*,I6 ME*&>3TP[:<1ZI-B-??]7;5T_557:; %UX)UTSINIE%-@7[',%+=[^U[IA M M5HCRP!EH:=(<'7 L#^/ECIZ4Z2L*5 J-1Z+3F! M$E"Q(3Q1YV::71448.N$,Q,OMN?C$S654T>@+\Y431I#<"F;8_[>RV!DD=ZQQ5V"E_3A%)G!*7Y_*(OPG2AB?8/62^K6Y0^<]N/.])=TN,)' MZF:&R]GG)":1JRITB;[5C!+<4$V:2K8*9/+&L:J48&( X[]Y$"G M0NE>LAE:L3WZ'[>^*9UYKM#V8/N&Z^D=6A[T)L0LG_90+K3.5M)A$TEO#QEV MI)2*3F"&FTERPRZWD9^8BL6/2RS-<)>[-G:Y$QX\*IQ+/BFU*;73;(]]SL0H M+30RH^Q"98%G\[R'XN=;:E.SA_88/FVR33[02!B[4JWC,^==]V0%GT&QV E2 M6G<^Q:,O*G[4D=L$8[,$IWHH'SDF)2.8LS3<W#YS=\$D'/I*#/T#PFT"D\&K3 ITW#4W'&9"3Q[*UU+T] M .T+WB9D8FQO TI>%C:L8')Z+(BB/%,K!!QY>UURPE6I40Q=U,V2A*9+JX:> MJ&CS R,?2E!)3FW=OK[OCVGVQC%"6 (]I]B7M2%$4,89>S4,U_('3H2L M"MQDCIUFUE3?:&0J]2@#\BK.HO:,QZ84PU%7JP?>V??=-@P&*:/+%Q7-B+0V MMCR,EA/XYFB-AIKOD43DOER*K+POZ'M2"!?/NN;@U/%R)5]3\E^KDF5/W0,O\W,SEHY"&7FU'OW]W"]4E MJPJ9G.A3?TI+/&>!^\>/IMPVA7A!@<2W!N;6]F+DN N_^V2&6W3?$6726&6Q M&*V@[G\OWV\V=P^*O!T0A);'F>.%_@&3[0#IIC= F@U9#4(>0+0?CYP>GC[* MFT1#6HLH%K[CSZ/]'*,_NNH]E-.^HM&> QCD*&A1BET5U#@-1-C3=P++Y.DX8*9)\TEUA3*CBX3^$1.\D> M-'O3T\]R'/2%%OS6^PEA0:U?Q?D.2SLP31N9>Y+<3'7ZE7?V XT]S&Q"W?1K4E2]IA)C8V8?E M7?:@/Z( \.E6[NKN%-S[?^01,?["'&;S#ERX!\CU)*=3\1[[U$I5 MZ*.'B<[K3L6/YD'22?PE_JJI-\G&Q*?'?N%PV?L-RE;"6O1+&WIX!FC6_!RE M^[;[,<^U^0W+_G;S2Z W,+9"1Y7+%9:ZT_GL3%3FUS7F0UWN^!&PO=V]R:W-H965T>=I MBFW)[S8)D*23F2R:QDAFNL N%@M:HFTBDN@1J3CNK]]S24E66B<[N_Y@ON$G?K&O5JM M+=_HG9]NQ$H^2/O'9E[@JM>@)"J3N5$ZIT(NSSH7X8?+(:]W"[XJN36M44SD'Y<$6>*JP MSY[?ZL*NX'WZHJTT-!<[L4AE0%^D/>U9".!EO;@"N_1@T2M@842W.K=K0[_D MB4Q> O2@6:->5*MW&;V)^$G&71J$ 47]*'H#;]"8.W!X@U?Q%I8^*1.GVI2% MI']>+(PM0(U_';+68PT/8W&Z?# ;$FPT73X M%OK_&IC_&XQ^7TM:ZA39J?(567[ V<9I8\CBX97.-B+?_?S3- HG'PUE-5CN MP#8>C(0AO20$3&8+631!(Y$G?!)^H#DV0I+2H$=<\BJ9T+Q @2FL M)=:8W% M2OZ2.]:9U$PG2UTH\0*W M/D;!>#I\@3EI,!_DIL*\UL]TKQ+$[++8";CTI#H!YCV%- ZFX03_L\F$!MW9 M%$!\J(%NQ0XXPTD+YVHMF&Y1X=5)1=0=7=U>/G@P\"8,IU"GWQR' MW7'?A6'>=DS&D;!9-2O#U%W.G-.F,[J797R@Y!^+;1Y-6Z<[]=Z81N\!LY0%9^E2Y2*/.3%C;:P)*$?E0):)&(E,S'8=C>]$)SO_8= MC2;>[3B;#H,(M/MW\W/%X$JD<:4?SP"T=6V:M7V2!<.BI2,0F&X(6=WX"26D M58S>*FW?WPV[H'7A"N?#W?5][_/-Y=V]&QP22D$:F-FZKW*2KI21L&[/0J1P MM"0_D25A@&'Z(N#TIU$*.PLG2$.3U)%!,&EB32"I6:KLN^KP(5S[4B%IXZX[P3$<8$ MZW;.C6^&IED_Z)\D2$+O\L,[\+]=JWA-3 9G&=8)-$*#Y.<-KAJS 2J'7]C* MJ/^Q\8.[#C_R0]]HG-KL'!*K0DJ,L9B=7:^MVBG33<>.F.]0B;HC3'9LFP++:4$ MDU.Y0N#XW(%ID*2H=@EC=*R1]89"UF24CGN-H?(9 MKR!8IY&RCH?,2F<37V#)IN+[7O.]TZDT-;?WB=% 9Q+-'5GU1[X7G;SF"-9P M)7/4C11>K;2">6B%/G?V)B<\9RKVG0=A'A;L24K.!E3:FZ$>Y7AL0SE(M$NK7F4E4ZW1B/E]4&[4MI=5=1V*B'- M7%*SD]=5U=E;N@4)][!=NCC,G: ]&=):)+1)D>!,YGYW1HN*RHI?W* \7,UD M53FJ@>,/N".LZ&1,)>?NEC!?]<03 MBH6K)*"404$RRUU%5 Y21=Q%JE;"^[;,4VFX"!3@1[6A9M K;=1(1 ZV+W:\ MRG"AK(?:ESF?B4>_S5,31FU04V*U@=JL1\W+@-G2D%3GZ2Z MHBN:T?E1OL M,_'54N$-0/Y9JD(VJ%(@W"^4#7S[R_CU#.1U70]U6V>RSJ,WQ_QV0E7"N!IL M4N6ZEI?))IB\(Q$ACGGNIH16R+2Q1^=U*Q= M<4RXX%N8O MLH_[(\1^KXZ/Q 'IK78U:MK5%>*'_+@6,1JMZTXG=%U:?D><-R&:UX'C6/EN M\CNGI>M@OIT1?S9)RE2^#&X5\A\"=.[PLU.I3%5@K@:]\S% M$%R,06(_BN&)UW53@N:QN]EUTV0S%=_E$/;DG8SQO6J(+>4"W_]<;4$>"7HW MQ+C99"?WYSU%Z(AW5OVK+:=J8<<^0)$\:9(K:%C0"D,]726EI"J'ZBKL9JT#XC9<+!$LOLD5A%-=<:/P[LXM MI\*+'4P#T'+#_<0+*:1>=@]]$^BU/MQDLEBYSU-<#C&#^6\XS=WF"]B%__"S M7^X_G]V* O.504M>8FL?KX$=*OPG*7]A]<9]!EIH:W7F3M=2)++@!7B^U*!; M=<$"FN^"Y_\!4$L#!!0 ( -9!<58;.Z$02AT *MH 9 >&PO=V]R M:W-H965T9 +8SNR'9,5),(==8">RU4T6B_7XJE@L MO]IF^6>]DK((OJR35/]TM"J*S8OGSW6TDFNA^]E&IO#-(LO7HH ?\^5SOEH>&1_ M\5$M5P7^XOGK5QNQE'>R^&USF\-/S]THL5K+5*LL#7*Y^.GH99_QAW?Q3T<#)$@F,BIP! '_W,MKF20X$)#QAQGSR$V)+_J? M[>AO:>VPEKG0\CI+_JGB8O73T?E1$,N%*)/B8[;]19KU3'&\*$LT_3?8\K.C MV5$0E;K(UN9EH&"M4OY7?#%\\%XX'^QX861>&!'=/!%1^484XO6K/-L&.3X- MH^$'6BJ]#<2I%#?EKLCA6P7O%:^OIY 6/C$\\C M,\X5CS/:,8R^._+N2YRD(K_Z5HMCS7I'@LUY87>B$C^ M= 2JH&5^+X]>__4OP[/!RSV43AREDWVC?\6>/&6B/2AV EXJ" MGQ=9 NJITF40\4L+]U( JJP+D<;XK8 ?%P%LC5S/9>ZV)X"O\QZM'=Q$O2&@Y.@OJX'D+BHQ*=D M'-SF8*YR(KLW/&':D"[O4WV>]Z(H8)3I_WD:Q)T#L_ M"3[)?!W\FHDT&$YY#/OOM#\M^@)K[9V=>.^_D0N9(PL6*A5I1%N9 MZ0+Y$,ZFP+7>*+RXF'B3A$$*TC"C*3ZTTEUR+OU X4\#YM$NJW_*-$ MAB@CZYH4-)<)B#S\BYY*PY>D^L84D'#.7NI@NP);\!!DVQ0>U>5+ &4 )]3E%-+ M5(-76J;P@@[04. "O&U*LHB8#5Q^F\"@L0B#_Y" GA1\>)=M!6W)>Q6MU!(4 M?I=AW:IB%8@@$GG^@#/6Z]%9M +',I 26CI?=V%'1%JV4*CX&BPW=(V%<,"\0M M ='#KW MX\%I+!YXC!A@5 AR(L%VPL,SY]7> /WW CG%UN874$EK_,@JG.6M1#$;0F_6^(#:686 M(1C:D$9.)_TS*ZUF]Q.U1O8;#O[Z[NKF8P ;/.Y/!\_JY,4JQE&K)>%2P1[& M/E\U+=-P6$11EJ,<)P\A\25:B12_!)O#.D1/P=B1T"L0MDC"*& E\VS=-3@X M%D*S*?(#EPSCH!0$/8#, ()@4=7S/I_)J.#\6:JS!%0?!R"3;[Y>!&A&!+*, M22<7(%<8W-%0\#,X9)2J&!!ZJ2GF(S-/CW]'47N'[0$+ #G? ME+GUPP]2Y %ZRKC]<.A[BT!^D7FDT.2A;&<;BJ]!JN47<"U,^-KBZBPU(\/W M@%9!)1"N]@G-5^"_OCS>>-S"^YJQ1=L3+&G;V5+@H$C0+L-&%I),*VMXAJZQ MJ-D$Z];@.X(*B+YQ9J,))+/!ILPWF99@4-XM0 CVSF<0FAW8",;>E>;2S$80 MI;'H'A #4D"A:@G2LT@R^(U:!&*#WAD>+>2)$QCX90)^!M]>"W"^*1H#PZS' MO%V_BHTJVPK1YW MZHH3^[G)=A2']C0/7B>;MD#V&9,(^T3V]11A*?JJ4^.6/8 JX!8W\)EBM&Z]4%/(FD$$T_#)DAJ@S06"Z!%6R">2]R#,D "LNZ M%6@ 6[+&SC$P@( /1B(BRQ7W$, M1VJ B=XE.4+5;X'T.7"#7MH='UM)=7'HB76O#\ QS"/B6PUJ-0LVZRG-O-^6 M]GW#5JS D0,$IO04&[@[N2F,%@RZ+!Q(._ =67<,(7B%0>W"]XML>TO[P66W M\H6[S!'\MC&U)]+[IS?[Y@7Z!HE*,DR @EIFK\H\=!N)(0PAT^:CL)-&1W%D M5CXB<.=R/61]W.2K]_YC)D'Z%M:NX3'W.I>1*#E6A==I###E_JQ.NCV)IW#Q M$9%&2Z?(# #*45G,P.Y;%PC6<:W8W&$8#B$]V@-8;(^6R'9F E:Z&] GW1!<$],(P%Y9X(@QR/ !//F0DA:_KQ M +7><47L)W:6B4;R:.!SQ*,\W+T>4"X#6'1-( E!,ZA$0QQM+/'1@.F:8J- M8?GW BRR]O;UD)P/BNT^LI^2T@">X!]9*O MP$%@I_7BP3@L'(O7EQ_\2?$7F1S.' M,=W9PJQ,8HO]#9M8F?TDT6^[,EF=XKXSNX%J,.@/*S40">:6ERMCBR*!P0Y: M(^!(F:. XF#&KE7^.E%_E"HV1#JGP4N9(Q[@C5[*5!+B(-:45DYT(S-GQ&R/ MIB$8UH$Q&CS(VE*U@]N-?%)+Y*\M/ S)X7OY). ]D'$QC3.-F3D+&\YJA7+'-R*9 MK,8"#5-9PO<-OG-Y=AIF/WDRCJS\MQV0L$^SV]SC9JN8X91R0C@Z!9J,_CF\ M'(Y)[>"_X#5_MT$BQJ&G'.%BD$KYA;J\.9GE>):)J<#.5TT^X;<+.A( SJX5 MVPI/-%JP&.S \=ET6D&&T.2\D!6 );QO#I$PDUQJ(17*HJ'AAT&8LJ*"(R:C M!#,L)"W-PA)2SK5X\!4 QLI=\K^]2(.(G%SM2NQ#1%YN.)#WP.;#)]I# MYB>FVC M/+=IX4^5D:P<'AJR18EK\&*]P]"*LO"D7ZW+-7M\],8J0AY7L:#*6@ZY/6[_W^0L:/=>?=,1T$[(VPB\ MT']WVW4MDQ)Q2I>U/#)(2+,P'LP[D\<-4ZD.]B\,T-XDP:7 MY1(=W[ K7N4?;FY#EXG\((SZ7AIHAU,#YE/W*BXY*9'RV<<238+=++L[-C=@ M?V9'K=8$:^A? < _KW&A[?*KM SXLEKVCTL=*,$C7(+'AH]-#^VYJF92J/)8 M_U2(Y(K.U%$]MF>85@FL2FWUD!<#.*+XB/]Z)?(E#F$4_R,I/MJ!5&!JJI&7 MLNS$)08+I2/8B#]*X)>+3$WZXV^@EB[ST0]NRUR7HF)%]T+<)N&YB(% <1FQ MPEN#E4L";?%A"\ \%T:Y=>"'MOX^4PSY3:*)5'E7Q:KW,)H;T/Q_($U MJ97,H^R'Q$.9U*59_+"<$W4$ .KY/7.T8OPZT(SP34>YFEOV5UE<3CK1,YM' M.%L_ J*HQO /7L!<6('G+\+D+5F=8/V8^PPY XK/@VLBSI!N^;;BZ4Z07"W9 MGH+,>E%/9P!8!5B,M#%[T+'D*O(/>-+8X.HFG[8P!,8Z"7 77L50$7'%4J4I M1XA$FI5;94_2? E9B\^,8:KJOC0.C1TC8"\PMO#2NHA/,!6[]I"(ERLWLS62 MJ71&^_^!]%2T4O5F<@M!IW-ED%C!#?P+;,2]X("&80#[-P 9#;"!4W M#T3B*FWZ"'L<2& T@JSQC_\8J]7"_2+K>H2 @$%7/?D%=4C;\W$P#A$>PBSE M"2J'.7: ?3\;]:?/G+MH4K3/]G2D\ZW97&,0CZ>D='S!EK+#E&HD!;,K%3G# M_G2 RQMB(4\M_/+%[C_Y_7JXTS#3;?L\)&].9AUK.MR3A,"BAE,QW&C-V7W4 M;#-"K""5PE8R4">KG=I Y"32&>LB\VW<" .CPKB>O)O"%X8"]!S:@3.-NU,T>L!C"&((N9*36X-8#76319Q1? M$@],<:4V,TJ_J0_1JU@$^UV". -:H.$T&!FI=Z6__,E.:@F)R+A/^262!#>8 MG5IZOW$U+[ FG)I0-.B4J[>8]<+=*)#$APU%%R-4/).1J M%R&-/4Q %G%7-NYIWO%6EA'E!C6:BV4,IUW-3%T,4K!_6HO\H8;.\#P08]I2 ML]/Z^/.[3VT5M;*Y8VA/PFK;O(O_=,:]@R5U5C0X<$(FH0H]LK[3:2RICA"=E(CN#@K4Y08H4,[0>,=P'Z M"(^^SV)%)RAOW]X F9ZT-;%8%#84[W3I[ZJ\7MC&^8=+ M#D>*AMT];*,JNB;HE]9;-^$C;B7F6E3AZ\H6,?"E$2^[&$%&I7 M:#C2B=(]]]'T7VQ.3&$+Q5#-( .=I8L):KFF74CXS\#FF,-^ALY[9X:FA=DP M"Y@\F#)@DQS0P1*1>VKYOQ9?.,/PW984FDPH1MQV%B\'X87?+KMAYQ;Q[T"W MC.LS_'SU[M.;R];$7/ ;43A"IRMVN#IY(N64*8+6;48Y*CH].2 7W _N-C(" M1:?"G_ '\0NWV:0X8+/.P,"82C"DLWP$JU4WC*IPWN:Q6;\IIF/'^1WY7<_C M[0X,'8YH(P244!LJU=*H9(<[H\9VP-@3)Q >CJHPT1I:8V--@H(89,_"=P>% MHUKJJQ%O^0^.PZ WQYG'TR?.C+]OE4N-]\W?#!/')""]",F8? L9M4!R8O-, MA4I+H[ZY)-/[$N,]=-=Q"&AB"P"'7 KLJPG_XD><5H>)L@)0Z>.^+ .(K)\3 MJ$OU8VJO.$#6)?F;GCK!\ZY153VP24H$C/#[&3MY>\"=@:O)S;4-#GY+$*L/.$^67>G)5V)G-0-*I>33$50=0"!(2/F,.D\_X7 M9'3INE,[76SL+X[0JK4G)<[II"B$US9&DK+NT_5$\CZ'[)9&_>'@&1(QZI]/ MG[U$6T)&'E^]0@;3A>4#+/H/HW" A+%/.T.(?UTID35-7Y^T)4FAW?U3-QSL M)!T$_C#F$<]X>\?39]XT5=*6^VH8L,M'FG94S/J;_%9) M?[VT5K5D3S9'/]#V#*;6]@QVV9X?:5<&1I#(7_S9=N5;=DK\X)TB%ADS,OAW M,2-V]P>X^\UJ%*ZD.*S F$7 1/MT4\Y6,-8OT)C;5!HF'TUWFZXV*/D.MLM) MUX'3;NFN'.?(%"$LAUC-\205F=JLV<[**)K.7*]E\/ A [+8.1=&:'63$C4 MG5JFE%""C;B,(E07W-);".+XV>EKA%K-Z!7G470#;V3C@*6G7O*,4Y'*=YMGE6= M"&S'@7*S0\7,+4SB>E38RQT^!0!FE;PWW0&J9?!9CW:4U.(ZMJEX\6H;*#[& M]!*WA3GS-7SH![]4J9>#Y[6G&'/I'T:W9W+5QWLKS>QM#_NPMC9T9 )BLCIC M$R(^+2XUJ7<3#(*2S?G>)NPQ[%4>T(6*F%2)382]?,#U=,$2&+T!4RA4@N?K M'4O=E[[@$SK,LQ2J*+'X)^4Z.;],SIX.S$5"LK:C$MM=)(FKTU!4HG[KZFXV M1S6@FF#J<($+Y32POU3=O58;MFR$!MV=EQ:D==<1@&-AU+:+GS;27,(;IN&* M*55@;Z:[0F2OX@Y4!/N5P.9B7'U*QSSV9H57_K'99'E1IJ:/5@G!L_H7E4Q@ MYX+*ZG'+[WOXEQLT\>N+7IM1!Z]ME@U<#CDNMY-&MQ$159--CQK M%2ZS?>,*]].."G>SF5C=7*LA%F"C:-KFS1C7+X2+ZXDQ^/BN:SJDW[9PVC^E M:/:U:MRF>71Z&MB_#4NH9#\=_N/OP6:HA8"]? #;DY(B_OKK=4C8#V0O450E MNZB]5*MZZ^CV91;QDK>AJQV8M5*MMEX8O;D,*B)XV S5+"MW=[(?DP]+"<^7 M+27E:DU =^ 8(!]5%=^EO5*Z%K&L- XS8E4'&>[:A?T+)-5<^AQ 0NRB87G> MY%CAEV2$:' /%?7R9;2CJ M5RB38K!:[.N?T\?2'S#%_O&D'1)@BMQJP["]37@LV%%XAVNC\D,N+OO0G=O^ M[)VBY[HV:?6%^U_P77/NW;&O@0;V.>&"8=BIKCFQ?XB";:Q5R:(\AHI/;#8# 4&LAL\<4.5E3YZ:?-*I!,\GUK%R)3=TTJ+>0 M@?P]@UA<#SICVI7G!" *+(&]%S&-LU%)EAYZEWELC>XVP5R:%=0 M+PUX>^)%?3"MYK*RNX+FWS&VEP'\R%NQ@$5]6KM1)9.I$3D3U? MW']:R9=$N1 #+\">%MDI*TN!5_$P[TBKO04 &JD-ED:*!Q;A3RN_+2MW?.'6 MR>I?TIP01Z"L98+:Y?FW!27'8<#,/AF'IOAK,S_/6EX$0Y@#.H0.IY=A..+<3 > M3\+99!#,AA.88(Q?SH*+495%P<^?JN/!X?D%C'CAOK8_,ZU 'E Q/!]2DU#; M5!3H&\["T>C%B?.K$0U MSMJ-#Z)55XO@Y& M#N2?'[],8*;4UAG;9DL?B<1K<[=9NAQ #-+.M9"4M3-H^(9JS):KPK(1%LT' M;;;P^.;MQPJ!<]ZB.M 7'@F%Z2;#5_OJ3H0K OQ\'7?TTG3)DM-,T]"TQGEL M4^'EA@[O6;EN3Q%+$V!+:[C4[)4 (RAPE1^ZZ[J:<)S:>-CJ. M]^6W4G[FO=EFI]0_*?CM[HU9I)9%09E-M09*,"3 WI;.8+4Z"+'%KSH\=8S$ M5)FLH;VDA*3I%>U:1TJJ=8&.@(RM,4;[ )RSO8MRV15$5UTU#,B@A"[8V<^R M?3\/N* *3A<@8R0:J4_JS=W6KT)A5&,LKA7:OPLE-MG*YT_G.E$EG# M]56W.GUL!%[LCU:HG>:R M[J+:\MV/F+Z\]2IIYKQI\< 9/5D_\SJH?L[(A%UH\Y2I_[0>F]_6@2Y+._OS M=?4:;#)%>,E2CPH<[G@\.^]/'26UG-'-5=44SAK O=T%NVA9=9T8Z()/$[[8$^5*A'S.P^3R>-F!A"IHWMK=#4&NX68N;!-.:QW[Y#K M-@G[I@:Y3N4R*RC;ARANDXC()CAKG2W1!EE;9B)6OZ.#QUE**LB<0 NJQL') MF^/I]+P_V]5-SSMG[1V/IZ.ZNA@OJ]VIX&GN>J8^O4E??1N\9GV*?+*%.:T) M]BONC^_TU_4'2IY[?T!F+?,E_9D/\9WS>4T4 M'O(OX-5!?S8]XB8S]@<(,.C/T&ULQ5I;C]LV%OXKA%L4*:#,^#:9R6V 2;)I FS:;))V'Q;[ M0$NTQ482'9(:Q_WU^YU#2J9M>2;= KL/R>A"GOOYSCF4GVV,_>Q*I;SX6E>- M>SXJO5\_.3]W>:EJZ<[,6C5XLS2VEAZW=G7NUE;)@C?5U?ET/'YT7DO=C*Z? M\;/W]OJ9:7VE&_7>"M?6M;3;%ZHRF^>CR:A[\$&O2D\/SJ^?K>5*?53^U_5[ MB[OSGDJA:]4X;1IAU?+YZ&;RY,6MU1?\VZ0Y>%=.JEJ?ZI"U\^'UV-1*&6 MLJW\![-YHZ(^%T0O-Y7C_\4FK)T]&HF\==[4<3,DJ'43_LJOT0[)AJOQB0W3 MN&'*<@=&+.4KZ>7U,VLVPM)J4*,+5I5W0SC=D%,^>HNW&OO\]6NIK?A-5JT2 M9BE>ZT8VN9:5>-LX;UM8W[MGYQZ,:/EY'HF^"$2G)XA.IN*=:7SIQ-^:0A7[ M!,XA82_FM!/SQ?1.BJ]4?B9FDTQ,Q]/I'?1FO=HSIC>[7^U7VN65<:U53OSK M9@&U$2G_'E(ZD)P/DZ3L>>+6,E?/1T@/I^RM&EW_\-WDT?CI'0+/>X'G=U'_ M;_WTEXF*GVYNW@OEO%Q4&F'FA!2E5E;:O-S2KEMLEYQ@7N5EH[^T6$-Y4@AZ M5H+T@HPA%[K2GK?H9MV"C]_RELNG,-"FV8L@7A^E74MX)==K2;FW,6U5 M4)YT04:&))^=%) M)8-.3B$7&P]=&^-W*1D9UNL M0II!&5($86T1X!#9X*];JYR64HB>EQD(D7QKXYRF# I0,!A!M=QRRE=X!UV@=^\)A#B[ MIF,+%>/EF7@#J]PJ&SS1*_(5,=1E:@ZD6@5([8CG,F3F0OF-4DWGZ8VN*I(! M:@/^ANOENV#,@F SK:_027Q0>6NYTKV0#FJ_4E;?2D;QE,1-Y4M.PU1DPN]H4(/, ML)N!+7H?U:5+HTI:%-LQJF$IY:C("0#Y*9M8#_&-L*P/C(DLT2+J>H%HJ=K,WDC M+B;9D2,H/!U;&"]VR17*/WL!:P'^\>Y.RW5=$D0AK^P64:>TYS=*$QT"DT0[ M%1%W^PFH0N5@ !$&)4@T[^M7XM4S<4,=(1(?AC^VTZ%X!_KTG+K*@-#KD"=4 ML5VR?UND!KS:TR#AIY,DTWO2A0Y/,I)QF*#P2%>*)4 5QI;5EO(UNBJ@1[J$ M XB1;\>-1-%NMSDV!*'+.FPY^BJ2V#:+#1-)QL4?KPPG-=*DM5R[8>,-)EH. MX6-5ID_T67 M;P>93C$1&GRV)=N(9S0.A"8<;; R"]/Z08%.]--U@O9)/-Z/*'*ULFK%-HIP M]:>[!./V(YI _4P\>$L44&/!R_W830WO^ZGA)DP-[^+4\#'!@?1ZKZ^-C?TG MX^&08ZV2,A;,E!V8XP&<^! ##NB3QC^*[_O^^7LQRRYGEP-/[J>:4NQVSQYE MCR?CP]N$5N*]0X+=IE-_@_ZII/-Q]FA^.?3HT$J3OVBER>7\Z/[;M-HSTX/) M+'L\GB47QTK1J\OIXQ^'']X R&[IM.T.%#[HHPAK 7A%RZ#)G5!LS]"X+:@3 M.A,O=TT84?7;M4J."JCW"S6&!U]<'W @',F5]5+'WC%D/>!HH[CB"GJ+3>>6-PG1(FO\*)$C[=%DY@_K+@ X^X&B)E JD=$*J[$B@7\PBLK#% M<@E)CG"-1:4PM;VH[+^N,M*P9BI=!%R3%2-S.%R^#Q*YDQA:L=]58'8&Z1' FD]EQ<D%\X,>B%)--I@*7!#;/#0APG(KD)AWJ"OX-YZWZH% MG5F$4DX]6FS5B[2L[X^*9%0.PS7!!LL36O_9+1$DPS'2[!YDE?_AT#H>TM0 M)R%YDO@?!44'FB'#0Q_663@8A)S9=SW:HBOMIGA('?#THU+ 1TBP.W9+H3'! MLTS\#*AYR,NFXZ\K*NVP4+C A25^XTIA]A M\4=X,ZR^"V[)YV'"V>%LHSSCM/Z#FZY[$+<[Z%NIAL>V[>"P-+M_6.KBK- % M3X:<=/3@5,U(^,@CE>Y%^>%3$[CW5'E,9>0QBD\,>0Z*YT[J4$.(L.S9[+7( M?4K':P=!#\-&3Z4,X#*OQ>\.G@^D%Q%UIK'_(1\7#?+HS#1X0^123+DAR M$ F!2@,8FO)NC,P$?7BBLO&0OM((/OV SY7F%CRCZ,@(3!&Q!:--XV+R!B3M M>LJB^\:1&T?WO"^.6U!8;EE9CIX\MZW:$4OVVN[T%1:&E(LV#.G][C50X&MG M*DK^P])S7SM P*!VV)$8M*'9=MCL0W.95?3EF3@/>Z+_MD"A'3YZ#'4U]TE+ M%/K=\0/-T"!TV/0?3&,A*5]VQKJI>0A.@OV.5S]9X] )0X257+$^:M^?_:L9 M^O6+JUEV-:'1Y.("$\GT$5T]'F?SZ05?S;/9_$J\#-/\:YF'.D([)U?C;#P> M\XSQ.)L_IIV3B_[9_(KIOI9-HVF,I'^.X'J?%M4'HC:[F&9C'I%F%[-L/)OS MU06>7?#5.+M$(_7I*'_Y:'-85^V26O--!S?9_D'Y37&KG;%]#%$" (3)W7QV MZ72MZ=,'#2$<> OZS,1G!W /S2FQV*BOZ?E,+WMZ/C;TZ?<\^5Q?*Q19^E%" M/)\,7^[[I_WO'F["Y_[=\O"C"8SQ*X2[J-026\=GEQ&ULK1K;4N,X]E=4#+,% M52$X-P+TI0KH8:=GIYLN>F:GMK;V0;$5HL&VTI),R'S]GG,DV[+C)#2[#]TX MMG3N=^GM2NE'LQ#"LNEKP3RE6 M)GAFR,E,J4?\\3%Y=Q A02(5L44('/X\B1N1I@@(R/CF81Y4*'%C^%Q"OR7> M@9<9-^)&I7_(Q"[>'9P?L$3,>9':>[7Z67A^)@@O5JFA_]G*K3V#Q7%AK,K\ M9J @D[G[RY^]'((-Y]&6#4._84AT.T1$Y0=N^?NW6JV8QM4 #1^(5=H-Q,D< ME?+5:O@J89]]_T%H^<11,H;Q/&$_B^1!Y@_L"J4EK13F[:D%/+CZ-/8PKQW, MX1:8@R'[I'*[,.RG/!%)$\ I$%A1.2RIO![NA/A!Q'TV&O38,!H.=\ ;55R/ M"-YH+]?L8VZL+L#,[#8!L _2Q*DRA1;LWUX _,<(_20.WO_MA\%9]&8'2^.*I?$NZ*]4Y/\*D]U+\\@^\1P<&&7([F9_ M"G(TIN;L=X.K0RB_+02[4=F2YVNPXC4KC ?JI0QESG/8\E3)FNU].!'G!8) MPI*Y%2 [RS2W@ID57\+GV/VOTI1K>%!+]'=XF*=*:4>YL@NA6[L#O#&8*VH5 M-EG%%L"F8#Q-F=*,LZ72%$" (8#2 J*1?VZ, JJM2,![[8))L*69TJ!!H-GT MB>NE!B[D$EA3H8A,$2\8UYKG3H"&28,T@*O+3/XE""4B(3Y.@:!8&335%DI; M"_9O/YP/!],W!@0A@$84&XJ@EBU*-K9HSMRP%01$_%OQ;98BEG,9PR8KD6+$ M =+)#:= "OQ<)8G$1Q#1&K4#:MQ43BU>E&J@=RXS0L>3!$CA,YE*N\87U7[Q M##D'+ /)1EF0>9%4X8MSQ' YH&MJ,RX 1<.F.$@,A+$8,-3 T;.T?%( MDS58+5#O ',AE]L,J'8'IP@2PYP0;; %+C7G,B7CQ@H"[&WDA$48^Y$0$8%WX/!/PK/DZY.Y?!8)_1Z\<2DA M (V!4F!Q2""!Q+I\,UKX8.!4023H@-)"?N0#4:]BVC4X!F- MZKOYCE_*7F\ZFB+>Z9C=<+-@MVADF, %:;6">H]0*8N'5A\76@-ZKTC:-'B(T:$Q< W N!DG:A^VPS]YWQ%A,:O'Y8]UO",\HD+)A!PDL"CGH)"OW-I4SBLWK\,P13?HHFK8?@G%['2-8,&"* M[\OKL M0Z'+C+$64 Q!B(8"?(<+]UP!$J;"E2AU4I4$"*^41RW S2*D*;-$S&R7YG>[ M%L5G[+.:NZ"@$G8E1,X&_='%CXZ!_FCXH\,,=8'4+K0B%6LG!:T*R"T5]\#P MF2/(211UWQ%NDRUQ":L'M/=OD%[E?-UM3 9M2&F4NL2>,RXRK"E$68+&8!A: M++"K!3Z/H*V 4 FY7F6NW $ II@9\:UP[@?0?-PFB* 2T&M.2=(3#[EX7 2]2.H#=(4 MEZ8*"J&,)Z"N-<28I;1@B7>YZ+'/W-OEE3<0P@S[:T@O//=V=-QC2>T&Z%VP9=R)4VNDPG7LA5O&MG5W3 M%GH/U)S]/7@4N@_[X@6/T M(P'_^O'Z[AYE\_7N]AYZQ4J*V$>_)BP&XF[D*:RR9Z)I'9U=9% ^5-D7"P^* M7;X.;A<<7:DLT%@NGBT;@$_2G,N;UB\\AS"S9DYSH\T$Y'4Z:NH4Z**8X,NI MP\&TMO!N+@E;E^#*1 +\ 9$:]0-'-"BI0 JAW3X_09'7!$Q^5 MRV@7:I38I_)C3\F&;==&07C9047[S:!5]P:%].>"%E)I7'=1G\LH[\SXA:M: MG5#K)_K%"58XR7<51EC-3X;GO4D4!7U%^41>]PJH0S:)>A& O&"3J0/^F[+4 M2[X'S^T>-Q&0Y%/7XJ9E0UC68,%X"C#Z&GGNUQJ7\AYR^1?&C/8 M9EO)UF$[987NRJ;]%?(E^Q=&YY\VE[746C>VF,%*4P .'K"P\2$M8.*[X^!. MK@])CQ?GV/*->R,@Y9 =C:/>V6!\'-#B(1))FR%E'SV>$"I#ZU"S$5P \Z W MF(R.Z6G0BP81/4Y[%Q<7Q]Z^ZK)I8[\?A3@94>'))H/>=(S=^AB 1)%[,QE< M@.OE)Q]JC;=FS:8I)!YT-GZHV!7[7S!D[+%985NAS77T=-[D4$"]APVTFR;' MU#-21;0E9O8@]KGVAP9K9;UOQ!-T/2ZKRLU9@*M,.\O1T63D*M,6V\@@(PI>1V[+&D,H,B8Q2= M)'SMR:]GXBB>47\2N4:.F"[;MKJ5(_BF2J,5BG&?70LH5',W*]E:YZ-('6+H MH85 !ZYQAKJ;04F?N^;_"6%654(U'VVWHR2_/OMC(=.CPD[EE^&G$Q[E MRC59*82)7&4RQ@E[-18B/'6?U2S@_B'6USQ_K%[VVXIE2AEP\MV& DL"0W'J<1.U8\D$AZQKP7]Y\*64<2'):))AP$ K1OH M#T,HV$4.3A_0%)*+S66AFV/-9D+QIR(X*:"6M!'A$,5K6Y:7$^G\SFT@1^V? MUVY:#_Z;JL&%47]4+H0V-X0PI21. G3ITBT?=/="S1'W9E6F"@M"RSN.W+KK MM4TCX?5X;9^%E#W2=XZ;O[/ ,R^MW0;'W[%R=Z77,;H]&AY3)0>QN7H/IQ*%NQ7%HF\*#@7HNZ\-VI1V 7IW_D,@@YH$=8;6<^Y.TA1:XP>_$ M#<&XT=M=G73K(;0;=Q[[5+-M N),;C(,4@XUEH-Q%)CW/B6W>W9_O,,?(2;2 MZ(H52]^R!8D"#U(AW:10J)&4*U[X3#TY[MUN@@H[W5G@PLU9JIK0\&R#K3ZI M[ H/@U\RFFY)M2,)5IG/C=H ?W>*0P_U9WF-_6X:NF?$!1*MQ*-QG7CQ#EPY,L(W9$QEYX;+61G7K_A^30I<'7 M)@N7O/KL;CXWPMJNNPZ=)WP0MS6&:/^"X+L^6?CI+&*N@/I<3?DRW++_:'#_ M$9XS,X0<.''2/E["4_#@G NTDON9A(*6+:U&853'GCM7 M 9?J22:BU2A2NMFD#5D)B6O:R/YCSC[[.VFC'%1!!/8:K>TEV-P\UFP%_"8D M8.J^[O>N'+F[EAS]6O/1!O9BDC[#OP"\1[O14^V <%NUXF'ZHU/$&[QD U$& MOMV7A4F-L,/0H&.#)G0\K085]>ABWX?-W.Z.,S3.9(^#+1NO M.CZYZ>D)CIQ.RM$D"!,]%7/EK>!XM<:T*BP39@50P3+E(&]W=L4AP_F;!(T[ M28X^Q1)+HSK3QHA%(E,$W>Q8B:V@6LQUK@&L6U^:(DK7URV M@[B+A:73KQFTZW0?J5G62M>\:/&MD-K%*%CH+F[$M1UO3/,#196G*NX"$9OI M4E=TCZE<5RO#]+MN\IT&US,SH1_H$JJ_->)N:E9OJWNN5^YZ9[W<79+]Q#74 MSU!7B#ELC?K3R0'3[N*I^V'5DBY[SI2U*J/'A> @/UP W^=*V?('(JAN_[[_ M+U!+ P04 " #607%680:?!GL9 !9 &0 'AL+W=OZU9QA9#\N/-LF,DS2SV6D3K]-TY\Z= M^P$B(0E;BE3XL.S]]7L> B I*RTN7/U5K*.KK? M9'GU_&A=U]MO3D^K9"TWHAH56YG#+\NBW(@:OI:KTVI;2I'22YOL=#H>GY]N MA,J/7CRC9S?EBV=%4VF+9UNQ MDA]D_7%[4\*W4SM+JC8RKU211Z5V27Q1?>SF?T-X0ZX+$0E7Q79 M/U1:KY\?71Y%J5R*)JMOB]U?I<9GCO,E15;1_Z,=CYW"BDE3U<5&OPS?-RKG M?\6]IH/SPN5XX(6I?F%*I4?7#L],:9L;?3Q,]RTN>93HPRV0:_5#D M];J*OLM3F?H3G )(%JZI@>OE=.^,KV4RBF:3.)J.I],]\\TLGC.:;S8P'V,6 M_<_UHJI+$(7_[4.2ISCKGP+5XYMJ*Q+Y_ CDOY+EG3QZ\9<_3<['W^X!\,P" M>+9O]H,9*WI5;#:@!C0BNJZB8AD!D>5F(4M+Z$CD*7Z MK_5:XBM;D3]$:Y%&D_$\'E^.X_EL0J.NKN+IY22^F)]%U5H /7#"A->H: TP M 54-0U6^BD%_JZTD#

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end XML 108 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 109 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 110 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 761 512 1 true 372 0 false 16 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.thehealthcarereit2.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.thehealthcarereit2.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 0000009 - Disclosure - Organization Sheet http://www.thehealthcarereit2.com/role/Organization Organization Notes 9 false false R10.htm 0000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Real Estate Investments, Net Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNet Real Estate Investments, Net Notes 11 false false R12.htm 0000012 - Disclosure - Mortgage Notes Payable, Net Notes http://www.thehealthcarereit2.com/role/MortgageNotesPayableNet Mortgage Notes Payable, Net Notes 12 false false R13.htm 0000013 - Disclosure - Credit Facilities, Net Sheet http://www.thehealthcarereit2.com/role/CreditFacilitiesNet Credit Facilities, Net Notes 13 false false R14.htm 0000014 - Disclosure - Fair Value of Financial Instruments Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 14 false false R15.htm 0000015 - Disclosure - Derivatives and Hedging Activities Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivities Derivatives and Hedging Activities Notes 15 false false R16.htm 0000016 - Disclosure - Stockholders' Equity Sheet http://www.thehealthcarereit2.com/role/StockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 0000017 - Disclosure - Related Party Transactions and Arrangements Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangements Related Party Transactions and Arrangements Notes 17 false false R18.htm 0000018 - Disclosure - Economic Dependency Sheet http://www.thehealthcarereit2.com/role/EconomicDependency Economic Dependency Notes 18 false false R19.htm 0000019 - Disclosure - Equity-Based Compensation Sheet http://www.thehealthcarereit2.com/role/EquityBasedCompensation Equity-Based Compensation Notes 19 false false R20.htm 0000020 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 20 false false R21.htm 0000021 - Disclosure - Non-Controlling Interests Sheet http://www.thehealthcarereit2.com/role/NonControllingInterests Non-Controlling Interests Notes 21 false false R22.htm 0000022 - Disclosure - Net Loss Per Share Sheet http://www.thehealthcarereit2.com/role/NetLossPerShare Net Loss Per Share Notes 22 false false R23.htm 0000023 - Disclosure - Segment Reporting Sheet http://www.thehealthcarereit2.com/role/SegmentReporting Segment Reporting Notes 23 false false R24.htm 0000024 - Disclosure - Commitments and Contingencies Sheet http://www.thehealthcarereit2.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 24 false false R25.htm 0000025 - Disclosure - Subsequent Events Sheet http://www.thehealthcarereit2.com/role/SubsequentEvents Subsequent Events Notes 25 false false R26.htm 0000026 - Disclosure - Real Estate and Accumulated Depreciation Schedule III Sheet http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIII Real Estate and Accumulated Depreciation Schedule III Notes 26 false false R27.htm 0000027 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies 27 false false R28.htm 0000028 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies 28 false false R29.htm 0000029 - Disclosure - Real Estate Investments, Net (Tables) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables Real Estate Investments, Net (Tables) Tables http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNet 29 false false R30.htm 0000030 - Disclosure - Mortgage Notes Payable, Net (Tables) Notes http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetTables Mortgage Notes Payable, Net (Tables) Tables http://www.thehealthcarereit2.com/role/MortgageNotesPayableNet 30 false false R31.htm 0000031 - Disclosure - Credit Facilities, Net (Tables) Sheet http://www.thehealthcarereit2.com/role/CreditFacilitiesNetTables Credit Facilities, Net (Tables) Tables http://www.thehealthcarereit2.com/role/CreditFacilitiesNet 31 false false R32.htm 0000032 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.thehealthcarereit2.com/role/FairValueofFinancialInstruments 32 false false R33.htm 0000033 - Disclosure - Derivatives and Hedging Activities (Tables) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables Derivatives and Hedging Activities (Tables) Tables http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivities 33 false false R34.htm 0000034 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.thehealthcarereit2.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.thehealthcarereit2.com/role/StockholdersEquity 34 false false R35.htm 0000035 - Disclosure - Related Party Transactions and Arrangements (Tables) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables Related Party Transactions and Arrangements (Tables) Tables http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangements 35 false false R36.htm 0000036 - Disclosure - Equity-Based Compensation (Tables) Sheet http://www.thehealthcarereit2.com/role/EquityBasedCompensationTables Equity-Based Compensation (Tables) Tables http://www.thehealthcarereit2.com/role/EquityBasedCompensation 36 false false R37.htm 0000037 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLoss 37 false false R38.htm 0000038 - Disclosure - Non-Controlling Interests (Tables) Sheet http://www.thehealthcarereit2.com/role/NonControllingInterestsTables Non-Controlling Interests (Tables) Tables http://www.thehealthcarereit2.com/role/NonControllingInterests 38 false false R39.htm 0000039 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.thehealthcarereit2.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.thehealthcarereit2.com/role/NetLossPerShare 39 false false R40.htm 0000040 - Disclosure - Segment Reporting (Tables) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.thehealthcarereit2.com/role/SegmentReporting 40 false false R41.htm 0000041 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://www.thehealthcarereit2.com/role/CommitmentsandContingencies 41 false false R42.htm 0000042 - Disclosure - Organization (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/OrganizationNarrativeDetails Organization (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/Organization 42 false false R43.htm 0000043 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables 43 false false R44.htm 0000044 - Disclosure - Summary of Significant Accounting Policies (Future Base Rent Payments on a Cash Basis) (Details) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails Summary of Significant Accounting Policies (Future Base Rent Payments on a Cash Basis) (Details) Details http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables 44 false false R45.htm 0000045 - Disclosure - Summary of Significant Accounting Policies (Income Taxes) (Details) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails Summary of Significant Accounting Policies (Income Taxes) (Details) Details http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables 45 false false R46.htm 0000046 - Disclosure - Real Estate Investments, Net (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails Real Estate Investments, Net (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 46 false false R47.htm 0000047 - Disclosure - Real Estate Investments, Net (Acquired Assets) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails Real Estate Investments, Net (Acquired Assets) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 47 false false R48.htm 0000048 - Disclosure - Real Estate Investments, Net (Geographic Concentrations) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails Real Estate Investments, Net (Geographic Concentrations) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 48 false false R49.htm 0000049 - Disclosure - Real Estate Investments, Net (Summary of Intangible Lease Assets and Liabilities) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails Real Estate Investments, Net (Summary of Intangible Lease Assets and Liabilities) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 49 false false R50.htm 0000050 - Disclosure - Real Estate Investments, Net (Summary of Amortization and Accretion Recognized) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails Real Estate Investments, Net (Summary of Amortization and Accretion Recognized) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 50 false false R51.htm 0000051 - Disclosure - Real Estate Investments, Net (Summary of Intangible Assets and Liabilities Future Amortization Expense) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails Real Estate Investments, Net (Summary of Intangible Assets and Liabilities Future Amortization Expense) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 51 false false R52.htm 0000052 - Disclosure - Real Estate Investments, Net (Real Estate Sales) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails Real Estate Investments, Net (Real Estate Sales) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 52 false false R53.htm 0000053 - Disclosure - Real Estate Investments, Net (Impairments) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails Real Estate Investments, Net (Impairments) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 53 false false R54.htm 0000054 - Disclosure - Mortgage Notes Payable, Net (Mortgage Notes) (Details) Notes http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails Mortgage Notes Payable, Net (Mortgage Notes) (Details) Details http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetTables 54 false false R55.htm 0000055 - Disclosure - Mortgage Notes Payable, Net (Narrative) (Details) Notes http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails Mortgage Notes Payable, Net (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetTables 55 false false R56.htm 0000056 - Disclosure - Credit Facilities, Net (Summary of Credit Facilities) (Details) Sheet http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails Credit Facilities, Net (Summary of Credit Facilities) (Details) Details http://www.thehealthcarereit2.com/role/CreditFacilitiesNetTables 56 false false R57.htm 0000057 - Disclosure - Credit Facilities, Net (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails Credit Facilities, Net (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/CreditFacilitiesNetTables 57 false false R58.htm 0000058 - Disclosure - Credit Facilities, Net (Future Principal Payments of Outstanding Debt) (Details) Sheet http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails Credit Facilities, Net (Future Principal Payments of Outstanding Debt) (Details) Details http://www.thehealthcarereit2.com/role/CreditFacilitiesNetTables 58 false false R59.htm 0000059 - Disclosure - Fair Value of Financial Instruments (Assets Measured at Fair Value) (Details) Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails Fair Value of Financial Instruments (Assets Measured at Fair Value) (Details) Details http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables 59 false false R60.htm 0000060 - Disclosure - Fair Value of Financial Instruments (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails Fair Value of Financial Instruments (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables 60 false false R61.htm 0000061 - Disclosure - Fair Value of Financial Instruments (Level 3 Inputs) (Details) Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails Fair Value of Financial Instruments (Level 3 Inputs) (Details) Details http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables 61 false false R62.htm 0000062 - Disclosure - Derivatives and Hedging Activities (Balance Sheet Location) (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails Derivatives and Hedging Activities (Balance Sheet Location) (Details) Details http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables 62 false false R63.htm 0000063 - Disclosure - Derivatives and Hedging Activities (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails Derivatives and Hedging Activities (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables 63 false false R64.htm 0000064 - Disclosure - Derivatives and Hedging Activities (Summary of Derivative Instruments) (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails Derivatives and Hedging Activities (Summary of Derivative Instruments) (Details) Details http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables 64 false false R65.htm 0000065 - Disclosure - Derivatives and Hedging Activities (Derivatives Included in AOCI) (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails Derivatives and Hedging Activities (Derivatives Included in AOCI) (Details) Details http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables 65 false false R66.htm 0000066 - Disclosure - Derivatives and Hedging Activities (Offsetting Derivatives) (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails Derivatives and Hedging Activities (Offsetting Derivatives) (Details) Details http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables 66 false false R67.htm 0000067 - Disclosure - Stockholders' Equity (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/StockholdersEquityTables 67 false false R68.htm 0000068 - Disclosure - Stockholders' Equity (Stock Redemption) (Details) Sheet http://www.thehealthcarereit2.com/role/StockholdersEquityStockRedemptionDetails Stockholders' Equity (Stock Redemption) (Details) Details http://www.thehealthcarereit2.com/role/StockholdersEquityTables 68 false false R69.htm 0000069 - Disclosure - Stockholders' Equity (Stock Dividends) (Details) Sheet http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails Stockholders' Equity (Stock Dividends) (Details) Details http://www.thehealthcarereit2.com/role/StockholdersEquityTables 69 false false R70.htm 0000070 - Disclosure - Related Party Transactions and Arrangements (Ownership) (Details) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails Related Party Transactions and Arrangements (Ownership) (Details) Details http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables 70 false false R71.htm 0000071 - Disclosure - Related Party Transactions and Arrangements (Fees Incurred in Connection with the Operations of the Company) (Details) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails Related Party Transactions and Arrangements (Fees Incurred in Connection with the Operations of the Company) (Details) Details http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables 71 false false R72.htm 0000072 - Disclosure - Related Party Transactions and Arrangements (Fees, Expenses and Related Payables) (Details) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails Related Party Transactions and Arrangements (Fees, Expenses and Related Payables) (Details) Details http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables 72 false false R73.htm 0000073 - Disclosure - Related Party Transactions and Arrangements (Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company???s Real Estate Assets) (Details) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails Related Party Transactions and Arrangements (Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company???s Real Estate Assets) (Details) Details http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables 73 false false R74.htm 0000074 - Disclosure - Equity-Based Compensation (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails Equity-Based Compensation (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/EquityBasedCompensationTables 74 false false R75.htm 0000075 - Disclosure - Equity-Based Compensation (Summary of Share-based Compensation Awards) (Details) Sheet http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails Equity-Based Compensation (Summary of Share-based Compensation Awards) (Details) Details http://www.thehealthcarereit2.com/role/EquityBasedCompensationTables 75 false false R76.htm 0000076 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossTables 76 false false R77.htm 0000077 - Disclosure - Non-controlling Interests - Balance Sheet Breakdown (Details) Sheet http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails Non-controlling Interests - Balance Sheet Breakdown (Details) Details 77 false false R78.htm 0000078 - Disclosure - Non-controlling Interests (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails Non-controlling Interests (Narrative) (Details) Details 78 false false R79.htm 0000079 - Disclosure - Non-controlling Interests (Summary of Non-controlling Interests) (Details) Sheet http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails Non-controlling Interests (Summary of Non-controlling Interests) (Details) Details 79 false false R80.htm 0000080 - Disclosure - Net Loss Per Share (Summary of Basic and Diluted Net Loss Per Share Computation) (Details) Sheet http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails Net Loss Per Share (Summary of Basic and Diluted Net Loss Per Share Computation) (Details) Details http://www.thehealthcarereit2.com/role/NetLossPerShareTables 80 false false R81.htm 0000081 - Disclosure - Net Loss Per Share (Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) Sheet http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails Net Loss Per Share (Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) Details http://www.thehealthcarereit2.com/role/NetLossPerShareTables 81 false false R82.htm 0000082 - Disclosure - Segment Reporting (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails Segment Reporting (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/SegmentReportingTables 82 false false R83.htm 0000083 - Disclosure - Segment Reporting (Reconciliation of Segment Activity) (Details) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails Segment Reporting (Reconciliation of Segment Activity) (Details) Details http://www.thehealthcarereit2.com/role/SegmentReportingTables 83 false false R84.htm 0000084 - Disclosure - Segment Reporting (Reconciliation of Segment Activity to Assets) (Details) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails Segment Reporting (Reconciliation of Segment Activity to Assets) (Details) Details http://www.thehealthcarereit2.com/role/SegmentReportingTables 84 false false R85.htm 0000085 - Disclosure - Segment Reporting (Reconciliation of Capital Expenditures by Segment) (Details) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails Segment Reporting (Reconciliation of Capital Expenditures by Segment) (Details) Details http://www.thehealthcarereit2.com/role/SegmentReportingTables 85 false false R86.htm 0000086 - Disclosure - Commitments and Contingencies (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables 86 false false R87.htm 0000087 - Disclosure - Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details) Sheet http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details) Details http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables 87 false false R88.htm 0000088 - Disclosure - Subsequent Events (Details) Sheet http://www.thehealthcarereit2.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.thehealthcarereit2.com/role/SubsequentEvents 88 false false R89.htm 0000089 - Disclosure - Real Estate and Accumulated Depreciation Schedule III (Summary of Real Estate Properties) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails Real Estate and Accumulated Depreciation Schedule III (Summary of Real Estate Properties) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIII 89 false false R90.htm 0000090 - Disclosure - Real Estate and Accumulated Depreciation Schedule III (Changes in Accumulated Depreciation) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails Real Estate and Accumulated Depreciation Schedule III (Changes in Accumulated Depreciation) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIII 90 false false R91.htm 0000091 - Disclosure - Real Estate and Accumulated Depreciation Schedule III (Changes in Accumulated Depreciation Additional Information) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails Real Estate and Accumulated Depreciation Schedule III (Changes in Accumulated Depreciation Additional Information) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIII 91 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: hct:LeaseIntangiblesLeaseupPeriod, hct:RelatedPartyTransactionBaseManagementFeeOfNetProceedsVariablePortionFactorPercent, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - hct-20221231.htm 4 [dqc-0015-Negative-Values] Fact us-gaap:RealEstateAccumulatedDepreciation has a value of -21000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:RealEstateAccumulatedDepreciation fact are: Context: if05ca15f9b62403a8d3716bbb87b618d_I20221231, Unit: usd, Rule Element Id: 2757. hct-20221231.htm 4 hct-20221231.htm ex211htisubsidiarylist1231.htm ex231hti12312022.htm ex311hti12312022.htm ex312hti12312022.htm ex32hti12312022.htm ex49htidescriptionofsecuri.htm hct-20221231.xsd hct-20221231_cal.xml hct-20221231_def.xml hct-20221231_lab.xml hct-20221231_pre.xml hct-20221231_g1.jpg http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 113 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hct-20221231.htm": { "axisCustom": 2, "axisStandard": 44, "baseTaxonomies": { "http://fasb.org/srt/2022": 197, "http://fasb.org/us-gaap/2022": 2603, "http://xbrl.sec.gov/dei/2022": 41 }, "contextCount": 761, "dts": { "calculationLink": { "local": [ "hct-20221231_cal.xml" ] }, "definitionLink": { "local": [ "hct-20221231_def.xml" ] }, "inline": { "local": [ "hct-20221231.htm" ] }, "labelLink": { "local": [ "hct-20221231_lab.xml" ] }, "presentationLink": { "local": [ "hct-20221231_pre.xml" ] }, "schema": { "local": [ "hct-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 1068, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 4, "http://www.thehealthcarereit2.com/20221231": 2, "http://xbrl.sec.gov/dei/2022": 4, "total": 10 }, "keyCustom": 121, "keyStandard": 391, "memberCustom": 312, "memberStandard": 53, "nsprefix": "hct", "nsuri": "http://www.thehealthcarereit2.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.thehealthcarereit2.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RealEstateDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Real Estate Investments, Net", "menuCat": "Notes", "order": "11", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNet", "shortName": "Real Estate Investments, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RealEstateDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Mortgage Notes Payable, Net", "menuCat": "Notes", "order": "12", "role": "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNet", "shortName": "Mortgage Notes Payable, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Credit Facilities, Net", "menuCat": "Notes", "order": "13", "role": "http://www.thehealthcarereit2.com/role/CreditFacilitiesNet", "shortName": "Credit Facilities, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Fair Value of Financial Instruments", "menuCat": "Notes", "order": "14", "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Derivatives and Hedging Activities", "menuCat": "Notes", "order": "15", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivities", "shortName": "Derivatives and Hedging Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "16", "role": "http://www.thehealthcarereit2.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Related Party Transactions and Arrangements", "menuCat": "Notes", "order": "17", "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangements", "shortName": "Related Party Transactions and Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "hct:EconomicDependencyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Economic Dependency", "menuCat": "Notes", "order": "18", "role": "http://www.thehealthcarereit2.com/role/EconomicDependency", "shortName": "Economic Dependency", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "hct:EconomicDependencyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Equity-Based Compensation", "menuCat": "Notes", "order": "19", "role": "http://www.thehealthcarereit2.com/role/EquityBasedCompensation", "shortName": "Equity-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorFirmId", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0000002 - Document - Audit Information", "menuCat": "Cover", "order": "2", "role": "http://www.thehealthcarereit2.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorFirmId", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "menuCat": "Notes", "order": "20", "role": "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLoss", "shortName": "Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Non-Controlling Interests", "menuCat": "Notes", "order": "21", "role": "http://www.thehealthcarereit2.com/role/NonControllingInterests", "shortName": "Non-Controlling Interests", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Net Loss Per Share", "menuCat": "Notes", "order": "22", "role": "http://www.thehealthcarereit2.com/role/NetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Segment Reporting", "menuCat": "Notes", "order": "23", "role": "http://www.thehealthcarereit2.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "24", "role": "http://www.thehealthcarereit2.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "25", "role": "http://www.thehealthcarereit2.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:RealEstateAndAccumulatedDepreciationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Real Estate and Accumulated Depreciation Schedule III", "menuCat": "Notes", "order": "26", "role": "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIII", "shortName": "Real Estate and Accumulated Depreciation Schedule III", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:RealEstateAndAccumulatedDepreciationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "27", "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Real Estate Investments, Net (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables", "shortName": "Real Estate Investments, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "3", "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Mortgage Notes Payable, Net (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetTables", "shortName": "Mortgage Notes Payable, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Credit Facilities, Net (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetTables", "shortName": "Credit Facilities, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Fair Value of Financial Instruments (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Derivatives and Hedging Activities (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables", "shortName": "Derivatives and Hedging Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Stockholders' Equity (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.thehealthcarereit2.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "hct:ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Related Party Transactions and Arrangements (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables", "shortName": "Related Party Transactions and Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "hct:ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Equity-Based Compensation (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.thehealthcarereit2.com/role/EquityBasedCompensationTables", "shortName": "Equity-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "menuCat": "Tables", "order": "37", "role": "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "hct:NoncontrollingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Non-Controlling Interests (Tables)", "menuCat": "Tables", "order": "38", "role": "http://www.thehealthcarereit2.com/role/NonControllingInterestsTables", "shortName": "Non-Controlling Interests (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "hct:NoncontrollingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Net Loss Per Share (Tables)", "menuCat": "Tables", "order": "39", "role": "http://www.thehealthcarereit2.com/role/NetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i77543bbdb1284733b24d59593d5732a6_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "4", "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i77543bbdb1284733b24d59593d5732a6_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Segment Reporting (Tables)", "menuCat": "Tables", "order": "40", "role": "http://www.thehealthcarereit2.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "41", "role": "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Organization (Narrative) (Details)", "menuCat": "Details", "order": "42", "role": "http://www.thehealthcarereit2.com/role/OrganizationNarrativeDetails", "shortName": "Organization (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)", "menuCat": "Details", "order": "43", "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-5", "lang": "en-US", "name": "hct:ProceedsFromGovernmentAssistanceCARESAct", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Summary of Significant Accounting Policies (Future Base Rent Payments on a Cash Basis) (Details)", "menuCat": "Details", "order": "44", "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails", "shortName": "Summary of Significant Accounting Policies (Future Base Rent Payments on a Cash Basis) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Summary of Significant Accounting Policies (Income Taxes) (Details)", "menuCat": "Details", "order": "45", "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails", "shortName": "Summary of Significant Accounting Policies (Income Taxes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfBusinessesAcquired", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Real Estate Investments, Net (Narrative) (Details)", "menuCat": "Details", "order": "46", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "shortName": "Real Estate Investments, Net (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icd9d9e89061e41f381c1d24740d570fd_D20220101-20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfBusinessesAcquired", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "hct:EquityInstrumentConsiderationPreferredUnitsIssued", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Real Estate Investments, Net (Acquired Assets) (Details)", "menuCat": "Details", "order": "47", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "shortName": "Real Estate Investments, Net (Acquired Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "hct:EquityInstrumentConsiderationPreferredUnitsIssued", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i81c51ab98d4649b79f0490bd15ad8922_D20220101-20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Real Estate Investments, Net (Geographic Concentrations) (Details)", "menuCat": "Details", "order": "48", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "shortName": "Real Estate Investments, Net (Geographic Concentrations) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i81c51ab98d4649b79f0490bd15ad8922_D20220101-20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Real Estate Investments, Net (Summary of Intangible Lease Assets and Liabilities) (Details)", "menuCat": "Details", "order": "49", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails", "shortName": "Real Estate Investments, Net (Summary of Intangible Lease Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "menuCat": "Statements", "order": "5", "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostsAndExpensesRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "hct:AccretionOfBelowMarketLeaseLiabilitiesAndAmortizationOfAboveMarketLeaseAssetsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Real Estate Investments, Net (Summary of Amortization and Accretion Recognized) (Details)", "menuCat": "Details", "order": "50", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "shortName": "Real Estate Investments, Net (Summary of Amortization and Accretion Recognized) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "ibe74ebfaef404b85b64ae90e383f347b_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i4d72f19a106140a69af8e910c17ad90a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Real Estate Investments, Net (Summary of Intangible Assets and Liabilities Future Amortization Expense) (Details)", "menuCat": "Details", "order": "51", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "shortName": "Real Estate Investments, Net (Summary of Intangible Assets and Liabilities Future Amortization Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i4d72f19a106140a69af8e910c17ad90a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainsLossesOnSalesOfInvestmentRealEstate", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Real Estate Investments, Net (Real Estate Sales) (Details)", "menuCat": "Details", "order": "52", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "shortName": "Real Estate Investments, Net (Real Estate Sales) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "ifa44b8059c16464292d38114d7ab4adc_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfRealEstate", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Real Estate Investments, Net (Impairments) (Details)", "menuCat": "Details", "order": "53", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "shortName": "Real Estate Investments, Net (Impairments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i472208620941474780f7ea33f7ee69cf_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ImpairmentOfRealEstate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Mortgage Notes Payable, Net (Mortgage Notes) (Details)", "menuCat": "Details", "order": "54", "role": "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "shortName": "Mortgage Notes Payable, Net (Mortgage Notes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i1908b8d398394e64a9bf6fb20c461e5c_I20221231", "decimals": "INF", "lang": "en-US", "name": "hct:NumberOfRealEstatePropertiesEncumbered", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "hct:RealEstateInvestmentAtCostRelatingtoNotesPayable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Mortgage Notes Payable, Net (Narrative) (Details)", "menuCat": "Details", "order": "55", "role": "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "shortName": "Mortgage Notes Payable, Net (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i1774cbebe9db4e73bd1de275bd980d09_I20211115", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Credit Facilities, Net (Summary of Credit Facilities) (Details)", "menuCat": "Details", "order": "56", "role": "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "shortName": "Credit Facilities, Net (Summary of Credit Facilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i9e98563f99ee427fbe305d3252168986_I20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RealEstateInvestmentPropertyAtCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Credit Facilities, Net (Narrative) (Details)", "menuCat": "Details", "order": "57", "role": "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "shortName": "Credit Facilities, Net (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "INF", "lang": "en-US", "name": "hct:DebtInstrumentCovenantsMinimumCashCashEquivalentsAndBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Credit Facilities, Net (Future Principal Payments of Outstanding Debt) (Details)", "menuCat": "Details", "order": "58", "role": "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails", "shortName": "Credit Facilities, Net (Future Principal Payments of Outstanding Debt) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i3b820bb8fe214b588792f6ee9d9bbc71_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Fair Value of Financial Instruments (Assets Measured at Fair Value) (Details)", "menuCat": "Details", "order": "59", "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "shortName": "Fair Value of Financial Instruments (Assets Measured at Fair Value) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i3b820bb8fe214b588792f6ee9d9bbc71_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "ica70323e791e4eac96159ac9fcc5ab78_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "menuCat": "Statements", "order": "6", "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "ica70323e791e4eac96159ac9fcc5ab78_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "ic50922c535f245d0910b506136217d95_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "hct:DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForUse", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Fair Value of Financial Instruments (Narrative) (Details)", "menuCat": "Details", "order": "60", "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "shortName": "Fair Value of Financial Instruments (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "ic50922c535f245d0910b506136217d95_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "hct:DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForUse", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icd0b075d60314c4e8659f2ac18a26f61_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Fair Value of Financial Instruments (Level 3 Inputs) (Details)", "menuCat": "Details", "order": "61", "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "shortName": "Fair Value of Financial Instruments (Level 3 Inputs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icd0b075d60314c4e8659f2ac18a26f61_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Derivatives and Hedging Activities (Balance Sheet Location) (Details)", "menuCat": "Details", "order": "62", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "shortName": "Derivatives and Hedging Activities (Balance Sheet Location) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i1b04baf449e140879267e118e2b2e3a3_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Derivatives and Hedging Activities (Narrative) (Details)", "menuCat": "Details", "order": "63", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "shortName": "Derivatives and Hedging Activities (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "hct:NumberOfInterestRateDerivativesNotYetInEffect", "reportCount": 1, "unique": true, "unitRef": "derivative", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Derivatives and Hedging Activities (Summary of Derivative Instruments) (Details)", "menuCat": "Details", "order": "64", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "shortName": "Derivatives and Hedging Activities (Summary of Derivative Instruments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "hct:NumberOfInterestRateDerivativesNotYetInEffect", "reportCount": 1, "unique": true, "unitRef": "derivative", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Derivatives and Hedging Activities (Derivatives Included in AOCI) (Details)", "menuCat": "Details", "order": "65", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "shortName": "Derivatives and Hedging Activities (Derivatives Included in AOCI) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i7b32d20a98464a6c88393de726673c9c_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Derivatives and Hedging Activities (Offsetting Derivatives) (Details)", "menuCat": "Details", "order": "66", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails", "shortName": "Derivatives and Hedging Activities (Offsetting Derivatives) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i77543bbdb1284733b24d59593d5732a6_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "ie181f877754544fc8a72e8be1cb2178e_D20201001-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Stockholders' Equity (Narrative) (Details)", "menuCat": "Details", "order": "67", "role": "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "shortName": "Stockholders' Equity (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i1758e135570b4a71a68b46b7ffd2948d_D20200226-20200226", "decimals": "-5", "lang": "en-US", "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i1758e135570b4a71a68b46b7ffd2948d_D20200226-20200226", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Stockholders' Equity (Stock Redemption) (Details)", "menuCat": "Details", "order": "68", "role": "http://www.thehealthcarereit2.com/role/StockholdersEquityStockRedemptionDetails", "shortName": "Stockholders' Equity (Stock Redemption) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i1f93cd2483cc4a3a8c3c0c633a93414a_D20221003-20221003", "decimals": "6", "first": true, "lang": "en-US", "name": "us-gaap:StockDividendsShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Stockholders' Equity (Stock Dividends) (Details)", "menuCat": "Details", "order": "69", "role": "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails", "shortName": "Stockholders' Equity (Stock Dividends) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "hct:CommonStockStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical)", "menuCat": "Statements", "order": "7", "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "hct:CommonStockStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Related Party Transactions and Arrangements (Ownership) (Details)", "menuCat": "Details", "order": "70", "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails", "shortName": "Related Party Transactions and Arrangements (Ownership) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i5461483715934472ad4b3f3b0703c356_I20221231", "decimals": "-5", "lang": "en-US", "name": "hct:RelatedPartyTransactionSpecialAllocationforTaxPurposesExcessDepreciationDeductionsMaximum", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i5c5555e9444c4e18b60a172d19623b7f_D20170217-20170217", "decimals": null, "first": true, "lang": "en-US", "name": "hct:RelatedPartyAgreementTermofAgreementRenewalPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Related Party Transactions and Arrangements (Fees Incurred in Connection with the Operations of the Company) (Details)", "menuCat": "Details", "order": "71", "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "shortName": "Related Party Transactions and Arrangements (Fees Incurred in Connection with the Operations of the Company) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i5c5555e9444c4e18b60a172d19623b7f_D20170217-20170217", "decimals": null, "first": true, "lang": "en-US", "name": "hct:RelatedPartyAgreementTermofAgreementRenewalPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "hct:ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Related Party Transactions and Arrangements (Fees, Expenses and Related Payables) (Details)", "menuCat": "Details", "order": "72", "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "shortName": "Related Party Transactions and Arrangements (Fees, Expenses and Related Payables) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "hct:ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i9030419ccb184c6baa2d7542bc9dfc29_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "hct:RelatedPartyTransactionSubordinatedIncentiveListingDistributionPercentageOfBenchmark", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Related Party Transactions and Arrangements (Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company\u2019s Real Estate Assets) (Details)", "menuCat": "Details", "order": "73", "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails", "shortName": "Related Party Transactions and Arrangements (Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company\u2019s Real Estate Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i9030419ccb184c6baa2d7542bc9dfc29_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "hct:RelatedPartyTransactionSubordinatedIncentiveListingDistributionPercentageOfBenchmark", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i1ca66b3c50654161997ca03167ac0b6c_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Equity-Based Compensation (Narrative) (Details)", "menuCat": "Details", "order": "74", "role": "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "shortName": "Equity-Based Compensation (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i1ca66b3c50654161997ca03167ac0b6c_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i3269828b445d4a72a80e2dc3ff511754_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Equity-Based Compensation (Summary of Share-based Compensation Awards) (Details)", "menuCat": "Details", "order": "75", "role": "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails", "shortName": "Equity-Based Compensation (Summary of Share-based Compensation Awards) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i2d39eacf51424d00b30a36e48d09dca1_I20191231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i77543bbdb1284733b24d59593d5732a6_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "menuCat": "Details", "order": "76", "role": "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "ic91f97c6ab8940b9af6e5f815d60d7df_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "hct:NoncontrollingInterestTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestInOperatingPartnerships", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Non-controlling Interests - Balance Sheet Breakdown (Details)", "menuCat": "Details", "order": "77", "role": "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails", "shortName": "Non-controlling Interests - Balance Sheet Breakdown (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "hct:NoncontrollingInterestTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestInOperatingPartnerships", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsOfDividendsMinorityInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - Non-controlling Interests (Narrative) (Details)", "menuCat": "Details", "order": "78", "role": "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "shortName": "Non-controlling Interests (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i6e8feb556e344e93bccf54bc0cb755fc_D20220101-20221231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:PaymentsOfDividendsMinorityInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - Non-controlling Interests (Summary of Non-controlling Interests) (Details)", "menuCat": "Details", "order": "79", "role": "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails", "shortName": "Non-controlling Interests (Summary of Non-controlling Interests) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i7b2cd5e22c344a14aeef55d7990a6507_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:MinorityInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "8", "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - Net Loss Per Share (Summary of Basic and Diluted Net Loss Per Share Computation) (Details)", "menuCat": "Details", "order": "80", "role": "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails", "shortName": "Net Loss Per Share (Summary of Basic and Diluted Net Loss Per Share Computation) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - Net Loss Per Share (Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)", "menuCat": "Details", "order": "81", "role": "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "shortName": "Net Loss Per Share (Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i7f39a6137b234c1299fc2f530ab45525_D20211001-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - Segment Reporting (Narrative) (Details)", "menuCat": "Details", "order": "82", "role": "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails", "shortName": "Segment Reporting (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - Segment Reporting (Reconciliation of Segment Activity) (Details)", "menuCat": "Details", "order": "83", "role": "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "shortName": "Segment Reporting (Reconciliation of Segment Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RealEstateInvestmentPropertyNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000084 - Disclosure - Segment Reporting (Reconciliation of Segment Activity to Assets) (Details)", "menuCat": "Details", "order": "84", "role": "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails", "shortName": "Segment Reporting (Reconciliation of Segment Activity to Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i612d7e110d994cdea0ed82cea2065ed6_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000085 - Disclosure - Segment Reporting (Reconciliation of Capital Expenditures by Segment) (Details)", "menuCat": "Details", "order": "85", "role": "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "shortName": "Segment Reporting (Reconciliation of Capital Expenditures by Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i612d7e110d994cdea0ed82cea2065ed6_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "hct:LesseeOperatingLeaseNumberOfContracts", "reportCount": 1, "unique": true, "unitRef": "lease", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000086 - Disclosure - Commitments and Contingencies (Narrative) (Details)", "menuCat": "Details", "order": "86", "role": "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "hct:LesseeOperatingLeaseNumberOfContracts", "reportCount": 1, "unique": true, "unitRef": "lease", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000087 - Disclosure - Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details)", "menuCat": "Details", "order": "87", "role": "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails", "shortName": "Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i1f93cd2483cc4a3a8c3c0c633a93414a_D20221003-20221003", "decimals": "6", "first": true, "lang": "en-US", "name": "us-gaap:StockDividendsShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000088 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "88", "role": "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i15c9d4fec90f4b7cb2c3f77670aadbcc_D20230101-20230317", "decimals": "INF", "lang": "en-US", "name": "hct:AssetAcquisitionNumberOfPropertiesAcquired", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "srt:RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000089 - Disclosure - Real Estate and Accumulated Depreciation Schedule III (Summary of Real Estate Properties) (Details)", "menuCat": "Details", "order": "89", "role": "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "shortName": "Real Estate and Accumulated Depreciation Schedule III (Summary of Real Estate Properties) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "icdceb37bc9bf4f05b23ad12e0042c90f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "srt:RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Organization", "menuCat": "Notes", "order": "9", "role": "http://www.thehealthcarereit2.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i77543bbdb1284733b24d59593d5732a6_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RealEstateGrossAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000090 - Disclosure - Real Estate and Accumulated Depreciation Schedule III (Changes in Accumulated Depreciation) (Details)", "menuCat": "Details", "order": "90", "role": "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails", "shortName": "Real Estate and Accumulated Depreciation Schedule III (Changes in Accumulated Depreciation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "hct:RealEstateInvestmentPropertyAtCostAcquisitions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i0c1739cc41524c32b3dfdb8ebcbd2939_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "hct:OtherRealEstateDisposalsAndReclasses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000091 - Disclosure - Real Estate and Accumulated Depreciation Schedule III (Changes in Accumulated Depreciation Additional Information) (Details)", "menuCat": "Details", "order": "91", "role": "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails", "shortName": "Real Estate and Accumulated Depreciation Schedule III (Changes in Accumulated Depreciation Additional Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20221231.htm", "contextRef": "i609a700b04c744a6a04689ff6e0c0f49_D20200101-20201231", "decimals": "-5", "lang": "en-US", "name": "hct:OtherRealEstateDisposalsAndReclasses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 372, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r744", "r745", "r746" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r744", "r745", "r746" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r744", "r745", "r746" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r744", "r745", "r746" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r742" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r741" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r741" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r741" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r748" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r741" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r741" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r741" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r741" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r749" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r744", "r745", "r746" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r740" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r743" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "hct_A2019BonusAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Bonus Awards", "label": "2019 Bonus Awards [Member]", "terseLabel": "2019 Bonus Awards" } } }, "localname": "A2019BonusAwardsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_A2020BonusAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Bonus Awards", "label": "2020 Bonus Awards [Member]", "terseLabel": "2020 Bonus Awards" } } }, "localname": "A2020BonusAwardsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_A757BuildingMunsterOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "757 Building - Munster - October [Member]", "label": "757 Building - Munster - October [Member]", "terseLabel": "757 Building - Munster, IN" } } }, "localname": "A757BuildingMunsterOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_A759BuildingMunsterOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "759 Building - Munster - October [Member]", "label": "759 Building - Munster - October [Member]", "terseLabel": "759 Building - Munster, IN" } } }, "localname": "A759BuildingMunsterOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_A761BuildingMunsterOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "761 Building - Munster - October [Member]", "label": "761 Building - Munster - October [Member]", "terseLabel": "761 Building - Munster, IN" } } }, "localname": "A761BuildingMunsterOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AboveMarketGroundLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Above Market Ground Lease [Member]", "label": "Above Market Ground Lease [Member]", "verboseLabel": "Above-market ground leases" } } }, "localname": "AboveMarketGroundLeaseMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "domainItemType" }, "hct_AboveandBelowMarketLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Above and Below Market Leases [Member]", "label": "Above and Below Market Leases [Member]", "terseLabel": "Above- and below-market leases, net" } } }, "localname": "AboveandBelowMarketLeasesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "domainItemType" }, "hct_AccretionOfBelowMarketLeaseLiabilitiesAndAmortizationOfAboveMarketLeaseAssetsNet": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment for noncash decrease (increase) in rental revenue related to assets (liabilities) associated with the acquisition of an off-market lease when the terms of the lease are favorable (unfavorable) to the market terms for the lease at the date of acquisition.", "label": "Accretion of Below-Market Lease Liabilities and Amortization of Above-Market Lease Assets, Net", "terseLabel": "(Accretion) amortization of market lease and other intangibles, net", "verboseLabel": "Accretion of above- and below-market leases, net" } } }, "localname": "AccretionOfBelowMarketLeaseLiabilitiesAndAmortizationOfAboveMarketLeaseAssetsNet", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "hct_AcquisitionCostsReimbursementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition Costs Reimbursements [Member]", "label": "Acquisition Costs Reimbursements [Member]", "terseLabel": "Acquisition cost reimbursements" } } }, "localname": "AcquisitionCostsReimbursementsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails" ], "xbrltype": "domainItemType" }, "hct_AcuitySpecialtyHospitalMesaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AcuitySpecialtyHospitalMesa [Member]", "label": "AcuitySpecialtyHospitalMesa [Member]", "terseLabel": "Acuity Specialty Hospital - Mesa, AZ" } } }, "localname": "AcuitySpecialtyHospitalMesaMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AcuitySpecialtyHospitalSunCityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AcuitySpecialtyHospitalSunCity [Member]", "label": "AcuitySpecialtyHospitalSunCity [Member]", "terseLabel": "Acuity Specialty Hospital - Sun City, AZ" } } }, "localname": "AcuitySpecialtyHospitalSunCityMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceNorthvilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place - Northville", "label": "Addington Place - Northville [Member]", "terseLabel": "Addington Place - Northville, MI" } } }, "localname": "AddingtonPlaceNorthvilleMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceatMillsRosewellMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AddingtonPlaceatMillsRosewell [Member]", "label": "AddingtonPlaceatMillsRosewell [Member]", "terseLabel": "Addington Place at Mills - Roswell, GA" } } }, "localname": "AddingtonPlaceatMillsRosewellMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofAlpharettaAlpharettaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Alpharetta - Alpharetta [Member]", "label": "Addington Place of Alpharetta - Alpharetta [Member]", "terseLabel": "Addington Place of Alpharetta - Alpharetta, GA" } } }, "localname": "AddingtonPlaceofAlpharettaAlpharettaMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofBrunswickBrunswickSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Brunswick - Brunswick - September [Member]", "label": "Addington Place of Brunswick - Brunswick - September [Member]", "terseLabel": "Addington Place of Brunswick - Brunswick, GA" } } }, "localname": "AddingtonPlaceofBrunswickBrunswickSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofCollegeHarbourStPetersburgSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AddingtonPlaceofCollegeHarbourStPetersburgSeptember [Member]", "label": "AddingtonPlaceofCollegeHarbourStPetersburgSeptember [Member]", "terseLabel": "Addington Place of College Harbour - St Petersburg, FL" } } }, "localname": "AddingtonPlaceofCollegeHarbourStPetersburgSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofDublinDublinSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Dublin - Dublin - September [Member]", "label": "Addington Place of Dublin - Dublin - September [Member]", "terseLabel": "Addington Place of Dublin - Dublin, GA" } } }, "localname": "AddingtonPlaceofDublinDublinSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofJohnsCreekJohnsCreekSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Johns Creek - Johns Creek - September [Member]", "label": "Addington Place of Johns Creek - Johns Creek - September [Member]", "terseLabel": "Addington Place of Johns Creek - Johns Creek, GA" } } }, "localname": "AddingtonPlaceofJohnsCreekJohnsCreekSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofLeesSummitLeesSummitSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Lee's Summit - Lee's Summit - September [Member]", "label": "Addington Place of Lee's Summit - Lee's Summit - September [Member]", "terseLabel": "Addington Place of Lee's Summit - Lee's Summit, MO" } } }, "localname": "AddingtonPlaceofLeesSummitLeesSummitSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofPrairieVillagePrairieVillageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Prairie Village - Prairie Village [Member]", "label": "Addington Place of Prairie Village - Prairie Village [Member]", "terseLabel": "Addington Place of Prairie Village - Prairie Village, KS" } } }, "localname": "AddingtonPlaceofPrairieVillagePrairieVillageMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofShoalCreekKansasCityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Shoal Creek - Kansas City [Member]", "label": "Addington Place of Shoal Creek - Kansas City [Member]", "terseLabel": "Addington Place of Shoal Creek - Kansas City, MO" } } }, "localname": "AddingtonPlaceofShoalCreekKansasCityMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofTitusvilleTitusvilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Titusville - Titusville [Member]", "label": "Addington Place of Titusville - Titusville [Member]", "terseLabel": "Addington Place of Titusville - Titusville, FL" } } }, "localname": "AddingtonPlaceofTitusvilleTitusvilleMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AdenaHealthCenterJacksonOHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adena Health Center - Jackson, OH [Member]", "label": "Adena Health Center - Jackson, OH [Member]", "terseLabel": "Adena Health Center - Jackson, OH" } } }, "localname": "AdenaHealthCenterJacksonOHMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AdjustmentstoAdditionalPaidinCapitalRebalancingOfOwnershipPercentage": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to Additional Paid in Capital, Rebalancing Of Ownership Percentage", "label": "Adjustments to Additional Paid in Capital, Rebalancing Of Ownership Percentage", "terseLabel": "Rebalancing of ownership percentage" } } }, "localname": "AdjustmentstoAdditionalPaidinCapitalRebalancingOfOwnershipPercentage", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "hct_AdvanceOnLoanOrOtherInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advance on Loan or Other Investment [Member]", "label": "Advance on Loan or Other Investment [Member]", "terseLabel": "Advance on Loan or Other Investment" } } }, "localname": "AdvanceOnLoanOrOtherInvestmentMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_AdvancedOrthopaedicMedicalCenterRichmondAprilMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advanced Orthopaedic Medical Center - Richmond - April [Member]", "label": "Advanced Orthopaedic Medical Center - Richmond - April [Member]", "terseLabel": "Advanced Orthopedic Medical Center - Richmond, VA" } } }, "localname": "AdvancedOrthopaedicMedicalCenterRichmondAprilMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AdventistHealthLaceyMedicalPlazaHanfordMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adventist Health Lacey Medical Plaza - Hanford [Member]", "label": "Adventist Health Lacey Medical Plaza - Hanford [Member]", "terseLabel": "Adventist Health Lacey Medical Plaza - Hanford, CA" } } }, "localname": "AdventistHealthLaceyMedicalPlazaHanfordMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AdvisorAndCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advisor And Company [Member]", "label": "Advisor And Company [Member]", "terseLabel": "Advisor And Company" } } }, "localname": "AdvisorAndCompanyMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_AdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advisor [Member]", "label": "Advisor [Member]", "terseLabel": "Advisor" } } }, "localname": "AdvisorMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "hct_AdvocateAuroraMOBElkhornWIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advocate Aurora MOB - Elkhorn WI [Member]", "label": "Advocate Aurora MOB - Elkhorn WI [Member]", "terseLabel": "Advocate Aurora MOB - Elkhorn, WI" } } }, "localname": "AdvocateAuroraMOBElkhornWIMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AllegroatElizabethtownElizabethtownSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allegro at Elizabethtown - Elizabethtown - September [Member]", "label": "Allegro at Elizabethtown - Elizabethtown - September [Member]", "terseLabel": "Allegro at Elizabethtown - Elizabethtown, KY" } } }, "localname": "AllegroatElizabethtownElizabethtownSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AllegroatJupiterJupiterSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allegro at Jupiter - Jupiter - September [Member]", "label": "Allegro at Jupiter - Jupiter - September [Member]", "terseLabel": "Allegro at Jupiter - Jupiter, FL" } } }, "localname": "AllegroatJupiterJupiterSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AllegroatStPetersburgLandStPetersburgSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allegro at St Petersburg - Land - St Petersburg - September [Member]", "label": "Allegro at St Petersburg - Land - St Petersburg - September [Member]", "terseLabel": "Allegro at St. Petersburg - Land - St. Petersburg, FL" } } }, "localname": "AllegroatStPetersburgLandStPetersburgSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AllegroatStuartStuartSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allegro at Stuart - Stuart - September [Member]", "label": "Allegro at Stuart - Stuart - September [Member]", "terseLabel": "Allegro at Stuart - Stuart, FL" } } }, "localname": "AllegroatStuartStuartSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AllegroatTarponTarponSpringsSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allegro at Tarpon - Tarpon Springs - September [Member]", "label": "Allegro at Tarpon - Tarpon Springs - September [Member]", "terseLabel": "Allegro at Tarpon - Tarpon Springs, FL" } } }, "localname": "AllegroatTarponTarponSpringsSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AmendedandRestatedPropertyManagementandLeasingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended and Restated Property Management and Leasing Agreement [Member]", "label": "Amended and Restated Property Management and Leasing Agreement [Member]", "terseLabel": "Amended and Restated Property Management and Leasing Agreement" } } }, "localname": "AmendedandRestatedPropertyManagementandLeasingAgreementMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_AmericanRealtyCapitalHealthcareAdvisorsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Realty Capital Healthcare Advisors, LLC [Member]", "label": "American Realty Capital Healthcare Advisors, LLC [Member]", "terseLabel": "American Realty Capital Healthcare Advisors, LLC" } } }, "localname": "AmericanRealtyCapitalHealthcareAdvisorsLLCMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Realty Capital Healthcare III Advisors, LLC [Member]", "label": "American Realty Capital Healthcare III Advisors, LLC [Member]", "terseLabel": "American Realty Capital Healthcare III Advisors, LLC" } } }, "localname": "AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "hct_AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Realty Capital Healthcare II Special Limited Partnership, LLC [Member]", "label": "American Realty Capital Healthcare II Special Limited Partnership, LLC [Member]", "terseLabel": "American Realty Capital Healthcare II Special Limited Partnership, LLC" } } }, "localname": "AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "hct_AmortizationExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization Expense [Member]", "label": "Amortization Expense [Member]", "terseLabel": "Amortization Expense" } } }, "localname": "AmortizationExpenseMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "hct_AmortizationOfTerminatedSwapPayment": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of Terminated Swap Payment", "label": "Amortization of Terminated Swap Payment", "terseLabel": "Amortization of terminated swap" } } }, "localname": "AmortizationOfTerminatedSwapPayment", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "hct_AnnualTargetedInvestorReturnMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual Targeted Investor Return [Member]", "label": "Annual Targeted Investor Return [Member]", "terseLabel": "Annual Targeted Investor Return" } } }, "localname": "AnnualTargetedInvestorReturnMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_ArborViewAssistedLivingandMemoryCareBurlingtonMarchMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arbor View Assisted Living and Memory Care - Burlington - March [Member]", "label": "Arbor View Assisted Living and Memory Care - Burlington - March [Member]", "terseLabel": "Arbor View Assisted Living and Memory Care - Burlington, WI" } } }, "localname": "ArborViewAssistedLivingandMemoryCareBurlingtonMarchMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ArcadianCoveAssistedLivingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arcadian Cove Assisted Living [Member]", "label": "Arcadian Cove Assisted Living [Member]", "terseLabel": "Arcadian Cove Assisted Living - Richmond, KY" } } }, "localname": "ArcadianCoveAssistedLivingMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ArrowheadMedicalPlazaIGlendaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrowhead Medical Plaza I - Glendale [Member]", "label": "Arrowhead Medical Plaza I - Glendale [Member]", "terseLabel": "Arrowhead Medical Plaza I - Glendale, AZ" } } }, "localname": "ArrowheadMedicalPlazaIGlendaleMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ArrowheadMedicalPlazaIIGlendaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrowhead Medical Plaza II - Glendale [Member]", "label": "Arrowhead Medical Plaza II - Glendale [Member]", "terseLabel": "Arrowhead Medical Plaza II - Glendale, AZ" } } }, "localname": "ArrowheadMedicalPlazaIIGlendaleMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AssetAcquisitionNumberOfPropertiesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Number Of Properties Acquired", "label": "Asset Acquisition, Number Of Properties Acquired", "terseLabel": "Number of properties acquired" } } }, "localname": "AssetAcquisitionNumberOfPropertiesAcquired", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "hct_AssetManagementFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Management Fees [Member]", "label": "Asset Management Fees [Member]", "terseLabel": "Asset management fees" } } }, "localname": "AssetManagementFeesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_AtlantaGastroenterologyAssociatesLawrencevilleGAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Atlanta Gastroenterology Associates - Lawrenceville, GA", "label": "Atlanta Gastroenterology Associates - Lawrenceville, GA [Member]", "terseLabel": "Atlanta Gastroenterology Associates - Lawrenceville, GA" } } }, "localname": "AtlantaGastroenterologyAssociatesLawrencevilleGAMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://www.thehealthcarereit2.com/20221231", "xbrltype": "stringItemType" }, "hct_AuraSheboyanClinicKielMarchMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aura Sheboyan Clinic - Kiel - March [Member]", "label": "Aura Sheboyan Clinic - Kiel - March [Member]", "terseLabel": "Aurora Healthcare Center - Kiel, WI" } } }, "localname": "AuraSheboyanClinicKielMarchMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AuroraHealthCenterGreenBayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurora Health Center - Green Bay [Member]", "label": "Aurora Health Center - Green Bay [Member]", "terseLabel": "Aurora Healthcare Center - Green Bay, WI" } } }, "localname": "AuroraHealthCenterGreenBayMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AuroraHealthCenterMilwaukeeAprilMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AuroraHealthCenterMilwaukeeApril [Member]", "label": "AuroraHealthCenterMilwaukeeApril [Member]", "terseLabel": "Aurora Health Center - Milwaukee, WI" } } }, "localname": "AuroraHealthCenterMilwaukeeAprilMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AuroraHealthcareCenterGreenvilleWIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurora Healthcare Center, Greenville,WI [Member]", "label": "Aurora Healthcare Center, Greenville,WI [Member]", "terseLabel": "Aurora Healthcare Center - Greenville, WI" } } }, "localname": "AuroraHealthcareCenterGreenvilleWIMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AuroraHealthcareCenterPlymouthWIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurora Healthcare Center Plymouth, WI [Member]", "label": "Aurora Healthcare Center Plymouth, WI [Member]", "terseLabel": "Aurora Healthcare Center - Plymouth, WI" } } }, "localname": "AuroraHealthcareCenterPlymouthWIMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AuroraHealthcareCenterWaterfordWIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurora Healthcare Center, Waterford, WI [Member]", "label": "Aurora Healthcare Center, Waterford, WI [Member]", "terseLabel": "Aurora Healthcare Center - Waterford, WI" } } }, "localname": "AuroraHealthcareCenterWaterfordWIMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AuroraHealthcareCenterWautomaWIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurora Healthcare Center, Wautoma, WI [Member]", "label": "Aurora Healthcare Center, Wautoma, WI [Member]", "terseLabel": "Aurora Healthcare Center - Wautoma, WI" } } }, "localname": "AuroraHealthcareCenterWautomaWIMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AutumnRidgeOfClarkstonClarkstonAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Autumn Ridge Of Clarkston - Clarkston - August", "label": "Autumn Ridge Of Clarkston - Clarkston - August [Member]", "terseLabel": "Autumn Ridge of Clarkston - Clarkston, MI" } } }, "localname": "AutumnRidgeOfClarkstonClarkstonAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BMOMOBLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BMO MOB Loan", "label": "BMO MOB Loan [Member]", "terseLabel": "BMO CMBS", "verboseLabel": "BMO MOB Loan" } } }, "localname": "BMOMOBLoanMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_BayshoreNaplesMemoryCareNaplesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bayshore Naples Memory Care - Naples", "label": "Bayshore Naples Memory Care - Naples [Member]", "terseLabel": "Bayshore Naples Memory Care - Naples, FL" } } }, "localname": "BayshoreNaplesMemoryCareNaplesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BeaumontMedicalCenterWarrenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beaumont Medical Center - Warren [Member]", "label": "Beaumont Medical Center - Warren [Member]", "terseLabel": "Beaumont Medical Center - Warren, MI" } } }, "localname": "BeaumontMedicalCenterWarrenMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BelmarMedicalBuildingLakewoodJuneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Belmar Medical Building - Lakewood - June [Member]", "label": "Belmar Medical Building - Lakewood - June [Member]", "terseLabel": "Belmar Medical Building -Lakewood, CO" } } }, "localname": "BelmarMedicalBuildingLakewoodJuneMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BelowMarketLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Below Market Lease [Member]", "label": "Below Market Lease [Member]", "terseLabel": "Below-market lease liabilities" } } }, "localname": "BelowMarketLeaseMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "hct_BelowMarketLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Below Market Leases", "label": "Below Market Leases [Member]", "terseLabel": "Below market leases" } } }, "localname": "BelowMarketLeasesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_BelpreVCancerCenterBelpreOHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Belpre V Cancer Center - Belpre, OH", "label": "Belpre V Cancer Center - Belpre, OH [Member]", "terseLabel": "Belpre V Cancer Center - Belpre, OH" } } }, "localname": "BelpreVCancerCenterBelpreOHMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BerwynMedicalCenterBerwynMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Berwyn Medical Center - Berwyn [Member]", "label": "Berwyn Medical Center - Berwyn [Member]", "terseLabel": "Berwyn Medical Center - Berwyn, IL" } } }, "localname": "BerwynMedicalCenterBerwynMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BloomMOBHarrisburgDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bloom MOB - Harrisburg - December [Member]", "label": "Bloom MOB - Harrisburg - December [Member]", "terseLabel": "Bloom MOB - Harrisburg, PA" } } }, "localname": "BloomMOBHarrisburgDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BoneAndJointSpecialistsMerrillvilleINMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bone and Joint Specialists - Merrillville, IN", "label": "Bone and Joint Specialists - Merrillville, IN [Member]", "terseLabel": "Bone and Joint Specialists - Merrillville, IN" } } }, "localname": "BoneAndJointSpecialistsMerrillvilleINMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BowieGatewayMedicalCenterBowieMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bowie Gateway Medical Center - Bowie [Member]", "label": "Bowie Gateway Medical Center - Bowie [Member]", "terseLabel": "Bowie Gateway Medical Center - Bowie, MD" } } }, "localname": "BowieGatewayMedicalCenterBowieMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BradyMOBHarrisburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brady MOB - Harrisburg [Member]", "label": "Brady MOB - Harrisburg [Member]", "terseLabel": "Brady MOB - Harrisburg, PA" } } }, "localname": "BradyMOBHarrisburgMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BuildingsFixturesandImprovements": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Buildings, Fixtures and Improvements", "label": "Buildings, Fixtures and Improvements", "terseLabel": "Buildings, fixtures and improvements" } } }, "localname": "BuildingsFixturesandImprovements", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "hct_BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Acquisition Cost Of Acquired Entity Cash Paid In Period", "label": "Business Acquisition Cost Of Acquired Entity Cash Paid In Period", "totalLabel": "Cash paid for real estate investments, including acquisitions" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationAssetsandLiabilitiesAssumedMortgageProceeds": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 2.0, "parentTag": "hct_BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Assets and Liabilities Assumed, Mortgage Proceeds", "label": "Business Combination, Assets and Liabilities Assumed, Mortgage Proceeds", "negatedTerseLabel": "Mortgage notes payable assumed, net" } } }, "localname": "BusinessCombinationAssetsandLiabilitiesAssumedMortgageProceeds", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredinPeriodNet": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 1.0, "parentTag": "hct_BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired in Period, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired in Period, Net", "totalLabel": "Total intangible assets and liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredinPeriodNet", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedBuildingFixturesandImprovementsCapitalLeasesAcquiredinPeriod": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 2.0, "parentTag": "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAcquiredDuringPeriod", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Building, Fixtures and Improvements, Capital Leases, Acquired in Period", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Building, Fixtures and Improvements, Capital Leases, Acquired in Period", "terseLabel": "Buildings, fixtures and improvements" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedBuildingFixturesandImprovementsCapitalLeasesAcquiredinPeriod", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangiblesAcquiredDuringThePeriod": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 1.0, "parentTag": "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredinPeriodNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Acquired During The Period", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Acquired During The Period", "terseLabel": "In-place and market leases" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangiblesAcquiredDuringThePeriod", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLandAcquiredinPeriod": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 1.0, "parentTag": "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAcquiredDuringPeriod", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Acquired in Period", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Acquired in Period", "verboseLabel": "Land" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLandAcquiredinPeriod", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLeaseLiabilitiesAcquired": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 2.0, "parentTag": "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredinPeriodNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities Acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities Acquired", "negatedTerseLabel": "Market lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLeaseLiabilitiesAcquired", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAcquiredDuringPeriod": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 3.0, "parentTag": "hct_BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired During Period", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired During Period", "totalLabel": "Total tangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAcquiredDuringPeriod", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_CamelliaWalkAssistedLivingAndMemoryCareEvansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Camellia Walk Assisted Living And Memory Care - Evans [Member]", "label": "Camellia Walk Assisted Living And Memory Care - Evans [Member]", "terseLabel": "Camellia Walk Assisted Living and Memory Care - Evans, GA" } } }, "localname": "CamelliaWalkAssistedLivingAndMemoryCareEvansMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CampusatCrooksAuburnBuildingCRochesterHillsJuneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Campus at Crooks & Auburn Building C - Rochester Hills - June [Member]", "label": "Campus at Crooks & Auburn Building C - Rochester Hills - June [Member]", "terseLabel": "Campus at Crooks & Auburn Building C - Rochester Mills, MI" } } }, "localname": "CampusatCrooksAuburnBuildingCRochesterHillsJuneMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CampusatCrooksAuburnBuildingDRochesterHillsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Campus at Crooks & Auburn Building D - Rochester Hills [Member]", "label": "Campus at Crooks & Auburn Building D - Rochester Hills [Member]", "terseLabel": "Campus at Crooks & Auburn Building D - Rochester Mills, MI" } } }, "localname": "CampusatCrooksAuburnBuildingDRochesterHillsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CapitalOneFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital One Facility [Member]", "label": "Capital One Facility [Member]", "terseLabel": "Capital One Facility" } } }, "localname": "CapitalOneFacilityMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CapitolHealthcareRehabCentreSpringfieldDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capitol Healthcare & Rehab Centre - Springfield - December [Member]", "label": "Capitol Healthcare & Rehab Centre - Springfield - December [Member]", "terseLabel": "Capitol Healthcare & Rehab Centre - Springfield, IL" } } }, "localname": "CapitolHealthcareRehabCentreSpringfieldDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CappedReimbursementAmountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capped Reimbursement Amount [Member]", "label": "Capped Reimbursement Amount [Member]", "terseLabel": "Capped Reimbursement Amount" } } }, "localname": "CappedReimbursementAmountMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_CareMeridianLittletonCO.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CareMeridian - Littleton, CO. [Member]", "label": "CareMeridian - Littleton, CO. [Member]", "terseLabel": "CareMeridian - Littleton, CO" } } }, "localname": "CareMeridianLittletonCO.Member", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CedarhurstOfEdwardsvilleEdwardsvilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cedarhurst Of Edwardsville - Edwardsville", "label": "Cedarhurst Of Edwardsville - Edwardsville [Member]", "terseLabel": "Cedarhurst of Edwardsville - Edwardsville, IL" } } }, "localname": "CedarhurstOfEdwardsvilleEdwardsvilleMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CedarhurstOfShilohShilohMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cedarhurst Of Shiloh - Shiloh", "label": "Cedarhurst Of Shiloh - Shiloh [Member]", "terseLabel": "Cedarhurst of Shiloh - Shiloh, IL" } } }, "localname": "CedarhurstOfShilohShilohMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CedarhurstOfSpartaSpartaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cedarhurst Of Sparta - Sparta", "label": "Cedarhurst Of Sparta - Sparta [Member]", "terseLabel": "Cedarhurst of Sparta - Sparta, IL" } } }, "localname": "CedarhurstOfSpartaSpartaMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CedarhurstofCollinsvilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cedarhurst of Collinsville [Member]", "label": "Cedarhurst of Collinsville [Member]", "terseLabel": "Cedarhurst of Collinsville - Collinsville, IL" } } }, "localname": "CedarhurstofCollinsvilleMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CenterForAdvancedDermatologyLakewoodCOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Center for Advanced Dermatology - Lakewood, CO", "label": "Center for Advanced Dermatology - Lakewood, CO [Member]", "terseLabel": "Center for Advanced Dermatology - Lakewood, CO" } } }, "localname": "CenterForAdvancedDermatologyLakewoodCOMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ChangeinControlFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in Control Fee [Member]", "label": "Change in Control Fee [Member]", "terseLabel": "Change in Control Fee" } } }, "localname": "ChangeinControlFeeMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_CirclevilleMOBCirclevilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Circleville MOB - Circleville", "label": "Circleville MOB - Circleville [Member]", "terseLabel": "Circleville MOB - Circleville, OH" } } }, "localname": "CirclevilleMOBCirclevilleMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ClassBUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class B Units [Member]", "label": "Class B Units [Member]", "terseLabel": "Class B units" } } }, "localname": "ClassBUnitsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "hct_ColonialHealthcareRehabCentrePrincetonDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Colonial Healthcare & Rehab Centre - Princeton - December [Member]", "label": "Colonial Healthcare & Rehab Centre - Princeton - December [Member]", "terseLabel": "Colonial Healthcare & Rehab Centre - Princeton, IL" } } }, "localname": "ColonialHealthcareRehabCentrePrincetonDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CommencementQuarterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commencement Quarter", "label": "Commencement Quarter [Member]", "terseLabel": "Commencement Quarter" } } }, "localname": "CommencementQuarterMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CommercialCenterPeoriaMayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial Center - Peoria - May [Member]", "label": "Commercial Center - Peoria - May [Member]", "terseLabel": "Commercial Center - Peoria, AZ" } } }, "localname": "CommercialCenterPeoriaMayMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CommonOPUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common OP Unit", "label": "Common OP Unit [Member]", "terseLabel": "Common OP Unit" } } }, "localname": "CommonOPUnitMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CommonOperatingPartnershipUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Operating Partnership Unit", "label": "Common Operating Partnership Unit [Member]", "terseLabel": "Common OP Unit" } } }, "localname": "CommonOperatingPartnershipUnitMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails" ], "xbrltype": "domainItemType" }, "hct_CommonShareEquivalentsSharesApprovedforIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Share Equivalents, Shares Approved for Issuance", "label": "Common Share Equivalents, Shares Approved for Issuance", "terseLabel": "Shares approved for issuance (in shares)" } } }, "localname": "CommonShareEquivalentsSharesApprovedforIssuance", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "sharesItemType" }, "hct_CommonShareEquivalentsSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Share Equivalents, Shares Outstanding", "label": "Common Share Equivalents, Shares Outstanding", "terseLabel": "Class B units (in shares)" } } }, "localname": "CommonShareEquivalentsSharesOutstanding", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "hct_CommonStockStockDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Stock Dividends, Per Share, Declared", "label": "Common Stock, Stock Dividends, Per Share, Declared", "terseLabel": "Distributions declared in common stock (in usd per share)" } } }, "localname": "CommonStockStockDividendsPerShareDeclared", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical" ], "xbrltype": "perShareItemType" }, "hct_CommonUnitIssuanceValueSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Unit, Issuance Value Share Price", "label": "Common Unit, Issuance Value Share Price", "terseLabel": "Units issued to fund purchase of A Building (in usd per share)" } } }, "localname": "CommonUnitIssuanceValueSharePrice", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "hct_CommunityHealthMOBHarrisburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Community Health MOB - Harrisburg [Member]", "label": "Community Health MOB - Harrisburg [Member]", "terseLabel": "Community Health MOB - Harrisburg, PA" } } }, "localname": "CommunityHealthMOBHarrisburgMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ConroeMedicalArtsandSurgeryCenterConroeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conroe Medical Arts and Surgery Center - Conroe [Member]", "label": "Conroe Medical Arts and Surgery Center - Conroe [Member]", "terseLabel": "Conroe Medical Arts and Surgery Center - Conroe, TX" } } }, "localname": "ConroeMedicalArtsandSurgeryCenterConroeMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ConsumerPriceIndexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consumer Price Index [Member]", "label": "Consumer Price Index [Member]", "terseLabel": "Consumer Price Index" } } }, "localname": "ConsumerPriceIndexMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_ContractPurchasePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Purchase Price [Member]", "label": "Contract Purchase Price [Member]", "terseLabel": "Contract Purchase Price" } } }, "localname": "ContractPurchasePriceMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_CopperSpringsSeniorLivingMeridianSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Copper Springs Senior Living - Meridian - September [Member]", "label": "Copper Springs Senior Living - Meridian - September [Member]", "terseLabel": "Copper Springs Senior Living - Meridian, ID" } } }, "localname": "CopperSpringsSeniorLivingMeridianSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CountrysideMedicalArtsSafetyHarborMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countryside Medical Arts - Safety Harbor [Member]", "label": "Countryside Medical Arts - Safety Harbor [Member]", "terseLabel": "Countryside Medical Arts - Safety Harbor, FL" } } }, "localname": "CountrysideMedicalArtsSafetyHarborMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CourtyardFountainsGreshamORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Courtyard Fountains - Gresham, OR [Member]", "label": "Courtyard Fountains - Gresham, OR [Member]", "verboseLabel": "Courtyard Fountains - Gresham, OR" } } }, "localname": "CourtyardFountainsGreshamORMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodAfterCommencementQuarterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period After Commencement Quarter", "label": "Covenant Period After Commencement Quarter [Member]", "terseLabel": "Covenant Period After Commencement Quarter" } } }, "localname": "CovenantPeriodAfterCommencementQuarterMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodAfterJune302021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period after June 30 2021", "label": "Covenant Period after June 30 2021 [Member]", "terseLabel": "Covenant Period after June 30 2021" } } }, "localname": "CovenantPeriodAfterJune302021Member", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodAugust112022UntilCommencementQuarterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period August 11, 2022 Until Commencement Quarter", "label": "Covenant Period August 11, 2022 Until Commencement Quarter [Member]", "terseLabel": "Covenant Period August 11, 2022 Until Commencement Quarter" } } }, "localname": "CovenantPeriodAugust112022UntilCommencementQuarterMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodFromAndAfterCommencementQuarterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period From And After Commencement Quarter", "label": "Covenant Period From And After Commencement Quarter [Member]", "terseLabel": "Covenant Period From And After Commencement Quarter" } } }, "localname": "CovenantPeriodFromAndAfterCommencementQuarterMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodFromJuly12021throughCommencementQuarterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period From July 1, 2021 through Commencement Quarter [Member]", "label": "Covenant Period From July 1, 2021 through Commencement Quarter [Member]", "terseLabel": "Covenant Period From July 1, 2021 through Commencement Quarter" } } }, "localname": "CovenantPeriodFromJuly12021throughCommencementQuarterMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodQuarterEndingJune302022ThroughJune302023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period Quarter Ending June 30, 2022 Through June 30, 2023", "label": "Covenant Period Quarter Ending June 30, 2022 Through June 30, 2023 [Member]", "terseLabel": "Covenant Period Quarter Ending June 30, 2022 Through June 30, 2023" } } }, "localname": "CovenantPeriodQuarterEndingJune302022ThroughJune302023Member", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodQuarterEndingMarch312024AndThereafterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period Quarter Ending March 31, 2024 And Thereafter", "label": "Covenant Period Quarter Ending March 31, 2024 And Thereafter [Member]", "terseLabel": "Covenant Period Quarter Ending March 31, 2024 And Thereafter" } } }, "localname": "CovenantPeriodQuarterEndingMarch312024AndThereafterMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodQuarterEndingSeptember302023ThroughDecember312023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period Quarter Ending September 30, 2023 Through December 31, 2023", "label": "Covenant Period Quarter Ending September 30, 2023 Through December 31, 2023 [Member]", "terseLabel": "Covenant Period Quarter Ending September 30, 2023 Through December 31, 2023" } } }, "localname": "CovenantPeriodQuarterEndingSeptember302023ThroughDecember312023Member", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CreeksideMOBDouglasvilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Creekside MOB - Douglasville [Member]", "label": "Creekside MOB - Douglasville [Member]", "terseLabel": "Creekside MOB - Douglasville, GA" } } }, "localname": "CreeksideMOBDouglasvilleMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CrittentonSterlingHeightsMOBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Crittenton Sterling Heights MOB [Member]", "label": "Crittenton Sterling Heights MOB [Member]", "terseLabel": "Crittenton Sterling Heights MOB - Sterling Heights, MI" } } }, "localname": "CrittentonSterlingHeightsMOBMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CrittentonWashingtonMOBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Crittenton Washington MOB [Member]", "label": "Crittenton Washington MOB [Member]", "terseLabel": "Crittenton Washington MOB - Washington Township, MI" } } }, "localname": "CrittentonWashingtonMOBMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_DRIPPeriodofNoticetoAlterAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DRIP, Period of Notice to Alter Agreement", "label": "DRIP, Period of Notice to Alter Agreement", "terseLabel": "DRIP, period of notice to alter agreement" } } }, "localname": "DRIPPeriodofNoticetoAlterAgreement", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "hct_DaVitaBayBreezeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DaVita Bay Breeze [Member]", "label": "DaVita Bay Breeze [Member]", "terseLabel": "DaVita Bay Breeze Dialysis Center - Largo, FL" } } }, "localname": "DaVitaBayBreezeMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_DaVitaHudsonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DaVita Hudson [Member]", "label": "DaVita Hudson [Member]", "terseLabel": "DaVita Dialysis - Hudson, FL" } } }, "localname": "DaVitaHudsonMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_DayPriortoCommencementQuarterMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Day Prior to Commencement Quarter [Member]", "label": "Day Prior to Commencement Quarter [Member] [Member]", "terseLabel": "Day Prior to Commencement Quarter" } } }, "localname": "DayPriortoCommencementQuarterMemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_DebtCovenantPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant Period", "label": "Debt Covenant Period [Axis]", "terseLabel": "Debt Covenant Period [Axis]" } } }, "localname": "DebtCovenantPeriodAxis", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "hct_DebtCovenantPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant Period", "label": "Debt Covenant Period [Domain]", "terseLabel": "Debt Covenant Period [Domain]" } } }, "localname": "DebtCovenantPeriodDomain", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_DebtInstrumentCovenantsCurrentBorrowingCapacityBasePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Current Borrowing Capacity Base Percent", "label": "Debt Instrument, Covenants, Current Borrowing Capacity Base Percent", "terseLabel": "Current borrowing capacity, base percent" } } }, "localname": "DebtInstrumentCovenantsCurrentBorrowingCapacityBasePercent", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_DebtInstrumentCovenantsDebtServiceCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Debt Service Coverage Ratio", "label": "Debt Instrument, Covenants, Debt Service Coverage Ratio", "terseLabel": "Debt service coverage ratio" } } }, "localname": "DebtInstrumentCovenantsDebtServiceCoverageRatio", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "pureItemType" }, "hct_DebtInstrumentCovenantsDistributionInExcessOfModifiedFundsFromOperationsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Distribution In Excess Of Modified Funds From Operations, Percent", "label": "Debt Instrument, Covenants, Distribution In Excess Of Modified Funds From Operations, Percent", "terseLabel": "Percent distribution in excess of modified funds from operations" } } }, "localname": "DebtInstrumentCovenantsDistributionInExcessOfModifiedFundsFromOperationsPercent", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_DebtInstrumentCovenantsFixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Fixed Charge Coverage Ratio", "label": "Debt Instrument, Covenants, Fixed Charge Coverage Ratio", "terseLabel": "Fixed charge coverage ratio" } } }, "localname": "DebtInstrumentCovenantsFixedChargeCoverageRatio", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "pureItemType" }, "hct_DebtInstrumentCovenantsMinimumCashCashEquivalentsAndBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Minimum Cash, Cash Equivalents, and Borrowing Capacity", "label": "Debt Instrument, Covenants, Minimum Cash, Cash Equivalents, and Borrowing Capacity", "terseLabel": "Minimum cash, cash equivalents, and borrowing capacity" } } }, "localname": "DebtInstrumentCovenantsMinimumCashCashEquivalentsAndBorrowingCapacity", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_DebtInstrumentCovenantsPercentOfNetOfferingProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Percent Of Net Offering Proceeds", "label": "Debt Instrument, Covenants, Percent Of Net Offering Proceeds", "terseLabel": "Net offering proceeds, percent" } } }, "localname": "DebtInstrumentCovenantsPercentOfNetOfferingProceeds", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_DebtInstrumentFloorInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Floor Interest Rate", "label": "Debt Instrument, Floor Interest Rate", "terseLabel": "Floor interest rate" } } }, "localname": "DebtInstrumentFloorInterestRate", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_DebtInstrumentInterestRateEconomicPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Interest Rate, Economic Percentage", "label": "Debt Instrument, Interest Rate, Economic Percentage", "terseLabel": "Economic interest rate" } } }, "localname": "DebtInstrumentInterestRateEconomicPercentage", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "hct_DecaturMedicalOfficeBuildingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Decatur Medical Office Building [Member]", "label": "Decatur Medical Office Building [Member]", "terseLabel": "Decatur Medical Office Building - Decatur, GA" } } }, "localname": "DecaturMedicalOfficeBuildingMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_DeferredTaxAssetValuationAllowancePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Asset, Valuation Allowance, Percentage", "label": "Deferred Tax Asset, Valuation Allowance, Percentage", "terseLabel": "Valuation allowance percentage" } } }, "localname": "DeferredTaxAssetValuationAllowancePercentage", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_DelistingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Delisting [Member]", "label": "Delisting [Member]", "terseLabel": "Delisting" } } }, "localname": "DelistingMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_DepreciationandAmortizationExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Depreciation and Amortization Expense [Member]", "label": "Depreciation and Amortization Expense [Member]", "terseLabel": "Depreciation and Amortization Expense" } } }, "localname": "DepreciationandAmortizationExpenseMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "domainItemType" }, "hct_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsCashReceived": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative Instruments Not Designated As Hedging Instruments, Cash Received", "label": "Derivative Instruments Not Designated As Hedging Instruments, Cash Received", "terseLabel": "Cash received from non-designated derivative instruments" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsCashReceived", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "hct_DerivativeNotionalAmountNotYetInEffect": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative, Notional Amount, Not Yet In Effect", "label": "Derivative, Notional Amount, Not Yet In Effect", "terseLabel": "Interest rate cap agreements excluded" } } }, "localname": "DerivativeNotionalAmountNotYetInEffect", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "hct_DerivativeNumberOfInstrumentsHeldActive": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative, Number Of Instruments Held, Active", "label": "Derivative, Number Of Instruments Held, Active", "terseLabel": "Number of instruments held, active" } } }, "localname": "DerivativeNumberOfInstrumentsHeldActive", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_DerivativeNumberOfInstrumentsHeldNotActive": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative, Number Of Instruments Held, Not Active", "label": "Derivative, Number Of Instruments Held, Not Active", "terseLabel": "Number of instruments held, not active" } } }, "localname": "DerivativeNumberOfInstrumentsHeldNotActive", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_DerivativeNumberOfInstrumentsTerminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative, Number of Instruments Terminated", "label": "Derivative, Number of Instruments Terminated", "terseLabel": "Number of instruments terminated" } } }, "localname": "DerivativeNumberOfInstrumentsTerminated", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "hct_DignityEmerusBlueDiamondRoadLasVegasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dignity Emerus Blue Diamond Road - Las Vegas [Member]", "label": "Dignity Emerus Blue Diamond Road - Las Vegas [Member]", "terseLabel": "Dignity Emerus Blue Diamond - Las Vegas, NV" } } }, "localname": "DignityEmerusBlueDiamondRoadLasVegasMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_DignityEmerusCraigRoadNorthLasVegasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dignity Emerus Craig Road - North Las Vegas [Member]", "label": "Dignity Emerus Craig Road - North Las Vegas [Member]", "terseLabel": "Dignity Emerus Craig Rd - North Las Vegas, NV" } } }, "localname": "DignityEmerusCraigRoadNorthLasVegasMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_DisposalGroupHeldforuseNotDiscontinuedOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group, Held-for-use, Not Discontinued Operations [Member]", "label": "Disposal Group, Held-for-use, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-use, Not Discontinued Operations" } } }, "localname": "DisposalGroupHeldforuseNotDiscontinuedOperationsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesDisposed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Disposed", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Disposed", "terseLabel": "Number of properties disposed" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesDisposed", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "integerItemType" }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Held For Sale", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Held For Sale", "terseLabel": "Number of properties held for sale" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForSale", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "integerItemType" }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForUse": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Held For Use", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Held For Use", "terseLabel": "Number of properties held-for-use" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForUse", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesMarketedForSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Marketed For Sale", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Marketed For Sale", "terseLabel": "Number of properties marketed for sale" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesMarketedForSale", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesUnderDisposalContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Under Disposal Contract", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Under Disposal Contract", "terseLabel": "Number of properties under contract for disposal" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesUnderDisposalContract", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails" ], "xbrltype": "integerItemType" }, "hct_DistributionsOnClassBUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributions On Class B Units [Member]", "label": "Distributions On Class B Units [Member]", "terseLabel": "Distributions on Class B Units" } } }, "localname": "DistributionsOnClassBUnitsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails" ], "xbrltype": "domainItemType" }, "hct_DyerBuildingDyerOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dyer Building - Dyer - October [Member]", "label": "Dyer Building - Dyer - October [Member]", "verboseLabel": "Dyer Building - Dyer, IN" } } }, "localname": "DyerBuildingDyerOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_EarningsPerShareBasicAndDilutedByCommonClassIncludingTwoClassMethodLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicAndDilutedByCommonClassIncludingTwoClassMethodLineItems", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "hct_EastCoastSquareNorthMoreheadCityOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "East Coast Square North - Morehead City - October [Member]", "label": "East Coast Square North - Morehead City - October [Member]", "terseLabel": "East Coast Square North - Morehead City, NC" } } }, "localname": "EastCoastSquareNorthMoreheadCityOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_EastCoastSquareWestCedarPointOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "East Coast Square West - Cedar Point - October [Member]", "label": "East Coast Square West - Cedar Point - October [Member]", "terseLabel": "East Coast Square West - Cedar Point, NC" } } }, "localname": "EastCoastSquareWestCedarPointOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_EasternCarolinaENTGreenvilleNCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eastern Carolina ENT - Greenville, NC", "label": "Eastern Carolina ENT - Greenville, NC [Member]", "terseLabel": "Eastern Carolina ENT - Greenville, NC" } } }, "localname": "EasternCarolinaENTGreenvilleNCMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_EastsideCancerinstituteGreenvilleOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eastside Cancer institute - Greenville - October [Member]", "label": "Eastside Cancer institute - Greenville - October [Member]", "terseLabel": "Eastside Cancer Institute - Greenville, SC" } } }, "localname": "EastsideCancerinstituteGreenvilleOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_EconomicDependencyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Economic Dependency [Abstract]", "label": "Economic Dependency [Abstract]", "terseLabel": "Economic Dependency [Abstract]" } } }, "localname": "EconomicDependencyAbstract", "nsuri": "http://www.thehealthcarereit2.com/20221231", "xbrltype": "stringItemType" }, "hct_EconomicDependencyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Matters related to services provided by affiliate.", "label": "Economic Dependency [Text Block]", "terseLabel": "Economic Dependency" } } }, "localname": "EconomicDependencyTextBlock", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/EconomicDependency" ], "xbrltype": "textBlockItemType" }, "hct_EquityInstrumentConsiderationPreferredUnitsIssued": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 4.0, "parentTag": "hct_BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Instrument Consideration, Preferred Units Issued", "label": "Equity Instrument Consideration, Preferred Units Issued", "negatedTerseLabel": "Issuance of Preferred OP Units" } } }, "localname": "EquityInstrumentConsiderationPreferredUnitsIssued", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_EstateatHydeParkTampaJulyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estate at Hyde Park - Tampa - July [Member]", "label": "Estate at Hyde Park - Tampa - July [Member]", "terseLabel": "Estate at Hyde Park - Tampa, FL" } } }, "localname": "EstateatHydeParkTampaJulyMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ExcessOfAdjustedMarketValueOfRealEstateAssetsPlusDistributionsOverAggregateContributedInvestorCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital [Member]", "label": "Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital [Member]", "terseLabel": "Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital" } } }, "localname": "ExcessOfAdjustedMarketValueOfRealEstateAssetsPlusDistributionsOverAggregateContributedInvestorCapitalMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_EyeSpecialtyGroupMedicalBuildingMemphisDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eye Specialty Group Medical Building - Memphis - December [Member]", "label": "Eye Specialty Group Medical Building - Memphis - December [Member]", "terseLabel": "Eye Specialty Group Medical Building - Memphis, TN" } } }, "localname": "EyeSpecialtyGroupMedicalBuildingMemphisDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FOCClinicalMechanicsburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FOC Clinical - Mechanicsburg [Member]", "label": "FOC Clinical - Mechanicsburg [Member]", "terseLabel": "FOC Clinical - Mechanicsburg, PA" } } }, "localname": "FOCClinicalMechanicsburgMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FOCIIMechanicsburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FOC II - Mechanicsburg [Member]", "label": "FOC II - Mechanicsburg [Member]", "terseLabel": "FOC II - Mechanicsburg, PA" } } }, "localname": "FOCIIMechanicsburgMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FOCIMechanicsburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FOC I - Mechanicsburg [Member]", "label": "FOC I - Mechanicsburg [Member]", "terseLabel": "FOC I - Mechanicsburg, PA" } } }, "localname": "FOCIMechanicsburgMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FannieCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fannie Credit Facility [Member]", "label": "Fannie Credit Facility [Member]", "terseLabel": "Fannie Credit Facility" } } }, "localname": "FannieCreditFacilityMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "hct_FelicitaVidaEscondidoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FelicitaVidaEscondido [Member]", "label": "FelicitaVidaEscondido [Member]", "terseLabel": "Felicita Vida - Escondido, CA" } } }, "localname": "FelicitaVidaEscondidoMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FiniteLivedIntangibleAssetsandLiabilitiesAccumulatedAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Assets and Liabilities, Accumulated Amortization", "label": "Finite-Lived Intangible Assets and Liabilities, Accumulated Amortization", "terseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsandLiabilitiesAccumulatedAmortization", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "hct_FloridaMedicalClinicTampaFLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Florida Medical Clinic - Tampa, FL", "label": "Florida Medical Clinic - Tampa, FL [Member]", "terseLabel": "Florida Medical Clinic - Tampa, FL" } } }, "localname": "FloridaMedicalClinicTampaFLMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FloridaMedicalHeartcareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Florida Medical - Heartcare [Member]", "label": "Florida Medical - Heartcare [Member]", "terseLabel": "Florida Medical Heartcare - Tampa, FL" } } }, "localname": "FloridaMedicalHeartcareMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FloridaMedicalSomersetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Florida Medical - Somerset [Member]", "label": "Florida Medical - Somerset [Member]", "terseLabel": "Florida Medical Somerset - Tampa, FL" } } }, "localname": "FloridaMedicalSomersetMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FloridaMedicalTampaPalmsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Florida Medical - Tampa Palms [Member]", "label": "Florida Medical - Tampa Palms [Member]", "terseLabel": "Florida Medical Tampa Palms - Tampa, FL" } } }, "localname": "FloridaMedicalTampaPalmsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FloridaMedicalWesleyChapelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Florida Medical - Wesley Chapel [Member]", "label": "Florida Medical - Wesley Chapel [Member]", "terseLabel": "Florida Medical Wesley Chapel - Tampa, FL" } } }, "localname": "FloridaMedicalWesleyChapelMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FortWayneOpthomologyDupontFortWayneINMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fort Wayne Opthomology Dupont - Fort Wayne, IN", "label": "Fort Wayne Opthomology Dupont - Fort Wayne, IN [Member]", "terseLabel": "Fort Wayne Opthomology Dupont - Fort Wayne, IN" } } }, "localname": "FortWayneOpthomologyDupontFortWayneINMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FortWayneOpthomologyEngleFortWayneINMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fort Wayne Opthomology Engle - Fort Wayne, IN", "label": "Fort Wayne Opthomology Engle - Fort Wayne, IN [Member]", "terseLabel": "Fort Wayne Opthomology Engle - Fort Wayne, IN" } } }, "localname": "FortWayneOpthomologyEngleFortWayneINMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FourSingleTenantMOBPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Single-Tenant MOB Properties", "label": "Four Single-Tenant MOB Properties [Member]", "terseLabel": "Four Single-Tenant MOB Properties" } } }, "localname": "FourSingleTenantMOBPropertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hct_FoxRidgeSeniorLivingatBryantBryantDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fox Ridge Senior Living at Bryant - Bryant - December [Member]", "label": "Fox Ridge Senior Living at Bryant - Bryant - December [Member]", "terseLabel": "Fox Ridge Senior Living at Bryant - Bryant, AR" } } }, "localname": "FoxRidgeSeniorLivingatBryantBryantDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FoxRidgeSeniorLivingatBryantBryantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fox Ridge Senior Living at Bryant - Bryant [Member]", "label": "Fox Ridge Senior Living at Bryant - Bryant [Member]", "terseLabel": "Fox Ridge Bryant - Bryant, AR" } } }, "localname": "FoxRidgeSeniorLivingatBryantBryantMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "domainItemType" }, "hct_FoxRidgeSeniorLivingatChenalLittleRockDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fox Ridge Senior Living at Chenal - Little Rock - December [Member]", "label": "Fox Ridge Senior Living at Chenal - Little Rock - December [Member]", "terseLabel": "Fox Ridge Senior Living at Chenal - Little Rock, AR" } } }, "localname": "FoxRidgeSeniorLivingatChenalLittleRockDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FoxRidgeSeniorLivingatChenalLittleRockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fox Ridge Senior Living at Chenal - Little Rock [Member]", "label": "Fox Ridge Senior Living at Chenal - Little Rock [Member]", "terseLabel": "Fox Ridge Chenal - Little Rock, AR" } } }, "localname": "FoxRidgeSeniorLivingatChenalLittleRockMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fox Ridge Senior Living at Parkstone - North Little Rock [Member]", "label": "Fox Ridge Senior Living at Parkstone - North Little Rock [Member]", "terseLabel": "Fox Ridge North Little Rock - North Little Rock, AR", "verboseLabel": "Fox Ridge North Little Rock - North Little Rock, AR" } } }, "localname": "FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FreseniusMedicalCareWinfieldALMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fresenius Medical Care - Winfield, AL [Member]", "label": "Fresenius Medical Care - Winfield, AL [Member]", "terseLabel": "Fresenius Medical Care - Winfield, AL" } } }, "localname": "FreseniusMedicalCareWinfieldALMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_GainonDispositionsofRealEstateInvestmentsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gain on Dispositions of Real Estate Investments Policy [Policy Text Block]", "label": "Gain on Dispositions of Real Estate Investments Policy [Policy Text Block]", "terseLabel": "Gain on Dispositions of Real Estate Investments" } } }, "localname": "GainonDispositionsofRealEstateInvestmentsPolicyPolicyTextBlock", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hct_GatewayMedicalOfficeBuildingClarksvilleOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gateway Medical Office Building - Clarksville - October [Member]", "label": "Gateway Medical Office Building - Clarksville - October [Member]", "terseLabel": "Gateway MOB - Clarksville, TN" } } }, "localname": "GatewayMedicalOfficeBuildingClarksvilleOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_GlendaleMOBFarmingtonHillsMIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glendale MOB - Farmington Hills MI [Member]", "label": "Glendale MOB - Farmington Hills MI [Member]", "terseLabel": "Glendale MOB - Farmington Hills, MI" } } }, "localname": "GlendaleMOBFarmingtonHillsMIMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_GreenfieldMOBGreenfieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GreenfieldMOBGreenfield [Member]", "label": "GreenfieldMOBGreenfield [Member]", "terseLabel": "Greenfield MOB - Greenfield, WI" } } }, "localname": "GreenfieldMOBGreenfieldMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_GreenfieldMedicalPlazaGilbertMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Greenfield Medical Plaza - Gilbert [Member]", "label": "Greenfield Medical Plaza - Gilbert [Member]", "terseLabel": "Greenfield Medical Plaza - Gilbert, AZ" } } }, "localname": "GreenfieldMedicalPlazaGilbertMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_GreenvilleHealthSystemGreenvilleSCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Greenville Health System - Greenville, SC [Member]", "label": "Greenville Health System - Greenville, SC [Member]", "terseLabel": "Greenville Health System - Greenville, SC" } } }, "localname": "GreenvilleHealthSystemGreenvilleSCMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_GrossRevenueExcludingStandAloneSingleTenantNetLeasedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties [Member]", "label": "Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties [Member]", "terseLabel": "Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties" } } }, "localname": "GrossRevenueExcludingStandAloneSingleTenantNetLeasedPropertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_GrossRevenueManagedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross Revenue, Managed Properties [Member]", "label": "Gross Revenue, Managed Properties [Member]", "terseLabel": "Gross Revenue, Managed Properties" } } }, "localname": "GrossRevenueManagedPropertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_GrossRevenueStandAloneSingleTenantNetLeasedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross Revenue, Stand-alone Single-tenant Net Leased Properties [Member]", "label": "Gross Revenue, Stand-alone Single-tenant Net Leased Properties [Member]", "terseLabel": "Gross Revenue, Stand-alone Single-tenant Net Leased Properties" } } }, "localname": "GrossRevenueStandAloneSingleTenantNetLeasedPropertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_HamptonRiverPortolioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hampton River Portolio", "label": "Hampton River Portolio [Member]", "terseLabel": "Hampton River Portfolio (two properties)" } } }, "localname": "HamptonRiverPortolioMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "hct_HealthcareTrustOperatingPartnershipL.P.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Healthcare Trust Operating Partnership, L.P. [Member]", "label": "Healthcare Trust Operating Partnership, L.P. [Member]", "terseLabel": "Healthcare Trust Operating Partnership, L.P." } } }, "localname": "HealthcareTrustOperatingPartnershipL.P.Member", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "hct_HealthcareTrustSpecialLimitedPartnershipLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Healthcare Trust Special Limited Partnership, LLC [Member]", "label": "Healthcare Trust Special Limited Partnership, LLC [Member]", "terseLabel": "Healthcare Trust Special Limited Partnership, LLC" } } }, "localname": "HealthcareTrustSpecialLimitedPartnershipLLCMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_HefnerPointeMedicalCenterOklahomaCityOKMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hefner Pointe Medical Center - Oklahoma City, OK", "label": "Hefner Pointe Medical Center - Oklahoma City, OK [Member]", "terseLabel": "Hefner Pointe Medical Center - Oklahoma City, OK" } } }, "localname": "HefnerPointeMedicalCenterOklahomaCityOKMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_HighDesertMedicalGroupMedicalOfficeBuildingLancasterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "High Desert Medical Group Medical Office Building - Lancaster [Member]", "label": "High Desert Medical Group Medical Office Building - Lancaster [Member]", "terseLabel": "High Desert Medical Group Medical Office Building - Lancaster, CA" } } }, "localname": "HighDesertMedicalGroupMedicalOfficeBuildingLancasterMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_IllinoisCancerCareGalesburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Illinois Cancer Care - Galesburg [Member]", "label": "Illinois Cancer Care - Galesburg [Member]", "terseLabel": "Illinois CancerCare - Galesburg, IL" } } }, "localname": "IllinoisCancerCareGalesburgMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_IncreaseDecreasePreferredStockDividendRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) Preferred Stock, Dividend Rate, Percentage", "label": "Increase (Decrease) Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Increase in preferred stock, dividend rate, percentage" } } }, "localname": "IncreaseDecreasePreferredStockDividendRatePercentage", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_InplaceLeasesandOtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In-place Leases and Other Intangible Assets [Member]", "label": "In-place Leases and Other Intangible Assets [Member]", "terseLabel": "In-place leases and other intangible assets" } } }, "localname": "InplaceLeasesandOtherIntangibleAssetsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "domainItemType" }, "hct_IntangibleMarketLeaseAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Market Lease Assets [Member]", "label": "Intangible Market Lease Assets [Member]", "terseLabel": "Market lease assets" } } }, "localname": "IntangibleMarketLeaseAssetsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "hct_KeyBankFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KeyBank Facility [Member]", "label": "KeyBank Facility [Member]", "terseLabel": "KeyBank Facility" } } }, "localname": "KeyBankFacilityMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_KingwoodExecutiveCenterKingwoodTXMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kingwood Executive Center - Kingwood, TX", "label": "Kingwood Executive Center - Kingwood, TX [Member]", "terseLabel": "Kingwood Executive Center - Kingwood, TX" } } }, "localname": "KingwoodExecutiveCenterKingwoodTXMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LIBORBasedBorrowingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LIBOR-Based Borrowings", "label": "LIBOR-Based Borrowings [Member]", "terseLabel": "LIBOR-Based Borrowings" } } }, "localname": "LIBORBasedBorrowingsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_LIBORBasedInterestRateSwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LIBOR Based Interest Rate Swap", "label": "LIBOR Based Interest Rate Swap [Member]", "terseLabel": "LIBOR-based interest rate \u201cpay-fixed\u201d swaps" } } }, "localname": "LIBORBasedInterestRateSwapMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hct_LIBORBasedVariableRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LIBOR Based Variable Rate", "label": "LIBOR Based Variable Rate [Member]", "terseLabel": "LIBOR Based Variable Rate" } } }, "localname": "LIBORBasedVariableRateMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_LaSallePropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LaSalle Properties", "label": "LaSalle Properties [Member]", "terseLabel": "LaSalle Properties" } } }, "localname": "LaSallePropertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "hct_LagunaProfessionalCenterElkGroveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laguna Professional Center - Elk Grove [Member]", "label": "Laguna Professional Center - Elk Grove [Member]", "terseLabel": "Laguna Professional Center - Elk Grove, CA" } } }, "localname": "LagunaProfessionalCenterElkGroveMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LakesideVistaHollandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lakeside Vista - Holland", "label": "Lakeside Vista - Holland [Member]", "terseLabel": "Lakeside Vista - Holland, MI" } } }, "localname": "LakesideVistaHollandMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LancasterMedicalArtsMOBLancasterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LancasterMedicalArtsMOBLancaster [Member]", "label": "LancasterMedicalArtsMOBLancaster [Member]", "terseLabel": "Lancaster Medical Arts MOB - Lancaster, PA" } } }, "localname": "LancasterMedicalArtsMOBLancasterMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LandisMemorialHarrisburgSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Landis Memorial - Harrisburg - September [Member]", "label": "Landis Memorial - Harrisburg - September [Member]", "terseLabel": "Landis Memorial - Harrisburg, PA" } } }, "localname": "LandisMemorialHarrisburgSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LeaseIntangiblesLeaseupPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Intangibles, Lease-up Period", "label": "Lease Intangibles, Lease-up Period", "terseLabel": "Lease intangibles, lease-up period" } } }, "localname": "LeaseIntangiblesLeaseupPeriod", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "hct_LeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease, Remaining Lease Term", "label": "Lease, Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "LeaseRemainingLeaseTerm", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "hct_LeeMemorialHealthSystemOutpatientCenterFortMeyersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lee Memorial Health System Outpatient Center - Fort Meyers [Member]", "label": "Lee Memorial Health System Outpatient Center - Fort Meyers [Member]", "terseLabel": "Lee Memorial Health System Outpatient Center - Ft. Myers" } } }, "localname": "LeeMemorialHealthSystemOutpatientCenterFortMeyersMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LegacyMedicalVillagePlanoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legacy Medical Village - Plano [Member]", "label": "Legacy Medical Village - Plano [Member]", "terseLabel": "Legacy Medical Village - Plano, TX" } } }, "localname": "LegacyMedicalVillagePlanoMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LesseeFinanceLeaseNumberOfContracts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Finance Lease, Number Of Contracts", "label": "Lessee, Finance Lease, Number Of Contracts", "terseLabel": "Number of finance lease contracts" } } }, "localname": "LesseeFinanceLeaseNumberOfContracts", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_LesseeLeaseRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Lease, Renewal Term", "label": "Lessee, Lease, Renewal Term", "terseLabel": "Renewal term" } } }, "localname": "LesseeLeaseRenewalTerm", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "hct_LesseeOperatingLeaseNumberOfContracts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Contracts", "label": "Lessee, Operating Lease, Number Of Contracts", "terseLabel": "Number of operating lease contracts" } } }, "localname": "LesseeOperatingLeaseNumberOfContracts", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_LesseeOperatingLeaseRenewalTermExcluded": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Renewal Term, Excluded", "label": "Lessee, Operating Lease, Renewal Term, Excluded", "terseLabel": "Term of lease excluded" } } }, "localname": "LesseeOperatingLeaseRenewalTermExcluded", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "hct_LibertyCourtDixonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liberty Court - Dixon [Member]", "label": "Liberty Court - Dixon [Member]", "terseLabel": "Liberty Court - Dixon, IL" } } }, "localname": "LibertyCourtDixonMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LienSettlementOnFormerlyDisposedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lien settlement on formerly disposed properties", "label": "Lien settlement on formerly disposed properties [Member]", "terseLabel": "Lien settlement on formerly disposed properties" } } }, "localname": "LienSettlementOnFormerlyDisposedPropertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "hct_LimitedPartnersCapitalAccountPotentiallyRedeemableAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Limited Partners' Capital Account, Potentially Redeemable Amount", "label": "Limited Partners' Capital Account, Potentially Redeemable Amount", "terseLabel": "Redeemable amount of shares (in shares)" } } }, "localname": "LimitedPartnersCapitalAccountPotentiallyRedeemableAmount", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "hct_LimitedPartnersCapitalAccountUnitsRedemptionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Limited Partners' Capital Account, Units, Redemption Period", "label": "Limited Partners' Capital Account, Units, Redemption Period", "terseLabel": "Limited partner units, redemption period" } } }, "localname": "LimitedPartnersCapitalAccountUnitsRedemptionPeriod", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "durationItemType" }, "hct_LineOfCreditFacilityExtensionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of Credit Facility, Extension Period", "label": "Line of Credit Facility, Extension Period", "terseLabel": "Extension period" } } }, "localname": "LineOfCreditFacilityExtensionPeriod", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "durationItemType" }, "hct_LineofCreditFacilityAccordionFeatureIncreaseLimit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line of Credit Facility, Accordion Feature, Increase Limit", "label": "Line of Credit Facility, Accordion Feature, Increase Limit", "terseLabel": "Line of credit facility, increase limit" } } }, "localname": "LineofCreditFacilityAccordionFeatureIncreaseLimit", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_LongTermLineOfCreditMaturityExtensionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Line Of Credit, Maturity, Extension Term", "label": "Long Term Line Of Credit, Maturity, Extension Term", "terseLabel": "Extension term" } } }, "localname": "LongTermLineOfCreditMaturityExtensionTerm", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails" ], "xbrltype": "durationItemType" }, "hct_LongtermLineofCreditIncludingFinancingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Line of Credit, Including Financing Costs", "label": "Long-term Line of Credit, Including Financing Costs", "terseLabel": "Term Loan, net" } } }, "localname": "LongtermLineofCreditIncludingFinancingCosts", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hct_LutzFloridaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lutz, Florida [Member]", "label": "Lutz, Florida [Member]", "terseLabel": "Lutz, Florida" } } }, "localname": "LutzFloridaMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "hct_MOBLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MOB Loan [Member]", "label": "MOB Loan [Member]", "terseLabel": "Capital One MOB Loan" } } }, "localname": "MOBLoanMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "domainItemType" }, "hct_MOBPropertyIllinoisSkilledNursingFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "M O B Property Illinois Skilled Nursing Facilities [Member]", "label": "M O B Property Illinois Skilled Nursing Facilities [Member]", "terseLabel": "Illinois skilled nursing facilities" } } }, "localname": "MOBPropertyIllinoisSkilledNursingFacilitiesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "hct_MOBPropertySassafrasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MOB Property, Sassafras", "label": "MOB Property, Sassafras [Member]", "terseLabel": "Sassafras MOB" } } }, "localname": "MOBPropertySassafrasMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "hct_MOBPropertySunCityArizonaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MOB Property, Sun City, Arizona", "label": "MOB Property, Sun City, Arizona [Member]", "terseLabel": "Sun City MOB" } } }, "localname": "MOBPropertySunCityArizonaMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "hct_MadisonMedicalPlazaJolietMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Madison Medical Plaza - Joliet [Member]", "label": "Madison Medical Plaza - Joliet [Member]", "terseLabel": "Madison Medical Plaza - Joliet, IL" } } }, "localname": "MadisonMedicalPlazaJolietMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MainlandMedicalArtsPavilionTexasCityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mainland Medical Arts Pavilion - Texas City [Member]", "label": "Mainland Medical Arts Pavilion - Texas City [Member]", "terseLabel": "Mainland Medical Arts Pavilion - Texas City, TX" } } }, "localname": "MainlandMedicalArtsPavilionTexasCityMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MasterCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Master Credit Facility [Member]", "label": "Master Credit Facility [Member]", "terseLabel": "Fannie Mae Master Credit Facilities", "verboseLabel": "Master Credit Facility" } } }, "localname": "MasterCreditFacilityMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MeadowbrookSeniorLivingAgouraHillsNovemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Meadowbrook Senior Living - Agoura Hills - November [Member]", "label": "Meadowbrook Senior Living - Agoura Hills - November [Member]", "terseLabel": "Meadowbrook Senior Living - Agoura Hills, CA" } } }, "localname": "MeadowbrookSeniorLivingAgouraHillsNovemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MedicalCenterIIIPeoriaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Center III - Peoria [Member]", "label": "Medical Center III - Peoria [Member]", "terseLabel": "Medical Center III - Peoria, AZ" } } }, "localname": "MedicalCenterIIIPeoriaMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MedicalCenterIIPeoriaMayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Center II - Peoria - May [Member]", "label": "Medical Center II - Peoria - May [Member]", "terseLabel": "Medical Center II - Peoria, AZ" } } }, "localname": "MedicalCenterIIPeoriaMayMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MedicalCenterIPeoriaMayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Center I - Peoria - May [Member]", "label": "Medical Center I - Peoria - May [Member]", "terseLabel": "Medical Center I - Peoria, AZ" } } }, "localname": "MedicalCenterIPeoriaMayMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MedicalCenterVPeoriaAZMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Center V - Peoria, AZ [Member]", "label": "Medical Center V - Peoria, AZ [Member]", "terseLabel": "Medical Center V - Peoria, AZ", "verboseLabel": "Medical Center V - Peoria, AZ" } } }, "localname": "MedicalCenterVPeoriaAZMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MedicalOfficeBuildingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Office Buildings [Member]", "label": "Medical Office Buildings [Member]", "terseLabel": "Medical Office Buildings", "verboseLabel": "MOB Segment:" } } }, "localname": "MedicalOfficeBuildingsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_MedicalSciencesPavilionHarrisburgDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Sciences Pavilion - Harrisburg - December [Member]", "label": "Medical Sciences Pavilion - Harrisburg - December [Member]", "terseLabel": "Medical Sciences Pavilion - Harrisburg, PA" } } }, "localname": "MedicalSciencesPavilionHarrisburgDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MetroHealthBuckeyeHealthCenterClevelandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MetroHealthBuckeyeHealthCenterCleveland [Member]", "label": "MetroHealthBuckeyeHealthCenterCleveland [Member]", "terseLabel": "MetroHealth Buckeye Health Center - Cleveland, OH" } } }, "localname": "MetroHealthBuckeyeHealthCenterClevelandMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MetropolitanEyeLakeshoreSurgeryStClairMIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Metropolitan Eye Lakeshore Surgery - St. Clair, MI", "label": "Metropolitan Eye Lakeshore Surgery - St. Clair, MI [Member]", "terseLabel": "Metropolitan Eye Lakeshore Surgery - St. Clair, MI" } } }, "localname": "MetropolitanEyeLakeshoreSurgeryStClairMIMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MichiganPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Michigan Properties", "label": "Michigan Properties [Member]", "terseLabel": "Michigan properties" } } }, "localname": "MichiganPropertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "hct_MillenniumEyeCareFreeholdNJMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Millennium Eye Care - Freehold, NJ", "label": "Millennium Eye Care - Freehold, NJ [Member]", "terseLabel": "Millennium Eye Care - Freehold, NJ" } } }, "localname": "MillenniumEyeCareFreeholdNJMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MilwaukeeMOBSouthMilwaukeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MilwaukeeMOBSouthMilwaukee [Member]", "label": "MilwaukeeMOBSouthMilwaukee [Member]", "terseLabel": "Milwaukee MOB - South Milwaukee, WI" } } }, "localname": "MilwaukeeMOBSouthMilwaukeeMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MonthlyBaseManagementFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Monthly Base Management Fee [Member]", "label": "Monthly Base Management Fee [Member]", "terseLabel": "Monthly Base Management Fee" } } }, "localname": "MonthlyBaseManagementFeeMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_MorrowMedicalCenterMorrowJuneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Morrow Medical Center - Morrow - June [Member]", "label": "Morrow Medical Center - Morrow - June [Member]", "terseLabel": "Morrow Medical Center - Morrow, GA" } } }, "localname": "MorrowMedicalCenterMorrowJuneMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MortonTerraceHealthcareRehabCentreMortonDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Morton Terrace Healthcare& Rehab Centre - Morton - December [Member]", "label": "Morton Terrace Healthcare& Rehab Centre - Morton - December [Member]", "terseLabel": "Morton Terrace Healthcare & Rehab Centre - Morton, IL" } } }, "localname": "MortonTerraceHealthcareRehabCentreMortonDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MortonVillaHealthcareRehabCentreMortonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Morton Villa Healthcare & Rehab Centre - Morton [Member]", "label": "Morton Villa Healthcare & Rehab Centre - Morton [Member]", "terseLabel": "Morton Villa Healthcare & Rehab Centre - Morton, IL" } } }, "localname": "MortonVillaHealthcareRehabCentreMortonMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MountVernonMedicalOfficeBuildingMountVernonNovemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mount Vernon Medical Office Building - Mount Vernon - November [Member]", "label": "Mount Vernon Medical Office Building - Mount Vernon - November [Member]", "terseLabel": "Mount Vernon Medical Office Building - Mount Vernon, WA" } } }, "localname": "MountVernonMedicalOfficeBuildingMountVernonNovemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MultiPropertyCMBSLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multi-Property CMBS Loan [Member]", "label": "Multi-Property CMBS Loan [Member]", "terseLabel": "Multi-Property CMBS Loan" } } }, "localname": "MultiPropertyCMBSLoanMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "domainItemType" }, "hct_MultitenantMOBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multi-tenant MOB [Member]", "label": "Multi-tenant MOB [Member]", "terseLabel": "Multi-tenant MOB" } } }, "localname": "MultitenantMOBMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_NaiduClinicOdessaTXMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Naidu Clinic - Odessa, TX", "label": "Naidu Clinic - Odessa, TX [Member]", "terseLabel": "Naidu Clinic - Odessa, TX" } } }, "localname": "NaiduClinicOdessaTXMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_NetSaleProceedsAfterReturnOfCapitalContributionsAndAnnualTargetedInvestorReturnMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return [Member]", "label": "Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return [Member]", "terseLabel": "Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return" } } }, "localname": "NetSaleProceedsAfterReturnOfCapitalContributionsAndAnnualTargetedInvestorReturnMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_NewCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Credit Facilities [Member]", "label": "New Credit Facilities [Member]", "terseLabel": "New Credit Facilities" } } }, "localname": "NewCreditFacilitiesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_NoncashorPartNoncashMortgageNotesPayableSecuredInConnectionWithTheAcquisitionOfRealEstate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash, or Part Noncash, Mortgage notes secured simultaneously with the acquisition of real estate assets, which includes land, buildings, fixtures, and land and building improvements.", "label": "Noncash, or Part Noncash, Mortgage Notes Payable Secured In Connection With The Acquisition Of Real Estate", "terseLabel": "Mortgage assumed in acquisition" } } }, "localname": "NoncashorPartNoncashMortgageNotesPayableSecuredInConnectionWithTheAcquisitionOfRealEstate", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "hct_NoncontrollingInterestPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-controlling Interest Policy [Policy Text Block]", "label": "Non-controlling Interest Policy [Policy Text Block]", "terseLabel": "Non-controlling Interests" } } }, "localname": "NoncontrollingInterestPolicyPolicyTextBlock", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hct_NoncontrollingInterestTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest", "label": "Noncontrolling Interest [Table Text Block]", "terseLabel": "Schedule of Noncontrolling Interest on Balance Sheet" } } }, "localname": "NoncontrollingInterestTableTextBlock", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterestsTables" ], "xbrltype": "textBlockItemType" }, "hct_NoncontrollingInterestsInPropertyOwningSubsidiaries": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails": { "order": 2.0, "parentTag": "us-gaap_MinorityInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interests In Property Owning Subsidiaries", "label": "Noncontrolling Interests In Property Owning Subsidiaries", "terseLabel": "Non-controlling interests in property owning subsidiaries" } } }, "localname": "NoncontrollingInterestsInPropertyOwningSubsidiaries", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails" ], "xbrltype": "monetaryItemType" }, "hct_NorthsideHospitalMedicalOfficeBuildingCantonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Northside Hospital Medical Office Building - Canton [Member]", "label": "Northside Hospital Medical Office Building - Canton [Member]", "terseLabel": "Northside Hospital - Canton, GA" } } }, "localname": "NorthsideHospitalMedicalOfficeBuildingCantonMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_NuVistaJupiterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NuVista Jupiter", "label": "NuVista Jupiter [Member]", "terseLabel": "NuVista Jupiter" } } }, "localname": "NuVistaJupiterMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "hct_NumberOfIndependentContractors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Independent Contractors", "label": "Number Of Independent Contractors", "terseLabel": "Number of independent contractors" } } }, "localname": "NumberOfIndependentContractors", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_NumberOfIntercompanyLeasesModified": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Intercompany Leases Modified", "label": "Number Of Intercompany Leases Modified", "terseLabel": "Number of intercompany leases modified" } } }, "localname": "NumberOfIntercompanyLeasesModified", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_NumberOfInterestRateDerivativesNotYetInEffect": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Interest Rate Derivatives Not Yet In Effect", "label": "Number Of Interest Rate Derivatives Not Yet In Effect", "terseLabel": "Interest rate cap agreements excluded" } } }, "localname": "NumberOfInterestRateDerivativesNotYetInEffect", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "integerItemType" }, "hct_NumberOfLandParcels": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Land Parcels", "label": "Number Of Land Parcels", "terseLabel": "Number of land parcels" } } }, "localname": "NumberOfLandParcels", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_NumberOfRealEstatePropertiesEncumbered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Real Estate Properties, Encumbered", "label": "Number of Real Estate Properties, Encumbered", "terseLabel": "Encumbered Properties" } } }, "localname": "NumberOfRealEstatePropertiesEncumbered", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "integerItemType" }, "hct_NumberOfRealEstatePropertiesFailedToRecoverCarryingValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Real Estate Properties, Failed To Recover Carrying Value", "label": "Number Of Real Estate Properties, Failed To Recover Carrying Value", "terseLabel": "Number of real estate properties, failed to recover carrying value" } } }, "localname": "NumberOfRealEstatePropertiesFailedToRecoverCarryingValue", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails" ], "xbrltype": "integerItemType" }, "hct_NumberOfSeniorHousingOperatingPropertiesSoldAndTransferred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Senior Housing Operating Properties Sold And Transferred", "label": "Number Of Senior Housing Operating Properties Sold And Transferred", "terseLabel": "Sale and transfer of SHOPs" } } }, "localname": "NumberOfSeniorHousingOperatingPropertiesSoldAndTransferred", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_NumberofSeniorHousingCommunities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Senior Housing Communities", "label": "Number of Senior Housing Communities", "terseLabel": "Number of senior housing communities" } } }, "localname": "NumberofSeniorHousingCommunities", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_OakLawnMedicalCenterOakLawnIL.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oak Lawn Medical Center - Oak Lawn, IL. [Member]", "label": "Oak Lawn Medical Center - Oak Lawn, IL. [Member]", "terseLabel": "Oak Lawn Medical Center - Oak Lawn, IL" } } }, "localname": "OakLawnMedicalCenterOakLawnIL.Member", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_OpUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OP Units [Member]", "label": "OP Units [Member]", "terseLabel": "OP Units", "verboseLabel": "Common OP Units" } } }, "localname": "OpUnitsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_OperatingIncomeLossBeforeGainLossonSaleofRealEstateInvestments": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Income (Loss) Before Gain (Loss) on Sale of Real Estate Investments", "label": "Operating Income (Loss) Before Gain (Loss) on Sale of Real Estate Investments", "totalLabel": "Operating loss before gain on sale of real estate investments" } } }, "localname": "OperatingIncomeLossBeforeGainLossonSaleofRealEstateInvestments", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "hct_OperatingLeaseNetInvestmentInLeaseCreditLossExpenseReversalFormerlyDisposedProperties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal), Formerly Disposed Properties", "label": "Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal), Formerly Disposed Properties", "terseLabel": "Disposed properties reduction in revenue" } } }, "localname": "OperatingLeaseNetInvestmentInLeaseCreditLossExpenseReversalFormerlyDisposedProperties", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_OperatingLeaseNetInvestmentinLeaseCreditLossExpenseReversal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal)", "label": "Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal)", "terseLabel": "Operating lease impairment loss" } } }, "localname": "OperatingLeaseNetInvestmentinLeaseCreditLossExpenseReversal", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_OrthoOneHilliardHilliardOHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OrthoOne Hilliard - Hilliard, OH", "label": "OrthoOne Hilliard - Hilliard, OH [Member]", "terseLabel": "OrthoOne Hilliard - Hilliard, OH" } } }, "localname": "OrthoOneHilliardHilliardOHMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_OtherRealEstateDisposalsAndReclasses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Real Estate, Disposals And Reclasses", "label": "Other Real Estate, Disposals And Reclasses", "negatedLabel": "Disposals, impairments and reclasses", "terseLabel": "Assets" } } }, "localname": "OtherRealEstateDisposalsAndReclasses", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "hct_OuachitaCommunityHospitalWestMonroeLAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ouachita Community Hospital - West Monroe, LA [Member]", "label": "Ouachita Community Hospital - West Monroe, LA [Member]", "terseLabel": "Ouachita Community Hospital - West Monroe, LA" } } }, "localname": "OuachitaCommunityHospitalWestMonroeLAMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PalmValleyMedicalPlazaAZMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Palm Valley Medical Plaza AZ [Member]", "label": "Palm Valley Medical Plaza AZ [Member]", "terseLabel": "Palm Valley Medical Plaza - Goodyear, AZ" } } }, "localname": "PalmValleyMedicalPlazaAZMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "domainItemType" }, "hct_PalmValleyMedicalPlazaGoodyearAprilMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Palm Valley Medical Plaza - Goodyear - April [Member]", "label": "Palm Valley Medical Plaza - Goodyear - April [Member]", "terseLabel": "Palm Valley Medical Plaza - Goodyear, AZ" } } }, "localname": "PalmValleyMedicalPlazaGoodyearAprilMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ParadiseValleyMedicalPlazaPhoenixDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paradise Valley Medical Plaza - Phoenix - December [Member]", "label": "Paradise Valley Medical Plaza - Phoenix - December [Member]", "terseLabel": "Paradise Valley Medical Plaza - Phoenix, AZ" } } }, "localname": "ParadiseValleyMedicalPlazaPhoenixDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PensacolaNephrologyMOBPensacolaFLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pensacola Nephrology MOB - Pensacola, FL", "label": "Pensacola Nephrology MOB - Pensacola, FL [Member]", "terseLabel": "Pensacola Nephrology MOB - Pensacola, FL" } } }, "localname": "PensacolaNephrologyMOBPensacolaFLMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PhilipProfessionalCenterLawrencevilleGAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Philip Professional Center - Lawrenceville, GA [Member]", "label": "Philip Professional Center - Lawrenceville, GA [Member]", "verboseLabel": "Philip Professional Center - Lawrenceville, GA" } } }, "localname": "PhilipProfessionalCenterLawrencevilleGAMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PhysiciansPlazaofRoaneCountyHarrimanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physicians Plaza of Roane County - Harriman [Member]", "label": "Physicians Plaza of Roane County - Harriman [Member]", "terseLabel": "Physicians Plaza of Roane County - Harriman, TN" } } }, "localname": "PhysiciansPlazaofRoaneCountyHarrimanMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PinnacleCenterSouthavenDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pinnacle Center - Southaven - December [Member]", "label": "Pinnacle Center - Southaven - December [Member]", "terseLabel": "Pinnacle Center - Southaven, MS" } } }, "localname": "PinnacleCenterSouthavenDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PioneerSpineSportsNorthamptonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PioneerSpineSportsNorthampton [Member]", "label": "PioneerSpineSportsNorthampton [Member]", "terseLabel": "Pioneer Spine Sports - Northampton, MA" } } }, "localname": "PioneerSpineSportsNorthamptonMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PioneerSpineSportsSpringfieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PioneerSpineSportsSpringfield [Member]", "label": "PioneerSpineSportsSpringfield [Member]", "terseLabel": "Pioneer Spine Sport - Springfield, MA" } } }, "localname": "PioneerSpineSportsSpringfieldMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PioneerSpineSportsWestSpringfieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PioneerSpineSportsWestSpringfield [Member]", "label": "PioneerSpineSportsWestSpringfield [Member]", "terseLabel": "Pioneer Spine Sports - West Springfield, MA" } } }, "localname": "PioneerSpineSportsWestSpringfieldMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PlazaDelRioMedicalOfficeCampusPortfolioAZMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plaza Del Rio Medical Office Campus Portfolio AZ [Member]", "label": "Plaza Del Rio Medical Office Campus Portfolio AZ [Member]", "terseLabel": "Plaza Del Rio Medical Office Campus Portfolio AZ" } } }, "localname": "PlazaDelRioMedicalOfficeCampusPortfolioAZMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "hct_PrairieHillsatCedarRapidsCedarRapidsAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prairie Hills at Cedar Rapids - Cedar Rapids - August [Member]", "label": "Prairie Hills at Cedar Rapids - Cedar Rapids - August [Member]", "terseLabel": "Prairie Hills at Cedar Rapids - Cedar Rapids, IA" } } }, "localname": "PrairieHillsatCedarRapidsCedarRapidsAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PrairieHillsatClintonClintonAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prairie Hills at Clinton - Clinton - August [Member]", "label": "Prairie Hills at Clinton - Clinton - August [Member]", "terseLabel": "Prairie Hills at Clinton - Clinton, IA" } } }, "localname": "PrairieHillsatClintonClintonAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PrairieHillsatDesMoinesDesMoinesAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prairie Hills at Des Moines - Des Moines - August [Member]", "label": "Prairie Hills at Des Moines - Des Moines - August [Member]", "terseLabel": "Prairie Hills at Des Moines - Des Moines, IA" } } }, "localname": "PrairieHillsatDesMoinesDesMoinesAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PrairieHillsatIndependenceIndependenceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prairie Hills at Independence - Independence [Member]", "label": "Prairie Hills at Independence - Independence [Member]", "terseLabel": "Prairie Hills at Independence - Independence, IA" } } }, "localname": "PrairieHillsatIndependenceIndependenceMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PrairieHillsatOttumwaOttumwaAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prairie Hills at Ottumwa - Ottumwa - August [Member]", "label": "Prairie Hills at Ottumwa - Ottumwa - August [Member]", "terseLabel": "Prairie Hills at Ottumwa - Ottumwa, IA" } } }, "localname": "PrairieHillsatOttumwaOttumwaAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PrairieHillsatTiptonTiptonAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prairie Hills at Tipton - Tipton - August [Member]", "label": "Prairie Hills at Tipton - Tipton - August [Member]", "terseLabel": "Prairie Hills at Tipton - Tipton, IA" } } }, "localname": "PrairieHillsatTiptonTiptonAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PreTaxNonCompoundedReturnOnCapitalContributionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre-tax Non-compounded Return on Capital Contribution [Member]", "label": "Pre-tax Non-compounded Return on Capital Contribution [Member]", "terseLabel": "Pre-tax Non-compounded Return on Capital Contribution" } } }, "localname": "PreTaxNonCompoundedReturnOnCapitalContributionMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_PreferredStockAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock, Additional Shares Authorized", "label": "Preferred Stock, Additional Shares Authorized", "terseLabel": "Preferred stock, additional shares authorized (in shares)" } } }, "localname": "PreferredStockAdditionalSharesAuthorized", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "hct_PreferredStockEquityLineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock Equity Line", "label": "Preferred Stock Equity Line [Member]", "terseLabel": "Preferred Stock Equity Line" } } }, "localname": "PreferredStockEquityLineMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_PreferredStockNumberOfAdditionalDirectors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock, Number Of Additional Directors", "label": "Preferred Stock, Number Of Additional Directors", "terseLabel": "Number of additional directors" } } }, "localname": "PreferredStockNumberOfAdditionalDirectors", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_PreferredStockNumberOfAdditionalDirectorsQuarterlyDividendsInArrearsRequirement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock, Number Of Additional Directors, Quarterly Dividends In Arrears Requirement", "label": "Preferred Stock, Number Of Additional Directors, Quarterly Dividends In Arrears Requirement", "terseLabel": "Number of dividends in arrears required for voting rights" } } }, "localname": "PreferredStockNumberOfAdditionalDirectorsQuarterlyDividendsInArrearsRequirement", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_PreferredStockOfferingAuthorizedValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred Stock Offering, Authorized Value", "label": "Preferred Stock Offering, Authorized Value", "terseLabel": "Authorized preferred stock offering, value" } } }, "localname": "PreferredStockOfferingAuthorizedValue", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_PreferredStockOfferingMaximumSharesPerOffer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock Offering, Maximum Shares per Offer", "label": "Preferred Stock Offering, Maximum Shares per Offer", "terseLabel": "Maximum shares per preferred stock offering (in shares)" } } }, "localname": "PreferredStockOfferingMaximumSharesPerOffer", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "hct_PreferredUnitFaceValueSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Unit, Face Value, Share Price", "label": "Preferred Unit, Face Value, Share Price", "terseLabel": "Preferred unit, face value (in usd per share)" } } }, "localname": "PreferredUnitFaceValueSharePrice", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "hct_PreferredUnitIssuanceValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred Unit, Issuance Value", "label": "Preferred Unit, Issuance Value", "terseLabel": "Preferred unit issuance value" } } }, "localname": "PreferredUnitIssuanceValue", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_PreferredUnitIssuanceValueSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Unit, Issuance Value, Share Price", "label": "Preferred Unit, Issuance Value, Share Price", "terseLabel": "Preferred units issued (in usd per share)" } } }, "localname": "PreferredUnitIssuanceValueSharePrice", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "hct_PreferredUnitsRedemptionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Units, Redemption Period", "label": "Preferred Units, Redemption Period", "terseLabel": "Preferred units, redemption period" } } }, "localname": "PreferredUnitsRedemptionPeriod", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "durationItemType" }, "hct_PrepaidExpensesAndOtherAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Expenses And Other Assets", "label": "Prepaid Expenses And Other Assets [Member]", "terseLabel": "Prepaid Expenses and Other Assets" } } }, "localname": "PrepaidExpensesAndOtherAssetsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails" ], "xbrltype": "domainItemType" }, "hct_PresenceHealingArtsPavilionNewLenoxDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Presence Healing Arts Pavilion - New Lenox - December [Member]", "label": "Presence Healing Arts Pavilion - New Lenox - December [Member]", "terseLabel": "Presence Healing Arts Pavilion - New Lenox, IL" } } }, "localname": "PresenceHealingArtsPavilionNewLenoxDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ProceedsFromGovernmentAssistanceCARESAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Government Assistance, CARES Act", "label": "Proceeds From Government Assistance, CARES Act", "terseLabel": "Proceeds from government assistance" } } }, "localname": "ProceedsFromGovernmentAssistanceCARESAct", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_ProceedsFromSaleofInterestRateCashFlowHedge": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Sale of Interest Rate Cash Flow Hedge", "label": "Proceeds From Sale of Interest Rate Cash Flow Hedge", "terseLabel": "Proceeds from sale of interest rate cash flow hedge" } } }, "localname": "ProceedsFromSaleofInterestRateCashFlowHedge", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_ProfessionalFeesCreditDueFromAdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Professional Fees Credit Due From Advisor", "label": "Professional Fees Credit Due From Advisor [Member]", "terseLabel": "Professional fees credit due from Advisor" } } }, "localname": "ProfessionalFeesCreditDueFromAdvisorMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails" ], "xbrltype": "domainItemType" }, "hct_PropertyManagementAndLeasingFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Management and Leasing Fees [Member]", "label": "Property Management and Leasing Fees [Member]", "terseLabel": "Property management fees" } } }, "localname": "PropertyManagementAndLeasingFeesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails" ], "xbrltype": "domainItemType" }, "hct_PropertyOperatingandMaintenanceExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Operating and Maintenance Expense [Member]", "label": "Property Operating and Maintenance Expense [Member]", "terseLabel": "Property Operating and Maintenance Expense" } } }, "localname": "PropertyOperatingandMaintenanceExpenseMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "domainItemType" }, "hct_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Offering", "label": "Public Offering [Member]", "terseLabel": "Public Offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_PublicStockOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Stock Offering [Member]", "label": "Public Stock Offering [Member]", "terseLabel": "Public Stock Offering" } } }, "localname": "PublicStockOfferingMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_PulmonaryCriticalCareMedicineAccocLemoyneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pulmonary & Critical Care Medicine Accoc - Lemoyne [Member]", "label": "Pulmonary & Critical Care Medicine Accoc - Lemoyne [Member]", "terseLabel": "Pulmonary & Critical Care Med - Lemoyne, PA" } } }, "localname": "PulmonaryCriticalCareMedicineAccocLemoyneMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PurchasePriceAllocationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Price Allocation Policy [Policy Text Block]", "label": "Purchase Price Allocation Policy [Policy Text Block]", "terseLabel": "Purchase Price Allocation" } } }, "localname": "PurchasePriceAllocationPolicyPolicyTextBlock", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hct_QuarterlyVariableManagementFeeBenchmarkOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Quarterly Variable Management Fee, Benchmark One [Member]", "label": "Quarterly Variable Management Fee, Benchmark One [Member]", "terseLabel": "Quarterly Variable Management Fee, Benchmark One" } } }, "localname": "QuarterlyVariableManagementFeeBenchmarkOneMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_QuarterlyVariableManagementFeeBenchmarkTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Quarterly Variable Management Fee, Benchmark Two [Member]", "label": "Quarterly Variable Management Fee, Benchmark Two [Member]", "terseLabel": "Quarterly Variable Management Fee, Benchmark Two" } } }, "localname": "QuarterlyVariableManagementFeeBenchmarkTwoMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_RAIClearwaterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RAI Clearwater [Member]", "label": "RAI Clearwater [Member]", "terseLabel": "RAI Care Center - Clearwater, FL" } } }, "localname": "RAIClearwaterMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_RamseyWoodsCudahyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ramsey Woods - Cudahy [Member]", "label": "Ramsey Woods - Cudahy [Member]", "terseLabel": "Ramsey Woods Memory Care - Cudahy, WI" } } }, "localname": "RamseyWoodsCudahyMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_RealEstateCostMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real Estate Cost [Member]", "label": "Real Estate Cost [Member]", "terseLabel": "Real Estate Cost" } } }, "localname": "RealEstateCostMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_RealEstateInvestmentAtCostRelatingtoNotesPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Real Estate Investment, At Cost Relating to Notes Payable", "label": "Real Estate Investment, At Cost Relating to Notes Payable", "terseLabel": "Real estate investments pledged as collateral" } } }, "localname": "RealEstateInvestmentAtCostRelatingtoNotesPayable", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_RealEstateInvestmentPropertyAtCostAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Real Estate Investment Property, at Cost, Acquisitions", "label": "Real Estate Investment Property, at Cost, Acquisitions", "verboseLabel": "Additions-acquisitions and capital expenditures" } } }, "localname": "RealEstateInvestmentPropertyAtCostAcquisitions", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "hct_RealEstateInvestmentsAcquiredIntangibleAssetsTotal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Real Estate Investments, Acquired Intangible Assets, Total", "label": "Real Estate Investments, Acquired Intangible Assets, Total", "terseLabel": "Acquired intangibles" } } }, "localname": "RealEstateInvestmentsAcquiredIntangibleAssetsTotal", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "hct_ReclassificationFromHeldForSaleToRealEstateInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reclassification From Held-For-Sale To Real Estate Investments", "label": "Reclassification From Held-For-Sale To Real Estate Investments [Member]", "terseLabel": "Reclassification From Held-For-Sale To Real Estate Investments" } } }, "localname": "ReclassificationFromHeldForSaleToRealEstateInvestmentsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hct_ReimbursementsOfEmployeeBonusesOfTheAdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reimbursements of Employee Bonuses of the Advisor", "label": "Reimbursements of Employee Bonuses of the Advisor [Member]", "terseLabel": "Reimbursements of Employee Bonuses of the Advisor" } } }, "localname": "ReimbursementsOfEmployeeBonusesOfTheAdvisorMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_ReimbursementsofAdministrativeServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reimbursements of Administrative Services [Member]", "label": "Reimbursements of Administrative Services [Member]", "terseLabel": "Reimbursements of Administrative Services" } } }, "localname": "ReimbursementsofAdministrativeServicesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_RelatedPartyAgreementTermofAgreementRenewalPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Agreement, Term of Agreement, Renewal Period", "label": "Related Party Agreement, Term of Agreement, Renewal Period", "terseLabel": "Renewal term" } } }, "localname": "RelatedPartyAgreementTermofAgreementRenewalPeriod", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "durationItemType" }, "hct_RelatedPartyFeesBenchmarkDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Fees, Benchmark [Domain]", "label": "Related Party Fees, Benchmark [Domain]", "terseLabel": "Related Party Fees, Benchmark [Domain]" } } }, "localname": "RelatedPartyFeesBenchmarkDomain", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_RelatedPartyFeesByBenchmarkAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Fees, by Benchmark [Axis]", "label": "Related Party Fees, by Benchmark [Axis]", "terseLabel": "Related Party Fees, by Benchmark [Axis]" } } }, "localname": "RelatedPartyFeesByBenchmarkAxis", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "stringItemType" }, "hct_RelatedPartyTransactionAssetThresholdQualifyingManagement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Asset Threshold Qualifying Management", "label": "Related Party Transaction, Asset Threshold Qualifying Management", "terseLabel": "Asset threshold for assignment of agreement" } } }, "localname": "RelatedPartyTransactionAssetThresholdQualifyingManagement", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "hct_RelatedPartyTransactionBaseManagementFeeOfNetProceedsVariablePortionFactorPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Base Management Fee Of Net Proceeds, Variable Portion Factor, Percent", "label": "Related Party Transaction, Base Management Fee Of Net Proceeds, Variable Portion Factor, Percent", "terseLabel": "Base management fee of net proceeds, variable portion factor, percent" } } }, "localname": "RelatedPartyTransactionBaseManagementFeeOfNetProceedsVariablePortionFactorPercent", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionBaseManagementFeeofNetProceedsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Base Management Fee of Net Proceeds, Percent", "label": "Related Party Transaction, Base Management Fee of Net Proceeds, Percent", "terseLabel": "Base management fee of net proceeds" } } }, "localname": "RelatedPartyTransactionBaseManagementFeeofNetProceedsPercent", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionBasisCostOfLivingPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction Basis Cost Of Living Percent", "label": "Related Party Transaction Basis Cost Of Living Percent", "terseLabel": "Cost of living percent multiplier" } } }, "localname": "RelatedPartyTransactionBasisCostOfLivingPercent", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "pureItemType" }, "hct_RelatedPartyTransactionBasisofCoreEarningsPerShareBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Basis of Core Earnings, Per Share Basis", "label": "Related Party Transaction, Basis of Core Earnings, Per Share Basis", "terseLabel": "Basis of core earnings (in usd per share)" } } }, "localname": "RelatedPartyTransactionBasisofCoreEarningsPerShareBasis", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "perShareItemType" }, "hct_RelatedPartyTransactionBasisofCoreEarningsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Basis of Core Earnings, Percent", "label": "Related Party Transaction, Basis of Core Earnings, Percent", "terseLabel": "Basis of core earnings, percent" } } }, "localname": "RelatedPartyTransactionBasisofCoreEarningsPercent", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionBasisofRealEstateCostPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction Basis of Real Estate Cost Percent", "label": "Related Party Transaction Basis of Real Estate Cost Percent", "terseLabel": "Real estate cost percent multiplier" } } }, "localname": "RelatedPartyTransactionBasisofRealEstateCostPercent", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "pureItemType" }, "hct_RelatedPartyTransactionContingentGoodFaithNegotiationsOfFixedComponentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Contingent Good Faith Negotiations Of Fixed Component, Term", "label": "Related Party Transaction, Contingent Good Faith Negotiations Of Fixed Component, Term", "terseLabel": "Contingent good faith negotiations of fixed component, term" } } }, "localname": "RelatedPartyTransactionContingentGoodFaithNegotiationsOfFixedComponentTerm", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "durationItemType" }, "hct_RelatedPartyTransactionCumulativeCapitalInvestmentReturnAsPercentageOfBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Cumulative Capital Investment Return, as a Percentage of Benchmark", "label": "Related Party Transaction, Cumulative Capital Investment Return, as a Percentage of Benchmark", "terseLabel": "Cumulative capital investment return to investors as a percentage of benchmark" } } }, "localname": "RelatedPartyTransactionCumulativeCapitalInvestmentReturnAsPercentageOfBenchmark", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionFeeMultiplier": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Fee Multiplier", "label": "Related Party Transaction, Fee Multiplier", "terseLabel": "Fee multiplier" } } }, "localname": "RelatedPartyTransactionFeeMultiplier", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "pureItemType" }, "hct_RelatedPartyTransactionFeePaymentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Fee Payment Period", "label": "Related Party Transaction, Fee Payment Period", "terseLabel": "Fee payment period" } } }, "localname": "RelatedPartyTransactionFeePaymentPeriod", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "durationItemType" }, "hct_RelatedPartyTransactionOversightFeesEarnedByRelatedPartyPercentageOfBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Oversight Fees Earned by Related Party, Percentage of Benchmark", "label": "Related Party Transaction, Oversight Fees Earned by Related Party, Percentage of Benchmark", "terseLabel": "Oversight fees earned by related party" } } }, "localname": "RelatedPartyTransactionOversightFeesEarnedByRelatedPartyPercentageOfBenchmark", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionPeriodofNoticeforTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Period of Notice for Termination", "label": "Related Party Transaction, Period of Notice for Termination", "terseLabel": "Period of notice of termination" } } }, "localname": "RelatedPartyTransactionPeriodofNoticeforTermination", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "durationItemType" }, "hct_RelatedPartyTransactionPeriodofNoticetoAlterAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Period of Notice to Alter Agreement", "label": "Related Party Transaction, Period of Notice to Alter Agreement", "terseLabel": "Period of notice" } } }, "localname": "RelatedPartyTransactionPeriodofNoticetoAlterAgreement", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "durationItemType" }, "hct_RelatedPartyTransactionPropertyManagementFeesEarnedByRelatedPartyPercentageOfBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Property Management Fees Earned by Related Party, Percentage of Benchmark", "label": "Related Party Transaction, Property Management Fees Earned by Related Party, Percentage of Benchmark", "terseLabel": "Property management fees" } } }, "localname": "RelatedPartyTransactionPropertyManagementFeesEarnedByRelatedPartyPercentageOfBenchmark", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionQuarterlyAssetManagementFeeEarnedByRelatedPartyPercentageOfBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Quarterly Asset Management Fee Earned By Related Party, Percentage of Benchmark", "label": "Related Party Transaction, Quarterly Asset Management Fee Earned By Related Party, Percentage of Benchmark", "terseLabel": "Quarterly asset management fee" } } }, "localname": "RelatedPartyTransactionQuarterlyAssetManagementFeeEarnedByRelatedPartyPercentageOfBenchmark", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionReductionofRealEstateCostPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction Reduction of Real Estate Cost Percent", "label": "Related Party Transaction Reduction of Real Estate Cost Percent", "terseLabel": "Reduction of real estate cost percent" } } }, "localname": "RelatedPartyTransactionReductionofRealEstateCostPercent", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "pureItemType" }, "hct_RelatedPartyTransactionReimbursedFeestoRelatedPartyCappedReimbursementAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Reimbursed Fees to Related Party, Capped Reimbursement Amount", "label": "Related Party Transaction, Reimbursed Fees to Related Party, Capped Reimbursement Amount", "terseLabel": "Reimbursed fees to related party, capped reimbursement amount" } } }, "localname": "RelatedPartyTransactionReimbursedFeestoRelatedPartyCappedReimbursementAmount", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "hct_RelatedPartyTransactionReimbursedFeestoRelatedPartyPercentageofBenchmarkExpectedCompanysPortfolioCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Company's Portfolio Costs", "label": "Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Company's Portfolio Costs", "terseLabel": "Financing advance fees as a percentage of benchmark, expected company portfolio cost" } } }, "localname": "RelatedPartyTransactionReimbursedFeestoRelatedPartyPercentageofBenchmarkExpectedCompanysPortfolioCosts", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionReimbursedFeestoRelatedPartyPercentageofBenchmarkExpectedThirdPartyAcquisitionCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Third Party Acquisition Costs", "label": "Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Third Party Acquisition Costs", "terseLabel": "Financing advance fees as a percentage of benchmark, expected third party costs" } } }, "localname": "RelatedPartyTransactionReimbursedFeestoRelatedPartyPercentageofBenchmarkExpectedThirdPartyAcquisitionCosts", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionSpecialAllocationforTaxPurposesExcessDepreciationDeductionsMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Special Allocation for Tax Purposes, Excess Depreciation Deductions Maximum", "label": "Related Party Transaction, Special Allocation for Tax Purposes, Excess Depreciation Deductions Maximum", "terseLabel": "Special allocation for tax purposes excess depreciation deductions maximum" } } }, "localname": "RelatedPartyTransactionSpecialAllocationforTaxPurposesExcessDepreciationDeductionsMaximum", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "monetaryItemType" }, "hct_RelatedPartyTransactionSubordinatedIncentiveListingDistributionPercentageOfBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Subordinated Incentive Listing Distribution, Percentage of Benchmark", "label": "Related Party Transaction, Subordinated Incentive Listing Distribution, Percentage of Benchmark", "terseLabel": "Subordinated participation fees as a percentage of benchmark" } } }, "localname": "RelatedPartyTransactionSubordinatedIncentiveListingDistributionPercentageOfBenchmark", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionSubordinatedPerformanceFeeEarnedByRelatedPartyPercentageOfBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Subordinated Performance Fee Earned by Related Party, Percentage of Benchmark", "label": "Related Party Transaction, Subordinated Performance Fee Earned by Related Party, Percentage of Benchmark", "terseLabel": "Subordinated performance fee as a percentage of benchmark" } } }, "localname": "RelatedPartyTransactionSubordinatedPerformanceFeeEarnedByRelatedPartyPercentageOfBenchmark", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionTermofAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Term of Agreement", "label": "Related Party Transaction, Term of Agreement", "terseLabel": "Term of agreement" } } }, "localname": "RelatedPartyTransactionTermofAgreement", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "durationItemType" }, "hct_RelatedPartyTransactionVotingPercentageRequiredtoAlterAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Voting Percentage Required to Alter Agreement", "label": "Related Party Transaction, Voting Percentage Required to Alter Agreement", "terseLabel": "Board of directors voting percentage" } } }, "localname": "RelatedPartyTransactionVotingPercentageRequiredtoAlterAgreement", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RenaissanceonPeachtreeAtlantaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renaissance on Peachtree - Atlanta [Member]", "label": "Renaissance on Peachtree - Atlanta [Member]", "terseLabel": "Renaissance on Peachtree - Atlanta, GA" } } }, "localname": "RenaissanceonPeachtreeAtlantaMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_RentalIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rental Income [Member]", "label": "Rental Income [Member]", "terseLabel": "Rental Income" } } }, "localname": "RentalIncomeMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "hct_RestrictedSharePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Share Plan [Member]", "label": "Restricted Share Plan [Member]", "terseLabel": "Restricted Share Plan" } } }, "localname": "RestrictedSharePlanMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "domainItemType" }, "hct_RivershoresHealthcareRehabCentreMarseillesDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rivershores Healthcare & Rehab Centre - Marseilles - December [Member]", "label": "Rivershores Healthcare & Rehab Centre - Marseilles - December [Member]", "terseLabel": "Rivershores Healthcare & Rehab Centre - Marseilles, IL" } } }, "localname": "RivershoresHealthcareRehabCentreMarseillesDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_RockwallMedicalPlazaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rockwall Medical Plaza [Member]", "label": "Rockwall Medical Plaza [Member]", "terseLabel": "Rockwall Medical Plaza - Rockwall, TX" } } }, "localname": "RockwallMedicalPlazaMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SECSchedule1228RealEstateCompaniesInvestmentInRealEstateAccumulatedDepreciationDisposalsImpairmentsAndReclassifications": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "SEC Schedule, 12-28, Real Estate Companies, Investment In Real Estate, Accumulated Depreciation, Disposals, Impairments And Reclassifications", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment In Real Estate, Accumulated Depreciation, Disposals, Impairments And Reclassifications", "negatedLabel": "Disposals, impairments and reclasses" } } }, "localname": "SECSchedule1228RealEstateCompaniesInvestmentInRealEstateAccumulatedDepreciationDisposalsImpairmentsAndReclassifications", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "hct_SOFRBasedInterestRateSwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SOFR Based Interest Rate Swap", "label": "SOFR Based Interest Rate Swap [Member]", "terseLabel": "SOFR-based interest rate \u201cpay-fixed\u201d swaps" } } }, "localname": "SOFRBasedInterestRateSwapMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "hct_SaleOfStockConsiderationReceivedOnTransactionGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Consideration Received on Transaction, Gross", "label": "Sale of Stock, Consideration Received on Transaction, Gross", "terseLabel": "Consideration received on transaction, gross" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransactionGross", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_SaleOfStockDiscountOnOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Discount On Offering", "label": "Sale Of Stock, Discount On Offering", "terseLabel": "Discount on offering" } } }, "localname": "SaleOfStockDiscountOnOffering", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_SaleOfStockStockIssuanceCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Stock Issuance Cost", "label": "Sale Of Stock, Stock Issuance Cost", "terseLabel": "Stock issuance costs" } } }, "localname": "SaleOfStockStockIssuanceCost", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_SassafrasMedicalBuildingErieMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sassafras Medical Building - Erie [Member]", "label": "Sassafras Medical Building - Erie [Member]", "terseLabel": "Sassafras Medical Building - Erie, PA" } } }, "localname": "SassafrasMedicalBuildingErieMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services [Table Text Block]", "label": "Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services [Table Text Block]", "terseLabel": "Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services" } } }, "localname": "ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables" ], "xbrltype": "textBlockItemType" }, "hct_ScheduleOfEarningsPerShareBasicAndDilutedByCommonClassIncludingTwoClassMethodTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table]", "label": "Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedByCommonClassIncludingTwoClassMethodTable", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "hct_ScheduleOfSharesRepurchasedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Schedule of Shares Repurchased [Table]", "label": "Schedule of Shares Repurchased [Line Items]", "terseLabel": "Schedule of Shares Repurchased [Line Items]" } } }, "localname": "ScheduleOfSharesRepurchasedLineItems", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "hct_ScheduleOfSharesRepurchasedTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Shares Repurchased [Table]", "label": "Schedule of Shares Repurchased [Table]", "terseLabel": "Schedule of Shares Repurchased [Table]" } } }, "localname": "ScheduleOfSharesRepurchasedTable", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "hct_ScherervilleBuildingScherervilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schererville Building - Schererville [Member]", "label": "Schererville Building - Schererville [Member]", "terseLabel": "Schererville Building - Schererville, IN" } } }, "localname": "ScherervilleBuildingScherervilleMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ScrippsCedarMedicalCenterVistaAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Scripps Cedar Medical Center - Vista - August [Member]", "label": "Scripps Cedar Medical Center - Vista - August [Member]", "terseLabel": "Scripps Cedar Medical Center - Vista, CA" } } }, "localname": "ScrippsCedarMedicalCenterVistaAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SecondAmendedandRestatedAdvisoryAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Amended and Restated Advisory Agreement [Member]", "label": "Second Amended and Restated Advisory Agreement [Member]", "terseLabel": "Second Amended and Restated Advisory Agreement" } } }, "localname": "SecondAmendedandRestatedAdvisoryAgreementMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_SecuredOvernightFinancingRateSOFRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR)" } } }, "localname": "SecuredOvernightFinancingRateSOFRMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_SeniorsHousingCommunitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seniors Housing Communities [Member]", "label": "Seniors Housing Communities [Member]", "terseLabel": "Seniors Housing \u2014 Operating Properties" } } }, "localname": "SeniorsHousingCommunitiesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_SeriesACumulativeRedeemablePerpetualPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Cumulative Redeemable Perpetual Preferred Stock", "label": "Series A Cumulative Redeemable Perpetual Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesACumulativeRedeemablePerpetualPreferredStockMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "http://www.thehealthcarereit2.com/role/CoverPage", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_SeriesAPreferredUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Preferred Unit", "label": "Series A Preferred Unit [Member]", "terseLabel": "Series A Preferred Unit" } } }, "localname": "SeriesAPreferredUnitMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_SeriesBCumulativeRedeemablePerpetualPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Cumulative Redeemable Perpetual Preferred Stock", "label": "Series B Cumulative Redeemable Perpetual Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock" } } }, "localname": "SeriesBCumulativeRedeemablePerpetualPreferredStockMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "http://www.thehealthcarereit2.com/role/CoverPage", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_SeverancePaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Severance Payments", "label": "Severance Payments [Member]", "terseLabel": "Severance Payments" } } }, "localname": "SeverancePaymentsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsStockDividend": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend", "terseLabel": "Stock dividend (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsStockDividend", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "sharesItemType" }, "hct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsStockDividendWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend, Weighted Average Grant Date Fair Value", "terseLabel": "Stock dividend (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsStockDividendWeightedAverageGrantDateFairValue", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "perShareItemType" }, "hct_SharePriceEquityInstrumentsNetofSellingCommissionsandDealerFees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Price, Equity Instruments, Net of Selling Commissions and Dealer Fees", "label": "Share Price, Equity Instruments, Net of Selling Commissions and Dealer Fees", "terseLabel": "Share price, net (in dollars per share)" } } }, "localname": "SharePriceEquityInstrumentsNetofSellingCommissionsandDealerFees", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "perShareItemType" }, "hct_ShilohIllinoisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shiloh - Illinois [Member]", "label": "Shiloh - Illinois [Member]", "terseLabel": "Shiloh - Illinois" } } }, "localname": "ShilohIllinoisMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "domainItemType" }, "hct_SingleTenantMOBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Single Tenant MOB [Member]", "label": "Single Tenant MOB [Member]", "terseLabel": "Single Tenant MOB" } } }, "localname": "SingleTenantMOBMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_SkilledNursingFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing Facilities [Member]", "label": "Skilled Nursing Facilities [Member]", "terseLabel": "Skilled Nursing Facilities" } } }, "localname": "SkilledNursingFacilitiesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "hct_SkyLakesKlamathMedicalClinicKlamathFallsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sky Lakes Klamath Medical Clinic - Klamath Falls [Member]", "label": "Sky Lakes Klamath Medical Clinic - Klamath Falls [Member]", "terseLabel": "Sky Lakes Klamath Medical Clinic - Klamath Falls, OR" } } }, "localname": "SkyLakesKlamathMedicalClinicKlamathFallsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SouthDouglasMOBMidwestCityOKMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "South Douglas MOB - Midwest City, OK", "label": "South Douglas MOB - Midwest City, OK [Member]", "terseLabel": "South Douglas MOB - Midwest City, OK" } } }, "localname": "SouthDouglasMOBMidwestCityOKMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SpecialLimitedPartnerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Special Limited Partner [Member]", "label": "Special Limited Partner [Member]", "terseLabel": "Special Limited Partner" } } }, "localname": "SpecialLimitedPartnerMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "hct_St.AndrewsMedicalParkVeniceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "St. Andrews Medical Park - Venice [Member]", "label": "St. Andrews Medical Park - Venice [Member]", "terseLabel": "St. Andrews Medical Park - Venice, FL" } } }, "localname": "St.AndrewsMedicalParkVeniceMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_StFrancisWIMOBStFrancisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "StFrancisWIMOBStFrancis [Member]", "label": "StFrancisWIMOBStFrancis [Member]", "terseLabel": "St. Francis WI MOB - St. Francis, WI" } } }, "localname": "StFrancisWIMOBStFrancisMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_StLukesHeartVascularCenterEastStroudsburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "St Lukes Heart Vascular Center - East Stroudsburg", "label": "St Lukes Heart Vascular Center - East Stroudsburg [Member]", "terseLabel": "St Lukes Heart Vascular Center - East Stroudsburg" } } }, "localname": "StLukesHeartVascularCenterEastStroudsburgMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_StPetersAlbany2PalisadesAlbanyNYMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "St. Peters Albany 2 Palisades - Albany, NY", "label": "St. Peters Albany 2 Palisades - Albany, NY [Member]", "terseLabel": "St. Peters Albany 2 Palisades - Albany, NY" } } }, "localname": "StPetersAlbany2PalisadesAlbanyNYMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_StPetersAlbanyNY4PalisadesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "St Peters - Albany, NY - 4 Palisades", "label": "St Peters - Albany, NY - 4 Palisades [Member]", "terseLabel": "St Peters - Albany, NY - 4 Palisades" } } }, "localname": "StPetersAlbanyNY4PalisadesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_StPetersAlbanyNY5PalisadesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "St Peters - Albany, NY - 5 Palisades", "label": "St Peters - Albany, NY - 5 Palisades [Member]", "terseLabel": "St Peters - Albany, NY - 5 Palisades" } } }, "localname": "StPetersAlbanyNY5PalisadesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_StPetersTroy2NewHampshireTroyNYMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "St. Peters Troy 2 New Hampshire - Troy, NY", "label": "St. Peters Troy 2 New Hampshire - Troy, NY [Member]", "terseLabel": "St. Peters Troy 2 New Hampshire - Troy, NY" } } }, "localname": "StPetersTroy2NewHampshireTroyNYMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_StockIssuanceCostsIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issuance Costs Incurred But Not Yet Paid", "label": "Stock Issuance Costs Incurred But Not Yet Paid", "terseLabel": "Accrued offering costs on Series B Preferred Stock" } } }, "localname": "StockIssuanceCostsIncurredButNotYetPaid", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "hct_StockRepurchaseProgramSharePricePercentageOfEstimatedPerShareNAV": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Repurchase Program, Share Price, Percentage Of Estimated Per-Share NAV", "label": "Stock Repurchase Program, Share Price, Percentage Of Estimated Per-Share NAV", "terseLabel": "Repurchase price per share, percentage of estimated per-share NAV" } } }, "localname": "StockRepurchaseProgramSharePricePercentageOfEstimatedPerShareNAV", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_StockbridgeFamilyMedicalStockbridgeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockbridge Family Medical - Stockbridge [Member]", "label": "Stockbridge Family Medical - Stockbridge [Member]", "terseLabel": "Stockbridge Family Medical - Stockbridge, GA" } } }, "localname": "StockbridgeFamilyMedicalStockbridgeMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SubjectFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subject Fees [Member]", "label": "Subject Fees [Member]", "terseLabel": "Subject Fees" } } }, "localname": "SubjectFeesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_SubjectFeesTransitionFeeNotinExcessoftheProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subject Fees (Transition Fee Not in Excess of the Product) [Member]", "label": "Subject Fees (Transition Fee Not in Excess of the Product) [Member]", "terseLabel": "Subject Fees (Transition Fee Not in Excess of the Product)" } } }, "localname": "SubjectFeesTransitionFeeNotinExcessoftheProductMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofBurlingtonBurlingtonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of Burlington - Burlington [Member]", "label": "Sunnybrook of Burlington - Burlington [Member]", "terseLabel": "Sunnybrook of Burlington - Burlington, IA" } } }, "localname": "SunnybrookofBurlingtonBurlingtonMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofBurlingtonLandBurlingtonAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of Burlington - Land - Burlington - August [Member]", "label": "Sunnybrook of Burlington - Land - Burlington - August [Member]", "terseLabel": "Sunnybrook of Burlington - Land - Burlington, IA" } } }, "localname": "SunnybrookofBurlingtonLandBurlingtonAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofCarrollCarrollAugust26Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of Carroll - Carroll - August26 [Member]", "label": "Sunnybrook of Carroll - Carroll - August26 [Member]", "terseLabel": "Sunnybrook of Carroll - Carroll, IA" } } }, "localname": "SunnybrookofCarrollCarrollAugust26Member", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofFairfieldFairfieldAugust26Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of Fairfield - Fairfield - August26 [Member]", "label": "Sunnybrook of Fairfield - Fairfield - August26 [Member]", "terseLabel": "Sunnybrook of Fairfield - Fairfield, IA" } } }, "localname": "SunnybrookofFairfieldFairfieldAugust26Member", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofFt.MadisonFt.MadisonAugust26Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of Ft. Madison - Ft. Madison - August26 [Member]", "label": "Sunnybrook of Ft. Madison - Ft. Madison - August26 [Member]", "terseLabel": "Sunnybrook of Ft. Madison - Ft. Madison, IA" } } }, "localname": "SunnybrookofFt.MadisonFt.MadisonAugust26Member", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofMT.PleasantMt.PleasantAugust26Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of MT. Pleasant - Mt. Pleasant - August26 [Member]", "label": "Sunnybrook of MT. Pleasant - Mt. Pleasant - August26 [Member]", "terseLabel": "Sunnybrook of Mt. Pleasant - Mt. Pleasant, IA" } } }, "localname": "SunnybrookofMT.PleasantMt.PleasantAugust26Member", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofMuscatineMuscatineAugust26Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of Muscatine - Muscatine - August26 [Member]", "label": "Sunnybrook of Muscatine - Muscatine - August26 [Member]", "terseLabel": "Sunnybrook of Muscatine - Muscatine, IA" } } }, "localname": "SunnybrookofMuscatineMuscatineAugust26Member", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SurgeryCenterofTempleTempleTX.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Surgery Center of Temple - Temple, TX. [Member]", "label": "Surgery Center of Temple - Temple, TX. [Member]", "terseLabel": "Surgery Center of Temple - Temple, TX" } } }, "localname": "SurgeryCenterofTempleTempleTX.Member", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SwedishAmericanMOBRoscoeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swedish American MOB - Roscoe", "label": "Swedish American MOB - Roscoe [Member]", "terseLabel": "Swedish American MOB - Roscoe, IL" } } }, "localname": "SwedishAmericanMOBRoscoeMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_TaxDepreciationDeductionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Depreciation Deduction [Member]", "label": "Tax Depreciation Deduction [Member]", "terseLabel": "Tax Depreciation Deduction" } } }, "localname": "TaxDepreciationDeductionMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "hct_TenderOfferMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tender Offer [Member]", "label": "Tender Offer [Member]", "terseLabel": "Tender Offer" } } }, "localname": "TenderOfferMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan [Member]", "label": "Term Loan [Member]", "terseLabel": "Term Loan" } } }, "localname": "TermLoanMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_TexasChildrensHospitalHoustonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Texas Children's Hospital - Houston [Member]", "label": "Texas Children's Hospital - Houston [Member]", "terseLabel": "Texas Children\u2019s Hospital - Houston, TX" } } }, "localname": "TexasChildrensHospitalHoustonMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_TheAtriumRockfordMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Atrium - Rockford [Member]", "label": "The Atrium - Rockford [Member]", "terseLabel": "The Atrium - Rockford, IL" } } }, "localname": "TheAtriumRockfordMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_TheHeightsHealthcarerehabCentrePeoriaHeightsDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Heights Healthcare & rehab Centre - Peoria Heights - December [Member]", "label": "The Heights Healthcare & rehab Centre - Peoria Heights - December [Member]", "terseLabel": "The Heights Healthcare & Rehab Centre - Peoria Heights, IL" } } }, "localname": "TheHeightsHealthcarerehabCentrePeoriaHeightsDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ThirdAmendedAndRestatedAdvisoryAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Amended And Restated Advisory Agreement [Member]", "label": "Third Amended And Restated Advisory Agreement [Member]", "terseLabel": "Third Amended And Restated Advisory Agreement" } } }, "localname": "ThirdAmendedAndRestatedAdvisoryAgreementMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_TransferAgentandOtherProfessionalFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transfer Agent and other professional fees [Member]", "label": "Transfer Agent and Other Professional Fees [Member]", "terseLabel": "Professional fees and other reimbursements" } } }, "localname": "TransferAgentandOtherProfessionalFeesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails" ], "xbrltype": "domainItemType" }, "hct_TransitionFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition Fee [Member]", "label": "Transition Fee [Member]", "terseLabel": "Transition Fee" } } }, "localname": "TransitionFeeMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_UCDavisMOBElkGroveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UC Davis MOB - Elk Grove [Member]", "label": "UC Davis MOB - Elk Grove [Member]", "terseLabel": "UC Davis MOB - Elk Grove, CA" } } }, "localname": "UCDavisMOBElkGroveMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_UMPCChambersHillHarrisburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UMPC Chambers Hill - Harrisburg", "label": "UMPC Chambers Hill - Harrisburg [Member]", "terseLabel": "UMPC Chambers Hill - Harrisburg, PA" } } }, "localname": "UMPCChambersHillHarrisburgMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_UMPCFisherRoadMechanicsburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UMPC Fisher Road - Mechanicsburg", "label": "UMPC Fisher Road - Mechanicsburg [Member]", "terseLabel": "UMPC Fisher Road - Mechanicsburg, PA" } } }, "localname": "UMPCFisherRoadMechanicsburgMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_UMPCSirThomasCourtHarrisburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UMPC Sir Thomas Court - Harrisburg", "label": "UMPC Sir Thomas Court - Harrisburg [Member]", "terseLabel": "UMPC Sir Thomas Court - Harrisburg, PA" } } }, "localname": "UMPCSirThomasCourtHarrisburgMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_UnencumberedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unencumbered Properties [Member]", "label": "Unencumbered Properties [Member]", "terseLabel": "Unencumbered Properties" } } }, "localname": "UnencumberedPropertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_UnityPointClinicMolineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UnityPoint Clinic - Moline [Member]", "label": "UnityPoint Clinic - Moline [Member]", "terseLabel": "UnityPoint Clinic - Moline, IL" } } }, "localname": "UnityPointClinicMolineMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_UnityPointClinicMuscatineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UnityPoint Clinic - Muscatine [Member]", "label": "UnityPoint Clinic - Muscatine [Member]", "terseLabel": "UnityPoint Clinic - Muscatine, IA" } } }, "localname": "UnityPointClinicMuscatineMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_UnityPointClinicPortfolioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UnityPoint Clinic Portfolio [Member]", "label": "UnityPoint Clinic Portfolio [Member]", "terseLabel": "UnityPoint Clinic Portfolio" } } }, "localname": "UnityPointClinicPortfolioMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_VAOutpatientClinicGalesburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "VA Outpatient Clinic - Galesburg [Member]", "label": "VA Outpatient Clinic - Galesburg [Member]", "terseLabel": "VA Outpatient Clinic - Galesberg, IL" } } }, "localname": "VAOutpatientClinicGalesburgMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_VariableManagementIncentiveFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Management - Incentive Fee [Member]", "label": "Variable Management - Incentive Fee [Member]", "terseLabel": "Variable Management - Incentive Fee" } } }, "localname": "VariableManagementIncentiveFeeMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_VariousSeniorsHousingCommunitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Various Seniors Housing Communities [Member]", "label": "Various Seniors Housing Communities [Member]", "terseLabel": "Various held for use SHOPs" } } }, "localname": "VariousSeniorsHousingCommunitiesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "hct_VascularSurgeryAssociatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vascular Surgery Associates [Member]", "label": "Vascular Surgery Associates [Member]", "terseLabel": "Vascular Surgery Associates - Tallahassee, FL" } } }, "localname": "VascularSurgeryAssociatesMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_VictoryMedicalCenteratCraigRanchMcKinneyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "VictoryMedicalCenteratCraigRanchMcKinney [Member]", "label": "VictoryMedicalCenteratCraigRanchMcKinney [Member]", "terseLabel": "Victory Medical Center at Craig Ranch - McKinney, TX" } } }, "localname": "VictoryMedicalCenteratCraigRanchMcKinneyMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_VillageCenterParkwayStockbridgeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Village Center Parkway - Stockbridge [Member]", "label": "Village Center Parkway - Stockbridge [Member]", "terseLabel": "Village Center Parkway - Stockbridge, GA" } } }, "localname": "VillageCenterParkwayStockbridgeMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_WellingtonGreenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wellington Green", "label": "Wellington Green [Member]", "terseLabel": "Wellington Green", "verboseLabel": "Wellington, Florida skilled nursing facility" } } }, "localname": "WellingtonGreenMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "hct_WellingtonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wellington", "label": "Wellington [Member]", "terseLabel": "Wellington" } } }, "localname": "WellingtonMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "hct_WellingtonatHersheysMillWestChesterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wellington at Hershey's Mill - West Chester [Member]", "label": "Wellington at Hershey's Mill - West Chester [Member]", "verboseLabel": "Wellington at Hershey's Mill - West Chester, PA" } } }, "localname": "WellingtonatHersheysMillWestChesterMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_WestMichiganSurgeryCenterBigRapidsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "West Michigan Surgery Center - Big Rapids [Member]", "label": "West Michigan Surgery Center - Big Rapids [Member]", "terseLabel": "West Michigan Surgery Center - Big Rapids, MI" } } }, "localname": "WestMichiganSurgeryCenterBigRapidsMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_WomensHealthcareGroupMOBYorkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "WomensHealthcareGroupMOBYork [Member]", "label": "WomensHealthcareGroupMOBYork [Member]", "terseLabel": "Women\u2019s Healthcare Group MOB - York, PA" } } }, "localname": "WomensHealthcareGroupMOBYorkMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_WoodGlenNursingandRehabCenterWestChicagoDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wood Glen Nursing and Rehab Center - West Chicago - December [Member]", "label": "Wood Glen Nursing and Rehab Center - West Chicago - December [Member]", "terseLabel": "Wood Glen Nursing and Rehab Center - West Chicago, IL" } } }, "localname": "WoodGlenNursingandRehabCenterWestChicagoDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_WoodlakeOfficeCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Woodlake Office Center [Member]", "label": "Woodlake Office Center [Member]", "terseLabel": "Woodlake Office Center - Woodbury, MN" } } }, "localname": "WoodlakeOfficeCenterMember", "nsuri": "http://www.thehealthcarereit2.com/20221231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r671", "r679", "r795", "r841", "r842", "r844" ], "lang": { "en-us": { "role": { "documentation": "An affiliate is a party that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with the entity.", "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r303", "r345", "r363", "r364", "r365", "r366", "r367", "r369", "r373", "r408", "r409", "r410", "r411", "r413", "r414", "r416", "r418", "r419", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r787", "r788", "r875", "r876" ], "lang": { "en-us": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r303", "r345", "r363", "r364", "r365", "r366", "r367", "r369", "r373", "r408", "r409", "r410", "r411", "r413", "r414", "r416", "r418", "r419", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r787", "r788", "r875", "r876" ], "lang": { "en-us": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r300", "r301", "r424", "r453", "r701", "r704", "r707" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r783" ], "lang": { "en-us": { "role": { "documentation": "Person serving on board of directors.", "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r404", "r405", "r406", "r407", "r485", "r616", "r644", "r675", "r676", "r722", "r729", "r739", "r789", "r847", "r848", "r849", "r850", "r851", "r852" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r404", "r405", "r406", "r407", "r485", "r616", "r644", "r675", "r676", "r722", "r729", "r739", "r789", "r847", "r848", "r849", "r850", "r851", "r852" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "auth_ref": [ "r660", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r678", "r680" ], "lang": { "en-us": { "role": { "documentation": "Information by type of real estate property.", "label": "Real Estate, Type of Property [Axis]", "terseLabel": "Real Estate, Type of Property [Axis]" } } }, "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "auth_ref": [ "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r678", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690" ], "lang": { "en-us": { "role": { "documentation": "Land and any structures permanently fixed to it.", "label": "Real Estate [Domain]", "terseLabel": "Real Estate [Domain]" } } }, "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r404", "r405", "r406", "r407", "r477", "r485", "r514", "r515", "r516", "r614", "r616", "r644", "r675", "r676", "r722", "r729", "r739", "r786", "r789", "r848", "r849", "r850", "r851", "r852" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r404", "r405", "r406", "r407", "r477", "r485", "r514", "r515", "r516", "r614", "r616", "r644", "r675", "r676", "r722", "r729", "r739", "r786", "r789", "r848", "r849", "r850", "r851", "r852" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationAmountOfEncumbrances": { "auth_ref": [ "r662", "r683" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lien or mortgage outstanding on real estate investment properties for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Amount of Encumbrances", "terseLabel": "Encumbrances" } } }, "localname": "RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "srt_RealEstateAndAccumulatedDepreciationByPropertyTable": { "auth_ref": [ "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r678", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about real estate investments and accompanying accumulated depreciation for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table]", "terseLabel": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table]" } } }, "localname": "RealEstateAndAccumulatedDepreciationByPropertyTable", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r672", "r681", "r702", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874" ], "lang": { "en-us": { "role": { "documentation": "Information by name of property.", "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]", "terseLabel": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDisclosureAbstract", "nsuri": "http://fasb.org/srt/2022", "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationDisclosureTextBlock": { "auth_ref": [ "r674", "r691" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of real estate investments and associated accumulated depreciation for entities with a significant portion of their business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Text Block]", "terseLabel": "Real Estate and Accumulated Depreciation Schedule III" } } }, "localname": "RealEstateAndAccumulatedDepreciationDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIII" ], "xbrltype": "textBlockItemType" }, "srt_RealEstateAndAccumulatedDepreciationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]", "terseLabel": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]" } } }, "localname": "RealEstateAndAccumulatedDepreciationLineItems", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r672", "r681", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874" ], "lang": { "en-us": { "role": { "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center.", "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateFederalIncomeTaxBasis": { "auth_ref": [ "r673", "r682" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost basis of real estate investments for federal income tax purposes for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Federal Income Tax Basis", "terseLabel": "Federal income taxes" } } }, "localname": "RealEstateFederalIncomeTaxBasis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r300", "r301", "r424", "r453", "r706", "r707" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r304", "r305", "r306", "r314", "r315", "r332", "r557", "r558", "r772", "r773", "r774", "r775", "r776", "r777", "r778" ], "lang": { "en-us": { "role": { "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period, Adjustment [Member]", "terseLabel": "Revision of Prior Period, Adjustment" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r251", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r332", "r383", "r384", "r540", "r556", "r557", "r558", "r559", "r581", "r599", "r600", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654" ], "lang": { "en-us": { "role": { "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Axis]", "terseLabel": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r251", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r332", "r383", "r384", "r540", "r556", "r557", "r558", "r559", "r581", "r599", "r600", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654" ], "lang": { "en-us": { "role": { "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Domain]", "terseLabel": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Cumulative increase (decrease) to previously issued financial statements for reclassification. Excludes adjustment for reclassification from amendment to accounting standards.", "label": "Revision of Prior Period, Reclassification, Adjustment [Member]", "terseLabel": "Revision of Prior Period, Reclassification, Adjustment" } } }, "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r376", "r377", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r678", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r723", "r738", "r793" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r376", "r377", "r660", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r678", "r680", "r723", "r738", "r793" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r783", "r843" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_FL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FLORIDA", "terseLabel": "Florida" } } }, "localname": "FL", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "domainItemType" }, "stpr_MI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MICHIGAN", "terseLabel": "Michigan" } } }, "localname": "MI", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "stpr_PA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PENNSYLVANIA", "terseLabel": "Pennsylvania" } } }, "localname": "PA", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "domainItemType" }, "stpr_TX": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TEXAS", "terseLabel": "TEXAS" } } }, "localname": "TX", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AboveMarketLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases acquired as part of a real property acquisition at above market lease rate.", "label": "Above Market Leases [Member]", "terseLabel": "Above-market lease assets", "verboseLabel": "Market lease and other intangible assets" } } }, "localname": "AboveMarketLeasesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r219", "r237" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses (including $47 due to related parties as of December\u00a031, 2022 and 2021)" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r41", "r42", "r43", "r264", "r636", "r650", "r654" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r279", "r280", "r570", "r571", "r572", "r573", "r574", "r576" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r40", "r43", "r155", "r600", "r645", "r646", "r754", "r755", "r756", "r769", "r770", "r771" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "verboseLabel": "Unrealized Gains (Losses) on Designated Derivative" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r20", "r737" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r523", "r524", "r525", "r769", "r770", "r771", "r833" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r120", "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "APIC, stock issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash\u00a0provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AffiliateCosts": { "auth_ref": [ "r51" ], "calculation": { "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs associated with revenues arising from an entity that is an affiliate of the reporting entity by means of direct or indirect ownership.", "label": "Affiliate Costs", "negatedTerseLabel": "Operating fees to related parties" } } }, "localname": "AffiliateCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r518" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r54", "r68", "r200", "r443" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of mortgage premiums and discounts, net" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r47", "r443", "r579", "r761" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization (including write-offs) of deferred financing costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r68", "r95", "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization/accretion of market least intangibles" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AncillaryFeeIncomeGeneratedByServicingFinancialAssetsAmount": { "auth_ref": [ "r615" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "All amounts that are due to the servicer of a financial asset, excluding contractually specified servicing fees and late fees.", "label": "Ancillary Fee Income Generated by Servicing Financial Assets, Amount", "terseLabel": "Ancillary revenue" } } }, "localname": "AncillaryFeeIncomeGeneratedByServicingFinancialAssetsAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AncillaryFeeIncomeServicingFinancialAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes ancillary fee income from servicing financial asset.", "label": "Ancillary Fee Income, Servicing Financial Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Ancillary Fee Income, Servicing Financial Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "AncillaryFeeIncomeServicingFinancialAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of real estate property" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r826" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r732", "r827", "r828", "r829" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Consideration transferred" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r826" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r68", "r104" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r212", "r228", "r259", "r298", "r353", "r365", "r371", "r381", "r408", "r409", "r411", "r412", "r413", "r415", "r417", "r419", "r420", "r547", "r551", "r569", "r737", "r787", "r788", "r845" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r8", "r110", "r254", "r255" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "terseLabel": "Assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r489", "r490", "r491", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r513", "r514", "r515", "r516", "r517" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r166", "r171" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BankingRegulationMortgageBankingNetWorthActual": { "auth_ref": [ "r656" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of net worth for mortgage banking as defined by regulatory framework.", "label": "Banking Regulation, Mortgage Banking, Net Worth, Actual", "terseLabel": "Consolidated tangible net worth" } } }, "localname": "BankingRegulationMortgageBankingNetWorthActual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Accounting and Out-of-Period Adjustment" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BelowMarketLeaseAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_BelowMarketLeaseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of leases acquired as part of a real property acquisition at below market lease rate with a finite life.", "label": "Below Market Lease, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "BelowMarketLeaseAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseAmortizationIncomeNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Below Market Lease, Amortization Income, Year One", "terseLabel": "Below market leases, amortization income, 2023" } } }, "localname": "BelowMarketLeaseAmortizationIncomeNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearFive": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Below Market Lease, Amortization Income, Year Five", "terseLabel": "Below market leases, amortization income, 2027" } } }, "localname": "BelowMarketLeaseAmortizationIncomeYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Below Market Lease, Amortization Income, Year Four", "terseLabel": "Below market leases, amortization income, 2026" } } }, "localname": "BelowMarketLeaseAmortizationIncomeYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Below Market Lease, Amortization Income, Year Three", "terseLabel": "Below market leases, amortization income, 2025" } } }, "localname": "BelowMarketLeaseAmortizationIncomeYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Below Market Lease, Amortization Income, Year Two", "terseLabel": "Below market leases, amortization income, 2024" } } }, "localname": "BelowMarketLeaseAmortizationIncomeYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseGross": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_BelowMarketLeaseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of leases acquired as part of a real property acquisition at below market lease rate with a finite life.", "label": "Below Market Lease, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "BelowMarketLeaseGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseNet": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of leases acquired as part of a real property acquisition at below market lease rate with a finite life.", "label": "Below Market Lease, Net", "totalLabel": "Net Carrying Amount" } } }, "localname": "BelowMarketLeaseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Below Market Lease, Net [Abstract]", "terseLabel": "Intangible liabilities:" } } }, "localname": "BelowMarketLeaseNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r545", "r727", "r728" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r146", "r147", "r545", "r727", "r728" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r145" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "negatedTerseLabel": "Acquisition and transaction related", "terseLabel": "Acquisition and transaction related" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r73", "r74", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accrued capital expenditures" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "terseLabel": "Direct Financing Leases" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r70", "r256", "r703" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r63", "r70", "r76" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year", "totalLabel": "Cash, cash equivalents and restricted cash, end of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r63", "r198" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, Uninsured Amount", "terseLabel": "Cash in excess of FDIC limit" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r260", "r261", "r262", "r298", "r323", "r324", "r326", "r328", "r335", "r336", "r381", "r408", "r411", "r412", "r413", "r419", "r420", "r451", "r452", "r455", "r459", "r466", "r569", "r677", "r750", "r763", "r779" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "http://www.thehealthcarereit2.com/role/CoverPage", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of securities called by share purchase right (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Distributions declared per share (in usd per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common Stock Dividends, Shares", "terseLabel": "Distributions declared in common stock (in shares)" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/OrganizationNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r769", "r770", "r833" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r120" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock held by related party (in shares)", "verboseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19", "r737" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value, 300,000,000 shares authorized, 105,080,531 shares and 99,281,754 shares issued and outstanding as of December\u00a031, 2022 and 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitIssuanceValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC).", "label": "Common Unit, Issuance Value", "terseLabel": "Units issued to purchase building" } } }, "localname": "CommonUnitIssuanceValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r44", "r275", "r277", "r285", "r633", "r638" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to common stockholders" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r55", "r284", "r632", "r637" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r82", "r83", "r195", "r196", "r379", "r661" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r82", "r83", "r195", "r196", "r379", "r655", "r661" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r82", "r83", "r195", "r196", "r379", "r661", "r858" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r82", "r83", "r195", "r196", "r379" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r80", "r82", "r83", "r84", "r195", "r197", "r661" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r82", "r83", "r195", "r196", "r379", "r661" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r152", "r709" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation and Basis of Presentation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpensesRelatedParty": { "auth_ref": [ "r51" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.", "label": "Costs and Expenses, Related Party", "terseLabel": "Operating fees to related parties" } } }, "localname": "CostsAndExpensesRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r823" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current Federal, State and Local, Tax Expense (Benefit)", "negatedTotalLabel": "Total income tax benefit (expense)" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Current" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r766", "r823", "r825" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current Federal Tax Expense (Benefit)", "negatedTerseLabel": "Federal (expense) benefit" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r766", "r823", "r825" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "negatedTerseLabel": "State (expense) benefit" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r116", "r296", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r437", "r444", "r445", "r447" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Credit Facilities, Net" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r213", "r215", "r227", "r303", "r421", "r422", "r423", "r424", "r425", "r427", "r433", "r434", "r435", "r436", "r438", "r439", "r440", "r441", "r442", "r443", "r580", "r717", "r718", "r719", "r720", "r721", "r764" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r16", "r215", "r227", "r448" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Outstanding loan amount", "totalLabel": "Total" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentCollateralAmount": { "auth_ref": [ "r224" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets pledged to secure a debt instrument.", "label": "Debt Instrument, Collateral Amount", "terseLabel": "Debt instrument, collateral amount" } } }, "localname": "DebtInstrumentCollateralAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r201", "r204", "r421", "r580", "r718", "r719" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r435", "r568", "r718", "r719" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Debt, fair value disclosure" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r27", "r201", "r450", "r580" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate", "verboseLabel": "Effective Interest Rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r28", "r303", "r421", "r422", "r423", "r424", "r425", "r427", "r433", "r434", "r435", "r436", "r438", "r439", "r440", "r441", "r442", "r443", "r580", "r717", "r718", "r719", "r720", "r721", "r764" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r28", "r121", "r124", "r125", "r126", "r200", "r201", "r204", "r226", "r303", "r421", "r422", "r423", "r424", "r425", "r427", "r433", "r434", "r435", "r436", "r438", "r439", "r440", "r441", "r442", "r443", "r446", "r580", "r717", "r718", "r719", "r720", "r721", "r764" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r200", "r201", "r202", "r203", "r204", "r790" ], "calculation": { "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "negatedTerseLabel": "Mortgage premiums and discounts, net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCostsCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of deferred costs.", "label": "Deferred Costs", "terseLabel": "Deferred costs" } } }, "localname": "DeferredCostsCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r766", "r824", "r825" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "negatedTerseLabel": "Federal (expense) benefit" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Deferred" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r202", "r790" ], "calculation": { "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Deferred financing costs", "negatedTerseLabel": "Deferred financing costs, net of accumulated amortization" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r68", "r144", "r536", "r542", "r543", "r766" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "negatedTotalLabel": "Total income tax benefit (expense)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCredit": { "auth_ref": [ "r248", "r839" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of rental payment required by lease over rental income recognized.", "label": "Deferred Rent Credit", "terseLabel": "Deferred rent" } } }, "localname": "DeferredRentCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentReceivablesNetNoncurrent": { "auth_ref": [ "r249", "r839" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of rental income recognized over rental payment required by lease, classified as noncurrent.", "label": "Deferred Rent Receivables, Net, Noncurrent", "terseLabel": "Straight-line rent receivable, net" } } }, "localname": "DeferredRentReceivablesNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r766", "r824", "r825" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "negatedTerseLabel": "State (expense) benefit" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r822" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Deferred tax asset, net" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r68", "r106" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "negatedTerseLabel": "Depreciation and amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r68", "r348" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock": { "auth_ref": [ "r710" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.", "label": "Depreciation, Depletion, and Amortization [Policy Text Block]", "terseLabel": "Depreciation and Amortization" } } }, "localname": "DepreciationDepletionAndAmortizationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "auth_ref": [ "r32", "r38", "r169" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset", "negatedTerseLabel": "Gross Amounts Offset in the Consolidated Balance Sheet", "terseLabel": "Gross amounts of recognized liabilities" } } }, "localname": "DerivativeAssetFairValueGrossLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r266", "r269", "r568", "r707" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivative assets, at fair value", "totalLabel": "Net Amounts of Assets presented in the Consolidated Balance Sheet" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAverageVariableInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average variable interest rate related to the group of interest rate derivatives.", "label": "Derivative, Average Variable Interest Rate", "terseLabel": "Average variable interest rate" } } }, "localname": "DerivativeAverageVariableInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeCapInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cap rate on an interest rate derivative such as an interest rate cap or collar. If market rates exceed the cap rate, a payment or receipt is triggered on the contract.", "label": "Derivative, Cap Interest Rate", "terseLabel": "Interest rate cap" } } }, "localname": "DerivativeCapInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "auth_ref": [ "r36", "r181", "r267", "r705" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset", "negatedTerseLabel": "Cash Collateral Received" } } }, "localname": "DerivativeCollateralObligationToReturnCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralObligationToReturnSecurities": { "auth_ref": [ "r36", "r267", "r705" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to return securities collateral under master netting arrangements that have not been offset against derivative assets.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Security Not Offset", "negatedTerseLabel": "Financial Instruments" } } }, "localname": "DerivativeCollateralObligationToReturnSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r37", "r169", "r209", "r265", "r707" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Gross amounts of recognized assets" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral": { "auth_ref": [ "r33", "r35", "r39", "r182" ], "calculation": { "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after offset of derivative liability, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, before offset against an obligation to return collateral under a master netting arrangement. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral", "terseLabel": "Derivative assets, at fair value (non-designated)" } } }, "localname": "DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral": { "auth_ref": [ "r36", "r180" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement.", "label": "Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction", "totalLabel": "Net Amount" } } }, "localname": "DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r37", "r169", "r209", "r265", "r707" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "negatedTerseLabel": "Gross Amounts of Recognized (Liabilities)" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral": { "auth_ref": [ "r33", "r35", "r39", "r182" ], "calculation": { "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral", "negatedTerseLabel": "Derivative liabilities, at fair value" } } }, "localname": "DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral": { "auth_ref": [ "r36", "r180" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement.", "label": "Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction", "negatedTotalLabel": "Net Amount" } } }, "localname": "DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFinancialInstrumentsAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).", "label": "Derivative Financial Instruments, Assets [Member]", "terseLabel": "Derivative assets, at fair value" } } }, "localname": "DerivativeFinancialInstrumentsAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.", "label": "Derivative Financial Instruments, Liabilities [Member]", "terseLabel": "Derivative liabilities, at fair value" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r167", "r170", "r175", "r177", "r707" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r186", "r554" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivatives and Hedging Activities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.", "label": "Derivative Instruments in Hedges, Assets, at Fair Value", "terseLabel": "Asset position with fair value" } } }, "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r174", "r832" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 10.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "negatedTerseLabel": "(Gain) loss on non-designated derivative instruments", "terseLabel": "Gain (loss) on non-designated derivatives", "verboseLabel": "Gain on non designated derivatives" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r266", "r269", "r568", "r707" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "negatedTotalLabel": "Net Amounts of Assets presented in the Consolidated Balance Sheet", "terseLabel": "Derivative liabilities, at fair value" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r830", "r831" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "auth_ref": [ "r161", "r163" ], "lang": { "en-us": { "role": { "documentation": "The number of derivative instruments of a particular group held by the entity.", "label": "Derivative, Number of Instruments Held", "terseLabel": "Number of instruments", "verboseLabel": "Number of Instruments" } } }, "localname": "DerivativeNumberOfInstrumentsHeld", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r160", "r162", "r163", "r164", "r165", "r172", "r175", "r178", "r183", "r184", "r554" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r160", "r162", "r164", "r165", "r179", "r302" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock": { "auth_ref": [ "r109", "r113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for impairment of long-lived assets held and used by an entity which includes a description of the impaired long-lived asset and facts and circumstances leading to the impairment, aggregate amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported.", "label": "Details of Impairment of Long-Lived Assets Held and Used by Asset [Table Text Block]", "terseLabel": "Schedule of Impairments Recorded" } } }, "localname": "DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r488", "r519", "r520", "r522", "r527", "r730" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Equity-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r136", "r140" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "terseLabel": "Schedule of Restricted Share Award Activity" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r105", "r111" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposed by sale" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r103", "r105", "r111" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Contract Sale Price" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r727", "r728" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r127", "r223" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedLabel": "Distributions declared in cash on common stock" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsDeclaredTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.", "label": "Dividends Declared [Table Text Block]", "terseLabel": "Schedule of Stock Dividends" } } }, "localname": "DividendsDeclaredTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r15", "r17", "r214", "r229" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "terseLabel": "Distributions payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Dividends Payable [Line Items]", "terseLabel": "Dividends Payable [Line Items]" } } }, "localname": "DividendsPayableLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableTable": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid.", "label": "Dividends Payable [Table]", "terseLabel": "Dividends Payable [Table]" } } }, "localname": "DividendsPayableTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r127", "r223" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 12.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock", "negatedTerseLabel": "Allocation for preferred stock" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromAffiliates": { "auth_ref": [ "r206", "r239", "r605" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Due from Affiliates", "terseLabel": "Due from affiliates" } } }, "localname": "DueFromAffiliates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r218", "r239", "r263", "r410", "r411", "r412", "r418", "r419", "r420", "r604", "r767" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "terseLabel": "Prepaid expenses and other assets, due from related parties" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r220", "r238", "r410", "r411", "r412", "r418", "r419", "r420", "r604", "r767" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Accounts payable and accrued expenses, due to related parties" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r286", "r309", "r310", "r312", "r313", "r314", "r320", "r323", "r326", "r327", "r328", "r332", "r558", "r559", "r634", "r639", "r713" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per share (in usd per share)", "verboseLabel": "Net loss per common share attributable to common stockholders - Basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r286", "r309", "r310", "r312", "r313", "r314", "r323", "r326", "r327", "r328", "r332", "r558", "r559", "r634", "r639", "r713" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share attributable to common stockholders - Diluted (in usd per share)", "verboseLabel": "Diluted net loss per share (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r78", "r79" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Per Share Data" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r329", "r330", "r331", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r521" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Nonvested awards, compensation cost not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Nonvested awards, compensation cost not yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r120", "r250", "r279", "r280", "r281", "r304", "r305", "r306", "r308", "r315", "r318", "r334", "r382", "r467", "r523", "r524", "r525", "r539", "r540", "r557", "r570", "r571", "r572", "r573", "r574", "r576", "r600", "r645", "r646", "r647" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r435", "r568", "r718", "r719" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair\u00a0Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r560", "r561", "r565" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r187", "r188", "r189", "r190", "r191" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of Recurring Fair Value Measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r187", "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r187", "r193" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of Fair Value by Balance Sheet" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r435", "r478", "r479", "r480", "r481", "r482", "r483", "r561", "r611", "r612", "r613", "r718", "r719", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r187", "r192", "r435", "r718", "r719" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r560", "r561", "r562", "r563", "r566" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r435", "r718", "r719" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r435", "r478", "r483", "r561", "r611", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r435", "r478", "r483", "r561", "r612", "r718", "r719", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r435", "r478", "r479", "r480", "r481", "r482", "r483", "r561", "r613", "r718", "r719", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r435", "r478", "r479", "r480", "r481", "r482", "r483", "r611", "r612", "r613", "r718", "r719", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r564", "r566" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Fair Value, Net Asset (Liability)", "totalLabel": "Total" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r583", "r592" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total present value of minimum lease payments" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Finance Lease, Liability, Maturity" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r592" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease liability.", "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r592" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: amounts representing interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r257", "r397" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Finite-lived intangible asset, amortization expense, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "Finite-lived intangible asset, amortization expense, 2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Finite-lived intangible asset, amortization expense, 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Finite-lived intangible asset, amortization expense, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Finite-lived intangible asset, amortization expense, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r395", "r396", "r397", "r398", "r618", "r619" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r99", "r619" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r96", "r98" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r99", "r618" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Acquired intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Intangible assets:" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Weighted-average remaining amortization periods" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Fixtures and improvements" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "auth_ref": [ "r641", "r642", "r643", "r757", "r758", "r761", "r854", "r856" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 7.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes.", "label": "Gains (Losses) on Sales of Investment Real Estate", "negatedTerseLabel": "(Gain) loss on sales of real estate investments, net", "terseLabel": "Gain (loss) on sale of real estate investments" } } }, "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r52" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "negatedTerseLabel": "General and administrative", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r81", "r661" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r49", "r298", "r353", "r364", "r370", "r373", "r381", "r408", "r409", "r411", "r412", "r413", "r415", "r417", "r419", "r420", "r569", "r715", "r787" ], "calculation": { "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "NOI" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r164", "r553" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfRealEstate": { "auth_ref": [ "r761", "r785" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value.", "label": "Impairment of Real Estate", "negatedLabel": "Impairment charges", "terseLabel": "Impairment charges" } } }, "localname": "ImpairmentOfRealEstate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r102", "r113" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r46", "r210", "r221", "r240", "r353", "r364", "r370", "r373", "r635", "r715" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r727", "r728" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r9", "r10", "r11", "r12", "r111", "r112" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r399", "r401" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r299", "r317", "r318", "r351", "r530", "r541", "r544", "r640" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": { "auth_ref": [ "r537" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.", "label": "Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability", "negatedTerseLabel": "Deferred tax asset valuation allowance" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r278", "r528", "r529", "r532", "r533", "r535", "r538" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r65", "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r67" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r67" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Straight-line rent receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r67" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Deferred rent" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r67" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r94", "r97" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "totalLabel": "Net Carrying Amount" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 9.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest and Other Income", "terseLabel": "Interest and other income" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r202", "r222", "r282", "r347", "r578" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 8.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense", "terseLabel": "Total amount of interest expense presented in the consolidated statements of operations and comprehensive loss", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r290", "r293", "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCapMember": { "auth_ref": [ "r735" ], "lang": { "en-us": { "role": { "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount.", "label": "Interest Rate Cap [Member]", "terseLabel": "Interest rate caps" } } }, "localname": "InterestRateCapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet": { "auth_ref": [ "r173" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of net gains or losses on interest rate cash flow hedges reclassified during the period to earnings from accumulated other comprehensive income upon the hedged transaction affecting earnings.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net", "negatedLabel": "Cash flow hedge reclassification current", "negatedTerseLabel": "Unamortized portion remaining in accumulated other comprehensive (loss) income" } } }, "localname": "InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r185" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "negatedLabel": "Cash flow hedge reclassification in next twelve months" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r707", "r724", "r735" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest rate contract" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r735" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Total interest rate \u201cpay-fixed\u201d swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Land": { "auth_ref": [ "r753" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to real estate held.", "label": "Land Improvements [Member]", "terseLabel": "Land Improvements" } } }, "localname": "LandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r794" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeasesAcquiredInPlaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired.", "label": "Leases, Acquired-in-Place [Member]", "netLabel": "In-place leases", "terseLabel": "In-place leases and other intangible assets", "verboseLabel": "In-place lease assets" } } }, "localname": "LeasesAcquiredInPlaceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases and Lessee Accounting" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r592" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r592" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r592" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r592" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r592" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r592" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r592" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r592" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: amounts representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorLeasesPolicyTextBlock": { "auth_ref": [ "r594", "r596", "r597", "r598" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.", "label": "Lessor, Leases [Policy Text Block]", "terseLabel": "Accounting for Leases, Lessor Accounting" } } }, "localname": "LessorLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r595" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "totalLabel": "Total" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r595" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "terseLabel": "2027" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r595" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "terseLabel": "2026" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r840" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Future Base Rent Payments on a Cash Basis" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r595" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "auth_ref": [ "r595" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r595" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "terseLabel": "2025" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r595" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "terseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesFutureBaseRentPaymentsonaCashBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r26", "r298", "r381", "r408", "r409", "r411", "r412", "r413", "r415", "r417", "r419", "r420", "r548", "r551", "r552", "r569", "r714", "r787", "r845", "r846" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r217", "r234", "r737", "r765", "r784", "r834" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LimitedPartnersCapitalAccountByClassAxis": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of limited partnership interests.", "label": "Limited Partners' Capital Account by Class [Axis]", "terseLabel": "Limited Partners' Capital Account by Class [Axis]" } } }, "localname": "LimitedPartnersCapitalAccountByClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LimitedPartnersCapitalAccountClassDomain": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Description of the type or class of limited partner's capital account.", "label": "Limited Partners' Capital Account, Class [Domain]", "terseLabel": "Limited Partners' Capital Account, Class [Domain]" } } }, "localname": "LimitedPartnersCapitalAccountClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "The number of limited partner units outstanding.", "label": "Limited Partners' Capital Account, Units Outstanding", "terseLabel": "Limited partner units (in shares)" } } }, "localname": "LimitedPartnersCapitalAccountUnitsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r16", "r215", "r227" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-Term Line of Credit", "terseLabel": "Credit facilities, net", "verboseLabel": "Outstanding balance" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r25", "r764" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r25", "r764" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Remaining borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r25", "r764" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Credit Facilities", "verboseLabel": "Revolving Credit Facility" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r16", "r215", "r230", "r434", "r449", "r718", "r719" ], "calculation": { "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Mortgage notes payable, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r114", "r303", "r791" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "verboseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r114", "r303", "r439" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r114", "r303", "r439" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r114", "r303", "r439" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r114", "r303", "r439" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r114", "r303", "r439" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r28", "r115" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinimumNetWorthRequiredForCompliance": { "auth_ref": [ "r656", "r657", "r658", "r659" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of minimum net worth required for mortgage banking as defined by regulatory framework.", "label": "Banking Regulation, Mortgage Banking, Net Worth, Minimum", "terseLabel": "Minimum net worth required for compliance" } } }, "localname": "MinimumNetWorthRequiredForCompliance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r31", "r216", "r233", "r298", "r381", "r408", "r411", "r412", "r413", "r419", "r420", "r569" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interests", "totalLabel": "Total Non-controlling Interests", "verboseLabel": "Third Party Net Investment Amount" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Distributions to non-controlling interest holders", "terseLabel": "Distributions" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r127", "r150", "r151" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedTerseLabel": "Buyout of non-controlling interest" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDisclosureTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest Disclosure [Text Block]", "terseLabel": "Non-Controlling Interests" } } }, "localname": "MinorityInterestDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterests" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestInOperatingPartnerships": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails": { "order": 1.0, "parentTag": "us-gaap_MinorityInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of the equity interests owned by noncontrolling partners in an operating partnership included in the entity's consolidated financial statements.", "label": "Noncontrolling Interest in Operating Partnerships", "terseLabel": "Total Non-controlling Interests in the OP" } } }, "localname": "MinorityInterestInOperatingPartnerships", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Noncontrolling Interest [Line Items]" } } }, "localname": "MinorityInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Non-Controlling Ownership Percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestTable": { "auth_ref": [ "r31", "r50", "r149", "r156" ], "lang": { "en-us": { "role": { "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest [Table]", "terseLabel": "Noncontrolling Interest [Table]" } } }, "localname": "MinorityInterestTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgageNotesPayableDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for mortgage notes payable.", "label": "Mortgage Notes Payable Disclosure [Text Block]", "terseLabel": "Mortgage Notes Payable, Net" } } }, "localname": "MortgageNotesPayableDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgage Notes Payable" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r292" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r292" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r63", "r66", "r69" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r153", "r158", "r273", "r276", "r317", "r318", "r756" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 11.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedTerseLabel": "Net loss (income) attributable to non-controlling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r309", "r310", "r312", "r313", "r320", "r321", "r325", "r328", "r353", "r364", "r370", "r373", "r715" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to stockholders", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]", "terseLabel": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r128", "r150", "r154" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Issuance of Series A Preferred OP Units" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r148", "r467", "r769", "r770", "r771" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfBusinessesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of businesses acquired by the entity during the period.", "label": "Number of Businesses Acquired", "terseLabel": "Number of properties purchased" } } }, "localname": "NumberOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfRealEstateProperties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of real estate properties owned as of the balance sheet date.", "label": "Number of Real Estate Properties", "terseLabel": "Number of real estate properties", "verboseLabel": "Number of properties" } } }, "localname": "NumberOfRealEstateProperties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/OrganizationNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r782" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states properties are located in" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OffMarketLeaseUnfavorable": { "auth_ref": [ "r29" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents a liability associated with the acquisition of an off-market lease when the terms of the lease are unfavorable to the market terms for the lease at the date of acquisition.", "label": "Off-Market Lease, Unfavorable", "terseLabel": "Market lease intangible liabilities, net" } } }, "localname": "OffMarketLeaseUnfavorable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsTableTextBlock": { "auth_ref": [ "r34", "r268" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Assets [Table Text Block]", "terseLabel": "Schedule of Offsetting Assets" } } }, "localname": "OffsettingAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "hct_OperatingIncomeLossBeforeGainLossonSaleofRealEstateInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r353", "r364", "r370", "r373", "r715" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r588", "r736" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r837" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Property operating and maintenance", "verboseLabel": "Property operating and maintenance" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r583" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r585", "r589" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r582" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r591", "r736" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate, percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r590", "r736" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r142" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r363", "r364", "r365", "r366", "r367", "r373" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r13", "r159" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r43", "r45", "r280", "r570", "r572", "r576", "r754" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive loss, before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r270", "r271" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Unrealized gain (loss) on designated derivatives", "verboseLabel": "Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r271", "r272" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r45", "r120", "r274", "r277", "r284", "r570", "r575", "r576", "r632", "r637", "r754", "r755" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Unrealized loss on designated derivative" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other intangible assets" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r288" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income", "terseLabel": "Interest and other income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForDepositsOnRealEstateAcquisitions": { "auth_ref": [ "r759" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow related to amounts given in advance to show or confirm an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate.", "label": "Payments for Deposits on Real Estate Acquisitions", "terseLabel": "Payments for deposits" } } }, "localname": "PaymentsForDepositsOnRealEstateAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash outflow or inflow from derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.", "label": "Payments for (Proceeds from) Derivative Instrument, Financing Activities", "negatedTerseLabel": "Payments for non-designated derivative instruments" } } }, "localname": "PaymentsForProceedsFromDerivativeInstrumentFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r60" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Common stock repurchases" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r60" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedTerseLabel": "Distributions paid on common stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsMinorityInterest": { "auth_ref": [ "r60" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.", "label": "Payments of Ordinary Dividends, Noncontrolling Interest", "negatedTerseLabel": "Distributions to non-controlling interest holders", "terseLabel": "Distributions to non-controlling interest holders" } } }, "localname": "PaymentsOfDividendsMinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": { "auth_ref": [ "r60" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock", "negatedTerseLabel": "Dividend paid on Preferred stock" } } }, "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r62" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedTerseLabel": "Payments of deferred financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": { "auth_ref": [ "r57" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Payments to Acquire Other Property, Plant, and Equipment", "negatedTerseLabel": "Capital expenditures and other assets acquired" } } }, "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "terseLabel": "Total capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRealEstate": { "auth_ref": [ "r57" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.", "label": "Payments to Acquire Real Estate", "negatedTerseLabel": "Property acquisitions and development costs", "terseLabel": "Payments to acquire property" } } }, "localname": "PaymentsToAcquireRealEstate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r62" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedTerseLabel": "Buyout of non-controlling interest holders", "terseLabel": "Payments to noncontrolling interests" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePerDollarAmount": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "The amount per share used to calculated dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Per-Dollar-Amount", "terseLabel": "Preferred stock, dividend rate (in usd per share)" } } }, "localname": "PreferredStockDividendRatePerDollarAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Preferred stock, dividend rate, percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding.", "label": "Preferred Stock, Dividends Per Share, Declared", "terseLabel": "Preferred stock distributions declared per share (in usd per share)" } } }, "localname": "PreferredStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r18", "r121", "r122", "r763", "r792" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Preferred stock, liquidation preference (in usd per share)" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r18", "r451" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r18", "r451" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r18", "r737" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Cumulative redeemable perpetual preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredUnitsIssued": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "The number of preferred units issued.", "label": "Preferred Units, Issued", "terseLabel": "Preferred units, issued (in shares)" } } }, "localname": "PreferredUnitsIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other assets (including $929 due from related parties as of December\u00a031, 2021)", "verboseLabel": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": { "auth_ref": [ "r289", "r708" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.", "label": "Proceeds from Derivative Instrument, Financing Activities", "terseLabel": "Cash received from derivatives" } } }, "localname": "ProceedsFromDerivativeInstrumentFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan": { "auth_ref": [ "r760" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan.", "label": "Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan", "terseLabel": "Proceeds from common stock issued through distribution reinvestment plan" } } }, "localname": "ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r58" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Proceeds from issuance of Preferred Stock, net" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": { "auth_ref": [ "r760" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.", "label": "Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants", "terseLabel": "Proceeds from issuance of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r59" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "Proceeds from mortgage notes payable" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r59", "r764" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from credit facilities" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from Loans", "terseLabel": "Proceeds from loans" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment": { "auth_ref": [ "r56" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from the sale of real estate that is held for investment, that is, it is part of an investing activity during the period.", "label": "Proceeds from Sale of Real Estate Held-for-investment", "terseLabel": "Proceeds from sales of real estate investments" } } }, "localname": "ProceedsFromSaleOfRealEstateHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r255", "r273", "r276", "r291", "r298", "r307", "r317", "r318", "r353", "r364", "r370", "r373", "r381", "r408", "r409", "r411", "r412", "r413", "r415", "r417", "r419", "r420", "r546", "r549", "r550", "r559", "r569", "r635", "r715", "r733", "r734", "r756", "r787" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r287", "r385" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Real Estate [Abstract]", "terseLabel": "Real Estate [Abstract]" } } }, "localname": "RealEstateAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RealEstateAccumulatedDepreciation": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation pertaining to real estate investments for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation", "periodEndLabel": "Balance at end of the year", "periodStartLabel": "Balance at beginning of year", "terseLabel": "Accumulated Depreciation" } } }, "localname": "RealEstateAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateAccumulatedDepreciationRealEstateSold": { "auth_ref": [ "r671" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to accumulated depreciation for real estate investments sold for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Investment in Real Estate Sold", "verboseLabel": "Accumulated depreciation" } } }, "localname": "RealEstateAccumulatedDepreciationRealEstateSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfLandAndBuildingsAndImprovementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross [Abstract]", "terseLabel": "Real estate investments, at cost:" } } }, "localname": "RealEstateAndAccumulatedDepreciationCarryingAmountOfLandAndBuildingsAndImprovementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstateAndAccumulatedDepreciationInitialCostOfBuildingsAndImprovements": { "auth_ref": [ "r663" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails": { "order": 2.0, "parentTag": "us-gaap_RealEstateGrossAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial cost of buildings and improvements for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Building and Improvements", "terseLabel": "Building\u00a0and Improvements" } } }, "localname": "RealEstateAndAccumulatedDepreciationInitialCostOfBuildingsAndImprovements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateAndAccumulatedDepreciationInitialCostOfLand": { "auth_ref": [ "r663" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails": { "order": 1.0, "parentTag": "us-gaap_RealEstateGrossAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial cost of land for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Land", "terseLabel": "Land" } } }, "localname": "RealEstateAndAccumulatedDepreciationInitialCostOfLand", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateAndAccumulatedDepreciationLifeUsedForDepreciation1": { "auth_ref": [ "r669" ], "lang": { "en-us": { "role": { "documentation": "Useful life on which depreciation was computed for entities with a substantial portion of business acquiring and holding investment real estate, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation", "terseLabel": "Useful life" } } }, "localname": "RealEstateAndAccumulatedDepreciationLifeUsedForDepreciation1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RealEstateDisclosureTextBlock": { "auth_ref": [ "r242", "r243", "r244", "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures.", "label": "Real Estate Disclosure [Text Block]", "terseLabel": "Real Estate Investments, Net" } } }, "localname": "RealEstateDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_RealEstateGrossAtCarryingValue": { "auth_ref": [ "r665" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation, of real estate investment by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate. Excludes real estate not held as investment or interest.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross", "periodEndLabel": "Balance at end of the year", "periodStartLabel": "Balance at beginning of year", "totalLabel": "Gross Amount" } } }, "localname": "RealEstateGrossAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "auth_ref": [ "r235" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes.", "label": "Real Estate Investment Property, Accumulated Depreciation", "negatedTerseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "auth_ref": [ "r236" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, at Cost", "terseLabel": "Real estate investments, at cost", "totalLabel": "Total real estate investments, at cost" } } }, "localname": "RealEstateInvestmentPropertyAtCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Real Estate Investment Property, at Cost [Abstract]", "terseLabel": "Real estate investments, at cost:", "verboseLabel": "Investments in real estate, net:" } } }, "localname": "RealEstateInvestmentPropertyAtCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstateInvestmentPropertyNet": { "auth_ref": [ "r236" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, Net", "totalLabel": "Total real estate investments, net", "verboseLabel": "Net Real Estate Assets Subject to Investment Arrangement" } } }, "localname": "RealEstateInvestmentPropertyNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Real Estate [Line Items]", "terseLabel": "Real Estate [Line Items]" } } }, "localname": "RealEstateLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstatePolicyTextBlock": { "auth_ref": [ "r199", "r241" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for entities that primarily develop and then sell real property at retail or otherwise.", "label": "Real Estate, Policy [Policy Text Block]", "terseLabel": "Investments in Real Estate" } } }, "localname": "RealEstatePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RealEstatePropertiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Real Estate Properties [Line Items]", "terseLabel": "Real estate investments" } } }, "localname": "RealEstatePropertiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstateTable": { "auth_ref": [ "r675" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about real estate investment companies including, but not limited to, real estate investment trusts, real estate owned, retail land sales, and time share transactions.", "label": "Real Estate [Table]", "terseLabel": "Real Estate [Table]" } } }, "localname": "RealEstateTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r43", "r45", "r280", "r570", "r574", "r576", "r754" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amount of loss reclassified from accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationTypeAxis": { "auth_ref": [ "r751" ], "lang": { "en-us": { "role": { "documentation": "Information by type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Type [Axis]", "terseLabel": "Reclassification, Type [Axis]" } } }, "localname": "ReclassificationTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationTypeDomain": { "auth_ref": [ "r751" ], "lang": { "en-us": { "role": { "documentation": "Type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Type [Domain]", "terseLabel": "Reclassification, Type [Domain]" } } }, "localname": "ReclassificationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReconciliationOfRealEstateAccumulatedDepreciationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation [Roll Forward]", "terseLabel": "Accumulated depreciation:" } } }, "localname": "ReconciliationOfRealEstateAccumulatedDepreciationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.", "label": "Redeemable Noncontrolling Interest [Table Text Block]", "terseLabel": "Schedule Related to Investment Arrangements with Unaffiliated Third Party" } } }, "localname": "RedeemableNoncontrollingInterestTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterestsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r484", "r603", "r604" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r208", "r603" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Transaction amount" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r247", "r603", "r604", "r844" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r410", "r411", "r412", "r418", "r419", "r420", "r767", "r842" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Related Party Transaction, Due from (to) Related Party", "terseLabel": "Payable (receivable)" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r205" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Expenses incurred" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.", "label": "Related Party Transaction, Other Revenues from Transactions with Related Party", "negatedTerseLabel": "Professional fees credit due from Advisor" } } }, "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r484", "r603", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r844" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r601", "r602", "r604", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions and Arrangements" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r61", "r764" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedTerseLabel": "Payments on credit facilities", "terseLabel": "Repayments of credit facility borrowings" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfSecuredDebt": { "auth_ref": [ "r61" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.", "label": "Repayments of Secured Debt", "negatedTerseLabel": "Payments on mortgage notes payable" } } }, "localname": "RepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r752", "r762", "r853", "r855" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r70", "r76", "r211", "r231", "r256" ], "calculation": { "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested Restricted Shares" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r21", "r127", "r232", "r649", "r654", "r737" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Distributions in excess of accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r250", "r304", "r305", "r306", "r308", "r315", "r318", "r382", "r523", "r524", "r525", "r539", "r540", "r557", "r645", "r647" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Distributions in Excess of Accumulated Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r711" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r711", "r712" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "CARES Act Grants" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r283", "r298", "r344", "r345", "r363", "r368", "r369", "r375", "r376", "r379", "r381", "r408", "r409", "r411", "r412", "r413", "r415", "r417", "r419", "r420", "r569", "r635", "r787" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "hct_OperatingIncomeLossBeforeGainLossonSaleofRealEstateInvestments", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue from tenants" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SECScheduleIIIRealEstateAccumulatedDepreciationDepreciationExpense": { "auth_ref": [ "r671" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of depreciation expense of real estate investments for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Depreciation Expense", "terseLabel": "Depreciation expense" } } }, "localname": "SECScheduleIIIRealEstateAccumulatedDepreciationDepreciationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SECScheduleIIIRealEstateAndAccumulatedDepreciationCostsCapitalizedSubsequentToAcquisitionBuildingsAndImprovements": { "auth_ref": [ "r861" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails": { "order": 3.0, "parentTag": "us-gaap_RealEstateGrossAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of building and improvement costs capitalized since acquisition for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Cost Capitalized Subsequent to Acquisition, Building and Improvements", "terseLabel": "Costs capitalized subsequent to acquisition, buildings and improvements" } } }, "localname": "SECScheduleIIIRealEstateAndAccumulatedDepreciationCostsCapitalizedSubsequentToAcquisitionBuildingsAndImprovements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SECScheduleIIIRealEstateAndAccumulatedDepreciationCostsCapitalizedSubsequentToAcquisitionLand": { "auth_ref": [ "r861" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails": { "order": 4.0, "parentTag": "us-gaap_RealEstateGrossAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of land costs capitalized since acquisition for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Cost Capitalized Subsequent to Acquisition, Land", "terseLabel": "Costs capitalized subsequent to acquisition, land" } } }, "localname": "SECScheduleIIIRealEstateAndAccumulatedDepreciationCostsCapitalizedSubsequentToAcquisitionLand", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Sale of stock, net proceeds" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Preferred stock, number of shares issued in public offering" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r379", "r781" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Sales Revenue, Net" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r43", "r835", "r836" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r146", "r147" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Derivatives Included in AOCI" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Benefit (Expense)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r28", "r121", "r124", "r125", "r126", "r200", "r201", "r204", "r226", "r718", "r720", "r768" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r160", "r162", "r163", "r164", "r165", "r172", "r175", "r178", "r183" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Schedule of Balance Sheet Location" } } }, "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r9", "r10", "r11", "r12", "r111", "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of Properties Sold" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r780" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r96", "r98", "r618" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r96", "r98" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Schedule of Line of Credit Facilities [Table Text Block]", "terseLabel": "Schedule of Credit Facilities" } } }, "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property.", "label": "Schedule of Real Estate Properties [Table]", "terseLabel": "Schedule of Real Estate Properties [Table]" } } }, "localname": "ScheduleOfRealEstatePropertiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesExpensesandRelatedPayablesDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsIncurredinConnectionwithaListingortheLiquidationoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r48", "r91" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r88", "r89", "r90", "r93" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r88", "r89", "r90", "r93" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r486", "r487", "r489", "r490", "r491", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r513", "r514", "r515", "r516", "r517" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r117", "r118", "r119", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r260", "r261", "r262", "r335", "r451", "r452", "r453", "r455", "r459", "r464", "r466", "r722", "r750", "r763" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": { "auth_ref": [ "r131", "r132", "r133", "r134" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table Text Block]", "terseLabel": "Schedule of Class of Treasury Stock" } } }, "localname": "ScheduleOfTreasuryStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r16", "r215", "r230" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt", "netLabel": "Secured debt", "terseLabel": "Mortgage notes payable, net" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r341", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r373", "r379", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r402", "r403", "r716", "r857" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r341", "r342", "r343", "r353", "r356", "r367", "r371", "r372", "r373", "r374", "r375", "r378", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r357", "r358", "r359", "r360", "r361", "r362", "r376" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Reportable Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Business acquisitions" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesIncurredinConnectionwiththeOperationsoftheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r67" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Equity-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r730" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Restricted share vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeitures (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeitures (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Common Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (usd per share)", "periodStartLabel": "Beginning balance (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Issue Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r137", "r138" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Unvested restricted stock (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Maximum authorized amount as a percentage of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r489", "r490", "r491", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r513", "r514", "r515", "r516", "r517" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r492", "r511", "r512", "r513", "r514", "r517", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Equity-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "terseLabel": "Shares outstanding (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r77", "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r253", "r341", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r373", "r379", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r400", "r402", "r403", "r716", "r857" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r260", "r261", "r262", "r298", "r323", "r324", "r326", "r328", "r335", "r336", "r381", "r408", "r411", "r412", "r413", "r419", "r420", "r451", "r452", "r455", "r459", "r466", "r569", "r677", "r750", "r763", "r779" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "http://www.thehealthcarereit2.com/role/CoverPage", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r30", "r120", "r250", "r279", "r280", "r281", "r304", "r305", "r306", "r308", "r315", "r318", "r334", "r382", "r467", "r523", "r524", "r525", "r539", "r540", "r557", "r570", "r571", "r572", "r573", "r574", "r576", "r600", "r645", "r646", "r647" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r304", "r305", "r306", "r334", "r617" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockDividendsShares": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common and preferred stock issued as dividends during the period. Excludes stock splits.", "label": "Stock Dividends, Shares", "terseLabel": "Stock dividends (in shares)" } } }, "localname": "StockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r73", "r74", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Common stock issued through stock dividends" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the shareholders to reinvest dividends paid to them by the entity on new issues of stock by the entity.", "label": "Stock Issued During Period, Shares, Dividend Reinvestment Plan", "terseLabel": "Common stock issued through distribution reinvestment plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesDividendReinvestmentPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock issued during period, issued for services (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r120", "r127" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of preferred stock, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/OrganizationNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan": { "auth_ref": [ "r120" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the holder of the stock to reinvest dividends paid to them by the entity on new issues of stock by the entity.", "label": "Stock Issued During Period, Value, Dividend Reinvestment Plan", "terseLabel": "Common stock issued through distribution reinvestment plan", "verboseLabel": "Common stock issued through distribution reinvestment plan" } } }, "localname": "StockIssuedDuringPeriodValueDividendReinvestmentPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r120", "r127" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of preferred stock, net" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r18", "r19", "r127", "r139" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation, net" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockDividend": { "auth_ref": [ "r30", "r120", "r127" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued to shareholders as a dividend during the period.", "label": "Stock Issued During Period, Value, Stock Dividend", "verboseLabel": "Distributions declared in common stock" } } }, "localname": "StockIssuedDuringPeriodValueStockDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchased, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Shares authorized for repurchase (in shares)" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r18", "r19", "r120", "r127" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Common stock repurchases (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r18", "r19", "r120", "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Common stock repurchases" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r22", "r23", "r92", "r737", "r765", "r784", "r834" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r148", "r149", "r157", "r250", "r251", "r280", "r304", "r305", "r306", "r308", "r315", "r382", "r467", "r523", "r524", "r525", "r539", "r540", "r557", "r570", "r571", "r576", "r600", "r646", "r647", "r765", "r784", "r834" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r135", "r297", "r452", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r467", "r555" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r577", "r609" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r577", "r609" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r577", "r609" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r577", "r609" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r608", "r610" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "verboseLabel": "Weighted-average price per share (in usd per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityStockRedemptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r19", "r120", "r127" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Number of shares repurchased (in shares)", "verboseLabel": "Number of shares repurchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityStockRedemptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r120", "r127", "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Stock repurchase, value" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r85", "r86", "r87", "r337", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r534" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "negatedTerseLabel": "Deferred tax valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r322", "r328" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted weighted-average shares outstanding (in shares)", "verboseLabel": "Weighted-average common shares outstanding - Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r320", "r328" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding - Basic (in shares)", "verboseLabel": "Basic weighted-average shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 16 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2599-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.F)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "15", "SubTopic": "20", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450852&loc=d3e24871-108386", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(d)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=126943897&loc=d3e24546-110282", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "970", "URI": "https://asc.fasb.org/topic&trid=2156125", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "972", "URI": "https://asc.fasb.org/topic&trid=2134617", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "974", "URI": "https://asc.fasb.org/topic&trid=2156429", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "976", "URI": "https://asc.fasb.org/topic&trid=2134846", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r246": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "978", "URI": "https://asc.fasb.org/topic&trid=2134977", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226006-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122596-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123605564&loc=d3e23415-158514", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123605564&loc=d3e23439-158514", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123605587&loc=d3e23528-158515", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 6))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28)", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Footnote": "5", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Footnote": "6", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "02", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "01", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "02", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "01", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "02", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(C)", "Subsection": "02", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "c", "Publisher": "SEC", "Section": "5", "Subparagraph": "Schedule III", "Subsection": "04", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3505-108585", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r741": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r742": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r743": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r744": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r745": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r746": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r747": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r748": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r749": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(14)(d))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r867": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r868": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r869": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r871": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r872": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r873": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r874": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r875": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(ii)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r876": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 114 0001561032-23-000003-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001561032-23-000003-xbrl.zip M4$L#!!0 ( -9!<58L)0.QWPP .!3 @ > 97@R,3%H=&ES=6)S:61I M87)Y;&ES=#$R,S$N:'1M[=UO4]M&'@?PY_U MNM7:BO/D1F !FAC+(XL0^NI/-I F)6GHS9EYU?G-=S!MV7A=Y4TS9S;*<7[)L6BS?L>WMAZUXM;BKR\NKANWN[/99 M5M7ORO?Y_>=-V8&]W=4K^AZORK&PO5Z_3.^ZNMG],UM/$ MY?5EF[ZSJFFJZ_O]?Y*(\_::%O7_/!6];Z6B_ZI-17ISMBRG95Z7[3ZK"Q86 M^:RY.L_KHKT%;Y;-"Q;-SSN?I^_+%A^3T>1GL^)Q@[.JGA;U=IN<6;Y8%D>/ M__-Z6BX7L_SNJ)RO3VK]I=>?7ZC53?"^J)OR/)\]'&1]O/N/'^Z/P_W.WLN# MU2W2U.V_T\<#/]P]G?7=TVVF3S_;?]79.^A]]>.=SM<_^Z/=]@\[_=W#9^VV MNS[E^]-N+\QRD<]_V>IO/7YAD4^G;4X]VEU\8+W/[YE9)0_I_G-)NK]__E:).KVIR^6T/%\5PZO,,:CJZWSURP_?[QV\;C-& M52^J>OV7S]+^#=>'/-%4BZ/V&K!E-2NG[#$U?T_TO2]>G]\7%DPMBM7E:)\N M25XW\Z)>7I6+%TQTDLXS;H[_]KK\I7?.EZ^,5\SRV_:Z_)G;@I*\,WV?SYO\ MLF!I,2^KFO$VL2VTX(0+@0VEU"%GCN,/PRS:Z<&0KB'7$1].5I4'G<*1OB,, MZ1J&@3M!>4K=<"Q@2-PP''C<@2%IPU.'JQ"&I V'D8^RE+BA%!D,B1LF N^E MU TS,X A>4,)0]J&PA%)X*"]S19'&!(VY /7O($A;4,QA"%Q0U]$Z(.RQQ&& MA U/1\E ("_:X@A#PH;2G^#=AKAAF@0H3^UQA"%E0S-"7K3'$8:$#4V*>H9% MCC D;)@IA7H&;4,9B-AY"T,+#'=A2-=0:>F-T2],VC")QT)&>#>UQ1&&= TU M%QIYT1Y'&-(U-%KQ"&TVUCC"D*[AV!WI#,]%:QQA2-;0Y<,XB#'NC;1AX*I, M>C"D;"A"-TC0]D;:4+HC_K&>R'ZZ6$?->[?^F;/U)EPQMZKKZK:HV?YZLY]A M3=0ZBS>Q'M)=!RX]>1H9]7?!;!?5?33?H[K=55.^+[X:WO8A^.G.;U_)SY;5 M[*9Y^I7[BW%R?+8ZD8]@\+"3',N-J\0L(JPTS':/RE;9BXHX%$/B1MJ%%!(F^8 MAB.)?$C<,$X$!C_;XPA#NH:9JT<(R&./(PS)&G)'^!G>;8@;:L51U[?"$!,1 M"!MR'FB4I<0- S?8Q XRJPQ3'F-P$&W#0:!]I5%'M,41AG0-0^ZD>*^A;J@$ M)I+8XPA#PH;^&'G1(D<8$C;$^ SZAHG9R$'-5AFF@0=#ZH9"X;W&'D<8DC=$ M?R)IP\2@/+7'$89T#26/-0*V$C<4D<&\-N*&:6ADM -$THB928%('%$Q5VFM M,E^S'B M@41]T1+(/B#M@-P#I!V0^X"D#)DF/I/%]5E1PY&N8\(CK4)4/$@; MAH[$>A^T#5,N,DSC)V[H*4S_IFXX]!$FC+AAYH\=A-.PQ_%Y<7A?(@XO76O/ M]48N\JP]CIMFB'C*3PZ+>,J(I_SE0L(+1QXJN\0-A:-A2-O0%^,T'L/0 D., M4R!L./ F.HJ1#RD;2H_K3:SXV&0XEKZ./#1"V.((0[*&/N>)B3D,21L&8Y'" MD+:AY!/D0]J&4CL3Q*NC;9A*7QK4$2D;#J00 M&YG D+:A)YP8[6VT#1QB2-1RZGRP( 4<[ M''< :0&X<6]@ECKB^6B'XTLX6N%X $!>]";"D'9K'&%(U]!+DP!#VFD;AHD9(W(D;4,YD!/D0^*&(2*XDC<4 M3@Q#XH:)B%%'I&V8^&*(:7JT#=-4KL/QH)YOAR,,Z1J.0^%]#.?"?KKXX?N] M@]?OUC]SMMZ$*^96=5W=%O5#U^//L*9H+5TG"#FF95KC"$.ZAERF(9Z=Q WC MS(LG,*1L&'(Q5B$,*1O*4V'0WTC"9C@7H&:4.A!-ILB!NJ4'@JW $B9<3$U4IA/7IK'&%(UC#A M//2Q7B1Q0R$GF]@IC)#*3PZ+D,H(J?R50B(1*0IZXH9I.)8I#"D;AEPG$6;Y M6.,(0\J&)D9>M,?Q>;-D7V&6+&5KST^19^UQ_.,\^_GB('Z]N%D^ M+%^ ]=TW@QGK'!)FECP9(F8,<QM]PSX,R1ONP9"\X3[: M:F@[IE'L862 /8XP)&P8AT;"D+9A&G@P)&Z8I0$,:1N.@XE&>PUQPR1\ T/B MAF,1#%/4+VQQA"%=PRP4Z-.G;?BOFWS*>-F4[7Z3JFXNJMEZ>/%J(#%8R;)J MAXL,(7]I&X;2T9BT2MW03U'E(&Z8CF(8TC:4.A-8/I2V8>*8]; W5/WM<'Q> MX)4^ J\0ML[XR,LP!<<:QTTS1(3G)X=%A&=$>/Y*(:%5BAQQA2-8P=317 M:#PD;CCV8S3BTS9TW9'&>&A[')_7:-%#HP5A:^Z:$#&8K##$W$S*AEP+/#OM M<7S>Z@B'>'92MA[RB53(L[8XPI"PH?$E!CT0-QRGAJ,MEK3A8" P)]XB1Q@2 M-DQY&"'^'7%#H] _2=M0#(6C- PI&TI?1PGR(6U#Z6$U2XL<84C9T/C(B_8X M/J^_H[>##@_"V$DB\ "UR!&&= U3(Q,,F"1M:'BH1NBTHFV8(!^2-]0I"Y7P MVC?5*((C7<>QB,9# M&-(V#%I#O-/0-@Q;PP3C-ZQQA"%APXD>PI"V813$@TV,%&N582H%#*D;FHW, MAXC8_.2PB-B,B,U?+B1$YDXD9D.3-I2N3K *(VW#+/ T#(D;9I, AE0-A1^E M(^TS$8VC.B9W EWYLF!HP=\3#]@^QG;2R/+\J+_/Y1M(&VHD]IITD\M(7 M+(IY![XV^89*B%88M/;1MJYI^U?0TJ2-!GZH1JG/MAG7D]60AI6OTDPEOG9, MI&)+^^,V2390PO-CYG#MIX"U"#9SA*=BEBGE =8>6"Z<]G$+3UL\[ZLW;ONJ MQ*%JC:HT'98(WTF=U9LP6"UA3=J7)!,%;2FLI&P]06L?;>9,P$J<-;X9E\LF M9Z)\WYXRRQMV>K,H6P4[.0?M8M?^YZJYGIW\!U!+ P04 " #607%653T#+-D" M "<" % &5X,C,Q:'1I,3(S,3(P,C(N:'1MS5;;;MI $'WO5TQ 35H) MWS#A'J06G 25 )'*$_58H_QML9K[2YQZ-=W;8/:-""E5=.&AY7',SMSYN(S M=$\&D[Y[-W4@E.L(IK&.S,R5S4C8DR@[DN_U.MF;]2)Q.^]Z9YH&@R8 MMUEC+,'C2"3ZL!$T7L'"1_$5-&UGU6?)EM-5**%J5FU8,/Z5WI-"+ZF,L+?W MTS4*N6OD0;I+YF][79_> _4O2K1%6G:SU3 MNUZM!>2\63-M#"P+K7H3Z][R MLZ5 &LJ\N"/D-L*+TIK&6HA9_':MJC?.$]E)J2_#MF6:;TN/3"4^2(U$=!6W M<\!*&[!8*B!<.2X>G_@_+MLYK].IM$"LJ;1MGWFTC4*&&,*,[8F M\5E%J,YH CD-"D-!OZ&"J1#G8EIDT5!^(AKC/BNKFN7A/(1T256-;=UZC/5I M10A?J:(LF91LW;:5^]T;R9)<_"DE3[4%^;,*\<=N7ZY4M8.EZD_&R_H _]_N1V[ ['5W YG-W\_$0RD"$"C3W&$\9)QE*@]!P#91A[F2JWF.&* M"KDSF$M%/CD/*>&2\37,-7L [\9,!]NV-:O5:)K5]\ "N$82R= C'!4/JN0K M,(P]/=.P#5=A5% )?LYE-X1[X6G9JIL=JU$IN(MCI$(JBML!#6A,8H^22)5N MAT$ B?U#"A!>B/XFP@JD(?5"($F"A(LB)2H*Y)9Y6FY6S5;GD_[[#3S<]__S MD9V6:XV.R$^89K>%#@W3>S_=D2TYUJ!87DE.R/WU M^TAV()#0AFYOFS+;#Q1;1]+1.8^>\TCXY.>SB][P/^_[)+5C2=Y?_?9VT"-; M]6;S8]AK-L^&9^3-\-U;TFZT C+4-#/""I51V6SVS[?(5FIMWFDVI]-I8QHV ME!XUAY=--U2[*94RO,$LVSH]<6_PDU-V^M/)S_4Z.5-Q,>:9);'FU')&"B.R M$?G(N+DF]7IEU5/Y3(M1:LEN:SD)$Q,BV*LM$<1C&47"XWZ;_#>!D$^9E'V-G MDK_:&HNLGG(W?^=@-[?'4\%LV@E:K5^V[ME9?F/K5(I1UO'>HC516%O5'"NI M=.=%R_\[=BWUA(Z%G'5^'8HQ-^2<3\FE&M/LUYI!A.N&:Y&4AD;\CV-&3.X? MIY4W&$>*C,^]"W:=2_V;5$3"DC!H!"=-9[]B30N^QH@;U]_)V5[_AU MAX.+<^#N\L-5]WQ(AA?D\NIMGP0AK0?M;;I#NN=G)-ACU=/5^5G_DFS\ZH9O M^N1#OW=U.1@.^A](_]^]-]WS?_5)MS/_?97ME:L_.=5A\TYJOZ M]K,_"$NKX4$P("F=<*+Y1/ I.-6FPI!NEA54DDN>*VV)RLAKI<YEZ3>\K"V@S\R=6?+VV0*PO7$ '-[+ULL7A[O!P;&I(%:I"T!\05,8<8($!$DKO,$@Z81E*8U)D[LS$(U)&H>V;"Q%*9 OT"8?^39S2;,1)%ZQU64A8>*6ZM\UW?%>O5-U3^2B< M!LU*R+KQB:.V!227R'*^K#U1&H57;M& 6J%+T9)P?PQW121$4Q0+=P" M1*D0?)'(W$B%<57;[U/C2[RG4&4X',(!W7?**1 ?%Y(ZYL>RO!-WU1\]2BVQ M*('P6\2=(<@9_3G[FF2\6<".-@C887L9V&M3VA*^UR?#M6&.K3$1S*&7&I51 MQ_K4 /E.F3I(XVPZAQ< +V@DI+ S)PA63>LVFT>B!UFY3^Z9+BA;7UQNJ@7E MA 9=(H%UM/#<;2)G OU>XAF;3>3@]^>+Z'B#$%U2 M=7]"9>'YS*6;)PE$II@@46:%6+R5'VOP<_FX6C]Z *,CN-64*C52A7W<@W4J M"+VUYDZ")Y\_1I%H+N[]GN1E)."/QY^;X%EBD&T0!BM6+=.[#!-WNJ_$GV]9 MB<4G<*F3 "J."^W L%!O5XPZ5L;BO;LZQ5@FQD!_%BC7&'K[D2X)4 V6>V!= M.8XS&/<7$^[.PE]#E7[ME%ZEU-R*$\>/?A=PY@N'CT=%ZC,BQ367U2W% _O: MWP[1UT;^1AWN]I[)X<[?;++YGJG=T9ACU47"RLY?P3-2-2[GH<[4S /S_(-M -BC:N!.!_)\GG6Y+_60BX[[=? MD<7^,F/GGS/2@16NE9##0"Z88 QX( MDE],57!6WMD];SFP>8>L+JI^HD$L->" >RX$DORE>06Y6EDT1391L'#;LOG$U7<%#?]=0=.RY;9PMQ&&P:/-K<:7MNV%X1?U_)2S M^^W&0;B_UK!-'X@R& BWR6GV:BOH=DIG-[\AP?T4NLWS,.)EL+\]I_@/ M0LZJ\R2$:W 1]]Q!6R)O_ D\\#\2*%>$=[O']T?*8"]5/"$]&]X M7+@;&7*Q< QYKZ'QF/_<[)^0KA_2[??E+2<$Q%)<=Y9#V?0%]@E?=ZV6 >M( MA,K-MI>KJORVL5/^:63"'_W>KZKYK;LN- )C%/;Q+D]P_=[/\CM&_T7EZ5]0 M2P,$% @ UD%Q5N6$P 58" C"H !0 !E>#,Q,FAT:3$R,S$R,#(R M+FAT;>U:[U,;NQ7]WK]"CTSS8,:_;7 PA!D_XS2>)I !,VD_=>25UJM!7NV3 MM#;N7]\C:8T--HE)T\1AF@^$75U)5_<>G7LD]O2W\\O>\)^?^B2Q$TD^W?SQ M8= C>^5J]7.S5ZV>#\_)^^''#Z15J=7)4-/4""M42F6UVK_8(WN)M5FG6IW- M9I59LZ+TN#J\JKJA6E6IE.$59MG>V:E[@Y^43GEH2:4XM M9R0W(AV3SXR;6U(N%U8]E6-&J-)OFL]*V8TM!NA97\;#'.:34\GU;] M)*9GITQ,B6!O]P1O'L?U-AMQ6F.M9KMUW&K$[&A$&[S=YG5V]*\ZG*S" M//0Q=B[YV[V)2,L)=_-WVHW,GLP$LTFG7JO]=>^!G>5WMDRE&*<=[RU:8X6U M%AF'!#+OB,7*D)37\O&42X;+@6<3 TXM\< M,V)R_S@KO,$X4J1\X5V]X5SJWR5B)"QIUBL-!=7=]T+X9D>$FN;C[T2;U)R_76/CT@W8MS4C]DQ=/-Q7G_ M:O=7-WS?)]?]WLW58#CH7Y/^/WKONQ=_ZY-N;T@NWY'Z<;-5(MUKTOW8QX+. M'RUH'8E4CP'&D;)633J'<*%X8U7F'O_GJVQM7.6@1*XC^$0^5L@'FF4PDHXR!&-G?Q266L5C8$ 2.N5$\ZG@,W"J380AW33-J217/%/:$I62=TI/2+U6 M_CM1,7G/J;1)1#4'N^?&EL@@C2I(VO')2\Q98^=R]@<=,%:5[F$A1>JA_O\P'?U0M4] MA4?A)&@:(.O&)X[:5I #5UW?";/-HAS"+ MH\"N@/:H^442 ^RB5US(]E>2>6U1\] M@I98E4#X;<2=(<@9_3G[GF2\6\ >[1"PFZUU8&]-:6OXWIX,MX8YML94,(=> M:E1*'>M3 ^0[9>H@335;P N %W0DI+!S)P@V3>LVFT>B!UG8)P],5Y2M+RYW MQ8*R7&< N?$")HJ49MX!KW''/(4ND< Z6GCF-I$S@7X/>,9F$QGX_>4B.MHA M1 >J[D^IS#V?N73S.(;(%%,DRFP0B_?R8PM^#H^;]:,',#J"6TU0J2.5VZ<] MV*:"T'MK[B1X_/5C%!DMQ+W?DSQ$ OYX_+D)7B0&V0YALD-YUF+C3?2'^ M?,M&+#Z#2YT$4%&4:P>&E7J[8=2),A;OWJJ[A=,II#WC/4RIH0OG>-0@Q; MIGD;_,./C_&>['"8.NA,B#Z!2 GCM'NQ-Y)#BP4A3W^[/4C--;5ZV#Z//U MVLM5?^FZN(EZ%@*+8T^XQ=C ?)2AH^'WQ/F/Q7 M)>?%H13JM]Z&K&;47U9\I#I*2OXCF'N@%E'YPH)KQ->T;4Q_A=B\?M4"1?F? M&[XZ>!"7+1'QC !M85KL?,<4L"7^SI0LPO*M@=[I;T!\6M93\?ACEI^6D5\) MW;U$\)B\NZ^TE^'T4R)#)P9S71R$KGFDN:5Z_O/Q_BM%=_]3N&=%8-="[..Z M;.\N+V<+@X/U6%=]^5Z1"\^0$D\+YN, MA8>U91"P% M "N%P $P &5X,S)H=&DQ,C,Q,C R,BYH=&WM6&U3VT80_MY?L3'3!&9L M2[+\;L(,-69"&P(#SC#]U#GK5NB:LTX]G3#NK^_>R:* ,:&=E+S5'S26=F_O MV6=?M+K=%P8K%H+L*FTI?>],RSIMJ>5"K')C>\MK=KG] 5 M&=_[8?=%HP$'*BKFF!J(-#*#'(IFZ3W9GBR[U=+JY \-DL8J-81#D]WR[YKY#8LJ<:2DTL,MW_U&5M*(V5S(Y?#5 M5,PQAW>X@#,U9^FK>DZ!:>2H15PJYN)/))B$V-TN2B=Z9$>*%"NG@I;U8W*= MB)DP$+;@*5 C8AOU9\)Z/AE/CT[>01!V?!A/SJ9'AT?C??OH_"[V]5@R?4GA MG"ECU'QH8[EZ8E3F;F^Y^'N1&Q$ORT3Q,.AG_WV V@\Z/4U$#F/4A$E$ M5"Q MS.TY<)1BBO45#Y9H?."$3:CP"0(&O\HA$9;&CFH&,XQLG5;$D?WXX1E M%$;HAK!]S(2$0\T*OF-%4UM($/1A>ZR=&RSE8/\**GLXU2I"7FC,G;+=ZWTJ M; 6?&\)&0!7'.C!:QE5F[D&K8 S\;K7ZG.D92S%OG%Q+7,)^9*RDY?NMNMLY M3YB4D"I3![R.,+MQD8)C&\C*4PZSY4?MS9 H(U(XQ$+:J](67D:-ZBY+_1MT M&!6:6A[))]=1PM)+K$P&@[!=.DHL<^3-S>7S52Y1A[B0DD@D M#6D5%L(D'^D9VXR*74/0V>8[3Z\,2@);NB*E,ILS9RHB?QGYR.EIB8R5ONG2 MMY@)3=@R:B\61=VJ61NTG.AS>GE&L$AB,<0WV46&N9M,W+:D5ONN]&=*4^=M$'#)LAR'U9\1%WDFV7(H4K>]6S1:9^C*EGW$Y&H3MU\I M7DVR@T&SWPGM,&LHOPRO-E[-N4TWYWJ&K\O"?K/7:F\4^\U@H^PQLYU!T^]U MGV36E;U'5%O9M56^'1>)\1J-)8// MGUSNJ^/E5KLWRMT5)GS!-(?C)ER@D'7X6=]J:I^6HE4FVLPE7YZV3[6@B2.CD6.-K)V'^*D KJR$CHQ/1MD= MU>\S(K<;XGE$2&QMOV59AD88]7\[?)R]9V/LWY+R#R; S]HZUSYTZ_1MBRPO M]*J+TO>21L/T\MY!U9=!\V?NI>O'!.6+IY+OTP=MD1I[YK6YV7IN#+XU=C_E MVVF%J&W3*5/EZ?90HV2VLV\\[UWEH/_W$C:C)E"8S4LV':$^ ._.M3S)=F?J M>W\!4$L#!!0 ( -9!<5:L$-J5RI8 %7C P > 97@T.6AT:61E)/;8RN3,IU,@V900@P #@)(YO_[M=>M>C1M!68Y%6E.U)Q8) HWNU:O7 MY5G/^L?_>?'Z^?G_O'D97=:++'KSZ_<_O7H>??7@ZZ]_.WW^]=;%38ZGWQR?/GUZ M_.QQ,GTTF\Z?)/_OQ [R:WLY_::JUYGY]Z\6:?[@TL#SOWWZ<%E_=YW.ZLMO M3XZ/__857O6T?5MH?TS_I'JT[U>9#_2#)THO\6WR?K^BG\O6TR(KR MV[\+-%M_^V_GZ<)4T2_F.GI;+)+\W^+*KL&#RI3IG"ZLTO\U MWY[ \/#/:QZOO4^6YD;&3X-^^7]_?/7]JW.[FM^$ ]X\U(ZWU#.5E!=VLB9% M71<+&HVZS]0ND"EO_9V/1[WSBY?OGK]]]>;\U>M?HM?_C-Z^_.'5N_.W9[^< M__TOSQZ>//WN7?3NY?-?W[XZ?_7R'7_[\NW+%W8KO'WWJ[TL.G\-KVXOPEN< M/(2[G/_X4O_LY?]]_N/9+S^\C,Z>G\/7)]^JSXJYE%EIJO2:@#[3/O7CR;)ZLMI M4AJK&E95'4>O\NE15)J+M+(+#KO:OE,9O3-3O(&=._NKVC[EG;_/RP_3RR2_ M,-'9M(:O8>[B*+$/M_MZ9N]Q #^ Q7IX_)V^&#\Z^>X0+[8_?&&F9C&QCSL] MB4%?/(R2?!9-35DG:1XMR^(JK>PH*AG#STFYSN"2'TQNRB2SVJ9<%F6"0_TI MN0X>_/,/SW^2!^)]BU49V;&4]CW=WQ-[O^OJ*()YU!.',UFM%G;EUW$T*^Q; MYT4=+5?PO#JJBVABHFFQ6&:F-G@W^XMJ-?G=SAM\"Y_\L;)[:9[:^; OD]95 M9&4E+4V]MD^U,SZWTYU/#5SMWLL.!G]J/].C/4CS:;::P1(G^3I*ELLLG2:3 MS#ZYK--I9N#9]D,#>M7>*YIF256E\S7^@OZ*BC("(2,Y6.+S8;VKNIB^IPFB MR8CM>RWYLNO+='H9@;3,T\Q>;)?-?+A,)_ V/,:S/+?O&;TU.#%VZOY9E(OH MY/C!?UK!+''9YFDUM9>L35)&)"#="P_/L6_*:VIFX3Q=VO^F^=$.;M*SRIZ5 M]G7H#6*<$[NLBTI$];D5)+NP,8NK?'QMFI_8"9=/8,+XTU4E'^)LP.8J>)\NTMN+ZOW:8-#0<\615H]S/S-R^E;Q!5%TF619=)E<&WV5A MDAPE#?;/Q*#X5BLK.'PGU"A_KCQO(R:?Z91C';:#\OQ:*])5?5F4]L<@,;#P M:56M3+1:PK]/'Q_'=BCP/Y"9DM8*5PBTC+5,JQJ6U'YX>MQUJ=6P"ZM2^!=+ MJS^NDLS>_J_'8-PN[?/QVAAW0^?#&H(Q<).CZ*S[4(JC:ZM]DAGI,G?8XOWH M=6=\GM15;?]AO_S[7QX_^\Z*^:%5A(_CXV?'\>/3DY[WLM=^ ]?:BT_C;YX^ MC4\>/5*7PKYY>G3Z]/'?[!&,XGX6/5\M5IG=N7;_O34S8Q:X=]Z8)0GYPVYYJ&>O+0#_7[[8?* W0#'ASJ]WU# MW<5C K;5I$C*&M Z"^3&K:I%;,^!EV8D0;'46_XA&DS:PX>&,T/>"@NR"EG*VC+$5) M!1L&!C@SDQH?64RL@X2GICVDBLS82\'RM4=OM8HAV4 -!,O],!CZ1W7OO31T=\*30-8/9_3 0-#BX.)1C*0@6@#\AJI:7"C=IF: S M8'\+>S%/*&"I8Q>&;[,#AOUSFC>4R1W<[.]\% /6;\D>>)W:!2%-&D'YD]Y#G#0S76(1]L:I0&KT1HZW&UU33:*5OLT++9 9R^B S\_K;QX\::_;@Y-EG6S3#MW%D;T(#Q;1U]:\^L<8UF<&ZG=B_B9.)1.+<[V&I/:Z^![9-<)6F& MY@^LIK%;%(YKF@7A*XP8#46M_:_C-+_UBE,U24,?S:FJ+T M8WLSZYZB.K5.N#QS/D_2W;0^?UUB.+9:)1 $A+F:K^QD+I,U)J.\@,(4!_/$ MKCF*G9T3^_7$X(_7]MQYD3^ !:DJ6 J, X.EAT>4W3LSLUC2%%=I_A[F M%#8*QBZN[/+P?%L5B===.5,373:KLI9*D?:;BT?1CP/+[5T2? ?64\FVL[F5;JTUFYM'['_B?)!+5'^R<; MLJ7T_R]+N?/2NET/)J5)WC](YO:=OTVRZV1=?77+&=HA61W^+EU<6#51__M7 MZ<(.]?\]/OI]>?%55)73YB?!_#YT7&H02&L$D MW-"=9P4Z#J@!ISZN:!\ 6WI[-?B9_(.&VWHG!HQW_!930-.]SEW\VDQ&Q3VV M:^Q"IDI(70@VQ@RQ-X&MG$^3E3T!=!*D-PL!9P.H>&L[+ J[7=!=,LIABN$F M]FRR1DE:778'1>T]3&+W8M/78O=JGGY0B<:ERZ-6VGJAB":Z;.+:\6Y:%M<8 M"=8G9&RMSH65$3HN$WQ3N^CVM /GP=TI<"]B28-/Y6>Y9!@I"6E-U5J.:F]P MH:'7]7I'47>8W-YIE& M$!#VE>UW97)!"4J(K!=7L%HR)VA*2-P=;J7T7*#C%NBX34R6FBO#. .R)%+[ MVG8Q[%\0SUU)DER MR9U@P9&UIZ$M%6C2RN]NV-E;FJU].:P=/)MZL2J/XJ>/-H!@HFLC1B?A$RE, M6UD_%F%WUK+KS?8M5R785'4#HGC'Q:%[#M\F&-/;P=4_1T!NSQ)94_.]P$94 M#%(L=:W&^)\848;5O"JR%2'NT+;T?XX(-S]8+??/2*E,GA:E$_961I20 &3C M&SM%]5HE+372TX%IS0>[&ZL*@M 4*21_@$QGG^^$18Q^7\G3ZX$%W[\S%XZ: M!"$\#OO4F_1'X/ G7(/^L70OQ-X9 %X(NZ!7=DYO?\[]KAN:[EUT*4%Q2XPB M$06JPQ2MR<090;SIJ$FQ&M_>H30$ATKF\[1]';[I6WV'MQY#'E M0_J",*QXX)%<9NG[1@B9 CP38W(( /&/I3[!?##E-.5LX1EL"/3PZA0RN0 2 MU$LGN$3TZC$DB"D\"&)C^4A>V7U04OAPX@!C+1$04 Y'8RI#=2@PC\M2R01" M,C'N(DXGQ=2'+05URJ >M>><^<# ;'CK^:I>86$&O)V9Y783TVW=!A^41P[: M8^20)\C_?,\RA>2#=E!TT1A4/J/^$9NES,& MMX8.@V0<)E3Z\&@"Z1;X#]Z/YSS62>%I4EVJY!2#,9)%L<)?P9%Z;(_4OYX< M/7MT^O2Q*C/!K!/4*@K,/*WPX+E*,I,[C D4*,+3N32'3\&_/GQ\='P<=?ZPPK,+@,;L"":7?X2$GCZV:FR58^/&O)%]A MB>J9M02R./K7"C%^L^BUG6+.%[H7B@ F91<'SN,DFD#]/ARW]E9DL>=6$,$@ MGQJ#ZDU?88T=KT_M\-,"2UX91 ,:%V;=#YLO 8_9OKL#]\X:I^V)-3QO]"J( MPLEGO3>&FRY!/-TGUA+V#^MZW>;KL4&D;&5[OZ)T.'=5MLA?V"7GO4#V8G73 M?1 @PN2I\T;5P0 BOZLF#2Q]!"1E186BZY:7WT>]!&2/!X<,^Y"@I#QG@J_K MT XT^P#:\S,,^+OV-*KO:7OC6,R5G<\TS"YB!!/DN.==7>EQ^%AX)@O55[+[7/K,3/.=XQ)7H!!(/8#W([@_:#,IJ;:\RW MVT].CD%W-3R^37MG%T6]!]_A/&>G4LF5OU9.]3)9-U;5 .QG,81GX!2&<[YDKK((R,V]FR_OT\ MF9)SSQJ&XD#N9P'^MFBX_0"G*)!;@D1;1\EBOWD@\EA3<**YK/L7"+\SZ^(# MMC=R GV%"8UQ"]W,$,@^;,[)(WAMU5@1H/<@Q0'S% MO:756=9W )PI;9Z,1R%_Q9$\+WRQ[CG[3&%^OJXH$=1E%FY 6-J33#&O-KC, M;IC5)Q]G=, U2)!#F:QU19K=IOA4*9E&D>X9M@LF].<=[Z[,QI0F$O\*5X@R M*B%WB*_=TNBECZ@4HQ<862M&?#GHORYB_*"=:X0M P#- -6R'U&\H[:'QL, MW'0.PL?&EI.\D6;*S:5,P%.?=V\S8(B3,QQY8S8GM\DD%&>'6TP1IFJ5-Y;8 MBXJ^')/ (M >^IT&*I/L/H8W%FA*B&RJMGN_JE N,KV,&[ZK9W(D0X-C;%_^ M:8:<5FB[%24B+&KC HL;?0:(I](90CB85OQ1GTH#5H-=5MY9"D4/@V,Z>ZGX4^_@#3\7=&UK^:QRW'4R0<,CW-"UXI3)MI' .\0 MLV?HU91H4",0/R_P@K\ZL!<*$ZK]7NB.GCU^*BG%5R!A.=+A7IE\!?1B,T,4 MR<^>]%(DPT5"A74(IAYMQ_ :'MD/L#&B,]0NCCZ+G^YW*&;&]7Q]^@W."QC_B\:D'L94 M2HC6.+\WOT[7*S.D+C@+.)DT]@B0'Z?*8/8ZT&OPQGC[)FB+)\M<:IG$R$HE M=VD^L_,7.(#F6;IA(93EOXO1&Y4-'^.W<&Y8YZ*3(($JX4')14+X)JDN8Q?( MP#GTA:PLB>YP53OK(XROBBG'@3(YF117=X3<;$O,TT\*[/+&@5UV4,B0:0CD MY"/]R0;I4HN&;#2Z:B):F3!1BCRJ&QC5))%J,FS8HZ4'F:0 481@4M3*RPQH M3'.Q:-$$E1TU:"8>-(+P*N3NW9K9H;U7[(C&G=T:^YP[ ,1=WA:<2)U)IX0) M!7$:9*W(])H2W%B($392U 5;?5OL?5,IZ]GFH,4$R*I,BX8M4NXE+<[\5)DW;7I]UK;;2[R18U&G/57>,'J%R5[%44I$(]$F>V !,Q# M(NWS1:4'H+[1A\"UG<3:KI/5CLRR<1M'E*OZ>A$Y;UO2KC.7J*Y[Q4=)#*:5O,FL>!!<^J@WX^(83M"/$XIMG4Z# MP!,,O*X=?3!<"TU[8J=>R=G#[34!O*X=P@QCI?JV" 4E:XE&#Y+%/IQ41)%W M[&<$^94J*V'5?,V)H!;++26SF7&,MSQJAU.LT>-39LHN MRB&Q1>=VHISJ"1DR%Z:\,)S^18F3O4A>F+V0KL/=O)8^ %626?L3])3]CT^P ME73SM6-V@E.]A.Y+<+##"H)E[ E7M4\G\$_O F+F/L\YEH,C3*+GDEZSZY77 M99$%L9^)R8KKPT">XV#%(7O,I& >[P1#^=BBHCOL!KY>6Z!0+1ZC0@*;E=+4 9T:[??CU] [C 0P=F$I%DB4 MM8C- 8ZD/8C>6>L"-%7'I#NZ?/ H5 :YNZN:IO"P+^[#C7SUF^U[L E-_W/5 M:NU[["P6/;#C# E7SQUZ&PH]7$8=5*MJYT*S<)_UW/FLI]+YSFG72(O0R"B- M!ST,5QG'4F7-R!TV-_@0& ON]H<"6\-P"S1O6]L;?Z:'*QQX-XBCJ J5JBNB M,C*.$K?0+3=A-X8,LWUW>PJF>0"(@6-[W@>4]':=V*,.M.6G"-2G@; I&)H0 MJB&N3*"%@!XN/ CIF@.S"R7?\ E$ *[LOXCQ&QO"(!&XO3=H(.@9N, @N2^, MET8C;U^^.M_IIE!<2M8MAO&P;',DB38%6<4PR<72'377UI@U3"0)N((X*'8H M.GH^Q7=2]*4AQ4 L48T8/=L#!OUT?0?DKCCC"N>I2WHH@Z:B:&%XJ+,6)_9D MG5-0:<#A[JD->&H\EJTWL*H26,@3Z9C&FTMRZ"EL!;G+T3JX^L+>CHJV*+* MV4E'7K[AP+TK6?5VR][[K/JGRZI'O%^27)^LVP94G;)'^GU@V:6DL$@_-BS'JM"2*'@=!S Z<9-UE!4U!+.;VRB5 M\= EL:MN;S5\T[\"]HWW655K6*Z)R83L\J7TTI]T7 M&5$&D/"!F_DBPF^.GOT-E ,U4N1K?5N^P?7S%L$!5\&3MJD&3QR(*F@D>)46&:EJ5_#-1->W:!51#%W[>K)@ M %]*B"58*A39-B5IHC#]R40C[5KL:/6% BJ M/B%&?Y.RB+2HU-(LDS;B^'RPB%0\=]M$2E<10^M(:0OY@.>5\!%0_ M>Z%ZTE7\W##:CB(97V4X:<>/<]>KX;H K+7!2@P(0J?.2]PVM%"41'(+.2F* M]P!UC.;V[5=TB%VD5Z;[G80>P2!#/!MH%A(C%P[VJ;B5$>+K9BG\Y4 M>U=])AK44OW.=S/15EF":E$_$<%$3A.0V_E2U0K^W%.9(H!T4-=7% $P<$0 MP/:A?B1&=;(L#<:A\EI0"&)@S%:8PI\5965\KMM/PECT28=#X/$\V1*;<,+J=\N6B&-7:4S^ M%5%6(!@2SJ) NX_@$6SK4L9M"WU6$QOMHJA\C+/7$YK+,4H28$2;,,^TAE(5QX96S]-GR=X='268< M#Z MM\"G%/][T1]5K%,R'%B'UT8MR_AC[H9@C)W$ 0Y TW;0"WEA#3'&+;%>@W,+ MM-/!:*S0H<_2;((69FFE.%=_2:I9\@=?\3.J-PH=_?(_[UX*2!;_?;:P-YXF M>?333\\QG2@W*J,_5@7?,LF5[J O"+57K>W%BTB82!,B1;8;QAF<-QM)=)#T MVW!W!4+P^ N $'S.>-#Q=R],Q@S!+Z^,KUJ/'<<')M664G^CTJ3;'5E]@"97 MH%),IQ@FG+HT9&-H3!O0!6ZZ1S5]8E13@[PZ*$+: O%T._BFNWL@J=B,*U;S M-$+N[4-13]J"3A4Q(@0PR6!U43M(*]]NODL(S+H3"5B]M]A/8&\_M+OF;[[A M0;-_PC==_1-\HP3,,\Z&&BK070_"#@U_?7ATZMHZT!7NGH?D:GA49:T*C3M> MXBCZIZ0X:5.LRBTF%:<2?(%R7.N(K5]]QX5X0&9;13B"\HZ;0%9U9&QY.(#' M8?\XD3)(+Q'2+J)&E>2J#CM*@WCHM$(C[TV('3@NJ7P_>X;DO6WN! M$]0J^T(AE.Q-)_:CZ<4.&OYN=9N-=0OQG]2=74$KNHCL:/5>6-FQ;E6KZ(RQ M9M=R5:]$]4A4L.G*D=I[0LWC6[C#$5M].ZBL[E%/GPSU5%]^*M23@D3>PYSN M84[W,*Z@5(^(*D\,-C86Q$C3RMQH1/;)U49G MC5JZM%QDP"2Y5%K,B(Z)'?^7 M#?*SX_B3:ZV?U7 DOU$A!2SXZT.N'\6" [>.W$JWEQQ&,<- 3PT+/'--&S X/3EWUV4O)NIY-K2:S'TY,;@"^" >OP #Z6^?4 MEW8<%Y<*!A(SH5*39JG-RM4X0'V1F]RJDGM5^F;5QKM5<>A;>/@7(7SH4+8* M@,F=@'3_@RFG *'T$8['QR[^36[+58%*?UE1!?$3$/4 M?XBHSGAE LB/H#&='<5#]37'LO ,7&TOF@RQV:H([G;G,]]/OH#,=UL]?:;) M9MFZE/ZP:%OCP8;NFZ>>\=^"7D8;&W0";QX*>F.Q:_!);B_I3:2HTEW70O)P M/VV.>9BJRZQ;2DE@Q!HJ9>C.2+L&K"4FJRPS5F$5*;1^ S[N.,JY%\NUP=BL M.TO08D72N?**$LU$7=<\3Y9):3RQI6)"''&G2ZS?X )E1_[;QHCO%VAH)T%O M9SZ)I1C3WBH(8 <<#HVO_8++O7(D0%#B(/@>C*[WY$&X?$ N]44;NL)CI7LA MA"F!D0$\>]1D[!&6X0(04CVUUUYQ+PEPW,H51QE\S0J]A6*?;J&$*$K7F>$= M)$H?G[!ESN8. $/'A;Y#S^#45$7/[' 4 ''AB'/4EAB6+,U7)04DW:O@;]A9 MD^92S)= N-TVA^KH@>*]B08&W]"9;^HX96KASO5ITR$=1>\WCNM%]I!G=%8@B&B/CG348<(E2N>4MT0!;'D MM8>@EZ<%)]@J=<\'[@C8 ^SL5O>WMA[K?=+$U->@@K!8M(G!&#D&E/72$-)8 MH]$[@BKCLD;8$!F"B!G.)MT;91EK/JQ'():5ZM?@A'H71?5L7)TCT5:[^EW4 MJE(VR&3T=BBYT/58-;(J'9J/:W?!9%5U*ROHB@X1'X+G\0B6[L&5+Z ?> 4 M,_>XPL..Z$ X B 4_M3J=TT+2,<)-&*#[Q ," DK_Q>Y'CB*A-:Z>;_VJ';2 MH-N,:-E!\?UU--*N%9.'/UHQ>8S'CV Z"YQ>J2C>%'T7B]!!=HNR W:%5;,2 MW0G!XV/2NIJ)N8%IZC#(%;-RBXGY/K%ZQVM5AZBRB:@=,;I501T#N$Q\I" ) M[8N"'07-^S9J$]_*KS-!Q(SYG:B.H"F0AP\/#3=L/H@_IR_48^T_JQ3X=97D M _B1R K[][ O6!#X[CV,WT 40_T1(L)6/Q42(J6#&C# ZYT!EZ"$,P]@-T> MD<;$A(-/'7YJ /&(!%VOF[H9-AM C5O2O5]08\@QKQ:'B <_D#KX8)^]06>P M/4O[&91]>/3L\=.30.N\0_%_GBQWF9L;/%?W(H@L6$U^9\_1L=0FL]]7Q%Q> MN8)Y)A5=9@"'/=#5T>#;NC+TL 8\T/,BG8=(S E_N;2=O6Z2DLV/-R^)#%\!R-P1T_3^0US;<'CDXH3RA4J?-I#^**@+=R4B-WGF'*32#W8[1Y$ MH'2<;*W'2K Y+/;!75D6L]6TCHH@ %F'"Y3SU$;I8F%FJ=W V3K4*VIT<03L M.*G])ZE[W,B)HQ!V'&YP0A8X<'\Q\[.(&?=6#3"-DQ2@?)P#,=78+HJD?F&D1EW'7#(NY2 M=Q"FE=0>)\^]F!\&^O4LPT;4B''_9U$N^LRY1/EOX\.>%$'#:*0&((R.QL-E M[].<"9U<[[?A02NXFI =(X,V>HF0D9\1X;').^-]E\E,_Q8M]FZ#NK6 @:D[ MRE[NWU&TLS$ "2P"=QXD\/0+ E\IJF5I'"[UUC/1NZ3-N?'RN$P3D;9]AWU M!,6PKYAPT"ZY8?#(GE4Z!\^F@G-*A_W0'3V,&IFO 96C>!&@->DJAYP_8*@R MJ92:@X(D;*E:4P%1LX;J%TC0:>!R<(=H$['XC!NN&T16*CX-+ M7%K=X,O%>J(B$IX)FF%?7Q98!)Q.TR6%6$*L6*):K2C#'H[?+%VD-5O8#D<- M?GCGXH:6<^GN%FLO6B+W_M:Q]R'LY$D^NK'[ &+"K6MY"L+9TPWN;TL0=G'S M_:9X'3&!T>X%TEHJAZ=JVSA]P@WKB$,@\RWW3K S.C4&)LS#B,)-_5&5 MQ1CQ&U%>?*ZO^Z+*BY$+<53)UH@-OX]%6R$#S?VTN&G)DDX6EDY#:Y WVU4? M$/QJ3$KNOEYVS^IE3;0PULQF=G'B<\0BP22;K@2KVVEZ[>?F:GO;B+UP!@EN M-_&!$H^X QJP>?IAD%!78O5P_LW--<)4DSQZ>(R3#Y_Z,J#33NM0:T0Z-?=Q M%6"6-K$0=3(.]=BTB+@MNSS#,0R*6_$%J>I@@4^,M*A[,<<2P1H;BQY?CQNC M$0(T#/:B-7D*2685YFQ-0>.^LN$FY>_'GAR[**9 7J&J]F$:ZO72#,3O>^-$ M.C:O0U6C0!'[-[.HW!+F0&=6)N>V$)>FS5\=5'E MEG8?=0J'0R4H0!VWC7)<6X$FRN#H'V# OID;!F-8%]K)'?+^ST_*N MENU__\OIL^^D3"V.7N73HSCZ7H[]W[!0\!/@@*%>:P[,0 M&HH;1ST&_'5,,B15D5N]M79F'BN?LDAFV1JIX0W5E,CY8:Y WZ@KF;8S"%L0?86U^>L@ED&,:]=F IU@8X&&4]^ P!Z _@9< MQZBK'C!P@#25H67FK"@,HP2^D[(DU$A\= O+'CMZ9_CH4V_H%66E^-Y?,^NX7T'U?L$]>N<%4U%U%K=TPJ/QZLT$4P@6\)?-1F7G0^!A M'/4S4S5IKQ+JFV'@2==E6MN=K0\L%K=!-BNW6S<06_G;QD)FU#P:J;RK_7P\ M%G"?#D?;[DH._MD7D(/?#9/D"^'MV;(M>4-A[.1)T .(Y^ /Q4,$OMD^)D3+ M ^@P[C$P1C2,&;'GP@\.B8(,W'-2.[]+!E94-RWA8SZ*BT!.JM9@OS>ZK MJFFR)N(>">Y07)3)PCH]*Y?T???VC8-6CX ##N9_R)+A&_>*4..U$ZN.DPMW M4R%#H;<-MGH;'$RB='*,^]S*&B$6[8.QW@)BM>$KV9U/.):> I&Q[[F#0OGC MB) I)*# ![D@ M7>9RH\2FSQ4)?,VAL#4);>=8QEK@NV\^R4OG(PRI_8MNVB-M6^_3$Z[T!>0) MF,?3VO*$>>Y=$-4OP)8CV6S =TX@M_5M?%B%XF>E@4;K&@_:B,F3NMO% M<^R7#HX2U5HJW$U,!4B>?9!KI %?>SOV%[VO6\@'+J7H*"-" MV3J! BF8A"VRZ&.)H#QOX^WW[X'V1#!HQOR[L8UFH,'R*-^Y_J-F/.D.08_- MTS-BDP[<O3N*)H;F&A" M2A..5U-R2HOP2@#$]+AR9?52)R\^%G5J1/*(G85[N#MD<10UCW.?<'$]JS=5 M,R#'WPA^GZZMZOA4-K]&&'AI%WUSI.1#[4#HJ >6=4-C-*,VI/^FR8JS>T+, MPE%8X6V?-X9[+ .&:UYJMFET; M"A3M;!?4$V]6/;%CM,".[LB,QD&QA3'X8ZX2X3(C M*X[ N6[7@\'"DO $K""8SO;U.D&K]G+ #=?1B6\XM&T9]2;A[EZ41HMU&B;" MDADKXZN@'G$5%#S)MX;^AIM ,TH4IB&W>LU>E:_41(%QKMDM(/[G5A]7DL.! M8,)R0]&:#R'?'F;XIG:]K@,6157MAE!?6M:X3XE.C8E^IELC@%[;V@W MQ8."2LT]5O;5$G28L,$:R2G2\X!R4$4<]M%C!&QBM?2B0\8ZQMFG?DBWP,[ M04,\1^S&RO3JBMAE(+9XX9D)7C@>J7"&5<<]8!V21T M4QTQX6J&F;YJ6P7N":OZSPY9D"KH9^/I?^=HY-)EV,%RJR*PKO?$.IO.XP3P M:XV"##X)X<]ED66M'33.. ZFWP5]@Q16HW$)Y\RV7*?@E!VKY(.%ZEPDV@H7 M($A7:,+,R6:C P5[, :)\Q3[*+W?CZX(R9& M$]1U,-+!CJTH3-.Q;YNJ6AW$KN%UWSE&LF;]TY0V28]7X-;->09X*L&O@(ZH M "K44C7O2RNN]^+7@LME#U28=?"/E!$Y@6XV M(C=.L%U\)=,DGZ[[ M_63)< .Q6D6)1[*'K" "6F@>[+Q=U*BME1\S]R[,Y/KLL<$RDW5 MRBD!!J^Q4HH;T2="(F)?QU;$2D!&UF]?,H*>Y((#EIUGB:.:[ AH-?:%#VK] M^;&L/T&O='7@ZU$RMQM8PUV%W@82&\DRCCY5A^)MC5XD<;\@\+$CAR%W'V;M MV!P&?F'GSRR3$@%(#5'L&2?YN!4(LWW\+FJ0=]24U/6@&R'Q9:-[*3M?I5:J M^MB6@+'5+P\0-E=]Q%XC.PZ7$KGDH1)-FGQL8;9LE?FXA6W:WIT%]Z#DU.C! MQG/^D(F^/?F!RUU%!\DAM8NT7LQL@4RN=QZG<')\#U3X5'.; 'T4I]A*Z[PF MF8=7L9,JE-<:P1A :L(M@NS>D#RO5LMEAMXR'-^5J>6HYFRC"ZH/AN%<(RUK M\"],>0$/U#04D# M,IQ M!G4O -?+/T/>*!B#<6K%&TK89E%2Z=1S\2K-S 4Y$J)H(%^W\?71]SN84!DS M!$'I+3U/3^FCP<)^X^*J*F,=0@TZU%^8&ZY,KAO2]*X-PZ! T]1K'>$8C:!2 MX+:..E9K/4[JC[UO6"\I5$=>AMI-F/Z$K'4;*UR'I3_J .DU# ?BE>'IH,R\ ML8=3D3?/B8]7%=IZ9-@F[9UJ_)G)V8.>.>&3?A?MJ_-+HUFD&%>L%YDI%^TD M?PY5M']%PR"J3GL2IF<;31H6[Y%;UXH^YG$ M3UI["R%@J=I]RV=/F>0,*\ M3_/G+R\IN1D$C'"8WV+O"KCJJ_\08.KG&QWHOI,GQT2!C#82G\.SPA#VW2G! M;34@@H'UKPYZNBNBS4UXR$ZO?IHL 55-MSV,<@,175A\Z/ )R8UZV"IM]O!- M*8./^=$IQ/%PMS@))S>$T+W[1P;1:\.1VKE[#A]5H ?M2_],M\\7:JIVCRT$ M[[7!X V\1[4JKUC"P09?;R[:!Z^I\K6$(W#N %83^*H7:G9S.-]!-77H#^$X M8!57U2$#4:I@KS5DOV9H^RHG :"[VRD2,U/4-Q5'^?PU16R=M4/3T3L@PKP' MZP ' 497^ 0@^H^BO-^"]UNPN073\<@:*;F#ZV^A*WS]34/8U/P YW"J[L,U:W9GRLU^*Z&\KY]U4NANK[G.NF##L0<@=[T*8G]G"U=?<'5X+B!8 MCPM@,[ZQ[PG;@'624$+F09]\*I##?'(*,G/R^&!V*"?Y2X%UGDUK!_>X29Y< M.%" V1C-*O!Y(?\%D%1G)J$O7%4HU@MCKV(1;0V%?>Y1X77T!M(2VZ-4NC^* M05XPDY125:X.,S E6\Q5G&##>VGC\Y M?O"?$[ELZX)G#_Z3,W9&-ZI'WTGGP^=I9G2,R^67X.9N M[H#L%2;8WEWSE[U[Z?C+@D*AL9*1(L'4M2E5BV-FRSI0W,J86/MPF4[2NM)I MR/8;40)+-7S5B'XTI80#M@(IOF\\R7&3X$CMFX,W.<_ M&IBLF#R;=2A':G#>87(OO)E$Y^Y3-)R';VN/NE& VK M;?GYERF ;FR^.X$.(5OBYV>5'].8U3D_BZ.'QPX=Q M=!H_>78AXIFIK(*%1U1N[?Z!*7%;BG49G=[-W3/X5O* M-^Z@0E4>9GN)((U:_?DYS@>KY?[!,3SHK'4\(.I'9PX[$MU!>)MLW!8E4.3S MG@I4!HNH$N%#Z>S]2Q!ND?-W95&?:@WZQ]*]$'O7!L9F@_&3E(-9BL2NT, M)F6V?A!6-' XV.XG[J??DOT2IV0H;97CC6J.FC;1 %+B <*=ZCIJH9)2I)FLD@,#[ M\9S'T72U6)&C3BW^/ J H;VN!2 GCJ*_GAP]?7;R\+&"(&#%VMHDI1#1 =3& MBO-5DAG/154R=N#ID?VU*T8="W-8(C]UOEH<12\"]A#[7OB>GC)$\8E(:[+' M=J<"@;U]Z+^2W%ZYCJ,SJRNS./K7BL'HK^T4,VC0O5#$E!R(" BX\&-?\(G0 M(>QH%EQACX,F>8\T6U/1[2;3"?H/]MWYM",F8*V/3H 3Z":O0C0^L]X;4X[6< [A)7 _4.6 A\W9T,]*W#V5XHG*M),=&H:U?>TO7$L M ,T!L=7%1!C/04A/][N*GF@\%A=V%U$^9VJN]9D>K($HCY!3JRT?LGA \)XF MK?G!NE5H_+#BYIMPLTE2I\_?%#=K%4"%,U"Q_ M0/A<4K7W4OO,2ORM'=V4=1?=\^N MQ[*)2B6BH&OE=BR3M6(%9B\,T&]6T'$9>&[B<-]LVB])@[5C_X)^/GH!7;PUO9: 9(R M@H0A$JAQLY29F2>07D9L$E. R!#W$NX/;Y@EUZZ;446PY\(A>6XTU?WGZ7W: M^(Z:$QL*_'V(8*,5@%4&'5T$&@2@?2Y?AY>W@];9V5"MQ:8IY&CIA,QW:O6T MBY/PVPULSL#DK$*,8<,QQA9,(2R',PY!^F!>&+=<_9IXBJ1UR\8A8A#VPRQ>34X.JY MIU>?/*@?'3" 'C(1DZ#+8I.UA1N-=P[;!9SZDW=W5Q1C2K:(#XXK1$=M2/#@ M.7Z;70>60;M"S:.B33L.A/I6A/0"(WHG,@J7!YD$R+W&<-L+H <;_M2S&T-7 M(KL#9RXP5"4+5W0:!&$V5F%UYR552K0IXMMLJL\B'>-VTJ&C7(1BA:PJ*-O* M'(44S?3=B 8. 8Q'JC3%^+-SD$9_%P_1S4W7[5RSQ> F>N19>_-I%G#-)Y'D M:GPZ5F6K7*4 RIP3,HE-VM$64T0Q6DT%>:FD4?:QADW?*20[VH$USW&]N6?9LAII=JS8<27(ZT;[5[?-5WHO1L! M6:V"!T3'KBJEJB:&8PSP6&@_4-%,6NLY2X'R=6!,NZ@07LUCEYJHDP\8U>8\ MK.H$[U"[JBF8<)5@CP:W+ (L.4#^X[FT)Y;JF&>/GTHF\'DQ,X=P?G)7/EUG M])SO_0/R-YRA%+O"HT(HJ442J,H<"QF:NUHBRH>D7-1J MQ:.=Z<8L2WM#]_*B<^LM]0;G!8S_16-:D%61:[[EO64Z.EZ9T3Z!SN$LSEA5 M(S].E16B6R&*IFB,MV^"MGBRS*66*O1"*[E+\YF=O\ !-'7[AH50YM0N[DF5 MAAYC#')25B>!DR!S*=$320*"JVN=OS@L >XF(8K#G?419WR[(<,N@HU^4BB3 M-PYELH-"]NN2:2X_M@>EQ.SG\R25CEZCC* &K&DB6IG 2(H=I1N1%,0S.,X? M4H_W=WAU2"2"#CF,T #="3#9#)DC!Z-ZIAZ.H4;Q"5,L9E4I; JG,R\.MH\' M;G4S846\@YS[Z%3KK;XM*KBIE/5LL\O(7/>DCG3XJ50&&C+0HYH/ M'>/.*KFAMQ%/_38"=NV7@99D\2TZP2C@3J)9U*F95;6"?C8I(]_ 7.P&@>F MPX_'7VP4:YZIC<:"H@U$P!)1]L_0OM@#8/4]]#[Z [A4HKSL-U^)@!\;CA1 MCJ(SQZPQ1H,R!1GWQMGZ^ J5CIZJF/60ZP6>%])_$C5UNA!SC:T"8H'$Q/62NK1V1%%S[\P_/?XJ=9:$X7J#EI;%#F#G:0[DMPH_)4:#1@V3I!L N M,.1G)-9M+"FQ1&X 8G!U8B/80GU\BSWQ%:Z^2F8SVLIJU+Y5(08[E(6^BW+X M>E4VN2]5?A/"14B6Z;H7-BG'FKRH'/"I$BB1 SUE/H9,4X1P 7.IBGB 1QA-'E\?QU6E:3E<+$,^IT0$O_#H%N#JW<)9X+(LC,XB3 M,2!$>]$[;K#6,>6Q!-K!E5;YZ*G= $F:]R?0C^QK^S@[7_TFN!KULSTD,G"# M?C"Y*1,@]RN7S.L>_91<<_%'"3L(\_+P]_?8=3=Z8,>IDO+V!^>N7@!*BUQ^ M'A0K5;33N^ L[*)>;*95 Y9%#M=HX$)XQI;&8PB&2U]C*?UE( R?MJP#Q^+I MO4YD8Q!N@=9=0[JIWU] ]YG>-'ZVJ6/]R/A9W(**E U9&P/_@ 0V,4,SHY]J M'9W.^VI-O%$CQI@#-ODI MWA:/LA1$%D77ZYB/3Z[N*99.-5Y;TXL[?&'!5!R4@T"-#O:IQ=J0@F7Z+LHJ M=JV'0L_^H*\:,?IA!T&;T?"[5/@-%7A1%SU1JE.%.\,X7F>U4J-7*+A3JCR> MI\8CN7HCX"K3".\G9YYI+XU?P29OL5=VN%T4AKS. ML=3"6^+V65=I6:^(M(*MFZ3V'O*R9>D #@'S1W S7PSXS=&SOX$(7R79RIW+ MR<5%:2Y4N*1[_?Q!<\#5[+0GJD&]B//9>"QJP%9O++JKN3+8D@+'[$[!*W,X M/+@>>AT_9OOQ55IDI%!\&WE4>+=YV%),7EO0LF" NDFH:YM4&K+!0])"P8C! MIF$=\.%YI+I_!S I_LAY=O:M;E>LP&4%-E=MM3A+_M:%;F_$J$]R=O$$D/(% M)+*F.GTXMU6,:=CP3U1@6.E+>US[@^648[Q0Q>R%ZDE7$7/#M#B*9'R5X1P@ M/\Y=KX;K@EI,D(V'='6)VX86BI)2;B&1*1O8+.;V[5=TB%VD5Z;[G83FP&#; M+&D0R%>B* .6"R:2.OI(C;)O &G%/IUA@*EUP+#H]JH)3W\/D4,2]TN3H0Y0 MAQ,&J*T-RL.ZIJ@1,W*P60AOF!]%+R$[*M?A%-=4U:Z:7NYG=7-#R/:/0;#+ MOMW/MZ3P]58';L,:/4ARBNF'AK R7SNV69_!VQI(XV'D'[JC_7!'JM0?W>=X MPQSOKJ?F=W6[+[.$#EO\1P4!0VGZMXV76F&S"B(D#*A 7(]N!Y@!JYJ:P(+9 M+X&3TF#@+*\%#".FZPR(JNRMB[+B>XNQ<=A [\R*Z8I:F%R[EEE=R2"OQ_>3 M8!6]G?%X7;14IM0.5;J]>=*JT'C<37-<@-.Z]X=00R#M%=ML;(!BLSJ2(71% M^[-'8,&RC0C0 W06]R7L^RM%)P=QX",9TSQW*F5Z:RM3A=W$IE@!?R\L3U#< MUUGQE]BE6D0*,-DD?JJYPV=/S=I0@5^,7=,VOT@SGLT1W)O@+Z&G3&IGM7;3 M('<]BE[E+C+K*B._D'4(^*94O6V["KR[>GW8Y6M4; ?EV1I7O(,EV#>KJ[Y) ME,]75.-S^NNI!V?J%DJK&\B=+ZZ\^O H>E=$68& -]!@@4X8P4_8WH$,2Q=. MU%BZQSGXHL[.8>%H,SU'4N76<_#L7)K\@3T WUM%@:*6L""BR3>:V],(/3@1 M>RRSU/<^5PQ^"%A@V'OE[$.V%YW**>GP1Y!1OV1_2JG^DB4Z8CT<1O%&S?9X MG7=#*,%.0K@&<$4[:)*VNUS"*0-*YV DSN70IX(V8<*RM%($K;\DU2SY@Z_X M&746Q:=^^9]W+P7=B/\^6]@;3Y,\^NFGYYBSE!N5T1^K@F^9Y$HAT!<$N*K6 M]N)%)+2EB>HUSZ)[LY%$!XE P5Z8C"EE7UX97VWM^TEC]F8IA2,J'[>=+NK# M=SAT.;:QED(]_*0Q-"Y8[\)ZW(,\/C'(H\%V'%00; $ V7NXAW?57)659UEQ M;Q^*>M(6]%KQ'!#[/9R[U$W-RK>;[Q+B-$XK 0WT%OL)#*F'=M?\S3/D-PGW MO^DBW/?,^MQ9?("!G^YZ$%+Z__7AT4/7!X"N M(J2_0(TJR94,=>#Z>=RS&,3=ZBT0B/O38@=."ZJ[#MY!-9I_@1/4JME (91@ M;B?(H.G'#!I_;G6;?2D+L:#5G5TU&CH);&KW7EC9L6Y5:.2,,55Y0X_TY094 M3D#55JZ:H+TGU#QBT]\CMOKNLY!C*TWOBJZ^1Q=],G11??FIT$4*>OBGPHGN M#-SA\=Z5XN]F8O@>J;5';_G12*W]G)8O$-$2ROP^+NN(H.W$8+M6R.?L_WN# GRH48QPJ33$B]A2Z,D9E_H#507@OC2.O&$RB!H3OHR@'9IS 0/!%FJ^* M5=6Q;)#3'$?=6VL%I88CZ8,*>5TA%#+D55.8/?"8R6-W>\FAP3*,@;5"$U8\ M33(C*C?L:.Q_TWC6/>*NC9?>F>,@:.X'QVP &K:2+K<^GFW5<@J:6KF0 F([@W9T?Q4'W=L"P\0P3;BR9#;'9Z47>[E.Z<:$VA*D.+U;-0^&]A M)Z)5!5+ TT419"Q1##[)[26]60E5<.FZS!WNYRDS#_->65%Q1A4164K\G5:T M:\!R,5EEF;$B6J30*PE(F>,HY[X/UP8C?4Y[H(V"]$OE%65MB<2IJ4&626D\ MQ9OB!!MQITO$1G-9J6. ;>,O]PN%L9,8HC.?$5+L06\5HJH#783'[7ZACUXY M@A& #PM8!F.U/5%UAN;*I1X0K='3*TV('P:81\8LIE8OLP]0A@M ,-W47GO% M#07 5"]7[%=Z/#B]A:(@;D%N*##1F2X=9,L>G_UDYMX.-$#'A;X=R.#45$7/ M[+#?A^A9A(WILQ?+ >:KDF(P[E7P-VR>2R,;KG(G&&2;37#T0/'>1-Z!;^@. M;'6\WCNM M%[I/5NY:LK(A@4.496+2M-K(]\ =Q'35)K&6SA8T82L8 -L;(R 4H-A:C;;: M:KSW21-37X,&QCJT)IYCY!APJY>&D*L:V]P111B7)\ &JA URW VZ=ZXE;$P MP,JW&):J9X';TSL9I1A70D7\M:XT$ \5J4AB1G8[E%PX9JP6794.&KSVJ_H6^,YGG)U] YOG.N J;@4<[J!E^'0V( M;,7WX8]6?!]C^R.8SX)PBM2!;HKDBZ_AD-5%V8&.PUI'B12%&/\Q.5+-=]N MGG6X>HJ_=BN^6^):1J1N51#I-]>.CARGL(PH]$W0>FZCL/I&=)VY#":][LS M!RUM/(AX:+C!V.CG](5ZK/UG99>2V'E5Y09QSU7>+X-[@;S@N/8ST@WA&G2A MBPFX*E0GB#8(;+8#KD^%8N40TCV X!Z1<N%H>("C^0ZN5@G[U!+[8]2_L933X]>O3HV6F@==ZA^#]/EJ)9 M=M&0!Y_3O0@FP5>3W]GGSW5543M$;JH9G#%^D\1!Y(^,MEF.QUDY2L=;PY60%3S'"Y3!N)X3L8@3MZFFYKF!8*'I]4 MG/NL4.'3'L(7!6WAID3,"D?,FD3JP6[W(%BBXV1K/5:BY&')#^[*LIBMIG54 M!)'3.ER@G*-&3AQCK:,,@Q.RP(&[ MHW'T^^@D'"E KEWC<;9'Y7QUN_@%1O!NX]ECYF,7-^BK'A 5@0!&F= !MJNS MX0=-_XYPD[6#,!^F]CCYW,7\,-"O9YF5IISX M6_Y9E(L^"W%OC",JG/EH],(<-G[-&>6%]>^:7C0"EDEW+I(V(Q. M""2/9\2O:_+.2-UE,M._18N]VZ!N+6!@ZHZRE_MW%.UL#!VJ]D(=+6-Z%K/O MB#;=T#^U^DHGD/FX<([)L"^RHPJID;89$#M5 M(0_=%5H3#)5.=/C&8N+'K3SO;XLL!PTG:9+A HXPY4 M<)8NTIJM+ ?[!%^L!**R:[8X%8MV$XCAR25'%( M"%]F.ZHJ/0_!A%MQZ=."H/N;K!:$ON:)T,XM7#*B%GJPGC2$G=XR6[V=T:DQ M,&$> A3JM(^J,<6@UXA"TW-]W1?%6X]L;Z,*;$9L^'TLL0FI6.ZGQ4U+EG32 MD73:F8-\L@XK3M"I,5FIG6"X?_H%)-YW0U07QGHPS.A+M'E8+I9DTY5@>#NM MVOWX^3#I[X@ MY+33\M3:ED[D?5P%F*5-5#^=M#X]]C+WB^YPNL?0%&[=_9M]?$$GC+36>['( M$AP<&^H=7YD9HX'#[=77Y(4DF?7^9FN*R?85D#:953_V5-I%,84Z?E6_#=-0 MKY=F(#S>&X+3H6\=!1R%.=B_F47EEC"#-'/_.)>("-OL@9_7"@/K)A:_V,^, MO/,(K5&MR^NVM"E75__^7TV7=2OA9'K_+I41Q]+\?^;UC ^.8M#+:Z3HE;^/NL*"!% M=>&O@Z^C@Z*,6=LBZ_=%DJ?_R^%H:4("">\/4(P&P0Y>8;P+ 3VX<91CX%8 .9ODJK(K=Y:.S./E4]9)+-LC0SU1<,?5><&L/)U5'YW@5KQZ,]<.YN+]9;-1 MR>\0UQ='_20]30:@A+H.&'C2=9G6=F?K XO%;9#8Q^W6#1P__K:QT-HTCT8J M^VH_'X\%W*?[&B2BHL0CS35O MUL&:1G2^]6@Z1Z*P8S<>>RR4I)#0JVZ"O&A'H*%(4>4=V3?%UU7V5) M@^3NW=LW8U!N@SD=H,M D9<;0B$21XNX/CT _B<"[8>ID+N^M'IC@5>^,>4# M@OO^QHPG]B!,+MQ-A42%)CI0LFUL+FWBDV/4L':7 M$V#0/AC+'2"6&[Z2U;D$(>JISQC[GCMX:/\X(J0*R2^P;&=EBB(J&]V$\ 6?XDSR?W=Y:%66;-70BY*ESG=J'#I$J+YV/,&'W+_II->NVWJDG:ND+V!,FDJ>UY2GSW+L@JU^ +4>RV:VZ M,_GG9_?YYSL@[-MZK#ZD0[&[TD!C90WS;>0#2)7NXAGY2P=QB.H=E6X@#K$& M#:*G[>Q<9,7$'B 0CXV[YP>V[-__\NCI=PPRZSJ 6HS%>"!A;&O=ZJ:I\A3V M)B_.MZ(VNRLK\&X4Q#*@#QYABWAE325#GN"0:UE!=?L[MM?J,JDXU:SOX75V M3^D2FK=^A?JK2_*!2RG0RL!5-F2@E DF88N$_%BN*4\->?O]=J"=$ R:*S/< MV$:SO& ADV\\_5$SGG1'L\>F_!EY4!5J")(<;;1^X5L.\2.U):#)Z$PYH6Y^ M+W["+FYXR12RV3]<-P/L<$DM02Q,TUVFY:PO[]1E[._@%+WJSCP$'EEGH+6= M-1+<>'"$V+]_/7IW%,T-3#0!N@ENK%D_I5=S)3AG>ERYLGJIDVP=RR\U<'K$ MSL(]W!U8.8J:I[//W;@NPYMJ3I!&< 312]=6=_DG##',\+;/N2(3VGNXX5"J$V!NDAJM/8C:+)+W M)DH9S#A+@"_04^7\1(C)(ETMVI27A1PK-7"92&$^\35>Q2]%K;&&@Z#5!=Q#(:LD7@\PV2O^//C;X!6C,X22EYKPS( M%E*R;O:M0/W>)T!W+@'ZFQ5#Z*J]11>>/T2HCCZM@]C6T36(8,2L%Q9_N/!SP M"$+2)\^_1D3CB?\GUL*#TKFR FT-Z)*;JO@_U8Z+$?@)DL_UK-3/QXG241C?LT&TBU%N>=<5^&)Z)7S#9"!OZ/4I($ZHH MHI]&'&10YEI-5/K59DS:S'%^6,V;6>\?:KFA;4N\6?'&CAL$NZ0CSQ@'KA;& MX(^Y*(2KBJPT O6Z73?&!DO^$J"!8-Z"&:G9,CPD,_ ?XAR5S MD[W2);DN5>+W!*[?.9K@=!EV5MRJ)*WK/;'JI_.H K1Z!]/O;)H@"];H+\)IMRW7*3C!QQX@P4)U+A+IP0L0I"NTB.9D!;<]K]"S MK4DQVZ/=IA@,>&A**\7 MI.J<6_&4OA[@QMQ\O2["B]'?(3^09#Z M6*&E!@1!>'M[!E5SP!5RJ0[23I>J&9J["3CE2X!K2;P3((X;4.),6 ?9K+:U MXE,E"GM>J@PUN&56EFLR8%0D"BNN,-6QBV'F\\$=,3&:B;"#>I \'G1Q.O9M M4U4K*\PU8NXS8DC6K)N=TB;I<3+UJJ%H-IQ=5G_%IP MN>R!"A,7_I$R(B?0#?M+:_:.O7X&Q9(BL/V$CK?MX8URG)G5U&XQ.]19S$)= M.D)&W)XQM0?%E9=DSF=S=2'7W8J'WF$W8^,B6 &AF 6Z$ET%Z=N-M,N;:-LE M UMR-%7'R%.[T=ESCD>L?=^K9)KDTW7@FDON')CE*DIIDIEDY1-P2/-@0^ZB MHFTM]HCICF\:A$-D:;'4/QS49GEKA?NOA<%FN!FTCST= -)K3LG99RO+@M:;74 \0B5I]K9Y)9C N/ M//Q0P2@-4K:P DFHS_39M-+>L@=##SU MB,LD1P?)(74QM5[[;($I)Y4!K[Y4+GKG&? 1 I%&-DK@

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�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�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�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

96!3J3Z+1S@QH(_A\19564X[$N-P^YXUZGB& MZNM;+[%E7-A6YZV"E[I^T=/EG6ZRY!;,2Y4@/A!)"9"32<$N#OA5 MTTW>$:BL!:HNL$O)&3>?I%Z-F]V13;^.B^3.\A$?&6W&34NQIBF M8\$EBH$OD'Y!W&X%\*@>9-)(!\#\JX$C6!C^8KU>Q1JB5N<)$QU]/M ME:(>@QB:*E 7!'Y\36\!^NTNSVHE9]..@IS8&;O&7-=)XGPSQG M1FOGBCDQS(UOX7A&Z!T=EXS]3"N:L''HO= 3B'.)(1V822TDL>O8?DS%> MO=4=I3Q7S7.+B'?(3B0A98E10IX'A+L@8W>W =<1_QPP"'K1[# YZ)!0C*T! M,6'/;O%<$["XRYSTD:ZS[I$Q@2RA8JUCUENL$3[1R1E#R!,8;\H/O@O#V]Z? M_/,\D0U# N$Q3?Z\621/HK?PA7(J/!'@&0TR#2P!<'7 D))8(.SJ>V2?!6#0 M"4EIQ]_@J&LP\@<7G5+,&58=RG>3Z"D(6I+C";=GBN::F-G;) M;3?U(B]R $/.)C[NZBEO]I5V%?7ZJ\L.["K%W&&!-7@VY5I']3@N-%4+M'9: MI_Z$"G4&^HXI1X2%%68##K,"+<=5Q'PFE*CB.@GO2@GO=Q[",R)=:[ZU$BL^ M_X51$$>^BSE>W#EK:5R3/VDEQAXC$GD[OE/ #Y/DCJ;J.&,T?\<4;?6U0[GW M-#](VH9H&K:6(0],K I/1.92,L]QDM2SSF3DP(3R?.;X?D!T*MTK13+#D# R/0V MEV66"-_'+E4!R=S^CB/?P2B!G-L/\.W&\3P?P[7"_LJN#4#2$6ACO*I2_; L5JO L[\G:&EP[''C:FD+ MZLL[R@\FDJ,=(^&.X=!C]HY3#NX,D[9.&4?]06OU(P+M2SVW-8$;CF&!,Q]DRJA:GG'*8-2@]Q5'-]BY.'E4)9>"9Y;&IFU<^#+\?^2CE" MO9@4,195LZB"H;YONH(#WRT%U3C%6^NW0W!8M9!7<2DH9G-3/ZEL8M0BI*GO MP:A-#)5S=)+/)WBDZ'G,.SAO/ #'W;&&G#@NH%D>E@-FC((-#+DRQ$H4R'+/ M%RT(,4@!R0\O[1!?'IA1M+6WEO][B/MORXFK#BC" 7M'* M0C!'F]YEC TGO-M *A?T,Y3/+ W,4Y1#=Q/=[>*,@+]P=M]TCIX)..@%^T9W ME@ 06DZ+(;-92?(*)@JH )E%# "5/-_*=,Q4%B++H3:J7$!,@P>9 +IR%3+L MHW+7"37(% KIAAD0W;(=IIQ/N>^';Y$K8BIU7O,9E.VC*QS?"/&M52C 3+V? M=K098 FS\[I%F011MM+_;9Z9)]]KU/ M & F2#%O8VM+N1Z5LSJ9'9[Y45[3\!CRPD)4K!'@!8[A(U* OWFI?2ME(W0L MF8V& *H$JPJE0:):&6R59/PHFP^$V-#ZKDC9GC^W;VJ7 '<]R@_&S/@*U,@9 M\MZ,!UFK.6#%5NT-QD^BY$>%&U'M5/D+N5"C;4="N@JUQ<[)J/XSAX5D15&O M\9MU(\%"(X&C&PD&L!;=2* ;"70CP:I&@K6- 0NQ1]_R+-\)K<1/33=V["B- M$^*Q?V09,;W$656AOS9F>2Q6T]737HW_4Z=>681?I((LM*_W1O)P%7H>C)W'.*+.-&#E)V6SZJN,"=)>Y MT!\=9<&V*PSXY!Z3]!KF$#QD65K//1"YUCGPH@[IK=0X-(05E8U2;(>I5]W@2I%"-4*Q:+$+?KB M-[P* \N#QDK[S1/AUY_DD,F.RR$X7$P+%=.&\NH/=*P+F>.7,0H98A<+>B=U M5D^H3\R[;:1NK@RX$V46,.ITI@P=0H6TH/[@='!P+3MT9J=/J (:H>K %0Y6 MJ^C8 ?&Q/")>H[X%!T R)2/+X(A4DQ1J\63$L*10&NR<"!(IR&^O3"6 MDQ)//&,VGE<"\( _$02MPQ28I><48^=,'Z <2GB>V6(L7*C?8Y0<4$3D]K9D M6J/N7+>+M[Q2,I^P+103J5O@R.[RV=(L&W8!-TS0D:+%J)>HVU'*]%9EBN#W MR'L+8"* @%X#D""-,]: M^G;[]^9(!#((%L:*J">_LDDS?$[(/!>-A:D_&;>]%J:@YRD"0(@AG/RDNES4 MZ*MUS/3"$KLA3/="@Z%:60&QQ>BNPZIHN.B6UO)C6-*<0REMYK0RVD4?HXZ_ MZH"G=&T/M11:0BR-5%R:WDF%6$D_YFRB]07I#81:OI28.M*MX$ M929>4I3Y;2[J7A$$"=T[^1J$5_II03G#U?T(]@;3<#3A*^0+_5OQ,*7ENXZ! MA&J:O>]VGHO#P8I*HA@?.+]:CAS,,*_,4P*86V\3??A6<228ZL' ^2GS=!K' M4UQN2KQ;&(98"O8 X%98H0SKQ$N*3YIW]724"I[ MR]W"$LMH(3LQ9]S+OI7P9'#&\V]U7D.=:JMRA1'7DZ;F9S]J,[YP;&.,#/!= M\IEN_(J:%"5"($V;@G DVKS;])T:_#"^EHE\.+XB9[=GHU:\Y$]BMDLA/,$ M>W[@_5\!_=1;(@%7]60NY\LK,SZ;J8)*69W 95KWRLC\O^\ZMFKC3K3"TJUB MD/&'A(I#E)A;LB^(^8%H^HA\?3,9KX&1$H/< 6F)K9$M98K)!C@WR 1>#^+48I-#4?[_7>*P+5T/3,^STMXZ(AG9Q11;;"FI"#S MRUT844UM-=8U-Y]EQP-0>" II_@<@$Y4RQ1$?=*B*FE3N9W/"E7 =W!F7#Q5 M&RML!:L;-;DC*59E-SJN$6G>X" 7KAB'@)"U(.E5)]TLAY\N[!+1.HYRY.Z% M= MPI7EC3&A$G5ZH"9'B*C(IXI.,"PH)O8JD:E*%"/&W<[3>8/OJ-@?\A:&.&?O M@WH*/4 %043B3]D_PRDN*VUR]/Q'&-V)J1+>7*QOZ*F87H[XT\AGSD%LQYF7 MN33VP\"V_-BW \N.7=N.#]&*7VT74[J]7>P=DEVLVI^Y&%O;M$;1A9G56$30 MF6/;!R_Y=.679'L0:E[A0P5\(OP*.ZTZS:23(L5GR0&[\E["BLE,3 ?>I.5K MLYNPC:E-6U0+!%A5WD6ZR)@"?;)I=E6-P)=W\Z*FVD4,X#ANUL_"F:&RB+#' M>9-MD^*^X $Y&5PCS,AG6EK<#H)7Q:^A_J<@R=U(_N)185S25+6V/-T8.0UC M+@3+V<60SWCM@;3_V'? "&TY!QZ M93IH)&G,08.;YT/Y(&ZAR$[!N!">D6@'_7;]NV@"?2>P8/GB96G?(S>>Q^-& MB2%\7+.(CF]CV2)394!@N$Q1-?&5,H>FRSB*4]#,*%>MDP1=8\F1ZG1?2[[ZP8X3?-^95I_P/L<'S"DK@L011 MB9_V1KR7*HYA#VNZ]%]:RK25A?'JA5:[6MWFI5>,%"?GB$9@^6K)U5M<'-@S M;ME[1VK8TLJ\A,1UW8+57*(Q!=7.>1LS?HOS6IM!T(6A"X6AKBX,'(EAD+?"? @RWIM7>/=9$,QP0^%KJ$8$V4R !#>68CC&Q"T> ?4<< ML :=(0S#+@(%@I^BY"SXQY7B"VY^84"KQ<\0@T.$;[N8-L4\4B5 E]HY'AL8IC>RQ 3SB.4SP/2JQ435LM+:/9:LFS2!.+PK*F]Z]YIUAX&]C@DPE&AE+S MRZL>VA)$HV;:,)7E%>P%L ZD!-8J/E"F[41:C0?KFKHW;(RD$VP*A: TK?,F M#+-0 B:'R)\/M:Z/M M8L2#6+&H5VR V!86RMB$TK1:0)]8[D;NL&P7CX5Q/2)9X4P\2,=A^$OYS ), M')[CPHZ;(FU^.J)2 TN$0%'@!]FK5H/905816VLY\/,"EBWG4CZE;=)F;(E, M\GJ.[ 7@\)264 MRBQ6#+SNU7=#;V%-W^@,0$ZGMVM,3W_SNVZC-,Q@[CI^ *ACQ)%L:EX>5+I) MS8]"L4;3@9XV!4GPXY4@?14_F]V.5NA![/N"0!+764L6297E1IWI?/+ !+.B MTQXP^8BY=/5##YI\V1)<; H0=OC\'2:P'#A!"X4\PI8A_":S($3.:"Z'@<7O7^^6_"C! M7!G%V=\Y0./%-+W@T. */F+/G1D>JW^HG@IJ*/4XCM$Y[&PX1QBRV1SN!ZZ0 M,1WGFLW7=KS0.DRCR@\SV7-<)3.)%- K\R*:!F\34 MW8"-!5CQX]I&:CNV'":/C*^W'-\V3L@]&V3T>K5]F6=G =+VUK#9+:=^4GF48 GL9JYRXUIU2@34GOOGO>9E7:2X;%4K:-_RCB6") M!FC KZ13FC'?Z: M[/9?>A"4]C:$05P%7L[7T*B5;$ZDJB5#@Q!XY"W@K5CTM>.JXM'6U*\]UTY' MOH3JE3AF9%CR*;*2%+&I5+$<5?V6Y:9T'*A>(+)4)!SYL MA4X*&P_J2K7.0QZH Z!W6]05XATQ;;>//H\Z9Z:#N2 ZP"#HNNYXT5+$D+MZ MID?)=Q<+^,@K )"[BI6WI6#+B<"7;@;D\L"+2%L\(>1 T3X1;W":=WK:@W' M$",%F? #JLO?N+KDY=3'[HQ=JC.[EN!$)'K#,JLIW(79=3Y]F>>]4#]4VW#8 M G:):A.M!JQYDO\QH;39HE1M7'4!4JIM$5)6WH\=U2DJS#L/Q=X2^3C4Z!PS M@OU@).X'N6!5OXK11%BA$(-U^ >=5*#KXMV=&DVS%R M3_OC,Q2FI/GE*C[>;&E==M[ETA1@D\6E=3E:6B-O'#;+-7VYYM.YD?Q0X]WG"B/"SC"KW/HRWR4K-P4#,"V>6T MW7U;-I6WYX ]+C2]I1RV @&X%BU49;P#XE LX9.!N1L795D\8.+9N)0>L^B% MHOQS]AO8X6Q@"2$#A!>J9!K5#C ?M 79;W9+3'7C( R>($Z64I,BC;("P M()H!BUV83WJ\#FE; 05U% @JJG!],_NCT^@*1D!;[''&^T._=]LDP4]D_A6" M3@JFZM:MJ"_A(PB:ES5#&N=MK4C[\9$*;9;/PHY;G="I9L*J_L_?X=XE/4>87]:6AURMF,4\3'(266)?6_X\SX MV#F.=@PE>S=O>Q,P#6+][5 :10D\>=Z,O30&^U:M-IYNM1G 6G2KC6ZUT:TV MJUIMUK;.+&*PVZ$5I'X:TB1U8Y/$ONDE5N*&<03R1 ;LN#RIKOM/9[W3UCT= M2B!+;'F6FWEN:-EQ:CHT(YYIQJY#[/3D' WA4=OL/^+H#.6$@T/S4E)2UV4> MSWD=&]SY",>6PW2X$HW:49/[6G8/.(:.TD2B7.-X\U>[,19@+(XLEX:)1PL5 MX&JU.D _<.OG<<93=(!UQCZQ:"4OK;T=8=.W=-4SZ8[>YI]NJNG9V]@O!:A[ M\MCN RNY>56PK-+C-I[\2E.+?6;\LFC7M6G!!NY- B%,2)W<*2.L!&@4P#>@ M9U:VA=%-<\VT8QRV3F+KJRSTXJ"1^)3))I^'9P(8%,H,2#&]&Z,\"^RF? W] M37X@"UPDL^VRWKD9(=]Y[0HZ\T+,PFT197*HX>*#2YQM5=,99<8A4@8 MOM2D=8C!5^92 M%8]H1B?GNW;+(W 4\TMQL P 8$DT.&(T+*2I.\KQO]^'S M%0!<:Q5AC[O70BJM9>M.:*7C_TE'"^&GP:F* 9.]5\GE0F"7J%\#Q KOV;G* MMB9\^W4>*.=[V6PKG=A0%[.FZ3Y )#?4(Q7O!@'H.X!97?$4.7PRX7O@*&TO M@'IJ<&1Y!T?10,5*^$E?=D'X^_/#')I%'DLY>$CF^Y@1_$OI,Z3NBFINU'6;#4]_-E M80JP?&^U'.S9[TW6>ZFLWTUW]ZG+7/TDLJ(@\MV,FK$7!C:Q_)"0.$BL[ VC MIJNG7C=0Q[PQKYL, !]!5&6S3V6T!!L9X+*X#0X?N?XJ5!2_I0"C>FDP@A+! MEJ:18O^2$F?]\!L!%1N7^/F49!DS'7EL^RXO4^Z64 $=QEZ"7@E_%/2T\%G@ MV 398F4W'HM2H;=RS"I/,9ZR;R-T'C,0/M(V 3>QHO&^VK.ZGO-EG?_NEVW$\5(>^9*TZ7T>Q:F M&S<6HF%%Q9MSH7J=7[W4R0]GKY RXUPFX];+_/A/W MUY*+-AP?:OWUQ9$*>QL M0VVFUJ/2W8]7$Q3^ ^T/#"#N(7RZ;' O*6(H&=: MON4XGIO%;AI[<4*C./"ST'*)$WI+91_P(@ZQ!W]17OG:%MAPY&#M$;:'AI\NQBMC))2");3?U(B]R4B]P;.+C#JS7W4%P M\<]K,*L\160WHPW8)-'7QR24DS@"S%$T0$! M:^::=6NC\GK.:V8$LD?S;; 2;^?,D&9LU'HUGVF*-40?^<>@S$ST*LG72X"J MSQ^O+AOL9=Z;B46-\O/C?)+79\;%2GJM'D;2K)&)_W_M78Y/O_%8>F)'G.6?!,LX"XY>Q[ _>9KO/$_K7VF[$MAL]L=T11TB' MF0)O1>/?I\BN%)K4YP#9L=T6+?/DW'7._&%2]*6;L]CF_#/["?JUE<.8)8 MBV[KW9Y*/Z!W 2C5G6< MZ#_-#L5T\2D4&& .O>+W42H_T.+9\WK8171Z/FST,TEX@O@GA!+*$$DO&XN\MP&__ZHJX%HVG MB3*ZIIT+ABTS/+HD'M"/"J-._FI/I.DZ4R#"5H\1DS6A+SFM3=ZS#&73(A^M ME(*-@8X.BHM_5SK25WH_6#P@AHS*@BF%C[ 1D0]5E)/N<"YVSGY5/$R9UX\# MFT7D__&,.YB0<9CCZW($X?P#BQN;\&:G"!;K--*"@_Z/(4#079(8S\=Q4_*I MB#SQVK-%B-.#W]SWE ,H&/T I M(3AMS&A"HES/!(SSU108BMV-@%DJLA=MTF()H"7*,LOW4M<*,L>E:4*<-(E= M.[-2UR4A31>3')^P5O$4WV^H"WAFIIER_F^[N$^*E609#,;+430(: M,3:F'B6!Z8"5M721_G/("TEQ2V" /,%$;\4P)=WD@%\_G?Q1E M-9*V<[4PYE?,>;^#N@+FXPL8?ZQ'/155JLQ10N]1@:G <23P.5K>YPEM"IU3 MD?3C_1/"\:HH7S-?(W;U3)@IB(E 8;C?0D6#D2+RRE+K"M^:A")31USS'M#F MJ>IT+XFK@G9I"J H &&-1R6>\/_8>]?>QG$L8?BO"-X=/-T/'+=XD4BF!@92 MJ51W!M5)H9*>Q;Y?!I1()9IV[#R27=697_\>4I(MWQ([MF/9X6"WVK$E7@[/ MG>=2UMB=;L!=Z:WEQBK;XZ>THSMMKVR5\/.D0S,LXL>]K@I#VB\GEK;^2V=Q MFL]LQ$;.V)RL!],4V_D?]Q"[BZO87>3Z'2]^I64L2'^QIGSK2RW M>3Y05@0AP4/O)_-(&0UH?JBB 6VC.4!1DT1N6\D]Z,J35OJZ8376L#7%ZKTB MV7S&9$!D+EVX0F%;*:RLK%#H!3!:T6"CVIX-!)I4%!A[\"*;AV3JGIDQ_NC< M=+RD#'@$*? XL%E%97H-C#J3K6J"BXSH-QE".J^2/(UN9$%:;:I*WRRTI'$X M4M&HK9:_8Q+&9,_4H2BC78TVE15ZDX74KV=G7VW&K)G"JCVFKKXV#?C,A(73 MM;8?Z?5M3RB;?93=R7Y9VK947<8)2;95ZD2_F,H+JO\R<89.XJJK[<.(P.P, M<&51N77H"?]OR^Y]%L&GBI.9>71JG\=(H[-H#4IJKVA+6^)W';TG!&N[YCU- M4XZ]R*[PJTX152J@R4@;@D[6U!E0D:9K1X>:3B5_A3QVZ77/?!C"(QW;:ZTI.W%:XJ6%XJXS22, MM,72,CW/LKB*P9EL]BD6ETS7F1AC6#(8395'J(,T[\SD$53XKA;1H6<A2G\D:[ J*=YPKL1V,T30UB^\".C[5X^#AO=:K:I384O\I% MS6Q+T4&9,UH($DN;93AOQ9@G2<93PJ,PU9>UV>MXOU92M[WD]*]%J+&L)6O;9.-(W\M>4A$XO#)#LK-E,4T4MDWI-:-7 MR>4_@*'T;&;V)*#9Y)X/RHLV@[:VC^+8=6'>ME4V[;VU*NKZ/$QZ+$[J^MBS MG4\WG]F[I=4*X$5IE3$42[HI=GJ4Z35G-K1W&4>N'V%Q1$M#^BNNM.T$,UO% MPBIW@^3&DL-O!3' NA[,['!."W*P4-#J!@M"^)_ID_G31!EEDQ]?)%YCOJYUNS=ZF(0J7]#:U'0_EZJ(88TE_4^1?648&2*P M!'Y;$J#Q@$[3[KC*P5/%$:Z_ D.HGGZ5>C6MDE2E@8TA,;XQ-[9*515ZIL!. M/;,"5,#O13>9?-PLQFI^#R;XHI?^J6U7)MF?M&@O"MR#+=8'[O)G43?"6#6Z MZA!C,T%FI+\M.%<82/([*'=6U2BNS,MF'..>S]J4>@.+IVZ$E$7O3(N'+ >\ ML,4,_BK#$"K-!300HVAF1DE+;!V#V 02 ";_>ZITWK2FT[:@>NS)0B>U?ES0 M4*?Q_F&@RJ)]-BJH+/545='T;?7_4L,KLFJFC\UT M((MZ:7YO]'FOZ-!K;>I>;_"CL$DMD0R2I*P^;I7S[RFPD-GJ2M-KJP75SBBF MD]+E"T\3H##\H4N/^+@9>Y42-)&X8Q6U!(4EH[(R7UH5:J^%JUG[M^S7ZCV. M,J,,321K-?[XK=I^)@]/#<@\6Q+M2(0KRA9,M[ M(B*>W8%\1CY5,3I:3:6GV)8C!:F]M+Y/HZP*B%OND,'^-+Y8(DF?DX667F;D M@Q2A#IC@+ A\JD/.&?>)PB%-<)2(2%GYX%?RP5]1/ES6R-1V]LE_+U>W2"2P M5A<'\Q+A)5JOA$14NFMJ3UM8J]'8IS'HWPT,1,^O_WGYZ00)$#0 THPFBVIL6OPOB7]S6XS@TM8\ZEK5"]+-&*IS3 M_\DKACS!^OLTMUX0\U8I#ZITP)+JP22RVG(U[NS)505_"J8U6^!GR6J,REZ2 M]#3QE/6D*A8/9VJ='/5Z> M%5AX*L3/M=YM2E$RYSD=@,7_9:J( V'4PDV(4 MA0KP$W-._0ASE3"B0\PC7Z@(1ZN2W76U@R^P@?/Z^M?&3P3* ^W0.00M(#S& MTJ5%+WYZ5=$#+,*(Q8&O:9#04&L1$"X38-I!HDS_; ,(Q VK?3- X%:7+2A] M, V'LB9 &0,^KG4[72(M9*BF N*:(! M:W%)$2XIPB5%+$N*>#')8:Y.)@HYBGF,(DJ%YI(2D$Q8)E@1T!K]W2<3Q/=: MC7KZ.CD?^SN-FZX,5+PHHJ8_%J:.)>?YJ$6\2A1B\^_@EW6*>BD <_I$)8M" M+;7 )##L,!$",2P%DQ2, A('1>A?,C!:0'%+8EBDTL,BM.:^K)6=3[6[F;4 MC?[T4QG1_O/8$*W":-:.71GG"51E0Z>"-,Q3"Z)5QCKX=)7UNH-O^CYLTJBB M%B"R>"?U$A[E75Z9"RX->"*; #R_/GLE/F?'OJFOC,P2V$65N#ZFJ6^PK/," M9V!'UV/?Y")?&0Y;7;^SP%?67G-;-(H0#3B/2!Q28%(2D!E00"$!LAK'H=T6 MJK8UIT%O>UMLR;;L8?ZTWM8VO*F K9E>++"^+>_1NCF##I_;Y<]_VX14IQUF MQ2W%=(S?5*60M/\\J0VVW"?G]?V?5@U0+SCFV*3)@ N<@(SHR<=G#_(3?33 %G%TYBYVP^+DT"H3H,)\9\3#,X/]5-7%I,G2L MY/AEJ.9_HZC#4+#T9[^#7OE;0,BKWGQNL:P3"N;6ZM;JUKJ#M3(?KS3J+Y;' M%'P&.)EAFX6 JIP;RH2]G/H>LEIR-=ZK'IT\6_+0DBO"\Y[E_EZE_ MS&@?YLRT62Y:C/3VQIOUW_RO"8RXF N,& NA-X:SF 6SD6V'#N,IFW@Y<%;: M\;N#''*0>R7D_-<0\8+=]70RI_GM>F^KI^+:W?YT671IA5'5I KG1@S_&)'B MW+8V'CKX+(%/=<_E +0Q FW&DH\2> Z['':],7:](/0C&?]YEPU&?752+C.. MM4Z2#Z^%RSY4A6<5@ZKMS[PG;Q4L6P:>91BV-;#ZWB$ ][]G8;B]_=?WG9DI M&[7Q-4)P-KP@.9F[2BB99(G8.+S8R(Q.7NVAUR\HZ2\+==G:^YMF^*]+=\+)^ER(6 M9G(BUM'I$=/I\NB3-R#4547K/%WB5I>@^6#^.=>Q(T='CH=$CFM0XX:!8,]H MO"_*SWEZ)*TNP\NRKAQ1.J)T1+DJ46YN?3ZOTM*#4VG7]H(G]G\'Y>B^L2'= M=2ZCD:[*^^N/-98/&N$EVU#]D;]5C>8SRG= MG^;VVEBU0[+2/\V7]%E0ZF87H6DK4>0"B!X(198>J=.^3F:+7WTIZQ<_K1NR0TV-O3:C6[AV=!CK&(L[IKV%"RW1 MR+;/8.9Y"&YU*9^OHN?PL]GXZ=C(01S37AT(>]=/"/"6-J@IS=!/WL.M[>U@ M.%U?NLI.&E_D[N("]Z7WIBM<$#@_-1B9*D(50);>V!]U5,J6H7,\G'#'.4YK M>U0IW=)E^):.>L_.6$?NCMR;%8RPV)&]>6P:#;86F^8X@., [XH#-"$DY-4" M/]Q29(@C=T?N[X/[SG6$O\K7%L()(:_'NFG3AB7J8?S#('C[ILTP@0[1=K*IN_/,A_FXX6\B\S[+]'69JK-"[: M1, +17>9F;;*L+!_ZWCX8K^(W?8_NI!9']:1:=WT M8H^C-1M9[ AO[8B+*@TO;G8%._?LUKU/S]E>I@-9-FZQ9/VQKOL!V]&N+%3?S(S:5/T><&J\I'I_@TT/!@- M\R%\,$M20&[PGWP$-%8TE._ **:KHUJP7+/UQ9LV75]@ZJSH0J5M\QOST./ MM.X#CM4S<(!Q3:N7F5;E21W[SZ__>?GI! D/P*'T0QIWO,\P05Z]K#S;7K.@E&QPE\F'HA\S MC!]IS_1+'C.)QTP_RB)FIFW^^&Y(TWPV6WBP:^W9%E% S': :O+B"3LL[!#V M;UD;/)#I]"$:F<[GDQV:V>ZU[ WOXZ*;5,$(RQ".HO43L).A;9H.5 7?#(=9 M&HV*WDRU:8$530"QJ-N5MZ31U92ZD,'#P'746KV"-[W6&S<-OH^'IU^S0:RU MRC]G@X=?36?YOHE5.LOSU/"[6%O\ LI:MXEP8,(?.\MJ'I:=A-OK]6+?T+OY M-OLFK6[0F;=P9KJS]]<[\DTMN[?9.FUUR8L-V8')5%S(-EF?\.X[R[MG&\&9 M7NFFB=NH;QLG/HXR,"5T/LW]AG;,HD7<,-.6J($=RF),"TM+Q68!=E;S\MUX M[T4_QS%S7$2@AKMFA8S]3S4X6,:CN&IG"4P&M('A4ZVINV5=8&" FF'@.F$S M:7]A9\G5VM,!$QHDB4E(,F/T]9WMC>VE,%9V2WP,T@KX+=AH$C2M MS*YE>"^'TXRYZ%@/BQP6C,S '2"0C#+3:]Z3#^8(\@E$"MX>%VY!4*%TU570 MO#G6K>#]X2BK [N:,=^KV@12^6R,54 1_8$Q6RV\"_UIJ18UUQG53V(I41#' M7"%*N!]%3&(5)_ =8A&AB[2NIFA.H#86IW=9Z. 3F'C30%E1I2+[U1N?W>N9 M&CR6C &(Y!\2S/+LR2NDM']ZC#KC9=\[&]W!FHR[@Q(M,>E]M\:.1/P!$X]G\^!8,P MCT%C,RP&!,Z#_C'(_CPYOY?].VU9I=ER[9EO^O^-TJSDJT8;7#S'CN'P[*X+ M832P3B3+31-[3N49&1/>- ]^,$JMKEFT\&A?YQ:UU7B_8U'3!WX\AL=$IZ\) MF<@(NP=0E/MW;>]AH "-[4Y]1(#L^\69I.IX.T::&&F1,8FN-T4 MNXI[Q@MG#&K0<6)9[P"=]@LEPWQ5CF =$W>PF\R:YB#\=4&W-2T 5.\X?>SI MO( 6'+R567DKJ+SJ:SI&RIG^, M^MJ@=?@L8PJ;R)C&IW39ST&HVV,Z.0?4A5/_,LB-CE=R*8)#X%)U]F44M*DG M 0\6#KCS73^[Q\*W'9><]'[PPS,*W3"%/QZ*W7AQL8U>L0U#91/TM2GSQMN8 M9:FAW:%1(+.A59YCL+ +.AL]&K3W="^UCG==N.AJG*304V5]*N_!"+3(:JZ1 M-\,V"-AGD95E7@<<6+K+]09K5II^%ES,#O,NV9+9S !DYRL*> M@T1#+]>PC +6A:MD#$:[]G'Y =,8_MXZ6,RWQB11,!&PEA_PM@9S[<>8S]KS MZ'C7ANR J>*@/:L3& -FD%N0%7MX*.]62NEC"-'\&?R]T,^Y:U?IC$(D*4<7ICY9W>_=(])LK,]%EBK#!>QYWUJ M/0[F*5B3;,Q:O/O,."7^*\6<)0EA,0X21B,D.:7F)CM61 8X8O)?K-6]M0++ MJ #&GV'M:ME=2M?+<*W[]RC[9?W7WIK8?[LX^W+[F_'1>;??_KBY;7N75^<@ M,J\^>3=_?+RY_'1Y]NWRXN98MW]U?7MQX]U>>^?75S?77RX_G=U>?/(^7UZ= M79U?GGWQ;F[AB]\OKF[7A\!;;V7N4F,1YUD8UJ$#%'(4\QA%E K-)24ZT5@F M6)%$:;^UY+T7G6I'9 B-?335I=ZL*61^.?'!3OIDM,.3XC\_TN&]82/?=997 M=PK75AV\?BP\Q:4)0IG_L_WU$ZSPNQ6(Q4W7;UK=&>W'.J#1!\N3,NM$!B/_ MPBK(8]_T-:B2%Z#'@LY<^5]0\/-$XZIINVH4EXK\)%2@9KL_#)3N%>9";%<_ M3*-*\4TGUH]=8?V!QZPJR66OY$O/A%%4B\G&.EFEYJG:=@MU$=1(_5A< A2S M3[8[-@G^#V@FL%=M]UKL;[PWV<58 MQN/4XA2J!1>3F'.>TU9K04QY35VU@GQRTXB"=AF6-=&NS:U#ECZ4$0JYQ1;K M"P(5?VK8CGP[+87C8;FX@">[*65I;'6JOQ7KFH&\&#Q M%#BC4XOCUD.5%M<4R:AG[H:'V:"Z./+@8/N%1@?6*@RO\M^\,VUQ-.XY=8SN.8S]KE@ 8GO30^SPRMRO3_'MQW/>1&R8KB*[]@XVM+W:SRL)88:;MLNG*QY>XI3VK!92V%C_EA0SL0)VJ^M M#UA6P3>,D]ZRQ"<;]M$KW-LF3*,6VEHX7 M((=RN(MBRP>CNOKC (;[]EG@V M0&;1SFH[&L3Q*)L+G5L2.>=/IQE4*S31_H^/O2(Z^1XDHJX+JQJL*XC""S^E M/X^]X)GE,>/XE]D@'#NBC4O4L;1QS)8SR3+JOTP9&-\]&!#^E-:&S_-QT,[T MQ:P5#T4PS)?+C]??+!'\96X49'[O)99=#HL0G8=:?(Y]RAL]&D9OKV3*,W7@ M=W\"+RWP>MY]/9/^L="!;=T=+_H.$>.MY1RX<4+& RD#O,$K4[Z]G0?!R]Z% M%=.36(\%H5OA;.A6',K8EPP+[G.*"8ND#@6.8QE$@B0AFPW=,O-XQ43>)6BZ M164_P!F3BC%_83&3[C/OY7IY_NGU1H0'-#:94CZC(HX$DIH#\TU(%,98!L<3 MTO^U"J<\BT&Q+W/'CE$1J7.SU**492Z3*/632HZ5 36I8:2/H)/+#%;C_7[] ML= !@$.FYHKU?C#*BQ@9"T$C=@NV"VS<6F!&.4ZM$9H\6;7W<9 -$]![BS2Z M,O3="I%I9@MF%BQC:=AR%0&[W7#URZO/<[&;UDJ]3CZ:C6HCQ'-U^&MP^/+4NV&,EE-!<^"'2%"6$HQ@I3!GU5<#\1&T7[+5( M<2"$V$2+_QAD"G!RT9& *!OT]?R1/(QZP_3$ADL/)XB][LZ9#A'AH9(TPA3C M1(8B3B0#=LD9\WFXSYV+5A=P0B_8NZ%9DV)2VWQB0[ ]>7>7F2AO/5;P310\ M*"(VM26-[7WB.MD$481!8PX1#X6DOHZC($"$$4W#6&HE7P+0))N@@L]7^63E MX.V@A,M$'J^;1!#Z0*Y!9[Y"U%06 2BJH/=-D0CPS$79-C8QJ,H M':NB9R? M>C-9G&&PW-9OB.38L4YU \:#&O7T!.WKHOCC4^VO>54K1+.J2R"DCY120G @ M3*&C*!$!#Q,I!95:XEE5RV9D#(P7R3)?67H4\\)79XPM^&TZEK2,.9,E;1;9 M7&6-Y8+-&]-*U5/8%F5NS7+T*80Z?5[+:9@C=VON+G":?M^ 6W+8O] MES.7/W?L3S,5?(K? MX)J%CZL]]!K_PM(,LG?>[-YQ:+4"=$;K$[6BPF*PW[ M0D^)%[N>K/$H"N:>75 PK2"Z/=4&F^-XE@S_UW@C+N;N3J9J::T(QX94B%L] M#Z266F@5 ME5Y%PRGA"XCK?73+>@=%<0^HLNT:%Q8,,5_@1,L(QS118$=3'8'<$Z0CR.8(4"+,D2(0*L4]1H 436 (M M1@$)1*3XRHTF&DF0I-5%N,TI=Q3I*/) *%+'?AS%*I:8[948Y71+K-?E2." ]:9=T $ C1C0ML84T<%C@H. M0IO>/A4P'W1FWB;A81#!EKREC=8*JV,U-7/*\\Y=4,\[7N26;**5D;Z6/% . M<6*>WU..HE^4V3D!4S'69>6:6K&:"9%4>7L[J78?=H(5%KH@'<^<\PGI+,B, M,(GQ18;73^CGF223/0G\XQ;K@8QT3&*J""<4%-I(A %C 1(H1CSTT=XLO,\I M+%I_,>VP+B<\?UJ\W][K5TIXU.J2-@N/,"[(H7:%VCAA3&E)XI +&IF&UQ$G M$>%4R%@)2O9FM^T6M7&KBWF;;N[P=;C=7-RF/(@0";02/N"V),"U(Q_L,A$C M% K*]V:-[1:W3?28#X99DW#[K5VHHV-4X-=7>U:_,SA3@-XRBA MB5"4ATD4X 1+3(G"7')^,&KH/,NB(([#C:-=79Q!HP]WFXBZ6+*:,A3(6E/K&"< 5PHK$<<(C M%K-#T2/G<3=L=:EH4GR7\UA.ZXGUZF'O32]\WW;N3\<0@6+#\^I?SY9)K?$B MUNJ2^2JI$ARS%T3:\+;W51.UP0&.4P^"@PN+&A'>OP6 $\ M-FP(DVV*2Y"0#@OVINT5D;SS3L"9TK'-<*^M7 KG0.C_&%2LZ4>J#(@K/5Q7 M@G'?7/>*K>5 K%,WZ5#\'.^8 !JKP6V/ %"KBUD[#+;ES',4<%04T%@-<'L4 M@.W5<>!O'/+S5A3PUO["O3@$!]GP3MYITS]2FX9D3[)4%,WAM[V^'C8V]>OX MN<*N%<."N!?2?8487[,!D)O*I\D]2?_2ZN0_.ALLHG32ZI:MT78=OO_6PLZA M]2&H>SM":^K0^OVA=9/<>*_&ZQ6T,U-\AK0YG]?.UG;@-4\QV]R[MZ<$$SC< MH@UXXGT=-YR__NK]T4\/,Y@/NV"^-Q"P&W:EG&9$%V#Z#9\N^_DP&YGR*.=E MOSG+DL98:3'RTO877T>FAEN3J2[(J<&2D481H@'G$8E#*HF0C&K0[!02.&(X M#M?2^#9$R!6$H>FJV@[8?-#HZK+0H6-SV:,4H0Z8X"P(?*I#T-.X3Q0.:8(C ML*K56GK:3MDC;R)[? ]^L7.9WWN/$A17TT U6];=(NW'O9'9U%33U7V4_]^@ M*D;C@+]VU>,5-W\T#&PG?L%:R]OS03Z\3BJG_T5_"!S.4,17((C+5];!X\+T M/FX'9%N%QP^BL(TC6T>VN_5[[IALA=_JHD"TB>\[NG5T^R[I=B=^W5W3+6IU M!6T+[DIH-07CKD:VB>D@\1ZSP:-9F+EQ'V7QOU/R-GT MT=INX,S&)WU _BR'W,\B]X:*Z<;(;:J*,(?=#KMW@MT;JF\;8S<%3>Q(D-NJ M:;\,38Q@=8.[_9W:7]"F2F%U7YC8%1"'_.Y6;7 M8?+O43Y,DZ?BJ[1O8F=/3W:1P!UT\ ;7[KC#5\R5?O.3FH$OZ@AJH/<_]@FM M3B2LV@2@9OI!IGWK2G\8P#[^8R]0O$=K_>36#9].U]ML>S(:?-^5B*4(4$B5"J4E(E@ MH:HWS2 6%D\HPG>^5?L\JVVSL/'0E)$'T(Y/U2A[TC*;,).@U>6=,3LIU]_U MS$, D.>V)6."(B0XEE10+2+AZP 8(Z610"Q 9*_;"H%'=LCB;=DC?6YGQ)>1 MB((X8H32!!/)HH E-%:F^B#L>*\[8Z;540P*$SHUY^$G' MV@B80D80U/;,LCO>%FC&PG(AV:Q,'IP)Y,>$2ZE-I2@=)4%(F08C2 BB_,5W M^6\%;9,IC3KX-?2!44A]JK$*@":0%AST Y)$!+8@91+HO>[+M 7PE^WK10)A M-") [DQ*9C2@)&)4(QXSS(5,&%VLW[_-UICO&XX6;$P?:"OTL2N9DF >8LT$ M)6!6@9W%E0(1$TDIA*](N+A1>=T;,SNC& M).-WG-:\6K!J4[3F&ZU?BOI-DHW69 <\->WOTOCE5=H#!E-Y4(0[G8+%JK," M>G^7S5V<=Y\9(O^O%'.6)(3%. Q&"')*9 [BV)%9( C)O^%C&_J:C#4'O_[ M+[*[6WQ8:WNMKE>&AGDWPT'\Y_V@!]O+[7?L@U>$I>TF1'PU ]U(5X/$!O:V M#$7!UN"O&;9CV)CAO6E_9']^AA$%TXPH: PCFKBNEAXBFX42"@!*-[#,- '^ MTQ]ZM[HOZ[VFGV?*"V#QPL[W4W@.V_8QSQ@VA?IF);(12FUO>*^]\\$#+//) M4ZDRN:G>/>ATGOEB6 #)^VD2>V28H&F=DO:J7$@P?M@8YHN%T-9;67_48OW:>P1=(!GTTD'G6=7D5=']TZK) M37ROU:BGKY-O^KONCW3^.1L\7/P%&P%:/0?<@05G^5E??1GT[ZP*4R@N'Y]^ MU8.[3#[>&Y%Y!GO/;XTW\!96][$';&BBI-#"#0M4#2\;;29004*C(%!)%%&9 M2+!)- +C41$?!8K@EJ?S6#[",H?9""3(+8 $P %JMSEDZW3T>FD.9V^ 9:,Q M9>&N]Y/P;8%XP_G[ER+5[9RN&#]F:3R$NS6^O0P"#LK5% M/N<)F"&8TUE%<)J!S'!7>SXOG\4BQK. S1@HZPR>+HZG\E\77FA@+CWYF.O3 MZL.'JKEJVK*W@'>H6/ZSWT&O_"T@^%5O/K=8T/M"PMQB=[-8NAH:O!":LD;WK144$..1WG]_ND Y<#EP-70YYTX'+@ MP/75DIA-K_JT6>8)E7R$,L;O4FOPATBQ%YMN36CO?LV"'LF MUINC.$ R$ES1D(J(B<2GPH\4"J3B N,7TG3([$7)>?TBX5N:__E59^8+>:?1 M.-;[!$]N/4P=-=&9;X/PMYWF=SF46(X2!(>A+V2$,664"%\$Q&?*I'#A1 G_ MI>26S5$B--DMG?G\%H<2>T.)B,:8)Y3[44P5YE$L(T4BEC#"PJ@,]5R>$;(Y M2I@"4WYGOCG>WYS7RBF;#EQ-?-*!RX'+@:LA3SIP.7 Y<#7D20=*! M:YO@.HIF1%]UOY\_];[+?BIWVHU[,[@U,"SH_SIP.7 U).A,T81B3E'D^XB& M6$4)"2),_5 H+J)H]T%GW-80G*\B[X+.G+AVX&KDDPY<#EP.7 UYTH'+@1)!RX'KAV#:^]-A_#KFP[-5.HEC:E:O%HAY_];5!^=_]=6 MQ"L+3N>O*'OZ0^:VMF]50G=X#WNSE55?K*4[KIA:EJ8>? M)JE6JQ:\;^R)O;Z&@W[;*XM*M&W5W$4#*?U=]P:/#W!T%2[90?XQ>DP!.<.(AI0 M&=WRVDG/#*^H/6V/[DLJ(P,]H/-CK)/^9G6_JX:%SS0I^?CTN_SW(#OOR3Q? M4-];S-;W1H(IQOR())I2/T%":&':)T4R9E$@Y6Q][VH)0 ?CDY:3D^Y-3MI, M! +#%-U]8-[GDUK-S (^M7_OLVH]C_).GT0@L?\\D0DL]U3V?LBG MO/7+- D"M97#"S/_[.ZWW+YDI3V^4;>23=>R>G,2UNK:XON& ,X-I[#-(^0\ M2W\)UY9(@OVAZ&*)\-O%V9?;W\[/OEUXM]_^N+EM>Y=7YQWO[.J3=_/'QYO+ M3Y=GWRXO;HYU^U?7MQW%)^_SY=79U?GEV1?OYA:^ M^/WBZG9]"+SU5NKUPKVI"M$UGK.P<8$2*B:^%#H@DDH<\$2*D*F Q)'4%/-9 MH>0SS9#20I+3_ZUHQ/+=8T<%\-PT>MK]6L'-8&!S(8D6'8H<$.T&" M$(D#62P@ :$KC>KZ9JS7-\-;L5/"^X$&.N!6(DN='8M]K#]=]L&&'8Q@5)7_ MO.4N(X=8YF\QAOR:#?+<.Y=9]F1L_[.'P:@_=#TR7@/*LS@>/8QZMF-9O0NM M@^9KH'FEAZ] R_<)*T?$CH@;"X< M/^>!=-:6ZQO M+3.C-FIO2[/X1KF:2>$+0H8U5KZ(PH#ZR.>:Q%$2B 1'OA2_NMR45.)$S)[ M#?_,I;M5CELFONE!FON+OX:G_='#B1K8VT(S8JO*[2/CNWCDM[HXY&U$@KGL MOB)4:Y/S,\QCS7-TU.2HJ0G45+./ZN;1VO2%3%<70U_CKW=&7[-$!6;R MQ5]Q;V1 ]NM@H'ZDO=[:%(5;W5"TA9AOB^,(RA%4,PF*)Q*+D(0^89JR4 H: M4$H210"=@T!J2U!S#:3>0/TC1OVC;4:1HR9'38Z:MJW^45#_.&G[C#CZ9_:F'A>^SO.#9Z?T.7@]\"QG,05-A"!2G M=")@^P%-(BTCHA$+P"##B?03OC>7H>E*2MN4S+>J79,"%U/!3D6:P[[F8-^V M="P&^(C;/G7XZ/!Q/SH)!RNZ383O$/!X$=!HP3$- =LHHEJ**.821]I/ .=8 MI,3>7#C"BF,4SI?G=-CGL._-Q3'V 1]1&UBQPT>'C_L0QQ@9<2R")B'@>XB/ MNA[>ZVR^),-.*X,_1XBKNB$/FA QPS%#<92$"E,):K%,1,*#.%2!8EJB?7D) M,&YU19N&1WA+ZY#O#9%O6UH) :T$E.0CC')SZ+AM=-R)4D);7=XF_L9*B4/ MYB*@D*&*"$%"A8SZ5,B$82ZHKP@*.$+QOGP$.'#"V"%?' MCGL1QLP(8QHV*>CMK6,(:K6KEA2HK:K1BGW4M+3H=EN4\EU:[7&F]M<6/7U; MR9 [QL"GM?=_- PM5K&."(MB$24T\8,($ZD0UKY/<2S\9&^>%G/[*'#;)]NZ M 5HG,7^?[GA'I(Y(WYY(MZ4$"R!;A-J$;NR3*#L>"W0RX< MG3HZ?=]TREA 212I"&%.&2$1IBH0@2 J8 3+<%\.3F*N_#EO$[:M2W]'I(Y( MF[3Q9A'IEG1@@DUUA*"-Q<:>.$>VCFP=V>Y,!R:MKB!MGQ\,G1Y7P-WBJI.U MBHNUED>O*[NXZKW6"F/4SI; Z:G!R*QP*S7NW"K=*MTJ-RZ^>.CIQ_4&;[M( M0EY1>I4]=)XYIN/7T%:$P=%H:=OR5'[4O<&/ JF_&)Q^G=N#MKJ8M -_RS=_ MJQWJ89A0CD@=D6Z+2+?E]@ALRJ:_>0D[1[:.;!W9OD2V5WJX-HF&-F+:=Q3J M*-11Z-9]E-O1?IG5?NFV[_PVCFRWH_V: MFD)^6]"-J]:^)8E:-_@OMLMYUZZ[WEJ].VD-#]NY&CW ><;3!^#'"'8>QQ0% MF,8$1T0E*N(ZBB.%!1'_^F3,#Q_YZ&1BATS#_B:^UVK4T]?),\$3MV:%MS#M MQ]X@_G,,=.JW/ U'\0CC#;.1GL[1J8&B;!\_E:1CLG;>'L6Q3=*YUX!>/4 Z M.$"OZ$ROTCSN#7*81-IF>+F7Z7APUX=AE?9ST_=0G4XG/=50! :Z@XW;.W5_4"IR+:@2$*4G'W-]6GWX ,<'X'LZ3?OVN.U+'\KA2QH.'N>HT;A0>\$]#=M(Q_W:@OM&&GB!_.8AG"A[38U89U3>-?#ACY M7RTS[P(DAO+J'=-=L_37XT+-%CB>=K9&O7' 60XJZPTZPPL(_/ [RU*SYU.KEH*5_,(=W0CH+5,4(=F(& M (Z,?IY6:%V4M8NRWJ&7)=*,ZBB1.J$^C7@0A51JX6O"24(HBQ8:^<^Y6^KD M>IW,VOKK>EZHZ1<9M'VV<6T*25 \F)\*1JB/5W9 J8H'0L:1A$$24ZE@$"G$6:!\3 M7X:HD*I^1:K^FY,JL:2*\,&0ZENG+QV&9;2J7[[TP!^@-80WL89>R$+93N;) M,3+N]0'0;,[]TSH&D1\Q/\ $)WY$A4H$,&>! XICDB A_!4,HAPV#)\J'GX? M#T_'I'J=S-Y'?YE #%O@"D5 'B:(442&BD,0"^1$B/O?1 MUN_"Y@G>I.\P?CP$/YW94^4];!D3Q$K9+O\J__=2%L8$7!]J>1GFSSW B;J"&J@!X38T_%PDFND]&,&%%9+\:F;R?JO M1]W/=<>=Z8)[R,:>:::_Z_Y(>TDV>/"&NB_[P]P=X2+G2&./\#$S67[#IRK9 MKW]GB?-!IGU[H+%>0IN_3*5QOE56Y^"YK,[/H^$HTW59?5$L?4FZ9_!LNF<- M.8,95&Q8JB> M3UIF^:FW(ED'TV0=6$"]>$2H$C(81/M1_',0ZTS[;1MG7>,K^"^6]_Z-YW_3LLYG[M MM)+ )&N2-O:W[&IW&6#-0F1'P4VE8%/0YO;'8&W"-:F;J(WYELL[.\)M%OXZ MPFTTX=YG6J]-NJ8371MT>D>YCG(=Y>Z'$VFG#AV;4)UZ3IM45P,$;N<;5^78QMUXL+P.VT]2M>#X0+^=5!TRU#6H4J M"D,2:BHB(;5&08A5$!/%-$9OY:6:)]'0U&O?E#X7D\$^\V4=ZNT7]<;NE7F, M8P[C',;MU"\PCW/P_=Y6\'0]DS M8V&](YPFX6_CG ;3;BOB8<(BWB(S2T& M1[F.(CP8([=TX%4+J4ZIS([? MLD/YC<98K>:06Z5;9>-7^1[\Z[:J]*+6Z?OPI[\#)>* ](1U*J4'2@D5:>$S M)"A3.J*AI%C'VI<":1(O5Q1F"J3O+!(K#$$YV*@IR6+J;K+&[NBI27L[('I: M'EX6,B C--\#U9%1DU#-D5%SR&A)S%S(6UT2$D=(CI <(6T0"!@*H",\WS3! MT5&3<,W147/H:'%T(_-;74SG+ROW0D?O(5'LXUQS7*\W:?_E\L5VFN?I2\05 M]Q/B,RJEX!%+1,R44@F1$5\YSW.V?UN=Y"[[\>!AX\@]9B+WV@&:;\;H0MT= M.JZ-CJ\,0V,F#*V-Q<97X@X+'18^O#ZFBA&#A\B?-YL='CH\?!4>+C$K&6UU M!44.SQR>;0G/EIA=0:L;XB;QL_=PZ[TPJVQ1XXL]9I6MU-;K/0?B;0- 1\/, M,(J#0"I$8HTIT:%4FG"-4$)C&E!*&V31FI(H;1]M.:-E"]C0<*^OXPN.+S28 M+RR/&6"LU>5[Z7KIZ-W1NZ/W'=+[DN &QEM=MN RR5&\HWA'\8=,\_I'($[PC>$7RS"'ZQWY+[K2[A&_LM&T/P"QK9S[8R7J.Y;7URTUPW39YV MAU=VQ$6=)N?ZJ]E6P9_2O.I;/7%OCC=L,"WMCRP23&VY'(.:W45&<'BCX?)7YKK3O3U%6CA]/L%H!CZU?^_'69N/\DZ?1)F6?Y[( M!)9[*GL_Y%/>^F4:8P YRN&%F7]V]TOWF"0[VV.!I< B!ID][U,@3)T53X/$.SY3]LOYKNT/1Q:3\V\79E]O?SL^^77BWW_ZXN6U[EU?G M'>_LZI-W\\?'F\M/EV??+B]NCG7[5]>W%S?>[;5W?GUU<_WE\M/9[<4G[_/E MU=G5^>79%^_F%K[X_>+J=GT(O/56/NE8/T0Z\PAJ>T9\+^(\,^S9BN+49YHA MI8. AYS*A$J)X4]"D10B\ 4IE =X1ZLSXZ.7,0\XXQ+,\XAR>,*7.F$D]H5@ MB$1\K(J4R,AQ^'J\Y.M'7?"#O-!(;H9RJ$VK^H^R M)_NQOKG7>GC65V>@ 9C'9,^\W1ODHTSGM[#LC[U!_.=$:X'5:-!E'LW19R/= MVE2J%U^EP*OZ<)3<*O_[$%:W]]I+!CU0Z " GE5CO'ST .N'07)O>*\+Q>PQ M&SP:-0B^ S&L/#7*[ O5[T^@\>6>AOVHXHL*,8N_*NRT_R)/]I7YX)^N0E\3 M/:A<7J4A6,T. -63C[D^K3Y\4( =/?ETFO;M=NU+'^:/:$:KLQ,6/YC02._A74A?<,C5]EVO=^^C+(\Y\] MJT$#@AC M(T]\DW+GG>1&_W%N^Q_U_GP0<\&&!UTZ-4J,'K.XC1ZA5=W3ISN M(OAJG3%665/,E^<3E@\]S3B$ M(Q;[+(F80-*GD<:2Z9_CRZG-EH]W'P],IJ^QY MHPQ,1# -KI.OX\47+VLU%10&H(E-8-@/P()<]\?>9']BE^%6-QF,LCEW<@TN MP%-+?K#58PK .ECAI!;X/ TVGY .6F"%1#+7!5?["?T\8\KOJ?Y50R7I8JKX M76;QO8=G7"%;A-S&D>_[DZN;WJPMVN&>[L96V]H:5V.$2R8BID(<2^HG-%(L M$EC[2&D:84J*J[%9!CA_-;8&#P05.$]5^<>ZL;#.96@;&?LJ-^:3SZ[XQG/+K9&(J&0.JL)\6$1)M=X M#)JUU-94PY1Z..Q9;[P'*&,X']AR3YXJ=<":[K9O2^Z@E)^K7\X:#*_&\:Y= M@^NY/,E5Z_$T#FAK\'LD BX2&?F@1]&0:J%"$W(D,".:Q#A>>.7WG'*U"9L/ M0%_:6B9!@RK5%$@CFLWT;=;D;BO3['F,E]Y;ZL=Z!]KLBGL_%K:72$HC[@)9D'"E)("":$6QR;MW#!EABPW*3O^)N2XE4XD.S! CF&,'?;'V.\J M#[I*XQ:NJ]$6KJL/1#$^FC'>VC>WKWOEW^3#XQ#DY;<45N9]'63#!"3&8/W+ M94J5'^F$8^6#1JPB'@8!0T(RI)B*>62E*D(@3T^J#TV[7.:M[O#'X-F[Y0WN M:-^KFW(^O&-1C2D20QBF)?48:UN4$*_(0K M1GCD:VZ-ZSE>LD?CVA299VV^N7'MBLT[$GL3$MM0;F_BME^/MH1OZH&1S6L@ M-L^KWW@M\6KTSQ0.S?O'Z#$%]>(P(^RPB[![383=DX?H!HK;JH [L#*S6^?# M ?)%I"GGOO:I9O!!A=Q/<(!"TUVYJ-: _ #19J@Z K6Z8=#VCS$DS2%E=;F5 MA"B1A) HH30*--=A(I".9"@5#20JE .#E">K8>?.E /.T V+B;-LL.$)'B$/*$BGC4 H=\3!F<4(%91SA,!(,=(3 QT3Q'6H' M\PA'6UV$-NX[Y'P#Z\N -+Y/[V#:F]^NO[XB*S$A' FL(AXA3A'QI=*19L1G M$?>C4 4E%B$4G%0?&G9Q)(*CS4JDSF>R/D7\0_9',@/-*'!^DYT+(> 1. J$ M9D'DTXA%@E"?(J1#[%,EXDHSFN$:N]*,DO0OK4[^H[-%]>U%V )YQ#'"'QID MICJ$W')\X88";3?QA<+$%[+YPLN'G/AV[,D0#8M/W+!X]?N*K5YO[XWF?6NP M/JT(%X*3.(H#JB27& 6$QV$@L*DDB:MXC:8D0P@.7)&0=K U/T4SLB$@]C[#!/8K^K/*IZ$*_(D_";5=;/C;'"&._%R_UE-/S/8;IP ^?" MW2!IH?3A^JZXW/NN?+5.1'6-@\[WOC5;9- Q-P( ))F/1EB*G OD@2\P'PCD8A]T6) M9*@H8&@_-"LP@<."NKG^KOM'&9G@N8#-]1-Y!M_+9-P-U%H7'[=B1;PDCI-0 M22)83*F(N @#GFC)1!S["D6E(H@:4F68^Z;*,')!FX>'E.N$)VPHUG82GL!] MVNK"$C8(3SC@R,T](,RY?-3>KVDF,Z7EJ"D5:0Y"A!8]!Y#8G5_HN$.IUHGM M"V/-?*(5U@'U(Q5QQ@1/V M841E$]8%M^ KM?LZ0M?L]N%S+-Q5(#^64B"M?4:#1'$2*1E1*DE,?55&\_N- M"2#D/FMUJ=\FVXX?W ).'$:,H6,.CCFLRAQDB,)0$LRD]$']HB(B% D=8@:F M01*5MSY5K.(*7&)GJA=O=8,V)L?#%*SB]HOMK=Y=L7O[5G'IY?;VR+0)_Y?] MW](N\]-=X0&.59_X,DJO M6)X1ZGB$^SE')KQ5=I7P&*G)Z8A[:]V:"#7]HM M7GYS@CM\Q4:36UTT7VG)4_!%'4$-]"X?'F6:V?Y0\3T<",PV2+S_7HD9>;IOOEV')!$RBJJ'8?EJQ5[.QXL)RRA M*!$1(Z 2^\PW"8:)TD&(*%%"O2C_=H3ER!1FI)UE?H8*RV5?K;5;%F&?<(ZY M &D?1U2*@)BFG5A@H1"79K=(E+M%XLUVBV"WHK,L#6$EFLZ7$+5O@61VTX9W M\T<=&X3O/3E:7[%TTQ'1NA*$!#+B09)0CA@/D1\F281I$!.*]R71$&YU_8YX M'OG;:^W4#Q#742A,@1B:T(A3@HAB)@?)5\Q/]L752*N+.\OJR;V6J>D(Q:;6 M;D)]06.12%]R&OD!G'42$4;WQ=3,]>M+Q_HZGN8XVP:8Y;&VJS;D[V>MVY@IN0,B01K M3I* BIAS)1(=$0)_@J1DI(JK(OZNXC%_TSWU>9 9E]&"L$MD:FV@YV(NO1\R M-Q#6 "+EI7UO')<'Q&06W_&,6\JT2S8 \^3#8-0?FE> >VAO.+#'41L/@-O/ M$YUE,)P"EWK';%-*GC8;4"J8#).$*1\BG26F@BD8F25T:1)&Q? M'(BWNN1%>_$57A'@WS,QP<4,0,!P+/$&2"]>QOD:RG?_'F6_=+=$;^M-_88> M5VQON>% "IX.N#G#E/J#H6%'T<"PH%29O^% 'X$Q&9R6L%3@K_HNC;W\/DT, MUP+6=0^<47H/\M\@''22 ).W+?IS* MGN%\H]XP[WAGL<$>@&3OJ5WQ1/.+66OM[6+E^=3:,_T@@2_'/9GG:9+"/GZD MPWOS32$>##+6AJA$&7R3#I01<':3\!KP[;0WRY M4]^$*P<+D6)W.&!'/$V' M,%W\?)JWQ8JS/-< 9B,F+6B,H'QIH\NWU11<_Y][#5I@L34)S"DU"RJ0(WH" ME.W+.VW9-:#P?;5U<]3M.OX"'B0]P(/6M3. 3967QC<]=/_&-13AHP V8>58@H: B#N?XHO]%^/N@_X7!).;9W5 MZN$-#;!],"AHGZGI96VO#_,"4<2#W*QR &OL]=H%F0Q@V&*0CG=94'PLL^S) M+*K04BI&4$Y5HZ!9L, Z8ZU5L8!J. 9DC8[\-)9^>CI_S<"\B^U MHW(U<#(_[M/X?H6EUIJ2.!\JAW>L)[/7$[G7"6Z8W!.>H M!@_ NRP*C/+R/*84YG(.@%\".P9,R_Z$Z;_+WDAOH-4UE]! J !Y605@'7M+ MQ6 %L"@644(3/X@PD0IA[?L4Q\)/%G?BKID%E993<*_K9 T3X<4JD#7K0*QU MZ%_5:W/]\[<=X(*FEMFA%( M*X1G34KLP>_;O/@Z((GY1_ZBP#Q$RK8B-$ZS>/0 I@-(N1RL7P46F;%JZPS: M,C>#%++BG$_+1 GP3&")3U:]C J3 0.E-%XQBU("?4K/T>]DW]F4I.N>$WU]&<06PWP]Z=E^%FNM95;W0 MJ0<3+TTKRDM MTZ<8E^%ZXW/\=[&T6.;W7M(;P &KD761?)>PR%%N%FO9F-&I2F0;9""%S>Y_ M6$DC'PU0,E"G9E!&&S0 = 8N'@MCQ6()C&>W+4$U2BLIT#:*D;%L8&U9J:B4VH95&0'XH*O$YA!44:6I MO6 +U:D4OR]9;(%]1AKD^8.E(P,JG1E5J%< #]#C?^SY@&YKV - 9= '6 Z M"YCHISP&C(:Q8 DI:*K31VO]R2LRR@>]T7#Y*W-)5'MB^9]/,)Z!3^W?^W&-O$>PGDZB3,L_3V0" MRSV5O1_R*6_],BW[0,R5PPLS_^SNE^XQ27:VQ^?*FOU=-F8MWGUF-,K_2C%G M24)8C(.$T0A)3FE 06]61 8X8O)?#%1P(S\-29X;913(\^^_R.4>K66X]H(C M[.U1=+'R]=O%V9?;W\[/OEUXM]_^N+EM>Y=7Y\ #KCYY-W]\O+G\='GV[?+B MYEBW?W5]>W'CW5Y[Y]=7-]=?+C^=W5Y\\CY?7IU=G5^>??%N;N&+WR^N;M>' MP%MO9IJ/:Y&=Y8]T]9UXL(:JWXUO:&0K^4 -7UEXKF9]H*E MA9Y4<]/ ;[TGH\G4U'40PRFL1A7Z& A;X\+IV9CL&>7&OSH MF^\-0*P/9_O.F\:8LK5[J_/BWFIZFU-W,C.Q0#%B1,0Q10&F,<$148F*N([B M2&%!BMH$N(H-*'TY,YD_&O3=G@GDK]U5?0&E]HNY:RW,;&-EG_45V-CJXY/] MZA:6\+$WB/^<.#1@9)W'\M%PMVRDUZ#_9GNQC8V0#'I $]9"M7*^O*[(YY$Y M-T2=ZSO[U;HQ 461&51&!F#_=,N7'<7BQRJRS8$ ,/;D8ZY/JP\?@!T\]N33 M:=JWP+ O?9B><$&I(3MA\?-$R>SXA:)9IK"6,Y<_=^Q/,SD=Q6\!Z02,+_W9 M[Z!7_A:0Y9,^]^9SBT6D0QC9P6()IVZQ*Z+!"YG2:Z3UOOBHJ8TW\VS#"G$L MJB7=ZOZOB0.XF&,\4\E5*X*Q&0F$2^7LDJ(_ET91&8Q@4)7/%Z_5LC M9;?(M1>YAW8 ,XRH#*+$V[>O5LMGO^S!=X,T]_(_TU[/A+.,,G.-9RX2S#6$ MN0(ZR(*KZ&?O)[;#7@(;5Y4ZW)(/QURJ&V-* X05$E+3A$524Q'52DM)3$YG MS 512^<2_1FU/?.30#VP>I19,>^SY68RGNHKL] >$D>4)!9RJ\B=:9P[LM>P4X-VF6!*$XIC&2(HHCX0-B)12PCZ.= M*%$KZ.^BU0W;/F]2^TB'>EM'O5!+1$*-8\I0('" E&")#_H[;-Y_>SV*^$UD M>=OL'8*#9KMJ;>\0JR[-!^3NNV7CTJ" XR93R0GB)$12(4ZQ]J,041Z')!0R MY*%@>_+P$%..%K9+&A") M=93$E.])HR%X2QJ-0]>C0E<_CA67BI(P$50GF(M$RQ@GG.&$R)CN00O:WN7V MF^!JJ1]5JZ@.(K"8N,>FGFZ,'8_QUC>U>P@OOOGM^FMCXHO=&"N,X;S>_RS+ MSTS5*3*(?*#QO]3YP-\H8I9) NJ/DBQ0-!:Q"#&2#"E-$NK'"=F7I4G!T@S: MB#IGY/'BGHJ#.*0\"J+8IXC&4H=!@&FH,$J24+*W#R8@01.=D0[OMHQWB"4R M3J14@:!(!D*3.(R4"(']B5BB/9A_VPMB:9X3_(#5JB_R1O9ZVILT8SA,=2IP MH9EOY+C'+-(4%"F*(ZHQ$R*2-.2@3&&<*+P;=>IYUM+(."6'=]O%NR!0IE%A M' 2,4QY*'HH !U$"""813N2^'/"F^09M Y0<[ATM[NE0F+8OBLDPH10A&6&* M0J8H'#_UT8L]]7; \T03>9[S4OV/-OGJ=T/3M?$SS)@JN2QS_>DP%:W0^:W> MAND@Q&0D Y8P#KH5I5' &:8D)"$6B<^2MU>T:",#F1S>;1?O!)9(^9J#7(BI M4$2"=""19*%IL9J(:&N*UCQ^H587U#J'6T>+6Y0$@#&"!!&/C1>4"XH$5TPD MC 5:OMAR?4=*/,6M+FYCMJR'GG--[0.O?D_C^_0.IGT\<-\4_WFVHX$STK;/ M6SB+PSA(J!0AHC'Q)8LDB@01 H6QP'O(=:%;#WERSH'FX5T@)0%5*> X"FBL MJ9 D]"62DDFJ=4C?_HZ/;J\"AL.[YN*=1C1D*(A\36B$(X&#).!A@G#@8TGV MIDO9QN_M@#7)(>H<4U>C?Z9PGMX_1H^IZ4UQD(H4VTU3\=4@>)@@$\Y5]P9W MHB#P.9(^(2*B,@PCHG'"?1$2%!$IXSVHGHT,MW!XMV45@"4$:Z624&+*M"\0 M9U@%D@0T#%1I\KRMZKF]NWB'=XW%.TU",&]PG/!(T0!L':8UA3^I5#0*=U2K M9@75DX/J2=OAYG?QS?/C'5">M[<:>]C*^! M;^.\MG ]Z?#UJ/ UBGP4\HA$F EJS#T-MJ!$&D>!2/"."B"O@*\(\#5L \L_ M"'QUV=;O=(QMJL>('()Z_#::\8KD/.D0ZJG!R+3_M"2] 2]O&M!7+]._3<@< MBW2C#&P#'F(?9!MEE'$_85H2 O_J4,2["4)<0;J9@!W6#LFV+IFV<>A[UM4< MQ3N*WT883>2;;&7A2QK2 $3,A-(VT5$DD]F5_D5:7^FT1($?QCN(=Q6^1 MXF,F.0UED' 9T3CTI2)Q*'PJI2 A+4LQ[L&"I;NQ8/="\=;,^64H8;KJ)KX6 M(_( 9D#:KZWL0_F-68WQ^4\'D?!I:OSW*!^FR5/Q5=I7IJC3B7EH!O.6&F9; M"&+ +R$E7A[#@#O\A4Z9.XF\X"LM>0KPJ".H >OMOUK=#K[I> #@/)=9]@2+_Z?LC::I#V 1&PK\ 3B?Z_Z8^/P)\06M;JZ_Z_X< M[=6CL7_H3)?VK%:>3$Q@T?!>>^<#^*[_Y&4ZUG#,\%/?&R0)_!H]V0>&NB_! M_AT.O,=1!E8P0%/V>L<-T7 %B+:]'_=I?._%:> M_NM1QT-XZ'[0,RCJP1#IH"B--;3X.1FVXYWE< #>)S@/LUF/H+9G0-.>>[0X MT_X F&.: \&:O$484<*7P#C@57, 9N5VHN(9V>M,!QF].6MK. ?#3>1@8\R* MM$FR@&/Y4P\-(@WOT[S"B"=[S'#"0.=]BX_)8)0-[[W_-Y*9(7? *H-(2S%L M9K0?,I]'+H=8KT4LTD#$JA\W<'9 +]WW#*O[KGM/)9II-<&K/.W'VKO1C\," MD_(0QN'/.>#?I[F0WOTZ^H".."2L$!BH16-.1>!4$)SE*B$(";D MB[I 9;T\IP^L*_-9JVLW_:P6M9PV.MYU8IGN40"#KP",]MMO]2UU0 $Z8/K7 M&CHU"-TG+3-/ Y=1\^QP(\6N[46CX=KP%HF0V*=)$E%*%8T$YJ!_AXQ2P8EX ML37G#. _E8SY5[!+'R_[<6]DV )\:^9,^R.MKF$1TJRL.J/)R?QA&'TUPGG) M[]<\DM!O=1,@O_DS&23S,-Q4#7Y/XB5HG'AYG=D>Q#@F,N"QKP6U?:RD<8EK MC 26#.DW1/A/)>6NB^,(455HWW,!#*L,6/@OU A4??-H7$I1[[L1HR6OG2P7'K8^#L -0'.C M$<&,Y;-F)Z E90\ !V4<2@!O(*^^LBLJWYRXE?JJ,#/D7::U>61Z:_=2P;3Z MNZDMWJOM]+_7<* G*HP#3D*98$09P1P!APBISYGBOH]>#(CMFN M]W9BK:XG'^%D9'P/8,OC+(V,TSP">\,1U50AE<,@JEE)FZ19/IQQF2(KFI9Z M5!TW79S%W)R#?TF] K5\ "<\<^HSQUK*9E#U86EQ\7=I"5@;8.K@RU51>^IS M@/R1JN%]=?M?>ZOTD/N35V24#WJCX?)7:@@4 \;H;-O8@OR5N.+G$TQFX%7[ MURS8J#HIYBQ)"(MQD# :(79[*W@_YE+=^F:8V(+5R4<*L>A9F2R&3)#N#3$'.RNBJ%DM.K4^BH)6_ MR\:LQ;O/C'[\7R\?$ .",K$1ADJ,(P>0+O_[+[*[E _LZI-W\\?'F\M/EV??+B]N MCG7[5]>W%S?>[;5W?GUU<_WE\M/9[<4G[_/EU=G5^>79%^_F%K[X_>+J=GT( MO/56YMPBB_C5TFO+8/[:,?ZPWR4:9O8:J/ MO4'\Y\3,)84Y;IUG9\8ZC@.AF0ZHQDK0F$=1&/ @$)("P\&F92K8,+%\-%B4 MC8!E5C-Z=DJOG+,-@!S."^CZZH&&= O@#6=!9VSRBF+ZBAN]!" M5]0K;JW6W>L-?MAX!RMY0%3UP'[-ZT$W%NW9A]Q[J#"D;S'DL< 08^76+E\* MZAC?5!OUWFA\IZLJ\@LIOUC<6)6S,8H IIY\S/5I]>&#T3U[\NDT[=O-VI<^ MS+.:&07;3EC\7*HU@G="3HUF4Z9DE1.72D_'*CTS\9;%;SCH,$27_NQWT"M_ M"^CR29][\[G%L@[C_$#6RCL!%@>S5L)?NYZW7FO0X2'>^EI1)V!LZVL-.RC8 M/@Z@#L/!#FC+I]NG+=P!EKKUM8(UOQM&P.EJ2+ X[1FC16G/V>#';"Y^(UH. MLY>T26LJ?P4)"B(W':R0[+I*LO%ZT"A,A";!XZ(?V^M=K6JMU[8!&W&8\+@> M#?,AJ$Q&(?LR@.G/'@:C_G!&Q3)6UIL!:=4*GSLW15?$J"0I[E^\2[,(G0^] M;W*XHUL7V@EFRU8N6M5R?R^E^\CY6 V2"Y!N]0+N[X%Y32'8EACZEAY=4D@$ M/U-(9#>K6YI/YL^GE#7[M*>\6AMN^+T!#FV7.E9.4FP\8!Q&-0.C7O'H04#J M=SD<9>GPZ;70>JDNT990<]M8_(YEV.KQ/Q9!?KHTU_2#$0RJ\I_?B$T[N&TH MWMX'235SRO7'>>L>9F\;'%3XM63OP?NG[/7TD_>[5F95WM>>_(_T3KQ?!P-E M F;;WMG_M]/JQYN!]"VYSFI 73=%(V(^)KX64OJ8:C^) NQS9++!>"P"NGD. MV,1;]V(M_%K:1;"\%OX^2OXUJ*S/:FBP=EF?)I3GV1##%Q28?15RSU?EF;[< MK](8"S?K&AT>PNUU%FE>(CH)LDI#*B/*$JY)@%BON4!KXE MH15*V:U.0B^7MPJ9Z3G+V;;JB3>(BL9C'%B+O@WQKF]5A*UP;_H\YE7^=^-^ M'U_[?-69T>3DWD[P! UYP]CY'D[T;TXYWQG^OX[U;HK_"_!'O\[A?S;,Q$%L#8C]8]3OF#A0LG6HO753TST K_*HG-MC]?[IG7A?]2!+ MY:M=*COH9W 0:+BN2T7&C*K$QSYLG\J \TA%2D64T'0G>+31;7L?OWLYL9Z1A#/!@S':G *Z"_Z]CO=LWVQDU9CO;EMG^ M7@__]6;[>X78C7[$(:3A.M(2DRC,)&!XLA' 8N%2#@+MFJVSYOG0:L[WY]IWXV_CTA7G;>1 M7G?@.[:1PE;W_V?O6YL:1[)$_XJ"W;U1%6%H*3/UR*H)(JC7-O=V%76+FMVX MGR;R)="TL3R2733[Z^\YF9(MVS+8Q@9CU+O= ]A*99X\[V?42X)X/R)*'=[M M .],$A 1)*E/0\J$YI+$<1"+0,,%\SBDSV*;QXAW/.[P[E#PKM4VV8SE[< V M28Y.Z0E/]@/;7HP!WJERJR#Y9OQU!TC.ER!Y=_E=W'RGH5]Q!_8WB[NP^6/L M[X_79B#Z8'__D8U&?0-KJS\W-L)?JR]H72,\4"0E-(PCH3B3W'#I1XK'OE8Z MX6'L[]8(3_RM&>%=P&@U8VBS"]^M,80M;X.P%]%')QAWD,I4PF+ QH+$4H* E]LF.[O N./[5YM-F%[]@\BHY. M>2_V'VT==4'*O<6[R ]Y&I @T21EG N>!$% ?9IR'6I&V+.8Y3'B'6?+YD%V M>/?2\*[58-F,Y>W 8$FV8Y5WP?'7KQ,E\3R<*4IS%- MV6[-;NX?G;(N'OZT_;8VNO'=VC\\.#JE<=(+?7\_(D4=YNT \Y)0F\3(D GJ M,["$9,J52@.6Q(&D.GJ6@#@G'>8=&N:U][K:B.UMWRSA%'-VXT=[>KJ(^.O6 MYUJ1?#,.NP,D9Q;)%S6[[O*?)2*^HN4WRH?;/FBTTD'?D%6&%1S&I7XRRA:O M1UW4?@/?RK@_RHXKZ_+.^_CUP^7F/H+7ZJ!:UT>@0A/S1'))L$$HX9)*J>,T M]1G\+2!RQSZ"\.B4=+'Y)[74-KOQ'5MJT=%I$"2]^/&66A0![Y]O;U B/?*Z4))+I@++ YR*5- W2T)=)DD0JV:D1SOVN;OWI\Y0W MN?"=6D+RT57M@3!(11AEAL>\+$\2$<9HH M+FFDU(ZM[?#H=+$S6!?QWJ'1L]F%[]CHB4 ^DUX<[DD@J$.\'2!>&H5!X#,9 MX0B?%,P#@P16X^>/+H99A?O M?MW*7"N2;\9@=X#D? F2=Y??Q;N?(.&9GA)MX5!G8&=/0>&=0Q.<%#SX-8 ME 87.#I]0]\^(I5]BPZF!E.EP%1U/I9]X]5@VZ8+ZS'QD4-2C-X\B]7I2.N+ MI2SS$\%+2.]%[IJ;.=&7U ([[6BZ/9,S>V@J)TZ'R31:T/1 M1_'ZIV'T+T,<=6N\BGC+USK2,BS,33:^*3TQT)[.2H7.+:=TO@K3YB"+09Y' MR6K:V'\?5":*T9\JI/KN,&T3J8:-07HT6LR@7UVJ;:="I$/!_5:B=H>"":(@ M"QZC6.TQ"G9K=&L\M^/M.;6@F7R3S96?EZ#6T?SH-(RWV3]N>Q?]S'Z2CN([BM_3 M))O'4#SQ,06,]0C=5DW#P5!\MT:WQOT.SM]&J.S6$5CX3[U6 U__.2Y'67JW M;684^ ]Q(X+30_>[B0%X$&18;<\ ]_@A#.$WD?15U6J D@1 MX;D5,'$!3H$&%^P^*Y';>Z+?G^3]EUX^'I4C,< E/5%BVL,GHPQF!CE^3H,> M=C0@UEW=^E%PXGV!94?7QKN\^/+CMS_./US\P/?!V_LYG+/7_'LV\(Q- ?+$ MR#XC11\#<%YY;0PP?SB"=PL;&8^R/GJ2IHNWC=#KV4],G5/D%?BXSN%<8&#" MNU1_K$WC.S:MPSFI\,#X@;#9I6"*@E@9Y=X()&,VP&7PPV%A?F7YV%JJQRE6 MZ'CEK1B>>)?&/)0&DJ:/P@&[X#L\<:8>Q@I+4""W\\*FJ+P#OF0*AZU_$_N[ M.>^Z0-WFWS*2Q&E*8T7"-&8R$ EC(8NETE2$1,;B'P&.U/N6P[W$?_M-G.Z6 M_M8ZWM&I][_^+0%3ZSW01Y']LGS$A7=^-_H*\>P,L3/#$HQGXQNP2TO\P#SP M#H".M!F)K%^>=*S^/E9/]H[5_YF?Y[1PW]V88 M^>3[U#_6XLYSO+G]"?CO[76FKCV4'Y8%PO>$5YARW+<,U::\(IIG V"@2 L$ M-?.*8=K?@_?XH4T"==M&+NJ)J\(8C!R4)]Y/Y/#Y#<#X#B54KJPL^_F48V:BH'?6%I9IP(AFAI+P5KV MG8HUE\Q/I!]1YL>4IX2#D1?I@$4\#'6[?;?+_;L1@B=M16&MMA\00!\/"3B1 MC-AJR9_[PL.6Y=X"5P&5JP0X MP^\W-]D(N8.7&@-*9-]<@=3"G^V]YZ"?%=53HBQSE5F.<9N-KKU<@F@;X*J3 M]2V'*4W]0&&\2; 2D6^"D^:OH1G ]W( IU4!42&TZ(>_P%>&E:HYW?F4C7GC MLE8KISKI9.D;,[K.0:%MQ$F!D)< G=X90:@O/>! *I=P?&NS<"IK=,C:R-' MR)Q!E7+); "< B&)*JTT0/3& [(?%]GH[L2SF6ZH&H_M>T$?+XWYLP$K /*H M@/MVI VD>2W0*6,U:M7/ 3:XM\F.,K>?(2!';G^KA(7=$N@85I]&(%]7"O_T MI+? +Z;+SA%QQ6*^C6]@9;4>42\UJ$__)HO?3E?D%N'LPN'#O&$7K&%%T_WL M'MO-64FU=+T6VAOV03-=4[XJK8RDH)-SF;+4#R6A0@?$^#XCBOOIDHA#TJQ. MGE8EGP] 2;;D?39"E/QA.=K@:I2CDE]^=Y'!U406GXHL>G3JGRSZ)CU9B2; MSP+VX!F["?BUW@4P&#&RM-=#<0/7AM9T@1P'B G%V3JPVC Z$VZ_(+(ASIDM MWSU9K*GQ&H+[ZIZ^ ,A#+9]I -!9VN(7Z)U6*05>6L)%ENE=Q:&1.U4<6P+A M",=4QH.^*5&?+( Q5@_4K+/]Y<"F@&4!SLH[_%:)QGE=V#ZK/MZ(/]UCCB?# MH8:@GJIL"-O&?=0,N8=L[!;9FG2'C8>XX&W+\+,T4G/M?XZPP MDU6- #XWL]F><[[< "I< ]>V/I=5=9,7Q6TN\QM3R\0*[-8&CM_/X4Y3.%;P M0\D^[&?6Z6.EM8)+!'%=W^<=Z J_3+\ACA0(8_C9B:W^V%Z/%7JP^U^9,O8+ MULME'0R #JMS0_0UP;OG]^0PK&4+AWF=N_)F3=^_C^ZL[>]N#7]6PBI_5K@S M?]:&YSLZW4V%VZ;NM)T/]>JP(H_9VKZR=:.-:6?E;0699. M\NJL\FS/N8 C]J_"EAR,R[)2]ZRI^A?:M*!9*5#)7(4K?.+@-!R#TJ;L'[O8DJW>!J=;A7CXU7&5BU;\H&?YTI-_.Z(;J0 M@/?A']&\1#LP0_>9XUZ#$1H5,T\@5P7=?HA>-O>2PN1IBX,)D3D;C(7S:C>N MJP( 0UI?]+K>9GIT76=P-9ZJ;M>?/B)DF??'H^6/+/0.>:9+_G),V!Q\&O^] M+NK]#$'*'$O _S^/10K;?2?ZM^*N//IM%ML!L:OE.;Y__O0[,S/VR:C8M0D1 M VE:SP@PI8_(E8'FFK;$?7E&,[CV@%?TZ5&T753__OGLCY^_?SS[\=G[^>/O MES][WOFWCV#K?_OD7?[]P^7YI_.S'^>?+P_U^-\N?GZ^]'Y>>!\OOEU>_''^ MZ>SGYT_>E_-O9]\^GI_]X5W^A#]\_?SMY_H0>.JC+$3RVCC/80C/O\U)&:NI M9'Z4Q#Q)4ZD2SHQ.1I-*>>T..Q5,RQR M98P\Y,O:M*<9FZN>TBG^]D(LNW<('WKATL:\WV5L;+;KSQ!"6^@MTJY$! M.;Z.(LA2$<8L,42SF,4B%8)J)A5-B&_"B"3_^%0K@L>K:80_3*U&7*1_ %3A M?YQ%L[9*&&$4^V19A4(S9CU IZ+1 _1,6X9L(?S#_,K[OQ!VLR85:,[N2R[@ MM6ZW5RWCF-.("Y4DC":"!\#P5<)"S4A*0]:N.K>$^^_K^#H#+$!AA0"[S0M= MFD%+#U@"(F4 P%Z,$%3X-W6Y.Q2J,NQL2LA0%*/Z>S(OBOP6889A:%3_,(DO M;\'A-QE@7SI&TW1_D*]V&'S)BT_&ZG+EQ6 *WS,%^J]3\,JUT=&.!%A,J9C% MQFR D0C[XEK;MJ0J45O6QH:J*H*V5AO&S(M?!DG?MA.8/C3%XUFCQ^G9A;FI M N7/"^^*@7TI\AM$B_6A:GO0+YMJ6$-UEE">\YU[:#?^7 K0I$9N+ZLXCE MJR"F7"D6A(0I2B35J9:)D4IJPBFWB$7\P ^.I_'314\"5I\#=8P+\Q.6_M#/ MU9\33*&^0V:X(J//$,$(8XQJ*IF6@G&?\ACXKR\I$\;G1L/W#>#;$-4G$*LM MSM<> &WD+20LS%Q]JQ;P\)MG=\J(,53S6"=$@LC0W)>*1$PP )L,(SI)-]L5 M<"\K1Z43R;5$GD*B!=S!_"%BGDH_9IHIZ3--X\0DDD2I##2G.C)\'MP'$F+[ M.9>!83-A\G[?24GE<"J=.FO7RLM'+OMN,^^EW7XKVQBYJ'OMV;!56#8M8EB: M=_4/[W56#OOB[ETVL&>V#[U??.-<M^3]VV6GY!DLU7O^XS JN$+V>M+@NM+VNMN M<" Y(6&T@[V&<;SUO48G?D1?"%SC$T*WO]?@) G92D\^T&QDC4K(9_HJ7_CJ MGK7C7E",K72[:,CUVI'@N6!72YK["DU1M@.HASHT/YD'<34H3KJ(>W5O<0^; MB]\#P1VGZ[=M<]-T??[6>Q/XJS=LWG]:?>"K*_*BO>IST8Z71!WYM@%ME>.%KA4V' M5/N!5"_J^#,*X2N&P])NT:!I]C9EP^ MAD5UN=!4MX/;WL+M=5#5$[WRT>][AG%9<_NI:NOIR20"-FE58/^V%Z;PNY5- MJ)?9X:U;HUNC6V-_1[XL8YO$/R'/Q#?;U8NEZ8:/8* OH?O]?;UB5QW*\7+; M'K>=\% :%Q,=Q31.1,BH9CX)I4PXUUHH/PC2E,J56Y4W5W_,? MWZE\_X:*=&1SD&2C3*AI%(0Z-)Q%?B1E)*F*=:28(0&E*_?[7DHVMBO;\?^8 M(F^C&-JHO#\TDIFL<9"CH-8;^;T9>][^R&_*CD[C$[(X\.E9L.T9KFVWH\T[ M3-^0HSX6TQ_@N$T*"/>,Y1X<$3S.P'S.($\[M.I>P'L,M'U3+K^*X@03YMDV M8+8RDHSRX;:/&ZUTW#?);(BB\KO4NYC4*-BKWQ?GT M=8VNY"*]^D]T:KVR- MSAV\A'_CI"[7U.;P_;^OU%9I*;#6/J.ICGTA!2,Q2Q+I&T%EY(=4;KWMGL2Z=;O:(!E*P)MGL.%K9/KB M9GO9\5W?S-I&%O/!R.K%X:*)M< 'UZ3?O1BZ_NK1;5N&_+;0+3@Z)3W.%UOR M'02Z=6MT:W0AC'5#&#W;@;.+8S376+E2\F6(K"=4D'">Y!_YX HGC*+[.:_< MS^?UC+@OM?9MA=C:$HR PL22'FE1F3;SGJQ3%/M27-:O%WT?JW#M>IHF_< M\_UM)=2^./3MUNC6V%>?U;Y5:__,1Z(_7W&X9_ZJ%^%"7W<,Q&;5%VN/@5@8 M]<#8T2E?G).VD9-XTWMZ/N<_6=L+\3A%9]^2H%>OL%O[^(>BWT6!4F%D8LYB MGQFF>)($6ONI)JE99"$I.'3G.D&.B_5#',8D( MC5FJ=>*+)(E)$DJ:Q#J13Y&HQJ*MV50OC!R[-;HU]M[QO6\VU1A\C*-?ME(4U.UR+W?9K?'*UMB2X\LJ(?%) M'.ZW0OU1#+&?IW(P"%(EB$Q4PCA)$PF&,N&,Q1S,9N'O MS(V%M2.+ZO^6_;(ECM'5JV%)HXX5XS?Z/N?L@!G\^SF.V T?F MBT#"=3UFD=8F$*'AJ9^P)(BDG\9$&6HTUX'0P:X\9B'FM2_JAB^]&'I%KLB6 M<\77U;:B)>%I(X3F9 AII%>1!:38#M,>YF8UFJK;L;6=F"KAD>GT4FT)RW.7HRM MVF'ZZO['C=CJ#C ]LEZ9;I!#9S@]=0_[0_7*O,1[?9Q7Y@ERF0XNX=05\:V0 M=KH?=7TO:DCTO8!?U_?##4_"B*:<&\-(G$I#_5!3$I(@2GBRI/7!%GP_,8:B M=Y(M]5H*>-H1X/ +>-9$_$6C?S.HX M0<<)9CB!EMS$L0DB+7U& LK3F(N(*QVGD50\?A+W'T=.$ (G"#M.T%41=FL\ M^QI;&4RV9Y4X+Z,6K-OE?F%-M\8+6N.I?5'/YE9:[D1Z7O>1@TP;3W@%_B4S M4-8#9/023Y/2RD@:@UHM4Y;ZH214Z( 8'S1OQ?UT5YZF"-N-!WR?7$U;0)2# MMD"W 9]#,5$W(YOMFJA1<'0:4K]'^.$XJ[;#K%^ -ZMC-AVS63D=+@X9E5++ M@"0LIE02ID,>%X.@;7F M1FTFT+>?&Q516YNYF-W<$=F>,_2ME-J]@ J)<+,*B8X+K9*AN9&DWP$78D>G M]*1EW'+'A3HNM.]+'_9LA7WQ6F+Y MO\=C'),3W/<\5Q&EP04 ^8.WS\.'[99GX!N JHK0 M^SSQ,WO#B=O7$X7Q1.GEJ??)*(.?.R9.@QXF_I*3[IKONV:R=]?\\]IXYE]C M'/V155H%W/) >_9@"KW[,;V#C=__KWQ(2Q.]+[_8Z[_?OO/QV M %\MQ[+,="8*Q)31M0#)G!6@G+@O>'GA]0W PBX$$+G*4&J/!].(!KQ4]#UC M8PV 9J6!%RMX8Y&5L'/[' CW(K_%WQ"LB(AV6W-33-X CFJ39K@K:?KY[5OO M6OR"IXT9>,.^T5C*Y 1086-O!>2L?+*&SM>#E!_CF:+,T 3EMZ MU_G8DDV#??=S98D:J/D+7$^F1<_[3Y,#RL(/Y_FML*3_-5/7V15>\)0HBCM\S2_1'UN"_/?==SD,[[>//@)3@G,6HG]V _K5BJ[1: KP"(PE MEIPL!C,]P. ^_-"QA'M9 GLM+.&)6GHTT!> HA"%;\'*!4IO8Q?QT>G(#+;+ M+WK %B['D?X=YA9P-D'O/LQ#(2QU$>9"*/8R$;-K'8-0O! MUJE1<++H<.E8R$HL)-P[%@+HKL9.*0:,%)Y; 7X#S;( !H(::59:M5+T^YYR M.FDZR9[R\O$(*'N 2]]/%4@[Z!;L@4)<#IU[KW]WXG48@ M0=.W\[!QPQ:!+B^^_.A93 %$N+T&G;],0!, 5 M2P E? W,//@,-[;&LK"Y*Y$!X[1GH?ZQ%G=N#0TSOYKSK L7=OV4DB=.4QHJ$: ^P MR1&GSY#9S22;/CDQPRXM#P>*QCL0?4#DDF%YXOULL$[0)7/O&ACT M4H5U^NB^FK]>U M'_C1:6E^M5D0\,MQ SRSPD#-BACG'P!%Z0K^=H5?&.05/0FK4J^KZ'.ITQAV M9SCEC$B9:,TIB[4 >"6Q7%9.W*+H3^!5;6@S%3_VL:"0G2SK>E/I^95L[V+'QZ([_6BR9N!X%Z<^2B&S7!R6^PX#C!VW#*0]#]FB4%G&N]X M2D!(6*6!WQN\OK1$57%]H4#2(=WV[WJ6"M6U&."'V: R!NVW8&TERFO0@92! M5;27%OE-V^*% >L5_CI [$0$A'50.?'>]/.R?(MJU_3[3:K&3^S[\X&-%UOT MMF9X]7'JH5%LA;+;NO5+FVLS*-U2\+OQWJ"RH[-2CD(1(8D.(A8S'G .>!1%"3&^]$.C'NH4>*U&]V7F5(>Y/S$GQC3< M$[(H1/ZC9]'B8;!,>SAO R2ABGQ#"2%&)8R&%(A+*\*X$@%+"%TB8K8+$I)UX6=5U+,D[U3S#^-BSJB>V=$X6',52_>:Z_IL/;,7X V&;I/4)/* MAQ:;08>"RS$5I8#Z-K9>_0KI02.&3:LY+2I@- I2PF,1,DY\P=(PB8BO&#-4 MQ.H?G_#=?N 'QU-5I'<. SF]R0 VCPS96:;'4L M;S@N .@&;-OS%&3TO>^K])"U.]S295S!WZ#6P&J1-Y_!B$>]K/ MX2]9ZHDA!J+@JR/S=B()X8^@9MFG'8JCI5 !:XELF'C347=94$WP,&BSH.*? M:0O(\:!O2K=5_$K/;F8 !@I^5XV+ DYBG0?5BSNZO#^US=\7PN0G=.(5JBD$ M?3<3G+T?[YT=CTC04&'A<6N:IHCHE64+%&7M^V-,>4)/^''E]&_$?\!XDRN6\:%4^F,U'=2ZU65E]G96C MO*C"& TV=-WJ!A+WL[@*(C/Q,_NLI7A4!A82P(#FKNU#/\ROO/\+'YG_3LU3 M4%1[?P!C?%O[K.X 8C5 MRG-IAJ.*7_EM.@_P)20M^.8ZKC*C>!(2(4(I07V7H=0FC R8.(IIJG6EQ/N< M^JO[%A_G*\,4IM!O"8?/^LJJZ[R?$!<1]<0[:V?^O67B$/ZZ#D 3%O-(A4(1 MP5F@!1=^+!43L"V:&+Z1L_9Q (U6 VB#_=P/U(K&)L30JV.2QHK[,E]4)N9Z MRL[JKO9WA&$V& M7:=*0C!6/9IBIOBA7;C,]NJ[+;1I/58+4GSXB9)GWQZ/E MCRP4/#Q3%OR78Q+.P:OQW^M)$ZPAL-AC61CQY[%(8;OO1/]6W)5'O\TJ%J!# M5,MS?/_\Z;?L9USIC$_D5GSL7E;W(L:@*5CQ!HSE(S(#X/Y-=^*"NK<,UT[_ M)HO?UG]L=RBZ4&AD4?3WSV=__/S]X]F/S][/'W^__-GSSK]]!,[Z[9-W^??SL]^G'^^/-3C?[OX^?G2^WGA?;SX=GGQQ_FGLY^?/WE?SK^=??MX?O:' M=_D3_O#U\[>?ZT/@J8^R( ;;.,\<>[:")6/$&*IYK!,B&4TT]Z4B$1-,!;$, M(^K$(CQC]!G**AK)E"A.9:1 +@8I#R(5A[&(E#:44G*T?7OH:,G68YY*/V:: M*>F#EA,G)I$D2F6@.=61X4_>$M]>Q42>+C%/ Q"S9C K>JUF6MD<*'V=,6&% M^%)%IY$SMHY>HYGFW%><*T&8G\8BC$(_H$:J)-6"FJ?7:^*U&FF0-(Z"B,+N MK9\ZXDJ9* Y]Y$0: M)<:N_ 8>MVL,\IFW3HRJAJ%E)><#EA2Z0C)K?0X!C+EV8>&7C8=\R3T^]MI M*H#VYN++8UF:?XW1N(8K7 QJ@''8I 8+J\*' =['#F^G.+-YU].*]V; M0'$V<'0VD^"^8 FNYREM+V>>\8ONPBVZHF5W=D\F=Y74LE#?D(^+F5K';/ + M?K*I)CU/H#>Z'-G8[3H\=,,.=LD\"YV6H)Q/ME45H]R=C3["UE9CIGS"3!,? MQX,MRY.2CI?VG/?M*4^,T;RVT[I3_K#NB,'5*$>.4'X7=V@-KGWVX.C4;ZLD MDU,1,KK.RMH;6E>GHF-Y4H-BJ:PN5$*7)*#OT.UG/7TOC$$;EL#TDL!GH6$2 M]"?)(QDDJ6+^LNC^D^ (03@MXLA#< +)6=K:+N!"O\1 62F*LL*@Y&LXKQ6 M&F*@8QJJQ,0A8XH1$8::,BIUF(21+_0S@I"NAVJ;E%:# >(J%EQ<8:%<>_%: M;%33!OD>>%L=BA._1-:WCA=SW-!$^#?O\P< MW5B64A71X'<&P/-19$C0OP:FA&==M*]GBRPFP<4JJOE75HY<^N_T"3QHKC)1 M9QC:;];5@1X U^T8(P15?7GSP\+K[ M+6/_OJQ)0*O@O+_B<$VI&D<@4P3PQE0))E0D I_R0+*0TS@-8_:,Y,Z0W%OJ MPB<"5?1'U_GXZKHR^93 C%0T^@"'QP4R2X1593Y.HW'][%_C3%=H-0F>..23 M&.USI'EE!L;&$RTRCVO*+N=Z.E2,X1YYADD)I5?ID6Z1FWI72^ACKH1U@4E] MK,/T/1O.:Y2TVKX4,T$A!:<%%N'= ,[;\VD]-:I7I,\Z37E@1O@R98PNIT2N ML[*.6%C4Q&_.P*BQOWH7X])MHC @Z#>VS!=CQHO\86%6-(_#)=,U'QZXL&LOWV0PNCG_;ZP:3[)L2TR0H#9 MM$27&>+R^0)JQ1'\MQS+?]:I7O=F+0IE1")\HF.=L" .)9@[B4E%J'E(DR!Z M*&NQD:U8;W:2K?C=NNU6RE=,0INO>-R:KVCJ!;U9)CMAU"YIT_D'I_[NM6#& MW-,C.Z("%#'LI>5>2&J+H."$3 MI$JP>278.#HP(A("SJY\'^QMQI.] $&,/MH'0;"*H*P*F1;\VK8^$"T.6,3A MVFCJYJVJE^ -J;'(6KM[K8YQ(^Z:U[Q;G=L8/.^ MVW2\8,UR0DHD47$<*[ 30)L/DU3&0G'B4+#HO%=1VK M>OD]^Y;?U=.WZMMO4K@_PK .SV/:9S35L2^D8"1F22)](ZB,_)!J[J]<0KW^ MW(DI9\?:S%4R%]%1TV[N-G(4UW7>[D*S6QL 6$[]F/,_H,6,!U;GF%+=C*=P M%6:YKH^,!I3%0H8FA1]23GBJ&&B+DOL!XR):YA)?25G\46=B/UI=Y.3HE/CT M9'$20]V2:RHB6MC6#MK>[C?;N1AX9^,K=$<%;=G4[I>+[[U) >HW46FC9Y6+ MW.9F ?;^RO38%0(,7#>C*]1P:Z9><_$Z'[_^W;G/X$16#N+_"F\HBAD<7G3$ M34LARMYL;11^/W5%%6)25%'GSLS[S1I>C?E"C(ESP_OO#/VKH]9RC=G,<^<\ MG0JV#!L1I*+JZ%3%4B:;^F+;/GV\!DS!)2H%X8=5$%!?& @L!YFK!:G!B4?T MT@S1W_O7&. U2"[H^CZZ)V;CBAF:VJJKA25XP'VC$[54A69K,$_K7%S MA1[V.\,'('N07*-97&4#7A5* R0D8^P&X>HRI\(-&@D9ZV6!;_L2*#\JLCGH]P>/SW\_3\9P/] M>*%'5\EC._$^FL)>C4-X-"F*3#6[G0QT%;^8Q_Q;6 )C2GV@%W@4@ZCH^ !L M';C8J;V9FA-E=3^<)LW?B#^=D\7TC;L+>&>ODK@V@"(PAM,HCD,'"A:TW31< M)8W:T.IM"\,\P@FAC!!0KQ3C*DQH8$BL%4VH\*-0[#'F,=#S_0=1 MKX<5SPB>:L18+U+C(]7_^LI[5W#V#' MQ#IV9CAB1K,5D/,PS>0!C/*VKU@+N'(KO#%_H5 HZQ:.PTG7B[?(&JLJ8W%/ MU^'6#AV!9"1BA!(64A:%/C<^#1(_TAS3GX.@-1"P+FY4 =0%+/@ DK+JWM'6 MNH.'1Z<1.0G;6G=4ZMT\P._3%5I*7FLUYP8C_=@0RA9C.\VF1?4I$=*85;(I MM&E*9*QU E:R!&AS(72L8L:(#HFB)-P*M"T,' AJ"%@ M'1GXUCXU]:,"Q$R M./']V6!ADT_^7P>2J?Z*LGI.4UQ4$0-K#EK-$AMG3[YIG45J3J^M+GCAG>V- MPNKD'L?1IQ)F2K6SVUJ2TH%BJ[",.'<29/Y17,W%D*IGJ%<=J76OBW6-71UC MHXXQZNH8]V O71UC5\?8U3$NJV-\L"YQKHXQ2*2FQD^UKP4+8E_X+.9QJ$4: MA2H,S!IUC/MMGO\=3MUO2'.TK*9)=0NR<-:"LKEI6$*&G;YM*P_0=:WM-)OS MYAIVNFHT;"0[\MZ48^R=8HT\IR*7 M-L0;43 X7R&=2Z.J95HM=$@9+LNH\\ M(O^M5YL3-C%E5.5!V@9&L$6WI\659Y45&\>W:G SX%X_AKV! !@@\LTO87.J M)VH,ON;&C)H9&.4X33.5F<%H!>O2;F-)VJ;+LVR\S%KATKZPSKVQ+M,JVQ#] MIAE.+RBF+UC5_12^3/Q> 9WA9E$-102;M2T!:Z[SOG5X6DOPYB;'D^3J3U0V M+<9CNNJ@SDNW?YE=XLWTU@&%QZ!\@N5DERM!SS?ELE36YLO>SJ2'J00.>-+A=S_A).6&!KP0%NQ)^B!*6$K#'TC@, M4Y9*L[KQ4X=XOMM>1$"EEWC 3]7VL#?D_3TA.6@Q\0F-VRS+2V.CUV?>Q_'- MV*G>P!*T,3=6[8&%A\;V%IN\W+-O?R!V"L]=XE7-^P)#D@J9".)'8! &D:04 M[$$M4\V8)'1)^LR#H/@NBHOBTF:#_A=Z#Z9O7S0!$TS\]ELROX',*]_#$+#2 M(IKWIC(%)U":@\(T@71]_(A ;J8'I\$/)J0/1PPI"253B9]HSD I]Y,@CGP9+ F&;A$_P'SR'X$@'Y8AR!S+ MZX,T0B8VG'S;,GK/4>E =K2 M^YNM++(E#RXP6 UWL>H):E GWH=Y!_K#XJQ6 >KZ#(1%"QR6R[89:>-BDHTP MP+S??]*2<>*IG8-WPW>7M7>BG=R/WI6N9D6*[7S*5HMR85)X:E6 M3V*-9"AN8;WU6*6O@IARI5@0$J8HD52G6B9&*JD)I_P!5DE6\")^:L#_?/#Y M+R2EB_1KKC,L1_L"^G+Y!9#K8M+(?KDC%WA(<'3*V[@I0*=>TOORY6*%>YXZ M;4LX0@WE.M<",\T&"["V3J-[W(GGT_37WF*T:75B<1'HT:36IE+4JB3;)RA& M7DB"LP9D%I;7<)_'*C-O30= M:\%[A*G!_;MJ[F<-9^\*@UZ#FE_)@KTJ/QER4^BV-A*-&8LHDE:E^ MM] (;:-GW_#YP_G/3V<++W;S^I0-Y-FJNWJYV>V)@Y1!P.'6==7L[@A?2997/U+];UR;4D8R!.0;48,:"+X30)M%^3 (0CX8^ M8W@:*!/CTVU:3=7T&^]A_( +*:T^ MWYHRL)@M\$:\75<4!3(**=RAC'RFP=37+.$I,UH'C)!T.RB_>HX W%J,20+D MGB2!6B.OE/$JG\HB==W48GE* )G)O9P+M#>_2'O>&[DN-).$1SI47#-I&"<2 MZ,%$FC'0I0EGPG]Z:"8(3;I( QM"$_^^T/>;W@?3^4 8M8SJC5H7M!C\DIQ0 MGE#!J#&)]"EEQ&@21BSQ']*9=@!:6]_&M@K:F4P/5JXQ: MH+32-(:_B42JS*@RZX%14_;QT#]:CDP*^XGR :Z%MAO#]2+IFG;$" M.DW35 ''A2M*.8]3*B*>"AJRD/*5&PAAB0V Z8>YLC&,?/"UZI]3?5"CZYF= MH[,^?E)+R0]4&L]0\WUUK&_@!1AOMLU-,C ZQ31WN_IDTI',W,LDY=AZ7)_= M2?RZM$W\\Z6[VH>% %LB!-YUJN:ZH,0Y*2!3Y\)]?'923==6A@-B;Y*Q5#N+YJM:7=-,5_N6 MK3LL-)8B\;4A4D6@=*E$&-1".1=QPAB37Y(JD0B$Y'ZQ##*2:)B0DG"&:.1\/F3@P][ MU[=Y>@[1:3T30%PR.G!1.\3?IX-';=W#IJWY),X]G8R> ]W"#GX88!Z*12FP M.N!'+&FP[4K>67,(QSFU5,54=@.NL# @T>HMA2U@[<%CPXJ!Y>W-0?K&L9>> M,X+7PV<6)SI.19#JU&<\-1SXOPS3@"L<*DR2I\9GCFVG@Y8P#()U32BF"5Q$/A13,.$ M:;#/*?P$ZA&+64KA3$]]-&*US;8X92T3&Y>\0<*X%8N62SXKXP03R];Y[PF" M*Y#Q'@>*^<8[U[@G4Q(!NHFPE3O@:II82*B D2[I,X%)JLX2'RICV:-S3:]8]X/.5?(.J]M6A/%I:95 M@YN< E@Q4INVZ+KQ8Z+6>GT)-BR-Z6IC[ZV-C;O:V#W82U<;V]7&=K6QRVIC M'ZQUG:N-):GD) 0[7H4Q"Z3A(I*!(O!G/PBT# ^F-O8+MN>RGK\'1WHU>PJM M;=I,&Y]O[ /:$YTR"(7Q&1:!"*2Y'Z 2J989@^N:D>H[KO;T6G9$ B M@/.&QW[(>)0DA%,"(B1DD:$A>VK?+$FLPZ=%IUSB\-D3#(E\+8V2$16"L40R MR5,)EBY/_(1%82J>&HS<.G.V8NOZ0I$X@G-(]-[["9 "2?TP3:2*:9(^M4N0 MNE2*$D1 .G,X&@3/L!IS01,DEU3 56?C[UI0?++GU] M?#8QP4*TD++$9]R7,E:19$9$L0!-03PUJ>+P<')"6TCU]?EN4D&PZI[R-$D9 M3V02RHB9)/0Y["AF3WXU=M!@V]5L@'6!3D"BQDH8PC2@6Z"9TK%)-572#]?H M9K>=H]E <*1YV5:EQ6 M::([F;"^PA2\O7"P/?V,]2 &EO'-.MD.Z$#YH1T(=''2](0^]8S()>/FK7PE M[[W+\MCWO(^MMLH='^#>[2XZB\Q?J&ZB MH:5[S:Q!8ZLRIY_VO $VU;]5:K1JKD[L>#CC-,2]QP..TP59"V M'!_7S\?ES&9KF?-FVDY$2/CKVY:VX$O%F,M?7?" @H96Y'9R$H -\QV=2C4> M+E')E:N)M%!7HWJ8=','TO0ST-M+"\[I,5R[EG*RDYD\9&+8S0?QKH @AF#BBJR/S0Q;4/*^4@_7# GK;T;9:(R]WP=N[D=S[$?= ML4**ON4)2P8E3L95ZVGC*61VLWVCD"7G$MF5G86&,];M05TE>/.H9?M9ZURZ MH2B!Q\IQ'4AO;]HH1E5D?1D\ZSSB*WABY-33JB^D\U*4;2G=C7$;P,I LN'E M8A[XL>V\4@\5;O3:' [S8H3XGJ'O8CP"D/V/[4^98\O(B:'5QC0;HZIG1GJ[ MK&/-R'YX,T6@- MAG>^SC&#E 6)AO^:T##" \G21,LX5&&$;9F<4XG6S'J%\]95CM@_"\]>;GQX MAIF[#Y]=%^)V8*GLUZ>UC@CF7G_+03H%\5X;2!/4J49G M/::SOSWK?)93REL=IFI_U8K$I/6,E4_IH=>;Q?^6'4Z MOQBX <4/[*/Y]:^@T&;N7D Q'E@M\8\_/O9LP D4(S![1RXWK?'0S'R7QM_G M#O'>74/+%R8J]/SQ;?KGI!0:0[MP&=G\#,=RTJ/G 92O=^+>EU\96W1=9S9DKN4,#6)NI.HC%>/65N+;KH',#K1@[#ZH) =Q(?6@X7N/E.,NF MGUNW"-ZA53U*IX0TOC;1@IL7]_7#)>J]V*7Q,!WFY^B#&0RJT6Q32^[AJUL, M2S3G 5IB=Z0^XX'"V0&-&SW!#LU@^S1;GM5+%F9@;LL*">Y;9.(%R@HTDC*G M *S1%V*I]IE-S/@Y)53ZL2$^DYJ9E,4D%7%"N0Y]1C26R"YI1](:T"RR7]87 M^,UZ)B[2J>N@_-WT]8P2"K>L4!&]S0L-QGN;ZX %1Z;-MR+PS? *B< MI;44&GJRU_D".JG3F$?<<#"LB)2)UIRR6 L 1A++):.G%]PF#T#B3+E7KPD/ M O#(_EJ$!IP?O:;(4>S"2XTP9"S["A/053<$"STZS0=F$2QNDB(L=BL*;)DA M"C=WM0+/V;#(^M:?]-9Q"Y1FDR[1$Z^K[>Z*0!WD50['=-3?.L;>9E!F]+1Z!&$K>FK_0'JYI/VVE4TY 9>?VT&I8WE#!2ZV-[LE]%8&O.< MQF'GP7CB^"ZO/1C[[,#XU*!")*3?@3\@6["R;,:>?A:-/T0,TJ GXRM M 74%8G&NS?"$D+VW%K[EOYQ^!$S?[[D8[N"?X\&< 8$CP)QM6,#[ M4@R'W-,0L0H\W,UGOB64"I*D.)^(J3"0A(O(IR0"3&=&N"QL/ZA]1 MIFH5ZM(,LKSX/1^C17A1!V"_3V(?ESGHF@/]L]HXK*U<1>L7&Q:)V5;E# MOH)RD%W!_6$8'RPIT,2\B?Z-II09*+M;#'%/(B,/VN0+3H@'IMPL=/P!C8/Q M5!!IF)!!H@1A) U\0;GO5QT,EH-[4>OZ@2$?*SPOTD=ZUN.C4[:TP^)$Z;)& MJ!T6#0J&A4/NG .3/ $O3DG>6-.,,!#FW[)S;BAI,9[G7LT!OF>7]VUAE *;<)/M,9=S.#]&S;O0I= MX9[N;TEH8[E5D_1^+O!>CIWJ.(*SEO->FZZJ>:ZJ.>FJFO=@+UU5K+0PCFQM3I:Z-'O?- M1?H5,T&MW <-+A]<814&YK=9%O03WOFAGZL_&WI:)W9ROL= M"_UI6__6PT%&E@.7-D\9%JDZFU=0TPV'Z'!RD;4F/.E'FJ+/Z,Z(HER2"C+7 M0&8V?0]MAOM2N9JY559Q>G-3M91&MQSLN$J9@UT][(N[=]G PML^]'X61U 3^X6J)5@$U5OL"]W' ME8;!^4D24E0R1@7\J^L75_K'B=4_?AOIQ<^BZ"3PZ=*/_9-@P\]"2C9Z\K[- M\A,PPKJ][F"OA,7\GZ;!+-J5BW%)DQE#6BV'+MOT@6VL.M#K^[JM&!X MO N 88?^+ O'48E13J3ZP7&.CC:H^I_>?]ID!Y#O9V+S/#!K]RK@Z^3W<_]1"8:ITMP9B(FN$RC M5!)?L2@PH5J2\$$7BA@:QNK4B&T&)"8:ROG@&[S^YZWI_S)?82_7Y6KA"=HP M>W'462^@?$F 8F<7CY^NB0 = 7<$O$,"C@*EPLC$G,4^,TSQ) FT]CF) ^Q! MN&Q0VS,3<.@?G8:]..H(N"/@5T[ 2BLC:2P52%Z6^B$6U>F &-]G1'$_W5," M#HY.HQXH#R^%@-0^ZW\;8R2.1TFVHOAU.+F_./DL*LW& M.(E=*A/095B\1SBYJ0_TA:DKX2[7?(>7S:RR;(66T75=5AY-[B)//I[%LAI/8KX[W_*T%0#H/ MR\HJ2]1Y6 Y29?F2CXOU"3$Y.J4Q[U%.]\AXZ)#R4%26S9"2 U)2UHO9H_7H M#BGW%RF?36?9""DC_^@T#E@OH/O$*5^)FR7NW"R'J;/83D0MQ!8>3R69[W[U+L4VY,?_8XJ\%1?)T6G5AZ3#Q\/%Q^?31I;Q0+IO// U M.$A^3BHF.S?)@:D<9WBK[1)@%?W?AEEYC\1=Z/^ \?(9U))[\/(!S233^HN0S:":/9)71/K+*U^ J6:Q%?-J\_VFG#D_G8^SI4)^Y*PS8&H .AK%M M2P><&Z FBN(.@+5.P^8F\XJ/3L,D[ 5)L-W2@"U<_ MM]/N@ ]TX-OC9HAN<(;MPVW[ZAYBC^;S@?>_Q_T['*X6]ZHANG:4J^AC>U<] M5B/O;#RZS@OL[_W&=0@OS-48VRM7LT5PI-D D%/A<+61'?,ST+85AQR'QM0CR!8^Q=%@_ M<% 9SDK'Z<&PQ8_Y#>QW9,QDH#5>7)9FU;.7U52V"Z"5 8*W!B,<&E?PWE0S MR2XOOOR83H)S0[B'D[%HHK$%@)*#0#:8F1J"I\OMM+-T13TS M/;1]&X.'+Q4>3K/B!E_O1KW#MP Y<:J(NXC1=8:S!81&]*GOVLT@$".\<3MP M5]F^YK:I.7"@>NAPU1XR![R[->9/=S>W^?$-EEE[?[_\5!VR-"/L@@\ N8&= MX&@Z0,IIP\OYWJV!&_=2F!N1#? ++2NY7>6VF:L%IZRV5E[;6VN9KSX[1":K M1L@@/X7'A]C?"B!W>VT&U23FEDG#_>Q?XTPC7*OQ+GCC'O"#/\UH87F 0C9R M,Y41, 8;AUDT%7'\$EE?R)E!Q:Z1.1PUQ][,%CNF MCTU&<-DF]3@+%GMSVHF$U5#DZ7 ;.]?:?6MV$LC.I* M=34#IT)][P8X*ZXQFC!L]QKA#8#@FZ2%ISCQ_OLZZYN966S5^"C ///7T.": M;@\.=RI@]_$PMF7J2%CXPM>1BNO94Z@5>#AFJ(\SE[#;_Z@=V29\;XJ[CA]. MMX'3 GX)UY9U9O ELEE@''E9V@;XEA ;X)3&C@(:#Z9['A89OBYWWQV!#$%L MS'#<$ XSSQ6\M6>W9/X2-\,^<+HLQ7F34]1V8Z+P@AT?!UW'<@18]$;\:1Q3 M+TL[GJC:<(6F&GOH P((0/83[_NX*,>-4V'^'#"#,\ .C1C2:\[A/IL.Q!0X M:<^-1;+(6>2_,OA1/U0?%5QQ)6 MT XY3KQ/XZ)F$-B]U\.!\?JA*8- ):C%P1?7&CJ, X"7C(?$TD"U.>QC1=>4;\X\V4)HP# M3.%/3L('8#PS:_;B@_='CJ/X %"UP+H/^JU0OLYOS2]L+=T$-6C+0%8X%;!N M(%WV%AM&>V\0(I,)GNL,IG4#>1NBJC$2SO+*:X':6#5V#G['J6^.(O-*#I]X M'P$!<.Z;57?RV;ER]OEY\0-Z7+\ ES7PH8&Y G*ULQ=QK$U?J'HPVKEF:_K\ D1Q2P*8BT8H\R7OE2Q2%)@S#0, M_$2%3\^'R=%I&"8GR[R9#3YL,:.28#(O"JO/ [VN@G9<9*B)'2/1.*:S#@P"JI+$R,CG/F.$ M&NFG(C(R]@4@H@SXT\. 0ZL)(J;*'"O2)[E;74]3Y_*O9%O\Y!.;\L,ML MX @*)ZBO,CK-#>AY<"QI$A\]J&B$JR@:3]\5W,UA JQR'"*:W...I_!\$5GQ M7^C2^329/UJVC-R)HZ.)ETV?(2-4R@1 M?)'W7[7S:.JJ;,P:]Q:""BN,A]EO3;%]U-3#L)N%-:B!/DDCL!H3PGP2)\Q/ ME0J# -0E3EAR=/J?9V?? > 8H4'/)[K0KS-3H(_X#N%=^1S166+4]2##&8U3 M^\8Z;R7ZSRLWH[6M!\,QW,FX=);#C1&EP(><KE32D;8EP+LFE^X7.74GH(1 M34(-2%UD$G=@8"?OO!:&M0QI7^/@1]X-?MR#O72#'[O!C^T*1S?X<07I.B>- M-1'"\,1$(DA98BU/0\+$$&%TJE)QM)[V6>5G'&.2TKMHA0&%QRA!]F$&E9@7-DZ+3XSNK'_:*1%.2<*P(ZARI55^\ .G(SGE0]OPXXK>ST-%"[(7:''N M]$N73P'7._#^-8!@(:N6H=S%Y7@.]1J%2PNT0=>%+E$ M05RMVERB4CP!081=;C;*C(LCOA5F$O4> [*BGZQ62=V[XUBW!=%JQGY&-S; M7\,=S4%M:N_TQ,UO4Q &;;!.@7HG9N;4:"P [D#+I5?"(;,4! _(AG^.]96S M4%UN2YG90%H*UY#CI-ZA4?C5.G6BC=[/!S;;1@R0@;E]C=JV;(< 3^SR&0F5 M-3P %;+:@*W.4AOZ&\U9PHUE)N?K59% I,'J[&U?JSFKBY,T6-R2K57 G'-1 MH.E?CB9O@QU7X=!9Z%906W9JEQ#@WH^0;$8CJMPLXU+VIMO74^>89P0(N<0_@:T:WQ@SJFZY3W>#89M7([3,[5-=,]VUW M/'YU"*)1D6LZ*N&>O!^8]6D=7Q]$F94O'"KMW&X:^)KSQQX>8S_KX\31>& ;V8WEK'!3NHDQNJ=Y1!S M5&PV7\W_'+O-_C3][#K/M4OW3,6X/T+/ZTR2U, %;N>R/J9<2> K75#CGIGS MTR3FYI4@DRS+*OMZRN*=_];>A\TDK7^[%X:UF_L79HOW&U^JTL@:&2RUI]79 MALMPX_X; ]F&BE:+7&K=0>/D$\VP<;\M6?'WH>[<>29OJO63K)C(/Z:-PHIXUT*57F;1U"ND0/LJU2^&U+1SN M+%W>&DS*+A=MTRI*4S.1Z6*S*>+ 1^I:!2#$/J+/KQS#&3VNK#PN".:)(3Y/-=.,^$$^@(/;0+--8\O*/R?Y@0L?U"SD MON2U)XK$GEF_U-E _S'U2M4*RL5@HH[ %[[E@Z+^U2HGUG??%KZ-Y\.Q"R[< M_:"_:3'(J$IH-Z4CNFG&@"=D/AZU7OX2E]Y-0[UKL#,QD\:W5"J)JZO"7%FD MK(3?VO9.7LZR$%01-N2A%IBMJJ2#V"1L:$L"X>[Z8EB:=_4/[X%/#?OB[ETV ML#=@'WJ_^,:YJO8HU8NKL-R)#(Y@NIP:0!D"S/?]A%?\5M0?8Q+^@V^;(W^1IZ*S8!8&_03 MHH6YBDJU]>Y+KZ!_TF%V0)(QI5Q3/Y0J8((1&401T812'[U1?K1Z!Z0:2R=. MJ(MT^D?KD'*54-_RT46:XJ]7 AT:']&M,$*']CH]B./D@*W&V-:@M9H&)A!^(@'/X MT9,%60%&/!]ULZ0-&49&J))*A(6$:,!UQ&3/E:T-(:!AC8ED' MJN?GH*SCH*\ />,T9EKH(-6(C226-*&^VZILB0[8E]6A M:(VB!AM:2-!UN E9"+_PD$0R4H;HD,9\OU$T[E#T%:"HC@5)4LZBR-=,ASY7 M(A9&A3KU*?7UMM2?W:#H(0>\.Q2=^#AD0GPID]20@,DP26).T@AXJ^92JJU% MB'>#HGP?4?0U^- WG[_[@.F\M=S70XOCK7W^@^%0VS)%)GSI&[ ==!A,>-(Z M/(=O+U"^03KW57O&_RZ[!\ M.(](Y'^Z>ML-UEBC$DN&,I6":*(-8S3@TL2Q(2R)="0EGZ$ /"Y@_Y'W5YF] M&V3]JL/USE+J6N@A00#-$4-7!+4Z:K]9ASE2(Q2H(5(F,>,) \,ZH#XQ44Q! M0=%T2\QQPQS+54)#'+@G[7&?+N#, L6^Q#J]G3*&D!L1*Z43HC336$4L Q$: M$FD1@947[!5C .3N&,.3,08>)7&B"2A.)&6A5#))_%C0."6A$H:E^\X8 C_8 M+\;P&MS^F^=>/](XJP*5U<2%EECEJ\UCV3Z ]IO'K=/B125\!;XU"HO,>&/4%XZ-M"Q@=?)!M;@ E'D*^,' MO@I%R@A1G =^3$)?1%$J4W_E6,R6E("M9PATU-]1_RNC_G64 !W'A,2)STS, M6<*5%":6@OJ)"4,J(O6L2D!X2$J ]7_\9@C6#OG_G29P^>N)]G$Z:QU5' M=T,[JKD:FXT#[MT(8_P"CC.>>P/.=%5P)0(_MEF8. K7%,:[-7:@LCYPJ3BST]MK/<\?,[(W 0LH;CM \!G1O1B;>/M)@-W 3;F?NO MP,OPYNL!TN\*T[=.PVIF9B7K&T]5Z.)/'Q$2,'D\6O[(PF2N9T*A+\?4GX-/ MX[_7DTJ2H;@RQ[(PXL]CD<)VWXG^K;@KCWZ;)1^@G6IYCN^?/_W2,Z;ISL[H MR!7X'8XDQKL!+@78#M^"/8F]V8MW7:!D^+>,)'&:TEB1,(V9#$3"6,ABJ305 M(9&Q^$=\=&HG!".!?$2A,AB5?_M-G"Z=1+L,UT[M(+JU'WO"L@>+HK]_/OOC MY^\?SWY\]G[^^/OESYYW_NWCB7?V[9-W^??SL]^G'^^/-3C?[OX^?G2 M^WGA?;SX=GGQQ_FGLY^?/WE?SK^=??MX?O:'=_D3_O#U\[>?ZT/@J8^R?+I= M@^?,L6>KEF2:"(&5]9$(4I:H)#'2D# Q1!B=JE0X@8E=LF\W:#J,? M1O2]S^4(1[.?#WZ9:K:Z][4Q_1J5/<]J>TZ"?\L'QY.)XIZ=(;[96.J]@4V[ ML%H&F\IT]7XW?6W5C[^79IL F-'XGGFV>C4LW0.#(/>NA?8R^#U#Q"@0.L9! M)VM Y[J&RK@TO6J8N=7$E "$69BG;C$*RV0F0^F=7H@?H+X%Q&FU=#=*7?3% M0!FOO#9FY$:Q.^7K@7GL)]XAWL_90^?O->?=>_GM $"XU&H<%OD0U.B[^2J4 MT.>$J)"&*6&A]GG@R]"/ AJ1(-8\;*^3/O_VI389K]7HW:>L!%U5]/\3C+;A M^4#UQVAHP5\KUFOT!;S;,F PD^ <%^EWMYW,E$AF7_("B&QB/OH-\S'"O,(% MTW$&#;WA9#%ON=F\! !1G$14&D,#K,9)J(S2@' 3 "R881%]6@ TC&M &X4& M]BW8M*49M ('E++Y>?"@M>:P+CC1 @<@DBQEE >62\53X0BI)06MD M2R:^[ DXDJ-32T"+\+C\_>)[^=8BC&-93K);XN61FIM#;A"\EP"\5AAB)MIB/^X73F(+!U\/L0+_ MZ'1TFQ\4F3T6),%#M"9 )Y &*>>F>I4E/]BO 7.KM+X>]/O,2C&#:H-5!O"O MJ(VH$>H*2)*5"](;Y99Y")@N.\43.LQ.I20_2E MY>.R?V?7!K/:+9;;6??+I)=C+-?B%^A 8UF:?XUAG^A*0Z\6Z$GZ@#4=;Z$A MP3;T&ZX9$T$BC>*G^1+E9R.FS%A( A-%,0D$DS%) M-$>/@%8FH&E"EH11]@08#' E'Q>/57TJ3M>N_#A6VK#YGH&_ES6#A]5QDUC[ M\E2\O@X4.)L3^?ZZ*)9$1 A ,\)TP*2.!(N#,% TXB86J9'_^(1RWP_\X-C^ M0'>':^YAH]?&M/!>3'.(@;*JCOBD65&.ZK@0WEY+&.4PY)AW:EK;'C3>O#JD7=LOT;\]S;4 M7LXX'BU#^X$A0V!%YQ-^5MHG@O<[/N[]A\,M8DP=[PZ.I\U(9/URJY3]\IS% M:$P=(F_[\9 _& 6_-?H:CN !8#E\H?]8:TYF&%XV<085_6.;4;KQ'+!QIQCA9YH%^X4C?'CWZD@W$0&4 ML_-!.2K&#EC ;)?$CPX1[YOX!#A:@$UNXR.@*6I0M/J@0LUC(Z!+.H%@-6NY?"YJ8+"XN5U7HR.09FZ<=C8_K)R#.\! MY%6BO+9X:G_ [<-*3OB "CTJ,JOHXX<]@&TA\.S'" ?X>(#DJPP\ 5OL(3GW MT+,!4DA;&V%05BJW[1 M:O9PII_PK@_]7/W9T,.C(\ 8)8:F*F)=#-+O!_7,86_#&K3",WZ/5'4CL@'> M73LN6X(0-MT+,7((-]46:7SHOG&%R=/2]//;=RNR++HBW[:9@=-$+IN-J+#\ M+EG^[77@/8+(E>RF;] M$Q:]F,V^-,C&JVWH@9+J-7HK/--7^<)76RH/7*;8TV38\XWZ'Y,52KY?"RQF M>T&OB*%[4F^RNF'OZBS.46_(Q["J+E=IC[0!Z;P('+#6]7;/OTXYQLIH\Y29 MJ*M![F-M>+CV'SOQR86@Z:VPF98R X3^,3T)6C1**4KCG,%S97DN@?:1%[M# M!-D_ZD'[S0%QUA/2T5%'1QT=;8>.-NWHN&ORJ98XQN^_"^C)Q#M0^5^.W=^> MJ9#T/XN\++V;O!A=B2OK03&S/KC)1[:"95B8FVQ\4WO>G,_.NO!V0H_1R3PY MMIUB.3G>2XW>ZH2XR]9V+X$Z5T0FVLTD[L:W/<5P#.U+/PYUY-. *6:2*.0I M$2I(!(G2:(VIZ7(TC5U-G.QK5[$'\=%IF-!>TE*+L*?#VYZ;.%\U91XH69+4 M1$281 4T95QJSH. LR1@6NDT39>DK>^0+!,@R]#O123:-5D>!$V^=K(\7,K4 M/DM9Q(QB8<(B$W+&(\&!SZ8B&JW>ZW1)ELL43C_!X/-"Z;DM0/QBGQG8Z_3TPE?@0Y<#Z #@802!\3N* )+[BE,4! MXXF,PT E\$<0#V)))?0.!0&.%TC\'@!HNYTZ5[C5E]&)LZ//UT2?VI=_.SHLZ-/I$_#=)1(0HR)M)UI'\4I4$%D-#>< M^^3)Z9,!?;)D&V&[)Z//IYY;^F(\'5_$8) 9[ZO ?TOL)3#K^\A,N1_Y'J_! M^[$=)_A*G=Q?F?C8 80.1[YP)I) 14$:$1:F::)%: 0'R\PG<2+3)[?/0J"? MD/1\MN6TD&U<^\N(@W4LH&,!:[$ %1@1,FZDI"P6H?2%BB3C 37&,/+T+IH( M60#M^91U+*!C 1T+V#T+8)'@:43#5,:&2:VD-,3W@?AEK%(9^D]N9<;( D+0 M K:F>_6!:PXV%G>].6INY*LZ1&*BO_/WOO_MPVDN0/_BL(W7'WZ>?,_* MO*@@;Q#QJ,@$HM/<9HLKH\Q@G[R@^6BE_!HL"PZYR&_IE46!<]04;*#XH< ^ M:>'5+H ALN_4']6%X1N>4T;3<-9#+(;FR;XCFZT>>H3PD'Z%U??(4$[OJD-H MH*:=SY._BP2HQ0JCR"<3U'3>0E+' #)T@2P9D; M^)%E6\SA9FRGJ0V*L L'5:]#8G2I]QOU HR>/'<1K_JSD]:OHKWJT R!H[CE M>$#0- Y"84;"C5,15GFL&I4]:2I$:JZTLOE82+R?Z,)"G RV0T<5][D9(DKV+!&:""!KM?9 M'$S8?R0:(A*.SN:O.+X340![9!S"@!3 MP5(:,.75]Q5^(2T;:4%:0,^1(17?^CB][CK_+@G8 2W-X1@1YPX_+1^W7, ; M_]-:H,0GA8TO93^T<;,L$,Z[1*ZN?R;!6%P! PTP]G6EJ^0*4%Q;3L0(&I\$ M>"VKL:QTV$TYUAP@NVR9Q:6?A]+LK M$!0CEG>/DET5,#[^\9K_"TZ@_<1LH< KZ1,]%/X)?9L0\-,43AIV >1$!:K& MLJ'@T4G6CY5]\/#,J^QFC(%J<5 BDB&E%[4VQ:(%#C$,V)>'+XF,3'S:(9$ M)1DZSKT=5Y[M!+-:)W5P(@$,[L<+ M"D%\PM 5+(Q39KK?+M(*:/VS=',0M/A\GM2_5A;QMSRFXR3--9 T<,Q^TB , R]B/&$V M\STG"!PO<:)0\-AU0N%VDP;H2$@08\)'1K3O4D$P#Z7,N@[\6J>JZ;]+U&X% MO2\WMA&*\R: _+^L3FT,LRTQU"#?CJ1"UM#VY>!!,WL:OAB,9=N;,MM](8NU M[*EM.R]EL=;4#S;#6#["%C^]^>]A]1YA>@\(IG?#\U?C(0R:#V%HCV _ $?W MD%P;(GO_3$B_^3RJM\Z_)J*$]9!_2B.CY-U:P]7]Y5YU M]3L$8=@92[_H1>[A"W;4X4,U'?[4=_=&:H9-]\?6S8,:=7C#[T[3[(=(U"!# M>=OW&*TH3]%#]1QDK951-7>K-1#I.=IZ?H)RO,.LI[,BDT4\92P4%C,#/[0] M7UA6(.S(%LXVP"2:*:M:NF;^BP:<;EUU.DYBL#0",]?E,5]G=VIOVW.]P7BU9S%- # M%%#;]3S7,=.0V8)%%N,^-Q-3N"Y+;3]VMN@@W%Y -PEX$+;&F82F\S*$]*DA M:YX[]XO%E8^4_WV$9-9S/V,#YGMI2_RIPY7X&)4\?Z)V-_[.>'?IS^/U;$B# M@_%]N.DD7'A^XCH1LX*$8X+5]L -"T(OM!/7#%@JDBARA1\X/+5%D(3F%G 'F\CL@%AZB$/]8("CIQ3* M-GA!KUMI@V;-/6XU?HN0 Q^P/AN;N@451%=.VA=TTK 9^5 ;4W6C6[PL"EC. M[,ZX@A!L5)SJF*P+)<8C$9FV(YS 9)YM\]CCEI>&ENE'J6FZPY;PXZ25O9D/>_).S.>R])W!#+=*JN:\0 MG9BTQJ6@-EG5)3CT /SNLI3?PI; L>K^E3VDP GXZ\N[J?%QX!VKUP:/_I[/ MOJOF81&+[(96\9T7&8KP*3V)TUSPTDB+_-K@S2;&.^SI%3_B*^P@I=[81:L7 M_4\,SF5JE)YTP^]D/T+^7;63SK*TZFJH6TNI8S-?+NIGJX_(EC.:5C[/96>Q M6M[4>+!%:0CX<+*N8V$B.ZN;/;ZW0A],U>LLX3XD46HJ]KNKVX1+ M1+08.OZ5-T^R\1213-K?*HU(+&Z%F(^+W)S$H"-N86A%012E2')F3QU[8#?$ >+'32;[(TODACO) MDF"/+Z\J5D3&\Z:':B>DQ*)N&>A>:LI94S=AQSWJTW\O85_IW;"R*E%'H1>3 MX,-Y'"^OL0]?:"B*&!1/(:[$O,2H_]4L+\O7V!^?7TN( 'A N8Q*\>^EM%_P M--4&14\$:0>],:?&?,9.O7\LY\)P3#1DEF^\PC\HB_+[Q1OC-UB+,BBO)T92 M&\4T7Q9P5B!A!:*XPR/A^V$;K@'^<)U)D=S>L8,C=/P03(KGQ"P6(@H\Q^%?Q8K5W]ZU:Y[8^'K-.SA:W^68N'C$W'"V_ M!->$8"XZ7@=2<1LN]YCOI%:4Q,(TF2W"*#%-QTF\U*<&83)??(DI(J6'(F2M U1+.$S M$ MF:U/FV80FP1CJPEFW/*V]3Z_>/M1PK=P]&R1D-6?>4E"EZ#A(Z8;PORI0HB\ MR,!P@DCB$6A->:C:RQW17@W%K8)+\JB$H4T"XDIA?)83$$W#6",K%Z-14X5V M0/^U=-ADMLU&RY':AO"X&2HX7_O>-\[ M.3.G8VDZ)0#;Z00[M7@8V&9J\I!%;A!X'HL2%H-B"@+39D072].EGX+<#[KX M2)=^W-?VG9"CMB$-F$QNVZ[/TP1HXKO"EQ+0JZL7I^.J;V"PF\FYX\9I&C/&1&"% MKNF%,=B=V'(B8:9KQ&\@)[.0:]/$<8->D68)K0SSE5ZQ.W2%$";!?9SCXUBK. M!O-GBB#FOF,Q3-,%IN F(@TC-I+D>DPB82N0'TS'@/;O0R0-^ZSRRK]] M?'/Q!>7SZ\6'+P>9&SNOE!."G]XGA]708JU\-<((1J+MA0W"9#;N$JI4/-Y" M4.I"80!U;Q^&4MH-A3$'XAJ6#<-_J;F4K1S*,4L^QG"3Q4V:'<6#R*$SLP!(\,D7HC8O,?9V!;_D;T31FDB:? M8$66_3L1XSZ.@4NCAP>SF)-]WZ/?18V7A'A+%[D5+?8O1NNFG1Q$]GM63G=5A]1L/;Q^SSZ=RC. 6-;N/VG-L M;T?AP1:D%]2&,UJ@P2)!+P$UXHF>$N^P;Z5XXN.SE[ M<'O<$0AMGYK;#AH([7[2LJIW[3YWB(UF-M<].7/M8.*:!X@G>%36W3X-._8# MRW%M;/)BP@K=V+6"T K2E#FVZ0VW3CZXR6M-W8CK[2,*WU&5'U7Y*E5^/UFZ MKRI?C63F^OLH03L"AMEK8: "F2<*33:%C%EE[09(?+#6SG+B(!"19V)KI>V( MR$RY)R+?Y/"&R'KLT"0X.>M7WM\/)&"/@#E^5BX;Z!"Y%WL]IB\?@B]O3LR' MN_)'MML7MAM7;HEK1:'C1*X3,^$'V*,A4C,6:1Q$GFJYWI$KWU=NGGER-M9" M<.2R%\=E \KM7NSUB,K-LT"Y^3M)5.R0[WZ&Y/NW?$%S2U],WGTEI-+XB**# MDNB]P/D9L!OV#NS&#H]YSY-#C\;)>Z=DMDXJ[80T+U2X!Y)1]Y+JQS37SL[, M]>&(^]&([>K2V1,^9PECG+N,^6&0FH%G178SN]QQ@P8NQHQ(Y&[&C$ M=GXY?B^I?DPCYAZ2$6N#P%)'UU];G8"M#J\]Z8A[LE[%5C=I^7$>SY:)2#[. MS^M>X OLY'S;;.3\2'V*9!UH;?2\;FMC&,;"Y7X8.Y;)$M/&%MG(#A(& MC.@G$>NV-B)XG^R;BP0V["5BP;-9*7$ZU<#S"M5/PL= N%XN8,4*U3-5GRTE MUL_E'.B?4,-W*Z8? P$NS6ZB[LPQ(WN%'Q!,.^OYN\ MS/ #O\CFV.]"M?LI?=/XEA(SL_X*CT"HEHOQK_0*0Y^)[S^<.G:'/HW_7A5U M@>RE.(T*P?\\Y2DL]Q<^N^5WYIX\>VF_HLLGC F,O\*$X<[MJ1S_\_ M'V25Y!0$[BWJ*>I+X&>C3;1CO';V7U'QU^V_]H3= \2B?W]__MNWO[\]__+> M^/;ECZ_?)L;'3V^GQOFG=\;7/]Y\_?CNX_F7C^^_'NKV/UU\>__5^'9AO+WX M]/7BMX_OSK^]?V=\^/CI_-/;C^>_&5^_P2]^?__IV_84>.JMC#<[-G1.1SV3 MA-7^2G(4M<,,:)Q[B7HH]G@=L' M7_;2P(JWZ.0?[S(?7.E:L_O4W>F@?:>FU,#;MJ=[_M2Q[]M[O+HO>?RE]^U+ M#J9>Z![7^BAK#?>MW=MR7VB+\_\BPM;['L+6"VYT?FG=8"^#3S:$ C@VFPY1 MSCI2[IZ4,W?2\G=?FNQ=HO6\@OF^1%!VA*V*AOR&/4,.SNJP\Z, M;[#_@TE_^Y%C)[;)PX!A;!0'@1,ZB?!MS_.=.(S7H2[W\N"K\I6#X'GGF$&J MT?-D;O%\GGSC/[;/G?NR,=ILZWTAYO8#KL*-D_SR2'8DP"LW %"SDS!5> M8(96ZMHN3X3%DMA?AQN^9Y*-DZ/8Q+$?W-UPE.RC9.^A9+_:!CD[C&*?6Z9K MAX)95A@Z0MP[YU1J-OGE?'PY(R9$\_J0][V<@//+MX_0Y]A M'?&HN(4"GS[:\+JH1X4[-%:M1B'NX@X_XQ1VAQKSVHW3_5-*]@\!G_Z3; NFV)K#HHW@? MQ?NG%N\]"GYV)][VR9D_"<-^@?\>2O?/TWY:#W;MS4@!'BGQTBY15;!4/@9\ M2H&F'"#6*H;-;X0>!4XC?UOQ$097SWC?,UP8;K9KPW\R#?L(%-IO%;R%!KY7 M"?RJS+)&P'\OA6M[]8E]?];$9T_2,;'=L;^,]/%1!1Q5P#8J@$61Q=P@B)S8 M8]P)N<\$Q%*)%=J1;\?>UI=+#U8![.2,@0OU-$U31Q5P5 $_NPK@H2=I(VZ:=1 >WVR5ZSV@8C\@:; M%9ZZ^G>DF26?G[ZK>_[>#12_'=#,UV\T;+K9[XCC5I>E'- *C^>78G#J*H2< M>;DLVK,ZJ5SP.O\N(\R)$2T7G0F-I3'/(5Z=B5C-B>4W-[,[V4R)-W88V@)[ M3HWV_,?&B.=; 8^!\)2*4R74:#X^4GP4-R$R?6&;.+->I,RW4^X'3IB TK"3 M, SYR)SG!^,_PSG%J#9N04@A5!_"5/"]D[-2?!?S_HA5.8.X3>X8QYW>9HLK M@R-MY12;.D>PU>3Z>]'D$<.RJ;=FK/,KV.CM519?C3-"S>+=P;Q1 MDOJA%PJ($9D=14&2A [S$PY[#OQH9#!O@Q&NXL5Z)CB/Y:NW9(4 6"'[T6<$ M>>@XS)33@SLCX8U6Q_&^T@28XYYD"4_.\KGHD^6*Q@C#PVYY0;FN NP?"HDD MS_E-D@MOVE. M>J[(<6K7] A,$).IVP\R_D+G3^KR.R_N<"0NZ.U,YOR(,F4U^KHB#IL:;P18 MKSE^7'?3Y\L"-,R_ET!1.7%,*F-),O$#7!/L%WH9U+)64JMIKR)QR:FT1&3? MD1K53')JBL:/EF) '4^-_[G*9BV["6Z8D+9OV.!I'('!Y]&8XSNRS (HF%^C M9Z8>HL>#:L '<[+%2J5:EU_8TH _- >ZPI(W M=#?H[=I!/B__+@^W\0%]$W6?^?*!C=(Y5BE?&?R,4$F0I]I\^MP$^USDJ O+ M#R O0\3[(&%)YI=D^;)%)LKM2>2G)/]MEY_NR)V*?A&@0, MV, M2"=I##QH<<474J'WS277!A,$=8VM+)4#2_^5FG ]PM#NDA5/#@@1AM/ =>Z# M!\&\J>_[+V5.O3GU+.>E+-::^@%[*8M]<93=#&OC"?$KPA<*7S&.X',D1@=V MX&6A>*SOY+U]@M1;&BRO*%)O-.U>%-W@\4,X$4B M^4^=Z8!7AH/<) 3A*^MUVYL\RM)1EHZRM$-96E>\O",VV35'/<,K]T8?C%85 M["FFV'Z\:G1XMRM"BC M"#;W$QILF$;;Z:*#C9;*ET4!_YC=Z8KMJF@$ MPFL2(V1,JM\0/VCB5GF/PNTXB47D^%$<@BBFIAO9#D\L6YC@U<6AF6Y4N%T; MP;J2MG&C!AO]7['X.'^?IB)>;%N['9HCM=OWJU3W?9/OWS\#5LG9XNK0@QL.9LK7D 6X)?P&5F,JJH;*Q@'HW:!#"H8 M?JT:/B[A.Y>8HNDT?FQ=X'8_OJG+'SOU_BVMO8)\F]2KA?;)F6NO;0%!]MEF MQ_=CG*?9L8.HLN;:(MAVS\=((5B[G&^B^AX6_$]A"%J>L;S))94&] M-LFRT/T:PQTU=2L-B<^BR/[$KHU!D3TQ'?ZZ<%?JB M&J\OTK04"VJ&.O"FZT>>Y%L3\KR$'T8'\H:]@;P.CT6NX M/(S,P+/]V%DWD+>*>+@!T7-9ZE\09TZDDT%N@V3V:IVJZXPZOYI?&;,[K7[U M3;P@J9CQ\0T'N7X*/ 0)98#;,LMXA'URF-L)AO6%W+/2_2- MDJR,9[(-'IY7-]+)UZW[%&PU_YXEHC/ F'H&^FO#K307U]9-RH5KJ9:(S_@< M+$=Y)> !T^/,X:UF#CO'F<-[L);CS.'CS.%AF);CS.%[SA >\(^J[0^^9:U7 M\ SM8;[IWZ<]S JF$/8\2E_0_;J-5H^U#?S[#B"KRI$VSVU"?L$#Q^]"?IO PW:L[X&T7\YRJ^ M_I0O#)F(J--@C=CTC8I-OV)LNMMR^,&/OH16QW!MXNSI>PM>, ="'/BE'H,L M4V%'X@P2Y]5O=6+IR$":1L^KOEX$P3X!?1HL)86L-X;BR6CW$EK(-B.LPHGB MLQ?64;I_E,09.<" ,QP$60 ]OZC;O:/4@M0^=WO;<&KJL:DR[$8-7R$]7@O9 MAJ6F>S]#>3/J'MX(Y"O*IS_PK/@G7C5>I/4OR4AO74H=^G(,,MMQ M%]W>CSJ_1U_./45V[WB7[MOM7X_G>Z#G^ZRZB=10I: H\M)1Z%U;.Z79#Y&< M_D<4^:!B"BI&_^ MY5_$8EG,OXIX60P@;:\T*[9I_JQFYZ-S[!,I%[54;^M%P;)>FA>U)H.LZ_]@)V*UV!\_>?SD]I]4[*<_HC6& MO%'8U+ZD]'];W94]YC,VF^9Y7.5QE<=5_D2KW)N[VB?H*'W ]:WU?->WAQ]+ M'&2X<$]P@XX_0C^X>\* '&/ O-MTDHO+W/TH*O2XRG]#'I@1Q>>MLEV MG=O;(_X[6M6C5=WJ9G) /MRC!3WJYNVXZ1'N#[T#UM)'3GP63MSZ%M _8!X\ M>@I'3^%QK^L&!"K8-]=BZSQ@)VUYB#T;#TGZK1'SO_).?_YTT4[2+Y:NRL+/BR^/WI&1\]HOVU? ^-D:T-G64=#=S1T+\'0 M[3Z3;=E'DW>4@,.0@&TSZ)9SY/VCNW=T]UZ@N[,?.V$$FV."VR\L]3FE\A$AH6 $3#X7H?! E)7-C=N9CP6G M%X1TC.#4YJ(L::!,:\02+G*6&* ;>=X=7R8$\>NC,G:'GN,CQ-HT!7O,YD57D/#"];.#:%QBSLY\$<_ MWY%)&/E"&(&AW%3CD8=+?5WD\9]7^0Q8I7P/)[ZXP_>_JT8<]>=,V9;;G3/% MF>5YIN.E@9TRQW>X2!P[-GT>V*[GND%WSE3SI6H(E"%?;JR>:C0XSV+]V]NK M32WP9QPAW-CUF1MP'J:^QUCB6U:<>DXZ>"V^'XRSK7G,KZ^!2D1NXZ?3A?7( MU$7+5JZ82UQ>@7TI.[YL8)H\ G&*G42PT!;<]BPSC;Q(. Y+TVCCF8M?Z>D7 MRT6Y@+6!@=S,,34;HN>!8VJZ$S,P)ZYC;3EU>7!WIIF @DABV^8^8VG"39Y8 M\,_(,D&EF.[:BFXS4 "7N$';?/7=U\^?J8?K5]?3\CPXA!>?!..$E\6,3AM-+%RGG06 M (93;@QD- ,)2^#?&2(L7\2+'.<*P8&84^-K[W==1J^?.&_,ED8S? .F]P<< MPP*G_6['+\(*K#3P,O-VD9=O">J[ULZ4UN>>:6_11=\@^W9(T+(HL,"A!Y,0>XTX( B5 M=A(K!,_$CCTBC:7-\48RA0OZ2(?XCF;-?@8]F2>2/*!#Z4_KL[]-&0M7I/.& M%<1]G(PGWI5MHM_4._:^"LDI;L&P6@VQ'M$IY$$KZ6E,^;T3O"@-X WX=6_, M%T9!THS!%CA$Z_Q2Z!>C^-] ^"\U@YYFF0V,?]QZ MLBQH@.\XR5,@GR^*G.OQWCQ!,RY]]T*D,Y( ?-WR>BEG0.(3P&DO\8>*1+6: M!9*($9G1P^XUQ?[!P5SK]684(I5%DKQ+7&:N1S$#"^D1_ XEBH- MGYE60.H->N!C\!$@L>>@^=(E1OUT?)P. 35O9YFW&4X)QL 2]H:!9-:BDJ*1 MFDW\58C*?1IQ M7F6@O##O0?[5=QS9>T<+>Y/S@F;Z_L[![S/L0*ZZDW?!&:>@F3#?(C=@C"P% M-P'V$E.^J,VEEL2IQ*# &E.6Z:T3/94XD2D^4K":($H-1D*:*?CS#)0^)M7 ML^1ST-SX@N5\)LJR16%8'5JI1=FRFCMEM;T)HK\)FEA_D8)-7YM)?A&BHVUR M.!D(&^#8P0>)27@60U M^4#!@1B*?X,4(EG_SZKK-] /M)L.(9.4FWYH!A:/.3,%BQ(7XS1;.$$0@,65 MP1H2\G2(HG:7GM_0*5P6=T37\UAFB,^E1_LV+Q?U,@:H P8]F+H#I %UIB)C MNK! /@.E)9T'I>MD2AG^FA3\%K//R-'@B?^XR<@Y_R"B@GC:GZCPN*E:I1,. MO^CQK0X"P8\FCY8C6='GCC,:PTZ?@=^7C8PE'9X@$8'U=0R!%J_H"'(8S(B MQI ?U2VL!BW%M;Q3QHQL7I3#S\5*C>[#>;J0M+B329,K,4-_65Q+-5'[Q3(% M- $W.OJ72AR6<+99"L[XG"[090PF"JLDH%E]I7[QY!TS] @:0< MSK^7E,*>2,))MQ]LU:CO?Y"A7\VV<.:M@XA%0=4+]2%,X,1 D372 M?#;+;W6J*A$ %[P J+N?[7:YTB(XZ$/UWGE$2;GY(;N2B OE*U2R'#/"*$@(5R!FIZ M3(WS*FF ]R7=NP\B,?ZPR?U\&Z:5(1OI"H-?J%H -ORK'BQ.9:6-;RE6-.NO M\ AX>[D8_TIO)M\S<>2'4X=UZ-/X[U6%7WL#3O(IUD+\>4KZYA<^N^5WY'^+[N[M_M SD/N4;'SN[Z$-8KTN5L%Y,3N/D9Z,*>NJ;D[^_/?_OV][?G7]X;W[[\\?7;Q/CXZ2T(_Z=WQM<_WGS]^.[C^9>/ M[[\>ZO8_77Q[_]7X=F&\O?CT]>*WC^_.O[U_9WSX^.G\T]N/Y[\97[_!+WY_ M_^G;]A1XZJWT;IV&-,]@FUFF73^?_K,*^4[L1]R&$VD L_!?MKHPEFL&;$FF*_E4N;R1GZ 8G_$Y_ M,!E7Z-K"HYQ+GVS,OMQ"@X/^%,J?R/DQ>$_EN"P."9^K,')!^FH7C12 M.;8WE&JM.7';HAW+=P-A.:[K@VQRW^)>$#$O JL'+,>"1*4;;-L[U3^L2="T M\@TJ'Z,2#MNG7[R3,]=T)\#R&Q?Q4)QU[_3+ ^GQ5.D7'S.@P;KT"V:!YX:N M$^CJ*"#&E74+/+JLK%1 M?07T;I]=C^"E3(&H!\L[5EFGT?BH^HW^QK*9*&A^#FR30;:I[%@EJ:.-T^9) M4TBN+\PL]0G8AOY5H'Z%9][]6D_]#_)']^7SW* :>TPPS"5[*5_//$C.^8GM M9'BTDT-VTC&/=I+H8!WMY*%IN^WLY%!-V6BGZ5-MX6B\G])X.WO-SEB(M[R$ M-1F6HTTW,(=4)E0W40 Y+E6IVC7/9(/IT!7)+ /EF*!>H:L^>(=.,E1Y*2.# MKTB>>WOQSX_O3D&5P#,2<9W%\A!SJH2&5\DKZ[F\EJ3N#'WE1RW#Q@<>2R66 MB#(NLD@69AR+?)^VR#=@JLC7W>,BWS;'9-BT\TDLGK/<5Y=HZ%ZF=G$FJ:_* MI-"MN_0EER!&,U11@L-):26EODH5320H_PUJ#U78*_F2*]7(>X-NM9$8.T2+%*6F$Y4RI!ZL6OUP+1Z:!J[MIJ_I6YO,'SE$FP+5A-(GT:^ M1A7KXVTO%B>N\FGZCLB@)9#TP$]5*\8^=*UVY"K*QJTZ>5F?2&&,ZHJ=*FF@E4'6_K.8?H/_T/[ITW_EP,(LD!9X9MT4-KNKRDZ& M.ZY_N7]U/ [T)2)6Y2 $BD-X$S>E^$7_\*N>$YS-Z2CH2[_VV:<#B4,OE'^N M"RJFIBRJ4'#[ZLWJSU/Z4P?D1_[-\Z:6:XW^V9S>]V^N,_[25=]AL]=LV@A"W&N&XS\;6%Y;1VYOJOO:*!IX'S6E]*0(S_J5).RA@U2JZ[ M*%5W3,^5_J%OW%#?-#A\'[GC$&;_;S+EJ MP+*M9LCGAO#<\""VNSB)XR!T;"]Q @C=?98$$4M#VW("*PF7'B."=G;!*$WL2S^\GQ^TWOV?B\GVA.UD;KV7:(UL.8^NEP.C?DZ:U' M;&V^_Q;#'LSYIZ+T9VGV$LU_,PUO\*7G3P3=HQWN/-XMH& M?OO@[>_N07./0C'L5X6V$S/T3AH"V9SFV<,(@MF-F,SMP_#B*(AX&/@]#*VH[C#LU09N$ M@/ZCA8 [8(CC/.\]LV,/9.;=1C_!;J.?W4\)J)I\FT#,H]=USHN">'C7A&_] MTH1O_3SC\T.\,N^6'"(R[:1=N8EE"F*F^N@UIFT+Z;8T;GA&-5+48JXNT1O8 M9?E(Q?)4,O4G1*,'22C@77,0DL)(A:#! 8C0@-4:^*6L+*NF=7H?E7$U4%K5 M.X8NS7%;ZF5X)]O[9+=D%C_?N&4'\=:H0AJ5<@%"OI"%8=5'8/5S1! MJ0)% M7^Q3-4B]_R949HL6C7(6)'DB$#P"D>GD^ 4-8( 4!LK(Q[9/(1*&^$%7N8DN M]&DB$ _LL4&3)C0P_IGV2Z4,6"574P4OF*FD1RY-_9;.XI'J"K#U$5\BD6#S M]%,.NDHL\O,9+.1<3PQH>0D@#O$OR;*X!:-27$0G]<52>UCQC?H$==J!6]VQ2"=ACS/,FV1@5_6M!?7<30U,>HCK<) YFY MK8?[Q'C-.]FD=7(VWP#H>"&YE\H]1CI)!G6%T>&T$4;K-.@H2=F.^CSTA.N# M ^:Z)A->$/B!Z22VQU([2L,HJ2"SB/KF>B#Q'1!_@^849I^0#&)J/"DWY(AT ;'\X59V3 M,XL-(+=KLDZ--R+FRU*,T9=Z?A#MAXJ85'D5J-\1PR]Q@N9"$K7"U&M94WC% MN LT:5D.K="5H9S-J.@JJO&M*J>J!M1&ZRZD=<&2KC(W9CGR0;N:]P:L6&<9 MF=XSCCD3/"%:/ B3;6^\\\9D&..+],;Z;OD1?J@#/^0>X8?V8"U'^*$C_- 1 M?F@4?F@=G%!WIIB3<-_QTC0-(0H)TB Q8]\+4X$-NMQT1I7Q4/8E?+;DRT<$ M?;];B;--L7_=3H,#JJIFA4ZG@[2(.&>(4(&KTQAUR7DU\@)US987 "R)8]!= MX$.F+(H];H6^)R+F0;C'7%?.O>IYD0-1$?4$7*3_PXL"?*6+@@Q[A?U;#3%_ MRV\_CJ_9G^W$_N)15W#\0);&3LWPN^LZD]ABIOK[NW:$T"/I@-*>P MZA_O 74W\SJ8 6KT8]S1IR,)](]^(R(U(@9II@945A"=AXF<^[G F3?H=Y,+ M=XAYU-:PAM;I@W\OPVW9(KPE1H7GF#&/A,] (?IA&$5A[-EQ:HG4-'G"-AXO M5QU!\WZM6N36-VS,170*Q-!>!VA_4YV]RG)^[ =7!*P..NP69!V3F&LQS[(24YD?,W3, M%7!Z[:.IP6X??DC@PWMCHC$X7VRHYWW@R$9/9B1CT?V8FJ/Z&Z@OXQ7'R<@I MM>9*25+P!=HGL1[Q_!PKC7QT\")/L-0* CL 5RXP?7 $0R^4YV>9[I.+%UZ_ M3EQG#\ZNJ03UB1BO:D0">6;M61;;SR_U+,>) P%'$"6,,YO#SRRT7"\T?12G MC2=\#AV$S+=N?PA;CR&,73OE4:[I*+U>W/@>)F+.E,]$8B&H]DM_@6;$5 MB<@,.&/"2KB=QKZ)0N7%8:@5FV6:[&D5FVLA-X*Y?*#?D-=$E* -UDI78CNT M7(X("]#UUYYX;$.[T7%:L;"3C8&BMW$!77M4_. M_"G\[P NKI+/-T:CNO&+2(2XIKP=//E&+' P4T=^)_<"'?-XBFZG'9F)8)87 M\C )?3"<(K* ,"*^)T=]YL5%\17'9"8$S;:J*,EU\%IK"(CNAA<*QJ#1FJZ' M@&@R=O8;L3 Z0B2D/& F8'E>V9D M)<]B+=C6%]2/N8N'3.IV75(U(S[4!H:OQS$CAN\9[-XSI%2&#=^8C_ R-GO/ M^YQ1QTBC,7W#.6F'Z.?\7=7BK?(.":1^OL@6,YEU:DQLKD<;ZU(DFB5]7QS, M-+299<;RQ-39*7GXJ/G,D2+"M'_/F?^ M2 FQWPC8CR1=_@&1Q@8/&2-S=SKDO,[J9RA_%1_2.'G\"2?67JMY8&,2)-', M"%1)8!'F B\?[M1X28)_0I#"E@E"U9!F0#Y1#\,MR!?$65Q 0:RL1O0G5;%Y MFY7-5IAD:EQ(0"HY9:S*=EK2C#&%9'LGIZ;A!P=FJ"U6;:I&_ZH\5-C#[17. M!J/!452K,M$SP[J9C)Q LN0R9/%I SI+HA+=4XL\4M"^.4>%HQQ5L<[$N)DM M2XD521JSFKB*%;ZU6N5Q7&@/93FG4J!7MU>":G2!R%COTXB1X#>ZAO/U!)': M@.!PBOF$H+MJ1"8*[F7E445R+!B54S]5+FIB+&\4MIA"X)O+,^' 33B+&=GT M_7>J6<*IEF^O^/RRJBXH\IGQBC1C(QVHC026, %'&^7RYD9BEB%"WF4./#W7 MA8!J-&FZF@E;PP'UA\[U\[\VGZ_#@TYB_YK?K1WH!CR*0:=F6J25H$?XF,P#0&/ LM-9<8;/*U_)OIY+ M470G>)EXP^\T]4=4WSTE\KEUO&>^7(G\8TP(^V>K$"BY+FJ0 -G&>F)OM K0Y:I%0E >'EDOU:E;MN]7:L MFFQX3Z4ER5T5*I![IDT:G FV6M7@BCA\J):V]I.'I!:$:3L_+TDP$LX.'%RPY:V(YEYSX9_VJ-=%=Q[BP4R=C:.[U])#KGUJJ1@6 M8TI@:GQHS34 G4$?)8#73951(4A/'DH,Z;D'&4-ZWLYBR#D$:F6)[G!CK'/# M8JXTN60U6\5C9']E5X"8&]=BL:;6XANV!Z0YND.C;\'&+O)<)"Y^US:#J* 3 M7S;V" 2+*66$F]%(L@.=/NW5Z&L@F6\]S#E$*],&!9__"4&2F&=Y871.=M+K M4JVU1]U0JGZL?*+N67W/9TL9?%&44O^SP;83+".DM@2JR, P1*8HEC<'>23_ MS$DO*](AMUYMD"05/T"?8]X"]IGI41"-TZ&X5^%VHX\M^YYO\V;I1UV_J;XP M5-F9TC02/7[[WQ(V?W;7B% V"T?P9^P5%?$24[FO,?J3[0'SU4H&!1J<>0Z_ MX@4&Q_-^Q_1W2<.\,0JCVE3/E[]J(?\KS.BRO8CAD/ZU+&/&F51%1L,^R#HG MH"E+0J^68T2KKN/U00L2A1JPF^="=_BZ;YR^6&-KCXU>YS=XY:*T,*T2Z5;+ M\JI53(T+.K]J4L(LN\XP.(NS(EY>8XX0,?KKDAV"S=955AO0;;(12R:UL\_*.;5Y[L)9CF]>QS>O8YC76 MYK6V;:O3YF5'0>I9IH@"6[# -\.0V4Z:FCRV1.BDR8.GS.^++WLA2WS5I5^W M-!&'E@F::]0ID+I91K,LKNNDMB_#3@++=UG*1)BRT(F#E =VY$5.*#S+=U3! MG>E:$N0"?U@'U!TMJM:O7 M=5"W)$G*(MOTA9?Z0!+3"KR0N8D?\I3YGN_[^T82')>]AB"-ZJE!S(.*I\#3 MU!@XU>6"=)RS0MVJ$2J.[HWKE<._7MM"@G':7"SN#6/Q0(X= :I3P?,< FQ MF33J7T#+@;>87&Q_/ WH"@^G^'K3,30W#0LB$Y6)2);Q0N%,X +32(NO4Z**;M2ZK.\,>)W2!6/$EC5I=EO*JK1 W>+-$.>JR5?]1 T!U M'O="R@YW%[3] 8QTD+5WW;ZVCGDFI!=*:J1+RI(2=I=6D;*L^?>+-_I6 CB& MIRFP"-48+:ZR(J%'W.%E)(+8:/F_^%RWCFYGPI(PT]*YM]'%0]U@R'.Y^#@KO*;FA358$B[+[1@\'+ M7O%(A_%4U0AEQH'L)+TU$MO"2'FF*]6KN^+Z2H@C2*<,^O'#VRC)^Q&[K1M; M=-982E25O[UBM%$Q]J&2.O8&W)4Z:'O^9$YQAY6 MZG-= :Q'WTV0CO&&_TJ)ML5LW62LC;*!3=5IRE'0W8>=,M*V4 M\1 E!NK*6F5$=5%#*%Z'7A: G",MS*;D&_REGR[S29TPQI5A?M*VKSK!SSUW= M(#Q^M8X56"2U""VAAIO7)9H0WEPOJ2VVUBT**9Q"*,P>X7UUC*X?.6T5%$*? MXU3]J*Y8K?FXP;B10!:Y%HLV1@*EP+8$21!V*M(H,1,@$1,LB)W$2?S0XG[J MI%:X!@OXU-D*C1;,!?VIW/[\7-0D*SN\-Y(&7:&\!NC7FJCF7=6C>UGD97GO MS-Y#B;PA0&VG"[HJ]9(8,/-$@8MM2/RF&O>P2;J?A>U'7@_)?^Z<2H^;__1] M)(JS4?J3,/^E#%=@_P=9N?01L^CD.K5 ^>:J@V0;=A"V%\;"M3Q;^,QA?I!R MT[$X3R-N<2\*A^%;1C.SE5Y"6<%1)=L?.-Y'3.TU!TY].R6U+Y\OH;!JS) M+O(=4W\.)1[5 MN 8N82GH,D:ZWOC$CG4KE'[B/)2R M;0EG?J/G]*F. O1B.U708!)@T$ MNBKRY>45)2:TL"D[_Z3'LF_P+#TDFY>QV8=="O?A>^X#S](9'.?LM1CVX5GZ M1'@Z>!;/"J(T#&S;=WP6>4$46V \K#3%%K[8>6IXE@ O@*=^, 2F]D3P+$], MD56M=<$*8+D'M-;YCAF%CN-YJ>,R,Q;<]2V1L"A-0A]\"?[8K77!+KI76_ L M?0EZ?G@6C4+GD>WRM@5GZ6]I;\%9'@E=;G-^8B\7"F*_P5GZ3#@ SO+F&@L[@K/LE89W7ZY$OA!PEA'[L!DXRP!JYD\&SI+&/$AMDR<\<%@*(I&8L<73 M$'P]QS=#]DS@+('WV. LN]OXP]U;'\%9#L^]W07ZX"[ 69[XJ-?&=HBA-[4W MCNUZX"S'KMZ57;W^L:MW#]9R[.H]=O4>NWK'NGK7=NEVNGIQG$& _;X@-LP4 M/F>VYZ0\2,(H=3W37-75NU%6^)G4]4O!&=NC9&AH'F0R-+2> V=L) #<,7OF28LOT^ MUTU@ROH'?B^8LE%-J6').FH2(D??">.86:[-8L>.G"1-HD!$<938H1-NER]I MZTJ-=%#7C[W3V&C;#NP-;;"MM_G*:7P;0K*MH)#D]OV@T']KM#AM2LN/\W.) MX_8%4P@%I>.WIJ-SK&KC8>"E+7W]QS@-3U5K$S MD+HQN@V!U TX"=N!U!U26W;!3U<0\1:70OMC"BWGG!GT4Z0A_JXJZ M"0*!2BS)A>&SU2'/8 ,/Q)4\LEP3<4R8L$7D"=_FGNWXPDGMA%6#!3T]6-![ M3E"?D*V:H+8;G*.0QQ (\M )&&..XP2N&\2FQ1.6I,PQPWTCB7MRQM80Y!EP MCK:+O ,?R.OX9LHCAZ41#QR/6Y;EV2QR_,@QMZ?Y_2-O;X/YEOUX*%BSX8GJ[0^R!/XY,;[ M$VZUS0_V(?<:Z'N+ZI12X;_G1E+P6QT_=;Z!KXORHLAOR9?6:R[E)K+D_@FR M9RB@'[F.0$2*+%K6O1]5+/PR@H4M&P;>RF3L+ MVW4"FWDBXJ%I.R%W/#^(F>NG:$ LQV24^,$?UF*IR0-NN6FE?OD[E489<"X< MDUJO_!'?@FX*)HW4.C8TMO.Z%"1(2F829A973 5?OW-PN'$3CS"4L#+I(D M\/Q$6#:X>!0R68'IR..C'Q[K^&R$,@CN>WR'J-016:-]^ IQZ!_+N3 <(CYT%\U':,R(/5R7:%IN."IXFUMFE5;D#E=T1SO&#MT1G> M(6$3=)M)/,ME1B1".%*L=*8GX$,;3:&@L^GF !Y[D($%*-SSY26LR4"/I>9D MJ6XE;$ RG+!O7KDW>=RXR<$=1*P/ U$J*'E_4PA8X'1$7@ MC814FLWY/,8\:3H3/S)U)PB?F1&D6HWG*2MPC+<7__SX[M0*@6N PM=9++VN M7"9?U4TC;]RU5%#:I7'PH^6D$NS-\^QVF66-:_;-"R&D+F$IF6TIL8?56IA#GN5VF'2 M>5?#L5,:7FJ@D2*,^BZQ'0A0WTP"^\7<@K)/$[I(G.>WTBQ34%7? LNPJKZ> MQ1_7W%0V:4)HR\E8ZR(0/+NF#&AM[.94CX3Y$H74W-X#0;3(6UBU][KWBBKO M)KADH?:!0-HS#24L"_,P;2(,O%B6,#MJ:1 <9?.Y&J!!ED[18*KS^Y^6U\!Z M\0Z* ]H^1.4X:(>!BH>_P2O>S&###:>!=:LH(^$Q-Q:"!Z EN/##A'$>6"8+ M+4<$=G "%([Y#5:8%DLAZXMJCV A:2; FDA$1;#WVERI)?VB'12U^;-CJ?[* M4OW@6*J_!VLYENH?2_6/I?ICI?H/*;W?-)\^^.*UUNKLOZ1)JDP!AD>G,;:? MW93B%_W#K^ :WV$C[#8P'9VOUAW M:EO!1H_]*YV:/#E@#N3__^?$.:GM;(+N]B_VS0_#:G/J3*0]_I"L\?3B3 PH M:RNT*VA(5U#*SCOP6BOA5B19L5L3]WJRT4<'""-UVCZ3AJ[9?WJB5-7!1H<\ M6/9CO*K"J=,)-HX![?F+QR)$ P"8\F?(0]$/S:L,;K'6J,A-?U2NK3(2+UQ>F MY;"PCP?Z,(V3TO^]*+WR#SZG"UDF$WKWXO_.MN_%_^M)MX?:0Q-/:8]]IMY+ MUQ$B-)F9^J:7F@FSAYY( M]-1K9MJG^H>'Z =?Z@?FN?TRB)_/AUA"*&?MO0G<0_4@*7?T'AY;.P2F[:6^ MSZ+0BL"DAZ'/_-2.A&<'H>.$87?$B/^P""-X-.WP KV'=N9BGVW@'BJ(3GYB MGZGWTG6$%[F^)RS;%CQA(K)"GJ8Q\Z+(]AQN<[MJN;)TR]6#=$1X]"#Z@;33 MN0[?[1AVAD(?;9!.ZA>FAF(?:9="]=._B6[2<" M7 4O\5C,!(?H IP'*^5I&,5,0Y_[6CL\+ MAV8^F'5Z@]Z #Z8=$&#^M_U!E M(?R]I]Y+UQ%6&CIQ8K/ B6/&'1[$3FS&GN/PT&$6XU)'P)-EA($_/$1'.$RQ)=Q#'5%E(8*]I]Y+UQ&Q[;-0!(&%?5LA-SDS(Q$&IBU"._)=B7_N MZ"R$\] L!-M*1_R5*MJ'VJM>*-S-< O#-_X#9V\A'>"1L+98PI"OQ?C9WW;Q M50UV=MD\"BE5]BG(F^6)9T.<4'NRD H:] MQ)[P"K!;C<4F[*\"A!C52N>/DR' ^RV\BH,7 4!&TAJ.,>&]OY#WE*U4OU MO#2-C( $^6/Z=6JD L'P9IJV=)#+XB8O12F1_6CX9OL J:46GMB 6>AVL]9C M!Z_X+-5=M2NG;=->8P7/!Y] #=CG#7E*]<9T>V\#S[<_%AP/97P2W4;OE2S4 MH$Z+IT8Y0][.:?XP.W 2PZVFA%S+88\)B'@6)PYPH#$026#YW'84_^]1[Q%F,$]?I^YT* MQF&B8?;!&9G=3<90'9I8F&TP(K1\Y\GWK$2 #?0N<%!(FF:S#"2\)"Q+L)A+ M^4>$UR084CDI&_%)X4F1:)H^]6HP7YLSJU[ E9AM>VZ^[\(Y14F$ Z=]QXEL MEKBA&SJ)ZSLV]S8^-R4H2D[*M](:GL>$S/H'K*%]D -G%6P=QB2Q0-CH.(Q MSYEN9#L\L6QAFLR.0S/=6*X>OO8007T'@IL>P)5ZQ55V0YNKW,:+SSB '0F M&09PX=0T:H6*"7^F=4S5^.E#1)OZUAC-T*03ORP$&4,M(D",5Q@07$M?:F3B MO"+@;Y_/];,6G:T+SL@\BP6.;X'(,>;;/&&1DSJ1Z9M.[+C>, ^W4:M' MO!AEPLZKW<&F(.K\K+;TGG;SKK&9=]5>?N<_LNOE];9PSHZ-4)T0Z_<97^-: M*R@MI;$@#.H>>7W(!- )Q)H+244U\BDK!P^NI0>1.Y!K%*PQZ&IPW3D-D(^S MA1'Q&8U3 -FC,5#*<^=2X+5(BN^*YW@+J[UF0E3"[5?=%#G&&_"-RR6$]O.% MF@.5B.LY(H8A9C[\(X+]$JA*;U(C>$!,W#9),^DR89-[F_H MQI8FU._]O_GUS:]?!EY5ZO[HZ.295&-CJKTF75RMA#S4PS=NX$809W+ M27"(F/5BMVBOV"*?SS.<_H3GOIS/4&4M&AP\RDG(%DB>3+HSK[+74MZ!&S(Y MXP)$CT:VH2K G!3I:42 XPMC)GBY6!GZ)XX96(E@=N3CV(LD0'AJGB8Q_#*% MV'\+4C8,IB1;GGZB5:*U5%OHCFO1Q$SX78.0SLF9X[D]&B8(*RR10O78NAJS M#3&7KIIDG@"Q@%H(.1Y%X\/S"-9<4IRG& ]W$7-@TL6 M^?D,>*[:Y]#0%\=F)V<#MQ#5K%6T$#>"S$1C;I[ZHP0=1+46\V4IY,1(" T- M^ :?(*NVK3T%A# [1(%(IM-"W0\)243,/J%@E/D2 MG)[ZUU+"Y>RC[CO[GZ;%H:N-::Q5=QB#CAV/S-1WPY@'G#-N!4$,IMQSW-3E MH1\&]MI8 M8!]V_JCI?FC>7P,C'G]9SSV4<_LT*#*/I:N)!PG6669W?D(Z!FOHJ%B2)]\Q M?)$,R8U9SFGW[8$8QY)1AS> 1CWH.U',&8CV#, M1S#FL4*5M84G/<3_P$MCWPT2+V&FQX,T34Q'!''@1P$/'EZH\DSJ>H'VER[ M[J2/H9SHVM'[8_.X'Z>/R=NL_H,.T =4GD+Y.2\6:3[+\A5^2WARQN[I_PV% MPS?ZE0?B!FY!2L=<0\I!%W V(R>P'/("*9K!:P.PF"46C-+5*O)J),1<,2Q- MFRKRY>55OX+RA5RAWC>VIJ$POU<9^CK=\$]>9.0XU'_\Z\_&*]^O*;M5,.5Y-XJ MC4XG (I]MBQ)6[7+V:]Y0H,801>C!I,J20:FRN1*I=+@@^07"?5'5XI MR5=L:352VS7!WTD#*TQ8S)P@,L'M,7T[,47$K?4%;RNLQMOE]5(&Q*K\[6.E MFK]0C?MY61N/B]IX#)L'Z^3,&R@#^HL15Z^9X-R_TP7_,8'#G)_B\#WLPB(Q M!"]QIDOKT4X(($TS5?X>R)+CY+Z_+XMD)C1O >O=R0N/?%X=;]V1DL>8: ,N ML%Y334^)%XGP'?NUKE-H3!M4U3^%\HOD Q8/N_D;-O%SWH:S^J9@8YH@A!GEDM<#1O%H*Y,+ M?HVTE=(44%ZH];:Z/PS93$]91%>';!0\]!>JO*%:1EFZ"L]X=?Y:S:[-L=J3 M?G7W6H4_I;SQE580%/4BNYEEDM%0YVQGK4PS=9AO>]P.& L"+_!L)PC<*+9B M8;O^2&GK9M:JF@!"?G'M^8*[^YX7]9:+@*]L )_,+;!F^]7;Z2) MD<:^K&8/8]7=G#Y2(AMA>;^JSREC< &0B@(,T6MY)81N";Y]GO"*.7Y5[6J2 MWEG6\570I@V.1%8SR/'#,ZR,MM^#!5[=EU:HHPI*OU.'(\-MN54!_!U%.HX]2OUY: M3%F#C0]JMY=J10J62H"E*X?Z354IYA ].P/4%T,-J]0CJL;$WHT-E^VU_Y2# MK:_PD?9Q<@IQ5*D#,-VEF%,_+97\)$!)_+HTXE6V3O$FT@KGN)#-I^A4GVQ> MUT[C<]"'+@3P18F/F>5EJ<+5\3/)RL&CP+(F]):GG0E+I>XAE@Y"-_1LC!B6 MN]=]*Q.<8G^%Z@>_ J\2US?T?EJ^&K[=: R&_23H$(A$GKXLO4.G S;X/>N4 MJU#E7HFF5";KMFLC\KEE.8".=JP7 .']5RMVYI<]C)F>.&$WM(K[59KN."9"/=%+QN-VT2NR'A M\,VJ_!L($4B1[[N$B70)91U>H@N],7<^!U< M$R=S>)"ATWOJ')'9YU[3 MR&9UD4H*V\/H,9_)VP6YG.:=-W.FX%]IB<]JYSQO(DU$>+S4R2<=9?(9@%L6 M5U+_I=D/M(4U- =^=> ]^ +M.4M?:9O./\]W(MMC$>( ,SN)N1D%+HL\EYF! MZX;^FE+Y4V=#,(-S&:=[LDP1 *!6B))W!3*@( M1MU0;$=2#'A.%[=BEBZN5EKUP>CS@>1E&P2A;V#]K= S3R%6^5SDE!=6,>=P ME(F]]],!:OY%DE'?1U;)4F,./O.->K*NRA84*4&D6)E.H "A4B&QU5_)+X3? M<6F'JC]C%R)( ET%JV]7SY<=M;" =U\^?GZMW>EV47#5[5XN(W ?,TZH*?@/ M>+%2USWQ-RK^4&:4W&*PHA6+M-D!F(&B^7I%33>OY0=42"]2AD=X2^N#CO*N M;V] G0KI>:-3/S$Z_=?X28T<0.H'UA#I3)[,5*<3E7;&TOT4WZBM5R>8DP8( MPH:X$$VQ:,()M!( 2/7V>JKE]!_?Z5Q _H(CQL C!Y.4YDO&C&%OJ>MZ[HQ1]U_+Y%(:8_+1(=(&^3E(6_=Q7@4] MN[=M U+QUZRZVD66'DPK5@H4+SHZN;YTB?F>))O1E91DY8Y#W<"ZZ*0 [==X M@];J=-Q0&[, HAY+V''@<6;%86 EV.C.+6:#-A9BNQAK7!\#X=*WX)IC$A!= MOI5*V M,[ 8>PTC" M[1F)2C4;?=R!)0=1/8Z!O0?Q#RUD^3V87J;F;2:9O$O"2GUP9\FFHM'W2( ?2M\!-%])G@]-9BI:[AKD[F7Z. M\0WRA@ S0DM50!")Q:T0\\&\T' %%VVTT!2TVBJ(Z6X5QRJH-%?Y M?Y]UFW:G;^(0$Y%_U/!<.J>HVYE*#2#5Z#-K5_/<( .%8FT*8;26O6Z=[+I M=/%.N?S9G92-29UYW"ZC8YM>S"W/LZ(D8D&4\$A$IFN;F*00H?>@2D&]H]9% M3?FP(D%FX?7-2/?398'&0&G[QEU*MXJ!DJS 2U36!TIG!D99U("(@N6"R\B-E.''BA(U(G]&P[%*FW'G_ZJRWYOW8K,R[^ 4]\4+%70G8##8U:U9_*>VN;%3WR])B]QZ)+9[2H4-( M*@'2CHX;2JRV$I6_J(L8):(#5ED,[TFF6PKKBLQF(GY)9;$-$'P8<-TG'C.J,WQB,H, ME"9O@*EH7P XM'E"8.6Y++%57ZA77$,D]8B6E1(<6"/&4HTAT.\*-*PH1G4@ M>CCZ;I73F:5K091D=16->M$^VZMF\=.&[MHAVK"/Z8C]DOL&)M)5:\J,96J\ M!GEDPZUV5$:KK]::C=::-^^TEU\E4UM?Z5O$;I'W]J4)@6>%S'%U #3MHY8::N!1G=E1Q1R56!BOJT9Z0G;%VCGJL MB-P=;V28]*JCIL+7KXJ;NQ_$D&*%ZR*#P*L1Q*CQ4VFO(0VUV\H\Q\H"?IETQW$OEAP&1KV4+#ZT!6V&I-*I? M^D9/SMM.HOQ&)JNV5:=1B_#Z$A$\QRT3*KP]&I93.(\0=8(^E#UYG6:6.OL(K[45^*2] ZU->]>>J[6V/,;GK)2AJ/N;\L](P<6KP=&,@2]!N.-3FQJ?!5RS[_GQ>(2 M_F[@5+[2^*SS_O3?H1*,1[K^WPJ=]\D+ G:UNLU+!*S 4I,26;,R8#^PD:O9 MC!M9RJJ[ G0U6N>9OMG&7.F-' \@'Z@]Y!^+"KB*_GU] M,\OO\#CT1(#JZ36.=/,2LVJ1;N=_%Q[G>ZX:?0@4T6 3I2,3$%LMH7BK]MKA\\6RI.G%DR@ ME\[&-@RL;$\OA$P*8C'9B*X\.)$-G%;>NN]@99/O/4 @N7IP-Q5 M'V$=F_JW9O/O'NLE;>GUHJ3 M[PUE;0M^K9?TY6H3&'RM4M:P#2,/W1ZI0?L-PT -Y5JD!E7B]0K+B%Y3Y74:90P"C(;0MBQ(S_[)F/!88;VRPMHZ M5ECOP5J.%=;'"NMCA?58A?7:BNDNU'H2,-]V73>P!8M"D\=A(ERL%PK]P&3Q M2ZVP;CH*)9_)]" :P@BL?$I0+(-3AUOXG]T9)176"V_WA]+TF& M+6;*-5R^P=EIS:$ JS[7C*%;-W&KO]1<5P7VJ5K759&4\A&[#O@P]$XCO]"2 MNUM.G0=:_&2DK1,0*#2SV1:!^D!6!0%>JN\_=HKE$'GVVQI>,6(\SE3G6B:] M2AKQ0\1+BI=R.*A8%-US[(*C;\!G_12-KFZ\+Z,-W=/T5SYI%O5HB-_>QZK" M&2H"Y1I7?6)<2_.-Z3391XQ))5)YYU^,O\WRB,\F@Y4V.L-TB SV05XP3AIW M:NMU$[^\Q$[AA6B@KE%E:Q%_TV%F"IB*L]'FW1N@# M_>VM_EL],A01PW$0;-U5,OR :I)$[QGKK]#WG\O>Y,J1Z]"INOGN;Q^YHZ!+ M8H6T+8'I-4[R+/LNLTS:K:OK[MJG1W,'MJL1C;AC6DEL,M]G+$T1NRH.;>&F M9FC%J2?AJT(37/13_<,]H1K0P;M(?Z.]K(*X<*V3,V>P')083&%(O_W\<6+T MIY*OM!]:V?ZY5QXAXM.BHH<;+956():=B-"N;&GVC-)Z#1(DWX"*J7KL971*55T(@ MH+6:.C* J47%F<1!#=SM[<34LCP;.")U M4\&9<,S(L8+$BI/ XE82)=Y.Q!3XX'<-Q%3T2_%@855M8Q]:Q75.SM)\6?1. M6J,D*O-)HY? Q2?<\3;NTQZ21(',X.'*L\6C7:F]&,:C=MA77_"'K1C"/3FS!]&_4*MTM085 MUQ&&<4$AGZXJT_WP25;JJPOJ3*HCQB9HHZPCJS[YJGRM\ ]I?+.>2 )?_]@X MG%?;6=/7$RG'&(1E\Y5UQ$X$W'32P<-9/TB( M\HB7L)2_Y7GR 3NH/XG+?"$AB^!M"#YNFWD#8B^N=J(Z'2(4YB*P[L&O(U?.ZC#6;HI7R ['OF\QS[-XZCBQ M*WR>>&'B6<_,MJVJ>-8 MERJGQ[E3HZDU5CMWCG+X?7\T6,M:%UC"#*P/#9%>WY(-' \ -G"5PV,74(4. MBO&#Y123GLE+\;NTDQ%_:,$P&@$T\2[<%1PS4[+BR2E?"-KTI?Z!!<"_GWK_ M:[).V_OO_FF[EE(O'C*3>I[R;< JLSB>$[3[^,I^PPX DJC5@"[:KQ(D3>DVI M>#G?RQAMJ-^NR68<7W\1.7'S?J:SMU8,>JJ$,&H(2WP2,YTF,J&8[*%B E\D M@1NB["^.=>X4V)&_!+ ]F[)J+ Z/\]!&M2Q%85-=EMFDH\0ZJ^&!/D9?>JZ' M<[^TCI:<.G3J?:U4C0HY Z9'D16NG3AWS84@ZB6 ME>)W/'>H(*#)EEX+-=S#UV6YZRX_F2I!)O-#T7YSS7IMG*S048IDS\>Q M' 7Y7HKG2B9**;[UE/"'I^N$_Y3TG0RF;U4OG!QGB(KA=G7"F2.ZHH$*A4ZV MBEN".)DO$J54S"30I-9!$IO03T.9^*%(XX 72>FL2$KW(Y14.R).VCH#@W\9 MZAQV34&:O:+$U*;C%*-QNJ,YU_FDLC::ASG&I2K8*EZ4Z83M,>Z:*I:*=Z>T0U:D2SO,MI)K;K->;&M'/W/=LSW;K MT\;\>MB-&@^SO[CYGZM/)V!&P!ZU>&(XT0&/_"0EA"4ZY=2/4Y)2%?D4I&!46WAR<&4FMCDRV"XX MWUJ6G<.7,!C7D?H[,AB!6>797TL8C-=PL#)D,/;G5"W'>F].4=:*#=/Z9NS, MR3=QYAQC^O-D:XV1F3<=_+#0'3EL:AP2*YIX:-X5^J\N(OVC(,AL;^_2*"J\ M<*YG03#:S_JK!773MTJ/0*47W!0B>']W&CTF@TY4M 6RR; M"9^M'#%S\YPQ#:-KG9,G[N+L>N-H5V\XF+ZN:O[AY-C4T<>C1**1+\S"V35% MG@DNODGBN.J.^8:+*[DA&8]&9Z.>/2/?<5P-/HWR>)#Q:=?<%.S)0<=%L\>3 MV%]R5LR6=MC*P;(Z#FM?LL<)-PMZIBNU@D5DDT^:F,ZW4.YELF*JT@*M<@C\ MKYE*2)H>8EZ.Y)VX$]$$\8D[2Z/<(NF[/75R1_01LZH57_K2]>9@@0MZF"%R3 ]VQB5M_8 M"H,)/U-]DL"LKV'<@'QV&R_[8FU'GA*Q"\]>,2+0W!=U#]-.]"ROWA$^NQ@8 M3L)A/^2)E[CE73=BAP?(%_]9%)']5*3C];$UJ9E\;%0+I!U5NUOO3\K541^@ M\:)%R<+\XIS);)&QHV]MM[3@DFO*A8I9Q&3"N2#"#P0-?6.4S[D+6>\[E&GS MB!:%,JOU5N/:NPFD+]U]JW53&;7VKV^GLK";RL2 R9<*1&8%YJ'TT+L=/MK. M]#BPV;BJUHISM!0VQ1RFJ6YL+Y@7:W5_'9L7M^K!Z&''W*2..M"%@;@Q1 T* M4.^\JS_W0*_X;KI7F$]9E-#_+Y#D37EA!6+>%@J-=8?GG+WK\[_W^]_%^:-3&D9;I]7@-(SC'>Q5L/4@ ML&"O2]+5+Y83]N==\!/VP>W>?_ ]8B7B"[BP\%$2CIXM6'W!O.%YS^IQ7BE> MR[6"I[]PM5]GO-S3S-ZMM&V1+1:YOJTP^3_4("]G-,B18-P 9.)M0JSL$_[3 MMU'$]V>G;*P+M"71N 8Z'9/.J ZO YL9_<_"QME0VT >.HT\J(H=.>9,1)9V M*,'6!>)[NPS27,;A7(:_$Y'S!F"S#;%\5!)F>6^2A<]/5W;^W! 6U?G/AR%[ M7H3::R9 +(=B5X5+9B>#*\)3'BZQBYJT-@3["3TE-?X1''#K4J6FL^A>EY4W MN-3@TA'ATN%)MVET:6!^,'9(HZ:N:3.LHX)A@>1]OS?LZI/B,$H9DZ;3 /+L M?_T:$5$- 9V(&C:W1\#=E#/91U.H)\/7'Y9!QT406@85YZVQ+5S?B;G8'+PY M^.$=_ UNG=K_'1N/KK>CS]6_AIE3FUWCRG[]4+Q5@#T%G^D+6P6NOG<8 MWHD78?B?TU!:Z835D_5QU4,ZVBKSNF00ZB15OF\$2R560T@1"1(%FD24)XL& MM=$E\\$NB[0AFQ0V_CC'E)S)%+$B"XR.4W!B']2Y>0,<-KG%DOY7N,V]2Y>& M3-\CF<:^#.- A)*3B 4Q%PD/N)&4!I0*SA<.%7P5,B75%H,-F39D^N[(E&@J M""61X=*PD+(D4&D2\S0(31@Q0Q9-OWP5,@U:9WQVY&5#I@V9OARU,-.PIS<#6R6>#.VH4T;)YLGCR, M)QOD;YY\MT^^\V"S:Y!XJ+'FMQQ<;,[VYL]VG&N\[] N=AKU8!5Y7_2H0-:X MBXCN:(U@-=#6FNS';-BR5!N>1*D?BX3YD9#*YZ%A@8ID&,F4O'X,=)DV&56+ M&"?(D3:GC5NWP?R57#HZEHGQ*0NT9EK'@B6A3H@DANC89^+UPXJK8GZ$F9[M MF#1QQP;S5\%\WP"'-XEA">? Z4D2JX3P1!LI9,B,?/U(W:J8'[?.B&@+'C>8 MWV#^"I@O.7#]*$Q#$\8XD7UD?NM,]8& M#7=3[O9"-.*8M,<&\9>L%R R9B*,=1Q()KGB1J4REH3Y\ ]G^N ]!IRTSF@; MSM @?H/XJV3@$ZI-J 5-!6-*L23D0J5-N@V?KXEF21BSVXU"2 MR+ T5$D8&)%H18A.>!"+UTHOY9A>RMX8HFTII/ZVC/[4Y#ER,TX_JYC4< MHQ? ^XG\[/U$-W$%-)[,)>5C1+4.@&F)) &9J),H,0H,(Z)(I$-=/_?^H!3# ML'7&VSQH0J@O(OYH*$?=S,>&*J;]^T',=*H2RJC/XL@DQ)6.7&LQO,+^V^-T7PC>!"6G$F(ZT#()8IM0GD0CAO^;5' 6\=48W=N\>6-3V MS2/:3ZNX"IC4$0]"#1H%TT$@N SB1,> 9T0PGLQW%>1P3/C3UE%.M,[B6?UY MIL/UL6#;.ZE)6M8SH/I&9P-/#XV;55J,J=QI<=)[=P>FJ8@,E3+58<(BYLLP M$"P!(X(P7[&4;54&K B3"LDX M$T0E4<)]S)&FL0J59OO.RA?T>+29!@O7Y[]IRH@D,4E(P*2D"36$A)H+W]?& MYR^DY>_(LA:L=<;#66_. 3'2;67,/V9:=\RV<21:#D>"28"^=K[ 'LCB4Y8/ M^EDRM"+? [*XZ,@\]SYZ?P!Y-!7WN\WUH8EF490H#J:]E &/:"A387@2DM 4 MU9=[BYDOD(3A\50&-0&20\)ZH1(=)2(UF#UI@@BL'+#H0Q(I::CO)_N-B2_ M^JC!^@;KU^JNXH>$^&D4*.6S4(8)DXF?4!4(%E*=L$/HB2TPYAWS!K,;S%X! MLT,E8X*I38E2S/B$AUJF,@JHSRGCE._=9F\JZ=\!%LI81U3'TH\$PU+4Q"@_ M9"&C.M*:B6C?E?2BJ:1?-TI^0 AYUQO(CM=W.. ](1)X6#4O+7K.:=^YBP#Y MHM\5T^@F4;.4D("SD'LSAB MD@H9@ST1$$U$D,2!VEK"Q^XX$'95"-K"WWB<3<.!&@[4<*#7MR)%9,)8\#@, M?68BSF/N4QU$+ V25"3ZT,M6F!\ !PK;--C8B]=PH(8#-1SHU3F0TLHD-$Z4 M2%*6^F$24*E)8'R?!4KXZ2N5#S&?ML[8MIKD'"H3:0B^(?B])YO%<''SQ2=X(_C7 MB:XUA->>;K**#1_:]GG#TV") \]K$A.<\A<[Q9(17F]UTWRI+4_ EYP*AM"[ MZJK.4!OM95WOWG1-7W9L6$'JQZR+^7KV=)XIC A\;/!@D*M8"K*QB7P _['A M!Z^7CF,4^:E7K)Y[_[E*TD[@"3B)SZF1,5/(.> MI4OW>F_B_9[; +[?/O-L9#_W3!>I_I-1YC$Q?;ANT"(A"GF RL23*>)")*4ASP%Z@N%C/TYFF4XK5 6FN-YFF:=#*@J7YUN M>.O,/YW7C:*D&UM5CM105):/ NT%(?7@AI_DLZ4? 62@?>QUQWFWOD/V==Y MV_OQD*F'MO<$9#:474N!X^ M(\\V5R/^-?>2'BR-7^H,;F+0Z^-KX-KZYE]#^,1N+C'PUR>9C79:+(+Y]-)[ MZO<\D+[2 XS, M]?[!.W_J M9QW+!1I"?Y'0Z<$1^J=A'R>[ECQ^BL67!.]/8 W@&1I&H/ ] >[\!40U !Z_ MFK[&)=>4"Q5C:4'"N2#"#P0-?6.4SUU2W@N2=O-TJ&6X@FB=!0NU#2"]0M.= MRJLIB:WD%BA+

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�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�XF1!1<0385&'%4)@G9\IBC30 MI7S4?3(TD]^PWUH5NDUI6&%>?6HG<%C$C784OWT49@^V<^#K\ GV=ZK@[O>O M]LC\8[,ZE!:U\C2Z!IN^^IWR% +67B6+M.CD(OTYY E&IN(W'!AOJ+#G3*TU MD11(7(6J1*!;X[=J$Y=\*J7R9]DK4#KSL4D)I6@KW7C*G9C8?I<\V_17V6.J MT"_S%7FQ"M MP 6ES$1*WLW(25#,3U/J1P-F&*M!6IA]A)PBK(ADKL']$;HEYJ\U@4ZBMFM( M[(SB3//W?(.86D5/^&G9W11XF_=$$3Y5JQHV%S1[7L -N?\C= .;FEDKM%(' M85*+S6[RKZ]_->UOB ML1BX'Q;G_VJC5S)F:+UQ6QH$;)KR M_1+_6NB==#+O((]6T_HYF>+\'NVP'YA@%21]0/%I;)N?V1]4Z5S\HKXI87OY M9]DWB-R)K;;\,4K'1.ZTXIR:SAT;AXH&%%>*91ZH0J$4^QTH@%GKR1@ULDUK M:\;?'A,"=9=4_@C>+@D8H7U;Y2=3JAF\P^#N8V?+[C M0RZCV)$ZM2JACU(U0RQ:C1# =/TZ9#>MZO(JRNG+ =%7^R)B[U76GV+>.:!- M%GE<'"T25G-?9L^7.2?;46VW1VSXS 7RY8PZU^B>&6YSL^@^9G"T(?SR@_RG:<%':@(N MAVQ]YB RM5>)T\= UMH*7@U%.\?*'WHH!(K>C,R?=#I-1=:>$,1,!:@,@!N. MD.9'DTRI DXH;_;A[3(5&0MSW;W.]ZKN\Q,9MWU M*,RMYT6NE71&Z::&<21I,K^Q31T-1HA"PAP"X[%PK>2O\D'[(>=I-+4*D\5Q# MK?R.2"O/L931PUC(+L 31]I$87E*333K7)NST2ZB7MP5C./NM M=W/T3 :,_80 S63IB (ROR+ 8":Y8ET)>H>GX"W\BB&VVV/%P60\81J$?Z]J M^(0>CZ78Z1YY.8N1L?+U\=VP1@@PSNX6F=FP^+A5.'$TT!Y@=$X/D(EW*6M' M/_ /6T[>&-J_524IYL)4E?EV+;NQ^VM7F#KRFM?VDRP K[^R?>^_D:QP/Z*= M,85MO%";T96:D #HT@?['J&:8?;C%V6SG\E;.*R?S"4&,=O?;V^=W;*)=VO0 M(OOAB=]UFN<[GZV8OPJT'.P+ &^H&1(\8%MD+4$0/UM,GS0#UZL'NY[N=6 5 MTGBSNL3&F5%KDUB^W'W>OMZ]^8F[V$F]'DR6PCTZ]X7 O6_1*8LE/I)\.-_:L.].;0-[=X@R[UH(FO- M_>AZBQ[J1\40L@BVY0!H ?"RU#=5"IPXI'HLRY,QT=__0SJ?AWML,5,\H&LB MKST_IW8F:)[^'JHZ #%S$KMJA_V_SXHFXRGE>K=C/EB0_U-/*<*0G>G?> M+;NM//P[^3;IIJ-U:/*#IJHCU1E?]-:>) ?.8F =B.OVC3Q4% 4^-OIR ^W' M'T?,MS)9WX*9"P$.(C-[P^DCDR2^')EWL%>2\0[?T).8;+*\!9R.U["'SAJK-7@P5]!0L#NV3G17V;NAGXCO-50U5F"S&*6XQT=]'X^8==5 M/5#.PUH(W!YU<2[V.#IYYZK8O*DTK5"'G++\OSX/R?^!:-#WPS?>]?TJ+$TU ML/Z>]JEZ;GTMEFQ3X!L*P'1DE;T06$:$+7DV?LO8ZEW>07?U,0.2$>'T.,W< MM*Z=";][M\>>3-\-Q&@I.+FN:9![4>.%V)FV%Y5L;H9NQ9X72_)ROOX\B.0> MBNCPW=Z^CQ@TL6DV=^SJ:UXI'V]%'#TL[;6P7PBL^(54)FX0Y((.*IOPT52+ MRX6?^LDA,693<;>^[NJ;X@Z1OJB23RDIPTU^52SST[?5@(? X. "^5*[(8-8A(6Q3]V->[$?)]X(OKN7FA MO1*^U_8& ).6D>];9]7[_^P"3<,>1G]'QEBB3-OL9PO=QM6ZG[L?Y!W^N&>6 M2?3]FAP :D/,(BSKE%LPN!&\29;Q.\I*?W@76@5SJBSNEOXH^[9_?:N7+/Y( MU(!.*V!N<.6>N8+O1^6UJ_<@]SV+H\<\$>Q;D*8AN$OX$6]]"B65Y6SE38[>?G84BG/A!4KC7[VX4?2H*,,EO.*EX4@ MZ^SJ^/(Q-ZMO"NA?=+ZM1].UN#FA2<&9Y:$?O M-D/JF;T!2B:^%X(B#0'I.NFWG_#86@R\5VMBCI55+Q,2PC_"]JSRO5>0VJ.? M,YF" YVE ?H+X<,5=PI1&"HC-,T9WO.[S=K<^[4P M24H('*USZ$9MYQ)DQR.7L $RTQBB0L"%^-AF*XM>@UMOA0^=KKGWSMOGT"BGN_NA M_6[-\HRRDBW%(SG ?:Y#ZD7$W?A_>K8X0*T9&*Y T?U!)%1UK%P)-1$&O+[B M('MY0M=WY,V]0ID31#?5.LT4G?GXD6M'M^_>UW*$VG#@U%(4L_4@-^(JM$^. M@_99;EM@5^G\3H7B*.K%;U.WUIN\[4DRVVT9T7 Y\L4'5=EG*[<"]^LVBL3] M.2F?HGY!2PAD!DBIVVL," $9"O,-8QED#\DU]U-D_8Q9Y)#R(XZ/.5>L>HGY MEED97LI!.SU2#_0^."+Z9AEG$X-ECNM,_KD'%R&_S+I&@9#T;I(ASW@-^&,- M\>(4ON0QKEOI.?-![QI#(0!9%^&&V[M)\-[TB5Z'U*+ZZ>";/401D\/8 MP_8;[2K#MJ M=OIK*,SA+BZSZ_63%3R!;A-A,P--8MUJ_RT/M6(MGI)NQ&K&[+*NLWTFNG[J MAV3%)=)_?VOQ[\1_S@5&B[R.XCV3S!="(0E8?#) MY1(HAQW;']E,G.?G%+&]@IQS1G-&[_'->KZ6.GB6.C M5B3 M[PA#' BZ=!S!)V&2\T+5;%:06)?(G75MWGQEM(>NW1_GHG!O9M2.9)V$KM,FX8N/VV-?J282Y8/0E8O MYZDVSQ'4\0IN5@6=-N"ZW2*C%FHXO46PND*Q*XO^S7>"?4L0A(RZ?C4S2O\H MF/?8FL$J0S9/"H'<8 88,P;,-:%:US>-K&KE:5C(:=630R:1X4PT1DD:3OY& M8>:@PVE3D%ECCZF'ELZW%4=H,5:VYVH#>4"*XM.329@4A[=O6@CY8W_&>"G> MZO'U:I%$"\!"RWP#.XC[E"4Z(032_,NH\NHLZL/)QPV%6>\,'6^.5RM]V(?7 MV[VKXBH<@?*=U80&!/"Y$4*-[=M>$O[L^K>[3B6J1BF?GTCS9>5GEG"'E@U0 M5 MP\*$PIGCTQT[XV$!=_\6:+9KU.T!B%V?![#B.Y5545?_J!2+//WEYRZHP M33 V 7P-$-[:A=.'8T,@YJA;Y[39+82WS8F,^!)7RB0 MPNPG=IK7N\EYXA?FCL2=O3=F(3E@.]9:WP!N.(QULPME,X))K'.F@0RICH/] MM# _#KA+7(M'T*Z^"B'5.]'UD9OO^*">?Y#CI%1=._E MGEWFE226 MD237^B?B+B^<76@UB<7VSR8M5][H<7C:&+<4OH^L70);DM$!.PSVGZ*^Q2G' M*V?>E77;))NJZ3FFLWO[[P\K'W]>X[3;0ZQJ[\9IK)_AG#;O4\5S8.Q_$E,U M0P]0ID(7UN+>8]GBPZ@V.UKY^Y-W9 'E[:YFF_O,OERZ8-I4N_1H>'30Z.$M M=W22*YS^U)P>@^^HJB92ZNZ9SP>:3U*8V6#>K=9Y@J:?GA4*GN81X*LDS!OO M\W&L$RB.I1):]GR!&2RJ?-^V(O#MV+O%*D(W!/'[:OHU0;Q&QJ,>N::;8HQ\U:OK=D(V%$-\:N)\FV1^&7D5-\)IF^A2[JB*]EHN>X7A! MB[^1SKTGBAB'5)?/#-9VH/[?\9QHJ>OG)+G0>=P R-^4PL7!]O;J=))4N4:& MNJ.[?-3.]M1G"RK/B O/],<9!BO\;K:"#KB'!O)L2O#/XO@C;,/GOH_":!*A M)Y[47_J8>(EW3O3J/^6@$'VZJ%S(?J@Z5/#$8"^TTP7%[(C[:51P43F])-+ M!P:;HOI VMTP8@,EXS&UL0U+'C\K @I\ <1VWV)M-ZC@!DTQU/Q6K8A4Z>UC-**SI[WRH1GFR&C 5[/OK7+\@ B*:7 MM:J+U,7BO&+KO,[/7S^7%3G?TKZ>F" WHYTY6\)60TYK4A976!$%F[\''_HJ M2B%\ 5EG5")P15I!&J;K_ ZRLN6WMMV]WWK=2\$Q)L8YZCDF8-<+L?FK9P]3 M]?':,UED>"MFTLW16*O:CA"R9V#+GCQJ4@FYU0W6P"(F2@-:@@A4=U*?F8\] M&S^,;=HYS5]7Q,W^(!W=OR+;G6Z7!NMQ< 6R MU#GU]OK;78XC9TY$B _3Q[K>K7U"Z\$AUZHOC[MK95#$XZG_Z@^.C:>P-4 M4X+,_*2]F,=X1V\7L>=]@^.S;L?Y-T#W3A+ZLL'I9&BA=[?(+%-&[5QO;XVM MTXZV4W)WJA_]]';>N_MG]"3N4"_Z7#:@G?^A!6,?U+G)-D<41L7VW<"F[-YK M]/6KZ#?I9DG.:S)?LHQ[N_2.U*!Y@,=9 _]3%__@Z8I\246NNSL)MF:LH?*Z M!,5@UCG1BO-Q\UP(WDN;Z':;J]#TTW:;\\JPG)=) ?F2W5S[ A2H_,2$P!** M.#\P"9.ZFYRP#V22L7F:Z6 LMIZT- MJLQ0"N[%U 9)=>!7N++R-O:K_^E=$ MQ4^C?4HN8%L1>V?\Z5-"P+:I=^&<:$[K^6[K.I^E7]9$-LH%J)8>N'7-=YWC MF:]_&&3CX-WTRL9G1RJEH$TFU0K!,1@J':3KGCSH[H?/,.*F;5E M7V^^O_PBP'G]9OF'ZY=,YMMKD[L*^BFU^9LQ)D9E+R MO%HT^.C3\BC4W@ GVNYKQ MXP@W/LQ8]E-;W29FA5U-<'?)<_O-C4OB9KU&#Z\^<=[115JLU1'X)Y# M,QY7AX/WV%="@16ZY2QJF,$>^)@A/7].S,M6@ZEF>?!C,S]_QNS_-\[_N] MW_M^_WZ_/^:?&??MNL[K/,[S.*[EO#14%]N4N6?]E@$R M"V!AN"/E_%C@&=I@!..H6'3EJ:4E2P49<<;7,RM2+"#D6#K*H%.X.3B(<0'Q M\&3,'0^ 6%K[QF_<3)CT1UDVE_6QK]S72 MR^0T37*7W!*=;QMGO-'+S'2WOG222YM+\FW4PS7&Z6[V8@-/[$&XGT"]WA5* M+%I:, ZB%K<0J2]L9VT<:ZHW4EZ^B_K]:UBK3>KJ;_G-JB?W8KPS46]].KTD M#B##TQ_<4:L0I5X*-9-SK6X^5[Q$^1[O,'5DG-8,!)G^H[@PZYZ5]&TQ(LL" M/.P1Q?53\6_5@5FQK?TO0H*/!: 0T?&,!23^IQP)^T>)O%BA$&Y<)OV/.W?PL93.^<$^FR"INB'.]'PJ@/V1HUM*L&X-NN;GJ M]ZT)]4XFNVJXVY!N^,1(\7YS(HXLSO6E[C6ZSL?(6EY!3$!YSZP7B?P&%V( M 5+Q3QG<6;;..D)0F-/]J0MA&*?BVK+;>S?UX&LMWU3.2=_G"KQQTW#*A31. MKPZ2WQ"%^5M[D[&/T=P>4;'KPPL3;$5M>VWS!:!-UTUKH582<\=*2^),]W77E,[1MSY"K]1CHGK# M$P8?&'PVNF*>#ISD=9?93((#Q9@[&-6K"F&Z/'[7R.#%%#__ M%>GK0:W9=_?<]0]45UO1]_2X'WHU*[;QPU/=PV'\7(="N=H.K:FPW8IBZ_S7 M]BG'$LN(;;CV$/3;'GL431/F<:-RDEKC5%&[H4Q*>=AJ;(#)Z\8 QQ,D%[?K M_!8-8:619_FY5C^E8B'Y\OD>7Q8@TQ+/Q@+J2@'[^>]"I/G'6")#L'C=I=2!@"2?BYB*//FIY4X@2#A%V5Z1:@;S M"%(-U^-IE9!''0O86RU/,?4W&KLZ?\*]%2>7WO'"JMXM,RGD_NG!XKRV]%W_ MU*_KJ0S938FA?)P=+OT<>?/$Z,+/FG>?Y"NO93\W%$%=^J[+_GNPDW 0)!4A M:@Q3U['IYM45G2:.*;M2$;#<[IE*.FYE M\39H5SVZ C^<"?T%[Z#B8'Y\R%Q+:B2JM@L*R168I5\=054XLJ M=4&U5Y;@/Q3IX&:,T5J#-9 D!1\.2UTK;8T,-$Z?&R"YGYS9>F)M'$:4;;H5 MSHN0E>FI=/Y[CQAS&YHPGW:\QSR99DJHH<@[,@HBH4'RTYG-P<5XADB( M$ETYT!RS=O(,PNWR=='Y_>;_>:*.'[W^1A2)8&C4UBM5%%,ZD? \@AP_0,#C MABU\@G_ 6N@U12P+F%%YR0C[!A?59H>(CA'>8R$U>VT<]<*TV0;#-!?'%,3^ M^ GJ8ZGWID<0N'>4;M"DT\%5.R X[.\>"XZJ/LY1%93O^XJ, M;F0Z6/>_^U!5B],KIUMV%'WS>2'K?\@D9]3W9K6VBHQ-3R)YLOAK>?*5IR9['EP3EWK4'O'+6L;Y4!)$";Z# ML6^-QZ[,#=: %@2J3;1E-0(F.\9M V'VP%$_NI0L7!K0K+*&Q_HDG:+T^2,[ M7$/:SS\WNL$E1<-*Z<&EP>\)>,)0!VRZ4D=85[P*SJ@\8F.,;A\\Y0)=>;66 M(+U;CNVSL3WVTP#Q[&]G]6 M-O7J[2V/7?R%3TED 3DB^YRA5F41D*;UC (^L9CX4*NK2OSWHO M,[7:E(01&++IE,B[LY S:G+01:7CY^6)WRU&QS_%SFR\^))V, S!)$.DGE11 MK4T7AN MRH$(VRZ13I<(L02^=_CIW4\\6Q[JHG/R&WI[%<_;_*V(CQ4,O+45 MI&"H%MCAVI%U.699 MR!"SH#N C>?AWQL2^WH7O]<*0[;[G)]_Q"Q.U-[BFP@KTPM_FC0\TI\RB/ = M-_!>'UT''E8DB5]:ZJ N-3M;U5L2N?FS#DR6!OMNUB<>YS=.QBP.3F67?AKU MC;]:W:_H+E557?MFT5TFH5SKQ_RU=_$/FB9PER_[7F[:B@P-M,AQ%;'L'SB= MG?!0?.%=DZ'KB*DHIS%GY9<\B?$4 &[-I.,N'OLY 1;B%L[DP$.8+QZA.D=< M)J4\]KCD;A0>9@'Q)DW??03 NCN&[-H&*/^U[Y/_7AV3XK6?[0]6B'!+\0FZ MA+]*.F_<(T*'DV90<.1IYWIFYAG5/KD8V97SK^K$^'T7L*^)5%LL=+BU4?$) MMOA.#>TA62<5$ZY8K4"SNSM\[G)UF4]9UY&F7H//US(?K;#O.2C==+-D7Q)= M'*N!>-=U-ZL5F#N+EB?LPT9V+:]?L_R-,9=EW[3EK5MH44I#A]UVWP/(^GJ;DH6F?^U2$'84SZ]D2_ _8)D@$F"[T4V1FJ5+-P5>F8!H]' M-2*\ >\C/[ZQ]%G0KM>>S9D7O)%B/:])]1Y0_94,<_=DLA]L.7Y3<$X%Z+>K MV*)=1/S%-?YU\%7\'RS,0Z!YU6YWQ0!6G.M0'-XNBQP5I#;T^ ?DIN0B+-%\ M^#(T50->0@M47ZKEI/)7%*@8./:J;"Y= ^@4V:$VIOPR.\R'1,'0NXC(%II? MBQ_>1[%/<*4(K_%=\M52=#G:DTJL=6?65/W7=EE>-?/7B/,T.VS*+)= 8ZQCW,]IE_PF@XG MXY(=<:6OT=J%!60,R++FW+'5N8I# M7^-<_3*/VFOLSS^V>FB9#W3D_Y#& BZ&P*HKB':7A+F3J..(=K?[^&LNA3_5 M:1Q5K.P,2Y677R$4?@5>;YRJ3SXQ-+KO#Y=,R*\;;+0EADBT1_&Z&90@P^:.25/_1,:H:!8H7BDJ_JDR J7PYIOD6CDK2+H+BXO^<92,V>.Z M!PG-,78*HV+KDGNON8\-W4E2&-+H.+WR_Q]7E@(T J;8@).V>@*0Q,C/C MD2W(8X>]#LFT)#\8FWGF2Y\J2E3G5BVCQ4HX$)F);MZ[C6PB0IG=_ M4"I)B^YG-6C^]L%#YKOX.5UTS,U@BY$0I1D[%C!?0%487W_#_!"(HL(#Y )' MFG>Q6[9J0VC+L,9MR\3KGAN7'WK&O:QS$%R+9^P9N6!G"_,44(/5[-I38IOJ M'"JO_3Z%>6SNS+YA1HID"%Q>=X(DR?FVHF!XL#A-L$DI/66C20ET-7U$0KU[ M,A2C-.M]Y+-QG>#J5+C6L2Q(M+$LY6)T]J\9$"?FH M,;W+F?]?*N!$*:\G<#,>4KO696*UE#-\\89.>YF1UH5QR\3OPFSK1A\XV%[O MT*A778EL14%'A.:[:(3&OB%3:JL^M;,_;,,:EN"\\+7L9L\+PZ>_X@T-KC]^ M?E]^SL9 .!TUD;I.8KYR1^((>KBX!;=[2:'V-RQ4NYQ1>:SH<\&$?@JWL('N MG2BC7R$7N255_V@&S2TJ0J>RO[F!I'Q[K00#OI_)KPZ/YQW8DP.WRY.'@:TN MF*N9SN&R?>?EB,)(0^W1Y(5 F?298M?*!ELCA\1)V;%3O;M ,E$J[RN^L\A6 M].+!8 ;C) (R2_@'@:LY9UVQGL#V[-/YUPJ*CTH(7V-B;FP6+]WRI0]UC6.3 M,=2[_&\3X5YP_^<=MG?*)2\XH&MNPZX/O,R"W_^6U' M.2ZV(5UMI_4QI"V1# 5FB-8^B2(:Y_4]=O:2XNJ&Q18Z67F%/\Y9W+[A7_7R M3)^WD2"404>D;'T+"Q#!.+\SH)M2=W=0BQN^'(A3RODKR>J=O^-BV_?;N$U* M44+?0P<9\E(<1CS0EF[$.-]?C1V/]:ZOJ!WX M,X]#M!%"MD$'H Z8YS"-0JRO%8J?3_:>55 MN.5G[G/(LJ_W=7]^%E"& M+D(S]JV0\?-\U%Y%%+1/+T(T[SF?R=4*7NF,?!V."[VDO173(3OMVS5D1C(/ M,N<<-XP@D'IQJS>&6UNHQ0Y\XKAP'SFF^&>$W[;JWYU%4UWN1-' ]PRW MG^^3#HXJ1B3J/EB1">A0PC'%&+F]$(LM1 M)Z4WP#&0A.J/@G#K>G^/L^N4"U?75:.U;TJ]IW MAL4KNZROP1]G13N,EC)\[T1HO$\X?[(RPNH2UZ&P?H$6383#?>07U: WXL\2 M+V.S<517M[&B +JO;^*8]ODM[2.#]8/6ZFKOG9:E'WHY/ZOPWZM^8.?C#?^W M@R5@O2](>E;)&1G(EA_H#F$R&]\;9X;Y46(Y.KUMC?D-YD9\6W::2A@G[ \_ M]NJ@W AC ^8[VW< .QQ "9K\>=F#_#1#HL'DZ\C:4 K [(^Y :Y5]N7^.R__ MUOH[AFJ]-,(5W(PIS(G1LG#Q6O<0F"T$;T[O%%,?<3]C<63K]7-C!_'0=4*I]QLJP;AR1043X4W'JZE=LKM(MOSPXY3.E;-2ZW>> M>W&$8%3A#OLZ!$P:CW(X7F'W'-8MG;YSI[^9< M.KH_Z@%&Y!]V*O\.PE$S&]$B6B>D(Q%:SS^=)M<]>6-Y9JLTQB?Y1V/FP8E+ M69&GM U,'UTQYVPG"(&D*&(QIL4,U94S%BA#78P\WG;.)X5'_&2 -Z8I^\A' M(^UW5Q^1'D?!_HB+9Q**OA,*XQ<>4[HB6(![ZJ7"WHFX*=/J%[=,4J_U.,;4 MGAIC=[L%[$KX*LBT5[=_R5A$<-QI]1X%'0LXQ:X,.5Q\$&2DK BWR[*O= DC MB>HI2$IA 8(@*4.H<@+D5TD5K0+Y-M'#0CZ#>:X[40HLX$2PQYO7\P]?MR#"3JS@*U=HT!@&Y%ZSVSAV+I54A?DOQ#S]$>QPB2# M5,9N,K8M^U8'U[L M3T CU[U@8,9&0RCPP3'K2R<_:7-M, ,0IR[V>'CTTS>I>]UM_)9)$5WX>T'Z M06;T(V"]DXX.W&;S[H._1ZQBM05YY$&>=#A%&&U>[,L"JD0UA0\#J,W;&23EU2+,-/1%H$;BDCX+>(:.>>2; M4$K@OVY2Z7K\+;>#^\YN)=(IML=UCI>CMJ(.AS/\!Y\>1XR0#O,Z*.1W*>9;]1ER3@*[XT?T6N@=K=:C\D32]1G4;U#,5 M.\4F$>GT';]_W55[YN5ZG^TW>PLI_T:(@:&YYF 7N)= BD,78YI/['75)(:- M"?0%-LD53Z_G7$A3>"VW_H??@)/ST/AS@S-;_F&](9AD/"2/G1?@9.S#KU?7 M4B^F!GGE0@_-BR*O]^;"C^D' ^]05P-J^N,[#-P#0X&ZP? M2.Y +SRC+GM0DAIX/CS^-A+P0!<)DK'!UQ!/B07\A>8[Z<>AE?4ZZ!TZK%9L M^J1O=%.BK;%W69X77]F1"QX.4C^>IM_V MB4>/NZF_#T,4X8S'CB7!S28L@"F\"]2#.@%0<8-(U8L?SC>;- O;&@$'-3N. M85:%GWU6;L52312'EO@Y%[+;M?1GYK,>1XQ/5'_9A5:)DGRC+I:8Q1%L@2VT1_>-]ZJ8F)PB_!QN M>)XC_@+ G-$5^M\WDY.VE[Z&<'7$4NSC!88ZC;UQ'9;J7EC*Z,\L23,6V$E- MM(AKN53G^/CRRQM&AT+/++I1]IS[F'D7#_CS!/TSR7/Y-CUV567V'LZS-B($ M$T=\AENV*&4!=*[?X'3+)Z6!\_3#HV7J=F8 MKDUT@:_'/$CG@+#K)VD^S>(.C>7^X?W$_8&&,D_=Q[]>$?A5?.#FSINZW^_V M&IW1(H=HRX_FIG,YAKM+>B6P&S2Z[E#^ZG-P%5/@*Q.#(25CBG/B*)5V>J3R MQIK!@.JA$RI&]R9N^;_KV7F(/J6SMLJWGXVQA1@^ "0EV LP0TE48KR.:/0( MAA-*V5RMJI&>]?YJ=W+)P61/A.'1876C"!];W)T0^1G+'0+8;OY(R=?W?Q]#XG?\( 6<#S.EP,/;29!9$:4YZ5$S8 MO.@5&OKIHG[IR\(W#F._CCYSNO%Q1ZBQ3+K.RXT#KQ #M<*]P^&5QHJ,0P<4 M&*__#'RXHS?M?M;8>,U=7-_O?L;KP3;H=??VMJ.?V)C+,-= MV++!9MR0B77<')D%Q%>;D+/"ZUUM7CBQ/4L*8C9\UQ-]EOD;>?W'[ M?D\;CP5CRCM-,K&%-TB]44*-<+N\3S7U0FOVW&4QV=B?SY:E;QG\WAMGS-ZA M>07>#XW7I^0TQ@O?34,/'I_J*XT]L&@K.G+MU;WD%8,_XEQKN[D8VO)JPC;< MB?IW#&,?6Z']C*8D$]HV6AZVJK QDPV\\3FK.=9-" 4^ZS$RL+(^SHQQ,WR* MYYN*T^(\.9WR_W>:O,W%!+*"A M&D_IFM>@^HRW/IT*32LQ\*V7I&99G]5J@$,6,X]>W3[]GULM1TK@\VW/J/[0J M#CY]Y["[W:&!\5I^Q1W;0*H.\F,!F*FYL&8004_96N(LM@C77.4G].BAK_+5 MV,>+?"\:"(D&5X!4U/CP4\^>)F M>SEM1+\O)^WJ? &IW.-X>X>H8LJ"['/!P%RNZMLIC$<8L]=.M"Y!I@98OZMD MHA?A#4D$;DG]%GK IG'K<5N+RGNX'R':XR3\_"MJZ[KGUZ^I=2"*(4FB1W^M MSH^.E3D?,>#2O>>LUM.,H0=L]5*WK=\;<&'ATM-1P+'$'4W^EZ?348>A OJN M0"'H#T6TTZ&9P,/@I/#=@FY1X!7]QXN+?ZF%KMP;,P)V)QHQ\E?88=XD!%3& MD!-59MW]IXYBX+'>1:T3ZA&+)XC6/92O?I\6W?Z\N;DB:7V\;7I96O=&%B_Y MS#=,<>GR!N- 5+,7&CHZU6+TRYTW8S/=(<,X\SZXHX(AR[YYW[(]?BJM= OQ M:PX82<^!0G3_P(NTM K:WH&Y*U3"XYNE5_HD*Q*'5$53PQ2(2N-RDRI7C>4^ M<2N\.=5>/O5<*PC#]*(C3>/ 7=T$B[N:3=Z"!;1=GVYOS9>WL8#N3B X)% 2 M\>[ 0 $(]?G:W=H]D 7)#F75]TQM..;T.;X =["ZN/#DL=;[0Y,UB4J/H:U+ M^/,V@%S-*FU8?WNM_Z^&\#%#MX]1RE\3?0&4/4:NT):#H$ @_6$!D"S"<^L\ M0H<-ZUD +]'8!1]X[O&BUQMR4+&MR]V1P'3_L/NS-Q=< L:UPZU>E/!7R9WANW,^ _'HW'G <0V-9 #%4^) M7"#3OKKX\^&?!A_R';%]J+5B>G]06>"YB$MV0F&N^N[B+X^?\SH)K^A;*<:$ M&M>UTKS6YE9UUI@J8+T X>:HT+H6\VG@"3_Q& SUE>^*6?F@UPA%W?3PFYW/ M1Q:UGD2H6W*=XJM>OMK-B72@>(,A$DWA\S .7:$X-76JZWV]+V*J>*90_?O; MW>R>QV)]^"<,?L=Q'U2=LR$P1,*I P$GRC#[M3P]?$HHUPKN:WE7TURJQ9)Y(/O SV/CZ-^S>]S6VC(:W9Y[>^#Q@,'SR8O?IR<+@ MO?7KV/!:T?BWK5G#>5WVA\]GTN9:3P8J04?'47O/?NKS!?5J^C/9? *[ZY;Y M-9<)!0!X DVUZ(IVHXVL4Z$B2GC2CS +FBK%1LWGSO"Q"W^!$[+=P8(=OHKK MAE !3>2'/![%4*&M5WF<^GYI!I:HK##6B4EX#O(P$?H=]@ DO;;A)Y"X:W48 MNCUN7C6&5ZN3T3RVQ,8I?5.GE5D!D:)?Z.L\R9 M?=.X&/%M+-SSJOT3CAT^IK"T!+G/8%:E!',0];,SB9F%#UZJQSQ%4[5/)&WO M. &O9,;;> &@-$8"0\(1A0EW%-D-*6;H0.U!AGQ&EX]XC,\KVD>#OLIBN?L/ M-RRZ+H[]',\P=!3ARS7IGP[^9X%58M MD^>[U)QB'YEI\PW,GQ/RO'9UQ'!C*LWP2JS0J8DB]H(@3@Q#8&K];3E:O1X4 M*>.DCN2#TJKUP?6XY4 ,)V;>MP=!P)UR2] M.O0!8?^'4_Y4WZ2S!3Z"0*<3/TJI 13W=VY9L#VOU$%H WV MW+.G0&TFS#HA-,/8GL#SD!$>/(\DX,$PS)?!1@Q= MY#8+Z+7&-]SKYK2F'M7JBAU#89=:H(MNSV$(!L]U(8U+8MQ+DI&GS/WY848] M?X5?8U[GG=^$]2!"N)>@$_W$8M/U5&H\92!/BHA2$+_1XQ4=,38FXBVY\4#B MH95E^CY?81_\?K$/R2S%:&"XR_%XPA0^OI MJ/D]'%DMY:SB&3?*3X96.X@#UB\9=-<'W$%M[$DC/P-VU!X._BW0U MX\-/-6O0MW$DWDYZR?&RQ+/5#FFHBI_&LD_!?^I@R#I'2AVR,MZA!1D[[43W.^=V)8SR\.^AO@NZO[45@KSW-\7J)"2:CF8 M7U:Q^P(O0&]R3/"^ 8U;3WM6:V2Z?&]45E[M=?GP(L/J1K34X2M_61VG/V87 MW/0F-C-,TM)^,O>!]<6G;_U"_I\R^>45]VJ:3J;\&0/T4)\YF;>?!KH%W^L#^?5'< MS0\)^V'I:0Q'-5L^E-\LDO4YFLS<,817Q'\6O>?=D]ZAM'CQ%.#X^CGP31CH MI1D^+6$!7-/6_MD% 2[9,_Z!*$\O'R^Y1K[JNR=_+#;)Y0I+I0%B@Q-+C/U" M,+];-X/[H1\9#*ET)#SSXHK6DWE6>M7N$=36AG$*DY?Z(!%'W^,U/"X,/81Y M$)6R*X'FQ-@OVK*1AN[^K%BM24UN"+PZ35XWSK\G(Z2>&KPBQG'UF[R$P([60J 8W!D5_%2\Z>T]A5\LZ/YDL4'_J!PSI3J#^^+!$!A9?\S\,G]B39$7 M.C)^D;I .B%1_MEDG5=8"!.D'G_22:3'W.1L+WTI3LJ1$9%JN">$416 M?;WP(O9R8RYI8M4QJMDA.;MCM9R>*7A^L]IEOB8:8;UV?OCP[C.69^6H'SEY MM'/9:2CR%$/$<_S$Q0%I&K9YB7]ZQ>&D?M;TRET>5/$W*4V"H"!QNQ!KEC^/ M;N!2;$KQ-^8$];LS1K$$-X4MO&+.22$BVJFW8[I@(HASW*W@^Z_#1PC4CK,5 M&PGNUUG >$2M"S,#0_H-#IN08M]NI!@D93#.%D9..I#GF(.:X-R3CGV:GAOF M&/=2IOCEZ_M@_VY.VK=Q]*XY-$K+V"MS;M@JZ_W=@8L.7XL)9:X!3Z]Z61NR MO: +;GPS^K=/W:Z.BUW[HCB5>/.D\\W3WGS(+"W\?OT&2 MS*Y=D*=._#B?M*Q7[@WG5?R>D7,<&5F8H^<)UR1'.Q 02 ;L$0;?= T_7+>E MJ<_'TPWG<'S5ECRM!<[J>6Z3ADE\_1?U]%1N/W[AVUY(DKBO>T,? *T(Q3_? MK>.H0O5J6^^:!FU>G.:+LC.5?Y7HHE]]<^CU\M4R8YW27Y9!V* M&D7>/_[%%B+7_/_KJ;Z3X)K;JBHC,-"%!20V4O#TW78L8'H#/R_Q/_^0SN\L MPNQ!XH0Y.#$4+ O^ZN!")+DEOJ%7?DT3YF)'K*L+:=)Y @_2)L-HRO:$'B\^ MUZM1<)M>=M>C8H/"G>ZW# Z%UHBR)\SIHJO//Y#%1UK#_-+,%U? -OK'8 EQ M N(C5\ F??27>":J,@?>5\X"&'=#="CO:Q'&_30*XXC>0GN9,60\$#;[$TT3 M,)S/9 %ZBWG;9VY9 L024=]S<5'@I0C\4.&<.3HY>U#MRP 5C5DG+.@RR(, MF_X1)&N"+* EEWUV:?C<^+H?;9 9O<$"MBZN,4+;E"2#7+<.0T@BY=P9W#$F M!RE1%M1-:65Y7KEW3ZN.%I1@J/%C.>_D&V:CDZ/9CQM*/<;^F*..TD:T68"" M+-OVX7>=",)[ J06 %N\=$)8AW0&"RB9V^S'^#"V1."HOQ<--@TL<RR1>@$50UP'0.;!EXQ2!T&F"5CO"/XYB!$FS",]W%*2 MWW31=F;K9@$%V%S\W-+V":2D0*HB,WH O64J#AYZ_G_Y!?!^M#WFEK]!GC\P M?^!^*KY.D1.\X:M^II"Z&+_^YC/\S3GZYL5?MT1Q< MOD;7"W0=P+A@XVKE:0-5DL8?H>)+N$NOV7$RW^]]<@8K/UH:WMAOSF'(D._T MA-'ET1&O'@5J2'RH-.X79@M;B%"6:["EC]DD'_+6^/273JYR>"7T+LH82 )9]Q88S9 M"B+ &L#Z3\0RQ77P:2"6BK&NE+CX ?5T5=![O-.\:/1=L?1TO-O## MN? ">(3PQ6^Q7'FN++!E\,LH/:JIZ[H"XM_C_+A MTPBD3]NEC-6"U&LY\W*24)3#2!%J(-#W/\(S M):-JY/YVO,,UY;9?M^? W;.N&;47:H.-M*4K@4*D&DGR5$3!(SM.X[Y'VA+U M%[S+3@=]L;6US38>3DCGR92B @7G_VUJ%Z)U7L$6KQXB#J_VCC&![_9G0-NW MI8!_A'TPZ\HNQ!_G =@K\OP_B_A+D2#RW?8B_GW)+!_B%SSC[48C@2Y<0F3* MQ85@\/OI83,F1KC[0<><@6RCU-1^AP2S]R&G,"'$8H\P\$Z0D&T?0^A]\WL; M*-ZF@L:1(?9 *S1@)#3[FLX#[[!278MP8#?/XF#.N(D^( A-(5AV0T$)@;PL MX/,6$0Z[B2UZ^<^W8!L["%O'\\\.^,:9?*)54 5"=2/><# M,*2\,3D,L5>E#(F.5]"]M0+X:@)IPA()1+N,:3*UL=EH1H@\:1A@(ODH[*)# M5ZMB=#QSE/\[..&#_VVNA(TD4%W*&P7Z\ %F]%CGV^#Z)^ MA&@-KMKHJ! M\IB2C05)"FYX9#R.,+YTT#ZUTP-;H5S&O5QP^;V>" O8[?S54B),1BH1- =) MLYAABIM9BSTW="SG8D/7A3!XKYV+1:&$BWKSO2?\,P=?%OIO3H,1A$.<9BO- MP.F#(GZ6 B;*8H^":=([C5GR/Z1(PGU-BTIS4? M2AYW6A)9U-]Y)JWJIEW1X]D88C,VC$ U0 ^MHX?U8!Y]ZJ!^3:EMI^(%PND_ MRZ<7X]N+#=[*HQ:KG^T5HZV,UX 6Q@WC?5& )+UD]C]W]O'H'.W^Q+!('W/Q M#R]13PG.]#A:^GUOKO-D;'^^)#\I[Q#]#@$!%NDW/JR5E+/PC6[F>RVP-;*^ MW.'LWE-S?["_T[^MZ1CK0#HOZ=Q'%O$8R(*NY"M*\HECN% \>"%OHO&@SI&[ MO'E0Z*S&[03\E/G(U2499]'7"Q<4IAQB$HTX,Q3/'\O]ZUC_]JV7KX]-;79S MOH4'<27VK^A'X65QCI/FFVM.$ M%CAIWO3+E72#"DJ7\-W.APH]E;8C'6]\Q )*$A])5%O/$1GBFG3'H%=$/]P(MYJ;]L5%N"M_-NZ Z2Z@_.(R.43I?L-0_GF)2L( M02W[[5JL+.O<.;XWV65MK_MK<+!6EIV,W@_=0F*(CFQ_B9O5@*OXY?.5B;V+ MPQ9E1M*Q46TQVGH[Y+&DJ68W6Y)3LP>_;\>9KVJ571&JLJJ:&H;4;[L?MP19 MRT?8D[;NU(YN%T,!;^,@)_S(C_%FFR!\4GK@Y5+X5XP<[KA]GH"]P:E9V]NM MXHOR*VL_QG\OCO\Y]4T,D8B>D+.28T^S?\F3SN MNV\HI%=?,*1)NNLM9E?=?R"_C('Y[C$1')#E(0<*(;2RE.3:Q=ONM< MME;\ MIJXB]LS$SCUG[^%^8FM6DC3\A-ZX3Z,M/@PC7&U+YJ5T!I#M[BP9O4W+6ICT MO0J[8']IP):,;&1(+O>.82#9C1;RO8=HAO3IA'M@X(]F%D"C$&,!7P%ZCL^H M-OAJ#3\3"?-MTNRFHC&D%S@^F\T/B:8ZIN=;U$%*G"8]7%?[Y?W,(==-G/XM MHN+UL,U'3%/0$DL]CPEYA2W&,/8UDLW"EA*-UGBUA3T\)#TC(@+R)&:-N@(S M+UQ."[8!M@YL0RNL-PIU'F @T G[S(%Q14=,P5D&B,2OF%LN(UPAD.;PFYKH M".*Z7#G\L@O[,J< "'ZZ7?(Q6"[./_[TMGJ]N(0VS>& M#724C(T['9SD0NGD:;4O[RXU4LWG^MSWP'9,KZK]-6I)87PPSM3+>"/H6'.1 M@?/_6(,^^]N&Z+1+_Y#.>! ? (H3]F$F,I&@NB[P%6E![%6' O= )!HFQN)9 MP"^#<62<56_&E;#1:_['U237Y7*8SQ#A3.>W#\TZ(""9D1+<^G"Z^W^_=)IS MBI,ACG1)=K(7,^]5B-C$M1(.>+48GP6>Q5(?F3$R4XV1=_:VL@#CQ;G-!7%9 M=H2#'"8PLFQ)B &>N&-6X_SA=/E-))^'BK* =LM:U+^-,YK"S^X(X7&-27M# M>6?@EXZ:\H'Y[9@XM^V_J#\KU%3I55A> D6_/Y-_P<([?\R@TT-1(NO6LV>+ MO?O&"%JZPTK39BOX03RDJ7T"08MCX,';&M6GW7.EL.L[R^C@I;5-'K,_/<[L M:]$PWQF:XY^N/ 1K'LGPN%O^_%3WNJX+ -A(?AP3I@?2X( M+)80.1AFT!LOL83AV?(#8Q)]WPZB_AQ+(T?F,A>^[O2Q6L7_.DH)V78;E!K" M"B>ZX6-(AS(_(N83*V7$$(@8&[@"O#P-DB\2I2IH/0_!RRX"R42Z/=WK!"=\G">4X>[[:]RLZ_ MMQ;+IOHD!T(PF,&PAHC5ZR1UX?JM\56)-:8+7(\^4$*,0Q=Y-"!YW.6RH6IV M%KE*>\23GN?PS"%%>3%1,F/C,O:;$W8C@*GQ _,R:!,QD3WB3=^W%X(QJ@-4 M;&QFY4\=P3F?LSY[XD^.-P[RA?0UU=A+CP<&^;8_'[H&8#+/R[^",+3X!H(X MC':!9:GN5=E0=./6>X_2FB^OC<7"OHXO%FH)GG+4VH,2[#_0# BN$!C[">M MW]\[0MA46 #[79'56O%XLT$WU0_5<=W7*S=M>WY>^1)BHW';_**NU-Z"&/1[ MML[];-CS1?$F?>2R9UI?"WH<]'_)RXG%0W&488I:W-4) MW>E97[DSLUQ2CS#C=Z* 3FKDDQ("&^3>9=BC4H/1[WT$-:F5J:G->'C<#7LO MY;SC8[RNDLV5?V(].A5'?13/R,S41QQLH /!GH?\YK*VZQ8?$L$^@'_$1129 M<678+1,_;!Q=QTX/[_6:J-D8NT"P]._(2%$:STR<")-<'[^$OIQ0@K M18;R6SY#&6E:MAGSJ#]#6MR9O9")PTS4^,K C0.8+?.73% ?_F2]S$[7 ;_Y M4\V8D9_ U0SY+3B:>36=\^^E=]N"TPFQ "B#I5X2Q95NAX]:#76FV?!P? -\ MDRG?[.-I7X& !, M@.5.+7G^;[0>%A35SZ5N0JL:78&K^-Q:Q'+UX@HLP!4' M'4U+HH'D3SY". $54SV+:,N>[81WVW#,L+9.=,\I9 MT[:2%);0[^] "*3-K*:CYK,;EC5'3DU&&?V)N%DC?E#042L4=99K2A)ODZH* M8?Z)'*$4$RK'N#&D1PNXXJ?%JV0;Q&M7$=1);JR[>L?A6XD4M95I)N8'SB)$ MZM%<&WX^,T58,D5X\'OLN%O[K-].@7JQ-3&)$C;MOTNLX(\R:]TP)9B;N)@! M9N 2^YQQ_/5?%^0'\I&8<<_6; $U)$-Y7;6VXKJ72PR\WU$LB(,US%3PFWB-=^")8H96Y?'U"1#!LR]N;4F\;X M#<E75%1^GR5AON XF8DOZL47$^;#QKJ==?U+C^6?B M!F21_MI^XXH:-5I5UO);[P1E_.$J'TJL]\JE?@7IJMI^F8#4-W]N]9K*)W[_ M;G;I:F+0]([T=7P?"E(CK/,6,S,(SN_,**^>W;-::23L'I;,KC_I'K5T!4Q1 MJR<]W<.MQ)PYK)V_HK6ZL?/&EO7J]O2;)C.-S$0T;0J6WRVXO6SK5=0)T:;! MA1B57GOU5 'WS:N[CX7U.0)!G@+M/F@;KR-OHVS^ R^N,2P@/BM8'3'1#UPQ M\Q-1+'@G--O2KY#U^?HWO^_+V[%:]>JU*\&\)],]2LP@=WJ2FX>#H^\GE2>(&/W[>?//JP6>%HZ9$11EW MSP3[0Z>#O>@(!>)(1][TA6&.1)M$-/,HPOG6T%0/%K" ?,Z]I'NR &[^1$^( MF1T/12*\"E&T[\\3(7,7#",)VZ<[@SCX282@(OQDP6W[ 0(UO1?/KL^*6?*N>,31ZX?<"@1V[5SLM;(<;AU M]N$2C%"-6A;@@MY4QXDC@96 D*P/R];+O#)$%:!O ^S*P$_C8;XTA$\X7D-^ M_Y8++IR&O?YOLW;3[*L'_A6:J#<@Z0MA.0;]'U-S)6FE_[>I.=P8OM]Z;85^ MZGL!71O:$W%)M''8CU/;<"@3/R%0@1HKK,,>S&>$QD>4(\[ MIK?Z&NVD$@LP]=+L80P7N;, 9]330=',U)9:Y20MP23K"DQG/(0\_I@VLAY# M59PGDJJZ]OC.-9_&1)3D'TQQ2E[^8_%6]D?_A:6$+D?].S(ARE%3A%O@B% C MMAQ;%XU]:K^O>.#X(]N.D7S9\?[W5R>EN2\X%GYJ=+TA\,-O@AW[+3O_D[WK M8.)UK)V=_<7?5::'$][2D[M4F:K;Y\("][$ +AG&WDRR=NWH%ZS-Z*S"KWI0 M9]UO/PZ;\,*IFP?86OS[9E]*%#Z/>";K5Z>7U_'[(R,MO2:293]C@8Z]_@ P M-QR"D4<(QS1^Y&@P.I"#2JROD9M6R!S/,\C_)*?^/26H"I[A6DWV_!I@>VK: M=<4,YJJ@2Y8O(,ZW:P?U3JR?^Z $FOJ[M2EEDERA%7V'/W>TZ'BGV.U'33$! MUHC3[5)G?LYFEF/MX M]U/3')@+_M;+=.1?I#$3$2X>3R"E!ZOUG'"#N]+G5E "SG4*_0?*+W06!=PZ M=JYH-]AU&-M_),;Z#X$AOH]^%(%&*_.-E@;-]F+I:%Z@3@U=XD,;0=EEXT+N MP8W#"EKIFFR:(@!#V)W=06[T%))>"ETWQF&^!.87#/D^W)Y2WC!Z:>[[0*WP M[U=%5O>J4QP;E;.5._P>^N6W\N#WC$C>$*9I MP]K4@]QYR6,>L\>Q,+1](OSD7]-6Z@+M ? T_V0()N],;]1MY>.T)7O+BIT2 M[W'_7L&S@?018>HOW+9%A$#R5MQ+!+*>UA\&4X-;",O. M("]FWJ*7L!HGMYKR7QB4_,HXS.^X#>3?") [W>RM6AJRAB\&D(G(=Q[P2\/K7#-V&_/Y+$!&F[H$M[@A2>5\)M** M9AW2UJ5>F=_H\_^9=^1I73 _POR?<]81MI8*6,"TFB!=&!L'4KT'&2$Z"+\? M#$(BY9G"=%1S+3$\Z#&2Y_9A:&4>3\ UH@4Z[8T?%KW.D-=K2#O^LQI%$36U MU>LOY9.Y4A2TON%MC=K5M#-F;]P'P5-2M[UV1@%P:R,[L49A%C9L72B@O8W? ME$?O3>U'O,'$'\3^9<$"^/)I.#B*T(1G'%,$H3\ >%TT=Q3;AE "-7P+N(5P MA;T$Z@=$R8R_ !OO,I! ]AY/0Q#$8T*$-731@QRS9W\/+I_Y;R_BH[LRG-GC MH]%[:_QH1Q=/*L5ONC(B[P);23 _(HA?9$*1<%W*31;0MJ.6M\!#U'?N.A1/ M.5;J(> J\KGFX_5=UQ2]1',JOCZ7YN;"BAW[JKM)A)2/95G)DX&1MR*=#3&/MN2G_:9WC=XM="?NK MC8,\*W*J?RHX/4_[U"FOA'FCVM7-.2O$$,DCA?\DN*'%77]\[,B$]!<&)1>U M-KPG_F(!(4V-TZX;I?[6%!1#Y%X1*IH%'!0G#"HDY#QA 3X_4C&Y-DS"_WQX MV4,**LI:>N!^;&2D:23J_D4-T5_-0I4EV]MC][ -\RP MDP6SB' 7% DTZM=J]MA_U^S$IXM#KJZ6FR?(76:)^\^US1KXIS!I2$#R)R ! MZ0X(R:S'?[Y[H-;L::TTHINY!8=N,RFV)\-+XIE]>Y]Y_OKQ$T*&>R>#^[W\^ZQ[)Q_<"6U.A,:W$8QPVBF1K7^NU\$P7M6&.)#<' MI]U6 ]Z>Q_?HB2P8)>CRI'L#NV^%_%U])I)P.X-N_+?4C'W0TF^*9RB]\(WZ M%;XY]M.@HVVE'R7[)KCP!*@^\99!]/7JPOO#;=7ZZ<.^F?K5?5Z\OHN?O+@D M!BC"0@\Z1?.L+VESJ3)2X5%LL2IQWH=NZSM'[NQMDZ2.Y4EY7V0Z%0>:>,@P M>(1BXS-NR;*;P-RC]*MVPR9].K(4M#Y]H-B5PB5 M4\&&$[3*D1_Q"VC7GHGE#;X1;_O=X[-\0' 3_XL[J:+/!*[=MXPXPQEF^AI/ MDU *@T$>H)-&C$'X8&3M[I_59_+M#!T^3'M?OBOTZF30B.^MV'=(>*S\:-8M M I^KU69<_ H-T;I:[)4J+Y7;RPTLKKE8TPL\E3OB&?X$I)$D$@XZ;A^9#RE? M@O91"5>CKWSM1R511N^TF'?K<1U*Y?IP>:7X+PG78\/[#_Z@?!:U00Y%YXF>NN+N[L>J9@FB,+-F'X]ZQG2'^D8P] MKC!WEA_];G"O5?#)P?DK#%4HP/O5JZ[3^PX4^*=KJ46=5N.V3NKA[XM7L5[U M0H_.1)%9@)/9$+$!_$)H$$?7P=R]MWJJ,1E-1R*D_DPZ=)A(>OD)/T.DG-1Z MW><_OON!DNW5;8D7YO[FG&040]P+"?0.U!&XV>J?^CT''RQE5S. MC$)B>M;#P?^/N2\/A_)M_[ZEDG62I:RCB,I6LF0=)5O2M(@B3:5"0I(L,;<( M)4Q(BA@5J=!DWTVR3"64;>PSAL@^8QECEMM[^WZ?W_-[GO?WO.^?[_$ZCON? M.1SW?2WG]3D_G_,ZK_/Z[3EMCGR-I-]T^P#6'\O^QA\8IJ1.@+-6Z+I5ON(7,;M3F<'7RW[W6-V!<];-BVTS=P2G+U_\7XPPWVT MNZ*5] BKH7;Z>%K4&K",:H%QO<2D"=E(S%!)SK?PU_EP/\F6,(8YQ>(PKGP# M.VH\&1ND4(ODLS4RW%Y'L6K&XV:S7:4> =J204EL@4T7C0N.>$K%W+(P%/@# MLVTTJJ2=*V4\LGVFE8&N'Q;HTB/"VFI'4,OYLE^S2P7B;ZHS/[?O:U2ME/O\ MB.]R_>X!UJGP0VPC^0?CQ!0\2X4401R![;#^F)EPK\Z+!]B])<1+UA07)\[A MT4EILQ2>@_:Q_UA:_N_B70'ZZ J*A3F2Y-O8OKJG_Q_A3#?''=,N^/\1>06P M\V ]+&$7/#'BQ)F;&)Y*!-$AQIE;\)\2_$O^%6#Y5M>+MQR%R8-A"9ZCH $N M9QL?M=Y&6A_!W7PZ73 MNFB]4@NI7"EU2"B#2F&IH;[8O5>M+NZNVSGU;$87B3IGUCUX#R64)4OI:T%R8F34/6^_.9E.W)QH,V!V?EG[Q? M.:U.P_?Y,ST93K/!C/;#=('(FW5]!4$1H]].]XD[6Z%Z[/<"M$.=_@=F!/@2 M)%NI\QM#C_*J4![O->_T#6WU2O\(IJ:Y:(M&_8+J&VV M.MD(B)_D'T9=1?6E'N'A0'>4$->(/D5@@M$WGVW&7[*J? M*6JLW4P=[,7#S&I2LIN;L![X!= C>KS#8#V"^%MJ_83]C!RL*'.2R0LO K_KFNF!O04!W*@P&8PA6.^* M^BV+DB7..%9!1\)1*?4K:<0@%+4+7-7%/*0P]7$\Y0BB ,F9![\S\C1J[)<9 M;&3]J*4$(8!W\J^=ZC8\ZQ )$EP-XSA"+669)O3:QQ=9U2/A:9,%M",=&,\B MP.>4NY 'A7C2;X]5-P]5WU=\RL?U/#"AQDK8#+:OSC;O^1/\ M5?$-;%_Y?AU$#)&Z?AK]L(*%14\I[C&&_\[=ZHZYQT->=9)%:,JYY!_)?5D< MQC8#7;OOH%"*\9D%,0]GP?-7':T==]YWK4"=()$IJ--\,YC"^=EYQAFF%(/ M)#<0)5T]O73OS]_I*S;+>,]7+V'>^&:;&'_XQTKO_)HTWJ?U/'&PO@DOO ;< MD+D9:L"050>CS70KU(7L_/3ON!ZQ^"S>-OC%IE$V-0%\F(P;%#5\ ?&61SF MMNZ;)@=IC[1K_.@U4O$EWWX/!;]I/J3MJ7Q'^.6JQG'O-I.R*R0V@H>'3%G6 MS%26?3:K\S.[^VWM2.MU;?WA\( /_R+_I 8 M;%9/[W@0F49]X*3F;]#,N@ \3/Q/ 5T/_A[4I?95,V0DR#3Q(+)=14'GZ0YB M$J[W((2.H5)X.%EM*-4"TU.U](_B/__SX5]X XG!'#G9B;6N](_CV<>66<>- MR'/M7 58M:@2Z.U0\PO44LHT_?E)@ M;@?R4 ONN=0E1-.MXAK,8&.SI1]$L+0U*<78_Y@OJ<7]V M<2CJ>4'9HX\G?E,:CMMLV"OXN^!@G 24I^36TM;>$OG$1=GSH@UI: V8#@MN MWB1TMZB<>"'QY;8#)%-__!&!"^+FR+X3Z:!8KIMH4\VO"X=O19S+CF_0>-BP M\VG">IFJ&4OT2S(UD"LN# F#?AR=X4FB(*1Y0^("U[ B(-*Z1\U-)5/F)D,^ MYF5_\CSG8X.O,.=7]I0^^V/&INZ"1@-'\JE'KY[MY<]^]WG_MEN^'@EY?$SO"_+B>9AM-I_ML.- MO+\B"S':=K8Q.R2)& 4>H]!]-8GK1T_26-ZJ*')['@IRF(M9(HR_/?/(A;&! M^-:7I;2IO ^D)F$$4[L#K-@39VNR$$5[6B5/"OS&O%#.O-6HNG\)$!I'&C ()9!S+V/ALFN\CF+SFI_M% M4(YWO3V!=6W7X"/:]*QG/;29[ME@MT>EJB;Z4(.,RJV\A DEQ 2F-_#+_!82 M?0T8R8TIV7$DWT@UW?ORCHNQA4?? 5Q)IP4$??C0;U;4*PW*E,O)\$/+BC?< MEUK!*W='MZIQ7H!PX4"PR)U!R)CU.$%?"G)@J$"X&^J**J M?%\11LFCVMR4>2FP]^(\+$%- ?_(W E,%8I^ \%--VA"<&3@@>IP('P9Z5PD M#"%8>OR0?1XMAA?W!)S7ZPEPB3P6S&3P'7,>V5[0L?9.*@%Q,%Z;3-9UCVF2QWK&Q4O,GE1@K$] M:EXS]:R]5I_W;*F=UZ,DD1J;#8].VYYZ$.FI7GEB/MG]CP!7PMU<<;W\2UBH M1''_AQ9J_"YK?LZ\NT3Y%"EM"G6#TI<+<[XRQ&>4..S&'-+BC!"/1A+DWFOL M/C?GMO#;]M2;ZXXGZT?/)&7[_20[T1?K]5&B)@*O68%V\:\Z[\CMT.78])5+ MQN[IT969CSIE+J<+C^&F0HS@^AE!9!F:J],^(_/!H\J;TL>U9QPBQN3?U5=) MZ'LJUV<=N@6=2MKY<2N34/42)@VG,*T$KOPFSE6PP0$:3FM.?CL4/+R==2.F MH6>GW,KM=CF)0(.WQROCQ+LOGS%'[@[E8QE^P/Y< ^2X>]^H84^H)O"PSQ"2J1*T>+16$=''MQ\0N5K.M^;L*AOGD28Z+]_H)G8")S6X.RLEN70J5 MA1+9@&O!PV/Q$QM*N=<4*_T_V+[WFLXS_K;FVV)HOG M-UX)1[W%LW:FSL+H* IR@*#KWD>FVQ@&]TEK!Q4G?H0W-^$< M*7^\9OPP;12N7!CGRAK08((=F*9F')O^MEX:R\EN9[J@XBO%B1(P3T)%2>SM M2-@F\.BI.&V9@8')V+^O3OJ_QB4_@7^')7/"_A^%)4UA-SWNAF.I>I/6 Y-0 M=Q9BXL*=CQSF6?@#F:S ]:S)=)@8GR)O"'$*YFB44?J]1OK6@/?I)V!T>OZ' MG[V(KC![6M(+T7A_Y9K](_MA%/88I6N $O(^N+R>F/_SICI3ARA/I,X25OFX M_\QW-$<^SB *L1N@+0$C]MK-L)MV($0972Q^VSO5']#4M)K4L[ I4U!HDGR\ M.K'N3/3)8 5S0G+3W\%,F-]'%*\?2?S(QD'I6G!3#)#%V@UWI^GK.604ADK9 MZ!H@G[,&1+NQUO>,UN-"+)7U&^35*V"?AE@#1$AT"@0[J0B0;NN]!C2>^I\_ M.?E9 K?@9OT 16&DP[-@I-GXC,*UA,?_.CIZ%/*$_[5R>@W89N<+*4^[=BO? MR4*,DR Q.;HCCJK-VHM[>/..J9K]KWRP2'<2V^YV\QE]?K](63=PE>H>RPJI M6X;50!+X>Z\B#/:?5%_ LZY._0#PX/9&VL=P+_YKHJ4>"[:0S>GZ9GKRJJ_PQ-+.96IFLSCF9_Y+LE M?Y3'W%4+=NR(UPR2I2U0+P-M63^ ^W*._KM&JV2QE!X^>#2B?(]LHY(NZ@, MD"K%6 :P66!]GJ(9[BBOI,9O9/6J>'S@%[3?#M1"A]V]=V("==^NHNXO$8;_ M))R\PU5?A1$[P@;JV I]AP?L)"&Z;E]=A4O8[F6]CE(U_P=V7J5>@7>9N!_; M_$EST^S,^*+P"<,)LQ)@:D^;QS_3)O_QJ$D"WVP=!;BQ$"Q?BBEE!W@E*%^D MU+2CTY&)+Y"<+\M:=VO!\\S^H1?.EK./KB^J*#"K$KHY&?#2(O *R4P]7H3) MV0_GAH(551FGUX OAJ]F;]H4#ZH+O+@WON=HT0;4HY.!A'$%_@O?I0)UX\SE M;I^OK6W/_;B'GWD/$KW 2]KT-F44%V^44S%TQSI:5^TJ::XKFWQ;*R3:=R>? M@KZ-<1HOP6D'AY(![JI#,.:;<(!'X21[V-6TT.OI^[:2WQ8YKIF1"TJK9%)T0E2?$%X;'KL:\.AQFPLWR!41VLFR-.87O% MH0'4I_8([C6]+ZV$PS=U,X+]%W?S*@25]\^.BR;S\?J>U27\-;T;?5*X"V!] M&V4AR0OD2,Z@EKQ;00OO#F(FFF4X )VVAXW_2D8,%%^9A6BK&J0C&D&)4*T> M8@E7D^"5J=!U=P?4G3/+A]7M?H,XZN?)SLY!.T)3#X;@AU[#W M4$Z."+IK(82,8F @(7>.>>B-GVH=-78,?]+V?N\ONO[]6CF[:PRV##D>?1@^ M9>W660HZ;,<@2HS'S+ QV:TO8:5=$@^]^#Z^OLU3!<^033R2^9PEY3^-6*Z?2J=[T_B9CHV&OR/O&%?^E] M]/N7+>U^W ^J /04NACQ2]S@G" 6)>YPYT^,3>57"Z@+ \[&E,VN1*L-T/YS*^7EC,# M/<(,FH?E[E857]$LS=@]6%!'N&XS)!>RG_/U\[8=_%\'\_EX%ZWV'YI,"[@% M%J-GY4;0_43JV\A1RJ8I]?<>LLL5::HJP65SAY)D'"3*; ;VM?1&1E@)SO^M M8+.67J_72]D"_I6$B?C7)$SL^_4CF0*0#FF$R(N-_SNR>0W /@3K"W]I$.FG M'QGLRZB3)"HKY[8+F#6Z(^G*F)_4*%O4/DB/N[">OVF!HI\.)LZ<[D(M7:L% M+1IR "OO-ZB%5D3AJ5@:5@UJQ2 @W3\KLN#C&HD1M/CYP;U.=KQ],I],#U]3 M41RYOW'KEOKZCU-I#8&_8P'NJ?4269=J$4Q-&&>?U*B-^(JJ/!ZQZM0.M$6U/9BR6JM_O4F/4A3HG3^$)\Y/+\@+HM:]*/]VY8 M]U>H$21;9OE2^ #_L87@:-/*1>OT?3Y#\47(IT^$V!TBB.9PA?\D$.Q3YPQ^ M=GXPCGSHPNLT1Y+ QF+\PW^+6V+$UX"Q5].4_XI;OOE'W'(".O!O5P40OA-9 M>CM@!J_&M8:MI !<2I+E.<@+_7M6UPC]#^*VS9 M\F]A2V:68+[6]4)B!*W?=F=%>>+56)MO8G%B#A&&&Q4/"^C-8?G@190._4*) ME#26_H+VMC<@V&?;[AE)&Q?^WEN&HP5WD?2CZ7OT$*Q][O6LN9W1 M--2L[<#5AS*W-=64"17(AX3)MHGZ_K.KOB6>(6&D*U?+K=2F$\V1+6WKQ8FB M>;FE VKEE:SV49LDR]Y6W]ME;5DKB!V. H/Z7A-$:5:#(^L^S;C S;6K5-3= ML2[Y1V5M747PG):\7^70\V+QA GB177V1QX!O(2*7@-*5^I%?>M#5F+NW,/, M&M^5#DDI3=(<3[EEF!!T 3B;4IAIKKSO=KXEJ W_J]I,-\VW3V*4]!!29!7] M*@C B0T^?Q'.&^JR7[0T<><_\#7J?,BM6^9*X7SL*!ARB% W2J1&^X,71:14 M 6'WLVZWUX)< >HB]CIY]K.CON6C5463[0[V>4J#=^>.E\]>!77%RSB[W(L3L;U@GS>!KZ-MX5BH20B-8Y(/VN/ M@H34Z,<]JWXWE>*;D(*?'Q7TBUCS#P\K-!27^/F M#D[M?\=%G[?/!#-3#EMWA+&_"!.F!=[E9>]A&/9H-Q!14].8%AU0U54 MW0%R6,ECGM>J0"K/"ZRQ!PQ8]N!)#-VB$\_:[5N_!G V#X*35Y>Y=OC%GR_&,!R-D:TT$,ADEI M5XLJCJG#NG\+.S.LXT'JOED _S/**R(.#L";)_ _,1P94=&5G5!EII/^1W& MK*M+,[G\ 'Y>J;3X\6JS!_]2X@E+S5U+.;#+.6CE;R[>HC@I56O:#D.J63>= MR)5,A[;8T=N94W84<0^_ 2Z*E;C'W:@TY1-'ZQV4^B2"'\F^\3R4FD3=1*C> MDX486P.8L):*" P]QXO@NO%2&?P-@=+/SGR_4MASQG(D;I(AF]]^; B0Q^7Z\56?"\>/?>%/>1>7H&QGK4)S(O6E K9\_N:(?OHMP=5 -"?E&-?98<]HE%K"@2Y\ M%\Q##VWNK%9D*><>GT"ACP'0]Q+.\_F;?^<<.ICXQ.R9LCI\YH_UKK>$!!0U M$E\2UCZ+A/U3-]VRY\TMLC,A2J1.IB:E[7S=#^O$I. AIGNDRK*A'M/,XS_& M4XW7@Y/_$E"%&7U\@ ?(-.Z%?]\]"YJY$H6 95SO?AC8;OV/;-AD[!CSF3G$/PYUZ/NX^;[*/7-M1.Z/!__J%E[.G%DWQXK%ME@#-$VLWQE, M^.^$2CGK_/W##;@SEV!9[K*\$!K@I_93+^KA&M#G11\8S2'U0_JL+[ZKTP47 M41,'TWA%ZQM2\^70-W";9K4%K3098I<\ &>>\K'?&CGX:\V/#!HG-&<+[(+Q M?7U/ I8[]<)@6>HY5BO=R58]Q.!B4&J#OA](@-1J2LS-6&,UYJLIODW- MCDX[G^8%;O3O14PN?97BI7S/2=^QBBU=A3NWJ19^E81V@E@AXS'U(Z[FWWAAMJS>]5'^7E^8]^V(&N^J2_^OL#/T/V-?C7[,DY\.@&=.TJZ!:+A MI?L027>!E'M9FOZC[C;RO[#Y$ >VP27?(A; M_TRU]&Z"92^#3HWS1IWH$LD+Z+6ZXRJ_R]K1^=/=)4]SA_T(Q)[SQ VRLX[8&^#?J3Y 3[./6; MND(2GA=;: 1N;4L?3=RA\S7[*OQNMU<*'ORL@>=87JV!.)N\! N]C/5IX'_]2']=',O%KOP$\:_Z=3[B<=K#,9LSIM(!2)&DZ%OH"2;(Z$(^0(B;&-'5'IU)R M28OW$=6+<4F-'[CZ<#UF\B>AX"/? L55*$-&&'$ M:ZF]=7O?+:5VK'<:?^88_AC T?GONQ?^/WGZT',#DQ@2V.2"*PT]P9#$+W:> MJ03;'%$]Q$_3[Z7W*#P?.7L"F\*]Q4I;NG%1I4MK>THFS9:/79@E9,[ 5()T MSYE57J;9OB8>9:LSL5.?PKO!/3B/*)X6JLIJ\JB=B'#MS+F?>?_4< MG(E9R$*0+W?$6D[^\TY-Q>\XJ]. M+(+4M&/$Q?8FV0AP]!-^&M/VYY"OWU?8 '?""%)]0WA]"VRT^XUCBW-0&Z0J M\P?;>GT-^'8_"]$AM&<=#M8=[VH,)'QH *2FK@$R.)XY&HH_!KF@G:'7(+7, M +E^0Y S]XJI@0XQT!I@G;;^[OZ+F6<*33QSU58TNC MWYLRXR=YB=5*_,/\/I.MFS[=,':KDO*=%^%Y=HAA:TX*M!/I#K[]<]J].*8: M(S?A3=JAY7>S)_"OWJ-T4Q?'#]DL+[3(V,P5'B+\OLZ>\S[-]IQ32;KW.,8] M<:AHX:!\TKD5E6735FP.6/\37X;F:H#] NM[^"7I!?U.X539A(_*OBFEP@\V M285/_W9)60,^/Q(XJ?Z;PMI%FGE(*4-R)?GKJRQ_$_ C%)&6-4!0M4QHSF)3 ML;J&>YG*OUX"RLTL+ Q\-S[9W9&R;L7^31;V282[",0$',=]Q.U%5Q!0S M>.+0D/ !CA)A-HK#QR);%!>[X,0]]-> ;9J-V^BO^"^O^R*IH;5N?#)%WQ3 MFT#MH'Z_U3%__ \R\[P?,KV>?X?2F'OD )?MM$#YZV[*).)(/-&7(!]TO:=W M@ 4Z5!C-10.-5]K&4K?@9YK47B!X15F(EZ$&-.-Y@: 8='?)P(O\4E&M<>/J M\S1O@DCAIZL!J&%'(>O.7O)R#&<3U'475>8TDTC%/2R+%VHE>/X)V.(VZ74/ M.?=1F72IZ,UL^]G^>^0%5VBC^#3,&B4P!"+=RWKVR1WH$, 7K& [IF38V?> 81,D)H?7PP)%C+R)Y , MV^$UX,_FNFA".HR;A'+D]?5R[5P/W_F@ZR.H^7SM]5HQX [)5V5Q[*V>!],$ MOEN$N*-R / "IM"D#ISQI6<0:ZD\-9@!TP@G"##X1OA/M] PO0AJ :WB;OKG M?OU%_*C+GK-$!M6K;_'O2W*%K\13",<2W!<@W[GWIF'K/%:5S)44(T-"4E2, M@E>/L]&D-%:*X4V)F971$AD]61:O'/31=E_U^9X3)]UW3+ MA0MQE^"%G3: I!^?C"$\6N)B3Y/_N&(#ULMC;E=$;!> MZ8,YQ.@L"S_A2IIIIFGW6X]PMDDBMGGVJ96SCS@A?HYV2G6%;JV!VECM(W)Q MH]]Z\L?85Z[J\O$B+:$"[-.IFVH'8@/^64M#B@6+/P$?,UW0PT%:P#,8+D>LYB+8/UF/&SG$87<7:BE92QJ(3T LY/< M3:%;<"B?P'J'.H3M2Y^N"31GJB/@KWU>]GU,M=UZNOU?GS,XMDC4+8%!RZ9]F1#EP;^< M!XD:^K+J,-L%>(&M'_/BU< MR IZ6G)2X#>&J\#'D6YEH*CH&&C_GS)O_5RJM!&V^#>A737]8$11F='#Z\H) M7P)--V'%Y[Y!P809=])%@0YH=Y"%PT^]%KDP.^N>@MV%=249@=;^(K&G?L6\ M.@U3TOUXN)$LM*\_EIQ_4U5'OUBUX,IR/YMH:Y<7.O'5/RZ8,::> MD/O[)D +-[LBXS@ZCVA06 -RP9M.2S!SW'B45S>[!OB@>RFVKD=6VAGD^U<> M6S(V&%_W+-/:66TX]NC-25C39#[>HZ"^FLXASB4(E-USJ@#K42@?O-1ZU,8C MPX!T46[7^"#XVDOV0KZC@G/K\^U1A2OGMLI@-K[98Q*7!X!.7_?O[1Y'%:%F M?:GX 3MJ7?HH;L-4X92L*_N^KMAG5\_B2]O+,W2.V50J-DI=VWVL<&GF)Y^E MS%\N7*8)D&E2"D U'EK)#I;TKW#ZC9IIX)R^B.W!T_UP<1]K3/-:_:AP3UB. M\T?BKSQYKG4YPB;)BCI[S2"I6/W^5\'(2'-DGOGXFU3C&,P)5/OJ^,L8?L64 M,4JY]:QA+D1"%:7&URG?4#RS!GPQ?FO#O&4(N [5*9?'_%G4X4^(5"O,0C3" MIF+,_+H&1*URKC71.<>K%FM0](]#^=GG!@ZTOF\I_>BB^&[CJ4L+LGM1M1?6 M *Y<*4<)UV_'7"AFZ.=X,G&B7,UP+[(<^4#MB/'-SMR-ME6G,E\/DAO,M!@7 M)8JW+ABD8C>O)JH_,=O^5K#JM S$TA\Q+<&:9-MO/!< M.=9>E"W++@1M&U;D3=\[.7=7KW05/"D\VPZT .#[*&",/'],] U#E8C3?@!* M!OA&8"1#34=%-U/[O2[*=%WJRL^!Q@IM%+!9B1%&=TUDH1+B=23."#UKS#%C M69/8;Q+0CN/+C'"(U MYP!8/.)J$H8*]L/\G#0A+ZZKK .#P13Z&6/8O6::R78FKP%6^&ES9.8RYRP\ M!2G?\()WMY@! M:X"3".6@UC"_[PF^PY@TDVUR9"+ZA&F8=9DZ9R-KA.[60"PQ^%)PK_ZB1N?E M[AICFIU!<6W9DUO?AV1.F#F=B7:4S]NCG(AI@8'_,9.?H<:5(#(3NT+E\H/) M::;-OKJBYTBE 5[Z5Z0JJ,?PMRUG6A)3KET'EO$LF,AQI3 GUXO9A;I#WQFB M3=WD+Q3I$WD%+O>(2\% SP#??^MA!7],,VOBC5N@C%HAVY]G=)?0I25FR"9>^^8W4& Y.())-=W#O^0$B3YPI=!/VQ&8HX57CMT=*MFY-/UN&1U=%98S-)Q]U3%Z-D?HHMZ%:\>Q M5R^-O4QJX/?\*E#'G[;WW0G#Y=S_$%S%/T^?C UPZO;I:#B1Z;ECGX6<3>,2 M(#(>CDH@R@^&Y36GU> 7.YC7N8-I+5+Z;PPKN]2>+"<=F6",OQ:(!7C=Z[I; M;8BC%6K_N(J5J<:^_DM@B="=3Q[#T$+3=B*(J(OO(C:+TG69'$W[G0ENZ[S$1 MK+WS];F3U1?/K0'S[X9 Y@THY^D85A?X9N"SZK4X#PG#[=]8@2PC?)M["*9=+ M[]?O:!:[!6(F)F/G4=F.4ASIJNX<& MN=]T?,#[GE7BUYBSI5^_KPSLFOMNP[?/INWL<^1D)_,&+]M$F7,^5.97:" U MXX0I^C!YYS:KO@TN@9\I(GG)10XF.DSEB,,;PP/7DP W*%CUF!YI]@I.N9K@ MT6]PYM?3.'%6+(2"#G'U*UF&C#=-P^(U(EHUVOE#DZ-FZ$O4(XF2GD MM=JUOJE O&:'NX\I[YYX/#L3AU5@97@JYOGN^ZALD/BZ*0");#Y_^G28NV() MW^I*)N\>#\9*,E=.AJ&%V@'6'\KY9=).";)N7.G9+3BF$J'^A'+D>FC(K-DR M=R$)K88'+_CQU)<6(=%H'N$FM!7JNKB+Y98_9.V;R[4K2; WS [59D9]I!4N M?E[C"8R1]D;$9M@->H>FB8#\:; M]'!.EZ\@IN+L>[?"9NUFUY]SO5 M]BD+YWK4=UFGJ,0QL?S50G^@$C-)^==])60"=8/ RKGE>196CV<"U@O7;;.E M1T*"@?2R_A$9G^4\P])OY2+2V_V_Z;I#/-U+]X0@_S7@JG9?BR.O@.B)WLPU M^N7F%DP+.V9\?G>S90D2Z_D24TM%32V1:+Y_XKN+!_5TCW6C&!K$MESY'');*831<7 ,>.%'; M'Y?:#Z"*2UQ:,BA#??QEX#$N[&HCS]0=&+BQ!O"9[0D2S1&^]YH58>JWM5Q3 MJDM0L-_H28''P83HP[!SR[]S>N=@Y41F<$[6AC?/3$FY-]VYL/N[<>Q@+ #! M;:*.X'KQMKPDE#=^%A3M:\AE>='.ID^?[#>/.)0_]R N]8#5F_#LE"=\7UX< M"Y?DPVQ:>,Z^_W(""57Q8(406;+\6(:+H5NCK="SZB[V5VA^B8F2N.O*[5PA M0U 9@U,2+Q>Q,AZ%/:ZIZ3O^E6)(].2S$>(5C*+50-W7.MW4EHU+;FZ>1&1T M^P^GJ5V9ZB.^+ ,WJCVI'LU2Q43/S6N.E=8P>E[YTZSCV:NW;T9O9NMN/3K: MI1\BCKGS+]M* ^M%#!)0U(PJ 1Y.>AWBM+U6%V?,4GBPZZWO"C2#M=*C=W5.F]^\.)L#1^7 M(F7]HY !+"=/KP%S:6$Z5)\H'EF2CQL4>KJ"X]1($8=IO:F>\3/NF!MF/??: M!7=//3KMUWA%!,8]QCS&N40:X9]Y?V"#77O7L>,+J;:_U[ .- MND4344;1 &K*=^G% 6@IT U>'5F(7J7;>[*M!DM* (?;$6BYJKOO]V0A8*K* MTB1PM[Y%Q0OGA5Y@'?TVL ?AKS'$5W MIK!V9A!F#;S?ASJP;'/KW1BR^\E&9;@MXI:TDSK.#I!DE6+M[JD3B\\ KKB\ MSH+#V%9K^AKPHO4)-!>U8@"9^CQ=D#P7=?G>:NCED1I;M.9K63Y1QMK@2"VK$&W#-W6@/JLN]"I=R2A%(>/%_UR@5U\+!M[&#MJZN3+@$Y MDX&@,\#66K^!"SU:_D54C1G.,J3A-DX7KJ:A8DM:XK6F/5I>V\GMA/6NMW\E M^@H?88S(C&%M)V!_K 'R)F@J7% M9ONH+[1#8BJP.W>X /T<%D;*F@B\+9V(,]&^?IFQ&>^M>*U[:>F;Q"YD>_?#V\,N!BC3.$N M4W&(4=U]",CW0V48UT^5_OK M5.]OEK)3++>IV8^:!D1T ITFN]Q_+RW_;??KS^F#4?)/S$JR:41C&,G&"/UE MR/NPAJJDNR:\8H+;0H\3'Z.C#Z7?_.8NG$_>MHS4.NJW50R-7\Y"_!(9CUW$ M]+:13Q?RGD#2%OD7[(/S+$84]FK[J%[I0!\J?F@S@][]^&I22-K2A_^XV/^? M/&U["/R\0A0UAPASMH)2:98VE-_)6H)WI<\"OD]JQMEF2X MO,139]I!0J4P+@ER4:P^SD%6^DCY%V.4^ VCF#@EH^NO\BCGA5V\O-1H5^// MUY "3[KM3#$7.T$SYV>4?T]L'TI\-*$BC_>?"\&' -[K-2%SZO9'DYO6 #E= M014>;_EM,BCI7M6XXC&&/:@*(IRY80LJT"CV[-)VKH0UJ7Q^N/=2P7N]CK!&)^2Q)2$GOK^/W\2*C=>O<1( Z /Y!PMKT7RR I7OI*C MQRKZ;JAG6.,]\NA%H(D!>V?ZY3F^^Q7#!V6.P_PY8%,$E<= M*?&-\"U+P_Z=I6I&P/6>+Z?K$?-OS#_/7$YI.V"N2!6SE.S%3H 7/;L B=B# M]D]H=5Z\/!2U -Q O#+_4'0$A0PJFK9G(/LZ9O,U2]*KWTNKM?5HRU\W.U8N M5TPZ?NF)J#9KWT3<3CJ**Q$X>FVF(UC=X('OC-3]B8 ?]CY98<>SL'K<#P=6 M<5C;=H(?VVF*R)5^# D7CV@/(*DB>"%(RA-2@K[U:(W@7;H#]FSZ,-@D$F%# MC=[_P\9SFX%[Z%9E8.]0"O?]U@.''+QKPT_O-\MXQU>[!HACJC'T&]IQEVMY M3\U4_JBKNG>&.I;/X8?.S^XR!R5\P'U MOW?U6%%4H@<^UAPMZUEBJ8@/\DM(B#9:UIUFS#^Y>85?(TXG5P1 Y3Z=/"9F MB059VI"8'>\YU\Y+/K4_-\X$I1+IE[ &'$ZR1E^YK"/"I&:F+%O/9, .U(!7 M7B,13$-&9RKY;O4,"6OO_9B1_U%3<=C[PX#0CX?8Z;U?-_J3E6*!Y7!_*S^; ME[%TQ( P).1/QS"E&68O7L-NR*'?C)#O'%;6TR:J/[5@'>FO_?SXJ:)WFG)\ M%1%W7YX4> &C)LBUJD.NWVW"/=T86T01U>\PPS+"C@W P^4CC/MRTWCF MZ]5TP'JOT-T<_]"]'9 L5[N8+&>..V6/=NR>+ZAK979N-7,X8%U1GEI9GC1B MZ_'3&[@*75K5Y/5PB>T72X#!T57R4C&,SG;PF\)9*&8A#V"J>/Z(Z_[R.$N%[SN-LQ..6M[^O%7FN?P58AIN]QI014DYUQ'@,H^8 MVCI\[L)0[]! &6L\PBK6IOU#T0*B%@"O)HH7+^]+W Y7=ZA<;VJIJ*\M+0L/CO-\Z6&WQ[Y8HG/_)6$!FV6AO;L4!:6@B^? MAR$[R@SH>M7#51_!;W/N1[]SKK@7ACY5516MMC"X3?%0RET!>6D=[]VWT!,& M38C^:EI,\[15.2.U$2T?]+8W8]B*4# X?(1X-' ?JEUJCD*W($8XX>5@V'U+ M$:&5EZ=Y(44P!H^TKPE6>KN56&CX#%X^_/+H"_Z\ @!$BX ?@(S MZA=X3;MONHDB;F+^7;==:++CHNZ]B/07 N)'LM?+5N. M%@LY^TW@<6EK".W;"Y-X@\-5/\;DL;,Y-J.&4X*7#*##7;*Q1EOBN*H8I_Y,!4HNI?O3"LR? VX MAI8(/5%5=OA]T(J#_MW;H^.<36^=(@?"&NP3*=^=N;+[=1#+/L9/!#"YG2]# M7H:A9Q%<<3(D_(CNQ/3F/:[1IA-IDE6DJ&6<8.D/]0#I=,W?F5G)%UH.!2Q$ MZE0LVEPZ(W,AL@T0F'&^ ]65S)"?0S W*)UOH PXC3RMTV1Y?52X=[B\-OG$ ML^O%:=VO,L05WGC\/GKIR#>9M@.+8EZ=47^%O97],2EX^IW &=P:("S #*2W M-]7J#-S-H1H39V;/_L*Z?ZJZ)-Z[(GXA^!*"'72#YT!X 6,=41$KPY7@Q9I< M\V(E3EO(1#V(2=D F:7I>XXG^X! M;.L:H%!*Z$L>)3[@AHU,UM2Z?*F*<_JYH>GTR=R)1XQN%?NO#1][S-Y6E#TJ M-_@^A#XTW8XA37F(E[\)6&)#KO8 >!%?;#TK, );!9Z*B0X-&[F74O&+:W\U M]5;$YQH1*Y4H1H<-Y?;^F>_WKE0_H:Y(<;O!>F606I@)6TB$]S396;$@=S@H M;R2SU" C.,=2OR7#"!L]WDMLJ0@W:+9Q^EQ_6A!5<)$/YN2QJ&L4^=T?+@2] M:93=2#[^Z/<-HTW?#AR\!+0*?MZJ))I[[-5? :*WA^;R M"[(Z?7Q5TG8;V_*^[S]5K;2]^>Y+I[$U@"L] 0G[4BD#:&H^2AB2=O9*]C1P M8ER<=B[E$?J2)B\-NI7'FJ3NN]I07'%A1Q??XC8 I4YLCEP:-,9=\(?"/+]L MAZ9#[G#W+%S P[@"K.>I^,9P);7K49)K@!M.A*O=S;5\ZUEG1C^;.%. M>?+I4IV:)W8^V=R1LXW7G#3J+MH L3S%J ;MLR@+3/.[A*-C@@*=RLL?*0VH M$G)C^\:!W74X!C])]OC^N%WGIYWV-^,MG79P]_"SF6V6NE_SN':KY 6,-P?+ MO5MTY!/7G54H-,HR.8\]N 8D>JDU4LJTF]KE>FV]"T)/LA[EN=@(U01BE6LR MMI@>1BB+A44!V!6PWA.D%F0B>(EU&UBX^KKMC$T)[QEG&I_=GGQ6YFBPRU;W MP*ZG]UY\3_ZMD[ED9$VE(%A[QVY@;.NH^C.V/Y^ M[Z5JD)A:X8") M TMMBUK>:@[<[/)B\G4!<_DY?A9FT,9TD%S;%>?U$'(#E3*_GQG+=02QBZ"4I=Q9BS5@ M4PQ+@*/(/5E#Q\1S+P=>H\6;'?I=V3E[)[WZ[0.;")OZ.W&D9T=R^1[Q1?O5 MH^*1] O:+/7U_*--B@Q\U!*X<3*M%!=1(S/1(E\5H>$DF_%CP*'2TJU([RC? M8>.B]LY=X69":X!LZ6O,MQPOZ?)3R&'G'TEQ=_L_QQ*8@?Q1WK5\_<%97RB# M/J,IH]P@TC3E%0!]+1%U5/ Z4EP;U4VMOJ\6?__KON\[+O&VY#V@$7>!U$P4 M_;9U R@(M6.WT\&F5H/&*O3#F@.Y36_U\]SP,>R,1&A3@)K_2FE(PV7. -'QGQ[$L*-,$G M'TCCEU\".O9 F-/+7_:/HW)/\AV^"1KM35*\M_B3LVB.4%LB-*)8QFJ-ZOX, MD#KW3,'NO*=1U*_CO%\:O[3\YL>@E!7?9@Q+&S/32;=NZI^(64;ON)':/Q$] M][:PMJ1SR>Y]6;O$TZ >JWBWFSI/MMR4#R TX%GJVV>7*/13A/ZJB>:R-&]F M\LB0_A=-Y:,EE3MS$_IDQMR?[-VG,)9DI20MM.7DC^U^P.J3.VL ZAA; A(\ M3-.CEW,E4ZDYG3:%^9F:A:6#)U!DV]]('F*9@ _-=&%1\BA4P MJJG6*.M26O?^U7##.^>6F1WDG>+L6L^6JQ."!H?5 MN^Z@HH?5D\_UZ*:C9X7S;)=:\@R5(V^_>B+C)O3YX#MC6^5;[:>>(%[QM4IV M4=TZ8P, F2:].CIW&DE#)BP1HZ M/2:V'R^JXE__T3]X8_O*B9QGPUL2LQ._ MOU.).JLF)'B(5K>=]0:F_"K0#TB0/OM[^%%>4'JS[(-]PY8IT8],*S.BCT2L M",N^4\MH?"EV"[V1?P$#"<_3=C.07*G'M#=O8A)^+4U;UK>9U!IUGP,I+GFC M:;-$#TI\2/GL7L9$T[!IC]NY96WI&\E3MYL?%%F,&UZ+MQW[H"6I6'$JT_\" M)E%M16XA"]%)8>FA&]6O<6X%C=I[2F&'J)773YXP*'$JB^3OHEFAS+U6&N7) M"R"\CAF\HF54KP0S#Y;TC?<4]$J][O%I?GR3.[]0-^"Y[VDB/W6DV>*]4OQ7 MG2TJ3K,KX40J#+E]Z4TA=T[?<$Z-,]&[U:LJ:G$DZ7K=.&K8/HH8Z$V)*5=48WG1^ F>TH'>;G[*?:U>*A(?WCR]FB)57/IS8H=Q MA8E\2)9AUH::!F85+Y$KQ;D9NKVK1GBT5>.&K"F=(EDXXE.R^GFGEE*H0I+6 M"812Q/?ZE!?HW%_FR!825Q(/":HSE"%!TJA,3K?F57*-0/ !W'&&WDNUF3E! MXRLO19ZK*K/.S5X1ZP@FI'R?10TUFX\FB!G=)C_3N?LL4QJ6M V3Q73H+J&TL.=)ZOK_7&(JP381R]T;<;U(6@@L]J 2IKUJ%[%3R\ N M=RJ1/R.YT6:CR$N=$;*_]^5D3 4LI%.Y\@?H[LRGI>LVBIHJCC M&'AMZ,#H_J$R<3[EN9;B3#YL+H/,3(-1V@#ZA2S*&2SX&&K<71JO)7VH.]0L MUZ'H&K(Y-+%.;S0_-J;7Z4?Y,P/9L($&DS.6NAJ.1Q./Z63&*"TM3<)"C[3D M?:7=M6.DMK"JO*:X\I3*F0:EI+T.2]6IT&66"&(#--$HKMT?(TP M0[AI6"I:?VC,LS_[YP *7;O5.[[S#7]'730=UHI\G/-!(=K:D'3,@'(S4/53 MMP]!-K-Q8\$?>G$P-I9V-4HF(^6LPS.U+/YD3*OT^@8A/]034J*(X6IN*G4< M75%4[-P*@>XJV :1HY(S<++H3R%#36XW@R+9N>YC%M]86:N5I9%_O,;I!XF M#JASW_$OKR?[P>YG$X5.^:+--XT2-1.9+F.O) 0<]5*P<.UT'_(:&?--:3S] M\6BJVJ;#%@_;SB6UQ#(P+-W%D:=IJ4W$QYEZB3OB#>R*?G4X(L,^7D]RJI]? M Q3?H;2ZPH /]6_+TO6Z:0V2MYJ?5!V)4]Z3 M:AHEBU<#Z7Y2R/PP!>.W0M2VK>&T/G# ,Z>;IVW\L M\P44.O2#MY@@]0_VUZ8RJV'_C(?D@E#U@66@P)*K?]/PGHKXI)XUX$R)OK-K M\GZ:E:/9G1RTV<4N =Q+IY&51N+#D)5FU$-94FRH;5A GE<_;S"53/:_O6BG M+*T6#DR' P#?_<]98A-,25[& +. 1ZA3Y)H*M7K3[*_OT+Z+K_0H&+_PB6V> M5!9F"3K+GGCA^VKR+M/Q"2-S9\N-\+ $V@.I)N-]]?;L-[ M"'K#,\*U84@G!W_PJ)(;) 5*O,H4*@83! M^CO$Z\0$_%83TQ%71#.YA8:0<&VZG-OOZA'X:35UF]'KHQ>:/DE?%Q*;?6/J MP3]S'/9QX9-*+8.59#0RK[1*ZOPGCZ!Y=O[@&^NWZ[QUKN^1KV M?)OZZD%>V1IP?6"^CY^9SR WI,_O7P.^:'^P]?56I_MHNB!\M;EBTO%U^5[L MWI:\I]8[!ZJ M6=CW^I&4W?]J[\O#H7S?OF_9URFDK%/V0E+6R/#U%:*0HDA3J61/=HT92U'6 M:$49D526L0U"QJX28U]C9NR[VS9NC/'>?K_G>9_G?8_W[_<]CO?X_G'ZB_L^ MK_,ZE\_G>K+\>MW37E8M-,1Y!7_J?S%9$E;TET4M1\Q-,KKUZL/0-'; M+4$W')WK(DTVKRZT]F1XKO%.*4I6C.R)\:RW -A+-A7MR3AHB\# M[JSWOLB_'^ ]TC_B4#K@\>D<7]*Q(RM0V 7 I082HF0;&9MRHI)&$K%O*!QV/>.8,+C6,@FP'L\H2SW@:78A-V?@ M*36D=EL5KGZF6 %F?QK_\CD25?6@9O8G2%ZVO$^VO&O1O?6Q19&VOV#&HF.A MZ96UN [B07Y7Z*FN\ / MXE;V,H(I@-IYBSF4X=B:-36YV>=$I'[4736I+B']9ZCUJ9(Z&(V5") MCG=]-=7[X106OXVVL@\8!6EML76>\:6^U>OYT:;M-'\A)!54 M&@MXL@O<7WJ\I157=>CK"2+M/5;F;-QHH^R-AY%WW'/#'$WOWC0"#"456?/( M&JL$AC"9R;U HT"*9?-3CV@J-C^[&(9.%4OU@[46ULKP8OO'?4+$(DL4$MYU//+2.B%L5&9D<,:Q6\P7#[B0 MQZN_O:;NM7^H3LPT2N''^U/5[FPO5I)$S7X5M' P#NR-$Z FH25)3I+^,WIF MU!#+RQVWG2; M@6XJ>;UBI$815X[&>K00BYM'$3,KJ]/8#?B1WKA:+%,!VY!R-N$QP]*559KH@0]T]I5@C\!^W[@+[,T9S".( MM33:;SQ3(/[)X4A._Q-9+J/=WY5K%A&?%;H9]>$(Z^HCIL#S99XY%&@M*=!Q MAW_G!35'Z9X5=DZC9_S=+E!S'?E):=6O>GFKCXBK-<2YQ2P-9=.)RUX-.3&B MZD,AKKXQED5.50.#1F*-/$+#I>GW9,)_-W\/)/T'',L@45_BB4WX;2'L\ WN MY1'B%*Y.UT.V]\RW./MST;VC\L\F>'2\E(M^AOU<649WH^IQSZ204#%U"+D_ MT.E:E]^"D'6LN4>(TX.R_6W9Y7=ED9;7HYFZL:H)ZW=6M&48S/ *0B1> N,- MWIB8!'$Q55=H.N\67=3C+KJ)X BO[=H?M7/2N5.TO-&_\O=NSM[:R5)_VG,; MZED^\.H<9VJ.F1IC7)9)=&A @Y=)@T:-(DS'OB;R,\4HPL#Z7,SMD&)13G#& M -G9MQ"U?3>0ERX'F>!&=P&).=L4C CXPWV^JF?[7L[)2[9<,FV._6,#)K\; M+XL@4Y"@QYLX#:]!(WKISD=]93>E,NL^J5Z7;L1KKB>ZJPQS75/HF5H(O\^.9W_/GQ[^4ZCWSG][9'T;WDN.,H9@ M%7AHWGHTX3#:_J?GB/8R;ZKT#[L%D=>%3WOZ4/539^MBO5?$@!UM82OM_\-M MO)11E M:Q(2*'J TIW1W!CV89DIVJ][Q6LSU[]29FOY4-4:O@_TE!2.Z\T1C M1^L\]&HTN23$QHZX?3?KG=C=GO$7?XF^P=Z.>W5NXM;JR1ET*@6\L@M VJ@: ME"3NGI<@1@,R<1Y5VJ8<,J+S[MS>^FWOX#"H)N5Z+G;$J22:[\ZI=)ZI2850 M%HBFY)F8\$5V^4*V2M7;[2(MUB0=O8!=8,[;)&D,VG.9?C*D7MG8WOR%X=DN M^T+HC]%'2CWRZ]'*>*/-*J-EPB [%:NQU\BL]A3*:\&)R=VX;6XT%J.B0OPN M3>]8:W6S6-4K#G*=SWOIOK]()J- UN<7*!J';8,XF0+7=E*JKKF(N]K=T 2[ MO.Q-9T(II"47_Y&.@<'$45(1C"2!IJ@>:1:P8V-Q2Y3=4S+>FQ M#UTV-!,\)M^LK,C'!7#T,_*Q"X_NH ,8QL"9?[72[?;A;Y8:>2?UAQFB-($; M]&+R*FVCL#_1PNN6[($MC1L/ C--N/KL0TH3 _S&BYN*,I(%3TN-YF>SE/\@ MPSS<<6_8A][?I90BSOH\U=_6=/*AD!S/X$U;GWP<0G>=4#NR"V2%[#4F*=_[ M;&:&!%ZRC)82)8*1J3DN3$[PLA;OO<'';I)M'[QU%5)UI8O9K J;A$54-I[5 MRIG4IQGM MXDF5;@411#Z'2#&\T24G2NU6WRB]98_O1*Z)ON7[EOK)O,SD9* MD7)Z].R6:VDA_K"!F7)=ZW%GS%36^4_,*N6X7,9TF,:*.KR+/\P:SK45L /N MO-^;\((.OW$*/)&Z"W#3\7!2"DP\B!'"JSPR:_,"<5=C6E)$.<0T)7(3 M"S:3C/5ROO AL-\ IB%S=A?PLY1UB@]:6/19)^2BJ"]QX&6\$*Y6DZD61)FQ M)]4O!%]&[Y\.:_Z=F4"LX1XLSGA'%^"V82A7?X>U8X4W.J!:&?L[[4AUK[Y8 M_PC& E32;=U?F.!?F*T@J]P[>_K$2!B-/^UJAC,K%;D?,KS"\>]AA>%9.Q+^O10N<:3AMZL M(?5-T\/!3;,71<79+=GL7%*8EW"WO"#%J48DI- 7GVH+GLBG#)2UY7VYGQ(Y MX]MJ%5QU*\RNF5%R(?];DZFRTOHJ/6#O3JT^?^"V.3%JE#,*8T<]>S5L2N\D MOXTEWTF! 9F&[!?O#I_CT-%KYYQI]ZB/WGS#Y(%7R;:UU_DO U\$9ZXGAI%] MC?:ZDC;U 9U\RH>>?@RZ&/PTRZ:P\!TF+U*191T]X$/_ FHMQ(%?54499_LX MOM,V/65+MDT&LDI]DS67SIE=N7K@FZ5,)L_:.5&8!T'ST!MPZ 9T=FS8H5Y? MH7-)W?&14;F;PYQN^2]S5L(]SNZ;X=I'PKG9Q+)I."%7*>[E$_A<%ZTW8IY? MLJXW!S@'L+Y\/7B__XSIQX>B5X]Q]DD6HSNG&,)+3*X)&#XP>=0^:&;+4W@8 MYPJB6KH81FY<7NI\B0>[,4&)X_BW^Z@^9VFPYB6YYG:NC? M>4#Q*\H[9>0S*'CS9*1)8FS MA>\/&$A8<:XC4[1ND]YOHR$=,OUE2=')$C3".9$TD9LB$TEN M/\\Y<\-D>0IF)ML6S';[D";\9XQ)=8=ORZL[CQPY1E2T'N*K^!+#3G MD*2Z M8>X$6S%GX)Q:ZN&U>4%6XC&[DSE#KGQ99Y700Y3IZK^HXSD_LQ?MW MI@P D.O;;(*(RTX-I))#C1Y.C2-RW2>(!.' I.7\_'S\,[E7"3S[P/1]PM*Q MBH>M8WF6]EJ.]*/&D N5HUE1-=6(/HQ!WR5DB9N0C/$M;NV6"W[R,C:QWDG- M!1K;,$AG^P:KP1*H2S_]O8OALLSCAI3$F!+]4OH.%';Z*K#M;Y>YV:)X$_%V M5O,Y3T;B]U"8#5$I>$AV86D^@7JM^CC&H-.>/,H9K5+U7K/.KV%0)*W?*QDW M\6[EGR"C7HY>^K/K]^SM,SM?8/RDO[E,* QI;&FEY M&-%<"\1VJ8W6&F$RD\F=N!WDB@/].R%>YM%[3 MYR_Z/;U3F-98+6;KB.Y.JIZ#9M@8F6NN6KA'VM]0X,/]#NX'%^VU:N(-U.H_ M'!\V3$?,\=(#=S(8A[8O852ZJIRHCL'--]K]U!$2[2@R[W[N^,O;'3^^ 9DW M$\XOGDYA_KT+.*,&NT9-YI-'20N$*/V3O57',#2+NE_N#L-A/ZZENS<>F5ST+P16*TY3A#\;C),G2I2!%W*[%)<[/Y15E]YO4TNW$\%4"E*_=I M+;N-ED5AN2#6R\MV,1INDHCZ+95*RZ"0 /D?-&O&SVGAO8G!LJ.D_1BGO8]N M,5=[U#=EVID2$*=%^4V#U[/FE079W8J).EOO0MQHE,$I)L^AY0CZ5*],ZJA" M#($8HQO$.SCS0'IHIC<_V#U<+3RH:8K]Z>&?Z0(Q3)[L;?\+L)-R[1"(9/'F M@XVD*.6Q"TKUO<429NR/+1IYZ?PRE3^&']P92A(6@J$#3-[9%IPY_B-<+5^U*G/HS'I\ MUM<9K1$6D#,ESSO/M;=5>.-8WXZ(2+U%,\PP7JNU':8>8X;A[GCU;]20"A5J M#6U&PZY:;$"?T,^$-*.$C-"#!E8 L*;*"=UNKM4_V.7K M>*)75T75K#2^K7-$;<60S_7 _D?'0SD+\HZ[:M(N_JO!"*NZY^=)<9+JQ>_? M&%MVOW:!$A)#Q)D>LO,">VPVC6]HY]F*P+",4)\<[>]VDW\/E^W^'4W.=&H>YW0B48?95QUD5]7> MV:!R]YK'V-VCKUZ>E"G78+@^'3]GR[/)>21>;1?HFXL86M;83M[FQ=6V(/ER MJSD" ^HI(O-Z%SY .7\51C9-61<7;M]]G3DAG='ZV$M-LJ;E1!U+&^(FRU;# M145.Z6K'G604M8!2O LLX)8OP6;E7'[5NA'MISW^NK=IS+22Z-+@71)_<#SV MG.G?]VK=:1>59KD<'F*UYU+^W<'JOPG'?96P*WYQYR7%+Z:M3!KR$S]>4"_: M;QHG+-@:U@?8U6,UX!H9B[I+XC8^?0W*:9 Z>=:M)UD@UK MOOX0T+>&?XW(L(@+ K5,;'?&W7)OG,?/%Q;]C8+FHAFNEI5#(.$SCIJ+ JUR M\- QA05M/4>OK.'[6/&.>:'S'>X*1[/CV?T3)UX26B9_RB3]-0XTH+U"+P=H:*M-F6544;>Q#$(VWB#Q!F-4?HT^[JMR&'6MO!Z MPZ_ N[Y\Y0PNPEBL\9'ICU)5$3\E=21B[_3->S&$?)@")B"A#A&J+PXBFA ( M*)&@IW17Y,W=_/N@L;=D3\EY0:2^O-]=OUAV.:TI3U.V%&#G UF=-1'-#P4P M!8[NO%K?E#&K\LB9^72/MW2IOBS[UEE681,)ZHKV0?I(PI?:O!G;C==%0;U] MB=.SZDW:,S%?TZ:\J[S^6L3]K&GYZ$7=^!3C]J&W[4(.\=;:AY)/&\3*L;==17D'-]LH7KVLV0PEDF) H M!C D L"RAEV@.#M&3P9,0PJYIVT=U5N:P'[&>:B55OH\)/-REWKK>5FRG,=$>=Q3 MI,-+,FT._9QY.:ZM\X\?C_?6*C-$[<8ZG$7^[)3[>4$*A(4+'QF&A84OKG3U MBJHO.%T0#$(/BIP:^VW5?^14D6S,\X<=!.OG!J@<#?7T21**P0*'H3SV-U:Y M2R;U4D\5FI8?J4N?3-AV9EJW:LDH;DL^PAA:#3&&<4%H4YV5%UEW;6 MS \G (7_<>P?SO5"OA?]T=;,\C*SQQ@#6"T;Q]_?N MJP?C%MY_I&!,(2]GYRR,;7'4[TKBX7A*HV+FH@[M$A78]^.!N+@#4HFPNC-* MX)F]P;XLQXS+O>HX$_SIC;=WH#KT2<>= 6,0,NG_^F\*' M=39_0AC\@@(*:!QRB$X'UYBG0-=KT^A#ZD/>$W\D3+Q&A8WK:A\$1_&N?,S6 MICDHA8[4E%$BAK 9R M]"\ Y:,;#L1Z%CZ&UP_0?^V-](F_ND$:E@C_UJRW/KEW?4D*UK8("7IUCVCW M:%A&X_:I][^Y7*X:E >=DY >_A'DDAME,/_07BHVR$)"!GMB+EAR*I(8DX>R M(E845A>_^I V."HC7'#FW:E3^WE>Z;#MYSHR22HZUO,6=KC8 TP?I@]:E3F" M DV](DB@E9*9EYYU1FG,Z$+J[67YQ%)^HR.W,'_"7WP^C*QB#P645 "TC_9.G1,GM7^*BHX$JY6R^:T0NBUA!20#(EON1B=PBZ, MS/)HVVI#Q666FU&-MN:5UF6&-5HGP6*6]HH#\CK2YUJ# A9@G,;1B?&%CJGT M;(3=Z\0JWD],LKIFJDPTB- CEGR4T3RI)A%O-B715TL19'('-E.K"P9Q,8QC MHZJ\(U''QETK?$L?"FI3M9%9 .XJNGAIP0FDT+/ *7I9/44L$-=H6_EW4MZK MP1+Z0+-@G6F2S ]:C^59I8[B%*8VYMB8BE.-_?R9UU%?7>WULUQ]^'N>M#B0 M16&08WST#:BQ]J;>"U)!+1B#!(OH+G.H=E3I\RT:CN@4<<4]^%!%O GJ63IB M]K3Z/5)*\MXGY)3!7Z:EA :WP_U\7F@!EP$G: @_K12UO,00P=,SH%?W>K<2 MFE""0R;R#WU+(LQO[0*LI7'BZ\(L.X+8061963VRWX;&&-Q(8!B[.*%>+MSZ M6#=ZP>3* P'!PX9_!F38XP\\Y#T5[[9)WLDAN2$/X6JODCPO*%SJ/3C_IN', M^_RP]!GN8TEGI0:O]6J/VH1]:]'?P/#_O@@<9ITB"4&5MLN+E?I9>:[VD85? M1M1<%@GYLN6O'P;)O7_F].ZAY10:YD^U;"0J7DH3ZMEV#50=Y?A \[ GTV L MX8DK_=A#\+#0W+ [<,SM?OH]P'341USRXY/+/Z<\#5 9'E)UD@KF9<2RN-ME MI7&WXPYE'(]E@9P.WDM%#-,7+O[O[>3^[TD!PP4S M$_X$^AA&=;44/,,E]1D: TZM5'Z!&RQ-I!0IQ2CZF''Z UDK7V(.->A\A1E=:F,(0=3-R,(=[NW M0B#FXW1IT?[6@T_>^4__/B/X.5WB46^/,-#?Q)D^?_98M[4!_ZW74G^8&FT0 MB:;ZA"FM[C6*X)L66_U+3;3;%_*,Q1E))RG!B4*[$C4P5*.I\A:#H!T.X7$1 MF6,D$7.9AZ$ 2U0YR(SAFENYVD3J+/N6G%RH^9_@I.W2BVC8*+@$"YN5'HD =/DE@WV M1:P1V%W<.BVXI3)9K"#^J\'RD"O)QX[8YTW;;;DW.PA M3J,BY+<.WW+4:J4$RW>!_!3CRJG5\_/PGI&Y M(909J/D\!1N3-;-E''OG55EAJ7F@W70TH;+?[^T-<* M#IMU-BSR60[, 954:]&QJL\O$F MUN!2"U52 $>"8\PY?\Z4O)87K^5$F=;CJV9L6)S&.P@%K1?L^(DC:U:0>[B=Q#OF_L M@BV$+AQ=5_YQX<(M4*LV&,UX%&A41]\%UEO,PU!)/+/P'OF"(M&)04XFG0VX MX6W90$;AY7RF &1IY30%H>N+G0G)G^KV=+579'V&IWM ;ZX("J*X^?BH K, MW@:4[.J0O!@M<.$3S+ >U6^=>$)/6"<-]%H/!54_*55L.[L+U%6(*;(4QJI: MV'S."#U:6>90GJ(CDOG=FP2VH@4&)S[I[P.=WQ_]L[03 MX_$MX>'%WR\6W$Y L]Q_*-W7XOK9< M3-5>W@72>QN%65I&X,CTS,27P"%AX\P,=GFNB=/('4H8R*0--R/V&M9ZX9?N MO\Z#N6IKP&4K#G2D'C(+4CKOP(\T[UI+5=PT?Z3K6_8$&YW.TW7Q9N^9G+^P:GMM MB; M4F=>I6Q3EZ)H]W10 QM:]H$,-L%T9*127#>).DP9T-]\ED!;_'#OK/2R M5 9N36>P>B0C5%^A *9H0:@[0Y;K>/[\Q>_CR_*?4&OB8.@-YR$P&*M6XU3FPK/!H8UQ?%<("6M0Z6Q8%:M=6'P/?5[97J M<2=XY63:G_;X=)8PW,"EOZ H9\GJ[QDSP1-5*M]E2,7QL]KDSW9LSC,+,PYP M>3CHO*W#0!4"]50T9YW=XF:P1L7"UBUV]P&,)KCS^-'-=M]'WC.2L>8[2@^C M@YPPD,Q3GO5#WBF^(.'(BPZ)^ !=JV_*BX435=8Q'3QNX@B M?Q5[5K-#)QAXN-0<3F56N#PO6[6'XTU #>00/L=]QK"4;\(<$T9E>K0M_$) M-WH&78(]JA-N2>;EJCD,U7UPBM;@>OH]U I &MK^!^1)E5Z\.Q9PMOF\GS#+ M;S<\AY[,:,XS^1X])5KK>1>!&^9YFJ+)S*P7\H7-\SE@8Y%E/7Y?!'Z+Q1ZV MZO,Y$HPE'%#PJYO>/))L).REU:$_?P68* ?+%>DY=^]/1K[]DD]R]HK:BOP@ M-]$Y.G M6@^1&?0(5;CVG32\?=QITY8HS$*^CCD.MBYM+?%/G]H%2+<.['5>TURB^X'L MNP #$XBL.QW1][M396@SS]_7BC/5$=N,XM;@0-V'',$5]PV\_OTSG+/DKT_!5&V9@MP8]$ 7;2=U<>\T.&JG56S M>U/._Z45!S^^CLPW,[8A)=G^86UE7AH]3E2G(-9T"Y^5.,H;ST028^'$A-E+ M3+^&&0+@W5U@:Q?@#KSGOKZJ_D-\,\\JE>X,^:"VR$#@".Q]C MX#9D3F-&@$=[GW61YOC]&-VCNXK]GQ8I+ MC_>IC>+#JQ'+BUGTX8"Z:HE> L ]19EY_L!DW,[SJ$8487MK7\7 #@_GV0+._,<U\D MG(^7^7\Y0V@_*4V<_E>(^-#RNK,FH$?49(EUY_:%Y(2QHDS<@"7MV2Z0XD.] M\6@7N&G_8F[DS!J/XKZHR"K53Y"N:7R]6=>\;^5AGXDA>X."1JD@[2L HHX0 MD0+'3F:R7LV5EZ?23@:+)44#R[@8"GAQ*0PO=2*[?!E=E[!OMN\-YZD126E% MS_&MUL/7=/&CA(-])"K%<@#E^/XCDN].\;TYNM?^65=2>&HX)ZTQ),L8P)S- MANM)!:4H+G8;7W/F5>>+I*3 &"N>D&JSETSB+(X71TW$%:-K6QKP?T-:U-(T M9?RS<5.CQ*'PQ[N"^E$8IE5HC$/UUB5&P5RP>&4<>]+K^=0^9]OMMASU3\Q$T7 MCSZ7$KC2'=%T)KZ'"&M''EN"9 CSS ?!(T MLC?Z%V3^W!BJ(D5IE0;-C$,)EU!;$JUH3VL#Y,%I"NB%FT_]6)2L+_H'?6I- M2TJZNQ_Y^1" _/6]C$IF")&IN/GU($ER!/,@I&I2'[-!%"O.;B\A,PD\E6TJ-F&2*1Y1QIQ/:N!BF M$0,P.!@B/68>ZKZZDUD?S+R M0ZH6J&DF BQA92;//%!8.=\=57-&LL@]P;@S$VUJW2 M$P3NV^#ZS+E242F][KM <5]H?NI&-2<8F[;TT:&,^<.M"$[=J>B!2MIB:HAD M3UDH0YR]6\'7QR3#0>D#_6;RP4&3C6 G,-O:X#!6$_)+9QB71E(:Q*02\QWJ MAD83K(KB9Z0]QSG96+O*;EVEXXKQ]=L"MT#5"-K-ASSWZ7.P64O@$,[#B@=B M?PE)G!%(X'.&G(J>&3+4KIQ@\@2BK&Y[ZBG0OA7W_>ZZ!>LW1NS>8\"PHI;U M7[)LO0!(;>"BD:1@_RO];P.,G*(NWVGUU,,+>1\B!T<.\DI8'[ELH MHL\[8 M=/Q7QM4T'FYVVNKZG([@W_E"HKY#LN/<=VQ;K*%$N(R>7Q;XDAU:0%$N&G1D MXSPJ=O6:9+N@J8GR-Z>FBVX#)?R"??7V%BIZ8D/US*>/\K9AU*S MAQ,CN5H7!FPVS#:4H)1MCSXO [4JKQ.D7/)VWC$A?_HOB>UU@EK/WG_MO 94 M;?V]H"N=#J;-N5+2/<*(=*W#.TH+,)"G#:$A+2>Z=>1?9*KD16M\!5.:Q+H+ M2+X4FZ[2V 781'=>8I3\)FO!^%^CE@[?G:TKT-N3YN&D2*5Y^*^;JF&657M6 M'T87W^/'ZO%<3*F9-]8L1;-G!8;SA1/,1,T3:OH*&GEJPIRN&%L!@!-KY\?_ M=\/)_Y%_Y!_Y1_Z1?^0?^4?^D7_D'_E'_I'_/P6U._ _ %!+ P04 " #6 M07%6(_BQZHD7 @ 0_14 % &AC="TR,#(R,3(S,5]L86(N>&ULW+U[<^0V MDB_Z_WX*7.^)73NB,.8#?,T^3DCJ;EOWJBV=5GN\>QTW*O"4N"Z1&I(EM_;3 M'X!D55%2%0FP0*K.C9AIJ]4DD/D#\4,BDOGV#\W?_\]W_XAW_]OR#\C_,O5^!#3M0/X+>\^"-]PA#^>_W21?[X7*1W]Q7P',]__:_%7T48.RC! M! K7B2$BD0^)%T30#UT?$2? /N>+N[]BGO@D1!Y,DE! %(4<)@$6,'*XQUV/ M4^Y$=:.K-/OCK^H/@DL.I')96?_UW[Z[KZK'O_[XXY]__OF7;Z18_24O[G[T M',?_[3'Y43_R8\3LULC>\2'-V6^&BNL*$KZ3T=6O5\R/_M^_* M].%QQ3>_NR^XV-_LJBA>M*JD3)24;JBD_,=#G?UXA/B6Y*W>RFI!N%K=7VS) MV(?I+];$_2KY@4\O<*>;HT5N/JB/&9OKV]UV=;3HTTMLZ[/(*[R:X;/8==,1 M>:5^<25_:KM1#?60:=U/2]T=4?FWBF>,-VSYHFF0LG_[3OZT7)?P#N/'Y4\\ MOROPXWU*+W))YEE5U 3^)2W_^,P?""^6,<-A$,BE27 W@D@N2Y (QY&$3*F+ MDH#ZC"VK[4>^Y!G\]78C3]VI88_?&>A>'9C#!2_S=4%WJ]_#:M^2)E/N'U!BJT,A4:3?]\)#%Y(#)3(__KC3D\;:*_FQW#UCO"!WQMY_[^# M..;TA60K96'DQ6ML_@>HW]3S6 M[^_'-Q_&6;'1"A=T8(S:)WZDJO7'"KX8+F6"$- M[#TJ;K_]>UHM/UU?7%Y^YO0>9RDMR;JX:S]W5UK H4WG#ULP34P9^Q$:Y@I] MF%B[X:L_\M';Z<&F3;$Z>+2L2JN:*5VOV;?]8^^KLQ"DCO ;3M1ZUHP& M-S1[OB[3C)?E&?W[.BU3]469!PWX?(8P0["7

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Í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end

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�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